<SEC-DOCUMENT>0001193125-23-105072.txt : 20230418
<SEC-HEADER>0001193125-23-105072.hdr.sgml : 20230418
<ACCEPTANCE-DATETIME>20230418164617
ACCESSION NUMBER:		0001193125-23-105072
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		13
FILED AS OF DATE:		20230418
DATE AS OF CHANGE:		20230418

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Calyxt, Inc.
		CENTRAL INDEX KEY:			0001705843
		STANDARD INDUSTRIAL CLASSIFICATION:	AGRICULTURE CHEMICALS [2870]
		IRS NUMBER:				271967997
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-269764
		FILM NUMBER:		23827383

	BUSINESS ADDRESS:	
		STREET 1:		2800 MOUNT RIDGE ROAD
		CITY:			ROSEVILLE
		STATE:			MN
		ZIP:			55113
		BUSINESS PHONE:		(651) 683-2807

	MAIL ADDRESS:	
		STREET 1:		2800 MOUNT RIDGE ROAD
		CITY:			ROSEVILLE
		STATE:			MN
		ZIP:			55113
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>d401831d424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML><HEAD>
<TITLE>424B3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(3)<BR>Registration No. 333-269764 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">


<IMG SRC="g401831g24o88.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">


<IMG SRC="g401831g93a75.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROPOSED MERGER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>YOUR VOTE IS VERY IMPORTANT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the
stockholders of Calyxt, Inc. and the members of Cibus Global, LLC: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;13, 2023, Calyxt, Inc., a Delaware corporation
(&#147;Calyxt, Inc.&#148;), and Calypso Merger Subsidiary, LLC, a Delaware limited liability company and wholly-owned subsidiary of Calyxt, Inc. (&#147;Merger Subsidiary&#148;) entered into an Agreement and Plan of Merger (the &#147;Merger
Agreement,&#148; and the transactions contemplated thereby, the &#147;Transactions&#148;) with Cibus Global, LLC, a Delaware limited liability company (&#147;Cibus Global&#148;), New Ventures I Holdings, LLC, a Delaware limited liability company
(&#147;Blocker 1&#148;), BCGF CB Holdings LLC, a Delaware limited liability company (&#147;Blocker 2&#148;), BCGFCP CB HOLDINGS LLC, a Delaware limited liability company (&#147;Blocker 3&#148;), BCGFK CB Holdings LLC, a Delaware limited liability
company (&#147;Blocker 4&#148;), FSBCGF CB Holdings LLC, a Delaware limited liability company (&#147;Blocker 5&#148;), PYLBCG CB Holdings LLC, a Delaware limited liability company (&#147;Blocker 6&#148;), FSGRWCO CB Holdings LLC, a Delaware limited
liability company (&#147;Blocker 7&#148;), GROWTHCO CB Holdings LLC, a Delaware limited liability company (&#147;Blocker 8&#148;), GRTHCOCP CB Holdings LLC, a Delaware limited liability company (&#147;Blocker 9&#148;), and GRWTHCOK CB Holdings LLC,
a Delaware limited liability company (&#147;Blocker 10&#148; and, collectively with Blocker 1, Blocker 2, Blocker 3, Blocker 4, Blocker 5, Blocker 6, Blocker 7, Blocker 8 and Blocker 9, the &#147;Blockers&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger Agreement provides that, among other things and upon the terms and subject to the conditions set forth therein (including receipt
of Calyxt, Inc. stockholder approval and Cibus Global member approval), on the date of the closing of the Transactions (the &#147;Closing&#148;): (i) each of the Blockers will merge with and into Calyxt, Inc. (each a &#147;Blocker Merger,&#148; and
collectively the &#147;Blocker Mergers&#148;), in each case with the Blockers ceasing to exist and Calyxt, Inc. surviving each such Blocker Merger (the resulting company, &#147;Cibus, Inc.&#148;); (ii) at the effective time of the Blocker Merger
with Blocker 1 (the &#147;First Blocker Merger Effective Time&#148;), Calyxt, Inc.&#146;s certificate of incorporation will be amended and restated (as amended and restated, the &#147;Amended Certificate of Incorporation&#148;) and its bylaws will
be amended and restated (as amended and restated, the &#147;Amended Bylaws&#148;); (iii) following the Blocker Mergers, Merger Subsidiary will merge with and into Cibus Global (the &#147;Cibus Merger&#148; and, collectively with the Blocker Mergers,
the &#147;Mergers&#148;), with Cibus Global as the surviving company and Merger Subsidiary ceasing to exist. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for the
Mergers, the equityholders of the Blockers and the equityholders of Cibus Global will receive the Merger Consideration (as defined below). In connection with the Mergers, Cibus, Inc. will contribute all of its assets and liabilities to Cibus Global,
as a contribution to the capital of Cibus Global, in exchange for newly issued membership units of Cibus Global (&#147;Cibus Common Units&#148;) under Cibus Global&#146;s third amended and restated limited liability company agreement (the
&#147;Cibus Amended Operating Agreement&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Closing is subject to the approval of Calyxt, Inc.&#146;s stockholders, the approval
of Cibus Global&#146;s members, approval of the Blocker members, the receipt of required regulatory approvals (to the extent applicable) and satisfaction of other customary closing conditions, as more particularly described in the Merger Agreement
and in the accompanying proxy statement/prospectus. The Closing is currently expected to occur in the second quarter of 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Amended
Certificate of Incorporation, once adopted at the First Blocker Merger Effective Time, will designate two classes of Cibus, Inc. common stock: (i)&nbsp;Class&nbsp;A Common Stock, par value $0.0001 (the &#147;Class&nbsp;A </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-i- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Common Stock&#148;), which shares will have full voting and economic rights, and (ii)&nbsp;Class&nbsp;B Common Stock, par value $0.0001 (the &#147;Class&nbsp;B Common Stock&#148; and, together
with the Class A Common Stock, the &#147;Shares&#148;), which shares will have full voting, but no economic rights. Upon adoption of the Amended Certificate of Incorporation, each share of Calyxt, Inc. common stock, par value $0.0001 per share
(&#147;Calyxt Common Stock&#148;), existing and outstanding immediately prior to the First Blocker Merger Effective Time shall remain outstanding as a share of Class&nbsp;A Common Stock at the First Blocker Merger Effective Time without any
conversion or exchange thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At each effective time of each Blocker Merger, the limited liability company interests of the applicable
Blocker will be cancelled and converted into the right of the equityholders of the applicable Blocker to receive shares of Class&nbsp;A Common Stock corresponding to that Blocker Merger (the &#147;Blocker Merger Consideration&#148;), in each case,
as set forth in the allocation schedule attached to the Merger Agreement (as such allocation schedule shall be amended and revised from time to time prior to the Closing, the &#147;Allocation Schedule&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the effective time of the Cibus Merger, all of the issued and outstanding membership units of Cibus Global (including profits interest
units), and all warrants or options to purchase membership units of Cibus Global, will be cancelled (or, in the case of warrants, surrendered to Cibus, Inc. for exchange) and converted into the right to receive the following (the &#147;Cibus Merger
Consideration,&#148; and together with the Blocker Merger Consideration, the &#147;Merger Consideration&#148;): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any <FONT STYLE="white-space:nowrap">pre-Closing</FONT> holder (excluding the Blockers, but including any
investor who has delivered an irrevocable commitment as of the date of the Merger Agreement to purchase Cibus Global membership units prior to Closing) of Cibus Global membership units that is as of the mailing date of the accompanying proxy
statement/prospectus among the 99 largest holders of membership units (on a fully diluted basis) of Cibus Global (collectively, the &#147;Top 99 Holders&#148;) shall have the option to elect, on a per unit basis, to receive Merger Consideration in
the form of either (a)&nbsp;the number of shares of Class&nbsp;A Common Stock set forth on the Allocation Schedule in exchange for all such holder&#146;s Cibus Global membership units (other than profits interest units) covered by such election or
(b)&nbsp;a number of shares of Class&nbsp;B Common Stock, with an equal number of Cibus Common Units, as set forth on the Allocation Schedule (a Cibus Common Unit and a share of Class&nbsp;B Common Stock, collectively, an <FONT
STYLE="white-space:nowrap">&#147;Up-C</FONT> Unit&#148;), in exchange for such holder&#146;s membership units (other than profits interest units) elected for exchange into Up-C Units, provided, that such holder will not be entitled to exchange more
than 95% of such holder&#146;s existing Cibus Global membership units for <FONT STYLE="white-space:nowrap">Up-C</FONT> Units and the remainder of such holder&#146;s Cibus Global membership units will be exchanged for shares of Class&nbsp;A Common
Stock (all Top 99 Holders who elect to receive <FONT STYLE="white-space:nowrap">Up-C</FONT> Units will be referred to as &#147;Electing Members&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all <FONT STYLE="white-space:nowrap">pre-Closing</FONT> holders of Cibus Global membership units, other than the
Top 99 Holders and the Blockers, shall receive the number of shares of Class&nbsp;A Common Stock set forth on the Allocation Schedule in exchange for their Cibus Global membership units (other than profits interest units of Cibus Global);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all <FONT STYLE="white-space:nowrap">pre-Closing</FONT> warrants to purchase Cibus Global membership units shall
automatically be exchanged for the right to receive the number of shares of Class&nbsp;A Common Stock set forth on the Allocation Schedule; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all <FONT STYLE="white-space:nowrap">pre-Closing</FONT> profits interest units of Cibus Global will, (a)&nbsp;to
the extent not a &#147;restricted unit&#148; (under the award agreements and governing documents applicable to such profits interest unit), be automatically cancelled and converted into the right to receive the number of shares of Class&nbsp;A
Common Stock set forth on the Allocation Schedule and (b)&nbsp;to the extent a &#147;restricted unit&#148; (i.e., an unvested unit), be automatically cancelled and converted into the right to receive the number of restricted shares of Class&nbsp;A
Common Stock pursuant to a Cibus, Inc. stock plan, as set forth on the Allocation Schedule and subject to the same vesting schedule as was applicable to such profits interest unit prior to Closing. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-ii- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately following the Cibus Merger, (i)&nbsp;each
<FONT STYLE="white-space:nowrap">pre-Closing</FONT> Cibus Global membership unit and <FONT STYLE="white-space:nowrap">pre-Closing</FONT> warrant to purchase Cibus Global membership units, in each case, held by Cibus, Inc. as a result of the Blocker
Mergers will be converted or exchanged for a number of Cibus Common Units set forth in the Allocation Schedule, (ii)&nbsp;each <FONT STYLE="white-space:nowrap">pre-Closing</FONT> warrant to purchase Cibus Global membership units held by Cibus, Inc.
as a result of the warrant exchanges described above will be converted or exchanged for a number of Cibus Common Units set forth in the Allocation Schedule, and (iii)&nbsp;Cibus will issue a number of Cibus Common Units to Cibus, Inc. in an amount
equal to the sum of (A)&nbsp;the number of shares of Class&nbsp;A Common Stock issued to former Cibus Global equity holders as Cibus Merger Consideration and (B)&nbsp;the number of shares of Calyxt Common Stock outstanding immediately prior to the
First Blocker Merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the Closing, the issuance of the Merger Consideration and the issuance of Cibus Common Units discussed
above, the combined company will be organized in an <FONT STYLE="white-space:nowrap">&#147;Up-C&#148;</FONT> structure, and Cibus, Inc.&#146;s only material asset will consist of Cibus Common Units. Upon the Closing, legacy Calyxt, Inc. stockholders
are expected to own approximately 5.0% of issued and outstanding Shares of Cibus, Inc., on a Fully-Exchanged Basis, taking into consideration all dilutive equity instruments as of that date, as described in the accompanying proxy
statement/prospectus, and legacy holders of Cibus Global membership units (including profits interest units) and warrants are expected to own approximately 95.0% of the issued and outstanding Shares of Cibus, Inc., on a Fully-Exchanged Basis, taking
into consideration all dilutive equity instruments as of that date as described in the accompanying proxy statement/prospectus, in each case, subject to dilution in connection with any additional equity issued in the Continuing Series F Financing or
the Potential Calyxt Financing, certain Calyxt RSU grants that Calyxt, Inc. is permitted to issue prior to Closing and outstanding options and warrants of Calyxt, Inc., which as of the mailing date of accompanying proxy statement/prospectus are
out-of-the-money. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately following the Closing, all of the issued and outstanding Cibus Common Units will be held by Cibus, Inc. and
the Electing Members (through their ownership of <FONT STYLE="white-space:nowrap">Up-C</FONT> Units), with the exact ownership interest held by Cibus, Inc. and the Electing Members being subject to the elections to be submitted by certain such
Electing Members prior to the Closing. In connection with the Up-C structure, at Closing, (i) Cibus, Inc. and the Electing Members will become party to the Cibus Amended Operating Agreement, (ii) Cibus, Inc., Cibus Global and the Electing Members
will enter into an Exchange Agreement, and (iii) Cibus, Inc. and the Electing Members will enter into a Registration Rights Agreement and a Tax Receivable Agreement. The <FONT STYLE="white-space:nowrap">Up-C</FONT> Units will generally be
exchangeable for shares of Class&nbsp;A Common Stock on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis, or, subject to certain restrictions, the cash equivalent with respect to all or a portion
thereof, based on a volume-weighted average price of a share of Class&nbsp;A Common Stock pursuant to the terms of the Exchange Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beginning at the earlier of (a)&nbsp;March&nbsp;15, 2023 and (b)&nbsp;the date Calyxt, Inc.&#146;s unrestricted cash balance first drops below
$1,500,000, Calyxt, Inc. can request, and Cibus Global has agreed to provide, an unsecured, interest-free revolving line of credit of up to $3,000,000 in cash, which amount may be increased to $4,000,000 if Cibus Global elects to extend the outside
date for the termination of the Merger Agreement from May&nbsp;15, 2023 to June&nbsp;30, 2023 (the &#147;Interim Funding&#148;). Funds can be drawn by Calyxt, Inc. in $500,000 increments and may only be used to fund operating expenses incurred in
the ordinary course of business consistent with past practice and consistent with the negative covenants in the Merger Agreement. Calyxt made an initial draw under the Interim Funding on March 15, 2023, an additional draw on March 30, 2023 and
expects to make additional draws prior to Closing. The full outstanding balance of the Interim Funding will be reduced to zero in connection with the Closing if the Mergers are consummated. The full outstanding balance of the Interim Funding will be
forgiven by Cibus Global if the Merger Agreement is terminated for any reason other than specified circumstances. See the section entitled &#147;<I></I><I>The Merger Agreement&#151;Cibus Global Interim Funding</I>&#148; in the accompanying proxy
statement/prospectus. The Interim Funding is subject to acceleration in connection with certain bankruptcy events. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt Common Stock is
currently listed on the Nasdaq Capital Market under the symbol &#147;CLXT.&#148; Calyxt, Inc. has filed an initial listing application for Cibus, Inc. with the Nasdaq Capital Market. After completion of the Transactions, Calyxt, Inc. is expected to
be renamed &#147;Cibus, Inc.&#148; and the Class A Common Stock will trade under the symbol &#147;CBUS.&#148; On April 17, 2023, the last trading day before the date of the accompanying proxy statement/prospectus, the closing sale price of Calyxt
Common Stock was $0.31 per share. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-iii- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt, Inc. stockholders are cordially invited to attend the special meeting of Calyxt,
Inc. stockholders (the &#147;Calyxt Special Meeting&#148;), which is being held in order to obtain the stockholder approvals necessary to complete the Transactions and related matters. The Calyxt Special Meeting will be held at 9:00 a.m., Central
Time, on May 18, 2023, unless postponed or adjourned to a later date, for the purpose of considering and voting upon the matters set forth in the Notice of Special Meeting of Stockholders and the accompanying proxy statement/prospectus. The Calyxt
Special Meeting will be a virtual meeting held exclusively via live webcast. Calyxt, Inc. stockholders will be able to attend the meeting online, vote during the meeting until polls are closed, and submit questions during the meeting at
www.virtualshareholdermeeting.com/CLXT2023SM. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with the execution of the Merger Agreement, certain Calyxt, Inc. stockholders,
directors and officers (solely in their respective capacities as Calyxt, Inc. stockholders) who as of January&nbsp;13, 2023, collectively and in the aggregate, beneficially held voting power of approximately 49.8% of outstanding Calyxt Common Stock,
and certain of Cibus Global&#146;s equityholders, directors and officers (including the Blockers), directors and officers (solely in their respective capacities as equityholders of Cibus Global) who as of January&nbsp;13, 2023, collectively and in
the aggregate, held voting power of approximately 54.3% of the outstanding voting Cibus Global membership units (the &#147;Supporting Unitholders&#148;), entered into support agreements with Calyxt, Inc. and Cibus Global whereby such stockholders
and Supporting Unitholders, have agreed to vote their shares or units, as applicable, in favor of the Merger Agreement, the Transactions and against any alternative acquisition proposals, and the Supporting Unitholders have agreed to vote to convert
all outstanding <FONT STYLE="white-space:nowrap">pre-Closing</FONT> Cibus Global preferred units into <FONT STYLE="white-space:nowrap">pre-Closing</FONT> Cibus Global voting common units on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After careful consideration, the Calyxt, Inc. board of directors (the
&#147;Calyxt Board&#148;) and the Cibus Global board of managers (the &#147;Cibus Board&#148;) have each approved the Merger Agreement and have determined that it is advisable and in the best interests of their respective stockholders and
unitholders, as applicable, to consummate the Transactions. The Calyxt, Board has approved the proposals described in the accompanying proxy statement/prospectus and unanimously recommends that its stockholders vote &#147;FOR&#148; the proposals
described in the accompanying proxy statement/prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>More information about Calyxt, Inc., Cibus Global, Merger Subsidiary, the
Merger Agreement, the Transactions and the proposals being considered at the Calyxt Special Meeting is contained in the accompanying proxy statement/prospectus. You are urged to read the accompanying proxy statement/prospectus carefully and in its
entirety. IN PARTICULAR, YOU SHOULD CAREFULLY CONSIDER THE MATTERS DISCUSSED UNDER THE SECTION ENTITLED &#147;<A HREF="#rom401831_6">RISK FACTORS</A>&#148; BEGINNING ON PAGE 40 OF THE ACCOMPANYING PROXY STATEMENT/PROSPECTUS. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt, Inc. and Cibus Global are excited about the opportunities the proposed Transactions bring to both Calyxt, Inc. stockholders and Cibus
Global unitholders, and thank you for your consideration and continued support. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g401831g01a06.jpg" ALT="LOGO">
</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">President and Chief Executive Officer</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Calyxt, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g401831g01b06.jpg" ALT="LOGO">
</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Executive Officer and Chair of the Cibus
Board</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Cibus Global, LLC</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or
disapproved of these securities or passed upon the adequacy or accuracy of the accompanying proxy statement/prospectus. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying proxy statement/prospectus is dated April 18, 2023, and is first being mailed to Calyxt, Inc. stockholders on or about April
18,&nbsp;2023. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-iv- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g401831g24o88.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CALYXT, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2800 Mount Ridge Road </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Roseville, MN 55113 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(651) <FONT STYLE="white-space:nowrap">683-2807</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF SPECIAL MEETING OF STOCKHOLDERS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO BE HELD ON MAY 18, 2023 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear
Stockholders of Calyxt, Inc.: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On behalf of the board of directors of Calyxt, Inc. (the &#147;Calyxt Board&#148;), a Delaware corporation
(&#147;Calyxt, Inc.&#148;), we are pleased to deliver this proxy statement/prospectus for a special meeting of stockholders of Calyxt, Inc., including any adjournment or postponement thereof (the &#147;Calyxt Special Meeting&#148;) for the proposed
transactions between Calyxt, Inc. and Cibus Global, LLC, a Delaware limited liability company (&#147;Cibus Global&#148;). On January&nbsp;13, 2023, Calyxt, Inc. and Calypso Merger Subsidiary, LLC, a Delaware limited liability company and
wholly-owned subsidiary of Calyxt, Inc. (&#147;Merger Subsidiary&#148;) entered into an Agreement and Plan of Merger (the &#147;Merger Agreement,&#148; and the transactions contemplated thereby, the &#147;Transactions&#148;) with Cibus Global; New
Ventures I Holdings, LLC, a Delaware limited liability company (&#147;Blocker 1&#148;); BCGF CB Holdings LLC, a Delaware limited liability company (&#147;Blocker 2&#148;); BCGFCP CB HOLDINGS LLC, a Delaware limited liability company (&#147;Blocker
3&#148;); BCGFK CB Holdings LLC, a Delaware limited liability company (&#147;Blocker 4&#148;); FSBCGF CB Holdings LLC, a Delaware limited liability company (&#147;Blocker 5&#148;); PYLBCG CB Holdings LLC, a Delaware limited liability company
(&#147;Blocker 6&#148;); FSGRWCO CB Holdings LLC, a Delaware limited liability company (&#147;Blocker 7&#148;); GROWTHCO CB Holdings LLC, a Delaware limited liability company (&#147;Blocker 8&#148;); GRTHCOCP CB Holdings LLC, a Delaware limited
liability company (&#147;Blocker 9&#148;); and GRWTHCOK CB Holdings LLC, a Delaware limited liability company (&#147;Blocker 10&#148;; and, collectively with Blocker 1, Blocker 2, Blocker 3, Blocker 4, Blocker 5, Blocker 6, Blocker 7, Blocker 8 and
Blocker 9, the &#147;Blockers&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger Agreement provides that, among other things and upon the terms and subject to the
conditions set forth therein (including receipt of Calyxt, Inc. stockholder approval and Cibus Global member approval), on the date of the closing of the Transactions: (a)&nbsp;each of the Blockers will merge with and into Calyxt, Inc. (each a
&#147;Blocker Merger,&#148; and collectively the &#147;Blocker Mergers&#148;), in each case with the Blockers ceasing to exist and Calyxt, Inc. surviving each such Blocker Merger, (b)&nbsp;at the effective time of the Blocker Merger with Blocker 1
(the &#147;First Blocker Merger Effective Time&#148;), Calyxt&#146;s amended and restated bylaws will be amended and restated in a manner to be mutually agreed by Calyxt, Inc. and Cibus Global (as amended and restated, the &#147;Amended
Bylaws&#148;) and Calyxt, Inc.&#146;s amended and restated certificate of incorporation will be amended and restated in a manner to be mutually agreed by Calyxt, Inc. and Cibus Global (as amended and restated, the &#147;Amended Certificate of
Incorporation&#148;), and (c) following the Blocker Mergers, Merger Subsidiary will merge with and into Cibus Global, with Cibus Global as the surviving company and Merger Subsidiary ceasing to exist. As consideration for the Mergers, the equity
holders of the Blockers and the equity holders of Cibus Global will receive the Merger Consideration (as defined in the Merger Agreement). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Calyxt Special Meeting will be held virtually via live webcast at www.virtualshareholdermeeting.com/CLXT2023SM on May 18, 2023 at 9:00
a.m. Central Time for the following purposes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To consider and vote upon a proposal to approve the Blocker Mergers and the issuance of Class&nbsp;A Common
Stock, par value $0.0001 (the &#147;Class&nbsp;A Common Stock&#148;), and Class&nbsp;B Common Stock, par value $0.0001 (the &#147;Class&nbsp;B Common Stock&#148;), as Merger Consideration pursuant to the Merger Agreement; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-v- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To consider and vote upon a proposal to approve, for purposes of Nasdaq Listing Rule 5635(a) and (b), the
issuance of shares of Class&nbsp;A Common Stock and Class&nbsp;B Common Stock pursuant to the terms of the Merger Agreement and the change of control of Calyxt, Inc. resulting from the Mergers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To consider and vote upon, on a non-binding, advisory basis, a proposal to approve the Amended Certificate of
Incorporation, which will amend and restate Calyxt, Inc.&#146;s amended and restated certificate of incorporation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To consider and vote upon a proposal to approve an amendment to Calyxt, Inc.&#146;s amended and restated
certificate of incorporation to effect a reverse stock split at the discretion of the Calyxt Board at or prior to the Closing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To consider and vote upon a proposal to approve an amendment to the Calyxt, Inc. 2017 Omnibus Incentive Plan;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To consider and vote upon, on a <FONT STYLE="white-space:nowrap">non-binding,</FONT> advisory basis, a proposal
to approve merger-related named executive officer compensation for Calyxt, Inc.&#146;s named executive officers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To consider and vote upon a proposal to approve an adjournment of the Calyxt Special Meeting, if necessary, to
solicit additional proxies if there are not sufficient votes in favor of one or more of the proposals presented to Calyxt Stockholders; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To transact such other business as may properly come before the Calyxt Special Meeting or any adjournment or
postponement thereof. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The record date for the Calyxt Special Meeting is April 12, 2023. Only stockholders of record at
the close of business on that date are entitled to notice of, and to vote at, the Calyxt Special Meeting or any adjournment or postponement thereof. At the close of business on the record date, Calyxt, Inc. had 49,735,490 shares of common stock
outstanding and entitled to vote. Calyxt, Inc.&#146;s list of stockholders as of April&nbsp;12, 2023 will be available for inspection 10 days prior to the Calyxt Special Meeting during ordinary business hours at Calyxt, Inc.&#146;s corporate
headquarters. In addition, the list of stockholders will also be available during the Calyxt Special Meeting through the meeting website for those stockholders who choose to attend. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Calyxt Special Meeting will be a virtual meeting held exclusively via live webcast. You may attend the Calyxt Special Meeting, vote your
shares and submit questions electronically during the Calyxt Special Meeting. Whether or not you expect to attend the Calyxt Special Meeting, you are respectfully requested to promptly either (i)&nbsp;sign, date and return the enclosed proxy card or
voting instruction form, or (ii)&nbsp;vote via telephone, mail, or the internet by following the instructions provided on the enclosed proxy card or voting instruction form. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To attend the Calyxt Special Meeting, you will need the 16-digit control number that is printed in the box marked by the arrow on your proxy
card. Calyxt, Inc. recommends that you log in starting 15 minutes before the Calyxt Special Meeting to ensure that you are logged in when the meeting starts. Online access will begin at 8:45&nbsp;a.m. Central Time. The Calyxt Special Meeting
platform is fully supported across browsers (Firefox, Chrome, and Safari) and devices (desktops, laptops, tablets, and cell phones) running the most updated version of applicable software and plugins. Stockholders should ensure that they have a
strong internet connection if they intend to attend and/or participate in the Calyxt Special Meeting. Attendees should allow plenty of time to log in (starting 15 minutes before the Calyxt Special Meeting) and ensure that they can hear streaming
audio prior to the start of the Calyxt Special Meeting. If you are a beneficial owner of shares registered in the name of a broker, bank or other nominee, you will also need to provide the registered name on your account and the name of your broker,
bank or other nominee as part of the registration process. Please be sure to follow the instructions found on your proxy card or voting instruction form. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Your vote as a stockholder of Calyxt, Inc. is very important. Each share of stock that you own represents one vote. The affirmative vote of
the majority of the votes cast at the Calyxt Special Meeting and entitled to vote on the subject matter is required for approval of Proposal Nos. 2 and 5. The </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-vi- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>
affirmative vote of the majority of the votes cast affirmatively or negatively by holders present or represented by proxy at the Calyxt Special Meeting and entitled to vote on the subject matter
is required for approval of Proposal Nos. 6 (on an advisory basis) and 7. Approval of Proposals No.&nbsp;1, 3 (on an advisory basis) and 4 require the affirmative vote of the holders of a majority of Calyxt Common Stock on the record date for the
Calyxt Special Meeting entitled to vote on the subject matter. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Proposal No.&nbsp;1 is conditioned upon the approval of Proposal
No.&nbsp;2, and the Mergers cannot be consummated without the approval of Proposal Nos. 1 and 2. Proposal Nos. 3 and 6, which are <FONT STYLE="white-space:nowrap">non-binding</FONT> and advisory in nature, are conditioned upon the approval of
Proposal Nos. 1 and 2. Proposal Nos. 4, 5 and 7 are not conditioned on the approval of any other proposal. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Even if you plan to
attend the Calyxt Special Meeting, Calyxt, Inc. requests that you sign and return the enclosed proxy card or voting instruction form to ensure that your shares will be represented at the Calyxt Special Meeting if you are unable to attend. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THE CALYXT BOARD HAS DETERMINED THAT EACH OF THE PROPOSALS OUTLINED ABOVE IS ADVISABLE TO, AND IN THE BEST INTERESTS OF, CALYXT AND ITS
STOCKHOLDERS AND HAS APPROVED EACH SUCH PROPOSAL. THE CALYXT BOARD UNANIMOUSLY RECOMMENDS THAT CALYXT STOCKHOLDERS VOTE &#147;FOR&#148; EACH SUCH PROPOSAL. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By Order of the Calyxt Board,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Michael A. Carr</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>President&nbsp;&amp; Chief
Executive Officer</I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Roseville, Minnesota</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">April 18,
2023</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-vii- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_1">FREQUENTLY USED TERMS AND TECHNICAL TERMS OF ART</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_2">REFERENCES TO ADDITIONAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_3">QUESTIONS AND ANSWERS ABOUT THE TRANSACTIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_4">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_5">MARKET PRICE AND DIVIDEND INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_6">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_7">Risks Related to the Mergers </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_8">Risks Related to the Reverse Stock Splits </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_9">Risks Related to Calyxt</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_10">Risks Related to Cibus</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_11">Risks Related to the Combined Company</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_12">Risks Related to the Organizational Structure of the Combined
Company</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_13">CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_14">THE SPECIAL MEETING OF CALYXT STOCKHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_15">THE MERGERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_16">Background of the Mergers</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_17">Calyxt Reasons for the Mergers</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_18">Cibus Reasons for the Mergers</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_18b">Unaudited Financial Projections</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_18a">Interests of the Financial Advisor to the Calyxt Committee</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_19">Interests of Calyxt, Inc. Directors and Executive Officers in the
Mergers</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_20">Interests of Cibus Global Directors and Executive Officers in the
Mergers</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_21">Form of the Mergers</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_22">Effective Time of the Mergers</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_23">Merger Consideration</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_24">Calyxt, Inc. Procedure for Exchange of Cibus Global Units</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_25">Regulatory Approvals</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_26">Nasdaq Listing</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_27">Accounting Treatment of the Business Combination</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_28">Appraisal Rights and Dissenters&#146; Rights</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_29">THE MERGER AGREEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_30">AGREEMENTS RELATED TO THE MERGERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_31">Support Agreements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-i- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(continued) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_32">Tax Receivable Agreement</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_33">Exchange Agreement</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_34">Registration Rights Agreement</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_35">Cibus Amended Operating Agreement</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_36">MATTERS BEING SUBMITTED TO A VOTE OF CALYXT STOCKHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_37">Proposal No.&nbsp;
1: Approval of the Blocker Mergers and the issuance of Class&nbsp;A Common Stock and Class&nbsp;B Common Stock as Merger Consideration pursuant to the Merger Agreement</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_38">Proposal No.&nbsp;
2: Approval, for purposes of Nasdaq Listing Rule 5635(a) and (b), the issuance of shares of Class&nbsp;A Common Stock and Class&nbsp;
B Common Stock pursuant to the terms of the Merger Agreement and the change of control of Calyxt resulting from the Mergers</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_40">Proposal No.&nbsp;
3: Approval of the Amended Certificate of Incorporation, which will amend and restate the Calyxt Certificate of Incorporation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_42">Proposal No.&nbsp;
4: Approval of an amendment to the Calyxt Certificate of Incorporation to effect the Subsequent Reverse Stock Split at the discretion of the Calyxt Board</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_43">Proposal No.&nbsp;
5: Approval of the Amendment to the Calyxt, Inc. 2017 Omnibus Incentive Plan</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_44">Proposal No.&nbsp;
6: <FONT STYLE="white-space:nowrap">Non-Binding,</FONT> Advisory Vote on Merger-Related Named Executive Officer Compensation for Calyxt, Inc.&#146;s Named Executive Officers</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_45">Proposal No.&nbsp;
7: Approval of possible adjournment of the Calyxt Special Meeting</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_46">CALYXT BUSINESS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_47">CIBUS BUSINESS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_48">CALYXT MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
 OF OPERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_49">CIBUS MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_50">MANAGEMENT FOLLOWING THE TRANSACTIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_51">CALYXT, INC. EXECUTIVE COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_52">CIBUS GLOBAL EXECUTIVE COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_53">RELATED PARTY TRANSACTIONS OF DIRECTORS AND EXECUTIVE OFFICERS OF THE COMBINED
 COMPANY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_54">UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_55">NOTES TO THE UNAUDITED PRO FORMA COMBINED FINANCIAL
INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_56">DESCRIPTION OF CAPITAL STOCK OF CIBUS, INC.</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_57">COMPARISON OF STOCKHOLDERS&#146; RIGHTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">339</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_58">PRINCIPAL STOCKHOLDERS OF CALYXT, INC.</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_59">PRINCIPAL UNITHOLDERS OF CIBUS GLOBAL</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">358</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-ii- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(continued) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_60">PRINCIPAL STOCKHOLDERS OF CIBUS, INC.</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_61">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">364</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_62">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">364</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_63">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">365</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_64">OTHER MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_65">INDEX TO FINANCIAL STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_66">ANNEX A-1: MERGER AGREEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-1-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_66a">ANNEX A-2: FIRST AMENDMENT TO MERGER AGREEMENT </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-2-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_67">ANNEX B: PROPOSED AMENDED CERTIFICATE OF INCORPORATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_68">ANNEX C: PROPOSED AMENDED BYLAWS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">C-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_69">ANNEX D: FORM OF TAX RECEIVABLE AGREEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">D-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_70">ANNEX E: FORM OF EXCHANGE AGREEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">E-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_71">ANNEX F: FORM OF REGISTRATION RIGHTS AGREEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_72">ANNEX G: FORM OF CALYXT SUPPORT AGREEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">G-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_73">ANNEX H: FORM OF CIBUS SUPPORT AGREEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">H-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_74">ANNEX I: FORM OF CIBUS AMENDED OPERATING AGREEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">I-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_75">ANNEX J: CERTIFICATE OF AMENDMENT TO EFFECT THE REVERSE STOCK
SPLIT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">J-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom401831_76">ANNEX K: CIBUS, INC. 2017 OMNIBUS INCENTIVE PLAN (AS AMENDED)</A></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">K-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-iii- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom401831_1"></A>FREQUENTLY USED TERMS AND TECHNICAL TERMS OF ART </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>2022 Annual Meeting</U>&#148; means the Annual Meeting of Calyxt Stockholders held on June&nbsp;1, 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>2023 Annual Meeting</U>&#148; means the Annual Meeting of Calyxt Stockholders to be held on May 2, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>AIML</U>&#148; means artificial intelligence and machine learning. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Allocation Schedule</U>&#148; means the schedule attached to the Merger Agreement as Exhibit G (as such schedule shall be amended and
revised from time to time prior to the Closing), setting forth for each holder of a Cibus Unit and of a Cibus Warrant and of an equity interest in each Blocker: (i) the number and class of interests of Cibus Global and each Blocker, as applicable,
held by such Person, and (ii) the portion of the Merger Consideration to be allocated to such Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Amended Bylaws</U>&#148;
means the bylaws of Cibus, Inc. following the consummation of the Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Amended Certificate of Incorporation</U>&#148;
means the certificate of incorporation of Cibus, Inc. following the consummation of the Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>APHIS</U>&#148; means the
Animal&nbsp;&amp; Plant Health Inspection Service, an agency of the USDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Blocker 1</U>&#148; means New Venture I Holdings, LLC,
a Delaware limited liability company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Blocker 2</U>&#148; means BCGF CB Holdings LLC, a Delaware limited liability company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Blocker 3</U>&#148; means BCGFCP CB Holdings LLC, a Delaware limited liability company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Blocker 4</U>&#148; means BCGFK CB Holdings LLC, a Delaware limited liability company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Blocker 5</U>&#148; means FSBCGF CB Holdings LLC, a Delaware limited liability company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Blocker 6</U>&#148; means PYLBCG CB Holdings LLC, a Delaware limited liability company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Blocker 7</U>&#148; means FSGRWCO CB Holdings LLC, a Delaware limited liability company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Blocker 8</U>&#148; means GROWTHCO CB Holdings LLC, a Delaware limited liability company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Blocker 9</U>&#148; means GRTHCOCP CB Holdings LLC, a Delaware limited liability company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Blocker 10</U>&#148; means GRWTHCOK CB Holdings LLC, a Delaware limited liability company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Blocker Approvals</U>&#148; means the approvals by the members of the Blockers of the Blocker Mergers and the Merger Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Blocker Merger Effective Time</U>&#148; means the effective time of the applicable Blocker Merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Blocker Mergers</U>&#148; means, collectively, the First Blocker Merger, Second Blocker Merger, Third Blocker Merger, Fourth Blocker
Merger, Fifth Blocker Merger, Sixth Blocker Merger, Seventh Blocker Merger, Eighth Blocker Merger, Ninth Blocker Merger and Tenth Blocker Merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Blockers</U>&#148; means, collectively, Blocker 1, Blocker 2, Blocker 3, Blocker 4, Blocker 5, Blocker 6, Blocker&nbsp;7, Blocker 8,
Blocker 9 and Blocker 10. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Calyxt</U>&#148; means Calyxt, Inc., a Delaware corporation, and all of its subsidiaries prior to the
Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Calyxt Board</U>&#148; means the board of directors of Calyxt, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Calyxt Bylaws</U>&#148; means the amended and restated bylaws of Calyxt, Inc., as amended as of May&nbsp;7, 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Calyxt Certificate of Incorporation</U>&#148; means the amended and restated
certificate of incorporation of Calyxt, Inc., dated July&nbsp;25, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Calyxt Committee</U>&#148; means the strategic
alternatives review committee of the Calyxt Board formed in a series of meetings in April and May 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Calyxt Common
Stock</U>&#148; means the common stock, $0.0001 par value per share, of Calyxt, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Calyxt Common Warrants</U>&#148; means the
warrants to purchase 7,760,000 shares of Calyxt Common Stock at an exercise price of $1.41 issued by Calyxt, Inc. in its February 2022 follow-on offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Calyxt Contracts</U>&#148; means the contracts listed in Schedule 4.12 in the Calyxt disclosure schedule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Calyxt PSU</U>&#148; means a performance stock unit of Calyxt, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Calyxt RSU</U>&#148; means a restricted stock unit of Calyxt, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Calyxt Special Meeting</U>&#148; means the Special Meeting of Calyxt Stockholders, including any adjournment or postponement of such
meeting, to be called for the purpose of considering and, if thought fit, approving, the Calyxt Stockholder Matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Calyxt
Stockholder Approval</U>&#148; means the approval by the Calyxt Stockholders of the Mergers and the Merger Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Calyxt
Stockholder Matters</U>&#148; means the proposals to be presented at the Calyxt Special Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Calyxt Stockholders</U>&#148;
means the stockholders of Calyxt, Inc. prior to the consummation of the Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Calyxt Support Agreements</U>&#148; means
the Voting Agreements, each dated January 13, 2023, between Cibus Global, on the one hand, and certain Calyxt Stockholders and certain directors and officers of Calyxt, Inc. on the other hand, who as of January&nbsp;13, 2023, collectively and in the
aggregate, beneficially held voting power of approximately 49.8% of the then outstanding Calyxt Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Canola</U>&#148;
refers to both Canola and Winter Oilseed Rape. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>cell culture</U>&#148; refers to the process by which cells, tissues or organs
are grown or maintained under controlled sterile conditions on a nutrient culture medium of known composition, generally outside of their natural environment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Cellectis</U>&#148; means Cellectis SA, a French <I>Soci&eacute;t&eacute; Anonyme.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>CFIA</U>&#148; means the Canadian Food Inspection Agency. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Cibus</U>&#148; means Cibus Global and all of its subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Cibus Amended Operating Agreement</U>&#148; means the third amended and restated limited liability company agreement of Cibus Global
following the consummation of the Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Cibus Board</U>&#148; means the board of managers of Cibus Global. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Cibus Common Units</U>&#148; means the units of Cibus Global designated as &#147;Common Units,&#148; with such rights and
restrictions as to be set forth in the Cibus Amended Operating Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Cibus Contracts</U>&#148; means the contracts listed
in Schedule 3.11 in the Cibus disclosure schedule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Cibus Global</U>&#148; means Cibus Global, LLC, a Delaware limited liability
company, which is classified as a partnership for United States federal income tax purposes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Cibus, Inc.</U>&#148; means Calyxt, Inc. following the consummation of the Blocker
Mergers, to be renamed Cibus, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Cibus, Inc. Board</U>&#148; means the board of directors of Cibus, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Cibus Managing Member</U>&#148; means Cibus, Inc., in its capacity as the managing member of Cibus Global under the Cibus Amended
Operating Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Cibus Member Approval</U>&#148; means the approval by the members of Cibus Global of the Mergers and the
Merger Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Cibus Merger</U>&#148; means the merger between Merger Subsidiary and Cibus Global, pursuant to which Merger
Subsidiary will merge with and into Cibus Global with Cibus Global being the surviving entity in such merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Cibus Merger
Effective Time</U>&#148; means the time when the Cibus Global certificate of merger has been duly filed with the Secretary of State of the State of Delaware or at such later time as may be agreed by Calyxt, Inc. and Cibus Global in writing and
specified in the Cibus Global certificate of merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Cibus Operating Agreement</U>&#148; means the second amended and restated
limited liability company agreement of Cibus Global prior to the Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Cibus PIU</U>&#148; means Cibus Units, which are
&#147;profits interests&#148; (as described in IRS Revenue Procedure <FONT STYLE="white-space:nowrap">93-27</FONT> and IRS Revenue Procedure <FONT STYLE="white-space:nowrap">2001-43)</FONT> in Cibus Global. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Cibus Preferred Units</U>&#148; means each of the Cibus Series A Preferred Units, Cibus Series B Preferred Units, Cibus Series C
Preferred Units, Cibus Series D Preferred Units, Cibus Series E Preferred Units and Cibus Series F Preferred Units. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Cibus Series
A Preferred Unit</U>&#148; means a membership unit representing a convertible preferred membership interest in Cibus Global, authorized as part of Cibus Global&#146;s Series A financing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Cibus Series B Preferred Unit</U>&#148; means a membership unit representing a convertible preferred membership interest in Cibus
Global, authorized as part of Cibus Global&#146;s Series B financing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Cibus Series C Preferred Unit</U>&#148; means a membership
unit representing a convertible preferred membership interest in Cibus Global, authorized as part of Cibus Global&#146;s Series C financing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Cibus Series D Preferred Unit</U>&#148; means a membership unit representing a convertible preferred membership interest in Cibus
Global, authorized as part of Cibus Global&#146;s Series D financing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Cibus Series E Preferred Unit</U>&#148; means a membership
unit representing a convertible preferred membership interest in Cibus Global, authorized as part of Cibus Global&#146;s Series E financing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Cibus Series F Preferred Unit</U>&#148; means a membership unit representing a convertible preferred membership interest in Cibus
Global, authorized as part of Cibus Global&#146;s Series F financing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Cibus Support Agreements</U>&#148; means the Voting
Agreements, each dated January 13, 2023, between Calyxt, Inc., on the one hand, and certain of Cibus Global&#146;s equityholders (including the Blockers) and certain directors and officers of Cibus Global, on the other hand, who as of
January&nbsp;13, 2023, collectively and in the aggregate, held voting power of approximately 54.3% of the then outstanding voting Cibus Units. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Cibus Unit</U>&#148; means a <FONT STYLE="white-space:nowrap">pre-Closing</FONT> Cibus Global membership unit representing a
membership interest in Cibus Global under the Cibus Operating Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Cibus Unitholders</U>&#148; means the holders of <FONT
STYLE="white-space:nowrap">pre-Closing</FONT> Cibus Units, <FONT STYLE="white-space:nowrap">pre-Closing</FONT> Cibus PIUs and Cibus Warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Cibus Warrant</U>&#148; means a warrant to purchase Cibus Units. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Class</U><U></U><U>&nbsp;A Common Stock</U>&#148; means the Class&nbsp;A common stock, par value $0.0001 per share, of Cibus, Inc.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Class</U><U></U><U>&nbsp;B Common Stock</U>&#148; means the Class&nbsp;B common stock, par value $0.0001 per share, of Cibus,
Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Closing</U>&#148; means the closing of the Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Closing Date</U>&#148; means (a)&nbsp;the second business day after the satisfaction or waiver of the conditions pursuant to the
Merger Agreement or (b)&nbsp;such other date as may be mutually agreed to in writing by Calyxt, Inc. and Cibus Global. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Code</U>&#148; means the Internal Revenue Code of 1986, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Combined Company</U>&#148; means Cibus, Inc. and all of its subsidiaries, including its wholly-owned subsidiary, Cibus Global,
following the consummation of the Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Continuing Series F Financing</U>&#148; means the sale of additional Cibus
Series F Preferred Units following the date of the Merger Agreement and prior to the Closing at a cash purchase price of $2.00 per Cibus Series F Preferred Unit and on other terms substantially the same as sales of Cibus Series F Preferred Units by
Cibus Global prior to the date of the Merger Agreement. For the avoidance of doubt, the Series F Purchase Commitment is part of the Continuing Series F Financing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Contribution</U>&#148; means the contribution by Calyxt, Inc. of all of its assets and liabilities to Cibus Global, as a contribution
to the capital of Cibus Global in exchange for Cibus Common Units. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Contribution Agreement</U>&#148; means the Contribution
Agreement, to be dated as of the Closing Date, by and between Calyxt, Inc. and Cibus Global. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Delaware Law</U>&#148; means, as
the context requires, the DGCL and/or the DLLCA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>DGCL</U>&#148; means the Delaware General Corporation Law, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Dilutive Issuances</U>&#148; means any potential issuances following the date of the Merger Agreement of (i) up to an additional
3,487,503 Calyxt RSUs (of which 3,468,083 have been issued as of the date of this proxy statement/prospectus), which Calyxt RSUs will, if issued, be subject to accelerated vesting upon Closing, (ii) 7,760,000 shares of Calyxt Common Stock issuable
upon the exercise of outstanding Calyxt Common Warrants with an exercise price of $1.41 per share issued by Calyxt, Inc. in its February 2022 <FONT STYLE="white-space:nowrap">follow-on</FONT> offering, (iii) shares of Calyxt Common Stock underlying
stock options issued by Calyxt pursuant to its Equity Plans, all of which were out-of-the-money as of January 13, 2023, (iv)&nbsp;shares of Calyxt Common Stock underlying 336,668 Calyxt PSUs subject to accelerated vesting, with the actual amount
determined based on the applicable performance metrics pursuant to Calyxt&#146;s Equity Plans (other than the issuance at Closing of 150,000 shares of Class A Common Stock upon the accelerated vesting of 150,000 outstanding Calyxt PSUs), (v) any
Cibus Series F Preferred Units pursuant to the Continuing Series F Financing, and (vi) any Class A Common Stock in connection with any Potential Calyxt Financing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>DLLCA</U>&#148; means the Delaware Limited Liability Company Act, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>DNA</U>,&#148; or deoxyribonucleic acid, is a molecule that carries the genetic code comprising four chemical bases: adenine (A),
guanine (G), cytosine (C)&nbsp;and thymine (T), the sequence of which determines the information available for building and maintaining an organism. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>ECJ</U>&#148; means the European Court of Justice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Eighth Blocker Merger</U>&#148; means the merger between Blocker 8 and Calyxt, Inc., pursuant to which Blocker 8 will merge with and
into Calyxt, Inc. with Calyxt, Inc. being the surviving entity in such merger. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Electing Members</U>&#148; means the Top 99 Holders that are entitled to and
validly elect to receive <FONT STYLE="white-space:nowrap">Up-C</FONT> Units in exchange for any one or more Cibus Units. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Election Form</U>&#148; means a merger consideration election form in a form mutually satisfactory to Cibus Global and Calyxt, Inc.
that Cibus Global will mail to each holder of Cibus Units that is a Top 99 Holder promptly after the date this proxy statement/prospectus is declared effective by the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>elite</U>&#148; refers to a plant that expresses well-documented and consistent observable characteristics (phenotypes). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>EPA</U>&#148; means the United States Environmental Protection Agency. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>EU</U>&#148; means the European Union. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Exchange Act</U>&#148; means the Securities Exchange Act of 1934, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Exchange Agreement</U>&#148; means the Exchange Agreement, to be dated as of the Closing Date, by and among Cibus, Inc., Cibus Global
and the Electing Members, pursuant to which the holders of <FONT STYLE="white-space:nowrap">Up-C</FONT> Units shall have the right to exchange (each, an &#147;<U>Exchange</U>&#148;) their <FONT STYLE="white-space:nowrap">Up-C</FONT> Units for shares
of Class&nbsp;A Common Stock on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis, or, subject to certain restrictions, the cash equivalent with respect to all or a portion thereof, based on a
volume-weighted average price of a share of Class&nbsp;A Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Exchange and Paying Agent</U>&#148; means Broadridge
Corporate Issuer Solutions, LLC, in its capacity as exchange and paying agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Exchange Ratio</U>&#148; means, without having
given effect to any Reverse Stock Splits, the exchange ratio of 3.17045722397476. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Excluded Units</U>&#148; means the Cibus Units
that will be exchanged for <FONT STYLE="white-space:nowrap">Up-C</FONT> Units by the Electing Members pursuant to a valid election. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>FDA</U>&#148; means the United States Food and Drug Administration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>FDCA</U>&#148; means the United States Federal Food, Drug, and Cosmetic Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Fifth Blocker Merger</U>&#148; means the merger between Blocker 5 and Calyxt, Inc., pursuant to which Blocker 5 will merge with and
into Calyxt, Inc. with Calyxt, Inc. being the surviving entity in such merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>First Amendment</U>&#148; means the First
Amendment to the Merger Agreement, dated as of April&nbsp;14, 2023, by and among Calyxt, Inc. and Cibus Global. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>First Blocker
Merger</U>&#148; means the merger between Blocker 1 and Calyxt, Inc., pursuant to which Blocker 1 will merge with and into Calyxt, Inc. with Calyxt, Inc. being the surviving entity in such merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>First Blocker Merger Effective Time</U>&#148; means the effective time of the First Blocker Merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Fourth Blocker Merger</U>&#148; means the merger between Blocker 4 and Calyxt, Inc., pursuant to which Blocker 4 will merge with and
into Calyxt, Inc. with Calyxt, Inc. being the surviving entity in such merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Fully-Exchanged Basis</U>&#148; means on a basis,
in each case, without taking into account the effect of the Reverse Stock Splits: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) giving effect to (a) the issuance at Closing of all
Merger Consideration, (b) the issuance at Closing of 1,260,461 shares of Class A Common Stock upon the accelerated vesting of 1,260,461 Calyxt RSUs that were </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
outstanding at the time the Merger Agreement was executed, (c) the issuance at Closing of 150,000 shares of Class A Common Stock upon the accelerated vesting of 150,000 outstanding Calyxt PSUs,
and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) without giving effect to (t) the issuance prior to Closing of up to an additional 3,487,503 Calyxt RSUs (of which 3,468,083 have
been issued as of the date of this proxy statement/prospectus), which are subject to accelerated vesting upon Closing, (u) the issuance of 7,760,000 shares of Calyxt Common Stock issuable upon the exercise of outstanding Calyxt Common Warrants with
an exercise price of $1.41 per share issued by Calyxt, Inc. in its February 2022 follow-on offering, (v) the issuance of any shares of Calyxt Common Stock underlying stock options issued by Calyxt pursuant to its Equity Plans, all of which were
out-of-the-money as of January 13, 2023, (w) the issuance of any shares of Calyxt Common Stock underlying 336,668 Calyxt PSUs subject to accelerated vesting, with the actual amount determined based on the applicable performance metrics pursuant to
its Equity Plans (other than those expressly covered by clause (1)(c) above), (x) the issuance of any Cibus Series F Preferred Units pursuant to the Continuing Series F Financing, (y) the issuance of any Calyxt securities in connection with any
Potential Calyxt Financing, and (z) the forfeiture of any Calyxt RSUs, Calyxt PSUs, or Calyxt Stock Options that may occur pursuant to Calyxt&#146;s Equity Plans, including 450,000 Calyxt PSUs that are expected to be forfeited in connection with the
departure of Calyxt&#146;s principal executive officer at Closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>GAAP</U>&#148; means United States generally accepted
accounting principles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>genome</U>&#148; refers to the genetic material of an organism. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>genomics</U>&#148; refers to the study of the structure, function, evolution, mapping and editing of genomes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>genotype</U>&#148; refers to the genetic constitution of an individual organism. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>germplasm</U>&#148; refers to living plant tissue from which new plants can be grown, which most commonly refers to seeds, but may
also include other parts of a plant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>GMO</U>&#148; means genetically modified organisms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>HC</U>&#148; means Health Canada. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>HSR Act</U>&#148; means the Hart-Scott-Rodino Antitrust Improvements Act of 1976. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>hybrid</U>&#148; refers to a plant that results from cross pollinating two different plant varieties and carries a combination of
traits from the respective parent plants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Initial Reverse Stock Split</U>&#148; means the reverse stock split of all of the
shares of Calyxt Common Stock outstanding at the time of effectiveness thereof by a ratio of 1-for-10, approved by Calyxt Stockholders at the 2022 Annual Meeting and expected to be effected, as determined in the discretion of the Calyxt Board and as
agreed to by Cibus, prior to the Subsequent Reverse Stock Split. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Interim Funding</U>&#148; means the additional funds that will
be made available to Calyxt, Inc. upon written request, under the terms and conditions set forth on Exhibit E to the Merger Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>IRS</U>&#148; means the U.S. Internal Revenue Service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Management Services Agreement</U>&#148; means that certain Management Services Agreement, dated January&nbsp;1, 2016, by and among
Cellectis, Cellectis, Inc., a Delaware corporation, and Calyxt, Inc., as amended by that certain First Amendment to the Management Services Agreement, dated July&nbsp;25, 2017, and that certain Second Amendment to Management Services Agreement,
dated January&nbsp;29, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Merger Agreement</U>&#148; means the Agreement and Plan of Merger, dated January&nbsp;13, 2023, by
and among Calyxt, Inc., Merger Subsidiary, Cibus Global and the Blockers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Merger Consideration</U>&#148; means the shares of Class&nbsp;A Common Stock and
Class&nbsp;B Common Stock, as applicable, calculated in accordance with the Merger Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Mergers</U>&#148; means,
collectively, the Cibus Merger and the Blocker Mergers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Merger Subsidiary</U>&#148; means Calypso Merger Subsidiary, LLC, a
Delaware limited liability company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>mutagen</U>&#148; refers to an agent that causes genetic change (mutation) in a cell. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>mutagenesis</U>&#148; is a method of plant breeding involving the induction of mutations in plants by exposing whole plants, seeds or
plant tissue to chemicals or radiation as a means of purposely damaging genetic material, thereby creating greater genetic variation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Ninth Blocker Merger</U>&#148; means the merger between Blocker 9 and Calyxt, Inc., pursuant to which Blocker 9 will merge with and
into Calyxt, Inc. with Calyxt, Inc. being the surviving entity in such merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>oligonucleotide-directed mutagenesis</U>&#148; or
&#147;<U>ODM</U>&#148; refers to a gene-editing technique in which chemically-synthesized nucleic acid sequences, referred to as oligonucleotides, act as a mutagen and DNA template in conferring a desired mutation without undergoing recombination.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Outside Date</U>&#148; means May 15, 2023, as may be extended pursuant to Section 8.1(b) of the Merger Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>parent seed</U>&#148; refers to seed that possesses desired traits and can be the male and female germplasm used for breeding
hybrids. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Participating Members</U>&#148; means the members of Cibus Global prior to the Closing, other than the Blockers and the
Electing Members. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Person</U>&#148; means any individual, partnership, firm, corporation, limited liability company, association,
trust, unincorporated organization or other entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Potential Calyxt Financing</U>&#148; means one or more potential private
placements and/or registered offerings by Calyxt, Inc., as agreed with Cibus Global, of Class A Common Stock, subject to compliance with the requirements of applicable Nasdaq shareholder approval rules and the issuance of which is subject to, and
conditioned upon, the Closing of the Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>PPA</U>&#148; means the Plant Protection Act, codified at 7 U.S.C. 7701 et
seq.<U></U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Registration Rights Agreement</U>&#148; means the Registration Rights Agreement, to be dated as of the Closing Date,
by and among Cibus, Inc. and the Electing Members. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Reverse Stock Splits</U>&#148; means, collectively, the Initial Reverse Stock
Split and the Subsequent Reverse Stock Split.<U></U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Royalty Liability</U>&#148; means the estimated total amount of future
royalty payments over the life of the Warrant Exchange Agreement that Cibus Global will be required to make to holders of certain Cibus Warrants that were exchanged for the rights to future royalty payments.<U></U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I><U>RTDS</U></I></B>&#148; means the gene-editing technology platform developed by Cibus, which it refers to as the Rapid Trait
Development System. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>R&amp;D</U>&#148; means research and development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>SEC</U>&#148; means the United States Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Second Blocker Merger</U>&#148; means the merger between Blocker 2 and Calyxt, Inc., pursuant to which Blocker 2 will merge with and
into Calyxt, Inc. with Calyxt, Inc. being the surviving entity in such merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Securities Act</U>&#148; means the Securities Act
of 1933, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Series F Purchase Commitment</U>&#148; means the commitment entered into in January 2023 by New Ventures
Agtech Solutions, LLC, an entity affiliated with Cibus Global&#146;s Chairman and Chief Executive Officer, Rory Riggs, to purchase $50,000,000 of Cibus Series F Preferred Units at a purchase price of $2.00 per Cibus Series F Preferred Unit and on
other terms substantially the same as sales of Cibus Series F Preferred Units by Cibus Global prior to the date of the Merger Agreement, except that, unless agreed otherwise, the Series F Purchase Commitment is conditioned upon, and the Cibus Series
F Preferred Units that are the subject of the Series F Purchase Commitment will be issued immediately prior to, the Closing of the Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Seventh Blocker Merger</U>&#148; means the merger between Blocker 7 and Calyxt, Inc., pursuant to which Blocker 7 will merge with and
into Calyxt, Inc. with Calyxt, Inc. being the surviving entity in such merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Shares</U>&#148; means the Class&nbsp;A Common
Stock and Class&nbsp;B Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Sixth Blocker Merger</U>&#148; means the merger between Blocker 6 and Calyxt, Inc.,
pursuant to which Blocker 6 will merge with and into Calyxt, Inc. with Calyxt, Inc. being the surviving entity in such merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Stockholders Agreement</U>&#148; means the Stockholders Agreement, dated as of July 25, 2017, by and among Calyxt, Inc., Cellectis
and the persons listed therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Subsequent Reverse Stock Split</U>&#148; means the proposed reverse stock split of all of the
shares of Calyxt Common Stock outstanding at the time of effectiveness thereof by a ratio in the range of not less than 1-for-2 and not greater than 1-for-10, with the implementation and timing of such Subsequent Reverse Stock Split, as determined
in the discretion of the Calyxt Board and as agreed to by Cibus, to be at or prior to the Closing of the Transactions, as described in Proposal No. 4 in the proxy statement/prospectus and to be considered and voted upon at the Calyxt Special
Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Subsequent Reverse Stock Split Factor</U>&#148; shall be equal to the number of shares of Calyxt Common Stock
converting onto one share of Calyxt Common Stock in connection with the Subsequent Reverse Stock Split. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>sulfonylurea
herbicides</U>&#148; means a specific broad-spectrum systemic herbicide employing sulfonylurea organic compounds inhibiting branched chain amino acid biosynthesis, eventually leading to the plant&#146;s death. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Tax Receivable Agreement</U>&#148; means the Tax Receivable Agreement, to be dated as of the Closing Date, by and among Cibus, Inc.,
Cibus Global, and the Electing Members. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Tenth Blocker Merger</U>&#148; means the merger between Blocker 10 and Calyxt, Inc.,
pursuant to which Blocker 10 will merge with and into Calyxt, Inc. with Calyxt, Inc. being the surviving entity in such merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Third Blocker Merger</U>&#148; means the merger between Blocker 3 and Calyxt, Inc., pursuant to which Blocker 3 will merge with and
into Calyxt, Inc. with Calyxt, Inc. being the surviving entity in such merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Top 99 Holders</U>&#148; means any holder of
Cibus Units (other than Blockers, but including any investor who has delivered an irrevocable commitment as of the date of the Merger Agreement to purchase Cibus Units prior to the Closing) that, prior to the Mailing Date (as defined in the Merger
Agreement), is among the 99 largest holders of Cibus Units, measured based on each member&#146;s Cibus Units (excluding Cibus PIUs, but including Cibus Warrants or options to purchase and instruments convertible into membership interests of Cibus
Global), on a fully diluted basis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>The Trait Machine</U>&#148; means Cibus&#146; <B><I>RTDS</I></B>, as applied in a
specific crop. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Transactions</U>&#148; means, collectively, the Mergers, the Contribution and the other transactions contemplated
by the Merger Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>transgenic</U>&#148; refers to an organism into which foreign genetic material has been incorporated.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>transgenic process</U>&#148; refers to a process in which foreign genetic material is integrated, temporarily or permanently,
into an organism&#146;s genetic code as a byproduct or end result of such process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>TRA Parties</U>&#148; means the Electing
Members from time to time party to the Tax Receivable Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Unitholder Representative</U>&#148; means Rory Riggs, or any
successor to such person pursuant to the Unitholder Representative Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Unitholder Representative Agreement</U>&#148;
means the Unitholder Representative Engagement Agreement, to be dated as of the Closing Date, by and among Unitholder Representative, Cibus Global and Cibus, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U><FONT STYLE="white-space:nowrap">Up-C</FONT> Unit</U>&#148; means one Cibus Common Unit and one share of Class&nbsp;B Common Stock,
collectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>USDA</U>&#148; means the United States Department of Agriculture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Warrant Exchange Agreement</U>&#148; means the Warrant Transfer and Exchange Agreement, dated December&nbsp;31, 2014, by and among
Cibus Global Ltd.; Richard Spizzirri, DTC CFBO Richard Spizzirri IRA, Rory Riggs, Rory Riggs Family Trust, Jean Pierre Lehmann, and New Venture Holdings, Inc. as sellers; and Rory Riggs, as the seller representative. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>WCC/RRC</U>&#148; means the Western Canada canola/rapeseed Recommending Committee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom401831_2"></A>REFERENCES TO ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This proxy statement/prospectus incorporates important business and financial information about Calyxt that is not included in or delivered
with this document. You may obtain this information without charge through the SEC website at www.sec.gov or upon your written or oral request by contacting the General Counsel of Calyxt, Inc., 2800 Mount Ridge Road, Roseville, MN 55113 or by
calling (651) <FONT STYLE="white-space:nowrap">683-2807.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>To ensure timely delivery of these documents, any request for
additional copies of materials should be made prior to the Calyxt Special Meeting. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For additional details about where you can find
information about Calyxt, see the section entitled &#147;<I>Where You Can Find More Information</I>&#148; of this proxy statement/prospectus. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ABOUT THIS PROXY STATEMENT/PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This proxy statement/prospectus, which forms part of a registration statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> filed with
the SEC by Calyxt, Inc. (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-269764),</FONT> constitutes a prospectus of Calyxt, Inc. under Section&nbsp;5 of the Securities Act, with respect to the Merger Consideration to be issued pursuant to the
Merger Agreement. This document also constitutes a notice of meeting and a proxy statement under Section&nbsp;14(a) of the Exchange Act, with respect to the Calyxt Special Meeting at which Calyxt Stockholders will be asked to consider and vote on
the proposals set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No one has been authorized to provide you with information that is different from that contained in, or
incorporated by reference into, this proxy statement/prospectus. This proxy statement/prospectus is dated April&nbsp;18, 2023. The information contained in this proxy statement/prospectus is accurate only as of that date or, in the case of
information in a document incorporated by reference, as of the date of such document, unless the information specifically indicates that another date applies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>This proxy statement/prospectus does not constitute an offer to sell, or a solicitation of an offer to buy, any securities, or the
solicitation of a proxy, in any jurisdiction in which or from any person to whom it is unlawful to make any such offer or solicitation in such jurisdiction. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information concerning Calyxt contained in this proxy statement/prospectus or incorporated by reference has been provided by Calyxt, Inc.,
and the information concerning Cibus contained in this proxy statement/prospectus has been provided by Cibus Global. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise
noted, references to &#147;we,&#148; &#147;us&#148; or &#147;our&#148; refer to both Calyxt and Cibus. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TRADEMARK NOTICE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt owns the names PlantSpring<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>, Plant Cell Matrix<SUP
STYLE="font-size:75%; vertical-align:top">TM</SUP>, PCM<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> and BioFactory<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>. Calyxt also owns the trademarks Calyxt&reg; and Calyno&reg; and
owns or licenses other trademarks, trade names, and service marks appearing in this this prospectus. The names and trademarks Cellectis&reg; and TALEN&reg;, along with any other trademarks, trade names, and service marks of Cellectis appearing in
this this prospectus are the property of Cellectis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Cibus<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>,&#148;
&#147;<B><I>RTDS</I></B><SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>,&#148; &#147;Rapid Trait Development System<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>,&#148;
&#147;FALCO<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>,&#148; &#147;SU Canola<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>,&#148; &#147;Nucelis<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>,&#148; &#147;ASAP<SUP
STYLE="font-size:75%; vertical-align:top">TM</SUP>,&#148;&nbsp;&#147;A Different Breed<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>,&#148; &#147;Trait Machine<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>,&#148; &#147;Inspired by
Nature<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>,&#148; &#147;Driving Sustainable Agriculture<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>,&#148;&nbsp;&#147;Reshaping Crop Protection<SUP
STYLE="font-size:75%; vertical-align:top">TM</SUP>,&#148; &#147;Reinventing Trait Development<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>,&#148; &#147;Timebound&nbsp;&amp;
Predictable<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>,&#148; &#147;Driving Trait&nbsp;&amp; Breeding Innovation<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>,&#148; &#147;Future of Breeding<SUP
STYLE="font-size:75%; vertical-align:top">TM</SUP>,&#148; the Cibus logo and other trademarks or service marks of Cibus appearing in this prospectus are the property of Cibus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This proxy statement/prospectus may also contain additional trade names, trademarks and
service marks belonging to other companies. Other trademarks, service marks and trade names referred to in this proxy statement/prospectus are the property of their respective owners. Solely for convenience, trademarks and trade names in this
prospectus may be referred to without the <SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> and <SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> symbols, but such references, or their failure to appear, should not be construed as
any indicator that their respective owners will not assert their rights with respect thereto. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MARKET AND INDUSTRY DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This proxy statement/prospectus includes industry and market data that Cibus and Calyxt have obtained from industry publications, third-party
studies and surveys, filings of public companies in their respective industries and related industry and internal company surveys. These sources include government and industry sources, which generally state that the information contained therein
has been obtained from sources believed to be reliable. Although we believe the industry and market data to be reliable as of the date of this proxy statement/prospectus, this information could prove to be inaccurate. Industry and market data could
be wrong because of the method by which sources obtained their data and because information cannot always be verified with complete certainty due to the limits on the availability and reliability of raw data, the voluntary nature of the data
gathering process and other limitations and uncertainties. We do not know all of the assumptions regarding general economic conditions or growth that were used in preparing the forecasts from the sources relied upon or cited herein. Assumptions and
estimates of future performance are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described in &#147;<I>Risk Factors</I>.&#148; These and other factors could cause future performance to
differ materially from our assumptions and estimates. See &#147;<I>Cautionary Statement Concerning Forward-Looking Statements</I>.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom401831_3"></A>QUESTIONS AND ANSWERS ABOUT THE TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Except where specifically noted, the following information and all other information contained in this proxy statement/prospectus does not
give effect to the Reverse Stock Splits described elsewhere in this proxy statement/prospectus</I> <I>and does not give effect to the issuance of any equity in the Continuing Series F Financing or the Potential Calyxt Financing.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following section provides answers to frequently asked questions about the Transactions. This section, however, provides only summary
information. For a more complete response to each of these questions and for additional information, refer to the <FONT STYLE="white-space:nowrap">cross-referenced</FONT> sections in this proxy statement/prospectus. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>What are the Mergers and Transactions? </I></B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On January&nbsp;13, 2023, Calyxt, Inc. and Merger Subsidiary entered into the Merger Agreement with Cibus
Global and the Blockers. The Merger Agreement provides that, among other things and upon the terms and subject to the conditions set forth therein (including receipt of Calyxt Stockholder Approval and the Cibus Member Approval and the Blocker
Approvals), at the Closing: (a)&nbsp;each of the Blockers will merge with and into Calyxt, Inc., in each case with the Blockers ceasing to exist and Calyxt, Inc. surviving each such Blocker Merger, (b)&nbsp;at the First Blocker Merger Effective
Time, the Calyxt Bylaws will be amended and restated in the form attached hereto as <I>Annex C</I> and the Calyxt Certificate of Incorporation will be amended and restated in the form attached hereto as <I>Annex B</I>, and (c)&nbsp;following the
Blocker Mergers, Merger Subsidiary will merge with and into Cibus Global, with Cibus Global as the surviving company and Merger Subsidiary ceasing to exist. As consideration for the Mergers, the equityholders of the Blockers and the Cibus
Unitholders will receive the Merger Consideration. In connection with the Mergers, Cibus, Inc. will contribute all of its assets and liabilities to Cibus Global, as a contribution to the capital of Cibus Global, in exchange for Cibus Common Units,
pursuant to the Contribution Agreement. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Amended Certificate of Incorporation, once adopted at the First Blocker
Merger Effective Time, will designate two classes of Cibus, Inc. common stock: (i)&nbsp;Class&nbsp;A Common Stock, which shares will have full voting and economic rights, and (ii)&nbsp;Class&nbsp;B Common Stock, which shares will have full voting,
but no economic rights. Upon adoption of the Amended Certificate of Incorporation, each share of Calyxt Common Stock existing and outstanding immediately prior to the First Blocker Merger Effective Time shall remain outstanding as a share of Class A
Common Stock without any conversion or exchange thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">At the applicable Blocker Merger Effective Time, the limited liability company
interests of the Blocker being merged will be cancelled and converted into the right of the equityholder of the applicable Blocker to receive shares of Class&nbsp;A Common Stock corresponding to that Blocker Merger, in each case, as set forth in the
Allocation Schedule, and as described in more detail in the section titled &#147;<I>The Merger Agreement&#151;Merger Consideration</I>&#148;<I> </I>beginning on page 162 of this proxy statement/prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">At the Cibus Merger Effective Time, all of the issued and outstanding Cibus Units, and all outstanding Cibus Warrants or options to purchase
Cibus Units, will be cancelled and converted into the right to receive Class&nbsp;A Common Stock or <FONT STYLE="white-space:nowrap">Up-C</FONT> Units, in each case as set forth in the Allocation Schedule, and as described in further detail in the
section titled &#147;<I>The Merger Agreement&#151;Merger Consideration</I>&#148;<I> </I>beginning on page 162 of this proxy statement/prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Immediately following the Cibus Merger, (i)&nbsp;each <FONT STYLE="white-space:nowrap">pre-Closing</FONT> Cibus Unit and <FONT
STYLE="white-space:nowrap">pre-Closing</FONT> Cibus Warrant, in each case, held by Cibus, Inc. as a result of the Blocker Mergers will be converted or exchanged for a number of Cibus Common Units set forth in the Allocation Schedule, (ii)&nbsp;each <FONT
STYLE="white-space:nowrap">pre-Closing</FONT> Cibus Warrant held by Cibus, Inc. as a result of the warrant exchanges described in the description of the Merger Consideration will be converted or exchanged for a number of Cibus Common Units set forth
in the Allocation Schedule, and (iii)&nbsp;Cibus Global will issue a number of Cibus Common Units to Cibus, Inc. in an amount equal to the number of shares of Class&nbsp;A Common Stock issued to Cibus Unitholders as Cibus Merger Consideration. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Following the Closing, the issuance of Merger Consideration and the issuance of Cibus Common
Units discussed above, the Combined Company will be organized in an <FONT STYLE="white-space:nowrap">&#147;Up-C&#148;</FONT> structure, with Cibus, Inc.&#146;s only material asset consisting of Cibus Common Units. Upon the Closing, Calyxt
Stockholders are expected to own approximately 5.0% of issued and outstanding Shares, on a Fully-Exchanged Basis, and Cibus Unitholders are expected to own approximately 95.0% of the issued and outstanding Shares, on a
<FONT STYLE="white-space:nowrap">Fully-Exchanged</FONT> Basis, in each case, subject to dilution in connection with any Dilutive Issuances. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Immediately following the Closing, all of the issued and outstanding Cibus Common Units will be held by Cibus, Inc. and the Electing Members
(through their ownership of <FONT STYLE="white-space:nowrap">Up-C</FONT> Units), with the exact ownership interest held by Cibus, Inc. and the Electing Members subject to the elections to be submitted by Top 99 Holders prior to the Closing. In
connection with the Up-C structure, at Closing, (i) Cibus, Inc. and the Electing Members will become party to the Cibus Amended Operating Agreement, (ii) Cibus, Inc., Cibus Global and the Electing Members will enter into an Exchange Agreement, and
(iii) Cibus, Inc. and the Electing Members will enter into a Registration Rights Agreement and a Tax Receivable Agreement. The <FONT STYLE="white-space:nowrap">Up-C</FONT> Units will generally be exchangeable for shares of Class&nbsp;A Common Stock
on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis, or, subject to certain restrictions, the cash equivalent with respect to all or a portion thereof, based on a volume-weighted average price of a
share of Class&nbsp;A Common Stock pursuant to the terms of the Exchange Agreement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>Why are the two companies proposing to merge? </I></B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Calyxt and Cibus believe that the merger will provide Cibus, Inc. with substantial capital resources,
positioning it to become a leader in the plant trait industry, deploying its gene editing technologies to develop and license gene edited plant traits that improve farming productivity or produce renewable
<FONT STYLE="white-space:nowrap">low-carbon</FONT> plant products. For a discussion of Calyxt&#146;s and Cibus&#146; reasons for the merger, see the sections entitled &#147;<I>The Mergers&#151;Calyxt Reasons for the Mergers</I>&#148; and
&#147;<I>The Mergers&#151;Cibus Reasons for the Mergers</I>&#148; beginning on pages 134 and 140, respectively, of this proxy statement/prospectus. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>Why am I receiving this proxy statement/prospectus? </I></B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">You are receiving this proxy statement/prospectus because you have been identified either (i) as a Calyxt
Stockholder as of the record date and you are entitled to vote at the Calyxt Special Meeting to approve the matters set forth herein or (ii) as a member of Cibus Global or an equityholder or Blocker and you are entitled to receive Class A Common
Stock as Merger Consideration. This document serves as: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a proxy statement of Calyxt, Inc. used to solicit proxies for the Calyxt Special Meeting to vote on the Calyxt
Stockholder Matters set forth herein; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a prospectus of Calyxt, Inc. used to offer shares of Class&nbsp;A Common Stock in exchange for Cibus Units, Cibus
Warrants and Cibus PIUs in the Mergers. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>What will Calyxt Stockholders, option holders and warrant holders receive in the Mergers?
</I></B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Upon adoption of the Amended Certificate of Incorporation at the First Blocker Merger Effective Time, each
share of Calyxt Common Stock existing and outstanding immediately prior thereto shall remain outstanding as a share of Class A Common Stock without any conversion or exchange thereof. Additionally, upon adoption of the Amended Certificate of
Incorporation at the First Blocker Merger Effective Time, each issued and outstanding warrant and stock option to purchase shares of Calyxt Common Stock will remain exercisable for the same number of shares of Class A Common Stock on the same terms
as those set forth in the underlying stock option award or warrant. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>What will Cibus Unitholders receive in the Mergers? </I></B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">At the applicable Blocker Merger Effective Time, the limited liability company interests of the applicable
Blocker will be cancelled and converted into the right of the equityholder of the applicable Blocker to receive shares of Class&nbsp;A Common Stock corresponding to that Blocker Merger, in each case, as set forth in the Allocation Schedule.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">At the Cibus Merger Effective Time, all of the issued and outstanding Cibus Units, all outstanding Cibus PIUs, and all
outstanding Cibus Warrants or options to purchase Cibus Units, will be cancelled (or, in the case of Cibus Warrants, surrendered to Cibus, Inc. for exchange) and converted into the right to receive the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Top 99 Holders shall have the option to elect, on a per unit basis, to receive Merger Consideration in the
form of either (a)&nbsp;the number of shares of Class&nbsp;A Common Stock set forth on the Allocation Schedule in exchange for all such holder&#146;s Cibus Units (excluding any Cibus PIUs) covered by such election or (b)&nbsp;the number of <FONT
STYLE="white-space:nowrap">Up-C</FONT> Units set forth on the Allocation Schedule, provided, that such holder will not be entitled to exchange more than 95% of such holder&#146;s existing Cibus Units for <FONT STYLE="white-space:nowrap">Up-C</FONT>
Units and the remainder of such Cibus Unitholder&#146;s Cibus Units will be exchanged for shares of Class&nbsp;A Common Stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all Cibus Unitholders (excluding Blockers) other than Top 99 Holders shall receive the number of shares of
Class&nbsp;A Common Stock set forth on the Allocation Schedule in exchange for their Cibus Units (other than Cibus PIUs); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all <FONT STYLE="white-space:nowrap">pre-Closing</FONT> Cibus Warrants shall automatically be exchanged for the
right to receive the number of shares of Class&nbsp;A Common Stock set forth on the Allocation Schedule; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all <FONT STYLE="white-space:nowrap">pre-Closing</FONT> Cibus PIUs will, (a)&nbsp;to the extent not a
&#147;restricted unit&#148; (under the award agreements and governing documents applicable to such Cibus PIU), be automatically cancelled and converted into the right to receive the number of shares of Class&nbsp;A Common Stock set forth on the
Allocation Schedule and (b)&nbsp;to the extent a &#147;restricted unit&#148; (i.e., an unvested unit), be automatically cancelled and converted into the right to receive the number of restricted shares of Class&nbsp;A Common Stock pursuant to a
Cibus, Inc. stock plan, as set forth on the Allocation Schedule and subject to the same vesting schedule as was applicable to such Cibus PIU prior to Closing. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">For a more complete description of what Cibus Unitholders will receive in the Mergers, see the section entitled &#147;<I>The Merger
Agreement&#151;Merger Consideration</I>&#148; beginning on page 162 of this proxy statement/prospectus. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>What are the Blockers? </I></B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Each Blocker is a special purpose entity owned by an entity advised or sub-advised by Fidelity
Management &amp; Research Company or BV Partners, LLC (each, a &#147;Blocker Owner&#148; and collectively, the &#147;Blocker Owners&#148;) that was newly formed in connection with the Blocker Owners&#146; ownership of Cibus Global&#146;s membership
units. The sole assets of each of the Blockers are units of Cibus Global owned by the respective Blocker Owner. Mark Finn, a director of Cibus Global and a future director of Cibus, Inc., serves as one of two managing members of BV Partners, LLC.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>What is an &#147;Up-C&#148; Structure? </I></B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Following the Closing, the Combined Company will be organized in a structure that that is commonly referred to
as an &#147;Up-C&#148; structure, which is often used by public companies involving partnerships and limited liability companies. The Up-C structure provides certain tax benefits and associated cash flow advantages to both the issuer corporation and
existing owners of the partnership or limited liability </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
company. The Up-C structure allows certain current Cibus Unitholders&#151;the Electing Members&#151;to retain their Cibus Unit ownership in Cibus Global, an entity that is classified as a
partnership for U.S. federal income tax purposes, in the form of Up-C Units. All other Cibus Unitholders will hold their equity ownership in Cibus, Inc. in the form of shares of Class A Common Stock. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Up-C structure allows future taxable income of Cibus Global that is allocated to the Electing Members to be generally taxed on a
pass-through basis, and therefore, such income will generally not be subject to corporate taxes at the entity level. Additionally, the holders of Up-C Units may exchange their Up-C Units for shares of Class A Common Stock, providing such holders
with potential liquidity that is not typically afforded to holders of equity interest in non-publicly traded limited liability companies. Such exchanges are expected to produce favorable tax attributes that Cibus, Inc. may be able to utilize and
that would not be available to Cibus, Inc. in the absence of those transactions. Pursuant to the Tax Receivable Agreement, the holders of Up-C Units that exchange such Up-C Units for shares of Class A Common Stock will generally be entitled to
receive a portion of the net income tax savings that Cibus, Inc. actually realizes. See &#147;<I>What is the Tax Receivable Agreement?</I>&#148; </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>What is the Tax Receivable Agreement? </I></B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Upon the completion of the Transactions, Cibus, Inc. will enter into the Tax Receivable Agreement,
pursuant to which Cibus, Inc. generally will be required to pay to the TRA Parties, in the aggregate, 85% of the net income tax savings that Cibus, Inc. actually realizes (or in certain circumstances, is deemed to realize) as a result of
(i)&nbsp;certain favorable tax attributes Cibus, Inc. will acquire from the Blockers in the Blocker Mergers (including net operating losses), (ii) increases to Cibus, Inc.&#146;s allocable share of the tax basis of Cibus Global&#146;s assets
resulting from future redemptions or exchanges of Cibus Common Units for shares of Class&nbsp;A Common Stock or cash, (iii)&nbsp;tax attributes resulting from certain payments made under the Tax Receivable Agreement and (iv)&nbsp;deductions in
respect of interest under the Tax Receivable Agreement. The payment obligations under the Tax Receivable Agreement are Cibus, Inc.&#146;s obligations and not obligations of Cibus Global. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">For a more complete description of the Tax Receivable Agreement, see the section entitled &#147;<I>Agreements Related to the Mergers&#151;Tax
Receivable Agreement</I>&#148; beginning on page 192 of this proxy statement/prospectus. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>What are the Reverse Stock Splits and why are they proposed?</I></B><B> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>A:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I></I></B>On May 17, 2022, Calyxt, Inc. received a written notice from the Listing Qualifications
Department of The Nasdaq Stock Market LLC that it was not in compliance with the requirement to maintain a minimum closing bid price of $1.00 per share (the &#147;<U>Bid Price Rule</U>&#148;) because the closing bid price of Calyxt Common Stock was
below $1.00 per share for 30 consecutive business days. Following the granting of an extension, Calyxt, Inc. now has until May 15, 2023 to comply with the Bid Price Rule. If at any time prior to May 15, 2023, the bid price of Calyxt Common Stock
closes at $1.00 per share or more for a minimum of 10 consecutive business days, Calyxt, Inc. will regain compliance with the Bid Price Rule. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">At the 2022 Annual Meeting, Calyxt Stockholders approved an amendment to the Calyxt Certificate of Incorporation to effect a reverse stock
split of Calyxt Common Stock at a ratio not less than 1-for-2 and not greater than 1-for-10, with the exact ratio set within that range at the discretion of the Calyxt Board. Calyxt, Inc. expects to effect the Initial Reverse Stock Split to regain
compliance with the Bid Price Rule prior to the Subsequent Reverse Stock Split and the Closing. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In addition, in connection with the
Transactions and subject to the approval of Proposal No. 4 by the Calyxt Stockholders at the Calyxt Special Meeting, at or prior to the Closing of the Transactions, and subsequent to the Initial Reverse Stock Split, Calyxt, Inc. may implement the
Subsequent Reverse Stock Split. If Proposal No.&nbsp;4 is approved, the implementation and timing of the Subsequent Reverse Stock Split will be determined in the discretion of the Calyxt Board and as agreed to by Cibus. Among other things, the
Subsequent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Reverse Stock Split may provide greater certainty regarding Cibus, Inc.&#146;s ability to maintain compliance with the Bid Price Rule and may make the Class A Common Stock more attractive to a
broader range of institutional and other professional investors. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>What will happen to Calyxt if, for any reason, the Mergers do not close? </I></B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If, for any reason, the Mergers do not close, the Calyxt Board may elect to, among other things, review and
evaluate another strategic transaction like the Transactions, attempt to sell or otherwise dispose of the various assets of Calyxt, resume its research and development activities and continue to operate the business of Calyxt or dissolve and
liquidate its assets. If Calyxt decides to dissolve and liquidate its assets, Calyxt would be required to pay all of its debts and contractual obligations, and to set aside certain reserves for potential future claims. There can be no assurances as
to the amount or timing of available cash left, if any, to distribute to Calyxt Stockholders after paying the debts and other obligations of Calyxt and setting aside funds for reserves. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>Will Calyxt, Inc. be receiving additional funding prior to the Closing? </I></B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Yes, Calyxt, Inc. will have access to the Interim Funding in connection with the Transactions. Beginning
at the earlier of March&nbsp;15, 2023 and the date Calyxt, Inc.&#146;s unrestricted cash balance first drops below $1,500,000, Calyxt can request, and Cibus Global has agreed to provide, an unsecured, interest-free revolving line of credit of up to
$3,000,000 in cash, which amount may be increased to $4,000,000 if Cibus Global elects to extend the Outside Date for the Closing from May&nbsp;15, 2023 to June&nbsp;30, 2023. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">On March 15, 2023, Calyxt, Inc. made an initial draw of $500,000 under the Interim Funding and made an additional draw on March 30, 2023.
Calyxt, Inc. anticipates continuing to draw on the Interim Funding in accordance with its terms through Closing. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Funds can be drawn by
Calyxt, Inc. in $500,000 increments and may only be used to fund operating expenses incurred in the ordinary course of business consistent with past practice and consistent with the negative covenants in the Merger Agreement. The full outstanding
balance of the Interim Funding will be reduced to zero in connection with the Closing if the Mergers are consummated. The full outstanding balance of the Interim Funding will be forgiven by Cibus Global if the Merger Agreement is terminated for any
reason other than (a)&nbsp;a termination by Cibus resulting from the fraud or willful breach of the Merger Agreement by Calyxt, Inc. (in which case Calyxt, Inc. will no longer be permitted to make draws on the line of credit the outstanding balance
will become due and payable on the date that is two years from the date funds are first drawn), (b) a termination by Calyxt, Inc. if it accepts a superior offer (in which case Calyxt, Inc. will no longer be permitted to make draws on the line of
credit and the outstanding balance will be due and payable within 30 days after termination) or (c)&nbsp;termination by Cibus Global in the event Calyxt, Inc. shall have an adverse change in condition or Calyxt, Inc. materially breaches its
obligations with respect to soliciting an alternative acquisition (in which case Calyxt, Inc. will no longer be permitted to make draws on the line of credit and the outstanding balance will be due and payable within 30 days after termination). The
Interim Funding is subject to acceleration in connection with certain bankruptcy events. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>What is the Continuing Series F Financing and what is its potential impact?</I></B><B>
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Prior to the date of the Merger Agreement, Cibus Global issued Cibus Series F Preferred Units in a private
placement transaction for a per unit cash purchase price of $2.00 per Cibus Series F Preferred Unit. Pursuant to the Merger Agreement, Cibus is permitted to issue additional Cibus Series F Preferred Units following the date of the Merger Agreement
and prior to the Closing at a cash purchase price of $2.00 per Cibus Series F Preferred Unit and on other terms substantially the same as sales of Cibus Series F Preferred Units by Cibus Global prior to the date of the Merger Agreement. The
Continuing Series F Financing includes a commitment, which was entered into in January 2023 by New Ventures Agtech Solutions, LLC, an entity affiliated with Cibus Global&#146;s Chairman and Chief Executive Officer, Rory Riggs, to purchase
$50,000,000 of Cibus Series F Preferred Units at a purchase price of $2.00 per Cibus Series F Preferred Unit and on other </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
terms substantially the same as sales of Cibus Series F Preferred Units by Cibus Global prior to the date of the Merger Agreement, except that the Series F Purchase Commitment is conditioned
upon, and the Cibus Series F Preferred Units that are the subject of the Series F Purchase Commitment will be issued immediately prior to, the Closing of the Transactions. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Cibus Series F Preferred Units issued pursuant to the Continuing Series F Financing, including those to be issued pursuant to the Series F
Purchase Commitment, will convert into Shares of Cibus, Inc. based on the Exchange Ratio. Any Cibus Series F Preferred Units issued pursuant to the Continuing Series F Financing, including those to be issued pursuant to the Series F Purchase
Commitment, will have the effect of diluting the anticipated post-Closing ownership percentage of Cibus, Inc. for both Calyxt Stockholders and Cibus Unitholders (other than those purchasing additional Cibus Series F Preferred Units in the Continuing
Series F Financing, to the extent of such purchases). </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>What is the Potential Calyxt Financing and what is its potential impact?</I></B><B>
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Prior to Closing, Calyxt, Inc. may, as agreed with Cibus Global, pursue one or more potential private
placements and/or registered offerings of Class A Common Stock, subject to compliance with the requirements of applicable Nasdaq shareholder approval rules and the issuance of which is subject to, and conditioned upon, the Closing of the
Transactions. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Because such shares of Class A Common Stock would be issued subject to, and conditioned upon, the Closing
of the Transactions, any Class A Common Stock issued pursuant to the Potential Calyxt Financing will have the effect of diluting the anticipated post-Closing ownership percentage of Cibus, Inc. for both Calyxt Stockholders and Cibus Unitholders
(other than Calyxt Stockholders and/or Cibus Unitholders purchasing Class A Common Stock in such Potential Calyxt Financing, to the extent of such purchases). </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>Do Calyxt Stockholders have appraisal rights? </I></B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No. Calyxt Stockholders as of the record date for the Special Meeting that do not vote in favor of the Mergers
or the Transactions are not entitled to appraisal rights under the DGCL in connection with the Mergers or the Transactions. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>Following the Mergers, will Cibus, Inc.&#146;s securities be traded on a stock exchange?
</I></B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Yes, as a condition to the Closing, Calyxt, Inc. must use its reasonable best efforts to, to the extent
required by Nasdaq Listing Rule 5110, file an initial listing application for the Class&nbsp;A Common Stock on the Nasdaq Capital Market, or Nasdaq, and to cause such Nasdaq initial listing application to be approved. The Class B Common Stock will
not be traded on a stock exchange. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>What is required to consummate the Mergers? </I></B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pursuant to the terms of the Merger Agreement, in order for the Mergers to close, the following proposals must
be approved by the requisite vote of Calyxt Stockholders at the Calyxt Special Meeting: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Proposal No.</B><B></B><B>&nbsp;1:</B> to consider and vote upon a proposal to approve the Blocker Mergers and
the issuance of Class&nbsp;A Common Stock and Class&nbsp;B Common Stock as Merger Consideration pursuant to the Merger Agreement, as amended by the First Amendment, copies of which are attached as <I>Annex A-1 </I>and <I>Annex A-2</I>, respectively,
to this proxy statement/prospectus; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Proposal No.</B><B></B><B>&nbsp;2: </B>to consider and vote upon a proposal to approve, for purposes of Nasdaq
Listing Rule&nbsp;5635(a) and (b), the issuance of shares of Class&nbsp;A Common Stock and Class&nbsp;B Common Stock pursuant to the terms of the Merger Agreement and the change of control of Calyxt, Inc. resulting from the Mergers.
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Cibus Global members must adopt the Merger Agreement, thereby approving the Mergers and the related transactions. The
adoption of the Merger Agreement and the approval of the Mergers and related </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
transactions by the Cibus Global members requires (i)&nbsp;approval by a majority of each of the issued and outstanding Cibus Series D Preferred Units, Cibus Series E Preferred Units and Cibus
Series F Preferred Units to convert all issued and outstanding Cibus Preferred Units into Cibus Global voting common units on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis and (ii)&nbsp;approval
by a majority of all issued and outstanding Cibus Preferred Units to approve the Transactions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In addition to the requirement of obtaining
the Calyxt Stockholder and Cibus Global member approvals described above, each of the other closing conditions set forth in the Merger Agreement must be satisfied or waived. For a more complete description of the closing conditions under the Merger
Agreement, see the section entitled &#147;<I>The Merger Agreement&#151;Conditions to the Completion of the Mergers</I>&#148; beginning on page&nbsp;173 of this proxy statement/prospectus. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>What stockholder votes are required to approve the proposals at the Calyxt Special Meeting?
</I></B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Approval of Proposal Nos. 2 and 5 requires the affirmative vote of a majority of the votes cast at the Calyxt
Special Meeting and entitled to vote on the subject matter. Approval of Proposal Nos. 6 (on an advisory basis) and 7 requires the affirmative vote of a majority of the votes cast affirmatively or negatively by holders present or represented by proxy
at the Calyxt Special Meeting and entitled to vote on the subject matter. Approval of Proposals No.&nbsp;1, 3 (on an advisory basis) and 4 requires the affirmative vote of the holders of a majority of Calyxt Common Stock on the record date for the
Calyxt Special Meeting entitled to vote on the matters. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Votes will be counted by the inspector of election appointed for
the Calyxt Special Meeting, who will separately count &#147;FOR&#148; and &#147;AGAINST&#148; votes, abstentions and broker <FONT STYLE="white-space:nowrap">non-votes.</FONT> Abstentions and broker <FONT STYLE="white-space:nowrap">non-votes</FONT>
will have the same effect as a vote &#147;AGAINST&#148; Proposals No. 1 and 3, but will have no effect on the outcome of Proposal Nos. 2, 5 and 6. Abstentions will have the same effect as a vote &#147;AGAINST&#148; Proposal No. 4. Abstentions will
have no effect on the outcome of Proposal No.&nbsp;7. Proposal Nos. 4 and 7 are matters on which Calyxt expects brokers, banks or other nominees to have discretionary authority to vote uninstructed shares and, therefore, broker <FONT
STYLE="white-space:nowrap">non-votes</FONT> are not expected with respect to these proposals. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Proposal No.&nbsp;1 is conditioned upon the
approval of Proposal No.&nbsp;2, and the Mergers cannot be consummated without the approval of Proposal Nos. 1 and 2. Proposal Nos. 3 and 6, which are non-binding and advisory in nature, are conditioned upon the approval of Proposal Nos. 1 and 2.
Proposal Nos. 4, 5 and 7 are not conditioned on the approval of any other proposal. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>Who will be the directors of Cibus, Inc. following the Mergers? </I></B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Immediately following the First Blocker Merger Effective Time, the Cibus, Inc. Board will be expected to be
composed of six directors. The Merger Agreement requires that all current members of the Calyxt Board resign as of the First Blocker Merger Effective Time. Pursuant to the Merger Agreement, at the First Blocker Merger Effective Time, Rory Riggs,
Peter Beetham, Ph.D., Mark Finn, Jean-Pierre Lehmann, Gerhard Prante, Ph.D. and Keith Walker, Ph.D. will be appointed to the Cibus, Inc. Board, with Rory Riggs serving as chair of the Cibus, Inc. Board. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>Who will be the executive officers of Cibus, Inc. following the Mergers? </I></B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Immediately following the First Blocker Merger Effective Time, Cibus, Inc.&#146;s executive management team is
expected to consist of the current members of Cibus Global&#146;s executive management team prior to the Mergers, including: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Title</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rory Riggs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Executive Officer and Chair</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Beetham, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>President and Chief Operating Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Greg Gocal, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Scientific Officer and Executive Vice President</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wade King, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Financial Officer</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>Do any of Calyxt, Inc.&#146;s directors and officers have interests in the Transactions that may differ
from or be in addition to the interests of Calyxt Stockholders? </I></B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Yes. In considering the recommendation of the Calyxt Board with respect to approving the Mergers, Calyxt
Stockholders should be aware that certain members of the Calyxt Board and certain Calyxt, Inc. executive officers have interests in the Mergers that may be different from, or in addition to, the interests of Calyxt Stockholders. The Calyxt Board and
the Cibus Board were aware of these potential conflicts of interest and considered them, among other matters, in reaching their respective decisions to approve the Merger Agreement and the Mergers. The Calyxt Board considered these in reaching its
decision to recommend that Calyxt Stockholders approve the proposals to be presented to Calyxt Stockholders for consideration at the Calyxt Special Meeting as contemplated by this proxy statement/prospectus. For more information, see the section of
this proxy statement/prospectus entitled &#147;<I>The Mergers&#151;Interests of Calyxt, Inc. Directors and Executive Officers in the Mergers</I>.&#148; </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>What are the material U.S. federal income tax consequences of the Mergers to Calyxt Stockholders?
</I></B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Calyxt Stockholders will not sell, exchange or dispose of any shares of Calyxt Common Stock as a result of the
Mergers. Thus, there will be no material U.S. federal income tax consequences to Calyxt Stockholders as a result of the Mergers. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>What are the material U.S. federal income tax consequences of the Cibus Merger to Cibus Participants?
</I></B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As discussed more fully under the section entitled &#147;<I>The Mergers&#151;Material U.S. Federal Income Tax
Consequences of the Cibus Merger</I>,&#148; the parties intend that the Cibus Merger qualify as a transaction described in Section&nbsp;351 of the Code (as defined herein). Assuming that the Cibus Merger so qualifies, Cibus Participants (as defined
in the section entitled &#147;<I>The Mergers&#151;Material U.S. Federal Income Tax Consequences of the Cibus Merger</I>&#148;) that receive solely shares of Class&nbsp;A Common Stock in the Transactions will generally not recognize gain or loss upon
the exchange of their Cibus Units or Cibus Warrants for shares of Class&nbsp;A Common Stock pursuant to the Cibus Merger, except to the extent that the Cibus Participant&#146;s allocable share of Cibus&#146; liabilities exceeds the Cibus
Participant&#146;s tax basis in its Cibus Units or Cibus Warrants exchanged for Class&nbsp;A Common Stock. There can be no assurance, however, that the IRS will not successfully assert an alternative characterization of the Transactions, including
the Cibus Merger. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The U.S. federal income tax consequences of the Cibus Merger depend on each Cibus Unitholder&#146;s
particular facts and circumstances. Accordingly, all Cibus Unitholders are urged to consult their tax advisors regarding the tax consequences to them of the Transactions, including the applicability and effect of U.S. federal, state, local and <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> tax laws. For a more complete discussion of the U.S. federal income tax considerations of the Transactions, see the section entitled &#147;<I>The Mergers&#151;Material U.S. Federal Income Tax Consequences
of the Cibus Merger</I>.&#148; </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>As a Calyxt Stockholder, how does the Calyxt Board recommend that I vote? </I></B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">After careful consideration, the Calyxt Board unanimously recommends that Calyxt Stockholders vote
&#147;FOR&#148; all of the proposals described in this proxy statement/prospectus. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>What risks should I consider in deciding whether to vote in favor of the Mergers?
</I></B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">You should carefully review the section entitled &#147;<I>Risk Factors</I>&#148; beginning on page&nbsp;40 of
this proxy statement/prospectus which sets forth certain risks and uncertainties related to the Transactions, risks and uncertainties to which the Combined Company&#146;s business will be subject, and risks and uncertainties to which each of Calyxt
and Cibus, as independent companies, are subject. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>Who can vote at the Calyxt Special Meeting? </I></B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Only holders of record of Calyxt Common Stock at the close of business on the record date for the Calyxt
Special Meeting, April 12, 2023, will be entitled to notice of, and to vote at, the Calyxt Special Meeting. There were 90 holders of record of Calyxt Common Stock at the close of business on such record date. At the close of business on such record
date, 49,735,490 shares of Calyxt Common Stock were issued and outstanding. Each share of Calyxt Common Stock entitles the holder thereof to one vote on each matter submitted for Calyxt Stockholder Approval. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Stockholder of Record: Shares Registered in Your Name </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If, at the close of business on the record date for the Calyxt Special Meeting, your shares of Calyxt Common Stock were registered directly in
your name with Calyxt, Inc.&#146;s transfer agent, Broadridge Corporate Issuer Solutions, LLC, then you are a Calyxt Stockholder of record. As a Calyxt Stockholder of record, you may vote virtually at the Calyxt Special Meeting or vote by proxy.
Whether or not you plan to attend the Calyxt Special Meeting, please vote as soon as possible by completing and returning the enclosed proxy card or vote by proxy over the telephone, by mail, or on the internet as instructed on the proxy card to
ensure your vote is counted. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Calyxt Stockholders are invited to attend the Calyxt Special Meeting, which will be a virtual meeting held
exclusively via live webcast. To attend the Calyxt Special Meeting, you will need the 16-digit control number that is printed in the box marked by the arrow on your proxy card. Calyxt, Inc. recommends that you log in starting 15&nbsp;minutes before
the Calyxt Special Meeting to ensure that you are logged in when the meeting starts. Online access will begin at 8:45&nbsp;a.m. Central Time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Beneficial Owner: Shares Registered in the Name of a Broker, Bank or Other Similar Organization </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If, at the close of business on the record date for the Calyxt Special Meeting, your shares of Calyxt Common Stock were not held in your name,
but rather in an account at a brokerage firm, bank, dealer or other similar organization, then you are the beneficial owner of shares held in &#147;street name&#148; and these proxy materials are being forwarded to you by that organization. The
organization holding your account is considered to be the stockholder of record for purposes of voting at the Calyxt Special Meeting. As a beneficial owner, you have the right to direct your broker or other agent how to vote the shares in your
account. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">You are also invited to attend and vote at the Calyxt Special Meeting. To attend the Calyxt Special Meeting, you will need the
16-digit control number that is printed in the box marked by the arrow on your proxy card. Calyxt, Inc. recommends that you log in starting 15&nbsp;minutes before the Calyxt Special Meeting to ensure that you are logged in when the meeting starts.
Online access will begin at 8:45&nbsp;a.m. Central Time. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>How many votes do I have? </I></B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On each matter to be voted upon, you have one vote for each share of Calyxt Common Stock you own as of the
record date. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>What is the quorum requirement? </I></B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A quorum of Calyxt Stockholders is necessary to hold a valid meeting. A quorum will be present if Calyxt
Stockholders holding at least a majority in voting power of the shares of Calyxt Common Stock issued and </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">outstanding and entitled to vote at the Calyxt Special Meeting are present or represented by proxy at the Calyxt Special Meeting. As of the record date, there were 49,735,490 shares of Calyxt Common Stock outstanding
and entitled to vote. Your shares of Calyxt Common Stock will be counted toward the quorum at the Calyxt Special Meeting only if you attend the Calyxt Special Meeting or are represented by proxy at the Calyxt Special Meeting. Abstentions and broker <FONT
STYLE="white-space:nowrap">non-votes</FONT> will be counted towards the quorum requirement. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>What are &#147;broker <FONT STYLE="white-space:nowrap">non-votes?&#148;</FONT>
</I></B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If you hold shares beneficially in &#147;street name&#148; and do not provide your broker, bank or other
nominee with voting instructions, your shares may constitute &#147;broker <FONT STYLE="white-space:nowrap">non-votes.&#148;</FONT> Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> occur on a matter when banks, brokers and other nominees are
not permitted to vote on certain <FONT STYLE="white-space:nowrap">non-discretionary</FONT> matters without instructions from the beneficial owner and instructions are not given. These matters are referred to as
<FONT STYLE="white-space:nowrap">&#147;non-routine&#148;</FONT> matters. Proposal Nos. 1, 2, 3, 5 and 6 are anticipated to be <FONT STYLE="white-space:nowrap">non-routine</FONT> matters, and Proposal Nos. 4 and 7 are anticipated to be routine
matters. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>If my shares of Calyxt Common Stock are held in &#147;street name,&#148; will my broker, bank or other
nominee vote my shares for me? </I></B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A</B>:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unless your broker, bank or other nominee has discretionary authority to vote on certain matters, your broker
will not be able to vote your shares of Calyxt Common Stock on matters without instructions from you. If you do not give instructions to your broker, your broker can vote your shares of Calyxt Common Stock with respect to discretionary, routine
items but not with respect to <FONT STYLE="white-space:nowrap">non-discretionary,</FONT> <FONT STYLE="white-space:nowrap">non-routine</FONT> items. Brokers are not expected to have discretionary authority to vote for any of the proposals other than
Proposal Nos. 4 and 7. To make sure that your vote is counted, you should instruct your broker to vote your shares, following the procedures provided by your broker. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>How can I view the list of Calyxt Stockholders eligible to vote at the Calyxt Special Meeting?
</I></B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A</B>:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The list of Calyxt Stockholders of record entitled to vote at the Calyxt Special Meeting will be made available
for ten days prior to the Calyxt Special Meeting, at the Calyxt offices at 2800 Mount Ridge Road, Roseville, Minnesota 55113. Please contact Calyxt&#146;s General Counsel at (651) <FONT STYLE="white-space:nowrap">683-2807</FONT> if you wish to
inspect the list of stockholders eligible to vote at the Calyxt Special Meeting prior to the Calyxt Special Meeting. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>When do you expect the Mergers to be consummated? </I></B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Calyxt and Cibus currently anticipate that the Mergers will close in the second quarter of 2023, but the
companies cannot predict the exact timing. For more information, see the section entitled &#147;<I>The Merger Agreement&#151;Conditions to the Completion of the Mergers</I>&#148; beginning on page&nbsp;173 of this proxy statement/prospectus.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>What do I need to do now? </I></B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Calyxt urges you to read this proxy statement/prospectus carefully, including its annexes, and to consider how
the Mergers affect you. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If you are a Calyxt Stockholder of record, meaning that you own your shares in your own name and
not through a broker, bank or other nominee, you may vote in one of three ways prior to the Calyxt Special Meeting: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>You may vote over the internet.</I> You may vote your shares by following the instructions in the enclosed
proxy card. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>You may vote by telephone.</I> You may vote your shares by following the instructions in the enclosed proxy
card. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>You may vote by mail.</I> You may vote by completing, dating and signing the enclosed proxy card and promptly
mailing it in the postage-paid envelope provided. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Please provide your proxy instructions only once, unless you are
revoking a previously delivered proxy instruction, and as soon as possible so that your shares can be voted at the Calyxt Special Meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>When and where is the Calyxt Special Meeting and may I vote in person? </I></B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Calyxt Special Meeting will be held virtually via live webcast at
www.virtualshareholdermeeting.com/CLXT2023SM on May 18, 2023 at 9:00 a.m. Central Time. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">To attend the Calyxt Special
Meeting, you will need the 16-digit control number that is printed in the box marked by the arrow on your proxy card. Calyxt, Inc. recommends that you log in starting 15&nbsp;minutes before the Calyxt Special Meeting to ensure that you are logged in
when the meeting starts. Online access will begin at 8:45&nbsp;a.m. Central Time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If your shares are held in &#147;street name,&#148; you
are also invited to attend and vote your shares of Calyxt Common Stock at the Calyxt Special Meeting live via webcast. To attend the Calyxt Special Meeting, you will need the 16-digit control number that is printed in the box marked by the arrow on
your proxy card. Calyxt, Inc. recommends that you log in starting 15&nbsp;minutes before the Calyxt Special Meeting to ensure that you are logged in when the meeting starts. Online access will begin at 8:45&nbsp;a.m. Central Time. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Even if you plan to attend the Calyxt Special Meeting, Calyxt requests that you sign and return the enclosed proxy card or voting instruction
form to ensure that your shares will be represented at the Calyxt Special Meeting if you become unable to attend. Please be sure to follow the instructions found on your proxy card or voting instruction form. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>What if I have technical difficulties or trouble accessing the Calyxt Special Meeting?
</I></B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Technical assistance will be available one hour prior to and during the Calyxt Special Meeting.
Information related to technical assistance will be provided in the email you receive with your unique link that will allow you to access the Calyxt Special Meeting. We recommend that you log in starting 15&nbsp;minutes before the Calyxt Special
Meeting to ensure you are logged in when the Calyxt Special Meeting starts. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>What happens if I do not return a proxy card or otherwise provide proxy instructions, as applicable?
</I></B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If you are a Calyxt Stockholder of record, the failure to return your proxy card or otherwise provide proxy
instructions will have the same effect as voting &#147;AGAINST&#148; Proposal Nos. 1 and 3, and will have no effect with respect to Proposal Nos.&nbsp;2, 5 and 6. If your shares of Calyxt Common Stock are held in &#147;street name,&#148; and you do
not provide voting instructions, your broker, bank or other nominee may still vote your shares of Calyxt Common Stock with respect to discretionary, routine items, but may not vote your shares of Calyxt Common Stock with respect to <FONT
STYLE="white-space:nowrap">non-discretionary,</FONT> <FONT STYLE="white-space:nowrap">non-routine</FONT> items. Brokers are not expected to have discretionary authority to vote for any of the proposals other than Proposal Nos.&nbsp;4 and 7. To make
sure that your vote is counted, you should instruct your broker to vote your shares, following the procedures provided by your broker. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>May I change or revoke my vote after I have submitted a proxy or provided proxy instructions?
</I></B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Calyxt Stockholders of record may change or revoke their vote at any time before their proxy is voted at the
Calyxt Special Meeting by doing any one of the following things: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submitting a new proxy via the internet or telephone by following the instructions on the enclosed proxy card;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">signing another proxy card and arranging for delivery of that proxy card by mail by 11:59 p.m., Central Time, the
day before the Calyxt Special Meeting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sending a timely written notice that you are revoking your proxy to Calyxt Inc.&#146;s General Counsel at 2800
Mount Ridge Road, Roseville, MN 55113; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">voting during the Calyxt Special Meeting. Your attendance at the Calyxt Special Meeting alone will not revoke a
previously submitted proxy. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If a Calyxt Stockholder who owns shares of Calyxt Common Stock in &#147;street name&#148;
has instructed a broker to vote its shares of Calyxt Common Stock, the Calyxt Stockholder must follow directions received from its </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
broker to change those instructions. Holders in &#147;street name&#148; will not be able to vote during the Calyxt Special Meeting unless such holder has requested and obtained a valid proxy from
such holder&#146;s broker or other agent in whose name the shares are held in advance of the Calyxt Special Meeting. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Your vote will be
counted in accordance with the last instruction received prior to the closing of the polls, whether your instruction is received by internet, telephone, mail or at the Calyxt Special Meeting. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>Who is paying for this proxy solicitation? </I></B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Calyxt and Cibus will share equally the cost of printing and filing this proxy statement/prospectus and the
proxy card. Calyxt also may be required to reimburse banks, brokers and other custodians, nominees and fiduciaries or their respective agents for reasonable expenses incurred in forwarding proxy materials to beneficial owners of Calyxt Common Stock.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><I>Q:</I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>Who can help answer my questions? </I></B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If you would like to request documents from Calyxt, Inc. or Cibus Global, please send a request in writing or
by telephone to either Calyxt, Inc. or Cibus Global at the following addresses: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Calyxt, Inc.</B><BR>2800 Mount Ridge Road<BR>Roseville, MN
55113<BR>Telephone: (651) <FONT STYLE="white-space:nowrap">683-2807</FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attn: Investor
Relations<BR></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Email: Investors@Calyxt.com</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B>Cibus Global, LLC</B><BR>6455 Nancy Ridge Drive<BR>San Diego, CA 92121<BR>Telephone: (858) <FONT STYLE="white-space:nowrap">450-0008</FONT><BR>Attn: Investor Relations<BR>Email:
Investors@Cibus.com</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom401831_4"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights selected information from this proxy statement/prospectus and may not contain all of the information that is
important to you. To better understand the Mergers and the proposals being considered at the Calyxt Special Meeting, you should read this entire proxy statement/prospectus carefully, including the Merger Agreement, as amended by the First Amendment,
copies of which are attached as Annex A-1 and Annex&nbsp;A-2, respectively, and the other annexes to which you are referred herein. For more information, see the section entitled &#147;Where You Can Find More Information&#148; on page&nbsp;365 of
this proxy statement/prospectus. Except where specifically noted, the following information and all other information contained in this proxy statement/prospectus does not give effect to the Reverse Stock Splits described elsewhere in this proxy
statement/prospectus and does not give effect to the issuance of any equity in the Continuing Series F Financing or the Potential Calyxt Financing. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Companies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Calyxt, Inc. </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I></I></B>2800 Mount Ridge Road </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Roseville, MN 55113 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(651) <FONT STYLE="white-space:nowrap">683-2807</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt is a plant-based synthetic biology company. Calyxt leverages its proprietary
PlantSpring<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> technology platform to engineer plant metabolism to produce innovative, high-value and sustainable materials and products for use in helping customers meet their sustainability
targets and financial goals. Calyxt&#146;s primary focus and commercialization strategy is on engineering synthetic biology solutions through its PlantSpring technology platform for manufacture using its proprietary and differentiated BioFactory<SUP
STYLE="font-size:75%; vertical-align:top">TM</SUP> production system for a diverse base of target customers across a range of end markets, including the cosmeceutical, nutraceutical, and pharmaceutical industries. Calyxt also commercializes its
PlantSpring technology platform by licensing elements of the platform and historically developed traditional agriculture seed-trait product candidates, as well as selectively developing product candidates for customers in traditional agriculture.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cibus Global, LLC </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6455 Nancy Ridge Drive
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, CA 92121 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(858)
<FONT STYLE="white-space:nowrap">450-0008</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus is a leading agricultural technology company that develops and licenses plant
traits to seed companies for royalties. The company is a technology leader in developing plant traits (or specific genetic characteristics) using gene editing. Its primary business is using gene editing to develop Productivity Traits in the major
agricultural crops: Canola, Rice, Soybean, Corn and Wheat. Productivity Traits are crop traits that improve crop yields and make farmers more productive, thereby driving greater farming profitability. They do this in several ways such as making
plants resistant to diseases or pests, thereby reducing the use of chemicals like fungicides and insecticides, enabling plants to process nutrients more efficiently, thereby reducing the use of fertilizers, and making crops more adaptable to their
environment and to climate change. In addition, Cibus is a leader in the development of sustainable low carbon ingredients to help major corporations meet their Net Carbon Zero climate goals. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Calypso Merger Subsidiary, LLC </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Merger Subsidiary is a Delaware limited liability company and a wholly-owned direct subsidiary of Calyxt, Inc. Merger Subsidiary is newly
formed and was organized for the sole purpose of completing the Cibus Merger. Merger Subsidiary has engaged in no business activities to date and it has no material assets or liabilities of any kind, other than those incident to its formation and
those incurred in connection with the Transactions. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Mergers </B>(see page 123) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Mergers are completed, (a)&nbsp;each of the Blockers will merge with and into Calyxt, Inc., in each case with the Blockers ceasing to
exist and Calyxt, Inc. surviving each such Blocker Merger, (b)&nbsp;at the First Blocker Merger Effective Time, the Calyxt Bylaws will be amended and restated in the form of the Amended Bylaws and the Calyxt Certificate of Incorporation will be
amended and restated in the form of the Amended Certificate of Incorporation, and (c)&nbsp;immediately following the consummation of the Blocker Mergers, Merger Subsidiary will merge with and into Cibus Global, with Cibus Global as the surviving
company and Merger Subsidiary ceasing to exist. As consideration for the Mergers, the equityholders of the Blockers and the equity holders of Cibus Global will receive the Merger Consideration. In connection with the Mergers, Cibus, Inc. will
contribute all of its assets and liabilities to Cibus Global, as a contribution to the capital of Cibus Global, in exchange for newly issued Cibus Common Units. In connection with adoption of the Amended Certificate of Incorporation, Calyxt,
Inc.&#146;s name will be changed to &#147;Cibus, Inc.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the Closing, the issuance of Merger Consideration and the issuance
of Cibus Common Units, the Combined Company will be organized in an <FONT STYLE="white-space:nowrap">&#147;Up-C&#148;</FONT> structure, with Cibus, Inc.&#146;s only material asset consisting of Cibus Common Units. Upon the Closing, Calyxt
Stockholders are expected to own approximately 5.0% of issued and outstanding Shares, on a Fully-Exchanged Basis and Cibus Unitholders are expected to own approximately 95.0% of the issued and outstanding Shares, on a Fully-Exchanged Basis in each
case, subject to dilution in connection with any Dilutive Issuances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately following the Closing, all of the issued and outstanding
Cibus Common Units will be held by Cibus, Inc. and the Electing Members (through their ownership of <FONT STYLE="white-space:nowrap">Up-C</FONT> Units), with the exact ownership interest held by Cibus, Inc. and the Electing Members being subject to
the elections to be submitted by such Electing Members prior to the Closing. In connection with the Up-C structure, at Closing, (i) Cibus, Inc. and the Electing Members will become party to the Cibus Amended Operating Agreement, (ii) Cibus, Inc.,
Cibus Global and the Electing Members will enter into an Exchange Agreement, and (iii) Cibus, Inc. and the Electing Members will enter into a Registration Rights Agreement and a Tax Receivable Agreement. The
<FONT STYLE="white-space:nowrap">Up-C</FONT> Units will generally be exchangeable for shares of Class&nbsp;A Common Stock on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis, or, subject to certain
restrictions, the cash equivalent with respect to all or a portion thereof, based on a volume-weighted average price of a share of Class&nbsp;A Common Stock pursuant to the terms of the Exchange Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the Closing, the Combined Company will be organized in an &#147;Up-C&#148; structure. The diagram below depicts the organizational
structures of Calyxt and Cibus Global prior to the Transactions and the Up-C structure of the Combined Company after giving effect to the Transactions at Closing. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g401831g01a45.jpg" ALT="LOGO">
 </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reasons for the Mergers </B>(see page 134) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the course of its evaluation of the Merger Agreement and the Transactions, the Calyxt Board (including the Calyxt Committee) held
numerous meetings, consulted with Calyxt, Inc.&#146;s senior management and with financial and legal advisors and consultants to the Calyxt Board and/or the Calyxt Committee. In reaching its decision to approve the Merger Agreement and the
Transactions, the Calyxt Board considered a number of factors that it viewed as supporting its decision to approve the Merger Agreement, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Calyxt Board&#146;s belief that Calyxt&#146;s business development efforts were not reasonably likely to
result in any significant developments or events in the near term that could reasonably be expected to serve as a meaningful catalyst for Calyxt&#146;s stock price; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extensive efforts of the Calyxt Board and Calyxt management over an extended period of time to identify a
fundable business model for Calyxt that could reasonably be expected to enhance and create long-term shareholder value; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the comprehensive and thorough process of reviewing and analyzing potential strategic alternatives undertaken by
the Calyxt Board (including through the Calyxt Committee) and management, including the exploration of potential sale of the company transactions, licensing transactions, transactions for the sale of key assets or businesses, and financing
transactions; the Calyxt Board&#146;s belief that no commercially viable alternative financing, strategic investment, merger, asset sale or licensing transaction was reasonably available to Calyxt; and the Calyxt Board&#146;s belief that that the
only reasonably executable alternative to the Mergers was a liquidation and dissolution of Calyxt that could not be reasonably expected to provide any dividend, liquidating distribution or other payments or value to Calyxt Stockholders;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Calyxt Board&#146;s belief that the exchange ratio for the Mergers is the highest exchange ratio to which
Cibus Global was willing to agree and that the other terms of the Merger Agreement represent in the aggregate the most favorable terms to Calyxt and its stockholders to which Cibus was willing to agree; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that following the Mergers, the Calyxt Stockholders will continue to own common equity in Cibus, Inc. and the
Calyxt Board&#146;s belief that this continuing equity interest will provide the Calyxt Stockholders with an opportunity to participate following the Mergers in the potential equity value of the Combined Company, which will focus on Cibus&#146;
product pipeline; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Calyxt Board&#146;s view, based on the scientific, regulatory and technical due diligence conducted by Calyxt
management and advisors of the potential market opportunity of Cibus&#146; product candidates, which the Calyxt Board anticipates will be the focus of the Combined Company. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After consideration and consultation with Cibus&#146; senior management, its advisors and legal counsel, and review and assessment of a
significant amount of information, the Cibus Board concluded that the Mergers, together with the additional financing from the Series F Purchase Commitment, was the best option to generate capital resources to support the advancement of Cibus&#146;
pipeline of productivity traits and fund a combined organization. The Cibus Board considered various factors to reach its determination. For example: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Mergers will provide current Cibus Global equityholders with greater liquidity by owning publicly-traded
stock, and expanding both the access to capital for Cibus and the range of investors potentially available as a public company, compared to the investors Cibus could otherwise gain access to if it continued to operate as a privately-held company;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential benefits from increased public market awareness of Cibus and its pipeline of productivity traits;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the historical and current information concerning Cibus&#146; business, including its financial performance and
condition, operations and management; </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the business, history, operations, assets and technology of Calyxt; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Combined Company is expected to be led by an experienced management team; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the expected timeline for the initial Cibus productivity traits to reach the market; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the projected financial position, operations, management structure, operating plans, and anticipated cash burn
rate of the Combined Company, including the ability to support the Combined Company&#146;s current and planned operations, as further discussed in the section entitled <I>&#147;Cibus Management&#146;s Discussion and Analysis of Financial Condition
and Results of Operations&#151;Liquidity and Capital Resources&#151;Future Capital Requirements&#148;</I> beginning on page&nbsp;277 of this proxy statement/prospectus. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For additional information, see the sections entitled &#147;<I>The Mergers&#151;Calyxt Reasons for the Mergers</I>&#148; and &#147;<I>The
Mergers&#151;Cibus Reasons for the Mergers</I>&#148; in this proxy statement/prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview of the Merger Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I></I><B><I>Merger Consideration </I></B><I>(see page 162) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Amended Certificate of Incorporation, once adopted at the First Blocker Merger Effective Time, will designate two classes of Cibus, Inc.
common stock: (i)&nbsp;Class&nbsp;A Common Stock, which shares will have full voting and economic rights, and (ii)&nbsp;Class&nbsp;B Common Stock, which shares will have full voting, but no economic rights. Upon adoption of the Amended Certificate
of Incorporation, each share of Calyxt Common Stock existing and outstanding immediately prior to the First Blocker Merger Effective Time shall remain outstanding as a share of Class&nbsp;A Common Stock at the First Blocker Merger Effective Time
without any conversion or exchange thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At each applicable Blocker Merger Effective Time, the limited liability company interests of
the applicable Blocker will be cancelled and converted into the right to receive shares of Class&nbsp;A Common Stock corresponding to that Blocker Merger, in each case, as set forth in the Allocation Schedule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the effective time of the Cibus Merger, all of the issued and outstanding Cibus Units (including Cibus PIUs), and all Cibus Warrants or
options to purchase Cibus Units, will be cancelled (or in the case of Cibus Warrants, surrendered to Cibus, Inc. for exchange) and converted into the right to receive the following, as described in further detail in the Merger Agreement: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Top 99 Holders shall have option to elect, on a per unit basis, to receive Merger Consideration in the form
of either (a)&nbsp;the number of shares of Class&nbsp;A Common Stock set forth on the Allocation Schedule in exchange for all such holder&#146;s Cibus Units (other than Cibus PIUs) or (b)&nbsp;a number of <FONT STYLE="white-space:nowrap">Up-C</FONT>
Units, as set forth on the Allocation Schedule, provided, that such holder will not be entitled to exchange more than 95% of such holder&#146;s existing Cibus Units for <FONT STYLE="white-space:nowrap">Up-C</FONT> Units and the remainder of such
holder&#146;s Cibus Units will be exchanged for shares of Class&nbsp;A Common Stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all <FONT STYLE="white-space:nowrap">pre-Closing</FONT> holders of Cibus Units, other than Top 99 Holders and
Blockers, shall receive the number of shares of Class&nbsp;A Common Stock set forth on the Allocation Schedule in exchange for their Cibus Units (other than Cibus PIUs); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all <FONT STYLE="white-space:nowrap">pre-Closing</FONT> Cibus Warrants shall automatically be exchanged for the
right to receive the number of shares of Class&nbsp;A Common Stock set forth on the Allocation Schedule; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all <FONT STYLE="white-space:nowrap">pre-Closing</FONT> Cibus PIUs will, (a)&nbsp;to the extent not a
&#147;restricted unit&#148; (under the award agreements and governing documents applicable to such Cibus PIUs), be automatically cancelled and converted into the right to receive the number of shares of Class&nbsp;A Common Stock set forth on the
Allocation Schedule and (b)&nbsp;to the extent a &#147;restricted unit&#148; (i.e., an unvested unit), be automatically cancelled and </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
converted into the right to receive the number of restricted shares of Class&nbsp;A Common Stock pursuant to a Cibus, Inc. stock plan, as set forth on the Allocation Schedule and subject to the
same vesting schedule as was applicable to such Cibus PIUs prior to Closing. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cibus Common Unit Issuance to Calyxt, Inc.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately following the Cibus Merger, (i)&nbsp;each <FONT STYLE="white-space:nowrap">pre-Closing</FONT> Cibus Unit and <FONT
STYLE="white-space:nowrap">pre-Closing</FONT> Cibus Warrant, in each case, held by Cibus, Inc. as a result of the Blocker Mergers will be converted or exchanged for a number of Cibus Common Units set forth in the Allocation Schedule, (ii)&nbsp;each <FONT
STYLE="white-space:nowrap">pre-Closing</FONT> Cibus Warrant held by Cibus, Inc. as a result of the warrant exchanges described above will be converted or exchanged for a number of Cibus Common Units set forth in the Allocation Schedule, and
(iii)&nbsp;Cibus Global will issue a number of Cibus Common Units to Cibus, Inc. in an amount equal to the sum of (A)&nbsp;the number of shares of Class&nbsp;A Common Stock issued to former Cibus Global equity holders as Cibus Merger Consideration
and (B)&nbsp;the number of shares of Calyxt Common Stock outstanding immediately prior to the First Blocker Merger. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Election of <FONT
STYLE="white-space:nowrap">Up-C</FONT> Units for Top 99 Holders </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Promptly after the date this proxy statement/prospectus is
declared effective by the SEC, Cibus Global will mail to each holder of Cibus Units that is a Top 99 Holder an Election Form. The Election Form will accompany the disclosure statement and copies of the form of Tax Receivable Agreement, Cibus Amended
Operating Agreement, Exchange Agreement and Registration Rights Agreement, and will include counterpart signatures to each of the foregoing agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Election Form will permit each holder that is a Top 99 Holder to elect on a <FONT STYLE="white-space:nowrap">per-Cibus</FONT> Unit basis
(other than in respect of Cibus PIUs), to receive as Merger Consideration in the Cibus Merger in the form of either (A)&nbsp;shares of Class&nbsp;A Common Stock or <FONT STYLE="white-space:nowrap">(B)&nbsp;Up-C</FONT> Units (subject to the
limitations in the Merger Agreement, any such holder validly electing to receive <FONT STYLE="white-space:nowrap">Up-C</FONT> Units in exchange for any one or more of its Cibus Units, an &#147;Electing Member,&#148; and the Cibus Units that such
Electing Member will exchange for <FONT STYLE="white-space:nowrap">Up-C</FONT> Units, the &#147;Excluded Units&#148;); provided, however, that no Electing Member will be entitled to receive <FONT STYLE="white-space:nowrap">Up-C</FONT> Units to the
extent such holder&#146;s Excluded Units exchanged therefor would represent more than ninety-five percent (95%), or such lower percentage as may be determined by Cibus Global and set forth on the Election Form, of the total number of Cibus Units
held by such person as of immediately prior to the Cibus Merger Effective Time (for the avoidance of doubt, any Cibus Units held by such person in excess of such amount will not constitute Excluded Units and will instead receive shares of
Class&nbsp;A Common Stock in exchange for the Cibus Units representing such excess, notwithstanding such person&#146;s election). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Allocation
Schedule </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger Agreement provides that Merger Consideration will be allocated to each of the Cibus Global equity holders and
the Blockers, as of immediately prior to the First Blocker Merger Effective Time, based on the Allocation Schedule. The initial version of the Allocation Schedule was attached as an exhibit to the Merger Agreement and calculated based on the
fully-diluted (other than with respect to out-of-the-money options and warrants) capitalization of Calyxt, Inc. and Cibus Global, in each case, as of the date of the Merger Agreement. Pursuant to the Merger Agreement, the Allocation Schedule will be
updated by Cibus Global no later than three business days prior to Closing to reflect (a)&nbsp;transfers of equity interests in Cibus Global or the Blockers, (b)&nbsp;the results of the elections by Top 99 Holders and (c)&nbsp;any additional Cibus
Series F Preferred Units issued or issuable pursuant to the Continuing Series F Financing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following provides a summary of the
calculation of Merger Consideration and the allocation among each of the Cibus Global equity holders and Blockers, as set forth in the Allocation Schedule. For purposes of this summary, the &#147;Conversion Factor&#148;, as used below, is defined as
3.17045722397476 shares of Class&nbsp;A </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Common Stock (or Class&nbsp;B Common Stock, in the case of Electing Members&#146; <FONT STYLE="white-space:nowrap">Up-C</FONT> Units) per fully-diluted voting common unit of Cibus Global. The
calculation of shares of Class&nbsp;A Common Stock (or Class&nbsp;B Common Stock, in the case of Electing Members&#146; <FONT STYLE="white-space:nowrap">Up-C</FONT> Units) is determined based on the underlying class of Cibus Units held by the
applicable member, as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Cibus Preferred Units</U>: Immediately prior to the Blocker Merger Effective Time for the First Blocker
Merger, each Cibus Preferred Unit is converted to a number of fully-diluted voting common units of Cibus Global on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis. Each fully-diluted voting common
unit is then multiplied by the Conversion Factor to yield the number of shares of Class&nbsp;A Common Stock (or Class&nbsp;B Common Stock, in the case of Electing Members) to be issued in respect of such Cibus Preferred Units. The number of Cibus
Common Units to be issued to an Electing Member in respect of their <FONT STYLE="white-space:nowrap">Up-C</FONT> Units will equal the number of shares of Class&nbsp;B Common Stock calculated by the foregoing. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Cibus Global <FONT STYLE="white-space:nowrap">non-voting</FONT> common units</U>: Cibus Global Class&nbsp;A <FONT
STYLE="white-space:nowrap">non-voting</FONT> common units represent membership units issued in connection with Cibus Global options previously exercised. Each <FONT STYLE="white-space:nowrap">non-voting</FONT> common unit is multiplied by the
Conversion Factor to yield the number of shares of Class&nbsp;A Common Stock to be issued in respect of such non-voting common units. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Cibus PIUs</U>: All Cibus PIUs are represented by the same class of securities
<FONT STYLE="white-space:nowrap">(non-voting</FONT> common units) in Cibus Global. Immediately prior to the Blocker Merger Effective Time for the First Blocker Merger, each Cibus PIU is hypothetically converted to a number of fully-diluted voting
common units of Cibus Global by multiplying (a)&nbsp;the number of issued and outstanding Cibus PIUs in a given class held by the applicable member by (b)&nbsp;the class&#146;s unique fully-diluted conversion factor (the applicable &#147;FD
Factor&#148;). The FD Factor for each class of Cibus PIUs is calculated based on the Cibus PIU&#146;s Black Scholes fair value (with the exercise price input used in such Black Scholes valuation being a present value calculation of the applicable
threshold value associated with the underlying Cibus PIU class). The hypothetical number of fully-diluted voting common units of Cibus Global is then multiplied by the Conversion Factor to yield the number of shares of Class&nbsp;A Common Stock to
be issued in respect of such Cibus PIU. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Cibus Warrants</U>: Each issued and outstanding Cibus Warrant outstanding immediately prior to the Blocker
Merger Effective Time for the First Blocker Merger is hypothetically converted to a number of fully-diluted voting common units of Cibus Global by multiplying (a)&nbsp;the number of Cibus Preferred Units, voting common units or <FONT
STYLE="white-space:nowrap">non-voting</FONT> common units, as applicable, subject to the warrant by (b)&nbsp;the warrant tranche&#146;s unique FD Factor. The FD Factor for each tranche of Cibus Warrants was calculated by dividing the Black Scholes
Fair Value of such Cibus Warrant tranche by $2.00. The hypothetical number of fully-diluted voting common units of Cibus Global is then multiplied by the Conversion Factor to yield the number of shares of Class&nbsp;A Common Stock to be issued in
respect of such Cibus Warrant. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a more complete description of the Merger Consideration, see the sections entitled
&#147;<I>The Merger Agreement&#151;Merger Consideration</I>&#148; and &#147;<I>The Mergers&#151;Merger Consideration&#151;Allocation </I><I>Schedule</I>&#148; in this proxy statement/prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I></I><B><I>Treatment of Cibus PIUs </I></B><I>(see page 172) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the Merger Agreement, each Cibus PIU issued and outstanding immediately prior to the Cibus Merger Effective Time shall,
(i)&nbsp;to the extent not a &#147;restricted unit&#148; under the award agreements and governing documents applicable to such Cibus PIU as of such time, be automatically cancelled and converted into the right to receive the number of shares of
Class&nbsp;A Common Stock set forth on the Allocation Schedule and (ii)&nbsp;to the extent a &#147;restricted unit&#148; (i.e., an unvested unit) under the award agreements and other governing documents applicable to such Cibus PIU as of such time,
be automatically cancelled and converted into the right </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to receive the number of restricted shares of Class&nbsp;A Common Stock pursuant to a Cibus, Inc. stock plan, as set forth on the Allocation Schedule and subject to the same vesting schedule as
was applicable to such Cibus PIU prior to the Closing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I></I><B><I>Conditions to the Completion of the Mergers </I></B><I>(see page 173) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consummation of the Mergers is subject to certain closing conditions, including the approval of Calyxt Stockholders of Proposal Nos. 1 and
2 and the receipt of written consents evidencing the approval of the Transactions by the requisite number of <FONT STYLE="white-space:nowrap">pre-Closing</FONT> holders of Cibus Units and of the Blockers. Additionally, each of the other closing
conditions set forth in the Merger Agreement must be satisfied or waived. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I></I><B><I>No Solicitation </I></B><I>(see page 177) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as expressly permitted by the Merger Agreement, each of Calyxt, Inc. and Cibus Global agreed that during the <FONT
STYLE="white-space:nowrap">pre-Closing</FONT> period, except as more fully described in the section &#147;<I>The Merger Agreement&#151;No</I> <I>Solicitation,&#148;</I> Calyxt, Inc. and Cibus Global will not, nor will either party authorize any of
its representatives to, directly or indirectly: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">solicit, initiate or knowingly encourage, induce or facilitate the communication, making, submission or
announcement of, any acquisition proposal or acquisition inquiry or take any action that could reasonably be expected to lead to an acquisition proposal or acquisition inquiry; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">furnish any information regarding such party to any person for the purpose of encouraging, or in response to, an
acquisition proposal or acquisition inquiry; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">engage in discussions or negotiations with any person with respect to any acquisition proposal or acquisition
inquiry; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approve, endorse or recommend any acquisition proposal; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">execute or enter into any letter of intent or any contract contemplating or otherwise relating to any acquisition
transaction, as defined below (other than a confidentiality agreement permitted under the Merger Agreement); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">publicly propose to do any of the above; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">agree, resolve or commit (or, for the avoidance of doubt, the Calyxt Board or Cibus Board, as applicable, or any
committee thereof to resolve, agree or commit) to do any of the above. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I></I><B><I>Termination of the Merger Agreement </I></B><I>(see
page 189) </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Either Calyxt, Inc. or Cibus Global can terminate the Merger Agreement under certain circumstances, which would prevent the
Transactions from being consummated. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I></I><B><I>Termination Fees </I></B><I>(see page 190) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Merger Agreement is terminated under certain circumstances, Calyxt, Inc. may be required to pay Cibus Global a termination fee of
$1,000,000 or Cibus Global may be required to pay Calyxt, Inc. a termination fee of $1,000,000 and reimburse Calyxt, Inc.&#146;s expenses up to a maximum of $500,000, depending on the circumstances surrounding such termination and any conditions
thereto. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Support Agreements </B>(see page 191)<B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Calyxt Support Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with the execution of the Merger Agreement and as a condition to Cibus Global entering into the Merger Agreement, Cibus Global
entered into Voting Agreements (the &#147;Calyxt Support Agreements&#148;), with </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
certain of Calyxt, Inc.&#146;s stockholders, directors and officers (the &#147;Supporting Stockholders&#148;) who, collectively and in the aggregate as of January 13, 2023, beneficially held
voting power of approximately 49.8% of the outstanding Calyxt Common Stock (the &#147;Subject Shares&#148;). Pursuant to the terms of the Calyxt Support Agreements, the Supporting Stockholders have agreed to take certain actions to support the
Transactions, including not transferring the Subject Shares during the term of the Calyxt Support Agreement, except under specified circumstances, and voting the Subject Shares in favor of the Merger Agreement and Transactions and against any
alternative acquisition proposals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the voting obligations in the Calyxt Support Agreements, if the Calyxt Board effects a
Calyxt Board Adverse Recommendation Change (as defined in the Merger Agreement) in response to a superior offer, then the Calyxt Support Agreements will terminate and Supporting Stockholders will have no obligations in respect of how to vote their
respective Subject Shares. The Calyxt Support Agreements also contain customary termination provisions, including termination with respect to a given Supporting Stockholder in the event of any modification or amendment to the Merger Agreement in a
manner that reduces the amount or changes the form of Merger Consideration payable to such Supporting Stockholder or otherwise adversely effects the Supporting Stockholder in any material respect without his, her or its prior written approval. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cibus Support Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with the execution of the Merger Agreement and as a condition to Calyxt, Inc. entering into the Merger Agreement, Calyxt, Inc.
entered into Voting Agreements (the &#147;Cibus Support Agreements&#148;), with certain of Cibus Global&#146;s equityholders (including the Blockers), directors and officers (the &#147;Cibus Supporting Unitholders&#148;) who, collectively and in the
aggregate as of January 13, 2023, held voting power of approximately 54.3% of the outstanding Cibus Global membership units (the &#147;Subject Units&#148;). Pursuant to the terms of the Cibus Support Agreements, the Cibus Supporting Unitholders have
agreed to take certain actions to support the Transactions, including not transferring the Subject Units during the term of the Cibus Support Agreement except under specified circumstances and voting (or acting by written consent) all of its Subject
Units in favor of the Mergers and the other Transactions, against any alternative acquisition proposals and to convert all outstanding <FONT STYLE="white-space:nowrap">pre-Closing</FONT> Cibus Preferred Units into
<FONT STYLE="white-space:nowrap">pre-Closing</FONT> Cibus Global voting common units on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Cibus Support Agreements also contain customary termination provisions, including termination with respect to a given Supporting
Stockholder in the event of any modification or amendment to the Merger Agreement in a manner that reduces the amount or changes the form of Merger Consideration payable to such Supporting Stockholder or otherwise adversely effects the Supporting
Stockholder in any material respect without his, her or its prior written approval. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tax Receivable Agreement </B>(see page 192) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the completion of the Mergers, Cibus, Inc. will enter into the Tax Receivable Agreement, pursuant to which Cibus, Inc. generally will be
required to pay to the TRA Parties, in the aggregate, 85% of the net income tax savings that Cibus, Inc. actually realizes (or in certain circumstances, is deemed to realize) as a result of (i)&nbsp;certain favorable tax attributes we will acquire
from the Blockers in the Blocker Mergers (including net operating losses), (ii) increases to Cibus, Inc.&#146;s allocable share of the tax basis of Cibus Global&#146;s assets resulting from future redemptions or exchanges of Cibus Common Units for
shares of Class&nbsp;A Common Stock or cash, (iii)&nbsp;tax attributes resulting from certain payments made under the Tax Receivable Agreement, and (iv)&nbsp;deductions in respect of interest under the Tax Receivable Agreement. The payment
obligations under the Tax Receivable Agreement are Cibus, Inc.&#146;s obligations and not obligations of Cibus Global. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exchange Agreement </B>(see page 193) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the Closing, Cibus, Inc. will enter into the Exchange Agreement, substantially in the form attached as <I>Annex E</I> to this proxy
statement/prospectus, with Cibus Global and the Electing Members pursuant to which, subject to the procedures and restrictions therein, the holders of <FONT STYLE="white-space:nowrap">Up-C</FONT> Units (or certain permitted transferees thereof) will
have the right from time to time from and after the effectiveness of Cibus, Inc.&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> to be filed pursuant to the terms and conditions of the Registration Rights Agreement
to exchange their <FONT STYLE="white-space:nowrap">Up-C</FONT> Units on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis for shares of Class&nbsp;A Common Stock (the &#147;Exchange&#148;); provided,
that, subject to certain exceptions, Cibus, Inc., at its sole election, subject to certain restrictions, may, other than in the case of certain secondary offerings, instead settle all or a portion of the Exchange in cash based on a volume weighted
average price of a share of Class&nbsp;A Common Stock. The Exchange Agreement will provide that, as a general matter, a holder of <FONT STYLE="white-space:nowrap">Up-C</FONT> Units will not have the right to exchange
<FONT STYLE="white-space:nowrap">Up-C</FONT> Units if Cibus, Inc. determines that such exchange would be prohibited by law or regulation or would violate other agreements with Cibus, Inc. and its subsidiaries to which the holder of <FONT
STYLE="white-space:nowrap">Up-C</FONT> Units may be subject, including the Cibus Amended Operating Agreement. Additionally, the Exchange Agreement will contain restrictions on redemptions and exchanges intended to prevent Cibus Global from being
treated as a &#147;publicly traded partnership&#148; for U.S. federal income tax purposes. These restrictions are modeled on certain safe harbors provided for under applicable U.S. federal income tax law. Cibus, Inc. may impose additional
restrictions on exchanges that it determines to be necessary or advisable so that Cibus Global is not treated as a &#147;publicly traded partnership&#148; for U.S. federal income tax purposes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights Agreement </B>(see page 193) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Registration Rights Agreement, Cibus, Inc. will, subject to the terms and conditions thereof, agree to register the resale of
the shares of Class&nbsp;A Common Stock that are issuable to the Electing Members upon exchange of their <FONT STYLE="white-space:nowrap">Up-C</FONT> Units that are issued to the Electing Members in connection with the Transactions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nasdaq Stock Market Listing </B>(see page 169) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt, Inc. has filed an initial listing application for Cibus, Inc. and the Class&nbsp;A Common Stock with Nasdaq. After completion of the
Transactions, Calyxt, Inc. is expected to be renamed &#147;Cibus, Inc.&#148; and to trade under the symbol &#147;CBUS.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Management Following the
Transactions </B>(see page 284) </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table lists the names, ages as of March 31, 2023 and positions of the individuals who are
expected to serve as executive officers and directors of Cibus, Inc. following completion of the Transactions. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="43%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Age</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Position</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Executive Officers</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rory Riggs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">69</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Executive Officer and Chair</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Beetham, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">60</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>President and Chief Operating Officer, Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Greg Gocal, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">54</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Scientific Officer and Executive Vice President</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wade King, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">66</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Financial Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Finn</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">79</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jean-Pierre Lehmann</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">84</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gerhard Prante, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">81</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Keith Walker, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">74</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
</TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Interests of Calyxt, Inc. Directors and Executive Officers in the Mergers </B>(see page 145) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In considering the recommendation of the Calyxt Board with respect to approving the Mergers, Calyxt Stockholders should be aware that certain
members of the Calyxt Board and certain Calyxt, Inc. executive officers have interests in the Mergers that may be different from, or in addition to, the interests of Calyxt Stockholders. These interests may present them with actual or potential
conflicts of interest. As of March&nbsp;31, 2023, Calyxt, Inc.&#146;s directors and current executive officers owned, in the aggregate, 1.7% of the shares of Calyxt Common Stock, which for purposes of this subsection excludes any Calyxt Common Stock
issuable upon (i)&nbsp;exercise of Calyxt, Inc. options held by such individuals or (ii)&nbsp;vesting of Calyxt RSUs or Calyxt PSUs held by such individuals. Certain Calyxt Stockholders, directors and officers have also entered into Calyxt Support
Agreements in connection with the Mergers whereby such stockholders, directors and officers have agreed to take certain actions to support the Transactions, including not transferring their shares during the term of such agreement, voting in favor
of the Merger Agreement and the Transactions and voting against any alternative acquisition proposals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, as a result of the
Transactions, equity awards, including Calyxt, Inc. stock options, Calyxt RSUs and Calyxt PSUs held by certain directors and executive officers will accelerate and vest on the Closing. In addition, on a qualifying termination of employment following
the Closing, certain executive officers would be owed cash severance payments and acceleration and vesting of equity awards under the Calyxt Executive Severance Plan or their applicable employment agreement. For more information, see the section of
this proxy statement/prospectus entitled &#147;<I>The Mergers&#151;Interests of Calyxt, Inc. Directors and Executive Officers in the Mergers.</I>&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Interests of Cibus Global Directors and Executive Officers in the Mergers </B>(see page 155) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In considering the recommendation of the Cibus Board with respect to approving the Mergers, Cibus Unitholders should be aware that certain
members of the Cibus Board and certain Cibus Global executive officers have interests in the Mergers that may be different from, or in addition to, the interests of Cibus Unitholders. As of March 31, 2023, Cibus Global&#146;s directors and current
executive officers beneficially owned, in the aggregate, 57,023,211 Cibus Units, which for purposes of this subsection excludes any Cibus PIUs and excludes Cibus Warrants. Certain Cibus Global directors and officers have also entered into Cibus
Support Agreements in connection with the Mergers whereby such executive officers and directors have agreed to take certain actions to support the Transactions, including voting or acting by written consent with respect to all of their outstanding
voting Cibus Units in favor of the Mergers and the other Transactions, against any alternative acquisition proposals, and agreed to convert all outstanding <FONT STYLE="white-space:nowrap">pre-Closing</FONT> Cibus Preferred Units into <FONT
STYLE="white-space:nowrap">pre-Closing</FONT> Cibus Global voting common units on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis. Cibus Global directors and executive officers will receive the
same consideration for their Cibus Units on the same terms and conditions as other Cibus Unitholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, certain members of the
Cibus Board and Cibus Global executive officers are expected to become the directors and executive officers of Cibus, Inc. upon the Closing. The compensation arrangements with Cibus Global&#146;s directors and executive officers are discussed in the
sections entitled &#147;<I>The Mergers&#151;Interests of Cibus Global Directors and Executive Officers in the Mergers</I>&#148; and &#147;<I>Cibus Global Executive Compensation</I>&#148; in this proxy statement/prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Material U.S. Federal Income Tax Consequences of the Cibus Merger </B>(see page 165) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since the Calyxt Stockholders will not sell, exchange or dispose of any shares of Calyxt Common Stock as a result of the Cibus Merger, there
will be no material U.S. federal income tax consequences to Calyxt Stockholders as a result of the Cibus Merger. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As discussed more fully under the section entitled &#147;<I>The Mergers&#151;Material U.S.
Federal Income Tax Consequences of the Cibus Merger</I>,&#148; the parties intend that the Cibus Merger qualify as a transaction described in Section&nbsp;351 of the Code. Assuming that the Cibus Merger so qualifies, Cibus Participants (defined
below) that receive solely shares of Class&nbsp;A Common Stock in the Transactions will generally not recognize gain or loss upon the exchange of their Cibus Units or Cibus Warrants for shares of Class&nbsp;A Common Stock pursuant to the Cibus
Merger, except to the extent that the Cibus Participant&#146;s allocable share of Cibus&#146; liabilities exceeds the Cibus Participant&#146;s tax basis in its Cibus Units or Cibus Warrants exchanged for Class&nbsp;A Common Stock. There can be no
assurance, however, that the IRS will not successfully assert an alternative characterization of the Transactions, including the Cibus Merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The U.S. federal income tax consequences of the Cibus Merger depend on each Cibus Unitholder&#146;s particular facts and circumstances.
Accordingly, all Cibus Unitholders are urged to consult their tax advisors regarding the tax consequences to them of the Transactions, including the applicability and effect of U.S. federal, state, local and
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax laws. For a more complete discussion of the U.S. federal income tax considerations of the Transactions, see the section entitled &#147;<I>The Mergers&#151;Material U.S. Federal Income Tax
Consequences of the Cibus Merger</I>.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risk Factors </B>(see page 40) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Both Calyxt and Cibus are subject to various risks associated with their businesses and their industries. In addition, the Mergers pose a
number of risks to each company and its respective stockholders, including the possibility that the Mergers may not be completed and the following risks: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks Related to the Mergers </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The exchange ratio will not change or otherwise be adjusted based on the market price of Calyxt Common Stock as
the exchange ratio is fixed as of the date of the Merger Agreement, so the Merger Consideration at the Closing may have a greater or lesser value than at the time the Merger Agreement was signed. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Because the exchange ratio is fixed as of the date of the Merger Agreement, any Dilutive Issuances will have the
effect of diluting the anticipated post-Closing ownership percentage of Cibus, Inc. for both Calyxt Stockholders and Cibus Unitholders. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Calyxt Stockholders and Cibus Unitholders may not realize a benefit from the Mergers commensurate with the
ownership dilution they will experience in connection with the Mergers and the potential Dilutive Issuances. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Failure to complete the Mergers may result in either Calyxt, Inc. or Cibus Global paying a termination fee to the
other party and could significantly harm the market price of Calyxt Common Stock and negatively affect the future business and operations of each company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Merger Agreement and the issuance of Shares to Cibus Unitholders pursuant to the Merger Agreement must be
approved by Calyxt Stockholders, and the Merger Agreement and the Mergers must be approved by the Cibus Unitholders and the equityholders of the Blockers. Failure to obtain these approvals would prevent the Closing. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Some Calyxt, Inc. and Cibus Global executive officers and directors have interests in the Mergers that are
different from the Calyxt Stockholders and Cibus Unitholders, respectively, and that may influence them to support or approve the Mergers without regard to the interests of the Calyxt Stockholders and Cibus Unitholders. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If the conditions to the Mergers are not satisfied or waived, the Mergers will not occur. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks Related to the Reverse Stock Splits </I></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Reverse Stock Splits could result in a significant devaluation of Calyxt&#146;s market capitalization and the
trading price of Calyxt Common Stock. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Reverse Stock Splits may not increase the price of the Class A Common Stock over the long term.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Reverse Stock Splits may decrease the liquidity of the Class&nbsp;A Common Stock. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Calyxt Board will determine the ratios of the Reverse Stock Splits in its discretion and may consider a
variety of factors in making its determination. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks Related to Calyxt </I></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">There is no assurance that the Transactions will be completed in a timely manner or at all. If the Transactions
are not consummated, Calyxt&#146;s business could suffer materially and its stock price could decline. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If the Transactions are not completed, the Calyxt Board may decide to pursue a liquidation and dissolution of
Calyxt. In such an event and in light of Calyxt&#146;s current capital resource constraints, it is unlikely that substantial resources would be available for distributions to stockholders. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Calyxt has engaged in cost reduction and other cash-focused measures, which may result in challenges in managing
its business and executing on its business strategy while successfully completing the Transactions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The issuance of Shares to Cibus Global equityholders in the Transactions will dilute substantially the voting
power of Calyxt Stockholders. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If the Mergers are not completed, Calyxt&#146;s ability to continue as a going concern will depend on its ability
to obtain additional near-term financing, which may not be available on acceptable terms or at all. Failure to obtain this necessary capital when needed may force it to delay, limit or terminate its product development efforts or cease operations.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Calyxt&#146;s operational and financial success depends on its ability to successfully deliver synthetic biology
solutions for an expanded group of end markets, which is subject to a variety of risks and uncertainties. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Patents and patent applications involve highly complex legal and factual questions, which, if determined
adversely to Calyxt, could negatively impact its competitive position. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Ethical, legal, and social concerns about products using genetically modified or edited plant cells could limit
or prevent the use of Calyxt&#146;s products and technologies and could harm its business. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If Calyxt, Inc. is unable to maintain compliance with Nasdaq&#146;s listing requirements, the Calyxt Common Stock
may be delisted from The Nasdaq Capital Market, which could have a material adverse effect on Calyxt&#146;s financial condition and could make it more difficult for holders of Calyxt Common Stock to sell their shares. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Changes to Calyxt&#146;s strategic business focus have placed significant demands on Calyxt&#146;s management and
Calyxt&#146;s infrastructure. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks Related to Cibus </I></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cibus&#146; operating history makes it difficult to assess its future prospects. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cibus has incurred significant losses and anticipates that it will continue to incur significant losses for
several years. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cibus faces significant competition and many of its competitors have substantially greater financial, technical
and other resources than Cibus does. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cibus relies on gene-editing technologies that may become obsolete in the future. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cibus&#146; success is partially dependent on its ability to make accurate predictions about customer demand in
its industries. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Ethical, legal and social concerns about the use of gene-edited plants and microorganisms could limit licensing
demand for Cibus&#146; intellectual property. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cibus&#146; ability to compete may decline if it does not adequately protect its intellectual property
proprietary rights. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cibus will need to develop and expand its company, and Cibus may encounter difficulties in managing this
development and expansion, which could disrupt its operations. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks Related to the Combined Company </I></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cibus&#146; Royalty Liability may contribute to net losses for the Combined Company and cause the value for
securities of the Combined Company to fluctuate. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The unaudited pro forma combined financial statements included in this proxy statement/prospectus are presented
for illustrative purposes only and may not be an indication of the Combined Company&#146;s financial condition or results of operations following the completion of the Transactions. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Combined Company may fail to realize the anticipated benefits of the Transactions. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The failure to successfully integrate the businesses and operations of Calyxt and Cibus in the expected time
frame may adversely affect the Combined Company&#146;s future results. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The future operating results of the Combined Company will suffer if the Combined Company does not effectively
manage its operations following the Transactions. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks Related to the Organizational Structure of the Combined Company
</I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cibus, Inc. will be a holding company and its only material asset after completion of the Transactions will be
its interest in Cibus Global, and it is accordingly dependent upon distributions from Cibus Global to pay taxes, make payments under the Tax Receivable Agreement and cover its corporate and other overhead expenses. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In certain circumstances, Cibus Global will be required to make distributions to Cibus, Inc. and the other
holders of Cibus Common Units, and the distributions that Cibus Global will be required to make may be substantial. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cibus, Inc. will be required to make payments to the TRA Parties pursuant to the Tax Receivable Agreement for
certain tax benefits Cibus, Inc. may receive and the amounts payable may be substantial. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In certain cases, payments under the Tax Receivable Agreement may be accelerated and/or significantly exceed the
actual benefits Cibus, Inc. realizes in respect of the tax attributes subject to the Tax Receivable Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If Cibus Global were to become a publicly traded partnership taxable as a corporation for U.S. federal income tax
purposes, Cibus, Inc. and Cibus Global might be subject to potentially significant tax inefficiencies, and Cibus, Inc. would not be able to recover payments previously made by it under the Tax Receivable Agreement even if the corresponding tax
benefits were subsequently determined to have been unavailable due to such status. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These risks and other risks are discussed in greater detail under the section entitled
&#147;<I>Risk Factors</I>&#148; in this proxy statement/prospectus. Calyxt and Cibus both encourage you to read and consider all of these risks carefully. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Regulatory Approvals </B>(see page 165) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt, Inc. must comply in all material respects with the rules of Nasdaq in connection with the issuance of Shares. If prior to the Closing
Date, Cibus Global determines, in its reasonable discretion after consultation with Calyxt, Inc. and its legal advisors, that the Transactions require filings under the HSR Act to be submitted with the applicable governmental entities, then as
promptly as reasonably practicable following such determination, Calyxt, Inc. and Cibus Global shall cooperate in the preparation of such filings and, upon completion thereof (in form and substance mutually agreeable to Calyxt, Inc. and Cibus
Global), each of Calyxt, Inc. and Cibus Global shall make or cause to be made any such required filings under the HSR Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Accounting Treatment of the
Business Combination </B>(see page 169) </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination is expected to be accounted for in accordance with ASC 805, Business
Combinations, using the acquisition method of accounting, with Calyxt, Inc. as the acquirer and Cibus Global as the acquiree. Under the acquisition method of accounting, Calyxt Inc.&#146;s assets and liabilities will be recorded at carrying value
and the assets and liabilities associated with Cibus Global will be recorded at estimated fair value as of the acquisition date. The excess of the purchase price over the estimated fair values of the net assets acquired, if applicable, will be
recognized as goodwill. For purposes of the unaudited pro forma combined balance sheet, the purchase consideration has been allocated to the assets acquired and liabilities assumed of Cibus Global based upon management&#146;s preliminary estimate of
their fair values. Calyxt, Inc. has not completed the valuation analysis and calculations in sufficient detail necessary to arrive at the required estimates of the fair market value of the Cibus Global assets acquired or liabilities assumed,
including the preliminary estimate for intangible assets. Accordingly, the assets and liabilities should be treated as preliminary values. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For accounting purposes, the acquirer is the entity that has obtained control of another entity and, thus, consummated a business combination.
The determination of whether control has been obtained begins with the evaluation of whether control should be evaluated based on the variable interest or voting interest model pursuant to ASC Topic 810, Consolidation (&#147;ASC 810&#148;). If the
acquiree is a variable interest entity, the primary beneficiary would be the accounting acquirer. Cibus Global meets the definition of a variable interest entity and Calyxt, Inc., which will be the managing member, has been determined to be the
primary beneficiary. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Appraisal Rights and Dissenters&#146; Rights </B>(see page 169) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt Stockholders are not entitled to dissenters&#146; or appraisal rights under the DGCL in connection with the Mergers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Comparison of Stockholders&#146; Rights </B>(see page 339) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt, Inc. is incorporated under the laws of the State of Delaware and the rights of Calyxt Stockholders are governed by the laws of the
State of Delaware, including the DGCL, the Calyxt Certificate of Incorporation and the Calyxt Bylaws. Cibus Global is a Delaware limited liability company and the rights of Cibus Unitholders are governed by the laws of the State of Delaware,
including the DLLCA and the Cibus Operating Agreement. If the Mergers are completed, (1) Cibus Unitholders who receive Shares will become stockholders of Cibus, Inc., and (2) each share of Calyxt Common Stock held by a Calyxt Stockholder will
automatically remain outstanding as a share of Class A Common Stock, and in each case the rights of the stockholders of Cibus, Inc. will be governed by the DGCL, the Amended Bylaws and the Amended Certificate of Incorporation. The rights of
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Calyxt Stockholders contained in the Calyxt Certificate of Incorporation and Calyxt Bylaws differ from (1) the rights of Cibus Unitholders under the Cibus Operating Agreement and (2) the
post-Mergers rights of Cibus, Inc. stockholders, as more fully described under the section entitled &#147;<I>Comparison of Stockholders&#146; Rights</I>&#148; in this proxy statement/prospectus. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom401831_5"></A>MARKET PRICE AND DIVIDEND INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt Common Stock is listed on Nasdaq under the symbol &#147;CLXT.&#148; Cibus is a private company and Cibus Global common membership units
and Cibus Preferred Units are not publicly traded. The closing price of Calyxt Common Stock on January&nbsp;13, 2023, the last trading day prior to the public announcement of the Transactions, was $0.19 per share, and the closing price of Calyxt
Common Stock on April&nbsp;17, 2023, the last practicable trading day prior to the date of this proxy statement/prospectus, was $0.31&nbsp;per share, each as reported on Nasdaq. Because the market price of Calyxt Common Stock is subject to
fluctuation, the market value of the Class&nbsp;A Common Stock that certain Cibus Unitholders will be entitled to receive in the Transactions may increase or decrease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Assuming stockholder approval of Proposal Nos. 1 and 2 and successful application for initial listing on Nasdaq, following the consummation of
the Transactions, the Class&nbsp;A Common Stock will trade on Nasdaq under the new name, &#147;Cibus, Inc.&#148; and new trading symbol &#147;CBUS.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of April 12, 2023, the record date for the Calyxt Special Meeting, there were approximately 90 holders of record of Calyxt Common Stock.
This number does not include stockholders for whom shares were held in &#147;street name.&#148; As of April 12, 2023, there were 813 holders of record of Cibus Units and Cibus Preferred Units. For detailed information regarding the beneficial
ownership of certain beneficial holders and management of Calyxt, Inc., Cibus Global, and Cibus, Inc. upon consummation of the Transactions, see the sections entitled &#147;<I>Principal Stockholders of Calyxt, Inc.</I>,&#148; &#147;<I>Principal
Unitholders of Cibus Global</I>,&#148; and &#147;<I>Principal Stockholders of Cibus, Inc.</I>&#148; in this proxy statement/prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt, Inc. has never declared or paid any cash dividends on Calyxt Common Stock. Notwithstanding the foregoing, any
determination to pay cash dividends on the Class&nbsp;A Common Stock subsequent to the consummation of the Transactions will be at the discretion of the Cibus, Inc. Board and will depend upon a number of factors, including the Combined
Company&#146;s results of operations, financial condition, future prospects, contractual restrictions, restrictions imposed by applicable law and other factors the Cibus, Inc. Board deems relevant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom401831_6"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The Combined Company will be faced with a market environment that cannot be predicted and that involves significant risks, many of which
will be beyond its control. In addition to the other information contained in this proxy statement/prospectus, you should carefully consider the material risks described below and those described in the section entitled &#147;Cautionary Statement
Concerning Forward-Looking Statements&#148; beginning on page 114 of this proxy statement/prospectus before deciding how to vote your shares of Calyxt Common Stock. Except where specifically noted, the information in these Risk Factors and all other
information contained in this proxy statement/prospectus does not give effect to the Reverse Stock Splits described elsewhere in this proxy statement/prospectus and does not give effect to the issuance of any equity in the Continuing Series F
Financing or the Potential Calyxt Financing. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom401831_7"></A>Risks Related to the Mergers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The exchange ratio will not change or otherwise be adjusted based on the market price of Calyxt Common Stock as the exchange ratio is fixed as of the
date of the Merger Agreement, so the Merger Consideration at the Closing may have a greater or lesser value than at the time the Merger Agreement was signed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger Agreement has set the exchange ratio (referred to as the &#147;Conversion Factor&#148; in the Allocation Schedule) of
3.17045722397476 for the calculation of Class&nbsp;A Common Stock and Class&nbsp;B Common Stock to be issued as Merger Consideration, and the exchange ratio is based on the fully-diluted (other than with respect to out-of-the-money options and
warrants) capitalization of Calyxt, Inc. and Cibus Global, in each case, as of the date of the Merger Agreement as described in the section entitled &#147;<I>The Mergers&#151;Merger Consideration&#151;Allocation </I><I>Schedule</I>&#148; beginning
on page 28 of this proxy statement/prospectus. The exchange ratio does not give effect to the Reverse Stock Splits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The closing price of
Calyxt Common Stock on January&nbsp;13, 2023, the last trading day prior to the public announcement of the signing of the Merger Agreement, was $0.1857 per share. The Merger Agreement does not include a price-based termination right. Therefore, if
before the completion of the Mergers the market price of Calyxt Common Stock declines from the market price on the date of the Merger Agreement, then Cibus Unitholders could receive Merger Consideration with substantially lower value than the value
of such Merger Consideration on the date of the Merger Agreement. Similarly, if before the completion of the Mergers the market price of Calyxt Common Stock increases from the market price of Calyxt Common Stock on the date of the Merger Agreement,
then Cibus Unitholders could receive Merger Consideration with substantially greater value than the value of such Merger Consideration on the date of the Merger Agreement. Because the exchange ratio does not adjust as a direct result of changes in
the market price of Calyxt Common Stock, changes in the market price of Calyxt Common Stock will change the value of the total Merger Consideration payable to Cibus Unitholders pursuant to the Merger Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock price changes may result from a variety of factors, including changes in Calyxt&#146;s or Cibus&#146; respective businesses, operations
and prospects, reductions or changes in U.S. government spending or budgetary policies, market assessments of the likelihood that the Mergers will be completed, interest rates, federal, state and local legislation, governmental regulation, legal
developments in the industry segments in which Calyxt or Cibus operate, the timing of the Mergers, and general market, industry and economic conditions, including pandemics and other public health emergencies. Recent events surrounding the global
economy, geopolitics and the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic continue to evolve and have introduced unusually high levels of volatility into financial and stock markets, and may affect the value of Calyxt Common Stock. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Because the exchange ratio is fixed as of the date of the Merger Agreement, any Dilutive Issuances
will have the effect of diluting the anticipated post-Closing ownership percentage of Cibus, Inc. for both Calyxt Stockholders and Cibus Unitholders. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger Agreement has set the exchange ratio for the calculation of Class A Common Stock and Class B Common Stock to be issued as Merger
Consideration as of the date of the Merger Agreement. Accordingly, the exchange ratio does not take into account the Dilutive Issuances that may occur prior to or in connection with the Transactions. Except with respect to the recipients of equity
instruments in connection therewith (to the extent of such equity instruments received), any Dilutive Issuances will have the effect of diluting the anticipated <FONT STYLE="white-space:nowrap">post-Closing</FONT> ownership percentage of Cibus, Inc.
for both Calyxt Stockholders and Cibus Unitholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Calyxt Stockholders and Cibus Unitholders may not realize a benefit from the Mergers
commensurate with the ownership dilution they will experience in connection with the Mergers and the Potential Dilutive Issuances. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Combined Company is unable to realize the full strategic and financial benefits currently anticipated from the Mergers, Calyxt
Stockholders and Cibus Unitholders will have experienced substantial dilution of their ownership interests in their respective companies, without receiving any commensurate benefit, or only receiving part of the commensurate benefit to the extent
the Combined Company is able to realize only part of the strategic and financial benefits currently anticipated from the Mergers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based
on the capitalization of Calyxt, Inc. and Cibus Global, the Calyxt Stockholders would be expected to own approximately 5.0% of issued and outstanding Shares immediately post-Closing, on a Fully-Exchanged Basis, and Cibus Unitholders would be
expected to own approximately 95.0% of the issued and outstanding Shares immediately post-Closing, on a Fully-Exchanged Basis in each case, subject to any Dilutive Issuance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Merger Agreement, Cibus Global is permitted to issue additional Cibus Series F Preferred Units pursuant to the Continuing
Series F Financing. Any additional Cibus Series F Preferred Units issued prior to Closing will have the effect of diluting the anticipated post-Closing ownership of Cibus, Inc. for both Calyxt Stockholders and Cibus Unitholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the Closing, Calyxt, Inc., as agreed with Cibus Global, may decide to pursue a Potential Calyxt Financing. Although any such
Potential Calyxt Financing may be arranged prior to the Closing, because a Potential Calyxt Financing would be subject to, and conditioned upon, the Closing of the Transactions, any Class A Common Stock issued pursuant to such a Potential Calyxt
Financing will have the effect of diluting the anticipated post-Closing ownership of Cibus, Inc. for both Calyxt Stockholders and Cibus Unitholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, pursuant to the Merger Agreement, at the discretion of the Calyxt Board and/or compensation committee, Calyxt, Inc. is permitted
to issue up to an additional 3,487,503 Calyxt RSUs (of which 3,468,083 have been issued as of the date of this proxy statement/prospectus) with respect to 3,487,503 shares of Calyxt Common Stock (which amount is subject to adjustment, as applicable
and appropriate, to reflect fully the effect of any reclassification, split, reverse split (including the Reverse Stock Splits), distribution, reorganization, recapitalization or other like change with respect to the equity securities of Calyxt,
Inc. or any securities convertible or exchangeable into or exercisable equity securities of Calyxt, Inc. that may occur after the date of the Merger Agreement and prior to the grant date of such equity awards) pursuant to the Calyxt, Inc. 2017
Omnibus Incentive Plan, with such equity awards having accelerated vesting of 100% on a Triggering Event (as defined therein, which includes the Transactions). Any additional Calyxt RSUs issued by Calyxt, Inc. in connection with the foregoing will
have the effect of diluting the anticipated post-Closing ownership of Cibus, Inc. for both Calyxt Stockholders and Cibus Unitholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lastly, certain stock options issued under the 2017 Omnibus Incentive Plan and the Calyxt Common Warrants are outstanding. Although such
options and the Calyxt Common Warrant are out-of-the-money as of the date of this proxy statement/prospectus, future increases in the stock price of Calyxt, Inc. prior to Closing or in the stock price of Cibus, Inc. following closing may make the
exercise of such options or the Calyxt Common Warrants economically viable. In the event that holders exercise such stock options or the Calyxt Common </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Warrants, such exercises would have the effect of diluting the anticipated post-Closing ownership of Cibus, Inc. for both Calyxt Stockholders and Cibus Unitholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Failure to complete the Mergers may result in either Calyxt, Inc. or Cibus Global paying a termination fee to the other party and could significantly
harm the market price of Calyxt Common Stock and negatively affect the future business and operations of each company. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the
Mergers are not completed and the Merger Agreement is terminated under certain circumstances, Cibus Global may be required to pay Calyxt, Inc. a termination fee of $1.0&nbsp;million and reimburse Calyxt, Inc.&#146;s expenses up to a maximum of
$500,000, and Calyxt, Inc. may be required to pay Cibus Global a termination fee of $1.0&nbsp;million. Even if a termination fee or reimbursement of expenses of the other party are not payable in connection with a termination of the Merger
Agreement, each of Calyxt, Inc. and Cibus Global will have incurred significant fees and expenses, which must be paid whether or not the Mergers are completed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if the Merger Agreement is terminated and either the Calyxt Board or Cibus Board determines to seek another business combination,
there can be no assurance that either Calyxt or Cibus will be able to find a partner and close an alternative transaction on terms that are as favorable or more favorable than the terms set forth in the Merger Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Failure to complete the Mergers under certain circumstances may result in the Interim Funding being forgiven and Cibus and the Cibus Unitholders will
lose the benefit from any funds that have been made available to Calyxt prior to termination. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Mergers are not completed and
the Merger Agreement is terminated other than under certain circumstances, the outstanding balance of all amounts loaned by Cibus Global to Calyxt, Inc. under the Interim Funding will be forgiven in full by Cibus Global. As a result, Calyxt, Inc.
will be entitled to retain all such funds and those amounts will be a loss to Cibus Global and, indirectly, the Cibus Unitholders. Whereas, if the Mergers are completed, and all amounts loaned by Cibus Global under the Interim Funding are forgiven
by Cibus Global after the Closing, Cibus Unitholders will indirectly benefit from all such amounts as stockholders of Cibus, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any
delay in the Closing may increase the likelihood that Calyxt, Inc. is required to borrow more funds from Cibus Global under the Interim Funding, up to the maximum amount permitted under the Merger Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Merger Agreement and the issuance of Shares to Cibus Unitholders pursuant to the Merger Agreement must be approved by Calyxt Stockholders, and the
Merger Agreement and the Mergers must be approved by the Cibus Unitholders and the equityholders of the Blockers. Failure to obtain these approvals would prevent the Closing. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before the Mergers can be completed, the Calyxt Stockholders must approve, among other things, the issuance of Shares to Cibus Unitholders
pursuant to the Merger Agreement, and Cibus Unitholders and the equityholders of the Blockers must each adopt the Merger Agreement and approve the Cibus Merger and Blocker Mergers, respectively, as well as the other Transactions. Failure to obtain
the required Calyxt Stockholder, Cibus Unitholder and Blocker equityholder approvals may result in a material delay in, or the abandonment of, the Mergers. Any delay in completing the Mergers may materially adversely affect the timing and benefits
that are expected to be achieved from the Mergers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Mergers may be completed even though certain events may occur prior to the Closing that
materially and adversely affect Calyxt or Cibus. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger Agreement provides that either Calyxt or Cibus can refuse to complete
the Mergers if there is a material adverse effect on the other party between the date of the Merger Agreement and the Closing. However, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
certain types of changes do not permit either party to refuse to complete the Mergers, even if such change could be said to have a material adverse effect on Calyxt or Cibus, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general business or economic conditions generally affecting the industry in which Cibus or Calyxt and their
respective subsidiaries operate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acts of war, the outbreak or escalation of armed hostilities, acts of terrorism (including cyberterrorism),
earthquakes, wildfires, hurricanes or other natural disasters, health emergencies, including pandemics (including <FONT STYLE="white-space:nowrap">COVID-19)</FONT> and related or associated epidemics, disease outbreaks and any governmental or
industry responses thereto (including quarantine restrictions); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in financial, banking, securities markets, or general economic, regulatory, legislative or political
conditions (including changes in interest or exchange rates); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any change in, or any compliance with or action taken for the purpose of complying with, any appliable law or
GAAP (or interpretations of any applicable law or GAAP); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">effects resulting from the announcement of the Merger Agreement or the pendency of the Transactions;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the failure of Cibus to meet internal expectations or projections or the results of operations of Cibus in and of
itself (it being understood, however, that any effect causing or contributing to such failure may be taken into account in determining whether a material adverse effect on Cibus has occurred, unless such effects are otherwise excepted elsewhere); or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">effects resulting from the taking of any action required to be taken by the Merger Agreement.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If material adverse effects occur and Calyxt, the Blockers and Cibus still complete the Mergers, the market price of
the Cibus, Inc. Class A Common Stock may suffer. This in turn may reduce the value of the Mergers to the Calyxt Stockholders, Cibus Unitholders or both. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Some Calyxt, Inc. and Cibus Global executive officers and directors have interests in the Mergers that are different from the Calyxt Stockholders and
Cibus Unitholders and that may influence them to support or approve the Mergers without regard to the interests of the Calyxt Stockholders and Cibus Unitholders. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain executive officers and directors of Calyxt, Inc. and Cibus Global participate in arrangements that provide them with interests in the
Mergers that are different from the interests of the Calyxt Stockholders and Cibus Unitholders, including, among others, severance benefits, the acceleration of equity vesting and continued indemnification. The compensation arrangements with Calyxt,
Inc.&#146;s executive officers and directors, as well as the interests of those individuals in the Mergers, are discussed in greater detail in the sections entitled &#147;<I>The Mergers&#151;Interests of Calyxt, Inc. Directors and Executive Officers
in the Mergers</I>&#148; and &#147;<I>Calyxt, Inc. Executive Compensation&#151;Director Compensation</I>&#148; beginning on pages 145 and 290, respectively, of this proxy statement/prospectus. The compensation arrangements with Cibus Global
executive officers and managers, as well as the interests of those individuals in the Mergers, are discussed in greater detail in the sections entitled &#147;<I>The Mergers&#151;Interests of Cibus Global Directors and Executive Officers in the
Mergers</I>&#148; and &#147;<I>Cibus Global Executive Compensation&#151;Cibus Global Director Compensation</I>&#148; beginning on pages 307 and 313, respectively, of this proxy statement/prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Rory Riggs, Peter Beetham, Ph.D., Mark Finn, Jean-Pierre Lehmann, Gerhard Prante, Ph.D. and Keith&nbsp;Walker, Ph.D., who currently serve on
the Cibus Board will become members of the Cibus, Inc. Board following the Mergers. Further, Rory Riggs, Cibus Global&#146;s Chief Executive Officer and Chair, will become Cibus, Inc.&#146;s Chief&nbsp;Executive Officer and Chair following the
Mergers; Peter Beetham, Ph.D., Cibus Global&#146;s President and Chief&nbsp;Operating Officer, will become Cibus, Inc.&#146;s President and Chief Operating Officer following the Mergers; Greg Gocal, Ph.D., Cibus Global&#146;s Chief Scientific
Officer and Executive Vice President, will become Cibus, Inc.&#146;s Chief&nbsp;Scientific Officer and Executive Vice President following the Mergers; and Wade King, M.D., Cibus Global&#146;s Chief Financial Officer, will become Cibus, Inc.&#146;s
Chief Financial Officer following the Mergers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, certain Cibus Global executive officers and directors, in the event they hold
Cibus Global membership units qualifying them as a Top 99 Holder, will have the right to elect to receive <FONT STYLE="white-space:nowrap">Up-C</FONT> Units in exchange for a portion of their Cibus Units (up to a maximum of 95%). To the extent such
Cibus Global executive officers and directors elect to receive <FONT STYLE="white-space:nowrap">Up-C</FONT> Units, they will be entitled to certain benefits pursuant to the Tax Receivable Agreement, Exchange Agreement and Registration Rights
Agreement. This right is not available to Cibus Unitholders who are not Top 99 Holders. The election rights of Cibus Unitholders are discussed in greater detail in the sections entitled &#147;<I>The Mergers&#151;Merger Consideration</I>&#148;
beginning on page&nbsp;162 of this proxy statement/prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These interests, among others, may influence the executive officers and
directors of Calyxt, Inc. and Cibus Global to support or approve the Mergers. For more information concerning the interests of Calyxt, Inc.&#146;s and Cibus Global&#146;s respective executive officers and directors, see the sections entitled
&#147;<I>The Mergers&#151;Interests of Calyxt, Inc. Directors and Executive Officers in the Mergers&#148;</I> and &#147;<I>The Mergers&#151;Interests of Cibus Global Directors and Executive Officers in the Mergers</I>&#148; beginning on pages 145
and 155, respectively, of this proxy statement/prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The market price of the Class A Common Stock following the Mergers may decline as a
result of the Mergers. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The market price of the Class A Common Stock may decline as a result of the Mergers for a number of
reasons, including if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">investors react negatively to the prospects of the Combined Company&#146;s product candidates, business and
financial condition following the merger; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of the Mergers on the Combined Company&#146;s business and prospects is not consistent with the
expectations of financial or industry analysts; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Combined Company does not achieve the perceived benefits of the Mergers as rapidly or to the extent
anticipated by financial or industry analysts. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Calyxt Stockholders and Cibus Unitholders will have a reduced ownership and voting
interest in, and will exercise less influence over the management of, the Combined Company following the Closing as compared to their current ownership and voting interest in the respective companies. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Mergers are completed, the current Calyxt Stockholders and Cibus Unitholders will own a smaller percentage of the Combined Company than
their ownership in their respective companies prior to the Mergers. Based on the capitalization of Calyxt and Cibus, the Calyxt Stockholders would be expected to own approximately 5.0% of the Shares immediately post-Closing, on a Fully-Exchanged
Basis, and Cibus Unitholders would be expected to own approximately 95.0% of the issued and outstanding Shares immediately post-Closing, on a <FONT STYLE="white-space:nowrap">Fully-Exchanged</FONT> Basis, in each case, subject to dilution in
connection with any Dilutive Issuances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Raising additional capital may cause dilution to Cibus, Inc.&#146;s stockholders, restrict the Combined
Company&#146;s operations or require the Combined Company to relinquish rights to its technologies or product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until
such time, if ever, as the Combined Company can generate substantial revenues from product sales, the Combined Company expects to finance its cash needs through a combination of public and private equity offerings, debt financings, collaborations,
strategic alliances and marketing, distribution or licensing arrangements. The Combined Company does not currently have any committed external source of funds following the Closing. The terms of any financing may adversely affect the holdings or the
rights of Cibus, Inc.&#146;s stockholders and the issuance of additional securities, whether equity or debt, by Cibus, Inc., or the possibility of such issuance, may cause the market price of the Class A Common Stock to decline. To the extent that
Cibus, Inc. raises additional capital through the sale of equity or convertible debt securities, the ownership interest of Cibus, Inc.&#146;s stockholders will be diluted, and the terms of those securities may include liquidation or other
preferences that adversely affect the rights of such stockholders. Debt financing and preferred equity financing, if available, would increase the Combined Company&#146;s fixed payment obligations and may involve agreements that include covenants
limiting or restricting the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Combined Company&#146;s operations and ability to take specific actions, such as incurring additional debt, making acquisitions, engaging in acquisition, merger or collaboration transactions,
selling or licensing the Combined Company&#146;s assets, making capital expenditures, redeeming its stock, making certain investments, declaring dividends or other operating restrictions that could adversely impact the Combined Company&#146;s
ability to conduct its business. The Combined Company could also be required to meet certain milestones in connection with debt financing and the failure to achieve such milestones by certain dates may force the Combined Company to relinquish rights
to some of its technologies or product candidates or otherwise agree to terms unfavorable to the Combined Company which could have a material adverse effect on the Combined Company&#146;s business, operating results and prospects. The Combined
Company also could be required to seek funds through arrangements with collaborators or otherwise at an earlier stage than otherwise would be desirable. If the Combined Company raises funds through additional collaborations, strategic alliances or
marketing, distribution or licensing arrangements with third parties, the Combined Company may have to relinquish valuable rights to its intellectual property, future revenue streams, discovery programs or product candidates, grant licenses on terms
that may not be favorable to the Combined Company or grant rights to develop and market product candidates that the Combined Company would otherwise prefer to develop and market itself, any of which may have a material adverse effect on the Combined
Company&#146;s business, operating results and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>During the pendency of the Mergers, Calyxt and Cibus may not be able to enter into a
business combination with another party on more favorable terms because of restrictions in the Merger Agreement, which could adversely affect their respective business prospects. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Covenants in the Merger Agreement impede the ability of Calyxt and Cibus to make acquisitions during the pendency of the Mergers, subject to
specified exceptions. As a result, if the Mergers are not completed, the parties may be at a disadvantage to their competitors during such period. In addition, while the Merger Agreement is in effect, each party is generally prohibited from directly
or indirectly soliciting, initiating or knowingly encouraging, inducing or facilitating the communication, making, submission or announcement of any acquisition proposal or acquisition inquiry by a third party or take any action that could
reasonably be expected to lead to an acquisition proposal or acquisition inquiry by a third party, including a merger, sale of assets or other business combination, subject to specified exceptions. Any such transactions could be favorable to such
party&#146;s stockholders or unitholders, but the parties may be unable to pursue them. For more information, see the section entitled &#147;<I>The Merger Agreement&#151;No Solicitation</I>&#148; beginning on page 177 of this proxy
statement/prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Certain provisions of the Merger Agreement may discourage third parties from submitting alternative takeover proposals,
including proposals that may be superior to the Transactions. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms of the Merger Agreement prohibit each of Calyxt, Inc. and
Cibus Global from soliciting alternative takeover proposals or cooperating with persons making unsolicited takeover proposals, except in limited circumstances when the Calyxt Board determines in good faith, after consultation with Calyxt,
Inc.&#146;s outside financial advisors and outside legal counsel, constitutes, or would be reasonably likely to result in, a superior takeover proposal and that the failure to take such action would be reasonably likely to be inconsistent with the
fiduciary duties of the Calyxt Board under applicable law. Any such transactions could be favorable to Calyxt Stockholders or Cibus Unitholders, as applicable. In addition, if Calyxt, Inc. terminates the Merger Agreement under certain circumstances,
including terminating because of a decision of the Calyxt Board to enter into a definitive agreement with respect to a superior takeover proposal, Calyxt, Inc. would be required to pay a termination fee of $1.0&nbsp;million to Cibus Global. This
termination fee described above may discourage third parties from submitting alternative takeover proposals to Calyxt, Inc. or Calyxt Stockholders, and may cause the Calyxt Board to be less inclined to recommend an alternative takeover proposal.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Because the lack of a public market for Cibus Units makes it difficult to evaluate the value of Cibus Units and Cibus Warrants, the Cibus
Unitholders may receive Shares in the Mergers that have a value that is less than, or greater than, the fair market value of Cibus Units or Cibus Warrants. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The outstanding Cibus Units and Cibus Warrants are privately held and are not traded in any public market. The lack of a public market makes it
extremely difficult to determine the fair market value of Cibus Units or Cibus </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Warrants. Because the percentage of the Shares to be issued to Cibus Unitholders was determined based on negotiations between the parties, it is possible the value of the Shares to be received by
Cibus Unitholders will be less than the fair market value of Cibus Units or Cibus Warrants, or the value of the Shares to be received by Cibus Unitholders may be more than the aggregate fair market value of Cibus Units or Cibus Warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If the conditions to the Mergers are not satisfied or waived, the Mergers will not occur. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if the Transactions are approved by the Calyxt Stockholders, the equityholders of the Blockers and the Cibus Unitholders, certain other
specified conditions set forth in the Merger Agreement must be satisfied or, to the extent permitted by applicable law, waived to complete the Mergers, including approval from Nasdaq to maintain the listing of the Calyxt Common Stock, as Class A
Common Stock, on Nasdaq following the Mergers and the listing of the Class A Common Stock being issued in the Mergers. These conditions are set forth in the Merger Agreement and each material condition to the completion of the Mergers is described
in the section entitled &#147;<I>The Merger Agreement&#151;Conditions to the Completion of the Mergers</I>&#148; beginning on page 173 of this proxy statement/prospectus. Calyxt and Cibus cannot assure you that all of the conditions will be
satisfied or waived. If the conditions are not satisfied or waived, the Mergers will not occur or will be delayed, and Calyxt and Cibus each may lose some or all of the intended benefits of the Mergers as a result. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Cibus Merger may fail to qualify as a transaction described under Section&nbsp;351 of the Code for U.S. federal income tax purposes, resulting in
recognition of taxable gain or loss by Cibus Participants in respect of their Cibus Global interests. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The parties intend for the
Cibus Merger to be treated for U.S. federal income tax purposes as a <FONT STYLE="white-space:nowrap">tax-free</FONT> exchange under Section&nbsp;351 of the Code. Assuming that the Cibus Merger so qualifies, Cibus Participants that receive solely
shares of Class&nbsp;A Common Stock in the Transactions will generally not recognize gain or loss upon the exchange of their Cibus Units or Cibus Warrants for shares of Class&nbsp;A Common Stock pursuant to the Cibus Merger, except to the extent
that the Cibus Participant&#146;s allocable share of Cibus&#146; liabilities exceeds the Cibus Participant&#146;s tax basis in its Cibus Units or Cibus Warrants exchanged for Class&nbsp;A Common Stock. However, as discussed further in the section
entitled &#147;<I>The Mergers&#151;Material U.S. Federal Income Tax Consequences of the Cibus Merger</I>&#148; the requirements for <FONT STYLE="white-space:nowrap">non-recognition</FONT> under such Code section is complex, and qualification under
Section&nbsp;351 of the Code could be adversely affected by events that are beyond the parties control. Moreover, there could be technical uncertainties as to whether the Cibus Merger qualifies for such intended tax treatment. If the Cibus Merger
does not meet the requirements of Section&nbsp;351 of the Code, the exchange of Cibus Units or Cibus Warrants for Class&nbsp;A Common Stock would be a fully taxable transaction for U.S. federal income tax purposes and Cibus Participants generally
would recognize taxable gain or loss on the respective consideration for Cibus Units or Cibus Warrants that they receive in connection with the Cibus Merger. Neither Cibus nor Calyxt has requested, or intends to request, a ruling from the IRS with
respect to the U.S. federal income tax consequences of the Cibus Merger. Consequently, no assurance can be given that the IRS will not assert, or that a court would not sustain, a position to the contrary. Each Cibus Unitholder and holder of Cibus
Warrants is urged to consult with his, her or its own tax advisor with respect to the tax consequences of the Transactions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Lawsuits have been
filed, and additional lawsuits may be filed in the future, against Calyxt, Inc. and the members of the Calyxt Board arising out of the Transactions, which may delay or prevent the Closing of the Transactions. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2023, complaints were filed in each of the Court of Chancery for the State of Delaware and in the U.S. District Court for District of
Minnesota against Calyxt, Inc. and the members of the Calyxt Board. Additional putative stockholder complaints, including stockholder class action complaints, and other complaints may be filed against Calyxt, Inc., the Calyxt Board, Cibus Global,
and/or the Cibus Board in connection with the Transactions contemplated by the Merger Agreement. The outcome of litigation is uncertain, and Calyxt, Inc. and Cibus Global may not be successful in defending against any such future claims. Lawsuits
that may be filed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
against Calyxt, Inc., the Calyxt Board, Cibus Global, and/or the Cibus Board could delay or prevent the merger, divert the attention of the management teams and employees of Calyxt, Inc. and
Cibus Global from <FONT STYLE="white-space:nowrap">day-to-day</FONT> business and otherwise adversely affect the business and financial condition of Calyxt, Inc., Cibus Global or the Combined Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom401831_8"></A>Risks Related to the Reverse Stock Splits </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Reverse Stock Splits could result in a significant devaluation of Calyxt&#146;s market capitalization and the trading price of Calyxt Common Stock.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although Calyxt expects that the Reverse Stock Splits will result in an increase in the market price of Calyxt Common Stock,
Calyxt cannot assure stockholders that the Reverse Stock Splits, if implemented, will increase the market price of Calyxt Common Stock in proportion to the reduction in the number of shares of Calyxt Common Stock outstanding or result in a permanent
increase in the market price. Accordingly, the total market capitalization of Calyxt Common Stock after either or both of the Reverse Stock Splits may be lower than the total market capitalization before such Reverse Stock Splits and, in the future,
the market price of Calyxt Common Stock following such Reverse Stock Splits may not exceed or remain higher than the market price prior to the corresponding Reverse Stock Split. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The effect the Reverse Stock Splits may have upon the market price of Calyxt Common Stock cannot be predicted with any certainty. The market
price of Calyxt Common Stock is dependent on many factors, including Calyxt&#146;s business and financial performance, general market conditions, prospects for future success and other factors detailed from time to time in the reports Calyxt, Inc.
files with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Reverse Stock Splits may result in some stockholders owning &#147;odd lots&#148; that may be more difficult to sell or
require greater transaction costs per share to sell. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Reverse Stock Splits may result in some stockholders owning &#147;odd
lots&#148; of less than 100 shares of Calyxt Common Stock on a post-split basis. These odd lots may be more difficult to sell, or require greater transaction costs per share to sell, than shares in &#147;round lots&#148; of even multiples of 100
shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Reverse Stock Splits may not generate additional investor interest. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While the Calyxt Board believes that a higher stock price may help generate investor interest, there can be no assurance that the Reverse Stock
Splits will result in a per share price that will attract institutional investors or investment funds or that such share price will satisfy the investing guidelines of institutional investors or investment funds. As a result, the trading liquidity
of Calyxt Common Stock may not necessarily improve. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Reverse Stock Splits may not increase the price of the Class A Common Stock over the long
term. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One of the purposes of the Reverse Stock Splits is to increase the per share market price of the Calyxt Common Stock and, if
the Mergers are consummated, the per share market price of the Class&nbsp;A Common Stock of Cibus, Inc. It cannot be assured, however, that the Reverse Stock Splits will accomplish this objective for any meaningful period of time. While it is
expected that the reduction in the number of outstanding shares of Calyxt Common Stock will proportionally increase the per share market price of Calyxt Common Stock, it cannot be assured that the Reverse Stock Splits will increase the per share
market price of Calyxt Common Stock by a multiple of the ratios of the Reverse Stock Splits or, if the Mergers are consummated, result in any permanent or sustained increase in the per share market price of the Class&nbsp;A Common Stock, which will
be dependent upon many factors, including the Combined Company&#146;s business and financial performance, general market conditions and prospects for future success. Thus, while the price of the Class A Common Stock might meet the continued listing
requirements for Nasdaq initially, it cannot be assured that it will continue to do so. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Reverse Stock Splits may decrease the liquidity of the Class&nbsp;A Common Stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the Calyxt Board believes that the anticipated increase in the per share market price of the Calyxt Common Stock and subsequently the
Cibus, Inc. Class&nbsp;A Common Stock as a result of the Reverse Stock Splits could encourage interest in the Calyxt Common Stock and subsequently the Class&nbsp;A Common Stock and possibly promote greater liquidity for stockholders of thereof, such
liquidity could also be adversely affected by the reduced number of shares outstanding after the Reverse Stock Splits. The reduction in the number of outstanding shares may lead to reduced trading and a smaller number of market makers for the Calyxt
Common Stock and subsequently the Class&nbsp;A Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should the market price of the Calyxt Common Stock or the Class&nbsp;A
Common Stock decline after the Reverse Stock Splits, the percentage decline may be greater, due to the smaller number of shares outstanding, than it would have been prior to the Reverse Stock Splits. The Reverse Stock Splits may be viewed negatively
by the market and, consequently, may lead to a decrease in the Cibus, Inc. overall market capitalization. If the per share market price does not increase in proportion to the exact ratios of the Reverse Stock Splits, then the value of the Combined
Company, as measured by its stock capitalization, will be reduced. In some cases, the per share market price of companies that have effected reverse stock splits subsequently declined back to <FONT STYLE="white-space:nowrap">pre-reverse</FONT> split
levels, and accordingly, it cannot be assured that the total market value of the Calyxt Common Stock and subsequently the Class&nbsp;A Common Stock will remain the same after the Reverse Stock Splits are effected, or that the Reverse Stock Splits
will not have an adverse effect on the price of the Calyxt Common Stock or the Class&nbsp;A Common Stock due to the reduced number of outstanding shares after the Reverse Stock Splits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Calyxt Board will determine the ratio of the Subsequent Reverse Stock Split in its discretion and may consider a variety of factors in making its
determination. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Proposal No.&nbsp;4 is approved by Calyxt Stockholders, Calyxt, Inc. intends to effect the Subsequent Reverse
Stock Split of its issued Calyxt Common Stock by a ratio of not less than <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-to-2</FONT></FONT> and not greater than 1-to-10, or any whole number in between. If Proposal Nos. 1 and 2
are approved, the exact ratio of the Subsequent Reverse Stock Split will be determined in the discretion of the Calyxt Board in consultation and cooperation with Cibus Global prior to the Effective Time of the Subsequent Reverse Stock Split, in
accordance with the terms set forth in Proposal No.&nbsp;4. If Proposal Nos. 1 and 2 are not approved or the Mergers are not consummated, the Calyxt Board may elect to proceed with the Subsequent Reverse Stock Split even in the absence of completion
of the Mergers, and the exact ratio of the Subsequent Reverse Stock Split will be determined by the Calyxt Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One of the purposes of
the Reverse Stock Splits is to increase the per share market price of Calyxt Common Stock. In addition, the Calyxt Board believes a higher stock price may help generate investor interest in Calyxt. Therefore, the Calyxt Board may consider additional
factors in determining to approve a Subsequent Reverse Stock Split ratio in an attempt to achieve a higher price per share. Such additional factors may include the historical trading price and trading volume of Calyxt Common Stock; the then
prevailing trading price and trading volume of Calyxt Common Stock, including as a result of the Initial Reverse Stock Split, and the anticipated impact of the Reverse Stock Splits on the trading market for Calyxt Common Stock; the anticipated
impact of the Reverse Stock Splits on Calyxt&#146;s ability to raise additional financing; and prevailing general market and economic conditions. For more information on the factors that may be considered in determining the Subsequent Reverse Stock
Split ratio, see &#147;<I>Proposal No.</I><I></I><I>&nbsp;4: Approval of an amendment to the Calyxt Certificate of Incorporation to effect the Subsequent Reverse Stock Split at the discretion of the Calyxt Board.&#148;</I> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom401831_9"></A>Risks Related to Calyxt </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>There is no assurance that the Mergers will be completed in a timely manner or at all. If the Mergers are not consummated, Calyxt&#146;s business could
suffer materially and its stock price could decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Closing is subject to a number of closing conditions, including the
approval by Calyxt Stockholders of the issuance of Shares pursuant to the Merger Agreement and other customary closing conditions. If the conditions are not satisfied or waived, the Mergers will not occur or will be delayed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Mergers are not consummated, Calyxt may be subject to a number of material risks, and
Calyxt&#146;s business and stock price could be adversely affected, as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Calyxt has incurred and expects to continue to incur significant expenses related to the Mergers even if the
Mergers are not consummated; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Calyxt could be obligated to pay Cibus a termination fee of up to $1.0&nbsp;million under certain circumstances
pursuant to the Merger Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the market price of Calyxt Common Stock may decline to the extent that the current market price reflects a market
assumption that the Mergers will be completed; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Calyxt may not be able to pursue an alternate merger or other strategic transaction if the Transactions with
Cibus are not completed. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If the Mergers are not completed, the Calyxt Board may decide to pursue a liquidation and dissolution of
Calyxt. In such an event and in light of Calyxt&#146;s current capital resource constraints, it is unlikely that substantial resources would be available for distributions to stockholders. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While Calyxt has entered into the Merger Agreement with Cibus, the Closing may be delayed or may not occur at all, and there can be no
assurance that the Mergers, if completed, will deliver the anticipated benefits Calyxt expects or enhance stockholder value. If the Mergers are not completed and the Merger Agreement is terminated under certain circumstances, Calyxt may be required
to pay Cibus a termination fee of $1.0&nbsp;million. Even if a termination fee is not payable in connection with a termination of the Merger Agreement, Calyxt will have incurred significant fees and expenses, which must be paid whether or not the
merger is completed. Further, beginning at the earlier of March&nbsp;15, 2023 and the date Calyxt&#146;s unrestricted cash balance first drops below $1.5&nbsp;million, Calyxt can request, and Cibus has agreed to provide, the Interim Funding. Calyxt
made an initial draw under the Interim Funding on March 15, 2023 and an additional draw on March 30, 2023. While the outstanding balance of the Interim Funding will be reduced to zero in connection with the Closing, if the Merger Agreement is
terminated under certain circumstances, any portion of the Interim Funding that has been drawn would become due and payable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If for any
reason the Mergers are not completed, the Calyxt Board may elect to, among other things, attempt to complete another strategic transaction, attempt to sell or otherwise dispose of the various assets of Calyxt, or seek to continue to operate
Calyxt&#146;s business. Any of these alternatives would be costly and time-consuming and would require that Calyxt obtain additional near-term funding. Calyxt expects that it would be difficult to secure such funding in a timely manner, on favorable
terms or at all. Further, in each of the foregoing scenarios, the failure to complete the Mergers may result in negative publicity and a negative impression of Calyxt in the investment community, could significantly harm the market price of Calyxt
Common Stock, may affect Calyxt&#146;s relationship with employees, customers and potential customers and other partners in the business community, and may make further impede the ability to raise additional financing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt cautions that it is unlikely that Calyxt will be able to obtain additional financing or to find a new strategic partner. If a new
strategic partner were identified, Calyxt can provide no assurance that it would be able to close an alternative transaction on terms that are at least as favorable as the terms set forth in the Merger Agreement. Accordingly, there is significant
risk that such alternatives, if any, may not be successfully consummated, if pursued. To the extent that Calyxt seeks and is able to raise additional capital through the sale of equity or convertible debt securities, Calyxt Stockholders&#146;
ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect their rights as a Calyxt Stockholder. Debt financing or preferred equity financing, if available, may involve
agreements that include covenants limiting or restricting Calyxt&#146;s ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If Calyxt raises funds through strategic transactions or
commercial or licensing arrangements with third parties, Calyxt may have to relinquish valuable rights to its intellectual property, technologies, future revenue streams or product candidates or to grant licenses on terms that may not be favorable
to it. Even if consummated, it is unlikely that any such transaction will fully address </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Calyxt&#146;s current capital resource constraints and liquidity challenges, and Calyxt may need to significantly delay or further scale back operations beyond its already narrowly focused
operational activities. In such circumstances, the Calyxt Board may decide that it is in the best interests of the Calyxt Stockholders to dissolve the company and liquidate its assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Mergers are not completed, the Calyxt Board may decide that it is in the best interests of the Calyxt Stockholders to dissolve the
company and liquidate its assets. In that event, the amount of cash, if any, available for distribution to the Calyxt Stockholders would depend on the timing of such decision and the timing of such liquidation since the amount of cash available for
distribution continues to decrease as Calyxt funds its operations and incurs fees and expenses related to the Mergers, including pursuant to the Interim Funding. In addition, if the Calyxt Board were to approve and recommend, and the Calyxt
Stockholders were to approve, a dissolution of Calyxt, it would be required under the DGCL to pay its outstanding obligations, as well as to make reasonable provision for contingent and unknown obligations, prior to making any distributions in
liquidation to the Calyxt Stockholders. As a result of this requirement, a portion of Calyxt&#146;s assets may need to be reserved pending the resolution of such obligations. In addition, Calyxt may be subject to litigation or other claims related
to a liquidation and dissolution of the company. If a liquidation and dissolution were pursued, the Calyxt Board, in consultation with its advisors, would need to evaluate these matters and make a determination about a reasonable amount to reserve.
Accordingly, in such a circumstance and in light of Calyxt&#146;s current capital resources, it is highly unlikely that substantial resources, if any, would be available for distributions to stockholders. Calyxt Stockholders would likely lose all or
a significant portion of their investment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Calyxt has engaged in cost reduction and other cash-focused measures, which may result in challenges in
managing its business and executing on its business strategy while successfully completing the Mergers. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In light of Calyxt&#146;s
capital resource constraints in recent quarters, management has implemented cost reduction and other cash-focused measures, including reduction of capital expenditures, headcount reductions, and renegotiation or termination of professional services
agreements. To conserve cash, Calyxt has also strategically evaluated its arrangements with suppliers and service providers and has, in several instances, transitioned such relationships to lower cost alternative providers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the course of discussions with Cibus regarding, and following the execution of, the Merger Agreement, Calyxt has further streamlined
and focused its business activities on preserving cash sufficient to achieve a closing of the Mergers. Accordingly, Calyxt has taken additional steps to reduce its operating expenses and has focused its continuing operations on scaling production of
its Plant Cell Matrix<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> with its manufacturing partner, licensing efforts with respect to its PlantSpring<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> technology and plant traits
and continuing to progress its three key customer projects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt&#146;s cost reduction measures have included headcount reductions,
which result in the loss of institutional knowledge and expertise as well as reallocations and combinations of certain roles and responsibilities, in each case, which could adversely affect Calyxt&#146;s operations. As of January 31, 2023, Calyxt
had 28 full-time employees, of which ten are within Calyxt&#146;s administrative, legal and finance functions. Calyxt&#146;s ability to continue its <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT>
operations and to successfully complete the Mergers depends in large part on its ability to retain certain remaining personnel. Despite Calyxt&#146;s efforts to retain employees, one or more key employees could terminate their employment with Calyxt
on short notice. The loss of the services of certain employees could potentially harm Calyxt&#146;s ability to consummate the Mergers, to continue its <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT>
business operations, including the progression of its key customer projects, or to fulfill its reporting obligations as a Nasdaq-listed public company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If for any reason the Mergers are not completed and the Calyxt Board seeks to continue to operate Calyxt&#146;s business, Calyxt will face
challenges resulting from its streamlined personnel, who will need to continue to implement Calyxt&#146;s managerial, operational, and financial systems, manage its facilities, and progress customer projects and licensing efforts. As a result,
Calyxt&#146;s management may need to divert a disproportionate amount of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
its attention away from Calyxt&#146;s <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> strategic and operational activities and devote a substantial
amount of time to managing organizational changes. Further, cash-focused headcount reduction measures may yield unintended consequences, such as attrition beyond Calyxt&#146;s intended reduction in headcount and reduced employee morale. In addition,
reductions in the size of Calyxt may result in employees who were not affected by the reductions in headcount seeking alternate employment. The loss of the services of certain employees could potentially harm Calyxt&#146;s ability to continue its <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> business operations, including the progression of its key customer projects, or to fulfill its reporting obligations as a Nasdaq-listed public company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, cost reduction and cash-focused measures that Calyxt has undertaken may result in weaknesses in Calyxt&#146;s infrastructure and
operations, an inability to effectively execute on customer acquisition and business development efforts, loss of business opportunities, reduced productivity among remaining employees, and challenges in complying with legal and regulatory
requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Mergers are not consummated, the negative events referred to above would have a material adverse impact on
Calyxt&#146;s business, operations, reputation, and long-term viability. Moreover, negative publicity associated with such cost-reduction activities and Calyxt&#146;s failure to consummate the Mergers could adversely affect Calyxt&#146;s
relationships with its suppliers, service providers, customers and potential customers, employees, and other third parties, which in turn could further adversely affect its operations and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The issuance of Shares to Cibus Global equityholders in the Transactions will dilute substantially the voting power of Calyxt Stockholders. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Mergers are completed, each outstanding equity interest in Cibus Global will be converted into the right to receive a number of Shares
equal to the exchange ratios determined pursuant to the Merger Agreement. Immediately following the Transactions, <FONT STYLE="white-space:nowrap">pre-Closing</FONT> Calyxt Stockholders are expected to own approximately 5.0% of the issued and
outstanding Shares, on a Fully-Exchanged Basis, and <FONT STYLE="white-space:nowrap">pre-Closing</FONT> holders of Cibus Global membership units and Cibus Warrants are expected to own approximately 95.0% of the issued and outstanding Shares, on a
Fully-Exchanged Basis, in each case, subject to dilution in connection with any Dilutive Issuances. Accordingly, the issuance of Shares to Cibus Global equity holders in the Transactions will reduce significantly the relative voting power of each
share of Calyxt Common Stock, which are to remain outstanding as Class A Common Stock in connection with the Mergers, held by current Calyxt Stockholders. Consequently, Calyxt Stockholders as a group will have significantly less influence over the
management and policies of the Combined Company after the Mergers than prior to the Mergers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Combined Company is unable to realize
the strategic and financial benefits currently anticipated from the Mergers, the Calyxt Stockholders will have experienced substantial dilution of their ownership interests without receiving the expected commensurate benefit, or receiving only part
of the commensurate benefit to the extent the combined organization is able to realize only part of the expected strategic and financial benefits currently anticipated from the Mergers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The pendency of the Mergers could have an adverse effect on the trading price of Calyxt Common Stock and Calyxt&#146;s business, financial condition,
results of operations or business prospects. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pendency of the Mergers could disrupt Calyxt&#146;s businesses in the following
ways, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the attention of Calyxt&#146;s management may be directed toward the Closing and related matters and may be
diverted from the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> business operations; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third parties may seek to terminate or renegotiate their relationships with Calyxt as a result of the Mergers,
whether pursuant to the terms of their existing agreements with Calyxt or otherwise. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should they occur, any of these
matters could adversely affect the trading price of Calyxt Common Stock or harm Calyxt&#146;s financial condition, results of operations or business prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Calyxt&#146;s Financial Position and Need for Additional Capital </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If the Mergers are not completed, Calyxt&#146;s ability to continue as a going concern will depend on its ability to obtain additional near-term
financing, which may not be available on acceptable terms or at all. Failure to obtain this necessary capital when needed may force it to delay, limit or terminate its product development efforts or cease operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December 31, 2022, Calyxt had $3.4&nbsp;million of cash and cash equivalents. Calyxt&#146;s net loss was $16.9&nbsp;million for the
fiscal year ended December 31, 2022, and it used $19.4&nbsp;million of cash for operating activities for the fiscal year ended December&nbsp;31, 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt has incurred losses since its inception. If the Mergers are not completed and Calyxt does not pursue a liquidation and dissolution or
an alternative strategic transaction, Calyxt expects to continue to incur significant expenses and operating losses for the next several years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In light of Calyxt&#146;s capital resource constraints in recent quarters, management has implemented cost reduction and other cash-focused
measures to manage liquidity, including reduction of capital expenditures, headcount reductions, and renegotiation or termination of professional services agreements. To conserve cash, Calyxt has also strategically evaluated its arrangements with
suppliers and service providers and has, in several instances, transitioned such relationships to lower cost alternative providers. During the course of discussions with Cibus regarding, and following the execution of, the Merger Agreement, Calyxt
has streamlined and focused its business activities on preserving cash sufficient to achieve the Closing. In light of these efforts, and taking into account the available Interim Funding from Cibus, Calyxt believes it has sufficient cash to fund
operations through the end of the second quarter of 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Mergers are not completed and Calyxt does not pursue a liquidation and
dissolution, its ability to continue as a going concern will depend on its ability to obtain near-term additional public or private equity or debt financing, obtain government or private grants and other similar types of funding, attain further
operating efficiencies, and to further reduce or contain expenditures. If Calyxt were unable to raise additional capital in the near term and in a sufficient amount, it would likely need to implement increasingly stringent cost saving measures and
significantly delay, scale back, or cease operations, in part or in full. Accordingly, Calyxt&#146;s management has concluded there is substantial doubt regarding its ability to continue as a going concern. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Calyxt were able to raise additional funds through the issuance of additional debt or equity securities in such circumstances, it could
result in substantial dilution to Calyxt Stockholders and increased fixed payment obligations, and these securities may have rights senior to those of the Calyxt Common Stock. Any of these events could significantly harm Calyxt&#146;s business,
financial condition, and prospects. In light of the current price of Calyxt Common Stock and capital resource constraints, there can be no assurance that a potential financing transaction, if any were available, would be sufficient for Calyxt&#146;s
financing needs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Calyxt currently has no source of material near-term revenue and may never become profitable. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the course of discussions with Cibus regarding, and following the execution of, the Merger Agreement, Calyxt has streamlined and focused
its business activities on preserving cash sufficient to achieve the Closing. Accordingly, Calyxt has taken additional steps to streamline its operations and to reduce its operating expenses. Calyxt has focused its operations on: scaling production
of its Plant Cell Matrix<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> with its manufacturing partner; licensing efforts with respect to its PlantSpring<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> technology and plant
traits; and continuing to progress its three key current customer projects&#151;(1) its research collaboration with a leading global food ingredient manufacturer to develop a soybean trait to serve as an alternative to palm oil, (2)&nbsp;its
plant-based chemistry pilot project for a major consumer packaged goods company, and (3)&nbsp;supporting late-stage development activities for Calyxt&#146;s improved digestibility alfalfa trait, which was developed with and licensed to S&amp;W Seed
Company. While these three projects are important for Calyxt&#146;s overall product development pipeline, none of these projects is expected to generate material revenue in the near term. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no guarantee that the Mergers will be completed within the anticipated timing
or at all. If the Mergers are not completed and Calyxt does not pursue a liquidation and dissolution, its ability to continue as a going concern and advance its operations and key products will depend on its ability to obtain in the near-term
additional financing. Over the longer term and until Calyxt can generate cash flows sufficient to support its operating capital requirements, it would expect to finance a portion of future cash needs through (i)&nbsp;any remaining cash on hand,
(ii)&nbsp;commercialization activities, which may result in various types of revenue streams from (a)&nbsp;future product development agreements and technology licenses, including upfront and milestone payments, annual license fees, and royalties;
and (b)&nbsp;product sales from its proprietary BioFactory production system; (iii)&nbsp;government or other third-party funding, (iv)&nbsp;public or private equity or debt financings, (v)&nbsp;the execution of an alternative strategic transaction,
or (v)&nbsp;a combination of the foregoing. However, capital generated by commercialization activities, if any, is expected to be received over a period of time and ramping up over the course of several years, with near-term capital potentially
unavailable on reasonable terms, if at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Calyxt has a limited operating history, which makes it difficult to evaluate its current business and
prospects and to assess its future viability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt is an early-stage synthetic biology company with a limited operating history
that to date has been focused primarily on R&amp;D and until October 2021 was pursuing prior <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">go-to-market</FONT></FONT> strategies. Calyxt&#146;s operating results for periods prior
to October 2021 reflect results under its prior <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">go-to-market</FONT></FONT> strategies, which involved different areas of focus, different cost structures, and different sources of
revenues, which, in combination with its limited operating history, may make it difficult to evaluate its current business and prospects and to assess its future viability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In implementing Calyxt&#146;s current strategic focus on the development of plant-based synthetic biology products, Calyxt encounters risks
and difficulties frequently experienced by companies in rapidly developing and changing emergent industries, including challenges in developing products, determining appropriate investments of its limited resources, capital raising, and gaining
customers for its novel products and innovations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Plant-based synthetic biology product development is a highly speculative endeavor. It
entails significant upfront R&amp;D investment to scale the BioFactory production system to sufficient levels to support commercialization, and there is significant risk that Calyxt will not be able to scale the BioFactory to these levels, or at
all. If the Mergers are not completed and Calyxt does not pursue a liquidation and dissolution, these risks will be exacerbated by Calyxt&#146;s limited capital resources. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To commercialize its products, Calyxt must be successful in using its PCM structures to produce target molecules at commercial scale and at a
commercially viable cost. If Calyxt cannot finance and achieve commercial scale production levels or commercially viable production economics for enough products to support its business plan, including through establishing and maintaining sufficient
commercial scale and volume, it will be unable to achieve a sustainable business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt&#146;s commercial scale production costs depend
on many factors that could have a negative effect on its ability to sell products developed for customers at competitive prices, including its ability to establish and maintain sufficient commercial scale and volume to attract third party contract
manufacturing, referred to as infrastructure partners. There can be no assurance that Calyxt will be able to engage infrastructure partners on acceptable terms, including reasonable costs per unit of production, or at all, or to maintain
relationships with existing infrastructure partners. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Mergers are not completed and Calyxt does not pursue a liquidation and
dissolution and Calyxt is unable to achieve these economies of scale and targeted unit commercial production, its revenues, profitability, and financial condition will be adversely affected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Calyxt&#146;s Business and its Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Calyxt&#146;s operational and financial success depends on its ability to successfully deliver synthetic biology solutions for an expanded group of end
markets, which is subject to a variety of risks and uncertainties. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since Calyxt&#146;s inception, it has deployed its technology
platform toward delivering plant-based innovations and solutions, primarily to the agriculture end market. In October 2021, Calyxt announced a strategic initiative to focus it on engineering plant-based synthetic biology solutions across an expanded
group of end markets, including its initial target <FONT STYLE="white-space:nowrap">end-markets&#151;the</FONT> cosmeceutical, nutraceutical, and pharmaceutical markets&#151;as well as other potential end markets, including advanced materials and
chemical industries, in addition to the agriculture end market. This expanded and diversified focus places significant demands on Calyxt&#146;s management, requires adaptations to its operational infrastructure, and necessitates incremental capital
expenditures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the course of discussions with Cibus regarding, and following the execution of, the Merger Agreement, Calyxt has
streamlined and focused its business activities on preserving cash sufficient to achieve a closing of the Mergers. Accordingly, Calyxt has streamlined its operations and reduced its operating expenses. Calyxt has focused its operations on: scaling
production of its Plant Cell Matrix<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> with its manufacturing partner; licensing efforts with respect to its PlantSpring<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> technology
and plant traits; and continuing to progress its three key current customer projects&#151;(1) its research collaboration with a leading global food ingredient manufacturer to develop a soybean trait to serve as an alternative to palm oil,
(2)&nbsp;its plant-based chemistry pilot project for a major consumer packaged goods company, and (3)&nbsp;supporting late-stage development activities for Calyxt&#146;s improved digestibility alfalfa trait, which was developed with and licensed to
S&amp;W Seed Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Mergers are not completed and Calyxt does not pursue a liquidation and dissolution, it would need to execute
on its business plan with limited capital resources. If Calyxt fails to effectively and efficiently manage and implement its business strategy, if it is unable to differentiate its offerings and capabilities from competitors in the synthetic biology
industry, who may have a more established position in the synthetic biology industry, greater financial and operational resources, and other competitive advantages, or if Calyxt is otherwise not successful in marketing its offerings and capabilities
to new target customers, its business, financial condition, and results of operations would be adversely impacted. In addition, to the extent Calyxt faces technological and other challenges, including unanticipated costs or delays in the development
of compounds intended to be produced using the BioFactory production system, challenges adapting its technology platform for specific customer-driven plant-based chemistry needs, or the inability to effectively or efficiently scale production, its
business, financial condition and results of operations would be adversely impacted. The BioFactory production system and Calyxt&#146;s ability to produce plant-based chemistries remain relatively unproven and may not be successful at scale or at
all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Market participants, including customers and potential investors, may be skeptical of the viability and benefits of Calyxt&#146;s
PlantSpring technology platform and its BioFactory production system because they are based on a novel approach and the adoption of complex and emerging technologies. There can be no assurance that Calyxt&#146;s technology will be understood,
approved, or accepted by customers, regulators, and potential investors or that Calyxt will be able to sell its services and products profitably at competitive prices and with features sufficient to establish demand. If market participants are
skeptical of Calyxt&#146;s technology, its ability to raise capital and the value of its common stock may be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, because of the novelty and complexity of the PlantSpring platform and BioFactory production system, achieving broad commercial
success may require that Calyxt overcomes potential customer skepticism regarding its capabilities, particularly in light of the historical challenges of scaling production in the field of synthetic biology. If Calyxt does not achieve the technical
specifications required by its customers or successfully manage new product development processes, or if development work is not performed according to schedule, then its revenue growth from new pipeline products may be prevented or delayed, and its
business and operating results may be harmed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order for novel products from the PlantSpring technology platform and its BioFactory
production system to be successfully commercialized, it will be important for Calyxt to establish relationships not only with customers, but also with their suppliers in order to gain visibility into market trends, feature and specification demands,
and manufacturing, regulatory, and distribution challenges. If Calyxt is unable to convince potential customers or their suppliers of the value of its synthetic biology products, it will not be successful in entering these markets and its business
and results of operations will be adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Calyxt faces significant competition and many of its competitors have substantially greater
financial, technical, and other resources than Calyxt. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The market for products developed with synthetic biology is highly
competitive, and Calyxt faces significant direct and indirect competition in several aspects of its business. See the section of this proxy statement/prospectus entitled &#147;<I>Calyxt Business</I><I>&#151;</I><I>Competition</I>.&#148; Many of
these competitors have substantially greater financial, technical, marketing, sales, distribution, and other resources than Calyxt. Many competitors engage in ongoing R&amp;D, and technological developments by its competitors could render
Calyxt&#146;s technology less competitive or obsolete, resulting in reduced revenues compared to expectations. As a result, Calyxt may be unable to compete successfully against its current or future competitors, which may result in reductions in
revenue, reduced margins, and the inability to achieve market acceptance for its products. Calyxt expects to continue to face significant competition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The synthetic biology industry is still emerging and is characterized by rapid and significant technological changes, frequent new product
introductions and enhancements, and evolving industry demands and standards. Calyxt&#146;s success depends on its ability to sign and initiate commercial programs using its customer demand-driven approach to selecting compounds for development and
scaling the production of those compounds in its BioFactory production system. To compete, Calyxt&#146;s development activity needs to occur on a timely and cost-effective basis, and it will need to continue to advance its technology. However, in
light of Calyxt&#146;s efforts to preserve cash, it has presently suspended non-core activities, such as efforts toward the development and integration of AIML capabilities and the initiation, development and commercialization of additional
synthetic biology products, or chemistries, beyond those involved in the continuing operations identified above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt&#146;s ability to
compete effectively and to achieve commercial success also depends, in part, on its ability to identify and attract customers who contract with it to develop products for use in their production and contracting with those same third parties for the
commercialization of those products. Calyxt may not be successful in achieving these factors and any such failure may adversely affect its business, results of operations and financial condition. Moreover, Calyxt&#146;s ability to attract and
contract with customers has been hampered by Calyxt&#146;s capital resource constraints and cost reduction efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to the lead time
involved in developing a product for a customer using Calyxt&#146;s platform, its potential customers will be required to make a number of assumptions and estimates regarding the commercial feasibility of the plant-based chemistry, including
assumptions and estimates regarding the demand for those <FONT STYLE="white-space:nowrap">end-products</FONT> and processes that will utilize the plant-based chemistry developed with Calyxt&#146;s technology, the existence or <FONT
STYLE="white-space:nowrap">non-existence</FONT> of products being simultaneously developed by competitors, potential market penetration and obsolescence, whether planned or unplanned. As a result, it is possible that Calyxt may reach an agreement
with a customer who wishes to develop a product that has been displaced by the time of launch, addresses a market that no longer exists or is smaller than previously thought, that end-consumers do not like or otherwise is not competitive at the time
of launch, in each case, after the incurrence of significant opportunity costs by Calyxt to develop such a product. In addition, potential customers will be required to make assumptions about Calyxt&#146;s ability to execute on such product
development initiatives, including Calyxt&#146;s ability to continue as a going concern through the product development lifecycle. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
certain circumstances, competitors who license Calyxt&#146;s technology could use those technologies to develop their own products that would compete with products commercialized by Calyxt&#146;s agriculturally focused collaboration partners, which
may impact its future royalties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt also anticipates that competition in the synthetic biology industry will increase in
the future as new companies enter the market and new technologies become available. Calyxt&#146;s technology may be rendered obsolete or uneconomical by technological advances or entirely different approaches developed by one or more of its
competitors that are more effective or that enable them to develop and commercialize products more quickly or with lower expense than Calyxt is able to. At the same time, the expiration of patents covering existing technologies reduces the barriers
to entry for competitors. If for any reason Calyxt&#146;s technology becomes obsolete or uneconomical relative to competitors&#146; technologies, this would prevent or limit its ability to generate revenues from the commercialization of its
products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If Calyxt cannot enter into new customer partnerships and successfully execute on the underlying product development projects to bring a
customer&#146;s plant-based chemistry to commercial scale production and ultimately sell them the product, its business will be adversely affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt&#146;s approach to product development is customer demand-driven and as a result, its success depends on the number, size, and scope of
customer collaborations. Calyxt&#146;s ability to win new business depends on many factors, including its reputation in the market, the differentiation of its PlantSpring technology platform and BioFactory production system relative to alternatives,
the pricing and efficiency of its offerings relative to alternatives, its financial stability (including market participants&#146; expectations about Calyxt&#146;s ability to continue as a going concern), and its technical capabilities. If Calyxt
fails to establish a position of strength in any of these factors, its ability to either sign new customer agreements may suffer and this could adversely affect its prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the course of discussions with Cibus regarding, and following the execution of, the Merger Agreement, Calyxt has streamlined and
focused its business activities on preserving cash sufficient to achieve a closing of the Mergers. Accordingly, Calyxt has streamlined its operations and reduced its operating expenses. While licensing efforts with respect to its PlantSpring<SUP
STYLE="font-size:75%; vertical-align:top">&#153;</SUP> technology and plant traits remains an operational focus, Calyxt&#146;s streamlined workforce and the prioritization of its available resources has substantially limited the number of
chemistries being actively pursued by Calyxt. The focus of Calyxt&#146;s management on the Mergers and the uncertainty arising from the Mergers has significantly reduced the number of active projects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the course of business development discussions, Calyxt may spend considerable time and money engaging in strategic and feasibility
assessments, including understanding the technical specifications of a particular plant-based chemistry, customer concerns and limitations, and the legal or regulatory landscape of a potential program or offering, which may not result in a
commercial agreement. Even if an agreement is reached, the resulting relationship may not be successful for many reasons, including Calyxt&#146;s inability to complete the development of a plant-based chemistry to the customers&#146; specifications
or within the customers&#146; time frames, or unsuccessful development or commercialization of products or processes by its customers. In such circumstances, Calyxt&#146;s revenues from such an agreement might be meaningfully reduced. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Development of new or improved plant-based synthetic biology products that meet customer demand-driven specifications involves risks of
failure inherent in the deployment of innovative and complex emerging technologies. Accordingly, if Calyxt or its infrastructure partners experience any significant delays in the development of new products or if new products do not meet customer
specifications, its business, operating results, and financial condition would be adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Calyxt relies on third parties for <FONT
STYLE="white-space:nowrap">at-scale</FONT> production and other services, and any performance issues by such third parties, or Calyxt&#146;s inability to engage third parties on acceptable terms, may impact Calyxt&#146;s ability to successfully meet
its commercial obligations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt&#146;s current plan is to contract with third-party infrastructure partners for <FONT
STYLE="white-space:nowrap">at-scale</FONT> production of its PCM structures and for other R&amp;D services. In the third quarter of 2022, Calyxt signed an agreement with its first infrastructure partner, Evologic Technologies GmbH (Evologic), to
further develop and scale its PCM structures. Evologic is currently scaling one of Calyxt&#146; PCM structures. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although Calyxt intends to provide for audit and/or inspection rights for all infrastructure
partners and provides infrastructure partners with protocols regarding the production and handing of its plant-based chemistries, it has limited control over the execution of their activities. Poor execution, failure to follow required protocols or
regulatory requirements, or mishandling of the plant-based chemistry by these infrastructure partners could impair success, delay production, cause Calyxt to incur incremental costs, or damage the customer relationship. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if Calyxt&#146;s infrastructure partners adhere to protocols, production runs and other R&amp;D activities may fail to succeed for a
variety of other reasons. Ultimately, Calyxt remains responsible for ensuring work performed is conducted in accordance with the applicable protocol and standards, and reliance on infrastructure partners does not relieve Calyxt of its
responsibilities. Should these infrastructure partners fail to comply with these standards, Calyxt&#146;s ability to develop plant-based chemistries in accordance with customer specifications or in a timely manner could be adversely impacted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, if Calyxt is unable to maintain or enter into agreements with infrastructure partners on acceptable terms, or if an engagement
is terminated prematurely, it may be unable to conduct or complete research, development, and production in the anticipated manner. For example, establishing and operating infrastructure partner facilities may require Calyxt to make significant
capital expenditures, which reduces its cash and places such capital at risk. Also, infrastructure partner agreements may contain terms that commit Calyxt to pay for other costs and amounts incurred or expected to be earned by the plant operators
and owners, which can result in contractual liability and losses for it even if it terminates a particular infrastructure partner arrangement or decides to reduce or stop production under such an arrangement. Further, Calyxt cannot be sure that
contract manufacturers will be available when it needs their services, that they will be willing to dedicate a portion of their capacity to its projects, or that it will be able to reach acceptable price, delivery, and other terms with the
infrastructure partners for the provision of their production services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Calyxt&#146;s relationship with any of these infrastructure
partners is terminated, it may be unable to enter arrangements with alternative infrastructure partners on commercially reasonable terms, or at all. Switching or adding infrastructure partners can involve substantial cost and require extensive
management time and focus. In addition, there is a natural transition period when any new infrastructure partner commences work. As a result, delays may occur, which could materially impact Calyxt&#146;s ability to meet desired development
timelines, its achievement of product-related revenues, and profitability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If Calyxt&#146;s technology licensees are delayed or unsuccessful in
their development activities associated with their license of Calyxt technology, Calyxt&#146;s financial results could be affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt&#146;s strategy includes licensing its technology and its historically developed seed-trait product candidates for traditional
agriculture to third parties. If Calyxt&#146;s licensees are delayed, are unsuccessful in their development and commercialization efforts, or if they fail to devote sufficient time and resources to support the marketing and selling efforts of
products developed using the licenses of Calyxt&#146;s technology, it may not receive milestone and/or royalty payments as expected, and its financial results could be harmed. Further, if these licensee customers fail to market the licensed
seed-trait products or products developed with Calyxt&#146;s licensed technology at prices that will achieve or sustain market acceptance for those products, its future royalty revenues could be further harmed. If a product is commercialized by a
licensee, its performance may also be impact by numerous risks, including competition from alternative products, product defects, changes in <FONT STYLE="white-space:nowrap">end-consumer</FONT> demand, changes in law or regulation, or changes in
economic conditions. Moreover, licensees have significant discretion in determining the efforts and resources applied to commercializing products utilizing the plant-based chemistries developed by Calyxt, and they may not commit sufficient resources
to successfully advance a product candidate or achieve commercial success. Disputes may arise with licensees that cause the delay or termination of commercial contracts for current or future products or that results in costly litigation or
arbitration that diverts management attention and resources. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Any outdoor agriculture product development agreements that Calyxt may enter in the future may be
delayed or may be unsuccessful, which could adversely affect its financial results. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt&#146;s strategy permits
opportunistically entering into product development arrangements with third parties for the development and commercialization of certain outdoor agriculture seed traits. For example, in 2021, Calyxt announced that it had entered into a research
collaboration with a global food ingredient manufacturer based in Asia to develop an improved soybean capable of producing an oil as a commercial alternative to palm oil. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent Calyxt enters into such product development agreements, their success will depend heavily on the efforts and activities of its
customer&#146;s commercialization efforts and as a result its ability to achieve milestone payments or generate royalties will not be within its direct control. If an outdoor agriculture product is commercialized by a licensee, its performance may
also be impacted by numerous risks, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse weather conditions, natural disasters, crop disease, pests and other natural conditions;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">climate change that may cause changes in weather patterns and conditions, including changes in rainfall and storm
patterns and intensities, water shortages, changes in sea levels, and changes in temperature levels; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">licensee field trials may be unsuccessful; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">licensee products, and food containing those products, may fail to meet standards established by third-party <FONT
STYLE="white-space:nowrap">non-GMO</FONT> verification organizations; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the unintended presence of Calyxt&#146;s traits in other products or plants may have a negative effect on the
licensee&#146;s operations. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Calyxt&#146;s Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patents and patent applications involve highly complex legal and factual questions, which, if determined adversely to Calyxt, could negatively impact its
competitive position. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent positions of biotechnology companies and other actors in Calyxt&#146;s fields of business can be
highly uncertain and involve complex scientific, legal, and factual analyses. The interpretation and breadth of claims allowed in some patents covering biological compositions may be uncertain and difficult to determine and are often affected
materially by the facts and circumstances that pertain to the patented compositions and the related patent claims. The issuance and scope of patents cannot be predicted with certainty. Patents, if issued, may be challenged, invalidated, narrowed, or
circumvented. Challenges to Calyxt or its licensors&#146; patents and patent applications, if successful, may result in the denial of it or its licensors&#146; patent applications or the loss or reduction in their scope. In addition, defending
against such challenges may be costly and involve the diversion of significant management time. Accordingly, rights under any of Calyxt or its licensors&#146; patents may not provide it with enough protection against competitive products or
processes and any loss, denial, or reduction in scope of any of such patents and patent applications may have a material adverse effect on its business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if not challenged, Calyxt or its licensors&#146; patents and patent applications may not adequately protect its product candidates or
technology or prevent others from designing their products or technology to avoid being covered by Calyxt or its licensors&#146; patent claims. If the breadth or strength of protection provided by the patents Calyxt owns or licenses is threatened,
it could dissuade companies from partnering with it to develop, and could threaten the ability to successfully commercialize, Calyxt&#146;s product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Calyxt or its licensors fail to obtain and maintain patent protection and trade secret protection of its product candidates and technology,
it could lose competitive advantage and competition Calyxt faces would increase, reducing any potential revenues and have a material adverse effect on its business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Calyxt will not seek to protect its intellectual property rights in all jurisdictions throughout the
world and it may not be able to adequately enforce its intellectual property rights even in the jurisdictions where it seeks protection. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Filing, prosecuting, and defending patents in all countries and jurisdictions throughout the world would be prohibitively expensive. Patent
protection must be sought on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, which is an expensive and time-consuming process with uncertain outcomes. Calyxt&#146;s intellectual property
rights in some countries outside the United States could be less extensive than those in the United States, assuming that rights are obtained in the United States. In addition, the laws of some foreign countries do not protect intellectual property
rights to the same extent as federal and state laws in the United States. Consequently, Calyxt may not be able to prevent third parties from practicing its inventions in all countries outside the United States, or from selling or importing products
made using its inventions in and into the United States or other jurisdictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competitors may use Calyxt&#146;s technologies in
jurisdictions where it or its licensors do not pursue and obtain patent protection. Further, competitors may export otherwise infringing products to territories where Calyxt or its licensors have patent protection, but where the ability to enforce
those patent rights is not as strong as in the United States. These products may compete with Calyxt&#146;s products and its intellectual property rights and such rights may not be effective or enough to prevent such competition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, changes in, or different interpretations of, patent laws in the United States and other countries may permit others to use
Calyxt&#146;s discoveries or to develop and commercialize its technology and products without providing any notice or compensation or may limit the scope of patent protection that Calyxt or its licensors are able to obtain. The laws of some
countries do not protect intellectual property rights to the same extent as United States laws and those countries may lack adequate rules and procedures for defending Calyxt&#146;s intellectual property rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, proceedings to enforce Calyxt&#146;s licensors&#146; and its patent rights and other intellectual property rights in foreign
jurisdictions could result in substantial costs and divert its efforts and attention from other aspects of its business, could put Calyxt or its licensors&#146; patents at risk of being invalidated or interpreted narrowly, could put it or its
licensors&#146; patent applications at risk of not issuing and could provoke third parties to assert claims against it or its licensors. Calyxt may not prevail in any lawsuits that initiates, and the damages or other remedies awarded to it, if any,
may not be commercially meaningful, while the damages and other remedies Calyxt may be ordered to pay such third parties may be significant. Accordingly, Calyxt&#146;s licensors and its efforts to enforce its intellectual property rights around the
world may be inadequate to obtain a significant commercial advantage from the intellectual property that it develops or licenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Third parties may
assert rights to inventions Calyxt develops or otherwise regards as its own. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third parties may in the future make claims
challenging the inventorship or ownership of Calyxt or its licensors&#146; intellectual property. Calyxt has written agreements with R&amp;D partners that provide for the ownership of intellectual property arising from the relationship. Some
agreements provide that Calyxt must negotiate certain commercial rights at a later date and others may not include or clearly address the allocation of intellectual property rights. If Calyxt cannot successfully negotiate sufficient ownership and
commercial rights to the inventions that result from Calyxt&#146;s use of a third-party partner&#146;s materials, or if disputes otherwise arise with respect to the intellectual property developed through the use of a partner&#146;s samples, Calyxt
may be limited in its ability to capitalize on the full market potential of these inventions. In addition, Calyxt may face claims by third parties that its agreements with employees, contractors, or consultants obligating them to assign intellectual
property to it are ineffective or are in conflict with prior or competing contractual obligations of assignment. Litigation may be necessary to resolve an ownership dispute, and if Calyxt is not successful, it may be precluded from using certain
intellectual property and associated products and technology, which could have a material adverse effect on its business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition,
the research resulting in certain of Calyxt&#146;s <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent rights and technology was funded in part by the United States government. As a result, the United States government has certain rights to
such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
patent rights and technology, which include <FONT STYLE="white-space:nowrap">march-in</FONT> rights. When new technologies are developed with government funding, the government generally obtains
certain rights in any resulting patents, including a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license authorizing the government to use the invention or to have others use the invention on its behalf. The government can exercise its <FONT
STYLE="white-space:nowrap">march-in</FONT> rights if it determines that action is necessary because Calyxt fails to achieve practical application of the government-funded technology, or because action is necessary to alleviate health or safety
needs, to meet requirements of federal regulations, or to give preference to United States industry. Any exercise by the government of any of the foregoing rights could have a material adverse effect on Calyxt&#146;s business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Any infringement, misappropriation, or other violation by Calyxt of intellectual property rights of others may prevent or delay its product development
efforts and may prevent or increase the costs of successful commercialization by Calyxt, its customers or its licensees. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt&#146;s success will depend in part on its ability to operate without infringing, misappropriating, or otherwise violating the
intellectual property and proprietary rights of third parties. Calyxt cannot assure that its business operations, products developed, historically developed agriculture-focused product candidates, and methods and the business operations, products,
product candidates and methods of its customers or licensees do not or will not infringe, misappropriate, or otherwise violate the patents or other intellectual property rights of third parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The biotechnology industry is characterized by extensive litigation regarding patents and other intellectual property rights. Other parties
may allege that Calyxt&#146;s product development activities, products, product candidates or the use of its technologies infringe, misappropriate, or otherwise violate patent claims or other intellectual property rights held by them or that it is
employing their proprietary technology without authorization. Patent and other types of intellectual property litigation can involve complex factual and legal questions, and their outcome is uncertain. Any claim relating to intellectual property
infringement that is successfully asserted against Calyxt may require it to pay substantial damages, including treble damages and attorneys&#146; fees if it or its partners are found to be willfully infringing another party&#146;s patents, for past
use of the asserted intellectual property and royalties and other consideration going forward if Calyxt is forced to take a license. Such a license may not be available on commercially reasonable terms, or at all. Even if Calyxt was able to obtain a
license, it could be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving its competitors access to the same intellectual property rights or technologies licensed to Calyxt. In addition, if any such claim were successfully asserted
against Calyxt and it could not obtain a license, Calyxt or its partners may be forced to stop or delay developing, manufacturing, selling or otherwise commercializing its products, product candidates or other infringing technology, or those it
develops with its R&amp;D partners. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if Calyxt is successful in these proceedings, it may incur substantial costs and divert
management time and attention pursuing these proceedings, which could have a material adverse effect on the organization. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there
is a risk that some of Calyxt&#146;s confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or
developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of Calyxt Common Stock. Such litigation or proceedings could substantially increase Calyxt&#146;s
operating losses and reduce the resources available for development activities or any future sales, marketing, or distribution activities. If Calyxt is unable to avoid infringing the patent rights of others, it may be required to seek a license,
defend an infringement action, or challenge the validity of the patents in court, or redesign its products. Patent litigation is costly and time consuming. Calyxt may not have enough resources to bring these actions to a successful conclusion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these risks coming to fruition could have a material adverse effect on Calyxt&#146;s business, results of operations, financial
condition, and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Calyxt may be unsuccessful in developing, licensing, or acquiring intellectual property that may be
required to develop and commercialize its product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt&#146;s programs may involve additional product candidates
that may require the use of intellectual property or proprietary rights held by third parties; the growth of its business may depend in part on its ability to acquire, <FONT STYLE="white-space:nowrap">in-license</FONT> or use these intellectual
property and proprietary rights. However, Calyxt may be unable to acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> any third-party intellectual property or proprietary rights that may be key to development. Even if Calyxt can acquire or
<FONT STYLE="white-space:nowrap">in-license</FONT> such rights, it may be unable to do so on commercially reasonable terms. The licensing and acquisition of third-party intellectual property and proprietary rights is a competitive area, and several
more established companies are also pursuing strategies to license or acquire third-party intellectual property and proprietary rights that Calyxt may consider attractive or necessary. These established companies may have a competitive advantage
over Calyxt due to their size, capital resources and agricultural development and commercialization capabilities. In addition, companies that perceive Calyxt to be a competitor may be unwilling to assign or license intellectual property and
proprietary rights to Calyxt. Calyxt also may be unable to license or acquire third-party intellectual property and proprietary rights on terms that would allow it to make an appropriate return on its investment or at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with his appointment as chair of the Scientific Advisory Board, Dr. Dan Voytas is no longer Calyxt&#146;s Chief Science Officer,
a position he held from Calyxt&#146;s founding in January 2010 through February 2021. The consulting agreement with Dr. Voytas, while he served as Chief Science Officer, and the current engagement letter with Dr. Voytas, as chair of the Scientific
Advisory Board, each generally obligates Dr. Voytas to assign to Calyxt any intellectual property solely or jointly conceived, developed or reduced to practice by him in the course of the performance of his services to Calyxt. However, Calyxt does
not have any rights, including any assignment or right of first refusal rights, to intellectual property conceived, developed, or reduced to practice by Dr. Voytas outside the course of the performance of his services to Calyxt, including in
connection with his employment at the University of Minnesota. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, companies that perceive Calyxt to be a competitor may be
unwilling to assign or license intellectual property and proprietary rights to Calyxt. Calyxt also may be unable to license or acquire third-party intellectual property and proprietary rights on terms that would allow it to make an appropriate
return on its investment or at all. If Calyxt is unable to successfully acquire or in-license rights to required third-party intellectual property and proprietary rights or maintain the existing intellectual property and proprietary rights Calyxt
has, it may have to cease development of the relevant program, product, or product candidate, which could have a material adverse effect on its business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Calyxt licenses a portion of its intellectual property from Cellectis, its largest stockholder, and the University of Minnesota. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt relies on the intellectual property it licenses from Cellectis and the University of Minnesota. If it does not comply with obligations
under the license agreements, it may be subject to damages, which may be significant, and in some cases Cellectis and/or the University of Minnesota may have the right to terminate the license agreement. Any termination of Calyxt&#146;s license
agreement with Cellectis or the University of Minnesota could have a material adverse effect on its business and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, any enforcement of the licensed intellectual property could be subject it to challenge by third parties and if any such challenge is
successful, such intellectual property could be narrowed in scope or held to be invalid or unenforceable, which could materially impair any competitive advantage afforded to Calyxt by such intellectual property. There can be no assurance that
Cellectis or the University of Minnesota will prosecute and maintain such intellectual property in the best interests of Calyxt&#146;s business or at all, and, if Cellectis or the University of Minnesota fails to properly prosecute and maintain such
intellectual property, Calyxt could lose rights to such intellectual property, which would materially impair any competitive advantage afforded to it by such intellectual property. For more information regarding Calyxt&#146;s license agreement with
Cellectis or the license agreement between Cellectis and the University of Minnesota, see the section entitled &#147;<I>Calyxt Business&#151;Intellectual Property</I>.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Calyxt&#146;s Regulatory and Legal Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ethical, legal, and social concerns about products using genetically modified or edited plant cells could limit or prevent the use of Calyxt&#146;s
products and technologies and could harm its business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt&#146;s technologies and products involve the use of genetically
modified or edited plant cells. Public perception about the safety of, and ethical, legal, or social concerns over, genetically engineered products, including genetically modified or edited plant genetic materials, could affect public acceptance of
Calyxt&#146;s products. If Calyxt is not able to overcome any such concerns relating to its products, these technologies may not be accepted by its customers or <FONT STYLE="white-space:nowrap">end-users</FONT> of the customers&#146; products that
incorporate Calyxt&#146;s products. In addition, the use of genetically modified or edited plant cells has in the past received negative publicity, which could lead to greater regulation or restrictions on imports of Calyxt&#146;s products. If
Calyxt&#146;s technologies and products are not accepted by its customers or their <FONT STYLE="white-space:nowrap">end-users</FONT> due to negative publicity or lack of public acceptance, Calyxt&#146;s business could be materially harmed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Calyxt may become subject to increasing regulation as a result of its hemp development activities, which could require it to incur additional costs
associated with compliance requirements. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt has developed hemp product candidates and is currently exploring licensing
opportunities in the crop. Hemp is legally distinct from marijuana and recognized as an agricultural crop by the United States government. Federal and state laws and regulations on hemp address production, monitoring, manufacturing, distribution,
and laboratory testing to ensure that that the hemp has a THC concentration of not more than 0.3&nbsp;percent on a dry weight basis. Federal laws and regulations may also address the transportation or shipment of hemp or hemp products. It is
difficult to predict whether regulators, such as the USDA or the MDA, will alter the manner in which they interpret existing federal and state laws and regulations on hemp or institute new regulations, or otherwise modify regulations in a way that
will render compliance more burdensome. As Calyxt continues to pursue hemp as a product candidate, it may become subject to increasing regulation particular to hemp, which could require it to incur additional costs associated with compliance
requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The regulatory environment outside the United States varies greatly from jurisdiction to jurisdiction and there is less certainty how
Calyxt&#146;s products will be regulated. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The regulatory environment around gene editing and genetic modification in plants is
greatly uncertain outside of the United States and varies greatly from jurisdiction to jurisdiction. Each jurisdiction may have its own regulatory framework regarding genetically modified and gene edited products and materials, which continue to
evolve, and which may encapsulate Calyxt&#146;s products. To the extent regulatory frameworks outside of the United States are not receptive to Calyxt&#146;s genetic modification and gene editing technologies, this may limit its ability to expand
into other global markets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Complying with the regulatory requirements outside the United States will be costly and time-consuming, and
there is no guarantee Calyxt will be able to commercialize its products outside the United States. Such regulatory requirements may also inhibit Calyxt&#146;s ability to market and sell its products to customers located outside of the United States.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt cannot predict whether or when any jurisdiction will change its regulations with respect to its products. Advocacy groups have
engaged in publicity campaigns and filed lawsuits in various countries against companies and regulatory authorities, seeking to halt regulatory approval or clearance activities or influence public opinion against genetically engineered and/or gene
edited products. In addition, governmental reaction to negative publicity concerning Calyxt&#146;s products could result in greater regulation of genetic research and derivative products or regulatory costs that render its products cost prohibitive.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The scale of the industries in which Calyxt intends as the end markets for its products may make it difficult to monitor and control the
distribution of Calyxt&#146;s products. As a result, Calyxt&#146;s products may be sold inadvertently within jurisdictions where they are not approved for distribution. Such sales may lead to regulatory challenges or lawsuits against Calyxt, which
could result in significant expenses and management attention. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Calyxt may use biological materials in its business and is subject to numerous environmental, health
and safety laws and regulations. Compliance with such laws and regulations and any claims relating to improper handling, storage or disposal of these materials could be time consuming and costly. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt is subject to numerous federal, state, local and foreign environmental, health and safety laws and regulations, including those
governing laboratory procedures, the handling, use, storage, treatment, manufacture and disposal of hazardous materials and wastes, discharge of pollutants into the environment and human health and safety matters. Calyxt&#146;s R&amp;D processes
involve the controlled use of hazardous materials, including biological materials. Calyxt may be sued for any injury or contamination that results from its use or the use by third parties of these materials, or may otherwise be required to remediate
such contamination, and its liability may exceed any insurance coverage and its total assets. Compliance with environmental, health and safety laws and regulations may be expensive and may impair Calyxt&#146;s R&amp;D efforts. If Calyxt fails to
comply with these requirements, it could incur substantial costs and liabilities, including civil or criminal fines and penalties, <FONT STYLE="white-space:nowrap">clean-up</FONT> costs or capital expenditures for control equipment or operational
changes necessary to achieve and maintain compliance. In addition, Calyxt cannot predict the impact on its business of new or amended environmental, health and safety laws or regulations or any changes in the way existing and future laws and
regulations are interpreted and enforced. These current or future laws and regulations may impair Calyxt&#146;s research, development or production efforts or result in increased expense of compliance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The regulatory environment in the United States is uncertain and evolving and may impact Calyxt&#146;s customers&#146; willingness to utilize its
products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt anticipates that its customers will be responsible for any regulatory activities associated with development of
compounds commissioned from Calyxt. Such regulatory activities may involve significant expense and changes in applicable regulatory requirements could result in substantial increases in the time and costs associated with such activities. It is
difficult for Calyxt and its customers to predict whether regulators, such as the USDA or FDA, will alter the manner in which they interpret existing laws and regulations or institute new regulations, or otherwise modify regulations in a way that
will subject products utilizing Calyxt&#146;s synthetic biology products to more burdensome standards, thereby substantially increasing the time and costs associated with the regulatory activities of its customers. If the regulatory burden and
expense required for the utilization of Calyxt&#146;s products becomes too significant, its customers may seek alternatives that involve lesser regulatory costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If Calyxt is sued for defective products and if such lawsuits were determined adversely, it could be subject to substantial damages, for which insurance
coverage is not available. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt expects that some applications of its products will be used as components of customers&#146; end
products and therefore its success will be tied, in part, to the success of such end products. Calyxt cannot be certain that material performance problems, defects, errors or delays will not arise in its products or the end products in which they
are used as components. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt expects to provide warranties that its products will meet customer specifications. The costs incurred in
correcting any failures to meet such specifications may be substantial and could adversely affect Calyxt&#146;s business. If Calyxt&#146;s products or the end products of which they are components, contain defects or are delayed, it may experience:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a failure to achieve commercial traction with Calyxt&#146;s target customers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">loss of customer contracts or delays in fulfilling Calyxt&#146;s contractual obligations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">damage to Calyxt&#146;s brand reputation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product recalls or replacements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability to attract new customers and collaboration opportunities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diversion of resources from Calyxt&#146;s R&amp;D and sales activities; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">legal and regulatory claims against Calyxt, including product liability claims, which could be costly, time
consuming to defend, result in substantial damages and result in reputational damage. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Ownership of Calyxt Common Stock if the Mergers Are Not Completed </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If Calyxt, Inc. is unable to maintain compliance with Nasdaq&#146;s listing requirements, the Calyxt Common Stock may be delisted from The Nasdaq Capital
Market, which could have a material adverse effect on Calyxt&#146;s financial condition and could make it more difficult for holders of Calyxt Common Stock to sell their shares. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;4, 2022, Calyxt, Inc.&#146;s application to list the Calyxt Common Stock on The Nasdaq Capital Market, or Nasdaq, was approved
by Nasdaq. Calyxt Common Stock was previously listed on The Nasdaq Global Market. Calyxt, Inc. is therefore subject to the continued listing requirements of Nasdaq, including requirements with respect to the market value of publicly held shares,
market value of listed shares, minimum bid price per share, and minimum stockholders&#146; equity, among others, and requirements relating to board and committee independence. If Calyxt, Inc. fails to satisfy one or more of these continued listing
requirements, it may be delisted from Nasdaq. In addition, pursuant to Nasdaq rules, if the closing bid price of Calyxt Common Stock is $0.10 or less for 10 consecutive days, Calyxt Common Stock would be subject to immediate delisting. From
October&nbsp;4, 2022 through March&nbsp;31, 2023, the closing price on Nasdaq of Calyxt Common Stock has ranged from a low of $0.13 to a high of $0.44. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The continued listing of Calyxt Common Stock on Nasdaq is a condition for the consummation of the Mergers. If the Transactions do not close
for any reason, including a delisting of Calyxt Common Stock prior to Closing, such a delisting, if applicable, or the continuing possibility of such delisting, may adversely affect Calyxt&#146;s ability to raise additional financing through the
public or private sale of equity securities, may significantly affect the ability of investors to trade Calyxt, Inc.&#146;s securities, and may negatively affect the value and liquidity of Calyxt Common Stock. Delisting, or the possibility of such
delisting, also could have other negative results, including the potential loss of investor confidence or interest in business development opportunities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the 2022 Annual Meeting, Calyxt Stockholders approved an amendment to the Calyxt Certificate of Incorporation to effect a reverse stock
split of Calyxt Common Stock at a ratio not less than <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-2</FONT></FONT> and not greater than 1-for-10, with the exact ratio set within that range at the discretion of the Calyxt
Board. The Calyxt Board has determined to effect the Initial Reverse Stock Split at a ratio of 1-for-10 and expects to effect the Initial Reverse Stock Split prior to the Subsequent Reverse Stock Split and prior to the Closing. If the Transactions
do not close for any reason and Calyxt has not yet implemented the Initial Reverse Stock Split, Calyxt, Inc. would continue to have the ability to implement this previously approved Initial Reverse Stock Split. However, there can be no assurance
that such a reverse stock split, if implemented, will increase the market price of Calyxt Common Stock in proportion to the reduction in the number of shares of Calyxt Common Stock outstanding before the Initial Reverse Stock Split or result in a
permanent increase in the market price. In addition, it is possible that the reduced number of issued shares of Calyxt Common Stock resulting from a reverse stock split could adversely affect the liquidity of Calyxt Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If Calyxt Common Stock becomes subject to the penny stock rules, it would become more difficult to trade shares of Calyxt Common Stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC has adopted rules that regulate broker-dealer practices in connection with transactions in penny stocks. Penny stocks are generally
equity securities with a price of less than $5.00, other than securities registered on certain national securities exchanges or authorized for quotation on certain automated quotation systems, provided that current price and volume information with
respect to transactions in such securities is provided by the exchange or system. If Calyxt, Inc. does not retain its listing on Nasdaq and if the price of Calyxt Common Stock is less than $5.00, Calyxt Common Stock may be deemed a penny stock. The
penny stock rules require a broker-dealer, before a transaction in a penny stock not otherwise exempt from those rules, to deliver a standardized risk disclosure document containing specified information. In addition, the penny stock rules require
that before effecting any transaction in a penny stock not otherwise exempt from those rules, a broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive: (i)&nbsp;the
purchaser&#146;s written acknowledgment of the receipt of a risk disclosure statement; (ii)&nbsp;a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
written agreement to transactions involving penny stocks; and (iii)&nbsp;a signed and dated copy of a written suitability statement. These disclosure requirements may have the effect of reducing
the trading activity in the secondary market for Calyxt Common Stock, and therefore Calyxt Stockholders may have difficulty selling their shares of Calyxt Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The market price of Calyxt Common Stock has been and could remain volatile, which could be exacerbated if the Mergers do not close. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The market price of Calyxt Common Stock has experienced, and may continue to experience, volatility in response to various factors, such as:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the proposed Transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Calyxt&#146;s strategic initiatives and technologies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fluctuations in Calyxt&#146;s financial results or outlook or peer companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in estimates of Calyxt&#146;s financial results or recommendations by securities analysts;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in Calyxt&#146;s capital structure, such as future issuances of common stock or the incurrence of debt;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements by Calyxt or its competitors of significant contracts, acquisitions or strategic partnerships;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory developments in the United States, and/or other foreign countries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">litigation involving Calyxt, its general industry or both; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions or departures of key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">investors&#146; general perception of Calyxt; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in general economic, industry and market conditions affecting Calyxt or Cellectis. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, stock markets have experienced price and volume fluctuations that have affected, and continue to affect, the market prices of
equity securities of many companies. These fluctuations often have been unrelated or disproportionate to the operating performance of those companies. These broad market fluctuations, as well as general economic, political and market conditions,
such as recessions, interest rate changes and international currency fluctuations, may negatively affect the market price of Calyxt Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If the Mergers do not close for any reason, Cellectis will continue to possess rights that prevent other stockholders from influencing significant
decisions. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March 31, 2023, Cellectis held 48.2% of the outstanding Calyxt Common Stock. As of that date, through its stock
ownership, together with its enumerated rights under its stockholders agreement with Calyxt, Inc., Cellectis remains Calyxt, Inc.&#146;s controlling stockholder. Pursuant to the stockholders&#146; agreement between Calyxt, Inc. and Cellectis,
Cellectis continues to retain substantial rights with respect to Calyxt, Inc. for so long as it beneficially owns at least 15&nbsp;percent of the outstanding shares of Calyxt Common Stock (&#147;Cellectis Rights&#148;). The Cellectis Rights include
the right to nominate a number of designees for the Calyxt Board representing a majority of the directors, to designate the chair of the Calyxt Board, and to have at least one designated director serve on each Calyxt Board committee. In addition,
the Cellectis Rights include information rights for Cellectis, as well as approval rights over a significant number of key aspects of Calyxt&#146;s operations and management, including certain changes to Calyxt, Inc.&#146;s constitutive documents,
the making of any regular or special dividends, the commencement of any voluntary bankruptcy proceeding or any consent to any bankruptcy proceeding, any appointment to or removal from the Calyxt Board, and the consummation of any public or private
offering, merger, amalgamation or consolidation of Calyxt, Inc., the spinoff of a business of Calyxt, Inc., or any sale, conveyance, transfer or other disposition of Calyxt, Inc.&#146;s assets. The Cellectis Rights are Iincorporated into, and form a
part of, the Calyxt Certificate of Incorporation and Calyxt Bylaws, which makes any amendment, repeal, or modification of such rights burdensome. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the Closing, Cellectis is expected to own approximately 2.4%&nbsp;of the Shares,
the Amended Certificate of Incorporation and the Amended Bylaws will no longer incorporate the Cellectis Rights, and all such Cellectis Rights will cease to apply. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, if for any reason the Mergers are not completed, Cellectis will continue to exercise control with respect to the Cellectis Rights and
such Cellectis Rights will continue to apply even after Cellectis&#146; stock ownership is substantially reduced, whether through dilution or otherwise. In addition, if the Mergers are not completed, certain provisions of the Calyxt Certificate of
Incorporation, the Calyxt Bylaws, and other agreements may make it difficult for Calyxt Stockholders to influence its decisions or for another third-party to acquire control of Calyxt, or may discourage other third-parties from attempting to acquire
control of Calyxt, in each case, even if these actions were considered beneficial by many stockholders or might involve transactions in which Calyxt Stockholders might otherwise receive a premium for their shares of Calyxt Common Stock. Further,
these provisions could limit the price that investors might be willing to pay in the future for shares of Calyxt Common Stock, possibly depressing the market price of Calyxt Common Stock. As a result, Calyxt Stockholders may be limited in their
ability to obtain a premium for their shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Provisions in the Calyxt Certificate of Incorporation and the Calyxt Bylaws and under Delaware Law
could make an acquisition of Calyxt, Inc., which may be beneficial to Calyxt Stockholders, more difficult and may prevent attempts by Calyxt Stockholders to replace or remove Calyxt, Inc.&#146;s current management. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If for any reason the Mergers are not completed and Calyxt does not pursue a liquidation and dissolution or an alternative strategic
transaction, the Calyxt Board may pursue an alternative strategic transaction. In such circumstances, provisions in the current Calyxt Certificate of Incorporation and the Calyxt Bylaws may discourage, delay or prevent a merger, acquisition or other
change in control of Calyxt that Calyxt Stockholders may consider favorable, including transactions in which Calyxt Stockholders might otherwise receive a premium for their shares of Calyxt Common Stock. These provisions could also limit the price
that investors might be willing to pay in the future for shares of Calyxt Common Stock, thereby depressing the market price of Calyxt Common Stock. In addition, because the Calyxt Board is responsible for appointing the members of Calyxt,
Inc.&#146;s management team, these provisions may frustrate or prevent any attempts by Calyxt Stockholders to replace or remove Calyxt, Inc.&#146;s current management by making it more difficult for Calyxt Stockholders to replace members of the
Calyxt Board. Among other things, these provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish a classified board of directors such that only one of three classes of directors is elected each year;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">allow the authorized number of directors to be changed only by resolution of the Calyxt Board;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limit the manner in which stockholders can remove directors from the Calyxt Board; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and
nominations to the Calyxt Board; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require that Calyxt Stockholder actions must be affected at a duly called stockholder meeting and prohibit
actions by Calyxt Stockholders by written consent; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limit who may call stockholder meetings; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorize the Calyxt Board to issue preferred stock without stockholder approval, which could be used to
institute a &#147;poison pill&#148; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by the Calyxt Board; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require the approval of the holders of at least 66 2/3% of the votes that all Calyxt Stockholders would be
entitled to cast to amend or repeal specified provisions of the Calyxt Certificate of Incorporation or Calyxt Bylaws. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, because Calyxt, Inc. is incorporated in Delaware, Calyxt, Inc. is governed by the provisions of Section&nbsp;203 of the DGCL, which
prohibits a person who owns in excess of 15% of Calyxt, Inc.&#146;s outstanding </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
voting stock from merging or combining with Calyxt, Inc. for a period of three years after the date of the transaction in which the person acquired in excess of 15% of Calyxt, Inc.&#146;s
outstanding voting stock, unless the merger or combination is approved in a prescribed manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cellectis and Calyxt, Inc.&#146;s directors who have
relationships with Cellectis may have conflicts of interest with respect to matters involving Calyxt, Inc., including the Mergers. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Calyxt Certificate of Incorporation provides that none of Cellectis, or any of its officers, directors, agents, shareholders, members,
partners, subsidiaries (other than Calyxt, Inc. and any future subsidiaries) and their affiliates will be liable to Calyxt, Inc. or its stockholders for breach of any fiduciary duty by reason of the fact that Cellectis or any such individual directs
a corporate opportunity to Cellectis or its affiliates instead of Calyxt, Inc., or does not communicate information regarding a corporate opportunity to Calyxt, Inc. that such person or affiliate has directed to Cellectis or its affiliates. The
Calyxt Certificate of Incorporation also provides that neither Cellectis nor any of its affiliates or any of Calyxt, Inc.&#146;s nonemployee directors will have any duty to refrain from engaging in a corporate opportunity in the same or similar
lines of business in which it or any future subsidiaries now engage or propose to engage or otherwise competing with it or any of its future subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt, Inc.&#146;s license agreement with Cellectis does not restrict Cellectis from competing with Calyxt generally. Cellectis could develop
and commercialize agricultural and food products that may compete with Calyxt&#146;s current products or products in its pipeline using Cellectis intellectual property or technologies other than the gene editing technologies Cellectis has licensed
to Calyxt. Cellectis could also use the licensed gene editing technologies to develop and commercialize products involving animals and animal cells and these animal-based products may be competitive with Calyxt&#146;s plant-based products in certain
circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One of Calyxt, Inc.&#146;s directors, Laurent Arthaud, is also a director of Cellectis, and prior to the Closing,
Cellectis has the right to designate additional directors to serve on the Calyxt Board. Mr.&nbsp;Arthaud and any other directors designated by Cellectis who have relationships with Cellectis will have fiduciary duties to Calyxt and in addition will
have duties to Cellectis. Accordingly, there may be real or apparent conflicts of interest with respect to matters, such as the Mergers, affecting both Calyxt and Cellectis, whose interests, in some circumstances, may be different than the interests
of other stockholders or its interests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Calyxt&#146;s ability to use its net operating losses to offset future taxable income may be subject to
certain limitations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, Calyxt had approximately $239.2&nbsp;million of net operating losses, or NOLs,
for federal and state income tax purposes, which may be available to offset federal income tax liabilities in the future. In addition, Calyxt may generate additional NOLs in future years. Calyxt has established a full valuation allowance for its
deferred tax assets, including NOLs, due to the uncertainty that enough taxable income will be generated to utilize the assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt&#146;s ability to utilize its NOLs may be limited if it experiences an &#147;ownership change&#148; as defined in Section&nbsp;382
(Section 382) of the Code. An ownership change generally occurs if certain direct or indirect five percent shareholders increase their aggregate percentage ownership of a corporation&#146;s stock by more than 50 percentage points over their lowest
percentage ownership at any time during the testing period, which is generally the three-year period preceding any potential ownership change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no assurance that Calyxt will not experience a current or future ownership change under Section&nbsp;382 that would significantly
limit or possibly eliminate its ability to use its NOLs. Current or potential future transactions by Calyxt involving the sale or issuance of its common stock, or the exercise of Calyxt Common Warrants, or a combination of such transactions, may
result in ownership changes under Section&nbsp;382. In addition, Calyxt may experience ownership changes as a result of shifts in the direct or indirect ownership of its stock, some of which may be outside of its control. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Section&nbsp;382, a current or future ownership change would subject Calyxt to an
annual limitation that applies to the amount of <FONT STYLE="white-space:nowrap">pre-ownership</FONT> change NOLs that may be used to offset post-ownership change taxable income. This limitation is generally determined by multiplying the value of a
corporation&#146;s stock immediately before the ownership change by the applicable long-term <FONT STYLE="white-space:nowrap">tax-exempt</FONT> rate. Any unused annual limitation may, subject to certain limits, be carried over to later years, and
the limitation may under certain circumstances be increased by <FONT STYLE="white-space:nowrap">built-in</FONT> gains in the assets held by such corporation at the time of the ownership change. This limitation could cause Calyxt&#146;s U.S. federal
income taxes to be greater, or to be paid earlier, than they otherwise would be, and could cause some of its NOLs to expire unused. Similar rules and limitations may apply for state income tax purposes. There is also a risk that future legal or
regulatory changes may limit Calyxt&#146;s ability to use current or future NOLs to offset its future federal income tax liabilities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to
the Organization and Governance of Calyxt </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes to Calyxt&#146;s strategic business focus have placed significant demands on Calyxt&#146;s
management and Calyxt&#146;s infrastructure. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since Calyxt, Inc.&#146;s initial public offering on July 25, 2017, the strategic
focus of the business has undergone changes. In October 2021, Calyxt announced the launch of a strategic initiative which focused it on engineering synthetic biology solutions. Most recently, in light of the proposed Transactions, Calyxt has focused
its current business activities on ensuring it has cash sufficient to achieve a closing of the proposed Transactions. Accordingly, Calyxt has taken additional steps to reduce its operating expenses. Calyxt has focused its operations on: scaling
production of its Plant Cell Matrix with its manufacturing partner, Evologic; licensing efforts with respect to its PlantSpring technology and plant traits, including the TALEN technology; and continuing to progress its current customer projects.
Calyxt&#146;s three key customer projects are (1) its research collaboration with a leading global food ingredient manufacturer to develop a soybean trait to serve as an alternative to palm oil, (2) its plant-based chemistry pilot project for a
major consumer packaged goods company, and (3) supporting late-stage development activities for its improved digestibility alfalfa trait, which was developed with and licensed to S&amp;W Seed Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The changes to Calyxt&#146;s strategic focus has placed, and may continue to place, significant demands on Calyxt&#146;s management and its
operational and financial infrastructure. Managing a significant change in business focus and negotiating the Transactions while overseeing day-to-day operations, each requires significant expenditures and allocation of valuable management
resources. If Calyxt fails to achieve the necessary level of efficiency in its organization as it evolves, its business, financial condition and results of operations would be adversely impacted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Calyxt depends on key management personnel and attracting and retaining other qualified personnel, and its business could be harmed if it loses key
management personnel. In addition, Calyxt is substantially dependent on its remaining employees to facilitate the consummation of the Transactions. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt&#146;s success depends to a significant degree upon the technical skills and continued service of certain members of its management and
other key employees. Although Calyxt has significantly streamlined its operations, the loss of the services of Calyxt&#146;s management or key employees may delay or prevent the timely and successful execution of its business strategies and
objectives and may have a negative impact on Calyxt&#146;s ability to facilitate the consummation of the Transactions. Calyxt&#146;s business is dependent on its ability to recruit and maintain a highly skilled and educated workforce with expertise
in a range of disciplines, including biology, biochemistry, plant genetics, mathematics, and other subjects relevant to its operations. In the event the Transactions are not consummated, Calyxt&#146;s ability to successfully implement its strategic
focus will also depend on recruiting and retaining personnel with the necessary background and ability to understand its systems at a technical level to effectively identify and sell to potential new customers. Competition for these highly skilled
employees is intense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If for any reason the Transactions are not completed and the Calyxt Board seeks to continue to operate
Calyxt&#146;s business, Calyxt will face challenges resulting from its streamlined personnel, who will need to continue </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to implement Calyxt&#146;s managerial, operational, and financial systems, manage its facilities, and progress customer projects and licensing efforts. As a result, Calyxt&#146;s management may
need to divert a disproportionate amount of its attention away from Calyxt&#146;s day-to-day strategic and operational activities and devote a substantial amount of time to managing organizational changes. Further, cash-focused headcount reduction
measures may yield unintended consequences, such as attrition beyond Calyxt&#146;s intended reduction in headcount and reduced employee morale. In addition, reductions in the size of Calyxt may result in employees who were not affected by the
reductions in headcount seeking alternate employment. The loss of the services of certain employees could potentially harm Calyxt&#146;s ability to continue its day-to-day business operations, including the progression of its key customer projects,
or to fulfill its reporting obligations as a Nasdaq-listed public company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, cost reduction and cash-focused measures that
Calyxt has undertaken may result in weaknesses in Calyxt&#146; infrastructure and operations, an inability to effectively execute on customer acquisition and business development efforts, loss of business opportunities, reduced productivity among
remaining employees, and challenges in complying with legal and regulatory requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no assurance that Calyxt will be
successful in attracting or retaining such personnel and the failure to do so could have a material adverse effect on its business, financial condition, and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Calyxt&#146;s business and operations would suffer in the event of computer system failures, cyber-attacks, or a deficiency in its cyber-security.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Increased information systems security threats, cyber- or phishing-attacks and more sophisticated, targeted computer invasions
pose a risk to the security of Calyxt&#146;s systems and networks, and the confidentiality, availability, and integrity of its data, operations, and communications, and the exposure to such risks is enhanced in Calyxt&#146;s remote work environment
as a result of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. Cyber-attacks against Calyxt&#146;s technology platform and infrastructure could result in exposure of confidential information, the modification of critical data, and/or
the failure of critical operations. Likewise, improper or inadvertent employee behavior, including data privacy breaches by employees and others with permitted access to Calyxt&#146;s systems, may pose a risk that sensitive data may be exposed to
unauthorized persons or to the public. While Calyxt attempts to mitigate these risks by employing a number of measures, including security measures, employee training, comprehensive monitoring of networks and systems, maintenance of backup and
protective systems, and incident response procedures, if these measures prove inadequate, Calyxt could be adversely affected by, among other things, loss or damage of intellectual property, proprietary and confidential information, data integrity,
and communications or customer data, increased costs to prevent, respond to, or mitigate these cyber security threats and interruptions of its business operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Calyxt&#146;s business activities are currently conducted at a limited number of locations, which makes it susceptible to damage or business disruptions
caused by natural disasters or acts of vandalism. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt&#146;s current headquarters and R&amp;D facilities, which include an
office, labs, the BioFactory pilot facility, greenhouses, and field-testing plots are in Roseville, Minnesota. Calyxt takes precautions to safeguard its facilities, including insurance, health and safety protocols, and
<FONT STYLE="white-space:nowrap">off-site</FONT> storage of critical research results and computer data. Although Calyxt maintains levels of insurance that it believes are customary for its industry, its insurance policies may not cover certain
losses, or losses may exceed Calyxt&#146;s coverage limits. A natural disaster, such as a hurricane, drought, fire, flood, tornado, earthquake, or other intentional or negligent acts, including acts of vandalism, could damage or destroy
Calyxt&#146;s equipment, inventory, development projects, data, and cause it to incur significant additional expenses to repair or replace the damaged physical facilities, which increase the development schedule for the products under development
for customers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom401831_10"></A>Risks Related to Cibus </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Cibus&#146; Business and Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cibus&#146; operating history makes it difficult to assess its future prospects. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus&#146; commercial strategy is focused on the development and licensing for royalties of intellectual property associated with agricultural
productivity traits and more sustainable industrial ingredients, in each case developed with Cibus&#146; <B><I>RTDS</I></B> gene-editing technology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While this focus has been a consistent part of Cibus&#146; commercial strategy since its inception, Cibus previously had a broader range of
activities in the agriculture market. In respect of agricultural products, Cibus&#146; commercial strategy was initially bifurcated between commercial sales of Cibus&#146; proprietary branded canola seed, SU Canola (canola tolerant to specific
sulfonylurea herbicides), and the development and licensing of its <B><I>RTDS</I></B>-developed productivity traits to leading seed companies. In October 2020, as part of a sharpening of its strategic direction and focus, Cibus divested its canola
seed breeding assets and focused its business solely on developing key productivity traits for the largest global crops: canola, rice, soybean, corn and wheat. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since October 2020, Cibus has focused primarily on research and development of <B><I>RTDS</I></B>-developed productivity traits and more
sustainable <FONT STYLE="white-space:nowrap">low-carbon</FONT> ingredients, and the licensing of the intellectual property associated with these product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus&#146; operating history under this more focused strategy has been limited, which may make it difficult to evaluate its current business
and future prospects. Cibus has encountered, and will continue to encounter, risks and difficulties frequently experienced by growing companies in the rapidly developing biotechnology industry. These risks and difficulties include challenges in
determining appropriate investments of Cibus&#146; limited resources, gaining market acceptance of the gene-edited trait and ingredient products developed using its <B><I>RTDS</I></B>, managing a complex regulatory landscape, developing new trait
products and competing against other companies operating in Cibus&#146; industries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus may not be able to fully implement or execute
on its commercial strategy or realize, in whole or in part within its expected time frames, the anticipated benefits of its growth strategies. Cibus&#146; business and prospects should be evaluated in light of the risks and difficulties it faces as
a growing company focused on developing novel disruptive technologies for the agriculture and the industrial ingredients markets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cibus has
incurred significant losses and anticipates that it will continue to incur significant losses for several years. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Historically,
Cibus has incurred net losses and had an accumulated deficit. The amount of Cibus&#146; future net losses will depend, in part, on the amount of its future operating expenses and the pace at which they are incurred, the satisfaction of its Royalty
Liability (as defined herein) and its interest expense related thereto, and its ability to obtain funding through its licensing activities, through equity or debt financings or through grants or partnerships. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to its Royalty Liability, Cibus expects the liability balance to continue to increase each year until 2035, as the accretion of
interest expense will outpace the cash payments for royalties due, and the related <FONT STYLE="white-space:nowrap">non-cash</FONT> interest expense recorded to increase in conjunction with the underlying liability balance. As a result of its
limited commercial licensing revenue, Cibus expects to continue to incur significant expenses and operating losses for at least the next several years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, Cibus has concluded that there is substantial doubt about its ability to continue as a going concern for at least 12 months from
the issuance date of the financial statements included in this proxy statement/prospectus. The accompanying consolidated financial statements of Cibus have been prepared on a going-concern basis, which contemplates the realization of assets and
satisfaction of liabilities in the normal course of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
business. The Cibus consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification
of liability that might result from the outcome of this uncertainty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus&#146; management is currently evaluating different strategies
to obtain the required funding for Cibus&#146; future operations. These strategies may include but are not limited to private placements or public offerings of equity or equity-linked instruments, or collaboration, licensing or other similar
arrangements. There is no assurance that such financing will be available when needed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus anticipates that such expenses will increase
substantially if it, directly or through partners: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conducts additional research and development activities with respect to current and future productivity traits
and sustainable ingredients products, including the development of additional Trait Machine/<B><I>RTDS</I></B> platforms, field trials with respect to productivity trait validation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continues to invest in scaling of the automation of the Trait Machine and its R&amp;D to develop new traits;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seeks to identify and validate additional productivity traits and sustainable ingredient products for commercial
licensing opportunities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acquires or <FONT STYLE="white-space:nowrap">in-licenses</FONT> technology, germplasm or biological material to
support its strategic development; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seeks regulatory determinations or approvals, if applicable, with respect to productivity traits and sustainable
ingredient products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">makes or receives royalty and other payments under any <FONT STYLE="white-space:nowrap">in-license</FONT>
agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintains, protects, expands and defends its intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seeks to attract and retain new and existing skilled personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">integrates the business and operations of Cibus and Calyxt into the Combined Company; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">experiences any delays or encounters issues with any of the above. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The net losses Cibus incurs may fluctuate significantly from
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-year</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">quarter-to-quarter,</FONT></FONT> such that a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">period-to-period</FONT></FONT> comparison of its results of operations may not be a good indication of its future performance. In any particular period or periods, Cibus&#146; operating results could be below the
expectations of investors, which could cause the value of its securities to decline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cibus faces significant competition and many of its
competitors have substantially greater financial, technical and other resources than Cibus does. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The markets for agricultural
productivity traits and more sustainable, <FONT STYLE="white-space:nowrap">low-carbon</FONT> ingredients are highly competitive, and Cibus faces significant competition in its businesses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In agriculture, competition for improving plant genetics comes from traditional and advanced plant breeding techniques, as well as from the
development of desirable plant traits through gene-editing techniques. Competition for the discovery of new desirable traits based on biotechnology is likely to come from a relatively small number of major global agricultural chemical companies,
smaller biotechnology research companies and institutions, and academic institutions. For improving crop yields, Cibus&#146; traits compete as a system with other practices, including the application of crop protection chemicals, fertilizer
formulations, farm mechanization, other biotechnology, and information management. Programs to improve genetics and chemistry are generally concentrated within a relatively small number of large companies, while
<FONT STYLE="white-space:nowrap">non-genetic</FONT> approaches are underway with a broader set of companies. With respect to more sustainable ingredients, competition comes from traditional chemical and
<FONT STYLE="white-space:nowrap">non-sustainable</FONT> ingredients primarily produced by global health and nutrition </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
companies, large international chemical companies and companies specializing in specific products, such as flavor or fragrance ingredients, as well as from emerging alternatives produced from
renewable sources, including fermentation and synthetic biology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of Cibus&#146; current or potential competitors, either alone or
with their research and development or collaboration partners, have significantly greater financial resources and expertise in research and development, marketing and licensing than Cibus does. Further, many competitors have well-developed networks
for their products, including valuable historical relationships with potential customers that we are seeking to engage with. Smaller or early-stage companies may also prove to be significant competitors, particularly through research and development
and collaborative arrangements with large and established companies. Competitors also compete with Cibus in recruiting and retaining qualified scientific and management personnel, as well as in acquiring technologies complementary to, or necessary
for, Cibus&#146; programs. Future mergers and acquisitions may result in a concentration of resources among an increasingly smaller number of competitors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus intends to compete on the basis of: innovation; product performance and quality; development cost and price; market priorities,
including increasing focus on sustainability, climate change and social responsibility. Cibus&#146; ability to compete effectively depends, in part, on its ability to successfully: evaluate needs and market demand in the seed and ingredients
markets; control costs; develop commercial licensing relationships with established seed companies and <FONT STYLE="white-space:nowrap">end-users</FONT> of industrial ingredients; innovate new productivity traits and more sustainable ingredients
that are attractive to the market; navigate regulatory requirements; and license traits and ingredients in a timely and cost-efficient manner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ultimately, if Cibus cannot demonstrate that its productivity traits and more sustainable ingredient products are better alternatives to
existing product options, Cibus may not succeed in its markets, which failure would adversely affect its business, results of operations and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of Cibus&#146; existing competitors invest substantial resources in ongoing research and development, and Cibus also anticipates
increased competition as new companies enter the market. To the extent that its competitors introduce new technologies, particularly in the area of gene editing, such developments could render Cibus&#146; products or technology obsolete, less
competitive or uneconomical. In this case, such technological advances or new approaches to trait development could prevent or limit Cibus&#146; ability to generate revenue from the commercial licensing arrangements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cibus relies on gene-editing technologies that may become obsolete in the future. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus relies on its proprietary <B><I>RTDS</I></B> technologies, such as the GRON, to develop its productivity traits and <FONT
STYLE="white-space:nowrap">low-carbon,</FONT> sustainable industrial ingredient products. If its competitors are able to refine existing gene-editing technologies to be, or develop new gene-editing technologies that are, superior to its
<B><I>RTDS</I></B> technologies, Cibus may face reputational damage and a decline in the demand for its productivity traits and sustainable ingredient products. Its technologies may be rendered obsolete or uneconomical by technological advances or
entirely different approaches developed by one or more of its competitors that are more effective than <B><I>RTDS</I></B> or that enable them to develop and commercialize products more quickly or with lower expense than Cibus is able to do. If for
any reason Cibus&#146; technologies become obsolete or uneconomical relative to its competitors&#146; technologies, this would prevent or limit Cibus&#146; ability to generate revenues from the commercial licensing of its traits or ingredient
products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cibus&#146; success is dependent on demand for its productivity traits and more sustainable ingredient products, which can be adversely
impacted by various factors. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus&#146; success depends on demand for its productivity traits and more sustainable ingredient
products, which may be adversely impacted by a variety of factors, including factors unrelated to Cibus and many of which are outside of Cibus&#146; control. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In agriculture, demand for seed generally and demand from seed companies for specific traits
depends on a variety of factors, including downstream demand for specific crops. For example, because China is the world&#146;s largest importer of soybeans, a severe downturn in the Chinese economy could have a negative effect on global soybean
sales and as a result, the demand for soybean seeds in the U.S. market, including soybean seeds that include Cibus&#146; productivity traits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to more sustainable, <FONT STYLE="white-space:nowrap">low-carbon</FONT> ingredients, demand is primarily driven by global
societal and political movements to accelerate a transition to sustainable consumption. For example, hundreds of companies, including numerous large multinational corporations, have publicly committed to achieving
<FONT STYLE="white-space:nowrap">net-zero</FONT> carbon emissions by 2040. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Demand for Cibus&#146; productivity traits and more
sustainable ingredient products could decline as a result of various factors, including because of availability of more cost effective or better performing alternatives or as a result of failure by its licensees to effectively compete in their
respective industries. A decline in demand for Cibus&#146; productivity traits, more sustainable industrial ingredient products, or downstream products containing Cibus intellectual property could have a material adverse effect on Cibus&#146;
business, results of operations and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cibus&#146; business activities are currently conducted at a limited number of locations,
and damage or business disruptions at these locations would have an adverse effect on its business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus&#146; current
headquarters is located in San Diego, California. Substantially all of its research and development operations, including its <B><I>RTDS</I></B><B> </B>automation capabilities and the facilities of Nucelis, are conducted at its headquarters
location. In addition, Cibus&#146; first generation parent seed is also produced by Cibus staff in greenhouses near its headquarters and hybrids designated for testing are developed using several different cooperators, primarily in Chile. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus takes precautions to safeguard its facilities, including maintaining customary insurance coverage, implementing safety protocols, and
keeping critical research results and computer data <FONT STYLE="white-space:nowrap">backed-up</FONT> on <FONT STYLE="white-space:nowrap">off-site</FONT> storage networks. However, damage to, or destruction of, critical facilities, equipment,
inventory or development projects, or any business disruptions at Cibus&#146; critical locations, whether due to natural disasters, acts of vandalism or otherwise, could cause substantial delays in research and development activities and commercial
licensing efforts and could cause Cibus to incur additional expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cibus&#146; research and development efforts may be slower than expected and
not be successful. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The development and advancement of Cibus&#146; productivity traits and more sustainable industrial ingredient
products entail substantial research and development efforts using complex technology platforms, such as its <B><I>RTDS</I></B>. These development efforts require significant investments, including expenses relating to laboratory, greenhouse and
field testing, and <FONT STYLE="white-space:nowrap">lab-</FONT> and pilot-scale fermentation infrastructure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Historically, Cibus has
incurred significant research and development expenses. Cibus intends to continue to invest in research and development to develop and validate its technologies, productivity traits and sustainable ingredient products. Notwithstanding its
investments in research and development, there is significant risk that Cibus will not be able to achieve its development goals in the desired timeframe or at all, and Cibus may not realize significant product revenue in the near term, if ever. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, the application of gene-editing technologies can be unpredictable, and may prove to be unsuccessful when attempting to achieve
desired productivity traits in different crops and plants or to produce sustainable ingredient products at scale. For example, Cibus&#146; productivity traits that perform in the greenhouse may not achieve similar performance levels in the field, or
may achieve varying performance levels as a result of environmental and geographic conditions, and Cibus&#146; sustainable ingredient products developed at <FONT STYLE="white-space:nowrap">lab-scale</FONT> or pilot-scale may not be successfully
generated at commercial scale. Any such variations could substantially harm Cibus&#146; ability to license the relevant intellectual property for such productivity traits or sustainable ingredient candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Development using innovative and complex technologies, such as Cibus&#146;
<B><I>RTDS</I></B>, is subject to the risks that, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">its productivity trait or sustainable ingredient product candidates fail to perform as expected in greenhouse
evaluation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">its productivity trait or sustainable ingredient product candidates fail to perform as expected in the field or
at commercial scale, as applicable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cibus is unable to achieve a desired trait or targeted sustainable ingredient using its <B><I>RTDS</I></B>;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">necessary regulatory approvals and governmental clearances, if applicable, in Cibus&#146; targeted markets are
not obtainable or not provided in a timely manner; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">its products exhibit unanticipated, undesirable performance or other unanticipated effects;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the value that Cibus ascribes to its productivity traits or sustainable ingredient products is not recognized by
potential licensors or such licensors&#146; downstream <FONT STYLE="white-space:nowrap">end-user</FONT> customers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">its productivity trait and sustainable ingredient candidates are difficult or impossible to produce on a large
scale; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cibus is unable to fully develop or license its productivity traits and sustainable ingredient products in a
timely manner or at all. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lastly, the field of gene editing, particularly in plants and microorganisms, is still in its
early stages. Unexpected or negative developments from the use of <B><I>RTDS</I></B>, including with respect to the exhibition of unanticipated undesirable traits or characteristics, could adversely affect the commercial value of Cibus&#146; product
offerings and harm its reputation. In addition, negative developments arising from its competitors&#146; use of certain gene-editing technologies could harm the reputation of gene-editing technology, generally. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cibus may direct its limited resources toward productivity trait or sustainable ingredient candidates that prove to be less profitable or successful
than others that it did not pursue. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus has limited financial and managerial resources, which Cibus must expend on the basis of
its expectations about, and forecasts of, market demand. As a result, Cibus may forego or delay the pursuit of opportunities with certain productivity trait or sustainable ingredient candidates that later prove to have greater commercial potential
than those that Cibus does choose to develop. Its resource allocation decisions may lead Cibus to fail to capitalize on commercially viable productivity trait or sustainable ingredient candidates or profitable market opportunities. Its spending on
current and future research and development programs and productivity trait or sustainable ingredient candidates may never yield commercially viable products sufficient to sustain its business and operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cibus intends to license the intellectual property with respect to its productivity traits and sustainable ingredient products to third parties for use
in their products, and will be dependent on them to successfully commercialize such products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus&#146; business model
contemplates that it will license to third parties the intellectual property with respect to substantially all of the productivity traits and sustainable ingredients it develops for sale in their product offerings. Cibus&#146; licensee customers
will typically oversee the development and commercialization of products containing such licensed intellectual property. In such cases, Cibus&#146; ability to achieve milestone payments or generate royalties is not within its direct control and will
substantially depend on the efforts and success of its licensee customers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Cibus&#146; licensees are delayed or unsuccessful in
introducing Cibus&#146; licensed intellectual property into their products or commercializing the products that contain Cibus&#146; licensed intellectual property, or if they fail to devote sufficient time and resources to support the marketing and
selling efforts of those products, Cibus may not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
receive royalty payments as expected and its financial results could be harmed. Further, if these licensee customers fail to market products incorporating Cibus&#146; intellectual property at
prices that will achieve or sustain market acceptance for those products, Cibus&#146; royalty revenues could be further harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Any partnerships
that Cibus may enter into in the future may not be successful. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus may seek research and development partnerships or joint
venture arrangements with third parties for the development or commercialization of certain intellectual property. To the extent that Cibus pursues such arrangements, Cibus will face significant competition in seeking appropriate partners. Moreover,
such arrangements are complex and time-consuming to negotiate, document, implement and maintain. Cibus may not be successful in establishing or implementing such arrangements. The terms of any partnerships, joint ventures or other arrangements that
Cibus may establish may not be favorable to Cibus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The success of any future partnerships or joint ventures is uncertain, and will depend
heavily on the efforts and activities of Cibus&#146; partners. Such arrangements are subject to numerous risks, including the risks that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">its partners may have significant discretion in determining the efforts and resources that they will apply to the
arrangement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">its partners may not contribute sufficient capital or resources toward development in light of changes in
strategic focus, competing priorities, availability of funding or capital resources, or other external factors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">its partners may delay or abandon development efforts, fail to conduct research and development activities that
produce sufficient conclusory data, or provide insufficient funding; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">its partners could develop, independently or with third parties, intellectual property or products that compete
with Cibus&#146; productivity traits or sustainable ingredient products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">partners who license intellectual property rights from Cibus may not commit sufficient resources to, or otherwise
not perform satisfactorily in executing, downstream product commercialization activities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to the extent that such arrangements provide for exclusive rights, Cibus may be precluded from collaborating with
others; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">its partners may not properly maintain or defend Cibus&#146; intellectual property rights, or may use Cibus&#146;
intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate Cibus&#146; intellectual property or proprietary information or expose Cibus to potential liability;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disputes may arise between Cibus and a partner that causes the delay or termination of research and development
activities or downstream product commercialization efforts, or that result in costly litigation or arbitration that diverts management attention and resources; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such arrangements may be terminated, and, if terminated, may result in a need for additional capital for
Cibus&#146; independent pursuit of matters previously covered by such arrangement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">its partners may own or <FONT STYLE="white-space:nowrap">co-own</FONT> intellectual property that results from
its arrangement; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a partner&#146;s activities may not be in compliance with applicable laws resulting in civil or criminal
proceedings. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If ongoing or future field trials are unsuccessful, Cibus may be unable to complete the development of productivity
trait candidates on a timely basis or at all. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus relies on field trials to evaluate and demonstrate the efficacy of
productivity traits that it has developed and evaluated in greenhouse conditions. Field trials allow Cibus to test the productivity traits that it has developed as well as to increase seed production, and to measure performance across multiple
geographies and conditions. The successful completion of field trials is critical to the success of Cibus&#146; productivity trait development efforts and supports its licensing efforts with respect to its productivity trait candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Cibus&#146; ongoing or future field trials are unsuccessful or produce inconsistent
results or unanticipated adverse effects on the agronomic performance of seeds with its traits, or if the field trials do not produce reliable data, Cibus&#146; productivity trait development efforts could be delayed, subject to additional
regulatory review or abandoned entirely. In addition, in order to support its licensing efforts, it is necessary to collect data across multiple growing seasons and from different geographies. Even in cases where initial field trials are successful,
Cibus cannot be certain that additional field trials conducted on a greater number of acres or in different geographies will also be successful. Many factors that are beyond Cibus&#146; control may adversely affect the success of these field trials,
including unique geographic conditions, weather and climatic variations, disease or pests, or acts of protest or vandalism. Field trials, which may take up to <FONT STYLE="white-space:nowrap">2-3</FONT> years, are costly, and any field trial
failures that Cibus may experience may not be covered by insurance and, therefore, could result in increased costs, which may negatively impact its business and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cibus relies on third parties to conduct, monitor, support and oversee field trials, and any performance issues by them may impact Cibus&#146; ability
to successfully commercialize products or license traits. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus currently relies on third parties, such as growers, consultants,
contractors, and universities, to conduct, monitor, support and oversee its field trials. Because field trials are conducted in multiple geographies, it is often difficult for Cibus to monitor the daily activity of the work being conducted by such
third parties that it engages. Although Cibus provides its third parties with extensive protocols regarding the establishment, management, data collection, harvest, transportation and storage of its productivity trait candidates, Cibus has limited
control over the execution of field trials. Poor field trial execution or data collection, failure to follow required agronomic practices, protocols or regulatory requirements, or mishandling of productivity trait candidates by these third parties
could impair the success of Cibus&#146; field trials. Any such failures may result in delays in the development of Cibus&#146; productivity trait candidates or the incurrence of additional costs. Ultimately, Cibus remains responsible for ensuring
that each of its field trials is conducted in accordance with the applicable protocol, legal and regulatory and agronomic standards, and its reliance on third parties does not relieve Cibus of its responsibilities. Should such third parties fail to
comply with these standards, Cibus&#146; ability to develop its productivity trait candidates for licensing could be adversely impacted, and Cibus may be forced to incur additional costs in regaining compliance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, if Cibus is unable to enter into, or maintain, agreements with such third parties on acceptable terms, or if any such engagement
is terminated prematurely, Cibus may be unable to conduct or complete its field trials in the manner it anticipates. If Cibus&#146; relationship with any of these third parties is terminated, Cibus may be unable to enter into arrangements with
alternative third parties on commercially reasonable terms, or at all. Switching or adding third parties can involve substantial cost and require extensive management time and focus. In addition, there is a natural transition period when any new
third party commences field trial work. As a result, delays may occur, which could materially impact Cibus&#146; ability to meet its desired development timelines. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cibus may lack the necessary expertise, personnel and resources to effectively license its productivity traits and sustainable ingredient products.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To successfully license the intellectual property underlying Cibus&#146; productivity traits and sustainable ingredient products,
Cibus must develop, foster and maintain commercial relationships with a range of potential customers across several industries, including potential customers that may have long-standing historical relationships with competitors. In order to be
successful in this regard, Cibus will need to develop and enhance its commercial team to both establish new relationships as well as to maintain relationships with existing customers. To foster the commercial success of Cibus&#146; licensee
customers in effectively marketing and commercializing their products containing Cibus licensed intellectual property, Cibus will need to develop and <FONT STYLE="white-space:nowrap">build-out</FONT> its own understanding of their respective
industries and capabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Factors that may affect Cibus&#146; ability to effectively license its intellectual property and support its
licensee&#146;s commercialization efforts include its ability to: recruit and retain adequate numbers of qualified personnel, effectively develop relationships with potential licensee customers in key industries, secure license agreements
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with companies requiring them to undertake specific commercialization activities within specified timeframes, and persuade downstream end users to purchase and use products that integrate Cibus
licensed intellectual property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Developing and maintaining such capabilities requires significant investment, is time-consuming and could
delay the licensing of Cibus&#146; intellectual property with respect to productivity traits or sustainable ingredient products or the commercial launch of its licensees&#146; products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interruptions in the production or transportation of parent seeds could adversely affect Cibus&#146; operations and profitability. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to productivity traits, Cibus&#146; licensee customers will provide elite germplasm to Cibus so that Cibus may introduce a desired
productivity trait. Cibus will produce parent or hybrid seeds containing such productivity traits for the licensee customer. Cibus&#146; licensee customers would then utilize the parent seed containing Cibus&#146; traits to produce their own
hybrids. Cibus will rely on contract seed producers for such parent seed production. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Poor execution, failure to follow required agronomic
practices, protocols or regulatory requirements, or mishandling of productivity trait candidates by these contract seed producers could adversely affect products. Any such failures may result in delays in Cibus&#146; ability to deliver parent seed
to Cibus&#146; licensee customers in a timely manner. Such delays could adversely affect the ability of Cibus&#146; licensee customers to deliver hybrid seed products to farmers to meet their planting window. Cibus&#146; dependency upon timely seed
deliveries means that interruptions or stoppages in such deliveries, or delays or limitations with respect to seed production, could adversely affect Cibus&#146; operations until alternative arrangements could be made. Such a delay would adversely
affect Cibus&#146;, and its licensee customers&#146;, reputations and revenues and could result in write-offs of inventory. If Cibus was unable to produce the necessary seed for an extended period of time for any reason, its business, customer
relations, and operating results could suffer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus may not be able to identify suitable seed producers to meet its production needs. If
Cibus does identify suitable seed producers, it may not be able to enter into cost effective agreements on acceptable terms. If any contract seed producers whom Cibus engages fail to perform their obligations as expected or breach or terminate their
agreements with Cibus, or if Cibus is unable to secure the services of such third parties when and as needed, Cibus may lose opportunities to generate revenue from product sales. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The unintended presence of Cibus&#146; productivity traits in other products or plants, or of transgenes in Cibus&#146; products, may negatively affect
Cibus. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Trace amounts of Cibus&#146; productivity traits may unintentionally be found outside its agricultural containment area in
the products of third parties, which may result in negative publicity and claims of liability brought by such third parties against Cibus. Furthermore, in the event of an unintended dissemination of Cibus&#146; gene-edited germplasm into the
environment, or the presence of unintended trace amounts of its traits in traditional seed, or in the grain or products produced from traditional crops, Cibus could be subject to claims by multiple parties, including environmental advocacy groups,
as well as governmental actions such as mandated crop destruction, product recalls, or additional stewardship practices and environmental cleanup or monitoring. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cibus&#146; productivity traits and sustainable ingredient products may not achieve commercial success quickly or at all. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus intends to license intellectual property with respect to its <B><I>RTDS</I></B>-developed productivity traits and sustainable ingredient
products to third parties. Cibus&#146; productivity traits and sustainable ingredient products are in various stages of development, and there are no established channels to market for their commercialization by potential licensee customers. If
Cibus is unable to license its productivity traits and sustainable ingredient products on a significant scale, then Cibus may not be successful in building a profitable business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus expects to price its licenses based on its assessment of the value that Cibus believes
its productivity traits and sustainable ingredient products will provide within the relevant end product market dynamics, rather than on the cost of production. If licensees, commercial product end users or other market participants attribute a
lower value to Cibus&#146; productivity traits or sustainable ingredient products than Cibus does, they may not be willing to pay the premiums that Cibus expects to charge. Pricing levels may also be negatively affected if Cibus&#146; productivity
traits or sustainable ingredient products traits are unsuccessful or suboptimal in producing or exhibiting the characteristics expected by Cibus and its licensees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Public understanding of Cibus&#146; RTDS technologies and public perception and acceptance of gene-editing technologies, including Cibus&#146; RTDS
technologies, could affect Cibus&#146; sales and results of operations and impact relevant government regulation. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ability of
Cibus&#146; licensees to successfully commercialize products containing Cibus&#146; productivity traits and sustainable ingredient products depends, in part, on public understanding and acceptance of gene editing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Such understanding is particularly relevant with respect to plant gene editing, where end products may enter consumer food supply chains.
Farmers, seed companies and <FONT STYLE="white-space:nowrap">end-product</FONT> consumers may not understand the nature of Cibus&#146; <B><I>RTDS</I></B> technologies or the scientific distinction between Cibus&#146;
<FONT STYLE="white-space:nowrap">non-transgenic</FONT> products and processes and transgenic products and processes of competitors. As a result, these parties may transfer negative perceptions and attitudes regarding transgenic products to
Cibus&#146; products and productivity trait candidates. A lack of understanding of Cibus&#146; <B><I>RTDS</I></B> technologies may also make consumers more susceptible to the influence of negative information provided by opponents of biotechnology.
Some opponents of biotechnology actively seek to raise public concern about gene editing, whether transgenic or <FONT STYLE="white-space:nowrap">non-transgenic,</FONT> by claiming that plant products developed using biotechnology are unsafe for
consumption or use, pose risks of damage to the environment, or create legal, social and ethical dilemmas. The commercial success of Cibus&#146; trait candidates may be adversely affected by such claims, even if unsubstantiated. In addition, extreme
opponents of biotechnology have vandalized the fields of farmers planting biotech seeds and facilities used by biotechnology companies. Any such acts of vandalism targeting the fields of farmers planting seed with Cibus traits, Cibus&#146; field
testing sites or its research, production or other facilities, could adversely affect Cibus&#146; sales and costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Negative public
perceptions about gene editing can also affect the regulatory environment in the jurisdictions in which Cibus is targeting the licensing of its intellectual property. Any increase in such negative perceptions or any restrictive government
regulations in response thereto, could have a negative effect on Cibus&#146; business and may delay or impair its ability to enter licensing agreements or to receive milestone and royalty payments pursuant to such licensing arrangements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Food products produced from crops containing Cibus&#146; productivity traits may fail to meet standards established by third-party <FONT
STYLE="white-space:nowrap">non-GMO</FONT> verification organizations, which could reduce the value of Cibus&#146; productivity traits to licensee customers. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain third-party organizations offer verification programs that seek to make <FONT STYLE="white-space:nowrap">non-GMO</FONT> products easily
identifiable for consumers. These organizations verify the <FONT STYLE="white-space:nowrap">non-GMO</FONT> status of products (such as foods, beverages and vitamins) based on independently developed standards, and often authorize the display of
specific markers or labels illustrating such status on the verified product&#146;s packaging. Although the verification programs seek to identify finished products as <FONT STYLE="white-space:nowrap">non-GMO</FONT> verified, the processes that they
employ typically examine the individual ingredients and precursors, rather than the finished products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Standards established by such
third-party organizations for the verification of <FONT STYLE="white-space:nowrap">non-GMO</FONT> status often differ from applicable regulatory legal standards governing <FONT STYLE="white-space:nowrap">non-GMO</FONT> classification in the United
States, Canada or other of Cibus&#146; target markets. As a result, notwithstanding a regulatory determination as to the <FONT STYLE="white-space:nowrap">non-GMO</FONT> status of its <B><I>RTDS</I></B> technologies, products containing Cibus&#146;
traits may fail to meet more restrictive or <FONT STYLE="white-space:nowrap">non-scientific</FONT> standards imposed by these independent verification organizations. For example, a third-party verification organization could determine that it will
withhold its <FONT STYLE="white-space:nowrap">non-GMO</FONT> verification from any product developed using biotechnology, whether it is transgenic or not. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If third-party verification organizations were to determine that any products containing
Cibus&#146; productivity traits, or gene-edited products generally, did not meet their <FONT STYLE="white-space:nowrap">non-GMO</FONT> verification standards, and certified <FONT STYLE="white-space:nowrap">non-GMO</FONT> seals or labels were not
available for such products, Cibus&#146; reputation could be harmed, these products may be unable to demand <FONT STYLE="white-space:nowrap">non-GMO</FONT> premiums, which could reduce the value of Cibus&#146; productivity traits to its licensee
customers, and Cibus&#146; operating results could be adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cibus&#146; insurance coverage may be inadequate to cover all the
liabilities Cibus may incur. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus faces the risk of exposure to liability claims if any product that uses Cibus&#146;
technologies or incorporates any of Cibus&#146; intellectual property causes injury. Although Cibus carries insurance at levels customary for companies in its industries, such coverage may become unavailable or be inadequate to cover all liabilities
Cibus may incur. There can be no assurance that Cibus will be able to continue to maintain such insurance, or obtain comparable insurance at a reasonable cost, if at all. If Cibus is unable to obtain sufficient insurance coverage at an acceptable
cost or otherwise, or if the amount of any claim against Cibus exceeds the coverage under its policies, Cibus may face significant expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>In the
past Cibus has identified material weaknesses in its internal control over financial reporting. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Cibus experiences material
weaknesses in the future or fails to remediate identified material weaknesses, it may not be able to accurately or timely report its financial condition or results of operations, which may adversely affect investor confidence in Cibus and, as a
result, the value of its securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Cibus&#146; Industries </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cibus&#146; success is partially dependent on its ability to make accurate predictions about customer demand in its industries. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to the lead time involved in developing a productivity trait or sustainable ingredient product candidate, Cibus and its licensee customers
must make a number of assumptions and estimates regarding the commercial feasibility of development, including assumptions and estimates regarding the demand for <FONT STYLE="white-space:nowrap">end-products</FONT> containing Cibus licensed
intellectual property, the existence or <FONT STYLE="white-space:nowrap">non-existence</FONT> of products being simultaneously developed by competitors, and potential market penetration and obsolescence, whether planned or unplanned. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, it is possible that Cibus and its licensee customers may involve substantial time and resources to develop intellectual property
for a contemplated end product that is quickly displaced or that addresses a market that no longer exists or is smaller than previously thought. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I><U>Agriculture</U> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cibus&#146; estimates and forecasts with respect to addressable acres, addressable trait acres, trait penetration rates and Cibus&#146; potential market
share may prove to be inaccurate, and Cibus&#146; business could fail to achieve the same growth rates as other companies operating in the seed and trait industries. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Estimates about current markets and market opportunity estimates, projections and forecasts are based on assumptions and estimates that may not
prove to be accurate and are therefore inherently uncertain. Cibus&#146; management makes estimates that it believes to be reasonable based on currently available information, but estimates, projections and forecasts relating to the size and
expected growth of Cibus&#146; industry, the biotech seeds market, the market for productivity traits and expected trait penetration, and estimates regarding Cibus&#146; ability to capture addressable acres may prove to be materially inaccurate. In
addition, management&#146;s estimates about the incremental value increase that a novel, newly developed productivity trait may produce, may prove to be materially inaccurate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In particular, management&#146;s estimates, projections and forecasts include an assumption that changes are likely to be made to the European
Union&#146;s regulatory landscape that would enable Cibus&#146; productivity traits to be licensed for use in seed distributed in EU member states. This assumption could prove to be incorrect and if the <B><I>RTDS </I></B>technologies by which
Cibus&#146; productivity traits are developed continues to be subject to GMO regulation in the EU, Cibus&#146; estimates, projections and forecasts would need to be materially revised. Assumptions regarding uncertain regulatory outcomes are subject
to numerous risk. See &#147;<I>&#151;Risks Related to Regulatory and Legal Matters</I>.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if Cibus&#146; general industry and market projections and forecasts are achieved,
Cibus&#146; business could fail to realize management&#146;s expectations with respect to Cibus&#146; ability to compete effectively, including by capturing addressable acres and realizing management&#146;s expectations regarding trait values. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The overall agricultural industry is susceptible to commodity and raw material price changes. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prices for agricultural commodities and their byproducts are often volatile and sensitive to local and international changes in supply and
demand caused by a variety of factors, including general economic conditions, farmer planting and selling decisions, government agriculture programs and policies, global and local inventory levels, demand for biofuels, weather and crop conditions,
food safety concerns, government regulations, and demand for and supply of, competing commodities and substitutes. As a result, Cibus may not be able to anticipate or react to changing costs by adjusting its practices, which could cause its
operating results to deteriorate. Cibus may engage in hedging or other financial transactions to mitigate these risks. If these efforts are not successful, it could materially affect Cibus&#146; business, operating results and prospects and cause
the value of its securities to decline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The successful licensing of Cibus&#146; productivity trait candidates, and the commercialization
by seed partners of seed products containing these traits, may also be adversely affected by fluctuations in the prices of agricultural commodities and agricultural inputs, such as fertilizer, energy, labor and water, in each case caused by market
factors beyond Cibus&#146; control. Changes in the prices of certain raw materials used by farmers in growing Cibus&#146; crops could result in higher overall costs along the agricultural supply chain. Depending on the nature of such price changes,
the cultivation of certain crops could be impacted to a greater extent than others. While increases in certain costs could make certain of Cibus&#146; productivity traits more valuable, increases in certain raw material costs could adversely affect
demand for Cibus&#146; productivity traits, including as a result of farmers being less willing to transition to new and unfamiliar seed products containing Cibus traits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Adverse weather and environmental conditions and natural disasters can cause significant costs and losses. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus&#146; revenues will depend, in part, on trait royalties paid to Cibus from seed sales by the companies that license Cibus&#146;
productivity traits for their commercial seed products. Calyxt&#146;s licensees&#146; seed crops are vulnerable to adverse weather conditions, including windstorms, floods, drought and temperature extremes, which are common but difficult to predict.
In addition, such seed crops are vulnerable to crop disease and to pests, which may vary in severity and effect, depending on the stage of production at the time of infection or infestation, the type of treatment applied and climatic conditions. The
weather also can affect the quality, volume and cost of seed produced for sale as well as demand and product mix. In addition, climate change may increase the frequency or intensity of extreme weather such as storms, floods, heat waves, droughts and
other events that could affect the quality, volume and cost of seed produced for sale as well as demand and product mix. Climate change may also affect the availability and suitability of arable land and contribute to unpredictable shifts in the
average growing season and types of crops produced. Unfavorable growing conditions can reduce both crop size and quality. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although Cibus
licenses its traits to seed companies that are responsible for the growing of their seed directly, these factors can still impact Cibus by potentially decreasing the quality and yields of seed containing Cibus&#146; productivity traits and reducing
Cibus&#146; licensees&#146; available inventory. These factors can adversely impact Cibus&#146; licensees sales, which would result in lower royalty payments to Cibus, which in turn may have a material adverse effect on Cibus&#146; business, results
of operations and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The agricultural industry is highly seasonal, which may cause Cibus&#146; sales and operating results to
fluctuate significantly. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The sale of plant and seed products is dependent upon growing and harvesting seasons, which vary from
year to year and across geographies as a result of weather-related shifts in planting schedules and purchase patterns of farmers. Seasonality in the seed industry is expected to result in both highly seasonal patterns and substantial fluctuations in
quarterly sales and profitability for Cibus&#146; business and may be further impacted by climate change. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Seasonality also relates to the limited windows of opportunity that farmers have to complete
required tasks at each stage of crop cultivation. Weather and environmental conditions and natural disasters, such as heavy rains, hurricanes, hail, floods, tornadoes, freezing conditions, excessively hot or cold weather, drought or fire, affect
decisions by farmers about the types and amounts of seeds to plant and the timing of harvesting and planting such seeds. Should adverse conditions occur during key growing and harvesting seasons, such conditions could substantially impact demand for
agricultural inputs. Any delayed or cancelled orders as a result of such conditions would negatively affect the quarter in which they occur and cause fluctuations in Cibus&#146; operating results. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I><U>Sustainable Ingredients</U> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The sustainable ingredients industry is still emerging. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The sustainable, <FONT STYLE="white-space:nowrap">low-carbon</FONT> ingredients industry is still emerging, driven by government policy and
regulations, <FONT STYLE="white-space:nowrap">low-carbon</FONT> technology advancement, and shifting sentiment and societal preferences, and as an emerging industry is characterized by rapid change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus&#146; future success will depend, in part, on its ability to adapt to address the evolving market environment and the changing needs of
its licensee customers on a timely and cost-effective basis. This will require Cibus to compete with an increasing number of new market entrants, including companies that are pursuing novel technologies and methods of production. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should Cibus be unable to effectively and efficiently address such market changes, this would have a material adverse effect on Cibus&#146;
business, results of operations and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Regulatory and Legal Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ethical, legal and social concerns about the use of gene-edited plants and microorganisms could limit licensing demand for Cibus&#146; intellectual
property. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The intellectual property that Cibus intends to license to third parties uses
<FONT STYLE="white-space:nowrap">non-transgenic</FONT> gene-editing of plants and microorganisms. Public perception about the safety of, and ethical, legal or social concerns over, gene-edited products, including plants and microorganisms, could
affect public acceptance of products incorporating Cibus&#146; licensed intellectual property. If potential licensees are concerned that downstream products incorporating such licensed intellectual property may not be accepted by their customers or <FONT
STYLE="white-space:nowrap">end-users,</FONT> this may adversely impact demand for the licensing arrangements that Cibus intends to pursue. If Cibus is not able to overcome any such concerns, this could have a material adverse effect on Cibus&#146;
business, results of operations and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Regulatory requirements for gene-edited products are uncertain and evolving. Adverse
changes in the current application of these laws would have a significant negative impact on Cibus&#146; ability to develop and commercialize its product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in regulatory requirements applicable to Cibus&#146; productivity trait or sustainable ingredient product candidates could result in a
substantial increase in the time and costs associated with their development and could negatively impact Cibus&#146; operating results. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, Cibus&#146; productivity trait products have been subject to the United States&#146; self-regulatory framework. Prior to August 2020,
Cibus used the USDA&#146;s AIR process for the assessment of its productivity traits. In 2004, APHIS informed Cibus in writing that products developed using its <B><I>RTDS</I></B> (specifically where Cibus used the GRON in an early version of its
technologies under the <B><I>RTDS</I></B> umbrella) are not subject to regulation under the PPA. In 2018, the USDA determined not to require an AIR assessment for products that used modern forms of mutagenesis if it was clear these outcomes could
occur in nature&#151;an opinion that applies to Cibus&#146; newer technologies under the <B><I>RTDS</I></B> umbrella. In August 2020, the AIR process was replaced by the USDA&#146;s SECURE rule, under which, certain categories of modified plants are
exempt from regulations because </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
they could have been developed through traditional breeding techniques and are unlikely to pose an increased plant pest risk. In addition, plants determined by APHIS to be <FONT
STYLE="white-space:nowrap">non-regulated</FONT> because they are unlikely to pose a plant pest risk, are exempt from the regulations, and a confirmation of this determination can be requested from APHIS. Cibus continues to work with the USDA, as
developing plants with new productivity traits for herbicide tolerance or plants with multiple gene-edited traits may need to be assessed through the SECURE rule&#146;s confirmation process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that any of Cibus&#146; productivity trait candidates are found to contain inserted genetic material or otherwise differ from the
descriptions Cibus has provided to the USDA, the USDA could determine that such products or productivity trait candidates are regulated articles, which would require Cibus to comply with the more onerous permit and notification requirements of the
PPA. Moreover, Cibus cannot assure you that the USDA will analyze any of Cibus&#146; future productivity trait candidates in a manner consistent with its analysis of Cibus&#146; products or productivity trait candidates to date. Complying with the
USDA&#146;s plant pest regulations, including permitting requirements, is a costly, time-consuming process and could substantially delay or prevent the commercialization of Cibus&#146; products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no guarantee that the governing regulations in the United States will not change. It is difficult for Cibus and its licensee
customers to predict whether U.S. regulators will alter the manner in which they interpret existing laws and regulations or institute new regulations, or otherwise modify regulations in a way that will subject products developed with Cibus&#146;
<B><I>RTDS</I></B> technologies to more burdensome standards, thereby substantially increasing the time and costs associated with required regulatory activities of Cibus and its customers. If the regulatory burden and expense required for the
utilization of Cibus&#146; products becomes too significant, its customers may seek alternatives that involve lesser regulatory costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some products containing Cibus&#146; productivity traits may be subject to FDA food product regulations or EPA environmental impact
regulations. Under the FDA, any substance that is reasonably expected to become a food or animal feed component or additive is subject to FDA premarket review and approval, unless generally recognized among qualified experts as having been
adequately shown to be GRAS or the use of the substance is otherwise excluded from the &#147;food additive&#148; definition. The FDA may classify some or all of Cibus&#146; productivity traits as containing a food additive that is not GRAS or
otherwise determine that further review is required. Such classification would cause these productivity traits to require premarket approval, which could delay a licensee customer&#146;s commercialization of products containing these productivity
traits. Such a classification could substantially increase the time and costs associated with required regulatory activities of Cibus and its customers. If the regulatory burden and expense required becomes too significant, Cibus&#146; customers may
seek alternatives that involve lesser regulatory costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA&#146;s thinking on the use of genome editing techniques to produce new
plant varieties that are used for human or animal food continues to evolve, and in January 2017, the FDA announced an RFC seeking public input to help inform its thinking about human and animal foods derived from new plant varieties produced using
genome editing techniques. If the FDA enacts new regulations or policies with respect to gene-edited plants, such policies could result in additional compliance costs and/or delay the commercialization of any products containing Cibus&#146;
productivity trait candidates, which could adversely affect Cibus&#146; profitability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the EU, GMOs and genetically modified food and
feed products can only be sold in the market once they have been properly authorized. With respect to GMOs and genetically modified food and feed products, an application for authorization must be submitted under Directive 2001/18/EC if a company
seeks to release GMOs for experimental purposes (e.g., field tests) and/or to sell GMOs, as such or in products, in the market (e.g., cultivation, importation or processing) and an application for authorization must be submitted under Regulation
(EC) 1829/2003 if a company seeks to sell GMOs in the market for food and feed use and/or food and feed products containing or produced from GMOs. At the national level, EU member states have the ability to restrict or prohibit GMO cultivation in
their territories by invoking various public policy grounds. In addition, EU directives establish specific labeling and traceability requirements for GMOs and products that contain or are produced from GMOs.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Finally, genetically modified plant varieties must be authorized in accordance with Directive 2001/18/EC and/or Regulation (EC) 1829/2003, as applicable, before they can be included in a
&#147;Common Catalogue of Varieties,&#148; which would permit the seeds of such genetically modified varieties to be marketed in the EU. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;25, 2018, the ECJ issued a final ruling that concluded that organisms obtained by modern mutagenesis plant breeding techniques,
including Cibus&#146; ODM technologies, are GMOs and are subject to Directive 2001/18/EC and its obligations, including stringent <FONT STYLE="white-space:nowrap">pre-market</FONT> authorization and associated environmental risk assessment
requirements. The ECJ found further that varieties obtained by modern forms of mutagenesis are genetically modified varieties required to be authorized in accordance with Directive 2001/18/EC and/or Regulation (EC) 1829/2003, as applicable, before
they can be included in a &#147;Common Catalogue of Varieties,&#148; which would permit the seeds of such genetically modified varieties to be marketed in the EU. As a result of the ECJ ruling, the authorities of EU member states are required to
treat organisms obtained by new techniques of directed mutagenesis, including those utilized in substantially all productivity traits in Cibus&#146; current pipeline, as GMOs. Such organisms therefore remain subject to the onerous <FONT
STYLE="white-space:nowrap">pre-market</FONT> assessments and authorization procedures derived from Directive 2001/18/EC or, if applicable, Regulation (EC) 1829/2003, as well as to the labeling and traceability requirements applicable to GMOs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Complying with such EU regulations is costly and time-consuming, and has no guarantee of success and could therefore substantially delay or
totally prevent the commercialization in the EU of products containing productivity traits developed by Cibus. Accordingly, the EU regulatory framework materially adversely affects demand among potential licensee customers for Cibus&#146;
gene-edited productivity traits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See &#147;<I>Cibus Business&#151;Government Regulations and Product Approval</I>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Potential changes in regulatory frameworks that would be beneficial to Cibus may not come to fruition. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Currently, authorities of EU member states are required under EU regulations to treat organisms obtained by new techniques of directed
mutagenesis, including those utilized in substantially all productivity traits in Cibus&#146; current pipeline, as GMOs. Such organisms therefore remain subject to onerous <FONT STYLE="white-space:nowrap">pre-market</FONT> assessments and
authorization procedures as well as labeling and traceability requirements applicable to GMOs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For so long as the UK was an EU member
state, the UK regulated GMOs in alignment with EU legislation. However, following the UK&#146;s departure from the EU, the UK has diverged from this historical alignment. In May 2022, a Bill was introduced in the UK aiming to remove plants and
animals produced using modern biotechnologies, and the food and feed derived from them, from Genetically Modified Organisms (GMO) regulation if those organisms could have occurred naturally or been produced by traditional methods. This Bill has
reached the penultimate stage of the legislative process and is due to have its final reading before being granted royal assent on February&nbsp;1, 2023. Although there can be no definitive certainty that the Bill will pass the final stage, given
the lack of opposition to date, it appears most likely that the Bill will become law in 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus believes that the EU is also
positioned for important regulatory changes that, if adopted, promise to enable more open and fair trade in agriculture for these new technologies. In connection with a <FONT STYLE="white-space:nowrap">follow-up</FONT> case to the ECJ&#146;s 2018
decision, the appointed Advocate General delivered an opinion suggesting to the ECJ that it declare certain GMOs&#151;namely, those resulting from random mutagenesis applied <I>in vitro</I>&#151;to be exempted from the EU&#146;s GMO Directive. At
the same time, the European Commission has announced that it is considering policy options aimed at facilitating the development and uptake of certain some new genomic techniques (NGTs) and their products, taking into account in particular the lower
risk profiles of certain plants produced by certain techniques&#151;namely, targeted mutagenesis and cisgenesis&#151;compared to plants obtained with traditional transgenic genetic modification techniques. A proposal for a new EU Regulation in this
field has been announced for the second half of 2023 which could potentially relax the rules applicable to the mentioned techniques and products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus&#146; management believes that there is strong momentum in the EU in support of changes to EU regulation of <FONT
STYLE="white-space:nowrap">non-transgenic</FONT> gene-editing, such as ODM techniques. Accordingly, although there cannot be any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
guarantee that any regulatory changes will be adopted in the EU, Cibus anticipates such changes occurring as early as 2023. Cibus management has reflected this expectation in its business plan,
including its forecasts and projections regarding Cibus&#146; market opportunities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whether the regulatory changes in the UK will
facilitate the sale of Cibus products in the UK and whether the regulatory changes in the EU will materialize and thereafter facilitate the sale of Cibus products in the EU remains speculative. If the EU regulatory changes do not come to fruition,
products containing Cibus&#146; productivity traits would remain subject to the stringent EU regulations applicable to GMOs, which would require material adjustments to a key assumption underlying Cibus&#146; business plan. Further, even if the
legal and regulatory regime in the UK and EU is relaxed as proposed, there can be no assurance that products including Cibus&#146; licensed productivity traits will be accepted by consumers and other market participants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Finally, if and to the extent that the EU regulatory proposal is ultimately published, it will likely have to follow the ordinary legislative
procedure, which means that approval by the European Council and the European Parliament will be necessary in order for European OGM law to be amended (and potentially relaxed) as regards the targeted NGTs, which process may take several years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The regulatory environment varies greatly from region to region and in many countries is less developed than in the United States and the EU.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Outside of the United States and the EU, the regulatory environment around gene editing in plants and microorganisms is uncertain
and varies greatly from jurisdiction to jurisdiction. Each jurisdiction may have its own regulatory framework regarding genetically modified organisms, which may include restrictions and regulations on planting and growing genetically modified
plants and in the consumption and labeling of genetically modified foods, which may encapsulate products containing Cibus licensed intellectual property. The two leading jurisdictions, the United States and the EU, have distinctly different
regulatory regimes. Cibus cannot predict how the global regulatory landscape regarding gene editing in plants and microorganisms will evolve, and Cibus may incur increased regulatory costs as regulations change in the jurisdictions in which it
operates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus cannot predict whether or when any jurisdiction will change its regulations with respect to products incorporating Cibus
licensed intellectual property. Advocacy groups have engaged in publicity campaigns and filed lawsuits in various countries against companies and regulatory authorities, seeking to halt regulatory approval activities or influence public opinion
against genetically engineered products. In addition, governmental reaction to negative publicity could result in greater regulation of genetic research and derivative products or regulatory costs that render Cibus&#146; product development and the
commercialization of products containing Cibus licensed intellectual property cost prohibitive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The scale of the commodity food industry
may make it difficult to monitor and control the distribution of products containing gene-edited Cibus traits. As a result, such products may be sold inadvertently within jurisdictions where they are not approved for distribution. Such sales may
lead to regulatory challenges or lawsuits against its licensees, which could seek to name Cibus as a party and which could result in significant expenses and management attention. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Government policies and regulations, particularly those affecting the agricultural sector and related industries, could adversely affect Cibus&#146;
operations and profitability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Agricultural production and trade flows are subject to government policies and regulations.
Governmental policies and approvals of technologies affecting the agricultural industry, such as taxes, tariffs, duties, subsidies, incentives and import and export restrictions on agricultural commodities and commodity products can influence the
planting of certain crops, the location and size of crop production, and the volume and types of imports and exports. Future government policies in the United States, Canada, the EU or in other countries could discourage farmers from using products
containing Cibus productivity traits or food processors from purchasing harvested </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
crops containing Cibus&#146; traits or could encourage the use of its competitors&#146; products, which would put Cibus at a commercial disadvantage and could negatively impact its future
revenues and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cibus uses hazardous chemicals and biological materials in its business. Compliance with environmental, health
and safety laws and regulations and any claims relating to improper handling, storage or disposal of these materials could be time consuming and costly. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus is subject to federal, state, local and foreign environmental, health and safety laws and regulations, including those governing
laboratory procedures, the handling, use, storage, treatment, manufacture and disposal of hazardous materials and wastes, discharge of pollutants into the environment and human health and safety matters. Cibus&#146; research and development
processes may involve the controlled use of hazardous materials, including chemicals and biological materials. Cibus cannot eliminate the risk of contamination or discharge and any resultant injury from these materials. Cibus may be sued for any
injury or contamination that results from its use or the use by third parties of these materials, or may otherwise be required to remediate such contamination, and Cibus&#146; liability with respect to such claims may exceed any insurance coverage
that it maintains or the value of its total assets. Compliance with environmental, health and safety laws and regulations is time consuming and expensive. If Cibus fails to comply with these requirements, it could incur substantial costs and
liabilities, including civil or criminal fines and penalties, <FONT STYLE="white-space:nowrap">clean-up</FONT> costs or capital expenditures for control equipment or operational changes necessary to achieve and maintain compliance. In addition,
Cibus cannot predict the impact on its business of new or amended environmental, health and safety laws or regulations or any changes in the way existing and future laws and regulations are interpreted and enforced. These current or future laws and
regulations may impair Cibus&#146; research, development or production efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Adverse outcomes in future legal proceedings could subject Cibus to
substantial damages, adversely affect its results of operations, harm its reputation and result in governmental actions. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus may
become party to legal proceedings, including matters involving personnel and employment issues, personal injury, product liability, environmental matters, intellectual property disputes and other proceedings. Cibus may be held liable if its traits
do not perform as anticipated by its customers, or if any product that uses its technologies or incorporates any of its traits causes injury or is found otherwise unsuitable during marketing, sale or consumption. Courts could levy substantial
damages against Cibus in connection with claims for injuries allegedly caused by use of such products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The detection of unintended traits
in Cibus&#146; products could result in governmental actions such as mandated crop destruction, product recalls or environmental cleanup or monitoring. Concerns about seed quality could also lead to additional regulations being imposed on
Cibus&#146; business, such as regulations related to testing procedures, mandatory governmental reviews of biotechnology advances, or the integrity of the food supply chain from the farm to the finished product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending on their nature, certain future legal proceedings could result in substantial damages or payment awards that exceed Cibus&#146;
insurance coverage. Cibus will estimate its exposure to any future legal proceedings and establish provisions for the estimated liabilities where it is reasonably possible to estimate and where an adverse outcome is probable. Assessing and
predicting the outcome of these matters will involve substantial uncertainties. Furthermore, even if the outcome is ultimately in Cibus&#146; favor, its costs associated with such litigation may be material. Adverse outcomes in future legal
proceedings or the costs and expenses associated therewith could damage Cibus&#146; market reputation and have an adverse effect on its results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I></I></B><B></B><B><I>Cibus is subject to governmental export and import controls that could impair its ability to compete in international markets due
to licensing requirements and subject Cibus to liability if it is not in compliance with applicable laws. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus&#146; productivity
trait and sustainable ingredient candidates are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, and various economic and trade sanction regulations
administered by the U.S. Treasury Department&#146;s Office of Foreign </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Assets Controls. Exports of Cibus&#146; technologies must be made in compliance with these laws and regulations. If Cibus fails to comply with these laws and regulations, Cibus and certain of its
employees could be subject to substantial civil or criminal penalties, including the possible loss of export or import privileges; fines, which may be imposed on Cibus and the responsible employees or managers; and, in extreme cases, the
incarceration of the responsible employees or managers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, changes in Cibus&#146; technologies or changes in applicable export
or import laws and regulations may create delays in the introduction and sale of products containing Cibus&#146; technologies in international markets, prevent Cibus&#146; customers from deploying their products or, in some cases, prevent the export
or import of Cibus&#146; technologies to certain countries, governments or persons altogether. Any change in export or import laws and regulations, shift in the enforcement or scope of existing laws and regulations, or change in the countries,
governments, persons or technologies targeted by such laws and regulations, could also result in decreased use of Cibus&#146; technologies, or in its decreased ability to export or sell its products to existing or potential customers. Any decreased
use of Cibus&#146; technologies or limitation on Cibus&#146; ability to export or sell such technologies would likely adversely affect its business, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cibus is subject to anti-corruption and anti-money laundering laws with respect to both its domestic and international operations, and <FONT
STYLE="white-space:nowrap">non-compliance</FONT> with such laws can subject Cibus to criminal and civil liability and harm its business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus is subject to the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &#167;
201, the U.S. Travel Act, the USA PATRIOT Act, and possibly other anti-bribery and anti-money laundering laws in countries in which it conducts activities. Anti-corruption laws are interpreted broadly and prohibit Cibus from authorizing, offering,
or directly or indirectly providing improper payments or benefits to recipients in the public or private sector. Cibus may have direct and indirect interactions with government agencies and state affiliated entities and universities in the course of
its business. Cibus may also have certain matters come before public international organizations such as the United Nations. Cibus uses third-party contractors, strategic commercial partners, law firms, and other representatives for certain aspects
of regulatory compliance, patent registration, lobbying, deregulation advocacy, field testing, and other purposes in a variety of countries. Cibus can be held liable for the corrupt or other illegal activities of these third-parties, Cibus&#146;
employees, representatives, contractors and agents, even if Cibus does not explicitly authorize such activities. In addition, although Cibus has implemented policies and procedures to ensure compliance with anti-corruption and related laws, there
can be no assurance that all of its employees, representatives, contractors, partners, or agents will comply with these laws at all times. Noncompliance with these laws could subject Cibus to whistleblower complaints, investigations, sanctions,
settlements, prosecution, other enforcement actions, disgorgement of profits, significant fines, damages, other civil and criminal penalties or injunctions, suspension and debarment from contracting with certain governments or other persons, the
loss of export privileges, reputational harm, adverse media coverage, and other collateral consequences. If any subpoenas or investigations are launched, or governmental or other sanctions are imposed, or if Cibus does not prevail in any possible
civil or criminal litigation, its business, results of operations and financial condition could be materially harmed. In addition, responding to any action will likely result in a materially significant diversion of management&#146;s attention and
resources and significant defense costs and other professional fees. Enforcement actions and sanctions could further harm Cibus&#146; business, results of operations and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Intellectual Property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cibus&#146;
ability to compete may decline if it does not adequately protect its intellectual property proprietary rights. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus&#146;
commercial success depends, in part, on obtaining and maintaining proprietary rights to its and its licensors&#146; intellectual property as well as successfully defending these rights against third party challenges. Cibus will only be able to
protect its products, productivity trait or sustainable ingredient candidates, processes and technologies from unauthorized use by third parties to the extent that valid and enforceable patents, or effectively
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
protected trade secrets, cover them. Cibus&#146; ability to obtain patent protection for its products, productivity trait or sustainable ingredient candidates, processes and technologies is
uncertain due to a number of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cibus or its licensors may not have been the first to invent the technology covered by Cibus&#146; or their
pending patent applications or issued patents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cibus cannot be certain that it or its licensors were the first to file patent applications covering Cibus&#146;
products, productivity trait or sustainable ingredient candidates, processes or technologies, as patent applications in the United States and most other countries are confidential for a period of time after filing; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may independently develop identical, similar or alternative products, productivity trait or sustainable
ingredient candidates, processes and technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the disclosures in Cibus&#146; or its licensors&#146; patent applications may not be sufficient to meet the
statutory requirements for patentability; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any or all of Cibus&#146; or its licensors&#146; pending patent applications may not result in issued patents;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cibus or its licensors may not seek or obtain patent protection in countries or jurisdictions that may eventually
provide Cibus a significant business opportunity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any patents issued to Cibus or its licensors may not provide a basis for commercially viable products, may not
provide any competitive advantages, or may be successfully challenged by third parties, which may result in Cibus&#146; or its licensors&#146; patent claims being narrowed, invalidated or held unenforceable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cibus&#146; products, productivity trait or sustainable ingredient candidates, processes and technologies may not
be patentable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may design around Cibus&#146; or its licensors&#146; patent claims to produce competitive products,
productivity trait or sustainable ingredient candidates, processes and technologies that fall outside of the scope of Cibus&#146; or its licensors&#146; patents; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may identify prior art or other bases upon which to challenge and ultimately invalidate Cibus&#146; or its
licensors&#146; patents or otherwise render them unenforceable. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if Cibus owns, obtains or <FONT
STYLE="white-space:nowrap">in-licenses</FONT> patents covering its products, productivity trait or sustainable ingredient candidates, processes and technologies, Cibus may still be barred from making, using and selling its products, productivity
trait or sustainable ingredient candidates, processes and technologies because of the patent rights or intellectual property rights of others. Others may have filed, and in the future may file, patent applications covering products, productivity
trait or sustainable ingredient candidates, processes or technologies that are similar or identical to Cibus&#146;, which could materially affect Cibus&#146; ability to successfully develop and commercialize its products and productivity trait or
sustainable ingredient candidates. In addition, because patent applications can take many years to issue, there may be currently pending applications unknown to Cibus that may later result in issued patents that Cibus&#146; products, productivity
trait or sustainable ingredient candidates, processes or technologies may infringe. These patent applications may have priority over patent applications filed by Cibus or its licensors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Obtaining and maintaining a patent portfolio entails significant expense of resources. Part of such expense includes periodic maintenance
fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications due over the course of several stages of prosecuting patent applications, and over the lifetime of maintaining and enforcing issued patents. Cibus or
its licensors may or may not choose to pursue or maintain protection for particular intellectual property in Cibus&#146; or its licensors&#146; portfolio. If Cibus or its licensors choose to forgo patent protection or to allow a patent application
or patent to lapse purposefully or inadvertently, Cibus&#146; competitive position could suffer. Furthermore, Cibus and its licensors employ reputable law firms and other professionals to help comply with the various procedural, documentary, fee
payment and other similar provisions Cibus and they are subject to and, in many cases, an inadvertent lapse can be cured by payment of a late fee or by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other means in accordance with the applicable rules. There are situations, however, in which failure to make certain payments or noncompliance with certain requirements in the patent prosecution
and maintenance process can result in abandonment or lapse of a patent or patent application, resulting in a partial or complete loss of patent rights in the relevant jurisdiction. In such an event, Cibus&#146; competitors might be able to enter the
market, which would have a material adverse effect on Cibus&#146; business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Legal action that may be required to enforce Cibus&#146;
patent rights can be expensive and may involve the diversion of significant management time. In addition, these legal actions could be unsuccessful and could also result in the invalidation of Cibus&#146; or its licensors&#146; patents or a finding
that they are unenforceable. Cibus or its licensors may or may not choose to pursue litigation or other actions against those that have infringed on Cibus&#146; or their patents, or have used them without authorization, due to the associated expense
and time commitment of monitoring these activities. In some cases, the enforcement and defense of patents Cibus <FONT STYLE="white-space:nowrap">in-licenses</FONT> is controlled by the applicable licensor. If such licensor fails to actively enforce
and defend such patents, any competitive advantage afforded by such patents could be materially impaired. In addition, some of Cibus&#146; competitors may be able to sustain the costs of such litigation or proceedings more effectively than Cibus or
its licensors can because of their greater financial resources and more mature and developed intellectual property portfolios. Accordingly, despite Cibus&#146; efforts, Cibus may not be able to prevent third parties from infringing upon or
misappropriating or from successfully challenging Cibus&#146; intellectual property rights. If Cibus fails to protect or to enforce its intellectual property rights successfully, its competitive position could suffer, which could harm its results of
operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to patent protection, because Cibus operates in the highly technical field of biotechnology, Cibus relies in part
on trade secret protection in order to protect its proprietary technology and processes. However, trade secrets are difficult to protect. Monitoring unauthorized uses and disclosures is difficult, and Cibus does not know whether the steps it has
taken to protect its proprietary technologies will be effective. Cibus cannot guarantee that its trade secrets and other proprietary and confidential information will not be disclosed or that competitors will not otherwise gain access to Cibus&#146;
trade secrets. Despite these efforts, any of these parties may breach the agreements and disclose Cibus&#146; proprietary information, including its trade secrets, and Cibus may not be able to obtain adequate remedies for such breaches. Cibus enters
into confidentiality and intellectual property assignment agreements with its employees, consultants, outside scientific collaborators, sponsored researchers and other advisors. These agreements generally require that the other party keep
confidential and not disclose to third parties all confidential information developed by the party or made known to the party by Cibus during the course of the party&#146;s relationship with Cibus. These agreements also generally provide that
inventions conceived by the party in the course of rendering services to Cibus will be Cibus&#146; exclusive property. However, these agreements may be breached or held unenforceable and may not effectively assign intellectual property rights to
Cibus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to contractual measures, Cibus tries to protect the confidential nature of its proprietary information using physical
and technological security measures. Such measures may not provide adequate protection for Cibus&#146; proprietary information. For example, Cibus&#146; security measures may not prevent an employee or consultant with authorized access from
misappropriating Cibus&#146; trade secrets and providing them to a competitor, and the recourse Cibus has available against such misconduct may not provide an adequate remedy to protect its interests fully. Enforcing a claim that a party illegally
disclosed or misappropriated a trade secret can be difficult, expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the United States may be less willing to protect trade secrets. Furthermore, Cibus&#146;
proprietary information may be independently developed by others in a manner that could prevent legal recourse by Cibus. If any of Cibus&#146; confidential or proprietary information, including its trade secrets, were to be disclosed or
misappropriated, or if any such information was independently developed by a competitor, Cibus&#146; competitive position could be harmed and its business could be materially and adversely affected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patents and patent applications involve highly complex legal and factual questions, which, if
determined adversely to Cibus, could negatively impact its competitive position. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent positions of biotechnology companies
and other actors in Cibus&#146; fields of business can be highly uncertain and typically involve complex scientific, legal and factual analyses. In particular, the interpretation and breadth of claims allowed in some patents covering biological
compositions may be uncertain and difficult to determine, and are often affected materially by the facts and circumstances that pertain to the patented compositions and the related patent claims. The standards of the United States Patent and
Trademark Office (the &#147;USPTO&#148;) and foreign patent offices are sometimes uncertain and could change in the future. Consequently, the issuance and scope of patents cannot be predicted with certainty. Patents, if issued, may be challenged,
invalidated, narrowed or circumvented. U.S. patents and patent applications may also be subject to interference proceedings, and U.S. patents may be subject to reexamination proceedings, post-grant review, inter partes review, or other
administrative proceedings in the USPTO. Foreign patents as well may be subject to opposition or comparable proceedings in corresponding foreign patent offices. Challenges to Cibus&#146; or its licensors&#146; patents and patent applications, if
successful, may result in the denial of Cibus&#146; or its licensors&#146; patent applications or the loss or reduction in their scope. In addition, such interference, reexamination, post-grant review, inter partes review, opposition proceedings and
other administrative proceedings may be costly and involve the diversion of significant management time. Accordingly, rights under any of Cibus&#146; or its licensors&#146; patents may not provide Cibus with sufficient protection against competitive
products or processes and any loss, denial or reduction in scope of any of such patents and patent applications may have a material adverse effect on Cibus&#146; business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, even if not challenged, Cibus&#146; or its licensors&#146; patents and patent applications may not adequately protect its
products, productivity trait or sustainable ingredient candidates, processes or technologies or prevent others from designing their products or technology to avoid being covered by Cibus&#146; or its licensors&#146; patent claims. If the breadth or
strength of protection provided by the patents Cibus owns or licenses with respect to its products, productivity trait or sustainable ingredient candidates, processes or technologies is threatened, it could dissuade companies from partnering with
Cibus to develop, and could threaten its ability to successfully commercialize, its products and productivity trait or sustainable ingredient candidates. Furthermore, for U.S. patent applications in which claims are entitled to a priority date
before March&nbsp;16, 2013, an interference proceeding can be provoked by a third party or instituted by the USPTO in order to determine who was the first to invent any of the subject matter covered by such patent claims. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, changes in, or different interpretations of, patent laws in the United States and other countries may permit others to use
Cibus&#146; discoveries or to develop and commercialize Cibus&#146; technologies and products without providing any notice or compensation to Cibus, or may limit the scope of patent protection that Cibus or its licensors are able to obtain. The laws
of some countries do not protect intellectual property rights to the same extent as U.S. laws and those countries may lack adequate rules and procedures for defending Cibus&#146; intellectual property rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Cibus or its licensors fail to obtain and maintain patent protection and trade secret protection of Cibus&#146; products, productivity
trait or sustainable ingredient candidates, processes and technologies, Cibus could lose its competitive advantage and competition it faces would increase, potentially reducing revenues and having a material adverse effect on its business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The lives of Cibus&#146; patents may not be sufficient to effectively protect its products and business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patents have a limited lifespan. Individual patent terms extend for varying periods of time, depending upon the date of filing of the patent
application, the date of patent issuance, and the legal term of patents in the countries in which they are obtained. In the United States, the natural expiration of a patent is generally 20 years after its first effective filing date. Although
various extensions may be available, the life of a patent, and the protection it affords, is limited. In addition, although a U.S. patent&#146;s life can be increased based on certain delays caused by the USPTO, this increase can be reduced or
eliminated based on certain delays caused by the patent applicant during patent prosecution. However, the actual protection afforded by a patent varies on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> basis, from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-to-country,</FONT></FONT> and depends upon many factors,
including the type of patent, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the scope of its coverage, the availability of legal remedies in a particular country, and the validity and enforceability of the patent. If Cibus or its licensors do not have sufficient patent
life to protect its products, productivity trait or sustainable ingredient candidates, processes and technologies, its business and results of operations will be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cibus will not seek to protect its intellectual property rights in all jurisdictions throughout the world and Cibus may not be able to adequately
enforce its intellectual property rights even in the jurisdictions where Cibus seeks protection. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Filing, prosecuting and defending
patents on Cibus&#146; products, productivity trait or sustainable ingredient candidates, processes and technologies in all countries and jurisdictions throughout the world would be prohibitively expensive, and Cibus&#146; intellectual property
rights in some countries outside the United States could be less extensive than those in the United States, assuming that rights are obtained in the United States. In addition, the laws of some foreign countries do not protect intellectual property
rights to the same extent as federal and state laws in the United States. Consequently, Cibus may not be able to prevent third parties from practicing Cibus&#146; inventions in all countries outside the United States, or from selling or importing
products made using Cibus&#146; inventions in and into the United States or other jurisdictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competitors may use Cibus&#146;
technologies in jurisdictions where Cibus or its licensors do not pursue and obtain patent protection to develop their own products and further, may export otherwise infringing products to territories where Cibus or its licensors have patent
protection, but where the ability to enforce Cibus&#146; or its licensors&#146; patent rights is not as strong as in the United States. These products may compete with Cibus&#146; products and its intellectual property rights and such rights may not
be effective or sufficient to prevent such competition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The laws of some foreign countries do not protect intellectual property rights to
the same extent as the laws of the United States. Patent protection must be sought on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, which is an expensive and time-consuming process with
uncertain outcomes. Accordingly, Cibus and its licensors may choose not to seek patent protection in certain countries, and Cibus will not have the benefit of patent protection in such countries. In addition, the legal systems of some countries,
particularly developing countries, do not favor the enforcement of patents and other intellectual property protection, especially those relating to biotechnologies, and the requirements for patentability differ, in varying degrees, from country to
country, and the laws of some foreign countries do not protect intellectual property rights, including trade secrets, to the same extent as federal and state laws of the United States. As a result, many companies have encountered significant
problems in protecting and defending intellectual property rights in certain foreign jurisdictions. Such issues may make it difficult for Cibus to stop the infringement, misappropriation or other violation of its intellectual property rights. For
example, many foreign countries, including the EU countries, have compulsory licensing laws under which a patent owner must grant licenses to third parties. In addition, many countries limit the enforceability of patents against third parties,
including government agencies or government contractors. In these countries, patents may provide limited or no benefit. In those countries, Cibus and its licensors may have limited remedies if patents are infringed or if Cibus or its licensors are
compelled to grant a license to a third party, which could materially diminish the value of those patents. This could limit Cibus&#146; potential revenue opportunities. Accordingly, Cibus&#146; and its licensors&#146; efforts to enforce intellectual
property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that Cibus owns or licenses. Similarly, if Cibus&#146; trade secrets are disclosed in a foreign jurisdiction, competitors
worldwide could have access to Cibus&#146; proprietary information and Cibus may be without satisfactory recourse. Such disclosure could have a material adverse effect on Cibus&#146; business. Moreover, Cibus&#146; ability to protect and enforce its
intellectual property rights may be adversely affected by unforeseen changes in foreign intellectual property laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore,
proceedings to enforce Cibus&#146; licensors&#146; and Cibus&#146; own patent rights and other intellectual property rights in foreign jurisdictions could result in substantial costs and divert Cibus&#146; efforts and attention from other aspects of
its business, could put Cibus&#146; or its licensors&#146; patents at risk of being invalidated or interpreted narrowly, could put Cibus&#146; or its licensors&#146; patent applications at risk of not issuing and could
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
provoke third parties to assert claims against Cibus or its licensors. Cibus may not prevail in any lawsuits that it initiates and the damages or other remedies awarded to Cibus, if any, may not
be commercially meaningful, while the damages and other remedies Cibus may be ordered to pay such third parties may be significant. Accordingly, Cibus&#146; licensors&#146; and Cibus&#146; own efforts to enforce its intellectual property rights
around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that Cibus develops or licenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Third parties may assert rights to inventions Cibus develops or otherwise regards as its own. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third parties may in the future make claims challenging the inventorship or ownership of Cibus&#146; or its licensors&#146; intellectual
property. Cibus has written agreements with research and development partners that provide for the ownership of intellectual property arising from its strategic alliances. These agreements provide that Cibus must negotiate certain commercial rights
with such partners with respect to joint inventions or inventions made by Cibus&#146; partners that arise from the results of the strategic alliance. In some instances, there may not be adequate written provisions to address clearly the allocation
of intellectual property rights that may arise from the respective alliance. If Cibus cannot successfully negotiate sufficient ownership and commercial rights to the inventions that result from Cibus&#146; use of a third-party partner&#146;s
materials when required, or if disputes otherwise arise with respect to the intellectual property developed through the use of a partner&#146;s samples, Cibus may be limited in its ability to capitalize on the full market potential of these
inventions. In addition, Cibus may face claims by third parties that its agreements with employees, contractors or consultants obligating them to assign intellectual property to Cibus are ineffective, or are in conflict with prior or competing
contractual obligations of assignment, which could result in ownership disputes regarding intellectual property Cibus has developed or will develop and could interfere with Cibus&#146; ability to capture the full commercial value of such inventions.
Litigation may be necessary to resolve an ownership dispute, and if Cibus is not successful, Cibus may be precluded from using certain intellectual property and associated products, processes and technologies, or may lose its rights in that
intellectual property. Either outcome could have a material adverse effect on Cibus&#146; business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cibus may not identify relevant third party
patents or may incorrectly interpret the relevance, scope or expiration of a third party patent which might adversely affect Cibus&#146; ability to develop and market its products or productivity trait or sustainable ingredient candidates.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus cannot guarantee that any of its patent searches or analyses, including but not limited to the identification of relevant
patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can Cibus be certain that it has identified each and every third party patent and pending application in the United States and abroad that is
relevant to or necessary for the commercialization of Cibus&#146; products or productivity trait or sustainable ingredient candidates in any jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#146;s
prosecution history. Cibus&#146; interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact Cibus&#146; ability to market its products. Cibus may incorrectly determine that its
products are not covered by a third party patent or may incorrectly predict whether a third party&#146;s pending application will issue with claims of relevant scope. Cibus&#146; determination of the expiration date of any patent in the United
States or abroad that Cibus considers relevant may be incorrect, which may negatively impact Cibus&#146; ability to develop and market its products or productivity trait or sustainable ingredient candidates. Cibus&#146; failure to identify and
correctly interpret relevant patents may negatively impact its ability to develop and market its products or productivity trait or sustainable ingredient candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Third parties may assert that Cibus&#146; employees or consultants have wrongfully used or disclosed confidential information or misappropriated trade
secrets. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus currently employs, and in the future may employ, individuals who were previously employed at universities or other
biotechnology companies, including Cibus&#146; competitors or potential competitors. Although Cibus tries to ensure that its employees and consultants do not use the proprietary information or <FONT STYLE="white-space:nowrap">know-how</FONT> of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
others in their work for Cibus, Cibus may be subject to claims that it or its employees, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual
property, including trade secrets or other proprietary information, of a former employer or other third parties. Litigation may be necessary to defend against these claims. If Cibus fails in defending any such claims, in addition to paying monetary
damages, Cibus may lose valuable intellectual property rights or personnel or damage its reputation. Even if Cibus is successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and
other employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Any infringement, misappropriation or other violation by Cibus of intellectual property rights of others may prevent or delay
Cibus&#146; product development efforts and may prevent or increase the costs of Cibus successfully commercializing its products or productivity trait or sustainable ingredient candidates, if approved. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The biotechnology industry is characterized by extensive litigation regarding patents and other intellectual property rights. Cibus&#146;
success will depend in part on its ability to operate without infringing, misappropriating or otherwise violating the intellectual property and proprietary rights of third parties. Cibus cannot assure you that its business operations, products,
productivity trait or sustainable ingredient candidates and methods and the business operations, products, productivity trait or sustainable ingredient candidates and methods of its partners do not or will not infringe, misappropriate or otherwise
violate the patents or other intellectual property rights of third parties. Cibus may, from time to time, utilize techniques or compounds for which Cibus has determined a license is not required. For example, in some cases, Cibus uses <FONT
STYLE="white-space:nowrap">DNA-breaking</FONT> reagents, such as CRISPR-Cas9, to make site-specific cuts in the DNA of a plant cell. In cases where Cibus has determined a license is not required, other parties may allege that the use of such
techniques or compounds infringes, misappropriates or otherwise violates patent claims or other intellectual property rights held by them or that Cibus is employing their proprietary technology without authorization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other parties may allege that Cibus&#146; products, productivity trait or sustainable ingredient candidates, processes or technologies
infringe, misappropriate or otherwise violate patent claims or other intellectual property rights held by them or that Cibus is employing their proprietary technology without authorization. Patent and other types of intellectual property litigation
can involve complex factual and legal questions, and their outcome is uncertain. Any claim relating to intellectual property infringement that is successfully asserted against Cibus may require Cibus to pay substantial damages, including treble
damages and attorneys&#146; fees if Cibus or its partners are found to be willfully infringing another party&#146;s patents, for past use of the asserted intellectual property and royalties and other consideration going forward if Cibus is forced to
take a license. Such a license may not be available on commercially reasonable terms, or at all. Even if Cibus was able to obtain a license, it could be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving Cibus&#146; competitors
access to the same intellectual property rights or technologies licensed to Cibus. In addition, if any such claim were successfully asserted against Cibus and Cibus could not obtain a license, Cibus or its partners may be forced to stop or delay
developing, manufacturing, selling or otherwise commercializing its products, productivity trait or sustainable ingredient candidates or other infringing technology, or those Cibus develops with its research and development partners. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if Cibus is successful in these proceedings, Cibus may incur substantial costs and divert management time and attention pursuing these
proceedings, which could have a material adverse effect on Cibus. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of Cibus&#146; confidential
information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if investors perceive these results
to be negative, it could have a substantial adverse effect on the value of Cibus&#146; securities. Such litigation or proceedings could substantially increase Cibus&#146; operating losses and reduce the resources available for development activities
or any future sales, marketing or distribution activities. If Cibus is unable to avoid infringing the patent rights of others, Cibus may be required to seek a license, defend an infringement action or challenge the validity of the patents in court,
or redesign its products. Patent litigation is costly and time consuming. Cibus may not have sufficient resources to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
bring these actions to a successful conclusion. In addition, intellectual property litigation or claims could force Cibus to do one or more of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cease developing, selling or otherwise commercializing its products or productivity trait or sustainable
ingredient candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pay substantial damages for past use of the asserted intellectual property; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain a license from the holder of the asserted intellectual property, which license may not be available on
reasonable terms, if at all; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of trademark claims, redesign, or rename trademarks Cibus may own, to avoid infringing the
intellectual property rights of third parties, which may not be possible and, even if possible, could be costly and time-consuming. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these risks coming to fruition could have a material adverse effect on Cibus&#146; business, results of operations, financial condition
and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cibus may be unsuccessful in licensing or acquiring intellectual property from third parties that may be required to develop and
commercialize Cibus&#146; products or productivity trait or sustainable ingredient candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because Cibus&#146; programs may
involve the use of intellectual property or proprietary rights held by third parties, the growth of Cibus&#146; business will likely depend in part on its ability to acquire, <FONT STYLE="white-space:nowrap">in-license</FONT> or use these
intellectual property and proprietary rights. For example, if Cibus determined to use a technology to perform its gene editing, Cibus may need one or more licenses to use that technology. However, Cibus may be unable to acquire or <FONT
STYLE="white-space:nowrap">in-license</FONT> any third-party intellectual property or proprietary rights. Even if Cibus is able to acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> such rights, Cibus may be unable to do so on
commercially reasonable terms. The licensing and acquisition of third party intellectual property and proprietary rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third party
intellectual property and proprietary rights that Cibus may consider attractive or necessary. These established companies may have a competitive advantage over Cibus due to their size, capital resources and agricultural development and
commercialization capabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus sometimes partners with academic institutions to accelerate its research and development under
written agreements with these institutions. Typically, these institutions provide Cibus with an option to negotiate a license to any of the institution&#146;s rights in technology resulting from the strategic alliance. Regardless of such option,
Cibus may be unable to negotiate a license within the specified time frame or under terms that are acceptable to Cibus, and the institution may license such intellectual property rights to third parties, potentially blocking Cibus&#146; ability to
pursue its development and commercialization plans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, companies that perceive Cibus to be a competitor may be unwilling to
assign or license intellectual property and proprietary rights to Cibus. Cibus also may be unable to license or acquire third party intellectual property and proprietary rights on terms that would allow it to make an appropriate return on its
investment or at all. If Cibus is unable to successfully acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> rights to required third party intellectual property and proprietary rights or maintain the existing intellectual property and
proprietary rights Cibus has, Cibus may have to cease development of the relevant program, product or productivity trait or sustainable ingredient candidate, which could have a material adverse effect on its business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If Cibus fails to comply with its obligations in the agreements under which Cibus licenses intellectual property rights from third parties or otherwise
experience disruptions to its business relationships with its licensors, Cibus could lose license rights that are important to its business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus is a party to a number of intellectual property license agreements that are important to its business and expects to enter into
additional license agreements in the future. Cibus&#146; existing license agreements impose, and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Cibus expects that future license agreements will impose, various diligence, royalty and other obligations on Cibus. If Cibus fails to comply with its obligations under these agreements, or Cibus
is subject to a bankruptcy, its licensors may have the right to terminate the license, in which event Cibus would not be able to market products or productivity trait or sustainable ingredient candidates covered by the license. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, disputes may arise regarding the payment of the royalties or other considerations due to licensors in connection with Cibus&#146;
exploitation of the rights it licenses from them. Licensors may contest the basis of payments Cibus retained and claim that Cibus is obligated to make payments under a broader basis. In addition to the costs of any litigation Cibus may face as a
result, any legal action against Cibus could increase its payment obligations under the respective agreement and require Cibus to pay interest and potentially damages to such licensors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some cases, patent prosecution of Cibus&#146; licensed technology is controlled solely by the licensor. If such licensor fails to obtain
and maintain patent or other protection for the proprietary intellectual property Cibus licenses from such licensor, Cibus could lose its rights to such intellectual property or the exclusivity of such rights, and its competitors could market
competing products using such intellectual property. In addition, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of Cibus&#146; business. In that event, Cibus may be required to
expend significant time and resources to develop or license replacement technology. If Cibus is unable to do so, Cibus may be unable to develop or commercialize the affected products and productivity trait or sustainable ingredient candidates, which
could harm its business significantly. In other cases, Cibus controls the prosecution of patents resulting from licensed technology. In the event Cibus breaches any of its obligations related to such prosecution, Cibus may incur significant
liability to its licensing partners. Cibus may also require the cooperation of its licensors to enforce any licensed patent rights, and such cooperation may not be provided. Moreover, Cibus has obligations under these license agreements, and any
failure to satisfy those obligations could give its licensor the right to terminate the agreement. Termination of a necessary license agreement could have a material adverse impact on Cibus&#146; business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Licensing of intellectual property is of critical importance to Cibus&#146; business and involves complex legal, business and scientific
issues and is complicated by the rapid pace of scientific discovery in its industry. Disputes may arise regarding intellectual property subject to a licensing agreement, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of rights granted under the license agreement and other interpretation-related issues;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the basis of royalties and other consideration due to its licensors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which its products, productivity trait or sustainable ingredient candidates, technology and
processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sublicensing of patent and other rights under its development relationships; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cibus&#146; diligence obligations under the license agreement and what activities satisfy those diligence
obligations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from the joint
creation or use of intellectual property by its licensors and Cibus and its partners; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the priority of invention of patented technology. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If disputes over intellectual property that Cibus has licensed from third parties prevent or impair Cibus&#146; ability to maintain its
current licensing arrangements on acceptable terms, Cibus may be unable to successfully develop and commercialize the affected products or productivity trait or sustainable ingredient candidates, which could have a material adverse effect on its
business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Some of the licenses Cibus may grant to its licensing partners to use Cibus&#146; proprietary genes in
certain crops may be exclusive within certain jurisdictions, which could limit Cibus&#146; licensing opportunities. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of the
licenses Cibus may grant its licensing partners to use Cibus&#146; proprietary traits in certain crops may be exclusive within specified jurisdictions, so long as its licensing partners comply with certain diligence requirements. That means that
once traits are licensed to a licensing partner in a specified crop or crops, Cibus may be generally prohibited from licensing those traits to any third party. The limitations imposed by such exclusive licenses could prevent Cibus from expanding its
business and increasing its product development initiatives with new licensing partners, both of which could adversely affect Cibus&#146; business and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cibus&#146; results of operations will be affected by the level of royalty payments that Cibus is required to pay to third parties. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus is, or may become, party to agreements, including licensing agreements and its Warrant Exchange Agreement (as defined herein), that
require Cibus to remit royalty payments and other payments related to its owned or licensed intellectual property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under its <FONT
STYLE="white-space:nowrap">in-license</FONT> agreements, Cibus may pay <FONT STYLE="white-space:nowrap">up-front</FONT> fees and milestone payments and be subject to future royalties. Cibus cannot precisely predict the amount, if any, of royalties
it will owe in the future, and if its calculations of royalty payments are incorrect, Cibus may owe additional royalties, which could negatively affect its results of operations. As its product sales increase, Cibus may, from time to time, disagree
with its third-party collaborators as to the appropriate royalties owed and the resolution of such disputes may be costly and may consume management&#146;s time. Furthermore, Cibus may enter into additional license agreements in the future, which
may also include royalty, milestone and other payments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If Cibus&#146; trademarks and trade names are not adequately protected, then Cibus may not
be able to build name recognition in its markets of interest and its business may be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus&#146; trademarks or
trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. Cibus may not be able to protect its rights to these trademarks and trade names or may be forced to stop using these names and
trademarks, which Cibus needs for name recognition by potential partners or farmers or processors in its markets of interest. If Cibus is unable to establish name recognition based on its trademarks and trade names, Cibus may not be able to compete
effectively and its business may be adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Cibus&#146; Organization and Operation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cibus will need to develop and expand its company, and Cibus may encounter difficulties in managing this development and expansion, which could disrupt
its operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus expects to increase its number of employees and the scope and location of its operations. To manage its
anticipated development and expansion, including the development and licensing of its productivity trait or sustainable ingredient candidates, Cibus must continue to implement and improve its managerial, operational and financial systems, expand its
facilities and continue to recruit and train additional qualified personnel. Members of Cibus&#146; management team may need to divert a disproportionate amount of their attention away from their <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities and devote a substantial amount of time to managing these development activities. Due to Cibus&#146; limited resources, it may not be able to effectively manage the expansion of its
operations or recruit and train additional qualified personnel. This may result in weaknesses in Cibus&#146; infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity among
remaining employees. The physical expansion of its operations may lead to significant costs and may divert financial resources from other projects, such as the development of Cibus&#146; productivity trait or sustainable ingredient candidates. If
its management is unable to effectively manage Cibus&#146; expected development and expansion, Cibus&#146; expenses may increase more than expected, its ability to generate or increase its revenue could
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be reduced and Cibus may not be able to implement its business strategy. Cibus&#146; future financial performance and its ability to commercialize its products and productivity trait or
sustainable ingredient candidates and compete effectively will depend, in part, on Cibus&#146; ability to effectively manage the future development and expansion of the company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cibus depends on key management personnel and attracting and retaining other qualified personnel, and its business could be harmed if Cibus loses key
management personnel or cannot attract and retain other qualified personnel. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus&#146; success depends to a significant degree
upon the technical skills and continued service of certain members of its management team, particularly Rory Riggs, Peter Beetham and Greg Gocal. The loss of the services of any of these key executive officers could have a material adverse effect on
Cibus. Cibus does not maintain &#147;key person&#148; insurance policies on the lives of any of its employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus&#146; success will
also depend upon its ability to attract and retain additional qualified management, regulatory, technical, and licensing executives and personnel. The failure to attract, integrate, motivate, and retain additional skilled and qualified personnel
could have a material adverse effect on Cibus&#146; business. Cibus competes for such personnel against numerous companies, including larger, more established companies with significantly greater financial resources than Cibus possesses. In
addition, failure to succeed in Cibus&#146; productivity trait or sustainable ingredient candidates&#146; development may make it more challenging to recruit and retain qualified personnel. There can be no assurance that Cibus will be successful in
attracting or retaining such personnel and the failure to do so could have a material adverse effect on its business, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cibus&#146; internal computer systems, or those of its third-party contractors or consultants, may fail or suffer security breaches, which could result
in a material disruption of Cibus&#146; operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite the implementation of security measures, Cibus&#146; internal computer
systems, and those of third parties on which Cibus relies, are vulnerable to damage from computer viruses, malware, natural disasters, terrorism, war, telecommunication and electrical failures, cyber-attacks or cyber-intrusions over the Internet,
attachments to emails, persons inside its organization, or persons with access to systems inside its organization. While Cibus does not believe that it has experienced any such material system failure, accident, or security breach to date, if such
an event were to occur and cause interruptions in its systems, it could result in a material disruption of Cibus&#146; operations. For example, the loss of field trial data for Cibus&#146; productivity trait or sustainable ingredient candidates
could result in delays in Cibus&#146; commercialization efforts and significantly increase Cibus&#146; costs to recover or reproduce the data. Additionally, there have been reported cases in the industry where productivity trait or sustainable
ingredient candidates have been stolen from the field during field trials. To the extent that any disruption or security breach results in a loss of or damage to Cibus&#146; data or applications or other data or applications relating to its
technology or productivity trait or sustainable ingredient candidates, or inappropriate disclosure of confidential or proprietary information, Cibus could incur liabilities, damage to its reputation, and the further development of its productivity
trait or sustainable ingredient candidates could be delayed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Public Health Crisis Risks </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cibus is subject to various risks related to public health crises, including the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, that could
have material and adverse impacts on its business, financial condition, liquidity, and results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any outbreaks of
contagious diseases and other adverse public health developments could have a material and adverse impact on Cibus&#146; business, financial condition, liquidity, and results of operations. As has occurred with the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, a global pandemic could cause significant disruption to the global economy, including in regions in which Cibus, Cibus&#146; suppliers, infrastructure partners, and customers do business. A
regional epidemic or global pandemic and efforts to manage it, including those by governmental authorities, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
could have significant impacts on national and global financial markets, and could have a significant, negative impact on Cibus&#146; and its customers&#146; operating results. Disruptions could
include partial shutdowns of Cibus&#146; facilities as mandated by government decree, significant travel restrictions, &#147;work-from-home&#148; orders, limited availability of Cibus&#146; workforce, supplier constraints, supply chain
interruptions, logistics challenges and limitations, and reduced demand from customers. The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has had, and could continue to have, these effects on the economy and Cibus&#146; business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The extent to which the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic will continue to impact Cibus&#146; business going forward
will be dependent on future developments such as the length and severity of the crisis, the potential resurgence of the crisis, variant strains of the virus, vaccine availability and effectiveness, future government actions in response to the crisis
and the overall impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on the global economy and capital markets, among many other factors, all of which remain highly uncertain and unpredictable. This unpredictability could limit
Cibus&#146; ability to respond to future developments quickly. Additionally, the impacts described above and other impacts of a global pandemic, including the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and responses to it, could
substantially increase the risk to Cibus from the other risks described under the caption &#147;<I>&#151;Risks Related to Cibus</I>.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom401831_11">
</A>Risks Related to the Combined Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>In determining whether you should approve the issuance of Class&nbsp;A Common Stock and
Class&nbsp;B Common Stock and other matters related to the Transactions to Cibus Unitholders as Merger Consideration you should carefully read the following risk factors in addition to the risks described under &#147;Risk Factors&#151;Risks Related
to the Mergers,&#148; &#147;Risk Factors&#151;Risks Related to the Reverse Stock Splits,&#148; &#147;Risk Factors&#151;Risks Related to Calyxt&#148; and &#147;Risk Factors&#151;Risks Related to Cibus,&#148; which will also apply to the Combined
Company. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cibus&#146; Royalty Liability may contribute to net losses for the Combined Company and cause the value for securities of the Combined
Company to fluctuate. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with two series of financings between November 2013 and December 2014, Cibus Global issued to
each investor in these financings Cibus Warrants to purchase Cibus Series A Preferred Units. Subsequently, certain of the investors sold the Cibus Warrants to Cibus Global in exchange for ongoing quarterly payments equal to a portion of Cibus&#146;
aggregate amount of certain worldwide revenues received during the applicable quarter. Cibus refers to its ongoing warrant purchase payment obligations as its &#147;Royalty Liability.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to its Royalty Liability, Cibus is required to make quarterly royalty payments equal to 10% of all revenue attributable to its
<B><I>RTDS</I></B> technologies, subject to certain exceptions, to the applicable investors which includes members of the Cibus Board and certain officers, who will also serve as directors and officers of Cibus, Inc. The financial interest of such
directors and officers under the Royalty Liability may create real or perceived conflicts of interest between stockholders&#146; interests and those of such affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The requirement to make quarterly payments pursuant to the Royalty Liability commences with the first quarter in which the aggregate revenue
attributable to <B><I>RTDS</I></B> technologies during any consecutive <FONT STYLE="white-space:nowrap">12-month</FONT> period equals or exceeds $50&nbsp;million. At commencement, Cibus will be required to pay all aggregated but unpaid royalty
payment amounts. Its Royalty Liability has an initial term of 30 years following the date on which the first royalty payment becomes due and payable, subject to a subsequent <FONT STYLE="white-space:nowrap">30-year</FONT> extension, at the option of
the holders, for a payment of $100. Cibus&#146; payments under, and performance of, the Royalty Liability are secured by a security interest in substantially all of Cibus&#146; intellectual property. The satisfaction of its Royalty Liability and the
interest expense related thereto may adversely affect the cash flow available for the Combined Company&#146;s operations, particularly in connection with the initial payment of aggregated, but unpaid, royalty payment amounts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus has previously recorded a Royalty Liability on its consolidated balance sheets. Changes in expected royalty payments, as a result of
changes to estimates of the underlying revenues, are accreted to interest expense </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
using the effective interest method. As royalties are paid over the life of the arrangement, Cibus estimates the total amount of future royalty payments over the life of the Royalty Liability
that will be required to be paid to holders of royalty rights. Cibus reassesses these estimated royalty payments periodically and, if the amount or timing of royalty payments differs materially from its prior estimates, Cibus will prospectively
adjust the accretion of the effective interest expense. Fluctuations in the liability balance of its Royalty Liability due to changes in Cibus&#146; business model and anticipated revenues from productivity trait or sustainable ingredient candidates
in development may cause the value of its securities to fluctuate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The unaudited pro forma combined financial statements included in this proxy
statement/prospectus are presented for illustrative purposes only and may not be an indication of the Combined Company&#146;s financial condition or results of operations following the completion of the Transactions. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma combined financial statements contained in this proxy statement/prospectus are presented for illustrative purposes only
and may not be an indication of the Combined Company&#146;s financial condition or results of operations following the Transactions for several reasons. The unaudited pro forma combined financial statements have been derived from the historical
consolidated financial statements of Calyxt and Cibus, and certain adjustments and assumptions have been made regarding the Combined Company after giving effect to the Transactions. The information upon which these adjustments and assumptions have
been made is preliminary, and these kinds of adjustments and assumptions are difficult to make with accuracy and precision. Moreover, the unaudited pro forma combined financial statements do not reflect all costs that are expected to be incurred by
the Combined Company in connection with the Transactions. For example, the impact of any incremental costs incurred in integrating the two companies is not reflected in the unaudited pro forma combined financial statements. As a result, the actual
financial condition of the Combined Company following the Transactions may not be consistent with, or evident from, these unaudited pro forma combined financial statements. The assumptions used in preparing the unaudited pro forma combined financial
information may not prove to be accurate, and other factors may affect the Combined Company&#146;s financial condition following the Transactions. For more information, please see the section titled &#147;<I>Unaudited Pro Forma Combined Financial
Statements</I>&#148; in this proxy statement/prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Combined Company may fail to realize the anticipated benefits of the Transactions.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The success of the Combined Company will depend on, among other things, its ability to combine each of Calyxt&#146;s and
Cibus&#146; businesses in a manner that realizes anticipated synergies. Calyxt and Cibus anticipate that the Combined Company will benefit from synergies. If the Combined Company is not able to successfully achieve these synergies, or the cost to
achieve these synergies is greater than expected, then the anticipated benefits of the Transactions may not be realized fully or at all or may take longer to realize than expected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither Calyxt nor Cibus has ever been profitable and neither company generates significant revenue under its current business strategy. Both
Calyxt and Cibus expect the Combined Company to incur substantial net losses for at least the next several years. Because of the risks and uncertainties associated with identifying, developing and licensing productivity traits and sustainable
ingredient products, Calyxt and Cibus are unable to predict if and when the Combined Company may generate material licensing revenue or if it will ever become profitable. These uncertainties also make it difficult to forecast the extent of any
future losses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The failure to successfully integrate the businesses and operations of Calyxt and Cibus in the expected time frame may adversely
affect the Combined Company&#146;s future results. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt and Cibus have operated and, until the completion of the Transactions,
will continue to operate independently. Accordingly, their respective businesses may not be integrated successfully. It is possible that the integration process could result in: the loss of key employees, customers, service providers, suppliers or
business partners; the disruption of either company&#146;s or both companies&#146; operations; inconsistencies in standards, controls, procedures and policies; potential unknown liabilities; unforeseen expenses, delays, or regulatory conditions
associated with and following completion of the Transactions; or higher than expected integration </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
costs and an overall post-completion integration process that takes longer than originally anticipated. Specifically, the following issues, among others, must be addressed in integrating the
operations of Calyxt and Cibus in order to realize the anticipated benefits of the Transactions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">combining the companies&#146; operations and corporate functions and the resulting difficulties associated with
managing a larger, more complex, integrated business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">combining the businesses of Calyxt and Cibus in a manner that permits the Combined Company to achieve any cost
savings or operating synergies anticipated to result from the Transactions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reducing additional and unforeseen expenses such that integration costs are not more than anticipated;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">avoiding delays in connection with the Transactions or the integration process; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">minimizing the loss of key employees; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying and eliminating redundant functions and assets; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintaining existing agreements with customers, service providers, suppliers and business partners and avoiding
delays in entering into new agreements with prospective licensee customers, service providers, suppliers or business partners; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">consolidating the companies&#146; operating, administrative and information technology infrastructure.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, until the Transactions are consummated, the attention of certain members of either company&#146;s or both
companies&#146; management and resources may be focused on completion of the Transactions and the integration of the two companies&#146; businesses and diverted from
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> business operations or other opportunities that would have been beneficial to such company. Such diverted focus may disrupt each company&#146;s ongoing
business and the business of the Combined Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The future operating results of the Combined Company will suffer if the Combined Company does
not effectively manage its operations following the Transactions. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the Transactions, the Combined Company will be a
larger, more complex, integrated business that will continue to seek to expand its operations through research and development and licensing opportunities, which may be supplemented from time to time by other strategic transactions. The future
success of the Combined Company will depend, in part, upon the ability of the Combined Company to manage the complex challenges and opportunities arising from these circumstances in an efficient and timely manner, and to successfully monitor its
operations and costs, and to maintain other necessary internal controls. The Combined Company cannot assure you that it will realize its expected operating efficiencies, cost savings, revenue enhancements, synergies or other benefits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The market price of the Class&nbsp;A Common Stock is expected to be volatile, and the market price of the Class&nbsp;A Common Stock may drop following
the Transactions. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The market price of the Class&nbsp;A Common Stock following the Transactions could be subject to significant
fluctuations. Some of the factors that may cause the market price of the Class&nbsp;A Common Stock to fluctuate include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">results of the Combined Company&#146;s research and development activities or those of the Combined
Company&#146;s competitors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Combined Company&#146;s ability to enter into, and generate meaningful revenue from, licenses with potential
customers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to meet or exceed financial, development and licensing projections that the Combined Company may provide
to the public from time to time or that may be independently established by analysts and others in the investment community; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure of the Combined Company to achieve anticipated benefits of the Transactions as rapidly or to the extent
anticipated; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements of significant transactions, including financing transactions, by the Combined Company or its
competitors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory or legislative actions relating to the Combined Company&#146;s industry or with respect to the
Combined Company&#146;s own technologies, development processes or product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disputes, litigation or other developments relating to the Combined Company&#146;s intellectual property rights;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions or departures of qualified scientific and management personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant lawsuits, including patent or stockholder litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if securities or industry analysts do not publish research or reports about the Combined Company&#146;s business,
or if they adopt negative or misleading views regarding its business, prospectus and value proposition; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the market valuations of similar companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general market or macroeconomic conditions or market conditions in the biotechnology, gene-editing, synthetic
biology or related industries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales of securities by the Combined Company or its stockholders in the future; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the Combined Company fails to raise an adequate amount of capital to fund its operations and continued
research and development pipeline; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">trading volume of the Class&nbsp;A Common Stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements by competitors regarding development progress or lack thereof, significant contracts, commercial
relationships or capital commitments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse publicity relating to the Combined Company, its technology or industry; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the introduction of technological innovations that compete with the Combined Company&#146;s core technologies;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-to-period</FONT></FONT> fluctuations in
the Combined Company&#146;s financial results. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, the capital markets in general have recently experienced
substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of the Class&nbsp;A Common Stock. In addition, a recession,
depression or other sustained adverse market event could materially and adversely affect the Combined Company&#146;s business and the value of the Class&nbsp;A Common Stock. In the past, following periods of volatility in the market price of a
company&#146;s securities, stockholders have often instituted class action securities litigation against such companies. Furthermore, market volatility may lead to increased shareholder activism if the Combined Company experiences a market valuation
that activists believe is not reflective of its intrinsic value. Activist campaigns that contest or conflict with the Combined Company&#146;s strategic direction or seek changes in the composition of the Cibus, Inc. Board could have an adverse
effect on the Combined Company&#146;s operating results and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>It is expected that the Combined Company will need to raise
additional funding, which may not be available on acceptable terms or at all. Failure to obtain this necessary capital when needed may force the Combined Company to delay, limit or terminate its research and development efforts or other operations.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The process of developing productivity trait and sustainable ingredient candidates is expensive, lengthy and risky. It is expected
that the Combined Company&#146;s research and development expenses will increase substantially as the Combined Company integrates the research and development activities of the two companies </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and continues to identify and develop productivity trait and sustainable ingredient candidates for development and licensing. Further, as a result of the Combined Company&#146;s expected
licensing efforts, the Combined Company&#146;s selling, general and administrative expense may increase significantly in the next several years. These expenses may further increase in the near term as Cibus and Calyxt integrate their operations,
research and development activities, and administrative function. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to advance the Combined Company&#146;s ongoing research and
development processes, pursue regulatory approvals, where applicable, and pursue licensing and commercialization efforts, as applicable, it is expected that the Combined Company will require additional funding. Also, in light of the Transactions,
the operating plan for the Combined Company may change as a result of many factors currently unknown to Cibus and Calyxt, and the Combined Company may need to seek additional funds sooner than contemplated, through public or private equity or debt
financings, government or other third-party funding, marketing and distribution arrangements and other strategic alliances and licensing arrangements, or a combination of these approaches. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that the Combined Company raises additional capital through the sale of additional equity or convertible securities, holders of
Class&nbsp;A Common Stock and the Class&nbsp;B Common Stock will experience dilution, and the terms of the new securities may include liquidation or other preferences that adversely affect such stockholders&#146; rights. Debt financing, if
available, would result in increased fixed payment obligations and a portion of the Combined Company&#146;s operating cash flows, if any, being dedicated to the payment of principal and interest on such indebtedness. Because the Royalty Liability is
secured by a security interest in substantially all of Cibus&#146; intellectual property, lenders may be unwilling to extend unsecured debt, which would be effectively subordinated to the Royalty Liability, to the Combined Company. In addition, debt
financing may involve agreements that include restrictive covenants that impose operating restrictions, such as restrictions on the incurrence of additional debt, the making of certain capital expenditures or the declaration of dividends. To the
extent that the Combined Company raises additional funds through arrangements with research and development partners or otherwise, the Combined Company may be required to relinquish some of its technologies, trait candidates or revenue streams,
license its technologies or traits on unfavorable terms, or otherwise agree to terms unfavorable to the Combined Company. Any additional fundraising efforts may divert management from their <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities, which may adversely affect the Combined Company&#146;s ability to develop and commercialize its productivity trait or sustainable ingredient candidates. In addition, there can be no
guarantee that future financing will be available in sufficient amounts or on terms acceptable to the Combined Company, if at all. Even if the Combined Company believes it has sufficient funds for its current or future operating plans, it may seek
additional capital if market conditions are favorable or in light of specific strategic considerations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Combined Company is unable
to obtain funding on a timely basis, it may be required to significantly curtail, delay or discontinue one or more of its research and development programs or be unable to expand its operations or otherwise capitalize on its business opportunities,
as desired, which could materially affect its business, operating results and prospects and cause the value of its securities to decline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cibus,
Inc. expects to be heavily reliant on its ability to access funding through capital markets transactions. Due to Cibus, Inc.&#146;s anticipated small public float, low market capitalization, limited operating history and lack of revenue, it may be
difficult and expensive for the Combined Company to raise additional funds. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt and Cibus anticipate that the Combined Company
will be heavily reliant on its ability to raise funds through the issuance of shares of Class&nbsp;A Common Stock or securities linked to its Class&nbsp;A Common Stock. The Combined Company&#146;s ability to raise these funds may be dependent on a
number of factors, including the risk factors further described in this proxy statement/prospectus and the anticipated small public float, low market capitalization, limited operating history and lack of revenue. The stocks of small cap companies in
the biotechnology sector, like Cibus, Inc., tend to be highly volatile, and Cibus, Inc. expects that the price of its Class&nbsp;A Common Stock will be highly volatile for the next several years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if the Combined Company begins generating substantial licensing revenue, it may never
successfully achieve profitability. As a result, Cibus, Inc. may be unable to access funding through sales of its Class&nbsp;A Common Stock or other equity-linked securities. Even if the Combined Company were able to access funding, the cost of
capital may be substantial due to Cibus, Inc.&#146;s expected low market capitalization and its anticipated small public float. The terms of any funding that the Combined Company is able to obtain may not be favorable to it and may be highly
dilutive to its stockholders. Further, the Combined Company may be unable to access capital due to generally unfavorable market conditions or other market factors outside of the Combined Company&#146;s control. There can be no assurance that the
Combined Company will be able to raise additional capital when needed. The failure to obtain additional capital when needed would have a material adverse effect on the Combined Company&#146;s business, results of operations, financial condition and
prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Combined Company will incur additional costs and increased demands upon management as a result of complying with the laws and
regulations affecting public companies. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Combined Company will incur significant legal, accounting and other expenses as a
public company that Cibus did not incur as a private company. For example, Cibus, Inc. will be subject to the reporting requirements of the Exchange Act to which Calyxt, Inc. is currently subject, which requires, among other things, that Cibus, Inc.
file with the SEC annual, quarterly and current reports with respect to the Combined Company&#146;s business and financial condition as well as other disclosure and corporate governance requirements. The Combined Company will incur significant
legal, accounting and other expenses in connection with its compliance with such requirements. If the Combined Company is not able to comply with the requirements in a timely manner or at all, the Combined Company&#146;s financial condition or the
market price of Cibus, Inc.&#146;s Class&nbsp;A Common Stock may be harmed. For example, if Cibus, Inc. or its independent auditor identifies deficiencies in Cibus, Inc.&#146;s internal control over financial reporting that are deemed to be material
weaknesses, then the Combined Company could face additional costs to remedy those deficiencies, the market price of Cibus, Inc.&#146;s Class&nbsp;A Common Stock could decline, or the Combined Company could be subject to sanctions or investigations
by the SEC or other regulatory authorities, each of which would require additional financial and management resources. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus, Inc.&#146;s
management team will be primarily comprised of current executive officers of Cibus, which prior to the consummation of the Transactions has operated as a private company. These executive officers and other personnel will need to devote substantial
time related to public company reporting requirements and compliance with applicable laws and regulations to ensure that Cibus, Inc. complies with all of these requirements. Any changes Cibus, Inc. makes to comply with these obligations may not be
sufficient to allow it to satisfy its obligations as a public company on a timely basis, or at all. These reporting requirements, rules and regulations, coupled with the increase in potential litigation exposure associated with being a public
company, could also make it more difficult for Cibus, Inc. to attract and retain qualified persons to serve on the Cibus, Inc. Board or on committees thereof or to serve as executive officers, or to obtain certain types of insurance, including
directors&#146; and officers&#146; insurance, on acceptable terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If Cibus, Inc. fails to maintain an effective system of internal control over
financial reporting, Cibus, Inc. may not be able to accurately report its financial results or prevent fraud. As a result, stockholders could lose confidence in Cibus, Inc.&#146;s financial and other public reporting, which would harm its business
and the trading price of its Class&nbsp;A Common Stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective internal control over financial reporting is necessary for
Cibus, Inc. to provide reliable financial reports and, together with adequate disclosure controls and procedures, is designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their
implementation, could cause Cibus, Inc. to fail to meet its reporting obligations. In addition, any testing by Cibus, Inc. as and when required, conducted in connection with Section&nbsp;404 of the Sarbanes-Oxley Act, or Section&nbsp;404, or any
subsequent testing by Cibus, Inc.&#146;s independent registered public accounting firm, as and when required, may reveal deficiencies in Cibus,&nbsp;Inc.&#146;s internal control over financial reporting that are deemed to be significant deficiencies
or material weaknesses or that may require prospective or retroactive changes to its financial statements or identify other areas </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in Cibus, Inc.&#146;s reported financial information, which could have a negative
effect on the trading price of its Class&nbsp;A Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Section&nbsp;404, Cibus, Inc. will be required to furnish a
report by its management on Cibus, Inc.&#146;s internal control over financial reporting. However, pursuant to Section&nbsp;404(c), for so long as Cibus, Inc. is a <FONT STYLE="white-space:nowrap">&#147;non-accelerated&#148;</FONT> filer, Cibus,
Inc. will not be required to include an attestation report on internal control over financial reporting issued by its independent registered public accounting firm. To maintain compliance with Section&nbsp;404, Cibus, Inc. will be engaged in a
process to document and evaluate its internal control over financial reporting, which is both costly and challenging. In this regard, Cibus, Inc. will need to dedicate internal resources, potentially engage outside consultants and adopt a detailed
work plan to assess and document the adequacy of internal control over financial reporting, take steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous
reporting and improvement process for internal control over financial reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite its efforts, there is a risk that neither Cibus,
Inc. nor Cibus, Inc.&#146;s independent&nbsp;registered public accounting firm once Cibus, Inc. is required to obtain an attestation report on internal control over financial reporting from such firm, will be able to conclude within the prescribed
timeframe that Cibus, Inc.&#146;s internal control over financial reporting is effective as required by Section&nbsp;404. This could result in an adverse reaction in the financial markets due to&nbsp;a loss of confidence in the reliability of Cibus,
Inc.&#146;s financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Provisions that will be in the Amended Certificate of Incorporation and Amended Bylaws and provisions under
Delaware Law could make an acquisition of Cibus, Inc., which may be beneficial to its stockholders, more difficult and may prevent attempts by its stockholders to replace or remove its management. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Transactions are completed, the Calyxt Certificate of Incorporation and the Calyxt Bylaws, as amended by the amendments thereto attached
to this proxy statement/prospectus as <I>Annex B </I>and<I> Annex C</I>, respectively, will become Cibus, Inc.&#146;s certificate of incorporation and bylaws. Provisions that will be included in the Amended Certificate of Incorporation and Amended
Bylaws may discourage, delay or prevent a merger, acquisition or other change in control of Cibus, Inc. that stockholders may consider favorable, including transactions in which its Class&nbsp;A Common Stockholders might otherwise receive a premium
price for their shares. These provisions could also limit the price that investors might be willing to pay in the future for the Class&nbsp;A Common Stock, thereby depressing the market price of the Class&nbsp;A Common Stock. In addition, because
the Cibus, Inc. Board will be responsible for appointing the members of the Cibus, Inc. management team, these provisions may frustrate or prevent any attempts by Cibus, Inc.&#146;s stockholders to replace or remove its current management by making
it more difficult for stockholders to replace members of the Cibus, Inc. Board. Among other things, these provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">allow the authorized number of Cibus, Inc.&#146;s directors to be changed only by resolution of the Cibus, Inc.
Board; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and
for nominations to the Cibus, Inc. Board; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limit who may call stockholder meetings; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prohibit actions by Cibus, Inc.&#146;s stockholders by written consent; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require that stockholder actions be effected at a duly called stockholders meeting; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorize the Cibus, Inc. Board to issue preferred stock without stockholder approval, which could be used to
institute a &#147;poison pill&#148; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by the Cibus, Inc. Board. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, because Cibus, Inc. is incorporated in Delaware, it is governed by the provisions of Section&nbsp;203 of the DGCL which prohibits a
person who owns 15% or more of Cibus, Inc.&#146;s outstanding voting stock from </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
merging or combining with Cibus, Inc. for a period of three years after the date of the transaction in which the person acquired 15% or more of Cibus, Inc.&#146;s outstanding voting stock, unless
the merger or combination is approved in a manner prescribed by the statute. For more information about provisions that will be included in the Amended Certificate of Incorporation and Amended Bylaws, see the section entitled &#147;<I>Comparison of
Stockholders&#146; Rights</I>&#148; beginning on page 339 of this proxy statement/prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The provision of the Amended Certificate of
Incorporation provide that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for substantially all disputes between Cibus, Inc. and its stockholders, which could limit the ability of Cibus, Inc.&#146;s stockholders
to obtain a favorable judicial forum for disputes with Cibus, Inc. or its directors, officers, or employees. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Amended
Certificate of Incorporation will provide that, unless Cibus, Inc. consents in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(i)&nbsp;any derivative action or proceeding brought on behalf of Cibus, Inc., (ii) any action asserting a claim of breach of a fiduciary duty owed by any of
Cibus, Inc.&#146;s directors, officers and employees to Cibus, Inc. or its stockholders, (iii)&nbsp;any action asserting a claim arising pursuant to any provision of the DGCL, the Amended Certificate of Incorporation or Amended Bylaws, or
(iv)&nbsp;any action asserting a claim that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery having jurisdiction, failing which the federal district court for the District of Delaware shall be the
applicable forum. This choice of forum provision does not apply to any claim arising under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although Cibus, Inc.
believes this provision benefits it by providing increased consistency in the application of Delaware law in the types of lawsuits to which it applies, the provision may have the effect of discouraging lawsuits against the Cibus, Inc. Board and
Cibus, Inc.&#146;s officers. The choice of forum provision may limit a stockholder&#146;s ability to bring a claim in a judicial forum that it finds favorable for disputes with Cibus, Inc. or any of its directors, officers, other employees or
stockholders, which may discourage lawsuits with respect to such claims. Alternatively, if a court were to find the choice of forum provisions contained in the Amended Certificate of Incorporation to be inapplicable or unenforceable with respect to
one or more of the specified types of actions or proceedings, Cibus, Inc. may incur additional costs associated with resolving such action in other jurisdictions, which could harm the Combined Company&#146;s business, operating results and financial
condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>An active trading market for the Class&nbsp;A Common Stock may not develop and holders of Class&nbsp;A Common Stock may not be able to
resell their Class&nbsp;A Common Stock for a profit, if at all. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the Transactions, there had been no public market for
Cibus Units. An active trading market for the Class&nbsp;A Common Stock may never develop or be sustained. If an active market for the Class&nbsp;A Common Stock does not develop or is not sustained, it may be difficult for holders of Class&nbsp;A
Common Stock to sell their shares at an attractive price or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cibus, Inc. may issue shares of preferred stock in the future, which could make
it difficult for another company to acquire Cibus, Inc. or could otherwise adversely affect holders of its Class&nbsp;A Common Stock, which could depress the price of the Class&nbsp;A Common Stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Amended Certificate of Incorporation will authorize Cibus, Inc. to issue one or more series of preferred stock. The Cibus, Inc. Board will
have the authority to determine the preferences, limitations and relative rights of the shares of preferred stock and to fix the number of shares constituting any series and the designation of such series, without any further vote or action by its
stockholders. Cibus, Inc.&#146;s preferred stock could be issued with voting, liquidation, dividend and other rights superior to the rights of the Class&nbsp;A Common Stock. The potential issuance of preferred stock may delay or prevent a change in
control of Cibus, Inc., discourage bids for the Class&nbsp;A Common Stock at a premium to the market price, and materially and adversely affect the market price and the voting and other rights of the holders of the Class&nbsp;A Common Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>After completion of the Transactions, Cibus, Inc.&#146;s executive officers, directors and principal
stockholders will have the ability to control or significantly influence all matters submitted to its stockholders for approval. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the completion of the Transactions, it is anticipated that Cibus, Inc.&#146;s executive officers, directors and principal stockholders
will, in the aggregate, beneficially own approximately 49.84% of Cibus, Inc.&#146;s outstanding Shares, subject to certain assumptions. As a result, if these stockholders were to choose to act together, they would be able to control or significantly
influence all matters submitted to Cibus, Inc.&#146;s stockholders for approval, as well as the Combined Company&#146;s management and affairs. For example, these persons, if they choose to act together, would control or significantly influence the
election of directors and approval of any merger, consolidation or sale of all or substantially all of the Combined Company&#146;s assets. This concentration of voting power could delay or prevent an acquisition of the Combined Company on terms that
other stockholders may desire. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Combined Company will have broad discretion in the use of the cash and cash equivalents of the Combined Company
and may invest or spend the proceeds in ways with which you do not agree and in ways that may not increase the value of your investment. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Combined Company will have broad discretion over the use of the cash and cash equivalents of the Combined Company. You may not agree with
the Combined Company&#146;s decisions, and its use of the available capital resources may not yield any return on your investment. The Combined Company&#146;s failure to apply these resources effectively could compromise its ability to pursue its
growth strategy and the Combined Company might not be able to yield a significant return, if any, on its investment of these capital resources. You will not have the opportunity to influence the Combined Company&#146;s decisions on how to use its
cash resources. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in tax laws, treaties or regulations or adverse outcomes resulting from examination of tax returns, and/or inability to
qualify for tax treaty benefits, could adversely affect the Combined Company&#146;s financial results. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Combined Company&#146;s
future effective global tax rates could be adversely affected by changes in tax laws, treaties and regulations, both in the United States and internationally. Tax laws, treaties and regulations are highly complex and subject to interpretations.
Consequently, the Combined Company will be subject to changing tax laws, treaties and regulations in and between countries in which it operates or is resident. The Combined Company&#146;s income tax expense will be based upon the interpretation of
the tax laws in effect in various countries at the time that the expense was incurred. A change in these tax laws, treaties or regulations, or in the interpretation thereof, could result in a materially higher tax expense or a higher effective tax
rate on the Combined Company&#146;s worldwide earnings. If any country successfully challenges the Combined Company&#146;s income tax filings, or those of Calyxt and Cibus prior to the Transactions, based on its structure, or if the Combined Company
otherwise loses a material tax dispute, its effective tax rate on worldwide earnings could increase substantially and the Combined Company&#146;s financial result could be materially adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Combined Company&#146;s overall global effective tax rate will be impacted by the extent to which its <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> subsidiaries (and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> operations) qualify for the benefits of various international tax treaties. The Combined Company&#146;s ability to qualify for the benefits
of international tax treaties will require its <FONT STYLE="white-space:nowrap">non-U.S.</FONT> subsidiaries (and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> operations) to satisfy various requirements, including those relating to ownership
and/or residency. Neither Cibus nor Calyxt can make any assurances as to the extent to which the Combined Company may be able to satisfy all of these requirements at all times. If any of the Combined Company&#146;s
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> subsidiaries (or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> operations) are not eligible for international tax treaty benefits, such subsidiaries (or operations) may be subject to additional
U.S. and/or international income taxation, which, in turn, would adversely impact the Combined Company&#146;s pro forma financial expectations for its operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The&nbsp;U.S. net operating loss carryforwards and certain other tax attributes of Cibus, Inc. attributable to periods preceding the Mergers are
expected to be subject to limitations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, Calyxt had approximately $239.2 million of NOLs for federal
and state income tax purposes, which may be available to offset federal income tax liabilities in the future. In addition, Cibus, Inc. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may generate additional NOLs in future years. Calyxt has established a full valuation allowance for its deferred tax assets, including NOLs, due to the uncertainty that enough taxable income will
be generated to utilize the assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus, Inc.&#146;s ability to utilize its NOLs following the Transaction may be limited if it
experiences an &#147;ownership change&#148; as defined in Section&nbsp;382. An ownership change generally occurs if certain direct or indirect five percent shareholders increase their aggregate percentage ownership of a corporation&#146;s stock by
more than 50 percentage points over their lowest percentage ownership at any time during the testing period, which is generally the three-year period preceding any potential ownership change. It is expected that the Mergers will cause Cibus, Inc. to
experience an ownership change, which will cause Cibus, Inc. to be subject to an annual limitation that applies to the amount of <FONT STYLE="white-space:nowrap">pre-ownership</FONT> change NOLs that may be used to offset post-ownership change
taxable income. This limitation is generally determined by multiplying the value of a corporation&#146;s stock immediately before the ownership change by the applicable long-term <FONT STYLE="white-space:nowrap">tax-exempt</FONT> rate. Any unused
annual limitation may, subject to certain limits, be carried over to later years, and the limitation may under certain circumstances be increased by <FONT STYLE="white-space:nowrap">built-in</FONT> gains in the assets held by such corporation at the
time of the ownership change. This limitation could cause Cibus, Inc.&#146;s U.S. federal income taxes to be greater, or to be paid earlier, than they otherwise would be, and could cause some of its NOLs to expire unused. Similar rules and
limitations may apply for state income tax purposes. There is also a risk that future legal or regulatory changes may limit Cibus, Inc.&#146;s ability to use current or future NOLs to offset its future federal income tax liabilities. The amount of
NOLs that would be subject to the annual limitation under Section&nbsp;382 has not yet been determined. However, as set forth above, there is currently a full valuation allowance for Calyxt&#146;s deferred tax assets, including NOLs, due to the
uncertainty that enough taxable income will be generated to utilize the assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no assurance that Cibus, Inc. will not
experience a future ownership change under Section&nbsp;382 that would significantly limit or possibly eliminate its ability to use its NOLs. In addition, Cibus, Inc. may experience ownership changes as a result of shifts in the direct or indirect
ownership of its stock, some of which may be outside of its control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If following the Transactions, Cibus, Inc. fails to continue to meet the
requirements for continued listing on Nasdaq, the Class&nbsp;A Common Stock could be delisted from trading, which would decrease the liquidity of the Class&nbsp;A Common Stock and the Combined Company&#146;s ability to raise additional capital.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At completion of the Transactions, the Class&nbsp;A Common Stock will be listed for quotation on Nasdaq. Cibus, Inc. will be
required to meet Nasdaq&#146;s specified continued listing standards, including the requirement to maintain a minimum trading price greater than $1.00. If Cibus, Inc. is unable to comply with Nasdaq&#146;s listing standards, Nasdaq may determine to
delist the Class&nbsp;A Common Stock from Nasdaq. If the Class&nbsp;A Common Stock is delisted for any reason, it could reduce the value of the Class&nbsp;A Common Stock and its liquidity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>At the Closing, Cibus, Inc. will not be immediately eligible for the scaled disclosure requirements otherwise available to low revenue companies.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the end of its fiscal year ended December&nbsp;31, 2022, which was the fiscal year ending after the fifth anniversary of
Calyxt&#146;s initial public offering, Calyxt ceased to qualify as an &#147;emerging growth company,&#148; as defined in the Jumpstart Our Business Startups Act. Further, as a majority-owned subsidiary of Cellectis S.A., which as a foreign private
issuer is not eligible to use the requirements for smaller reporting companies, as of June&nbsp;30, 2022, Calyxt did not qualify as a &#147;smaller reporting company&#148; at that determination date. Accordingly, Calyxt is no longer able to follow
the scaled disclosure requirements for newly public companies and is presently ineligible to rely on the scaled disclosure requirements for smaller reporting companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following consummation of the Transactions (assuming such consummation occurs prior to June&nbsp;30, 2023), Cibus, Inc. will remain
unqualified as a smaller reporting company until the next annual determination on June&nbsp;30, 2023, at which time because Cibus, Inc. had less than $100&nbsp;million in revenue for the year ended December&nbsp;31, 2022. Cibus, Inc. will become a
&#147;smaller reporting company.&#148; Cibus, Inc. will then remain a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
&#147;smaller reporting company&#148; until the last day of the fiscal year in which (1)&nbsp;the market value of its Class A Common Stock held by
<FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $250&nbsp;million as of the end of the prior second fiscal quarter, or (2)&nbsp;its annual revenues exceed $100&nbsp;million during such completed fiscal year and the market value of its
Class&nbsp;A Common Stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700&nbsp;million as of the prior second fiscal quarter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the consummation of the Transactions and until such time as Cibus, Inc. qualifies as a smaller reporting company, Calyxt and Cibus,
respectively, will be required to incur additional expenses associated with complying with the full panoply of the Exchange Act&#146;s reporting requirements. During this time, the companies&#146; management and finance and legal personnel will need
to devote a substantial amount of time to such reporting compliance obligations. <B><I></I></B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If equity research analysts do not publish research
or reports, or publish unfavorable research or reports, about the Combined Company, its business or its market, the stock price and trading volume of the Class&nbsp;A Common Stock could decline. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading market for the Class&nbsp;A Common Stock will be influenced by the research and reports that equity research analysts publish about
the Combined Company and its business. Equity research analysts may elect not to provide research coverage of the Class&nbsp;A Common Stock after the completion of the Transactions, and such lack of research coverage may adversely affect the market
price of its Class&nbsp;A Common Stock. In the event that the Class&nbsp;A Common Stock does have equity research analyst coverage, the Combined Company will not have any control over the analysts or the content and opinions included in their
reports. The price of the Class&nbsp;A Common Stock could decline if one or more equity research analysts downgrades the Class&nbsp;A Common Stock or issues other unfavorable commentary or research regarding the Combined Company or its industry. If
one or more equity research analysts ceases coverage of the Class&nbsp;A Common Stock or fails to publish reports on it regularly, demand for the Class&nbsp;A Common Stock could decrease, which in turn could cause its stock price or trading volume
to decline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Calyxt and Cibus do not anticipate that Cibus, Inc. will pay any cash dividends in the foreseeable future. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The current expectation is that Cibus, Inc. will invest its future earnings, if any, to fund growth of Cibus&#146; operating business and will
not pay any dividends to holders of Class&nbsp;A Common Stock for the foreseeable future. Therefore, holders of Class&nbsp;A Common Stock are not likely to receive any dividends for the foreseeable future, and the value of such Class A Common Stock
will depend upon any future appreciation. Such price appreciation may never occur. In addition, the terms of any future debt agreements may preclude Cibus, Inc. from paying dividends. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future sales of shares of Class&nbsp;A Common Stock into the market, or the perception that these sales may occur, could cause the market price of
Class&nbsp;A Common Stock to decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If existing stockholders of Calyxt, Inc. or Cibus Global sell, or indicate an intention to
sell, substantial amounts of the Class&nbsp;A Common Stock in the public market following consummation of the Transactions, the trading price of the Class&nbsp;A Common Stock could decline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the support agreements entered into by certain Calyxt Stockholders and Cibus Unitholders restrict sales and other transfers prior to
the consummation of the Transactions, such agreements do not impose any post-Transaction <FONT STYLE="white-space:nowrap">lock-up</FONT> restrictions. Accordingly, subject to any restrictions imposed on shares of Class&nbsp;A Common Stock held by
&#147;affiliates&#148; pursuant to Rule 144, approximately 1,008,785,000&nbsp;Shares are expected to be freely transferable into the public market upon consummation of the Transactions, without taking into account the effect of the Reverse Stock
Splits or any Up-C elections. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a substantial number of these shares of Class&nbsp;A Common Stock are sold into the market, or if it is
perceived that they will be sold in the public market, the trading price of the Class&nbsp;A Common Stock could decline. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom401831_12"></A>Risks Related to the Organizational Structure of the Combined Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cibus, Inc. will be a holding company and its only material asset after completion of the Transactions will be its interest in Cibus Global, and it is
accordingly dependent upon distributions from Cibus Global to pay taxes, make payments under the Tax Receivable Agreement and cover its corporate and other overhead expenses. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of the Transactions, Cibus, Inc. will be a holding company with no material assets other than its ownership of Cibus Common
Units. As a result, Cibus, Inc. will have no independent means of generating revenue or cash flow. Cibus, Inc.&#146;s ability to pay taxes, make payments under the Tax Receivable Agreement and cover its corporate and other overhead expenses will
depend on the financial results and cash flows of Cibus Global and its subsidiaries and the distributions that Cibus, Inc. receives from Cibus Global. Deterioration in the financial condition, earnings or cash flow of Cibus Global and its
subsidiaries, for any reason, could limit or impair Cibus Global&#146;s ability to pay such distributions. Additionally, to the extent that Cibus, Inc. needs funds and Cibus Global and/or any of its subsidiaries are restricted from making such
distributions under applicable law or regulation or under the terms of any financing arrangements, or Cibus Global is otherwise unable to provide such funds, it could materially adversely affect Cibus, Inc.&#146;s liquidity and financial condition.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the potential risk of being treated as a publicly traded partnership discussed below, Cibus Global will continue to be treated
as a partnership for U.S. federal income tax purposes and, as such, generally will not be subject to any entity-level U.S. federal income tax. Instead, the taxable income of Cibus Global will be allocated to holders of Cibus Common Units, including
Cibus, Inc. Accordingly, Cibus, Inc. will be required to pay income taxes on its allocable share of any net taxable income of Cibus Global. Under the terms of the Cibus Amended Operating Agreement, Cibus Global will be obligated to make tax
distributions to holders of Cibus Common Units (including Cibus, Inc.) calculated at certain assumed tax rates. In addition to tax expenses, Cibus, Inc. will also incur expenses related to its operations, including payment obligations under the Tax
Receivable Agreement (and the cost of administering such payment obligations), which could be significant and some of which may be reimbursed by Cibus Global (excluding payment obligations under the Tax Receivable Agreement). See the section
entitled &#147;<I>Agreements Related to the Mergers&#151;Tax Receivable Agreement</I>&#148; in this proxy statement/prospectus. Cibus, Inc. intends to cause Cibus Global to make distributions to holders of Cibus Common Units in amounts sufficient to
cover all applicable taxes (calculated at assumed tax rates), relevant operating expenses, payments under the Tax Receivable Agreement and dividends, if any, declared by Cibus, Inc. However, as discussed below, Cibus Global&#146;s ability to make
such distributions may be subject to various limitations and restrictions including, but not limited to, restrictions on distributions that would either violate any contract or agreement to which Cibus Global is then a party, including debt
agreements, or any applicable law, or that would have the effect of rendering Cibus Global insolvent. If Cibus, Inc.&#146;s cash resources are insufficient to meet its obligations under the Tax Receivable Agreement and to fund its obligations,
Cibus, Inc. may be required to incur additional indebtedness to provide the liquidity needed to make such payments, which could materially adversely affect its liquidity and financial condition and subject Cibus, Inc. to various restrictions imposed
by any such lenders. To the extent that Cibus, Inc. is unable to make payments under the Tax Receivable Agreement for any reason, such payments will be deferred and will accrue interest until paid; provided, however, that nonpayment for a specified
period may constitute a material breach of a material obligation under the Tax Receivable Agreement and therefore accelerate payments due under the Tax Receivable Agreement, which could be substantial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, although Cibus Global generally will not be subject to any entity-level U.S. federal income tax, it may be liable under federal
tax legislation for adjustments to its tax return, absent an election to the contrary. In the event Cibus Global&#146;s calculations of taxable income are incorrect, its members, including Cibus, Inc., in later years may be subject to material
liabilities pursuant to this federal legislation and its related guidance. Cibus, Inc. anticipates that the distributions it will receive from Cibus Global may, in certain periods, exceed Cibus, Inc.&#146;s actual tax liabilities and obligations to
make payments under the Tax Receivable Agreement. The Cibus, Inc. Board, in its sole discretion, may make any determination from time to time with respect to the use of any such excess cash so accumulated, which may include, among other uses, to pay
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
dividends on Class&nbsp;A Common Stock. Cibus, Inc. will have no obligation to distribute such cash (or other available cash other than any declared dividend) to its stockholders. See the section
entitled &#147;<I>Agreements Related to the Mergers&#151;Cibus Amended Operating Agreement</I>&#148; in this proxy statement/prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends on Class&nbsp;A Common Stock, if any, will be paid at the discretion of the Cibus, Inc. Board, which will consider, among other
things, Cibus, Inc.&#146;s business, operating results, financial condition, current and expected cash needs, plans for expansion and any legal or contractual limitations on its ability to pay such dividends. Financing arrangements may include
restrictive covenants that restrict Cibus, Inc.&#146;s ability to pay dividends or make other distributions to its stockholders. In addition, Cibus Global is generally prohibited under Delaware Law from making a distribution to a member to the
extent that, at the time of the distribution, after giving effect to the distribution, liabilities of Cibus Global (with certain exceptions) exceed the fair value of its assets. Cibus Global&#146;s subsidiaries are generally subject to similar legal
limitations on their ability to make distributions to Cibus Global. If Cibus Global does not have sufficient funds to make distributions, Cibus, Inc.&#146;s ability to declare and pay cash dividends may also be restricted or impaired. The current
expectation is that Cibus, Inc. will invest its future earnings, if any, to fund growth of Cibus Global&#146;s operating business and will not pay any dividends to holders of Class&nbsp;A Common Stock for the foreseeable future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>In certain circumstances, Cibus Global will be required to make distributions to Cibus, Inc. and the other holders of Cibus Common Units, and the
distributions that Cibus Global will be required to make may be substantial. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus Global will generally be required from time to
time to make pro rata distributions in cash to Cibus, Inc. and the other holders of Cibus Common Units at certain assumed tax rates in amounts that are intended to be sufficient to cover the taxes on Cibus, Inc.&#146;s and the other Cibus
unitholders&#146; respective allocable shares of the taxable income of Cibus Global. As a result of (i)&nbsp;potential differences in the amount of net taxable income allocable to Cibus, Inc. and the other holders of Cibus Common Units,
(ii)&nbsp;the lower tax rate applicable to corporations than individuals and (iii)&nbsp;the use of an assumed tax rate (based on the tax rate applicable to individuals) in calculating Cibus Global&#146;s distribution obligations, Cibus, Inc. may
receive tax distributions significantly in excess of its tax liabilities and obligations to make payments under the Tax Receivable Agreement. Cibus, Inc. will determine in its sole discretion the appropriate uses for any excess cash so accumulated,
which may include, among other uses, dividends, the payment of obligations under the Tax Receivable Agreement and the payment of other expenses. Cibus, Inc. will have no obligation to distribute such excess cash (or other available cash other than
any declared dividend) to the other holders of Class&nbsp;A Common Stock. The current expectation is that Cibus, Inc. will invest its future earnings, if any, to fund growth of Cibus Global&#146;s operating business and will not pay any dividends to
holders of Class&nbsp;A Common Stock for the foreseeable future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No adjustments to the redemption or exchange ratio of Cibus Common Units
for shares of Class&nbsp;A Common Stock will be made as a result of either (i)&nbsp;any cash dividend by Cibus, Inc. or (ii)&nbsp;any cash that Cibus, Inc. retains and does not distribute to its stockholders. To the extent that Cibus, Inc. does not
distribute such excess cash as dividends on Class&nbsp;A Common Stock and instead, for example, holds such cash balances or lends them to Cibus Global, Cibus Global equity holders would benefit from any value attributable to such cash balances as a
result of their ownership of Class&nbsp;A Common Stock following a redemption or exchange of their Cibus Common Units. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cibus, Inc. will be required
to make payments to the TRA Parties pursuant to the Tax Receivable Agreement for certain tax benefits Cibus, Inc. may receive and the amounts payable may be substantial. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus, Inc. will acquire certain favorable tax attributes from certain Blockers in the Blocker Mergers. In addition, future redemptions or
exchanges of Cibus Common Units for shares of Class&nbsp;A Common Stock or cash, and other transactions described herein, are expected to result in favorable tax attributes for Cibus, Inc. These tax attributes would not be available to Cibus, Inc.
in the absence of those transactions and are expected to reduce the amount of tax that we would otherwise be required to pay in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the completion of the Transactions, Cibus, Inc. will enter into the Tax Receivable
Agreement, pursuant to which Cibus, Inc. generally will be required to pay to the TRA Parties, in the aggregate, 85% of the net income tax savings that Cibus, Inc. actually realizes (or in certain circumstances, is deemed to realize) as a result of
(i)&nbsp;certain favorable tax attributes we will acquire from the Blockers in the Blocker Mergers (including net operating losses), (ii) increases to Cibus, Inc.&#146;s allocable share of the tax basis of Cibus Global&#146;s assets resulting from
future redemptions or exchanges of Cibus Common Units for shares of Class&nbsp;A Common Stock or cash, (iii)&nbsp;tax attributes resulting from certain payments made under the Tax Receivable Agreement and (iv)&nbsp;deductions in respect of interest
under the Tax Receivable Agreement. The payment obligations under the Tax Receivable Agreement are Cibus, Inc.&#146;s obligations and not obligations of Cibus Global. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is expected that the payments Cibus, Inc. will be required to make under the Tax Receivable Agreement will be substantial. Because
potential future tax savings that Cibus, Inc. will be deemed to realize, and the Tax Receivable Agreement payments made by Cibus, Inc., will be calculated based in part on the market value of the Class&nbsp;A Common Stock at the time of each
redemption or exchange under the Exchange Agreement and the prevailing applicable tax rates applicable to Cibus, Inc. over the life of the Tax Receivable Agreement and will depend on Cibus, Inc. generating sufficient taxable income to realize the
tax benefits that are subject to the Tax Receivable Agreement, the actual amounts Cibus, Inc. will be required to pay are difficult to predict and may differ materially from any management projections that may be made from <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">time-to-time.</FONT></FONT> Payments under the Tax Receivable Agreement will not be conditioned on the Cibus Global equity holders&#146; or Blocker equity holders&#146; continued ownership
of Cibus, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>In certain cases, payments under the Tax Receivable Agreement may be accelerated and/or significantly exceed the actual benefits
Cibus, Inc. realizes in respect of the tax attributes subject to the Tax Receivable Agreement. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payments under the Tax Receivable
Agreement will be based on the tax reporting positions Cibus, Inc. determines, and the IRS or another tax authority may challenge all or a part of the tax basis increases, net operating losses or other tax attributes subject to the Tax Receivable
Agreement, and a court could sustain such challenge. The parties to the Tax Receivable Agreement will not reimburse Cibus, Inc. for any payments previously made if such tax basis, or other tax benefits are subsequently disallowed, except that any
excess payments made to a party under the Tax Receivable Agreement will be netted against future payments otherwise to be made under the Tax Receivable Agreement, if any, after the determination of such excess. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Tax Receivable Agreement will provide that if (1)&nbsp;Cibus, Inc. breaches any of its material obligations under the Tax
Receivable Agreement (including in the event that Cibus, Inc. is more than three months late making a payment that is due under the Tax Receivable Agreement, except in the case of certain liquidity exceptions), (2) Cibus, Inc. is subject to certain
bankruptcy, insolvency or similar proceedings, (3)&nbsp;upon certain mergers, asset sales or other forms of business combination, or certain other changes of control, or (4)&nbsp;at any time, Cibus, Inc. elects an early termination of the Tax
Receivable Agreement, Cibus, Inc.&#146;s obligations under the Tax Receivable Agreement (with respect to all Cibus Common Units, whether or not such units have been exchanged or redeemed before or after such transaction) would accelerate and become
payable in a lump sum amount equal to the present value of the anticipated future tax benefits calculated based on certain assumptions, including that Cibus, Inc. would have sufficient taxable income to fully utilize the deductions arising from the
tax deductions, tax basis and other tax attributes subject to the Tax Receivable Agreement. As a result, upon any acceleration of Cibus, Inc.&#146;s obligations under the Tax Receivable Agreement and upon a change of control, Cibus, Inc. could be
required to make payments under the Tax Receivable Agreement that are greater than 85% of its actual cash tax savings, which could negatively impact its liquidity. The change of control provisions in the Tax Receivable Agreement may also result in
situations where the Cibus Global equity holders and the relevant Blocker Owners that will be TRA Parties will have interests that differ from or are in addition to those of the other holders of Class&nbsp;A Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Finally, because Cibus, Inc. is a holding company with no operations of its own, its ability to make payments under the Tax Receivable
Agreement will depend on the ability of Cibus Global to make distributions </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to it. To the extent that Cibus, Inc. is unable to make payments under the Tax Receivable Agreement for any reason, such payments will be deferred and will accrue interest until paid, which could
negatively impact Cibus, Inc.&#146;s results of operations and could also affect its liquidity in periods in which such payments are made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If Cibus
Global were to become a publicly traded partnership taxable as a corporation for U.S. federal income tax purposes, Cibus, Inc. and Cibus Global might be subject to potentially significant tax inefficiencies, and Cibus, Inc. would not be able to
recover payments previously made by it under the Tax Receivable Agreement even if the corresponding tax benefits were subsequently determined to have been unavailable due to such status. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus&#146; management intends to operate Cibus Global such that it does not become a publicly traded partnership taxable as a corporation for
U.S. federal income tax purposes. A &#147;publicly traded partnership&#148; is a partnership the interests of which are traded on an established securities market or are readily tradable on a secondary market or the substantial equivalent thereof.
Under certain circumstances, exchanges of Cibus Common Units pursuant to the Exchange Agreement or other transfers of Cibus Common Units could cause Cibus Global to be treated as a publicly traded partnership. Applicable Treasury Regulations provide
for certain safe harbors from treatment as a publicly traded partnership, and it is intended that Cibus Global will be operated such that exchanges or other transfers of Cibus Common Units qualify for one or more such safe harbors. For example, the
Exchange Agreement and the Cibus Amended Operating Agreement, which will be entered into in connection with the consummation of the Transactions, will provide for limitations on the ability of Cibus Global equity holders to transfer their Cibus
Common Units and will provide Cibus, Inc. with the right to cause the imposition of limitations and restrictions (in addition to those already in place) on the ability of Cibus Global equity holders to exchange their Cibus Common Units pursuant to
the Exchange Agreement to the extent Cibus, Inc. believes it is necessary to ensure that Cibus Global will continue to be treated as a partnership for U.S. federal income tax purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Cibus Global were to become a publicly traded partnership taxable as a corporation for U.S. federal income tax purposes, significant tax
inefficiencies might result for Cibus, Inc. and Cibus Global, including as a result of Cibus, Inc.&#146;s inability to file a consolidated U.S. federal income tax return with Cibus Global. In addition, Cibus, Inc. may not be able to realize tax
benefits covered under the Tax Receivable Agreement, and Cibus, Inc. would not be able to recover any payments previously made by it under the Tax Receivable Agreement, even if the corresponding tax benefits (including any claimed increase in the
tax basis of Cibus Global&#146;s assets) were subsequently determined to have been unavailable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If Cibus, Inc. were deemed to be an investment
company under the Investment Company Act of 1940, as amended (the &#147;1940 Act&#148;), as a result of its ownership of Cibus Global, applicable restrictions could make it impractical for Cibus, Inc. to continue its business as contemplated and
could have a material adverse effect on the Combined Company&#146;s business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Sections 3(a)(1)(A) and (C) of the 1940 Act, a
company generally will be deemed to be an &#147;investment company&#148; for purposes of the 1940 Act if (i) it is, or holds itself out as being, engaged primarily, or proposes to engage primarily, in the business of investing, reinvesting or
trading in securities or (ii) it engages, or proposes to engage, in the business of investing, reinvesting, owning, holding or trading in securities and it owns or proposes to acquire investment securities having a value exceeding 40% of the value
of its total assets (exclusive of U.S. government securities and cash items) on an unconsolidated basis. It is not expected that Cibus, Inc. would be an &#147;investment company,&#148; as such term is defined in either of those sections of the 1940
Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt and Cibus regard the Combined Company, following the completion of the Transactions, to be a plant trait company. Calyxt and
Cibus believe that the Combined Company will be engaged primarily in the business of using gene editing technologies to develop and license gene edited plant traits that improve farming productivity or produce renewable low carbon plant products and
not in the business of investing, reinvesting or trading in securities. Calyxt and Cibus also believe the Combined Company&#146;s primary source of income will be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
properly characterized as income earned in exchange for products and services derived from such applications of the Combined Company&#146;s gene editing technologies. The Combined Company will
hold itself out as being engaged primarily in the plant trait business and does not propose to engage primarily in the business of investing, reinvesting or trading in securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As the sole managing member of Cibus Global, Cibus, Inc. will control and operate Cibus Global. It is intended that Cibus, Inc. and Cibus
Global will conduct their operations so that Cibus, Inc. will not be deemed an investment company. However, if Cibus, Inc. were to be deemed an investment company, restrictions imposed by the 1940 Act, including limitations on Cibus, Inc.&#146;s
capital structure and its ability to transact with affiliates, could make it impractical for Cibus, Inc. to continue its business as contemplated and could have a material adverse effect on the Combined Company&#146;s business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>In certain cases, the holders of Class&nbsp;B Common Stock will have the sole power to approve a reorganization of the Combined Company, resulting in
the Combined Company no longer being structured as an umbrella partnership C corporation. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of Class&nbsp;B Common Stock
have the sole power to vote on any merger, consolidation or conversion in connection with a reorganization of the <FONT STYLE="white-space:nowrap">Up-C</FONT> structure (an <FONT STYLE="white-space:nowrap">&#147;Up-C</FONT> Reorganization&#148;) or
any necessary amendment to the Amended Certificate of Incorporation in order to effect an <FONT STYLE="white-space:nowrap">Up-C</FONT> Reorganization. For purposes of this right of the holders of Class&nbsp;B Common Stock, an <FONT
STYLE="white-space:nowrap">Up-C</FONT> Reorganization means any transaction or series of transactions intended to result in the Combined Company no longer being structured as an umbrella partnership C corporation so long as (i)&nbsp;such transaction
or series of transactions does not have a material adverse effect on the rights or preferences of the Class&nbsp;A Common Stock (in the sole determination of the independent members of the Cibus, Inc. Board) and (ii)&nbsp;such transaction or series
of transactions shall not be treated as resulting in a &#147;Change of Control&#148; under the Tax Receivable Agreement. If the holders of Class&nbsp;B Common Stock were to approve an <FONT STYLE="white-space:nowrap">Up-C</FONT> Reorganization, such
decision could have an adverse effect on the trading price of the Combined Company&#146;s Class&nbsp;A Common Stock to the extent investors perceive a disadvantage in owning stock of a company that is no longer in an
<FONT STYLE="white-space:nowrap">Up-C</FONT> structure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>In the event that Cibus, Inc.&#146;s payment obligations under the Tax Receivable Agreement
are accelerated upon certain mergers, other forms of business combinations or other changes of control, the consideration payable to holders of Class&nbsp;A Common Stock could be substantially reduced. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Cibus, Inc. experiences a change of control (as defined under the Tax Receivable Agreement), its obligation to make a substantial, immediate
<FONT STYLE="white-space:nowrap">lump-sum</FONT> payment under the Tax Receivable Agreement could result in holders of Class&nbsp;A Common Stock receiving substantially less consideration in connection with a change of control transaction than they
would receive in the absence of such obligation. Further, holders of rights under the Tax Receivable Agreement may not have an equity interest in Cibus, Inc. Accordingly, the interests of holders of rights under the Tax Receivable Agreement may
conflict with those of the holders of Class&nbsp;A Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cibus, Inc. will not be reimbursed for any payments made under the Tax Receivable
Agreement in the event that any tax benefits are subsequently disallowed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payments under the Tax Receivable Agreement will be
based on the tax reporting positions that Cibus, Inc. will determine. The holders of rights under the Tax Receivable Agreement will not reimburse Cibus, Inc. for any payments previously made under the Tax Receivable Agreement if such basis increases
or other benefits are subsequently disallowed, except that excess payments made to any such holder will be netted against payments otherwise to be made, if any, to such holder after determination of such excess. However, a determination that Cibus,
Inc. has made an excess payment might not occur until a number of&nbsp;years after such payment has been made. Additionally, if any of Cibus, Inc.&#146;s tax reporting positions are challenged by a taxing authority, Cibus, Inc. will not
be&nbsp;permitted to reduce any future cash payments under the Tax Receivable Agreement until any such challenge is finally settled or determined. The applicable U.S.&nbsp;federal income tax rules for determining our
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
tax reporting positions are complex and factual in nature, and there can be no assurance that the IRS or a court will not disagree with our tax reporting positions. As a result, in such
circumstances, Cibus, Inc. could make payments that are greater than actual cash tax savings, if any, and may not be able to recoup those payments, which could adversely affect Cibus, Inc.&#146;s liquidity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom401831_13"></A>CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This proxy statement/prospectus contains forward-looking statements (including within the meaning of Section&nbsp;21E of the Exchange
Act and Section&nbsp;27A of the Securities Act) concerning, among other things, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that the conditions to the Closing of the proposed Transactions are not satisfied, including the failure
to obtain stockholder approval of the Calyxt Stockholder Matters in a timely manner or at all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">uncertainties as to the timing of the consummation of the proposed Transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks related to Calyxt&#146;s capital resources and the ability of Calyxt and Cibus, respectively, to correctly
estimate and manage their respective operating expenses and expenses associated with the proposed Transactions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks related to Calyxt&#146;s continued listing on the Nasdaq Capital Market until the Closing of the proposed
Transactions and Cibus, Inc.&#146;s ability to maintain the listing after Closing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks associated with the possible failure to realize certain anticipated benefits of the proposed Transactions,
including with respect to future financial and operating results; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">uncertainties regarding the impact that any delay in the Closing would have on the anticipated cash resources of
the Combined Company upon the Closing and other events and unanticipated spending and costs that could reduce the Combined Company&#146;s cash resources; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential for the occurrence of any event, change or other circumstance or condition that could give rise to
the termination of the Merger Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possible effect of the announcement, pendency or completion of the Mergers on Calyxt&#146;s or Cibus&#146;
business relationships, operating results and business generally; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential for unexpected costs related to the Mergers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential for, and uncertainty associated with the outcome of, any legal proceedings that have been and may
be instituted against Calyxt or Cibus or any of their respective directors or officers related to the Merger Agreement or the Transactions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks associated with the ability of Calyxt and Cibus to protect their respective intellectual property rights;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential for any Dilutive Issuances and the dilutive impacts thereof; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential impact of competitive responses to the proposed Transactions and changes in expected or existing
competition; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possibility that Calyxt, Cibus or the Combined Company may be adversely affected by other economic, business,
or competitive factors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks associated with the loss of key employees of Calyxt or Cibus; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks associated with changes in applicable laws or regulations and the potential impact of such changes on
Calyxt&#146;s, Cibus&#146; or the Combined Company&#146;s ability to advance product development and commercialization; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other risks and uncertainties identified from time to time in documents filed or to be filed with the SEC by
Calyxt, Inc. or Cibus, Inc. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These forward-looking statements should not be relied upon as predictions of future events
as Calyxt and Cibus cannot assure you that the events or circumstances reflected in these statements will be achieved or will occur. You can identify forward-looking statements by the use of forward-looking terminology including
&#147;believes,&#148; &#147;expects,&#148; &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;seeks,&#148; &#147;intends,&#148; &#147;plans,&#148; &#147;pro forma,&#148; &#147;estimates,&#148; or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
&#147;anticipates&#148; or the negative of these words and phrases or other variations of these words and phrases or comparable terminology. All statements other than statements of historical
fact are statements that could be deemed forward-looking statements. The events and circumstances reflected in forward-looking statements may not be achieved or occur and actual results could differ materially from those contained in any
forward-looking statement as a result of various factors, including, without limitation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Calyxt Stockholders and Cibus Unitholders may not realize a benefit from the Mergers commensurate with the
ownership dilution they will experience in connection with the Mergers, the Continuing Series F Financing, the Potential Calyxt Financing or any other Dilutive Issuance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Merger Consideration at the Closing of the Mergers may have a greater or lesser value than at the time the
Merger Agreement was signed; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to complete the Mergers may result in either Calyxt, Inc. or Cibus Global paying a termination fee to the
other party and could harm the future business and operations of each company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to complete the Mergers under certain circumstances may result in the Interim Funding being forgiven and
Cibus Global and the Cibus Unitholders losing the benefit from any funds that have been made available to Calyxt, Inc. prior to termination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the conditions to the Mergers are not met, including failure to obtain Calyxt Stockholder Approval, Cibus
Member Approval and Blocker Approvals for the Mergers, the Mergers will not occur; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Mergers may be completed even though material adverse changes may occur; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">some Calyxt, Inc. and Cibus Global executive officers and directors have interests in the Mergers that are
different from the Calyxt Stockholders and Cibus Unitholders and that may influence them to support or approve the Mergers without regard to the interests of the Calyxt Stockholders and Cibus Unitholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the market price of Class&nbsp;A Common Stock may decline following the Mergers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Calyxt Stockholders and Cibus Unitholders will have a reduced ownership and voting interest in, and will exercise
less influence over the management of, the Combined Company following the Closing as compared to their current ownership and voting interest in the respective companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">raising additional capital may cause dilution to Cibus, Inc.&#146;s stockholders, restrict the Combined
Company&#146;s operations or require the Combined Company to relinquish rights to its technologies or product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions in the Merger Agreement may prevent Calyxt, Inc. and Cibus Global from entering into a business
combination with another party at a favorable price; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain provisions of the Merger Agreement may discourage third parties from submitting alternative takeover
proposals, including proposals that may be superior to the Transactions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cibus Unitholders may receive consideration in the Mergers that is greater or less than the fair market value of
Cibus Units or Cibus Warrants due to the lack of a public market for Cibus Units; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the pro forma combined financial statements may not be an indication of the Combined Company&#146;s financial
condition or results of operations following the completion of the Transactions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Combined Company may fail to realize the anticipated benefits of the Transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the failure to successfully integrate the businesses and operations of Calyxt and Cibus in the expected time
frame may adversely affect the Combined Company&#146;s future results; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the future operating results of the Combined Company will suffer if the Combined Company does not effectively
manage its operations following the Transactions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the market price of the Class&nbsp;A Common Stock is expected to be volatile, and the market price of the
Class&nbsp;A Common Stock may drop following the Transactions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Combined Company may need to raise additional funding, which may not be available on acceptable terms or at
all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Combined Company&#146;s small public float, low market capitalization, limited operating history and lack of
revenue may make it difficult and expensive for the Combined Company to raise additional funds; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Combined Company will incur additional costs and increased demands upon management as a result of complying
with the laws and regulations affecting public companies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if Cibus, Inc. fails to maintain an effective system of internal control over financial reporting, Cibus, Inc.
may not be able to accurately report its financial results or prevent fraud; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provisions in the Amended Certificate of Incorporation, the Amended Bylaws or Delaware Law might discourage,
delay or prevent a change in control of Cibus, Inc. or changes in its management, which may depress the price of the Class&nbsp;A Common Stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an active trading market for the Class&nbsp;A Common Stock may not develop and holders of Class&nbsp;A Common
Stock may not be able to resell their Class&nbsp;A Common Stock for a profit, if at all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">after completion of the Transactions, the Combined Company&#146;s executive officers, directors and principal
stockholders will have the ability to control or significantly influence all matters submitted to Cibus, Inc.&#146;s stockholders for approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Combined Company will have broad discretion in the use of its cash and cash equivalents and may not use them
effectively; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in tax laws, treaties or regulations or adverse outcomes resulting from examination of tax returns,
and/or inability to qualify for tax treaty benefits, could adversely affect the Combined Company&#146;s financial results; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. net operating loss carryforwards and certain other tax attributes of Cibus, Inc. attributable to periods
preceding the Mergers are expected to be subject to limitations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if Cibus, Inc. were to be delisted from Nasdaq, it could reduce the visibility, liquidity and price of the
Class&nbsp;A Common Stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">securities analysts&#146; published reports could cause a decline in the price of the Class&nbsp;A Common Stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Calyxt and Cibus do not anticipate that Cibus, Inc. will pay any cash dividends in the foreseeable future; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">future sales of shares of Class&nbsp;A Common Stock into the market (including the Potential Calyxt Financing),
or the perception that these sales may occur, could cause the market price of Class&nbsp;A Common Stock to decline. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
foregoing risks should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere. Calyxt and Cibus can give no assurance that the conditions to the Mergers will be satisfied. For further
discussion of the factors that may cause Calyxt, Cibus or the Combined Company&#146;s actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied in such forward-looking
statements, or for a discussion of risks associated with the ability of Calyxt and Cibus to complete the Mergers and the effect of the Mergers on the business of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Calyxt, Cibus and the Combined Company, see the section entitled &#147;<I>Risk Factors</I>&#148; in this proxy statement/prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additional factors that could cause actual results to differ materially from those expressed in the forward-looking statements are discussed
in reports filed with the SEC by Calyxt, Inc. See the section entitled &#147;<I>Where You Can Find More Information</I>&#148; in this proxy statement/prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of these risks or uncertainties materialize or any of these assumptions prove incorrect, the results of operations of Calyxt, Cibus or
the Combined Company could differ materially from the forward-looking statements. All forward-looking statements in this proxy statement/prospectus are current only as of the date of this proxy statement/prospectus. Calyxt and Cibus do not undertake
any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any statement is made, the occurrence of unanticipated events or any new information that becomes available in the future.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom401831_14"></A>THE SPECIAL MEETING OF CALYXT STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Calyxt Special Meeting will be held virtually via live webcast at www.virtualshareholdermeeting.com/CLXT2023SM on May 18, 2023 at
9:00&nbsp;a.m. Central Time. Calyxt, Inc. is sending this proxy statement/prospectus to Calyxt Stockholders in connection with the solicitation of proxies by the Calyxt Board for use at the Calyxt Special Meeting and any adjournments or
postponements of the Calyxt Special Meeting. This proxy statement/prospectus is first being furnished to Calyxt Stockholders on or about April 18, 2023. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Purposes of the Calyxt Special Meeting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purposes of the Calyxt Special Meeting are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to consider and vote upon a proposal to approve the Blocker Mergers and the issuance of Class&nbsp;A Common
Stock and Class&nbsp;B Common Stock as Merger Consideration pursuant to the Merger Agreement, as amended by the First Amendment, copies of which are attached as <I>Annex A-1 </I>and <I>Annex&nbsp;A-2</I>, respectively, to this proxy
statement/prospectus; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to consider and vote upon a proposal to approve, for purposes of Nasdaq Listing Rule 5635(a) and (b), the
issuance of shares of Class&nbsp;A Common Stock and Class&nbsp;B Common Stock pursuant to the terms of the Merger Agreement and the change of control of Calyxt resulting from the Mergers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to consider and vote upon, on a non-binding, advisory basis, a proposal to approve the Amended Certificate of
Incorporation, a copy of which is attached as <I>Annex B </I>to this proxy statement/prospectus, which will amend and restate the Calyxt Certificate of Incorporation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to consider and vote upon a proposal to approve an amendment to the Calyxt Certificate of Incorporation to
effect the Subsequent Reverse Stock Split at the discretion of the Calyxt Board, a copy of which is attached as <I>Annex J</I> to this proxy statement/prospectus, at the discretion of the Calyxt Board at or prior to Closing; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to consider and vote upon a proposal to approve an amendment to the Calyxt, Inc. 2017 Omnibus Incentive Plan;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to consider and vote upon, on a <FONT STYLE="white-space:nowrap">non-binding,</FONT> advisory basis, a proposal
to approve merger-related named executive officer compensation for Calyxt, Inc.&#146;s named executive officers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to consider and vote upon a proposal to approve an adjournment of the Calyxt Special Meeting, if necessary, to
solicit additional proxies if there are not sufficient votes in favor of one or more of the proposals presented to Calyxt Stockholders; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to transact such other business as may properly come before the Calyxt Special Meeting or any adjournment or
postponement thereof. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Recommendation of the Calyxt Board </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Calyxt Board has determined that it is fair to, advisable and in the best interests of Calyxt and Calyxt
Stockholders to approve the Blocker Mergers and the issuance of Class&nbsp;A Common Stock and Class&nbsp;B Common Stock as Merger Consideration pursuant to the Merger Agreement and has approved such proposal. The Calyxt Board unanimously recommends
that Calyxt Stockholders vote &#147;FOR&#148; Proposal No.&nbsp;1 to approve the Blocker Mergers and the issuance of Class&nbsp;A Common Stock and Class&nbsp;B Common Stock as Merger Consideration pursuant to the Merger Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Calyxt Board has determined that it is fair to, advisable and in the best interests of Calyxt and Calyxt
Stockholders to approve, for purposes of Nasdaq Listing Rule 5635(a) and (b), the issuance of shares of Class&nbsp;A Common Stock and Class&nbsp;B Common Stock pursuant to the terms of the Merger Agreement and the change of control of Calyxt
resulting from the Mergers and has approved such proposal. The Calyxt Board unanimously recommends that Calyxt Stockholders vote &#147;FOR&#148; Proposal </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
No.&nbsp;2 to approve, for purposes of Nasdaq Listing Rule 5635(a) and (b), the issuance of shares of Class&nbsp;A Common Stock and Class&nbsp;B Common Stock pursuant to the terms of the Merger
Agreement and the change of control of Calyxt resulting from the Mergers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Calyxt Board has determined that it is fair to, advisable and in the best interests of Calyxt and Calyxt
Stockholders to approve the Amended Certificate of Incorporation, which will amend and restate the Calyxt Certificate of Incorporation, and has approved such proposal; provided, that for the avoidance of doubt, this vote will be non-binding and
advisory in nature given the Amended Certificate of Incorporation will automatically become the certificate of incorporation of Cibus, Inc. upon consummation of the First Blocker Merger pursuant to the applicable provisions of Delaware Law. The
Calyxt Board unanimously recommends that Calyxt Stockholders vote &#147;FOR&#148; Proposal No.&nbsp;3 to approve the Amended Certificate of Incorporation, which will amend and restate the Calyxt Certificate of Incorporation, as described in this
proxy statement/prospectus; provided, that for the avoidance of doubt, this vote will be non-binding and advisory in nature given the Amended Certificate of Incorporation will automatically become the certificate of incorporation of Cibus, Inc. upon
consummation of the First Blocker Merger pursuant to the applicable provisions of Delaware Law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Calyxt Board has determined that it is fair to, advisable and in the best interests of Calyxt and Calyxt
Stockholders to approve an amendment to the Calyxt Certificate of Incorporation to effect the Subsequent Reverse Stock Split at the discretion of the Calyxt Board, and has approved such proposal. The Calyxt Board unanimously recommends that Calyxt
Stockholders vote &#147;FOR&#148; Proposal No.&nbsp;4 to approve an amendment to the Calyxt Certificate of Incorporation to effect the Subsequent Reverse Stock Split at the discretion of the Calyxt Board, as described in this proxy
statement/prospectus. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Calyxt Board has determined that it is fair to, advisable and in the best interests of Calyxt and Calyxt
Stockholders to approve an amendment to the Calyxt, Inc. 2017 Omnibus Incentive Plan, and has approved such proposal. The Calyxt Board unanimously recommends that Calyxt Stockholders vote &#147;FOR&#148; Proposal No.&nbsp;5 to approve an amendment
to the Calyxt, Inc. 2017 Omnibus Incentive Plan, as described in this proxy statement/prospectus. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Calyxt Board has determined that it is fair to, advisable and in the best interests of Calyxt and Calyxt
Stockholders to approve, on a <FONT STYLE="white-space:nowrap">non-binding,</FONT> advisory basis, merger-related named executive officer compensation for Calyxt&#146;s named executive officers and has approved such proposal. The Calyxt Board
unanimously recommends that Calyxt Stockholders vote &#147;FOR&#148; Proposal No.&nbsp;6 to approve, on a <FONT STYLE="white-space:nowrap">non-binding,</FONT> advisory basis, merger-related named executive officer compensation for Calyxt&#146;s
named executive officers, as described in this proxy statement/prospectus. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Calyxt Board has determined that it is fair to, advisable, and in the best interests of Calyxt and Calyxt
Stockholders to approve the adjournment of the Calyxt Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of one or more of the proposals presented to Calyxt Stockholders and has approved such
proposal. The Calyxt Board unanimously recommends that Calyxt Stockholders vote &#147;FOR&#148; Proposal No.&nbsp;7 to adjourn the Calyxt Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of one
or more of the proposals presented to Calyxt Stockholders. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Record Date and Voting Power </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only holders of record of Calyxt Common Stock at the close of business on the record date, April 12, 2023, are entitled to notice of, and to
vote at, the Calyxt Special Meeting. There were 90 holders of record of Calyxt Common Stock at the close of business on the record date. At the close of business on the record date, 49,735,490 shares of Calyxt Common Stock were issued and
outstanding. Each share of Calyxt Common Stock entitles the holder thereof to one vote on each matter submitted for stockholder approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting and Revocation of Proxies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The proxy accompanying this proxy statement/prospectus is solicited on behalf of the Calyxt Board for use at the Calyxt Special Meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you are the &#147;record holder&#148; of your shares, meaning that you own your shares in your own name and not through a broker, bank or
other nominee, you may vote in one of three ways prior to the Calyxt Special Meeting: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>You may vote over the internet.</I> You may vote your shares by following the instructions in the enclosed
proxy card. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>You may vote by telephone.</I> You may vote your shares by following the instructions in the enclosed proxy
card. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>You may vote by mail.</I> You may vote your shares by completing, dating and signing the enclosed proxy card
and promptly mailing it in the postage-paid envelope provided. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may also vote during the Calyxt Special Meeting. To
attend the Calyxt Special Meeting, you will need the 16-digit control number that is printed in the box marked by the arrow on your proxy card. Calyxt, Inc. recommends that you log in starting 15 minutes before the Calyxt Special Meeting to ensure
that you are logged in when the meeting starts. Online access will begin at 8:45 a.m. Central Time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All proxies that are executed or are
otherwise submitted over the internet or by telephone will be voted on the matters set forth in this proxy statement in accordance with the stockholders&#146; instructions. However, if no choice is specified on a proxy as to one or more of the
proposals, the proxy will be voted in accordance with the Calyxt Board&#146;s recommendations on such proposals as set forth in this proxy statement/prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After you have submitted a proxy, you may still change your vote and revoke your proxy by doing any one of the following things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submitting a new proxy via the internet or telephone by following the instructions on the enclosed proxy card;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">signing another proxy card and arranging for delivery of that proxy card by mail by 11:59 p.m., Central Time, the
day before the Calyxt Special Meeting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">giving Calyxt, Inc.&#146;s Corporate Secretary a written notice before the Calyxt Special Meeting that you want
to revoke your proxy; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">voting during the Calyxt Special Meeting. Your attendance at the Calyxt Special Meeting alone will not revoke a
previously submitted proxy. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt, Inc. will count your vote in accordance with the last instruction Calyxt, Inc.
receives from you prior to the closing of the polls, whether your instruction is received by internet, telephone, mail, or at the Calyxt Special Meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Shares Held in &#147;Street Name&#148; </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the shares of Calyxt Common Stock you own are held in &#147;street name&#148; by a broker, bank or other nominee, then that broker, bank or
other nominee, as the record holder of your shares of Calyxt Common Stock, is required to vote your shares of Calyxt Common Stock according to your instructions. In order to vote your shares of Calyxt Common Stock, change your vote or revoke your
instructions, you will need to follow the directions your broker, bank or other nominee provides you. Many brokers, banks or other nominees also offer the option of providing for voting over the internet or by telephone, instructions for which, if
available, would be provided by such broker, bank or other nominee on the voting instruction form that it delivers to you. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you do not
give instructions to your broker, bank or other nominee, such nominee can vote your shares of Calyxt Common Stock with respect to &#147;discretionary&#148; items but not with respect to
<FONT STYLE="white-space:nowrap">&#147;non-discretionary&#148;</FONT> items. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Discretionary items are proposals considered routine under certain rules applicable to brokers and on which your broker may vote shares of Calyxt Common Stock held in &#147;street name&#148; in
the absence of your voting instructions. On <FONT STYLE="white-space:nowrap">non-discretionary</FONT> items for which you do not give your broker instructions, your shares of Calyxt Common Stock will be treated as broker <FONT
STYLE="white-space:nowrap">non-votes.</FONT> It is anticipated that Proposal Nos. 1, 2, 3, 5 and 6 will be <FONT STYLE="white-space:nowrap">non-discretionary.</FONT> To make sure that your vote is counted, you should instruct your broker to vote
your shares, following the procedures provided by the institution that holds your shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If your shares are held in &#147;street
name,&#148; you are also invited to attend and vote your shares of Calyxt Common Stock at the Calyxt Special Meeting live via webcast. To attend the Calyxt Special Meeting, you will need the 16-digit control number that is printed in the box marked
by the arrow on your proxy card. Calyxt, Inc. recommends that you log in starting 15 minutes before the Calyxt Special Meeting to ensure that you are logged in when the meeting starts. Online access will begin at 8:45 a.m. Central Time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If your shares of Calyxt Common Stock are held in &#147;street name,&#148; you must follow the instructions provided by your broker, bank or
other nominee to revoke your voting instructions, or, if you have obtained a legal proxy to vote your shares of Calyxt Common Stock at the Calyxt Special Meeting, by attending the Calyxt Special Meeting and voting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Required Vote </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The presence, in person or
represented by proxy, of Calyxt Stockholders holding at least a majority in voting power of the shares of Calyxt Common Stock issued and outstanding and entitled to vote at the Calyxt Special Meeting is necessary to constitute a quorum at the Calyxt
Special Meeting. Abstentions and broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will be treated as shares present for the purpose of determining the presence of a quorum for the transaction of business at the Calyxt Special Meeting.
Approval of Proposal Nos. 2 and 5 requires the affirmative vote of a majority of the votes cast and entitled to vote on the subject matter. Approval of Proposal Nos. 6 (on an advisory basis) and 7 requires the affirmative vote of a majority of the
votes cast affirmatively or negatively by holders present or represented by proxy at the Calyxt Special Meeting and entitled to vote on the subject matter. Approval of Proposals No.&nbsp;1, 3 (on an advisory basis) and 4 require the affirmative vote
of the holders of a majority of Calyxt Common Stock on the record date for the Calyxt Special Meeting entitled to vote on the subject matter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Votes will be counted by the inspector of election appointed for the Calyxt Special Meeting, who will separately count &#147;FOR&#148; and
&#147;AGAINST&#148; votes, abstentions and broker <FONT STYLE="white-space:nowrap">non-votes.</FONT> Abstentions and broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will have the same effect as a vote &#147;AGAINST&#148; Proposals
No.&nbsp;1 and 3, but will have no effect on the outcome of Proposal Nos. 2, 5 and 6. Abstentions will have the same effect as a vote &#147;AGAINST&#148; Proposal No. 4. Abstentions will have no effect on the outcome of Proposal No. 7. Proposal Nos.
4 and 7 are matters on which Calyxt expects brokers, banks or other nominees to have discretionary authority to vote uninstructed shares and, therefore, broker <FONT STYLE="white-space:nowrap">non-votes</FONT> are not expected with respect to these
proposals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Proposal No.&nbsp;1 is conditioned upon the approval of Proposal No.&nbsp;2, and the Mergers cannot be consummated without the
approval of Proposal Nos. 1 and 2. Proposal Nos. 3 and 6, which are non-binding and advisory in nature, are conditioned upon the approval of Proposal Nos. 1 and 2. Proposal Nos. 4, 5 and 7 are not conditioned on the approval of any other proposal.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Solicitation of Proxies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition
to solicitation by mail, the directors, officers, employees and agents of Calyxt and Cibus may solicit proxies from Calyxt Stockholders by personal interview, telephone or otherwise. Calyxt and Cibus will
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
share equally the cost of printing and filing this proxy statement/prospectus and the proxy card. Calyxt also may be required to reimburse brokers, banks and other custodians, nominees and
fiduciaries or their respective agents for reasonable expenses incurred in forwarding proxy materials to beneficial owners of Calyxt Common Stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Matters </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this
proxy statement/prospectus, the Calyxt Board does not know of any business to be presented at the Calyxt Special Meeting other than as set forth in the notice accompanying this proxy statement/prospectus. If any other matters should properly come
before the Calyxt Special Meeting, it is intended that the shares of Calyxt Common Stock represented by proxies will be voted with respect to such matters in accordance with the judgment of the persons voting the proxies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom401831_15"></A>THE MERGERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This section and the section entitled &#147;The Merger Agreement&#148; in this proxy statement/prospectus describe the material aspects of
the Transactions, including the Merger Agreement. While Calyxt and Cibus believe that this description covers the material terms of the Transactions and the Merger Agreement, it may not contain all of the information that is important to you. You
should read carefully this entire proxy statement/prospectus for a more complete understanding of the Transactions and the Merger Agreement, including the Merger Agreement, as amended by the First Amendment, copies of which are attached as Annex A-1
and Annex A-2, respectively, and the other documents to which you are referred herein. See the section entitled &#147;Where You Can Find More Information&#148; on page 365 of this proxy statement/prospectus. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom401831_16"></A>Background of the Mergers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In an effort to enhance stockholder value, the Calyxt Board, in consultation with members of the Calyxt management team, regularly reviews and
discusses Calyxt&#146;s business, capital resources and funding needs and near and long-term operating and strategic priorities, opportunities and challenges. As part of these regular reviews and the Calyxt Board&#146;s consideration of the
additional capital required to fund Calyxt&#146;s business plan, in May 2019 the Calyxt Board formed a strategic alternatives review committee to conduct a review of Calyxt&#146;s strategic alternatives. This committee retained independent
financial, legal and industry advisors and conducted a detailed review of Calyxt&#146;s business plan, funding needs and strategic alternatives, including potential strategic transactions and financings. As part of this process, through August 2020
the strategic alternatives review committee with the assistance of its financial advisor and management, contacted 19 potential counterparties, five of which executed confidentiality agreements and received
<FONT STYLE="white-space:nowrap">non-public</FONT> diligence materials and presentations. All confidentiality agreements containing a standstill provision provided the standstill would automatically terminate if Calyxt publicly announced that it had
entered into a definitive agreement relating to a strategic transaction or financing. None of these discussions with potential counterparties resulted in any actionable proposals for a strategic transaction or financing. In addition, during this
time period strategic alternatives review committee&#146;s financial advisor contacted an additional six potential counterparties to assess their interest in a potential private investment in public equity, or PIPE investment, in Calyxt, and none of
these discussions proceeded beyond preliminary exploratory stages. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based in part on feedback received during the strategic transaction
review process, in August 2020 the Calyxt Board approved a revised business plan for Calyxt that streamlined its business model to focus on three <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">go-to-market</FONT></FONT>
strategies: technology licensing arrangements, trait and product licensing arrangements, and seed sales to agricultural processors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the remainder of 2020 and the first three quarters of 2021, Calyxt sought to execute on this new business model and raise additional
capital. Despite repeated fundraising attempts during this period, Calyxt experienced substantial fundraising challenges and had only limited success in raising additional capital, raising approximately $15.0&nbsp;million of gross proceeds in a
registered direct offering of common stock in October 2020, with Cellectis, Calyxt&#146;s largest shareholder, as the anchor with a $5.0&nbsp;million investment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In response to feedback from potential investors during these fundraising efforts, the Calyxt Board directed further revisions to the Calyxt
business plan and a strategic initiative focused on engineering synthetic biology solutions for a diversified base of customers across an expanded group of end markets, which was announced in October 2021. Calyxt sought to execute on this further
revised business model and continued to seek additional financing. However, Calyxt continued to experience substantial fundraising challenges and through the end of the first quarter of 2022 had only raised an additional approximately
$10.0&nbsp;million of net proceeds in a registered direct offering of common stock in February 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;5, 2022, the Calyxt
Board held a meeting at which, among other things, Calyxt management reviewed with the Calyxt Board Calyxt&#146;s technology advancements, business development activities, capital resources and funding needs, current and anticipated financing market
conditions, and the feedback received </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
from market participants and potential financing sources in connection with Calyxt&#146;s prior strategic review and fundraising efforts. At the invitation of the Calyxt Board, representatives of
Cellectis attended this meeting and provided their perspectives and feedback. At the conclusion of this meeting the Calyxt Board determined to commence a new strategic alternatives review process. At this meeting, and from time to time after this
meeting continuing through the January&nbsp;13, 2023 Calyxt Board meeting at which the Merger Agreement was approved, representatives of Cellectis attended portions of Calyxt Board meetings at the request of the Calyxt Board in order to provide
Cellectis&#146;s perspectives and feedback. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In a series of meetings in April and May 2022, the Calyxt Board formed a strategic
alternatives review committee (the &#147;Calyxt Committee&#148;) consisting of four members: Ms.&nbsp;Kozicz, Ms.&nbsp;Nelson, Mr.&nbsp;Neugent, and Dr.&nbsp;Ribeill, with Mr.&nbsp;Neugent appointed as chair of the Calyxt Committee, to oversee the
strategic transactions review process and make recommendations to the Calyxt Board with respect to potential strategic transactions. In addition, after interviewing a number of potential financial and legal advisors, and confirming no conflicts of
interest would prevent fulfillment of their obligations as advisors to the Calyxt Committee, the Committee retained Canaccord Genuity LLC as its independent financial advisor (&#147;Canaccord Genuity&#148;) and Sidley Austin LLP as its independent
legal advisor (&#147;Sidley&#148;), and the Calyxt Committee directed management to provide an updated financial model and seven-year financial projections for Calyxt to the Calyxt Committee and its advisors. As part of the strategic transaction
review process, the Calyxt Committee from time to time identified, analyzed and monitored actual or potential conflicts of interest that could arise in connection with potential strategic transactions, including actual or potential conflicts of
interest of each of Cellectis and management, and such matters were discussed as part of executive sessions that the Calyxt Committee and the Calyxt Board regularly held during portions of their respective meetings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;10, 2022, the Calyxt Committee met with Calyxt management and Sidley. At this meeting, among other things, management provided an
update on Calyxt&#146;s business development activities, cash position and funding needs and reviewed and discussed with the Calyxt Committee the seven-year financial model and projections that had been previously circulated by management. The
Calyxt Committee provided feedback to management on the seven-year model and projections and subsequently directed the Calyxt Committee&#146;s financial advisors to utilize the seven-year model and projections, as updated to reflect the Calyxt
Committee&#146;s feedback, for purposes of its analysis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;24, 2022, the Calyxt Committee held a meeting at which members of
management, representatives from Canaccord Genuity, and a representative from Sidley were present. Representatives from Canaccord Genuity reviewed and discussed their preliminary financial analysis of Calyxt utilizing the previously approved
financial projections. Calyxt management discussed with the Calyxt Committee an unsolicited financing proposal from a potential investor received after the June&nbsp;10, 2022 Calyxt Committee meeting. The proposed investment structure was not
permitted by the terms of Calyxt&#146;s most recent financing until late August 2022. Given the then current market environment and proposed investment terms, the Calyxt Committee determined that it was not in the best interest of the stockholders
to pursue the unsolicited proposal at that time. The Calyxt Committee further discussed with Canaccord Genuity the nature of the market outreach to be conducted by Canaccord Genuity as part of the strategic alternatives review process and the
importance of maximizing value and certainty for Calyxt Stockholders. At the meeting, the Calyxt Committee unanimously approved commencing the market outreach process and directed Canaccord Genuity to begin outreach. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Calyxt Board met on June&nbsp;29, 2022 with members of Calyxt management and representatives from Sidley present, and the Calyxt Committee
and its advisors reviewed and discussed with the Calyxt Board the status of the strategic alternatives review process, including the list of potential strategic transaction counterparties to be contacted, certain potential interim financings that
could be explored in an effort to extend Calyxt&#146;s cash runway, and current and anticipated conditions in the capital markets and the biotechnology industry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beginning in July 2022, Canaccord Genuity conducted outreach to 33 potential strategic transaction counterparties. Calyxt entered into
confidentiality agreements with nine potential counterparties and six potential </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
counterparties participated in meetings with Calyxt management. All confidentiality agreements containing a standstill provision provided the standstill would automatically terminate if Calyxt,
Inc. publicly announced that it had entered into a definitive agreement relating to a strategic transaction or financing. Calyxt management regularly updated members of the Calyxt Committee and other directors regarding the status of these outreach
efforts, and representatives of Canaccord Genuity provided updates on the status of these outreach efforts to Calyxt periodically, with Calyxt management providing an update at a Calyxt Board meeting on August&nbsp;2, 2022 and Canaccord Genuity
providing an update at a Committee meeting on August&nbsp;31, 2022, and Calyxt management and Sidley participated in each of these sessions. At these meetings Canaccord Genuity and Calyxt management provided preliminary feedback from potential
counterparties, including that most of the potential counterparties were not interested in pursuing discussions with Calyxt regarding potential strategic transactions. In response, members of the Calyxt Committee and other directors, with the
assistance of Canaccord Genuity and Calyxt management, sought to identify additional potential counterparties that could be contacted. As part of these discussions, the Calyxt Board authorized individual directors to contact potentially interested
third parties in order to assess their potential level of interest in a strategic transaction or other investment involving Calyxt. Over the course of the next several weeks individual directors contacted a number of potential transaction
counterparties or investors, but ultimately none expressed interest in pursuing a strategic transaction with or other investment in Calyxt. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&nbsp;19, 2022, representatives of Cibus conducted an onsite visit to Calyxt&#146;s headquarters in which they received a tour of
Calyxt&#146;s facilities and the parties discussed common interests in their respective fields. The visit occurred in the ordinary course of Calyxt&#146;s business development activities and was not part of Calyxt&#146;s strategic alternatives
review process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August of 2022, Mr.&nbsp;Rory Riggs, Chairman and Chief Executive Officer of Cibus, had a dinner with Jonathan
Fassberg, a member of the Calyxt Board. While Calyxt&#146;s ongoing pursuit of strategic alternatives was not discussed, the two discussed, among other things, their respective companies&#146; common histories and the development of the underlying
science in the industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;7, 2022, Cibus and Calyxt entered into a mutual confidentiality and <FONT
STYLE="white-space:nowrap">non-disclosure</FONT> agreement with customary <FONT STYLE="white-space:nowrap">18-month</FONT> <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and <FONT STYLE="white-space:nowrap">12-month</FONT> standstill
provisions. Following execution of the mutual <FONT STYLE="white-space:nowrap">non-disclosure</FONT> agreement, each of Cibus and Calyxt provided the other party with limited <FONT STYLE="white-space:nowrap">non-public</FONT> diligence information.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the period commencing in September 2022 through the execution of the Merger Agreement on January&nbsp;13, 2023, each of Cibus and
Calyxt continued to conduct their respective business and financial due diligence investigations of the other company and its business, with the assistance of the respective advisors of Cibus and Calyxt, including various subject matter specific due
diligence conference calls. In addition to customary due diligence regarding finance, legal, tax, accounting, environmental, human resources, operations and related matters, the parties focused significant effort on the identification and validation
of potential cost synergies and understanding each party&#146;s financial plan and the achievability of such synergies by the Combined Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;12, 2022, the Calyxt Board met with Calyxt management and representatives from Ballard Spahr LLP, Calyxt&#146;s outside
counsel (&#147;Ballard Spahr&#148;). The Calyxt Board discussed multiple topics, including discussions regarding scenario planning in the event no strategic transaction or financing alternatives were available to Calyxt. The members of the Calyxt
Committee present directed Calyxt management to have Canaccord Genuity expedite soliciting bids from potential strategic transaction counterparties and to concurrently seek interim financing proposals from potential structured financing sources. In
light of, among other things, Calyxt&#146;s funding needs and limited capital resources, the Calyxt Board determined (with the members of the Calyxt Committee unanimously agreeing) that it would be appropriate for the whole Calyxt Board to take a
more active role in the strategic transaction review process and for the members of the Calyxt Committee and the Calyxt Committee&#146;s advisors to participate directly in those discussions. Following this meeting, Canaccord
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Genuity sent a process letter to potential counterparties requesting that interested counterparties provide written indications of interest by September&nbsp;29, 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Calyxt Board met on September&nbsp;21, 2022, at which Calyxt management and representatives from Ballard Spahr and Sidley attended.
Management updated the Calyxt Board on Calyxt&#146;s funding needs, cash runway, expense management initiatives, and the status of discussions with potential investors regarding potential financing transactions, and Calyxt management noted that
Calyxt would likely need to include a going concern qualification in its third quarter 2022 financial statements. The Calyxt Board also reviewed the status of discussions with potential strategic transaction counterparties, including a discussion of
the limited interest expressed at that time by potential counterparties, Calyxt&#146;s ability to successfully complete a transaction with the potentially interested counterparties, and the range of strategic alternatives potentially available to
Calyxt, including structured financings, strategic transactions, and potential dissolution of Calyxt. After further discussion, including a discussion of actions that could be taken to seek to ensure that all potential counterparties interested in a
potential strategic transaction and reasonably capable of executing one had been contacted, the Calyxt Board determined it was in the best interest of the stockholders to publicly announce the strategic alternatives review process. On
September&nbsp;22, 2022, Calyxt announced that it was evaluating strategic alternatives to maximize stockholder value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
September&nbsp;28, 2022, the Calyxt Board met with Calyxt management and outside counsel to discuss Calyxt&#146;s strategic alternatives and related matters. First, Calyxt management reviewed Calyxt&#146;s cash burn, cash balance and expense
reduction efforts. Then, in executive session without management, the Calyxt Board discussed alternatives for Calyxt in the event that no indications of interest were received and no financing alternatives materialized, including potential
dissolution of Calyxt if all higher value alternatives were exhausted. The Calyxt Board noted that in light of Calyxt&#146;s cash position and payment obligations, it was unlikely that cash would be available for distributions to stockholders in a
dissolution and liquidation of Calyxt. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From September&nbsp;29, 2022 to October&nbsp;3, 2022, Cibus and three other potential
counterparties, referred to as Company A, Company B, and Company C, submitted written <FONT STYLE="white-space:nowrap">non-binding</FONT> indications of interest with respect to a potential strategic or financing transaction with Calyxt as described
below: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The indication of interest from Cibus proposed a reverse merger transaction with the proposed ownership split and
valuation to be determined. Cibus&#146; proposal included a requirement that Cibus must have closed on an additional financing round prior to the closing of the proposed transaction and that all executive officers and directors of Calyxt would be
replaced by individuals designated by Cibus. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The indication of interest from Company A, a company that was not listed on a stock exchange, proposed a series
of transactions that would split Calyxt into two companies as follows: (a)&nbsp;Cellectis would sell its shares in Calyxt to Company A for $2.5&nbsp;million cash and a $1.5&nbsp;million promissory note; (b)&nbsp;Calyxt would contribute its operating
business to a wholly-owned subsidiary of Calyxt but retain ownership of all patents and related intellectual property rights and enter into a royalty-free license with the new subsidiary for such retained rights; (c)&nbsp;the new Calyxt subsidiary
would be distributed in a <FONT STYLE="white-space:nowrap">tax-free</FONT> <FONT STYLE="white-space:nowrap">split-off</FONT> to all Calyxt stockholders (other than Company&nbsp;A and certain other stockholders) and the newly-spun off entity would
then be merged (in a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">stock-for-stock</FONT></FONT> reverse merger transaction) into an OTC company to be subsequently identified with the proposed ownership split and valuation to be
determined; and (d)&nbsp;Calyxt would merge into Company A in a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">stock-for-stock</FONT></FONT> merger with the proposed ownership split and valuation to be determined.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The indication of interest from Company B, an institutional investor, was for a capital investment in Calyxt. The
total proposed investment was $3.8&nbsp;million in the form of monthly share subscription over 12 months. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The indication of interest from Company C, an institutional investor, was for a capital investment in Calyxt. The
total proposed investment was $3.25&nbsp;million in convertible notes and warrants by investors. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt, Inc. entered into a customary non-disclosure agreement with Company&nbsp;A (which
contained a standstill provision provided the standstill would automatically terminate if Calyxt, Inc. publicly announced that it had entered into a definitive agreement relating to a strategic transaction or financing). Calyxt, Inc. did not enter
into any non-disclosure agreements with Company&nbsp;B or Company&nbsp;C. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;6, 2022, the Calyxt Board and Calyxt Committee
held a joint meeting at which Calyxt management and representatives from Canaccord Genuity and Sidley were present. Mr.&nbsp;Godard attended portions of this meeting. Representatives from Canaccord Genuity reviewed and discussed with the Calyxt
Board and the Calyxt Committee the status of outreach efforts and feedback from potential counterparties, including the four <FONT STYLE="white-space:nowrap">non-binding</FONT> indications of interest received to date. The Calyxt Board and the
Calyxt Committee reviewed and discussed the risks and potential benefits of all four proposals, including the lack of specificity as to the value to be received by Calyxt&#146;s unaffiliated stockholders in, and substantial uncertainty as to
Calyxt&#146;s ability to complete and timing of, the first two proposals and the small size and unattractive financing terms of the latter two proposals. Following discussion and deliberation, the Calyxt Board and the Calyxt Committee each
determined that Calyxt should continue to explore a potential strategic transaction with each of Cibus and Company A on an expedited basis and continue to seek to identify additional potential counterparties that could be interested in and
reasonably capable of executing a strategic transaction, while at the same time preparing for an orderly dissolution and winding up of Calyxt. The Calyxt Board and the Calyxt Committee also each determined not to further engage with Company B or
Company C as the Calyxt Board and the Calyxt Committee believed that the proposed financing terms were very unattractive and that neither transaction would meaningfully increase Calyxt&#146;s funding runway, meaningfully enhance Calyxt&#146;s
ability to execute on its business plan or meaningfully increase Calyxt&#146;s ability to identify a strategic alternative that would be more beneficial to Calyxt and its stockholders than an orderly dissolution and liquidation of Calyxt. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;12, 2022, the Calyxt Committee held a meeting that Calyxt management and representatives from Sidley attended and discussed
with the Calyxt Committee the status of the strategic transaction review process and Calyxt&#146;s strategic alternatives, including a potential dissolution and liquidation of Calyxt. Immediately following the Calyxt Committee meeting, the Calyxt
Board held a meeting that Calyxt management, Mr.&nbsp;Godard and representatives from Sidley attended to discuss, among other things, Calyxt&#146;s recent business development activities, the status of the discussions with potential counterparties,
including the status of discussions with each of Cibus and Company A and the due diligence meetings and information exchanged with each of them, and Calyxt&#146;s liquidity position, expense control initiatives, potential sources of liquidity and
fundraising efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;19, 2022, the Calyxt Board met with Calyxt management and representatives from Canaccord Genuity and
Sidley present. Among other things, the Calyxt Board reviewed the list of potential counterparties and the status of discussions with Cibus and, Company A, including a detailed discussion of the proposals from each of Cibus and Company A. As part of
this discussion, the Calyxt Board discussed with management and the representatives of Canaccord Genuity the business and prospects of Cibus, Canaccord Genuity&#146;s preliminary financial analysis of Cibus, key financial terms of a potential
transaction with Cibus, Cibus&#146; liquidity position, anticipated funding needs and ongoing financing activities, the status of Calyxt&#146;s diligence review of Cibus and proposed due diligence workplan and potential transaction timelines. The
Calyxt Board also discussed with management and representatives of Sidley Calyxt&#146;s liquidity position, funding needs and potential financing sources and the potential process, funding needs and timelines for an orderly dissolution and
liquidation of Calyxt. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;24, 2022, Calyxt management and Cibus management held a videoconference to discuss the terms of a
potential transaction as well as preliminary financial and legal due diligence matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;26, 2022, the Calyxt Board met
with Calyxt management with representatives from Canaccord Genuity, representatives from Sidley and Mr.&nbsp;Godard present. Among other things, the Calyxt Board reviewed the status of the discussions with Cibus, Company A and other potentially
interested transaction counterparties </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and discussed in detail Cibus&#146; business model and Cibus liquidity position, financing needs and ongoing fundraising efforts. In addition, the Calyxt Board discussed with Calyxt management,
Canaccord Genuity and Sidley the potential terms for a reverse merger with Cibus, including the potential pro forma ownership levels of the Calyxt Stockholders of the Combined Company, and provided negotiating direction to Calyxt management and
Canaccord Genuity for further discussions with Cibus. The Calyxt Board also reviewed Calyxt&#146;s current and anticipated liquidity position, expense control initiatives and potential financing sources, and discussed the process and potential
timelines for a potential orderly dissolution and liquidation of Calyxt and the potential challenges and benefits involved, and the Calyxt Board directed Calyxt management to provide a briefing to Cellectis regarding the status of Calyxt&#146;s
strategic transaction review process and possibility for an orderly dissolution and liquidation of Calyxt. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;31, 2022,
Cibus sent a revised <FONT STYLE="white-space:nowrap">non-binding</FONT> letter of intent with an ascribed valuation of Calyxt of $30.0&nbsp;million and an ascribed valuation of Cibus to be based on the price to be paid in Cibus&#146; ongoing equity
financing round, with an implied ownership interest in the Combined Company of approximately 5.0% for existing Calyxt Stockholders. Cibus&#146; proposal also contemplated a $100.0&nbsp;million financing by Cibus closing condition prior to Cibus
being required to consummate the transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;2, 2022, the Calyxt Board met with Calyxt management and representatives
from Canaccord Genuity and Sidley and discussed a number of topics, including the status of the strategic alternatives review, ongoing discussions with Company A and Cibus and other potentially interested transaction counterparties, the terms of the
Cibus proposal, key risks and negotiating points relating to the Cibus proposal, including the pro forma ownership of the Combined Company to be held by Calyxt Stockholders, the status of Cibus&#146; ongoing fundraising efforts, conditionality
relating to financing and Cibus&#146; proposed transaction timeline, and the terms of a potential counterproposal by Calyxt. The Calyxt Board also discussed the process and potential timelines and budget for a potential orderly dissolution and
liquidation of Calyxt if no other more attractive executable alternatives emerged. The Calyxt Board provided negotiating guidance and direction to Calyxt management and the advisors relating to the Cibus proposal, and requested that Calyxt
management continue its expense control efforts and refine its analysis regarding a potential orderly liquidation of Calyxt. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As directed
by the Calyxt Board, on November&nbsp;3, 2022, Calyxt delivered a counter-proposal to Cibus which proposed an ascribed valuation of Calyxt of $40.0&nbsp;million and an ascribed valuation of Cibus to be based on the price to be paid in Cibus&#146;
ongoing Series F equity financing round. Calyxt&#146;s proposal also eliminated any financing closing condition with respect to Cibus&#146; obligation to consummate the transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;8, 2022, representatives of Cibus and Calyxt held a videoconference for Calyxt management and its advisors to conduct due
diligence and ask questions about the management organization and personnel of Cibus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;9, 2022, representatives of Cibus
and Calyxt held additional videoconferences to conduct due diligence on Cibus. On the first call, Calyxt management conducted a question and answer session on Cibus&#146; financial statements, operating results, pipeline and prospects and the status
of Cibus&#146; latest equity financing round. On a subsequent call, Calyxt management conducted a question and answer session on Cibus&#146; contract and legal functions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Later on November&nbsp;9, 2022 the Calyxt Board met with Calyxt management and representatives of Sidley and discussed developments in the
strategic alternatives review process, including that Company A had declined to provide further information regarding its potential financing sources and that as a result discussions with Company A had ceased. Management reviewed with the Calyxt
Board Calyxt&#146;s liquidity position, expense control initiatives and anticipated cash flows. Management also updated the Calyxt Board on the status of the negotiations with Cibus, the status of Cibus&#146; ongoing fundraising efforts and
potential transaction timelines. Also at this meeting, Messrs. Arthaud and Godard reported to the Calyxt Board on feedback from the Cellectis board of directors&#146; meeting earlier in the week, including noting that Cellectis had determined that,
in the event an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
actionable alternative transaction with Cibus or another third party could not be identified in the near term and the Calyxt Board submitted a proposal for an orderly dissolution and liquidation
of Calyxt to the shareholders of Calyxt for approval, Cellectis would vote its shares in Calyxt in favor of the orderly dissolution and liquidation of Calyxt. Management then reviewed with the Calyxt Board potential budgets and timelines for an
orderly dissolution and liquidation of Calyxt and the Calyxt Board discussed the potential challenges and risks involved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
November&nbsp;10, 2022, Cibus management participated in <FONT STYLE="white-space:nowrap">on-site</FONT> due diligence meetings with certain members of Calyxt management at Calyxt&#146;s headquarters as part of Cibus&#146; due diligence
investigation of Calyxt. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;14, 2022, the compensation committee of the Calyxt Board met to, among other things, discuss
Calyxt management&#146;s plans for potential headcount reductions and related expense control initiatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;16, 2022,
Cibus submitted a revised <FONT STYLE="white-space:nowrap">non-binding</FONT> letter of intent which proposed an ascribed valuation of Calyxt of $30.0&nbsp;million and an ascribed valuation of Cibus to be based on the price to be paid in Cibus&#146;
ongoing equity financing round, with an implied ownership interest in the Combined Company of approximately 5.0%, on a fully-diluted basis, for existing Calyxt Stockholders. Cibus&#146; proposal also contemplated a $50.0&nbsp;million financing
closing condition prior to Cibus being required to consummate the transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Later on November&nbsp;16, 2022 the Calyxt Board met with
Calyxt management and representatives of Canaccord Genuity and Sidley and discussed the revised letter of intent that had been received from Cibus earlier in the day in response to Calyxt&#146;s November&nbsp;3, 2022 counterproposal, reviewed and
discussed the key open issues, including transaction timelines to signing and to closing, conditionality and certainty of closing (including conditionality relating to Cibus&#146; ongoing fundraising efforts), and valuation, discussed potential
responses to the open issues, discussed potential transaction timelines, and reviewed and discussed Cibus&#146; ongoing fundraising efforts and related timelines. The Calyxt Board directed Calyxt management and the representatives of Canaccord
Genuity to seek to resolve the remaining issues with Cibus. The Calyxt Board then reviewed and discussed with Calyxt management and Sidley a potential timeline and budget for an orderly dissolution and liquidation of Calyxt, and the Calyxt Board
directed Calyxt management to further refine certain estimates and assumptions and report back to the Calyxt Board. Later in the day, Calyxt sent a further revised letter of intent to Cibus that removed certain closing conditions relating to
financing and intellectual property matters and reflecting an accelerated transaction timetable all consistent with the direction of the Calyxt Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;18, 2022, management of Cibus and Calyxt, together with representatives of Canaccord Genuity and Jones Day, counsel for Cibus
(&#147;Jones Day&#148;), held a videoconference to discuss certain intellectual property matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;20, 2022, Cibus
submitted a revised <FONT STYLE="white-space:nowrap">non-binding</FONT> letter of intent which required that Cellectis assign to Calyxt certain intellectual property rights used by Calyxt in its business as a condition to a closing of the
transaction. This revised <FONT STYLE="white-space:nowrap">non-binding</FONT> letter of intent was not executed and delivered by the parties, but reflected alignment between the parties on the underlying valuation and transaction structure that
served as the basis for negotiations going forward. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;21, 2022, Calyxt management and representatives of Canaccord Genuity
discussed with management of Cibus the key terms of a potential reverse merger transaction based on the November&nbsp;20, 2022 letter of intent, including the pro forma ownership of the Combined Company that would be held by the <FONT
STYLE="white-space:nowrap">pre-merger</FONT> stockholders of Calyxt, the closing conditions for the transaction and the timeline for negotiating definitive transaction document and a related exclusivity period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;22, 2022 the Calyxt Board met with Calyxt management and representatives of Canaccord Genuity and Sidley and reviewed the
status of the negotiations on the Cibus revised letter of intent, including the length of the exclusivity period, and approved the proposed letter of intent and exclusivity period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;23, 2022 Calyxt delivered a draft merger agreement to Cibus. The initial
draft merger agreement provided for, among other things, a reverse merger structure, wherein first the Blockers would merge with and into Calyxt, followed by the merger of Merger Subsidiary with and into Cibus with Cibus surviving as a wholly-owned
subsidiary of Calyxt. Cibus unitholders and warrant holders would all receive shares of Calyxt Common Stock as merger consideration, in each case, as set forth on the allocation statement contained therein. Under the initial draft merger agreement,
Cibus and Calyxt would also make largely reciprocal representations and warranties regarding their respective businesses and agree to largely reciprocal interim operating covenants and other <FONT STYLE="white-space:nowrap">pre-closing</FONT>
covenants. The draft merger agreement contained customary closing conditions, including a bring-down of the general representations and warranties at a &#147;Material Adverse Effect&#148; standard and the fundamental representations and warranties
at an &#147;all material respects&#148; standard. The Calyxt shares to be issued in the mergers would be listed on Nasdaq and at closing Calyxt would deliver an assignment from Cellectis assigning certain intellectual property used by Calyxt in its
business to Calyxt. Simultaneously with the signing of the merger agreement, Cellectis would also deliver the voting agreement committing to vote in favor of the mergers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;29, 2022 a videoconference was held among representatives of Jones Day, Sidley, and Calyxt management to discuss the draft
merger agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;5, 2022, representatives of Cibus and Calyxt held a series of
<FONT STYLE="white-space:nowrap">follow-up</FONT> videoconferences to continue Calyxt&#146;s financial due diligence on Cibus and to discuss potential synergies. On one videoconference, Calyxt management and its advisors conducted a question and
answer session on Cibus&#146; financial statements, operating results, pipeline and prospects and the status of Cibus&#146; latest equity financing round. On an additional videoconference, the parties discussed their respective personnel capacity
and needs, including synergies to be realized from the Combined Company&#146;s workforce. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Later on December&nbsp;5, 2022, the Calyxt
Board met with Calyxt management and representatives of Canaccord Genuity, Sidley, and Ballard Spahr. Management and the advisors updated the Calyxt Board on the status of the negotiations with Cibus and its advisors on the transaction documents,
the key open issues to be resolved, the status of Cibus&#146; financing efforts and the closing of its Series F financing round at a $2.00 price per unit (which implied an approximately $475 million pre-money equity valuation of Cibus on a Treasury
stock basis), and the status of Calyxt&#146;s ongoing due diligence review of Cibus. In addition, Calyxt management updated the Calyxt Board on Calyxt&#146;s liquidity position, initiatives to limit expenses and the process, timing and budget for a
potential orderly dissolution and liquidation of Calyxt. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;7, 2022, Jones Day delivered a revised draft of the merger
agreement to Calyxt. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;8, 2022, a videoconference was held among representatives of Jones Day, Sidley and Calyxt
management to discuss the revised draft of the merger agreement. The parties discussed, among other issues in the merger agreement, Calyxt directors and officers delivering voting agreements, the materiality standards for Cibus representations and
warranties, the closing conditions and termination in the event of a Calyxt &#147;Material Adverse Effect&#148;, Cibus&#146; interim operating covenants (including issuances of additional Cibus equity in connection with its ongoing financing round
and grants to employees, incurrence of indebtedness and capital expenditure commitments), the timing for delivery of Cibus&#146; member consents approving the mergers, and control of any <FONT STYLE="white-space:nowrap">pre-closing</FONT> litigation
in connection with the transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;9, 2022, representatives of Sidley, Willkie Farr&nbsp;&amp; Gallagher LLP, counsel
to Cellectis (&#147;Willkie Farr&#148;), and management of each of Calyxt and Cellectis held a videoconference to discuss the merger agreement and proposed transaction, and Willkie Far and Cellectis provided feedback to Sidley and Calyxt on the
draft of the merger agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Later on December&nbsp;9, 2022, Cibus granted access to Calyxt and its representatives and advisors to a
virtual data room Cibus established to share confidential information and facilitate Calyxt&#146;s due diligence review of Cibus. During the period commencing on December&nbsp;9, 2022 through the execution of the Merger Agreement on January&nbsp;13,
2023, Calyxt continued to conduct its business and financial due diligence investigations of Cibus, with the assistance of its advisors, including various subject matter specific due diligence conference calls. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;10, 2022, Calyxt provided a revised draft of the merger agreement to Jones
Day and Cibus addressing many of the issues discussed on the December&nbsp;8, 2022 call among the parties&#146; counsel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
December&nbsp;13, 2022 the Calyxt Board met with Calyxt management and representatives of Canaccord Genuity and Sidley. Management and the representatives of Canaccord Genuity reviewed the status of the negotiations with Cibus, the key open issues
remaining to be resolved and Calyxt&#146;s proposed approach to each, and the action items and timeline to a potential signing of the merger agreement. Management also reviewed and discussed with the Calyxt Board the results of Calyxt&#146;s due
diligence review of Cibus. Management also reviewed and discussed with the Calyxt Board the process and timeline for an orderly dissolution and liquidation of Calyxt, which management identified as Calyxt&#146;s only actionable alternative to the
Cibus transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the evening on December&nbsp;13, 2022, Jones Day provided a revised draft of the merger agreement to Sidley and
Calyxt. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;14, 2022, Calyxt provided drafts to Jones Day of the voting agreement to be signed by Cellectis, the amendment
to the license agreement between Calyxt and Cellectis proposed covenant relating to replacing Cellectis&#146; guaranty of Calyxt&#146;s headquarters office lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;15, 2022, a videoconference was held among Calyxt and Jones Day to discuss the merger agreement and related matters. On this
call, the representatives of Jones Day described the <FONT STYLE="white-space:nowrap">&#147;Up-C&#148;</FONT> structure that Cibus proposed to implement in connection with the transaction. Additionally, the parties discussed, among other issues in
the merger agreement, comments to the representations and warranties, Cibus&#146; interim operating covenants (including issuances of additional Cibus equity in connection with its ongoing financing round and grants to employees, incurrence of
indebtedness and capital expenditure commitments), the timing for delivery of Cibus&#146; member consents approving the mergers and termination in the event of a Calyxt &#147;Material Adverse Effect.&#148; Later in the day Calyxt and Cibus exchanged
draft disclosure schedules to the merger agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;16, 2022, Jones Day delivered to Calyxt and Sidley an updated draft
of the merger agreement including among other things changes reflecting the proposed &#147;Up-C&#148; structure, wherein certain Cibus unitholders would be entitled to elect, as merger consideration, either shares of Class&nbsp;A Common Stock or <FONT
STYLE="white-space:nowrap">Up-C</FONT> Units (constituting a share of Class&nbsp;B Common Stock coupled with a Cibus Common Unit). The revised draft of the merger agreement also reflected Cibus&#146; position on the issues discussed on the previous
day&#146;s call among counsel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;16, 2022, the Calyxt Board met with management and representatives of Canaccord Genuity
and Sidley and discussed the status of the negotiations with Cibus, including the key open issues for resolution, and described the <FONT STYLE="white-space:nowrap">&#147;Up-C&#148;</FONT> structure proposed by Cibus. In addition, management
reviewed Calyxt&#146;s liquidity position, cash forecast and financing needs, and discussed Calyxt&#146;s expense reduction initiatives and potential alternatives to a transaction with Cibus, including a potential orderly dissolution and
liquidation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;18, 2022, representatives of Canaccord Genuity and Cibus management held a videoconference to discuss the
exchange ratio for the merger and the pro forma capitalization of the Combined Company following the merger. Later in the day, Jones Day delivered to Calyxt and Sidley revised drafts of the voting agreement and license agreement amendment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;19, 2022, Akin Gump Strauss Hauer&nbsp;&amp; Feld LLP, tax counsel to Cibus (&#147;Akin Gump&#148;), delivered to Calyxt and
Sidley a draft term sheet for the proposed tax receivable agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;20, 2022, management of Calyxt provided Cellectis
with an update on the negotiations with Cibus, including the revised drafts of the voting agreement and license amendment provided by Jones Day on December&nbsp;18, 2022. Later in the day, following negotiations between Sidley and Akin Gump, Akin
Gump delivered an updated draft term sheet for the proposed tax receivable agreement. In the evening of December&nbsp;20, 2022, Jones Day delivered to Calyxt and Sidley a further revised draft of the merger agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;21, 2022, Sidley delivered an updated draft of the merger agreement to
Jones Day. Sidley subsequently provided the updated draft merger agreement to Willkie Farr. The updated draft of the merger agreement addressed issues that included Cibus&#146; interim operating covenants (including issuances of additional Cibus
equity in connection with its ongoing Series F financing round and grants to employees, incurrence of indebtedness and capital expenditure commitments), the timing for delivery of Cibus&#146; member consents approving the mergers. In addition to the
foregoing issues, the draft proposed that Cibus pay Calyxt (i)&nbsp;a $1.0&nbsp;million termination payment (plus transaction fees up to $500,000) if Cibus is unable to obtain the member consents approving the mergers by a date certain or if the
parties have not completed negotiation of all ancillary agreements (including the tax receivable agreement, the exchange agreement and the amended and restated limited liability company agreement of Cibus) by a date certain and (ii)&nbsp;a weekly
&#147;ticking fee&#148; commencing on March&nbsp;15, 2023 if the mergers had not been consummated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;22, 2022, Sidley
delivered a revised draft of the term sheet for the tax receivable agreement to Akin Gump and Jones Day. Later in the day, Calyxt delivered revised draft disclosure schedules to Jones Day. Following discussions between Sidley and Akin Gump, later in
the day Akin Gump delivered a further revised draft of the term sheet for the tax receivable agreement to Sidley and Calyxt. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
December&nbsp;23, 2022, representatives of Sidley, Jones Day and Willkie Farr held a videoconference to discuss the draft voting agreement and license agreement amendment. Among the issues discussed were Cellectis&#146; obligation to vote in favor
of the mergers if Calyxt made a board adverse recommendation change and the royalties to be paid under the Cellectis intellectual property license amendment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;28, 2022, Jones Day delivered a revised draft merger agreement to Sidley and Calyxt. The following morning Sidley updated
Willkie Farr on the status of the negotiations with Cibus and forwarded the revised draft merger agreement. Issues addressed in the draft merger agreement included, among others, Cibus&#146; interim operating covenants (including issuances of
additional Cibus equity in connection with its ongoing Series F financing round and grants to employees, incurrence of indebtedness and capital expenditure commitments) as well as the ability of new Series F subscribers to elect <FONT
STYLE="white-space:nowrap">Up-C</FONT> Units as merger consideration. In lieu of a ticking fee, the merger agreement proposed Cibus providing the Interim Funding of up to $2.0&nbsp;million <FONT STYLE="white-space:nowrap">pre-closing.</FONT> The
draft merger agreement also proposed that certain Cibus Unitholders would deliver voting agreements with the member consent approving the mergers to be delivered at some point <FONT STYLE="white-space:nowrap">pre-closing</FONT> (to be enforced by
Cibus&#146; obligation to pay the $1.0&nbsp;million termination fee if the member consent was not delivered on time). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
December&nbsp;30, 2022, the Calyxt Board held a meeting at which Calyxt management and representatives of Canaccord Genuity and Sidley attended. The representatives of Canaccord Genuity reviewed the conduct of the strategic transaction review
process to date, the representatives of Sidley described Calyxt&#146;s previous strategic review and fundraising processes, and the Calyxt Board reviewed with management and the representatives of Canaccord Genuity and Sidley the strategic
alternatives available to Calyxt. Management and the representatives of Canaccord Genuity and Sidley then reviewed the key areas of negotiation with Cibus, the proposed resolutions of the open points, and the key potential benefits and risks of the
proposed transaction. Management and the representatives of Canaccord Genuity and Sidley then reviewed and discussed with the Calyxt Board the principal terms and conditions of the proposed transaction with Cibus, the proposed pro forma equity
ownership of the existing stockholders of Calyxt in the Combined Company, the proposed &#147;Up-C&#148; structure and tax receivable agreement, and the anticipated liquidity position, cash runway and financing needs of the Combined Company. The
Calyxt Board provided feedback negotiating guidance to management, Canaccord Genuity and Sidley. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;30, 2022, Jones Day
delivered to Sidley, Calyxt and Willkie Farr revised drafts of the license agreement amendment and provisions of the voting agreement relating to the termination of Cellectis&#146; guaranty of Calyxt&#146;s headquarters office lease, wherein Cibus
would agree to take commercially reasonable efforts to cause Cellectis to be released from the guaranty once the Combined Company was able to meet certain financial metrics. Later in the day Calyxt and Jones Day exchanged updated draft disclosure
schedules. Other than the terms for the guaranty release, the form of voting agreement was largely settled. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;1, 2023, Willkie Farr provided a revised draft of the license agreement
amendment to Calyxt and Sidley. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;2, 2023, Jones Day delivered an initial draft of the interim funding term sheet to Calyxt
and Sidley which provided for up to $3.0&nbsp;million in interim funding on certain conditions, including accrual of interest and prepayment upon maturity if the mergers were not consummated. Later in the day on January&nbsp;2,&nbsp;2023, Calyxt
delivered to Jones Day revised drafts of the term sheet for the Interim Funding, the license agreement amendment, and the provisions of the voting agreement relating to the termination of Cellectis&#146; guaranty of Calyxt&#146;s headquarters office
lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;3, 2023, the Calyxt Board met with Calyxt management and representatives of Sidley. Management reviewed with the
Calyxt Board the key open topics for resolution with Cibus and discussed potential proposed resolutions with the Calyxt Board. The Calyxt Board discussed potential transaction timelines and management&#146;s cash forecasts through closing and the
funding mechanisms potentially available to Calyxt. The Calyxt Board also discussed Calyxt&#146;s alternatives to the Cibus transaction, that an orderly dissolution and liquidation of Calyxt was the only executable alternative that had been
identified to date, and the potential timelines, process and budgets for such an orderly dissolution of Calyxt. The Calyxt Board provided feedback and negotiating guidance to management and Sidley. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following discussions between Calyxt and Willkie Farr, on January&nbsp;4, 2023 Calyxt delivered a revised draft of the license agreement
amendment to Jones Day. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Later in the day on January&nbsp;4, 2023, Calyxt delivered a revised draft of the term sheet for the Interim
Funding to Cibus and Jones Day. Issues addressed in the revised draft of the term sheet included increasing potential funding to $4.0&nbsp;million, full forgiveness if the merger agreement is terminated and making the loan interest-free. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;5, 2023, Sidley delivered a revised draft of the merger agreement to Jones Day. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Over the course of the weekend from January&nbsp;6, 2023 through January&nbsp;8, 2023, Calyxt, Cibus and their respective advisors continued
to negotiate the terms of the transaction documents, and numerous revised drafts of the various agreements were exchanged. Remaining issues negotiated between the parties during this period included, among others, the timing for delivery of
Cibus&#146; member consents approving the mergers, confirming the form of merger consideration payable to Cibus warrant holders and holders of Cibus PIUs, the maximum amount and terms of the Interim Funding (including forgiveness under certain
circumstances if the merger agreement is terminated), the royalties payable to Cellectis under the amended intellectual property license and the final outside date of the merger agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;9, 2023, the compensation committee of the Calyxt Board met with management and representatives of Sidley and discussed the
status of the negotiations with Cibus, the key remaining items to be addressed and certain compensation-related matters relating to the proposed transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Over the course of the week from January&nbsp;9 to January&nbsp;13, 2023, Calyxt, Cibus and their respective counsel continued to negotiate
the terms of the transaction documents and exchanged numerous revised drafts. Remaining issues negotiated between the parties during this period included, among others, the timing for delivery of Cibus&#146; member consents approving the mergers,
confirming the form of merger consideration payable to Cibus warrant holders and holders of Cibus PIUs, the maximum amount and terms of the Interim Funding (including forgiveness under certain circumstances if the merger agreement is terminated),
the royalties payable to Cellectis under the amended intellectual property license and the final outside date of the merger agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
January&nbsp;13, 2023, the Calyxt Board held a meeting at which members of Calyxt management and representatives of Canaccord Genuity and Sidley were present. Calyxt&#146;s directors discussed, among other things,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the potential benefits and risks of the proposed transaction with Cibus. During the meeting, a representative from Sidley again reviewed the fiduciary duties of the Calyxt Board in connection
with the proposed transaction with Cibus and reviewed the material terms of the merger agreement. The Calyxt Board discussed various considerations with respect to the proposed transaction with Cibus, as summarized in the section
entitled<I>&nbsp;&#147;&#151;Calyxt Reasons for the Mergers.&#148;</I>&nbsp;Following discussion, the Calyxt Board unanimously (i)&nbsp;determined that the Mergers and the Transactions are advisable and in the best interests of Calyxt and its
stockholders, (ii)&nbsp;approved and declared advisable the Merger Agreement, the Mergers and the other Transactions, and (iii)&nbsp;resolved to recommend that the Calyxt Stockholders approve the Mergers and the Transactions. Later on
January&nbsp;13, 2023, Calyxt and Cibus executed the Merger Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;17, 2023, Calyxt and Cibus issued a joint press
release announcing the execution of the Merger Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom401831_17"></A>Calyxt Reasons for the Mergers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the course of its evaluation of the Merger Agreement and the Transactions, the Calyxt Board (including the Calyxt Committee) held
numerous meetings, consulted with Calyxt, Inc.&#146;s senior management and with financial and legal advisors and consultants to the Calyxt Board and/or the Calyxt Committee. In reaching its decision to approve the Merger Agreement and the
Transactions, the Calyxt Board considered a number of factors that it viewed as supporting its decision to approve the Merger Agreement, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the then-current and historical trading prices of Calyxt Common Stock, and the possibility that Calyxt Common
Stock could be delisted from the Nasdaq and only trade through the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> markets, if at all; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Calyxt Board&#146;s belief that Calyxt&#146;s business development efforts were not reasonably likely to
result in any significant developments or events in the near term that could reasonably be expected to serve as a meaningful catalyst for Calyxt&#146;s stock price; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extensive efforts of the Calyxt Board and Calyxt management over an extended period of time to identify a
fundable business model for Calyxt that could reasonably be expected to enhance and create long-term shareholder value; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risks associated with Calyxt&#146;s business plan, including execution risk, funding risk, technology risk,
regulatory risk, risks relating to the potential size and/or profitability of Calyxt&#146;s potential target markets, and risks relating to the evolving competitive landscape relating for Calyxt&#146;s products and services; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Calyxt&#146;s liquidity position, extremely limited funding runway and repeated inability to raise material
amounts of additional capital; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the comprehensive and thorough process of reviewing and analyzing potential strategic alternatives undertaken by
the Calyxt Board (including through the Calyxt Committee) and management, including the exploration of potential sale of the company transactions, licensing transactions, transactions for the sale of key assets or businesses, and financing
transactions, the Calyxt Board&#146;s belief that no commercially viable alternative financing, strategic investment, merger, asset sale or licensing transaction was reasonably available to Calyxt, and the Calyxt Board&#146;s belief that that the
only reasonably executable alternative to the Mergers was a liquidation and dissolution of Calyxt that could not be reasonably expected to provide any dividend, liquidating distribution or other payments or value to Calyxt Stockholders;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Calyxt Board&#146;s belief that the exchange ratio for the Mergers is the highest exchange ratio to which
Cibus Global was willing to agree and that the other terms of the Merger Agreement represent in the aggregate the most favorable terms to Calyxt and its stockholders to which Cibus was willing to agree; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that following the Mergers, the <FONT STYLE="white-space:nowrap">pre-Mergers</FONT> Calyxt Stockholders will
continue to own common equity in Cibus, Inc. and that Calyxt Board&#146;s belief that this continuing equity interest will provide the existing Calyxt Stockholders with an opportunity to participate following the Mergers in the potential equity
value of the Combined Company, which will focus on Cibus&#146; product pipeline; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Calyxt Board&#146;s view, based on the scientific, regulatory and technical due diligence conducted by Calyxt
management and advisors of the potential market opportunity of Cibus&#146; product candidates, which the Calyxt Board anticipates will be the focus of the Combined Company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Calyxt Board&#146;s view, following review with Calyxt management and advisors, of Cibus&#146; anticipated
fundraising and development plans and the potential ability of the Combined Company to successfully raise additional funds to enable the continued development of Cibus&#146; product pipeline through anticipated future value inflection points;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Calyxt Board&#146;s belief that the funding advances by Cibus Global provided for in the Merger Agreement are
reasonably likely to provide sufficient funding to Calyxt to allow Calyxt to close the Mergers and should provide a cash cushion that, in the event the Merger Agreement is terminated, will substantially enhance the ability of Calyxt to conduct an
orderly dissolution and liquidation; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of the Calyxt Board to respond to unsolicited acquisition proposals that third parties may make
before Calyxt Stockholders approve the Mergers, including the Calyxt Board&#146;s ability to change its recommendation regarding the Mergers and (subject to payment of the breakup fee described elsewhere in this proxy statement/prospectus) terminate
the Merger Agreement in response to a superior proposal. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Calyxt Board also considered the terms of the Merger
Agreement and related transaction documents, including those described below, and concluded that the terms of the Merger Agreement and related transaction documents, in the aggregate, were fair to and in the best interests of Calyxt and its
stockholders under the circumstances: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that under the terms of the Merger Agreement, the <FONT STYLE="white-space:nowrap">pre-Mergers</FONT> Calyxt
Stockholders are anticipated (subject to dilution from any equity issued by Cibus Global after the date of the Merger Agreement and before the Closing and other dilutive items provided for in the Merger Agreement) to own approximately 5% of the
fully-diluted equity interests of Cibus, Inc. at the Closing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the nature of the conditions to Calyxt&#146;s and Cibus&#146; respective obligations to complete the Mergers, as
more fully described below under the caption &#147;<I>The Merger Agreement&#151;Conditions to the Completion of the Mergers</I>,&#148; beginning on page&nbsp;173 in this proxy statement/prospectus, and the Calyxt Board&#146;s view of the likelihood
that the Mergers will be completed on a timely basis; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the respective rights of, and limitations on, Calyxt, Inc. and Cibus Global under the Merger Agreement to
consider and engage in discussions regarding unsolicited acquisition proposals under certain circumstances, and the limitations on the board of directors of each party to change its recommendation in favor of the Mergers, as more fully described
below under the caption &#147;<I>The Merger Agreement&#151;No Solicitation</I>,&#148; beginning on page&nbsp;177 in this proxy statement/prospectus; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential termination fee of $1.0&nbsp;million plus reimbursement of up to $500,000 of expenses, which could
become payable by Cibus Global to Calyxt, Inc. if the Merger Agreement is terminated in certain circumstances, as more fully described below under the caption &#147;<I>The Merger Agreement&#151;Termination</I>,&#148; beginning on page&nbsp;188 in
this proxy statement/prospectus; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Calyxt Support Agreements, pursuant to which certain stockholders of Calyxt, Inc. have agreed, solely in
their capacities as stockholders, to vote their shares of Calyxt Common Stock in favor of the Mergers and against any alternative acquisition proposals, and that such voting obligations terminate if the Calyxt Board changes its recommendation with
respect to the Mergers, all as more fully described below under the caption &#147;<I>Agreements Related to the Mergers&#151;Support Agreements&#151;Calyxt Support Agreements</I>,&#148; beginning on page&nbsp;191 in this proxy statement/prospectus;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the provisions in the Calyxt Support Agreement between Cibus Global, Calyxt, Inc. and Cellectis relating to the
guaranty by Cellectis of certain obligations under Calyxt&#146;s headquarters building lease, including the obligation of Cibus Global under certain circumstances to use commercially reasonable efforts to cause the landlord to terminate the
guarantee as more fully described below under the caption </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
&#147;<I>Agreements Related to the Mergers</I>&#151;<I>Support Agreements&#151;Calyxt Support Agreements</I>,&#148; beginning on page 191 in this proxy statement/prospectus;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the <FONT STYLE="white-space:nowrap">&#147;Up-C&#148;</FONT> structure to be implemented at the Closing for the
Combined Company and the terms of the Tax Receivable Agreement to be entered into in connection therewith, including the payments to be made to certain Cibus Unitholders thereunder, all as more fully described below under the caption
&#147;<I>Agreements Related to the Mergers&#151;Tax Receivable Agreement</I>,&#148; beginning on page 191 in this proxy statement/prospectus; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of Calyxt, Inc.&#146;s outstanding warrants and the impact of the Mergers on the warrants; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the provisions of the Merger Agreement relating to the officers and employees of Calyxt, including the treatment
of employee stock options and Calyxt RSUs in the Mergers, the treatment of Calyxt&#146;s obligations to pay severance to officers and employees, and the provisions relating to Calyxt&#146;s ability to change the compensation of officers and
employees and/or make any bonus payment or equity awards following the signing of the Merger Agreement. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the course
of its deliberations, the Calyxt Board also considered a variety of risks and other countervailing factors related to entering into the Mergers, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the $1.0&nbsp;million termination fee payable by Calyxt, Inc. upon the occurrence of certain events and the
potential effect of such termination fee in deterring other potential acquirors from proposing an alternative acquisition that may be more advantageous to Calyxt Stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the substantial expenses to be incurred by Calyxt, Inc. in connection with the Transactions and the potential for
events out of the control of Calyxt, Inc. to delay the vote of Calyxt Stockholders or Cibus Unitholders and/or delay or prevent the Closing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that Calyxt does not have sufficient liquidity to fund expenses through the Closing, and options,
including if the Closing were to be delayed; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that one of more of the conditions to the Closing will not be satisfied, including among others the risk
that Cibus Unitholders do not approve the Transactions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that Calyxt Common Stock is delisted by Nasdaq and/or the risk that a material adverse effect occurs
with respect to Calyxt, and the related risk that in the event the Merger Agreement is terminated without the Closing occurring (and without Calyxt, Inc. entering into an agreement for a superior proposal), Calyxt will not have sufficient remaining
cash to be able to fund an orderly dissolution and liquidation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the restrictions on Calyxt, Inc. soliciting alternative acquisition proposals during the pendency of the
Transactions, as more fully described below under the caption &#147;<I>The Merger Agreement&#151;No Solicitation</I>,&#148; beginning on page&nbsp;177 in this proxy statement/prospectus; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that the trading of Calyxt Common Stock, both prior to the Transactions and following the completion of the
Transactions, will likely be materially impacted by matters relating to Cibus and its financial condition, operating results, pipeline and prospects; that Cibus is not currently a public company and limited information relating to Cibus is publicly
available; that there is no established trading market or market prices for Cibus Units; and that as a result the price of Calyxt Common Stock could increase, decrease and/or be volatile; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that the ability of the Combined Company to execute on its business plan will be subject to substantial
challenges, some of which will be beyond the control of the Combined Company, including risks and challenges relating to execution, technology, regulatory matters, funding needs and the fact that the Combined Company is not anticipated to generate
any material amount of revenue in the near future, risks relating to the development and/or commercialization of Cibus&#146; product pipeline, and inherent uncertainties as to the extent to which the Combined Company will be able to successfully
execute its business plan on a timely basis, if at all, and achieve its projections; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the interests that Cellectis and Calyxt&#146;s directors and executive officers have with respect to the
Transactions that are or may be different from, or in addition to, the interests of Calyxt Stockholders generally, including those interests described in the sections entitled &#147;<I>The Mergers&#151;Interests of Calyxt, Inc. Directors and
Executive Officers in the Mergers</I>&#148; beginning on page 145 in this proxy statement/prospectus; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the complexity of the contemplated <FONT STYLE="white-space:nowrap">&#147;Up-C&#148;</FONT> structure for the
Combined Company and potential impact that the structure, including the change of control payments under the contemplated Tax Receivable Agreement, could have on potential future merger transactions involving Calyxt and/or the price that would be
paid to Calyxt Stockholders in any such transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that the Calyxt Board (including the Calyxt Committee) had determined not to request a formal fairness opinion
with respect to the Transactions in light of, among other things, the Calyxt Board&#146;s belief (a)&nbsp;that payment of the fee payable for such an opinion would substantially reduce the amount of Calyxt&#146;s available cash and potentially
impair Calyxt&#146;s ability to fund its expenses and operations through the Closing and Calyxt&#146;s ability to fund an orderly dissolution and liquidation in the event that the Transactions did not close and (b)&nbsp;that a fairness opinion would
provide modest, if any, benefit to the Calyxt Board because, among other things, (i) given the early stage nature of the business of each of Calyxt and Cibus, including that each company required substantial additional financing to fund its business
plan, that each company&#146;s business plan was subject to substantial risks and uncertainties and that neither company&#146;s business plan was anticipated to generate material revenues in the next several years and (ii) the Calyxt Board&#146;s
belief that the only reasonably executable alternative to the Mergers was a liquidation and dissolution of Calyxt that could not be reasonably expected to provide any dividend, liquidating distribution or other payments or value to Calyxt&#146;s
stockholders; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the various other risks associated with the Combined Company and the proposed Transactions, including those
described in the sections entitled &#147;<I>Risk Factors</I>&#148; and &#147;<I>Cautionary Statement Concerning Forward-Looking Statements</I>&#148; beginning on pages&nbsp;40 and 114, respectively, in this proxy statement/prospectus.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of its evaluation of the Merger Agreement and the Transactions, the Calyxt Board (including the Calyxt
Committee) considered various financial analyses relating to Calyxt, Inc., Cibus Global and the Transactions, including the following: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Historical
Stock Trading Data </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the January&nbsp;13, 2023 meeting of the Calyxt Board, the Calyxt Board considered and reviewed various
historical trading statistics relating to the Calyxt Common Stock as of January&nbsp;12, 2023 based on data from Bloomberg and Capital IQ, including the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Trading Range</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>VWAP</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Daily Volume</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">52-Week&nbsp;High</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">10-Day&nbsp;VWAP</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">52-Week&nbsp;High</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,585,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">52-Week&nbsp;Low</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">20-Day</FONT> VWAP</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">52-Week&nbsp;Low</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">52-Week&nbsp;Period&nbsp;Average</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">30-Day</FONT> VWAP</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>LTM&nbsp;Average</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">653,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Current</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">60-Day</FONT> VWAP</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">10-Day</FONT> Avg.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">599,908</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Market&nbsp;Cap&nbsp;($M)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">90-Day</FONT> VWAP</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">30-Day</FONT> Avg.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">320,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Illustrative Premiums Paid Analysis </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also at the January&nbsp;13, 2023 meeting of the Calyxt Board, the Calyxt Board considered and reviewed an illustrative premiums paid analysis
that analyzed the premiums paid in 269 acquisitions of U.S. public companies with equity purchase prices between $15&nbsp;million and $200&nbsp;million since 2018, based on data from CapitalIQ as of January&nbsp;12, 2023. The Calyxt Board considered
and reviewed the premiums of the equity purchase price paid in the transactions to the trading price one-day prior to announcement and the <FONT STYLE="white-space:nowrap">30-day</FONT> volume weighted average trading price (VWAP) for the target
company&#146;s stock as set forth in the table below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">Transaction&nbsp;Value<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">Offer&nbsp;Premium&nbsp;to</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">($&nbsp;in&nbsp;million)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="white-space:nowrap">1-Day&nbsp;VWAP</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="white-space:nowrap">30-Day&nbsp;VWAP</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3<SUP STYLE="font-size:75%; vertical-align:top">rd</SUP> Quartile:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">119.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mean:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">84.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Median:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First Quartile:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(1) Represents equity purchase price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Among other things, the Calyxt Board considered that for the median and mean transaction values in the
<FONT STYLE="white-space:nowrap">$70-85&nbsp;million</FONT> range, the offer premiums were in the <FONT STYLE="white-space:nowrap">35-50%</FONT> range and that an illustrative $31.7&nbsp;million equity purchase price for Calyxt represented (based on
diluted shares of Calyxt Common Stock outstanding of 50.3&nbsp;million and an implied per share price of $0.63) a 297.5% premium to the closing stock price of the Calyxt Common Stock and a 287.2% premium to the
<FONT STYLE="white-space:nowrap">30-day</FONT> VWAP of the Calyxt Common Stock, in each case as of January&nbsp;12, 2023. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Illustrative Pro Forma
Ownership Sensitivity Analysis </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, at the November&nbsp;2, 2022 meeting of the Calyxt Board, the Calyxt Board considered
and reviewed a preliminary pro forma ownership sensitivity analysis that analyzed the pro forma percentage ownership interest for the <FONT STYLE="white-space:nowrap">pre-transaction</FONT> Calyxt Stockholders in a reverse merger transaction with
Cibus Global based on a range of the illustrative equity values for each of Calyxt, Inc. and Cibus Global as set forth in the table below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center"><B>Illustrative Cibus Global Valuation</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>($ in millions)</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">400.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">450.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">500.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">550.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">570.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">600.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ROWSPAN="5" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Illustrative Calyxt, Inc. Valuation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Calyxt Board considered that a $7.0&nbsp;million illustrative valuation reflected the closing price of the
Calyxt Common Stock on October&nbsp;31, 2022. The Calyxt Board also considered that a $30.0&nbsp;million illustrative valuation of Calyxt, Inc. and a $570&nbsp;million illustrative valuation of Cibus Global resulted in a pro forma 5% percentage
ownership for the <FONT STYLE="white-space:nowrap">pre-transaction</FONT> Calyxt Stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preliminary Discounted Cash Flow Analysis
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, at the October&nbsp;19, 2022 meeting of the Calyxt Board, the Calyxt Board considered and reviewed a preliminary
discounted cash flow analysis of Cibus Global utilizing the Cibus Global Financial Projections. A discounted cash flow analysis is a valuation methodology used to derive a valuation of a company by calculating the present value of the company&#146;s
estimated future cash flows. A company&#146;s &#147;estimated future cash flows&#148; are its projected unlevered free cash flows, and &#147;present value&#148; refers to the value as of an assumed date of the future cash flows or amounts and is
obtained by discounting the estimated future cash flows or amounts by a discount </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
rate that takes into account macroeconomic assumptions and estimates of risk, the opportunity cost of capital, capital structure, income taxes, expected returns and other appropriate factors and
assumptions. The preliminary discounted cash flow analysis was based on the estimated net present value of (i)&nbsp;the unlevered,&nbsp;after-tax&nbsp;free cash flows of Cibus Global through December&nbsp;31, 2032 from the Cibus Global Financial
Projections and (ii)&nbsp;a terminal value for Cibus Global determined using the Cibus Global Financial Projections and perpetuity growth rates from 0.5% to 2.5%. The amounts were discounted using discount rates ranging from 12% to 20%, which were
based upon Cibus Global&#146;s weighted average cost of capital (determined using the capital asset pricing model and taking into account certain financial metrics, including capital structure, betas for a comparable group of companies, market risk
and tax rates). Based on this analysis, the Calyxt Board considered and evaluated a range of implied enterprise values for Cibus Global of $285&nbsp;million to $962&nbsp;million utilizing a terminal value based on the unlevered, <FONT
STYLE="white-space:nowrap">after-tax</FONT> free cash flow for 2028 and a range of implied enterprise values for Cibus Global of $1,646&nbsp;million to $5,466&nbsp;million utilizing a terminal value based on the unlevered, <FONT
STYLE="white-space:nowrap">after-tax</FONT> free cash flow for 2032. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preliminary Contribution Analysis </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also at the October&nbsp;19, 2022 meeting of the Calyxt Board, the Calyxt Board reviewed and considered a preliminary contribution analysis
that analyzed the relative contribution of Calyxt to the revenue and adjusted EBITDA for the pro forma combined company resulting from the Transactions based upon the Unaudited Financial Projections. The relative contribution of which are summarized
below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center">($ in millions)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="24"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cibus Global</B></P></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">FY2023</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">FY2024</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">FY2025</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">FY2026</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">FY2027</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">FY2028</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">199.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">309.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjusted EBITDA<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(47.1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(41.8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13.5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">124.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">218.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="25"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="24"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Calyxt, Inc.</B></P></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">FY2023</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">FY2024</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">FY2025</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">FY2026</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">FY2027</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">FY2028</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">151.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">312.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjusted EBITDA<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(20.0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(20.1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(20.0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">117.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjusted EBITDA<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP> (excluding public company
costs<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16.5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16.5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16.4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">121.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="25"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="24" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Calyxt, Inc. % Contribution<SUP
STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">FY2023</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">FY2024</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">FY2025</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">FY2026</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">FY2027</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">FY2028</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">% of Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">% of Adjusted EBITDA<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">NM</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">NM</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">NM</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">NM</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">% of Adjusted EBITDA<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP> (excluding public
company costs<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">NM</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">NM</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">NM</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Calyxt Financial Projections assumed incremental financing of $95 million over the 2022 to 2025 period,
including $25 million in 2022. &#147;NM&#148; represents not meaningful due to calculation including negative number. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Cibus Global and Calyxt, Inc. define Adjusted EBITDA differently. See &#147;<I>Unaudited Financial
Projections</I>&#148; for a discussion of Adjusted EBITDA, as defined by each of Cibus Global and Calyxt, Inc. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Assumes $3.4&nbsp;million of &#147;public company&#148; costs in 2022 with annual increases of 2% for each
subsequent year. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing information and factors considered by the Calyxt Board (including the Calyxt Committee)
are not intended to be exhaustive but are believed to include all of the material factors considered by the Calyxt Board and the Calyxt Committee. In view of the wide variety of factors considered in connection with its evaluation of the Mergers and
the complexity of these matters, the Calyxt Board (including the Calyxt Committee) did not find it </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
useful to attempt, and did not attempt, to quantify, rank or otherwise assign relative weights to these factors. In considering the factors described above, individual members of the Calyxt Board
and/or the Calyxt Committee may have given different weight to different factors. The Calyxt Board (including the Calyxt Committee) conducted an overall analysis of the factors described above, including thorough discussions with, and questioning
of, Calyxt&#146;s senior management team and financial and legal advisors and consultants to the Calyxt Board and/or the Calyxt Committee, and considered the factors overall to be favorable to, and to support, its determination. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom401831_18"></A>Cibus Reasons for the Mergers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the course of reaching its decision to approve the Cibus Merger, the Cibus Board held numerous meetings, consulted with Cibus&#146; senior
management, its advisors and legal counsel, and reviewed and assessed a significant amount of information. Ultimately, the Cibus Board concluded that a merger with Calyxt, Inc., together with the additional financing committed from the Cibus <FONT
STYLE="white-space:nowrap">pre-Closing</FONT> financing, was the best option to generate capital resources to support the advancement of Cibus&#146; pipeline of productivity traits and fund a combined organization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additional factors that the Cibus Board considered included the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Mergers would create more value for Cibus Global equityholders in the long-term than Cibus could create as an
independent, stand-alone company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Mergers will provide current Cibus Global equityholders with greater liquidity by owning publicly-traded
stock, and expanding both the access to capital for Cibus and the range of investors potentially available as a public company, compared to the investors Cibus could otherwise gain access to if it continued to operate as a privately-held company;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential benefits from increased public market awareness of Cibus and its pipeline of productivity traits;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the historical and current information concerning Cibus&#146; business, including its financial performance and
condition, operations and management; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the projected financial position, operations, management structure, operating plans, and anticipated cash burn
rate of the Combined Company, including the ability to support the Combined Company&#146;s current and planned operations, as further discussed in the section entitled <I>&#147;Cibus Management&#146;s Discussion and Analysis of Financial Condition
and Results of Operations&#151;Liquidity and Capital Resources&#151;Future Capital Requirements&#148;</I> beginning on page&nbsp;277 of this proxy statement/prospectus; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the additional financing from the Continuing Series F Financing, and the Series F Purchase Commitment, in
particular, to support the operations of the Combined Company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the business, history, operations, assets and technology of Calyxt; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Combined Company is expected to be led by an experienced management team; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the expected timeline for the initial Cibus productivity traits to reach the market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms and conditions of the Merger Agreement, including the following: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the determination that the expected relative percentage ownership of Calyxt Stockholders and holders of <FONT
STYLE="white-space:nowrap">pre-closing</FONT> Cibus Units, Cibus Warrants and Cibus PIUs in the Combined Company was appropriate, based on the Cibus Board&#146;s judgment and assessment of the approximate valuations of Calyxt (considering, among
other things, Calyxt&#146;s cash position) and Cibus; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the expectation that the Mergers will be treated as a reorganization for U.S. federal income tax purposes, with
the result that in the Mergers holders of <FONT STYLE="white-space:nowrap">pre-closing</FONT> Cibus Units, Cibus Warrants and Cibus PIUs will generally not recognize taxable gain or loss for U.S. federal income tax purposes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the limited number and nature of the conditions of the obligation of Calyxt, Inc. to complete the Mergers;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the conclusion of the Cibus Board that the potential termination fees payable by Calyxt, Inc. to Cibus Global,
and the circumstances when such fee may be payable, were reasonable; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the belief that the other terms of the Merger Agreement, including the parties&#146; representations, warranties
and covenants, and the conditions to their respective obligations, were reasonable in light of the entire transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the shares of Class&nbsp;A Common Stock issued to holders of <FONT STYLE="white-space:nowrap">pre-Closing</FONT>
Cibus Units (other than the Top 99 Holders who elect to receive Class&nbsp;B Common Stock), <FONT STYLE="white-space:nowrap">pre-Closing</FONT> Cibus Warrants and <FONT STYLE="white-space:nowrap">pre-Closing</FONT> Cibus PIUs will be registered on a
Form <FONT STYLE="white-space:nowrap">S-4</FONT> registration statement and will be freely tradable (subject to applicable securities law limitations with respect to shares of Class A Common Stock held by affiliates); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to obtain a Nasdaq listing and the change of the Combined Company&#146;s name to &#147;Cibus,
Inc.&#148; upon the closing of the Mergers; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the likelihood that the Mergers will be completed on a timely basis. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Cibus Board also considered a number of uncertainties and risks in its deliberations concerning the Mergers and the other Transactions,
including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possibility that the Mergers might not be completed and the potential adverse effect of the public
announcement of the Mergers on the reputation of Cibus and the ability of Cibus to obtain financing in the future in the event the Mergers are not completed; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the exchange ratio used to establish the number of shares of Class&nbsp;A Common Stock or Class&nbsp;B Common
Stock to be issued to holders of <FONT STYLE="white-space:nowrap">pre-Closing</FONT> Cibus Units, Cibus Warrants and Cibus PIUs in the Mergers is fixed and thus the relative percentage ownership of Calyxt Stockholders and Cibus Units, Cibus Warrants
and Cibus PIUs in the Combined Company immediately following the completion of the Mergers is similarly fixed; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Calyxt&#146;s cash position, the potential need to provide financing to Calyxt pursuant to the Interim Funding
and the cash position and needs of the Combined Company following completion of the Mergers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possibility that Calyxt, Inc. could, under certain circumstances, consider unsolicited acquisition proposals
if superior to the Mergers or change its recommendation to approve the Mergers upon certain events; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that the Mergers might not be completed in a timely manner or at all, for a variety of reasons, such as
the failure of Calyxt, Inc. to obtain the required stockholder vote, and the potential adverse effect on the reputation of Calyxt and the ability of Calyxt to obtain financing in the future in the event the Mergers are not completed;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs involved in connection with completing the Mergers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the current financial market conditions and historical market prices, volatility and trading information with
respect to Calyxt Common Stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Calyxt Board did not receive a fairness opinion from its financial advisor in connection with the Mergers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the time and effort of Cibus Global senior management required to complete the Mergers, the related disruptions
or potential disruptions to Cibus&#146; business operations and future prospects, including its relationships with its employees, suppliers and partners and others that do business or may do business in the future with Cibus, and related
administrative challenges associated with combining the companies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the additional expenses and obligations to which Cibus&#146; business will be subject following completion of the
Mergers that Cibus has not previously been subject to, and the operational changes to Cibus&#146; business, in each case that may result from being a public company; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the representations and warranties in the Merger Agreement do not survive the Closing and the
potential risk of liabilities that may arise post-Closing; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">various other risks associated with the combined organization and the merger, including the risks described in
the section entitled &#147;<I>Risk Factors</I>&#148; beginning on page 40 of this proxy statement/prospectus. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
foregoing information is not intended to be exhaustive, but summarizes the material factors considered by the Cibus Board in its consideration of the Merger Agreement and the Transactions. The Cibus Board concluded that the benefits, advantages and
opportunities of a potential transaction outweighed the uncertainties and risks described above. After considering these and other factors, the Cibus Board unanimously approved the Merger Agreement, the Mergers and the Transactions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom401831_18b"></A>Unaudited Financial Projections </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither Calyxt, Inc. nor Cibus Global, as a matter of course, makes public long-term forecasts or internal projections as to future
performance, revenues, earnings or other financial or operating results due to, among other reasons, the uncertainty of the underlying assumptions and estimates. However, in connection with the evaluation of the Transactions: (i)&nbsp;the following
unaudited internal financial information was prepared by Calyxt, Inc.: certain unaudited internal financial forecasts with respect to Calyxt, Inc. on a stand-alone basis, prepared by Calyxt management in May 2022, and provided to Cibus Global in
October 2022, which we refer to as the &#147;Calyxt Financial Projections,&#148; and (ii)&nbsp;the following unaudited internal financial information was shared with the Calyxt Board (including the Calyxt Committee): certain unaudited internal
financial forecasts with respect to Cibus Global on a stand-alone basis that were prepared by Cibus Global management in October 2022, and provided to Calyxt, Inc. on October&nbsp;11, 2022, which we refer to as the &#147;Cibus Global Financial
Projections.&#148; We refer to the Calyxt Financial Projections and the Cibus Global Financial Projections, collectively, as the &#147;Financial Projections.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The inclusion of the Financial Projections should not be regarded as an indication that any of Calyxt, Inc., Cibus Global, their respective
affiliates, officers, directors, advisors, other representatives, or any other recipient of the Financial Projections considered, or now considers, such Financial Projections to be predictive of actual future performance or events, or that they
should be construed as financial guidance, and such summary projections set forth below should not be relied on as such. Accordingly, the Financial Projections are not included to influence any person&#146;s views on the Mergers and are summarized
in this proxy statement/prospectus solely to provide access to information that was provided to the Calyxt Board (including the Calyxt Committee) and to Canaccord Genuity to assist in their respective analyses of the Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Financial Projections were prepared solely for internal use and are subjective in many respects. While presented with numeric specificity,
the Financial Projections reflect numerous estimates and assumptions (including, in the case of the Calyxt Financial Projections, assumed incremental financing) made at the time the Financial Projections were prepared that are inherently uncertain
and many of which are beyond the control of Calyxt&#146;s and Cibus Global&#146;s managements. Further, given that the Financial Projections cover multiple years, by their nature, they become subject to greater uncertainty with each successive year
beyond their preparation. The Financial Projections are subject to various risks, including, among others, the effect of future regulatory or legislative actions on the companies or the industries in which they operate, the potential impact of the
announcement or consummation of the Transactions on relationships with customers, providers, vendors, competitors, management and other employees, changes in the general economic environment, or social or political conditions, that could affect the
businesses, potential liability resulting from pending or future litigation, the uncertainties, costs and risks involved in Calyxt&#146;s and Cibus&#146; operations, including the matters described in the sections titled &#147;<I>Cautionary
Statement Concerning Forward-Looking Statements</I>,&#148; &#147;<I>Where You Can Find More Information</I>&#148; and &#147;<I>Risk Factors</I>&#148; beginning on pages 114, 365 and 40 of this proxy statement/prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Financial Projections reflect both assumptions as to certain business decisions that are subject to change and, in many respects, personal
judgment, and thus are susceptible to multiple interpretations and, in the ordinary </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
course, would be expected to undergo periodic revisions based on actual experience (e.g., Calyxt, Inc.&#146;s inability to obtain incremental financing in 2022 at the levels reflected in Calyxt,
Inc.&#146;s projections) and business developments. None of Calyxt, Inc., Cibus Global or their respective affiliates, officers, directors, advisors or other representatives can give assurance that the Financial Projections and the underlying
estimates and assumptions will be realized. The Financial Projections constitute &#147;forward-looking statements&#148; and actual results may differ materially and adversely from those set forth below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither Calyxt, Inc. nor Cibus Global, as a matter of course, make public projections as to future sales, earnings or other financial results.
As such, the Financial Projections were not prepared with a view toward public disclosure. The Financial Projections do not take into account any circumstances or events occurring after the date they were prepared and neither Calyxt, Inc. nor Cibus
Global can give assurance that, had the Financial Projections been prepared either as of the date of the Merger Agreement or as of the date of this proxy statement/prospectus, similar estimates and assumptions would be used. The Financial
Projections do not take into account all of the possible financial and other effects of the Transactions on Calyxt, Inc. or Cibus Global, the effect on Calyxt, Inc. or Cibus Global of any business or strategic decision or action that has been or
will be taken as a result of the Merger Agreement having been executed, or the effect of any business or strategic decisions or actions that would likely have been taken if the Merger Agreement had not been executed, but which were instead altered,
accelerated, postponed or not taken in anticipation of the Transactions. Further, the Financial Projections do not take into account the effect on Calyxt, Inc. or Cibus Global of any possible failure of the Transactions to occur. None of Calyxt,
Inc. or Cibus Global or any of their respective affiliates, officers, directors, advisors or other representatives has made, makes or is authorized in the future to make any representation to any Calyxt Stockholder or Cibus Global Unitholder or
other person regarding Calyxt, Inc.&#146;s or Cibus Global&#146;s ultimate performance compared to the information contained in the Financial Projections or that the Financial Projections will be achieved. The inclusion of the Financial Projections
herein should not be deemed an admission or representation by Calyxt, Inc., Cibus Global, their respective affiliates, officers, directors, advisors or other representatives or any other person that it is viewed as material information of Calyxt,
Inc. or Cibus Global, particularly in light of the inherent risks and uncertainties associated with such forecasts. The summary of the Financial Projections included below is not being included in this proxy statement/prospectus in order to
influence the decision of any Calyxt Stockholder or Cibus Global Unitholder or to induce any Calyxt Stockholder to vote in favor of any of the proposals at the Calyxt Special Meeting or to take any other action relating to the Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Financial Projections were not prepared with a view toward compliance with GAAP, published guidelines of the SEC or the guidelines
established by the American Institute of Certified Public Accountants for preparation or presentation of prospective financial information. Neither Ernst&nbsp;&amp; Young LLP nor BDO USA LLP has audited, reviewed, examined, compiled or applied
agreed-upon procedures with respect to the Financial Projections and, accordingly, neither Ernst&nbsp;&amp; Young LLP nor BDO USA LLP expresses an opinion or any other form of assurance on such information or its achievability, and assumes no
responsibility for, and disclaims any association with, the prospective financial information with respect thereto. The report of Ernst&nbsp;&amp; Young LLP which is included this proxy statement/prospectus relates to historical financial
information of Calyxt, Inc., and such report does not extend to the Calyxt Financial Projections and should not be read to do so. In addition, the report of BDO USA LLP which is included in this proxy statement/prospectus relates to historical
financial information of Cibus Global, and such report does not extend to the Cibus Global Financial Projections and should not be read to do so. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Financial <FONT STYLE="white-space:nowrap">Projections&nbsp;include&nbsp;non-GAAP&nbsp;financial&nbsp;measures,&nbsp;including</FONT>
Adjusted EBITDA for each of Calyxt, Inc. and Cibus Global, EBITDA for Calyxt, Inc. and Free Cash Flow for Cibus Global. Please see the tables below for a description of how Calyxt, Inc. and Cibus Global define
<FONT STYLE="white-space:nowrap">these&nbsp;non-GAAP&nbsp;financial</FONT> measures for purposes of the Financial Projections in this <FONT STYLE="white-space:nowrap">section.&nbsp;Non-GAAP&nbsp;financial</FONT> measures should not be considered in
isolation from, or as a substitute for, financial information presented in accordance with GAAP, and <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measures used by Calyxt, Inc. and Cibus Global may not be comparable to one another or to
similarly titled measures used by other companies. The SEC rules that would otherwise require a reconciliation </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of a <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measure to a GAAP financial measure do not apply to <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measures provided to
a board of directors or a financial advisor in connection with a proposed business combination transaction such as the Transactions if the disclosure is included in a document such as this proxy statement/prospectus. Accordingly, Calyxt, Inc. is not
presenting a reconciliation of the financial measures included in the Financial Projections to the relevant GAAP financial measures in this proxy statement/prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In light of the foregoing, and considering that the Calyxt Special Meeting will be held a substantial amount of time after the Financial
Projections were prepared, as well as the uncertainties inherent in any forecasted information, Calyxt Stockholders and Cibus Unitholders are cautioned not to place undue reliance on such information, and each of Calyxt, Inc. and Cibus Global
caution you that the Financial Projections should be evaluated, if at all, in conjunction with the historical financial statements and other information regarding Calyxt, Inc. and Cibus Global, as applicable, contained elsewhere in this proxy
statement/prospectus. See the section titled &#147;<I>Where You Can Find More Information</I>&#148; beginning on page&nbsp;365 of this proxy statement/prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Calyxt Financial Projections </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="26" ALIGN="center">For the Year Ended December 31<BR>($ in millions)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">FY<BR>2022</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">FY<BR>2023</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">FY<BR>2024</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">FY<BR>2025</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">FY<BR>2026</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">FY<BR>2027</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">FY<BR>2028</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">151.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">312.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Gross Profit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">76.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">167.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating Profit (EBIT)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(26.2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(25.2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(26.1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(26.9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7.2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">109.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">EBITDA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(25.5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(24.4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(24.5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(24.5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4.7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">113.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjusted EBITDA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(21.2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(20.0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(20.1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(20.0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">117.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Incremental Financing Assumed*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">* Incremental Financing of $95&nbsp;million is required over the 2022 to 2025 period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<U>EBITDA</U>&#148; is defined as net loss, excluding interest, net, depreciation expense, and amortization expense, and includes adjustments to exclude
restructurings and realignment costs, special charges and gain or loss from sale of businesses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<U>Adjusted EBITDA</U>&#148; is defined as EBITDA,
excluding operating lease <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset amortization expenses, <FONT STYLE="white-space:nowrap">non-cash</FONT> stock compensation expenses (including the recapture
of <FONT STYLE="white-space:nowrap">non-cash</FONT> stock compensation associated with the departure of Section&nbsp;16 officers), cash-based Section&nbsp;16 officer transition expenses, the gain upon the extinguishment of Calyxt&#146;s PPP loan,
commodity derivative impact, net, net realizable value adjustment to inventories, and <FONT STYLE="white-space:nowrap">non-operating</FONT> income (expenses). Adjusted EBITDA is not a measure of financial performance under GAAP. Accordingly, it
should not be considered as a substitute for net income (loss), operating income (loss) or other measures prepared in accordance with GAAP. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cibus Global Financial Projections </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="42" ALIGN="center">For the Year Ended December 31<BR>($ in millions)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">FY<BR>2022</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">FY<BR>2023</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">FY<BR>2024</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">FY<BR>2025</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">FY<BR>2026</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">FY<BR>2027</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">FY<BR>2028</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">FY<BR>2029</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">FY<BR>2030</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">FY<BR>2031</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">FY<BR>2032</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">199.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">309.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">539.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">833.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,322.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,773.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income Before Interest and Taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(49.9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(57.2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(55.6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(27.4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">127.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">233.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">459.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">748.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,233.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,682.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjusted Income Before Taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(50.0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(57.3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(55.7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(27.6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 5.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">110.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">205.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">406.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">665.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,087.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,485.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjusted Net Income (Loss)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(50.0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(57.3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(55.7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(27.6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 5.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">104.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">169.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">340.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">559.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 917.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,256.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjusted EBITDA</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(43.1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(47.1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(41.8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13.5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">124.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">218.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">419.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">680.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,105.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,502.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Free Cash Flow</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(52.6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(61.1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(57.8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16.3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">111.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">173.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">340.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">561.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 921.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,260.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<U>Adjusted EBITDA</U>&#148; is defined as earnings before interest, taxes, depreciation and amortization expense,
non-cash equity-based compensation, interest expense, royalty liability - related parties, other non-operating expenses and income and adjusted to include cash payments for the royalty obligation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<U>Free Cash Flow</U>&#148; is defined as Adjusted EBITDA less capital expenditures, plus or minus changes in net working capital. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom401831_18a"></A>Interests of the Financial Advisor to the Calyxt Committee </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with Canaccord Genuity&#146;s services as financial advisor to the Calyxt Committee, Calyxt, Inc. (i)&nbsp;paid Canaccord Genuity
a signing fee of $75,000, (ii) agreed to pay Canaccord Genuity a quarterly work fee of $50,000 (of which an aggregate of $225,000 has been paid as of the date of this proxy statement/prospectus), (iii) agreed to pay Canaccord Genuity an opinion fee
of $500,000 upon the delivery to the Calyxt Committee (if requested by the Calyxt Committee) of a fairness opinion, regardless of the conclusions reached in such opinion and (iv)&nbsp;agreed to pay Canaccord Genuity a transaction fee of the greater
of (x) 2.5% of the aggregate consideration paid in a sale transaction or (y) $1,750,000 upon the closing of a sale transaction. All amounts of the signing fee and the work fees will be credited against any transaction fee. In the event that the
Merger Agreement is terminated, Canaccord Genuity could be entitled to a portion of any termination fee paid to Calyxt, Inc. In addition, Canaccord Genuity could be entitled to a financing fee from Calyxt, Inc. in connection with a financing
transaction based on the percentage of gross proceeds received in such financing transaction. In addition, Calyxt agreed to reimburse Canaccord Genuity for certain expenses incurred in connection with Canaccord Genuity&#146;s engagement, and to
indemnify Canaccord Genuity and certain related persons against certain liabilities that may arise from or related to Canaccord Genuity&#146;s engagement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Canaccord Genuity has in the past provided, currently is providing, and in the future may provide certain other investment banking services to
Calyxt, Inc., for which Canaccord Genuity has received and may receive<B></B>&nbsp;compensation, including, during the past two years. During this period, Canaccord Genuity acted as lead placement agent in the offering of common stock and warrants
by Calyxt, Inc. that closed on February&nbsp;23, 2022, which raised approximately $10&nbsp;million in net proceeds, for which Canaccord Genuity received compensation of $531,913. Canaccord Genuity has not provided any investment banking services to
Cibus Global in the past two years. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom401831_19"></A>Interests of Calyxt, Inc. Directors and Executive Officers in the Mergers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In considering the recommendation of the Calyxt Board with respect to approving the Mergers, Calyxt Stockholders should be aware that certain
members of the Calyxt Board and certain Calyxt, Inc. executive </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
officers have interests in the Mergers that may be different from, or in addition to, the interests of Calyxt Stockholders. These interests may present them with actual or potential conflicts of
interest, and these interests, to the extent material, are described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Calyxt Board and the Cibus Board were aware of these
potential conflicts of interest and considered them, among other matters, in reaching their respective decisions to approve the Merger Agreement and the Mergers, and in the Calyxt Board reaching its decision to recommend that Calyxt Stockholders
approve the proposals to be presented to Calyxt Stockholders for consideration at the Calyxt Special Meeting as contemplated by this proxy statement/prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except where specifically noted, the information in this section and all other information contained in this proxy statement/prospectus does
not give effect to the Reverse Stock Splits described elsewhere in this proxy statement/prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ownership Interests </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March 31, 2023, Calyxt, Inc.&#146;s directors and current executive officers owned, in the aggregate, 1.7% of the shares of Calyxt Common
Stock, which for purposes of this subsection excludes any Calyxt Common Stock issuable upon (i)&nbsp;exercise of Calyxt, Inc. options held by such individuals or (ii)&nbsp;vesting of Calyxt RSUs or Calyxt PSUs held by such individuals. In addition,
Laurent Arthaud is a director of Cellectis, Calyxt, Inc.&#146;s largest stockholder. Certain Calyxt Stockholders, directors and officers have also entered into Calyxt Support Agreements in connection with the Mergers whereby such stockholders,
directors and officers have agreed to take certain actions to support the Transactions including not transferring their shares during the term of such agreement, voting in favor of the Merger Agreement and the Transactions and against any
alternative acquisition proposals. The affirmative vote of the majority of the votes cast at the Calyxt Special Meeting and entitled to vote on the subject matter is required for approval of Proposal Nos.&nbsp;2 and 5. The affirmative vote of the
majority of the votes cast affirmatively or negatively by holders present or represented by proxy at the Calyxt Special Meeting and entitled to vote on the subject matter is required for approval of Proposal Nos. 6 (on an advisory basis) and 7. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Approval of Proposals No.&nbsp;1, 3 (on an advisory basis) and 4 require the affirmative vote of the holders of a majority of Calyxt Common
Stock on the record date for the Calyxt Special Meeting entitled to vote on the subject matter. See the section entitled &#147;<I>Principal Stockholders of Calyxt, Inc.</I>&#148; on page 356 of this proxy statement/prospectus for a description of
the beneficial ownership of Calyxt, Inc.&#146;s directors and executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Effect of the Mergers on Calyxt, Inc. Options </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March 31, 2023, Calyxt, Inc.&#146;s directors and current executive officers held, in the aggregate, unvested stock options covering
1,605,794 shares of Calyxt Common Stock and vested stock options covering 1,293,079 shares of Calyxt Common Stock. Unvested and vested stock options to purchase Calyxt Common Stock are referred to herein as the &#147;Calyxt Stock Options.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent not previously vested, Calyxt Stock Options granted pursuant to the Calyxt, Inc. Equity Incentive Plan (the &#147;Equity
Incentive Plan&#148;) become vested (and thus exercisable) with respect to 25% of the total number of shares covered by the options upon a triggering event (as defined in the Equity Incentive Plan). Further, if the optionholder experiences a
termination without cause or resignation for good reason within 12&nbsp;months following the triggering event, the optionholder&#146;s stock options granted pursuant to the Equity Incentive Plan will vest (and become exercisable) with respect to
100% of the shares underlying the options. To the extent not previously vested, Calyxt Stock Options granted pursuant to the Calyxt, Inc. 2017 Omnibus Incentive Plan (the &#147;2017 Omnibus Plan&#148;) become vested (and thus exercisable) upon a
triggering event (as defined in the 2017 Omnibus Plan)&nbsp;(i) with respect to 25% of the total number of shares covered by the options held by an executive officer and (ii)&nbsp;with respect to 100% of the total number of shares covered by the
option held by <FONT STYLE="white-space:nowrap">non-employee</FONT> directors of Calyxt, Inc. Further, if an executive officer optionholder experiences a termination without cause or resignation for good reason within 12 months following the
triggering event, the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
optionholder&#146;s stock options granted pursuant to the 2017 Omnibus Plan will vest (and become exercisable) with respect to 100% of the shares underlying the options. The Cibus Merger will
constitute a triggering event under each of the Equity Incentive Plan and 2017 Omnibus Plan (collectively, the &#147;Equity Plans&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As permitted by the terms of the Merger Agreement, Calyxt amended the Calyxt Stock Options to permit the exercisability of vested Calyxt Stock
Options after termination of a participant&#146;s continuous service for up to five years from the grant date of the applicable Calyxt Stock Option, provided that the extended period not continue beyond the original expiration date for the Calyxt
Stock Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the Cibus Merger, all outstanding and unexercised Calyxt Stock Options granted under the Equity Plans will remain in
effect pursuant to their terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding the value of outstanding Calyxt Stock Options held
by Calyxt, Inc.&#146;s directors and executive officers as of March 31, 2023, assuming that the Cibus Merger occurs on March 31, 2023, that the employment of the executive officer is terminated without cause effective immediately after the closing
of the Cibus Merger and that the fair market value of a share of Class&nbsp;A Common Stock is equal to $0.29, which is the average closing price of a share of Calyxt Common Stock on Nasdaq over the first five trading days following the first public
announcement of the Cibus Merger on January&nbsp;17, 2023. The fair market value of each Calyxt Stock Option was determined by subtracting the exercise price of the Calyxt Stock Option from $0.29 per share. The number of shares of Calyxt Common
Stock underlying such Calyxt Stock Options will be equitably adjusted in accordance with the Equity Plans to reflect the Reverse Stock Splits, but the following table does not reflect such equitable adjustment. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares<BR>Underlying<BR>Previously Vested<BR>Options<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Value&nbsp;of&nbsp;Previously<BR>Vested&nbsp;Options&nbsp;($)<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares<BR>Underlying&nbsp;Options<BR>That&nbsp;will&nbsp;Vest&nbsp;in&nbsp;the<BR>Merger
<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Value&nbsp;of&nbsp;Options<BR>that will Vest in<BR>the&nbsp;Merger ($)<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Executive Officers</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael A. Carr</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">189,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">500,834</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William F. Koschak</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">270,164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">295,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Travis J. Frey, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">191,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">262,168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Debra Frimerman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">193,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">263,168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laurent Arthaud</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Yves J. Ribeill, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">211,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Philippe Dumont</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47,898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36,993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jonathan B. Fassberg</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,923</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anna Ewa Kozicz-Stankiewicz</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kimberly K. Nelson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,981</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher J. Neugent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44,708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This column includes the Calyxt Stock Options vested and exercisable immediately prior to the Cibus Merger.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This column reflects the value of the Calyxt Stock Options vested and exercisable immediately prior to the
Cibus Merger, based on the fair market value of a share of Class&nbsp;A Common Stock less the exercise price, assuming the following weighted average exercise prices: $3.65 for Mr.&nbsp;Carr, $9.52 for Mr.&nbsp;Koschak, $9.60 for Dr.&nbsp;Frey, and
$9.85 for Ms.&nbsp;Frimerman. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This column includes the Calyxt Stock Options that become vested and exercisable on or immediately after the
Cibus Merger, assuming, for executive officers, a termination without cause immediately after the Cibus Merger. Mr.&nbsp;Carr, Mr.&nbsp;Koschak, and Dr.&nbsp;Frey are also entitled to vesting of their Calyxt Stock Options
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
under the 2021 Executive Severance Plan upon a termination without cause or resignation for good reason (as defined in the plan), but the number vested would be the same, without duplication, as
the number vested under the Equity Plans and applicable award agreements for the Calyxt Stock Options. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This column reflects the value of the Calyxt Stock Options that become vested and exercisable on or immediately
after the Cibus Merger, based on the fair market value of a share of Class&nbsp;A Common Stock less the exercise price, assuming, for executive officers, a termination without cause or resignation for good reason immediately after the Cibus Merger
and assuming the following weighted average exercise prices: $1.78 for Mr.&nbsp;Carr, $4.15 for Mr.&nbsp;Koschak, $3.64 for Dr.&nbsp;Frey, and $3.74 for Ms.&nbsp;Frimerman. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Effect of the Merger on Calyxt RSUs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March 31, 2023, Calyxt, Inc.&#146;s directors and current executive officers held, in the aggregate, Calyxt RSUs covering 2,293,236
shares of Calyxt Common Stock granted pursuant to the 2017 Omnibus Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the restricted stock unit agreements applicable to
the Calyxt RSUs, upon a triggering event (as defined in the 2017 Omnibus Plan) (i) 25% of the total number of shares covered by Calyxt RSUs held by an executive officer will vest, except for those Calyxt RSUs granted on March 1, 2023, (ii) 100% of
the total number of shares covered by the Calyxt RSUs granted on March 1, 2023 will vest and (iii) 100% of the total number of shares covered by the Calyxt RSUs held by a <FONT STYLE="white-space:nowrap">non-employee</FONT> director will vest, to
the extent not previously vested. Further, if the executive officer experiences a termination without cause or resignation for good reason within 12 months following the triggering event 100% of the shares underlying the Calyxt RSUs will vest, to
the extent not previously vested. The Cibus Merger will constitute a triggering event under the 2017 Omnibus Plan. Upon the Cibus Merger, all outstanding Calyxt RSUs granted pursuant to the 2017 Omnibus Plan will remain in effect pursuant to their
terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding the outstanding Calyxt RSUs held by Calyxt, Inc.&#146;s directors and
executive officers as of March 31, 2023, assuming that the Cibus Merger occurs on March 31, 2023, that the employment of the executive officer is terminated without cause effective immediately after the closing of the Cibus Merger and that the fair
market value of a share of Class&nbsp;A Common Stock is equal to $0.29, which is the average closing price of a share of Calyxt Common Stock on Nasdaq over the first five trading days following the first public announcement of the Cibus Merger on
January&nbsp;17, 2023. The number of shares of Calyxt Common Stock underlying such Calyxt RSUs will be equitably adjusted to reflect the Reverse Stock Splits in accordance with the 2017 Omnibus Plan, but the following table does not reflect such
equitable adjustment. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares<BR>Underlying<BR>Unvested Calyxt<BR>RSUs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Unvested<BR>Calyxt&nbsp;RSUs&nbsp;that&nbsp;will<BR>vest in the Merger<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Value&nbsp;of&nbsp;Calyxt<BR>RSUs that will<BR>vest in the<BR>Merger ($)<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Executive Officers</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael A. Carr</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">643,901</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">643,901</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">186,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William F. Koschak</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">546,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">546,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">158,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Travis J. Frey, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">546,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">546,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">158,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Debra Frimerman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">546,901</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">546,901</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">158,601</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laurent Arthaud</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Yves J. Ribeill, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Philippe Dumont</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jonathan B. Fassberg</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anna Ewa Kozicz-Stankiewicz</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kimberly K. Nelson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher J. Neugent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This column includes the number of Calyxt RSUs that will vest on or immediately after the Cibus Merger,
assuming, for executive officers, a termination without cause immediately after the Cibus Merger. Mr.&nbsp;Carr, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Mr.&nbsp;Koschak, and Dr.&nbsp;Frey are also entitled to vesting of their Calyxt RSUs under the 2021 Executive Severance Plan upon a termination without cause or resignation for good reason (as
defined in the plan), but the number vested would be the same, without duplication, as the number vested under the 2017 Omnibus Plan and applicable award agreements for the Calyxt RSUs. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The values in this column have been calculated based on the number of Calyxt RSUs that will vest on or
immediately after the Cibus Merger and the fair market value of a share of Class&nbsp;A Common Stock. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Effect of the Merger on
Calyxt PSUs </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March 31, 2023, certain of Calyxt, Inc.&#146;s current executive officers held, in the aggregate, unvested
Calyxt PSUs covering 936,668 shares of Calyxt Common Stock, assuming maximum level of achievement of the applicable performance factors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the performance stock unit agreements under the 2017 Omnibus Plan in the case of a triggering event (as defined in the 2017
Omnibus Plan) that occurs during the performance period, the performance period will be truncated and will end as of the end of Calyxt&#146;s most recently completed fiscal quarter prior to the triggering event and achievement of the performance
factor for the remaining award will be measured as of such date. Pursuant to the performance stock unit agreement under the 2021 Employee Inducement Incentive Plan (the &#147;2021 Inducement Plan&#148;) in the case of a triggering event (as defined
in the 2021 Inducement Plan) during the performance period, 25% of the Calyxt PSUs will vest immediately, to the extent not already vested. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Cibus Merger will constitute a triggering event under the 2017 Omnibus Plan and 2021 Inducement Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding the outstanding Calyxt PSUs held by certain of Calyxt, Inc.&#146;s executive officers as
of March 31, 2023, assuming that the Cibus Merger occurs on <B></B>March 31, 2023, that the service of the executive officer is terminated without cause effective immediately after the closing of the Cibus Merger, that the performance factor
achieved is at maximum level or as stated in the award agreement in the case of awards made under the 2021 Inducement Plan, and that the fair market value of a share of Class&nbsp;A Common Stock is equal to $0.29, which is the average closing price
of a share of Calyxt Common Stock on Nasdaq over the first five trading days following the first public announcement of the Cibus Merger on January&nbsp;17, 2023. The number of shares of Calyxt Common Stock underlying such Calyxt PSUs will be
equitably adjusted to reflect the Reverse Stock Splits in accordance with the 2017 Omnibus Plan and 2021 Inducement Plan, but the following table does not reflect such equitable adjustment. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares&nbsp;Underlying<BR>Unvested&nbsp;Calyxt&nbsp;PSUs<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Unvested&nbsp;Calyxt&nbsp;PSUs<BR>that will vest in the<BR>Cibus Merger<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Value of<BR>Calyxt&nbsp;PSUs&nbsp;that&nbsp;will&nbsp;vest<BR>in&nbsp;the&nbsp;Cibus Merger ($)<SUP STYLE="font-size:75%; vertical-align:top">
(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Executive Officers</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael A. Carr</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">736,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">286,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">83,133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William F. Koschak</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Travis J. Frey, Ph.&nbsp;D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Debra Frimerman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The number in this column reflects the number of Calyxt PSUs assuming maximum level of achievement of the
applicable performance factors. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The number of Calyxt PSUs granted under the 2017 Omnibus Plan that are included in this column assumes the
service of the executive officers and directors is terminated without cause effective immediately after the closing of the Cibus Merger and that the performance factor achieved is at maximum level. The number of
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Calyxt PSUs included in this column for Mr.&nbsp;Carr also includes 25% of his Calyxt PSUs issued under the 2021 Inducement Plan. Mr.&nbsp;Carr, Mr.&nbsp;Koschak, and Dr.&nbsp;Frey are also
entitled to vesting of their Calyxt PSUs under the 2021 Executive Severance Plan upon a termination without cause or resignation for good reason (as defined in the plan), but the number vested would be the same, without duplication, as the number
vested under the 2017 Omnibus Plan and applicable award agreements for the Calyxt PSUs. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The values in this column have been calculated based on the number of Calyxt PSUs that will vest on or
immediately after the Cibus Merger and the fair market value of a share of Class&nbsp;A Common Stock. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Potential Going-Forward
Roles with Cibus, Inc. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The initial September&nbsp;30, 2022 indication of interest from Cibus specified that the executive officers
of Calyxt, Inc. and the Calyxt Board would resign and be replaced by designees of Cibus Global at the closing of the transaction. Following the initial indication of interest and through the January&nbsp;13, 2023 signing of the Merger Agreement,
there were no negotiations between any executive officer or director of Calyxt, Inc., on the one hand, and any representative of Cibus Global, regarding a going-forward role with the Combined Company. Following the signing of the Merger Agreement,
Rory Riggs, the Chairman and Chief Executive Officer of Cibus Global, has had conversations with certain executive officers and directors of Calyxt, Inc. regarding potential going-forward roles with the Combined Company, but as of the date of this
proxy statement/prospectus, no agreements have been reached regarding any such going-forward roles. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Termination of Existing Calyxt, Inc. Executive
Officers Following the Mergers and Related Severance Payments </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt, Inc. maintains the 2021 Executive Severance Plan (the
&#147;Calyxt Severance Plan&#148;) that provides for severance benefits for executives on a termination without cause or resignation for good reason, each as defined under the Calyxt Severance Plan (a &#147;Qualifying Termination&#148;). The
executive officers that are participants in the Calyxt Severance Plan are Mr.&nbsp;Carr, Mr.&nbsp;Koschak, and Dr.&nbsp;Frey. Ms.&nbsp;Frimerman is not a participant in the Calyxt Severance Plan but may become a participant prior to the Closing.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a participant experiences a Qualifying Termination during the <FONT STYLE="white-space:nowrap">27-month</FONT> period beginning three
months before the effective date of a change in control (as defined in the Calyxt Severance Plan), the participant is entitled to the following enhanced severance benefits under the Calyxt Severance Plan: (i)&nbsp;base salary continuation for the
&#147;Severance Coverage Period&#148; (24 months for Mr.&nbsp;Carr and 12 months for Mr.&nbsp;Koschak and Dr.&nbsp;Frey), (ii) for Mr. Koschak and Dr. Frey, a pro rata amount of the participant&#146;s target incentive under Calyxt&#146;s annual cash
incentive plan for the year in which the Qualifying Termination occurs and any unpaid bonus amounts from the previous plan year, and for Mr. Carr, his full target incentive under the Calyxt&#146;s annual cash incentive plan for the year in which the
Qualifying Termination occurs and any unpaid bonus amounts from the previous plan year, (iii)&nbsp;a lump sum equal to the total monthly premiums for medical and dental coverage under COBRA at the time of the participant&#146;s Qualifying
Termination for the severance coverage period, (iv)&nbsp;full accelerated vesting of all time-based equity awards such that the awards become vested or vested and exercisable in full, and (v)&nbsp;vesting of performance based equity awards at a
level reasonably determined by the Calyxt Board based on actual performance as of the date of the Qualifying Termination. If Ms.&nbsp;Frimerman becomes a participant in the Calyxt Severance Plan, she is expected to have a severance coverage period
of 12 months. The cash severance benefits for (i)&nbsp;and (ii) above are payable such that any portion of the cash severance which is exempt from Section 409A will be paid in substantially equal installments over the Severance Coverage Period and
any portion of the cash severance not exempt from Section 409A, will be paid on or before the 60<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> day following the Qualifying Termination and cash severance benefits for (iii)&nbsp;above are to
be paid on or before the 60<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> day following the Qualifying Termination (for a termination that occurs after a change in control). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Merger Agreement, each participant in the Calyxt Severance Plan who is employed by Calyxt, Inc. immediately prior
to the Closing and who (a)&nbsp;resigns from employment with Calyxt, Inc., Cibus Global, and their affiliates on the Closing Date for any reason or (b)&nbsp;is terminated by Calyxt, Inc. or Cibus Global other than for cause, death, or disability (as
such terms are defined in the Calyxt Severance Plan) on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Closing Date, will be deemed to undergo a Qualifying Termination during a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">change-in-control</FONT></FONT> period, which will
entitle the participant to receive the corresponding enhanced severance benefits as set forth above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt, Inc.&#146;s obligation to
pay the severance payments to participants of the Calyxt Severance Plan is contingent upon the participant&#146;s execution and <FONT STYLE="white-space:nowrap">non-revocation</FONT> of a release of claims in favor of Calyxt, Inc. In addition,
Calyxt, Inc.&#146;s obligation to pay such severance payments is subject to the participant&#146;s compliance with certain covenants, including <FONT STYLE="white-space:nowrap">non-disparagement</FONT> which is perpetual in duration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Calyxt Severance Plan also provides that to the extent that any severance or other compensation payment to a participant constitutes an
&#147;excess parachute payment&#148; within the meaning of Sections 280G and 4999 of the Code, then the executive officer will receive the greater of such severance and other payments, or a reduced amount intended to avoid the application of
Sections 280G and 4999 of the Code, whichever provides the executive officer with the highest amount on an <FONT STYLE="white-space:nowrap">after-tax</FONT> basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table describes the potential payments to the executive officers upon a Qualifying Termination assuming that the Cibus Merger
occurs on March 31, 2023 and that the executive officer has a Qualifying Termination immediately after the closing of the Cibus Merger. It does not reflect any reductions that may be implemented to avoid the application of Sections 280G and 4999 of
the Code. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Base&nbsp;Salary<BR>($)<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus<BR>($)<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accelerated<BR>Vesting of<BR>Calyxt&nbsp;RSUs<BR>and Calyxt<BR>PSUs<BR>($)<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accelerated<BR>Vesting of<BR>Calyxt&nbsp;Options<BR>($)<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Health<BR>Benefits<BR>Continuation<BR>($)<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>($)<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Executive Officers</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael A. Carr</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">269,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,806,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William F. Koschak</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">340,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">177,837</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,352</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">575,439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Travis J. Frey, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">177,692</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">529,614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts listed in these columns represent cash severance amounts payable to the executive officer pursuant
to the Calyxt Severance Plan equal to the base salary continuation for 24 months for Mr.&nbsp;Carr and 12 months for Mr.&nbsp;Koschak and Dr.&nbsp;Frey and bonus equal to the pro rata amount of their target incentive for the year of termination for
the period from January&nbsp;1, 2023, to the Closing for Mr.&nbsp;Koschak and Dr.&nbsp;Frey, and the full target incentive for the year of termination for Mr.&nbsp;Carr, payable to each aforementioned executive officer such that any portion of the
cash severance which is exempt from Section&nbsp;409A will be paid in substantially equal installments over the Severance Coverage Period and any portion of the cash severance not exempt from Section&nbsp;409A, to be paid on or before the 60th day
following the Qualifying Termination. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts listed in this column represent, without duplication of benefits, (i)&nbsp;the value of the full
acceleration of vesting of the unvested Calyxt RSUs held by the named executive officer under the Calyxt Severance Plan and (ii)&nbsp;the value of the acceleration of Calyxt PSUs as determined under the Calyxt Severance Plan, and the 2021 Inducement
Plan, as applicable. The amounts assume the fair market value of a share of Class&nbsp;A Common Stock is equal to $0.29, which is the average closing price of a share of Calyxt Common Stock on Nasdaq over the first five trading days following the
first public announcement of the Cibus Merger on January&nbsp;17, 2023. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts listed in this column represent, without duplication of benefits, the value of the full
acceleration of vesting of the unvested Calyxt Stock Options under the Calyxt Severance Plan, based on the fair market value of a share of Class&nbsp;A Common Stock less the exercise price and assuming the following weighted average exercise prices:
$1.78 for Mr.&nbsp;Carr, $4.15 for Mr.&nbsp;Koschak, and $3.64 for Dr.&nbsp;Frey, and assuming the fair market value of a share of Class&nbsp;A Common Stock is equal to $0.29, which is the average closing price of a share of Calyxt Common Stock on
Nasdaq over the first five trading days following the first public announcement of the Cibus Merger on January&nbsp;17, 2023. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts listed in this column represent the value of the total monthly premiums for medical and dental
coverage under COBRA continued group health and dental insurance benefits for the executive officer (and his or her eligible dependents) at the time of the executive&#146;s termination multiplied by the Severance Coverage Period to be provided under
to the Calyxt Severance Plan for Mr.&nbsp;Carr, Mr.&nbsp;Koschak, and Dr.&nbsp;Frey to be on or before the 60th day following the Qualifying Termination. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts in this column include the aggregate dollar value of the sum of all amounts reported in the
preceding columns. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Frimerman Employment Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt, Inc. is party to an employment agreement with Ms.&nbsp;Frimerman dated January&nbsp;21, 2019 (the &#147;Frimerman Agreement&#148;).
Pursuant to the Frimerman Agreement if Ms.&nbsp;Frimerman&#146;s employment is terminated by Calyxt, Inc. without cause (as defined in the Frimerman Agreement), she is eligible to receive severance payments that include a pro rata annual performance
bonus and 12 months of base salary paid in installments. Assuming Ms.&nbsp;Frimerman&#146;s employment is terminated by Calyxt, Inc. without cause immediately after the closing of the Cibus Merger, the estimated amount of her severance payments
would be $321,000 in the aggregate for continued base salary and $32,100 for the pro rata annual performance bonus, assuming the performance metrics were achieved at target. Calyxt, Inc. may condition any severance pay to Ms.&nbsp;Frimerman upon her
entering into a full release of claims in favor of Calyxt, Inc. If Ms.&nbsp;Frimerman becomes a participant in the Calyxt Severance Plan, she will not be entitled to the severance payments under the Frimerman Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Golden Parachute Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This section sets forth the information required by Item 402(t) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> regarding the
compensation that is based on or otherwise relates to the Transactions and that is payable or may become payable to Calyxt, Inc.&#146;s named executive officers. This compensation is referred to as &#147;golden parachute&#148; compensation by the
applicable SEC disclosure rules. For purposes of calculating these amounts, Calyxt, Inc. has assumed: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effective time occurred on March 31, 2023; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a price per share of Calyxt Common Stock of $0.29, which represents the average closing market price of Calyxt
Common Stock on Nasdaq over the first five business days following the public announcement on January&nbsp;17, 2023, of the entry into the Merger Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the employment of the named executive officer is terminated immediately after the closing of the Cibus Merger in
a manner that entitles the named executive officer to receive the severance payments and benefits under the terms of the Calyxt Severance Plan or Frimerman Employment Agreement, as applicable; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the named executive officer does not enter into a new agreement or otherwise become legally entitled to, prior to
the effective time, additional compensation or benefits. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amounts set forth in the table are estimates based on
multiple assumptions that may or may not actually occur, including assumptions described below and elsewhere in this proxy statement/prospectus and in the footnotes to the table. Furthermore, the amounts set forth in the table do not reflect any
reductions in payments or benefits that could result from the operation of Section&nbsp;280G of the Code modified cutback provision that is in the Calyxt Severance Plan, as described above. As a result, the actual amounts, if any, that Calyxt,
Inc.&#146;s named executive officers will receive may materially differ from the amounts set forth in the table. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a narrative
description of the terms and conditions applicable to the payments quantified in the table below, see the section entitled &#147;<I>The Mergers&#151;Interests of Calyxt, Inc. Directors and Executive Officers in the Mergers&#151;Termination of
Existing Calyxt, Inc. Executive Officers Following the Mergers and Related Severance Payments</I>&#148; beginning on page 150 of this proxy statement/prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Cash<BR>($)<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity<BR>($)<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Health&nbsp;Benefits<BR>Continuation<BR>($)<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>($)<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael A. Carr</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">269,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,806,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William F. Koschak</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">378,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">177,837</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,352</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">575,439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Travis J. Frey, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">333,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">177,692</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">529,614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Debra Frimerman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">353,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">177,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">531,034</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts listed in this column represent (i)&nbsp;cash severance amounts payable to the named executive
officer pursuant to the Calyxt Severance Plan (Mr.&nbsp;Carr, Mr.&nbsp;Koschak, and Dr.&nbsp;Frey) or the Frimerman </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Agreement (Ms.&nbsp;Frimerman) equal to 24 months for Mr.&nbsp;Carr and 12 months for Mr.&nbsp;Koschak, Dr.&nbsp;Frey, and Ms.&nbsp;Frimerman of base salary continuation ($1,000,000 for
Mr.&nbsp;Carr, $340,000 for Mr.&nbsp;Koschak, $300,000 for Dr.&nbsp;Frey, and $321,000 for Ms.&nbsp;Frimerman), which amounts are payable to Mr.&nbsp;Carr, Mr.&nbsp;Koschak, and Dr.&nbsp;Frey such that any portion of the cash severance which is
exempt from Section&nbsp;409A will be paid in substantially equal installments over the Severance Coverage Period and any portion of the cash severance not exempt from Section&nbsp;409A, to be on or before the 60th day following the Qualifying
Termination; and to Ms.&nbsp;Frimerman in installments over 12 months following her termination of employment; (ii)&nbsp;for Mr.&nbsp;Carr, a cash severance amount equal to his target incentive under the Calyxt annual cash incentive plan for the
year of termination ($500,000), for Mr.&nbsp;Koschak and Dr.&nbsp;Frey, a cash severance amount equal to the pro rata amount of their target incentive under Calyxt&#146;s annual cash incentive plan for the year of termination ($38,250 for
Mr.&nbsp;Koschak and $33,750 for Dr.&nbsp;Frey), and for Mr.&nbsp;Carr, Mr. Koschak, and Dr&nbsp;Frey, any unpaid earned bonus for the previous plan year (which was zero for Mr.&nbsp;Carr, Mr.&nbsp;Koschak, and Dr.&nbsp;Frey), such that any portion
of the cash severance which is exempt from Section&nbsp;409A will be paid in substantially equal installments over the Severance Coverage Period and any portion of the cash severance not exempt from Section&nbsp;409A, to be on or before the 60th day
following the Qualifying Termination, and (iii)&nbsp;a cash severance amount payable to Ms.&nbsp;Frimerman equal to a prorated amount of her annual performance bonus ($32,100), which is assumed to be paid based on achievement of target performance
metrics. The cash severance payments payable to Mr.&nbsp;Carr, Mr.&nbsp;Koschak, and Dr.&nbsp;Frey are a double-trigger benefit because they will be paid only if the named executive officer experiences a Qualifying Termination of employment within 3
months before or 24 months after the Cibus Merger. The cash severance payments to Ms.&nbsp;Frimerman pursuant to the Frimerman Agreement are a double-trigger benefit because they will be paid upon a termination of employment without cause. Payments
to the named executive officers under the Calyxt Severance Plan or Frimerman Agreement are subject to the named executive officer signing and not revoking a release of claims and to continued compliance with restrictive covenants. </TD></TR></TABLE>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts listed in this column represent, without duplication of benefits (i)&nbsp;the value of the full
acceleration of vesting of the unvested restricted stock units held by the named executive officer under the Calyxt Severance Plan or the 2017 Omnibus Plan, as applicable, (ii)&nbsp;the value of the acceleration of performance stock units as
determined under the Calyxt Severance Plan, 2017 Omnibus Plan, as applicable, in each case assuming the performance factor achieved is at maximum level, and for Mr.&nbsp;Carr, the number of Calyxt PSUs included in this column also includes 25% of
his Calyxt PSUs issued under the 2021 Inducement Plan, and (iii)&nbsp;the value of the Calyxt Stock Options that become vested and exercisable on a Qualifying Termination immediately after the Cibus Merger under the Calyxt Severance Plan or the 2017
Omnibus Plan, as applicable, based on the fair market value of a share of Class&nbsp;A Common Stock less the exercise price and assuming the following weighted average exercise prices: $1.78 for Mr.&nbsp;Carr, $4.15 for Mr.&nbsp;Koschak, $3.64 for
Dr.&nbsp;Frey, and $3.74 for Ms.&nbsp;Frimerman. The acceleration of vesting of the named executive officers&#146; unvested equity awards is a double-trigger benefit in that it will occur only if the executive experiences a Qualifying Termination of
employment within 3 months before (for Mr.&nbsp;Carr, Mr.&nbsp;Koschak, and Dr.&nbsp;Frey) or 24 months following the Closing. The following table breaks down the amounts in this column by type of equity award. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Value&nbsp;of&nbsp;Calyxt<BR>RSUs<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Value of Calyxt<BR>PSUs&nbsp;at&nbsp;Maximum<BR>Performance($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Value&nbsp;of&nbsp;Calyxt<BR>Options<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael A. Carr</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">186,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">83,133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">269,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William F. Koschak</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">158,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">177,837</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Travis J. Frey, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">158,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">177,692</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Debra Frimerman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">158,601</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">177,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">All payments under the Calyxt Severance Plan are subject to the named executive officer signing and not
revoking a release of claims. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If the named executive officers do not experience a Qualifying Termination entitling them to double-trigger
vesting as set forth above, the named executive officers would still be entitled to vesting of 25% of the total number of shares covered by each of the Calyxt Stock Options and Calyxt RSUs (for grants other than the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Calyxt RSUs granted on March 1, 2023 which will vest 100% upon the closing of the Cibus Merger) held by the named executive officers pursuant to the 2017 Omnibus Plan. Additionally, pursuant to
the 2017 Omnibus Plan, the performance period of Calyxt PSUs held by the named executive officers would truncate and the Calyxt PSUs would vest based on the achievement of the performance factor would be measured as of Calyxt&#146;s most recently
completed fiscal quarter prior to the Closing. Further, Mr.&nbsp;Carr would be entitled to vesting of 25% of the total number of shares covered by Calyxt PSUs pursuant to the 2021 Inducement Plan. All such vesting would be single-trigger because it
will occur upon the closing of the Cibus Merger. </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts listed in this column represent the value of the total monthly premiums for medical and dental
coverage under COBRA continued group health and dental insurance benefits for the named executive officer (and his eligible dependents) at the time of the named executive officer&#146;s termination, multiplied by the Severance Coverage Period to be
provided under the Calyxt Severance Plan for Mr.&nbsp;Carr, Mr.&nbsp;Koschak, and Dr.&nbsp;Frey paid on or before the 60<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> day following the Qualifying Termination. This is a double-trigger
benefit because it will be provided only if the named executive officer experiences a Qualifying Termination of employment within 3 months before or 24 months following the Cibus Merger. Payments to the named executive officers under the Calyxt
Severance Plan are subject to the named executive officer signing and not revoking a release of claims and to continued compliance with restrictive covenants. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts in this column include the aggregate dollar value of the sum of all amounts reported in the
preceding columns. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Indemnification and Insurance </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Merger Agreement, from the Closing through the sixth anniversary of the Closing Date, Calyxt, Inc. is required to indemnify and
hold harmless each person who is or has served as a director, manager or officer of Cibus Global or Calyxt, Inc. or their subsidiaries against all claims, losses, liabilities, damages, judgments, fines and reasonable fees, costs and expenses,
including attorneys&#146; fees and disbursements, incurred in connection with any claim, action, suit, proceeding or investigation, whether civil, criminal, administrative or investigative, arising out of or pertaining to the fact that the person is
or was an officer, director, manager, employee, trustee, fiduciary or agent of Cibus Global, Calyxt, Inc. or any of their respective subsidiaries, or, while a director, manager or officer of Cibus Global, Calyxt, Inc. or any of their respective
subsidiaries, is or was serving at the request of Cibus Global, Calyxt, Inc. or any of their respective subsidiaries as a director, manager, officer, employee or agent of another Person, whether asserted or claimed prior to, at or after the Closing,
to the extent permitted under the applicable certificate of incorporation and bylaws or other organizational document. In addition, each such director, manager or officer, or former director and officer, is entitled to advancement of expenses
(including attorney&#146;s fees) incurred in the defense of any such claim, action, suit, proceeding or investigation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the
Merger Agreement, for six years following the Closing, the Amended Certificate of Incorporation and the Amended Bylaws shall contain provisions no less favorable with respect to indemnification, advancement of expenses and elimination of liability
for monetary damages set forth set forth in the Calyxt Certificate of Incorporation and Calyxt Bylaws immediately prior to the First Blocker Merger Effective Time. The Merger Agreement also provides that Calyxt, Inc. shall purchase a <FONT
STYLE="white-space:nowrap">six-year</FONT> prepaid directors&#146; and officers&#146; liability insurance policy commencing at the Closing, on terms, conditions, retentions and limits of liability to be mutually agreed by Calyxt, Inc. and Cibus
Global prior to the Closing with coverage that is no more favorable than the coverage provided under Calyxt, Inc.&#146;s existing policies as of the date of the Merger Agreement with respect to coverage of any actual or alleged error, misstatement,
misleading statement, act, omission, neglect, breach of duty or any matter claimed against a director or officer of Calyxt, Inc. or Cibus Global, as applicable, by reason of him or her serving in such capacity that existed or occurred at or prior to
the Closing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Calyxt Support Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with the execution of the Merger Agreement and as a condition to Cibus Global entering into the Merger Agreement, Cibus Global
entered into the Calyxt Support Agreements, with certain Calyxt Stockholders, directors and officers (the &#147;Supporting Stockholders&#148;) who, collectively and in the aggregate, beneficially held voting power of approximately 49.8% of
outstanding Calyxt Common Stock on January 13, 2023 (the &#147;Subject Shares&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Pursuant to the terms of the Calyxt Support Agreements, the Supporting Stockholders have agreed to take certain actions to support the Transactions, including not transferring the Subject Shares
during the term of the Calyxt Support Agreement, except under specified circumstances, and voting the Subject Shares in favor of the Merger Agreement and Transactions and against any alternative acquisition proposals. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interests of Cellectis </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cellectis
is Calyxt, Inc.&#146;s largest stockholder. In addition, Cellectis licenses intellectual property rights to Calyxt, Inc. and has guaranteed Calyxt, Inc.&#146;s obligations under Calyxt, Inc.&#146;s real property lease for its headquarters facility.
As such, Cellectis has additional interests in the Transactions related to the amendment of the license agreement and obligations of Cibus related to the headquarters guarantee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a condition to the obligations of Cibus Global to consummate the Mergers, Calyxt, Inc. and Cellectis will enter into the First Amendment to
the License Services Agreement, which amends the License Agreement dated July 25, 2017, between Calyxt, Inc. and Cellectis (as amended, the &#147;Amended Cellectis License&#148;). The form of the amendment was attached as an exhibit to the Merger
Agreement. For more information regarding the Amended Cellectis License, please see &#147;<I>The Merger Agreement&#151;Amendment to the Cellectis License Agreement</I>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the provisions in the Calyxt Support Agreement between Cibus Global, Calyxt, Inc. and Cellectis relating to the guaranty by
Cellectis of certain obligations under Calyxt&#146;s headquarters building lease, including the obligation of Cibus Global under certain circumstances to use commercially reasonable efforts to cause the landlord to terminate the guarantee as more
fully described below under the caption &#147;<I>Agreements Related to the Mergers&#151;Support Agreements&#151;Calyxt Support Agreements</I>,&#148; beginning on page 191 in this proxy statement/prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interests of Calyxt Directors in Cibus Global </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March 31, 2023, Calyxt, Inc&#146;s. director, Mr. Fassberg, is the beneficial owner, through his affiliate Trout Capital, LLC
(&#147;Trout Capital&#148;), of Cibus Warrants to purchase 467,647 Cibus Series B Preferred Units and 116,616 Cibus Series C Preferred Units. These Cibus Warrants were issued to Trout Capital for services provided to Cibus Global. Upon consummation
of the Transactions, these Cibus Warrants will be exchanged into 510,003&nbsp;shares of Class A Common Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Litigation Related to the Mergers
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Two lawsuits have been filed by purported stockholders of Calyxt, Inc. The first suit, captioned <I>Melton v. Calyxt, Inc., et
al.</I>, No. 0:23-cv-00540 (the &#147;Melton Lawsuit&#148;) was filed in the United States District Court for the District of Minnesota on March 6, 2023.&nbsp;The second suit, captioned <I>Keller v. Calyxt, Inc., et al.</I>, No. 2023-0297 (the
&#147;Keller Lawsuit&#148; and with the Melton Lawsuit, the &#147;Lawsuits&#148;) was filed in the Court of Chancery of the State of Delaware on March 9, 2023.&nbsp;Both of the Lawsuits assert claims against Calyxt, Inc. and the members of the
Calyxt Board, and generally allege that the proxy statement/prospectus filed with the SEC on February 14, 2023 is deficient, and both seek preliminary and injunctive relief.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, Calyxt, Inc. has received a written demand from a purported stockholder pursuant to 8 Del. C. &#167;&nbsp;220 seeking certain
books and records, as well as certain informal demand letters from other purported stockholders (collectively, the &#147;Demands&#148;), each alleging deficiencies in the proxy statement/prospectus and/or requesting supplements thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt believes that the claims and allegations asserted in the Lawsuits and in the Demands are without merit, and intends to vigorously
defend against the Lawsuits and Demands. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom401831_20"></A>Interests of Cibus Global Directors and Executive Officers in the Mergers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In considering the recommendation of the Cibus Board with respect to approving the Mergers, Cibus Unitholders should be aware that certain
members of the Cibus Board and certain Cibus Global executive officers have interests in the Mergers that may be different from, or in addition to, the interests of Cibus </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Unitholders. These interests may present them with actual or potential conflicts of interest, and these interests, to the extent material, are described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Calyxt Board and the Cibus Board were aware of these potential conflicts of interest and considered them, among other matters, in reaching
their respective decisions to approve the Merger Agreement and the Mergers, and in the Calyxt Board reaching its decision to recommend that Calyxt Stockholders approve the proposals to be presented to Calyxt Stockholders for consideration at the
Calyxt Special Meeting as contemplated by this proxy statement/prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except where specifically noted, the information in this
section and all other information contained in this proxy statement/prospectus does not give effect to the Reverse Stock Splits described elsewhere in this proxy statement/prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ownership Interests </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March
31, 2023, Cibus Global&#146;s directors and current executive officers beneficially owned, in the aggregate, 57,023,211 Cibus Units, which for purposes of this subsection excludes any Cibus PIUs and excludes Cibus Warrants. The Cibus Global
directors and executive officers will receive the same consideration for their Cibus Units on the same terms and conditions as other Cibus Unitholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Merger Agreement, at the effective time of the Cibus Merger, each of the Cibus Units will be cancelled and converted into the
holder&#146;s right to receive the applicable Merger Consideration. Any Cibus Unitholder who is a Top 99 Holder shall have the option to elect, on a per unit basis, to receive Merger Consideration in the form of either (a)&nbsp;the number of shares
of Class&nbsp;A Common Stock set forth on the Allocation Schedule in exchange for all such holder&#146;s Cibus Units (other than Cibus PIUs) covered by such election or (b)&nbsp;a number of <FONT STYLE="white-space:nowrap">Up-C</FONT> Units,
provided, that such holder will not be entitled to exchange more than 95% of such holder&#146;s existing Cibus Units for <FONT STYLE="white-space:nowrap">Up-C</FONT> Units and the remainder of such holder&#146;s Cibus Units will be exchanged for
shares of Class&nbsp;A Common Stock. The Merger Consideration for Cibus Unitholder other than a Top 99 Holder shall equal the number of shares of Class&nbsp;A Common Stock set forth on the Allocation Schedule. For a more detailed discussion of the
conversion of the Merger Consideration, see the section entitled &#147;<I>The Merger Agreement&#151;Merger Consideration</I>&#148; beginning on page 162 of this proxy statement/prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the number of Cibus Units (which, for this purpose, excludes Cibus PIUs) beneficially owned as of March 31,
2023, by each of Cibus Global&#146;s executive officers and directors and his or her affiliates. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Cibus</B><br><B>Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares</B><br><B>of&nbsp;Class&nbsp;A&nbsp;Common</B><br><B>Stock&nbsp;Received
<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Value&nbsp;of&nbsp;Class&nbsp;A</B><br><B>Common</B><br><B>Stock</B><br><B>Received($)<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B></B><B><I>Executive Officers</I></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Beetham, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">174,923</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">554,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">160,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Greg Gocal, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">141,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">447,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">129,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wade King, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">142,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">450,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">130,601</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rory Riggs <SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,640,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71,781,756</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,816,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B></B><B><I>Directors</I></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Finn</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">221,573</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">702,488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">203,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jean-Pierre Lehmann <SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,022,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66,651,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,328,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gerhard Prante, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95,329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">302,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">87,649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eugene Linden</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,535</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Lu <SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,063,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,246,006</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,091,342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alain Pompidou, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60,662</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">192,326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Keith Walker, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">459,706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,457,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">422,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Directors and executive officers as a group (11 persons)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57,023,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">180,789,622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52,428,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This column reflects the number of shares of Class&nbsp;A Common Stock to be received as Merger Consideration
and assumes that no executive officer or director who is a Top 99 Holder elected to receive <FONT STYLE="white-space:nowrap">Up-C</FONT> Units. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The values in this column have been calculated assuming that the fair market value of a share of Class&nbsp;A
Common Stock is equal to $0.29, which is the average closing price of a share of Calyxt Common Stock on Nasdaq over the first five trading days following the first public announcement of the Cibus Merger on January&nbsp;17, 2023.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 22,218,173 Cibus Units held directly by Mr.&nbsp;Riggs as well as 75,866 Cibus Units held jointly with
Robin Riggs, and 346,792 Cibus Units held by the Rory Riggs Family Trust, for which Mr.&nbsp;Riggs is trustee and has sole voting and dispositive power with respect to the Cibus Units held by the trust. Does not reflect the Series F Preferred Units
to be acquired by New Ventures Agtech Solutions, LLC, an entity affiliated with Mr. Riggs pursuant to the Series F Purchase Commitment. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 20,995,907 Cibus Preferred Units and 26,667 Cibus Global non-voting common units held by JPL
Investments SA, which Mr.&nbsp;Lehmann is deemed to beneficially own. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 8,279,472 Cibus Units held by Lufam Genetic Biotech Ltd. and 3,783,774 Cibus Units held by Rowiss
Biotech Investment Ltd., which Mr.&nbsp;Lu is deemed to beneficially own. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Effect of the Merger on Cibus Equity Interests
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Profits Interests </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March 31, 2023, Cibus Global&#146;s directors and current executive officers owned, in the aggregate, 30,113,653 Cibus PIUs. Under the
terms of the Merger Agreement, at the effective time of the Cibus Merger, each Cibus PIU will, (a)&nbsp;to the extent not a &#147;restricted unit&#148; (under the award agreements and governing documents applicable to such Cibus PIU), be
automatically cancelled and converted into the right to receive the number of shares of Class&nbsp;A Common Stock set forth on the Allocation Schedule and (b)&nbsp;to the extent a &#147;restricted unit&#148; (i.e., an unvested unit), be
automatically cancelled and converted into the right to receive the number of restricted shares of Class&nbsp;A Common Stock pursuant to a Calyxt, Inc. stock plan, as set forth on the Allocation Schedule and subject to the same vesting schedule as
was applicable to such Cibus PIU prior to the Closing. The number of shares and restricted shares of Class&nbsp;A Common Stock to be issued in consideration for Cibus PIUs was calculated based on a Black Scholes valuation of such Cibus PIUs, with
the exercise price input used in such Black Scholes valuation being a present value calculation of the applicable threshold value associated with the underlying Cibus PIU. The conversion factor for each Cibus PIU will be determined by dividing the
Black Scholes valuation by $2.00 (the price at which Cibus most recently sold Cibus Series F Preferred Units prior to the date of the Merger Agreement). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Executive Employment Agreement, effective as of October&nbsp;4, 2021, between Cibus Global and Rory Riggs (the &#147;Riggs
Agreement&#148;), 3,766,988 of the Cibus PIUs held by Mr.&nbsp;Riggs will vest and cease being restricted units upon Cibus becoming a public company with its shares listed on a major exchange. The Cibus Merger will be treated as Cibus becoming a
public company under the terms of the Riggs Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Allocation Schedule includes 4,817,845 Shares issuable as Merger Consideration
for an aggregate of 1,765,000 Cibus PIUs that Cibus expects to grant prior to Closing, of which 520,400 Cibus PIUs have been granted as of the date of this proxy statement/prospectus. The Cibus Board has not yet made any allocation determinations
with respect to the remaining amount of such Cibus PIUs. It is expected that following pre-Closing allocations, if any, of such remaining Cibus PIUs by the Cibus Board, the remaining balance, if any, of such Cibus PIUs would be allocated to Rory
Riggs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the aggregate value of the consideration that each of Cibus
Global&#146;s executive officers and directors would receive for the Cibus PIUs held as of the effective time of the Cibus Merger, assuming such effective time occurs on March 31, 2023. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of</B><br><B>Cibus<BR>PIUs<BR>Not</B><br><B>Restricted</B><br><B>Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of</B><br><B>Shares&nbsp;of</B><br><B>Class&nbsp;A</B><br><B>Common</B><br><B>Stock<BR>Received</B><br><B><SUP
STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Value&nbsp;of</B><br><B>Class&nbsp;
A</B><br><B>Common</B><br><B>Stock</B><br><B>Received</B><br><B>($)<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of</B><br><B>Cibus<BR>PIUs<BR>that&nbsp;are</B><br><B>Restricted</B><br><B>Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of</B><br><B>Restricted</B><br><B>Shares of</B><br><B>Class&nbsp;A</B><br><B>Common</B><br><B>Stock</B><br><B>Received</B><br><B><SUP
STYLE="font-size:75%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Value&nbsp;of</B><br><B>Class&nbsp;
A</B><br><B>Common</B><br><B>Stock</B><br><B>Received<BR>($)<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B></B><B><I>Executive Officers</I></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Beetham, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,715,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,957,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,047,641</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,646,428</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,609,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,336,651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Greg Gocal, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,830,982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,321,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,283,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,471,820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,111,312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,192,281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wade King, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,425,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,062,884</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,178,236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,324,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,519,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,890,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rory Riggs <SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,479,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,203,586</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,569,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,432,846</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,366,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,846,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B></B><B><I>Directors</I></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Finn</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,064,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,155,006</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">914,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jean-Pierre Lehmann</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">796,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,346,384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">680,451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gerhard Prante, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,133,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,286,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">953,113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eugene Linden</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">983,805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,910,409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">844,019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Lu</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">380,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alain Pompidou, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">521,321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,531,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">444,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Keith Walker, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,161,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,473,254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,007,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The number of shares of Class&nbsp;A Common Stock listed in this column reflect the number of shares of
Class&nbsp;A Common Stock the executive officer or director will receive for the Cibus PIUs that are not restricted units. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The values in this column have been calculated assuming that the fair market value of a share of Class&nbsp;A
Common Stock is equal to $0.29, which is the average closing price of a share of Calyxt Common Stock on Nasdaq over the first five trading days following the first public announcement of the Cibus Merger on January&nbsp;17, 2023.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The number of restricted shares of Class&nbsp;A Common Stock listed in this column reflects the number of
restricted shares of Class&nbsp;A Common Stock the executive officer or director will receive for the Cibus PIUs that are restricted units. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 30,000 Cibus PIUs held by the Rory Riggs Family Trust, for which Mr.&nbsp;Riggs is trustee and has
sole voting and dispositive power with respect to the Cibus PIUs held by the trust. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Warrants </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March 31, 2023, Cibus Global&#146;s directors and current executive officers owned, in the aggregate, 17,392,496 Cibus Warrants. Under
the terms of the Merger Agreement, at the effective time of the Cibus Merger, each Cibus Warrant will be automatically exchanged for the right to receive the number of shares of Class&nbsp;A Common Stock set forth on the Allocation Schedule. The
number of shares of Class&nbsp;A Common Stock to be issued in consideration of such Cibus Warrant will be calculated based on a Black Scholes valuation of such Cibus Warrant. The conversion factor for each such Cibus Warrant will be determined by
dividing the Black Scholes valuation by $2.00 (the price at which Cibus Global most recently sold Cibus Series F Preferred Units prior to the date of the Merger Agreement). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the aggregate value of the consideration that each of Cibus
Global&#146;s executive officers and directors would receive for the Cibus Warrants held as of the effective time of the Cibus Merger, assuming such effective time occurs on March 31, 2023. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of</B><br><B>Units</B><br><B>Underlying<BR>Cibus</B><br><B>Warrants</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of</B><br><B>Shares of</B><br><B>Class&nbsp;A</B><br><B>Common</B><br><B>Stock</B><br><B>Received</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Value of</B><br><B>Class&nbsp;A</B><br><B>Common</B><br><B>Stock</B><br><B>Received($)<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Executive Officers</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Beetham, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Greg Gocal, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">161,093</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46,717</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wade King, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rory Riggs <SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,524,973</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,799,082</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,741,734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Directors</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Finn</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jean-Pierre Lehmann<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,740,842</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,355,342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,453,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gerhard Prante, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eugene Linden</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67,480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Lu</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alain Pompidou, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85,662</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">179,837</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Keith Walker, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,793</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The values in this column have been calculated assuming that the fair market value of a share of Class&nbsp;A
Common Stock is equal to $0.29, which is the average closing price of a share of Calyxt Common Stock on Nasdaq over the first five trading days following the first public announcement of the Cibus Merger on January&nbsp;17, 2023.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 14,981 Cibus Warrants held jointly with Robin Riggs. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 7,740,842 Cibus Warrants held by JPL Investments SA, which Mr.&nbsp;Lehmann is deemed to beneficially
own. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Annual Bonus, Base Salary </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Riggs Agreement and the Amended and Restated Executive Employment Agreement, effective as of December&nbsp;17, 2021 between
Cibus US, LLC and Wade King (the &#147;King Agreement&#148;), Rory Riggs and Wade King will be eligible to receive an annual bonus in the discretion of the Cibus Board upon Cibus becoming a public company with its shares listed on a major exchange.
The Mergers will be treated as Cibus becoming a public company with its shares listed on a major exchange. For each to receive the bonus, Mr.&nbsp;Riggs </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and Dr. King must remain employed through December&nbsp;31 of the applicable year. The Cibus Board has not yet determined the amount of such annual bonus for
Mr.&nbsp;Riggs or Dr. King. In addition, under the Riggs Agreement, Mr. Riggs&#146; base salary will commence being paid upon Cibus becoming a public company with its shares listed on a major exchange and amounts of his previously credited base
salary will be paid in equal installments over a six-month period starting on such date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Golden Parachute Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This section sets forth the information required by Item 402(t) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> regarding the
compensation that is based on or otherwise relates to the Transactions and that is payable or may become payable to Cibus Global&#146;s named executive officers. This compensation is referred to as &#147;golden parachute&#148; compensation by the
applicable SEC disclosure rules. For purposes of calculating these amounts, Cibus Global has assumed: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effective time of the Transactions occurred on March 31, 2023; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a price per share of Calyxt Common Stock of $0.29, which represents the average closing market price of Calyxt
Common Stock on Nasdaq over the first five business days following the public announcement on January&nbsp;17, 2023 of the entry into the Merger Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the employment of the named executive officer is terminated effective immediately after the closing of the Cibus
Merger in a manner that entitles the named executive officer to receive the severance payments and benefits under the terms of the employment agreement with the named executive officer; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the named executive officer does not enter into a new agreement or otherwise become legally entitled to, prior to
the effective time, additional compensation or benefits. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amounts set forth in the table are estimates based on
multiple assumptions that may or may not actually occur, including assumptions described below and elsewhere in this proxy statement/prospectus and in the footnotes to the table. As a result, the actual amounts, if any, that Cibus Global&#146;s
named executive officers will receive, may materially differ from the amounts set forth in the table. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Cash</B><br><B>($)<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity</B><br><B>($)<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Health&nbsp;Benefits</B><br><B>Continuation</B><br><B>($)<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Other&nbsp;($)<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>($)<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rory Riggs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,114,642</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46,429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">666,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,827,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wade King</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">562,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">577,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Beetham</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">750,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">779,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts listed in this column represent cash severance amounts payable to the named executive officer
pursuant to his employment agreement equal to 18 months of base salary continuation, which amounts are payable to the executive in installments over 18 months following the executive&#146;s termination of employment without cause by Cibus Global or
the executive&#146;s resignation for good reason. The cash severance payments payable to Dr.&nbsp;King and Dr.&nbsp;Beetham pursuant to their respective employment agreements are a double-trigger benefit in that they will be paid only if the
executive experiences a qualifying termination of employment during the term of their applicable employment agreement (i.e., the King Agreement and Beetham Agreement). Dr.&nbsp;Beetham is required to execute a release of claims against Cibus Global
that becomes irrevocable as a condition to receiving the cash severance amounts on a termination without cause or a resignation for good reason and Dr.&nbsp;King must execute a release of claims against Cibus Global that becomes irrevocable as a
condition to receiving the cash severance amounts on a resignation for good reason. The employment agreements for Drs. King and Beetham also provide for enhanced severance on a qualifying termination in connection with a change in control, however
Cibus Global will not experience a change in control (as defined in the applicable employment agreements) in the Transactions. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts listed in this column represent the value of Class&nbsp;A Common Stock received due to the vesting
of unvested Cibus PIUs upon Cibus becoming a public company with its shares listed on a major exchange. The Cibus Merger will be treated as Cibus becoming a public company with its shares listed on a major exchange under the terms of the Riggs
Agreement. This is a single-trigger benefit because it will be owed by reason of the Transactions even if Mr.&nbsp;Riggs does not terminate employment. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts listed in this column represent the value of continued group health and dental insurance benefits
to be provided to the named executive officer (and his eligible dependents) pursuant to their respective employment agreements for a period of up to 18 months for Mr.&nbsp;Riggs and Drs. King and Beetham. This is a double-trigger benefit in that it
will be provided if the executive experiences a qualifying termination of employment during the term of their applicable employment agreement. Dr.&nbsp;Beetham is required to execute a release of claims against Cibus Global that becomes irrevocable
as a condition to receiving these benefits on a termination without cause or a resignation for good reason and Dr.&nbsp;King must execute a release of claims against Cibus Global that becomes irrevocable as a condition to receiving these benefitted
on a resignation for good reason. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amount listed in this column represents the portion of Mr.&nbsp;Riggs&#146; base salary that he was
credited with prior to the effective time of the Transaction, which, under the Riggs Agreement, will commence being paid in equal installments over a six month period following Cibus becoming a public company with its shares
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
listed on a major exchange. The Cibus Merger will be treated as Cibus becoming a public company with its shares listed on a major exchange under the terms of the Riggs Agreement. This is a
single-trigger benefit because it will be owed by reason of the Transactions even if Mr.&nbsp;Riggs does not terminate employment. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts in this column include the aggregate dollar value of the sum of all amounts reported in the
preceding columns. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Support Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with the execution of the Merger Agreement and as a condition to Calyxt, Inc. entering into the Merger Agreement, Calyxt, Inc.
entered into the Cibus Support Agreements with certain of Cibus Global&#146;s equity holders and directors and officers, including Rory Riggs, Gregory Gocal, Peter Beetham, Wade King, Jean-Pierre Lehmann, Mark Finn, Gerhard Prante, Keith Walker,
Cibus Investments LLC, Lufam Genetic Biotech Ltd. (&#147;Lufam&#148;) and Rowiss Biotech Investment Ltd. (&#147;Rowiss&#148;) (each of Lufam and Rowiss controlled by Mark Lu) (the &#147;Cibus Supporting Unitholders&#148;) who as of January&nbsp;13,
2023, collectively and in the aggregate, held voting power of approximately 54.3% of the outstanding voting Cibus Units (the &#147;Subject Units&#148;). Pursuant to the terms of the Cibus Support Agreements, the Cibus Supporting Unitholders have
agreed to take certain actions to support the Transactions (including not transferring the Subject Units during the term of the Cibus Support Agreement except under specified circumstances) and voting or acting by written consent with respect to all
of its Subject Units in favor of the Mergers and the other Transactions, against any alternative acquisition proposals, and to agree to convert all outstanding <FONT STYLE="white-space:nowrap">pre-Closing</FONT> Cibus Preferred Units into <FONT
STYLE="white-space:nowrap">pre-Closing</FONT> Cibus Global voting common units on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis in connection with the Mergers. For a more detailed discussion of
the support agreements, see the section entitled &#147;<I>Agreements Related to the Mergers&#151;Support Agreements</I>&#148; beginning on page 191 of this proxy statement/prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Management Following the Transactions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As described in the section entitled &#147;<I>Management Following the Transactions</I>&#148; beginning on page 284 of this proxy
statement/prospectus, certain members of the Cibus Board and Cibus Global executive officers are expected to become the directors and executive officers of Cibus, Inc. upon the Closing. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Indemnification and Insurance </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Merger Agreement, from the Closing through the sixth anniversary of the Closing Date, Calyxt, Inc. is required to indemnify and
hold harmless each person who is or has served as a director, manager or officer of Cibus Global or Calyxt, Inc. against all claims, losses, liabilities, damages, judgments, fines and reasonable fees, costs and expenses, including attorneys&#146;
fees and disbursements, incurred in connection with any claim, action, suit, proceeding or investigation, whether civil, criminal, administrative or investigative, arising out of or pertaining to the fact that the person is or was an officer,
director, manager, employee, trustee, fiduciary or agent of Cibus Global, Calyxt, Inc. or any of their respective subsidiaries, or, while a director, manager or officer of Cibus Global, Calyxt, Inc. or any of their respective subsidiaries, is or was
serving at the request of Cibus Global, Calyxt, Inc. or any of their respective subsidiaries as a director, manager, officer, employee or agent of another Person, whether asserted or claimed prior to, at or after the Closing, to the extent permitted
under the applicable certificate of incorporation and bylaws or other organizational document. In addition, each such director, manager or officer, or former director and officer, is entitled to advancement of expenses (including attorney&#146;s
fees) incurred in the defense of any such claim, action, suit, proceeding or investigation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Merger Agreement, for six
years following the Closing, the Amended Certificate of Incorporation and the Amended Bylaws shall contain provisions no less favorable with respect to indemnification, advancement of expenses and exculpation of present and former directors and
officers than those that are presently set forth in the Calyxt Certificate of Incorporation and Calyxt Bylaws immediately prior to the First Blocker Merger Effective Time. The Merger Agreement also provides that Cibus Global shall purchase a <FONT
STYLE="white-space:nowrap">six-year</FONT> prepaid directors&#146; and officers&#146; liability insurance policy commencing at the Closing for the <FONT STYLE="white-space:nowrap">non-cancellable</FONT> extension of the directors&#146; and
officers&#146; liability coverage of Cibus Global&#146;s existing directors&#146; and officer&#146;s insurance policy with respect to any claim related </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to any period of time at or prior to the Closing with terms, conditions, retentions and limits of liability that are no less favorable than the coverage provided under Cibus Global&#146;s
existing policies as of the date of the Merger Agreement with respect to coverage of any actual or alleged error, misstatement, misleading statement, act, omission, neglect, breach of duty or any matter claimed against a director or officer of Cibus
Global, by reason of him or her serving in such capacity that existed or occurred at or prior to the Closing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom401831_21"></A>Form of the
Mergers </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger Agreement provides that at the applicable Blocker Merger Effective Time, each of the Blockers will merge with and
into Calyxt, Inc., in each case with Calyxt, Inc. surviving each Blocker Merger. Immediately thereafter, Merger Subsidiary will merge with and into Cibus Global, with Cibus Global as the surviving company and Merger Subsidiary ceasing to exist. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom401831_22"></A>Effective Time of the Mergers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the provisions of the Merger Agreement, Calyxt, Inc. and each Blocker shall cause the corresponding Blocker certificate of merger to
be executed, acknowledged and filed with the secretary of state of the State of Delaware (and for the avoidance of doubt, each Blocker shall only be responsible for causing its applicable Blocker certificate of merger to be executed, acknowledged
and filed). The applicable Blocker Merger shall become effective at the time when the corresponding Blocker certificate of merger has been duly filed with the secretary of state of the State of Delaware or at such later time as may be agreed by
Calyxt, Inc., Cibus Global and the applicable Blocker in writing and specified in the corresponding Blocker certificate of merger (the effective time of each Blocker Merger being such Blocker Merger&#146;s applicable &#147;Blocker Merger Effective
Time&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt Stockholders as of the record date will be asked to approve the Calyxt Stockholder Matters, which include the
amendment of Calyxt, Inc.&#146;s organizational documents, to, among other things, authorize the shares of Class&nbsp;A Common Stock and Class&nbsp;B Common Stock to be issued pursuant to the Merger Agreement in connection with the Mergers. For more
information, see section entitled &#147;<I>Description of Capital Stock of Cibus, Inc.</I>&#148; beginning on page 333 of this proxy statement/prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At and after the First Blocker Merger Effective Time, the size of the Calyxt Board will be set at six and will consist of Rory Riggs, Peter
Beetham, Mark Finn, Jean-Pierre Lehmann, Gerhard Prante, and Keith Walker. All other Calyxt, Inc. directors prior to the First Blocker Merger Effective Time will resign effective as of the First Blocker Merger Effective Time. Calyxt, Inc.&#146;s
officers at such time will be Rory Riggs, Peter Beetham, Greg Gocal, and Wade King, and all other current Calyxt, Inc. officers will resign at such time, subject to ongoing discussions with certain officers at Calyxt, Inc. For more information, see
the section entitled &#147;<I>The Mergers</I><I>&#151;</I><I>Interests of Calyxt, Inc. Directors and Executive Officers in the Mergers</I><I>&#151;</I><I>Potential Going-Forward Roles with Cibus, Inc.&#148;</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the provisions of the Merger Agreement, immediately following completion of all Blocker Mergers, Calyxt, Inc., Merger Subsidiary
and Cibus Global shall cause the Cibus Global certificate of merger to be executed, acknowledged and filed with the secretary of state of the State of Delaware. The Cibus Merger shall become effective at the time when the Cibus Global certificate of
merger has been duly filed with the secretary of state of the State of Delaware or at such later time as may be agreed by Calyxt, Inc. and Cibus Global in writing and specified in the Cibus Global certificate of merger. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom401831_23"></A>Merger Consideration </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Merger Consideration </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Amended
Certificate of Incorporation, once adopted at the First Blocker Merger Effective Time, will designate two classes of Cibus, Inc. common stock: (i)&nbsp;Class&nbsp;A Common Stock, which shares will have full voting and economic rights and
(ii)&nbsp;Class&nbsp;B Common Stock, which shares will have full voting, but no economic rights. Upon adoption of the Amended Certificate of Incorporation, each share of Calyxt Common Stock existing and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
outstanding immediately prior to the First Blocker Merger Effective Time shall remain outstanding as a share of Class&nbsp;A Common Stock at the First Blocker Merger Effective Time without any
conversion or exchange thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At each applicable Blocker Merger Effective Time, the limited liability company interests of the
applicable Blocker will be cancelled and converted into the right of the equityholders of the applicable Blocker to receive shares of Class&nbsp;A Common Stock corresponding to that Blocker Merger (the &#147;Blocker Merger Consideration&#148;), in
each case, as set forth in the Allocation Schedule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the effective time of the Cibus Merger, all of the issued and outstanding Cibus
Units, (including Cibus PIUs), and all outstanding Cibus Warrants or options to purchase Cibus Units, will be cancelled (or, in the case of Cibus Warrants, surrendered to Cibus, Inc. for exchange) and converted into the right to receive the
following, as described in further detail in the Merger Agreement (the &#147;Cibus Merger Consideration&#148;): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Top 99 Holders shall have the option to elect, on a per unit basis, to receive Merger Consideration in the
form of either (a)&nbsp;the number of shares of Class&nbsp;A Common Stock set forth on the Allocation Schedule in exchange for all such holder&#146;s Cibus Units (other than Cibus PIUs) covered by such election or (b)&nbsp;a number of <FONT
STYLE="white-space:nowrap">Up-C</FONT> Units, as set forth on the Allocation Schedule in exchange for such holder&#146;s Cibus Units (other than Cibus PIUs) elected for exchange into Up-C Units, provided, that such holder will not be entitled to
exchange more than 95% of such holder&#146;s existing Cibus Units for <FONT STYLE="white-space:nowrap">Up-C</FONT> Units and the remainder of such holder&#146;s Cibus Units will be exchanged for shares of Class&nbsp;A Common Stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all <FONT STYLE="white-space:nowrap">pre-Closing</FONT> Cibus Unitholders, other than Top 99 Holders and
Blockers, shall receive the number of shares of Class&nbsp;A Common Stock set forth on the Allocation Schedule in exchange for their Cibus Units (other than Cibus PIUs); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all <FONT STYLE="white-space:nowrap">pre-Closing</FONT> Cibus Warrants shall automatically be exchanged for the
right to receive the number of shares of Class&nbsp;A Common Stock set forth on the Allocation Schedule; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all <FONT STYLE="white-space:nowrap">pre-Closing</FONT> Cibus PIUs will, (a)&nbsp;to the extent not a
&#147;restricted unit&#148; (under the award agreements and governing documents applicable to such Cibus PIU), be automatically cancelled and converted into the right to receive the number of shares of Class&nbsp;A Common Stock set forth on the
Allocation Schedule and (b)&nbsp;to the extent a &#147;restricted unit&#148; (i.e., an unvested unit), be automatically cancelled and converted into the right to receive the number of restricted shares of Class&nbsp;A Common Stock pursuant to a
Cibus, Inc. stock plan, as set forth on the Allocation Schedule and subject to the same vesting schedule as was applicable to such Cibus PIU prior to Closing. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cibus Global Common Unit Issuance to Calyxt, Inc. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately following the Cibus Merger, (i)&nbsp;each <FONT STYLE="white-space:nowrap">pre-Closing</FONT> Cibus Unit and <FONT
STYLE="white-space:nowrap">pre-Closing</FONT> Cibus Warrant, in each case, held by Cibus, Inc. as a result of the Blocker Mergers will be converted or exchanged for a number of Cibus Common Units set forth in the Allocation Schedule, (ii)&nbsp;each <FONT
STYLE="white-space:nowrap">pre-Closing</FONT> Cibus Warrant held by Cibus, Inc. as a result of the warrant exchanges described above will be converted or exchanged for a number of Cibus Common Units set forth in the Allocation Schedule, and
(iii)&nbsp;Cibus Global will issue a number of Cibus Common Units to Cibus, Inc. in an amount equal to the sum of (A)&nbsp;the number of shares of Class&nbsp;A Common Stock issued to former Cibus Global equity holders as Cibus Merger Consideration
and (B)&nbsp;the number of shares of Calyxt Common Stock outstanding immediately prior to the First Blocker Merger. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Election of <FONT
STYLE="white-space:nowrap">Up-C</FONT> Units for Top 99 Holders </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Promptly after the date this proxy statement/prospectus is
declared effective by the SEC, Cibus Global will mail to each holder (other than the Blockers) of Cibus Units that is a Top 99 Holder an Election Form. The Election Form will accompany the disclosure statement and copies of the form of Tax
Receivable Agreement, Cibus Amended Operating Agreement, Exchange Agreement and Registration Rights Agreement and the Election Form will include counterpart signatures to each of the foregoing agreements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Election Form will permit each holder that is a Top 99 Holder, to elect on a <FONT
STYLE="white-space:nowrap">per-Cibus</FONT> Unit basis (other than in respect of Cibus PIUs), to receive as Merger Consideration in the Cibus Merger in the form of either (A)&nbsp;shares of Class&nbsp;A Common Stock or
<FONT STYLE="white-space:nowrap">(B)&nbsp;Up-C</FONT> Units (subject to the limitations in the Merger Agreement, any such holder validly electing to receive <FONT STYLE="white-space:nowrap">Up-C</FONT> Units in exchange for any one or more of its
Cibus Units, an &#147;Electing Member&#148;, and the Cibus Units that such Electing Member will exchange for <FONT STYLE="white-space:nowrap">Up-C</FONT> Units, the &#147;Excluded Units&#148;); provided, however, that no Electing Member will be
entitled to receive <FONT STYLE="white-space:nowrap">Up-C</FONT> Units to the extent such holder&#146;s Excluded Units exchanged therefor would represent more than ninety-five percent (95%), or such lower percentage as may be determined by Cibus
Global and set forth on the Election Form, of the total number of Cibus Units held by such person as of immediately prior to the Cibus Merger Effective Time (for the avoidance of doubt, any Cibus Units held by such person in excess of such amount
will not constitute Excluded Units and will instead receive shares of Class&nbsp;A Common Stock in exchange for the Cibus Units representing such excess, notwithstanding such person&#146;s election). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Allocation Schedule </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger
Agreement provides that Merger Consideration will be allocated to each of the Cibus Global equity holders and the Blockers, as of immediately prior to the First Blocker Merger Effective Time, based on the Allocation Schedule. The initial version of
the Allocation Schedule was attached as an exhibit to the Merger Agreement and calculated based on the fully-diluted (other than with respect to out-of-the-money options and warrants) capitalization of Calyxt, Inc. and Cibus Global, in each case, as
of the date of the Merger Agreement. Pursuant to the Merger Agreement, the Allocation Schedule will be updated by Cibus Global no later than three business days prior to Closing to reflect (a)&nbsp;transfers of equity interests in Cibus Global or
the Blockers, (b)&nbsp;the results of the elections by Top 99 Holders and (c)&nbsp;any Cibus Series F Preferred Units issued or issuable pursuant to the Continuing Series F Financing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following provides a summary of the calculation of Merger Consideration and the allocation among each of the Cibus Global equity holders
and Blockers, as set forth in the Allocation Schedule. For purposes of this summary, the &#147;Conversion Factor,&#148; as used below, is defined as 3.17045722397476 shares of Class&nbsp;A Common Stock (or Class&nbsp;B Common Stock, in the case of
Electing Members&#146; <FONT STYLE="white-space:nowrap">Up-C</FONT> Units) per fully-diluted voting common unit of Cibus Global. The calculation of shares of Class&nbsp;A Common Stock (or Class&nbsp;B Common Stock, in the case of Electing
Members&#146; <FONT STYLE="white-space:nowrap">Up-C</FONT> Units) is determined based on the underlying class of Cibus Units held by the applicable member, as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Cibus Preferred Units</U>: Immediately prior to the Blocker Merger Effective Time for the First Blocker
Merger, each Cibus Preferred Unit is converted to a number of fully-diluted voting common units of Cibus Global on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis. Each fully-diluted voting common
unit is then multiplied by the Conversion Factor to yield the number of shares of Class&nbsp;A Common Stock (or Class&nbsp;B Common Stock, in the case of Electing Members) to be issued in respect of such Cibus Preferred Units. The number of Cibus
Common Units to be issued to an Electing Member in respect of their <FONT STYLE="white-space:nowrap">Up-C</FONT> Units will equal the number of shares of Class&nbsp;B Common Stock calculated by the foregoing. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Cibus Global <FONT STYLE="white-space:nowrap">non-voting</FONT> common units</U>: Cibus Global Class&nbsp;A <FONT
STYLE="white-space:nowrap">non-voting</FONT> common units represent membership units issued in connection with Cibus Global options previously exercised. Each <FONT STYLE="white-space:nowrap">non-voting</FONT> common unit is multiplied by the
Conversion Factor to yield the number of shares of Class&nbsp;A Common Stock to be issued in respect of such non-voting common units. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Cibus </U><U>PIUs</U>: All Cibus PIUs are represented by the same class of securities <FONT
STYLE="white-space:nowrap">(non-voting</FONT> common units) in Cibus Global. Immediately prior to the Blocker Merger Effective Time for the First Blocker Merger, each Cibus PIU is hypothetically converted to a number of fully-diluted voting common
units of Cibus Global by multiplying (a)&nbsp;the number of issued and outstanding Cibus PIUs in a given class held by the applicable member by (b)&nbsp;the class&#146;s unique fully-diluted conversion factor (the applicable &#147;FD Factor&#148;).
The FD Factor for each class of Cibus PIUs is calculated based on the Cibus PIU&#146;s Black Scholes fair value (with the exercise price input used in such Black Scholes valuation being a present value calculation of the applicable threshold value
associated with the underlying Cibus PIU class). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">164 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
The hypothetical number of fully-diluted voting common units of Cibus Global is then multiplied by the Conversion Factor to yield the number of shares of Class&nbsp;A Common Stock to be issued in
respect of such Cibus PIU. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Cibus Warrants</U>: Each issued and outstanding Cibus Warrant outstanding immediately prior to the Blocker
Merger Effective Time for the First Blocker Merger is hypothetically converted to a number of fully-diluted voting common units of Cibus Global by multiplying (a)&nbsp;the number of Cibus Preferred Units, voting common units or <FONT
STYLE="white-space:nowrap">non-voting</FONT> common units, as applicable, subject to the warrant by (b)&nbsp;the warrant tranche&#146;s unique FD Factor. The FD Factor for each tranche of Cibus Warrants was calculated by dividing the Black Scholes
Fair Value of such Cibus Warrant tranche by $2.00. The hypothetical number of fully-diluted voting common units of Cibus Global is then multiplied by the Conversion Factor to yield the number of shares of Class&nbsp;A Common Stock to be issued in
respect of such Cibus Warrant. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom401831_24"></A>Calyxt, Inc. Procedure for Exchange of Cibus Global Units </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the date this proxy statement/prospectus is declared effective by the SEC, Calyxt, Inc. shall cause the Exchange and Paying Agent to
mail to each person who will be a member of Cibus Global or any Blocker as of immediately prior to the effective time of each respective Mergers (i)&nbsp;a letter of transmittal and (ii)&nbsp;instructions for effecting the issuance of the portion of
the Merger Consideration, as applicable, payable with respect thereto pursuant to the terms of the Merger Agreement and the Allocation Schedule. Upon proper delivery of a duly completed and executed letter of transmittal, each such person shall be
entitled to receive the number of shares of Class&nbsp;A Common Stock or Up-C Units (shares of Class&nbsp;B Common Stock and Cibus Common Units) as determined in accordance with the Merger Agreement and reflected on the Allocation Schedule. If
delivery is to be made to a person other than the person who is reflected in the books and records of the applicable company as the applicable member, it shall be a condition of delivery that the person requesting such delivery shall have
established to the satisfaction of Calyxt, Inc. and the Exchange and Paying Agent that any transfer and other taxes required by reason of such delivery to a person other than the applicable member have been paid or are not applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From and after the Cibus Merger Effective Time, or each applicable Blocker Merger Effective Time, as applicable, each Person that was a member
of Cibus Global or the corresponding Blocker being merged, respectively (or the holder of an economic interest therein) shall have no rights as a member or holder of any such economic interests and, until the procedures contemplated by the Merger
Agreement have been complied with, any such former limited liability company or economic interest shall represent only the right to receive the applicable portion of the Merger Consideration, respectively, on the terms and subject to the conditions
of the Merger Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom401831_25"></A>Regulatory Approvals </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt, Inc. must comply in all material respects with the rules of Nasdaq in connection with the issuance of Shares. If prior to the Closing
Date, Cibus Global determines, in its reasonable discretion after consultation with Calyxt, Inc. and its legal advisors, that the Transactions require filings under the HSR Act to be submitted with the applicable governmental entities, then as
promptly as reasonably practicable following such determination, Calyxt, Inc. and Cibus Global shall cooperate in the preparation of such filings and, upon completion thereof (in form and substance mutually agreeable to Calyxt, Inc. and Cibus
Global), each of Calyxt, Inc. and Cibus Global shall make or cause to be made any such required filings under the HSR Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Material U.S. Federal
Income Tax Consequences of the Cibus Merger </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a general discussion of the expected material U.S. federal income tax
consequences of the Cibus Merger to Participating Members of Cibus that are U.S. holders (as defined below) (&#147;Cibus Participants&#148;). This discussion is limited to Cibus Participants who hold their Cibus Units or Cibus Warrants, and, if
applicable, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">165 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
will hold their Class&nbsp;A Common Stock received in connection with the Cibus Merger, as &#147;capital assets&#148; within the meaning of Section&nbsp;1221 of the Code (generally, property held
for investment). No rulings have been or will be sought from the IRS with respect to any of the tax consequences discussed below. As a result, there can be no assurance that the IRS will not assert, or that a court would not sustain, a position
contrary to any of the conclusions set forth below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion does not address the U.S. federal income tax consequences to
Participating Members that are not U.S. holders. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax advisors with respect to the U.S. federal income tax consequences of the Cibus Merger and the ownership and
disposition of any Class&nbsp;A Common Stock received pursuant to the Cibus Merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion does not address the U.S. federal
income tax consequences to Cibus equityholders other than to Participating Members in respect of their Cibus units. Additionally, this discussion does not address the U.S. federal income tax consequences to Electing Members, the Blockers, or Blocker
Owners. Such equityholders should consult their tax advisors with respect to the U.S. federal income tax consequences of the Transactions and the ownership and disposition of any Class&nbsp;A Common Stock received pursuant to the Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion is based on the provisions of the Code, applicable U.S. Treasury regulations, administrative rulings and judicial decisions,
all as in effect on the date hereof and all of which are subject to change, possibly with retroactive effect. Any such change could affect the accuracy of the statements and conclusions set forth herein. This discussion does not address all aspects
of U.S. federal income taxation that may be relevant to U.S. holders in light of their particular facts and circumstances. In addition, this discussion does not address any tax consequences under any U.S. federal laws other than those pertaining to
income taxes, nor does it address any tax consequences arising under the Medicare tax on certain investment income or arising under the laws of any state, local, or foreign jurisdiction. Furthermore, this discussion does not apply to U.S. holders
that may be subject to special treatment under U.S. federal income tax laws, including, without limitation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">banks, insurance companies or other financial institutions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> or governmental organizations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">qualified foreign pension funds (or entities all of the interests of which are held by a qualified foreign
pension fund); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">dealers or brokers in stocks, securities or foreign currencies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons whose functional currency is not the U.S. dollar; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;controlled foreign corporations,&#148; &#147;passive foreign investment companies,&#148; or corporations
that accumulate earnings to avoid U.S. federal income tax; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">traders in securities that use the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> method of accounting for U.S. federal income tax purposes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons subject to the alternative minimum tax; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">partnerships or other pass-through entities for U.S. federal income tax purposes or holders of interests therein;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulated investment companies or mutual funds; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">holders of Cibus Units or Cibus Warrants that acquired those interests as compensation or through a <FONT
STYLE="white-space:nowrap">tax-qualified</FONT> retirement plan; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">holders of restricted units or bonus units granted under any benefit plan of the Cibus; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">holders subject to Section&nbsp;1061 of the Code; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain former citizens or long-term residents of the U.S.; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">166 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">holders of Cibus Units or Cibus Warrants or, if applicable, Class&nbsp;A Common Stock that hold such interests or
Class&nbsp;A Common Stock as part of a straddle, appreciated financial position, synthetic security, hedge, conversion transaction or other integrated investment or risk reduction transaction. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this discussion, the term &#147;U.S. holder&#148; means a beneficial owner of Cibus Units or Cibus Warrants or Class&nbsp;A
Common Stock, as applicable, that, for U.S. federal income tax purposes, is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an individual who is a citizen or resident of the U.S.; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation (or other entity treated as a corporation for U.S. federal income tax purposes) created or
organized in or under the laws of the U.S., any state thereof or the District of Columbia; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an estate the income of which is subject to U.S. federal income tax regardless of its source; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust (i)&nbsp;the administration of which is subject to the primary supervision of a U.S. court and which has
one or more U.S. persons (as defined in the Code) who have the authority to control all substantial decisions of the trust or (ii)&nbsp;which has made a valid election under applicable U.S. Treasury regulations to be treated as a U.S. person.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a partnership (including an entity or arrangement treated as a partnership for U.S. federal income tax purposes)
holds Cibus Units, Cibus Warrants or Class&nbsp;A Common Stock, the tax treatment of a partner in such partnership generally will depend upon the status of the partner, the activities of the partnership, and certain determinations made at the
partner level. Accordingly, partners in partnerships (including entities or arrangements treated as partnerships for U.S. federal income tax purposes) holding Cibus Units or Cibus Warrants should consult their tax advisors regarding the U.S. federal
income tax consequences of the Cibus Merger to them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS DISCUSSION IS PROVIDED FOR GENERAL INFORMATION ONLY AND IS NOT A COMPLETE
ANALYSIS OR DESCRIPTION OF ALL POTENTIAL U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE CIBUS MERGER AND THE OWNERSHIP AND DISPOSITION OF CLASS A COMMON STOCK RECEIVED IN CONNECTION WITH THE CIBUS MERGER. EACH UNITHOLDER IS STRONGLY URGED TO CONSULT
WITH ITS OWN TAX ADVISOR AS TO THE SPECIFIC U.S. FEDERAL, STATE, LOCAL, AND <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> TAX CONSEQUENCES TO SUCH HOLDER OF THE MERGER AND THE OWNERSHIP AND DISPOSITION OF CLASS A COMMON STOCK RECEIVED IN
CONNECTION WITH THE CIBUS MERGER, TAKING INTO ACCOUNT ITS OWN PARTICULAR CIRCUMSTANCES. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tax Consequences of the Cibus Merger to Cibus Participants
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>In General </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Cibus Merger is
intended to constitute an &#147;interests-over&#148; transaction in which the Cibus Participants are deemed to contribute their Cibus Units or Cibus Warrants to Cibus, Inc. in exchange for Class&nbsp;A Common Stock in a transaction described under
Section&nbsp;351 of the Code (&#147;Section&nbsp;351 Treatment&#148;). Accordingly, a Cibus Participant is expected to not recognize gain from the Cibus Merger, except to the extent that the Cibus Participant&#146;s allocable share of Cibus&#146;
liabilities exceeds the Cibus Participant&#146;s tax basis in its Cibus Units or Cibus Warrants exchanged for Class&nbsp;A Common Stock. As a consequence, in order to determine the U.S. federal income tax consequences of the Cibus Merger, each Cibus
Participant should consult its own tax advisor regarding its tax basis in its interests and its allocable share of Cibus&#146; liabilities. It is anticipated that most Cibus Participants will not recognize a material amount of gain as a consequence
of the Cibus Merger. The IRS could disagree with the intended Section&nbsp;351 Treatment and assert an alternative characterization, which, if upheld, could result in Cibus Participants recognizing additional gain. We urge each Cibus Participant to
consult its own tax advisor regarding the risk of an alternative treatment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing description of the tax characterization of the
Cibus Merger is based on the assumption that the Participating Members and Blocker Owners will own, in the aggregate, at least 80% of Class&nbsp;A Common </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">167 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Stock and Class&nbsp;B Common Stock outstanding immediately after the Cibus Merger, excluding from the numerator any stock received in connection with the Cibus Merger that is sold after the
Cibus Merger pursuant to a plan or arrangement established before the Cibus Merger (the &#147;Control Assumption&#148;). The Control Assumption should be correct unless, contrary to the knowledge of Cibus, a group of Participating Members and
Blocker Owners that will receive more than a significant amount of Class&nbsp;A Common Stock and Class&nbsp;B Common Stock agree prior to the Cibus Merger to sell the stock they receive in connection with the Cibus Merger. If the Control Assumption
were not correct, a Cibus Participant would recognize gain or loss in connection with the Cibus Merger equal to the difference between: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sum of (i)&nbsp;the respective fair market values of the Class&nbsp;A Common Stock received in exchange for
the Cibus Participant&#146;s Cibus Units or Cibus Warrants and (ii)&nbsp;for Cibus Units, the Cibus Participant&#146;s share of Cibus&#146; liabilities immediately prior to the Cibus Merger; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Cibus Participant&#146;s respective adjusted tax basis in its Cibus Units or Cibus Warrants (which, for Cibus
Units, includes the Cibus Participant&#146;s share of Cibus&#146; liabilities immediately prior to the Cibus Merger). Gain or loss recognized by a Cibus Participant generally would be taxable as capital gain or loss. However, a portion of this gain
or loss would be separately computed and taxed as ordinary income or loss to the extent attributable to Section&nbsp;751 property. Passive losses that were not deductible by a Cibus Participant in prior taxable periods, because they exceed a Cibus
Participant&#146;s share of Cibus&#146; income, may become available to offset a portion of the gain recognized by the Cibus Participant. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The remainder of this discussion assumes that the Section&nbsp;351 Treatment will apply to the Cibus Merger. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Tax Basis and Holding Period in the Class&nbsp;A Common Stock Received in Connection with the Cibus Merger </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A Cibus Participant&#146;s aggregate basis in its Class&nbsp;A Common Stock received in exchange for Cibus Units or Cibus Warrants in
connection with the Cibus Merger should equal the Cibus Participant&#146;s aggregate basis in its exchanged Cibus Units or Cibus Warrants immediately before the Cibus Merger, reduced by the Cibus Participant&#146;s share of Cibus&#146; liabilities
deemed assumed by Cibus, Inc., and increased by the gain, if any, recognized by the Cibus Participant in connection with the Cibus Merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, a Cibus Participant&#146;s holding period for Class&nbsp;A Common Stock received in exchange for Cibus Units or Cibus Warrants
should include the Cibus Participant&#146;s holding period for those Cibus Units or Cibus Warrants. If a Cibus Participant acquired Cibus Units or Cibus Warrants at different times, such Cibus Participant would generally have a split holding period
in its Class&nbsp;A Common Stock received for purposes of determining long-term or short-term capital gain or loss. Additionally, to the extent that the value of Class&nbsp;A Common Stock received by a Cibus Participant is attributable to a Cibus
Participant&#146;s share of Cibus&#146; Section&nbsp;751 property, a Cibus Participant&#146;s holding period for Class&nbsp;A Common Stock received in the Cibus Merger should begin on the day following the Cibus Merger. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Information Reporting </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information
returns may be required to be filed with the IRS in connection with the Cibus Merger. U.S. holders that receive Class&nbsp;A Common Stock or Class&nbsp;B Common Stock and, upon consummation of the Cibus Merger, own Class&nbsp;A Common Stock or
Class&nbsp;B Common Stock representing at least 5% of the total combined voting power or value of the total outstanding Cibus, Inc. shares, are required to attach to their tax returns for the year in which the Mergers are consummated, and maintain a
permanent record of, a statement containing the information listed in Treasury Regulations section <FONT STYLE="white-space:nowrap">1.351-3.</FONT> The facts to be disclosed by a U.S. holder include the aggregate fair market value of, and the U.S.
holder&#146;s basis in, the Cibus Units or Cibus Warrants exchanged pursuant to the Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>The foregoing summary is of a
general nature only and is not intended to be, and should not be construed to be, legal, business or tax advice to any particular Cibus stakeholder. This summary does not take into account your particular circumstances and does not address
consequences that may be particular to you. Therefore, you should consult your tax advisor regarding the particular consequences of the Transactions to you. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">168 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom401831_26"></A>Nasdaq Listing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt Common Stock currently is listed on the Nasdaq Capital Market under the symbol &#147;CLXT.&#148; Calyxt, Inc. has agreed to use
reasonable best efforts (i)&nbsp;to maintain its existing listing on the Nasdaq Capital Market and to obtain approval of the listing of the Class A Common Stock on the Nasdaq; Capital Market (ii)&nbsp;to prepare and submit to Nasdaq a notification
form for the listing of the shares of Class&nbsp;A Common Stock to be issued in connection with the Mergers; (iii)&nbsp;if not previously implemented, to prepare and timely submit to Nasdaq a notification form of any reverse stock split effected
with Cibus Global&#146;s consent and, to the extent required to effect the foregoing, to submit a copy of the amendment to Calyxt, Inc.&#146;s certificate of incorporation to effect such reverse stock split certified by the Secretary of State of the
State of Delaware to Nasdaq; (iv)&nbsp;to file an initial listing application for the Class&nbsp;A Common Stock on Nasdaq and to cause such Nasdaq initial listing application to be approved; and (v)&nbsp;in the event of receipt of a Nasdaq delisting
determination, Calyxt, Inc. shall request a hearing to appeal the delisting determination and shall pay the appropriate fee to Nasdaq to appeal the delisting determination. In addition, under the Merger Agreement, the obligations of Cibus Global and
the Blockers to consummate the Mergers are subject to the satisfaction (subject to waiver by Cibus Global) of various conditions, including that (i)&nbsp;the existing shares of Calyxt Common Stock must be listed on the Nasdaq Capital Market and not
subject to any pending <FONT STYLE="white-space:nowrap">de-listing</FONT> notice or <FONT STYLE="white-space:nowrap">de-listing</FONT> appeal process that would not be remedied by the consummation of the Transactions; (ii)&nbsp;the Nasdaq listing
application shall have been approved; and (iii)&nbsp;the shares of the Class&nbsp;A Common Stock to be issued as Merger Consideration shall have been approved for listing on Nasdaq. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt, Inc. has filed an initial listing application for Cibus, Inc. and the Class&nbsp;A Common Stock with the Nasdaq Capital Market. If
such application is accepted, Calyxt, Inc. anticipates that the shares of Class&nbsp;A Common Stock will be listed on the Nasdaq Capital Market following the Closing under the trading symbol &#147;CBUS.&#148; In order to meet the requirements for
listing on Nasdaq, the Combined Company will be required to satisfy Nasdaq&#146;s initial listing requirements, including the financial and liquidity requirements for the applicable Nasdaq market tier upon which the Combined Company&#146;s shares
will trade following the Transactions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom401831_27"></A>Accounting Treatment of the Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination is expected to be accounted for in accordance with ASC 805, Business Combinations, using the acquisition method of
accounting, with Calyxt, Inc. as the acquirer and Cibus Global as the acquiree. Under the acquisition method of accounting, Calyxt Inc.&#146;s assets and liabilities will be recorded at carrying value and the assets and liabilities associated with
Cibus Global will be recorded at estimated fair value as of the acquisition date. The excess of the purchase price over the estimated fair values of the net assets acquired, if applicable, will be recognized as goodwill. For purposes of the
unaudited pro forma combined balance sheet, the purchase consideration has been allocated to the assets acquired and liabilities assumed of Cibus Global based upon management&#146;s preliminary estimate of their fair values. Calyxt, Inc. has not
completed the valuation analysis and calculations in sufficient detail necessary to arrive at the required estimates of the fair market value of the Cibus Global assets acquired or liabilities assumed, including the preliminary estimate for
intangible assets. Accordingly, the assets and liabilities should be treated as preliminary values. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For accounting purposes, the acquirer
is the entity that has obtained control of another entity and, thus, consummated a business combination. The determination of whether control has been obtained begins with the evaluation of whether control should be evaluated based on the variable
interest or voting interest model pursuant to ASC Topic 810, Consolidation (&#147;ASC 810&#148;). If the acquiree is a variable interest entity, the primary beneficiary would be the accounting acquirer. Cibus Global meets the definition of a
variable interest entity and Calyxt, Inc., which will be the managing member, has been determined to be the primary beneficiary. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom401831_28">
</A>Appraisal Rights and Dissenters&#146; Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt Stockholders are not entitled to dissenters&#146; or appraisal rights under
the DGCL in connection with the Mergers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">169 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom401831_29"></A>THE MERGER AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following is a summary of the material terms of the Merger Agreement. Copies of the Merger Agreement and the First Amendment are
attached as Annex A-1 and Annex A-2, respectively, to this proxy statement/prospectus and is incorporated by reference into this proxy statement/prospectus. The Merger Agreement has been attached to this proxy statement/prospectus to provide you
with information regarding its terms. It is not intended to provide any other factual information about Calyxt, Cibus, Merger Subsidiary or the Blockers. The following description does not purport to be complete and is qualified in its entirety by
reference to the Merger Agreement. You should refer to the full text of the Merger Agreement for details of the Merger and the terms and conditions of the Merger Agreement. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The Merger Agreement contains representations and warranties that Calyxt, Inc. and Merger Subsidiary, on the one hand, and Cibus Global and
the Blockers, on the other hand, have made to one another as of specific dates. These representations and warranties have been made for the benefit of the other parties to the Merger Agreement and may be intended not as statements of fact but rather
as a way of allocating the risk to one of the parties to the Merger Agreement if those statements prove to be incorrect. In addition, the assertions embodied in the representations and warranties are qualified by information in confidential
disclosure schedules exchanged by the parties in connection with signing the Merger Agreement. While Calyxt, Inc. and Cibus Global do not believe that these disclosure schedules contain information required to be publicly disclosed under the
applicable securities laws, other than information that has already been so disclosed, the disclosure schedules do contain information that modifies, qualifies and creates exceptions to the representations and warranties set forth in the attached
Merger Agreement. Accordingly, you should not rely on the representations and warranties as current characterizations of factual information about Calyxt, Inc. and Cibus Global because they were made as of specific dates, may be intended merely as a
risk allocation mechanism between Calyxt, Inc., Merger Subsidiary, Cibus Global and the Blockers, and are modified by the disclosure schedules. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Structure </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Merger Subsidiary was formed
as a wholly-owned subsidiary of Calyxt, Inc. for the sole purpose of completing the Cibus Merger. Under the Merger Agreement: (a)&nbsp;each of the Blockers will merge with and into Calyxt, Inc., in each case with the Blockers ceasing to exist and
Calyxt, Inc. surviving each such Blocker Merger, (b)&nbsp;at the First Blocker Merger Effective Time, Calyxt, Inc.&#146;s bylaws will be amended and restated in the form of the Amended Bylaws and Calyxt, Inc.&#146;s certificate of incorporation will
be amended and restated in the form of the Amended Certificate of Incorporation, and (c)&nbsp;immediately following consummation of the Blocker Mergers, Merger Subsidiary will merge with and into Cibus Global, with Cibus Global as the surviving
company and Merger Subsidiary ceasing to exist. In connection with adoption of the Amended Certificate of Incorporation, Calyxt, Inc.&#146;s name will be changed to &#147;Cibus, Inc.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the Closing and the issuance of the Merger Consideration and the issuance of Cibus Common Units, the Combined Company will be
organized in an <FONT STYLE="white-space:nowrap">&#147;Up-C&#148;</FONT> structure, and Cibus, Inc.&#146;s only material asset will consist of Cibus Common Units. Based on the capitalization of Calyxt, Inc. and Cibus Global, the Calyxt Stockholders
would be expected to own approximately 5.0% of issued and outstanding common stock at the time of signing the Merger Agreement of Cibus, Inc. immediately post-Closing, on a Fully-Exchanged Basis, and Cibus Unitholders would be expected to own
approximately 95.0% of the issued and outstanding Shares of Cibus, Inc. immediately post-Closing, on a Fully-Exchanged Basis, in each case, subject to dilution in connection with any Dilutive Issuances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately following the Closing, all of the issued and outstanding Cibus Common Units will be held by Cibus, Inc. and the Electing Members
(through their ownership of <FONT STYLE="white-space:nowrap">Up-C</FONT> Units), with the exact ownership interest held by Cibus, Inc. and the Electing Members being subject to the elections to be submitted by Top 99 Holders prior to the Closing. In
connection with the Up-C structure, at Closing, (i) Cibus, Inc. and the Electing Members will become party to the Cibus Amended Operating Agreement, (ii) Cibus, Inc., Cibus Global and the Electing Members will enter into an Exchange Agreement, and
(iii) Cibus, Inc. and the Electing Members will enter into a Registration Rights Agreement and a Tax Receivable Agreement. The <FONT STYLE="white-space:nowrap">Up-C</FONT> Units will generally be exchangeable for shares of Class&nbsp;A Common Stock
on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis, or, subject to certain restrictions, the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">170 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
cash equivalent with respect to all or a portion thereof, based on a volume-weighted average price of a share of Class&nbsp;A Common Stock pursuant to the terms of the Exchange Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Merger Consideration </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Amended
Certificate of Incorporation, once adopted at the First Blocker Merger Effective Time, will designate two classes of Cibus, Inc. common stock: (i)&nbsp;Class&nbsp;A Common Stock, which shares will have full voting and economic rights and
(ii)&nbsp;Class&nbsp;B Common Stock, which shares will have full voting, but no economic rights. Upon adoption of the Amended Certificate of Incorporation, each share of Calyxt Common Stock existing and outstanding immediately prior to the First
Blocker Merger Effective Time shall remain outstanding as Class&nbsp;A Common Stock at the First Blocker Merger Effective Time without any conversion or exchange thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At each applicable Blocker Merger Effective Time, the limited liability company interests of the applicable Blocker will be cancelled and
converted into the right of the equityholders of the applicable Blocker to receive shares of Class&nbsp;A Common Stock corresponding to that Blocker Merger, in each case, as set forth in the Allocation Schedule. The initial version of the Allocation
Schedule was attached as an exhibit to the Merger Agreement and calculated based on the fully-diluted capitalization of Calyxt, Inc. and Cibus Global, in each case, as of the date of the Merger Agreement. Pursuant to the Merger Agreement, the
Allocation Schedule will be updated by Cibus Global no later than three business days to Closing to reflect (a)&nbsp;transfers of equity interests in Cibus Global or the Blockers, (b)&nbsp;the results of the elections by Top 99 Holders and
(c)&nbsp;the sale of additional Cibus Series F Preferred Units after the date of the Merger Agreement (at a cash price of $2.00 per Cibus Series F Preferred Unit and other terms substantially the same as issuances of Cibus Series F Preferred Units
prior to the date of the Merger Agreement). For a summary of the calculations and allocations set forth in the Allocation Schedule, see &#147;<I>The Mergers&#151;Merger Consideration&#151;Allocation Schedule</I>&#148; beginning on page&nbsp;164 of
this proxy statement/prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the effective time of the Cibus Merger, all of the issued and outstanding Cibus Units (including
Cibus PIUs), and all outstanding Cibus Warrants or options to purchase Cibus Units, will be cancelled (or, in the case of Cibus Warrants, surrendered to Cibus, Inc. for exchange) and converted into the right to receive the following, as described in
further detail in the Merger Agreement (the &#147;Cibus Merger Consideration&#148;): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Top 99 Holders shall have the option to elect, on a per unit basis, to receive Merger Consideration in the
form of either (a)&nbsp;the number of shares of Class&nbsp;A Common Stock set forth on the Allocation Schedule in exchange for all such holder&#146;s Cibus Units (other than Cibus PIUs) covered by such election or (b)&nbsp;a number of Up-C Units, as
set forth on the Allocation Schedule in exchange for such holder&#146;s Cibus Units (other than Cibus PIUs) elected for exchange into Up-C Units, provided, that such holder will not be entitled to exchange more than 95% of such holder&#146;s
existing Cibus Units for <FONT STYLE="white-space:nowrap">Up-C</FONT> Units and the remainder of such holder&#146;s Cibus Units will be exchanged for shares of Class&nbsp;A Common Stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all <FONT STYLE="white-space:nowrap">pre-Closing</FONT> Cibus Unitholders, other than Top 99 Holders or Blockers,
shall receive the number of shares of Class&nbsp;A Common Stock set forth on the Allocation Schedule in exchange for their Cibus Units (other than Cibus PIUs); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all <FONT STYLE="white-space:nowrap">pre-Closing</FONT> Cibus Warrants shall automatically be exchanged for the
right to receive the number of shares of Class&nbsp;A Common Stock set forth on the Allocation Schedule; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all <FONT STYLE="white-space:nowrap">pre-Closing</FONT> Cibus PIUs will, (a)&nbsp;to the extent not a
&#147;restricted unit&#148; (under the award agreements and governing documents applicable to such Cibus PIUs), be automatically cancelled and converted into the right to receive the number of shares of Class&nbsp;A Common Stock set forth on the
Allocation Schedule and (b)&nbsp;to the extent a &#147;restricted unit&#148; (i.e., an unvested unit), be automatically cancelled and converted into the right to receive the number of restricted shares of Class&nbsp;A Common Stock pursuant to a
Cibus, Inc. stock plan, as set forth on the Allocation Schedule and subject to the same vesting schedule as was applicable to such Cibus PIUs prior to Closing. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">171 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately following the Cibus Merger, (i)&nbsp;each
<FONT STYLE="white-space:nowrap">pre-Closing</FONT> Cibus Unit and <FONT STYLE="white-space:nowrap">pre-Closing</FONT> Cibus Warrant, in each case, held by Cibus, Inc. as a result of the Blocker Mergers will be converted or exchanged for a number of
Cibus Common Units set forth in the Allocation Schedule, (ii)&nbsp;each <FONT STYLE="white-space:nowrap">pre-Closing</FONT> Cibus Warrant held by Cibus, Inc. as a result of the warrant exchanges described above will be converted or exchanged for a
number of Cibus Common Units set forth in the Allocation Schedule, and (iii)&nbsp;Cibus Global will issue a number of Cibus Common Units to Cibus, Inc. in an amount equal to the sum of (A)&nbsp;the number of shares of Class&nbsp;A Common Stock
issued to former Cibus Global equity holders as Cibus Merger Consideration and (B)&nbsp;the number of shares of Calyxt Common Stock outstanding immediately prior to the First Blocker Merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Promptly after the date this proxy statement/prospectus is declared effective by the SEC, Cibus Global will mail to each holder (other than
Blockers) of Cibus Units that is a Top 99 Holder an Election Form. The Election Form will accompany the disclosure statement and copies of the form of Tax Receivable Agreement, Cibus Amended Operating Agreement, Exchange Agreement and Registration
Rights Agreement and the Election Form will include counterpart signatures to each of the foregoing agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Election Form will
permit each holder of Cibus Units that is a Top 99 Holder to elect on a <FONT STYLE="white-space:nowrap">per-Cibus</FONT> Unit basis (other than in respect of Cibus PIUs), to receive as Merger Consideration in the Cibus Merger in the form of either
(A) shares of Class&nbsp;A Common Stock or <FONT STYLE="white-space:nowrap">(B)&nbsp;Up-C</FONT> Units (subject to the limitations in the Merger Agreement, any such holder validly electing to receive <FONT STYLE="white-space:nowrap">Up-C</FONT>
Units in exchange for any one or more of its Cibus Units, an &#147;Electing Member&#148;, and the Cibus Units that such Electing Member will exchange for <FONT STYLE="white-space:nowrap">Up-C</FONT> Units, the &#147;Excluded Units&#148;); provided,
however, that no Electing Member will be entitled to receive <FONT STYLE="white-space:nowrap">Up-C</FONT> Units to the extent such holder&#146;s Excluded Units exchanged therefor would represent more than 95%, or such lower percentage as may be
determined by Cibus Global and set forth on the Election Form, of the total number of Cibus Units held by such person as of immediately prior to the Cibus Merger Effective Time (for the avoidance of doubt, any Cibus Units held by such person in
excess of such amount will not constitute Excluded Units and will instead receive shares of Class&nbsp;A Common Stock in exchange for the Cibus Units representing such excess, notwithstanding such person&#146;s election). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Treatment of Cibus PIUs </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms
of the Merger Agreement, each Cibus PIU issued and outstanding immediately prior to the Cibus Merger Effective Time shall, (i)&nbsp;to the extent not a &#147;restricted unit&#148; under the award agreements and governing documents applicable to such
Cibus PIU as of such time, be automatically cancelled and converted into the right to receive the number of shares of Class&nbsp;A Common Stock set forth on the Allocation Schedule and (ii)&nbsp;to the extent a &#147;restricted unit&#148; (i.e., an
unvested unit) under the award agreements and other governing documents applicable to such Cibus PIU as of such time, be automatically cancelled and converted into the right to receive the number of restricted shares of Class&nbsp;A Common Stock
pursuant to a Cibus, Inc. stock plan, as set forth on the Allocation Schedule and subject to the same vesting schedule as was applicable to such Cibus PIU prior to the Closing. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Procedures for Exchange </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the
date this proxy statement/prospectus is declared effective by the SEC, Calyxt, Inc. shall cause the Exchange and Paying Agent to mail to each person who was a member of Cibus Global or any Blocker as of immediately prior to the effective time of
each respective Mergers, (i)&nbsp;a letter of transmittal and (ii)&nbsp;instructions for effecting the issuance of the portion of the Merger Consideration, as applicable, payable with respect thereto pursuant to the terms of the Merger Agreement and
the Allocation Schedule. Upon proper delivery of a duly completed and executed letter of transmittal, each such person shall be entitled to receive the number of shares of Class&nbsp;A Common Stock or Up-C Unit (shares of Class&nbsp;B Common Stock
and/or Cibus Common Units) as determined in accordance with the Merger Agreement and reflected on the Allocation Schedule. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Directors and Officers of
Calyxt, Inc. Following the Merger </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At and after the First Blocker Merger Effective Time, the size of the Calyxt Board will be set at
six and will consist of Rory Riggs, Peter Beetham, Mark Finn, Jean-Pierre Lehmann, Gerhard Prante, and Keith Walker. All </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">172 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other Calyxt, Inc. directors prior to the First Blocker Merger Effective Time will resign effective as of the First Blocker Merger Effective Time. Calyxt, Inc.&#146;s officers at such time will
be Rory Riggs, Peter Beetham, Greg Gocal, and Wade King, and all other current Calyxt, Inc. officers will resign at such time, subject to ongoing discussions with certain officers at Calyxt, Inc. For more information, see the section entitled
&#147;<I>The Mergers</I><I>&#151;</I><I>Interests of Calyxt, Inc. Directors and Executive Officers in the Mergers</I><I>&#151;</I><I>Potential Going-Forward Roles with Cibus, Inc.&#148;</I> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amendments to the Calyxt Certificate of Incorporation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt Stockholders as of the record date will be asked to approve the Calyxt Stockholder Matters, which include the amendment of Calyxt,
Inc.&#146;s organizational documents, to, among other things, authorize the shares of Class&nbsp;A Common Stock and Class&nbsp;B Common Stock to be issued pursuant to the Merger Agreement in connection with the Mergers. For more information, see
section entitled &#147;<I>Description of Capital Stock of Cibus, Inc.</I>&#148; beginning on page&nbsp;333 of this proxy statement/prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conditions to the Completion of the Mergers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following contains a description of material conditions to the completion of the Mergers. The obligation of each of Calyxt, Inc. and Merger
Subsidiary to consummate the Mergers is subject to the satisfaction of the following conditions precedent, each of which may be waived in writing in the sole discretion of Calyxt, Inc.: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fundamental representations of Cibus Global and the Blockers contained in the Merger Agreement must be true
and correct in all material respects as of the Closing Date with the same force and effect as if made on and as of such date. The representations and warranties contained in the Merger Agreement (other than the fundamental representation of Cibus
Global and the Blockers contained in the Merger Agreement) must be true and correct on and as of the Closing Date with the same force and effect as if made on the Closing Date, except (i)&nbsp;in each case, or in the aggregate, where the failure to
be true and correct would not reasonably be expected to result in a material adverse effect (without giving effect to any references therein to any material adverse effect or other materiality qualifications) or (ii)&nbsp;for those representations
and warranties which address matters only as of a particular date (which representations shall have been true and correct, subject to the qualifications as set forth in the preceding clause (i), as of such particular date); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cibus Global and the Blockers shall each have performed or complied with, in all material respects, the
agreements and covenants required to be performed or complied with by it under the Merger Agreement at or prior to the Closing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Calyxt, Inc. shall have received a certificate of an officer of Cibus Global certifying that certain closing
conditions have been duly satisfied; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no judgment, order, decree, stipulation or injunction shall be in effect that would reasonably be expected to
(i)&nbsp;temporarily or permanently prevent or enjoin consummation of the transactions, or (ii)&nbsp;cause the transactions to be rescinded following consummation of such transaction; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no effect that, individually or taken together with all other effects, has had, or would reasonably be expected
to result in, a material adverse effect on Cibus Global and its subsidiaries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Calyxt, Inc. shall have received copies of the written consents evidencing the Cibus Member Approval and the
Blocker Approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Calyxt, Inc. shall have obtained the Calyxt, Inc. Stockholder Approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">this proxy statement/prospectus shall have become effective under the Securities Act and no stop order suspending
the effectiveness of this proxy statement/prospectus shall have been issued and no legal proceeding for that purpose, and no similar legal proceeding with respect to this proxy statement/prospectus, shall have been initiated or threatened in writing
by the SEC or its staff that has not been withdrawn; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if filings under the HSR Act are required, any applicable waiting period shall have expired or been terminated;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">173 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the approval of the listing of the Class&nbsp;A Common Stock on Nasdaq must have been obtained, and the shares of
the Calyxt, Inc. Class&nbsp;A Common Stock to be issued as Merger Consideration shall have been approved for listing on Nasdaq; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cibus Global shall have delivered to Calyxt, Inc. a copy of (i)&nbsp;the Tax Receivable Agreement, the Exchange
Agreement and the Cibus Amended Operating Agreement, each duly executed by Cibus Global and each Electing Member and (ii)&nbsp;the Registration Rights Agreement, duly executed by each Electing Member. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The obligations of Cibus Global and the Blockers to consummate the Mergers is subject to the satisfaction of the following conditions
precedent, each of which may be waived in writing in the sole discretion of Cibus Global: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fundamental representations of Calyxt, Inc. and Merger Subsidiary contained in the Merger Agreement must be
true and correct in all material respects as of the Closing Date with the same force and effect as if made on and as of such date. The representations and warranties contained in the Merger Agreement (other than the fundamental representation of
Calyxt, Inc. and Merger Subsidiary contained in the Merger Agreement) must be true and correct on and as of the Closing Date with the same force and effect as if made on the Closing Date, except (i)&nbsp;in each case, or in the aggregate, where the
failure to be true and correct would not reasonably be expected to result in a material adverse effect (without giving effect to any references therein to any material adverse effect or other materiality qualifications) or (ii)&nbsp;for those
representations and warranties which address matters only as of a particular date (which representations shall have been true and correct, subject to the qualifications as set forth in the preceding clause (i), as of such particular date);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Calyxt, Inc. and Merger Subsidiary shall each have performed or complied with, in all material respects, the
agreements and covenants required to be performed or complied with by it under the Merger Agreement at or prior to the Closing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Calyxt, Inc. shall have received a certificate of an officer of Cibus Global certifying that certain closing
conditions have been duly satisfied; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no judgment, order, decree, stipulation or injunction shall be in effect that would reasonably be expected to
(i)&nbsp;temporarily or permanently prevent or enjoin consummation of the transactions, or (ii)&nbsp;cause the transactions to be rescinded following consummation of such transaction; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no effect that, individually or taken together with all other effects, has had, or would reasonably be expected
to result in, a material adverse effect on Calyxt, Inc. and its subsidiaries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Calyxt, Inc. shall have obtained the Calyxt Stockholder Approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cibus Global shall have obtained the written consents evidencing the Cibus Member Approval and the Blocker
Approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Calyxt, Inc. shall have delivered to Cibus Global an amendment to the license agreement between Calyxt, Inc. and
Cellectis S.A. in substantially the form agreed upon and attached as an exhibit to the Merger Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">this proxy statement/prospectus shall have become effective under the Securities Act and no stop order suspending
the effectiveness of this proxy statement/prospectus shall have been issued and no legal proceeding for that purpose, and no similar legal proceeding with respect to this proxy statement/prospectus, shall have been initiated or threatened in writing
by the SEC or its staff that has not been withdrawn; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(i) the existing shares of Calyxt Common Stock shall be listed on Nasdaq and not subject to any pending <FONT
STYLE="white-space:nowrap">de-listing</FONT> notice (except as set forth in the Calyxt, Inc. disclosure schedule) or <FONT STYLE="white-space:nowrap">de-listing</FONT> appeal process that would not be remedied by the consummation of the
transactions, (ii)&nbsp;the approval of </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">174 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
the listing of the Class&nbsp;A Common Stock on Nasdaq must have been obtained and (iii)&nbsp;the shares of the Calyxt Class&nbsp;A Common Stock to be issued as Merger Consideration shall have
been approved for listing on Nasdaq; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Calyxt Support Agreements will continue to be in full force and effect as of immediately following the Cibus
Merger Effective Time; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if filings under the HSR Act are required, any applicable waiting period shall have expired or been terminated;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cibus Global shall have received a written resignation, in a form reasonably satisfactory to Cibus Global, dated
as of the Closing Date and effective as of the Cibus Merger Effective Time, executed by each of the officers and directors of Calyxt, Inc. not listed under the Merger Agreement, from their positions as such, of Calyxt, Inc., including any
characterization of the resigning officers cessation from employment; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Calyxt, Inc. shall have delivered to Cibus Global a copy of (i)&nbsp;the Tax Receivable Agreement, the Exchange
Agreement, and the Cibus Amended Operating Agreement, each duly executed by Cibus Global and each Electing Member and (ii)&nbsp;the Registration Rights Agreement, duly executed by each Electing Member; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Calyxt, Inc. shall have delivered to Cibus Global an agreement evidencing termination of Calyxt, Inc. as a party
to that certain Management Services Agreement by and among Cellectis S.A., Cellectis, Inc. and Calyxt, Inc., in form and substance reasonably acceptable to Cibus Global, effective as of or prior to the Closing; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Calyxt, Inc. shall have taken all steps necessary to effectuate certain conversions under the Merger Agreement,
including amending the Calyxt Stock Plans as needed to issue the awards contemplated by the Merger Agreement and filing applicable registration statements with respect thereto. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As noted above, portions of the representations and warranties are qualified as to &#147;material adverse effect.&#148; Under the Merger
Agreement, a material adverse effect means any change, event, effect, circumstance or development (collectively, &#147;Effects&#148;) that, considered together with all other Effects, has or would reasonably be expected to have a material adverse
effect on the business, condition (financial or otherwise), assets, liabilities or results of operations of Cibus Global or its subsidiaries or Calyxt, Inc. or its subsidiaries, as applicable, taken as a whole; provided, however, that Effects
resulting from the following shall not be taken into account in determining whether there has been a material adverse effect: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general business or economic conditions generally affecting the industry in which Cibus Global and its
subsidiaries operate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acts of war, the outbreak or escalation of armed hostilities, acts of terrorism (including cyberterrorism),
earthquakes, wildfires, hurricanes or other natural disasters, health emergencies, including pandemics (including <FONT STYLE="white-space:nowrap">COVID-19)</FONT> and related or associated epidemics, disease outbreaks and any governmental or
industry responses thereto (including quarantine restrictions); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in financial, banking, securities markets, or general economic, regulatory, legislative or political
conditions (including changes in interest or exchange rates); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any change in, or any compliance with or action taken for the purpose of complying with, any Law or GAAP (or
interpretations of any Law or GAAP); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">resulting from the announcement of the Merger Agreement or the pendency of the Transactions;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the failure of Cibus Global or Calyxt, Inc., as applicable, to meet internal expectations or projections or the
results of operations of Cibus Global or Calyxt, Inc., as applicable, in and of itself (it being understood, however, that any Effect causing or contributing to such failure may be taken into account in determining whether a material adverse effect
has occurred, unless such Effects are otherwise excepted from this definition); or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">175 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">resulting from the taking of any action required to be taken by the Merger Agreement, except in each case with
respect to clauses (a)&nbsp;through (c), to the extent disproportionately affecting Cibus Global and its subsidiaries or Calyxt, Inc. and its subsidiaries, as applicable, taken as a whole, relative to other similarly situated companies in the
industries in which Cibus Global and its subsidiaries or Calyxt, Inc. and its subsidiaries, as applicable, operate (and then only the amount of such disproportionate impact shall be taken into account). </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Representations and Warranties </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Merger Agreement contains customary representations and warranties of Cibus Global for a transaction of this type relating to, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">corporate organization, standing and power, and similar corporate matters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">capitalization; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subsidiaries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authority to enter into the Merger Agreement and the related agreements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">financial statements and liabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">material changes or events; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">tax matters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ownership of real property and leasehold interests; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">intellectual property; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the validity of material contracts to which the parties or their subsidiaries are a party and any violation,
default or breach to such material contracts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">legal proceedings and orders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">environmental matters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">labor and employment; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">employee matters and benefit plans; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory compliance and restrictions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with anti-bribery laws; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">permits; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">insurance; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">data security and privacy; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any brokerage or finder&#146;s fee or other fee or commission in connection with the merger.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger Agreement contains customary representations and warranties of Blockers for a transaction of this type
relating to, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">corporate organization, standing and power, and similar corporate matters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">capitalization; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">operations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authority to enter into the Merger Agreement and the related agreements; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">176 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory compliance and restrictions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any brokerage or finder&#146;s fee or other fee or commission in connection with the merger; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">tax matters. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger Agreement contains customary representations and warranties of Calyxt, Inc. and the Merger Subsidiary for a transaction of this
type relating to, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">corporate organization, standing and power, and similar corporate matters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">capitalization; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subsidiaries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authority to enter into the Merger Agreement and the related agreements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">with respect to the Merger Subsidiary, business operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">financial statements, liabilities, and documents filed with the SEC and the accuracy of information contained in
those documents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">material changes or events; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">tax matters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ownership of real property and leasehold interests; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">intellectual property; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the validity of material contracts to which the parties or their subsidiaries are a party and any violation,
default or breach to such material contracts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">legal proceedings and orders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory compliance and restrictions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with anti-bribery laws; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">permits; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">insurance; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">data security and privacy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any brokerage or finder&#146;s fee or other fee or commission in connection with the merger;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain transactions or relationships with affiliates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Nasdaq market quotation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">shareholder rights plan and antitakeover law; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">valid issuance in the merger of Calyxt Common Stock. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The representations and warranties are, in many respects, qualified by materiality and knowledge and will not survive the Merger, but their
accuracy forms the basis of one of the conditions to the obligations of Calyxt, Inc., Merger Subsidiary, Cibus Global and Blockers to complete the Mergers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Solicitation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as expressly
permitted by the Merger Agreement, each of Calyxt, Inc. and Cibus Global agreed that during the <FONT STYLE="white-space:nowrap">pre-Closing</FONT> period, except as described below, Calyxt, Inc. and Cibus Global will not, nor will either party
authorize any of its representatives to, directly or indirectly: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">177 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">solicit, initiate or knowingly encourage, induce or facilitate the communication, making, submission or
announcement of, any acquisition proposal or acquisition inquiry (each as defined below) or take any action that could reasonably be expected to lead to an acquisition proposal or acquisition inquiry; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">furnish any information regarding such party to any person for the purpose of encouraging, or in response to, an
acquisition proposal or acquisition inquiry; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">engage in discussions or negotiations with any person with respect to any acquisition proposal or acquisition
inquiry; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approve, endorse or recommend any acquisition proposal; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">execute or enter into any letter of intent or any contract contemplating or otherwise relating to any acquisition
transaction, as defined below (other than a confidentiality agreement permitted under the Merger Agreement); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">publicly propose to do any of the above; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">agree, resolve or commit (or, for the avoidance of doubt, the Calyxt Board or Cibus Board, as applicable, or any
committee thereof to resolve, agree or commit) to do any of the above. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An &#147;acquisition inquiry&#148; means, with
respect to a party, an inquiry, indication of interest or request for information (other than an inquiry, indication of interest or request for information made or submitted by Cibus Global, on the one hand, or Calyxt, Inc., on the other hand, to
the other party) that could reasonably be expected to lead to an acquisition proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An &#147;acquisition proposal&#148; means, with
respect to a party, any offer or proposal, whether written or oral (other than an offer or proposal made or submitted by or on behalf of Cibus Global or any of its subsidiaries, on the one hand, or by or on behalf of Calyxt, Inc. or any of its
subsidiaries, on the other hand, to the other party) contemplating or otherwise relating to or that could reasonably be interpreted to lead to any acquisition transaction with such party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An &#147;acquisition transaction&#148; means any transaction or series of related transactions involving: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any merger, consolidation, amalgamation, share exchange, business combination, issuance of securities,
acquisition of securities, reorganization, recapitalization, tender offer, exchange offer or other similar transaction: (i)&nbsp;in which a party is a constituent entity; (ii)&nbsp;in which a person or &#147;group&#148; (as defined in the Exchange
Act and the rules promulgated thereunder) of persons directly or indirectly acquires beneficial or record ownership of securities representing (A)&nbsp;with respect to Calyxt, Inc. more than 20% of the outstanding securities of any class of voting
securities of a party or any of its subsidiaries or (B)&nbsp;with respect to Cibus Global more than 35% of the outstanding securities of any class of voting securities of a party or any of its subsidiaries; or (iii)&nbsp;in which (Y)&nbsp;Calyxt,
Inc. or any of its subsidiaries issues securities representing more than 20% of the outstanding securities of any class of voting securities of Calyxt, Inc. or any of its subsidiaries or (Z)&nbsp;Cibus Global or any of its subsidiaries issues
securities representing more than 35% of the outstanding securities of any class of voting securities of Cibus Global or any of its subsidiaries; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any sale, lease, exchange, transfer, license, acquisition or disposition of any business or businesses or assets
that constitute or account for 20% or more of the consolidated book value or the fair market value of the assets of a party and its subsidiaries, taken as a whole. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, before obtaining the applicable approvals of the Calyxt Stockholders or Cibus Unitholders required to
consummate the Mergers, each party may furnish <FONT STYLE="white-space:nowrap">non-public</FONT> information regarding such party to, and enter into discussions or negotiations with, any person in response to an unsolicited bona fide written
acquisition proposal by such person, which such party&#146;s board of directors, or board of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">178 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
managers, as applicable, determines in good faith, after consultation with such party&#146;s outside financial advisors and outside legal counsel, constitutes, or would be reasonably likely to
result in a &#147;superior offer,&#148; (as defined below) (and is not withdrawn) if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">neither such party nor any of its representative has materially breached the
<FONT STYLE="white-space:nowrap">non-solicitation</FONT> provisions of the Merger Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such party&#146;s board of directors or board of managers, as applicable, concludes in good faith based on the
advice of outside legal counsel, that the failure to take such action is reasonably likely to be inconsistent with the fiduciary duties of such party&#146;s board of directors under applicable law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at least two business days prior to initially furnishing any such nonpublic information to, or entering into
discussions with, such person, such party gives the other party written notice of the identity of such person and of that party&#146;s intention to furnish <FONT STYLE="white-space:nowrap">non-public</FONT> information to, or enter into discussions
with, such person; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such party receives from the person an executed confidentiality agreement containing provisions (including <FONT
STYLE="white-space:nowrap">non-disclosure,</FONT> use restrictions, <FONT STYLE="white-space:nowrap">non-solicitation</FONT> and no hire provisions), in the aggregate, at least as favorable to such party as those contained in the confidentiality
agreement; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at least two business days prior to furnishing any <FONT STYLE="white-space:nowrap">non-public</FONT> information
to such person, such party furnishes such <FONT STYLE="white-space:nowrap">non-public</FONT> information to the other party (to the extent such information has not been previously furnished). </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A &#147;superior offer&#148; means an unsolicited bona fide written acquisition proposal (with all references to 20% or 35% in the definition
of &#147;acquisition transaction&#148; being treated as references to greater than 50% for these purposes) that: (a)&nbsp;was not obtained or made as a result of a breach of (or in violation of) the Merger Agreement; (b)&nbsp;is on terms and
conditions that the Calyxt Board (in the case of a superior offer, with regards to Calyxt, Inc.) or, (in the case of a superior offer with respect to Cibus Global) determines in good faith, based on such matters that it deems relevant (including the
likelihood of consummation thereof, the financing terms thereof, any <FONT STYLE="white-space:nowrap">break-up</FONT> fees, and conditions to consummation), as well as any written offer by Cibus Global (in the case of a superior offer with regards
to Calyxt, Inc.) (or by Calyxt, Inc. in the case of a superior offer with respect to Cibus Global) to amend the terms of the Merger Agreement, and following consultation with its outside legal counsel and outside financial advisors, if any, are more
favorable, from a financial point of view, to Calyxt Stockholders (or, in the case of a superior offer with respect to Cibus Global, the members of Cibus Global and the Blockers) than the terms of the transactions; (c)&nbsp;is not subject to any
financing conditions (and if financing is required, such financing is then fully committed to the third party); and (d)&nbsp;is reasonably capable of being completed on the terms proposed without unreasonable delay. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger Agreement also provides that if Cibus Global or Calyxt, Inc. receives an acquisition proposal or acquisition inquiry at any time
during the <FONT STYLE="white-space:nowrap">pre-Closing</FONT> period, then such party shall promptly (and in any event within 24 hours) advise the other party orally and in writing of (i)&nbsp;the receipt of such acquisition proposal or acquisition
inquiry, (ii)&nbsp;any <FONT STYLE="white-space:nowrap">non-public</FONT> information provided to a person who has made an acquisition proposal or acquisition inquiry in response to a request from such person, (iii)&nbsp;the identity of the person
making or submitting such acquisition proposal or acquisition inquiry, and (iv)&nbsp;the material terms thereof as well as complete copies of any written acquisition proposals, acquisition inquiries or any other written communications from such
person, including any proposed agreements, and such party thereafter shall keep the other party reasonably informed, on a reasonably current basis, with respect to the status and material terms of any such acquisition proposal or acquisition
inquiry, including informing the other party on a reasonably current basis of any material amendment or modification or proposed material amendment or modification to any such acquisition proposal or acquisition inquiry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger Agreement also provides that each of Calyxt, Inc. and Cibus Global will immediately cease and cause to be terminated any existing
discussions, negotiations and communications with any person that relate to any acquisition proposal or acquisition inquiry that has not already been terminated as of the date of the Merger </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">179 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Agreement and request the destruction or return of any <FONT STYLE="white-space:nowrap">non-public</FONT> information of Calyxt, Inc. and Cibus Global, as applicable, provided to such person as
soon as practicable after the date of the Merger Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Changes in Board Recommendation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As described above, and subject to the provisions described below, (i)&nbsp;the Calyxt Board recommends that Calyxt Stockholders vote
&#147;FOR&#148; all of the proposals described in this proxy statement/prospectus and (ii)&nbsp;the Cibus Board recommends that Cibus Global equityholders execute the written consent to approve the Cibus Merger, the Merger Agreement, and the
Transactions, substantially in accordance with the terms of the Merger Agreement and the other agreements contemplated by the Merger Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Merger Agreement, subject to certain exceptions described below, Calyxt, Inc. agreed that neither the Calyxt Board nor any of its
committees may take any of the following actions, each of which are referred to in this proxy statement/prospectus as a &#147;Calyxt Board Adverse Recommendation Change&#148;: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withhold, amend, qualify, withdraw or modify (and the Calyxt Board or any its committees shall not resolve to or
publicly propose to withhold, amend, qualify, withdraw or modify) the Calyxt Board&#146;s recommendation in favor of the proposals described in this proxy statement/prospectus in a manner adverse to Cibus Global; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">within ten business days of Cibus Global&#146; written request to do so, fail to recommend after the commencement
of an acquisition proposal through a tender or exchange offer pursuant to Rule <FONT STYLE="white-space:nowrap">14d-2</FONT> under the Exchange Act for outstanding shares of Calyxt Common Stock, against acceptance of such tender offer or exchange
offer by its stockholders (which request may only be made once with respect to any such acquisition proposal and each material modification thereto). </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, if at any time prior to the approval of Calyxt Stockholder Matters at the Calyxt Special Meeting by the required Calyxt Stockholder
votes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if Calyxt, Inc. has received a bona fide written acquisition proposal, from any person that has not been
withdrawn and after consultation with outside legal counsel, the Calyxt Board shall have determined, in good faith, that such acquisition proposal is a superior offer, the Calyxt Board may make a Calyxt Board Adverse Recommendation Change if and
only if all of the following apply: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Calyxt Board determines in good faith, after consultation with Calyxt, Inc.&#146;s outside legal counsel,
that the failure to do so would be reasonably likely to be inconsistent with the fiduciary duties of the Calyxt Board to Calyxt Stockholders under applicable law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Calyxt, Inc. shall have given Cibus Global prior written notice of its intention to consider making a Calyxt
Board Adverse Recommendation Change at least three business days prior to making any such Calyxt Board Adverse Recommendation Change (a &#147;Determination Notice&#148;) (which notice shall not constitute a Calyxt Board adverse recommendation
change); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(1) Calyxt, Inc. provided Cibus Global a copy of such acquisition proposal, (2)&nbsp;Calyxt, Inc. gives Cibus
Global the three business days after the Determination Notice to propose revisions to the terms of the Merger Agreement or make another proposal and shall have made its representatives reasonably available to negotiate in good faith with Cibus
Global with respect to such proposed revisions or other proposal, if any, and (3)&nbsp;after considering the results of any such negotiations and giving effect to the proposals made by Cibus Global, if any, after consultation with outside legal
counsel, the Calyxt Board still determines, in good faith, that such acquisition proposal is a superior offer and that the failure to make the Calyxt Board Adverse Recommendation Change would be reasonably likely to be inconsistent with the
fiduciary duties of the Calyxt Board to Calyxt Stockholders under applicable law. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">180 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Other than in connection with an acquisition proposal, the Calyxt Board may make a Calyxt Board Adverse
Recommendation Change in response to a Calyxt, Inc. change in circumstance, if and only if: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Calyxt Board determines in good faith, after consultation with Calyxt, Inc.&#146;s outside legal counsel,
that the failure to do so would be reasonably likely to be inconsistent with the fiduciary duties of the Calyxt Board to Calyxt Stockholders under applicable law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Calyxt, Inc. shall have given Cibus Global a Determination Notice at least three business days prior to making
any such Calyxt Board Adverse Recommendation Change; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(1) Calyxt, Inc. specified the applicable change in circumstance in reasonable detail, (2)&nbsp;Calyxt, Inc.
gives Cibus Global the three business days after the Determination Notice to propose revisions to the terms of the Merger Agreement or make another proposal, and shall have made its representatives reasonably available to negotiate in good faith
with Cibus Global with respect to such proposed revisions or other proposal, if any, and (3)&nbsp;after considering the results of any such negotiations and giving effect to the proposals made by Cibus Global, if any, after consultation with outside
legal counsel, the Calyxt Board still determines, in good faith, that the failure to make a Calyxt Board Adverse Recommendation Change in response to such Calyxt, Inc. change in circumstance would be reasonably likely to be inconsistent with the
fiduciary duties of the Calyxt Board to Calyxt Stockholders under applicable law. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Merger Agreement, Cibus
Global shall use reasonable best efforts to secure the written consent from Cibus Unitholders necessary to secure the Cibus Member Approval as promptly as practical following the date that the SEC declares this proxy statement/prospectus effective
and each Blocker shall secure the written consents necessary to secure the applicable Blocker Approvals as promptly as practical following the date that the SEC declares this proxy statement/prospectus effective. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Meetings of Calyxt Stockholders; Approval of Cibus Global Members </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt, Inc. is obligated under the Merger Agreement to call, give notice of and hold a meeting of the Calyxt Stockholders for the purpose of
seeking approval of the Calyxt Stockholder Matters. Cibus Global is obligated under the Merger Agreement to seek (i)&nbsp;approval by a majority of each of the issued and outstanding Cibus Series D Preferred Units, Cibus Series E Preferred Units and
Cibus Series F Preferred Units to convert all issued and outstanding Cibus Preferred Units into Cibus Global voting common units on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis and
(ii)&nbsp;approval by a majority of all issued and outstanding Cibus Preferred Units to approve the Transactions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Covenants; Conduct of Business
Pending the Merger </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operations of Cibus Global </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as contemplated by the Merger Agreement, as set forth on the Cibus Global disclosure schedule or as required by applicable law
(including any <FONT STYLE="white-space:nowrap">COVID-19</FONT> measures), during the <FONT STYLE="white-space:nowrap">pre-Closing</FONT> period, or pursuant to the written consent of Calyxt, Inc. (which consent shall not be unreasonably withheld,
conditioned or delayed), Cibus Global must use commercially reasonable efforts to, and must cause each of its subsidiaries to use commercially reasonable efforts to, conduct its operations only in the ordinary course of business and in compliance
with all applicable laws in all material respects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Without limiting the generality of the foregoing, during the <FONT
STYLE="white-space:nowrap">pre-Closing</FONT> period and except as contemplated by the Merger Agreement or as set forth on the Cibus Global disclosure schedule, Cibus Global shall not, and shall cause each of its subsidiaries not to, without the
written consent of Calyxt, Inc. (such consent shall not be unreasonably withheld, conditioned or delayed): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issue or sell any equity interests in Cibus Global or any options, warrants or rights to acquire any such equity
interests, or declare, accrue, set aside or pay any dividend or make any other distribution in </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">181 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
respect of its equity interests, or repurchase or redeem any equity interests in Cibus Global or any subsidiary; provided that Cibus Global (i)&nbsp;may issue additional equity interests to Cibus
Global employees, to the extent contemplated in the Allocation Schedule, and (ii)&nbsp;may issue additional Cibus Series F Preferred Units to other persons for a per unit cash purchase price of $2.00 and otherwise on terms consistent with the terms
and conditions for issuances of Cibus Series F Preferred Units prior to the date of the Merger Agreement (which threshold and minimum subscription price is subject to adjustment adjusted, as applicable and appropriate, to reflect fully the effect of
any reclassification, split, reverse split, distribution (including any distribution of securities convertible into membership units of Cibus Global), reorganization, recapitalization or other like change with respect to the equity securities of
Cibus Global or any securities convertible or exchangeable into or exercisable equity securities of Cibus Global); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">split, combine or reclassify any equity interests, other than the conversion of Cibus Preferred Units to voting
common units of Cibus Global as contemplated by the Cibus Member Approval and in a manner consistent with the Allocation Schedule; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">create, incur or assume any indebtedness (other than (x)&nbsp;interest accrued with respect to indebtedness
outstanding as of the date hereof in accordance with its terms, (y)&nbsp;new indebtedness for borrowed money not exceeding $5,000,000 in the aggregate, or (z)&nbsp;indebtedness payable in connection with leases for equipment); (ii) assume,
guarantee, endorse or otherwise agree to be liable (whether directly, contingently or otherwise) for the obligations of any other person, other than for subsidiaries of Cibus Global; or (iii)&nbsp;make any loans, advances or capital contributions
to, or investments in, any other person (other than investments of cash in cash equivalents in the ordinary course of business); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">except as required to comply with applicable law or pursuant to agreements, plans or arrangements existing on the
date hereof, (i)&nbsp;adopt, enter into, terminate or amend any employment or severance plan, agreement or arrangement, any Cibus Global employee benefit plan or any collective bargaining agreement, that in each case, would result in materially
increased costs to the Combined Company after the Closing, (ii)&nbsp;increase the compensation or fringe benefits of, or pay any bonus to, any director, officer, employee or consultant, except for increases in compensation consistent with the
ordinary course of business and in no event more than 20% or that would require disclosure in this proxy statement/prospectus after it is filed with the SEC, (iii)&nbsp;amend or accelerate the payment, right to payment or vesting of any compensation
or benefits, including any outstanding equity awards, that in each case, would result in materially increased costs to the Combined Company after the Closing, (iv)&nbsp;except as contemplated in any other provision under the Merger Agreement, pay
any material benefit not provided for as of the date of the Merger Agreement under any Cibus Global employee benefit plan, or the removal of existing restrictions in any benefit plans or agreements or awards made thereunder, or (v)&nbsp;take any
action to fund any Cibus Global employee benefit plan other than the payment of premiums due or contributions owed in the ordinary course of business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acquire, sell, lease, <FONT STYLE="white-space:nowrap">in-license,</FONT>
<FONT STYLE="white-space:nowrap">out-license,</FONT> abandon, allow to lapse, agree to coexist with respect to or otherwise dispose of any material assets or property (including any intellectual property or any shares or other equity interests in or
securities of any subsidiary or any other person), in each case, other than in the ordinary course of business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">mortgage or pledge any of its material property or material assets or enter into an agreement that subjects any
such material property or material assets to any lien other than permitted liens; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">form any subsidiary or acquire any equity interest or other interest in any other person (other than investments
of cash and cash equivalents in the ordinary course of business) or enter into a joint venture with any other person; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">forgive any loans to any person, including its employees, officers, directors or affiliates, other than the
settlement of accounts receivable in the ordinary course of business; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">182 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">change the nature or scope of its business being carried on as of the date of the Merger Agreement in any
material respect or commence any new business not being ancillary or incidental to such business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">change its accounting methods, principles or practices in any material respect, except insofar as may be required
by a generally applicable change in GAAP or applicable law; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">except as required by applicable law, make or change any material tax election, amend any material tax return,
change an annual accounting period, enter into any Closing agreement, waive or extend any statute of limitations with respect to taxes, settle or compromise any tax liability, claim or assessment, or surrender any right to claim a material refund of
taxes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">settle any legal proceedings involving cash payments by Cibus Global in excess of $1,000,000 in the aggregate;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">amend its organizational documents (other than connection with implementing the transactions in a manner
consistent with the Merger Agreement); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make or commit to make capital expenditures in excess of $4,000,000 in the aggregate; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">agree in writing or otherwise to take any of the foregoing actions. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operations of Calyxt, Inc. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except
as contemplated by the Merger Agreement, as set forth on the Calyxt, Inc. disclosure schedule or as required by applicable law (including any <FONT STYLE="white-space:nowrap">COVID-19</FONT> measures), during the
<FONT STYLE="white-space:nowrap">pre-Closing</FONT> period, or pursuant to the written consent of Cibus Global (which consent shall not be unreasonably withheld, conditioned or delayed), Calyxt, Inc. must use commercially reasonable efforts to, and
must cause each of its subsidiaries to use commercially reasonable efforts to, conduct its operations only in the ordinary course of business and in compliance with all applicable laws in all material respects and take all necessary steps (including
timely making all filings required by the SEC) to prepare for the filing of the annual meeting proxy statement (including all required Form <FONT STYLE="white-space:nowrap">10-K,</FONT> Item III information). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Without limiting the generality of the foregoing, during the <FONT STYLE="white-space:nowrap">pre-Closing</FONT> period and except as
contemplated by the Merger Agreement or as set forth on the Calyxt, Inc. disclosure schedule, Calyxt, Inc. shall not, and shall cause each subsidiary not to, without the written consent of Cibus Global (such consent shall not be unreasonably
withheld, conditioned or delayed): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issue, grant, pledge or sell, or authorize the issuance of, any equity interests in Calyxt, Inc. or any of its
subsidiaries or any options, warrants or rights to acquire any such equity interests, or other securities or any other instrument convertible into or exchangeable for any equity interests of Calyxt, Inc. or its subsidiaries, or declare, accrue, set
aside or pay any dividend or make any other distribution in respect of its equity interests, or repurchase or redeem any equity interests in Calyxt, Inc. or any of its subsidiaries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">split, combine or reclassify any equity interests, effect any merger, consolidation, share exchange, business
combination, recapitalization or similar transaction other than the Mergers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(i) create, incur or assume any indebtedness (other than interest accrued with respect to indebtedness
outstanding as of the date hereof in accordance with its terms); (ii) assume, guarantee, endorse or otherwise agree to be liable (whether directly, contingently or otherwise) for the obligations of any other person; or (iii)&nbsp;make any loans,
advances or capital contributions to, or investments in, any other person (other than investments of cash in cash equivalents in the ordinary course of business); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">hire, engage or offer to hire any new officers, directors, employees or consultants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">except as required to comply with applicable law or pursuant to agreements, plans or arrangements existing on the
date hereof and disclosed in the Calyxt, Inc. disclosure schedule, (i)&nbsp;adopt, enter into, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">183 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
terminate or amend any employment or severance plan, agreement or arrangement, any Calyxt, Inc. employee benefit plan or any collective bargaining agreement, (ii)&nbsp;increase the compensation
or fringe benefits of, or pay any bonus to, any director, officer, employee or consultant, (iii)&nbsp;amend or accelerate the payment, right to payment or vesting of any compensation or benefits, including any outstanding Calyxt, Inc. stock options,
Calyxt RSUs, or Calyxt PSUs, (iv)&nbsp;except as contemplated in any other provision of the Merger Agreement, pay any material benefit not provided for as of the date of the Merger Agreement under any Calyxt, Inc. employee benefit plan, or the
removal of existing restrictions in any benefit plans or agreements or awards made thereunder, or (v)&nbsp;take any action to fund any Calyxt, Inc. employee benefit plan other than the payment of premiums due or contributions owed in the ordinary
course of business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acquire, sell, lease, <FONT STYLE="white-space:nowrap">in-license,</FONT>
<FONT STYLE="white-space:nowrap">out-license</FONT> or dispose of any material assets or material property (including any intellectual property or any shares or other equity interests in or securities of any subsidiary or any other person), other
than in the ordinary course of business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">mortgage or pledge any of its material property or material assets or enter into an agreement that subjects any
such material property or material assets to any lien other than permitted liens; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">discharge or satisfy any lien other than in the ordinary course of business or as required by law or a contract
existing on the date of the Merger Agreement or entered into in compliance with the Merger Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">form any subsidiary or acquire any equity interest or other interest in any other person (other than investments
of cash and cash equivalents in the ordinary course of business) or enter into a joint venture with any other person; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other than as contemplated by the transactions set forth in the Merger Agreement, amend its organizational
documents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(i) materially change pricing or royalties or other payments set or charged by Calyxt, Inc. or any of its
subsidiaries to its customers or licensees or (ii)&nbsp;agree to materially change pricing or royalties or other payments set or charged by persons who have licensed rights to intellectual property to Calyxt, Inc. or any of its subsidiaries;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">accelerate collection of accounts receivable or delay payment of accounts payable, other than in accordance with
GAAP; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">forgive any loans to any person, including its employees, officers, directors or affiliates, other than the
settlement of accounts receivable in the ordinary course of business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">change the nature or scope of its business being carried on as of the date of the Merger Agreement in any
material respect or commence any new business not being ancillary or incidental to such business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">change its accounting methods, principles or practices in any material respect, except insofar as may be required
by a generally applicable change in GAAP or applicable law; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">except as required by applicable Law, make or change any material tax election, amend any material tax return,
change an annual accounting period, enter into any Closing agreement, waive or extend any statute of limitations with respect to taxes, settle or compromise any tax liability, claim or assessment, or surrender any right to claim a material refund of
taxes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make or commit to make any capital expenditure in excess of $25,000 per item or $50,000 in the aggregate;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">institute or settle any legal proceeding (other than to enforce the terms of the Merger Agreement and the other
agreements relating to the transaction); or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">agree in writing or otherwise to take any of the foregoing actions. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">184 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, at the discretion of the Calyxt Board and/or Compensation
Committee, Calyxt, Inc. is permitted to issue up to an additional 3,487,503 Calyxt RSUs (of which 3,468,083 have been issued as of the date of this proxy statement/prospectus) with respect to 3,487,503 shares of Calyxt Common Stock (which amount is
subject to adjustment, as applicable and appropriate, to reflect fully the effect of any reclassification, split, reverse split (including the Reverse Stock Splits), distribution, reorganization, recapitalization or other like change with respect to
the equity securities of Calyxt, Inc. or any securities convertible or exchangeable into or exercisable equity securities of Calyxt, Inc. that may occur after the date hereof and prior to the grant date of such equity awards), pursuant to the
Calyxt, Inc. 2017 Omnibus Incentive Plan (as amended, effective May&nbsp;18, 2021), with such equity awards having accelerated vesting of 100% on a Triggering Event (as defined therein, which shall include the Transactions), and any related
corporate approvals and/or registration statements that may be necessary to implement the same. These issuances are permitted only to the extent it they would not result in <FONT STYLE="white-space:nowrap">non-compliance</FONT> with or additional
taxes or other penalties under Section&nbsp;409A of the Code, as determined by Calyxt, Inc. on the advice of external counsel. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operations of
Blockers </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the <FONT STYLE="white-space:nowrap">pre-Closing</FONT> period and except (a)&nbsp;as set forth on the Cibus
Global disclosure schedule, (b)&nbsp;in connection with implementing the transactions in a manner consistent with the Merger Agreement, (c)&nbsp;the distribution of cash or other liquid amounts held by such Blocker as of the date of the Merger
Agreement or received by such Blocker in a Cibus Global distribution permitted under the Merger Agreement, (d)&nbsp;in the ordinary course of business, or (e)&nbsp;as required by the terms of the Merger Agreement, each Blocker shall not, without the
written consent of Calyxt, Inc. (such consent shall not be unreasonably withheld, conditioned or delayed), conduct any business, take any action or enter into, amend or terminate any agreement or commitment. Further, during the <FONT
STYLE="white-space:nowrap">pre-Closing</FONT> period, each Blocker, to the extent it has not already done so, shall file all tax returns due on or prior to the Closing Date and pay all taxes reasonably owing in connection with such tax returns. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the terms and
subject to the conditions of this Agreement, each of Calyxt, Inc. and Cibus Global shall each use its reasonable best efforts to take all actions and to do all things necessary, proper or advisable to consummate the transactions to be completed at
Closing as promptly as practicable, including using its reasonable best efforts to ensure that the conditions to the obligations of the other parties to consummate the Merger are satisfied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt, Inc. and Cibus Global shall each use its respective reasonable best efforts to obtain, at its expense, all waivers, permits, consents,
approvals or other authorizations from governmental entities or from third parties pursuant to the Calyxt Contracts or Cibus Contracts (as applicable), and to effect all registrations, filings and notices with or to Governmental Entities, in each
case, as may be required for such party to consummate the Transactions and to otherwise comply with all applicable Laws in connection with the consummation of the Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the generality of the foregoing obligations, Calyxt, Inc. agrees to use its reasonable best efforts: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to maintain its existing listing on Nasdaq and to obtain approval of the listing of the combined corporation on
Nasdaq; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to the extent required by the rules and regulations of Nasdaq, to prepare and submit to Nasdaq a notification
form for the listing of the shares of Class&nbsp;A Common Stock to be issued in connection with the Mergers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if not previously implemented, to prepare and timely submit to Nasdaq a notification form of any reverse stock
split effected with the Cibus Global&#146; consent and, to the extent required to effect the foregoing, to submit a copy of the amendment to Calyxt, Inc.&#146;s certificate of incorporation to effect such reverse stock split certified by the
Secretary of State of the State of Delaware to Nasdaq; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">185 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to the extent required by Nasdaq Listing Rule 5110, to file an initial listing application for the Class&nbsp;A
Common Stock on Nasdaq and to cause such Nasdaq initial listing application to be approved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the event of receipt of a Nasdaq delisting determination, Calyxt, Inc. shall request a hearing to appeal the
delisting determination and shall pay the appropriate fee to Nasdaq to appeal the delisting determination; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Calyxt, Inc. will promptly inform Cibus Global of all material verbal or written communications between Nasdaq
and Calyxt, Inc. or its representatives. Calyxt, Inc. and Cibus Global will use commercially reasonable efforts to coordinate with respect to compliance with Nasdaq rules and regulations. Cibus Global will cooperate with Calyxt, Inc. to cause the
Nasdaq initial listing application to be approved and shall promptly furnish to Calyxt, Inc. all information concerning Cibus Global, the Blockers and their respective equity holders that may be required or reasonably requested in connection with
any action contemplated by the Merger Agreement. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification and Insurance for Directors and Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Merger Agreement, from the Closing through the sixth anniversary of the of the Closing Date, Cibus, Inc. shall indemnify and hold
harmless each person who is now, or has been at any time prior to the date hereof, or who becomes prior to the Closing, a director, manager or officer of Cibus Global, Calyxt, Inc. or any of their respective subsidiaries (the &#147;Indemnified
Persons&#148;), against all claims, losses, liabilities, damages, judgments, fines and reasonable fees, costs and expenses, including attorneys&#146; fees and disbursements, incurred in connection with any claim, action, suit, proceeding or
investigation, whether civil, criminal, administrative or investigative, arising out of or pertaining to the fact that the Indemnified Person is or was an officer, director, manager, employee, trustee, fiduciary or agent of Cibus Global, Calyxt,
Inc. or any of their respective subsidiaries, or, while a director, manager or officer of Cibus Global, Calyxt, Inc. or any of their respective subsidiaries, is or was serving at the request of Cibus Global, Calyxt, Inc. or any of their respective
subsidiaries as a director, manager, officer, employee or agent of another person, whether asserted or claimed prior to, at or after the Closing, to the extent permitted under the applicable certificate of incorporation and bylaws or other
organizational document. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Indemnified Person will be entitled to advancement of expenses (including attorneys&#146; fees) incurred in
the defense of any such claim, action, suit, proceeding or investigation from Calyxt, Inc. following receipt by Calyxt, Inc. from the Indemnified Party of a request therefor;<I>&nbsp;provided</I>&nbsp;that any person to whom expenses are advanced
provides an undertaking, to the extent then required by the DGCL, to repay such advances if it is ultimately determined that such person is not entitled to indemnification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger Agreement also provides that from the Closing through the sixth anniversary of the Closing Date, the certificate of incorporation
and bylaws of Calyxt, Inc. will contain provisions at least as favorable as the provisions relating to the indemnification, advance of expenses and elimination of liability for monetary damages set forth in the certificate of incorporation and
bylaws of Calyxt, Inc. immediately prior to the Closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the Closing, Calyxt, Inc. and Cibus Global will each purchase <FONT
STYLE="white-space:nowrap">a&nbsp;six-year&nbsp;prepaid</FONT> &#147;tail policy&#148; for <FONT STYLE="white-space:nowrap">the&nbsp;non-cancellable&nbsp;extension</FONT> on each of their respective existing directors&#146; and officers&#146;
insurance policies pursuant to the terms set forth under the Merger Agreement. The Merger Agreement also provides that Calyxt, Inc. shall pay all expenses, including reasonable attorneys&#146; fees, that may be incurred by a person in successfully
enforcing such director and officer indemnification rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Warrant Restructuring </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From and after the date hereof until the date that is five business days prior to the Closing Date or the earlier termination of Merger
Agreement pursuant to its terms, Cibus Global shall use commercially reasonable efforts to obtain any and all consents from each holder of Cibus Warrants necessary to effectuate the treatment of the Cibus Warrants set forth in the Merger Agreement.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">186 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Antitrust </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If prior to the Closing Date, Cibus Global determines, in its reasonable discretion after consultation with Calyxt, Inc. and its legal
advisors, that the Transactions require filings under the HSR Act to be submitted with the applicable governmental entities, then as promptly as reasonably practicable following such determination, Calyxt, Inc. and Cibus Global shall cooperate in
the preparation of such filings and, upon completion thereof (in form and substance mutually agreeable to Calyxt, Inc. and Cibus Global), each of Calyxt, Inc. and Cibus Global shall make or cause to be made any such required filings under the HSR
Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cibus Global Interim Funding </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following Cibus Global&#146;s receipt of a written request from Calyxt, Inc., Cibus Global shall make available to Calyxt, Inc. and its
subsidiaries, funds up to a maximum aggregate amount of $3,000,000 in cash; provided, however, that in the event Cibus Global elects to extend the Outside Date to June&nbsp;30, 2023, the maximum aggregate amount of the Interim Funding shall
automatically increase to $4,000,000. The loan will be unsecured and interest-free. Calyxt, Inc. may first request Interim Funding upon the earlier to occur of (a)&nbsp;March&nbsp;15, 2023 and (b)&nbsp;Calyxt, Inc.&#146;s unrestricted cash balance
dropping below $1,500,000. Calyxt, Inc. may draw in $500,000 increments to the extent necessary to maintain its unrestricted cash balance at $1,500,000 or above. Calyxt, Inc. may only use the funds for operating expenses incurred in the ordinary
course of business consistent with past practice and consistent with the negative covenants in the Merger Agreement. For the avoidance of doubt, this will exclude capital expenditures that has not been disclosed other than equipment repairs in the
ordinary course of business, bonuses to officers and employees, dividends to stockholders, and loans to Calyxt, Inc.&#146;s affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The loan will automatically accelerate and become immediately due and payable in connection with a voluntary bankruptcy or involuntary
bankruptcy of Calyxt, Inc. that is not dismissed in 180 days. No further draws may be made under the loan following the occurrence of a bankruptcy related event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The full outstanding balance of the loan will be forgiven if the Merger Agreement is terminated other than in connection with (a)&nbsp;a
termination by Cibus Global resulting from the fraud or willful breach of Calyxt, Inc., in which case Calyxt, Inc. will no longer be permitted to make draws under the loan and loan will become due and payable on the date that is two years from the
date funds are first drawn or (b)&nbsp;(i) a termination of the Merger Agreement by Calyxt, Inc. pursuant to Section&nbsp;8.1(g) (regarding superior offers) of the Merger Agreement or (ii)&nbsp;a termination of the Merger Agreement by Cibus Global
pursuant to Section&nbsp;8.1(f) (regarding Board Adverse Recommendation Changes) of the Merger Agreement, in which case Calyxt, Inc. will no longer be permitted to make draws under the loan and the loan will become due and payable on the date that
is 30 days of termination of the Merger Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Transactions are closed, the loan will mature on the third business day after
Closing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amendment to the Cellectis License Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a condition to the obligations of Cibus Global to consummate the Mergers, Calyxt, Inc. and Cellectis will enter into the First Amendment to
the License Services Agreement, which amends the License Agreement dated July&nbsp;25, 2017, between Calyxt, Inc. and Cellectis (as amended, the &#147;Amended Cellectis License&#148;). The form of the amendment was attached as an exhibit to the
Merger Agreement. Under the Amended Cellectis License, Cellectis will grant to Cibus, Inc. an exclusive worldwide, perpetual license, with the right to sublicense certain intellectual property licensable by Cellectis in the field of developing and
commercializing microorganism, agricultural and food products, including, but not limited to traits, seeds, proteins, oils, carbohydrates, food, and food and animal feed ingredients, excluding (i) any application in connection with animals and
animal cells and (ii) therapeutic applications (the &#147;Calyxt Field&#148;). However, this grant is <FONT STYLE="white-space:nowrap">non-exclusive</FONT> solely in the <FONT STYLE="white-space:nowrap">non-exclusive</FONT> fields as described in
the Amended Cellectis License. Cellectis will also grant to Cibus, Inc. a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> worldwide, perpetual, irrevocable, royalty-free and fully <FONT STYLE="white-space:nowrap">paid-up</FONT> license (with
certain rights to sublicense) under certain licensed plant patents in the Calyxt Field. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">187 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus, Inc. and Cellectis will acknowledge that certain of the intellectual property
licensable by Cellectis is owned by the University of Minnesota and subject to the terms of the Exclusive Patent License Agreement between the Reagents of the University of Minnesota and Cellectis, dated as of January&nbsp;10, 2011 (as amended) (the
&#147;UMinn License&#148;). Accordingly, in exercising its rights under the Amended Cellectis License, Cibus, Inc. shall comply with any and all terms and conditions of the UMinn License as they would apply to Cibus, Inc. as a sublicensee with
respect to any intellectual property owned by University of Minnesota. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus, Inc. will have the sole and exclusive right to prosecute
and maintain all intellectual property rights owned or otherwise controlled by Cibus, Inc. or any of its affiliates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Termination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger Agreement may be terminated at any time prior to the Closing (whether before or after receipt of the required Calyxt, Inc.
stockholder vote and the required approval of the Cibus Global and/or Blockers members, unless otherwise specified below: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by mutual written consent of Calyxt, Inc. and Cibus Global; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by either Calyxt, Inc. or Cibus Global if the Mergers shall not have been consummated by the Outside Date;
<I>provided</I>, however, that this right to terminate the Merger Agreement shall not be available to a party if the failure of the Mergers to have been consummated on or before the Outside Date was primarily due to such party&#146;s action or
failure to act, where such action or failure to act constitutes a breach of the Merger Agreement (with any action or failure to act by a Blocker being considered an action or failure to act by Calyxt, Inc.);<I> provided</I>, further, however, that
if on the Outside Date, each of the conditions to Closing set forth in the Merger Agreement shall not have been satisfied or waived by the parties entitled to the benefit thereof (other than conditions that, by their nature, are to be satisfied or
waived at the Closing), then at the written election of Cibus Global pursuant to the terms of the Merger Agreement<B> </B>(which written election shall include acknowledgment and agreement by Cibus Global the Interim Funding provided by Cibus Global
to Calyxt, Inc. shall be increased to $4,000,000 pursuant to the Merger Agreement), the Outside Date may be extended to June&nbsp;30, 2023 (and in the case of such extension, any reference to the Outside Date in any other provision of the Merger
Agreement shall be a reference to the Outside Date, as extended); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by either Calyxt, Inc. or Cibus Global if a governmental entity of competent jurisdiction shall have issued a
nonappealable final order, decree or ruling or taken any other nonappealable final action, in each case having the effect of permanently restraining, enjoining or otherwise prohibiting any of the Mergers; <I>provided</I>, <I>however</I>, that this
right to terminate the Merger Agreement shall not be available to a party if the triggering event was primarily due to such party&#146;s action or failure to act, where such action or failure to act constitutes a breach of the Merger Agreement (with
any action or failure to act by a Blocker being considered an action or failure to act by Cibus Global); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by Calyxt, Inc., if there has been a breach of or failure to perform any representation, warranty, covenant or
agreement on the part of Cibus Global or a Blocker set forth in the Merger Agreement, which breach or failure to perform (i)&nbsp;would cause the conditions set forth in the Merger Agreement not to be satisfied and (ii)&nbsp;shall not have been
cured, if capable of being cured, or waived within 30 days following receipt by Cibus Global of written notice of such breach or failure to perform from Calyxt, Inc.; provided, however, that the right to terminate the Merger Agreement under the
Merger Agreement shall not be available to Calyxt, Inc. if Calyxt, Inc. or Merger Subsidiary then in material breach of any representation, warranty or covenant set forth in the Merger Agreement; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by Cibus Global, if there has been a breach of or failure to perform any representation, warranty, covenant or
agreement on the part of Calyxt, Inc. or Merger Subsidiary set forth in the Merger Agreement, which breach or failure to perform (i)&nbsp;would cause the conditions set forth in the Merger Agreement not to be satisfied and (ii)&nbsp;shall not have
been cured, if capable of being cured, or waived </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">188 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
within 30 days following receipt by Calyxt, Inc. of written notice of such breach or failure to perform from Cibus Global; provided, however, that the right to terminate the Merger Agreement
under the Merger Agreement shall not be available to Cibus Global if Cibus Global is then in material breach of any representation, warranty or covenant set forth in the Merger Agreement (if Cibus Global terminates pursuant to this clause
(e)&nbsp;at a time when Calyxt, Inc. had the right to terminate pursuant to clause (i)&nbsp;below, then Cibus Global must pay Calyxt, Inc. a termination fee of $1,000,000); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by Cibus Global, at any time prior to receipt of the Calyxt Stockholder Approval<B>,</B> if:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Calyxt Board shall have effected a Calyxt Board Adverse Recommendation Change; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Calyxt, Inc. shall have committed a material breach of Calyxt, Inc.&#146;s
<FONT STYLE="white-space:nowrap">non-solicitation</FONT> obligations under Section&nbsp;5.4 of the Merger Agreement; </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">in
which case, Calyxt, Inc. will be obligated to pay Cibus Global a termination fee of $1,000,000 within three business days of such termination; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by Calyxt, Inc., at any time prior to receipt of the Calyxt Stockholder Approval, if each of the following
occur: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Calyxt, Inc. shall have received a superior offer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Calyxt, Inc. shall have complied with its obligations under the Merger Agreement with respect to such superior
offer, including with respect to making a Calyxt Board recommendation change with respect to such superior offer; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Calyxt Board approves such superior offer, and Calyxt, Inc. substantially concurrently with the termination
of the Merger Agreement enters into, a definitive agreement with respect to such superior offer; </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">in which case, Calyxt,
Inc. will be obligated to pay Cibus Global a termination fee of $1,000,000 within three business days of such termination; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by either Calyxt, Inc. or Cibus Global if (i)&nbsp;the Calyxt Special Meeting (including any adjournments and
postponements thereof) shall have been held and completed and Calyxt Stockholders shall have taken a final vote on Calyxt Stockholder Matters and (ii)&nbsp;any of the Calyxt Stockholder Matters shall not have been approved at the Calyxt Special
Meeting (or at any adjournment or postponement thereof) by the affirmative vote of the holders of a majority of the issued and outstanding shares Calyxt Common Stock (the &#147;Calyxt Stockholder Vote&#148;); <I>provided</I>, <I>however</I>, that
the right to terminate the Merger Agreement pursuant to this clause (h)&nbsp;shall not be available to Calyxt, Inc. if Calyxt, Inc.&#146;s actions or failure to act has been a principal cause of the failure of Calyxt, Inc. to obtain the required
Calyxt Stockholder Vote and such action or failure to act constitutes a breach by Calyxt, Inc. of the Merger Agreement; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by Calyxt, Inc., if (x)&nbsp;the Cibus Member Approval and the Blocker Approvals shall not have been obtained
prior to 5:00 p.m., New York time, on the date that is ten (10)&nbsp;business days following the date that the SEC declares the registration statement effective or (y)&nbsp;Cibus Global shall have committed a material breach of Cibus Global&#146; <FONT
STYLE="white-space:nowrap">non-solicitation</FONT> obligations under Section&nbsp;5.5 of the Merger Agreement, in which case, Cibus Global must pay Calyxt, Inc. a termination fee of $1,000,000. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Merger Agreement (i)&nbsp;is terminated pursuant to section (b), (e) or (h)&nbsp;above, (ii) an acquisition proposal with respect to
Calyxt, Inc. shall have been publicly announced or disclosed to Calyxt, Inc. or the Calyxt Board after the date of the Merger Agreement but prior to the termination of the Merger Agreement (which shall not have been withdrawn), and (iii)&nbsp;within
12 months after the date of such termination, Calyxt, Inc. enters into a definitive agreement with respect to or consummates an acquisition proposal, then Calyxt, Inc. must pay Cibus Global a termination fee of $1,000,000 within three business days
of the date of the applicable triggering event. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">189 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In any instance where Cibus Global is obligated to pay Calyxt, Inc. a termination fee
hereunder, then in addition to the termination fee, Cibus Global shall reimburse Calyxt, Inc. for Calyxt, Inc.&#146;s reasonable and documented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs and
expenses incurred in connection with the Merger Agreement (such reimbursement not to exceed $500,000) within three business days of the termination. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amendment </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the Closing, the
Merger Agreement may be amended by the parties at any time before or after receipt of the Calyxt Stockholder Approval or the Cibus Member Approval, but, after receipt of the Calyxt Stockholder Approval or the Cibus Member Approval, no amendment
shall be made which by law requires further approval by such stockholders or members, as applicable, without such further approval. Notwithstanding the foregoing, however, any such amendment that adversely effects a Blocker also requires the
approval of such Blocker. The Merger Agreement may not be amended except by an instrument in writing signed by Calyxt, Inc., Cibus Global and the applicable Blockers (if any). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fees and Expenses </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger Agreement
provides all fees and expenses incurred in connection with the Merger Agreement and the Transactions (including legal and accounting fees and expenses) shall be paid by the party incurring such expenses, except as described above in the section
entitled &#147;&#151;<I>Termination</I>&#148; beginning on page 189 of this proxy statement/prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">190 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom401831_30"></A>AGREEMENTS RELATED TO THE MERGERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom401831_31"></A>Support Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Calyxt Support Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with the execution of the Merger Agreement and as a condition to Cibus Global entering into the Merger Agreement, Cibus Global
entered into the Calyxt Support Agreements, with certain of Calyxt, Inc.&#146;s stockholders, directors and officers (the &#147;Supporting Stockholders&#148;) who, collectively and in the aggregate as of the date of the Merger Agreement,
beneficially hold voting power of approximately 49.8% of the outstanding Calyxt Common Stock, on January 13, 2023 (the &#147;Subject Shares&#148;). Pursuant to the terms of the Calyxt Support Agreements, the Supporting Stockholders have agreed to
take certain actions to support the Transactions, including not transferring the Subject Shares during the term of the Calyxt Support Agreement, except under specified circumstances, and voting the Subject Shares in favor of the Merger Agreement and
Transactions and against any alternative acquisition proposals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the voting obligations in the Calyxt Support Agreements,
if the Calyxt Board effects a Calyxt Board Adverse Recommendation Change in response to a superior offer, then the Calyxt Support Agreements will terminate and Supporting Stockholders will have no obligations in respect of how to vote their
respective Subject Shares. The Calyxt Support Agreements also contain customary termination provisions, including termination with respect to a given Supporting Stockholder in the event of any modification or amendment to the Merger Agreement in a
manner that reduces the amount or changes the form of Merger Consideration payable to such Supporting Stockholder or otherwise adversely affects the Supporting Stockholder in any material respect without his, her or its prior written approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Voting Agreement between Cellectis and Cibus, at such time that the annual revenues of the Combined Company equals $25,000,000
or more for two consecutive 12-month periods after the Closing, Cibus Global shall use commercially reasonable efforts to terminate the Lease Guaranty executed by Cellectis in favor of the landlord (the &#147;Cellectis Guaranty&#148;) of the
property leased by Calyxt pursuant to a lease agreement (the &#147;Calyxt Lease&#148;). Cibus Global, however, will not be required to replace Cellectis as guarantor or pay any fees in connection with termination of the Cellectis Guaranty. Until the
parties are able to terminate the Cellectis Guaranty, the Combined Company may not renew or extend the Calyxt Lease or enter into any amendment that would increase the liability of Cellectis under the Cellectis Guaranty. Further, the Combined
Company, from and after the Closing, agrees to indemnify Cellectis and any of its affiliates in connection with the Calyxt Lease and Cellectis Guaranty. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing summary of the Calyxt Support Agreements is not complete and is qualified in its entirety by the full text of the form of Calyxt
Support Agreement, which is attached to this proxy statement/prospectus as <I>Annex G</I> and is incorporated by reference herein. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cibus Support
Agreements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with the execution of the Merger Agreement and as a condition to Calyxt, Inc. entering into the Merger
Agreement, Calyxt, Inc. entered into the Cibus Support Agreements, with certain of Cibus Global&#146;s equityholders (including the Blockers), directors and officers (the &#147;Cibus Supporting Unitholders&#148;) who, collectively and in the
aggregate as of the date of the Merger Agreement, hold voting power of approximately 54.3% of the outstanding Cibus Global membership units, on January 13, 2023 (the &#147;Subject Units&#148;). Pursuant to the terms of the Cibus Support Agreements,
the Cibus Supporting Unitholders have agreed to take certain actions to support the Transactions, including not transferring the Subject Units during the term of the Cibus Support Agreement except under specified circumstances and voting (or acting
by written consent) all of its Subject Units in favor of the Mergers and the other Transactions, against any alternative acquisition proposals and to convert all outstanding <FONT STYLE="white-space:nowrap">pre-Closing</FONT> Cibus Preferred Units
into <FONT STYLE="white-space:nowrap">pre-Closing</FONT> Cibus Global voting common units on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">191 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Cibus Support Agreements also contain customary termination provisions, including
termination with respect to a given Supporting Stockholder in the event of any modification or amendment to the Merger Agreement in a manner that reduces the amount or changes the form of Merger Consideration payable to such Supporting Stockholder
or otherwise adversely affects the Supporting Stockholder in any material respect without his, her or its prior written approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
foregoing summary of the Cibus Support Agreements is not complete and is qualified in its entirety by the full text of the form of Cibus Support Agreement, which is attached to this proxy statement/prospectus as <I>Annex H</I> and is incorporated by
reference herein. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom401831_32"></A>Tax Receivable Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus, Inc. will acquire certain favorable tax attributes from the Blockers in the Blocker Mergers. In addition, future redemptions or
exchanges of Cibus Common Units for shares of Class&nbsp;A Common Stock or cash, and other transactions described herein, are expected to result in favorable tax attributes for Cibus, Inc. These tax attributes would not be available to Cibus, Inc.
in the absence of those transactions and are expected to reduce the amount of tax that we would otherwise be required to pay in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the completion of the Mergers, Cibus, Inc. will enter into the Tax Receivable Agreement, pursuant to which Cibus, Inc. generally will be
required to pay to the TRA Parties, in the aggregate, 85% of the net income tax savings that Cibus, Inc. actually realizes (or in certain circumstances, is deemed to realize) as a result of (i)&nbsp;certain favorable tax attributes we will acquire
from the Blockers in the Blocker Mergers (including net operating losses), (ii) increases to Cibus, Inc.&#146;s allocable share of the tax basis of Cibus Global&#146;s assets resulting from future redemptions or exchanges of Cibus Common Units for
shares of Class&nbsp;A Common Stock or cash, (iii)&nbsp;tax attributes resulting from certain payments made under the Tax Receivable Agreement and (iv)&nbsp;deductions in respect of interest under the Tax Receivable Agreement. The payment
obligations under the Tax Receivable Agreement are Cibus, Inc.&#146;s obligations and not obligations of Cibus Global. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that the
payments Cibus, Inc. may be required to make under the Tax Receivable Agreement may be substantial. The actual amounts Cibus, Inc. will be required to pay may materially differ from any projected amounts, because potential future tax savings that
Cibus, Inc. will be deemed to realize, and the Tax Receivable Agreement payments made by Cibus, Inc., will be calculated based in part on the market value of the Class&nbsp;A Common Stock at the time of each redemption or exchange under the Exchange
Agreement and the prevailing tax rates applicable to Cibus, Inc. over the life of the Tax Receivable Agreement and will depend on Cibus, Inc. generating sufficient taxable income to realize the tax benefits that are subject to the Tax Receivable
Agreement. Payments under the Tax Receivable Agreement are not conditioned on the Cibus Global equity holders&#146; continued ownership of Cibus, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payments under the Tax Receivable Agreement will be based on the tax reporting positions Cibus, Inc. determines, and the IRS or another tax
authority may challenge all or a part of the tax basis increases, net operating losses or other tax attributes subject to the Tax Receivable Agreement, and a court could sustain such challenge. The TRA Parties will not reimburse Cibus, Inc. for any
payments previously made if such tax basis, or other tax benefits are subsequently disallowed, except that any excess payments made to a TRA Party under the Tax Receivable Agreement will be netted against future payments otherwise to be made to such
TRA Party under the Tax Receivable Agreement, if any, after the determination of such excess. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Tax Receivable Agreement
provides that if (1)&nbsp;Cibus, Inc. breaches any of its material obligations under the Tax Receivable Agreement (including in the event that Cibus, Inc. is more than three months late making a payment that is due under the Tax Receivable
Agreement, except in the case of certain liquidity exceptions), (2) Cibus, Inc. is subject to certain bankruptcy, insolvency or similar proceedings, (3)&nbsp;upon certain mergers, asset sales or other forms of business combination, or certain other
changes of control, or (4)&nbsp;at any time, Cibus, Inc. elects an early termination of the Tax Receivable Agreement, Cibus, Inc.&#146;s obligations </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">192 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
under the Tax Receivable Agreement (with respect to all Cibus Common Units, whether or not such units have been exchanged or redeemed before or after such transaction) would accelerate and become
payable in a lump sum amount equal to the present value of the anticipated future tax benefits calculated based on certain assumptions, including that Cibus, Inc. would have sufficient taxable income to fully utilize the deductions arising from the
tax deductions, tax basis and other tax attributes subject to the Tax Receivable Agreement. As a result, upon any acceleration of Cibus, Inc.&#146;s obligations under the Tax Receivable Agreement and upon a change of control, Cibus, Inc. could be
required to make payments under the Tax Receivable Agreement that are greater than 85% of its actual cash tax savings, which could negatively impact its liquidity. The change of control provisions in the Tax Receivable Agreement may also result in
situations where the Cibus Global equity holders and the relevant Blocker Owners have interests that differ from or are in addition to those of the other holders of Class&nbsp;A Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Finally, because Cibus, Inc. is a holding company with no operations of its own, its ability to make payments under the Tax Receivable
Agreement depends on the ability of Cibus Global to make distributions to it. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that Cibus, Inc. is unable to make payments
under the Tax Receivable Agreement for any reason, such payments will be deferred and will accrue interest until paid, which could negatively impact Cibus, Inc.&#146;s results of operations and could also affect its liquidity in periods in which
such payments are made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>The foregoing description of the Tax Receivable Agreement is not complete and is qualified in its entirety by
reference to the Tax Receivable Agreement, which is attached as </B><B><I>Annex D</I></B><B> to this proxy statement/prospectus and is incorporated herein by reference. </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom401831_33"></A>Exchange Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the Closing, Cibus, Inc. will enter into the Exchange Agreement, substantially in the form attached as <I>Annex E</I> to this proxy
statement, with Cibus Global and the Electing Members pursuant to which, subject to the procedures and restrictions therein, the holders of <FONT STYLE="white-space:nowrap">Up-C</FONT> Units (or certain permitted transferees thereof) will have the
right from time to time from and after the effectiveness of Cibus, Inc.&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> to be filed pursuant to the terms and conditions of the Registration Rights Agreement to
exchange their <FONT STYLE="white-space:nowrap">Up-C</FONT> Units on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis for shares of Class&nbsp;A Common Stock (the &#147;Exchange&#148;); provided,
that, subject to certain exceptions, Cibus, Inc., at its sole election, subject to certain restrictions, may, other than in the case of certain secondary offerings, instead settle all or a portion of the Exchange in cash based on a volume weighted
average price of a share of Class&nbsp;A Common Stock. The Exchange Agreement will provide that, as a general matter, a holder of <FONT STYLE="white-space:nowrap">Up-C</FONT> Units will not have the right to exchange
<FONT STYLE="white-space:nowrap">Up-C</FONT> Units if Cibus, Inc. determines that such exchange would be prohibited by law or regulation or would violate other agreements with Cibus, Inc. and its subsidiaries to which the holder of <FONT
STYLE="white-space:nowrap">Up-C</FONT> Units may be subject, including the Cibus Amended Operating Agreement. Additionally, the Exchange Agreement contains restrictions on redemptions and exchanges intended to prevent Cibus Global from being treated
as a &#147;publicly traded partnership&#148; for U.S. federal income tax purposes. These restrictions are modeled on certain safe harbors provided for under applicable U.S. federal income tax law. Cibus, Inc. may impose additional restrictions on
exchanges that it determines to be necessary or advisable so that Cibus Global is not treated as a &#147;publicly traded partnership&#148; for U.S. federal income tax purposes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom401831_34"></A>Registration Rights Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Merger Agreement, Cibus, Inc. intends to enter into a Registration Rights Agreement with the Electing Members in
connection with the Transactions. The Registration Rights Agreement will provide the Electing Members certain registration rights whereby, at any time following the consummation of the Transactions and the expiration of any related <FONT
STYLE="white-space:nowrap">lock-up</FONT> period, the Electing Members can require Cibus, Inc. to register under the Securities Act shares of Class&nbsp;A Common Stock issuable to them upon exchange of the
<FONT STYLE="white-space:nowrap">Up-C</FONT> Units that are issued to the Electing Members in connection with the Transactions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">193 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom401831_35"></A>Cibus Amended Operating Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with the Closing, Cibus Global will amend and restate the Cibus Operating Agreement to be in the form of the Cibus Amended
Operating Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Rights of the Units </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Cibus Amended Operating Agreement, the Cibus Common Units will be entitled to share in the profits and losses of Cibus Global
and to receive distributions as and if declared by the Cibus Managing Member and will generally have no voting rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Management
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus Global will be managed by the Cibus Managing Member. The Cibus Managing Member will have the sole vote on all matters that
require a vote of the manager under the Cibus Amended Operating Agreement or applicable law. The business, property and affairs of Cibus Global will be managed solely by the Cibus Managing Member, and the Cibus Managing Member cannot be removed or
replaced without the consent of the Cibus Managing Member. The Cibus Amended Operating Agreement cannot be amended without the consent of the Cibus Managing Member. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Cibus Amended Operating Agreement, the Cibus Managing Member may designate officers of Cibus Global and may delegate to such
officers or others the authority to act on behalf of Cibus Global. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Distributions </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Cibus Managing Member may, in its sole discretion, authorize distributions to the holders of Cibus Common Units to the extent of Available
Cash (as defined in the Cibus Operating Agreement). Subject to provisions in the Cibus Amended Operating Agreement governing tax distributions to the members of Cibus Global, all such distributions will be made pro rata in accordance with the number
of Cibus Common Units held by the members. Upon the dissolution of Cibus Global, all net proceeds in connection with the dissolution would be distributed pro rata in accordance with each member&#146;s number of Cibus Common Units. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of Cibus Common Units will generally incur U.S. federal, state and local income taxes on their proportionate share of any net
taxable income of Cibus Global. Net profits and net losses of Cibus Global will generally be allocated to its members pro rata in accordance with the percentages of their respective ownership of Cibus Common Units. The Cibus Amended Operating
Agreement will provide for pro rata cash distributions to the holders of Cibus Common Units for purposes of funding their tax obligations in respect of the taxable income of Cibus Global that is allocated to them. Generally, these tax distributions
will be computed based on Cibus Global&#146;s estimate of net taxable income of Cibus Global allocable to each holder of Cibus Common Units multiplied by an assumed tax rate equal to the highest effective marginal combined U.S. federal, state and
local income tax rate (including the tax imposed under Section&nbsp;1411 of the Code on net investment income) for a taxable year prescribed for an individual or corporate resident of New York, New York (whichever results in the application of the
highest state and local tax rate for a given type of income), and taking into account (a)&nbsp;the limitations imposed on the deductibility of expenses and other items, (b)&nbsp;the character (e.g., long-term or short-term capital gain or ordinary
or exempt income) of the applicable income, and (c)&nbsp;the deductibility of state and local income taxes, to the extent applicable (and with any dollar limitation on state and local income tax deductibility assumed to be exceeded), but not taking
into account any deduction under Section&nbsp;199A of the Code or any similar state or local law, as determined in good faith by the Cibus Managing Member. As a result of (i)&nbsp;potential differences in the amount of net taxable income allocable
to Cibus, Inc. and the other holders of Cibus Common Units, (ii)&nbsp;the lower tax rate applicable to corporations than individuals, and (iii)&nbsp;the use of an assumed tax rate in calculating Cibus Global&#146;s distribution obligations, Cibus,
Inc. may receive tax distributions significantly in excess of its tax liabilities and obligations to make payments under the Tax Receivable Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">194 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Transfer Restrictions </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Transfers of Cibus Common Units will require the prior consent of the Cibus Managing Member for such transfers, except in specified cases,
including (i)&nbsp;certain transfers to permitted transferees under certain conditions and (ii)&nbsp;exchanges of the <FONT STYLE="white-space:nowrap">Up-C</FONT> Units for shares of Class&nbsp;A Common Stock or cash pursuant to the Exchange
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing description of the Cibus Amended Operating Agreement is not complete and is qualified in its entirety by
reference to the Cibus Amended Operating Agreement, attached to this proxy statement as <I>Annex I</I>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">195 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom401831_36"></A>MATTERS BEING SUBMITTED TO A VOTE OF CALYXT STOCKHOLDERS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom401831_37"></A>Proposal No.&nbsp;1: Approval of the Blocker Mergers and the issuance of Class&nbsp;A Common Stock and Class&nbsp;B
Common Stock as Merger Consideration pursuant to the Merger Agreement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the Calyxt Special Meeting, Calyxt Stockholders will be asked
to approve the Blocker Mergers and the issuance of Class&nbsp;A Common Stock and Class&nbsp;B Common Stock pursuant to the Merger Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger Agreement provides that, among other things and upon the terms and subject to the conditions set forth therein (including receipt
of Calyxt Stockholder Approval and Cibus Member Approval), on the Closing Date: (a)&nbsp;each of the Blockers will merge with and into Calyxt, Inc., in each case with the Blockers ceasing to exist and Calyxt, Inc. surviving each such Blocker Merger,
(b)&nbsp;at the First Blocker Merger Effective Time, the Calyxt Bylaws will be amended and restated in a manner to be mutually agreed by Calyxt, Inc. and Cibus Global and the Calyxt Certificate of Incorporation will be amended and restated in a
manner to be mutually agreed by Calyxt, Inc. and Cibus Global, (c)&nbsp;following the Blocker Mergers, Merger Subsidiary will merge with and into Cibus Global, with Cibus Global as the surviving company and Merger Subsidiary ceasing to exist. As
consideration for the Mergers, the equity holders of the Blockers and the equity holders of Cibus Global will receive the Merger Consideration. In connection with the Mergers, Cibus, Inc. will contribute all of its assets and liabilities to Cibus
Global, as a contribution to the capital of Cibus Global, in exchange for newly issued Cibus Common Units under the Cibus Amended Operating Agreement, pursuant to a contribution agreement in a form to be agreed by Calyxt, Inc. and Cibus Global. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Amended Certificate of Incorporation, once adopted at the First Blocker Merger Effective Time, will designate two classes of Cibus, Inc.
common stock: (i)&nbsp;Class&nbsp;A Common Stock, which shares will have full voting and economic rights, and (ii)&nbsp;Class&nbsp;B Common Stock, which shares will have full voting, but no economic rights. Upon adoption of the Amended Certificate
of Incorporation, each share of Calyxt Common Stock existing and outstanding immediately prior to the First Blocker Merger Effective Time shall remain outstanding as a share of Class&nbsp;A Common Stock at the First Blocker Merger Effective Time
without any conversion or exchange thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the applicable effective time of each Blocker Merger, the limited liability company
interests of the applicable Blocker will be cancelled and converted into the right of the equityholder of the applicable Blocker to receive shares of Class&nbsp;A Common Stock corresponding to that Blocker Merger, in each case, as set forth in the
Allocation Schedule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the effective time of the Cibus Merger, all of the issued and outstanding Cibus Units, all outstanding Cibus
PIUs, and all outstanding Cibus Warrants or options to purchase Cibus Units, will be cancelled (or, in the case of Cibus Warrants, surrendered to Cibus, Inc. for exchange) and converted into the right to receive the following, as described in
further detail in the Merger Agreement: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any <FONT STYLE="white-space:nowrap">pre-Closing</FONT> holder (excluding the Blockers, but including any
investor who has delivered an irrevocable commitment as of the date of the Merger Agreement to purchase Cibus Global membership units prior to Closing) of Cibus Units (other than Cibus PIUs) shall have the option to elect, on a per unit basis, to
receive Merger Consideration in the form of either (a)&nbsp;the number of shares of Class&nbsp;A Common Stock set forth on the Allocation Schedule in exchange for all such holder&#146;s Cibus Units covered by such election or (b)&nbsp;a number of
shares of Class&nbsp;B Common Stock, with an equal number of Cibus Common Units set forth on the Allocation Schedule, provided, that such holder will not be entitled to exchange more than 95% of such holder&#146;s existing Cibus Units for <FONT
STYLE="white-space:nowrap">Up-C</FONT> Units and the remainder of such holder&#146;s Cibus Units will be exchanged for shares of Class&nbsp;A Common Stock; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">196 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all <FONT STYLE="white-space:nowrap">pre-Closing</FONT> Cibus Unitholders (excluding Blockers) other than Top 99
Holders shall receive the number of shares of Class&nbsp;A Common Stock set forth on the Allocation Schedule in exchange for their Cibus Units (other than Cibus PIUs); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all <FONT STYLE="white-space:nowrap">pre-Closing</FONT> Cibus Warrants shall automatically be exchanged for the
right to receive the number of shares of Class&nbsp;A Common Stock set forth on the Allocation Schedule; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all <FONT STYLE="white-space:nowrap">pre-Closing</FONT> Cibus PIUs will, (a)&nbsp;to the extent not a
&#147;restricted unit&#148; (under the award agreements and governing documents applicable to such Cibus PIU), be automatically cancelled and converted into the right to receive the number of shares of Class&nbsp;A Common Stock set forth on the
Allocation Schedule and (b)&nbsp;to the extent a &#147;restricted unit&#148; (i.e., an unvested unit), be automatically cancelled and converted into the right to receive the number of restricted shares of Class&nbsp;A Common Stock pursuant to a
Cibus, Inc. stock plan, as set forth on the Allocation Schedule and subject to the same vesting schedule as was applicable to such Cibus PIU prior to Closing. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately following the Cibus Merger, (i)&nbsp;each <FONT STYLE="white-space:nowrap">pre-Closing</FONT> Cibus Unit and <FONT
STYLE="white-space:nowrap">pre-Closing</FONT> Cibus Warrant, in each case, held by Cibus, Inc. as a result of the Blocker Mergers will be converted or exchanged for a number of Cibus Common Units set forth in the Allocation Schedule, (ii)&nbsp;each <FONT
STYLE="white-space:nowrap">pre-Closing</FONT> Cibus Warrant held by Cibus, Inc. as a result of the warrant exchanges described in the description of the Merger Consideration will be converted or exchanged for a number of Cibus Common Units set forth
in the Allocation Schedule, and (iii)&nbsp;Cibus Global will issue a number of Cibus Common Units to Cibus, Inc. in an amount equal to the sum of (A)&nbsp;the number of shares of Class&nbsp;A Common Stock issued to former Cibus Global equity holders
as Cibus Merger Consideration and (B)&nbsp;the number of shares of Calyxt Common Stock outstanding immediately prior to the First Blocker Merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the Closing and the issuance of the Merger Consideration and the issuance of Cibus Common Units discussed above, the Combined
Company will be organized in an <FONT STYLE="white-space:nowrap">&#147;Up-C&#148;</FONT> structure, and Cibus, Inc.&#146;s only material asset will consist of Cibus Common Units. Upon the Closing, <FONT STYLE="white-space:nowrap">pre-Closing</FONT>
Calyxt Stockholders are expected to own approximately 5.0% of issued and outstanding Shares, on a Fully-Exchanged Basis, and <FONT STYLE="white-space:nowrap">pre-Closing</FONT> holders of Cibus Global membership units and Cibus Warrants are expected
to own approximately 95.0% of the issued and outstanding Shares, on a Fully-Exchanged Basis, in each case, subject to dilution in connection with any Dilutive Issuances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately following the Closing, all of the issued and outstanding Cibus Common Units will be held by Cibus, Inc. and the Electing Members
(through their ownership of <FONT STYLE="white-space:nowrap">Up-C</FONT> Units), with the exact ownership interest held by Cibus, Inc. and the Electing Members being subject to the elections to be submitted by Top 99 Holders prior to the Closing. In
connection with the Up-C structure, at Closing, (i) Cibus, Inc. and the Electing Members will become party to the Cibus Amended Operating Agreement, (ii) Cibus, Inc., Cibus Global and the Electing Members will enter into an Exchange Agreement, and
(iii) Cibus, Inc. and the Electing Members will enter into a Registration Rights Agreement and a Tax Receivable Agreement. The <FONT STYLE="white-space:nowrap">Up-C</FONT> Units will generally be exchangeable for shares of Class&nbsp;A Common Stock
on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis, or, subject to certain restrictions, the cash equivalent with respect to all or a portion thereof, based on a volume-weighted average price of a
share of Class&nbsp;A Common Stock pursuant to the terms of the Exchange Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms of, reasons for and other aspects of the
Merger Agreement, the Transactions and the issuance of shares of Class&nbsp;A Common Stock and Class&nbsp;B Common Stock pursuant to the terms of the Merger Agreement are described in detail in the other sections in this proxy statement/prospectus.
Copies of the Merger Agreement and the First Amendment are attached as <I>Annex A-1</I> and <I>Annex A-2</I>, respectively, to this proxy statement/prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Vote Required </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The affirmative
vote of the holders of a majority of the outstanding shares of Calyxt Common Stock on the record date for the Calyxt Special Meeting entitled to vote on the matter is required for approval of Proposal No.&nbsp;1. Abstentions and broker <FONT
STYLE="white-space:nowrap">non-votes</FONT> will have the same effect as votes &#147;against&#148; Proposal No.&nbsp;1. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">197 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recommendation of Calyxt Board </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THE CALYXT BOARD UNANIMOUSLY RECOMMENDS THAT CALYXT STOCKHOLDERS VOTE &#147;FOR&#148; PROPOSAL NO. 1 TO APPROVE THE BLOCKER MERGERS AND THE
ISSUANCE OF CLASS A COMMON STOCK AND CLASS B COMMON STOCK AS MERGER CONSIDERATION PURSUANT TO THE MERGER AGREEMENT. PROPOSAL NO. 1 IS CONDITIONED UPON THE APPROVAL OF PROPOSAL NO. 2, AND THE MERGERS CANNOT BE CONSUMMATED WITHOUT THE APPROVAL OF
PROPOSAL NOS. 1 AND 2. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">198 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom401831_38"></A>Proposal No.&nbsp;2: Approval, for purposes of Nasdaq Listing Rule 5635(a) and
(b), the issuance of shares of Class&nbsp;A Common Stock and Class&nbsp;B Common Stock pursuant to the terms of the Merger Agreement and the change of control of Calyxt resulting from the Mergers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the Calyxt Special Meeting, Calyxt Stockholders will be asked to consider and vote upon a proposal to approve, for purposes of Nasdaq
Listing Rule 5635(a) and (b), the issuance of shares of Class&nbsp;A Common Stock and Class&nbsp;B Common Stock pursuant to the terms of the Merger Agreement and the change of control of Calyxt resulting from the Mergers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the Closing, the issuance of Merger Consideration and the issuance of Cibus Common Units, the Combined Company will be organized in
an <FONT STYLE="white-space:nowrap">&#147;Up-C&#148;</FONT> structure, with Cibus, Inc.&#146;s only material asset consisting of Cibus Common Units. Upon the Closing, Calyxt Stockholders are expected to own approximately 5.0% of issued and
outstanding Shares, on a Fully-Exchanged Basis, and Cibus Unitholders are expected to own approximately 95.0% of the issued and outstanding Shares, on a Fully-Exchanged Basis, in each case, subject to dilution in connection with any Dilutive
Issuances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms of, reasons for and other aspects of the Merger Agreement, the Mergers and the issuance of shares of Class&nbsp;A
Common Stock and Class&nbsp;B Common Stock in the Mergers are described in detail in the other sections in this proxy statement/prospectus. Copies of the Merger Agreement and the First Amendment are attached as <I>Annex A-1</I> and <I>Annex A-2</I>,
respectively, to this proxy statement/prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nasdaq Listing Rule 5635(a) requires a company listed on Nasdaq to obtain stockholder
approval prior to the issuance of common stock (or other securities convertible into or exercisable for common stock) in connection with the acquisition of the stock or assets of another company, if such securities are not issued in a public
offering for cash, and (i)&nbsp;the common stock has, or will have upon issuance, voting power equal to or in excess of 20% of the voting power outstanding before the issuance of such securities, or (ii)&nbsp;the number of shares of common stock to
be issued is or will be equal to or in excess of 20% of the number of shares of common stock outstanding before the issuance of such securities. The potential issuance of the shares of Class&nbsp;A Common Stock and Class&nbsp;B Common Stock in the
Mergers will exceed the 20% threshold under the Nasdaq Listing Rules. Accordingly, in order to ensure compliance with Nasdaq Listing Rule 5635(a), Calyxt, Inc. must obtain the approval of Calyxt Stockholders for the issuance of these shares of
Class&nbsp;A Common Stock and Class&nbsp;B Common Stock in the Mergers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nasdaq Listing Rule 5635(b) requires a company listed on Nasdaq
to obtain stockholder approval prior to an issuance of securities that will result in a &#147;change of control&#148; of the company. Although Nasdaq has not adopted any rule as to what constitutes a &#147;change of control&#148; for purposes of
Rule 5635(b), Nasdaq has previously indicated that the acquisition of, or right to acquire, by a single investor or affiliated investor group, as little as 20% of the common stock (or securities convertible into or exercisable for common stock) or
voting power of an issuer could constitute a change of control. Accordingly, in order to ensure compliance with Nasdaq Listing Rule 5635(b), Calyxt, Inc. must obtain the approval of Calyxt Stockholders for the potential change in control of Calyxt
resulting from the Mergers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms of, reasons for and other aspects of the Merger Agreement, the Mergers, the issuance of shares of
Class&nbsp;A Common Stock and Class&nbsp;B Common Stock pursuant to the terms of the Merger Agreement and the resulting change of control are described in detail in the other sections in this proxy statement/prospectus. Copies of the Merger
Agreement and the First Amendment are attached as <I>Annex A-1 </I>and <I>Annex A-2</I>, respectively, to this proxy statement/prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Vote
Required </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The affirmative vote of a majority in voting power of the votes cast by the holders of Calyxt Common Stock present or
represented by proxy at the Calyxt Special Meeting and entitled to vote on the matter is required for approval of Proposal No.&nbsp;2. Abstentions and broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will have no effect on Proposal
No.&nbsp;2. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">199 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recommendation of Calyxt Board </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THE CALYXT BOARD UNANIMOUSLY RECOMMENDS THAT CALYXT STOCKHOLDERS VOTE &#147;FOR&#148; PROPOSAL NO. 2 TO APPROVE, FOR PURPOSES OF NASDAQ
LISTING RULE 5635(a) AND (b), THE ISSUANCE OF SHARES OF CLASS A COMMON STOCK AND CLASS B COMMON STOCK PURSUANT TO THE TERMS OF THE MERGER AGREEMENT AND THE CHANGE OF CONTROL OF CALYXT RESULTING FROM THE MERGERS. PROPOSAL NO. 1 IS CONDITIONED UPON
THE APPROVAL OF PROPOSAL NO. 2, AND THE MERGERS CANNOT BE CONSUMMATED WITHOUT THE APPROVAL OF PROPOSAL NOS. 1 AND 2. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">200 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom401831_40"></A>Proposal No.&nbsp;3: Approval of the Amended Certificate of Incorporation,
which will amend and restate the Calyxt Certificate of Incorporation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the Calyxt Special Meeting, Calyxt Stockholders will be asked to consider and vote, on a non-binding, advisory basis, upon a proposal to
approve the adoption of the Amended Certificate of Incorporation, in the form attached to this proxy statement/prospectus as <I>Annex B</I>. In the judgment of the Calyxt Board, the Amended Certificate of Incorporation is necessary to adequately
address the needs of the Combined Company following the consummation of the Transactions. For the avoidance of doubt, this vote will be advisory in nature given the Amended Certificate of Incorporation will automatically become the certificate of
incorporation of Cibus, Inc. upon consummation of the First Blocker Merger pursuant to the applicable provisions of Delaware Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If
Proposal 1 is approved and the Transactions are to be consummated, Calyxt, Inc. will amend and restate the Calyxt Certificate of Incorporation by filing the Amended Certificate of Incorporation, as an attachment to the applicable certificate of
merger, with the Secretary of State of the State of Delaware at the First Blocker Merger Effective Time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the Calyxt Certificate of
Incorporation to the Amended Certificate of Incorporation and Reasons for the Amendments </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See the section titled
&#147;<I>Comparison of Stockholders&#146; Rights</I>&#148; for a summary of certain proposed changes between the Calyxt Certificate of Incorporation and the Amended Certificate of Incorporation, which is qualified by reference to the complete text
of the Amended Certificate of Incorporation, a copy of which is attached to this proxy statement/prospectus as <I>Annex B</I>. All stockholders are encouraged to read the Amended Certificate of Incorporation in its entirety for a more complete
description of its terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Amended Certificate of Incorporation was negotiated as part of the Mergers. The change in name of Calyxt,
Inc. to Cibus, Inc. is desirable to reflect the Mergers and the combined business going forward. The division of common stock into two classes is desirable for Cibus, Inc. to effectuate the <FONT STYLE="white-space:nowrap">Up-C</FONT> structure. The
number of authorized shares of common stock is necessary to have a sufficient number of authorized shares to issue the Merger Consideration in connection with the Mergers and to have enough additional authorized shares for financing the Combined
Company&#146;s business, for acquiring other businesses, for forming strategic partnerships and alliances and for stock dividends and stock splits and to issue shares upon exercise of the warrants and equity awards currently outstanding.
Additionally, the proposed Amended Certificate of Incorporation removes any special rights that Cellectis had in the Calyxt Certificate of Incorporation. The other changes from the Calyxt Certificate of Incorporation are generally to reflect changes
in market practice for similarly-situation public companies with an &#147;Up-C&#148; structure as well as the DGCL since the date of the Calyxt Certificate of Incorporation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Vote Required </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The affirmative
vote of the holders of a majority of the outstanding shares of Calyxt Common Stock on the record date for the Calyxt Special Meeting entitled to vote on the matter is required for approval of Proposal No.&nbsp;3; provided, that for the avoidance of
doubt, this vote will be advisory in nature given the Amended Certificate of Incorporation will automatically become the certificate of incorporation of Cibus, Inc. upon consummation of the First Blocker Merger pursuant to the applicable provisions
of Delaware Law. Abstentions and broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will have the same effect as votes &#147;AGAINST&#148; Proposal No.&nbsp;3. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recommendation of Calyxt Board </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THE CALYXT BOARD UNANIMOUSLY RECOMMENDS THAT CALYXT STOCKHOLDERS VOTE &#147;FOR&#148; PROPOSAL NO. 3 TO APPROVE THE AMENDED CERTIFICATE OF
INCORPORATION ON AN ADVISORY BASIS. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">201 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom401831_42"></A>Proposal No.&nbsp;4: Approval of an amendment to the Calyxt Certificate of
Incorporation to effect the Subsequent Reverse Stock Split at the discretion of the Calyxt Board </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the Calyxt Special Meeting, Calyxt Stockholders will be asked to consider and vote upon a proposal to allow for the amendment to the Calyxt
Certificate of Incorporation to effect the Subsequent Reverse Stock Split of all of the then-outstanding shares of Calyxt Common Stock by a ratio in the range of not less than 1-for-2 and not greater than 1-for-10. The proposal provides that the
Calyxt Board shall have sole discretion pursuant to Section&nbsp;242(c) of the DGCL to elect, as it determines to be in Calyxt&#146;s best interests, whether or not to effect the Subsequent Reverse Stock Split before April 1, 2024, or to abandon it.
Should the Calyxt Board proceed with the Subsequent Reverse Stock Split, the exact ratio shall be set at a whole number within the above range as determined by the Calyxt Board in consultation with the Cibus Board. The Calyxt Board believes that the
availability of alternative reverse stock split ratios will provide it with the flexibility to implement the Subsequent Reverse Stock Split in a manner designed to maximize the anticipated benefits for Calyxt, Inc. and its stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In determining whether to implement the Subsequent Reverse Stock Split following the receipt of stockholder approval, the Calyxt Board may
consider, among other things, factors such as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the historical trading price and trading volume of Calyxt Common Stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the then prevailing trading price and trading volume of Calyxt Common Stock and the anticipated impact of the
Subsequent Reverse Stock Split on the trading market for Calyxt Common Stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to have shares of Calyxt Common Stock remain listed on Nasdaq; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the anticipated impact of the Subsequent Reverse Stock Split on Calyxt&#146;s ability to raise additional
financing; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prevailing general market and economic conditions. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Calyxt Board determines that effecting the Subsequent Reverse Stock Split is in Calyxt&#146;s best interest, the Subsequent Reverse
Stock Split will become effective upon filing of an amendment to the Calyxt Certificate of Incorporation with the Secretary of State of the State of Delaware. The amendment filed thereby will set forth the number of shares of outstanding Calyxt
Common Stock to be combined into one share of Calyxt Common Stock within the limits set forth in this proposal. Except for adjustments that may result from the treatment of fractional shares as described below, each stockholder will generally hold
the same percentage of outstanding Calyxt Common Stock immediately following the Subsequent Reverse Stock Split as such stockholder holds immediately prior to the Subsequent Reverse Stock Split. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The text of the form of amendment to the Calyxt Certificate of Incorporation (the &#147;Subsequent Reverse Stock Split Certificate of
Amendment&#148;), which would be filed with the Secretary of State of the State of Delaware to effect the Subsequent Reverse Stock Split, is set forth in <I>Annex J </I>to this proxy statement/prospectus. The text of the Subsequent Reverse Stock
Split Certificate of Amendment accompanying this proxy statement/prospectus is, however, subject to amendment to reflect the exact ratio for the Subsequent Reverse Stock Split and any changes that may be required by the office of the Secretary of
State of the State of Delaware or that the Calyxt Board may determine to be necessary or advisable ultimately to comply with applicable law and to effect the Subsequent Reverse Stock Split. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Calyxt Board believes that approval of the amendment to the Calyxt Certificate of Incorporation to effect the Subsequent Reverse Stock
Split is in the best interests of Calyxt and its stockholders and has unanimously recommended that the proposed amendment be presented to Calyxt Stockholders for approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">202 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Calyxt Board Discretion to Implement or Abandon the Subsequent Reverse Stock Split </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Subsequent Reverse Stock Split will be effected, if at all, only upon a determination by the Calyxt Board that the Subsequent Reverse Stock
Split (with a reverse stock split ratio determined by the Calyxt Board as described above) is in Calyxt&#146;s best interest. Such determination shall be based upon certain factors, including those identified above. No further action on the part of
stockholders would be required to either implement or abandon the Subsequent Reverse Stock Split. If Calyxt Stockholders approve the proposal, and the Calyxt Board determines to effect the Subsequent Reverse Stock Split, Calyxt, Inc. would
communicate to the public, prior to the Effective Date (as defined below), additional details regarding the Subsequent Reverse Stock Split, including the specific ratio selected by the Calyxt Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Calyxt Board does not implement the Subsequent Reverse Stock Split prior to April 1, 2024, the authority granted in this proposal to
implement the Subsequent Reverse Stock Split will terminate. The Calyxt Board reserves its right to elect not to proceed with the Subsequent Reverse Stock Split if it determines, in its sole discretion, that this proposal is no longer in
Calyxt&#146;s best interest. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Effective Date </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the proposed amendment to the Calyxt Certificate of Incorporation to give effect to the Subsequent Reverse Stock Split is approved at the
Calyxt Special Meeting and the Calyxt Board determines to effect the Subsequent Reverse Stock Split, the Subsequent Reverse Stock Split will become effective as of a date and time to be determined by the Calyxt Board that will be specified in the
Subsequent Reverse Stock Split Certificate of Amendment (the &#147;Effective Date&#148;). It is currently contemplated that the Calyxt Board will effect the Subsequent Reverse Stock Split such that the Effective Date immediately precedes the
Closing. Except as explained below with respect to fractional shares, each issued share of Calyxt Common Stock immediately prior to the Effective Date will automatically be changed, as of the Effective Date, into a fraction of a share of Calyxt
Common Stock based on the Subsequent Reverse Stock Split exchange ratio within the approved range determined by the Calyxt Board. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Principal Effects
of the Subsequent Reverse Stock Split </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Calyxt Common Stock</I>. If this proposal is approved by the Calyxt Stockholders at the
Calyxt Special Meeting and the Calyxt Board determines to effect the Subsequent Reverse Stock Split and thus amend the Calyxt Certificate of Incorporation, Calyxt, Inc. will file a certificate of amendment to the Calyxt Certificate of Incorporation
with the Secretary of State of the State of Delaware. Except for adjustments that may result from the treatment of fractional shares of Calyxt Common Stock as described below, each issued share of Calyxt Common Stock immediately prior to the
Effective Date will automatically be changed, as of the Effective Date, into a fraction of a share of Calyxt Common Stock based on the Subsequent Reverse Stock Split exchange ratio within the approved range determined by the Calyxt Board. In
addition, proportional adjustments will be made to the maximum number of shares of Calyxt Common Stock issuable under, and other terms of, Calyxt, Inc.&#146;s equity compensation plans, as well as to the number of shares of Calyxt Common Stock
issuable under, and the exercise price of, outstanding awards under Calyxt, Inc.&#146;s equity compensation plans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the
Exchange Ratio and the Allocation Schedule will be proportionately adjusted based on the Subsequent Reverse Stock Split exchange ratio determined by the Calyxt Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except for adjustments that may result from the treatment of fractional shares of Calyxt Common Stock as described below, because the
Subsequent Reverse Stock Split would apply to all issued and outstanding shares of Calyxt Common Stock, the proposed Subsequent Reverse Stock Split would generally not alter the relative rights and preferences of Calyxt, Inc.&#146;s existing
stockholders nor affect any stockholder&#146;s proportionate equity interest in Calyxt, Inc. For example, a holder of two percent (2%) of the voting power of the outstanding shares of Calyxt Common Stock immediately prior to the effectiveness of the
Subsequent Reverse Stock Split will generally continue to hold two percent (2%) of the voting power of the outstanding shares of Calyxt Common Stock immediately after the Subsequent Reverse Stock Split. Moreover, the number of stockholders of record
will not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">203 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be affected by the Subsequent Reverse Stock Split. The amendment to the Calyxt Certificate of Incorporation itself would not change the number of authorized shares of Calyxt Common Stock.
Accordingly, the Subsequent Reverse Stock Split will have the effect of creating additional unreserved shares of authorized Calyxt Common Stock. Although at present Calyxt, Inc. has no current arrangements or understandings providing for the
issuance of the additional shares of Calyxt Common Stock that would be made available for issuance upon effectiveness of the Subsequent Reverse Stock Split, other than those shares needed to satisfy the exercise of Calyxt, Inc.&#146;s outstanding
awards under its equity compensation plans and any shares that it may issue pursuant to its existing <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">at-the-market</FONT></FONT> equity program under the Open Market Sale Agreement<SUP
STYLE="font-size:75%; vertical-align:top">SM</SUP> with Jefferies LLC, these additional shares of Calyxt Common Stock may be used by Calyxt, Inc. for various purposes in the future without further stockholder approval, including, among other things:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">raising capital to fund Calyxt&#146;s operations and to continue as a going concern; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing strategic relationships with other companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">providing equity incentives to Calyxt&#146;s employees, officers or directors; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expanding Calyxt&#146;s business or product lines through the acquisition of other businesses or products.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Effect on Employee Plans, Options, Restricted Stock Awards and Convertible or Exchangeable Securities</I>. Pursuant
to the terms of the Calyxt, Inc. Equity Incentive Plan, the Calyxt, Inc. 2017 Omnibus Incentive Plan, as amended, and the Calyxt, Inc. 2021 Employee Inducement Incentive Plan (collectively, the &#147;Plans&#148;), the Calyxt Board or a committee
thereof, as applicable, will adjust the number of shares of Calyxt Common Stock available for future grant under the Plans, the number of shares of Calyxt Common Stock underlying outstanding awards, the exercise price per share of outstanding stock
options, and other terms of outstanding awards issued pursuant to the Plans to equitably reflect the effects of the Subsequent Reverse Stock Split. Based upon the Subsequent Reverse Stock Split ratio determined by the Calyxt Board, proportionate
adjustments are also generally required to be made to the per share exercise price and the number of shares of Calyxt Common Stock issuable upon the exercise or conversion of outstanding warrants, options, and any convertible or exchangeable
securities entitling the holders to purchase, exchange for, or convert into, shares of Calyxt Common Stock. This would result in approximately the same aggregate price being required to be paid under such options, and convertible or exchangeable
securities upon exercise, and approximately the same value of shares of Calyxt Common Stock being delivered upon such exercise, exchange or conversion, immediately following the Subsequent Reverse Stock Split as was the case immediately preceding
the Subsequent Reverse Stock Split. The number of shares of Calyxt Common Stock subject to Calyxt RSUs will be similarly adjusted, subject to Calyxt, Inc.&#146;s treatment of fractional shares of Calyxt Common Stock. The number of shares of Calyxt
Common Stock reserved for issuance pursuant to these securities and the Plans will be adjusted proportionately based upon the Subsequent Reverse Stock Split ratio determined by the Calyxt Board, subject to the treatment of fractional shares of
Calyxt Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Listing</I>. Shares of Calyxt Common Stock currently trade on the Nasdaq Capital Market. The Subsequent Reverse
Stock Split will not directly affect the listing of Calyxt Common Stock on the Nasdaq Capital Market, although Calyxt believes that the Subsequent Reverse Stock Split could potentially increase the stock price. Following the Subsequent Reverse Stock
Split, Calyxt Common Stock will continue to be listed on the Nasdaq Capital Market under the symbol &#147;CLXT,&#148; although Calyxt Common Stock would have a new committee on uniform securities identification procedures (&#147;CUSIP&#148;) number,
a number used to identify Calyxt Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Public Company&#148; Status</I>. Calyxt Common Stock is currently registered
under Section&nbsp;12(b) of the Exchange Act, and Calyxt, Inc. is subject to the &#147;public company&#148; periodic reporting and other requirements of the Exchange Act. The proposed Subsequent Reverse Stock Split will not affect Calyxt,
Inc.&#146;s status as a public company or this registration under the Exchange Act. The Subsequent Reverse Stock Split is not intended as, and will not have the effect of, a &#147;going private transaction&#148; covered by Rule <FONT
STYLE="white-space:nowrap">13e-3</FONT> under the Exchange Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">204 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Odd Lot Transactions</I>. It is likely that some Calyxt Stockholders will own <FONT
STYLE="white-space:nowrap">&#147;odd-lots&#148;</FONT> of less than 100 shares of Calyxt Common Stock following the Subsequent Reverse Stock Split. A purchase or sale of less than 100 shares of Calyxt Common Stock (an &#147;odd lot&#148;
transaction) may result in incrementally higher trading costs through certain brokers, particularly &#147;full service&#148; brokers, and generally may be more difficult than a &#147;round lot&#148; sale. Therefore, those stockholders who own less
than 100 shares of Calyxt Common Stock following the Subsequent Reverse Stock Split may be required to pay somewhat higher transaction costs and may experience some difficulties or delays should they then determine to sell their shares of Calyxt
Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Authorized but Unissued Shares; Potential Anti-Takeover Effects</I>. Prior to giving effect to the Reverse Stock Splits,
the Calyxt Certificate of Incorporation authorizes 275,000,000 shares of Calyxt Common Stock and 50,000,000 shares of preferred stock. The Subsequent Reverse Stock Split would not change the number of authorized shares of the Calyxt Common Stock or
preferred stock as designated, in each case immediately prior to the Subsequent Reverse Stock Split. Therefore, because the number of issued and outstanding shares of Calyxt Common Stock would decrease, the number of shares of Calyxt Common Stock
remaining available for issuance by us in the future would increase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Such additional shares of Calyxt Common Stock would be available for
issuance from time to time for corporate purposes such as issuances of Calyxt Common Stock in connection with capital-raising transactions and acquisitions of companies or other assets, as well as for issuance upon conversion or exercise of
securities such as convertible preferred stock, convertible debt, warrants or options convertible into or exercisable for Calyxt Common Stock. Calyxt believes that the availability of the additional shares of Calyxt Common Stock will provide Calyxt
with the flexibility to meet business needs as they arise, to take advantage of favorable opportunities and to respond effectively in a changing corporate environment. For example, Calyxt, Inc. may elect to issue shares of Calyxt Common Stock to
raise equity capital, to make acquisitions through the use of stock, to establish strategic relationships with other companies, to adopt additional employee benefit plans or reserve additional shares of Calyxt Common Stock for issuance under such
plans, where the Calyxt Board determines it advisable to do so, without the necessity of soliciting further stockholder approval, subject to applicable stockholder vote requirements under Delaware Law and Nasdaq rules. If Calyxt, Inc. issues
additional shares of Calyxt Common Stock for any of these purposes, the aggregate ownership interest of Calyxt, Inc.&#146;s current stockholders, and the interest of each such existing stockholder, would be diluted, possibly substantially. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The additional shares of Calyxt Common Stock that would become available for issuance upon an effective Subsequent Reverse Stock Split could
also be used by Calyxt, Inc. to oppose a hostile takeover attempt or delay or prevent a change of control or changes in or removal of Calyxt, Inc.&#146;s management, including any transaction that may be favored by a majority of Calyxt Stockholders
or in which Calyxt Stockholders might otherwise receive a premium for their shares of Calyxt Common Stock over then-current market prices or benefit in some other manner. Although the increased proportion of authorized but unissued shares of Calyxt
Common Stock to issued shares of Calyxt Common Stock could, under certain circumstances, have an anti-takeover effect, the Subsequent Reverse Stock Split is not being proposed to respond to a hostile takeover attempt or to an attempt to obtain
control of Calyxt. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fractional Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt, Inc. will not issue fractional certificates for post-Subsequent Reverse Stock Split shares of Calyxt Common Stock in connection with
the Subsequent Reverse Stock Split. To the extent any holders of <FONT STYLE="white-space:nowrap">pre-Subsequent</FONT> Reverse Stock Split shares of Calyxt Common Stock are entitled to fractional shares of Calyxt Common Stock as a result of the
Subsequent Reverse Stock Split, Calyxt, Inc. will round up and issue an additional share to all holders of fractional shares of Calyxt Common Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">205 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>No Dissenters&#146; Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Delaware Law, Calyxt Stockholders would not be entitled to dissenters&#146; rights or rights of appraisal in connection with the
implementation of the Subsequent Reverse Stock Split, and Calyxt, Inc. will not independently provide Calyxt Stockholders with any such rights. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Certain Risks Associated with the Subsequent Reverse Stock Split </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before voting on this proposal, stockholders should consider the risks associated with the implementation of the Subsequent Reverse Stock Split
described in the section entitled &#147;<I>Risk Factors&#151;Risks Related to the Reverse Stock Splits</I>&#148; in this proxy statement/prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Certain United States Federal Income Tax Consequences </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of certain United States federal income tax consequences of the Subsequent Reverse Stock Split to Calyxt
Stockholders. It does not address all U.S. federal income tax consequences that may be relevant to any particular stockholder, including tax considerations that arise from rules of general application to all taxpayers or to certain classes of
taxpayers or that are generally assumed to be known by investors. This summary also does not address the tax consequences to (a)&nbsp;persons that may be subject to special treatment under U.S. federal income tax law, such as banks and other
financial institutions, insurance companies, thrift institutions, regulated investment companies, real estate investment trusts, <FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations, partnerships (or other entities classified as
partnerships for U.S. federal income tax purposes) and investors therein, &#147;United States holders&#148; (as defined below) whose functional currency is not the U.S. dollar, U.S. expatriates, controlled foreign corporations, passive foreign
investment companies, persons subject to the alternative minimum tax, persons who acquired Calyxt Common Stock through the exercise of employee stock options or otherwise as compensation, traders in securities that elect to mark to market and
dealers in securities or currencies, (b)&nbsp;persons that hold Calyxt Common Stock as part of a position in a &#147;straddle&#148; or as part of a &#147;hedging,&#148; &#147;conversion&#148; or other integrated investment transaction for U.S.
federal income tax purposes, (c)&nbsp;stockholders who own or have owned, actually or constructively, 5% or more of Calyxt Common Stock (by vote or value) at any time during the shorter of the five-year period ending on the date of the Subsequent
Reverse Stock Split or any such stockholder&#146;s holding period or (d)&nbsp;persons that do not hold Calyxt Common Stock as &#147;capital assets&#148; (generally, property held for investment). The discussion is based on the Code, its legislative
history, existing, temporary, and proposed regulations under the Code, published rulings and court decisions, all as of the date hereof. These laws, regulations and other guidance are subject to change, possibly on a retroactive basis. Calyxt, Inc.
has not sought and will not seek an opinion of counsel or a ruling from the IRS regarding the United States federal income tax consequences of the Subsequent Reverse Stock Split. This summary does not address any state, local or foreign income or
other tax consequences, which, depending upon the jurisdiction and the status of the stockholder, may vary from the United States federal income tax consequences, or the effects of other U.S. federal tax laws, such as estate and gift tax laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">PLEASE CONSULT YOUR OWN TAX ADVISOR CONCERNING THE CONSEQUENCES OF THE SUBSEQUENT REVERSE STOCK SPLIT IN YOUR PARTICULAR CIRCUMSTANCES UNDER
THE CODE AND THE LAWS OF ANY OTHER TAXING JURISDICTION. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a partnership (or other entity classified as a partnership for U.S. federal
income tax purposes) is the beneficial owner of Calyxt Common Stock, the U.S. federal income tax treatment of a partner in the partnership </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">206 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
will generally depend on the status of the partner and the activities of the partnership. Partnerships that hold Calyxt Common Stock, and partners in such partnerships, should consult their own
tax advisors regarding the U.S. federal income tax consequences of the Subsequent Reverse Stock Split. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Tax Consequences to United
States Holders</I>. A &#147;United States holder&#148; is a beneficial owner of Calyxt Common Stock that is, for United States federal income tax purposes: (a)&nbsp;a citizen or individual resident of the United States, (b)&nbsp;a corporation
organized in or under the laws of the United States or any state thereof or the District of Columbia, (c)&nbsp;an estate whose income is subject to United States federal income tax regardless of its source, or (d)&nbsp;a trust, if a United States
court can exercise primary supervision over the trust&#146;s administration and one or more United States persons are authorized to control all substantial decisions of the trust. The discussion in this section applies only to United States holders.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Subsequent Reverse Stock Split is intended to be treated as a recapitalization for U.S. federal income tax purposes. Assuming that
the Subsequent Reverse Stock Split qualifies as a recapitalization (and subject to the discussion of fractional shares below), no gain or loss will be recognized by a United States holder upon such holder&#146;s exchange of <FONT
STYLE="white-space:nowrap">pre-Subsequent</FONT> Reverse Stock Split shares of Calyxt Common Stock for post-Subsequent Reverse Stock Split shares of Calyxt Common Stock pursuant to the Subsequent Reverse Stock Split. A United States holder&#146;s
aggregate adjusted basis in the post-Subsequent Reverse Stock Split shares of Calyxt Common Stock received will be the same as such holder&#146;s aggregate adjusted basis in the Calyxt Common Stock exchanged for such new shares. The United States
holder&#146;s holding period for the post-Subsequent Reverse Stock Split shares of Calyxt Common Stock will include the period during which such holder held the <FONT STYLE="white-space:nowrap">pre-Subsequent</FONT> Reverse Stock Split shares of
Calyxt Common Stock surrendered. United States holders that acquired <FONT STYLE="white-space:nowrap">pre-Subsequent</FONT> Reverse Stock Split shares of Calyxt Common Stock on different dates and at different prices should consult their own tax
advisors regarding allocating the tax basis and holding period from <FONT STYLE="white-space:nowrap">pre-Subsequent</FONT> Reverse Stock Split shares of Calyxt Common Stock to post-Subsequent Reverse Stock Split shares of Calyxt Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The treatment of fractional post-Subsequent Reverse Stock Split shares of Calyxt Common Stock being rounded up to the next whole share is
uncertain, and a United States holder that receives a whole share in lieu of a fractional share may recognize income, which may be characterized as either capital gain or as a dividend, in an amount not to exceed the excess of the fair market value
of such whole share over the fair market value of the fractional share to which the United States holder is otherwise entitled. United States holders should consult their own tax advisors regarding the U.S. federal income tax consequences of
fractional shares being rounded to the next whole share (including the tax basis and holding period of a whole share received in lieu of a fractional share). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders</I>. A <FONT STYLE="white-space:nowrap">&#147;non-U.S.</FONT> holder&#148; is a
beneficial owner of Calyxt Common Stock that is neither a United States holder nor a partnership (or other entity classified as a partnership for U.S. federal income tax purposes). The discussion in this section applies only to <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holders. Generally, <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders will not recognize any gain or loss upon the Subsequent Reverse Stock Split. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that receives a whole post-Subsequent Reverse Stock Split share of Calyxt Common
Stock in lieu of a fractional post-Subsequent Reverse Stock Split share of Calyxt Common Stock may be treated as described above under &#147;&#151;<I>Tax Consequences to United States Holders</I>,&#148; and in such case, Calyxt may withhold tax on
any deemed contribution to such non-U.S. holder. In addition, in the event that the distribution is treated as capital gain for U.S. federal income tax purposes, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder may be subject to tax if
(a)&nbsp;any income or gain from the exchange of <FONT STYLE="white-space:nowrap">pre-Subsequent</FONT> Reverse Stock Split shares of Calyxt Common Stock for post-Subsequent Reverse Stock Split shares of Calyxt Common Stock is effectively connected
with the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s conduct of a trade or business in the United States (or, if certain income tax treaties apply, is attributable to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holder&#146;s permanent establishment or fixed base in the United States), or (b)&nbsp;such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is an individual and is present in the United States for 183 days or more in the taxable year of the
Subsequent Reverse Stock Split and other conditions are met. Such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders should consult their own tax advisors regarding the U.S. federal income tax consequences of fractional shares being rounded to
the next whole share. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">207 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accounting Consequences </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the Effective Date of the Subsequent Reverse Stock Split, if any, the net income or loss and net book value per share of Calyxt
Common Stock will be increased because there will be fewer shares of Calyxt Common Stock outstanding. Calyxt does not anticipate that any other accounting consequences would arise as a result of the Subsequent Reverse Stock Split. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Effect on Registered &#147;Book-Entry&#148; Holders of Common Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt, Inc.&#146;s registered stockholders hold their shares electronically in book-entry form with Calyxt, Inc.&#146;s transfer agent,
Broadridge Corporate Issuer Solutions, LLC (the &#147;Transfer Agent&#148;). Stockholders do not have stock certificates evidencing their ownership of Calyxt Common Stock. They are, however, provided with a statement reflecting the number of shares
of Calyxt Common Stock registered in their accounts. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If you hold registered shares of Calyxt Common Stock in book-entry form, you do not need to take any action to
receive your post-Subsequent Reverse Stock Split shares of Common Stock in registered book-entry form. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If you are entitled to post-Subsequent Reverse Stock Split shares of Calyxt Common Stock, a transaction statement
will automatically be sent to your address of record by Calyxt, Inc.&#146;s transfer agent as soon as practicable after the Effective Date indicating the number of shares of Calyxt Common Stock that you hold. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the implementation of the Subsequent Reverse Stock Split, Calyxt, Inc. intends to treat shares held by stockholders through a bank,
broker, custodian, or other nominee in the same manner as registered stockholders whose shares are registered directly in their names with the Transfer Agent. Banks, brokers, custodians, or other nominees will be instructed to effect the Subsequent
Reverse Stock Split for their beneficial holders holding Calyxt Common Stock in street name. However, these banks, brokers, custodians, or other nominees may have different procedures for processing the Subsequent Reverse Stock Split. Stockholders
who hold Calyxt Common Stock with a bank, broker, custodian, or other nominee and who have any questions in this regard are encouraged to contact their banks, brokers, custodians, or other nominees. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interests of Directors and Executive Officers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt, Inc.&#146;s directors and executive officers have no substantial interests, directly or indirectly, in the matters set forth in this
proposal except to the extent of their ownership of shares of Calyxt Common Stock and equity awards under granted to them under the Plans. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Vote
Required </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The affirmative vote of the holders of a majority of the outstanding shares of Calyxt Common Stock on the record date for
the Calyxt Special Meeting entitled to vote on the matter is required for approval of Proposal No.&nbsp;4. Abstentions will have the same effect as votes &#147;AGAINST&#148; Proposal No.&nbsp;4. Because Proposal No.&nbsp;4 is considered a routine
matter, it is expected that there would not be any broker <FONT STYLE="white-space:nowrap">non-votes.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recommendation of Calyxt Board
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THE CALYXT BOARD UNANIMOUSLY RECOMMENDS THAT CALYXT STOCKHOLDERS VOTE &#147;FOR&#148; PROPOSAL NO. 4 TO APPROVE AN AMENDMENT TO
THE CALYXT CERTIFICATE OF INCORPORATION TO EFFECT THE SUBSEQUENT REVERSE STOCK SPLIT. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">208 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom401831_43"></A>Proposal No.&nbsp;5: Approval of the Amendment to the Calyxt, Inc. 2017
Omnibus Incentive Plan </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the Calyxt Special Meeting, Calyxt Stockholders will be asked to approve an amendment (the &#147;Amendment&#148;) to the Calyxt, Inc. 2017
Omnibus Incentive Plan (the &#147;Plan&#148;). The Calyxt Board believes that the Combined Company&#146;s growth and success will depend on its ability to attract, retain and motivate key employees with experience, thereby creating value for
stockholders. Central to these objectives is a stock-based compensation program. The Plan was originally established effective June&nbsp;14, 2017 and was previously amended by the Calyxt Board and approved by Calyxt Stockholders effective
May&nbsp;18, 2021. The Amendment has been approved and adopted by the Calyxt Board, subject to approval by Calyxt Stockholders, and is submitted for stockholder approval, contingent and effective upon the Closing, at which time the Plan will be
renamed the Cibus, Inc. 2017 Omnibus Incentive Plan. The key terms of the Amendment are described in additional detail below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes to the Plan
Pursuant to the Amendment </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information in this proposal does not give effect to the Reverse Stock Splits and shall be
proportionately adjusted in respect of such Reverse Stock Splits upon their respective effectiveness. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is anticipated that, following
the Mergers, including as a result of the dilutive impact of the Mergers, the total number of shares available for issuance under the Plan (the &#147;Overall Share Limit&#148;) will not be sufficient to meet the Combined Company&#146;s needs,
especially in light of the significant role that equity compensation is intended to have, and will impede the Combined Company&#146;s ability to properly compensate, motivate, incentivize and retain key talent. The primary reasons for the Amendment
are to (1)&nbsp;increase the Overall Share Limit (as defined below) (and other <FONT STYLE="white-space:nowrap">sub-limits</FONT> under the Plan that are expressed in shares) and (2)&nbsp;extend the term of the Plan 10 years from the effective date
of the Amendment. A more detailed description of the material changes that would result from the Amendment are expected to be as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Amendment increases the Overall Share Limit from 13,675,493 shares to a number of shares equal to 10% of the
total shares outstanding immediately following the Mergers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Amendment revises the annual evergreen provision in the Plan to provide that the Overall Share Limit will
increase on the first fiscal day of each fiscal year during the term of the Plan, starting in 2024 by 7.5% of the outstanding shares on the last day of the immediately preceding fiscal year (or such lesser amount as determined by the Cibus, Inc.
Board) as it currently does, but it will no longer contain the alternative set share increase limit of 4,900,000. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Amendment allows shares subject to awards that are retained by Cibus, Inc. upon exercise, vesting or
settlement of awards to satisfy a tax withholding obligation or pay an exercise price to be available for future grants under the Plan. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Amendment increases the number of shares that may be issued under the Plan pursuant to the exercise of
&#147;incentive stock options&#148; to a number of shares equal to 10% of the total shares outstanding immediately following the Mergers, which limit will increase annually (beginning in 2024) by a number of shares equal to 7.5% of the total shares
outstanding immediately following the Mergers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Amendment removes the annual limit on awards that any one employee may receive, which annual limit was
originally included in large part to comply with the <FONT STYLE="white-space:nowrap">now-discontinued</FONT> performance-based exception to the deductibility limit under Code Section&nbsp;162(m). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Amendment extends the term of the Plan to the tenth (10th) anniversary of the Closing. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Amendment is not approved by Calyxt Stockholders, the Combined Company may not be able to attract and retain the best available
personnel for positions of substantial responsibility. In addition, if the number of shares available for issuance under the Plan is insufficient to meet the Combined Company&#146;s needs, the Combined Company could be forced to increase cash
compensation, which will reduce the resources available to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">209 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Combined Company to meet the rest of its needs. The Calyxt Board has determined the requested number of shares for the Amendment based on the Combined Company&#146;s expected needs for the
foreseeable future, taking into account the dilutive effect of the Mergers on the existing share pool under the Plan and the Combined Company&#146;s intended emphasis on equity compensation as the primary incentive compensation vehicle. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Plan will have a term of ten years following the Closing. If Calyxt Stockholders do not approve the Amendment, the Plan will remain in
effect pursuant to its terms. Similarly, if the Mergers are not consummated, the Plan will remain in effect pursuant to its terms. The key terms of the Plan, as amended by the Amendment, are described in additional detail below. For additional
information about the outstanding awards and shares available for issuance under the Plan, see the table under the header &#147;Equity Compensation Plan Information&#148; below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Summary of Material Terms of the Plan (as Amended by the Amendment) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The actual text of the Plan, as amended by the Amendment, is attached as <I>Annex K</I> to this proxy statement/prospectus. The following
description of the Plan is only a summary of its principal terms and provisions and is qualified by reference to the actual text as set forth in <I>Annex K</I> to this proxy statement/prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Purpose </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of the Plan is to
attract and retain the best available personnel for positions of substantial responsibility, to provide additional incentives to participants, and to promote the success of the Combined Company&#146;s business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Plan Term </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Plan is scheduled to
expire ten years following the Closing. The term will expire sooner if, prior to the end of the <FONT STYLE="white-space:nowrap">ten-year</FONT> term or any extension period, the maximum number of shares available for issuance under the Plan has
been issued or the Cibus, Inc. Board terminates the Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Eligibility </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Employees, consultants, <FONT STYLE="white-space:nowrap">non-employee</FONT> directors (and director nominees) and any other individuals who
provide services to Cibus, Inc. or any of its affiliates are eligible to receive awards under the Plan, if permitted by applicable laws or accounting and tax rules and regulations. As of March&nbsp;31, 2023, there were 25 employees, 4 consultants, 7
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors, and no other service providers eligible to participate in the Plan. The basis for participation in the Plan is being eligible and being selected by the Administrator (as defined below)
to receive a grant thereunder. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Authorized Shares and Award Limits </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to adjustment, 4,900,000 shares of Calyxt Common Stock were originally available for awards to be granted under the Plan (other than
substitute awards; that is, awards that are granted in assumption of, or in substitution for, an outstanding award previously granted by a company or other business acquired by Calyxt, Inc. or with which Calyxt, Inc. combines). As of March&nbsp;31,
2023, the Overall Share Limit (after taking into account the evergreen refresh for the last six years) was 13,675,493 (of which 2,390,326 remained available for future issuance). The Amendment increases the Overall Share Limit to a number of shares
equal to 10% of the total shares outstanding immediately following the Mergers. The Overall Share Limit will continue to be increased on the first day of each Cibus, Inc. fiscal year beginning in 2024, in an amount equal to the lesser of
(i)&nbsp;7.5% of outstanding shares on the last day of the immediately preceding fiscal year and (ii)&nbsp;such number of shares as determined by the Cibus, Inc. Board in its discretion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to adjustment, the maximum number of shares of Class A Common Stock actually issued or transferred by Cibus, Inc. upon the exercise of
incentive stock options will not exceed a number of shares equal to 10% of the total shares outstanding immediately following the Mergers (or, in any event, the Overall Share Limit). The incentive stock option limit will be increased on the first
day of each fiscal year following the Closing by a number of shares equal to 7.5% of the total shares outstanding immediately following the Mergers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">210 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An individual who is a <FONT STYLE="white-space:nowrap">non-employee</FONT> director may not
be granted compensation for such service in any one calendar year having an aggregate maximum grant date fair value in excess of $1,000,000; provided an individual who serves as executive chair and is a
<FONT STYLE="white-space:nowrap">non-employee</FONT> director may not be granted compensation for such service in any one calendar year having an aggregate maximum grant date fair value in excess of $2,000,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an award is forfeited, expires, terminates, or otherwise lapses or is settled for cash, the shares covered by such award will again be
available for issuance under the Plan. In addition, any shares that are retained by Cibus, Inc. upon exercise, vesting or settlement of an award to satisfy (i)&nbsp;the exercise or purchase price for such award or (ii)&nbsp;any withholding
obligations for taxes due with respect to such award shall be available for future grants under the Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Administration </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Cibus, Inc. Board or, to the extent authority is delegated by the Cibus, Inc. Board, its compensation committee or other committee, will
administer the Plan. The Cibus, Inc. Board or, to the extent authority is delegated by the Cibus, Inc. Board, its compensation committee or other committee (in either event, the &#147;Administrator&#148;) will administer the Plan and have the
authority to do the following items (among others): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">determine the fair market value of the common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">select the participants to whom awards may be granted; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approve forms of agreements, amend, or modify outstanding awards or award agreements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">correct any defect, supply any omission, and reconcile any inconsistency in the Plan or any award, in the manner
and to the extent it will deem desirable to carry the Plan into effect; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish, amend, suspend or waive rules and regulations and appoint agents, trustees, brokers, depositories, and
advisors and determine such terms of their engagement as it will deem appropriate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">construe and interpret the terms of the plan, any award agreement and any agreement related to any award; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make any other determination and take any other action that it deems necessary or desirable to administer the
Plan. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent not inconsistent with applicable law, the Administrator may delegate to one or more Cibus, Inc.
officers the authority to grant certain awards under the Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Types of Awards </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Plan provides for grants of incentive and <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock options, stock appreciation rights
(&#147;SARs&#148;), restricted stock, restricted stock units (&#147;RSUs&#148;), performance awards, deferred awards, other share-based awards, and other cash-based awards as described below: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Stock Options</U>. A stock option is a contractual right to purchase shares at a future date at a specified
exercise price. The per share exercise price of a stock option (except in the case of substitute awards) will be determined by the Administrator at the time of grant but may not be less than the fair market value of a share of Class A Common Stock
on the grant date. The Administrator will determine the date on which each stock option becomes vested and exercisable and the expiration date of each option. No stock option will be exercisable more than ten years from the grant date, except that
the Administrator may generally provide for an extension of such <FONT STYLE="white-space:nowrap">ten-year</FONT> term in the event the exercise of the option would be prohibited by law on the expiration date. Stock options that are intended to
qualify as incentive stock options must meet the requirements of Section&nbsp;422 of the Code. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">211 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>SARs</U>. A SAR represents a contractual right to receive, in cash or shares, an amount equal to the
appreciation of one share of Class A Common Stock from the grant date over the exercise or hurdle price of such SAR. The per share exercise price of a SAR (except in the case of substitute awards) will be determined by the Administrator but may not
be less than the fair market value of a share of Class A Common Stock on the grant date. The Administrator will determine the date on which each SAR may be exercised or settled and the expiration date of each SAR. However, no SAR will be exercisable
more than ten years from the grant date. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Restricted Stock</U>. Restricted stock is an award of shares of Class A Common Stock that are subject to
restrictions on transfer and a substantial risk of forfeiture. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>RSUs</U>. An RSU represents a contractual right to receive the value of a share of Class A Common Stock at a
future date, subject to specified vesting and other restrictions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Performance Awards</U>. Performance awards, which may be denominated in cash or shares, will be earned upon
the satisfaction of performance conditions specified by the Administrator. The performance conditions may include, but not be limited to, the following: return measures (including total shareholder return; return on equity; return on assets or net
assets; return on risk-weighted assets; and return on capital (including return on total capital or return on invested capital)); revenues (including total revenue; gross revenue; net revenue; and net sales); income/earnings measures (including
earnings per share; earnings or loss (including earnings before or after interest, taxes, depreciation and amortization); gross income; net income; operating income (before or after taxes); <FONT STYLE="white-space:nowrap">pre-or</FONT> <FONT
STYLE="white-space:nowrap">after-tax</FONT> income or loss (before or after allocation of corporate overhead and bonus); <FONT STYLE="white-space:nowrap">pre-</FONT> or <FONT STYLE="white-space:nowrap">after-tax</FONT> operating income; net
earnings; net income or loss (before or after taxes); operating margin; gross margin; and adjusted net income); expense measures (including expenses; operating efficiencies; and improvement in or attainment of expense levels or working capital
levels (including cash and accounts receivable)); cash flow measures (including cash flow or cash flow per share (before or after dividends); and cash flow return on investment); share price measures (including share price; appreciation in and/or
maintenance of share price; and market capitalization); strategic objectives (including market share; debt reduction; customer growth; employee satisfaction; research and development achievements; mergers and acquisitions; management retention;
dynamic market response; expense reduction initiatives; reductions in costs; risk management; regulatory compliance and achievements; recruiting and maintaining personnel; and business quality); and other measures (including economic value-added
models or equivalent metrics; economic profit added; gross profits; economic profit; comparisons with various stock market indices; financial ratios (including those measuring liquidity, activity, profitability or leverage); cost of capital or
assets under management; and financing and other capital raising transactions (including sales of Cibus, Inc.&#146;s equity or debt securities; factoring transactions; sales or licenses of Cibus, Inc.&#146;s assets, including its intellectual
property, whether in a particular jurisdiction or territory or globally; or through partnering transactions)). These performance criteria may be measured on an absolute (e.g., plan or budget) or relative basis, may be established on a corporate-wide
basis or with respect to one or more business units, divisions, subsidiaries, or business segments, may be based on a ratio or separate calculation of any performance criteria and may be made relative to an index or one or more of the performance
goals themselves. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Deferred Awards</U>. The Administrator is authorized to grant awards denominated in a right to receive shares
of Class A Common Stock or cash on a deferred basis. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Other Share-Based Awards</U>. The Administrator is authorized to grant other share-based awards, which may be
denominated in shares of Class A Common Stock or factors that may influence the value of the Class A Common Stock. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Other Cash-Based Awards</U>. The Administrator is authorized to grant other cash-based awards either
independently or as an element of or supplement to any other award under the Plan. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">212 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Adjustments </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that the Administrator determines that, as result of any stock split, reverse stock split, stock dividend, combination,
consolidation, recapitalization (including a recapitalization through a large nonrecurring cash dividend) or reclassification of the shares, repurchase, exchange or subdivision of the Shares or other securities of the Company, a rights offering, a
reorganization, merger, <FONT STYLE="white-space:nowrap">spin-off,</FONT> <FONT STYLE="white-space:nowrap">split-up,</FONT> change in corporate structure or other similar occurrence, in each case excluding any triggering event, an adjustment is
appropriate to prevent dilution or enlargement of the benefits or potential benefits intended to be made available under the Plan, the Administrator will, subject to compliance with Section&nbsp;409A of the Internal Revenue Code, adjust equitably
any or all of </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number, type and class of shares or other stock or securities available for future awards and covered by each
outstanding award; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the grant, purchase, exercise, or hurdle price covered by each such outstanding award; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any repurchase price per share applicable to shares issued pursuant to any award, or, if deemed appropriate, will
make a provision for a cash payment to the holder of an outstanding award. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Administrator may adjust
the terms and conditions of, and the criteria included in, outstanding awards in recognition of events affecting Cibus, Inc. or the financial statements of Cibus, Inc., or changes in applicable laws, regulations, or accounting principles, whenever
the Administrator determines that such adjustments are appropriate in order to prevent dilution or enlargement of the benefits or potential benefits intended to be made available under the Plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>No Repricing </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as provided in the
Plan&#146;s adjustment provisions, no action will directly or indirectly, through cancellation and regrant or any other method, reduce, or have the effect of reducing, the exercise or hurdle price of any award established at the time of grant
thereof without approval of Cibus, Inc.&#146;s stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Termination of Service and Corporate Transactions </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Administrator will determine the effect of a termination of employment or service on outstanding awards, including whether the awards will
vest, become exercisable, settle, or be forfeited. In the event of a dissolution or liquidation of Cibus, Inc. or a triggering event, except as otherwise provided in the applicable award agreement, the Administrator may provide for: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assumption or substitution with equivalent awards of outstanding awards under the Plan by Cibus, Inc. (if Cibus,
Inc. is the surviving corporation) or by the surviving corporation or its parent or subsidiary; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">termination of outstanding awards under the Plan in exchange for a payment of cash, securities and/or other
property equal to the excess of the fair market value of the portion of the awards stock that is vested and exercisable immediately prior to the consummation of the corporate transaction over the per share exercise price; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any combination of assumption, substitution, or termination of outstanding awards under the Plan as described
above; provided that outstanding awards of stock options and SARs may be cancelled without consideration if the fair market value on the date of the event is greater than the exercise or hurdle price of such award; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acceleration of the vesting (including the lapse of any restrictions, with any performance criteria or conditions
deemed met at target) and exercisability of outstanding award in full prior to the date of the corporate transaction and the expiration of awards not timely exercised by the date determined by the Administrator. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">213 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A triggering event as defined in the plan includes (i)&nbsp;a sale, transfer or disposition
of all or substantially all of Cibus, Inc.&#146;s assets other than to (A)&nbsp;a corporation or other entity of which at least a majority of its combined voting power is owned directly or indirectly by Cibus, Inc., (B)&nbsp;a corporation or other
entity owned directly or indirectly by the holders of capital stock of Cibus, Inc. in substantially the same proportions as their ownership of Shares, or (C)&nbsp;an Excluded Entity (as defined in subsection (ii)&nbsp;below); or (ii)&nbsp;any
merger, consolidation or other business combination transaction of Cibus, Inc. with or into another corporation, entity or person, other than a transaction with or into another corporation, entity or person in which the holders of at least a
majority of the shares of voting capital stock of Cibus, Inc. outstanding immediately prior to such transaction continue to hold (either by such shares remaining outstanding in the continuing entity or by their being converted into shares of voting
capital stock of the surviving entity) a majority of the total voting power represented by the shares of voting capital stock of Cibus, Inc. (or the surviving entity) outstanding immediately after such transaction (an &#147;Excluded Entity&#148;);
or (iii)&nbsp;any direct or indirect purchase or other acquisition by any person or group, other than a parent company or another person that is controlled by a parent company, of more than 50% of the total outstanding equity interests in or voting
securities of Cibus, Inc., excluding any transaction that is determined by the Cibus, Inc. Board in its reasonable discretion to be a bona fide capital raising transaction. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Amendment and Termination </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Cibus,
Inc. Board may amend, alter, suspend, discontinue, or terminate the Plan, but, subject to certain exceptions, no amendment or termination that would materially and adversely affect the rights of any participant under any outstanding award shall be
made without his or her consent. The Administrator may also amend, alter, suspend, discontinue, or terminate, or waive any conditions or rights under, any outstanding award. However, subject to the adjustment provision and corporate transaction
provision, any such action by the Administrator that would materially adversely affect the rights of a holder of an outstanding award may not be taken without the holder&#146;s consent, subject to certain exceptions. Cibus, Inc. will also seek, to
the extent necessary and desirable to comply with applicable laws, the approval of holders of capital stock with respect to any amendment of the Plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>New Plan Benefits </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is not possible to
determine the specific amounts and types of awards that may be awarded in the future under the Plan because the grant and actual settlement of awards under the Plan are subject to the discretion of the Administrator. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Existing Plan Benefits </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since its
inception, the following option and Calyxt RSU grants have been made under the Plan to the persons and categories of persons identified below as of March 31, 2023: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B>Name and Position</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares<BR>Subject to Stock<BR>Options Granted</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;</B><br><B>Calyxt&nbsp;RSUs<BR>Granted <SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael A. Carr, President and Chief Executive Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">690,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,096,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William F. Koschak, Chief Financial Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">566,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">896,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Travis J. Frey, Ph.D., Chief Technology Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">454,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">796,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Debra Frimerman, General Counsel and Corporate Secretary</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">457,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">853,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Executive Officers as a Group</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,167,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,642,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-Executive</FONT> Directors as a Group</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">731,873</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">298,615</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-Executive</FONT> Officer Employees as a Group</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">318,851</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,319,580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">214 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes all Calyxt PSUs granted under the Plan. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The closing price per share of Calyxt Common Stock, as reported on the Nasdaq Stock Market on April&nbsp;17, 2023 was $0.31. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Federal Income Tax Consequences </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following is a brief summary of certain of the federal income tax consequences of certain transactions under the Plan based on federal income tax laws in effect. This summary, which is presented for the information of Calyxt Stockholders considering
how to vote on this proposal and not for Plan participants, is not intended to be complete and does not describe federal taxes other than income taxes (such as Medicare and Social Security taxes), or state, local or foreign tax consequences. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tax Consequences to Participants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>RSUs, Performance Awards, Deferred Awards and Cash-Based Awards</I>. No income generally will be recognized upon the grant of RSUs,
performance awards, deferred awards, or cash-based awards. Upon payment in respect of such awards, the recipient generally will be required to include as taxable ordinary income in the year of receipt an amount equal to the amount of cash received
and the fair market value of any unrestricted shares received (reduced by any amount paid by the recipient). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock</I>. The
recipient of restricted stock generally will be subject to tax at ordinary income rates on the fair market value of the restricted stock (reduced by any amount paid by the recipient) at such time as the restricted stock is no longer subject to a
substantial risk of forfeiture. However, a recipient who so elects under Section&nbsp;83(b) of the Code within 30 days of the date of transfer of the shares will have taxable ordinary income on the date of transfer of the shares equal to the excess
of the fair market value of such shares over any purchase price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Nonqualified Stock Options and SARs</I>. In general: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no income will be recognized by a grantee at the time a <FONT STYLE="white-space:nowrap">non-qualified</FONT>
stock option or SAR is granted; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at the time of exercise of a <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock option or SAR, ordinary
income will be recognized by the grantee in an amount equal to, in the case of a <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock option, the difference between the option price paid for the shares and the fair market value of the
unrestricted shares on the date of exercise and, in the case of a SAR, the amount of cash received, and the fair market value of any unrestricted shares received. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Incentive Stock Options</I>. No income generally will be recognized by an optionee upon the grant or exercise of an &#147;incentive stock
option&#148; as defined in Section&nbsp;422 of the Code, but the exercise may give rise to alternative minimum tax. If shares are issued to the optionee pursuant to the exercise of an incentive stock option, and if no disqualifying disposition of
such shares is made by such optionee within two years after the date of grant or within one year after the transfer of such shares to the optionee, then upon sale of such shares, any amount realized in excess of the option price will be taxed to the
optionee as a long-term capital gain and any loss sustained will be a long-term capital loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If shares acquired upon the exercise of an
incentive stock option are disposed of prior to the expiration of either holding period described above, the optionee generally will recognize ordinary income in the year of disposition in an amount equal to the excess (if any) of the fair market
value of such shares at the time of exercise (or, if less, the amount realized on the disposition of such shares if a sale or exchange) over the exercise price paid for such shares. Any further gain (or loss) realized by the participant generally
will be taxed as short-term or long-term capital gain (or loss) depending on the holding period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">215 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tax Consequences to Cibus, Inc. and its Subsidiaries </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that a participant recognizes ordinary income in the circumstances described above, Cibus, Inc. or the subsidiary for which the
participant performs services will be entitled to a corresponding deduction provided that, among other things, it is not disallowed by the $1&nbsp;million limitation on certain executive compensation under Section&nbsp;162(m) of the Code. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration with the SEC </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus, Inc.
intends to file a Registration Statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> relating to the issuance of shares of Class A Common Stock under the Plan with the SEC pursuant to the Securities Act, as soon as practicable after the
consummation of the Mergers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vote Required </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Amendment to the Calyxt, Inc. 2017 Omnibus Incentive Plan will be approved by the affirmative vote of the majority of the votes cast at the
Calyxt Special Meeting and entitled to vote on the subject matter. Abstentions and broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will have no effect on the outcome of the vote on Proposal No.&nbsp;5. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE CALYXT BOARD UNANIMOUSLY RECOMMENDS A VOTE &#147;FOR&#148; THE APPROVAL OF THE AMENDMENT TO THE CALYXT, INC. 2017 OMNIBUS INCENTIVE
PLAN. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Securities Authorized for Issuance under Equity Compensation Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information related to Calyxt, Inc.&#146;s compensation plans under which shares of Calyxt Common Stock
are authorized for issuance as of December&nbsp;31, 2022: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Plan Category</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(A) <BR>Number of<BR>securities&nbsp;to&nbsp;be<BR>issued upon<BR>exercise of<BR>outstanding<BR>options,<BR>warrants and<BR>rights</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Weighted-average</FONT><BR>exercise price of<BR>outstanding<BR>options, warrants<BR>and rights&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;securities&nbsp;remaining<BR>available&nbsp;for&nbsp;future&nbsp;issuance&nbsp;under<BR>equity compensation plans<BR>(excluding
securities reflected in<BR>column (A))</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans approved by security holders <SUP
STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,600,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,112,568</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans not approved by security holders <SUP
STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">600,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,200,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,112,568</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes the Calyxt, Inc. Equity Incentive Plan (2014 Plan) and the 2017 Omnibus Plan (2017 Plan).
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of stock options, Calyxt RSUs, and Calyxt PSUs. No Calyxt PSUs granted in 2019 are included in these
amounts since none of them were earned. The number of Calyxt PSUs granted in 2022 included in these amounts consists of the maximum number of shares that participants are eligible to receive if applicable performance metrics are fully achieved under
the terms of the outstanding 2022 Calyxt PSUs. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents the weighted average exercise price of stock options outstanding under the 2014 Plan and the 2017
Plan. Does not take into account outstanding Calyxt RSUs and Calyxt PSUs which, when settled, will be settled in shares of Calyxt Common Stock on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis at
no additional cost. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Of these shares, none are available for future issuance from the 2014 Plan and 3,112,568 remain available for
future issuance from the 2017 Plan. The total number of Shares available for issuance under the 2017 Plan will be increased on the first day of each Company fiscal year following the effective date of Calyxt, Inc.&#146;s IPO in an amount equal to
the least of (i)&nbsp;4,900,000 Shares, (ii) 5% of outstanding Shares on the last day of the immediately preceding fiscal year or (iii)&nbsp;such number of Shares as determined by the Calyxt Board in its discretion. All these shares are available
for issuance other than upon exercise of options, warrants, or rights. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">216 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes the Calyxt, Inc. 2021 Employee Inducement Plan (Inducement Plan). In July 2021, Calyxt, Inc. adopted
the Inducement Plan, pursuant to which shares of common stock are issuable upon the settlement of Calyxt PSUs granted to Mr.&nbsp;Michael&nbsp;A. Carr in July 2021 as a material inducement to accept employment as Calyxt, Inc.&#146;s President and
Chief Executive Officer. The Calyxt PSUs will vest if Calyxt, Inc.&#146;s stock remains above three specified price levels for 30 calendar days over the three-year performance period. The Calyxt PSUs will be settled in unrestricted shares of Calyxt
Common Stock on the vesting date. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">217 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom401831_44"></A>Proposal No.&nbsp;6: <FONT STYLE="white-space:nowrap">Non-Binding,</FONT>
Advisory Vote on Merger-Related Named Executive Officer Compensation for Calyxt, Inc.&#146;s Named Executive Officers </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;14A
of the Exchange Act and the applicable SEC rules issued thereunder require that Calyxt, Inc. seek a <FONT STYLE="white-space:nowrap">non-binding,</FONT> advisory vote from Calyxt Stockholders to approve certain compensation that may be paid or
become payable to the Calyxt, Inc. named executive officers in connection with the Transactions, as described in this proxy statement/prospectus in the table titled &#147;<I>Golden Parachute Compensation</I>&#148; under &#147;<I>The
Mergers&#151;Interests of Calyxt, Inc. Directors and Executive Officers in the Mergers</I>&#148; beginning on page 145, and including the accompanying footnotes and related narrative discussion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, Calyxt, Inc. is asking Calyxt Stockholders to vote in favor of the following resolution on a
<FONT STYLE="white-space:nowrap">non-binding,</FONT> advisory basis: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;RESOLVED, that the compensation that may be paid or become
payable to Calyxt, Inc.&#146;s named executive officers that is based on or otherwise relates to the Mergers, and the agreements or understandings pursuant to which such compensation may be paid or become payable, in each case as disclosed pursuant
to Item 402(t) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> in &#145;<I>The Mergers&#151;Interests of Calyxt, Inc. Directors and Executive Officers in the Mergers&#151;Golden Parachute Compensation</I>,&#146; including the footnotes to
the table and the related narrative discussion, are hereby APPROVED.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt Stockholders should note that approval of the
merger-related named executive officer compensation proposal is not a condition to completion of the Mergers, and the vote with respect to the merger-related named executive officer compensation proposal is advisory only and will not be binding on
Calyxt, Inc., the Calyxt Board, or Cibus Global. Further, the underlying plans and arrangements are contractual in nature and not, by their terms, subject to stockholder approval. Accordingly, if Proposal No.&nbsp;1 is adopted by Calyxt Stockholders
and the Mergers are completed, the merger-related compensation will be payable to Calyxt, Inc.&#146;s named executive officers, subject only to the conditions applicable thereto, regardless of the outcome of the vote on the merger-related named
executive officer compensation proposal. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Vote Required </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The affirmative vote of a majority in voting power of the votes cast affirmatively or negatively by the holders of Calyxt Common Stock present
or represented by proxy at the Calyxt Special Meeting and entitled to vote on the matter is required for approval of Proposal No.&nbsp;6. Abstentions and broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will have no effect on Proposal
No.&nbsp;6. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recommendation of Calyxt Board </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THE CALYXT BOARD UNANIMOUSLY RECOMMENDS THAT CALYXT STOCKHOLDERS VOTE &#147;FOR&#148; PROPOSAL NO. 6 TO APPROVE ON A <FONT
STYLE="white-space:nowrap">NON-BINDING,</FONT> ADVISORY BASIS, THE MERGER-RELATED NAMED EXECUTIVE OFFICER COMPENSATION DESCRIBED IN THIS PROXY STATEMENT/PROSPECTUS. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">218 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom401831_45"></A>Proposal No.&nbsp;7: Approval of possible adjournment of the Calyxt Special
Meeting </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the Calyxt Special Meeting, Calyxt Stockholders will be asked to consider and vote upon a proposal to approve one or more
adjournments of the Calyxt Special Meeting, if necessary or appropriate, to solicit additional proxies if there are not sufficient votes in favor of one or more of the proposals presented to Calyxt Stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the number of shares of Calyxt Common Stock present or represented by proxy at the Calyxt Special Meeting voting in favor of one or more of
the proposals presented to Calyxt Stockholders is insufficient to approve such proposal at the time of the Calyxt Special Meeting, then Calyxt, Inc. may move to adjourn the Calyxt Special Meeting in order to enable the Calyxt Board to solicit
additional proxies in respect of such proposals. In that event, Calyxt Stockholders will be asked to vote only upon the adjournment proposal, Proposal No.&nbsp;7, and not on any other proposal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt, Inc. currently does not intend to propose adjournment at the Calyxt Special Meeting if there are sufficient votes to approve each of
the proposals presented to Calyxt Stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Vote Required </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The affirmative vote of a majority in voting power of the votes cast affirmatively or negatively by the holders of Calyxt Common Stock present
or represented by proxy at the Calyxt Special Meeting and entitled to vote on the matter is required for approval of Proposal No.&nbsp;7. Abstentions will have no effect on Proposal No.&nbsp;7. Because Proposal No.&nbsp;7 is considered a routine
matter, it is expected that there would not be any broker <FONT STYLE="white-space:nowrap">non-votes.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recommendation of Calyxt Board
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THE CALYXT BOARD UNANIMOUSLY RECOMMENDS THAT CALYXT STOCKHOLDERS VOTE &#147;FOR&#148; PROPOSAL NO. 7 TO APPROVE THE ADJOURNMENT
OF THE CALYXT SPECIAL MEETING, IF NECESSARY OR APPROPRIATE, TO SOLICIT ADDITIONAL PROXIES IF THERE ARE NOT SUFFICIENT VOTES IN FAVOR OF ONE OR MORE OF THE PROPOSALS PRESENTED TO CALYXT STOCKHOLDERS. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">219 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom401831_46"></A>CALYXT BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt, Inc. was
founded in 2010 and incorporated in Delaware. Calyxt is a plant-based synthetic biology company. Calyxt leverages its proprietary PlantSpring<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> technology platform to engineer plant metabolism to
produce innovative, high-value and sustainable materials and products for use in helping customers meet their sustainability targets and financial goals. Calyxt&#146;s primary focus and commercialization strategy is on engineering synthetic biology
solutions through its PlantSpring technology platform for manufacture using its proprietary and differentiated BioFactory<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> production system for a diverse base of target customers across a
range of end markets, including the cosmeceutical, nutraceutical, and pharmaceutical industries. Calyxt also commercializes its PlantSpring technology platform by licensing elements of the platform and historically developed traditional agriculture
seed-trait product candidates, as well as selectively developing product candidates for customers in traditional agriculture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
production of Calyxt&#146;s plant-based chemistries occurs in its proprietary BioFactory<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> production system. This strategic initiative was announced in October 2021. In the context of
Calyxt&#146;s PlantSpring technology platform and BioFactory production system, the term &#147;sustainable&#148;, as used in this proxy statement/prospectus, refers to the plant-based chemistry production methods that use plant biomass as a raw
material and are therefore renewable and do not completely use up or destroy natural resources. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt also <FONT
STYLE="white-space:nowrap">out-licenses</FONT> elements of the PlantSpring technology platform, has historically developed seed-trait product candidates for the traditional agriculture market, and may selectively develop products for customers in
traditional agriculture. For example, in the third quarter of 2021, Calyxt announced it had entered into a research collaboration with a global food ingredient manufacturer based in Asia to develop an improved soybean capable of producing oil that
would serve as a commercial alternative to palm oil. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt was previously focused on the development of traits for traditional
agriculture that it planned to commercialize using either a vertically integrated or licensing business model. Calyxt&#146;s first commercial product, a high oleic soybean, was launched in this manner in the first quarter of 2019. In August 2020,
Calyxt announced it was winding down the vertically integrated soybean product line. The wind-down of this product line was completed in late 2021 with the final sales of soybean grain to a large soybean processor. Calyxt&#146;s second product, an
improved digestibility alfalfa, was developed with and licensed to S&amp;W Seed Company (S&amp;W). S&amp;W is pursuing regulatory clearance for their product candidate and is targeting commercialization in 2023 at which time Calyxt expects to begin
to receive initial royalty payments. Calyxt intends to use this licensing strategy for other historically developed, traditional agriculture seed-trait product candidates.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt has historically operated in a single segment primarily within the United States and its assets are located within the United
States.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to its initial public offering (IPO) on July&nbsp;25, 2017, Calyxt was a wholly owned subsidiary of Cellectis S.A.
(Cellectis). As of December&nbsp;31, 2022, Cellectis owned 49.1% of issued and outstanding Calyxt Common Stock. Cellectis has certain contractual rights as well as rights pursuant to the Calyxt Certificate of Incorporation and Calyxt Bylaws, in each
case, for so long as it maintains threshold beneficial ownership levels in Calyxt, Inc.&#146;s shares. See &#147;<I>Risk Factors&#151;Risks Related to Calyxt&#151;Risks Related to Ownership of Calyxt Common Stock if the Mergers Are Not
Completed&#151;</I><I>If</I><I> </I><I>the</I><I> </I><I>Mergers</I><I> </I><I>do</I><I> </I><I>not</I><I> </I><I>close</I><I> </I><I>for</I><I> </I><I>any</I><I> </I><I>reason,</I><I> </I><I>Cellectis</I><I> </I><I>will</I><I>
</I><I>continue</I><I> </I><I>to</I><I> </I><I>possess</I><I> </I><I>rights</I><I> </I><I>that</I><I> </I><I>prevent</I><I> </I><I>other stockholders</I><I> </I><I>from</I><I> </I><I>influencing</I><I> </I><I>significant</I><I>
</I><I>decisions.</I>&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September 22, 2022, Calyxt announced that the Calyxt Board had begun evaluating potential strategic
alternatives to maximize shareholder value, including financing alternatives, merger, reverse merger, other business combinations, sale of assets, licensing, or other transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January 13, 2023, Calyxt and Merger Subsidiary entered into the Merger Agreement with Cibus Global and certain other parties thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">220 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Merger Agreement, following the Transactions, Calyxt will be organized in an
&#147;Up-C&#148; structure and re-named &#147;Cibus, Inc.&#148; and its only material asset will consist of common units of Cibus Global. If the Transactions are completed, the business of Cibus will continue as the primary business of the Combined
Company and the equity holders of Cibus Global will own a substantial majority of the issued and outstanding Calyxt Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Closing is subject to the approval of Calyxt Stockholders, the approval of Cibus Global&#146;s members, the receipt of required regulatory approvals (to the extent applicable) and satisfaction of other customary closing conditions. The Closing is
currently expected to occur in the second quarter of 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Transactions, beginning at the earlier of March 15,
2023 and the date Calyxt&#146;s unrestricted cash balance first drops below $1,500,000, Calyxt, Inc. can request, and Cibus Global has agreed to provide, an unsecured, interest-free revolving line of credit of up to $3,000,000 in cash, which amount
may be increased to $4,000,000 if Cibus elects to extend the Outside Date to June 30, 2023. Funds can be drawn by Calyxt in $500,000 increments and may only be used to fund operating expenses incurred in the ordinary course of business consistent
with past practice and consistent with the negative covenants in the Merger Agreement. The full outstanding balance of the Interim Funding will be reduced to zero in connection with the Closing, if the Transactions are consummated. The full
outstanding balance of the Interim Funding will be forgiven by Cibus Global if the Merger Agreement is terminated for any reason other than certain under certain conditions, as detailed in the Merger Agreement. The Interim Funding is subject to
acceleration in connection with certain bankruptcy events. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of Calyxt&#146;s substantially narrowed operational focus and in
light of the available Interim Funding from Cibus Global in connection with the proposed Transactions, Calyxt believes it has sufficient cash to fund operations through the end of the second quarter of 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If, for any reason, the Transactions are not completed, Calyxt will reconsider its available alternatives at such time and could pursue one of
the following courses of action, which Calyxt currently believes to be the most likely alternatives: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Dissolve and liquidate</I>. Calyxt may decide to dissolve and liquidate its assets. In such a circumstance,
Calyxt would be required to pay all of its debts and contractual obligations and to set aside certain reserves for potential future claims. In light of Calyxt&#146;s current capital resources, it is highly unlikely, in this case, that substantial
resources, if any, would be available for distributions to stockholders. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Pursue another strategic transaction</I>. Calyxt may decide to resume the process of evaluating a potential
merger, reorganization or other business combination transaction or to sell or otherwise dispose of certain of Calyxt&#146;s assets. Any of these alternatives would be costly and time-consuming and would require that Calyxt obtain additional
near-term funding in parallel to, or as part of, such a strategic transaction. Calyxt expects that it would be difficult to secure such funding in a timely manner, on favorable terms or at all. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Operate the business</I>. Although substantially less likely than the alternatives above, the Calyxt Board
could elect to seek to continue to operate Calyxt&#146;s business. This alternative would require that Calyxt obtain additional near-term funding, which Calyxt expects would be difficult to secure in a timely manner, on favorable terms or at all. If
pursued, Calyxt would likely need to significantly delay or further scale back operations beyond its already narrowly focused operational activities. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Current Operational Focus </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior
to the announcement of the Transactions, Calyxt&#146;s primary focus was on the development of synthetic biology products for its customers using its PlantSpring technology to develop various plant-based chemistries for production in its proprietary
BioFactory production system. In light of the proposed Transactions and recent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">221 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
capital resource constraints, Calyxt has substantially scaled back its operations and has focused its current business activities on ensuring it has cash sufficient to achieve a closing of the
proposed Transactions. Accordingly, Calyxt&#146;s management has implemented cost reduction and other cash-focused measures, including reduction of headcount, reductions of capital expenditures, and renegotiation or termination of professional
services agreements. To conserve cash, Calyxt has also strategically evaluated its arrangements with suppliers and service providers and has, in several instances, transitioned such relationships to lower cost alternative providers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In limiting operations to core activities, Calyxt has focused its continuing operations on </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">scaling production of a single Plant Cell MatrixTM (PCMTM) structures with its manufacturing partner, Evologic;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">licensing efforts with respect to its PlantSpring technology and plant traits, including the TALEN<SUP
STYLE="font-size:75%; vertical-align:top">&#153;</SUP> technology; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continuing to progress its three current customer projects&#151;(1) its research collaboration with a leading
global food ingredient manufacturer to develop a soybean trait to serve as an alternative to palm oil, (2) its plant-based chemistry pilot project for a major consumer packaged goods company, and (3) supporting late-stage development activities for
its improved digestibility alfalfa trait, which was developed with and licensed to S&amp;W Seed Company. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt has
suspended non-core activities, such as efforts toward the development and integration of AIML capabilities and the initiation, development and commercialization of additional synthetic biology products, or chemistries, beyond those involved in the
continuing operations identified above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The PlantSpring Technology Platform and Calyxt&#146;s Development Process </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The PlantSpring technology platform is founded on Calyxt&#146;s more than a decade of experience engineering plant metabolism and incorporates
its scientific knowledge and its proprietary systems, tools and technologies. PlantSpring also has the potential to incorporate AIML capabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">PlantSpring offers the potential to unleash the natural capabilities of plants&#151;the original biological systems&#151;and make available
commercial innovations that produce unique plant-based chemistries from plant species, including rare or undomesticated species, in a manner that Calyxt believes is more robust and sustainable than other methods of production. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Plants naturally produce many chemistries that may be valuable inputs for end products. Of the approximately 170,000 known and classified
compounds derived from plants, bacteria, and fungi, approximately 78&nbsp;percent are derived from plants. Moreover, some estimates suggest that there may be up to one million additional chemical compounds yet to be discovered.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, the yield of plant-based chemistries that occurs naturally may be insufficient for commercialization using traditional production
methods, the plant that produces the chemistry may be scarce in nature or difficult to harvest, or there may be a socioeconomic concern with the harvest of the plant producing the chemistry. Additionally, the quality or quantity of a natural plant
chemistry may be inconsistent, varying considerably over each variety, harvest, or field, and can be impacted by different contaminants in the soil where grown. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In PlantSpring, Calyxt identifies metabolic pathways to produce plant-based chemistries, designs strategies to reprogram host cells, engineers
plant cell metabolism to optimally produce targeted compounds or plant traits.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt uses an efficient development process to deliver
innovation through the PlantSpring technology platform, leveraging its extensive knowledge of plants and their metabolism when developing a plant-based </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">222 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
chemistry or plant trait. Calyxt&#146;s synthetic biology product development process is comprised of three primary stages: Design, Engineer, and Verify, and activities within each stage are as
follows:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Design</B> &#150; identify metabolic pathways to produce the target compound and the genes controlling these
pathways, develop strategies for the optimized expression of the target genes, and design the technical approach to achieve the production of the targeted compound or trait. A metabolic pathway is a linked series of chemical reactions occurring
within a cell. The reactants, products, and intermediates of an enzymatic reaction are known as metabolites, which are modified by a sequence of chemical reactions catalyzed by enzymes. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Engineer</B> &#150; direct changes in the plant cells using one or more&nbsp;genetic transformation and plant
tissue culture techniques, and enhancements of genes in that plant species. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Verify</B> &#150; use a combination of analytical tools to verify the compound or trait produced against the
intended specification. The analytical tools used include natural product chemistry, metabolomics, genomics, gene expression tools, and other analytics. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The typical timeline to complete the Design-Engineer-Verify process is currently estimated at 12 months. Calyxt is in the process of scaling
plant-based chemistry production beyond the laboratory with its third-party manufacturing partner, Evologic.</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commercialization Strategies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt contemplates three commercialization strategies for its PlantSpring technology platform: (i)&nbsp;the development and sale of high-value
synthetic biology products from Calyxt&#146;s proprietary BioFactory production system, (ii)&nbsp;the licensing of elements of the PlantSpring technology platform and historically developed, traditional agriculture seed-trait product candidates, and
(iii)&nbsp;selective product development for customers in traditional agriculture. In light of Calyxt&#146;s capital resource constraints, the implementation of these strategies has been limited to implementation of the core activities described
under &#147;&#151;<I>Current Operational Focus</I>.&#148;</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The BioFactory Production System </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The BioFactory production system is a bioreactor-based production system that is designed to be capable of continuous production of plant-based
chemistries. The bioreactor can be of any size depending upon factors including yield and titer necessary to reach the required commercial scale. For production, multicellular PCM<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> structures are
placed inside the bioreactor, and growth media provides the PCM structures with nutrition. A PCM structure is a living system of various cell types, which is designed to emulate the intercellular metabolism of an entire plant, that grows over time
and produces and stores, or excretes, the target chemistries. The growth media&nbsp;is the feedstock of the BioFactory production system and contains the essential inputs to support growth of the PCM structures and necessary chemistry production.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2022, Calyxt signed an agreement with an infrastructure partner, Evologic. Under the terms of the agreement, Evologic will work
alongside Calyxt to grow and scale Calyxt&#146;s proprietary PCM structures and is currently scaling one PCM for Calyxt. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In combination
with Calyxt&#146;s Design-Engineer-Verify stages of the development process, Calyxt estimates that the timeline to achieve commercial availability of a potential product is currently approximately 36 months, subject to potential regulatory
extensions for certain industries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, Calyxt believes that in combination its PlantSpring technology platform and its
BioFactory production system are capable of unlocking the power of plants to produce high value and complex plant-based chemistries and plant traits that are finite, are difficult to source sustainably, and may not be able to be produced through
other production systems or cannot be produced as efficiently in single cell plant culture systems.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">223 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Technology Licensing&nbsp;&amp; Product Development for Agriculture </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt maintains the capability to implement broad technology licensing arrangements and to selectively develop agricultural products.
Potential commercial opportunities include the licensing of elements of the PlantSpring technology platform as well as historically developed, traditional agriculture seed-trait product candidates.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to licensing opportunities for select elements of the PlantSpring technology platform, the opportunities span Calyxt&#146;s
intellectual property portfolio built for more than a decade as a leading plant-based biotechnology company, including multiple gene editing platforms, plant breeding, and other capabilities. Calyxt&#146;s PlantSpring technology platform has been
utilized to drive industry-leading modernization of the hemp species, including improved characteristics for protein and oil production and use in advanced materials. Hemp can also contribute to enhancing a wide variety of materials, including
strengthening plastics, reducing petroleum-based content, and providing greater strength and longevity compared to other plant-based fabrics like linen or cotton. Calyxt has successfully transformed the hemp genome and also has produced
&#147;pollen-proof&#148; (seedless) hemp with its triploid breeding technology. Combined, Calyxt&#146;s hemp advancements offer significant potential advantages in innovation, crop management, and harvest yield. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additional technology-licensing activity may also continue in connection with the licensing of historically developed, traditional agriculture
seed-trait product candidates, including soybeans with improved fatty-acid profiles; an improved digestibility alfalfa, which has been licensed for commercialization to S&amp;W; wheat with a higher fiber content than traditionally bred varieties,
and its second generation soybean product, which has an improved fatty acid profile compared to commodity soybeans and Calyxt&#146;s initial soybean product launched in 2019. Among Calyxt&#146;s other development successes are a soybean with
improved flavor to help enable wider adoption for plant-based protein applications and controlling the production of storage sugars in potatoes to improve fry quality and reduce acrylamide. While Calyxt will pursue licensing opportunities for these
product candidates, it does not intend to invest in further development until specific licensee customers are contracted with.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
potential to opportunistically develop seed-trait product candidates for customers focused on traditional outdoor agriculture market also remains. In 2021, Calyxt entered into a research collaboration with a global food ingredient manufacturer based
in Asia to develop an improved soybean capable of producing an oil that would serve as a commercial alternative to palm oil. The food ingredient manufacturer is funding Calyxt&#146;s development costs over the term of the agreement and holds an
option for future development and commercialization. Calyxt achieved the first $100,000 milestone payment in the fourth quarter of 2022, with the overall project scheduled for completion in the first quarter of 2024, at which time the second
milestone payment of $100,000 would be due. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To manage prioritization of resources and to drive returns on its investment, Calyxt has
developed a set of criteria by which all agricultural seed trait licensing and seed trait development opportunities are evaluated, which include the size of the overall opportunity, the nature of the product to be developed, and the amount of cash
it expects to receive both up front and over time. At present, no new investments are being made in light of the limited implementation of Calyxt&#146;s core activities described under &#147;&#151;<I>Current Operational Focus</I>.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Research and Development</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt&#146;s
proprietary technologies and intellectual property portfolio are focused on the PlantSpring technology platform, the BioFactory production system, TALEN, and other adjacent technologies, data analytics, plant breeding, systems, and work
processes.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt&#146;s R&amp;D team has technical expertise primarily in biochemistry, bioinformatics, chemistry, genetics and genetic
engineering, molecular biology, plant physiology, tissue culture techniques, and other related fields. Calyxt&#146;s R&amp;D activities are conducted principally at its Minnesota facility. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Historically, Calyxt&#146;s R&amp;D cash usage has included investments in the development, enhancement and deployment of AIML capabilities,
expenses to continue to enhance the capabilities of its PlantSpring technology </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">224 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
platform and BioFactory production system, and various expenses and capital expenditures to expand its BioFactory production system from lab through various pilot vessel sizes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In light of Calyxt&#146;s capital resource constraints, it has limited R&amp;D cash usage. Calyxt&#146;s current R&amp;D cash usage primarily
consists of expenses to continue to scaling production of a single PCM structure with its manufacturing partner, Evologic. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt has
made substantial investments in R&amp;D. For more information on R&amp;D expenses, see Calyxt&#146;s consolidated financial statements and related notes starting on page <FONT STYLE="white-space:nowrap">F-4.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Market and Industry Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt
believes that its technology platforms have the potential to revolutionize how the world uses plants, providing innovation opportunities in the space where customers&#146; needs to consume finite resources and their enhanced focus on the
sustainability of the planet intersect. The global economy today faces numerous sustainability challenges, as evidenced by metrics such as carbon pollution, water scarcity, and soil erosion. To address their sustainability goals, many companies must
produce products differently, and plant&#150;based chemistries represent a differentiated and a more sustainable alternative to many products and materials in use today. More than 20&nbsp;percent of the world&#146;s 2,000 largest public companies
have committed to carbon-neutrality, supporting a shift to plant-based solutions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The synthetic biology industry has expanded
significantly over the past several years. New companies are being formed, investment capital is being deployed, and the number of public exits for once-private synthetic biology companies have accelerated. Companies within this group are pursuing
novel methods of production to replace current approaches to the production of various compounds or products. Examples of such compounds include plant-based proteins, colorants, advanced materials, pharma-grade products (such as vaccine adjuvants
and antibiotics), and many others. Calyxt believes it is the only company in the synthetic biology industry that has exclusively used plants as its core innovation species, with most competitors focused on single-cell organisms including yeast,
bacteria (such as e coli), and algae.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt believes that potential end markets for plant-based sustainable solutions are broad and
diverse because plant-based synthetic biology can be used to produce compounds and products with many desirable sustainability features. These end markets include the cosmeceutical, nutraceutical, and pharmaceutical industries. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Intellectual
property protection is key to Calyxt. As of December&nbsp;31, 2022, Calyxt&#146;s patent estate is composed of patents and patent applications owned by Calyxt and <FONT STYLE="white-space:nowrap">in-licensed</FONT> from other parties. Most of the <FONT
STYLE="white-space:nowrap">in-licensed</FONT> patents and patent applications are licensed from Cellectis or the University of Minnesota. The license from Cellectis includes technologies invented at Cellectis, technologies invented by Calyxt when it
was a wholly owned subsidiary of Cellectis, and technologies licensed to Cellectis from third parties. Calyxt also has access to additional patents and patent applications through <FONT STYLE="white-space:nowrap">in-licensing</FONT> agreements with
other research institutions and universities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt&#146;s patent portfolio is categorized into three major platforms: PlantSpring,
BioFactory and other products, and Licensing. Some patents and patent applications are applicable to multiple platforms, and as such are included in multiple categories. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The PlantSpring platform elements of Calyxt&#146;s patent portfolio is intellectual property used with its PlantSpring platform and includes
gene-editing technologies and hemp breeding technologies. This portion of Calyxt&#146;s patent portfolio includes more than 160 patents and patent applications worldwide.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The BioFactory and products platform elements of Calyxt&#146;s patent portfolio includes outputs from its BioFactory, gene edited crops, and
its PCM structures. This portion of Calyxt&#146;s patent portfolio includes approximately 45 patents and patent applications worldwide. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">225 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The technologies available for licensing within Calyxt&#146;s patent portfolio includes <FONT
STYLE="white-space:nowrap">in-licensed</FONT> technology and Calyxt-originated IP, and includes gene-editing technologies (<I>e.g.,</I> TALEN<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>), gene-edited traits for agriculture, and hemp
breeding technologies. This portion of Calyxt&#146;s patent portfolio includes approximately 490 patents and patent applications worldwide.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt is actively involved in the prosecution and protection of its technology. Calyxt&#146;s global patent portfolio includes 67 patent
families comprised of 369 patents and 113 patent applications. Of those patents, 47&nbsp;have been issued in the United States, with the remaining issued in key geographies outside the United States, primarily Europe, Japan, and China. This number
also includes European patents validated in individual European countries. Of those patent applications, 26 are pending in the United States, with the remaining pending as international applications or country-specific applications in key
geographies outside the United States.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Individual patent terms extend for varying periods of time, depending upon the date of filing of
the patent application, the date of patent issuance, and the legal term of patents in the countries in which they are obtained. The issued patents that Calyxt has licensed in will expire on dates ranging from 2023 to 2037. If patents are issued on
the pending patent applications owned by Calyxt or that it has <FONT STYLE="white-space:nowrap">in-licensed,</FONT> the resulting patents are projected to expire on dates ranging from 2023 to 2043. Calyxt does not believe that the expiration of any
patents expected to occur during 2023 would have a material effect on Calyxt&#146;s business, including any impact on its future operations and financial position. For more information regarding the risks related to Calyxt&#146;s intellectual
property, please see &#147;<I>Risk Factors&#151;Risks Related to Calyxt&#151;Risks Related to Calyxt&#146;s Intellectual Property</I>.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>License Agreement with Cellectis </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Through its license agreement with Cellectis, Calyxt has access to intellectual property that broadly covers the use of engineered nucleases
for plant gene editing. This intellectual property covers methods to edit plant genes using &#147;chimeric restriction endonucleases,&#148; which include TALEN, CRISPR/Cas9, zinc finger nucleases, and some types of meganucleases. Calyxt believes
this umbrella intellectual property applies broadly across gene editing in plants and makes this license an important element in the gene editing intellectual property space. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under its license agreement with Cellectis, Calyxt has exclusive sublicense rights (subject to existing
<FONT STYLE="white-space:nowrap">non-exclusive</FONT> sublicenses to third parties) to intellectual property exclusively licensed to Cellectis from the University of Minnesota in the field of researching, developing, and commercializing agricultural
and food products, including traits, seeds, and feed and food ingredients (excluding any application in connection with animals or animal cells). These patent applications cover the use of DNA replicons for gene editing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt has also been granted a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license to use the TALEN trademark in connection with its
use of licensed products under the agreement. Any improvements it makes to the <FONT STYLE="white-space:nowrap">in-licensed</FONT> intellectual property are owned by Calyxt and licensed back to Cellectis on an exclusive basis for any use outside of
its exclusive agricultural field of use. The exclusivity of Calyxt&#146;s license agreement with Cellectis is subject to certain <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses Cellectis granted to third parties in the field of
research. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration for the license from Cellectis, Calyxt is required to pay to Cellectis, on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">product-by-product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, a royalty of three percent of net sales less certain items as defined,
including costs for grain and seed of any products that are covered by the patents licensed from Cellectis. In addition, Calyxt is required to pay Cellectis 30&nbsp;percent of revenue it receives for sublicensing its rights under the agreement to
third parties. Calyxt&#146;s payment obligations to Cellectis will expire upon the expiration of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> valid claim of the patents licensed to Calyxt by
Cellectis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Calyxt&#146;s license agreement with Cellectis, and as between the parties, Cellectis has the first right to control the
prosecution, maintenance, defense and enforcement of the licensed intellectual property and Calyxt will have the right to step in and assume such control with respect to the patents owned by Cellectis and exclusively licensed to it under the
agreement if Cellectis elects to not prosecute, maintain, defend, or enforce </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">226 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such patents. In certain circumstances, if Cellectis elects to abandon any patents owned by Cellectis and exclusively licensed to Calyxt under the agreement, it has the right to assume ownership
of such patents. In addition, some of the intellectual property that is licensed to Calyxt by Cellectis consists of a sublicense of intellectual property originally licensed to Cellectis by the University of Minnesota. Calyxt&#146;s license from
Cellectis is subject to the license agreement between the University of Minnesota and Cellectis and should its activities under such sublicense violate the license agreement between Cellectis and the University of Minnesota, Calyxt is responsible
for any related damages that Cellectis may incur. In addition, Calyxt is required to reimburse Cellectis for any payments made by Cellectis to the University of Minnesota pursuant to the license agreement between the University of Minnesota and
Cellectis to the extent that such payments are required to be made as a result of its applicable activities. Under the license agreement between Cellectis and the University of Minnesota, the University of Minnesota has the first right to control
the prosecution and maintenance of the licensed intellectual property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt&#146;s license agreement with Cellectis is perpetual.
However, the agreement may be terminated at any time upon the mutual written agreement of both parties, either party&#146;s uncured material breach of the agreement, or upon certain bankruptcy and insolvency related events. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>License Agreement between Cellectis and Regents of the University of Minnesota&#151;TALEN</I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2011, Cellectis entered into an exclusive license agreement with the University of Minnesota, which was amended in 2012, 2014 and
2015. Pursuant to the agreement, as amended, Cellectis and its affiliates were granted an exclusive, worldwide, royalty-bearing, sublicensable license, under certain patents and patent applications owned by the University of Minnesota, to make, use,
sell, import, and otherwise dispose of products covered by the licensed patents, in all fields of use. These licensed patents relate to TALEN molecules and their use in gene editing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the agreement, with respect to the agricultural field, Cellectis is required to pay to the University of Minnesota an annual fee,
as well as a commercialization fee for every seed variety containing new traits developed using the licensed technology. Cellectis is also required to pay the University of Minnesota milestone payments based on the net sales of licensed products in
the agricultural field. Cellectis must also pay the University of Minnesota certain patent-related expenses for prosecuting and maintaining the licensed patents; and under Calyxt&#146;s license agreement with Cellectis, it is obligated to reimburse
Cellectis for these prosecution costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The agreement will expire upon the expiration of the last to expire valid claim of the licensed
patents. The University of Minnesota may terminate the agreement upon advance written notice in the event of the insolvency or bankruptcy of Cellectis, and immediately upon written notice if Cellectis challenges the validity or enforceability of any
licensed patent in a court or other applicable authority. Cellectis and the University of Minnesota may terminate the agreement by written notice in the event of the other party&#146;s breach that has not been cured within a specified number of days
after receiving notice of such breach. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Trademarks </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, Calyxt had four registered trademarks in the United States. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Government Regulation and Product Compliance </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt&#146;s PlantSpring technology platform and its BioFactory production system operate in contained environments without the need for
outdoor cropping systems. Any regulated materials used under this process, such as specific bacteria, are therefore subject to well-defined regulations in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt&#146;s development and production processes involve the use, generation, handling, storage, transportation and disposal of hazardous
chemicals and regulated biological materials. Calyxt is subject to a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">227 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
variety of federal, state, and local laws, regulations and permit requirements governing the use, generation, manufacture, transportation, storage, handling and disposal of these materials in the
United States. In the future, to the extent Calyxt may operate or sell its products outside the United States, Calyxt would be subject to corresponding international laws and regulations. These laws, regulations and permits can require expensive
fees, exposure or pollution control equipment or operational changes to limit actual or potential impact of Calyxt&#146;s technology on the environment and violation of these laws could result in significant fines, civil sanctions, permit revocation
or costs from environmental remediation. Future developments, including the commencement of or changes in the processes relating to commercial manufacturing of one or more of Calyxt&#146;s products, more stringent environmental regulation, policies
and enforcement, the implementation of new laws and regulations or the discovery of unknown environmental conditions, may require expenditures that could have a material adverse effect on Calyxt&#146;s business, results of operations or financial
condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Hemp, as defined in the 2018 Farm Bill as Cannabis sativa containing a <FONT STYLE="white-space:nowrap">delta-9</FONT>
tetrahydrocannabinol (THC) concentration of not more than 0.3&nbsp;percent on a dry weight basis, has been removed from the United States Federal Controlled Substances Act and is legally distinct from marijuana/cannabis, which is Cannabis sativa
containing a THC concentration of more than 0.3&nbsp;percent on a dry weight basis. Hemp is recognized as an agricultural crop by the United States federal government. Federal and state laws and regulations on hemp address production, monitoring,
manufacturing, distribution, and laboratory testing to ensure that that the hemp has a THC concentration of not more than 0.3&nbsp;percent on a dry weight basis. Federal laws and regulations also address the transportation or shipment of hemp or
hemp products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Consistent with the 2018 Farm Bill, the Minnesota Department of Agriculture (MDA) operates a Hemp Program under its USDA
approved Minnesota state plan. This plan establishes that a commercial hemp production license is required for growing and processing of hemp in the State of Minnesota. Calyxt holds an MDA Hemp Program License and has implemented an internal hemp
compliance system including procedures, quality control and internal audits. USDA and/or MDA may audit Calyxt at any time for compliance with license requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, Calyxt has obtained USDA permits for specific regulated materials (e.g., bacteria) that are used as part of its PlantSpring
technology platform and BioFactory production system. Calyxt has implemented the required compliance system in order to meet USDA permit conditions and ensure adequate documentation is in place. The USDA may audit Calyxt at any time for compliance
with permit requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The BioFactory production system has the capability of producing a diverse range of plant-derived compounds
that may be used for applications in cosmeceuticals, nutraceuticals, pharmaceuticals, and more. As Calyxt delivers these valuable compounds to its customers, each customer will be responsible for determining for which applications the compounds are
utilized and such customer-determined specific uses will determine applicable regulatory requirements. It is anticipated that because Calyxt&#146;s customers would incorporate the purchased compounds into their existing product development processes
and areas of applications, the customers will be best positioned to apply their specific expertise in the field to establish regulatory compliance and determine any additional requirements.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt also expects to continue to license its technology and develop seed traits for agricultural customers based on their needs. This would
include the use of gene editing in crops for outdoor use. Neither Calyxt, nor its commercial partners, currently deploy Calyxt&#146;s technology for use outside of the United States with the exception of Calyxt&#146;s High Oleic Soybean product,
which in addition to having clearance from the USDA and FDA, also has clearance from the Canadian Food Inspection Agency and Health Canada for use in Canada. In today&#146;s global market, overall business development strategy for plant biology
companies depends, in part, on the availability of regulatory clearance in strategic export markets, which enables broader flexibility for product expansion and is a key consideration in evaluating global trade opportunities. Regulatory
predictability is critical in order to establish accurate product launch strategies. The costs of achieving clearance in foreign countries is often high, due to stricter regulatory environments than the United States, and there can be no assurance
Calyxt will be granted clearance on favorable terms, if at all. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">228 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Calyxt&#146;s partner-driven model, agricultural customers would likely be
contractually responsible for obtaining the needed global regulatory clearance for agricultural products developed by Calyxt or using its licensed technology. Accordingly, outside of permitting expenses incurred in the ordinary course of business,
Calyxt does not expect compliance with government regulations, including environmental regulations, to have a material effect on Calyxt&#146;s capital expenditures, earnings, or competitive position. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The market for more
sustainably produced products is highly competitive. Competition in synthetic biology is largely from fermentation-based companies who generally pursue the development of compounds by combining a single cell organism like a microbe, bacteria, or
yeast with another organism&#146;s DNA to achieve a desired result. These compounds are then marketed by third parties or directly by the fermentation company. These organizations may have substantially larger budgets for R&amp;D, product
commercialization, and regulatory process management and greater available capital resources. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Through its technology licensing, Calyxt
believes that it faces competition from large agricultural biotechnology, seed, and chemical companies, certain of which have been actively involved in new trait discovery, development, and commercialization. Many of Calyxt&#146;s
competitors&#151;particularly large chemical companies&#151;have substantially larger budgets for R&amp;D, product commercialization, and regulatory process management as well as substantially greater access to capital. Trait research and
development companies as well as research universities and institutions are competitors that typically focus on a limited number of traits and do not generally have the product development, gene editing technologies, and regulatory infrastructure
necessary to bring traits to market. They generally <FONT STYLE="white-space:nowrap">out-license</FONT> trait technologies to large industry players with <FONT STYLE="white-space:nowrap">in-house</FONT> development and regulatory capabilities at a
relatively early stage of development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt competes based on its expertise and the precision, specificity, cost effectiveness and
development speed of its proprietary technologies. Nevertheless, certain of Calyxt&#146;s competitors are more established in the synthetic biology industry and many of Calyxt&#146;s current or potential competitors, either alone or with their
R&amp;D or collaboration partners, have significantly greater financial resources and expertise in R&amp;D, manufacturing, testing, and marketing approved products than Calyxt. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt&#146;s commercial opportunity could be reduced or eliminated if its competitors develop and commercialize products faster, with lower
research costs than Calyxt. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Human Capital </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, Calyxt had 48 employees, 30 of whom were in R&amp;D. None of Calyxt&#146;s employees are represented by a labor
union or covered by a collective bargaining agreement. Calyxt considers its relationship with employees to be good. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt&#146;s
employees are a critical asset. Recognizing the core importance of its personnel, Calyxt has sought to provide: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">competitive wages and benefits, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">support to employees by promoting health and safety, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">training and development that builds technical and professional skills, and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a culture of compliance that focuses on adhering to its code of conduct and business ethics and labor policy at
all levels. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt values and celebrates the diversity of its employee base and provides regular opportunities to learn
about contributions of various ethnic and minority groups on the culture and achievements of the United States, including scientific advancements.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">229 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Human capital management strategies have been developed collectively by senior management
and are overseen by the Calyxt Board. Calyxt is committed to efforts that ensure that the workplace is respectful, equitable, ethical, and fosters an inclusive work environment across its workforce. This commitment has been reinforced through
required diversity and inclusion trainings for all employees.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with Calyxt&#146;s cost reduction measures, Calyxt has
undertaken headcount reductions, primarily </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">in the first quarter of 2023. As of January 31, 2023, Calyxt had 28 full-time employees, of which ten employees
are within Calyxt&#146;s administrative, legal and finance functions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Seasonality</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt maintains the capability to implement broad arrangements for technology licensing and product development for agriculture. Technology
licensing opportunities span Calyxt&#146;s intellectual property portfolio built over more than a decade as a leading plant-based biology company, including multiple gene editing platforms, plant breeding, and other capabilities. Calyxt may be
exposed to the impact of seasonality that exits with traditional agriculture depending on the arrangement.</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt incorporated in Delaware on January&nbsp;8, 2010, and its largest stockholder is Cellectis. Calyxt&#146;s principal executive offices
are located at 2800 Mount Ridge Road, Roseville, Minnesota 55113, United States of America, and its telephone number is +1 (651) <FONT STYLE="white-space:nowrap">683-2807.</FONT> Calyxt also maintains a website at www.calyxt.com. The information
contained in, or that can be accessed through, its website is not part of this proxy statement/prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Proceedings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt is not a party to any material pending legal proceedings as of December&nbsp;31, 2022. From time to time, Calyxt may be involved in
legal proceedings arising in the ordinary course of business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">230 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom401831_47"></A>CIBUS BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>For the purposes of this section, references to &#147;us,&#148; &#147;our,&#148; &#147;we&#148; and derivations thereof refer to Cibus
Global. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BUSINESS OVERVIEW </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> is a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties. The company is a technology leader in developing plant traits (or specific
genetic characteristics) using gene editing. Its primary business is using gene editing to develop Productivity Traits in the major agricultural crops: Canola, Rice, Soybean, Corn and Wheat. Productivity Traits are crop traits that improve crop
yields and make farmers more productive, thereby driving greater farming profitability. They do this in several ways such as making plants resistant to diseases or pests, thereby reducing the use of chemicals like fungicides and insecticides,
enabling plants to process nutrients more efficiently, thereby reducing the use of fertilizers, and making crops more adaptable to their environment and to climate change. In addition, Cibus is a leader in the development of sustainable low carbon
ingredients to help major corporations meet their Net Carbon Zero climate goals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Founded in 2001, Cibus has developed a proprietary core
technology platform called the Rapid Trait Development System (<B><I>RTDS</I></B><SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>). <B><I>RTDS</I></B> is covered by over 400 patents or patents pending. <B><I>RTDS</I></B> is the underlying
technology platform for Cibus&#146; Trait Machine<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>: the first standardized <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-to-end</FONT></FONT> semi-automated crop
specific gene editing system that directly edits seed companies&#146; elite germplasm. It is a timebound, reproducible and predictable science-based breeding process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus believes that <B><I>RTDS</I></B> and the Trait Machine represent the technological breakthrough in plant breeding that is the ultimate
promise of plant gene editing: the ability to materially change the productivity of the breeding process that currently averages more than a decade. The Trait Machine materially changes not only the scale and speed of the breeding process, but it
also exponentially changes the range of possible genetic solutions from breeding and with it, the capability to develop desired characteristics or traits needed for greater farming sustainability and food security. Cibus is currently completing
construction of the first stand-alone production facility housing the Trait Machine (the Trait Machine Facility). When the Trait Machine Facility is completed, it is expected to initially be operational for Canola, Rice and Soybean. Cibus&#146;
technologies and trait products are accelerating agriculture&#146;s jump to a climate smart, more sustainable crop production system and industry&#146;s move to sustainable low carbon ingredients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus currently has a pipeline of six traits. Four of the six traits are applicable to multiple crops. Three of the traits are fully developed
and have begun shipping. In the first quarter of 2023, Cibus successfully transferred its Pod Shatter (PSR) trait in the elite germplasm of a leading Canola seed company for commercialization. In addition, in the first quarter of 2023, Cibus
transferred two different herbicide tolerance traits in the elite germplasm of a leading Rice seed company for commercialization. Cibus already has ten different leading seed company customers for its PSR trait in Canola. It expects to transfer its
PSR trait in the elite germplasm of these seed companies by the end of the second quarter of 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus sees its business as the start
of the gene editing industry&#151;an industry characterized by high throughput gene editing facilities serving as extensions of plant breeding operations for seed company customers. Cibus is the leader in this vision. Cibus and its Trait Machine do
not compete with breeding operations, they augment them. Cibus provides traits that it edits in the elite germplasm of its customers for commercialization. Its role is to improve the efficiency and effectiveness of developing the complex traits
needed to address agriculture&#146;s (and, farmers&#146;) most pressing productivity issues. Importantly, Cibus and its Trait Machine<B><I> </I></B>provide the ability to efficiently gene edit these new traits directly into elite germplasm of any of
the major crops. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Toward this vision, Cibus now has a pipeline of six traits, including three fully developed gene edited traits products,
it has leading seed company partners/customers, it has completed the transfer of its first three traits in the elite germplasm of customers in two different crops, and it is completing the industry&#146;s first trait production facility. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">231 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus believes that this is the Future of Breeding<SUP
STYLE="font-size:75%; vertical-align:top">&#153;</SUP>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WHAT EXACTLY ARE PLANT GENETICS OR GENE EDITING? WHAT DIFFERENTIATES CIBUS? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Background on the Plant Genetics Industry. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Plant genetics&nbsp;is the study of&nbsp;genes,&nbsp;genetic variation, and&nbsp;heredity&nbsp;specifically in&nbsp;plants, seeds or germplasm.
Germplasm&nbsp;is the term used to describe the&nbsp;seeds,&nbsp;plants, or&nbsp;plant&nbsp;parts useful in&nbsp;plant breeding. The Plant Genetics Industry consists of the activities, like breeding and genetics, that are focused on understanding
and improving germplasm. Plant genetics for germplasm and traits are the core technologies in seeds and ultimately, the varieties and parental lines of seed companies. These technologies underpin the expected performance of a given seed and are the
primary basis for competition in the seed business. These technologies are generally developed internally by seed companies, but they are often bought or licensed from third parties such as other seed companies or the many academic institutions that
have large plant genetics programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Increasing yields, lowering costs and making crop outcomes more predictable are the core targets of
trait development programs. Each of these targets has a readily quantifiable economic basis for determining the trait value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The targets
addressed by the two early <FONT STYLE="white-space:nowrap">GMO-based</FONT> traits were weed and insect management. Each of these had a material impact on farming productivity and sustainability. They are now used in multiple crops and are planted
on over 300&nbsp;million acres in North America and South America. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Bt trait (a GMO trait for insect resistance) is an excellent
example. It is used to control Corn borers and is credited with materially increasing farming productivity both through improved yield and through material reduction in the use (and cost) of insecticides. A 2010 National Research Council study
concurred that Bt crops led to reduced pesticide use and /or the use of pesticides with lower toxicity compared to those used on conventional crops. Based on the underlying positive economics of the Bt trait, it is estimated by AgBioInvestor that
the average trait fee paid by farmers for the Bt traits is over $10 per acre. At this price, it is also estimated that the Bt Trait is incorporated in the genetics of seeds that are planted on over 300&nbsp;million acres. The annual royalties are
estimated by AgBioInvestor to be approximately $4&nbsp;billion. It is further estimated by AgBioInvestor that the <FONT STYLE="white-space:nowrap">GMO-based</FONT> weed management traits are also planted on over 300&nbsp;million acres and earn
annual trait fees of approximately $4&nbsp;billion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Novel traits or genetic characteristics in seeds will continue to be the driving
force of the plant genetics industry and the growth of the seed business. Given peak acres, there is increasing pressure on improved crop productivity to meet the growing demands for food and food security. The promise of the new gene editing
industry is to be a key driver behind a new generation of plant traits that can meet the current and future challenges of farming, in general, and climate change, specifically. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Gene Editing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gene editing in plants is
essentially a tool used in plant breeding that can precisely and predictably introduce new traits or improve upon existing ones. Gene editing, like breeding, is the science of optimizing plant genetics to increase a plant&#146;s yield potential and
to improve its ability to withstand challenges, such as climate change, diseases, and pests, as well as to deliver <FONT STYLE="white-space:nowrap">end-use</FONT> characteristics such as nutritional quality or renewable plant-based
ingredients.&nbsp;What differentiates gene editing from traditional breeding is that it makes deliberate edits in the existing DNA sequence of a plant as opposed to the lengthy and random conventional breeding process. The promise of gene editing is
that it can change the scale and range of possible genetic solutions from breeding by its ability to make genetic changes in less time and more accurately. As challenges to farming sustainability increase with climate change, the ultimate promise of
gene editing is that it can help meet those challenges with a timely and predictable process. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">232 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, gene editing is an important tool in building genetic diversity needed to
address climate resilience in crops. During the process through which wild species were domesticated into the crops we know today, genetic bottlenecks were encountered as a result of selecting traits such as bigger fruits and higher yields, while
diversity was reduced for genetic traits like disease resistance. Gene editing is a breeding tool that can augment this lost diversity. Using the suite of technologies underlying <B><I>RTDS</I></B> and through our understanding of the genetic and
trait expression relationships, we can apply gene editing to develop more diverse germplasm while eliminating these bottlenecks. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What Differentiates
Cibus </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">What differentiates Cibus in the gene editing industry is its patented <B><I>RTDS </I></B>technology platform and its crop
specific Trait Machine process. Using <B><I>RTDS</I></B><I>,</I> Cibus developed the Trait Machine: the first standardized <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-to-end</FONT></FONT> semi-automated crop specific gene
editing system that directly edits a seed company&#146;s elite germplasm. The Trait Machine transforms the lengthy and random conventional breeding process into a timebound, reproducible and predictable science-based breeding process. The Cibus
trait products are indistinguishable from plant traits developed using conventional breeding processes. Cibus believes that the Trait Machine represents the technological breakthrough in plant breeding that is the ultimate promise of plant gene
editing: the ability to change the scale and range of possible genetic solutions from breeding and to develop desired characteristics or traits with greater speed and accuracy. Cibus expects to have its stand-alone Trait Machine Facility operational
in 2023. The Trait Machine drives and differentiates Cibus&#146; operating plan and its commercial model. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WHAT ARE CIBUS&#146; PRODUCTS? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus&#146; business and its products are based on the use of its gene editing technologies to develop and license a new generation of high
value Productivity Traits and Sustainable Plant-Based Low Carbon Ingredients. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Productivity Traits:</B> Productivity Traits are the plant traits that are associated with improving crop
yields in the face of challenges such as weeds, pests, and diseases, in the face of factors such as heat and drought as a result of climate change, as well as environmental challenges such as fertilizer use. They are the primary target of plant
breeding programs and a key basis of competition in the &#147;seed and trait&#148; business. The key application of Cibus&#146; Trait Machine is the development of a new class of high value Productivity Traits. Its focus is on the five major crops:
Canola, Rice, Soybean, Wheat, and Corn. Together they are grown on over one billion acres and represent over 90% of the world&#146;s protein and 70% of the world&#146;s vegetable oils. Cibus&#146; product goal for its Productivity Trait business is
a new generation of high value Productivity Traits that make crops more adaptable to their environment and have increased yields while reducing chemical inputs. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Cibus has a pipeline of six Productivity Traits, three of which are fully developed. Each of the Cibus&#146; developed traits has its initial
customers, and Cibus has begun transferring each of these traits to customers in their elite germplasm for commercialization. The lead developed trait is PSR in Canola, which has ten leading seed company customers for whom Cibus is currently editing
PSR into their elite germplasm. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In the first quarter and early second quarter of 2023, Cibus successfully transferred its three developed
traits in Canola and Rice to leading seed companies for commercial development. Cibus&#146; developed trait for Pod Shatter Reduction was successfully transferred in the elite germplasm of Nuseed, a leading Canola seed company with operations in
North America and Australia. Cibus&#146; two developed traits for herbicide tolerance (HT) in Rice were successfully transferred in the elite germplasm of Nutrien, a leading North American Rice seed company. These successful transfers of three
traits in two different crops for commercial development are important milestones for Cibus and for gene edited crops in general. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Cibus&#146; lead Productivity Trait in advanced development is for <I>Sclerotinia </I>white mold. It has had successful initial greenhouse
trials. If successful, this Productivity Trait is expected to materially improve yield while reducing fungicide use. Cibus&#146; advanced development Productivity Trait for nitrogen use efficiency is a
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">233 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
very important trait that, if successfully developed, will be applicable to many crops. Its goal is more efficient processing of nutrients like fertilizer, thereby reducing fertilizer use. This
would be a major cost savings for virtually every farmer. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Each of the Productivity Traits have an important role for farming
sustainability. Cibus estimates that for every dollar of trait royalty, a farmer receives approximately a <FONT STYLE="white-space:nowrap">two-fold</FONT> benefit in cost and yield improvement. In addition, the Productivity Traits for challenges
like disease, insects and nutrient use lower the use of chemicals such as fungicides, insecticides and fertilizer. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g401831g01a43.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Sustainable Low Carbon Ingredients:</B> Sustainable Low Carbon Ingredients are a key target market for
Cibus&#146; gene editing platform. The goal of the Global Net Carbon Zero Climate Goals being set by many muti-national companies is to replace the many ingredients that are fossil fuel based or linked to environmental challenges. Using gene editing
to develop plant- or micro-organism-based solutions is a key element of this drive to new renewable low carbon materials. To address this market, Cibus is using both its Trait Machine platform as well as ASAP<SUP
STYLE="font-size:75%; vertical-align:top">&#153;</SUP>, its advanced <FONT STYLE="white-space:nowrap">(non-transgenic</FONT> gene editing) fermentation platform. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Cibus&#146; product goal for its Sustainable Low Carbon Ingredient business is to use its non-transgenic gene editing platforms to work with
companies to develop a new generation of specific high value sustainable low carbon ingredients to replace existing ingredients linked to fossil fuels or environmental challenges such as increased greenhouse gases, deforestation, plastic waste, and
human health. Cibus is working with several consumer product, industrial, pharmaceutical and energy companies to develop a new generation of sustainable low carbon ingredients to address these challenges. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In the first quarter of 2023, Cibus and Procter &amp; Gamble (P&amp;G), a leading multi-national consumer product company, entered into a
collaboration to develop sustainable low carbon ingredients or materials that do not negatively impact the environment during production, use, or disposal. Under the terms of the agreement, P&amp;G will fund a multi-year program to develop
Sustainable Low Carbon Ingredients that help P&amp;G advance its sustainability objectives. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Cibus believes that gene editing will play an
important role in achieving these Global 2040 Climate Goals. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THE TRAIT MACHINE </B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#232;</FONT><B></B><B> THE
OPERATIONAL AND COMMERCIAL MODEL </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Operational Model </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The operational advantage of the Trait Machine is that it is a high throughput standardized <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">end-to-end</FONT></FONT> gene editing process that can directly edit a customer&#146;s elite germplasm in a timebound, reproducible and predictable process. It provides the ability to prototype new traits and, once
developed, the ability to materially accelerate the time to commercialize new traits. By materially changing the speed and accuracy to develop new traits, the Trait Machine revolutionizes the business of trait development by exponentially changing
the speed and scale of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">234 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prototyping new traits relative to conventional breeding. By working directly with a customer&#146;s elite germplasm, the Trait Machine enables the introduction of high value traits directly into
a customer&#146;s market-ready varieties and parent lines: dramatically reducing the time to commercialization. This is our vision for the Future of Breeding and our position in this new industry. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g401831g01a44.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The key to our model is the Trait Machine. It is based on crop specific trait editing platforms using
Cibus&#146; <B><I>RTDS</I></B> technology platform. A crop-specific platform means that the specific Trait Machine process is based on crop-specific single cell models that can grow into a plant after being edited. Once developed, in the specific
crop, Cibus is able to edit directly in a customer&#146;s elite germplasm and grow it into the customer&#146;s gene&nbsp;edited plant. This is what we mean when we say that Cibus is able to operate as an extension of a customer&#146;s breeding
program. This means that in any crop in which the Trait Machine is operational, Cibus will able to edit any trait in its pipeline directly into the customer&#146;s elite germplasm and transfer back the gene edited elite germplasm to the customer for
commercialization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, Cibus had two operational crop platforms in Canola and Rice, which Cibus has used to
begin editing the elite germplasm of our customers in Canola and Rice. Cibus has begun transferring their elite germplasm with these traits back to these customers ready for commercial development. Cibus has developed a pipeline of six traits in
Canola and Rice. All six traits are being developed on these two Trait Machine platforms. Three of the traits are fully developed and Cibus has begun transfers back to Canola and Rice customers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus expects to have an operational Soybean trait machine platform by the end of 2023, a Wheat platform by the end of 2024 and a Corn
platform by the end of 2025. Once the Soybean platform is complete, Cibus&#146; Trait Machine platform will be operational for approximately 250&nbsp;million acres of addressable acres in North America, South America and Europe. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Having Trait Machine Platforms for each of the five major crops would enable Cibus to introduce any of our multi-crop traits to any customer
in these crops. It would also enable us to prototype new traits for any customer in any of the five crops in their elite germplasm. This is the scale and breadth of trait development enabled by the Trait Machine Model. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This is the operational vision behind the Trait Machine model. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Commercial Model </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The commercial
model of the Trait Machine is to develop families of Productivity Traits and license them to seed companies for royalties. Seed companies paying royalties for Productivity Traits is a long-standing practice
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">235 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in agriculture, and is central to how major <FONT STYLE="white-space:nowrap">GMO-based</FONT> traits have been commercialized. Cibus&#146; commercial plan is based on this model. The trait
provider gets a royalty for every bag sold or each acre used. Virtually every seed has royalties due to third parties for intellectual property associated with either the germplasm or the traits in a seed. In each case, the trait provider is not
involved in seed <FONT STYLE="white-space:nowrap">bulk-up</FONT> or launch once a trait is transferred to the seed company. This is the same way in which holders of pharmaceutical royalties are not involved in the production or sale of the drugs.
Cibus&#146; commercial model is based on this practice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The agricultural trait business is driven by three factors: Type of Trait,
Addressable Acreage and Trait Fees. The big traits from the <FONT STYLE="white-space:nowrap">GMO-based</FONT> trait era were for two types of traits: weeds and insects. Each of these trait groups have been incorporated in over five different major
crops and planted on over 300 acres. Cibus believes that on average each of these key traits earns over $10 per acre. The actual trait fee for a given trait for a given crop is based on the economics of the trait in a given crop and geography. Cibus
estimates that for every dollar of trait royalty, a farmer receives approximately a <FONT STYLE="white-space:nowrap">two-fold</FONT> benefit (i.e., $2.00) in cost and yield improvement. In other words, traits are very valuable to farmers. Increased
productivity means higher yields and/or lower costs. If an insect trait fee is $10 per acre it means that the improvement in farming profitability between yield improvement and lower costs, is estimated to be approximately $20 per acre. The $10
trait fee is then divided between the trait company and the seed company. The percent of the fee that accrues to the trait developer can vary depending on the type of trait, value and IP protection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Historically, trait development has been a crop by crop and trait by trait process. Under the new gene editing regime this is expected to
change because of the expected scale, scope and speed of trait discovery using gene editing. This is why the Cibus commercial strategy differs from <FONT STYLE="white-space:nowrap">pre-gene</FONT> editing commercial models. In Cibus&#146; Trait
Machine Model, Cibus is not focused on a specific crop, its focus is specific traits. The goal of Cibus&#146; model is to find and develop important blockbuster traits that are applicable to multiple crops and have economics that would earn
approximately $10 or more per acre royalties across multiple crops. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Cibus model is driven by its vision of a high throughput gene
editing facility or service with the ability to develop families of multi-crop traits. The goal of this vision is to be an extension of major seed companies&#146; breeding operations. This is the difference of the Cibus model. With the benefit of
the Trait Machine, our job is to make the traits available in a way that is coordinated with any seed company&#146;s breeding operation in order to most efficiently commercialize each trait regardless of trait, crop, customer or geography. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stated differently, the big difference between the Cibus commercial model and the historical models is the Trait Machine and its speed, scale
and breadth of operations. Its ability to develop complex traits and to deliver these traits in the elite germplasm of any seed company in the five major crops. Our job is not to develop a specific trait, our model is to develop a family of complex
traits applicable to multiple crops that are needed to address the global productivity challenges facing farmers of virtually every crop. In other words, we look at the trait market from an agricultural need as opposed to a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">crop-by-crop</FONT></FONT> needs. Our aim is to solve major multi-crop challenges across the multiple crops at the same time. With the Trait Machine, we have the ability to launch traits
within a crop for multiple customers and across crops by editing into any customer&#146;s elite germplasm for commercialization, and to do so with superior speed, scale and breadth compared to conventional breeding. At Cibus, we see this as
comparable to the scale change that occurred in the move from analogue to digital. We are starting in Canola, Rice and Soybean with multiple traits and multiple customers. For both Canola and Soybean, we have a pipeline of 5 different traits at all
stages of development. We then expect to expand to all the five major crops in all the major accessible markets and apply our pipeline to each where appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This is the commercial vision behind the Trait Machine model. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">236 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This chart below shows our initial commercial vision with just our first three crop
platforms and six trait pipeline, assuming addressable acres in North and South America and Europe. See &#147;<I>Risk Factors&#151;Risks Related to Cibus&#151;Risks Related to Regulatory and Legal Matters&#151;Potential changes in regulatory
frameworks that would be beneficial to Cibus may not come to fruition.&#148;</I> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g401831g01a46.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Breeding Challenge that the Trait Machine Addresses </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Historically, the introduction of desirable traits in plants was achieved by major seed companies using conventional breeding or by employing
transgenic processes. Both traditional breeding and transgenic bioengineering require substantial development time frames. The average time for trait development using transgenic techniques is approximately 14.5 years, while conventional breeding
techniques can require more than a decade. Further, for transgenic techniques, the integration of recombinant DNA typically results in seeds being classified as genetically engineered or bioengineered producing genetically modified organisms
(&#147;GMO&#148;) that are subject to strict regulatory filings and specific GMO approvals prior to commercialization. Both methods produce genetic diversity in the genetic material (DNA) of plants: one through traditional breeding methods and the
other by making precise changes to the plant&#146;s DNA sequence through the use of tools such as CRISPR-Cas9. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g401831g02b46.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Trait Machine transforms a lengthy and random conventional breeding process into a timebound,
reproducible and predictable system </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">237 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In contrast, Cibus views gene editing as an extension of plant breeding. The Trait Machine
provides an extension of conventional breeding that provides a standardized gene editing process that operates in an end-to-end semi-automated system that can achieve the identical changes as conventional breeding more precisely and efficiently. The
Trait Machine provides a process that enables plant gene editing to occur in a timebound, reproducible and predictable process. Importantly, it has the ability to develop the complex traits that are difficult to achieve using conventional breeding
technologies. In addition, the Trait Machine enables the introduction of high value traits directly into a customer&#146;s market-ready varieties or parent lines in a process using the Trait Machine that takes on average 2 to 3 years. In other
words, by working directly with a customer&#146;s elite germplasm, the Trait Machine accelerates the time to market for developed traits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Another critically important challenge that <B><I>RTDS </I></B>and the Trait Machine process addresses is that its gene edits are
indistinguishable from genetic changes that could occur from conventional breeding or that could occur in nature. This aspect of gene editing is driving a global regulatory movement in which traits from gene editing are being regulated in an
increasing number of countries on a similar basis as traits from conventional breeding. The U.S., South America and certain other countries have already determined not to treat traits from <B><I>RTDS </I></B>as GMO. Each of Cibus&#146; three
developed traits and its three advanced traits have been determined not to be regulated articles through the USDA&#146;s &#147;Am I Regulated&#148; process, which was replaced with the USDA&#146;s Sustainable, Ecological, Consistent, Uniform,
Responsible, Efficient (SECURE) Rule&#146;s confirmation process. In 2023, there are several important countries or regions, including the European Union (EU), that are considering similar regulations to separate GMO technology from gene editing.
This is the additional promise of the Trait Machine: a science-based <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-to-end</FONT></FONT> gene editing system whose output would be regulated on a similar basis as traits
developed using conventional breeding. The ability to transform trait development from a lengthy and random conventional breeding process to a timebound and predictable scientific process. The ability to transform plant trait development and
commercialization from decades to years. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1-</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>TECHNOLOGY OVERVIEW: DEVELOPING A TRAIT MACHINE PLATFORM </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>&#150; Single Cells to Edited Plants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Background </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the heart of Cibus&#146;
Trait Machine is <B><I>RTDS</I></B>, which is a suite of technologies that enable Cibus to isolate a single plant cell, make the desired genetic edits in that cell, and regenerate that cell into an entire plant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>What to edit</U>: Differences in DNA sequences, many of which are variations in one or a few single base pair(s) (letter(s)) in a DNA
sequence, underlie some of the most important traits in plants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Plant biologists have recognized that we are in the &#147;genomics
information age&#148;. Across the plant kingdom, plants show enormous diversity driven by the enormous diversity in their genome sequences &#150; the plant&#146;s software. Their genome sequence drives all the characteristics (traits) that define
each plant, crop and variety of a crop. In truly understanding this diversity, and the DNA sequences that underly that diversity, one can leverage these characteristics across plants. Cibus is focused on both understanding this diversity and on
leveraging this diversity to improve farmer productivity and to develop sustainable ingredients. Trait Platforms are cases where differences in DNA sequences that result in these desired traits are leveraged across multiple crops. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Over our history, Cibus has accessed the sequences of thousands of genomes (and fragments thereof) allowing us to analyze, classify and
catalog plant DNA sequences. Analysis using comparative genomics allows our scientists to understand and associate those sequences with important plant traits. We have a team of informatics specialists that use computational biology and artificial
intelligence using our systems approach to plant genetic data to identify key sequence differences in targets that represent potential candidates or components for our traits. This computational biology analysis can also identify multiple genes and
gene edits that influence important traits. These traits include improving plants to address the increase in diseases, to manage the increased challenges of weeds, insects, and pests and to adapt to less water or increased temperatures. For many
traits in our pipeline, Cibus combines computational prediction with hypothesis testing in the laboratory to explore sequence differences in potential targets (genes/loci) to iterate to a list of preferred edits to assess in crops. These discovery
efforts are often performed in a variety of microbial hosts that became the basis for our business division Nucelis. Our long discovery history has enabled sequence changes in microbial assays to be correlated with precise edit performance in
plants. By knowing exactly which genes or edits to those genes </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">238 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
contribute to specific characteristics of a plant, Cibus can rapidly deploy its <FONT STYLE="white-space:nowrap">gene-editing</FONT> capabilities to obtain plant traits to improve farmer
productivity and to develop sustainable ingredients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Finally, we were able to leverage our microbial competence from trait discovery that catalyzed the
formation of Nucelis and its focus on enabling our sustainable ingredients business. This has now come full circle where vignettes driving sustainable ingredients in microbes have catalyzed cost effective crop-based opportunities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Benefits of using Elite Germplasm to Edit </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The developed &#147;crop platform&#148; and associated <B><I>RTDS </I></B>has been applied to elite germplasm from seed company customers.
Importantly, this application allowed Cibus to confirm the ability to edit complex genetic traits. In many cases, as many as eight loci have been targeted directly in elite germplasm. Cibus&#146; ability to perform direct editing in elite genetics
allows seed company plant breeders to rapidly incorporate these new traits into commercial lines or hybrid seed. Increased speed of breeding is of paramount importance for follow on speed to market. Traditionally, trait development has been a slow
process and farmers access to innovation very slow, <B><I>RTDS </I></B>allows Cibus&#146; partners to accelerate this process. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Accelerating Trait
Development Increases Scale </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An important challenge of trait development for Cibus&#146; seed company customers is to ensure traits can
be added to many of their elite germplasm. This allows plant breeders to incorporate Cibus&#146; Productivity Traits into the often-large breeding populations at a stage that is close to full commercialization. Scaling trait development using
<B><I>RTDS </I></B>is unique to Cibus. Once Cibus has established this process flow as a predictable, reproducible progression, the crop <B><I>RTDS </I></B>platform is complete and can effectively function as an automated Trait Machine, which allows
for the rapid and efficient production of customizable crops with multiple stacked traits. Recently, Cibus has included automation to help scale the Trait Machine. This not only improves the scale and speed but allows Cibus to take on more seed
company customers and their elite genetics. This expansion to a semi-automated Trait Machine will help to address specific needs across the agricultural value chain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is now clear that Cibus can provide the seed industry an
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-to-end</FONT></FONT> trait development Trait Machine, that will accelerate breeding timelines for the very best genetics to reach the market. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g401831g01a48.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">239 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2-</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DEVELOPING TRAITS - </B><B><I>Cibus&#146; RTDS Technologies</I></B><B> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Background </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><U>How we edit</U></B>: A
key component of its <B><I>RTDS</I></B> are oligonucleotides, which edit specific targeted bases within the genome by acting as a &#147;DNA template&#148; to guide the cell&#146;s innate repair machinery to make specific edits to the DNA&#146;s
targeted base pairs. In some cases, Cibus combines these powerful oligonucleotides with <FONT STYLE="white-space:nowrap">DNA-breaking</FONT> reagents, such as CRISPR-Cas9, to enhance the efficiency and precision of its <B><I>RTDS</I></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Another key component of RTDS is </B>Cibus&#146; proprietary cell culture expertise. Gene edits introduced into a single plant cell are
only commercially viable if they can be cultured and regenerated into whole plants having the desired trait associated with the gene edited genotype. Cibus&#146; proprietary cell culture expertise enables it to regenerate and grow an entire plant
with the desired traits introduced by its targeted edits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once Cibus has identified which genes to edit, <B><I>RTDS</I></B> can operate
within the genome, such as through an Oligo Directed Mutagenesis (ODM) technique. The first application of ODM as a gene-editing technique in plants occurred over 20 years ago, when researchers, including Cibus&#146; President and Chief Operating
Officer, Dr.&nbsp;Peter Beetham, were able to edit plant cells to become resistant to sulfonylurea herbicides. Following this breakthrough, modified plant cells were cultured and regenerated into whole plants that produced hybrid progeny with
heritable and stable gene mutations for this herbicide resistance trait. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus believes that it has been at the forefront of continuously
improving the efficiency of gene editing and subsequent cell culture processes, which have made <B><I>RTDS</I></B> increasingly faster and more efficient. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>RTDS Gene Editing Process&#151;GRONs are Chemically Synthesized Directed Mutagens</I></B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus&#146; <B><I>RTDS</I></B> can effect ODM using a carefully designed oligonucleotide, which Cibus refers to as the Gene Repair
OligoNucleotide (GRON). The GRON is a chemically-engineered combination of DNA and modified nucleotides and other <FONT STYLE="white-space:nowrap">end-protective</FONT> chemistries, the structure of which is carefully and purposefully designed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Validating the <FONT STYLE="white-space:nowrap">non-transgenic</FONT> nature of Cibus&#146; <B><I>RTDS</I></B>, the GRON is blocked from
undergoing recombination (or insertion) with the plant DNA by its <FONT STYLE="white-space:nowrap">end-protective</FONT> chemical structure. A GRON contains no biologically derived material; it is produced with an automated chemical synthesizer and
purified like any other chemical mutagen. In addition, the GRON is formulated without the need for a delivery vector, which ensures that no foreign or extraneous DNA is inserted into the plant DNA. As a result of this carefully designed structure,
the GRON acts as a mutagen, and <B><I>RTDS</I></B> can serve as a targeted mutagenesis system, rather than a transgenic process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To
effect precision gene editing, the GRON contains carefully sequenced DNA building blocks, but is specifically designed to include a mismatch in one or a few base pairs compared to the target gene&#146;s DNA sequence. This genome sequencing and
purposeful mismatch permits the GRON to act as a &#147;DNA template&#148; for the DNA sequence to be edited. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mechanism of GRON Action </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The GRON&#146;s DNA template operates by using the plant DNA&#146;s natural or inherent mismatch-repair system to effect a change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once inside the cell, the GRON is transported to the nucleus and based on the GRON&#146;s sequence design, binds with the specific DNA
sequence targeted for editing&#151;a process referred to as specific hybridization. However, in connection with this pairing, the designed mismatch between the GRON and the DNA sequence ensures that there is no correspondence between the GRON and
the plant genome at the specific target site. Consequently, no binding occurs at this specific site. The cell detects this mismatch and signals the cell&#146;s natural repair system to change the gene&#146;s sequence in order to match the GRON
template. The cell uses enzymes to remove the mismatched nucleotide or nucleotides from the plant&#146;s DNA sequence, and a new DNA sequence, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">240 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which corresponds to the GRON DNA template, is resynthesized to correct the mismatch, thereby producing a continuous sequence using the cell&#146;s own source of nucleotides. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ability of the GRON to specifically hybridize with great affinity to its target, and its resistance to premature degradation, allows the
cellular gene-repair machinery time to locate and replace, insert or delete the targeted DNA nucleotide(s) on both strands of the genomic DNA. When the DNA strands are corrected to the GRON&#146;s DNA sequence, the GRON is degraded by the
cell&#146;s natural processes, and the gene functions under its natural control mechanisms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Through the controlled and precise mode of
action of ODM utilizing the GRON, random or excessive mutations are prevented. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ODM in Combination with Engineered Nucleases </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The key to specific gene editing to truly edit genes requires the GRON. While significant and practical gene-editing frequency is possible
through ODM utilizing the GRON alone, various techniques can enhance the efficiency of the GRON&#146;s editing process. For example, Cibus&#146; GRON has achieved significant gene editing efficiency improvements when combined with certain engineered
nucleases designed to precisely introduce controlled DNA double-strand breaks. These engineered nucleases include meganucleases, zinc finger nucleases, TAL effector nucleases (TALENs) and clustered regularly interspaced short palindromic repeats
(CRISPR)-associated endonuclease Cas9 (CRISPR-Cas9). Cibus&#146; <B><I>RTDS</I></B> technologies have been significantly enhanced where its GRONs are used to reliably and precisely target DNA sequence changes close to a cut site made by such <FONT
STYLE="white-space:nowrap">DNA-breaking</FONT> reagents. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>GRON Mode of Action in Combination with CRISPR-Cas9 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following diagram depicts Cibus&#146; <B><I>RTDS</I></B> process deploying the GRON in combination with a CRISPR-Cas9 DNA breaker: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g401831g01w46.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">241 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A <FONT STYLE="white-space:nowrap">Non-Transgenic</FONT> Process and Product </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until the advent of Cibus&#146; <B><I>RTDS</I></B> technologies, the preponderance of commercial plant traits derived from biotechnology was
based on transgenic products and processes. <B><I>RTDS</I></B> introduces a commercially viable, <FONT STYLE="white-space:nowrap">non-transgenic</FONT> alternative. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The mode of action of ODM utilizing the GRON does not incorporate extra genes into the plant genome. Rather, the GRON functions only as a DNA
template, guiding the plant to effect a change to its DNA with its own natural mechanisms. This is central to the design and structuring of the GRON, which uses <FONT STYLE="white-space:nowrap">end-protective</FONT> chemical structures to prevent
recombination with the plant&#146;s DNA. Moreover, GRONs contain no biologically derived material&#151;they are produced with an automated chemical synthesizer and purified like any other chemical agent. As a result, the GRON operates solely as a
traditional mutagen. Because the GRON is fully degraded by the cell&#146;s natural processes, the final trait products of Cibus&#146; <B><I>RTDS</I></B> are indistinguishable from those that could occur in nature. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the GRON does not require a delivery vector, which ensures that no foreign or extraneous DNA is inserted into the plant cell as
part of the <B><I>RTDS</I></B> process. This enables the <B><I>RTDS</I></B> process to serve as a targeted mutagenesis system, rather than a transgenic process. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Uniqueness of Cibus Trait Machine Technology </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Cibus believes its Trait Machine is unique in the following ways: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">It materially changes the scale and speed of trait development by changing the speed to precisely edit a specific
trait in a plant. In so doing, it changes speed and scale with which a breeder can optimize the genetics associated with a specific trait. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">It materially changes the scale and speed at which traits can be commercialized because it edits directly into a
customer elite germplasm and is able to edit and transfer back a customer&#146;s entire crop product line that is market ready in a timebound, reproducible and predictable manner. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is able to do this because: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">It moves from single cell to regenerated whole plant possessing desired traits more quickly and efficiently than
other comparable technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">It uses elite genetic parental lines as the starting material for the gene-editing process, making trait
development and trait stacking more efficient; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">It is standardized, precise, reproducible and automated, making trait development customizable and trait stacking
efficient and rapid; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">It is scalable using newly acquired robotics and has been largely automated to further accelerate the trait
development process; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">It is <FONT STYLE="white-space:nowrap">non-transgenic,</FONT> making it cost and speed advantaged in the growing
number of markets where it is not subject to heightened GMO regulation. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3-</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>TRAIT AND GENETIC SEQUENCE LICENSING </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus&#146; business is the development and licensing of intellectual property associated with plant traits or genetic characteristics in
plants. Its products and initiatives can be divided into three groups. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Productivity Traits</B>: For its Productivity Trait business, Cibus&#146; goal is to have its Trait Machine
platform operational for all five major crops and to have separate trait development and licensing efforts for each of the five crops. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Low Carbon Ingredients:</B> For its Low Carbon Ingredient Business, Cibus&#146; goal is to have a series of
contracts with major global corporations to develop specific products for their specific needs. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">242 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Other Initiatives</B>: In crops other than the five majors, Cibus&#146; goal is to build Trait Machine
platforms in partnership with leading seed companies to address specific Productivity Trait or end product initiatives. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In each area above, Cibus&#146; product is the intellectual property associated with the specific trait or end product for which Cibus would
generate a specific annual royalty or royalty-like payment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Below is a summary of Cibus current efforts for Productivity Traits in the
five major crops. In our current pipeline of six traits, four of the six traits are multi-crop traits. These are reflected below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Trait Product
Pipeline: By Crop </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#149; Canola </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Canola was the first crop for which Cibus successfully implemented its Trait Machine/<B><I>RTDS</I></B> breeding platform. As a result, Canola
is the first crop for which Cibus has built an integrated family of Productivity Traits for a single crop platform&#151;pod shatter reduction (PSR), herbicide tolerance, disease resistance and nitrogen use efficiency. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus&#146; lead trait is its pod shatter reduction trait (PSR), which is Cibus&#146; first developed trait, meaning it has been gene edited
in customers&#146; elite germplasm, has been confirmed in greenhouse trials and has been validated though field trials and was transferred to its first customers in the first quarter of 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to PSR, Cibus has three traits in advanced stages of development meaning that the editing process is underway with known edit
targets. These traits include a trait for <I>Sclerotinia</I> (white mold disease) resistance, a trait for a nutrient use efficiency trait and an herbicide tolerance trait. All three of these traits are multi-crop traits meaning that they have
applicability in other crops. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#149; Rice </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Rice is the second crop for which Cibus has successfully implemented a Trait Machine/<B><I>RTDS </I></B>breeding platform. In addition, like
PSR in Canola, Cibus has two fully developed herbicide tolerance traits in Rice meaning they have been gene edited in a customer&#146;s elite germplasm, have been confirmed in greenhouse trials and have been validated though field trials. In the
first quarter of 2023, Cibus made its first transfer of both of its herbicide tolerance traits Nutrien for commercial development. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#149; Soybean,
Wheat and Corn </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus is also developing crop specific Trait Machine/<B><I>RTDS</I></B> platforms for Soybean, Wheat and Corn. Cibus
expects to have the Trait Machine operational for Soybean in 2023, Wheat in 2024 and Corn in 2025. In each case, Cibus has multi-crop traits that are being developed in Canola and Rice that are applicable to these crops. Cibus believes that the
initial traits commercialized in these crops will be the initial multi-crop traits from Canola and Rice. We believe that we have demand for specific traits in each crop. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As the Soybean platform is completed in 2023, it will be part of the initial operations of the Trait Machine Facility. Two of the advanced
traits: one for <I>Sclerotinia</I> resistance and one for a new herbicide; are expected to be the initial traits for the Soybean platform. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Importantly, Cibus expects to have operational crop specific Trait Machine platforms in each of the five major crops by 2025. Once all five
platforms are operational, it will be possible to develop and commercialize </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">243 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any trait contemporaneously in any or all of the five crops. This will accelerate the trait commercialization of our current pipeline. It will also materially accelerate the development and
commercialization of any new trait Cibus develops. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This is what we mean when we say that our Trait Machine technology platform materially
changes the scale and speed of trait development and commercialization. From a development perspective, it changes the speed with which new trait ideas can be implemented and tested. From a commercialization platform it speeds commercialization two
different ways. On one side, edits are made directly in a customer&#146;s elite germplasm. On the other side, any given trait can be launched globally contemporaneously across each major crop. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>NUCELIS&#151;</B><B><I>Applications of Cibus&#146; Technology in Microorganisms developed for Fermentation
</I></B> </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus launched its subsidiary, Nucelis, to deploy its <B><I>RTDS</I></B> technologies to develop low carbon and
<FONT STYLE="white-space:nowrap">non-GMO</FONT> ingredients. These are critically important areas of need. Developing this new generation of ingredients can be done in both plants and microorganisms such as yeast and bacteria. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to Cibus&#146; core strength in plant gene editing, Nucelis has developed important gene editing strengths in microorganisms.
Specifically, Cibus is applying <B><I>RTDS</I></B>, together with its advanced fermentation capabilities and downstream purification processes, for the efficient development of innovative traits in microorganisms, such as yeast, bacteria and algae,
to produce high-value, sustainably sourced specialty ingredients for the personal care, nutrition and flavor and fragrance industries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nucelis&#146; Accelerated Strain Advancement Platform (ASAP<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>) is a powerful
specialty ingredient development platform that combines the precision of <B><I>RTDS </I></B>with two pillars of Nucelis&#146; business: its advanced fermentation and pilot scale facilities and its proprietary downstream purification processes.
Through this combination, Nucelis has positioned itself as a leader in the efficient development and delivery of high-value, performance-focused, <FONT STYLE="white-space:nowrap">non-transgenic</FONT> specialty ingredients for partners in the
nutrition, personal care, flavor and fragrance markets, and for future applications in Ag biologicals, active pharmaceutical ingredients (API&#146;s), human health and animal health. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Through its ASAP platform, Cibus has developed and produced two high-value nutritional products&#151;ergosterol and vitamin D2. Nucelis&#146;
first product, ergosterol, is the key intermediate in the production of vitamin D2, which serves as a supplement to prevent and treat vitamin D deficiency. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nucelis oversees both the plant-based and microorganism-based solutions for <FONT STYLE="white-space:nowrap">low-carbon</FONT> ingredients.
</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4-</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>INTELLECTUAL PROPERTY </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus is an innovator in precision gene editing. Cibus relies on a combination of patent, trademark, copyright, and trade secret laws in the
United States and other jurisdictions to protect its intellectual property rights. No single patent or trademark is material to its business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Its proprietary technologies and trait product candidates are protected by more than 400 patents and patent applications worldwide across 17
patent families. The scope of such intellectual property protection depends on the laws of the local jurisdiction, which, in some jurisdictions, may provide less protection than the laws of the United States. Moreover, the duration of protection
varies between different types of intellectual property rights. For instance, in the United States patents generally remain in force for 20 years from the filing of the patent application. Cibus&#146; issued patents are expected to expire between
2037 and 2039. Cibus holds key patents and patent applications with respect to <B><I>RTDS</I></B> gene-editing methods, its PSR trait, applications of its <B><I>RTDS</I></B> technologies, and products of its <B><I>RTDS</I></B> technologies. Cibus
believes its patent portfolio provides Cibus with a significant competitive advantage and creates a barrier to entry for potential competitors. In addition, as of January 2023, Cibus owns more than 40 trademark registrations and applications related
to its products, product </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">244 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
candidates, processes, and technologies. Cibus anticipates it will apply for additional patents and trademark registrations in the future as it develops new products, product candidates,
processes, and technologies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus also relies on trade secrets to develop and maintain its proprietary position and protect aspects of
its business that are not amenable to, or that Cibus does not consider appropriate for, patent protection. Cibus seeks to protect its proprietary technologies, in part, through confidentiality agreements with its employees, consultants, scientific
advisors, contractors and others with access to its proprietary information. There can be no assurance, however, that these agreements will provide meaningful protection or adequate remedies for any breach, or that its trade secrets will not
otherwise become known or be independently discovered by its competitors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to its own intellectual property, Cibus has also
entered into licensing arrangements pursuant to which Cibus licenses third-party technologies and intellectual property. These are typically <FONT STYLE="white-space:nowrap">non-exclusive</FONT> contracts for developing traits in plants. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5-</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>GOVERNMENT REGULATIONS AND PRODUCT APPROVAL </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Overview </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus plans to license
its products globally into its key target agricultural markets, including the United States and Canada. Each country or region has sets of regulations that govern the use of gene editing technologies in plants. The regulations for gene edited
products varies from country to country. Because of the use of transgenes and the integration of foreign DNA in GMO technologies, there are very severe regulations in many countries, ranging from outright bans to specific controls regarding the use
of GMO technology. In light technological advances since the development of GMO technologies, there has been tremendous effort globally to develop separate regulations for gene editing technologies that did not integrate transgenes or foreign DNA.
These efforts are focused on technologies whose genetic changes are similar to genetic changes from conventional breeding. Accordingly, there are global efforts seeking to regulate technologies that meet this standard in the same manner as the
products of mutagenesis and traditional breeding. While Cibus views the overall regulatory trajectory positively, regulatory change has encountered headwinds, including organized and vocal opponents of modifying existing, restrictive regulatory
frameworks.&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In many countries in North America and South America, there are new regulations in place.
Specifically, in these markets, the first product outcomes of Cibus&#146; <B><I>RTDS</I></B> technologies have determined to be <FONT STYLE="white-space:nowrap">non-transgenic</FONT> and, consequently, products developed using <B><I>RTDS</I></B>
technologies will be regulated in the same manner as the products of mutagenesis and traditional breeding. In other markets, there are processes in various stages of advancement. In the UK, for example, an Act of Parliament was passed in March 2023.
The EU has been under engaged in a multi-year regulatory process. It is expected that the European Commission will produce a proposal for new EU legislation in the second quarter of 2023. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">245 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Below is a map graphically showing this trend. For the major markets: the United States,
South American and Europe we have a provided detailed overview of the process that has taken place or is in progress. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g401831g01a54.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See &#147;<I>Risk Factors&#151;Risks Related to Cibus&#151;Risks Related to Regulatory and Legal Matters&#151;Potential
changes in regulatory frameworks that would be beneficial to Cibus may not come to fruition.&#148;</I> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>United States </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, the United States Department of Agriculture (&#147;USDA&#148;), the Food and Drug Administration (&#147;FDA&#148;) and
the Environmental Protection Agency (&#147;EPA&#148;) have a coordinated framework to regulate the application of biotechnology to agriculture through a system of environmental (and food) laws and regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The United States is deemed a self-regulatory jurisdiction, wherein it is the industry&#146;s responsibility to comport with applicable rules
in the first instance, subject to appropriate regulatory oversight by government agencies. Currently, transgenic technologies used in agriculture are overseen by the USDA&#146;s Animal&nbsp;&amp; Plant Health Inspection Service (&#147;APHIS&#148;).
Under the Plant Protection Act (&#147;PPA&#148;), the USDA requires anyone who wishes to import, transport interstate, or plant a &#147;regulated article&#148; to apply for a permit or notify APHIS that the introduction will be made. Regulated
articles are defined as any organism which has been altered or produced through genetic engineering which APHIS determines is a plant pest or has reason to believe is a plant pest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus&#146; <B><I>RTDS</I></B> technologies do not involve insertion or integration of foreign genetic material into plant DNA but result in
site-specific mutations identical to those occurring in nature. The final product does not contain foreign genetic material. Consequently, both process and product are <FONT STYLE="white-space:nowrap">non-transgenic.</FONT> Under a legacy rule,
developers could submit a petition to APHIS requesting an agency determination that a developed plant is unlikely to pose a plant pest risk, and therefore, is not a &#147;regulated article&#148; and is not subject to APHIS&#146; biotechnology
regulations. If, upon the completion of the review, APHIS granted the petition, the product would no longer be deemed a &#147;regulated article&#148; and the petitioner could commercialize the product, subject to any conditions set forth in the
decision. Through this process, in 2004, APHIS informed Cibus in writing that products developed using its <B><I>RTDS</I></B> (specifically where Cibus used the GRON in an early version of its technologies under the <B><I>RTDS</I></B> umbrella) are
not subject to regulation under the PPA. Therefore, it was not necessary under USDA and APHIS regulations to file a notification to conduct a field trial or seek permission to commercialize a product created using those technologies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">246 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus has continued to work closely with the USDA and the coordinated framework to ensure
the compliance of more recent technologies developed as part of <B><I>RTDS</I></B>. Prior to August 2020, the USDA utilized a process known as AIR (&#147;Am I Regulated?&#148;), which was used by many companies to help evaluate the novel breeding
technologies under the broad umbrella of gene editing. In 2018, Cibus had favorable letters for 14 AIRs filed with this agency for multiple modes of action associated with its traits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;28, 2018, U.S. Secretary of Agriculture Sonny Perdue issued a statement providing clarification on the USDA oversight of plants
produced through innovative new breeding techniques including gene editing. The statement confirmed that under its biotechnology regulations, USDA does not regulate and had no plans to regulate plants produced by gene editing that could otherwise
have been developed through traditional breeding techniques as long as they are not plant pests or developed using plant pests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The AIR
process was discontinued on June&nbsp;17, 2020, and was replaced with the Sustainable, Ecological, Consistent, Uniform, Responsible, Efficient (SECURE) Rule beginning on August&nbsp;17, 2020. Under the revised regulations, certain categories of
modified plants are exempt from regulations because they could otherwise have been developed through conventional breeding techniques and thus are unlikely to pose an increased plant pest risk compared to conventionally bred plants. These exemptions
apply only to plants. In addition, plants that have a plant-trait-mode of action combination that is the same as in a plant that has been determined by APHIS to be unlikely to pose a plant pest risk and therefore to be not regulated, are exempt from
the regulations. Under the SECURE rule, developers can request a confirmation from APHIS that a modified plant qualifies for an exemption and is not subject to the regulations. APHIS provides a written response within 120 days of receiving a
sufficiently detailed request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For modified plants that do not qualify for exemption based of the
<FONT STYLE="white-space:nowrap">pre-specified</FONT> criteria, developers can seek a Regulatory Status Review (RSR) whereby APHIS evaluates whether the plant requires oversight based on the characteristics of the plant itself. If the plant is found
to be unlikely to pose a plant pest risk, APHIS will determine the plant <FONT STYLE="white-space:nowrap">non-regulated.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus
continues to work with the USDA with pipeline products qualifying for exemption and those with multiple edits that may need to be assessed through the SECURE rule&#146;s RSR. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no guarantee that the governing regulations will not change further. Government regulations, regulatory systems, and the politics
that influence them vary widely among jurisdictions. Historically, changes to the U.S. regulatory paradigm for these technologies have been infrequent, are typically preceded by notice, and are often subject to public comment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, some of Cibus&#146; future products may be subject to FDA food product regulations or EPA environmental impact regulations. The FDA
primarily derives its regulatory power from the Federal Food, Drug, and Cosmetic Act (&#147;FDCA&#148;), which has been amended over time by several subsequent laws. To support its oversight responsibilities, the FDA employs a dedicated inspectorate
to conduct inspections and collect and analyze product samples. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA regulates ingredients, packaging, and labeling of foods,
including nutrition and health claims and the nutrition facts panel. Foods are typically not subject to premarket review and approval requirements, with limited exceptions. Under Section&nbsp;409 of the FDCA, any substance that is reasonably
expected to become a component of food is considered a &#147;food additive&#148; that is subject to premarket approval by the FDA, unless the substance is generally recognized as safe, or GRAS. Companies are responsible for making an initial
determination of whether a food substance falls under an existing food additive regulation, requires a new food additive petition, or is GRAS. In order for a substance to be GRAS, there must be a consensus among qualified experts on the safety of
the substance under the conditions of its intended use. A company may market a new food ingredient based on its self-affirmed determination that the substance is GRAS; however, the FDA can disagree and take enforcement action. Developers routinely
consult with the FDA prior to marketing and, in most cases, foods derived from modified plant varieties are not subject to premarket review and approval processes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">247 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA&#146;s thinking on the use of genome editing techniques to produce new plant
varieties that are used for human or animal food continues to evolve. In January 2017 the FDA announced a request for comment (&#147;RFC&#148;) seeking public input to help inform its thinking about human and animal foods derived from new plant
varieties produced using genome editing techniques. Among other things, the RFC asked for data and information in response to questions about the safety of foods from <FONT STYLE="white-space:nowrap">gene-edited</FONT> plants, such as whether
categories of gene-edited plants present food safety risks different from other plants produced through traditional plant breeding. On December&nbsp;19, 2022, the White House Office of Science and Technology Policy (OSTP), in coordination with the
FDA, EPA, and USDA, announced a request for information related to the Coordinated Framework for the Regulation of Biotechnology. This action requests relevant data and information to help identify regulatory ambiguities, gaps, inefficiencies, or
uncertainties in the Coordinated Framework for the Regulation of Biotechnology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the FDA enacts new regulations or policies with
respect to gene-edited plants, such policies could result in additional compliance costs and/or delay the commercialization of Cibus&#146; product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, it is also possible that some products, into which Cibus introduces novel herbicide tolerances, will be subject to EPA
regulation. If the specific novel trait is deemed to be a possible pest or the novel herbicide is part of a new registration, the EPA will regulate the distribution, sale or use. The Biopesticides and Pollution Prevention Division of the office of
Pesticide Programs under the Federal Insecticide, Fungicide, and Rodenticide Act administers such regulatory oversight. This evaluation will determine the reasonable certainty that no harm from pesticide residues occurs in food and feed. Exemptions
and tolerances are set by the FDCA. In addition, the EPA has the authority on reporting and testing requirements for herbicides and food provided by the Toxic Substances Control Act. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Canada </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In Canada, the sale of new
plant traits, or foods derived from genetically modified plants, is initially regulated through a <FONT STYLE="white-space:nowrap">pre-market</FONT> notification requirement. Canada considers these to be &#147;novel foods.&#148; Health Canada
(&#147;HC&#148;) is responsible for ensuring that all foods, including those derived from biotechnology, are safe prior to their entering the Canadian food system. HC uses a <FONT STYLE="white-space:nowrap">pre-market</FONT> notification system to
conduct a thorough safety assessment of all biotechnology-derived foods to determine that a novel food is safe and nutritious before allowing it in Canada. The Canadian Food Inspection Agency (&#147;CFIA&#148;) is responsible for regulating the
environmental release of plants with novel traits (&#147;PNTs&#148;). The CFIA reviews and inspects PNTs. PNTs, defined in the Seeds Regulations, are (i)&nbsp;plants into which a trait or traits have been intentionally introduced and (ii)&nbsp;where
the trait is new in Canada and has the potential to impact the environment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Approval of a PNT or a novel food product does not take into
account the method with which such product was produced. Rather, Canada employs a product-based (as opposed to a process-based) approach to its regulatory practice. Therefore, crops developed through Cibus&#146; <B><I>RTDS</I></B> technologies are
evaluated in the same manner as crops developed through other breeding methods, whether Cibus derived products through conventional or modern forms of mutagenesis. Additionally, the CFIA operates a Remutation Policy whereby plants containing the
same mutation as a previously authorized plant of the same species are included in the authorization of the original PNT and are subject to the same conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In recent years, Health Canada and CFIA have been working on new guidance to ensure the Novel Food Regulations are clearer, more predictable
and more transparent regarding products of plant breeding, including those developed using gene editing techniques. In July 2022, Health Canada published a scientific opinion regarding the regulation of gene-edited plant products within the context
of the Novel Food Regulations. This opinion helped to inform the development of the Department&#146;s new Health Canada Guidance on the Novelty Interpretation of Products of Plant Breeding. The Guidance provides criteria that need to be met in order
for food products derived from gene edited varieties to be determined as &#145;not novel&#146; and so fall outside the scope of the Novel Food. Guidance documents from CFIA are in production. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">248 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Canola, as one of Canada&#146;s major field crops, is subject to variety registration. The
variety registration is a regulatory requirement of the Seeds Act and like PNTs, is administered by the CFIA. Generally, variety registration is a <FONT STYLE="white-space:nowrap">two-year</FONT> process in which potential new varieties (hybrids)
are grown during the normal season at a defined number of suitable locations. In the first year, data is privately generated and in the second year, the Western Canada Canola/Rapeseed Recommending Committee (&#147;WCC/RRC&#148;) manages public
trials of potential new varieties. At the end of each season, the collected data is compared to a set of reference varieties. In order for the WCC/RRC to recommend to CFIA that new hybrids be registered, candidates must meet or exceed a defined set
of criteria for grain quality (composition) and disease resistance. The criteria include oil and protein content and a maximum level of saturated fat, erucic acid and glucosinolates in the meal. Since Canada exports 90% of its Canola grain, oil and
meal, to be registered for sale, hybrids including traits are cleared for export trade. Finally, to sell a registered hybrid, it must also meet hybridity standards. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The United Kingdom </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2023,
an Act of Parliament (the Genetic Technology (Precision Breeding) Act 2023) was passed into law in the United Kingdom. This Act, which remove plants produced using modern biotechnologies and the food and feed derived from them from GMO regulations
if those organisms could have occurred naturally or been produced by conventional methods, will enable the development and marketing of gene edited crops in England. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Act creates a science-based and streamlined regulatory system for gene edited or &#145;precision bred&#146; crops, which have been
developed with targeted genetic changes that could have arisen through traditional breeding or other natural processes. In addition, the Act includes provisions to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Introduce two mandatory notification systems for precision bred organisms, one for
<FONT STYLE="white-space:nowrap">non-marketing</FONT> purposes (research and development) and one for marketing purposes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Create a duty on the Secretary of State to create and maintain a new public register of notified information. The
register is to be kept in electronic form and accessible on the UK government website; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Grant powers to create a new regulatory framework for food and feed derived from precision-bred organisms,
ensuring that appropriate regulation is in place before placing these products on the market. This framework will include a procedure for making precision bred food and feed marketing authorizations including a new proportionate risk assessment. The
framework will also set out the requirements to be satisfied before the Secretary of State could issue a food and feed marketing authorization; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Grant powers for the Food Standards Agency (FSA) to establish, publish and update a public register for
precision-bred organisms authorized for food and feed use. An entry on this register would indicate that the Secretary of State has made a determination to authorize the precision-bred organism, and products derived from it to enter the market for
food and feed uses based on the recommendation of the FSA; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Grant powers to create an inspection and enforcement regime, including civil sanctions, in order to secure
compliance with the obligations under the Act. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The passing of the Act aligns England&#146;s regulatory path for gene
editing technologies with other countries that have passed new regulations that regulate traits from Cibus&#146; gene editing platform on a similar basis as traits developed using conventional breeding technologies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Act as a major accomplishment of DEFRA (UK&#146;s Department of Environment, Food and Rural Affairs) in its efforts to unlock modern
breeding technologies to improve food security, reduce pesticide use, and enhance climate-resilience in crops. DEFRA has been commended for enabling the agriculture industry in England to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">249 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
realize the benefits of gene editing to improve farming productivity and sustainability. In addition to the introduction of the Act enabling the commercialization of gene edited crops, DEFRA
previously introduced legislation (The Genetically Modified Organisms (Deliberate Release)(Amendment)(England) Regulations 2022) to simplify research and development with gene edited crops. These regulations simplify the approval process for
researchers to take crops to field trials to develop crops better able to withstand the changing environment and reduce inputs such as fertilizers, fungicides, herbicides and pesticides. Productivity Traits such as these are the primary target of
Cibus&#146; gene editing efforts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>European Union </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The European Commission has stated its intent to produce a proposal for new EU legislation in this field in the second quarter of 2023. Its
intent in this process is to consider legislation that would enable gene editing to be regulated similar to conventional breeding. The language to be released in the second quarter of 2023 is expected to be the text of the legislative proposal. If
and to the extent that such proposal is ultimately published, it will likely have to follow the ordinary legislative procedure, which means that approval by the European Council and the European Parliament will be necessary in order for European law
to be amended and potentially enable the use of the targeted NGTs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The background of EU regulation is primarily based on EU Directive
2001/18/EC. The Directive defines GMOs broadly as &#147;organism[s], with the exception of human beings, in which the genetic material has been altered in a way that does not occur naturally by mating and/or natural recombination.&#148; Food that
contains, consists of, or is produced from GMOs is referred to as genetically modified food. In the EU, GMOs or genetically modified food or feed products can only be sold in the market once they have been properly authorized. Any genetically
modified micro-organisms that are for contained use are regulated under a different directive, EU Directive 2009/41/EC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The procedures
for the evaluation and authorization of GMOs or genetically modified food or feed products are established by Regulation (EC) 1829/2003 on genetically modified food and feed and Directive 2001/18/EC on the release of GMOs into the environment. An
application for authorization must be submitted under Directive 2001/18/EC if a company seeks to release GMOs for experimental purposes (e.g., field tests) and/or to sell GMOs, as such or in products, in the market (e.g., cultivation, importation or
processing). In turn, an application for authorization must be submitted under Regulation (EC) 1829/2003 if a company seeks to sell GMOs in the market for food and feed use and/or food and feed products containing or produced from GMOs. At the
national level, EU member states have the ability to restrict or prohibit GMO cultivation in their territories by invoking grounds such as environmental or agricultural policy objectives, town and country-planning, land use, coexistence,
socio-economic impacts or public policy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Directive 2001/18/EC, Regulation (EC) 1829/2003 and Regulation (EC) 1830/2003
establish specific labeling and traceability requirements for GMOs and products that contain or are produced from GMOs. Finally, Directives 2002/53/EC and 2002/55/EC require genetically modified varieties to be authorized in accordance with
Directive 2001/18/EC and/or Regulation (EC) 1829/2003, as applicable, before they can be included in a &#147;Common Catalogue of Varieties,&#148; which would permit the seeds of such genetically modified varieties to be marketed in the EU. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the EU, one of Cibus&#146; <B><I>RTDS</I></B> technologies is well known as ODM. In the period between 2011 and 2015, Cibus requested
guidance from EU competent authorities in Germany, Sweden, the UK, Ireland, Finland and Spain to determine the requirements in order to conduct field trials with oilseed rape lines developed using ODM technology. These competent authorities issued
opinions that the line could be excluded from Directive 2001/18/EC and be tested in field trials like any other new variety. These opinions were consistent with submissions to the European Court of Justice (&#147;ECJ&#148;) Case 528/16 made by,
amongst others, the European Commission. The opinions were also consistent with the <FONT STYLE="white-space:nowrap">non-binding</FONT> opinion of the Advocate-General in the same case. However, the final ruling, issued on July&nbsp;25, 2018,
concluded that organisms obtained by modern </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">250 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
mutagenesis plant breeding techniques, including ODM technologies, are GMOs and fall, in principle, under Directive 2001/18/EC and are subject to the obligations established in such directive,
including the stringent <FONT STYLE="white-space:nowrap">pre-market</FONT> authorization and associated environmental risk assessment requirements. The ECJ found further that varieties obtained by modern forms of mutagenesis are genetically modified
varieties covered by Directive 2002/53/EC, and are therefore subject to the obligations of such directive. The ECJ clarified that only mutagenesis techniques which have been used in a number of applications and have a long safety record can be
exempted from these requirements, although EU member states remain free to subject even such exempted organisms to the obligations under Directive 2001/18/EC, or to other obligations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of the ECJ ruling, the authorities of EU member states were required to treat organisms obtained by new techniques of directed
mutagenesis, including those utilized in substantially all of the product candidates in Cibus&#146; current pipeline, as GMOs. Such organisms are therefore still subject to the <FONT STYLE="white-space:nowrap">pre-market</FONT> assessments and
authorization procedures derived from Directive 2001/18/EC or, if applicable, Regulation (EC) 1829/2003, as well as to the labeling and traceability requirements applicable to GMOs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;8, 2019, in light of the ECJ Case <FONT STYLE="white-space:nowrap">C-528/16,</FONT> the Council of the European Union asked
the European Commission to submit, by April&nbsp;30, 2021, a study regarding the status of new genomic techniques under EU law. The Council asked that, if appropriate in view of the outcomes of the study, the Commission should also submit a proposal
for new legislation. In the report, the Commission concluded that there were strong indications that EU GMO legislation was not fit for purpose for some New Genomic Techniques (NGTs) and their products, and that it needed adaptation to science-based
and technological progress. The Commission then announced the initiation of a policy action for new legislation aimed at providing a proportionate regulatory oversight for plants derived from targeted mutagenesis and cisgenesis. The Commission
stated that the policy should allow reaping benefits from innovation by enabling safe NGT products to contribute to the sustainability and resilience of the EU agri-food system. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Jurisdictions with Established Procedures Applicable to New Plant Breeding Techniques </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Argentina </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Argentinian authority, CONABIA, is responsible for the regulation of GMOs under Resolution 763/11, which provides an overall regulatory framework, and Resolution 701/11, which provides specific procedures for plant GMOs, including field trials and
commercial release. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2015, CONABIA introduced Resolution 173/15, which provides procedures to establish if a crop obtained with the aid
of new plant breeding techniques is a GMO as defined under Resolution 763/11. The analysis is <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> and can provide a preliminary answer in the design stage of a
new product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2018, CONABIA reviewed a Cibus Canola line developed using ODM technology within the <B><I>RTDS</I></B> and concluded
that it was not a GMO as defined by Resolution 763/11. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Brazil </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Brazilian authority, CTNBio, is responsible for the regulation of GMOs under Law No.&nbsp;11.105 of 2005, which provides for safety norms
and inspection mechanisms for activities with GMOs and their <FONT STYLE="white-space:nowrap">by-products.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2018, CTNBio
introduced Normative Resolution No 16, which provides procedures to establish if a crop obtained with the aid of new plant breeding techniques is a GMO as defined under Law No.&nbsp;11.105 of 2005. The analysis is <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">case-by-case</FONT></FONT> with the primary determining factor for <FONT STYLE="white-space:nowrap">non-GMO</FONT> status being the absence of recombinant DNA/RNA in the product. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Chile </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Chilean
authority, SAG, is responsible for the regulation of GMOs under Resolution No 1523/2001, which controls the entry and introduction to the environment of Living Modified Organisms. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">251 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2017, SAG issued a statement indicating that scientific advances had allowed the
development of a new generation of biotechnological techniques of plant breeding other than transgenic, and as a result, SAG considers it necessary to solve case by case if the material of propagation developed by any of these techniques is found
within or out of the scope of Resolution No.&nbsp;1523/2001. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SAG has provided procedures to establish if a crop product obtained with the
aid of new plant breeding techniques is a GMO as defined under Resolution No 1523/2001. SAG will evaluate the background information presented on the technique and will verify if the crop product in question possesses a new combination of genetic
material. Thereafter, SAG will pronounce by resolution, if the crop product is within or out of the scope of Resolution No.&nbsp;1523/2001. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For these purposes, a new combination of genetic material will be understood as a stable insertion of one or more genes or DNA sequences
encoding proteins, interfering RNA, double stranded RNA, signaling peptides or regulatory sequences. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2019, SAG reviewed a Cibus Canola
line developed using ODM technology and site directed nuclease within the <B><I>RTDS</I></B> and concluded that it was not a GMO and was outside the scope Resolution No.&nbsp;1523/2001. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6-</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>COMPETITION </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The market for agricultural Productivity Traits is highly competitive, and Cibus faces significant competition. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The development of Productivity Traits are the primary target of plant breeding programs and a key basis of competition in the &#147;seed and
trait&#148; business. These technologies underpin the expected performance of a given seed and are the primary basis for competition in the seed business. These technologies are generally developed internally by seed companies, but they are often
bought or licensed from third parties such as other seed companies, the many academic institutions that have large programs or independent trait developers. The most likely competitors are likely to come from a relatively small number of major
global agricultural chemical companies, including BASF, Bayer, Corteva AgriScience and Syngenta, smaller biotechnology research companies and institutions, including Arcadia Biosciences, Benson Hill Biosystems, Inari Agriculture, KeyGene, Pairwise
Plants, Precision BioSciences now Elo Life Systems Yield10 and academic institutions. Our major competitors in some instances also be our customers Many of the companies above license out traits they have developed but sometimes they retain the
rights for both competitive reasons and technical reasons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of Cibus&#146; current or potential competitors, either alone or with
their research and development or collaboration partners, have significantly greater financial resources and expertise in research and development, manufacturing, testing and marketing approved products than Cibus does. Smaller or early-stage
companies may also prove to be significant competitors, particularly through research and development and collaborative arrangements with large and established companies. These competitors also compete with Cibus in recruiting and retaining
qualified scientific and management personnel, as well as in acquiring technologies complementary to, or necessary for, Cibus&#146; programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patents and proprietary technologies are important competitive barriers to competition. In addition to patents that may exist on technology to
develop traits, virtually all of the leading traits that are licensed or sublicensed from 3<SUP STYLE="font-size:75%; vertical-align:top">rd</SUP> parties have specific intellectual property on the trait itself. Cibus expects to have patents and
proprietary technology associated with its traits. For example, Cibus was issued a patent in 2022 for its lead trait: pod shatter reduction in Canola. With patents, it is still possible for competition to develop the trait in other ways such as
conventional breeding but gene editing patents should provide strong competitive barriers to other gene edited traits for the same genetic characteristics. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">252 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cibus&#146; Competitive Strengths </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus believes that it is strategically well-positioned to develop innovative traits and products with high-value commercial applications.
Cibus&#146;<B><I> RTDS </I></B>technology platform and the Trait Machine provide a significant competitive advantage in development and commercialization of new traits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Cibus believes that all of Cibus&#146; traits are going to be treated as gene edited meaning that that are developed without integrating
foreign DNA in the process or the product</I></B><I>. </I>This designation that our traits are not being regulated as GMO in many jurisdictions is an important competitive factor. The <FONT STYLE="white-space:nowrap">non-transgenic</FONT>
categorization of Cibus&#146; trait products in these key target markets provide Cibus with significant advantages. All six traits in Cibus&#146; traits have been determined not to be regulated articles through the USDA&#146;s &#147;Am I
Regulated&#148; process, which was replaced with the SECURE Rule&#146;s confirmation process. Numerous regulatory agencies in the Americas, including the United States, Canada and Argentina, have confirmed that Cibus&#146;
<B><I>RTDS</I></B>-developed trait products are <FONT STYLE="white-space:nowrap">non-transgenic</FONT> and are not subject to heightened GMO regulation in these markets. In addition, Cibus is able to bring its products to market quickly and at a low
cost, in part because its products are not subject to the time-consuming regulatory hurdles that apply to transgenic products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>The
Trait Machine materially accelerates the time and ability to develop new traits</I></B><I>. </I>Time to develop and time to commercialize traits are important competitive factors. The ability of Cibus to collaborate with seed companies and edit
directly into a customer&#146;s germplasm accelerates time to launch and established need and commercial viability of each trait Cibus develops. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Cibus has a pipeline of six traits. Cibus believes that these traits are novel traits for which competition for these genetic
charactersistic from gene editing will be limited.</I></B><B> </B>Cibus has selected its initial trait based on customer demand and the competitive position for each trait once developed. Once traits are developed and intellectual property has been
developed around the trait, competition for traits has historically been limited. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Proprietary RTDS technologies and The Trait
Machine provide the ability to stack traits and develop customized seed products quickly and efficiently</I></B>.<B> </B>Cibus&#146; patent-protected <B><I>RTDS</I></B> can deliver multiple desirable traits within the same plant without the
integration of foreign genetic material. Cibus has developed cell culture technologies that enable it to design and transfer a plant in the greenhouse with desirable traits within just a few months. Through <B><I>RTDS</I></B>, Cibus has established
a predictable, reproducible and scalable process whereby it can develop customized plant products with multiple desirable traits specifically chosen to meet needs across the agricultural value chain. This process has been developed into the
industry&#146;s first standardized, semi-automated <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-to-end</FONT></FONT> gene editing facility&#151;The Trait Machine. As a result, Cibus can use The Trait Machine to offer
differentiated products that stack multiple, desirable traits in plants. With <B><I>RTDS</I></B>, Cibus is developing a trait portfolio across major crops that addresses significant market opportunities. Cibus has already establihed an
<B><I>RTDS</I></B> technology platform for trait development in Canola and Rice. It expects to complete the development of its Soybean <B><I>RTDS</I></B> platforms by the end of 2023, Wheat by 2024 and its Corn <B><I>RTDS</I></B> platform by 2025.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Capital-efficient and highly scalable business model</I></B>.<B> </B>Cibus has<B> </B>a capital-efficient, <FONT
STYLE="white-space:nowrap">low-cost</FONT> and <FONT STYLE="white-space:nowrap">highly-scalable</FONT> business model. Its trait licensing strategy is based on Cibus&#146; core strengths in research and development and trait development. Cibus will
continue to focus on advancing its gene-editing technologies toward developing plant traits for desired characteristics and intends to largely partner and license its traits to leading seed companies who will manage plant breeding and
commercialization. Focusing on trait development while leveraging Cibus&#146; licensing partners&#146; breeding and commercialization expertise, market presence and geographic reach will reduce Cibus&#146; expenses and allow Cibus to pursue
diversified growth across crop and trait platforms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Recognized as <FONT STYLE="white-space:nowrap">non-transgenic</FONT> in key
target markets due to Cibus&#146; unique process and products</I></B>. Numerous regulatory agencies in the Americas, including the United States, Canada and Argentina, have confirmed that Cibus&#146; <B><I>RTDS</I></B>-developed trait products are <FONT
STYLE="white-space:nowrap">non-transgenic</FONT> and are not subject to heightened GMO </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">253 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regulation in these markets. The <FONT STYLE="white-space:nowrap">non-transgenic</FONT> categorization of Cibus&#146; trait products in these key target markets provide Cibus with significant
advantages. In particular, Cibus is able to bring its products to market quickly and at a low cost, in part because its products are not subject to the time-consuming regulatory hurdles that apply to transgenic products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Premier management team with broad expertise</I></B>.<B> </B>Cibus&#146; management and senior leadership team has more than 300 years
of cumulative industry experience and brings broad knowledge across key areas of its business, including research and development, product marketing, patent royalty management and regulatory compliance and oversight. Cibus&#146; Chief Executive
Officer and Chairman, Rory Riggs, its President and Chief Operating Officer, Dr.&nbsp;Peter Beetham, and its Chief Scientific Officer and Executive Vice President, Dr.&nbsp;Greg Gocal, are founding members of the management team and each played a
key role in developing Cibus&#146; business. Cibus&#146; leadership has a significant track record of scientific breakthroughs, including the development of <B><I>RTDS</I></B>, and product development at prestigious academic and research
institutions and well-known agri-business companies. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7-</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>EMPLOYEES AND HUMAN CAPITAL RESOURCES </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, Cibus had 189 full-time employees, including a total of 26 employees with Ph.D. degrees. Of these full-time
employees, approximately 143 employees are engaged in research and development, including trait development and production. None of Cibus&#146; employees are represented by a labor union or collective bargaining agreement. We consider our
relationship with our employees to be good. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus views its employees as among its most valuable assets. Its ability to hire and retain
highly skilled professionals remains a key element to its success in developing and licensing novel Productivity Traits and high-value, <FONT STYLE="white-space:nowrap">low-carbon</FONT> ingredients. Cibus&#146; human capital objectives are focused
on identifying, recruiting, retaining, incentivizing and integrating its existing and newly hired employees. We strive to be equitable and inclusive. Cibus designs its compensation and benefit programs to help meet the needs of its employees,
focusing on programs that promote well-being across all aspects of their lives, including healthcare, retirement planning and paid time off. Cibus pays its employees competitively in line with Cibus&#146; compensation philosophy, which includes
paying employees at a rate consistent with an employee&#146;s position, knowledge and skills. Cibus&#146; use of equity incentive compensation is designed to attract, retain and motivate its employees, consultants and directors through the granting
of equity-based compensation awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus also strive to make the company an inclusive, safe and healthy workplace, with opportunities
for each of its employees to grow and develop in their careers. Additionally, Cibus promotes opportunities for employees of all backgrounds and seeks to actively support, promote and maintain a culture that fosters inclusion and diversity with
respect to age, disability, gender identity or expression, ethnicity, military veteran status, national origin, race, religion, sexual orientation, and other backgrounds and experiences. We have a highly matrixed team that fosters diversity in ideas
and background with 40% holding advanced degrees and approximately half who are women. We are committed to continuing to improve representation and diversity, while fostering a welcoming environment where everyone belongs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our dynamic culture has been developed over time by teams of employees who represent six major components of engagement: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Team Building </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Diversity, Equity&nbsp;&amp; Inclusion </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Communications </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Wellness </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Social Events </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Safety Action </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">254 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These components are important threads which weave through our culture and encourage
involvement and empowerment, while providing everyone with the ability to positively influence the work environment. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8-</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>RESEARCH AND DEVELOPMENT </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus&#146; research and development is involved in multiple aspects of platform and trait development. It is involved in building the
crop-specific single cell platforms that are integral to the Trait Machine. In addition, they are integral to the development and implementation of the <B><I>RTDS</I></B> and ODM gene editing technologies and the development building and
implementation of the crop-specific Trait Machine platforms. The team has technical expertise in genomics, genome engineering, molecular biology, biochemistry, genetics and genetic engineering, cell biology, plant physiology, plant breeding, strain
engineering and fermentation. Cibus&#146; research and development activities are conducted principally at its San Diego, California facilities. Cibus has made, and will continue to make, substantial investments in research and development. Its
research and development expenses were $33.5&nbsp;million and $22.2&nbsp;million for the years ended December&nbsp;31, 2022 and 2021, respectively. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9-</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>FACILITIES </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus&#146; headquarters is located in San Diego, California, where it has leases for its office space, including its corporate headquarters
and laboratory space, and stand-alone laboratory space (the Trait Machine Facility) in San Diego, California, totaling 53,423 and 31,939 square feet, respectively, with terms that expire in May 2025 and September 2025, respectively. Cibus has 1
option to extend the laboratory space lease, for 1 year. However, as Cibus is not reasonably certain to exercise this option at lease commencement, the option was not recognized as part of the associated operating lease <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT> (ROU) asset or liability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, Cibus has
certain leases for greenhouse and warehouse facilities, totaling 30,800 and 6,207 square feet, respectively, with terms that expire in September 2023 and August 2026, respectively. Cibus has 1&nbsp;option to extend the term of the greenhouse lease,
for 5 years, and 1 option to extend the warehouse lease, for 5&nbsp;years. However, as Cibus is not reasonably certain to exercise either of those options at lease commencement, neither option was recognized as part of the associated operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT> (ROU) asset or liability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain leases
include rent abatement, rent escalations, tenant improvement allowances and additional charges for common area maintenance and other costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Cibus has offices in different locations in Canada, the United States and Europe. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the years ended December&nbsp;31, 2022 and 2021, Cibus incurred rent expenses under these leases of $3.4&nbsp;million and
$2.5&nbsp;million, respectively. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10-</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>LEGAL PROCEEDINGS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, Cibus may be subject to legal proceedings and claims in the ordinary course of business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;3, 2019, Houston Casualty Company filed a Complaint for Declaratory Relief and Recoupment with the United States District Court
located in the Southern District of California related to an insurance claim involving Cibus Global&#146;s hybrid canola products sold in 2018. On October&nbsp;10, 2019 Cibus Global filed a counterclaim for certain breaches and damages. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">255 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom401831_48"></A>CALYXT MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FINANCIAL CONDITION AND RESULTS OF OPERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following discussion and analysis should be read in conjunction with Calyxt&#146;s financial statements and related notes included
elsewhere in this proxy statement/prospectus. This discussion contains forward-looking statements based upon current expectations that involve risks and uncertainties. Calyxt&#146;s actual results and the timing of selected events could differ
materially from those anticipated in these forward-looking statements as a result of several factors, including those set out under the section entitled &#147;Risk Factors&#148; in this proxy statement/prospectus. See also the section entitled
&#147;Cautionary Statement Concerning Forward-Looking Statements&#148; in this proxy statement/prospectus. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt is a plant-based synthetic biology company. Calyxt leverages its proprietary
PlantSpring<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> technology platform to engineer plant metabolism to produce innovative, high-value, and sustainable materials and products for use in helping customers meet their sustainability
targets and financial goals. In October 2021, Calyxt announced the launch of a strategic initiative which focused on engineering synthetic biology solutions through its PlantSpring platform for manufacture using its proprietary and differentiated
BioFactory<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> production system for a diverse base of target customers across a range of end markets, including the cosmeceutical, nutraceutical, and pharmaceutical industries. Calyxt also
commercializes its PlantSpring technology platform by licensing elements of the platform and historically developed traditional agriculture seed-trait product candidates, as well as selectively developing product candidates for customers in
traditional agriculture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The business is described in greater detail in &#147;<I>Calyxt Business&#151;Company Overview</I>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt is an early-stage company and has incurred net losses since its inception. As of December 31, 2022, Calyxt had an accumulated deficit
of $212.2&nbsp;million. Calyxt&#146;s net losses were $16.9&nbsp;million for the year ended December 31, 2022. Calyxt expects to continue to incur significant expenses and operating losses for the next several years. Those expenses and losses may
fluctuate significantly from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">quarter-to-quarter</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-year.</FONT></FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Historically, Calyxt&#146;s expenses in connection with the execution of its long-term business plan have been primarily driven by: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">R&amp;D expenses associated with developing and enhancing the capabilities of its PlantSpring technology
platform; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">R&amp;D expenses and capital expenditures to expand its BioFactory production system; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory expenses associated with R&amp;D and product development; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintaining, protecting, expanding, and defending its intellectual property portfolio, including intellectual
property related to the PlantSpring technology platform and BioFactory production system; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">human capital related expenses associated with attracting and retaining skilled personnel; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pursuing and negotiating agreements with customers, licensees, and infrastructure partners.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September 22, 2022, Calyxt announced that the Calyxt Board had begun evaluating potential strategic alternatives to
maximize stockholder value, including financing alternatives, merger, reverse merger, other business combinations, sale of assets, licensing, or other transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January 13, 2023, Calyxt and Merger Subsidiary entered into the Merger Agreement with Cibus Global. Pursuant to the Merger Agreement,
following the Transactions, Calyxt will be organized in an &#147;Up-C&#148; structure </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">256 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and re-named &#147;Cibus, Inc.&#148; and its only material asset will consist of common units of Cibus Global. If the Transactions are completed, the business of Cibus will continue as the
primary business of the Combined Company and the equity holders of Cibus Global will own a substantial majority of the issued and outstanding Calyxt Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Closing is subject to the approval of Calyxt Stockholders, the approval of Cibus Global&#146;s members, the receipt of required regulatory
approvals (to the extent applicable) and satisfaction of other customary closing conditions. The Closing is currently expected to occur in the second quarter of 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If, for any reason, the Transactions are not completed, Calyxt will reconsider its available alternatives at such time and could pursue one of
the following courses of action, which Calyxt currently believes to be the most likely alternatives: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Dissolve and liquidate</I>. Calyxt may decide to dissolve and liquidate its assets. In such a circumstance,
Calyxt would be required to pay all of its debts and contractual obligations and to set aside certain reserves for potential future claims. In light of Calyxt&#146;s current capital resources, it is highly unlikely, in this case, that substantial
resources, if any, would be available for distributions to stockholders. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Pursue another strategic transaction</I>. Calyxt may decide to resume the process of evaluating a potential
merger, reorganization or other business combination transaction or to sell or otherwise dispose of certain of Calyxt&#146;s assets. Any of these alternatives would be costly and time-consuming and would require that Calyxt obtain additional
near-term funding in parallel to, or as part of, such a strategic transaction. Calyxt expects that it would be difficult to secure such funding in a timely manner, on favorable terms or at all. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Operate the business</I>. Although substantially less likely than the alternatives above, the Calyxt Board
could elect to seek to continue to operate Calyxt&#146;s business. This alternative would require that Calyxt obtain additional near-term funding, which Calyxt expects would be difficult to secure in a timely manner, on favorable terms or at all. If
pursued, Calyxt would likely need to significantly delay or further scale back operations beyond its already narrowly focused operational activities. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Current Operational Focus </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior
to the announcement of the Transactions, Calyxt&#146;s primary focus was on the development of synthetic biology products for its customers using its BioFactory production system. In light of the proposed Transactions and recent capital resource
constraints, Calyxt has substantially scaled back its operations and has focused its current business activities on ensuring it has cash sufficient to achieve a closing of the proposed Transactions. Accordingly, Calyxt&#146;s management has
implemented cost reduction and other cash-focused measures, including reduction of capital expenditures, headcount reductions, and renegotiation or termination of professional services agreements. To conserve cash, Calyxt has also strategically
evaluated its arrangements with suppliers and service providers and has, in several instances, transitioned such relationships to lower cost alternative providers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In limiting operations to core activities, Calyxt has focused its continuing operations on: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">scaling production of a single Plant Cell Matrix with its manufacturing partner, Evologic; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">licensing efforts with respect to its PlantSpring technology and plant traits, including the TALEN technology;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continuing to progress its three current customer projects&#151;(1) its research collaboration with a leading
global food ingredient manufacturer to develop a soybean trait to serve as an alternative to palm oil, (2) its plant-based chemistry pilot project for a major consumer packaged goods company, and (3) supporting late-stage development activities for
its improved digestibility alfalfa trait, which was developed with and licensed to S&amp;W Seed Company. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">257 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt has suspended non-core activities, such as efforts toward the development and
integration of AIML and the initiation, development and commercialization of additional synthetic biology products, or chemistries, beyond those involved in the continuing operations identified above. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Relationship with Cellectis and Comparability of Results </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt, Inc.&#146;s largest shareholder is Cellectis. As of December 31, 2022, Cellectis owned 49.1% of issued and outstanding Calyxt Common
Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cellectis has certain contractual rights as well as rights pursuant to the Calyxt Certificate of Incorporation and Calyxt Bylaws,
in each case, for so long as it maintains threshold beneficial ownership levels in Calyxt Common Stock. See &#147;<I>Risk Factors&#151;Risks Related to Calyxt&#151;Risks Related to Ownership of Calyxt Common Stock if the Mergers Are Not
Completed&#151;If the Mergers do not close for any reason, Cellectis will continue to possess rights that prevent other stockholders from influencing significant decisions.</I>&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Cellectis has guaranteed the lease agreement for Calyxt&#146;s headquarters. However, Calyxt previously agreed to indemnify
Cellectis for any obligations under this guaranty, effective upon Cellectis&#146; ownership falling to 50&nbsp;percent or less of outstanding Calyxt Common Stock. Accordingly, Calyxt&#146;s indemnification obligation was triggered in October 2022.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt holds an exclusive license from Cellectis that broadly covers the use of engineered nucleases for plant gene editing. This
intellectual property covers methods to edit plant genes using &#147;chimeric restriction endonucleases,&#148; which include TALEN<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, CRISPR/Cas9, zinc finger nucleases, and some types of
meganucleases. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Operations Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue is recognized from
sales of products, from licenses of technology, and from product development activities for customers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cost of Goods Sold </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cost of goods sold are recognized as products are sold. There are minimal cost of goods sold associated with Calyxt&#146;s technology licensing
activities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt&#146;s R&amp;D expenses primarily consist of employee-related costs for personnel who research and develop its product candidates, fees
for contractors who support product development activities, purchasing material and supplies for its laboratories, licensing, an allocation of facility and information technology expenses, and other costs associated with owning and operating its own
laboratories and pilot BioFactory capabilities. This includes the costs of performing activities to discover and develop products and advance Calyxt&#146;s PlantSpring technology platform, including its intellectual property portfolio. BioFactory
expenses from lab through pilot, unless incurred related to a specific product sold to a customer, are also classified as R&amp;D expense. R&amp;D expenses also include costs to write and support the research for filing patents. Calyxt recognizes
R&amp;D expenses as they are incurred. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Selling, General, and Administrative Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Selling, general, and administrative (SG&amp;A) expenses consist primarily of employee-related expenses for selling and licensing Calyxt&#146;s
products and employee-related expenses for its executive, legal, intellectual </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">258 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
property, information technology, finance, and human resources functions. In periods prior to 2021, these expenses also included employee-related and other expenses for selling soybean oil and
meal, soybean acreage acquisition, and managing the soybean product supply chain. Other SG&amp;A expenses include facility and information technology expenses not otherwise allocated to R&amp;D expenses, professional fees for auditing, tax and legal
services, expenses associated with maintaining patents, consulting costs and other costs of Calyxt&#146;s information systems, and costs to market its products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest, net </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest, net is
comprised of interest income resulting from investments of cash and cash equivalents, short-term investments, unrealized gains and losses on short-term investments, issuance costs associated with Calyxt Common Warrants issued in February 2022, and
interest expense incurred related to financing lease obligations. It is also driven by balances, yields, and timing of financing and other capital raising activities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Non-operating income (expenses) </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">Non-operating</FONT> income (expenses) are income or expenses that are not directly related to ongoing operations and are primarily comprised of gains and losses from the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">mark-to-market</FONT></FONT> of Calyxt Common Warrants, gain from a legal settlement, expenses associated with the evaluation of strategic alternatives, foreign exchange-related transactions, and disposals of land,
buildings, and equipment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes Between Revenues and Costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt was previously focused on the development of traits for traditional agriculture that it planned to commercialize using either a
vertically integrated or licensing business model. Calyxt&#146;s first commercial product, a high oleic soybean, was launched in this manner in the first quarter of 2019. In August 2020, Calyxt announced it was winding down the vertically integrated
soybean product line. The wind-down of this product line was completed in late 2021 with the final sales of soybean grain to a large soybean processor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As Calyxt transitioned its business model, the composition of revenues and costs has evolved, with soybean-related revenues declining to zero,
the negative gross profit margins experienced from sales of those products no longer occurring, and the significant working capital investment to support those activities also declining. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent any revenue is generated under Calyxt&#146;s current business model, such revenue would derive from product development
activities for customers for both the BioFactory production system and agricultural production and technology licensing arrangements. Any such cash and revenue-generating opportunities associated with these activities would be expected to primarily
arise from <FONT STYLE="white-space:nowrap">up-front</FONT> and milestone payments, annual license fees, and royalties. If and when the BioFactory begins to produce products for customers, it is anticipated that such revenues would grow and surpass
revenues from other sources. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the course of discussions with Cibus regarding, and following the execution of, the Merger Agreement,
Calyxt has streamlined and focused its business activities on preserving cash sufficient to achieve a closing of the Transactions. Accordingly, Calyxt has taken additional steps to streamline its operations and to reduce its operating expenses,
while focusing on a limited scope of core projects. While these projects are important for Calyxt&#146;s overall product development pipeline, none of these projects is expected to generate material revenue in the near term. While Calyxt
continuously implemented cost reduction measures including not filling open positions throughout 2022, the principal impact of these actions affects results of operations beginning in early 2023 following the reduction in employees from 48 to 28,
including attrition, in January 2023. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">259 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations for the Year Ended December 31, 2022, Compared to the Year Ended December 31, 2021
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A summary of Calyxt&#146;s results of operations for the years ended December 31, 2022 and 2021 follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$&nbsp;Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%&nbsp;Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B></B>(In thousands, except percentage values)<B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>157</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(25,830</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(99</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of goods sold</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(28,557</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(100</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>157</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,570</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">106</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>11,553</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general, and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>10,974</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,453</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(22,370</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29,332</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain upon extinguishment of Payroll Protection Program loan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,528</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(100</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(87</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,414</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-operating</FONT> income (expenses)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>5,566</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,547</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,195</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(16,891</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29,199</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(0.37</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.78</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue, Cost of Goods Sold, and Gross Profit </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenues were $0.2&nbsp;million in 2022, a decrease of $26.0&nbsp;million, or 99&nbsp;percent, from 2021. Cost of goods sold was zero in 2022,
a decrease of $28.6&nbsp;million, or 100&nbsp;percent, from 2021. Gross profit was $0.2&nbsp;million, constituting 100&nbsp;percent of revenue, in 2022, compared to negative $2.6&nbsp;million, or negative 47&nbsp;percent of revenue, in 2021. The
decreases in revenue and cost of goods sold and improvement in gross profit were driven by the late 2021 completion of the wind-down of Calyxt&#146;s soybean product line and transition of Calyxt&#146;s focus to synthetic biology, which remains an
early stage field and has not yet generated significant revenue. Revenue in 2022 was primarily associated with Calyxt&#146;s agreement with a large food ingredient manufacturer to develop a palm oil alternative. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">R&amp;D expense was $11.6&nbsp;million in 2022, an increase of $0.2&nbsp;million, or 2&nbsp;percent, from 2021. The increase was primarily
driven by an increase in allocated SG&amp;A costs of $2.0&nbsp;million as Calyxt adjusted its cost allocation methodology at the beginning of 2022, partially offset by $0.7 million of cost savings due to the change in Calyxt&#146;s business model,
$0.6 million lower cash compensation expense, and $0.5 million lower non-cash stock compensation expense. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Selling, General, and Administrative
Expense </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SG&amp;A expense was $11.0&nbsp;million in 2022, a decrease of $4.5&nbsp;million, or 29&nbsp;percent, from 2021. The
decrease was driven by cost allocations to R&amp;D expense of $2.0&nbsp;million, lower cash compensation expense of $1.0 million, other expense reductions of $0.9 million, and a $0.6 million one-time benefit from the modification of Calyxt&#146;s
former Chief Executive Officer&#146;s severance agreement. These decreases were partially offset by $0.8&nbsp;million in higher rent expense as a result of the adoption of the lease accounting standard. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Gain Upon Extinguishment of Payroll Protection Program Loan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April 8, 2021, Calyxt was notified by the U.S Small Business Administration (SBA) that the full principal amount and all accrued interest of
the Paycheck Protection Program loan had been forgiven. Accordingly, Calyxt recognized a gain upon the extinguishment of the Payroll Protection Program Loan (the PPP loan) of $1.5 million in 2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">260 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest, net </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest, net was an expense of $0.1&nbsp;million in 2022, an improvement of $1.3&nbsp;million, or 94&nbsp;percent, from 2021. The improvement
was driven by the adoption of the lease accounting standard, which shifted amounts previously reported as interest expense to SG&amp;A expense. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT
STYLE="white-space:nowrap">Non-operating</FONT> income (expenses) </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-operating</FONT> income
(expenses) were income of $5.6&nbsp;million in 2022, an improvement of $5.5&nbsp;million from 2021. The improvement was driven by the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> of Calyxt Common
Warrants derivative liability, which declined in value due to a decline in stock price in 2022, partially offset by expenses associated with the strategic alternatives review. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Loss </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net loss was
$16.9&nbsp;million in 2022, an improvement of $12.3&nbsp;million, or 42&nbsp;percent, from 2021. The improvement in net loss was driven by the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> of Calyxt
Common Warrants derivative liability, the completion of the wind-down of the soybean product line in late 2021, and lower operating expenses. These improvements were partially offset by the gain realized on the forgiveness of the PPP loan in the
second quarter of 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Loss Per Share </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net loss per share was $0.37 in 2022, an improvement of $0.41 per share, or 53&nbsp;percent, from 2021. The improvement in net loss per share
was driven by the improvement in net loss and a year-over-year increase in the weighted average shares outstanding. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidity</I></B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt&#146;s
primary sources of liquidity are its cash and cash equivalents. As of December 31, 2022, Calyxt had $3.5&nbsp;million of cash, cash equivalents, and restricted cash. Calyxt&#146;s restricted cash balances are cash and cash equivalents deposited in
an amount equal to future equipment rent payments, as required under its equipment lease facility. Calyxt may request the return of excess restricted cash collateral annually in December. Calyxt&#146;s restricted cash was $0.1&nbsp;million as of
December&nbsp;31, 2022. Current liabilities were $1.7&nbsp;million as of December&nbsp;31, 2022. Calyxt&#146;s current cash, cash equivalents, and restricted cash is sufficient to cover all of its current liabilities as of December&nbsp;31, 2022.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt&#146;s liquidity funds its non-discretionary cash requirements and its discretionary spending. Prior to the wind-down of
Calyxt&#146;s soybean go-to-market strategy, working capital was its principal non-discretionary funding requirement. In addition, Calyxt has contractual obligations related to recurring business operations, primarily related to lease payments for
its headquarters and laboratory facilities. Calyxt&#146;s principal discretionary cash spending is for capital expenditures, short-term working capital payments, and professional and other transaction-related expenses incurred as Calyxt pursues
additional financing and evaluates potential alternative transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt incurred net losses of $16.9 million for the year ended
December 31, 2022. As of December 31, 2022, Calyxt had an accumulated deficit of $212.2 million and expects to continue to incur losses in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">261 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash Flows from Operating Activities </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">In Thousands (except percentage values)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$&nbsp;Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%&nbsp;Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(16,891</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)</B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29,199</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain upon extinguishment of Payroll Protection Program loan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp; </B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,528</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,534</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(804</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(34</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>3,998</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,908</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized (gain) loss on mark-to-market of common stock warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(5,120</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)</B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B><B></B><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B></B><B></B><B></B><B>&#151;</B>&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,120</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">NM</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(2,885</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)</B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B></B><B></B><B></B>7,488</TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,373</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(139</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash used by operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(19,364</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)</B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(18,811</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(553</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NM- not
meaningful </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used by operating activities was $19.4&nbsp;million in 2022, an increase in cash used of $0.6&nbsp;million, or
three&nbsp;percent, from 2021. The net cash used by operating activities result was driven by a $12.3&nbsp;million improvement in net loss, a $1.9&nbsp;million increase in <FONT STYLE="white-space:nowrap">non-cash</FONT> stock compensation,
primarily the result of the forfeiture of unvested stock awards in the first quarter of 2021, and the $1.5&nbsp;million gain upon extinguishment of the PPP loan in the second quarter of 2021, which were more than offset by a $5.1&nbsp;million gain
on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> of the Calyxt Common Warrants and a $10.4&nbsp;million decline in cash provided by operating assets and liabilities due to the completion of the
wind-down of the soybean product line in late 2021 and transition of Calyxt&#146;s focus to synthetic biology, which remains an early stage field and has not yet generated significant revenue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt expects cash used by operating activities in 2023 to be lower than 2022 driven by reductions in operating expenses as a result of
Calyxt&#146;s cost reduction initiatives and streamlining of operational focus prior to the anticipated Closing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash Flows from Investing
Activities </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">In Thousands</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$&nbsp;Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%&nbsp;Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and (purchases) of short-term investments, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;</B>&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,698</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11,698</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(100</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of land, buildings, and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(1,520</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)</B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(497</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,023</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(206</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash (used) provided by investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(1,520</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)</B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B><B></B>$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B></B><B></B><B></B>11,201</TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,721</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(114</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used by investing activities was $1.5&nbsp;million in 2022, an increase in cash used of
$12.7&nbsp;million, or 114&nbsp;percent, from 2021. This increase in cash used by investing activities was driven by the 2021 sale of short-term investments to fund operations and higher capital expenditures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt expects cash used for purchases of land, buildings, and equipment in 2023 to be lower than 2022, driven by reductions in cash
expenditures as a result of Calyxt&#146;s cost reduction initiatives and streamlining of operational focus prior to the anticipated Closing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">262 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash Flows from Financing Activities </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B>In Thousands<B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$&nbsp;Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%&nbsp;Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from common stock issuance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>11,538</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">163</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Costs incurred related to the issuance of stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(1,173</B><B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B>)</B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(501</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(672</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(134</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repayments of financing lease obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(376</B><B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B>)</B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(364</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from the exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;</B>&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(227</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(100</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash provided by financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>9,989</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">167</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities was $10.0&nbsp;million in 2022, an increase of $6.2&nbsp;million, or
167&nbsp;percent, from 2021. The increase was primarily driven by $10.0&nbsp;million of net proceeds from the <FONT STYLE="white-space:nowrap">Follow-On</FONT> Offering in February 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt expects net cash provided by financing activities in 2023 to decrease compared to 2022, as a result of Calyxt&#146;s cost reduction
initiatives and streamlining of operational focus prior to the anticipated Closing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Capital Resources </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt has an effective shelf registration on Form S-3 on file with the SEC and additional capital is accessible from the capital markets,
including pursuant to its ATM Facility. However, amounts available under the shelf registration statement, including the ATM Facility, are significantly limited because Calyxt&#146;s public float is less than $75,000,000. Subject to Instruction
I.B.6 to Form S-3, which is referred to as the &#147;baby shelf&#148; rules, for so long as Calyxt&#146;s public float is less than $75,000,000, it may not sell more than the equivalent of one-third of its public float during any 12 consecutive
months pursuant to the baby shelf rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Such additional liquidity and access to capital resources is subject to market conditions and
other factors, including challenges associated with raising sufficient capital to meet Calyxt&#146;s financing needs in light of Calyxt, Inc.&#146;s current stock price and related constraints. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to December 31, 2022, Calyxt completed the following capital raising transactions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On July 25, 2017, Calyxt completed its IPO of common stock. In the aggregate, Calyxt received net proceeds from
the IPO of $58.0 million, all of which have been used to fund R&amp;D costs, build out commercial capabilities, and for general corporate purposes. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On May 22, 2018, Calyxt completed a follow-on offering of its common stock. In the aggregate, Calyxt received net
proceeds from the follow-on offering of $57.0 million. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On October 20, 2020, Calyxt completed a follow-on offering of its common stock. In the aggregate, Calyxt received
net proceeds from the follow-on offering of $14.0 million. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On September 21, 2021, Calyxt entered into an ATM Facility. In the aggregate, Calyxt received net proceeds from
the ATM Facility of $4.1 million through early January 2022. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">During the February 2022 Offering, Calyxt issued 3,880,000 shares of its common stock, 3,880,000 Pre-Funded
Warrants, and 7,760,000 Calyxt Common Warrants. In the aggregate, Calyxt received net proceeds of $10.0 million, after deducting approximately $0.9 million of underwriting discounts and estimated other offering expenses. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October 3, 2022, Calyxt, Inc. entered into an amendment to the Open Market Sale Agreement with Jefferies for the ATM Facility that enables
it, subject to the applicable baby shelf rules, to offer and sell up to 15,661,000 shares of its common stock. At its discretion, Calyxt, Inc. determines the timing and number of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">263 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shares to be issued under the ATM Facility. During the fourth quarter of 2022, Calyxt, Inc. issued approximately 2.0 million shares of common stock under the ATM Facility for proceeds of $0.1
million net of commissions and payments for other share issuance costs. From December 31, 2022 through the date of this proxy statement/prospectus, Calyxt has not issued any additional shares under the ATM Facility. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Capital Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt has incurred losses since its inception and its net loss was $16.9 million for the year ended December 31, 2022, and it used $19.4
million of cash for operating activities for the year ended December 31, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt has incurred losses since its inception. If the
Transactions are not consummated for any reason, Calyxt may decide to dissolve and liquidate its assets. In such a circumstance, Calyxt would be required to pay all of its debts and contractual obligations and to set aside certain reserves for
potential future claims. In light of Calyxt&#146;s current capital resources, it is highly unlikely, in this case, that substantial resources, if any, would be available for distributions to stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent the Transactions are not consummated for any reason and Calyxt is not liquidated and dissolved, it anticipates that it will
continue to generate losses for the next several years or until such time as an alternative strategic transaction is consummated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the
less likely scenario in which Calyxt seeks to continue to operate its business and until Calyxt can generate cash flows sufficient to support its operating capital requirements, it would seek to finance a portion of future cash needs through
(i)&nbsp;cash on hand, (ii)&nbsp;commercialization activities, which may result in various types of revenue streams from (a)&nbsp;future product development agreements and technology licenses, including upfront and milestone payments, annual license
fees, and royalties; and (b)&nbsp;product sales from its proprietary BioFactory production system; (iii)&nbsp;government or other third-party funding, (iv)&nbsp;public or private equity or debt financings, or (v)&nbsp;a combination of the foregoing.
However, capital generated by commercialization activities, if any, is expected to be received over a period of time and near-term additional capital may not be available on reasonable terms, if at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Transactions, beginning at the earlier of March 15, 2023 or the date Calyxt&#146;s unrestricted cash balance first
drops below $1,500,000, Calyxt can request, and Cibus Global has agreed to provide, an unsecured, interest-free revolving line of credit of up to $3,000,000 in cash, which amount may be increased to $4,000,000 if Cibus Global elects to extend the
Outside Date to June 30, 2023. Funds can be drawn by Calyxt in $500,000 increments and may only be used to fund operating expenses incurred in the ordinary course of business consistent with past practice and consistent with the negative covenants
in the Merger Agreement. The full outstanding balance of the Interim Funding will be reduced to zero in connection with the Closing, if the Transactions are consummated. The full outstanding balance of the Interim Funding will be forgiven by Cibus
Global if the Merger Agreement is terminated for any reason other than certain under certain conditions, as detailed in the Merger Agreement. The Interim Funding is subject to acceleration in connection with certain bankruptcy events. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt faces uncertainty regarding the adequacy of its capital resources and presently has limited access to additional financing and expects
to rely upon the Interim Funding in order to continue operations through the consummation of the Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While alternative public
and private transaction structures may be available, these may require additional time and cost, may result in fixed payment obligations, may result in substantial dilution to existing stockholders, particularly in light of Calyxt, Inc.&#146;s
current stock price, may impose operational restrictions on Calyxt, Inc., may grant holders rights senior to those of Calyxt Common Stock, and may not be available on attractive terms. Further, during the pendency of the Transactions, any such
transactions could only be entered into with the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">264 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consent of Cibus Global. Accordingly, although Calyxt continuously assesses market conditions and available financing alternatives, in light of Calyxt, Inc.&#146;s current stock price, the
restrictions imposed by the Merger Agreement and the availability of the Interim Funding, Calyxt does not anticipate any additional third-party funding prior to the consummation of the Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt believes its cash, cash equivalents, and restricted cash as of December 31, 2022, considering continuing actions taken to reduce its
operating expenses to enable the proposed Transactions to close, the legal settlement discussed in Note 8 to the consolidated financial statements, and the availability of the Interim Funding are sufficient to fund its operations through the second
quarter of 2023. Calyxt&#146;s management has concluded there is substantial doubt regarding its ability to continue as a going concern for a period of 12 months or more from the date of its Annual Report on Form 10-K for the year ended December 31,
2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and
satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that
might result from the outcome of the uncertainties described above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In light of Calyxt&#146;s current liquidity challenges and capital
resource constraints, management has implemented cost reduction and other cash-focused measures to manage liquidity, including reduction of capital expenditures, headcount reductions, and renegotiation or termination of professional services
agreements. To conserve cash, Calyxt has also strategically evaluated its arrangements with suppliers and service providers and has, in several instances, transitioned such relationships to lower cost alternative providers. During the course of
discussions with Cibus regarding, and following the execution of, the Merger Agreement, Calyxt has further streamlined and focused its business activities on preserving cash sufficient to achieve a closing of the Mergers. Accordingly, Calyxt has
taken additional steps to reduce its operating expenses and has focused its continuing operations on scaling production of its Plant Cell Matrix structures with its manufacturing partner, licensing efforts with respect to its PlantSprin technology
and plant traits and continuing to progress its three key customer projects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Calyxt is unable to consummate the Transactions, Calyxt
may have to implement increasingly stringent cost saving measures and significantly delay, scale back, or cease operations, in part or in full. If Calyxt decided to cease operations and dissolve and liquidate its assets, it is unclear to what extent
Calyxt would be able to pay its existing obligations. In such a circumstance and in light of Calyxt&#146;s current capital resources position, it is unlikely that substantial resources would be available for distributions to stockholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual</B><B> </B><B>Obligations,</B><B> </B><B>Commitments,</B><B> </B><B>and Contingencies</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December 31, 2022, Calyxt&#146;s contractual obligations consisted of minimum lease payments for its corporate headquarters and
laboratory facilities and equipment leases. In the aggregate, $7.5 million is due within the next five years, of which $1.5 million is payable in 2023. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sale-Leaseback of Headquarters and Laboratory Facilities</I></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2017, Calyxt consummated a sale-leaseback transaction with a third party for its corporate headquarters and laboratory facilities
in Roseville, Minnesota, which encompasses approximately 44,000 square feet including office and lab space, the first pilot BioFactory production system, greenhouses, and outdoor research plots. Calyxt is deemed the owner for accounting purposes.
The lease has a term of twenty years with four options to extend its term for five years each subject to there being no default under the lease terms beyond any cure period and Calyxt occupying the property at the time of extension. In 2017, Calyxt
received $7.0 million in connection with the sale of the land and uncompleted facility. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The lease commenced in May 2018. Under the lease,
Calyxt pays an annual base rent of eight percent of the total project cost with scheduled increases in rent of 7.5 percent on the sixth, eleventh, and sixteenth </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">265 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
anniversaries of the start of the lease commencement as well as on the first day of each renewal term. Currently, Calyxt pays an annual base rent of $1.4 million. The first increase will occur
during 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt is also responsible for all operating costs and expenses associated with the property. If the landlord decides to
sell the property, Calyxt has a right of first refusal to purchase the property on the same terms offered to any third party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrent
with entering the lease, Cellectis guaranteed the lease agreement for Calyxt&#146;s headquarters. However, Calyxt previously agreed to indemnify Cellectis for any obligations under this guaranty, effective upon Cellectis&#146; ownership falling to
50 percent or less of outstanding Calyxt Common Stock. Calyxt&#146;s indemnification obligation was triggered in October 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to
2022, this lease was considered a failed sale leaseback based on the nature of the transactions and was reported as a financing-type lease. As discussed below in Note 1 to the Consolidated Financial Statements, with Calyxt&#146;s adoption of the New
Lease Standard on January 1, 2022, this lease is now considered an operating lease. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sale-Leaseback of Equipment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt also has an equipment financing arrangement that is considered a financing-type lease which matures in 2023. Calyxt was required to
deposit cash into a restricted account in an amount equal to the future rent payments required by the lease. As of December 31, 2022, this restricted cash totaled $0.1 million, and will be returned following the payoff of the lease obligations in
2023. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying discussion and analysis of Calyxt&#146;s financial condition and results of operations are based upon its consolidated
financial statements and the related disclosures, which have been prepared in accordance with U.S. GAAP. The preparation of these consolidated financial statements requires Calyxt to make estimates, assumptions, and judgments that affect the
reported amounts in its consolidated financial statements and accompanying notes. Calyxt bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances, the results of which
form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. Calyxt believes the
following policies to be the most critical to understanding its financial condition and results of operations because they require the use of estimates, assumptions, and judgments about matters that are inherently uncertain. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
valuation of stock options is a critical accounting estimate that requires the use of judgments and assumptions that are likely to have a material impact on Calyxt&#146;s consolidated financial statements. Calyxt generally measures the fair value of
employee and nonemployee stock-based awards on their grant date and records compensation expense on a straight-line basis over the related service period of the award, which is generally the vesting period. Calyxt uses the Black-Scholes option
pricing model to value its stock option awards, which requires Calyxt to make predictive assumptions regarding employee exercise behavior, future stock price volatility, and dividend yield. Calyxt generally measures compensation expense for grants
of restricted stock units using Calyxt&#146;s share price on the date of grant. Calyxt uses a Monte Carlo simulation pricing model when estimating the fair values of Calyxt PSUs, which requires Calyxt to make predictive assumptions. Calyxt estimates
fair values and accounts for employee and nonemployee awards in a similar manner. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">266 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to the limited historical experience of Calyxt&#146;s stock awards program, it has
elected to account for forfeitures of awards as they occur. If an award is forfeited prior to vesting, the associated reduction in expense is reflected net in stock-based compensation expense in that period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stock Options </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The estimated fair values
of stock options granted, and the assumptions used for the Black-Scholes option-pricing model were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B><FONT STYLE="white-space:nowrap">5.5&nbsp;-&nbsp;6.9</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">5.5&nbsp;-&nbsp;6.5</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B><FONT STYLE="white-space:nowrap">89.7%&nbsp;-&nbsp;92.8%</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="white-space:nowrap">80.1%&nbsp;-&nbsp;91.0%</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B>1.9%&nbsp;-&nbsp;3.5%</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0.6%&nbsp;-&nbsp;1.2%</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to Calyxt&#146;s limited history, it does not always have sufficient historical stock option activity to
make predictive assumptions based solely on its stock or stock option activity for the Black-Scholes option pricing model. As a result, Calyxt may need to use data from other comparable public companies or alternative calculation methods as allowed
by GAAP to make predictive assumptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt estimates its future stock price volatility using the weighted-average historical
volatility calculated from a group of comparable public companies over the expected term of the option. The group of comparable public companies is determined by management on an annual basis. When selecting a comparable company, management
considers relevant factors including industry and strategy, size, maturity, and financial leverage. The comparable companies used by management to calculate expected volatility may change from year-to-year because of changes in those factors and
because a new comparable company may become publicly traded. A one percentage point increase in Calyxt&#146;s volatility assumption, leaving all other assumptions constant, would increase the grant date fair value by one percent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The expected term of stock options is estimated using the average of the vesting tranches and the contractual life of each grant for employee
options, or the simplified method, as Calyxt has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The use of the simplified
method is dependent upon the type of equity award granted and the term of the award. Management reviews the expected term of stock options before issuance to ensure that the use of the simplified method is appropriate and that Calyxt does not have
sufficient historical exercise data to estimate the expected term using a different method. An increase in the expected term by one year, leaving all other assumptions constant, would increase the grant date fair value by five percent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt estimates the risk-free interest rate based on the United States Treasury zero-coupon yield curve at the date of grant for the expected
term of the option. A one percentage point increase in the risk-free interest rate, leaving all other assumptions constant, would not change the grant date fair value. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt does not, nor does it expect to pay dividends in the foreseeable future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Performance Stock Units </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to
time, Calyxt issues Calyxt PSUs to certain individuals in management to align their objectives with Calyxt Stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2022,
Calyxt granted 530,000 Calyxt PSUs under the 2017 Plan to five employees, including four executive officers. The Calyxt PSUs include three annual performance periods (2022, 2023, and 2024) and target performance levels for each of those periods
linked to the achievement of Calyxt objectives as determined </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">267 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
annually for the respective period by the Compensation Committee of the Calyxt Board. Once the annual objectives are approved, the associated expense will be recognized on a straight-line basis
over the period from the date of grant through the determination date, which can be no later than March 15 of the following year. Earned awards will be settled in shares of Calyxt Common Stock no later than the March 15 determination date in the
following calendar year. The grant date for the tranche of awards linked to 2022 performance is May 4, 2022. The Calyxt Board approved the level of performance for the 2022 grant on March 1, 2023, and at the same time established the performance
criteria for the 2023 awards. Determination of expense for the 2024 tranche of Calyxt PSUs will be made when the associated business objectives are determined. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2021, Calyxt granted 600,000 Calyxt PSUs under the Inducement Plan to Mr. Michael A. Carr, its President and Chief Executive Officer.
The estimated fair values of Calyxt PSUs granted in 2021, and the assumptions used were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated fair values of Calyxt PSUs granted:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">At least $12 per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B><B></B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B></B><B>2.16</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">At least $15 per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B><B></B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B></B><B>1.89</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">At least $20 per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B><B></B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B></B><B>1.55</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumptions:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>3.0</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>90.0</B><B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B>%</B>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>0.4</B><B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B>%</B>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt estimated the fair value of each tranche of the Calyxt PSUs on the grant date using the Monte Carlo
simulation pricing model, which required it to make predictive assumptions as to the expected term of the grant, future stock price volatility, and dividend yield. The expected term represents the expected service period of the Calyxt PSUs granted.
It does not represent a significant accounting estimate. Due to the expected term of the award being three years and Calyxt having been publicly traded for more than three years, the volatility assumption was based on the historical volatility of
Calyxt Common Stock over the expected term. Calyxt estimates the risk-free interest rate based on the United States Treasury zero-coupon yield curve at the date of grant for the expected term of the Calyxt PSU. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Valuation of Calyxt Common Warrants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Calyxt Common Warrants have been classified as a liability in Calyxt&#146;s consolidated balance sheet because the warrants include a put
option election available to the holder of a Common Warrant that is contingently exercisable if Calyxt enters into a Fundamental Transaction through a Change of Control Put. If the Change of Control Put is exercised by the holder of a Common
Warrant, they may&nbsp;elect to receive either the consideration of the Fundamental Transaction or put the Common Warrant back to Calyxt in exchange for cash, based on terms and timing specified in the Common Warrant. If the put option is exercised,
Calyxt is required to pay cash to the holder in an amount as determined by the Black Scholes pricing model, with assumptions determined in accordance with the terms of the Calyxt Common Warrants. Those assumptions were as follows on December 31,
2022: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="24%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of<BR>December&nbsp;31,&nbsp;2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated fair value of Calyxt Common Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>0.04</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumptions:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>4.0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>85.0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term to liquidation (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>4.6</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A ten percent change in any of the assumptions would not have had a material effect on Calyxt&#146;s results
of financial condition or results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">268 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Realizable Value of Inventories </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to the wind-down of its soybean product line in 2021, Calyxt did not have any inventory balances, nor does it anticipate having any such
balances in 2023 based on the nature of its business activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Calyxt&#146;s prior go-to-market soybean strategy, the
determination of the net realizable value of inventories was a critical accounting estimate that required the use of judgments and assumptions that may have had a material impact on Calyxt&#146;s consolidated financial statements. At each
period-end, Calyxt made assumptions regarding projected selling prices of its products considering futures market prices for the underlying agricultural markets and its associated risk management strategies, anticipated costs, and other factors that
take into consideration Calyxt&#146;s limited operating history and compare those prices to the current weighted average costs of its inventories. If Calyxt&#146;s costs were higher than the projected selling prices, then a valuation adjustment was
recorded. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Tax Valuation Allowances </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The determination of the income tax valuation allowances requires the use of judgments and assumptions that may have a material impact on the
Calyxt&#146;s consolidated financial statements, especially at the early stage of commercialization. Calyxt provides deferred taxes for deductible and taxable temporary differences. Deferred tax assets are reduced by a valuation allowance when
Calyxt believes it is more likely than not that some portion or all the deferred tax assets will not be realized. Because Calyxt has generated losses cumulatively, management believes it is more likely than not that some portion or all the deferred
tax assets will not be realized and have reflected a full valuation allowance against its net deferred tax assets. If Calyxt were to generate profits, the valuation allowance may change. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recently Issued Accounting Pronouncements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For more information on recently issued accounting pronouncements, see Calyxt&#146;s consolidated financial statements and related financial
statement schedules on page F-1. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quantitative and Qualitative Disclosure About Market Risk </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to Calyxt&#146;s shift in business strategy which began in 2020, Calyxt&#146;s primary exposure to market risk was commodity price
sensitivity under its former soybean <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">go-to-market</FONT></FONT> strategy. Calyxt was susceptible to changes in commodity market prices that could impact the selling price for grain
inventories, which were carried at historical cost. Prior to the purchase, Calyxt also had market exposure associated with fixed price grain production agreements. Under this former strategy, Calyxt managed its exposure to changes in market prices
by entering commodity hedges to convert fixed price grain inventories and fixed price grain production agreements to floating market prices. By executing these hedging strategies, Calyxt could closely match the expected economic terms of the grain
sale with the market. In a rising market these positions resulted in losses, and in a falling market these positions resulted in gains once any losses, if any, are recaptured. At time of sale, the gains or losses on the commodity derivatives were
realized and fully offset by gains or losses on the grain inventories. As a result of the completed wind-down of the soybean product line in 2021, Calyxt&#146;s market risk related to commodity price sensitivity has been eliminated and Calyxt no
longer holds commodity derivative contracts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt is exposed to potential losses related to the price of its common stock. At each
balance sheet date, the fair value of Calyxt Common Warrants liability is remeasured using current fair value inputs, one of which is the price of its common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During any period, if the price of Calyxt Common Stock increases, there will likely be an increase in the fair value of the associated
liability. These potential increases in fair value will result in losses in Calyxt&#146;s </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">269 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consolidated statements of operations from the change in fair value of the Calyxt Common Warrant liability. Conversely, a decrease in the price of Calyxt Common Stock during any period will
likely result in decreases in the fair value of the associated liability. These potential decreases in fair value will result in gains in Calyxt&#146;s consolidated statements of operations from the change in the value of the Calyxt Common Warrant
liability. Given the significant current and historical volatility of Calyxt Common Stock price, any changes period-over-period have and could in the future result in a significant change in the fair value of its Calyxt Common Warrant liability and
significantly impact its net loss during the period of change. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">270 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom401831_49"></A>CIBUS MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>You should read the following discussion and analysis of our financial condition and results
of operations together with our financial statements and the related notes appearing elsewhere in this proxy statement/prospectus. Some of the information contained in this discussion and analysis or set forth elsewhere in this proxy
statement/prospectus, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks, uncertainties and assumptions. As a result of many factors, including those factors set
forth in the section titled &#147;Risk Factors,&#148; our actual results could differ materially from the results described in or implied by these forward-looking statements. You should carefully read the section titled &#147;Risk Factors&#148; to
gain an understanding of the factors that could cause actual results to differ materially from our forward-looking statements. Please also see the sections titled &#147;Cautionary Statement Concerning Forward-Looking Statements&#148; and
&#147;Market and Industry Data.&#148; For the purposes of this section, references to &#147;us,&#148; &#147;our,&#148; &#147;we&#148; and derivations thereof refer to Cibus Global. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Business Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> is a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties. The company is a technology leader in developing plant traits (or specific
genetic characteristics) using gene editing. Its primary business is using gene editing to develop Productivity Traits in the major agricultural crops: Canola, Rice, Soybean, Corn and Wheat. Productivity Traits are crop traits that improve crop
yields and make farmers more productive, thereby driving greater farming profitability. They do this in several ways such as making plants resistant to diseases or pests, thereby reducing the use of chemicals like fungicides and insecticides,
enabling plants to process nutrients more efficiently, thereby reducing the use of fertilizers, and making crops more adaptable to their environment and to climate change. In addition, Cibus is a leader in the development of sustainable low carbon
ingredients to help major corporations meet their Net Carbon Zero climate goals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gene editing in plants is essentially a tool used in
plant breeding that can precisely and predictably introduce new traits or improve upon existing ones. Gene editing, like breeding, is the science of optimizing plant genetics to increase a plant&#146;s yield potential and to improve its ability to
withstand challenges, such as climate change, diseases, and pests, as well as to deliver end-use characteristics such as nutritional quality or renewable plant-based ingredients.&nbsp;What differentiates gene editing from traditional breeding is
that it makes deliberate edits in the existing DNA sequence of a plant as opposed to the lengthy and random conventional breeding process. The promise of gene editing is that it can change the scale and range of possible genetic solutions from
breeding by its ability to make genetic changes in less time and more accurately. As challenges to farming sustainability increase with climate change, the ultimate promise of gene editing is that it can help meet those challenges with a timely and
predictable process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">What differentiates Cibus in the gene editing industry is its patented <B><I>RTDS </I></B>technology platform and
its crop specific Trait Machine process. Using <B><I>RTDS</I></B><I>,</I> Cibus developed the Trait Machine: the first standardized end-to-end semi-automated crop specific gene editing system that directly edits a seed company&#146;s elite
germplasm. The Trait Machine transforms the lengthy and random conventional breeding process into a timebound, reproducible and predictable science-based breeding process. The Cibus trait products are indistinguishable from plant traits developed
using conventional breeding processes. Cibus believes that the Trait Machine represents the technological breakthrough in plant breeding that is the ultimate promise of plant gene editing: the ability to change the scale and range of possible
genetic solutions from breeding and to develop desired characteristics or traits with greater speed and accuracy. Cibus expects to have its stand-alone Trait Machine Facility operational in 2023. The Trait Machine drives and differentiates
Cibus&#146; operating plan and its commercial model. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus has a pipeline of six Productivity Traits, three of which are fully developed.
Each of the Cibus&#146; developed traits has its initial customers, and Cibus has begun transferring each of these traits to customers in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">271 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
their elite germplasm for commercialization. The lead developed trait is PSR in Canola, which has ten leading seed company customers for whom Cibus is currently editing PSR into their elite
germplasm. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus&#146; business and its products are based on the use of its gene editing technologies to develop and license a new
generation of high value Productivity Traits and Sustainable Plant-Based Low Carbon Ingredients. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Productivity Traits:</B> Productivity Traits are the plant traits that are associated with improving crop
yields in the face of challenges such as weeds, pests, and diseases, in the face of factors such as heat and drought as a result of climate change, as well as environmental challenges such as fertilizer use. They are the primary target of plant
breeding programs and a key basis of competition in the &#147;seed and trait&#148; business. The key application of Cibus&#146; Trait Machine is the development of a new class of high value Productivity Traits. Its focus is on the five major crops:
Canola, Rice, Soybean, Wheat, and Corn. Together they are grown on over one billion acres and represent over 90% of the world&#146;s protein and 70% of the world&#146;s vegetable oils. Cibus&#146; product goal for its Productivity Trait business is
a new generation of high value Productivity Traits that make crops more adaptable to their environment and have increased yields while reducing chemical inputs. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Sustainable Low Carbon Ingredients: </B>Low Carbon Ingredients are a key target market for Cibus&#146; gene
editing platform. The goal of the Global Net Carbon Zero Climate Goals being set by many muti-national companies is to replace the many ingredients that are fossil fuel based or linked to environmental challenges. Using gene editing to develop
plant- or micro-organism-based solutions is a key element of this drive to new renewable low carbon materials. To address this market, Cibus is using both its Trait Machine platform as well as
ASAP<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>, its advanced (non-transgenic gene editing) fermentation platform. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus now has a pipeline of six traits, including three fully developed gene edited traits products, it has leading seed company
partners/customers, it has completed the transfer of its first three traits in the elite germplasm of customers in two different crops, and it is completing the industry&#146;s first trait production facility. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an early-stage company and have incurred net losses since our inception. As of December 31, 2022, we had an accumulated deficit of
$412.1&nbsp;million. Our net losses for the years ended December 31, 2022 and 2021 were $55.6&nbsp;million and $34.0&nbsp;million, respectively. Substantially all of our net losses resulted from costs incurred in connection with our research and
development programs and from selling, general and administrative expenses associated with our operations. As we continue to develop our pipeline of product candidates and as a result of our limited commercial activities, we expect to continue to
incur significant expenses and operating losses for the foreseeable future, and those expenses and losses may fluctuate significantly from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">quarter-to-quarter</FONT></FONT> and <FONT
STYLE="white-space:nowrap">year-to-year.</FONT> See &#147;<I>Risk Factors&#151;Risks Related to Cibus&#151;Risks Related to Cibus&#146; Business and Operations&#151;Cibus has incurred significant losses and anticipates that it will continue to incur
significant losses for several years</I>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, until such time that we can generate a sufficient amount of revenue from
product sales or other sources, if ever, we expect to finance our operations through private or public equity or debt financings, loans or other capital sources, which could include income from collaborations, partnerships or other marketing,
distribution, licensing or other strategic arrangements with third parties, or from grants. However, we may be unable to raise additional capital from these sources on favorable terms, or at all. Our failure to obtain sufficient capital on
acceptable terms when needed could have a material adverse effect on our business, results of operations or financial condition, including requiring us to delay, reduce or curtail our research, product development or future commercialization
efforts. We may also be required to license rights to product candidates at an earlier stage of development or on less favorable terms than we would otherwise choose. We cannot provide assurance that we will ever generate positive cash flow from
operating activities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The 2019 Corporate Conversion </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2019, we domesticated from a British Virgin Islands business company under the name of Cibus Global, Ltd. into a Delaware limited
liability company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">272 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Developments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Merger Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
January&nbsp;13, 2023, Cibus Global entered into the Merger Agreement with Calyxt, Inc. Please see the sections titled &#147;<I>The Mergers</I>&#148; and &#147;<I>The Merger Agreement</I>&#148; beginning on pages 123 and 170, respectively, of this
proxy statement/prospectus for more information. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Components of Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table
presents Cibus Global&#146;s revenue for the periods indicated: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration and research</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration and research &#150; related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">908</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,563</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Collaboration and research revenues are primarily related to revenues earned from performance obligations
under collaboration arrangements. Pursuant to the terms of the collaboration agreements, we receive <FONT STYLE="white-space:nowrap">non-refundable</FONT> payments for ongoing research and development activities, reimbursements of research and
development costs, and milestone payments upon the achievement of certain scientific, regulatory, or commercial milestones. Pursuant to the collaboration agreements, we also receive royalty payments in connection with the sale of commercialized
products containing the traits that are subject to those agreements. The majority of collaboration and research revenues for the periods presented in the table above were related to revenues received pursuant to a collaborative agreement with a
China-based producer and marketer of specialty ingredients under which we utilize our suite of technologies, including <B><I>RTDS</I></B> to develop a series of bacterial strains with specific traits for such producer. Additionally, in the year
ended December 31, 2022 we recognized revenue from a research and development agreement with a large U.S headquartered international health care company, pursuant to which we developed a new fermentation based process to make a key sterol
intermediate for the production of a corticosteroid drug. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Collaboration and research&#151;related party revenues represent revenues
earned under an agreement with RTDC Company Limited (&#147;RTDCCL&#148;), a company influenced by Mark Lu, a member of the Cibus Board, to develop and commercialize certain crop varieties that include traits produced using our proprietary
technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the future, we may continue to generate revenue from collaboration and research agreements, but we expect an increasing
amount of our revenue to come from our trait development efforts. We are using advanced technologies, including <B><I>RTDS</I></B>, to develop desirable plant traits for the global seed industry. We plan to sell or license our traits developed in
the future with revenue from these licensing agreements increasingly becoming our main source of future revenues. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to generate
substantial revenue from plant traits depends upon the ability to further expand our Trait Machine/<B><I>RTDS</I></B> platforms, which are fundamental for multiple different plant traits. We are advancing the commercialization of traits developed
using <B><I>RTDS</I></B> and currently have three &#147;developed&#148; traits for two global crops. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">273 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses consist of expenses incurred while performing research and development activities to discover and develop
potential product candidates and to establish Trait Machine/<B><I>RTDS</I></B> platforms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research and development expenses consist
primarily of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">personnel costs, including salaries and related benefits, for our employees engaged in scientific research and
development functions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cost of third-party contractors and consultants who support our product candidate and Trait
Machine/<B><I>RTDS</I></B> platform development; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">development costs associated with seed increases (small-scale and large-scale testing) for trait validation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchases of laboratory supplies and <FONT STYLE="white-space:nowrap">non-capital</FONT> equipment used for our
research and development activities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">facilities costs, including rent, utilities and maintenance expenses, allocated to our research and development
activities; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs of <FONT STYLE="white-space:nowrap">in-licensing</FONT> or acquiring technology from third parties.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research and development efforts are focused on advancing our existing product candidates, enhancing our product
candidate pipeline through the development of additional traits within our Trait Machine/<B><I>RTDS</I></B> platforms, and establishing additional Trait Machine/<B><I>RTDS</I></B> platforms for the development and advancement of additional traits.
Our infrastructure resources are utilized across multiple research and development programs. In addition, employees typically work across multiple research and development programs. We manage certain activities, such as field trials and seed
production, through third-party vendors. Due to the number of ongoing projects and our ability to use resources across several projects, we do not record or maintain information regarding the costs incurred for our research and development programs
on a program-specific basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research and development efforts are central to our business and account for a significant portion of
our operating expenses. We expect that our research and development expenses will increase for the foreseeable future as we expand our product candidate pipeline, establish additional Trait Machine/<B><I>RTDS</I></B> platforms, develop or acquire
additional technologies and hire additional personnel to support our product development. Additionally, product candidates in later stages of development generally have higher development costs than those in earlier stages of development, primarily
due to the increased expense associated with large-scale field testing and seed increases (small-scale and large-scale) for trait validation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognize research and development expenses as they are incurred, primarily due to the uncertainty of future commercial value. At this
time, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary to complete the development of our current product candidates or any new product candidates that we may identify and develop.
The duration, costs and timing of development of our product candidates are subject to numerous uncertainties and will depend on a variety of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our levels of hiring and retaining research and development personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which we encounter any serious adverse events in our field trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of any business interruptions to our operations or to those of the third parties with whom we work;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of any new or changing government regulations related to our product candidates;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">274 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these factors could significantly impact the costs, timing and viability associated
with the development of our product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Selling, General and Administrative Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expenses consist primarily of personnel-related expenses, including salaries and related benefits, for our
executive, business development, intellectual property, finance, legal, human resource and other administrative functions. Other selling, general and administrative expenses include facility-related costs not otherwise allocated to research and
development expense, professional fees for auditing, tax and legal services, expenses associated with obtaining and maintaining patents, consulting costs and costs of our information systems. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that our selling, general and administrative expenses will increase in the future to support the commercialization of our product
candidates. In addition, if we complete the Mergers, we will incur significant additional expenses associated with being a public company, including expenses related to accounting, audit, legal, regulatory, public company reporting and compliance,
director and officer insurance, investor and public relations, and other administrative and professional services. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Other (Income)
Expense</I></B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest Expense, Royalty Liability &#150; Related Parties </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense, royalty liability &#150; related parties (&#147;Royalty Liability&#148;) primarily consists of estimated future royalty
payments due to certain related parties as a result of the Warrant Exchange Agreement, in which certain warrants were exchanged for rights to future royalty payments. Pursuant to the Warrant Exchange Agreement, we granted participating warrant
holders a right, over a <FONT STYLE="white-space:nowrap">30-year</FONT> period, to receive an aggregate of 10% of revenue attributable to product sales, license fees, distribution fees, milestone payments and maintenance payments relating to
products developed or manufactured by, or otherwise utilizing, our <B><I>RTDS</I></B> technologies, subject to certain exclusions (&#147;Subject Revenues&#148;). Royalty payments on Subject Revenues will commence in the first fiscal quarter in which
the aggregate Subject Revenues during any consecutive <FONT STYLE="white-space:nowrap">12-month</FONT> period equals or exceeds $50&nbsp;million, at which point we will be obligated to pay all aggregated but unpaid amounts due under the Warrant
Exchange Agreement. This condition has not yet occurred as of December&nbsp;31,&nbsp;2022. The initial term of the Warrant Exchange Agreement is 30&nbsp;years and may be extended for an additional <FONT STYLE="white-space:nowrap">30-year</FONT> term
if the holders provide written notice and make a payment of $100. Our payments under, and performance of, the obligations under the Warrant Exchange Agreement, including payment of the Royalty Liability, are secured by a security interest in
substantially all of our intellectual property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect the Royalty Liability balance to continue to increase each year until the
accretion of interest expense, which increases the liability, outpaces the cash payments for royalties due, which decreases the liability. Similarly, we also expect the related <FONT STYLE="white-space:nowrap">non-cash</FONT> interest expense we
record to increase in conjunction with the underlying liability </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">balance. There are risks associated with the Royalty Liability. See &#147;<I>Risk
Factors&#151;Risks Related to the Combined Company&#151;Cibus&#146; Royalty Liability may contribute to net losses for the Combined Company and cause the value for securities of the Combined Company to fluctuate</I>.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Interest Expense </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense primarily consists of interest incurred related to financed equipment and license payments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Gain on Debt Extinguishment </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gain on debt extinguishment consists of loans received in May of 2020 under the Paycheck Protection Program, which were completely forgiven in
2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Other Expense </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other expense primarily consists of realized and unrealized net losses on foreign currency remeasurement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">275 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the Years Ended December&nbsp;31, 2022 and 2021 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes key components of our results of operations for the periods indicated: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2022&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Revenues:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration and research</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration and research &#150; related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">908</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total revenue</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,563</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating expenses:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,461</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,779</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(49,130</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(32,112</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other income (expense), net</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense, royalty liability &#150; related parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on extinguishment of debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,178</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss from continuing operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(55,553</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(33,962</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss from discontinued operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(23</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net Loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(55,553</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(33,985</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Revenues </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenues were $1.1 million for the year ended December 31, 2022, compared to $1.6 million for the year ended December 31, 2021, representing a
decrease of $0.5 million. The decrease was primarily attributable to the completion of the term of our research and development agreement with a China-based producer and marketer of specialty ingredients during the year ended December 31, 2021. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses were $33.5 million for the year ended December 31, 2022, compared to $22.2 million for the year ended
December 31, 2021, representing an increase of $11.3 million. The increase was primarily attributable to increased salary expenses and employee benefits of $5.7&nbsp;million due to a more competitive employment market and additional headcount of 52
employees, increased lab and field activities and consumables expenses of $2.3&nbsp;million, increases in IT/facilities expenses of $2.1&nbsp;million, and increases in professional fees, consulting and other expenses of $1.2 million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Selling, General and Administrative Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expenses were $16.8 million for the year ended December 31, 2022, compared to $11.5 million for the year
ended December 31, 2021, representing an increase of $5.3 million. The increase was primarily attributable to increased salary expenses and employee benefits of $1.0 million due to a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">276 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
more competitive employment market and increased headcount of two employees, a $2.6 million increase in professional services costs and a $1.7 million increase in IT, related general and
administrative expenses and other expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Interest Expense, Royalty Liability - Related Parties </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense, Royalty Liability&#151;Related Parties was $6.1 million for the year ended December 31, 2022, compared to $3.6 million for
the year ended December 31, 2021, representing an increase of $2.5 million. The increase was attributable to an increase in our estimate of future royalties owed, mostly driven by the interest growth of the Royalty Liability calculation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><I>Gain on Extinguishment of Debt</I><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognized a $2.2 million gain in June of 2021 upon the receipt of the notice of forgiveness of the loan granted under the Paycheck
Protection Program. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sources of Liquidity </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have
experienced net losses and negative cash flows from operations since our inception, and we expect to continue to incur net losses for at least the next several years. To date, we have funded our operations primarily through private placements of our
Cibus Preferred Units for gross proceeds of $364.5&nbsp;million before issuance costs. As of December 31, 2022, we had cash and cash equivalents of $24.3&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As described in Note 1 to our consolidated financial statements, management has prepared cash flow forecasts which indicate that based on our
expected operating losses and negative cash flows, there is substantial doubt about our ability to continue as a going concern without raising additional capital within 12 months after the date that the financial statements for the year ended
December 31, 2022 were issued. Our ability to continue as a going concern is dependent upon our ability to raise additional funding. In the near-term, we intend to raise additional capital through a combination of equity or equity-linked securities
offerings, debt issuances, commercial sales transactions, and collaboration, and licensing agreements. However, we may not be able to secure additional financing in a timely manner or on favorable terms, if at all. Furthermore, if we issue equity or
equity-linked securities to raise additional funds, our existing members may experience dilution, and the new equity securities may have rights, preferences and privileges senior to those of our existing stockholders. If we raise additional funds
through collaboration, licensing or other similar agreements, it may be necessary to relinquish valuable rights to our potential products or proprietary technologies or grant licenses on terms that are not favorable to us. If we are unable to raise
capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or other operations. If any of these events occur, our ability to achieve the development and commercialization goals
would be adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our primary uses of cash to date have been to fund our research and development activities, including with
respect to our <B><I>RTDS</I></B> programs and our other programs, business planning, establishing and maintaining our intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these
activities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future Capital Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the future, we expect our operating and capital expenditures to increase as we increase headcount, expand our sales and marketing
activities, grow our customer base, and incur costs associated with operating as a public company. Our estimates of the period of time through which our financial resources will be adequate to support our operations and the costs to support research
and development and our sales and marketing activities are forward-looking statements and involve risks and uncertainties and actual results could vary materially and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">277 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
negatively as a result of a number of factors, including the factors discussed in the section &#147;<I>Risk Factors</I>&#148; of this proxy statement/prospectus. We have based our estimates on
assumptions that may prove to be wrong and we could utilize our available capital resources sooner than we currently expect. Our future funding requirements will depend on many factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">market acceptance of our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of our research and development activities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of competing technological and market developments; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost and timing of establishing additional sales, marketing and distribution capabilities.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may be unable to obtain additional funds on acceptable terms, or at all. If we raise additional funds by issuing
equity or equity-linked securities, our equity holders may experience dilution. Future debt financing, if available, may involve covenants restricting our operations or our ability to incur additional debt. Any debt or equity financing that we raise
may contain terms that are not favorable to us or our equity holders. If we raise additional funds through collaboration, licensing or other similar agreements, it may be necessary to relinquish valuable rights to our potential products or
proprietary technologies or grant licenses on terms that are not favorable to us. If we do not have or are not able to obtain sufficient funds, we may have to reduce our commercialization efforts or delay our development of new products. We also may
have to reduce marketing, customer support or other resources devoted to our products or cease operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash Flows </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below summarizes our sources and uses of cash from continuing operations for the periods presented (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2022&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities, continuing operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(44,550</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(32,243</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities, continuing operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,213</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,842</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities, continuing operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52,364</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of exchange rate changes on cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase in cash and cash equivalents, continuing operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cash Flows from Operating Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Continuing operations: Net cash used in operating activities from continuing operations was $44.6 million and $32.2 million for the years ended
December 31, 2022 and 2021, respectively. The $12.4&nbsp;million increase in net cash used in operating activities from continuing operations compared to the previous period primarily reflects an increase in net loss of $21.6&nbsp;million, offset in
part by the effects of changes in operating assets and liabilities primarily driven by increases in accounts payable and accrued expenses and a decrease in prepaid expenses and other current assets. The increase in net loss was further offset by an
increase in <FONT STYLE="white-space:nowrap">non-cash</FONT> items of $4.2 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Discontinued operations: Net cash used in operating
activities from discontinued operations was $0 and $1.1&nbsp;million for the years ended December 31, 2022 and 2021, respectively. The $1.1 million decrease in net cash used in operating activities from discontinued operations compared to the
previous period, is due to the sale of the canola breeding program in 2021, resulting in no further spend on the discontinued program. See further discussion of discontinued operations in Note 3 of the consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">278 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Cash Flows from Investing Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities was $3.2 million and $1.8&nbsp;million for the years ended December&nbsp;31, 2022 and 2021, respectively,
in each case related to the purchase of property and equipment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Cash Flows from Financing Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities was $52.4 million for the year ended December 31, 2022, which consisted of proceeds from the issuance
of Simple Agreements for Future Equity of $34.5 million, proceeds from the issuance of Cibus Series F Preferred Units of $18.4 million and proceeds from notes payable of $0.6&nbsp;million, offset partially by principal payments on notes payable and
financing leases of $1.1 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities was $52.5&nbsp;million for the year ended December&nbsp;31,
2021, which consisted of proceeds from the issuance of Cibus Series D Preferred Units and Cibus Series E Preferred Units of $17.3&nbsp;million and $34.4&nbsp;million, respectively, and proceeds from notes payable and capital leases of
$1.5&nbsp;million, offset partially by principal payments on notes payable and capital leases of $0.7&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Contractual Obligations and
Commitments </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our contractual obligations and commitments as of December 31, 2022 (in thousands):
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Thereafter&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing lease obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notes payable including interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have also entered into agreements in the normal course of business with certain vendors for the provision
of goods and services. These agreements may include certain provisions for purchase obligations and termination obligations that could require payments for the cancellation of committed purchase obligations or for early termination of the
agreements. The amount of the cancellation or termination payments vary and are based on the timing of the cancellation or termination and the specific terms of the specific agreement. These obligations and commitments are not separately presented.
In addition, the table does not include obligations under the Royalty Liability and the Impact Royalty, each described below, because such obligations are dependent on future events that are uncertain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we have recorded an asset retirement obligation of $0.3 million as certain lease agreements require us to return designated
areas of leased space to its original condition upon termination of the lease agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Royalty Liability </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with two series of financings between November 2013 and December 2014, we issued to each investor in these financings warrants to
purchase Cibus Series A Preferred Units. Subsequently, certain of the investors sold the warrants in exchange for ongoing quarterly payments equal to a portion of our aggregate amount of certain worldwide revenues received during such quarter. We
refer to our ongoing warrant purchase payment obligations as its &#147;Royalty Liability.&#148; Pursuant to its Royalty Liability, we are required to make quarterly royalty payments equal in aggregate to 10% of all revenue attributable to its
<B><I>RTDS</I></B> technologies, subject to certain exceptions, to the applicable investors, who include individuals who will serve as directors and officers of Cibus, Inc. The requirement to make quarterly payments pursuant to the Royalty Liability
commences with the first quarter in which the aggregate revenue attributable to <B><I>RTDS</I></B> technologies during any consecutive </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">279 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap">12-month</FONT> period equals or exceeds $50&nbsp;million. At commencement, we will be required to pay all aggregated but unpaid royalty payment amounts. The
Royalty Liability has an initial term of 30&nbsp;years following the date on which the first royalty payment becomes due and payable, subject to a subsequent <FONT STYLE="white-space:nowrap">30-year</FONT> extension, at the option of the holders,
for a payment of $100. Our payments under, and performance of, the Royalty Liability are secured by a security interest in substantially all of our intellectual property. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cibus Non-Profit Foundation (&#147;Impact Royalty&#148;) </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During 2022, we created the Cibus Charitable Foundation, Inc., a nonprofit legal entity referred to as the Cibus Foundation. As of the date of
this proxy statement/prospectus, the Cibus Foundation has not received any donations or commenced operations. We are obligated to make donations to the Cibus Foundation each fiscal year at a rate of 1.0% of all net royalty revenue in the applicable
fiscal year that is equal to or greater than $100&nbsp;million up to, and including, $1.0&nbsp;billion, and then up to 2.0% in respect of any portion of such net royalty revenue in excess of $1.0&nbsp;billion. For purposes of this calculation,
&#147;net royalty revenue&#148; refers to all royalty payments we receive, net of all taxes (other than income taxes) and all amounts payable pursuant to the Royalty Liability. The donation payable by us may be reduced, including to zero, to the
extent necessary to comply with any covenant or obligation in any instrument evidencing third-party indebtedness, to permit a financing to occur, to preclude undercapitalization, to satisfy working capital requirements or provide for strategic needs
of our company, to ensure timely payment of our liabilities and debts to third parties as they become due, or to comply with applicable law. We have agreed not to enter any change of control transaction unless the surviving entity assumes the
obligation to pay such donations to the Cibus Foundation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This obligation is contingent upon the Cibus Foundation obtaining and
maintaining its status as a charitable organization (IRS&nbsp;501(C)3 registration not yet achieved) and must use all donations received consistent with its mission statement: to drive sustainable agriculture and sustainable agricultural communities
in the developing world. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Off-Balance Sheet Arrangements </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We enter into seed and grain production agreements with settlement values based on acreage and production yield. Otherwise, we do not have any
<FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements as defined under SEC rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and Estimates </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of the accounting methods and policies used in preparing our consolidated financial statements and related disclosure in conformity with
U.S. GAAP require us to make estimates and assumptions that affect the reported amounts. Estimates are based on past experience as well as assumptions and assessments deemed realistic and reasonable under the circumstances, the results of which form
the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on a periodic basis. The actual value of our assets, liabilities and
stockholders&#146; equity and of our losses could differ from the value derived from these estimates if conditions changed and these changes differ from the assumptions adopted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While our significant accounting policies are described in more detail in the notes to our financial statements appearing elsewhere in this
proxy statement/prospectus, we believe that the following accounting policies are critical to understanding our historical and future performance, as the policies relate to the more significant areas involving management&#146;s judgments and
estimates used in the preparation of our financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Royalty Liability&#151;Related Parties </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Royalty Liability relates to our obligations under the Warrant Exchange Agreement that was a component of the Cibus Series A Preferred Unit
financing transaction. In 2014, we entered into the Warrant </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">280 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Exchange Agreement with certain members holding Cibus Series A Preferred Units, including current and former members of the Cibus Board, who were also the holders of warrants to purchase Cibus
Series A Preferred Units. Under the Warrant Exchange Agreement, the holders of certain warrants (the &#147;Royalty Holders&#148;) were provided the right to exchange their warrants for future royalty payments equal to 10% of the Subject Revenues.
The exchange right was limited to 12,397,200 warrants, which were fully exchanged in 2014 and 2015. The aggregate value of warrants exchanged was $9.9&nbsp;million, and the amount was initially recorded as a Royalty Liability in the years ended
December&nbsp;31, 2015 and 2014. See Note 2 of our audited financial statements appearing elsewhere in this proxy statement/prospectus for further information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in expected royalty payments, as a result of changes to estimates of the underlying revenues, are accreted to interest expense using
the effective interest method. As royalties are paid over the life of the arrangement, we estimate the total amount of future royalty payments over the life of the Royalty Liability that will be required to be paid to holders of royalty rights. We
reassess these estimated royalty payments periodically and, if the amount or timing of royalty payments differs materially from our prior estimates, we will prospectively adjust the accretion of the effective interest expense. If global net sales of
our products developed using <B><I>RTDS</I></B> technologies are greater than or less than expected, the interest expense recorded with respect to the Royalty Liability would be greater or less, respectively, over the term of the arrangement. Our
estimate resulted in an effective annual interest rate of 27% and 9% for the years ended December&nbsp;31, 2022 and 2021, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As the Royalty Liability is calculated based on certain management assumptions including future projected revenues through the life of the
Warrant Exchange Agreement, potential material adjustments to the Royalty Liability could occur in future periods if these estimates are incorrect. No such material changes to these assumptions have occurred in the current periods presented. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Equity-Based Compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
recognize awards for incentive purposes of <FONT STYLE="white-space:nowrap">non-voting</FONT> restricted units to employees, <FONT STYLE="white-space:nowrap">non-employee</FONT> directors, consultants and independent advisors as equity-based
compensation based on their fair value on the grant date, determined based on the estimated number of awards that are ultimately expected to vest, less any consideration to be paid by the employee. We do not apply a forfeiture rate to estimate
forfeitures expected to occur. The compensation expense resulting from equity-based compensation to employees is recognized in operating expenses ratably over the vesting period of the award. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Determination of the Fair Value of our Common Units </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are required to estimate the fair value of our common units underlying our equity-based awards when performing the fair value calculations
using either the probability-weighted expected return model or the Black-Scholes Merton option pricing model. Because our common units are not currently publicly traded, the fair value of the common units underlying our equity-based awards has been
determined on each grant date by the Cibus Board, with input from management, considering our most recently available third-party valuation of common units. All options to purchase our common units are intended to be granted with an exercise price
per unit no less than the fair value per unit of our common units underlying those options on the date of grant, based on the information known to us on the date of grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The third-party valuations of our common units were performed using methodologies, approaches and assumptions consistent with the American
Institute of Certified Public Accountants Audit and Accounting Practice Aid Series: <I>Valuation of Privately Held Company Equity Securities Issued as Compensation</I> (&#147;Practice Aid&#148;). In accordance with the Practice Aid, the Cibus Board
considered the following methods: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Probability-Weighted Expected Return Method. The probability-weighted expected return method (PWERM) is a
scenario-based analysis that estimates the fair value of equity securities based upon an analysis of future values for the business, assuming various outcomes. The equity security&#146;s value is based on the probability-weighted present value of
expected future investment returns considering each </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">281 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
of the possible forecasted outcomes as well as the rights of each class of stock. The future value of the equity security under each outcome is discounted back to the valuation date at an
appropriate risk-adjusted discount rate and probability weighted to arrive at a <FONT STYLE="white-space:nowrap">non-marketable</FONT> indication of value for such equity security. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Option Pricing Method. Under the option pricing method (OPM), equity securities are valued by creating a series
of call options, representing the present value of the expected future returns to the equity holders, with exercise prices based on the liquidation preferences and conversion terms of each equity class. The estimated fair values of the equity
securities are inferred by analyzing these options. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Current Value Method. Under the Current Value Method, once the fair value of the enterprise is established based
on the balance sheet, the value is allocated to the various series of equity securities based on their respective liquidation preferences or conversion values, whichever is greater. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Hybrid Method. The Hybrid Method is a blended approach using aspects of both the PWERM and OPM, in which the
equity value in one of the scenarios is calculated using an OPM. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Cibus Board considered various
objective and subjective factors to determine the fair value of our common units, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prices of our Cibus Preferred Units sold to investors in arm&#146;s length transactions;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rights, preferences and privileges of our Cibus Preferred Units as compared to those of our common units,
including the liquidation preferences of our Cibus Preferred Units; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our results of operations and financial position; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the composition of, and changes to, our management team and the Cibus Board; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the lack of liquidity of our common units as a private company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the material risks related to our business and industry; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">external market conditions affecting the life sciences and biotechnology industry sectors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. and global economic conditions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the likelihood of achieving a liquidity event for the holders of our common units, such as an initial public
offering, or a sale of our company, given prevailing market conditions; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the market value and volatility of comparable companies. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During our fiscal years ended December&nbsp;31, 2022 and 2021, the fair value of the underlying Cibus common units was determined using an
option pricing model (&#147;OPM&#148;). Under the OPM, once the fair market value of the enterprise value is established, equity securities are valued by creating a series of call options with exercise prices based on the liquidation preferences and
conversion behavior of the different classes of equity. Accordingly, the aggregate equity value is allocated to each of the classes of equity securities issued and outstanding based on their rights and preferences. In order to determine the fair
market value of the enterprise, we utilized a market approach to estimate the equity value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assumptions underlying these valuations
represented the Cibus Board and our management&#146;s best estimates, which involved inherent uncertainties and the application of management&#146;s judgment. As a result, if we had used significantly different assumptions or estimates, the fair
value of our equity-based compensation expense could be materially different. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the Closing, the fair value of our common units
will be the closing price thereof on the date of the grant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">282 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recently Issued Accounting Pronouncements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A description of recently issued accounting pronouncements that may potentially impact our financial condition and results of operations is
disclosed in Note 2 of our audited financial statements appearing elsewhere in this proxy statement/prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quantitative and Qualitative
Disclosures About Market Risks </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Interest Rate Risk </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December 31, 2022 and 2021, our cash and cash equivalents consisted of readily available checking and money market accounts. We seek to
engage in prudent management of our cash and cash equivalents, with cash held in a <FONT STYLE="white-space:nowrap">non-interest-bearing</FONT> operating account at a financial institution and cash equivalents. Due to the short-term duration and low
risk profile of our investments, the interest rate risk related to cash and cash equivalents is not significant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Foreign Currency Exchange Risk
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to a limited amount of foreign currency exchange risk, principally in Euros, primarily as a result of our foreign
subsidiaries, whose revenues and expenses are translated into U.S. dollars using average exchange rates in effect during the applicable reporting period. We do not currently engage in any hedging activity to reduce our potential exposure to currency
fluctuations, although we may choose to do so in the future. We believe a hypothetical 100 basis point increase or decrease in foreign exchange rates during any of the periods presented would not have had a material impact on our financial condition
or results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">283 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom401831_50"></A>MANAGEMENT FOLLOWING THE TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers and Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Cibus, Inc. Board will initially be fixed at six members. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the name, age as of March&nbsp;31, 2023 and
position of each of the individuals who are expected to serve as executive officers and directors of Cibus, Inc. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="55%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Position</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Executive Officers</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rory Riggs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Executive Officer and Chair</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Beetham, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>President and Chief Operating Officer, Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Greg Gocal, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Scientific Officer and Executive Vice President</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wade King, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Financial Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Finn</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jean-Pierre Lehmann</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gerhard Prante, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Keith Walker, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Executive Officers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Rory Riggs</B> is Cibus&#146; <FONT STYLE="white-space:nowrap">co-founder</FONT> and currently serves as its Chief Executive Officer and
Chair of the Cibus Board, serving on the Cibus Board since its founding in 2001 and as Chair of its Board since 2014. Mr.&nbsp;Riggs is a <FONT STYLE="white-space:nowrap">co-founder,</FONT> director and former chair of the investment committee of
Royalty Pharma, an investment company focused on drug royalties; and founder and Chief Executive Officer of Locus Analytics, LLC, and of Syntax, LLC, data analytics and Fintech companies based on a new information technology platform for economics,
business and portfolio management. Mr.&nbsp;Riggs has served as President and a director of Biomatrix, Inc. (acquired by Genzyme Corp.); Chief Executive Officer of RF&amp;P Corporation, an investment company owned by the State of Virginia Retirement
System; and a managing director in PaineWebber&#146;s mergers and acquisitions department. Mr.&nbsp;Riggs was a <FONT STYLE="white-space:nowrap">co-founder</FONT> and Managing Member of Scientia Venture&#146;s predecessor, New Venture Funds, a
venture fund focused on healthcare, and served on the board of FibroGen, Inc. <FONT STYLE="white-space:nowrap">(co-founder,</FONT> publicly-traded). Mr.&nbsp;Riggs currently serves on the boards of Intra-Cellular Therapies, Inc. (publicly-traded);
StageZero Life Sciences Ltd. (publicly-traded); and eReceivables (private). Mr.&nbsp;Riggs graduated from Middlebury College and holds an M.B.A. from Columbia University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus believes that Mr.&nbsp;Riggs&#146;s significant experience in the biopharmaceutical and biotechnology industries, and his founding and
leading of Cibus&#146; business, qualifies him to serve on the Cibus, Inc. Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Peter Beetham, Ph.D.</B> is Cibus&#146; <FONT
STYLE="white-space:nowrap">co-founder</FONT> and currently serves as its President and Chief Operating Officer. Dr.&nbsp;Beetham also serves on the Cibus Board. Previously, Dr.&nbsp;Beetham served as Cibus&#146; Chief Executive Officer, Senior Vice
President of Research and Development and in other executive capacities. Dr.&nbsp;Beetham has over 30 years of experience in agriculture. Prior to joining Cibus, Dr.&nbsp;Beetham was Research Director of the Plant and Industrial Products Division at
ValiGen and a Senior Scientist at Kimeragen where he led research teams exploring gene targeting. Part of his extensive research experience was at the Boyce Thompson Institute at Cornell University, where he was a postdoctoral scientist and one of
the pioneers of the early work that led to Cibus&#146; <B><I>RTDS</I></B> technologies. Dr.&nbsp;Beetham was employed by the Department of Agriculture and Rural Affairs, Victoria, Australia from 1985 to 1992. He served as a scientific officer based
at the Plant Research Institute, working with research groups throughout Southeast Asia and the South Pacific. Dr.&nbsp;Beetham received his Ph.D. in Plant Molecular Virology from QUT in Brisbane, Australia and is a B.Sc. (Hons) graduate of Monash
University, Melbourne, Australia. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">284 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus believes Dr.&nbsp;Beetham&#146;s expertise in the agricultural industry, and his role
as Cibus&#146; <FONT STYLE="white-space:nowrap">co-founder,</FONT> qualifies him to serve on the Cibus, Inc. Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Greg Gocal,
Ph.D.</B> is Cibus&#146; <FONT STYLE="white-space:nowrap">co-founder</FONT> and has served as its Chief Scientific Officer&nbsp;&amp; Executive Vice President since 2016. Prior to that, he served as Cibus&#146; Senior Vice President of Research and
Development from 2014 to 2016, and from 2010 to 2014 served as Vice President of Research. In 2000, Dr.&nbsp;Gocal joined an innovative cross disciplinary team at ValiGen, Cibus&#146; predecessor, as the lead molecular biologist. Within the Plant
and Industrial Products Division, his team began developing the <B><I>RTDS</I></B> suite of technologies in plant and microbial systems in what was then the nascent field that has become gene editing. Continuing this focus and enabling Cibus&#146;
technologies and product pipeline, Dr.&nbsp;Gocal has held various research management positions. Dr.&nbsp;Gocal has studied many aspects of plant biology. He was awarded undergraduate and graduate degrees from the University of Calgary. He worked
at CSIRO Plant Industry in Canberra, Australia where he received his Ph.D. in Plant Molecular Biology from the Australian National University, then continued studying in this field as a postdoctoral scientist at the Salk Institute for Biological
Studies in La Jolla, California. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Wade King, M.D.</B> currently serves as Cibus&#146; Chief Financial Officer. Prior to joining Cibus,
he was Chief Executive Officer of Prota Therapeutics, a Phase 2 stage peanut allergy therapeutics development company based in Melbourne, Australia. Before Prota, Dr.&nbsp;King led Corporate Development and Strategy and served on the management team
of Insmed, a multi-billion-dollar public rare disease company, leading global licensing deals and exploring numerous gene therapy opportunities. Dr.&nbsp;King also led both finance and business development for Neomend, a surgical sealant company
that was acquired by CR Bard, now part of Becton Dickinson. Prior to his work in the corporate sector, Dr.&nbsp;King was Chief of Anesthesiology for a <FONT STYLE="white-space:nowrap">20-physician</FONT> practice in Silicon Valley. Dr.&nbsp;King is
a board-certified anesthesiologist and completed residencies in Surgery and Anesthesiology at University of California, San Francisco. He holds an M.S.M. from Stanford Business School, M.D. and M.P.H. degrees from UNC Chapel Hill Schools of Medicine
and Public Health, and a B.A. cum laude from Princeton University. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Mark Finn</B> serves on the Cibus Board. Mr.&nbsp;Finn has also chaired Cibus&#146; Finance and Audit Committee since 2009. Mr.&nbsp;Finn
has been the Chair and Chief Executive Officer of the Vantage Consulting Group since August 1985. Mr.&nbsp;Finn&#146;s previous involvements include the Virginia National Bank, the State of Virginia Retirement Plan&#146;s Investment Advisory
Committee, and the Board of Trustees of the Virginia Retirement System. Mr.&nbsp;Finn also chaired the Operations Advisory Committee for the State of Alaska Retirement System. Mr.&nbsp;Finn is also former Chair of the Board of Directors of RF&amp;P
Corporation, a privately held railroad and real estate company. Currently Mr.&nbsp;Finn serves on the advisory board of Auven Therapeutics, a private equity company focused on life science investment, as well as on the board of managers of the
Managing Member of New Ventures I, LLC, a venture capital fund investing in biotechnology related entities, and New Ventures Select, LLC, a pharmaceutical royalty fund, as well as the New Ventures III, LLC, Vantage Multi-Strategy Fund, LP, New
Ventures III VO, LLC, New Ventures as Solutions, LLC and New Ventures as Solutions II, LLC Managing Member boards. He also is a Director of Enterin Inc. (private), a life sciences company focused on Parkinson&#146;s disease. Mr. Finn serves as an
independent director on the Legg Mason Partners Fund Board. He has taught at the University of Virginia Graduate Business School and the College of William and Mary&#146;s Mason School of Business, where he received his M.B.A. in 1987. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus believes that Mr.&nbsp;Finn&#146;s leadership role in its development and growth, and his experience in the life sciences investment
space, qualifies him to serve on the Cibus, Inc. Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Jean-Pierre Lehmann</B> has served on the Cibus Board since November 2009.
Mr.&nbsp;Lehmann has been a private investor for the past 30 years, with a diversified portfolio in venture capital, private equity, especially in Asia, as well as hotels and commercial and residential real estate in the United States. Prior to
this, Mr.&nbsp;Lehmann resided in Geneva, Switzerland, where he managed portfolios for Morval Bank and its holding company. He </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">285 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
previously oversaw a diversified holding company for Edmond de Rothschild. Mr.&nbsp;Lehmann is a graduate of the Ecole des Hautes Etudes Commerciales in Paris and holds an M.B.A. from Harvard
Business School; he was also an officer in the French Navy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus believes that Mr.&nbsp;Lehmann&#146;s extensive background in financial
investments brings valuable skills to the Cibus Board and qualifies him to serve on the Cibus, Inc. Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Gerhard Prante, Ph.D.</B>
serves as Vice Chair of the Cibus Board, and has served on the Cibus Board since 2011. Dr.&nbsp;Prante became Head of the Agriculture division of Hoechst AG in 1985. After forming AgrEvo GmbH (a joint venture of Hoechst AG and Schering AG), he
served as its Chief Executive Officer and Chair of the Board. Following the merger of Hoechst and Rhone Polenc into Aventis SE, Dr.&nbsp;Prante served as Deputy Chief Executive Officer of Aventis CropScience (which was later acquired by Bayer AG).
He then worked as an industry consultant, and served on several boards, including Bayer CropScience AG, Gerresheimer AG, Allessa GmbH and Direvo Industrial Biotechnology GmbH. He studied Agriculture at Kiel University in Germany, and finished his
Ph.D. in Agricultural Sciences in 1970. Dr.&nbsp;Prante has served on numerous industry associations, at times as their president, including German Crop Protection and Fertilizer Association (IVA), Europe Crop Protection Association (ECPA), Global
Crop Protection Federation (GCPF), Global Plant Science Industry Federation (Croplife International), German Association of Biotech Industry (DIB), and the Federation of Sustainable Agriculture. In his career, Dr.&nbsp;Prante has been a strong
proponent of the integration of biotechnology into agribusiness since the <FONT STYLE="white-space:nowrap">mid-1980s,</FONT> led the $0.7&nbsp;billion acquisition of Plant Genetic Systems by AgrEvo, and built the InVigor canola business in Canada,
in addition to buying and integrating several seed companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus believes that Dr.&nbsp;Prante&#146;s experience in the biotechnology
industry, and particularly the integration of biotechnology and agribusiness, qualifies him to serve on the Cibus, Inc. Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Keith
Walker, Ph.D.</B> has served on the Cibus Board since July 2014. In 2014, Dr.&nbsp;Walker founded Valley Oils Partners, LLC and currently serves as Chair of its Board of Directors and Chief Executive Officer. Dr.&nbsp;Walker was instrumental in
transforming the Plant and Industrial Products Division of ValiGen into, and thus founding, Cibus Global, and served as Cibus Global&#146;s President and Chief Executive Officer from November 2001 to July 2014. Previously, Dr.&nbsp;Walker worked at
Agrigenetics, Inc. and held a variety of management positions at Mycogen Seeds, an agricultural company that engages in the research, development, and testing of genetics in certain crops, after it acquired Agrigenetics, Inc. He was also a <FONT
STYLE="white-space:nowrap">co-founder,</FONT> director, and Vice President of Research at Plant Genetics, Inc. (&#147;PGI&#148;). Before founding PGI, Dr.&nbsp;Walker served in a variety of research roles with Monsanto, an agricultural biotechnology
company. He received a B.A. from the College of Wooster and a Ph.D. in Biology from Yale University. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus believes that
Dr.&nbsp;Walker&#146;s experience in agricultural biotechnology, which spans over 40 years, and his leadership role in our development, qualifies him to serve on the Cibus, Inc. Board. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Independence </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Applicable Nasdaq
Listing Rules require that the Cibus, Inc. Board be comprised of a majority of independent directors. Based upon information requested from and provided by each proposed director concerning their background, employment and affiliations, including
family relationships, Cibus expects that the Cibus, Inc. Board will determine that each member of the Cibus, Inc. Board, except Rory Riggs and Peter Beetham, Ph.D., will qualify as an &#147;independent director&#148; as defined under applicable
Nasdaq Listing Rules. In making such determination, the Cibus, Inc. Board will consider the current and prior relationships that each director has with Calyxt and Cibus and all other facts and circumstances that the Cibus, Inc. Board deems relevant
in determining the independence of each director, including the interests of each director in the Transactions, any relevant related party transactions and the beneficial ownership of Calyxt Common Stock, Cibus Common Units, Class&nbsp;A Common
Stock or Class&nbsp;B Common Stock by each director. See the sections </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">286 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
entitled &#147;<I>The Mergers&#151;Interests of Cibus Global Directors and Executive</I> <I>Officers in the Mergers</I>,&#148; &#147;<I>Related Party Transactions of Directors and Executive
Officers of the Combined Company</I>&#148; and &#147;<I>Principal Stockholders of Cibus</I><I>, Inc.</I>&#148; of this proxy statement/prospectus for additional information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Nasdaq Listing Rules require that, subject to specified exceptions, each member of Cibus, Inc.&#146;s audit, compensation and
nominating and corporate governance committees be independent under the Exchange Act. Audit committee members must also satisfy the independence criteria set forth in Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under the Exchange Act, and
compensation committee members must also satisfy the independence criteria set forth in Rule <FONT STYLE="white-space:nowrap">10C-1</FONT> under the Exchange Act. Under applicable Nasdaq Listing Rules, a director will only qualify as an
&#147;independent director&#148; if, in the opinion of the Cibus, Inc. Board, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. In order to be
considered independent for purposes of Rule <FONT STYLE="white-space:nowrap">10A-3,</FONT> a member of an audit committee of Cibus, Inc. may not, other than in their capacity as a member of the audit committee, the Cibus, Inc. Board, or any other
committee of the Cibus, Inc. Board, accept, directly or indirectly, any consulting, advisory or other compensatory fee from the Combined Company or otherwise be an affiliated person of the Combined Company. In order to be considered independent for
purposes of Rule <FONT STYLE="white-space:nowrap">10C-1,</FONT> the Cibus, Inc. Board must consider, for each member of a compensation committee of Cibus, Inc., all factors specifically relevant to determining whether a director has a relationship
to such company which is material to that director&#146;s ability to be independent from management in connection with the duties of a compensation committee member, including, but not limited to: (1)&nbsp;the source of compensation of the director,
including any consulting advisory or other compensatory fee paid by such company to the director; and (2)&nbsp;whether the director is affiliated with the company or any of its subsidiaries or affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are no family relationships among any of the proposed directors or officers of Cibus, Inc. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Committees of the Cibus, Inc. Board Following the Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Calyxt Board has an established audit committee, compensation committee and a nominating and corporate governance committee, each of which
operate pursuant to a charter adopted by the Calyxt Board. After completion of the Transactions, the Cibus, Inc. Board will continue to have such standing committees. Members will serve on these committees until their resignation or until as
otherwise determined by the Cibus, Inc. Board. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Audit Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Calyxt, Inc. audit committee is responsible for, among other things, the oversight of the integrity of Calyxt, Inc.&#146;s financial
statements and system of internal controls, the qualifications and independence of Calyxt, Inc.&#146;s independent registered accounting firm and the performance of Calyxt, Inc.&#146;s internal auditor and independent auditor. The audit committee
also has the sole authority and responsibility to select, determine the compensation of, evaluate and, when appropriate, replace Calyxt, Inc.&#146;s independent registered public accounting firm. In addition, the Calyxt, Inc. audit committee reviews
reports from management, legal counsel and third parties relating to the status of compliance with laws, regulations and internal procedures. The Calyxt, Inc. audit committee is also responsible for reviewing and discussing with management Calyxt,
Inc.&#146;s policies with respect to risk assessment and risk management. A copy of Calyxt, Inc.&#146;s current audit committee charter is available on Calyxt, Inc.&#146;s website at www.calyxt.com. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit committee of Cibus, Inc. is expected to retain these duties and responsibilities following the consummation of the Transactions. A
copy of Cibus, Inc.&#146;s audit committee charter will be available on Cibus, Inc.&#146;s website following the consummation of the Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of the Transactions, it is expected that the audit committee of the Cibus, Inc. Board will consist of Messrs.&nbsp;Finn and
Lehmann and Dr.&nbsp;Walker. The Cibus, Inc. Board will also determine that at least one member of the audit committee will qualify as an &#147;audit committee financial expert,&#148; as defined by the rules of the SEC and will satisfy the financial
sophistication requirements of Nasdaq. Messrs. Finn and Lehmann and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">287 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Dr.&nbsp;Walker will serve as financial experts on the audit committee. Calyxt, Inc. and Cibus Global believe that, following the completion of the Transactions, the composition of the audit
committee will meet the requirements for independence under current Nasdaq and SEC rules and regulations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Calyxt, Inc. compensation committee is responsible for, among other things, reviewing and approving Calyxt, Inc.&#146;s overall
compensation philosophy and overseeing the administration of related compensation benefit programs, policies and practices. The Calyxt, Inc. compensation committee is also responsible for annually reviewing and approving the corporate goals and
objectives relevant to the compensation of Calyxt, Inc.&#146;s chief executive officer and other executive officers and evaluating their performance in light of these goals, reviewing the compensation of Calyxt, Inc.&#146;s executive officers and
other appropriate officers, and administering Calyxt, Inc.&#146;s incentive and equity-based compensation plans. A copy of Calyxt, Inc.&#146;s current compensation committee charter is available on Calyxt, Inc.&#146;s website at www.calyxt.com. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The compensation committee of Cibus, Inc. is expected to retain these duties and responsibilities following the consummation of the
Transactions. A copy of Cibus, Inc.&#146;s compensation committee charter will be available on Cibus, Inc.&#146;s website following the consummation of the Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of the Transactions, it is expected that the compensation committee of the Cibus, Inc. Board will consist of Messrs.&nbsp;Finn
and Lehmann and Dr.&nbsp;Prante. Calyxt, Inc. and Cibus Global believe that, following the completion of the Transactions, the composition of the compensation committee will meet the requirements for independence under current Nasdaq and SEC rules
and regulations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Nominating and Corporate Governance Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Calyxt, Inc. nominating and corporate governance committee is responsible for, among other things, matters of corporate governance and
matters relating to the practices, policies and procedures of the Calyxt Board, identifying and recommending candidates for election to the Calyxt Board and each committee of the Calyxt Board, and reviewing, at least annually, Calyxt, Inc.&#146;s
corporate governance principles. The Calyxt, Inc. nominating and corporate governance committee also advises on and recommends director compensation, which is approved by the full Calyxt Board. A copy of Calyxt, Inc.&#146;s current nominating and
corporate governance committee charter is available on Calyxt, Inc.&#146;s website at www.calyxt.com. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The nominating and corporate
governance committee of Cibus, Inc. is expected to retain these duties and responsibilities following completion of the Transactions. A copy of Cibus, Inc.&#146;s nominating and corporate governance committee charter will be available on Cibus,
Inc.&#146;s website following the consummation of the Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of the Transactions, it is expected that the
nominating and corporate governance committee of the Cibus, Inc. Board will consist of Messrs.&nbsp;Finn and Lehmann and Drs.&nbsp;Prante and Walker. Calyxt, Inc. and Cibus Global believe that, following the completion of the Transactions, the
composition of the nominating and corporate governance committee will meet the requirements for independence under current Nasdaq and SEC rules and regulations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Committee Interlocks and Insider Participation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Closing, the Cibus, Inc. Board is expected to select members of the compensation committee. None of the proposed
executive officers of Cibus, Inc. serve, or in the past year has served, as a member of the board of directors or compensation committee, or other committee serving an equivalent function, of any other entity that has one or more of its executive
officers who is proposed to serve on the Cibus, Inc. Board or compensation committee following the completion of the Transactions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">288 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Business Conduct and Ethics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus, Inc. will adopt a written code of business conduct and ethics, substantially in the form of Calyxt, Inc.&#146;s current Code of Business
Conduct and Ethics, that applies to its directors, officers and employees, including the principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions, of Cibus, Inc.
Cibus, Inc. will post a current copy of the code on its website, www.cibus.com. In addition, Cibus, Inc. intends to post on its website all disclosures that are required by law or Nasdaq Listing Rules concerning any amendments to, or waivers from,
any provision of the code of business conduct and ethics. The information contained on, or that can be accessed through, the website is not a part of this prospectus. The website address is included in this proxy statement/prospectus solely as an
inactive textual reference. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus Global pays its directors annual retainer fees for their participation on the Cibus Board. The chairperson and vice chairperson of the
Cibus Board each receives $100,000 per year for his services and all other directors receive $60,000 per year. The directors may elect to receive such fees in cash, in Cibus PIUs or a combination of the two. Cibus Global pays fees in cash on a
monthly basis and issues Cibus PIUs once a year. For additional information on compensation paid to directors of Cibus, see the section entitled &#147;<I>Cibus Global Executive Compensation&#151;Cibus Global Director Compensation</I>&#148; beginning
on page&nbsp;313 of this proxy statement/prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Closing and the transition of the board of directors, Cibus,
Inc. expects to evaluate Calyxt, Inc.&#146;s director compensation practices and finalize Cibus, Inc.&#146;s <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation program, pursuant to which
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors will be eligible to receive compensation for service on the Cibus, Inc. Board and its committees. The Cibus, Inc. Board expects to review director compensation periodically to ensure
that director compensation remains competitive such that the Combined Company is able to recruit and retain qualified directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">289 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom401831_51"></A>CALYXT, INC. EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The information in this section does not give effect to the Reverse Stock Splits described elsewhere in this proxy
statement/prospectus.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Discussion and Analysis </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Named Executive Officers </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This
Compensation Discussion and Analysis provides information regarding Calyxt&#146;s compensation programs for its principal executive officer, principal financial officer, and each of its other executive officers serving at the end of the 2022 fiscal
year (collectively, the &#147;Calyxt NEOs&#148;), who are identified below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="58%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Calyxt NEO</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Position</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Michael&nbsp;A.&nbsp;Carr</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">President&nbsp;&amp; Chief Executive Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">William F. Koschak</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Travis J. Frey, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Technology Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Debra Frimerman</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">General Counsel and Corporate Secretary</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Philosophy and Objectives </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt&#146;s compensation program is designed to recognize the level of responsibility of an executive within Calyxt, taking into account the
Calyxt NEO&#146;s role and expected leadership within Calyxt&#146;s organization, and to encourage and reward decisions and actions that have a positive impact on Calyxt&#146;s overall performance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt&#146;s compensation philosophy is based upon the following objectives: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to reward Calyxt&#146;s executives for their outstanding performance and business results; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to emphasize the enhancement of shareholder value; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to value the executive&#146;s unique skills and competencies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to attract, retain and motivate qualified executives; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide a competitive compensation structure in the life sciences market based on select market survey data.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Overview of Compensation Process </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Compensation Committee administers Calyxt&#146;s compensation program. The Compensation Committee is responsible for, among other things,
reviewing and approving Calyxt&#146;s overall compensation philosophy and overseeing the administration of related compensation benefit programs, policies, and practices. The Compensation Committee is also responsible for annually reviewing and
approving the corporate goals and objectives relevant to the compensation of Calyxt&#146;s Chief Executive Officer and other Calyxt NEOs and evaluating their performance in light of these goals, reviewing the compensation of Calyxt NEOs, and
administering Calyxt&#146;s incentive and equity-based compensation plans. Executive compensation is recommended by the Compensation Committee and set by the Calyxt Board. In performing this function, the Compensation Committee and the Calyxt Board
rely on the Chief Executive Officer to provide information regarding the other Calyxt NEOs, their roles and responsibilities, and the general performance of Calyxt. The Chief Executive Officer also suggests performance measures and targets for each
of the executive officers under Calyxt&#146;s short-term cash incentive program. The final decisions regarding salaries, bonuses (including measures, targets, and amounts to be paid), equity grants, and other compensation matters related to
executive officers are made by the Calyxt Board. None of the Calyxt NEOs (including the Chief Executive Officer) has a role in determining his or her own compensation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Consultant </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In fiscal
2022, the Compensation Committee engaged Vareo Advisors, LLC to serve as its compensation consultant. The compensation consultant has periodically been engaged to assist the Compensation Committee with
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">290 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
evaluation of Calyxt&#146;s compensation program to review, comment and make recommendations on executive compensation matters, to help select appropriate market data for compensation
determinations, to assist in executive compensation disclosures, and to provide updates on regulatory changes in compensation-related issues and other developments and trends in executive compensation. The Compensation Committee determined that
Vareo Advisors, LLC is free of conflicts of interest under applicable Nasdaq and SEC rules. The compensation consultant reported directly to the Compensation Committee and works with the Compensation Committee, the Calyxt Board, and management to,
among other things, provide advice regarding compensation structures and programs in general and competitive compensation data. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Elements of
Compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt&#146;s compensation program has three primary elements: a base salary, an annual cash incentive, and incentive
equity awards. In addition, we also offer Calyxt&#146;s executives the ability to participate in a 401(k) plan and health and welfare programs. Calyxt pays the cost of executives&#146; insurance premiums for medical and dental plans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt&#146;s Compensation Committee has not adopted any policies for allocating compensation between long-term and currently <FONT
STYLE="white-space:nowrap">paid-out</FONT> compensation, between cash and <FONT STYLE="white-space:nowrap">non-cash</FONT> compensation or among different forms of <FONT STYLE="white-space:nowrap">non-cash</FONT> compensation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Base Salary </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt pays base salaries to
recognize and reward each named executive officer&#146;s unique value and skills, competencies and experience in light of the executive&#146;s position. The Compensation Committee and the Calyxt Board consider a variety of factors such as market
survey data, a subjective assessment of the nature and scope of the Calyxt NEO&#146;s responsibilities, each Calyxt NEO&#146;s unique value and historical contributions, historical increases, internal equity considerations, and the experience of the
Calyxt NEO in setting base salaries. The Calyxt NEOs were entitled to base salaries at the following annual rates during 2022: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="19%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022&nbsp;Base&nbsp;Salary&nbsp;Rate</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael A. Carr</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William F. Koschak</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">340,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Travis J. Frey, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Debra Frimerman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">321,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt did not modify the base salary rates of any Calyxt NEOs for 2022. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Annual Cash Incentive </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Annual cash
incentive awards are used to reward and motivate Calyxt NEOs for achieving key financial and operational objectives. The annual incentive bonus awards are generally payable based on Calyxt&#146;s performance and, in some cases, the level of
individual contributions to that performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;3, 2022, Calyxt established the 2022 Short Term Incentive Plan
(&#147;STIP&#148;), which provides performance-based cash awards for certain of Calyxt&#146;s executives, subject to a maximum limit of 200% of the executive&#146;s target bonus level. Under the STIP, the eligible executives (including the Calyxt
NEOs) will receive a performance bonus opportunity based on a percentage of the individual&#146;s annual base salary, with Calyxt performance objectives and individual performance objectives established by the Calyxt Board, and each comprising 50%
of the bonus determination for executive officers other than the Chief Executive Officer. The achievement against Calyxt performance objectives comprises 100% of the bonus determination for the Chief Executive Officer. To be eligible to receive a
bonus under the STIP, a participant in the plan must be employed by Calyxt as of both December&nbsp;31, 2022 and the payment date, unless otherwise provided in a written agreement between Calyxt and the participant, and bonuses are subject to
clawback to the extent required or permitted by law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">291 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>STIP Targets </U></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="22%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="21%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus&nbsp;Target&nbsp;(as&nbsp;a&nbsp;Percentage</B><br><B>of Base Salary)</B><br><B>(%)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022&nbsp;Bonus&nbsp;Target</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael A. Carr</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William F. Koschak</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">153,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Travis J. Frey, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">135,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Debra Frimerman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">128,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Company Objectives (100% for Chief Executive Officer and 50% <FONT STYLE="white-space:nowrap">for&nbsp;non-Chief</FONT>
Executive Officer Plan Participants)</U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The portion of bonus attributable to Company Objectives is weighted as follows: 40% Collaboration
(Measure 1), 20% Cash Balance (Measure 2) and 40% Innovation (Measure 3). Each <FONT STYLE="white-space:nowrap">Measure&nbsp;1-3&nbsp;will</FONT> be determined by the Compensation Committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to the Company Objectives, the STIP provides the Compensation Committee with the authority to determine whether (and by what
amount) the actual result used to calculate the achievement of a Measure should be adjusted to account for extraordinary events or circumstances (including, without limitation, overall financial market performance factors relative to assumptions
used in establishing target Measures), or should otherwise be adjusted in order to be consistent with the purpose or intent of the 2022 annual performance bonus program. The following are the performance targets and corresponding potential payouts
for each of the three measures used in the STIP for 2022: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Multiplier/</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Achievement&nbsp;Level</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Measure 1</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Collaboration</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Measure 2</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Cash Balance</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Measure 3</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Innovation</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">50%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Signed BioFactory Collaboration(s) AND Licensing Deal(s), collectively having NPV of $40mm</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Cash Balance at 12/31/22 sufficient to fund 6 months of operations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">BioFactory Pilot Plant Fully Operational with Full</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Analytics</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">100%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Signed BioFactory Collaboration(s) AND Licensing Deal(s), collectively having NPV of $75mm</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Cash Balance at 12/31/22 sufficient to fund 12 months of operations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">AI/ML Advancement to include Pathway Discovery and Vector Creation at a 25% improvement over baseline. Use of Lab Analytics (LC) in validating targets cumulating in AI/ML with Predictive Capabilities</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">200%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Signed BioFactory Collaboration(s) AND Licensing Deal(s), collectively having NPV of $100mm</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Cash Balance at 12/31/22 sufficient to fund 18 months of operations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">First BioFactory Infrastructure Partner Announced OR Scaling Production in Calyxt System</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Weighting of Company Objectives</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">40%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">20%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">40%</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Individual Objectives (50% <FONT STYLE="white-space:nowrap">for&nbsp;non-Chief</FONT> Executive Officer Plan
Participants)</U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Compensation Committee will determine, in its discretion, the level of achievement of the goals identified below and
the overall achievement of the Individual Objectives, with a multiplier of 0.7x at a minimum level of achievement, 1x at a target level of achievement and 2x at a maximum level of achievement. Achievement at less than the minimum level determined by
the Compensation Committee will result in no bonus </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">292 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
being earned for that particular goal or for the Individual Objectives as determined by the Compensation Committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Specific individual measures will be determined by the Compensation Committee drawn from the categories identified below, together with
individual weighting of such Individual Objectives: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Internal&nbsp;&amp; External Communications Achievement / Advancement </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial Reporting Achievement / Advancement </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information Technology Achievement / Advancement </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and Development Achievement / Advancement </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Safety&nbsp;&amp; Compliance Achievement / Advancement </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Leadership Achievement / Advancement </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Risk Management Achievement / Advancement </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Intellectual Property Achievement / Advancement </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Business Development Achievement / Advancement </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2022 STIP Results </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Given
Calyxt&#146;s cash position, the Compensation Committee determined that payment under the 2022 STIP would not be consistent with the purpose or the intent of the 2022 STIP. Therefore, no STIP amounts were earned or paid to the Calyxt NEOs for 2022
given that the goal for the cash balance metric was not met. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Incentive Equity Awards </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt uses the grant of equity awards under Calyxt, Inc.&#146;s 2017 Omnibus Incentive Plan (as amended, effective May&nbsp;18, 2021) (the
&#147;Omnibus Plan&#148;) to provide long-term incentive compensation opportunities intended to align the Calyxt NEOs&#146; interests with those of Calyxt Stockholders, and to attract, retain and reward Calyxt NEOs. Calyxt&#146;s equity program
generally consists of a mix of three types of equity awards: stock option awards (&#147;options&#148;), Calyxt RSUs, and Calyxt PSUs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
March&nbsp;24, 2022, Calyxt granted equity awards to certain of Calyxt&#146;s employees, including the Calyxt NEOs, pursuant to the Omnibus Plan. The amount of the awards was determined based on ownership percentage of Calyxt, on a fully diluted
basis, by role based on general practice for similar roles in early stage technology companies. The number of options, Calyxt RSUs and Calyxt PSUs granted to each Calyxt NEO is set forth below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Options<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Calyxt<BR>RSUs<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Calyxt<BR>PSUs<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael A. Carr</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">490,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">368,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">205,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William F. Koschak</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">219,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Travis J. Frey, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">205,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Debra Frimerman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">200,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The options have a term of ten years from the grant date, and will vest 25% on the first, second, third and
fourth anniversaries of the grant date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Certain of the Calyxt RSUs granted vested in full on January&nbsp;1, 2023, and the remaining Calyxt RSUs will
vest 1/3 on each of the first, second and third anniversaries of the grant date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Calyxt PSUs have a three-year performance period of 2022, 2023, and 2024. Vesting and settlement of the
Calyxt PSUs will occur each year based on achievement of objectives approved by the Calyxt Board for the applicable year; provided that, upon a change in control, the performance period shall be truncated, and the Calyxt PSUs will vest and settle
based on performance through such date, as determined by the Compensation </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">293 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Committee of the Calyxt Board and otherwise in accordance with the Omnibus Plan and the applicable award agreements. The Calyxt PSU objectives for 2022 match the target performance goals under
the STIP, described above. However, the Compensation Committee determined that the 2022 Calyxt PSUs would be earned at 100% of target given Calyxt&#146;s execution of its strategic objectives during 2022. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Compensation and Benefits </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Health and Welfare
and Retirement Benefits </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt NEOs are generally eligible to participate in the same health and welfare programs and 401(k) plan as
other employees and receive company matching contributions under the 401(k) plan. The monthly medical and dental benefit plan premiums of Calyxt NEO&#146;s are fully paid by Calyxt. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Perquisites </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt generally does not
offer any additional perquisites to Calyxt NEOs. However, Calyxt&#146;s Chief Executive Officer is entitled to receive commuter expense reimbursements of up to $40,000 per calendar year for documented reasonable and customary expenses incurred by
him in connection with commuting from his place of residence to Calyxt&#146;s headquarters. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Post-Employment Compensation </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt has entered into employment agreements with certain Calyxt NEOs, which provide for certain post-employment compensation including
severance. Calyxt also maintains a 2021 Executive Severance Plan, as amended, in which certain Calyxt NEOs participate via voluntary participation agreements. These post-employment benefits are described in additional detail in &#147;Potential
Payments Upon Termination or Change in Control&#148; below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Considerations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Compensation Risk Assessment </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to
time, Calyxt&#146;s Compensation Committee oversees a risk assessment of Calyxt&#146;s compensation arrangements. The last review was conducted in December 2021 and, through discussions with management and Calyxt&#146;s compensation consultant, the
Compensation Committee determined that Calyxt&#146;s policies and practices of compensating its employees, including executive officers, are not reasonably likely to have material risk for the company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">294 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth total compensation for the years ended December&nbsp;31, 2022, December&nbsp;31, 2021 and December&nbsp;31,
2020, as applicable, for each Calyxt NEO. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name and Principal Position</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fiscal<BR>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus<BR>($)<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>Awards<BR>($)<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<BR>($)<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-Equity</FONT><BR>Incentive Plan<BR>Compensation<BR>($)<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></B></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation<BR>($)<SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael A. Carr<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">495,923</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">474,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43,561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,514,006</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>President and Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">216,984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">450,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,346,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">503,306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,533,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William F. Koschak</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">340,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">292,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">241,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">891,629</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Financial Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">338,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">144,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">144,635</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">643,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">329,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">341,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">133,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,751</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">823,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Travis J. Frey, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">275,109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">242,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">832,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Technology Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">295,263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">132,825</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">133,509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">576,061</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">279,538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">248,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">113,193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">675,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Debra Frimerman</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">321,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">268,505</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">242,085</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,076</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">844,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>General Counsel and Corporate Secretary</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">312,078</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">152,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">150,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,076</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">628,302</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">285,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">248,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">102,142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,983</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">650,752</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Carr was appointed as Chief Executive Officer effective July&nbsp;27, 2021. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This column reflects Mr.&nbsp;Carr&#146;s <FONT STYLE="white-space:nowrap">one-time</FONT> <FONT
STYLE="white-space:nowrap">new-hire</FONT> bonus of $450,000. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This column reflects the fair value of Calyxt RSUs and Calyxt PSUs granted in 2022, 2021 and 2020, as
applicable, based on the stock price on the date of grant. These amounts reflect Calyxt&#146;s accounting expense for these awards and do not correspond to the actual value that will be realized by the Calyxt NEOs. Amounts listed in this column are
calculated in accordance with FASB ASC Topic 718, as disclosed in Note 6 &#147;Stock-Based Compensation&#148; to Calyxt&#146;s audited financial statements included in Calyxt&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT>
for the year ended December&nbsp;31, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This column reflects the fair value of options granted in 2022, 2021 and 2020 based on their grant date fair
value calculated in accordance with FASB ASC Topic 718. These amounts reflect Calyxt&#146;s accounting expense for these awards and do not correspond to the actual value that will be realized by the Calyxt NEOs. The assumptions used in the
calculation of the amounts are described in Note 6 &#147;Stock-Based Compensation&#148; to Calyxt&#146;s audited financial statements included in Calyxt&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended
December&nbsp;31, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This column reflects the annual cash bonus earned for the applicable fiscal year. No annual cash bonus was
earned by Calyxt NEOs pursuant to Calyxt&#146;s 2022 or 2021 short-term cash incentive plan. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Carr&#146;s other compensation for the year ended December&nbsp;31, 2022 includes $28,635 of commuter
expenses and $11,600 of matching contributions under Calyxt&#146;s 401k benefit plan. Mr.&nbsp;Koschak&#146;s other compensation for the year ended December&nbsp;31, 2022 includes $11,600 of matching contributions under Calyxt&#146;s 401k benefit
plan and $5,100 of premiums for medical, dental, and life insurance that were paid by Calyxt. Dr.&nbsp;Frey&#146;s other compensation for the year ended December&nbsp;31, 2022 includes $11,434 of matching contributions under Calyxt&#146;s 401k
benefit plan. Ms.&nbsp;Frimerman&#146;s other compensation for the year ended December&nbsp;31, 2022 includes $11,600 of matching contributions under Calyxt&#146;s 401k benefit plan. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">295 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Grants of Plan-Based Awards </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information regarding grants of awards made to Calyxt&#146;s NEOs during the year ended
December&nbsp;31, 2022. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="29%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:7pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant</B><br><B>Date</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated Possible Payouts<BR>under <FONT STYLE="white-space:nowrap">Non-Equity</FONT> Incentive<BR>Plan Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated Future Payouts<BR>Under Equity Incentive Plan<BR>Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All<BR>Other<BR>Stock<BR>Award:<BR>Number<BR>of<BR>Shares<BR>of Stock</B><br><B>or Units</B><br><B>(#)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Option<BR>Awards:<BR>Number of<BR>Securities<BR>Underlying</B><br><B>Options</B><br><B>(#)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exercise<BR>or Base<BR>Price of<BR>Option</B><br><B>Awards</B><br><B>($/Sh)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant Date<BR>Fair&nbsp;Value&nbsp;of<BR>Stock
and<BR>Option</B><br><B>Awards</B><br><B>($)<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Threshold<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Target</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maximum</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Threshold<BR>(#)<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Target</B><br><B>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maximum<BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ROWSPAN="4"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Michael A. Carr</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3/24/22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">490,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">474,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3/24/22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">368,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">467,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3/24/22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">205,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">205,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,563</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ROWSPAN="4"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">William F. Koschak</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3/24/22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">241,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3/24/22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">219,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">279,019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3/24/22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,933</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">76,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">153,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">306,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ROWSPAN="4"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Travis J. Frey, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3/24/22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">242,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3/24/22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">205,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">261,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3/24/22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,933</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">135,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">270,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ROWSPAN="4"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Debra Frimerman</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3/24/22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">242,085</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3/24/22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">200,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">254,572</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3/24/22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,933</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">128,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">256,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The values in this column reflect the grant date fair value for each award in accordance with FASB ASC Topic
718. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Calyxt PSU awards granted on March&nbsp;24, 2022 do not have a threshold level. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">296 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Outstanding Equity Awards at 2022 Fiscal <FONT STYLE="white-space:nowrap">Year-End</FONT></I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information regarding outstanding equity awards of Calyxt NEOs as of December&nbsp;31, 2022. The market
value of the shares in the following table is the fair value of such shares as of December&nbsp;31, 2022. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="15" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant Date</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options<BR>(#)<BR>Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options<BR>(#)<BR>Unexercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Exercise<BR>Price<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option</B><br><B>Expiration</B><br><B>Date</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael A. Carr</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">March&nbsp;24, 2022<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">490,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">March&nbsp;24,&nbsp;2032</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>President and Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">July&nbsp;27, 2021<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">133,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">July&nbsp;27, 2031</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William F. Koschak</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">March&nbsp;24, 2022<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">March&nbsp;24, 2032</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Financial Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">March&nbsp;12, 2021<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">March&nbsp;12, 2031</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">August&nbsp;4, 2020<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36,668</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">August&nbsp;4, 2030</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">February&nbsp;8,&nbsp;2019<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">108,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">February&nbsp;8,&nbsp;2029</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Travis J. Frey, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">March&nbsp;24, 2022<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">March&nbsp;24, 2032</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Technology Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">March&nbsp;12, 2021<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">March&nbsp;12, 2031</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">August&nbsp;4, 2020<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,668</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">August&nbsp;4, 2030</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">May&nbsp;20, 2019<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">May&nbsp;20, 2029</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Debra Frimerman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">March&nbsp;24, 2022<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">March&nbsp;24, 2032</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>General Counsel and</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">March&nbsp;12, 2021<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">March&nbsp;12, 2031</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Corporate Secretary</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">August&nbsp;4, 2020<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,668</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">August&nbsp;4, 2030</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">May&nbsp;13, 2019<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">May&nbsp;13, 2029</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="15" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock Awards</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant Date</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares or<BR>Units of<BR>Stock<BR>That<BR>Have Not<BR>Vested (#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Market<BR>Value&nbsp;of<BR>Shares&nbsp;or<BR>Units of<BR>Stock&nbsp;That<BR>Have
Not<BR>Vested&nbsp;($)<SUP STYLE="font-size:75%; vertical-align:top">(7)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity<BR>Incentive<BR>Plan&nbsp;Awards;<BR>Number of<BR>Unearned<BR>Shares, Units<BR>or Other<BR>Rights That<BR>Have Not<BR>Vested (#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity<BR>Incentive&nbsp;Plan<BR>Awards;<BR>Number of<BR>Unearned<BR>Shares, Units<BR>or Other<BR>Rights That<BR>Have Not<BR>Vested&nbsp;($)<SUP
STYLE="font-size:75%; vertical-align:top">(7)</SUP></B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael A. Carr</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">March&nbsp;24, 2022<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">368,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">205,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">30,340</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>President and Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">July&nbsp;27, 2021<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,933</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">600,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">88,800</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William F. Koschak</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">March&nbsp;24,&nbsp;2022<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">219,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">14,800</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Financial Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">March&nbsp;12, 2021<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,776</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">June&nbsp;28, 2019<SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Travis J. Frey, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">March&nbsp;24, 2022<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">205,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,436</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">14,800</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Technology Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">March&nbsp;12, 2021<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Debra Frimerman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">March&nbsp;24, 2022<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">200,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">14,800</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>General Counsel and</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">March&nbsp;12, 2021<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Corporate Secretary</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">June&nbsp;28, 2019<SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The stock option grant vesting schedule is as follows: 25% of the total number of stock options vest on the
first, second, third, and fourth anniversaries of the grant date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The stock option grant vesting schedule is as follows: (i) 33.3% of the total number of stock options vest on
the first and second anniversaries of the grant date; and (ii) 33.4% of the total number of stock options vest on the third anniversary of the grant date. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">297 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The stock option grant vesting schedule is as follows: (i) 15% of the total number of stock options vest on the
first anniversary of the grant date; (ii) 10% of the total number of stock options vest on the second anniversary of the grant date and (iii) 5% of the total number of stock options vest on the last day of the next 15 quarters.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For Mr.&nbsp;Carr, the Calyxt RSU grant vesting schedule is as follows: 163,000 of the 368,000 Calyxt RSUs
granted vest on January&nbsp;1, 2023, and the vesting schedule for the remaining 205,000 Calyxt RSUs is as follows: (i) 33.3% of the total number of Calyxt RSUs vest on the first anniversary of the grant date; (ii) 33.4% of the total number of
Calyxt RSUs vest on the second anniversary of the grant date and (iii) 33.3% of the total number of Calyxt RSUs vest on the third anniversary of the grant date. For Mr.&nbsp;Koschak, the Calyxt RSU grant vesting schedule is as follows: 119,700 of
the 219,700 Calyxt RSUs granted vest on January&nbsp;1, 2023, and the vesting schedule for the remaining 100,000 Calyxt RSUs is as follows: (i) 33.3% of the total number of Calyxt RSUs vest on the first anniversary of the grant date; (ii)&nbsp;33.4%
of the total number of Calyxt RSUs vest on the second anniversary of the grant date and (iii) 33.3% of the total number of Calyxt RSUs vest on the third anniversary of the grant date. For Dr.&nbsp;Frey, the Calyxt RSU grant vesting schedule is as
follows: 105,650 of the 205,650 Calyxt RSUs granted vest on January&nbsp;1, 2023, and the vesting schedule for the remaining 100,000 Calyxt RSUs is as follows: (i) 33.3% of the total number of Calyxt RSUs vest on the first anniversary of the grant
date; (ii) 33.4% of the total number of Calyxt RSUs vest on the second anniversary of the grant date and (iii) 33.3% of the total number of Calyxt RSUs vest on the third anniversary of the grant date. For Ms.&nbsp;Frimerman, the Calyxt RSU grant
vesting schedule is as follows: 100,450 of the 200,450 Calyxt RSUs granted vest on January&nbsp;1, 2023, and the vesting schedule for the remaining 100,000 Calyxt RSUs is as follows: (i) 33.3% of the total number of Calyxt RSUs vest on the first
anniversary of the grant date; (ii) 33.4% of the total number of Calyxt RSUs vest on the second anniversary of the grant date and (iii) 33.3% of the total number of Calyxt RSUs vest on the third anniversary of the grant date. Mr.&nbsp;Carr was
granted 205,000 Calyxt PSUs, Mr.&nbsp;Koschak was granted 100,000 Calyxt PSUs, Dr.&nbsp;Frey was granted 100,000 Calyxt PSUs, and Ms.&nbsp;Frimerman was granted 100,000 Calyxt PSUs. The Calyxt PSUs have a three-year performance period of 2022, 2023,
and 2024. Vesting and settlement of the Calyxt PSUs will occur each year based on achievement of objectives approved by the Calyxt Board for the applicable year; provided that, upon a change in control, the performance period shall be truncated, and
the Calyxt PSUs will vest and settle based on performance through such date, as determined by the Compensation Committee of the Calyxt Board and otherwise in accordance with the Omnibus Plan and the applicable award agreements.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For all Calyxt NEOs, the Calyxt RSU grant vesting schedule is as follows: (i) 33.3% of the total number of
Calyxt RSUs vest on the first anniversary of the grant date; (ii) 33.3% of the total number of Calyxt RSUs vest on the second anniversary of the grant date and (iii) 33.4% of the total number of Calyxt RSUs vest on the third anniversary of the grant
date. For Mr.&nbsp;Carr, the Calyxt PSUs will vest if Calyxt Common Stock remains above three specified price levels for 30&nbsp;calendar days over the three-year performance period. The Calyxt PSUs will be settled in unrestricted shares of Calyxt
Common Stock on the vesting date. Upon a change of control as defined in the award agreement, 25% of the Calyxt PSUs will vest with the remainder continuing to vest pursuant to the terms of the award provided that he maintains continuous service.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The performance conditions in these Calyxt PSUs were not met and the awards were forfeited.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Value of unvested Calyxt RSUs and Calyxt PSUs are based on Calyxt&#146;s closing price per common share of
$0.15 on December&nbsp;31, 2022. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Option Exercises and Stock Vested </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information with respect to stock options that were exercised, and Calyxt RSUs that vested, during the year
ended December&nbsp;31, 2022. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock Awards</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of Shares<BR>Acquired&nbsp;on&nbsp;Exercise<BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Value&nbsp;Realized&nbsp;on<BR>Exercise</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares<BR>Acquired&nbsp;on&nbsp;Vesting</B><br><B>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Value&nbsp;Realized&nbsp;on<BR>Vesting</B><br><B>($)</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael A. Carr</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">16,666</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3,742</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William F. Koschak</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">7,260</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Travis J. Frey, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5,500</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6,655</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Debra Frimerman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6,333</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">7,663</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">298 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Potential Payments Upon Termination or Change in Control </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Agreements with Named Executive Officers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following provides a discussion of the agreements between Calyxt, Inc. and each Calyxt NEO. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Michael A. Carr </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;13, 2021,
Mr.&nbsp;Carr entered into an offer letter agreement with Calyxt, Inc. (the &#147;Carr Agreement&#148;). Pursuant to the Carr Agreement, Mr.&nbsp;Carr joined Calyxt on July&nbsp;27, 2021, as Calyxt&#146;s President and Chief Executive Officer.
Mr.&nbsp;Carr&#146;s employment is <FONT STYLE="white-space:nowrap">at-will</FONT> and may be terminated at any time for any reason, subject to the terms of Calyxt&#146;s 2021 Executive Severance Plan (the &#147;Severance Plan&#148;), as modified by
Mr.&nbsp;Carr&#146;s Participation Agreement with respect thereto, as described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Carr is or was entitled to receive the
following compensation and benefits in connection with his service as President and Chief Executive Officer of Calyxt, Inc.: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an annual base salary of $500,000; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a <FONT STYLE="white-space:nowrap">one-time</FONT> <FONT STYLE="white-space:nowrap">new-hire</FONT> bonus of
$450,000; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a <FONT STYLE="white-space:nowrap">one-time</FONT> equity award of (i)&nbsp;stock options for the purchase of
200,000 shares of Calyxt Common Stock and (ii) 50,000 Calyxt RSUs, which, in each case, will vest in equal installments on the first three anniversaries of Mr.&nbsp;Carr&#146;s start date; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a <FONT STYLE="white-space:nowrap">one-time</FONT> inducement award to be granted outside of Calyxt&#146;s
existing equity compensation plans in accordance with Rule 5635(c)(4) of the Nasdaq Listing Rules of Calyxt PSUs to acquire up to 600,000 shares of Calyxt Common Stock, which will vest based on Calyxt&#146;s achievement for a period of 30
consecutive calendar days of specified trading price levels; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">during a three-year performance period following the grant date (300,000 shares for a $12.00 price level, an
additional 150,000 shares for a $15.00 price level and an additional 150,000 shares for a $20.00 price level) and otherwise have terms substantially similar to those of Calyxt PSUs issued under the Omnibus Plan; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">eligibility to receive an annual cash performance bonus under Calyxt&#146;s existing short-term incentive plan
with a 2021 annual target of 100% of base salary (prorated for the number of days of employment during 2021), based on the achievement of performance goals, as determined by the Calyxt Board; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">eligibility under the Severance Plan, as amended by Mr.&nbsp;Carr&#146;s participation agreement, to receive upon
termination of employment by Mr.&nbsp;Carr for Good Reason (as defined in the Severance Plan) or by Calyxt for any reason other than Cause (as defined in the Severance Plan, but modified to be subject to a notice and cure period with respect to <FONT
STYLE="white-space:nowrap">non-willful</FONT> performance deficiencies) severance benefits equal to 12 months (24 months, if occurring during a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Change-in-Control</FONT></FONT> Period
(as defined in the Severance Plan)) of base salary and a prorated portion (the full amount, if occurring during a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Change-in-Control</FONT></FONT> Period) of Mr.&nbsp;Carr&#146;s
target cash incentive bonus for the applicable year; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">eligibility for certain travel, temporary living, and relocation benefits for up to three years from
Mr.&nbsp;Carr&#146;s start date; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">participation in the benefit plans and programs of Calyxt in which similarly situated employees of Calyxt
participate, as may be in effect from time to time, and accrual of 20 days of vacation per year. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;13, 2021,
the Calyxt Board and the independent directors of the Calyxt Board approved the Calyxt, Inc. 2021 Employee Inducement Incentive Plan (the &#147;Inducement Plan&#148;) and reserved 600,000 shares of Calyxt Common Stock for issuance upon vesting of
the Calyxt PSUs granted to Mr.&nbsp;Carr on July&nbsp;27, 2021. The Inducement Plan&#146;s terms are substantially similar to the terms of the Omnibus Plan. The Inducement Plan was </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">299 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
adopted without Calyxt Stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. The Calyxt PSUs granted to Mr.&nbsp;Carr on July&nbsp;27, 2021, constitute an inducement
material to Mr.&nbsp;Carr&#146;s entering into employment with Calyxt within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Carr is the only participant in the Inducement Plan, and the Calyxt PSUs granted in connection with the commencement of
Mr.&nbsp;Carr&#146;s employment are the only awards that will be granted under the Inducement Plan. The Calyxt PSUs will vest if Calyxt Common Stock remains above three specified price levels for 30 calendar days over the three-year performance
period. The Calyxt PSUs will be settled in unrestricted shares of Calyxt Common Stock on the vesting date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Carr has also entered
into a customary <FONT STYLE="white-space:nowrap">non-competition,</FONT> <FONT STYLE="white-space:nowrap">non-solicitation,</FONT> confidentiality and inventions agreement and Calyxt&#146;s standard indemnification agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>William Koschak </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;21,
2018 Mr.&nbsp;Koschak entered into an offer letter agreement with Calyxt (the &#147;Koschak Agreement&#148;) . Pursuant to the Koschak Agreement, Mr.&nbsp;Koschak joined Calyxt on January&nbsp;7, 2019, as its Chief Financial Officer.
Mr.&nbsp;Koschak is or was entitled to receive the following compensation and benefits in connection with his service as Chief Financial Officer of Calyxt: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an annual base salary of $320,000; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a <FONT STYLE="white-space:nowrap">one-time</FONT> <FONT STYLE="white-space:nowrap">sign-on</FONT> bonus of
$180,000; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a <FONT STYLE="white-space:nowrap">one-time</FONT> <FONT STYLE="white-space:nowrap">sign-on</FONT> equity award
of 30,000 stock options; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">eligibility to receive an annual cash performance bonus with an amount equal to up to 45% of
Mr.&nbsp;Koschak&#146;s base salary and a multiplier on the annual target of 0.7 to 1.5x (prorated for the number of days of his employment during 2019), based on his achievement of individual and/or Calyxt performance goals as determined by the
Calyxt Board; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a <FONT STYLE="white-space:nowrap">one-time</FONT> equity award of 150,000 shares of Calyxt Common Stock pursuant
to Calyxt&#146;s existing equity incentive plan; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">participation in the benefit plans and programs of Calyxt in which substantially all of Calyxt&#146;s employees
participate, as may be in effect from time to time, and accrual of 20 days of vacation per year as well as a <FONT STYLE="white-space:nowrap">one-time</FONT> grant of 5 days of vacation to be used prior to January&nbsp;7, 2020.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Koschak Agreement also provides for severance benefits in the event that Mr.&nbsp;Koschak&#146;s employment is
terminated by Calyxt without Cause, in which case Mr.&nbsp;Koschak will be entitled to receive a <FONT STYLE="white-space:nowrap">pro-rata</FONT> portion of his annual performance bonus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Koschak Agreement also includes customary <FONT STYLE="white-space:nowrap">non-solicitation,</FONT>
<FONT STYLE="white-space:nowrap">non-compete,</FONT> intellectual property and confidentiality provisions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Travis J. Frey, Ph.D. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;13, 2019, Dr.&nbsp;Frey entered into an offer letter agreement with Calyxt (the &#147;Frey Agreement&#148;) . Pursuant to the Frey
Agreement, Dr.&nbsp;Frey joined Calyxt on May&nbsp;20, 2019, as its Chief Technology Officer. Dr.&nbsp;Frey is or was entitled to receive the following compensation and benefits in connection with his service as Chief Technology Officer of Calyxt:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an annual base salary of $300,000; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a <FONT STYLE="white-space:nowrap">one-time</FONT> <FONT STYLE="white-space:nowrap">sign-on</FONT> equity award
of 100,000 stock options, which will be granted, subject to the approval of the Calyxt Board; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">300 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">eligibility to receive an annual cash performance bonus with an amount equal to up to 45% of Dr.&nbsp;Frey&#146;s
base salary and a multiplier on the annual target of 0.7 to 1.5x (prorated for the number of days of his employment during 2019), based on his achievement of individual and/or Calyxt performance goals as determined by the Calyxt Board.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Frey&#146;s offer letter also included customary <FONT STYLE="white-space:nowrap">non-solicitation,</FONT> <FONT
STYLE="white-space:nowrap">non-compete,</FONT> intellectual property, and confidentiality provisions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Debra Frimerman </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;21, 2019, Ms.&nbsp;Frimerman entered into an offer letter agreement with Calyxt (the &#147;Frimerman Agreement&#148;). Pursuant
to the Frimerman Agreement, Ms.&nbsp;Frimerman joined Calyxt on February&nbsp;11, 2019, as its General Counsel&nbsp;&amp; Corporate Secretary. Ms.&nbsp;Frimerman&#146;s employment agreement provides for
<FONT STYLE="white-space:nowrap">at-will</FONT> employment and may be terminated at any time, with or without cause, subject to certain severance benefits described below. Ms.&nbsp;Frimerman is or was entitled to receive the following compensation
and benefits in connection with her service as General Counsel&nbsp;&amp; Corporate Secretary of Calyxt: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an annual base salary of $321,000; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a <FONT STYLE="white-space:nowrap">one-time</FONT> <FONT STYLE="white-space:nowrap">sign-on</FONT> equity award
of 100,000 stock options; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">eligibility to receive an annual cash performance bonus with an amount equal to up to 40% of
Ms.&nbsp;Frimerman&#146;s base salary and a multiplier on the annual target of 0.7 to 1.5x (prorated for the number of days of her employment during 2019), based on her achievement of individual and/or Calyxt performance goals as determined by the
Calyxt Board. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under her employment agreement, if Ms.&nbsp;Frimerman&#146;s employment is terminated by Calyxt without
cause (as defined in her employment agreement), she is eligible to receive a pro rata annual performance bonus and 12 months of base salary paid in installments. Calyxt may condition any severance pay to Ms.&nbsp;Frimerman upon her entering into a
full release of claims in favor of Calyxt. If Ms.&nbsp;Frimerman voluntarily terminates her employment or her employment terminates due to death or disability, she will be entitled only to accrued base salary and other accrued amounts.
Ms.&nbsp;Frimerman is eligible to participate in the Severance Plan, which would supersede the applicable terms of her employment agreement, if she executes a Severance Plan participation agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ms.&nbsp;Frimerman&#146;s employment agreement also included customary <FONT STYLE="white-space:nowrap">non-solicitation,</FONT> <FONT
STYLE="white-space:nowrap">non-compete,</FONT> intellectual property, and confidentiality provisions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Executive Severance Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt maintains the 2021 Executive Severance Plan, as amended on January&nbsp;13, 2023 (the &#147;Executive Severance Plan&#148;) for certain
key management employees who agree to participate. The Executive Severance Plan provides plan participants with certain severance benefits upon termination of the plan participant&#146;s employment with Calyxt. Mr.&nbsp;Carr, Mr.&nbsp;Koschak, and
Dr.&nbsp;Frey are participants in the Executive Severance Plan. Ms.&nbsp;Frimerman is eligible to become a participant in the Executive Severance Plan by executing a plan participation agreement. Until such time as Ms.&nbsp;Frimerman may become a
participant under the Executive Severance Plan, upon a qualifying termination Ms.&nbsp;Frimerman will be entitled to receive severance benefits under her employment agreement as described above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Executive Severance Plan provides plan participants with severance benefits upon termination of the plan participant&#146;s employment by
the plan participant for Good Reason or by Calyxt for any reason other than for Cause or other than the plan participant&#146;s death or Disability (each as defined in the Executive Severance Plan). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">301 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the Executive Severance Plan, plan participants are entitled to the
following compensation (&#147;Severance Benefits&#148;) upon such a qualifying termination: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">An amount equal to the plan participant&#146;s base salary for a period of (i) 12 months, for the Chief Executive
Officer, Chief Financial Officer, Chief Legal Officer/General Counsel and any other chief executive, and (ii) 6 months, for Senior Vice Presidents and Vice Presidents or other participants, beginning on the plan participant&#146;s date of
termination, each a &#147;Severance Coverage Period;&#148; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A <FONT STYLE="white-space:nowrap">pro-rated</FONT> portion of the plan participant&#146;s target incentive bonus
under Calyxt&#146;s annual cash incentive plan for the applicable year, <FONT STYLE="white-space:nowrap">pro-rated</FONT> for the number of days elapsed in the applicable year. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Plan participants are also entitled to any unpaid amounts earned under the annual cash incentive plan for the preceding year, based upon
actual performance and, in certain circumstances, continuing medical and dental benefits. Severance Benefits will generally be paid in substantially equal installments over the applicable Severance Coverage Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock option awards held by plan participants shall be exercisable as to the vested portion for a period of 90 days following the plan
participant&#146;s qualifying termination or the stated expiration date, whichever is earlier, so long as the qualifying termination does not occur during a period of 27 months beginning three months before the effective date of a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">change-in-control</FONT></FONT> (the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;Change-in-Control</FONT></FONT> Period&#148;). If a qualifying termination
occurs during a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Change-in-Control</FONT></FONT> Period, (i)&nbsp;all time-based vesting conditions applicable to Calyxt equity or equity-based awards held by the plan participant will
lapse and such awards will be immediately vested, and (ii)&nbsp;all performance-based vesting conditions applicable to outstanding equity awards will be deemed satisfied at a level reasonably determined by the compensation committee of the Calyxt
Board based on actual performance (unless otherwise specified in the plan participant&#146;s participation agreement). In addition, with respect to Mr.&nbsp;Carr, if a qualifying termination occurs during a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Change-in-Control</FONT></FONT> Period, Mr.&nbsp;Carr&#146;s Severance Benefits are increased to 24 months of base salary and the full amount of his target cash incentive bonus for the applicable year. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2017 Omnibus Incentive Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt maintains the 2017 Omnibus Incentive Plan, as amended on May&nbsp;18, 2021. Employees, consultants,
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors (and director nominees) and any other individuals who provide services to us or any of Calyxt&#146;s&nbsp;affiliates are eligible to receive awards under the Omnibus Plan, if permitted
by applicable laws or accounting and tax rules and regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a dissolution or liquidation of Calyxt or a triggering
event, except as otherwise provided in the applicable award agreement, the plan administrator may provide for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assumption or substitution with equivalent awards of outstanding awards under the Plan by Calyxt (if Calyxt is
the surviving corporation) or by the surviving corporation or its parent or subsidiary; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">termination of outstanding awards under the Omnibus Plan in exchange for a payment of cash, securities and/or
other property equal to the excess of the fair market value of the portion of the awards stock that is vested and exercisable immediately prior to the consummation of the corporate transaction over the per share exercise price;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any combination of assumption, substitution, or termination of outstanding awards under the Omnibus Plan as
described above; provided that outstanding awards of stock options and SARs may be cancelled without consideration if the fair market value on the date of the event is greater than the exercise or hurdle price of such award; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acceleration of the vesting (including the lapse of any restrictions, with any performance criteria or conditions
deemed met at target) and exercisability of outstanding award in full prior to the date of the corporate transaction and the expiration of awards not timely exercised by the date determined by the plan administrator. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">302 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A triggering event as defined in the plan includes (i)&nbsp;a sale, transfer or disposition
of all or substantially all of Calyxt&#146;s assets other than to (A)&nbsp;a corporation or other entity of which at least a majority of its combined voting power is owned directly or indirectly by Calyxt, (B)&nbsp;a corporation or other entity
owned directly or indirectly by the holders of capital stock of Calyxt in substantially the same proportions as their ownership of Calyxt Common Stock, or (C)&nbsp;an Excluded Entity (as defined in subsection (ii)&nbsp;below); or (ii)&nbsp;any
merger, consolidation or other business combination transaction of Calyxt with or into another corporation, entity or person, other than a transaction with or into another corporation, entity or person in which the holders of at least a majority of
the shares of voting capital stock of Calyxt outstanding immediately prior to such transaction continue to hold (either by such shares remaining outstanding in the continuing entity or by their being converted into shares of voting capital stock of
the surviving entity) a majority of the total voting power represented by the shares of voting capital stock of Calyxt (or the surviving entity) outstanding immediately after such transaction (an &#147;Excluded Entity&#148;); or (iii)&nbsp;any
direct or indirect purchase or other acquisition by any person or group, other than a parent company or another person that is controlled by a parent company, of more than 50% of the total outstanding equity interests in or voting securities of
Calyxt, excluding any transaction that is determined by the Calyxt Board in its reasonable discretion to be a bona fide capital raising transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Calyxt RSU and option awards granted to Calyxt NEOs under the Omnibus Plan provide that in the event that a triggering event occurs during
the vesting period, an additional 25% of the total number of Calyxt RSUs or shares underlying the options shall immediately vest. In addition, these awards provide that 100% of the total number of Calyxt RSUs or shares underlying the options shall
vest in the event of the termination of the Calyxt NEO&#146;s employment without cause within 12 months following a triggering event or resignation of the Calyxt NEO for &#147;good reason&#148; following a triggering event. The Calyxt PSUs granted
to Calyxt NEOs under the Omnibus Plan that remain outstanding provide that, upon a change in control, the performance period shall be truncated, and the Calyxt PSUs will vest and settle based on performance through such date, as determined by the
Compensation Committee of the Calyxt Board and otherwise in accordance with the Omnibus Plan and the applicable Calyxt PSU agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2021 Employee
Inducement Incentive Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2021, Calyxt adopted the Inducement Plan, pursuant to which shares of Calyxt Common Stock are
issuable upon the settlement of Calyxt PSUs granted to Mr.&nbsp;Michael&nbsp;A. Carr in July 2021 as a material inducement to accept employment as Calyxt&#146;s President and Chief Executive Officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Inducement Plan mirrors the Omnibus Plan with regard to impacts of a dissolution or liquidation of Calyxt or a triggering event.
Mr.&nbsp;Carr&#146;s award agreement under the Inducement Plan provides that in the event of a triggering event (as defined in the Inducement Plan) during the performance period, 25&nbsp;percent of the total Calyxt PSUs will immediately vest to the
extent not already vested. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">303 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below quantifies the payments and benefits potentially payable to each Calyxt NEO
upon a change in control or certain employment terminations as described above, assuming a termination date of December&nbsp;31, 2022 and a fair market value of a share of Class&nbsp;A Common Stock of $0.14, which is the average closing price per
share of Calyxt Common Stock on Nasdaq over the last five trading days in the period ending December&nbsp;31, 2022. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:9pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Death/<BR>Disability<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Retirement<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change of<BR>Control<BR>Without<BR>Termination<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Qualifying</B><br><B>Termination</B><br><B>(no&nbsp;Change&nbsp;in</B><br><B>Control)</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Qualifying<BR>Termination</B><br><B>(in&nbsp;Connection</B><br><B>with a</B><br><B>Change&nbsp;of<BR>Control)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Michael A. Carr</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Cash Severance</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Equity Payout</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63,747</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">105,887</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Other Benefits</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>TOTAL</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>50,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>63,747</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,033,133</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,639,020</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>William F. Koschak</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Cash Severance</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">493,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">493,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Equity Payout</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Other Benefits</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,829</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,829</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>TOTAL</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>50,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>22,110</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>518,829</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>565,267</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Travis Frey, Ph.D.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Cash Severance</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">435,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">435,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Equity Payout</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Other Benefits</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>TOTAL</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>50,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>21,583</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>451,567</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>495,898</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Debra Frimerman</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Cash Severance</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">449,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">449,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Equity Payout</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Other Benefits</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>TOTAL</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>50,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>21,459</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>449,400</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>493,236</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Chief Executive Officer Pay Ratio </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the fiscal year ending December&nbsp;31, 2022, the ratio of the annual total compensation of Mr.&nbsp;Carr, Calyxt&#146;s Chief Executive
Officer (&#147;CEO Compensation&#148;), to the median of the annual total compensation of all of Calyxt&#146;s employees and those of Calyxt&#146;s consolidated subsidiaries other than Calyxt&#146;s Chief Executive Officer (&#147;Median Annual
Compensation&#148;) was 17.3 to 1. This ratio is a reasonable estimate calculated in a manner consistent with Item 402(u) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> using the data and assumptions summarized below. In this summary,
Calyxt refers to the employee who received such Median Annual Compensation as the &#147;Median Employee.&#148; For purposes of this disclosure, the date used to identify the Median Employee was December&nbsp;31, 2022 (the &#147;Determination
Date&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CEO Compensation for purposes of this disclosure was $1,514,006 and matches the total compensation reported for
Mr.&nbsp;Carr under the Summary Compensation Table for the 2022 fiscal year. For purposes of this disclosure, Median Annual Compensation was $87,763, and was calculated by totaling for Median Employee all applicable elements of compensation for the
2022 fiscal year in accordance with Item 402(c)(2)(x) of <FONT STYLE="white-space:nowrap">Regulation&nbsp;S-K.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">304 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To identify the Median Employee, Calyxt first determined its employee population as of the
Determination Date. Calyxt had 48 employees, representing all full-time, part-time, seasonal and temporary employees of Calyxt and its consolidated subsidiaries as of the Determination Date. Calyxt then measured compensation for the period beginning
on January&nbsp;1, 2022 and ending on December&nbsp;31, 2022 for these employees. This compensation measurement was calculated by totaling, for each employee, <FONT STYLE="white-space:nowrap">W-2</FONT> compensation as shown in Calyxt&#146;s payroll
and human resources records for fiscal year 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the amount of compensation Calyxt paid to its directors during Calyxt&#146;s fiscal year 2022. The Calyxt Board
had determined there will be no cash stipends paid for Calyxt Board service in 2022. Directors also receive equity compensation upon joining the Calyxt Board and each year for their service. Directors received grants of stock options in 2022 for
service in amounts determined by the Calyxt Board. Mr.&nbsp;Arthaud elected not to receive compensation for his Calyxt Board service during 2022. Mr.&nbsp;Carr does not receive any additional compensation for his Calyxt Board service. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees<BR>Earned<BR>or&nbsp;Paid&nbsp;in<BR>Cash ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>Awards<BR>($)<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<BR>($)<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laurent Arthaud</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael A. Carr<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Philippe Dumont<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jonathan B. Fassberg<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anna Ewa Kozicz-Stankiewicz<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kimberly K. Nelson<SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher J. Neugent<SUP STYLE="font-size:75%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Yves J. Ribeill, Ph.D.<SUP STYLE="font-size:75%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No Calyxt RSU awards were granted to Calyxt&#146;s non-employee directors in 2022. As of December&nbsp;31,
2022, Mr.&nbsp;Fassberg held 5,880 Calyxt RSUs and Mr.&nbsp;Neugent held 5,880 Calyxt RSUs. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This column reflects the fair value of stock options granted in 2022 based on their grant date fair value
calculated in accordance with FASB ASC Topic 718. As of December&nbsp;31, 2022, Calyxt&#146;s directors held stock options for the following number of shares of Calyxt Common Stock: (i)&nbsp;Mr.&nbsp;Dumont, 84,891 shares,
(ii)&nbsp;Mr.&nbsp;Fassberg, 82,391 shares, (iii)&nbsp;Ms.&nbsp;Kozicz, 87,061 shares, (iv)&nbsp;Ms.&nbsp;Nelson, 114,831 shares, (v)&nbsp;Mr.&nbsp;Neugent, 92,708 shares, and (vi)&nbsp;Dr.&nbsp;Ribeill, 269,991 shares. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For Mr.&nbsp;Carr&#146;s share information, see &#147;<I>&#151;Summary Compensation Table</I>&#148; above.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Dumont and Mr.&nbsp;Fassberg were granted options to purchase 32,700 shares of Calyxt Common Stock on
June&nbsp;13, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ms.&nbsp;Kozicz was granted options to purchase 34,900 shares of Calyxt Common Stock on June&nbsp;13, 2022.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ms.&nbsp;Nelson was granted options to purchase 37,100 shares of Calyxt Common Stock on June&nbsp;13, 2022.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Neugent was granted options to purchase 36,400 shares of Calyxt Common Stock on June&nbsp;13, 2022.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Ribeill was granted options to purchase 47,200 shares of Calyxt Common Stock on June&nbsp;13, 2022.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">305 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Committee Interlocks and Insider Participation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During 2022, the following directors served as a member of Calyxt, Inc.&#146;s Compensation Committee: Mr.&nbsp;Arthaud, Mr.&nbsp;Dumont,
Mr.&nbsp;Neugent (chair), and Dr.&nbsp;Ribeill. During 2022, no member of Calyxt&#146;s Compensation Committee was an officer or employee of Calyxt. Other than Dr.&nbsp;Ribeill, no member of Calyxt, Inc.&#146;s Compensation Committee was formerly an
officer of Calyxt, Inc. Dr.&nbsp;Ribeill served as Calyxt, Inc.&#146;s interim Chief Executive Officer from August 2018 until October 2018 and as Executive Chair from February 2021 until August 2021. During 2022, none of Calyxt, Inc.&#146;s
executive officers served as a member of the Compensation Committee (or other committee performing similar functions) or as a director of any other entity of which an executive officer served on the Calyxt Board or its Compensation Committee. None
of the directors who served on Calyxt, Inc.&#146;s Compensation Committee during 2022 has any relationship requiring disclosure under this caption under SEC rules. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">306 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom401831_52"></A>CIBUS GLOBAL EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary Compensation Table </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following
table sets forth total compensation for the years ended December&nbsp;31, 2022 and December&nbsp;31, 2021, as applicable, for each person who served as a Cibus Global principal executive officer during 2022, as well as the two other most highly
compensated executive officers of Cibus Global in 2022 (&#147;Cibus NEOs&#148;). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Principal Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary</B><br><B>($)<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus</B><br><B>($)<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option</B><br><B>Award</B><br><B>($)<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other</B><br><B>Compensation</B><br><B>($)<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rory Riggs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">2022</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">523,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Executive Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">125,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,611,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,743,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Beetham, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">2022</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">408,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">324,142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">798,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President&nbsp;&amp; Chief Operating Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">400,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">149,512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">565,572</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wade King, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">2022</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">306,270</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">416,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">768,762</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">300,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">226,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">534,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amounts in this column for Rory Riggs represent his deferred salary. For more information, see the section of
this proxy statement/prospectus entitled &#147;<I>The Mergers&#151;Interests of Cibus Global Directors and Executive Officers in the Mergers</I>.&#148; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amounts in this column represent a <FONT STYLE="white-space:nowrap">one-time</FONT> bonus for Drs. Beetham and
King pursuant to their respective employment agreements providing a bonus upon closing a private placement of securities of gross proceeds of $50,000,000 or more. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each of the Cibus NEOs received, as incentive compensation, certain Cibus PIU awards in 2021 and 2022. A
description of these awards may be found in the footnotes and the narrative following the &#147;Outstanding Equity Awards at Fiscal <FONT STYLE="white-space:nowrap">Year-End&#148;</FONT> table. Despite the fact that the awards that are intended to
constitute profits interests and do not require the payment of an exercise price, Cibus Global believes that they are most similar economically to stock options, and as such, they are properly classified as &#147;options&#148; under the definition
provided in Item 402(a)(6)(i) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> as an instrument with an &#147;option-like feature.&#148; Amounts disclosed in this column reflect a grant date fair value of the Cibus PIUs in accordance with
FASB ASC Topic 718, but with respect to such award, Cibus Global recognizes share-based compensation equal to the difference between the grant date fair value and $0.01, which is the amount per share paid by each Cibus NEO. Assumptions used to
calculate the grant date values are described within the notes to Cibus Global&#146;s consolidated financial statements included elsewhere in this prospectus. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amounts reflected within the &#147;All Other Compensation&#148; column are comprised of the following amounts:
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Insurance&nbsp;Premiums&nbsp;($)<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Director<BR>Compensation&nbsp;($)<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rory Riggs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">2022</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;6,605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Beetham, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">2022</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wade King, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">2022</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amount in this column reflects the cost of health, dental, life and long-term disability insurance policy
premiums that Cibus Global incurred during the applicable fiscal years. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amount in this column reflects the grant date fair value of Cibus PIUs, determined in accordance with FASB
ASC Topic 718, paid to Mr.&nbsp;Riggs for service on the Cibus Board for 9 months of service prior to being appointed Chief Executive Officer of Cibus. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">307 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Narrative Disclosure to Summary Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary elements of compensation for the Cibus NEOs are base salary and equity compensation awards. The Cibus NEOs also participate in
employee benefit plans and programs that Cibus Global offers to its other full-time employees on the same basis. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Base Salaries </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus Global pays its NEOs a base salary to compensate them for the satisfactory performance of services rendered to Cibus Global. The base
salary payable to each Cibus NEO is intended to provide a fixed component of compensation reflecting the executive&#146;s skill set, experience, role and responsibilities. Base salaries for Cibus NEOs have generally been set at levels deemed
necessary to attract and retain individuals with superior talent. For 2021 and 2022, until December&nbsp;2, 2022, Dr.&nbsp;Beetham received an annual base salary of $400,005 and Dr.&nbsp;King received an annual base salary of $300,020. On
December&nbsp;2, 2022, Dr.&nbsp;Beetham received a base salary increase of $100,000 and Dr.&nbsp;King received a base salary increase of $75,000, in each case pursuant to their employment agreements. For 2021 and 2022, Mr.&nbsp;Riggs earned an
annual base salary of $500,000. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Equity Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus Global has granted equity awards to its employees, including the Cibus NEOs, as the long-term incentive component of Cibus Global&#146;s
compensation program. Historically, the Cibus Board has, for incentive purposes, granted Cibus PIUs on an annual basis to key employees as it has determined appropriate to motivate, retain or reward such employees, and such grants have been made
pursuant to the terms of a restricted unit plan, restricted unit purchase agreements and the Cibus Global Amended and Restated Memorandum of Association and Articles of Association, as currently in effect. These Cibus PIUs entitle the holder to
participate in Cibus Global&#146;s future appreciation from and after the date of grant of the applicable Cibus PIU. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus PIUs granted
to Cibus NEOs are typically subject to time-based vesting conditions and are subject to accelerated vesting in the event of a change of control, as defined in the applicable award agreement, provided that the Cibus NEO continues to provide services
immediately prior to the consummation of such change of control. Refer to the &#147;Outstanding Equity Awards at Fiscal Year End&#148; table below for a description of the vesting terms that apply to these awards. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Retirement, Health, Welfare and Additional Benefits </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus NEOs are eligible to participate in Cibus Global&#146;s employee benefit plans and programs, including medical and dental benefits and
flexible spending accounts, to the same extent as Cibus Global&#146;s other full-time employees, subject to the terms and eligibility requirements of those plans. Cibus Global also sponsors a 401(k) defined contribution plan in which Cibus NEOs may
participate, subject to limits imposed by the Code, to the same extent as Cibus Global&#146;s other full-time employees. Currently, Cibus Global does not match any of the contributions made by participants to the 401(k) plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Outstanding Equity Awards at Fiscal <FONT STYLE="white-space:nowrap">Year-End</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information with respect to outstanding Cibus PIUs for each of the Cibus NEOs as of December&nbsp;31, 2022. The
table reflects both vested and unvested Cibus PIUs. The Cibus PIUs are subject to time-based vesting and to an additional requirement that a minimum valuation threshold be met before the holder of the Cibus PIU is entitled to a distribution in
respect of such award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the effective time of the Cibus Merger, each Cibus PIU will, (a)&nbsp;to the extent not a &#147;restricted
unit&#148; (under the award agreements and governing documents applicable to such Cibus PIU), be automatically </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">308 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
cancelled and converted into the right to receive the number of shares of Class&nbsp;A Common Stock set forth on the Allocation Schedule and (b)&nbsp;to the extent a &#147;restricted unit&#148;
(i.e., an unvested unit), be automatically cancelled and converted into the right to receive the number of restricted shares of Class&nbsp;A Common Stock pursuant to a Calyxt, Inc. stock plan, as set forth on the Allocation Schedule and subject to
the same vesting schedule as was applicable to such Cibus PIU prior to the Closing. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="16" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Date of<BR>Grant</B><br><B>of Options<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of</B><br><B>Securities</B><br><B>Underlying</B><br><B>Unexercised</B><br><B>Options (#)</B><br><B>Exercisable<SUP
STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of</B><br><B>Securities</B><br><B>Underlying</B><br><B>Unexercised</B><br><B>Options (#)</B><br><B>Unexercisable<SUP
STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option</B><br><B>Exercise</B><br><B>Price<BR>($)<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option</B><br><B>Expiration</B><br><B>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Peter Beetham, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">8/4/2008</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">4/30/2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">11/30/2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">2/1/2010</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">5/1/2011</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">12/31/2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">12/31/2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">4/30/2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66,662</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">11/30/2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">271,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">12/31/2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">558,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">4/30/2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">270,271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">5/8/2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">5/8/2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">9/24/2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">9/24/2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">12/16/2019</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">3/31/2021</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">824,034</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,059,460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">12/31/2022</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Wade King, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">3/15/2021</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">831,256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,068,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">3/31/2021</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">415,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">534,372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">12/31/2022</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">900,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Rory Riggs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">1/1/2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">12/31/2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">185,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">12/31/2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">6/30/2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">4/21/2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">4/21/2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">121,384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">4/21/2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">204,081</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">4/30/2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74,774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">11/30/2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">12/31/2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,793</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">9/24/2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56,498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">4/30/2021</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">304,612</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">4/30/2021</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101,351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">10/4/2021<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,766,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">10/4/2021</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,098,705</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,668,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">These awards vest with respect to 25% of the Cibus PIUs on the one year anniversary of the date of grant and
with respect to the remainder of the Cibus PIUs in monthly installments until fully vested on the fourth anniversary of the date of grant, subject to the Cibus NEO&#146;s continued employment through each vesting date. These awards are subject to
accelerated vesting upon a change of control, provided that the Cibus NEO continues to provide services immediately prior to the consummation of such change of control. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">309 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">These Cibus PIUs do not require the payment of an exercise price, but rather entitle the holder to participate
in Cibus Global&#146;s future appreciation from and after the date of grant of the applicable Cibus PIUs. Despite the fact that the Cibus PIUs do not require the payment of an exercise price, for purposes of this table, Cibus Global believes the
Cibus PIUs are most similar economically to stock options and are properly classified as &#147;options&#148; under the definition provided in Item 402(a)(6)(i) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> as an instrument with an
&#147;option-like feature.&#148; Awards reflected as &#147;Unexercisable&#148; are Cibus PIUs that have not yet vested. Awards reflected as &#147;Exercisable&#148; are Cibus PIUs that have vested. For a description of how and when the Cibus PIUs
could become vested and when such awards could begin to receive payments, please read footnotes&nbsp;(1) and (4). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Cibus PIUs do not have an &#147;exercise price&#148; in the same sense that a true stock option award would
have an exercise price. Each Cibus PIUs award does have a &#147;value threshold&#148; associated with the award. Each Cibus PIUs award entitles the holder to receive distributions only if the aggregate distributions made by Cibus Global in respect
of each common unit issued and outstanding on or prior to the date of the grant of the Cibus PIUs exceeds a specified amount, the value threshold. The value threshold is set at the time of grant and represents the estimated fair value of a common
unit on the date of grant. The figure reflected in this column is the value threshold assigned to each Cibus PIUs award. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This award vests upon Cibus Global becoming a public company with its shares listed on a major exchange.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Additional Narrative Disclosure Relating to Cibus PIUs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the Cibus NEOs has received certain <FONT STYLE="white-space:nowrap">non-voting</FONT> Cibus PIUs, pursuant to a restricted unit plan
and restricted unit purchase agreements. A Cibus PIUs award has a $0 value at the time of grant for tax purposes, which provides the award holder with value only if and when the company grows in value following the grant date of the award. If Cibus
Global makes periodic cash distributions or there is a liquidation or termination event, the holders of Cibus PIUs are eligible to receive cash distributions in accordance with the terms of the Cibus Global Amended and Restated Memorandum of
Association and Articles of Association as currently in effect. Pursuant to each restricted unit purchase agreement issued under the applicable restricted unit plan, each Cibus NEO paid an amount equal to $0.01 per each unit received (the par value
for such <FONT STYLE="white-space:nowrap">non-voting</FONT> common unit) on the date of grant. In addition, the Cibus NEO&#146;s Cibus PIUs generally vest with respect to 25% of the Cibus PIUs on the one year anniversary of the date of grant and
with respect to the remainder of the Cibus PIUs in monthly installments until fully vested on the fourth anniversary of the date of grant, subject to the Cibus NEO&#146;s continued employment through each vesting date. Furthermore, the Cibus PIUs
vest in full upon a change of control, provided that the Cibus NEO continues to provide services immediately prior to the consummation of such change of control. In addition, except with respect to certain grants made on December&nbsp;31, 2015, the
Cibus PIUs are generally subject to Cibus Global&#146;s right of repurchase, pursuant to which, if a grantee ceases to provide continuous services to Cibus Global or its subsidiaries for any reason, Cibus Global, or its assigns, may exercise its
right of repurchase with respect to all of the Cibus PIUs subject to the agreement within 90 days after such termination of continuous service. If the Cibus PIUs have not vested, or become exercisable, as of the grantee&#146;s termination of
service, Cibus Global will pay the grantee an amount equal to the par value per Cibus PIU. If the Cibus PIUs have vested, or become exercisable, as of the grantee&#146;s termination of service, Cibus Global will pay fair market value, as determined
by Cibus Global in good faith, for each Cibus PIU. Notwithstanding the foregoing regarding the repurchase prices, if the grantee is terminated for cause (as defined therein), Cibus Global will pay the lesser of the par value per Cibus PIU or the
fair market value, regardless if all or any portion of the Cibus PIUs have vested. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Employment Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus Global has entered into employment agreements with each of Rory Riggs, Peter Beetham, Ph.D., and Wade King, M.D. (each, an
&#147;Employment Agreement,&#148; and collectively, the &#147;Employment Agreements&#148;). The material terms of the Employment Agreements are summarized below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Position and Employment Term</I>. During their respective terms of employment, Mr.&nbsp;Riggs will serve as Cibus Global&#146;s Chief
Executive Officer, Dr.&nbsp;Beetham will serve as Cibus Global&#146;s President and Chief Operating </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">310 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Officer, and Dr. King will serve as Cibus Global&#146;s Chief Financial Officer. Mr.&nbsp;Riggs and Dr.&nbsp;Beetham also serve as members of the Cibus Board. Unless earlier terminated in
accordance with the terms of their respective Employment Agreement, the initial term of employment for Dr. Beetham is four years after the Effective Date and for Dr. King and Mr. Riggs one year after the Effective Date or one year after Cibus
becomes a public company, each subject to automatic <FONT STYLE="white-space:nowrap">one-year</FONT> extensions unless either party provides written notice of termination not less than 30 days (for Dr. Beetham) or 60 days (for Dr. King and Mr.
Riggs) prior to the date of the expiration of the then-current term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Base Salary, Annual Bonus, and Benefits</I>. The Employment
Agreements provide for annual base salaries of $500,000, $400,000, and $300,000 (each, as may be adjusted from time to time in Cibus Global&#146;s sole discretion, their &#147;Base Salary&#148;), respectively, for Mr. Riggs and Drs. Beetham and
King. The base salary for Mr. Riggs is payable upon Cibus becoming a public company with its shares listed on a major stock exchange. In addition, subject to the adoption of an executive bonus plan by the Cibus Board, Dr. Beetham will be eligible to
receive an annual bonus. Additionally, in the event Cibus becomes a public company Mr. Riggs and Dr. King will be eligible to receive an annual bonus. Further, Dr. Beetham will be eligible to receive equity compensation awards pursuant to applicable
equity compensation plans and related award agreements adopted by the Cibus Board and Mr. Riggs and Dr. King were awarded equity compensation pursuant to their Employment Agreements. Each executive is also eligible to participate in employee benefit
plans, such as pension, profit sharing and other retirement plans, incentive compensation plans, group health, hospitalization, disability and other insurance plans, and other employee welfare plans, in each case in accordance with the employee
benefit plans established by Cibus Global, and as may be amended from time to time in Cibus Global&#146;s sole discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Success
Bonus. </I>The Employment Agreement for Drs. Beetham and King provide that upon (i) Cibus becoming a public company with its shares listed on a major exchange or (ii) closing a private placement of securities of gross proceeds of $50,000,000 or
more, Drs. Beetham and King are entitled to receive (a) an increase in their base salary and (b) an immediate cash bonus equal to 50% of the base salary increase. Dr. Beetham&#146;s salary increase will be equal to the greater of $100,000 or an
amount equal to 50% of the difference between his current base salary of $400,000 and the comparable base salary of presidents of peer public companies comparable to Cibus. Dr. King&#146;s salary increase will be equal to the greater of $75,000 or
an amount equal to 50% of the difference between his current base salary of $300,000 and the comparable base salary of presidents of peer public companies comparable to Cibus. Under the agreements, the Compensation Committee of the Cibus Board has
the discretion to determine the amount of the comparable base salary of presidents of peer public companies but has not yet made that determination. Cibus achieved prong (ii) above in December 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Equity Acceleration</I>. Pursuant to Mr. Riggs Employment Agreement, upon Cibus becoming a public company with its shares listed on a major
exchange 3,766,988 of his Cibus PIUs will vest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Restrictive Covenants</I>. Mr. Riggs and Drs. Beetham and King will not, without Cibus
Global&#146;s prior written consent, during the term of their Employment Agreement: (i)&nbsp;be employed elsewhere; (ii)&nbsp;engage, directly or indirectly, in any other business activity (whether or not pursued for pecuniary advantage) that might
interfere with their duties and responsibilities described in their Employment Agreement or create a conflict of interest with Cibus Global; or (iii)&nbsp;acquire any interest of any type in any other business which is in competition with Cibus
Global. Notwithstanding the foregoing, nothing will prohibit Drs. Beetham and King from acquiring, solely as an investment, up to 5% of the outstanding equity interests of any publicly-held company. The executives are also prohibited from soliciting
employees of Cibus Global during their employment and for a period of 12 months after termination for any reason. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Payments Upon
Termination</I>. The employment of Mr. Riggs and Drs. Beetham and King is &#147;at will&#148; at all times and can be terminated by Cibus Global or the executive without advance notice, for any or no reason. The Employment Agreements provide
executives with certain rights in connection with a termination of employment. All payments of Base Salary in connection with severance shall be made according to Cibus Global&#146;s normal payroll practices, less applicable withholdings and any
remuneration paid to such executive during each applicable payroll period because of the executive&#146;s employment or self-employment during such period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">311 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon termination of employment due to death or disability, the executive is eligible to
receive any accrued and unpaid compensation through the date of termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon a termination by Cibus Global without cause or by the
executive for good reason, Drs. Beetham and King, as applicable, will be eligible to receive severance consisting of (i)&nbsp;their Base Salary for 18&nbsp;months (the &#147;Severance Period&#148;) and (ii)&nbsp;if the executive qualifies for and
timely completes all documentation necessary to continue health insurance coverage pursuant to the Consolidated Omnibus Budget Reconciliation Act (&#147;COBRA&#148;), the applicable COBRA premiums for the executive and his dependents, during the
Severance Period (the &#147;Severance Benefits&#148;). Cibus Global&#146;s obligation to pay COBRA premiums will cease upon (x)&nbsp;a determination that such payments would violate applicable law, (y)&nbsp;the applicable executive or his dependents
ceasing to be eligible for COBRA coverage, or (z)&nbsp;the executive obtaining subsequent employment through which the executive is eligible to obtain substantially equivalent or better health insurance (the &#147;COBRA Conditions&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon a termination by Cibus Global without cause Mr. Riggs will be eligible to receive severance consisting of, if he qualifies for and timely
completes all documentation necessary to continue health insurance coverage pursuant to COBRA, the applicable COBRA premiums for Mr. Riggs and his dependents for 18&nbsp;months, provided that Cibus Global&#146;s obligation to pay COBRA premiums will
cease upon the occurrence of any of the COBRA Conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon a termination in connection with a change in control without cause, or
termination by an executive in connection with a change in control for good reason, Drs. Beetham and King will be eligible to receive (i)&nbsp;their Base Salary for 24 months (such period, the &#147;Change In Control Severance Period&#148;); and
(ii)&nbsp;payment of a lump sum equal to the target annual bonus which such executive is eligible to receive for the year in which the termination occurs less applicable withholdings; and (iii)&nbsp;if such executive qualifies for and timely
completes all documentation necessary to continue health insurance coverage pursuant to COBRA, COBRA premiums for such executive and his dependents for up to the end of the Change In Control Severance Period (&#147;Change In Control Severance
Benefits&#148;). In addition, any and all unvested stock options and any other unvested equity in Cibus Global held by such executive will become fully vested upon the employment termination date. Cibus Global&#146;s obligation to pay COBRA premiums
will cease upon the occurrence of any of the COBRA Conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Employment Agreements, an executive&#146;s eligibility to
receive the Severance Benefits or the Change In Control Severance Benefits is conditioned on execution of a release by the executive, which becomes irrevocable by its terms within 55 calendar days following the date of the executive&#146;s
termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon termination by Cibus Global for cause or termination by the executive without good reason, all obligations of Cibus
Global under the respective Employment Agreement cease, except that the executive is eligible to receive any accrued and unpaid compensation through the date of termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of the Employment Agreements, &#147;cause&#148; means the executive has (i)&nbsp;engaged in a material act of misconduct,
including but not limited to misappropriation of trade secrets, fraud, or embezzlement; (ii)&nbsp;committed a crime involving dishonesty, breach of trust, or physical harm to any person; (iii)&nbsp;breached the Employment Agreement;
(iv)&nbsp;refused to implement or follow a lawful policy or directive of Cibus Global; (v)&nbsp;engaged in misfeasance or malfeasance demonstrated by the executive&#146;s failure to perform his job duties diligently and/or professionally; or
(vi)&nbsp;violated a Cibus Global policy or procedure which is materially injurious to Cibus Global, including violation of Cibus Global&#146;s policy concerning sexual harassment, discrimination or retaliation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of the Employment Agreements, &#147;good reason&#148; means: (i)&nbsp;a material breach of the Employment Agreement by Cibus
Global; or (ii)&nbsp;a material adverse change in the executive&#146;s position, duties, authority or responsibilities. A termination shall only be for good reason if (x)&nbsp;the executive provides written notice to Cibus Global of the good reason
within thirty (30)&nbsp;days of the event constituting the good reason and provides Cibus Global with a period of 30 days to cure the event constituting the good reason, (y)&nbsp;Cibus Global </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">312 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
fails to cure the good reason within the applicable 30 day period, and (z)&nbsp;the executive terminates their employment with Cibus Global within 90 days of the event constituting the good
reason. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of the Employment Agreements, &#147;change in control&#148; means the sale of Cibus Global or the sale of all or
substantially all of Cibus Global&#146;s assets, by means of any transaction or series of related transactions (including, without limitation, any reorganization, merger or consolidation, but excluding any merger effected exclusively for the purpose
of changing the domicile of Cibus Global), after which Cibus Global&#146;s stockholders of record as constituted immediately prior to such acquisition will, immediately after such acquisition, hold less than 50% of the voting power of the surviving
or acquiring entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of the Employment Agreements, termination of the executive&#146;s employment will be &#147;in
connection with a change in control&#148; when it occurs within 90 days before a change in control or within 12&nbsp;months after a change in control. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cibus Global Director Compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus
Global pays its directors annual retainer fees for their participation on the Cibus Board. The chairperson and vice chairperson of the Cibus Board each receives $100,000 per year for his services and all other directors receive $60,000 per year. The
directors may elect to receive such fees in cash, in Cibus PIUs or a combination of the two. Cibus Global pays fees in cash on a monthly basis and issues Cibus PIUs once a year. The following table sets forth the amount of compensation Cibus Global
paid to the members of the Cibus Board during its fiscal year 2022. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees&nbsp;Earned</B><br><B>or Paid in</B><br><B>Cash ($)<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option</B><br><B>Awards&nbsp;($)<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Finn</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jean-Pierre Lehmann</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gerhard Prante, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68,299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alain Pompidou, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eugene Linden</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Lu</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Keith Walker, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Rory Riggs and Peter Beetham each serve on the Cibus Board, but are not included for purposes of this table
because they do not receive additional compensation for serving on the Cibus Board. All compensation provided to Mr.&nbsp;Riggs and Dr.&nbsp;Beetham is fully reflected in the Summary Compensation Table included earlier in this prospectus.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents annual retainer fees that each director elected to receive in cash. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Six of Cibus Global&#146;s directors received, for incentive purposes, Cibus PIUs. Despite the fact that Cibus
PIUs do not require the payment of an exercise price, Cibus Global believes that they are most similar economically to stock options, and as such, they are properly classified as &#147;options&#148; under the definition provided in
Item&nbsp;402(a)(6)(i) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> as an instrument with an &#147;option-like feature.&#148; Amounts disclosed in this column reflect a grant date fair value of the Cibus PIUs in accordance with FASB ASC
Topic 718, but with respect to such shares, Cibus Global recognizes share-based compensation equal to the difference between the grant date fair value and $0.01, which is the amount per share paid by each director.<B> </B>Assumptions used to
calculate the grant date values are described within the notes to Cibus Global&#146;s financial statements included elsewhere in this prospectus. These awards were fully vested on their date of grant. As of December&nbsp;31, 2022, Messrs. Finn,
Lehmann, Prante, Pompidou, Linden, Lu, and Walker held an aggregate of 1,064,029, 796,716, 1,133,485, 478,921, 983,805, 125,906 and 1,161,441 Cibus PIUs, respectively. All of these outstanding awards were &#147;exercisable&#148; as of
December&nbsp;31, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">These fees owed to Dr.&nbsp;Pompidou were paid in fully vested Cibus PIUs in January 2023.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">313 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Both the amount of the retainer fees paid in 2022 and the directors&#146; elections
regarding the form of payment of their fees remained unchanged as of the date of this prospectus. As a result, at least until the registration statement becomes effective, each of the directors will receive the same amount of cash fees set forth in
the table above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the Closing of the Transactions, Cibus, Inc. will be the managing member of Cibus Global. At the effective
time of the Cibus Merger, each Cibus PIU will, (a)&nbsp;to the extent not a &#147;restricted unit&#148; (under the award agreements and governing documents applicable to such Cibus PIU), be automatically cancelled and converted into the right to
receive the number of shares of Class&nbsp;A Common Stock set forth on the Allocation Schedule and (b)&nbsp;to the extent a &#147;restricted unit&#148; (or an unvested unit), be automatically cancelled and converted into the right to receive the
number of restricted shares of Class&nbsp;A Common Stock pursuant to a Calyxt, Inc. stock plan, as set forth on the Allocation Schedule and subject to the same vesting schedule as was applicable to such Cibus PIU prior to the Closing. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity-Based Awards </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus Global
believes its ability to grant equity-based awards is a valuable and necessary compensation tool that aligns the long-term financial interests of Cibus Global&#146;s personnel with the financial interests of Cibus Global&#146;s stockholders. In
addition, Cibus Global believes that its ability to grant equity-based awards helps Cibus Global to attract and retain top talent, and encourages them to drive performance to promote the success of Cibus Global&#146;s business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2016 Restricted Unit Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus
Global&#146;s 2016 Amended and Restated Restricted Units Plan, effective as of May&nbsp;10, 2019, is administered by the Cibus Board. It authorizes the Cibus Board to issue <FONT STYLE="white-space:nowrap">non-voting</FONT> Common Units to officers,
directors, employees, executives, consultants, advisors or other similar service providers of Cibus Global&#146;s company or any of Cibus Global&#146;s subsidiaries. The Cibus Board, in its sole discretion, may convert all or any portion of the <FONT
STYLE="white-space:nowrap">non-voting</FONT> Common Units into voting restricted units. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2016 Amended and Restated Restricted Units
Plan provides that all grants of Cibus PIUs under the plan must be made pursuant to a restricted unit purchase agreement. See &#147;&#151;<I>Additional Narrative Disclosure Relating to Cibus PIUs</I>&#148; above for details regarding the material
terms of the restricted units purchase agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the effective time of the Cibus Merger, all awards under the 2016 Amended and
Restated Restricted Units Plan, will (a)&nbsp;to the extent no longer a &#147;restricted unit&#148; (under the award agreements and governing documents applicable to such Cibus PIU), be automatically cancelled and converted into the right to receive
the number of shares of Class&nbsp;A Common Stock set forth on the Allocation Schedule and (b)&nbsp;to the extent a &#147;restricted unit&#148; (i.e., an unvested unit), be automatically cancelled and converted into the right to receive the number
of restricted shares of Class&nbsp;A Common Stock pursuant to a Calyxt, Inc. stock plan, as set forth on the Allocation Schedule and subject to the same vesting schedule as was applicable to such Cibus PIUs prior to the Closing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">314 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom401831_53"></A>RELATED PARTY TRANSACTIONS OF DIRECTORS AND </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXECUTIVE OFFICERS OF THE COMBINED COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the compensation arrangements, including employment, termination of employment and change in control arrangements, with Calyxt,
Inc.&#146;s and Cibus Global&#146;s directors and executive officers, including those discussed in the sections entitled &#147;<I>Management Following the Transactions</I>,&#148; &#147;<I>Calyxt, Inc. Executive Compensation</I>&#148; and
&#147;<I>Cibus Global Executive Compensation</I>,&#148; beginning on pages 284, 290 and 307, respectively, of this proxy statement/prospectus, the following is a description of each transaction occurring since January&nbsp;1, 2020 and any currently
proposed transactions in which: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">either Calyxt, Inc. or Cibus Global was or is to be a participant; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amounts involved exceeded or will exceed the lesser of $120,000 or 1% of the average of Calyxt, Inc.&#146;s
or Cibus Global&#146;s total assets at year end for the last two completed fiscal years; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any director, executive officer, holder of more than 5% of the voting securities of Calyxt, Inc., Cibus Global,
or an affiliate or immediate family member of the foregoing persons, had or will have a direct or indirect material interest. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Calyxt, Inc. Transactions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Relationship with
Cellectis </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the completion of Calyxt, Inc.&#146;s initial public offering, Calyxt, Inc. was a wholly owned subsidiary of
Cellectis. As of March 31, 2023, Cellectis owned approximately 48.2% of Calyxt Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;16, 2020, Cellectis
purchased 1,250,000 shares of Calyxt Common Stock at a purchase price of $4.00 per share in a <FONT STYLE="white-space:nowrap">follow-on</FONT> offering, for a value of $5,000,000. Cellectis purchased the shares on the same terms as the
institutional investors who participated in the <FONT STYLE="white-space:nowrap">follow-on</FONT> offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>IPO Framework Documents </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with Calyxt, Inc.&#146;s initial public offering, Calyxt, Inc. and Cellectis entered into certain agreements that relate to
Calyxt, Inc.&#146;s relationship with Cellectis and provide a framework for their ongoing relationship. The material agreements are filed as exhibits to Calyxt, Inc.&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed
with the SEC on March&nbsp;3, 2022. The discussions below are qualified in their entirety by reference to the full text of such agreements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Management
Services Agreement </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt, Inc. is party to a management services agreement dated January&nbsp;1, 2016, with Cellectis and Cellectis,
Inc., a wholly owned subsidiary of Cellectis, pursuant to which Cellectis and Cellectis, Inc. provide certain services to Calyxt, Inc., including certain general management, finance, investor relations, communication, legal, intellectual property,
human resources and information technology services. In consideration for such services, Calyxt, Inc. pays certain fees, consisting of reimbursement of all costs and expenses reasonably incurred by Cellectis and Cellectis, Inc. in connection with
the provision of such services, payment of a <FONT STYLE="white-space:nowrap">mark-up,</FONT> ranging between zero and 10%, corresponding to a percentage of certain of the costs and expenses, and reimbursement of certain subcontracting costs and
expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt, Inc. made payments to Cellectis for services provided under the Management Services Agreement, which exclude direct <FONT
STYLE="white-space:nowrap">re-invoicing</FONT> and royalties paid to Cellectis, of $0.0 million during the year ended December&nbsp;31, 2022, of a nominal amount during the year ended December&nbsp;31, 2021 and of approximately $0.3&nbsp;million
during the year ended December&nbsp;31, 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">315 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stockholders Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March 31, 2023, Cellectis owned 48.2% of the Calyxt Common Stock. Pursuant to Calyxt, Inc.&#146;s stockholders&#146; agreement, Cellectis
had certain contractual rights for so long as it beneficially owned at least 50&nbsp;percent of the then outstanding shares of Calyxt Common Stock, including approval rights over a significant number of key aspects of Calyxt, Inc.&#146;s operations
and management. In addition, though Cellectis&#146; rights are diminished compared to when Cellectis owned more than 50&nbsp;percent of the then outstanding shares of Calyxt Common Stock, Cellectis continues to maintain certain significant rights,
including a right to nominate a majority of the Calyxt Board, as long as it beneficially owns at least 15&nbsp;percent of the then outstanding shares of Calyxt Common Stock. As a result, through the Closing, Cellectis has the power to control the
direction of Calyxt, Inc.&#146;s business, and the concentrated ownership of Calyxt Common Stock and the contractual rights described above may prevent stockholders from influencing significant decisions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>License Agreement with Cellectis </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Through
Calyxt, Inc.&#146;s perpetual license agreement with Cellectis, Calyxt, Inc. has (i)&nbsp;access to intellectual property that broadly covers the use of engineered nucleases for plant gene editing, (ii)&nbsp;exclusive sublicense rights (subject to
existing <FONT STYLE="white-space:nowrap">non-exclusive</FONT> sublicenses to third parties) to intellectual property exclusively licensed to Cellectis from the University of Minnesota in the field of researching, developing, and commercializing
agricultural and food products, and (iii)&nbsp;a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license to use the TALEN trademark in connection with Calyxt, Inc.&#146;s use of licensed products under the agreement. In consideration for the
license from Cellectis, Calyxt, Inc. is required to pay to Cellectis, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, a royalty of three percent of net sales less certain items as defined, including costs for grain and seed of any products that are covered by
the patents licensed from Cellectis. In addition, Calyxt, Inc. is required to pay Cellectis 30&nbsp;percent of revenue Calyxt, Inc. receives for sublicensing Calyxt, Inc.&#146;s rights under the agreement to third parties. Cibus Global&#146;s
payment obligations to Cellectis will expire upon the expiration of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> valid claim of the patents licensed to Calyxt, Inc. by Cellectis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt, Inc. incurred expenses related to the stated license agreements with Cellectis in the amounts of $0.2 million during the year ended
December&nbsp;31, 2022, $0.2&nbsp;million during the year ended December&nbsp;31, 2021 and $0.2&nbsp;million during the year ended December&nbsp;31, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See &#147;<I>The Merger Agreement&#151;Amendment to the Cellectis License Agreement</I>&#148; and &#147;<I>Agreements Related to the
Mergers&#151;Support Agreements&#151;Calyxt Support Agreements</I>&#148; for additional information on the relationship with Cellectis. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Lease
Guarantee and Indemnification </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cellectis has guaranteed the lease agreement for Calyxt, Inc.&#146;s headquarters. Cellectis&#146;
guarantee of Calyxt,&nbsp;Inc.&#146;s obligations under the lease will terminate at the end of the second consecutive calendar year in which Calyxt, Inc.&#146;s tangible net worth exceeds $300 million. Calyxt, Inc. agreed to indemnify Cellectis for
any obligations incurred by Cellectis under its guaranty of the obligations under the lease, effective upon Cellectis&#146; ownership falling to 50 percent or less of outstanding Calyxt Common Stock. This indemnification obligation was triggered in
October 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Indemnification Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Calyxt Board has adopted a policy to enter into indemnification agreements with each of its directors and officers. Such indemnification
agreements and the Calyxt Certificate of Incorporation and Calyxt Bylaws will require Calyxt, Inc., subject to certain exceptions, to indemnify and hold harmless its directors and officers to the fullest extent permitted by Delaware Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">316 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Policy Concerning Related Person Transactions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt, Inc. maintains a written related person transaction approval policy, for the review of any transaction, arrangement, or relationship in
which Calyxt, Inc. is a participant, if the amount involved exceeds $100,000 and one of Calyxt, Inc.&#146;s executive officers, directors, director nominees, or beneficial holders of more than 5% of Calyxt, Inc.&#146;s total equity (or their
immediate family members), each of whom Calyxt, Inc. refers to as a related person, has a direct or indirect material interest. This policy was not in effect when Calyxt, Inc. entered into the management, stockholders, or license agreements with
Cellectis described above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the agreements between Calyxt, Inc. and Cellectis that were entered into in connection with Calyxt,
Inc.&#146;s initial public offering, and any transactions contemplated thereby, were and will be deemed approved under and not subject to the terms of such policy. Any future amendment to such agreements would be subject to Calyxt, Inc.&#146;s
related person transaction approval policy. If a related person, other than Cellectis and its affiliates, proposes to enter into such a transaction, arrangement, or relationship, which Calyxt, Inc. refers to as a related person transaction, the
related person must report the proposed related person transaction to the General Counsel, who will present the proposed related party transaction to the Audit Committee. The policy calls for the proposed related person transaction to be reviewed
and, if deemed appropriate, approved by the Audit Committee. If the proposed related person transaction involves related persons constituting a majority of the members of the Audit Committee, such review will be undertaken by the disinterested
members of the Calyxt Board who are also independent directors (each such body, as applicable, referred to as the &#147;Committee&#148; for the purpose of this paragraph). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In approving or rejecting such proposed transactions, the Committee will be required to consider relevant facts and circumstances. The
Committee will approve only those transactions that, considering known circumstances, are deemed to be in Calyxt, Inc.&#146;s best interests. If any member of the Committee is not a disinterested person with respect to the related person transaction
under review, that member will be excluded from the review and approval or rejection of such related person transaction; provided, however, that such Committee member may be counted in determining the presence of a quorum at the meeting of the
Committee at which such transaction is considered. If Calyxt, Inc. becomes aware of an existing related person transaction which has not been approved under the policy, the matter will be referred to the Committee. The Committee will evaluate all
options available, including ratification, revision, or termination of such transaction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cibus Global Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Described below are transactions and series of similar transactions, during Cibus Global&#146;s last three fiscal years to which Cibus Global
was a party or will be a party, in which: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amounts involved exceeded or will exceed $120,000; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any of Cibus Global&#146;s directors, executive officers or beneficial holders of more than 5% of Cibus
Global&#146;s outstanding voting securities had or will have a direct or indirect material interest. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than as
described below, there have not been, nor are there any currently proposed, transactions or series of similar transactions meeting this criteria to which Cibus Global has been or will be a party other than compensation arrangements, which are
described where required under &#147;<I>Cibus Global Executive Compensation</I>.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Warrant Transfer and Exchange Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2014, Cibus Global entered into the Warrant Exchange Agreement with certain seller parties and Rory Riggs, as representative of the
seller parties (the &#147;seller representative&#148;). In connection with two series of financings between November 2013 and December 2014, Cibus Global issued to certain investors (the &#147;investors&#148;) four tranches of warrants to purchase
Cibus Series A Preferred Units (collectively, the &#147;warrants&#148;). The Warrant Exchange Agreement granted each investor the right to sell some or all of its respective warrants to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">317 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Cibus Global in exchange for an interest in certain future revenues of Cibus Global. The warrants were fully exchanged in 2014 and 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The investors sold the warrants in exchange for ongoing quarterly payments (each, a &#147;warrant purchase payment&#148;) equal to a portion
of Cibus Global&#146;s aggregate amount of certain worldwide revenues (the &#147;subject revenues&#148;) received during such quarter. The aggregate portion payable to the investors each quarter is the product of the subject revenues and a
percentage, which is capped at 10%. Subject revenues broadly includes all cash attributable to product sales, license fees, sublicense payments, distribution fees, milestones, maintenance payments, royalties and distributions to Cibus Global,
subject to certain exceptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The warrant purchase payments are due to the investors within 45 calendar days after the end of each
calendar quarter. Any payments made after such <FONT STYLE="white-space:nowrap">45-day</FONT> period are subject to a late fee of 4% over the prime rate. Warrant purchase payments will commence in the first quarter in which the aggregate subject
revenues during any consecutive <FONT STYLE="white-space:nowrap">12-month</FONT> period equals or exceeds $50.0&nbsp;million, at which point Cibus Global will be obligated to pay all aggregated but unpaid payments under the Warrant Exchange
Agreement. Further, Cibus Global is subject to ongoing reporting requirements under the Warrant Exchange Agreement, including delivery to the seller representative of (i)&nbsp;an annual report following the end of each calendar year and
(ii)&nbsp;copies of written notices or correspondence with any counterparty to an <FONT STYLE="white-space:nowrap">in-license</FONT> relating to <B><I>RTDS</I></B> that could reasonably be expected to adversely affect the warrant purchase payments.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Warrant Exchange Agreement has an initial term of 30 years following the date on which the first warrant purchase payment becomes due
and payable. The investors have the option to renew the Warrant Exchange Agreement for an additional <FONT STYLE="white-space:nowrap">30-year</FONT> term after expiration of the initial term upon delivery by the seller representative of written
notice to Cibus Global and payment of $100. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payments to the investors under the Warrant Exchange Agreement are secured by a senior
security interest in certain Cibus Global collateral pursuant to an Intellectual Property Security Agreement (the &#147;IP Security Agreement&#148;). See &#147;&#151;<I>Intellectual Property Security Agreement.</I>&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investors entitled to payments, including through entities controlled by them, pursuant to the Warrant Exchange Agreement include the
following directors and executive officers: Messrs. Linden, Prante, Riggs and Walker and Drs. Beetham and Gocal. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual Property Security
Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Warrant Exchange Agreement, Cibus Global and certain related entities (collectively, the
&#147;grantors&#148;) entered into the IP Security Agreement with the seller representative. Pursuant to the IP Security Agreement, the grantors granted the seller representative a continuing security interest in certain intellectual property of the
grantors (the &#147;collateral&#148;) to secure the payment and performance of Cibus Global&#146;s obligations under the Warrant Exchange Agreement. The collateral includes any and all of the grantors&#146; respective copyrights, patents,
trademarks, trade secrets, claims for damages from infringement of any of the proceeding rights, licenses and all cash and <FONT STYLE="white-space:nowrap">non-cash</FONT> proceeds and products of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No lien is permitted to exist on the collateral, except for permitted licenses in accordance with the Warrant Exchange Agreement, certain
permitted liens and security interests subordinated to the security interests granted by the IP Security Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Series F Purchase
Agreement</I></B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with a private placement of securities which occurred in December 2022, Cibus Global received funding
from both Rory Riggs and the Blockers established by entities advised or <FONT STYLE="white-space:nowrap">sub-advised</FONT> by Fidelity Management&nbsp;&amp; Research Company, pursuant to which Cibus Global issued (a) 2,500,000 Cibus Series F
Preferred Units to Mr.&nbsp;Riggs and (b)&nbsp;an aggregate of 3,740,098 Cibus Series F Preferred Units to such Blockers established by entities advised or <FONT STYLE="white-space:nowrap">sub-advised</FONT> by Fidelity Management&nbsp;&amp;
Research Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">318 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Series F Purchase Commitment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2023, New Ventures Agtech Solutions, LLC, an entity affiliated with Rory Riggs, committed to purchase $50,000,000 of Cibus Series F
Preferred Units, which commitment was conditioned upon the consummation of the Transactions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Promissory Note; Pledge Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2020, Rory Riggs advanced to Cibus Global an aggregate of $6.2&nbsp;million in cash. In December 2020, Mr.&nbsp;Riggs elected to exercise
certain warrants to purchase Cibus Series A Preferred Units by way of cancelling his prior advances and through Mr.&nbsp;Riggs and Cibus Global entering into a Promissory Note and Pledge Agreement in the original principal amount of $4,065,845.44.
Cibus Global and Mr.&nbsp;Riggs entered into an amendment to the promissory note in March 2022 (collectively, the &#147;Riggs Note&#148;). The Riggs Note bears simple interest at the annual rate of 0.15% and is collateralized by the Cibus Series A
Preferred Units purchased with the Riggs Note. The Riggs Note is payable by Mr. Riggs on the earlier of January&nbsp;31, 2024 and ninety (90)&nbsp;days after any underwriter <FONT STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT> period
applicable to Mr.&nbsp;Riggs after the date of the consummation of Cibus Global&#146;s first underwritten public offering. It is expected that the Riggs Note will be satisfied at or prior to Closing. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>RTDCCL License and Marketing Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2012, certain of Cibus Global&#146;s subsidiaries entered into a license and marketing agreement with RTDCCL under which Cibus develops and
commercializes certain crop varieties that include traits produced using Cibus&#146;proprietary technology and RTDCCL is obligated to make certain funding payments to Cibus. Mark Lu, a member of the Cibus Board, is affiliated with RTDCCL. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cibus <FONT STYLE="white-space:nowrap">Non-Profit</FONT> Foundation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During 2022, Cibus created the Cibus Charitable Foundation, Inc., a nonprofit legal entity referred to as the Cibus Foundation. As of the date
of this proxy statement/prospectus, the Cibus Foundation has not received any donations or commenced operations. Cibus is obligated to make donations to the Cibus Foundation each fiscal year at a rate of 1.0% of all net royalty revenue in the
applicable fiscal year that is equal to or greater than $100&nbsp;million up to, and including, $1.0&nbsp;billion, and then steps up to 2.0% in respect of any portion of such net royalty revenue in excess of $1.0&nbsp;billion. For purposes of this
calculation, &#147;net royalty revenue&#148; refers to all royalty payments received by Cibus, net of all taxes (other than income taxes) and all amounts payable pursuant to the Royalty Liability. The donation payable by Cibus may be reduced,
including to zero, to the extent necessary to comply with any covenant or obligation in any instrument evidencing third-party indebtedness, to permit a financing to occur, to preclude undercapitalization, to satisfy working capital requirements or
provide for strategic needs of Cibus, to ensure timely payment of Cibus&#146; liabilities and debts to third parties as they become due, or to comply with applicable law. Cibus has agreed not to enter any change of control transaction, unless the
surviving entity assumes the obligation to pay such donations to the Cibus Foundation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This obligation is contingent upon the Cibus
Foundation obtaining and maintaining its status as a charitable organization (IRS 501c3 registration not yet achieved) and must use all donations received consistent with its Mission Statement: to drive sustainable agriculture and sustainable
agricultural communities in the developing world. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Policy Concerning Related Person Transactions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the Closing, the Cibus Board will adopt a written policy, which Cibus refers to as the related person transaction approval policy, for
the review of any transaction, arrangement or relationship in which Cibus is a participant, if the amount involved exceeds $120,000 and one of Cibus&#146; executive officers, directors, director nominees or beneficial holders of more than 5% of
Cibus&#146; total equity (or their immediate family members), each </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">319 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of whom Cibus refers to as a related person, has a direct or indirect material interest. This policy was not in effect when Cibus entered into the transactions described above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a related person proposes to enter into such a transaction, arrangement or relationship, which Cibus refers to as a related person
transaction, the related person must report the proposed related person transaction to the Audit Committee (for purposes of this section only, Cibus refers to the Audit Committee as the Committee). The policy calls for the proposed related person
transaction to be reviewed and, if deemed appropriate, approved by the Committee. In approving or rejecting such proposed transactions, the Committee will be required to consider relevant facts and circumstances. The Committee will approve only
those transactions that, in light of known circumstances, are deemed to be in Cibus&#146; best interests. In the event that any member of the Committee is not a disinterested person with respect to the related person transaction under review, that
member will be excluded from the review and approval or rejection of such related person transaction; provided, however, that such Committee member may be counted in determining the presence of a quorum at the meeting of the Committee at which such
transaction is considered. If Cibus becomes aware of an existing related person transaction which has not been approved under the policy, the matter will be referred to the Committee. The Committee will evaluate all options available, including
ratification, revision or termination of such transaction. In the event that management determines that it is impractical or undesirable to wait until a meeting of the Committee to consummate a related person transaction, the chair of the Committee
may approve such transaction in accordance with the related person transaction approval policy. Any such approval must be reported to the Committee at its next regularly scheduled meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">320 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom401831_54"></A>UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following unaudited pro forma combined financial information presents the combination of the historical financial statements of Calyxt,
Inc. and the historical financial statements of Cibus Global, after giving effect to the Mergers, as further described in Note 1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following unaudited pro forma combined financial information gives effect to the transaction accounting adjustments, which consist of the Mergers, but does not give effect to the Reverse Stock Splits described elsewhere in this proxy
statement/prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the unaudited pro forma combined financial information, the Mergers have been accounted for as a business
combination, using the acquisition method of accounting under U.S. GAAP where Calyxt, Inc. is considered the acquirer of Cibus Global for accounting purposes. For accounting purposes, the acquirer is the entity that has obtained control of another
entity and, thus, consummated a business combination. The determination of whether control has been obtained begins with the evaluation of whether control should be evaluated under the variable interest or voting interest model pursuant to ASC Topic
810, Consolidation (&#147;ASC 810&#148;). If the acquiree is a variable interest entity, the primary beneficiary would be the accounting acquirer. Cibus Global meets the definition of a variable interest entity, and Calyxt, Inc., which will be the
managing member, has been determined to be the primary beneficiary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the acquisition method of accounting, the assets and
liabilities associated of Cibus Global will be recorded at their estimated fair value as of the acquisition date. The excess of the purchase price over the estimated fair values of the net assets acquired, if applicable, will be recognized as
goodwill. For purposes of the unaudited pro forma combined balance sheet, the purchase consideration has been allocated to the assets acquired and liabilities assumed of Cibus Global based upon management&#146;s preliminary estimate of their fair
values and are subject to change. Accordingly, the value of Cibus Global assets and liabilities recognized should be treated as preliminary values. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma combined balance sheet data as of December 31, 2022 assumes that the Mergers took place on December 31, 2022 and
combines the Calyxt, Inc., and Cibus Global historical balance sheets as of December&nbsp;31, 2022. The unaudited pro forma combined statement of operations data for the year ended December&nbsp;31, 2022 gives effect to the Mergers as if they took
place on January&nbsp;1, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The historical financial statements of Calyxt, Inc. and Cibus Global have been adjusted to give pro forma
effect to reflect the accounting for the transaction in accordance with U.S. GAAP. The adjustments presented on the unaudited pro forma combined financial statements have been identified and presented to provide relevant information necessary for an
accurate understanding of the Combined Company upon consummation of the Mergers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma combined financial information
is based on assumptions and adjustments that are described in the accompanying notes and is for illustrative purposes only. The unaudited pro forma combined financial information should not be relied upon as being indicative of the historical
results that would have been achieved had the companies always been combined or the future results that the Combined Company will experience. The actual amounts recorded as of the completion of the Mergers may differ materially from the information
presented in the unaudited pro forma combined financial information as a result of changes in timing of the Closing, as well as other changes in Cibus Global&#146;s assets and liabilities that occur prior to the completion of the Mergers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma combined financial information, including the notes thereto, should be read in conjunction with the separate
historical consolidated financial statements of Calyxt, Inc. and Cibus Global and the sections of this proxy statement/prospectus titled &#147;<I>Cibus Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations</I>&#148; and &#147;<I>Calyxt Management&#146;s Discussion and Analysis of Financial</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">321 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<I>Condition and Results of Operations</I>.&#148; Calyxt, Inc.&#146;s audited historical consolidated financial statements as of and for the year ended December&nbsp;31, 2022 are included
elsewhere in this proxy statement/prospectus. Cibus Global&#146;s audited consolidated financial statements as of and for the year ended December&nbsp;31, 2022 are included elsewhere in this proxy statement/prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">322 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Unaudited Pro Forma Combined Balance Sheet </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>As of December 31, 2022 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Calyxt, Inc.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Cibus<BR>Global</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Transaction<BR>Accounting<BR>Adjustments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Note&nbsp;6</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma<BR>Combined<BR>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Due from related parties, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">606</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,660</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,845</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Land, buildings, and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(h</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)</B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,819</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease right-of-use-assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,615</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other non-current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43,966</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(h</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)</B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43,966</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">330,424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(h</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)</B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">330,424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43,183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">378,862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">444,466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities and shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,443</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(a</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)(f)</B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,951</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Due to related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notes payable, current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of financing lease obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,662</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notes payable, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing lease obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Royalty liability - related parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other non-current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">127,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shareholders&#146; equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A preferred units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64,097</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(64,097</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(i</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)</B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B preferred units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(54,710</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(i</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)</B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C preferred units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(67,012</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(i</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)</B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series D preferred units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54,195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(54,195</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(i</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)</B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series E preferred units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(34,381</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(i</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)</B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series F preferred units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(52,810</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(i</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)</B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Voting common units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nonvoting common units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,278</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(i</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)</B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(i</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)</B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock in treasury, at cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,043</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,043</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unit subscription receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,078</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,078</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(i</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)</B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional paid-in capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">220,422</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56,829</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">215,034</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(i</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)</B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">492,285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(i</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)</B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(212,151</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(412,138</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">402,546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(i</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)</B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(221,743</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non-controlling interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(i</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)</B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total shareholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(30,912</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">340,849</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">317,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and shareholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43,183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$<BR></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">378,862<BR></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">444,466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">323 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Unaudited Pro Forma Combined Statement of Operations </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the Year Ended December&nbsp;31, 2022 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share and per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Calyxt, Inc.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Cibus<BR>Global</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Transaction<BR>Accounting<BR>Adjustments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Note 6</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma</B><br><B>Combined</B><br><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration and research</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration and research - related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">908</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">908</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,553</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,461</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,779</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><B>(a)(e)(f)(h)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">83,539</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(22,370</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(49,130</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,772</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(82,272</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense, royalty liability - related parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other (income) expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,566</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other (income) expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,479</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,891</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(55,553</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,772</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(83,216</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to non-controlling interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,482</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><B>(g)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,482<BR></TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;<BR></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to combined company</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,891</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(55,553</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(70,734</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.07</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average common shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,997,525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">860,228,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center"><B>(d)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">944,851,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">324 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom401831_55"></A>NOTES TO THE UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Description of the Mergers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;13, 2023, Calyxt, Inc. and Merger Subsidiary entered into the Merger Agreement with Cibus Global and the Blockers. The Merger
Agreement provides that, among other things and upon the terms and subject to the conditions set forth therein (including receipt of Calyxt Stockholder Approval and the Cibus and Blocker member approvals), at the Closing: (a)&nbsp;each of the
Blockers will merge with and into Calyxt, Inc., in each case with the Blockers ceasing to exist and Calyxt, Inc. surviving each such Blocker Merger, (b)&nbsp;at the First Blocker Merger Effective Time, the Calyxt Bylaws will be amended and restated
and the Calyxt Certificate of Incorporation will be amended and restated, and (c)&nbsp;following the Blocker Mergers, Merger Subsidiary will merge with and into Cibus Global, with Cibus Global as the surviving company and Merger Subsidiary ceasing
to exist. As consideration for the Mergers, the equity holders of the Blockers and the Cibus Unitholders will receive the Merger Consideration. In connection with the Mergers, Cibus, Inc. will contribute all of its assets and liabilities to Cibus
Global, as a contribution to the capital of Cibus Global, in exchange for Cibus Common Units, pursuant to the Contribution Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon adoption of the Amended Certificate of Incorporation, each share of Calyxt Common Stock existing and outstanding immediately prior to the
First Blocker Merger Effective Time shall remain outstanding as a share of Class&nbsp;A Common Stock at the First Blocker Merger Effective Time without conversion or exchange. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the applicable Blocker Merger Effective Time, the limited liability company interests of the Blocker being merged will be cancelled and
converted into the right of the equityholders of the applicable Blocker to receive shares of Class&nbsp;A Common Stock corresponding to that Blocker Merger, in each case, as set forth in the Allocation Schedule, and as described in more detail in
the section titled &#147;<I>The Merger Agreement&#151;Merger Consideration</I>&#148; included elsewhere in this proxy statement/prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the Cibus Merger Effective Time, all of the issued and outstanding Cibus Units, all Cibus Warrants and all options to purchase Cibus Units,
will be cancelled (or, in the case of warrants, surrendered to Cibus, Inc. for exchange) and converted into the right to receive Class&nbsp;A Common Stock or <FONT STYLE="white-space:nowrap">Up-C</FONT> Units, in each case as set forth in the
Allocation Schedule, and as described in further detail in the section titled &#147;<I>The Merger Agreement&#151;Merger Consideration</I>&#148; included elsewhere in this proxy statement/prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately following the Cibus Merger, (i)&nbsp;each <FONT STYLE="white-space:nowrap">pre-Closing</FONT> Cibus Unit and <FONT
STYLE="white-space:nowrap">pre-Closing</FONT> Cibus Warrant, in each case, held by Cibus, Inc. as a result of the Blocker Mergers will be converted or exchanged for a number of Cibus Common Units set forth in the Allocation Schedule, (ii)&nbsp;each <FONT
STYLE="white-space:nowrap">pre-Closing</FONT> Cibus Warrant held by Cibus, Inc. as a result of the warrant exchanges described in the description of the Merger Consideration will be converted or exchanged for a number of Cibus Common Units set forth
in the Allocation Schedule, and (iii)&nbsp;Cibus will issue a number of Cibus Common Units to Cibus, Inc. in an amount equal to the sum of (A) the number of shares of Class&nbsp;A Common Stock issued to Cibus Unitholders as Cibus Merger
Consideration and (B) the number of shares of Calyxt Common Stock outstanding immediately prior to the First Blocker Merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following
the Closing, the issuance of Merger Consideration and the issuance of Cibus Common Units discussed above, the Combined Company will be organized in an <FONT STYLE="white-space:nowrap">&#147;Up-C&#148;</FONT> structure, with Cibus, Inc.&#146;s only
material assets consisting of Cibus Common Units. Upon the Closing, Calyxt Stockholders are expected to own approximately 5.0% of issued and outstanding Shares, on a Fully-Exchanged Basis, and Cibus Unitholders are expected to own approximately
95.0% of the issued and outstanding Shares, on a Fully-Exchanged Basis taking into consideration all dilutive equity instruments as of that date, in each case, subject to dilution in connection with any additional equity issued in the Continuing
Series F Financing or the Potential Calyxt Financing, certain Calyxt RSU grants that Calyxt, Inc. is permitted to issue prior to Closing and outstanding options and warrants of Calyxt, Inc., which as of the mailing date of the accompanying proxy
statement/prospectus are out-of-the-money. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately following the Closing, all of the issued and outstanding Cibus Common Units will
be held by Cibus, Inc. and the Electing Members (through their ownership of <FONT STYLE="white-space:nowrap">Up-C</FONT> Units), with the exact ownership interest </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">325 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
held by Cibus, Inc. and the Electing Members subject to the elections to be submitted by Top 99 Holders prior to the Closing. In connection with the Up-C structure, at Closing, (i) Cibus, Inc.
and the Electing Members will become party to the Cibus Amended Operating Agreement, (ii) Cibus, Inc., Cibus Global and the Electing Members will enter into an Exchange Agreement, and (iii) Cibus, Inc. and the Electing Members will enter into a
Registration Rights Agreement and a Tax Receivable Agreement. The <FONT STYLE="white-space:nowrap">Up-C</FONT> Units will be exchangeable for shares of Class&nbsp;A Common Stock on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis pursuant to the terms of the Exchange Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tax
Receivable Agreement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the completion of the Transactions, Cibus, Inc. will enter into the Tax Receivable Agreement, pursuant to
which Cibus, Inc. generally will be required to pay to the TRA Parties, in the aggregate, 85% of the net income tax savings that Cibus, Inc. actually realizes (or in certain circumstances, is deemed to realize) as a result of (i)&nbsp;certain
favorable tax attributes we will acquire from the Blockers in the Blocker Mergers (including net operating losses), (ii) increases to Cibus, Inc.&#146;s allocable share of the tax basis of Cibus Global&#146;s assets resulting from future redemptions
or exchanges of Cibus Common Units for shares of Class&nbsp;A Common Stock or cash, (iii)&nbsp;tax attributes resulting from certain payments made under the Tax Receivable Agreement and (iv)&nbsp;deductions in respect of interest under the Tax
Receivable Agreement. The payment obligations under the Tax Receivable Agreement are Cibus, Inc.&#146;s obligations and not obligations of Cibus Global. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to the uncertainty of sufficient projected taxable income of Cibus, Inc. to realize all tax benefits, the unaudited pro&nbsp;forma
combined financial information does not assume that any TRA Party will become entitled to a payment under the Tax Receivable Agreement or that any post-Mergers Cibus equity holder will exchange post-Mergers Cibus Common Units. Therefore, no
increases in tax basis in Cibus, Inc.&#146;s assets have been reflected in the unaudited combined pro&nbsp;forma financial information, nor have any liabilities that Cibus may incur under the Tax Receivable Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should Cibus, Inc. change its assessment of realizability of its tax attributes in future periods, resulting in expected cash tax savings, the
arising Tax Receivable Agreement liability will be recorded at the exchange date against equity, or at a later point through income. Other remeasurements of the Tax Receivable Agreement liability (e.g., due to change in tax rates) will be recorded
through income. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Basis of Presentation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma combined financial information was prepared in accordance with U.S. GAAP and pursuant to the rules and regulations of
Article 11 of Regulation <FONT STYLE="white-space:nowrap">S-X.</FONT> The unaudited pro forma combined balance sheet as of December 31, 2022 was prepared using the historical consolidated balance sheets of Calyxt, Inc. and Cibus Global as of
December 31, 2022. The unaudited pro forma combined statement of operations for the year ended December&nbsp;31, 2022 was prepared using the historical consolidated statements of operations of Calyxt, Inc. and Cibus Global for the year ended
December&nbsp;31, 2022 and gives effect to the Mergers as if they occurred on January&nbsp;1, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma combined
financial information has been prepared using the acquisition method of accounting under U.S.&nbsp;GAAP. Calyxt, Inc. is deemed the accounting acquirer in the Mergers for accounting purposes and Cibus Global is treated as the accounting acquiree.
For accounting purposes, the acquirer is the entity that has obtained control of another entity and, thus, consummated a business combination. The determination of whether control has been obtained begins with the evaluation of whether control
should be evaluated under the variable interest or voting interest model pursuant to ASC 810. If the acquiree is a variable interest entity, the primary beneficiary would be the accounting acquirer. Cibus Global meets the definition of a variable
interest entity and Calyxt, Inc., which will be the managing member, has been determined to be the primary beneficiary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The application
of acquisition accounting to Cibus Global is dependent upon other factors such as the share price of Calyxt, Inc. as well as certain valuations that have yet to progress to a stage where there is sufficient
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">326 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
information for a definitive measurement. The Combined Company will complete the valuations upon completion of the Mergers and will finalize the purchase price allocation as soon as practicable
within the measurement period, but in no event later than one year following the Closing. The assets and liabilities of Cibus Global and other pro forma adjustments have been measured based on various preliminary estimates using assumptions that
Calyxt, Inc. and Cibus Global believe are reasonable, based on information that is currently available. Accordingly, the pro forma adjustments are preliminary. Differences between these preliminary estimates and the final acquisition accounting
could be significant, and these differences could have a material impact on the accompanying unaudited pro forma combined financial information and the Combined Company&#146;s future results of operations and financial position. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma combined financial information does not include the impact of any cost or other operating synergies that may result
from the Mergers or any related restructuring costs that may be contemplated and does not give effect to the Reverse Stock Splits described elsewhere in this proxy statement/prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent there are significant changes to the business of either of the two companies that will comprise the Combined Company following
completion of the Mergers, the assumptions and estimates set forth in the unaudited pro forma combined financial information could change significantly. Accordingly, the pro forma adjustments are subject to change as additional information becomes
available and as additional analyses are conducted following the completion of the Mergers. There can be no assurances that these additional analyses will not result in material changes to the estimates of fair value. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Preliminary Purchase Price </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant
to the Merger Agreement, at the Closing, Calyxt, Inc. expects to issue to Cibus Unitholders a number of Shares representing approximately 95.0% of the outstanding Shares on a Fully-Exchanged Basis. The estimated preliminary purchase price is
calculated based on the fair value of the Shares that Cibus Unitholders will own as of the Closing. With no active trading market for units of Cibus Global, the fair value of the Calyxt Common Stock represents a more reliable measure of the fair
value of consideration transferred in the Mergers. Accordingly, the accompanying unaudited pro forma combined financial information reflects an estimated purchase price of approximately $315.3&nbsp;million, which consists of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated number of Shares to be owned by Cibus Global stockholders&nbsp;<SUP
STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">900,946,624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Multiplied by the fair value per share of the Calyxt Common Stock <SUP
STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 0.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated purchase price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">315,331,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This share number represents the number of Shares to be owned by Cibus Global members, as set forth in the
Allocation Schedule attached to the Merger Agreement, subsequent to the Mergers, excluding (i) 50,067,772 restricted shares of Class A Common Stock issuable in respect of restricted profits interest units of Cibus Global and subject to the same
vesting schedule as was applicable to such profits interest unit prior to Closing, (ii) 4,030,612 shares of Class A Common Stock issuable in respect of profits units of Cibus Global that Cibus Global is permitted to grant prior to the Closing, and
(iii) the effect of any Cibus Series F Preferred Units pursuant to the Continuing Series F Financing. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The estimated purchase price was based on the closing price of Calyxt Common Stock as reported on The Nasdaq
Capital Market on April 3, 2023. The final purchase price will be based on the number of shares and fair market value of Calyxt Common Stock outstanding immediately prior to the Closing and could result in a purchase price different from that
assumed in this unaudited pro forma combined financial information, and that difference may be material. An increase or decrease in the fair market value of Calyxt Common Stock of 10% would result in an increase or decrease in total purchase
consideration of $31.5&nbsp;million. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">327 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The actual purchase consideration may vary based on the Calyxt Common Stock share price at
Closing as described above, and that difference could be material. As such, the estimated purchase consideration reflected in these unaudited pro forma combined financial information does not purport to represent what the actual purchase
consideration will be when the Mergers are completed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Purchase Price Allocation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt, Inc., has performed a preliminary valuation analysis of the fair market value of Cibus Global&#146;s assets and liabilities. The
following table summarizes the preliminary purchase price allocation as of the acquisition date (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Due from related parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">right-of-use-assets</FONT></FONT></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43,966</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">330,424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,103</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,946</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Due to related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(80</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notes payable, current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(736</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities, current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,654</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing lease liabilities, current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(150</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notes payable, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(670</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,833</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing lease liabilities, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(87</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Royalty liability - related parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(81,944</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,495</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimate of consideration expected to be transferred</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">315,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This preliminary purchase price allocation has been used to prepare pro forma adjustments in the pro forma
balance sheet. The final purchase price allocation will be determined when the Combined Company has completed the detailed valuations and necessary calculations. The final allocation could differ materially from the preliminary allocation used in
the pro forma adjustments. The final allocation may include material changes in allocations to the Royalty Liability, tax receivables liability, deferred tax liabilities and intangible assets such as trademark, developed technologies, <FONT
STYLE="white-space:nowrap">in-process</FONT> research and development technologies as well as goodwill and other changes to assets and liabilities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">328 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Shares Issued to Cibus Unitholders upon Closing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the Cibus Merger Effective Time, all outstanding Cibus Global equity will be converted into the right to receive Shares as consideration for
the Mergers in the amounts as set forth in the Allocation Schedule. The estimated exchange ratios for purposes of the unaudited pro forma combined financial information was derived on a Fully-Exchanged Basis as of January&nbsp;13, 2023 based on
stipulated values of Cibus Global and Calyxt, Inc. Based on the preliminary estimated exchange ratio of approximately 3.1705 determined in accordance with the terms of the Merger Agreement and Allocation Schedule, Calyxt, Inc. expects to issue
900,946,624 Shares to Cibus Unitholders in the Mergers, excluding (i) 50,067,772 restricted shares of Class A Common Stock issuable in respect of restricted profits interest units of Cibus Global and subject to the same vesting schedule as was
applicable to such profits interest unit prior to Closing, (ii) 4,030,612 shares of Class A Common Stock issuable in respect of profits units of Cibus Global that Cibus Global is permitted to grant prior to the Closing, and (iii) the effect of any
Cibus Series F Preferred Units pursuant to the Continuing Series F Financing, determined as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cibus:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cibus Global <FONT STYLE="white-space:nowrap">non-voting</FONT> common units with threshold <SUP
STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44,834,123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cibus Warrants <SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,751,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total pre-Closing Cibus Warrants and <FONT STYLE="white-space:nowrap">non-voting</FONT> common
units with threshold</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74,585,173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average exchange ratio applicable to Cibus Warrants and
<FONT STYLE="white-space:nowrap">non-voting</FONT> common units with threshold (rounded)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.5715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Cibus, Inc. post-Mergers Shares for Cibus Warrants and
<FONT STYLE="white-space:nowrap">non-voting</FONT> common units with threshold</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">191,798,365</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Plus:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cibus Global <FONT STYLE="white-space:nowrap">non-voting</FONT> common units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,479,735</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cibus Preferred Units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">222,194,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total pre-Closing Cibus Preferred Units and <FONT STYLE="white-space:nowrap">non-voting</FONT>
common units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">223,673,814</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchange ratio (rounded)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.1705</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Cibus, Inc. post-Mergers Shares for Cibus Preferred Units and
<FONT STYLE="white-space:nowrap">non-voting</FONT> common units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">709,148,259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Cibus, Inc. post-Mergers Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">900,946,624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Per the Merger Agreement, the outstanding <FONT STYLE="white-space:nowrap">non-voting</FONT> restricted common
units, as well as outstanding warrants, will convert based on the fair value of such unit, as a percentage of the Calyxt Common Stock value, multiplied by the conversion ratio of approximately 3.1705. This results in a weighted average conversion
ratio applicable to the units which varies from the conversion ratio applied to Cibus Preferred Units and pre-Mergers Cibus Global <FONT STYLE="white-space:nowrap">non-voting</FONT> common units without an applied threshold value.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exchange ratio and estimated Shares to be issued to Cibus Unitholders have not been adjusted to give retrospective
effect to the Reverse Stock Splits described elsewhere in this proxy statement/prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Pro Forma Adjustments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma combined financial information includes pro forma adjustments that reflect transaction accounting adjustments, as well
as other adjustments deemed to be directly related to the Mergers, irrespective of whether or not such adjustments are deemed to be recurring. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">329 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on Calyxt, Inc.&#146;s management&#146;s review of Cibus Global&#146;s summary of
significant accounting policies, the nature and amount of any adjustments to the historical financial statements of Cibus Global to conform to the accounting policies of Calyxt, Inc. are not expected to be significant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma combined financial information does not reflect the proposed Reverse Stock Splits described elsewhere in this proxy
statement/prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pro forma adjustments, based on preliminary estimates that may change significantly as additional information
is obtained, are as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect preliminary estimated transaction costs of $2.6&nbsp;million in connection with the Mergers, such as
adviser, legal, and accounting expenses that are expected to be incurred by Calyxt, Inc., as an increase in accrued liabilities and accumulated deficit in the unaudited pro forma combined balance sheet, and an increase in selling, general and
administrative expenses in the unaudited proforma combined statement of operations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect the change in Calyxt Common Stock&#146;s par value and additional
<FONT STYLE="white-space:nowrap">paid-in</FONT> capital upon the exchange of Cibus Global equity interests for Shares upon the Closing. Share to Cibus Unitholders represents the number of Shares to be owned by Cibus Global members, as set forth in
the Allocation Schedule attached to the Merger Agreement, subsequent to the Mergers, excluding (i) 50,067,772 restricted shares of Class A Common Stock issuable in respect of restricted profits interest units of Cibus Global and subject to the same
vesting schedule as was applicable to such profits interest unit prior to Closing, (ii) 4,030,612 shares of Class A Common Stock issuable in respect of profits units of Cibus Global that Cibus Global is permitted to grant prior to the Closing, and
(iii) the effect of any Cibus Series F Preferred Units pursuant to the Continuing Series F Financing. Shares to Calyxt Stockholders represents the Calyxt common stock outstanding as of the date of the Merger Agreement and excludes up to an
additional 3,487,503 Calyxt RSUs (of which 3,468,083 have been issued as of the date of this proxy statement/prospectus), which Calyxt RSUs will, if issued, be subject to accelerated vesting upon Closing. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares to Cibus Unitholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">900,946,624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares to Calyxt Stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,251,747</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">951,198,371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Par value per Share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aggregate par value of Shares (in thousands)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aggregate par value of Calyxt Common Stock (in thousands)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Par value adjustment (in thousands)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect the elimination of Cibus Global&#146;s historical accumulated deficit, accumulated other
comprehensive loss, unit subscription receivable, and additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital balances. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">330 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The pro forma combined basic and diluted net loss per Share have been adjusted to reflect the pro forma net
loss for the year ended December&nbsp;31, 2022. In addition, the number of shares used in calculating the pro forma combined basic and diluted net loss per share has been adjusted to reflect the estimated total number of Shares that would be
outstanding as of the Closing Date. For the year ended December 31, 2022, the pro forma weighted average shares outstanding has been calculated as follows: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended</B><br><B>December&nbsp;31,&nbsp;2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical Cibus Global weighted-average common units outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,624,893</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Impact of Cibus Preferred Units assuming conversion as of January 1, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">222,194,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Subtotal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">260,818,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Application of exchange ratio to historical Cibus Preferred Units outstanding </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.1705</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(a) Subtotal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">826,915,394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Impact of accelerated vesting for Cibus Global non-voting common units with threshold, assuming
conversion as of January 1, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,766,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Application of weighted average exchange ratio for accelerated vesting of Cibus Global non-voting
common units with threshold </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.8511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(b) Subtotal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,740,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Impact of Cibus Global warrants, assuming conversion as of January&nbsp;1, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,751,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Application of exchange ratio to Cibus Global warrants outstanding </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.0096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(c) Subtotal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59,787,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjusted Cibus weighted-average common units outstanding (after giving effect to the Exchange
Ratio) (a + b + c)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">897,443,126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical weighted average of Calyxt Common Stock outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,997,525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Impact on Calyxt Common Stock of accelerated vesting of equity awards as of January 1,
2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,410,461</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total weighted average units outstanding</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">944,851,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Historical Cibus Global weighted-average units outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,624,893</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Historical Calyxt, Inc. weighted-average shares of common stock outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,997,525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total weighted average units outstanding - pro forma adjustment</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">860,228,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect $4.2&nbsp;million in share-based compensation expense for Calyxt, Inc. as a result of the
transaction, based on the fair value of awards for which vesting was accelerated based on the original grant terms, in connection with the Mergers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect Calyxt, Inc.&#146;s estimated compensation expense of $2.8&nbsp;million related to severance
payments resulting from <FONT STYLE="white-space:nowrap">pre-existing</FONT> employment agreements that will be payable in cash in connection with the Mergers but were not incurred as of December 31, 2022. These expenses are reflected as an increase
to accrued expenses and accumulated deficit in the unaudited pro forma combined balance sheet. Calyxt, Inc.&#146;s compensation costs of $2.8&nbsp;million are reflected as selling, general and administrative expenses in the unaudited pro forma
combined statement of operations for the year ended December&nbsp;31, 2022. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect the impact of the <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest created upon the
election of historical Cibus Unitholders to become Electing Members, which Cibus Global estimates to be approximately 15% of the historical Cibus Global units. Cibus Global estimates the potential range of Electing Members to be between
approximately 0% and 21% of historical Cibus Global units. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">331 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect the impact of the preliminary purchase price allocation as described in Note 3, including the
preliminary estimate of goodwill, the acquisition date fair value of land, buildings, and equipment, the royalty liability - related parties, and the deferred tax liability, and recognition of the intangible assets at the preliminary fair value,
offset by the associated impact on amortization expense. The following table summarizes the intangible assets acquired (in thousands): </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preliminary<BR>Fair&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated<BR><FONT STYLE="white-space:nowrap">Weighted-Average</FONT><BR>Useful&nbsp;Life</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amortization<BR>Expense&nbsp;for<BR>Year&nbsp;Ended<BR>December&nbsp;31,&nbsp;2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IPR&amp;D<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Developed&nbsp;technology</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade name</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total&nbsp;Pro&nbsp;forma&nbsp;Adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43,966</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">IPR&amp;D assets are initially recognized at fair value and are classified as indefinite-lived assets until the
successful completion or abandonment of the associated research and development efforts. Accordingly, during the research and development period after the closing date of the Mergers, these assets will not be amortized. Such IPR&amp;D projects will
become amortizable when applicable products, which are currently in various stages of development, are complete. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The total impact to equity for the above adjustments is reflected in the table below: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional</B><br><B>Paid-in</B><br><B>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unit<BR>Subscription</B><br><B>Receivable</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AOCI</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Non-<BR>Controlling<BR>Interest</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stockholders</B><br><B>Equity</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Cibus Global</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Calyxt, Inc.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom"><B>(amounts in thousands,<BR>except share amounts)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Preliminary purchase price allocation fair value</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">(h)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">346,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">346,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Pre-combination stock-based compensation costs for Calyxt, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">(e)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,198</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Elimination of historical Cibus Global additional paid in capital and accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">(c)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(416,224</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,078</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">412,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Exchange of outstanding Cibus Global units into Calyxt Common Stock based on the assumed exchange
ratio</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">(b)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(264,104,040</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(328,483</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">900,946,624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">328,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Severance payments to Calyxt, Inc. employees</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">(f)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,834</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,834</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Transaction costs incurred by Calyxt Inc., associated with the Mergers</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">(a)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,560</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,560</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Impact of non-controlling interest</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">(g)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(47,576</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Pro forma adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(264,104,040</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(328,483</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">900,946,624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">215,034</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,078</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">402,546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">340,849</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">332 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom401831_56"></A>DESCRIPTION OF CAPITAL STOCK OF CIBUS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following summary sets forth the material terms of Cibus, Inc.&#146;s capital stock following the consummation of the Transactions. The
following summary is not intended to be complete and is qualified by reference to the Amended Certificate of Incorporation, the form of which is attached as Annex B to this proxy statement/prospectus and the Amended Bylaws, the form of which is
attached as Annex C to this proxy statement/prospectus. We urge you to read the Amended Certificate of Incorporation and Amended Bylaws in their entirety for a complete description of the capital stock of Cibus, Inc. following the consummation of
the Transactions. Unless otherwise noted, the following information does not give effect to the Reverse Stock Splits described elsewhere in this proxy statement/prospectus. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon consummation of the
Transactions, the total number of authorized shares of capital stock of Cibus, Inc. will consist of (i)&nbsp;a number of shares of Class&nbsp;A Common Stock equal to (A)&nbsp;if the Subsequent Reverse Stock has not occurred, 1,050,000,000, and
(B)&nbsp;if the Subsequent Reverse Stock Split has occurred, 1,050,000,000 divided by the Subsequent Reverse Stock Split Factor, rounded up to the nearest whole number, (ii)&nbsp;a number of shares of Class&nbsp;B Common Stock equal to (A)&nbsp;if
the Subsequent Reverse Stock has not occurred, 450,000,000, and (B)&nbsp;if the Subsequent Reverse Stock Split has occurred, 450,000,000 divided by the Subsequent Reverse Stock Split Factor, rounded up to the nearest whole number, and (iii)&nbsp;a
number of shares of preferred stock equal to (A)&nbsp;if the Subsequent Reverse Stock has not occurred, 50,000,000, and (B)&nbsp;if the Subsequent Reverse Stock Split has occurred, 50,000,000 divided by the Subsequent Reverse Stock Split Factor,
rounded up to the nearest whole number, par value of $0.0001 per share. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Class&nbsp;A Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Voting Rights</I>. Holders of shares of Class&nbsp;A Common Stock will be entitled to one vote for each share held of record on all matters
on which stockholders are entitled to vote generally, except that holders of shares of Class&nbsp;A Common Stock will have no voting power with respect to, and will not be entitled to vote on, any amendment to the Amended Certificate of
Incorporation (including any certificate of designations relating to any series of Preferred Stock) that relates solely to the terms of any outstanding preferred stock if the holders of such preferred stock are entitled to vote as a separate class
thereon under the Amended Certificate of Incorporation or under the DGCL. The holders of Class&nbsp;A Common Stock will not have cumulative voting rights in the election of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of outstanding shares of Class&nbsp;A Common Stock will be entitled to vote separately upon any amendment to the Amended Certificate
of Incorporation (including by merger, consolidation, conversion, reorganization or similar event) that would alter or change the powers, preferences or special rights of Class&nbsp;A Common Stock in a manner that is materially and
disproportionately adverse as compared to the Class&nbsp;B Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Dividend Rights</I>. Holders of shares of Class&nbsp;A Common
Stock will be entitled to receive dividends when, as and if declared by the Cibus, Inc. Board out of funds legally available therefor, subject to any statutory or contractual restrictions on the payment of dividends and to any restrictions on the
payment of dividends imposed by the terms of any outstanding preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Liquidation Rights</I>. Upon its liquidation,
dissolution or winding up and after payment in full of all amounts required to be paid to creditors and to the holders of preferred stock having liquidation preferences, if any, the holders of shares of Class&nbsp;A Common Stock will be entitled to
receive pro rata the remaining assets available for distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All shares of Class&nbsp;A Common Stock that will be outstanding at the
time of the completion of the Transactions will be fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> The Class&nbsp;A Common Stock will not be subject to further calls or assessments by us. Holders of shares of Class&nbsp;A
Common Stock do not have preemptive, subscription or redemption rights. There will be no redemption or sinking fund provisions applicable to the Class&nbsp;A Common Stock. The rights powers, preferences and privileges of Class&nbsp;A Common Stock
will be subject to those of the holders of any shares of Class&nbsp;B Common Stock and preferred stock or any other series or class of stock Cibus, Inc. may authorize and issue in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">333 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Class&nbsp;B Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Voting Rights</I>. Holders of shares of Class&nbsp;B Common Stock will be entitled to one vote for each share held of record on all matters
on which stockholders are entitled to vote generally, except that holders of shares of </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;B Common Stock will have no voting power with respect
to, and will not be entitled to vote on, any amendment to the Amended Certificate of Incorporation (including any certificate of designations relating to any series of Preferred Stock) that relates solely to the terms of any outstanding preferred
stock if the holders of such preferred stock are entitled to vote as a separate class thereon under the Amended Certificate of Incorporation or under the DGCL. The holders of Class&nbsp;B Common Stock will not have cumulative voting rights in the
election of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of outstanding shares of Class&nbsp;B Common Stock will be entitled to vote separately upon any amendment
to the Amended Certificate of Incorporation (including by merger, consolidation, conversion, reorganization or similar event) that would alter or change the powers, preferences or special rights of Class&nbsp;B Common Stock in a manner that is
materially and disproportionately adverse as compared to the Class&nbsp;A Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of outstanding shares of Class&nbsp;B
Common Stock will be entitled to vote separately upon any (A)&nbsp;merger, consolidation, conversion, reorganization or similar event in connection with any transaction or series of transactions intended to result in the Combined Company no longer
being structured as an umbrella partnership C corporation (an <FONT STYLE="white-space:nowrap">&#147;Up-C</FONT> Reorganization Transaction&#148;) or (B)&nbsp;amendment to the Amended Certificate of Incorporation (including by merger, consolidation,
conversion, reorganization or similar event) to effect an <FONT STYLE="white-space:nowrap">Up-C</FONT> Reorganization Transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of the Shares will vote together as a single class on all matters (or, if any holders of preferred stock are entitled to vote together
with the holders of the Shares, as a single class with the holders of preferred stock) except as otherwise required in the Amended Certificate of Incorporation or by applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Dividend Rights</I>. Holders of Class&nbsp;B Common Stock will not have any right to receive dividends. In no event will any dividend be
declared or made on any Shares unless (1)&nbsp;a corresponding dividend for all other Shares not so adjusted at the time outstanding is made in the same proportion and the same manner and (2)&nbsp;the dividend has been reflected in the same
economically equivalent manner on all Shares. Dividends with respect to Shares may only be paid with shares of stock of the same class of common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Liquidation Rights</I>. Holders of Class&nbsp;B Common Stock will not have any right to receive a distribution upon a liquidation,
dissolution or winding up of Cibus, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Retirement of Shares</I>. No holder of Class&nbsp;B Common Stock may transfer shares of
Class&nbsp;B Common Stock to any Person unless such holder transfers a corresponding number of Cibus Common Units to the same Person in accordance with the provisions of the Cibus Amended Operating Agreement. If any outstanding share of Class&nbsp;B
Common Stock ceases to be held by a holder of the corresponding Cibus Common Unit, such share shall automatically and without further action on the part of Cibus, Inc. or any holder of Class&nbsp;B Common Stock be transferred to Cibus, Inc. for no
consideration and retired. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Issuance of Cibus Common Units</I>. To the extent Cibus Common Units are issued pursuant to the Cibus
Amended Operating Agreement to anyone other than Cibus, Inc. or a wholly owned subsidiary of Cibus, Inc., an equivalent number of shares of Class&nbsp;B Common Stock (subject to adjustment) will be issued at par to the same Person to which such
Cibus Common Units are issued. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No shares of preferred stock will be issued or outstanding immediately after the Transactions. The Amended Certificate of Incorporation will
authorize the Cibus, Inc. Board to establish one or more series of preferred stock. The Cibus, Inc. Board will be able to determine, with respect to any series of preferred stock, the powers </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">334 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(including voting powers), and the designations, preferences and relative, participating, optional or other special rights, and any qualifications, limitations or restrictions thereof. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dividends </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The DGCL permits a corporation
to declare and pay dividends out of &#147;surplus&#148; or, if there is no &#147;surplus,&#148; out of its net profits for the fiscal year in which the dividend is declared and/or the preceding fiscal year. &#147;Surplus&#148; is defined as the
excess of the net assets of the corporation over the amount determined to be the capital of the corporation by its board of directors. The capital of the corporation is typically calculated to be (and cannot be less than) the aggregate par value of
all issued shares of capital stock. Net assets equals the fair value of the total assets minus total liabilities. The DGCL also provides that dividends may not be paid out of net profits if, after the payment of the dividend, remaining capital would
be less than the capital represented by the outstanding stock of all classes having a preference upon the distribution of assets. Declaration and payment of any dividend will be subject to the discretion of the Cibus, Inc. Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus, Inc. has no current plans to pay dividends on its Class&nbsp;A Common Stock. Any decision to declare and pay dividends in the future
will be made at the sole discretion of the Cibus, Inc. Board and will depend on, among other things, its results of operations, cash requirements, financial condition, contractual restrictions and other factors that the Cibus, Inc. Board may deem
relevant. Because Cibus, Inc. will be a holding company and will have no direct operations, it will only be able to pay dividends from funds it receives from its subsidiaries. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Annual Stockholder Meetings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Amended
Bylaws will provide that annual stockholder meetings will be held at a date, time and place, if any, as may be designated by the Cibus, Inc. Board or, in the absence of a designation by the Cibus, Inc. Board, by the chair, the chief executive
officer or the secretary. To the extent permitted under applicable law, Cibus, Inc. may conduct meetings by remote communications, including by webcast. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Effects of the Amended Certificate of Incorporation, the Amended Bylaws and Certain Provisions of Delaware Law </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Amended Certificate of Incorporation, the Amended Bylaws and certain provisions of the DGCL will contain provisions, which are summarized
in the following paragraphs, that are intended to enhance the likelihood of continuity and stability in the composition of the Cibus, Inc. Board. These provisions are intended to avoid costly takeover battles, reduce Cibus, Inc.&#146;s vulnerability
to a hostile or abusive change of control and enhance the ability of the Cibus, Inc. Board to maximize stockholder value in connection with any unsolicited offer to acquire Cibus, Inc. However, these provisions may have an <FONT
STYLE="white-space:nowrap">anti-takeover&nbsp;effect</FONT> and may delay, deter or prevent a merger or acquisition of Cibus, Inc. by means of a tender offer, a proxy contest or other takeover attempt that a stockholder might consider in its best
interest, including those attempts that might result in a premium over the prevailing market price for the Shares held by stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Authorized but
Unissued Capital Stock </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Delaware Law does not require stockholder approval for any issuance of shares that are authorized and available
for issuance. However, the listing requirements of Nasdaq, which would apply so long as Class&nbsp;A Common Stock remains listed on Nasdaq, require stockholder approval of certain issuances equal to or exceeding 20% of the then outstanding voting
power of Cibus, Inc.&#146;s capital stock or then outstanding number of shares of Class&nbsp;A Common Stock. These additional shares may be used for a variety of corporate purposes, including future public offerings, to raise additional capital or
to facilitate acquisitions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Cibus, Inc. Board will be authorized to generally issue shares of one or more series of preferred stock
on terms calculated to discourage, delay or prevent a change of control of Cibus, Inc. or the removal of its management. Moreover, Cibus, Inc.&#146;s authorized but unissued shares of preferred stock will be available for future issuances in one or
more series without stockholder approval and could be utilized for a variety of corporate purposes, including future offerings to raise additional capital, to facilitate acquisitions and employee benefit plans. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">335 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One of the effects of the existence of authorized and unissued and unreserved Class&nbsp;A
Common Stock or preferred stock may be to enable the Cibus, Inc. Board to issue shares to persons friendly to current management, which issuance could render more difficult or discourage an attempt to obtain control of Cibus, Inc. by means of a
merger, tender offer, proxy contest or otherwise, and thereby protect the continuity of its management and possibly deprive its stockholders of opportunities to sell their shares of Class&nbsp;A Common Stock at prices higher than prevailing market
prices. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Vacancies and Newly Created Directorships </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Amended Certificate of Incorporation and the Amended Bylaws will provide that any vacancies on the Cibus, Inc. Board, and any newly created
directorships, will be filled only by the affirmative vote of a majority of the remaining directors then in office, even if less than a quorum, and any director so chosen will hold office until the earlier expiration of the term of office of the
director whom he or she has replaced or his or her successor shall be duly elected and qualified or until such director&#146;s earlier death, disqualification, resignation or removal. No decrease in the number of directors shall shorten the term of
any director then in office. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>No Cumulative Voting </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Delaware Law, the right to vote cumulatively does not exist unless the certificate of incorporation specifically authorizes cumulative
voting. The Amended Certificate of Incorporation will not authorize cumulative voting. Therefore, stockholders holding a majority in voting power of the shares of Cibus, Inc. stock entitled to vote generally in the election of directors will be able
to elect all directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Special Stockholder Meetings </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Amended Certificate of Incorporation and the Amended Bylaws will provide that special meetings of stockholders may be called only by the
chair of the Cibus, Inc. Board, the chief executive officer of Cibus, Inc. or at the direction of the Cibus, Inc. Board pursuant to a written resolution adopted by a majority of the total number of directors that Cibus, Inc. would have if there were
no vacancies. Any business transacted at a special meeting of stockholders will be limited to matters set forth in the notice of the special meeting. These provisions may have the effect of deterring, delaying or discouraging hostile takeovers, or
changes in control or management of Cibus, Inc. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Director Nominations and Stockholder Proposals </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Amended Bylaws will establish advance notice procedures with respect to stockholder nominations for the election as directors. In order for
any matter to be &#147;properly brought&#148; before a meeting, a stockholder will have to comply with advance notice requirements and provide Cibus, Inc. with certain information. Generally, to be timely, a stockholder&#146;s notice must be
received at Cibus, Inc.&#146;s principal executive offices not less than 90&nbsp;days nor more than 120&nbsp;days prior to the first anniversary date of the immediately preceding annual meeting of stockholders. The Amended Bylaws will also specify
requirements as to the form and content of a stockholder&#146;s notice. The Amended Bylaws will allow the chair of the meeting at a meeting of the stockholders to adopt rules and regulations for the conduct of meetings which may have the effect of
precluding the conduct of certain business at a meeting if the rules and regulations are not followed. These provisions may also defer, delay or discourage a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#146;s
own slate of directors or otherwise attempting to influence or obtain control of Cibus, Inc. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stockholder Action by Written Consent </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Section&nbsp;228 of the DGCL, any action required to be taken at any annual or special meeting of the stockholders may be taken
without a meeting, without prior notice and without a vote if a consent or consents in writing, setting forth the action so taken, is or are signed by the holders of outstanding stock having not less
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">336 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares of stock entitled to vote thereon were present and voted, unless the
certificate of incorporation provides otherwise. The Amended Certificate of Incorporation will preclude stockholder action by written consent; provided, however, that any action required or permitted to be taken by the holders of Class&nbsp;B Common
Stock, voting separately as a class, may be effected by the consent in writing of the holders of a majority of the total voting power of the Class&nbsp;B Common Stock entitled to vote thereon, voting together as a single class in lieu of a duly
called annual or special meeting of holders of Class&nbsp;B Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These provisions may have the effect of deterring hostile
takeovers or delaying or preventing changes in control of Cibus, Inc. or its management, such as a merger, reorganization or tender offer. These provisions are intended to enhance the likelihood of continued stability in the composition of the
Cibus, Inc. Board and its policies and to discourage certain types of transactions that may involve an actual or threatened acquisition of the Cibus, Inc. Board. These provisions are designed to reduce Cibus, Inc.&#146;s vulnerability to an
unsolicited acquisition proposal. The provisions are also intended to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for Cibus, Inc. shares
and, as a consequence, they also may inhibit fluctuations in the market price of Cibus, Inc. shares that could result from actual or rumored takeover attempts. Such provisions may also have the effect of preventing changes in management. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>DGCL Section&nbsp;203 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus, Inc. will
be subject to the provisions of Section&nbsp;203 of the DGCL regulating corporate takeovers. In general, those provisions prohibit a Delaware corporation, including those whose securities are listed for trading on Nasdaq, from engaging in any
business combination with any interested stockholder for a period of three&nbsp;years following the date that the stockholder became an interested stockholder, unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the transaction is approved by the board of directors before the date the interested stockholder attained that
status; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the
interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on or after such time the business combination is approved by the board of directors and authorized at a meeting
of stockholders by at least <FONT STYLE="white-space:nowrap">two-thirds&nbsp;of</FONT> the outstanding voting stock that is not owned by the interested stockholder. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dissenters&#146; Rights of Appraisal and Payment </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the DGCL, with certain exceptions, including the circumstances where the Shares are, at the effective date of a merger or consolidation,
either listed on a national securities exchange or held of record by more than 2,000 holders, Cibus, Inc. stockholders will have appraisal rights in connection with a merger or consolidation of Cibus, Inc. Pursuant to the DGCL, stockholders who
properly request and perfect appraisal rights in connection with such merger or consolidation will have the right to receive payment of the fair value of their shares as determined by the Delaware Court of Chancery. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stockholders&#146; Derivative Actions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the DGCL, any Cibus, Inc. stockholders may bring an action in Cibus, Inc.&#146;s name to procure a judgment in Cibus, Inc.&#146;s favor,
also known as a derivative action, provided that the stockholder bringing the action is a holder of Cibus, Inc. shares at the time of the transaction to which the action relates or such stockholder&#146;s stock thereafter devolved by operation of
law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">337 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exclusive Forum </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Amended Certificate of Incorporation will provide that unless Cibus, Inc. consents in writing to the selection of an alternative forum, the
Court of Chancery in the State of Delaware (or, if the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware) shall be the sole and exclusive forum for any (i)&nbsp;derivative action or proceeding
brought on behalf of Cibus, Inc., (ii)&nbsp;action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of Cibus, Inc. to Cibus, Inc. or Cibus, Inc. stockholders, (iii)&nbsp;action asserting a claim arising
pursuant to any provision of the DGCL or the Amended Certificate of Incorporation or Amended Bylaws, or (iv)&nbsp;action asserting a claim governed by the internal affairs doctrine. This provision does not apply to any actions arising under the
Securities Act. Any person or entity purchasing or otherwise acquiring or holding any interest in any security of Cibus, Inc. shall be deemed to have notice of and consented to the forum provisions in the Amended Certificate of Incorporation.
However, the enforceability of similar forum provisions in other companies&#146; certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be unenforceable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations on Liability and Indemnification of Officers and Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The DGCL authorizes corporations to limit or eliminate the personal liability of directors and officers to corporations and their stockholders
for monetary damages for breaches of directors&#146; and officers&#146; fiduciary duties, subject to certain exceptions. The Amended Certificate of Incorporation will include a provision that eliminates the personal liability of directors and
officers for monetary damages to the corporation or its stockholders for any breach of fiduciary duty as a director or an officer.&nbsp;The effect of these provisions is to eliminate the rights of Cibus, Inc. and its stockholders, through
stockholders&#146; derivative suits on Cibus, Inc.&#146;s behalf, to recover monetary damages from a director or an officer for breach of fiduciary duty as a director or an officer, including breaches resulting from grossly negligent behavior.
However, exculpation will not apply to any breaches of a director&#146;s or officer&#146;s duty of loyalty, acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law, or for any transaction from which
such director or officer derived an improper personal benefit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Amended Certificate of Incorporation will generally provide that
Cibus, Inc. must defend, indemnify and advance expenses to Cibus, Inc. directors and officers to the fullest extent permitted or required by the DGCL.&nbsp;Cibus, Inc. will also be expressly authorized to carry directors&#146; and officers&#146;
liability insurance providing indemnification for its directors, officers and certain employees for some liabilities. Cibus, Inc. believes that these indemnification and advancement provisions and insurance are useful to attract and retain qualified
directors and executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The limitation of liability, indemnification and advancement provisions in the Amended Certificate of
Incorporation and the Amended Bylaws may discourage stockholders from bringing a lawsuit against directors or officers for breach of their fiduciary duties. These provisions also may have the effect of reducing the likelihood of derivative
litigation against directors and officers, even though such an action, if successful, might otherwise benefit Cibus, Inc. and its stockholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon
consummation of the Transactions, the transfer agent and registrar for Class&nbsp;A Common Stock will be Broadridge Corporate Issuer Solutions, LLC. The transfer agent&#146;s address is 1155 Long Island Avenue, Edgewood, NY 11717. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the Transactions,
Class&nbsp;A Common Stock is expected to be listed on the Nasdaq Capital Market under the symbol &#147;CBUS.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">338 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom401831_57"></A>COMPARISON OF STOCKHOLDERS&#146; RIGHTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt, Inc. is incorporated under the laws of the State of Delaware and the rights of Calyxt Stockholders are governed by the laws of the
State of Delaware, including the DGCL, the Calyxt Certificate of Incorporation, the Calyxt Bylaws and the Stockholders Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus
Global is a Delaware limited liability company and the rights of Cibus Unitholders are governed by the laws of the State of Delaware, including the DLLCA, and the Cibus Operating Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Mergers are completed, Cibus Unitholders who receive Shares will become stockholders of Cibus, Inc., and their rights will be governed
by the DGCL, the Amended Bylaws and the Amended Certificate of Incorporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below summarizes the material differences between
the current rights of Calyxt Stockholders under the Calyxt Certificate of Incorporation, the Calyxt Bylaws and the Stockholders Agreement, the rights of Cibus Unitholders under the Cibus Operating Agreement, and the rights of holders of the Shares
under the DGCL, the Amended Bylaws and the Amended Certificate of Incorporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While Calyxt, Inc. and Cibus Global believe that the
summary table below covers the material differences between the rights of their respective stockholders prior to the Transactions and the rights of stockholders of Cibus, Inc. following the Transactions, these summary tables may not contain all of
the information that is important to you. These summaries are not intended to be a complete discussion of the respective rights of Calyxt Stockholders or Cibus Unitholders and are qualified in their entirety by reference to the DGCL, the DLLCA and
the various documents of Calyxt, Inc. and Cibus Global that are referred to in the summaries. You should carefully read this entire proxy statement/prospectus and the other documents referred to in this proxy statement/prospectus for a more complete
understanding of the differences between being a stockholder of Calyxt, Inc. or Cibus Global before the Transactions and being a stockholder of Cibus, Inc. after the Transactions. Calyxt, Inc. has filed copies of the Calyxt Certificate of
Incorporation and Calyxt Bylaws with the SEC and will send copies of the documents referred to in this proxy statement/prospectus to you upon your request. Cibus Global will also send copies of its documents referred to in this proxy
statement/prospectus to you upon your request. See the section entitled &#147;<I>Where You Can Find More Information</I>&#148; in this proxy statement/prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Pre-Merger</FONT>
Calyxt, Inc.</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Common Stock)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Pre-Merger</FONT> Cibus
Global, LLC<BR>(Common and Preferred Units)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Cibus, Inc. (Post-Mergers)</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" ALIGN="center"><B>Name</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Calyxt, Inc.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Cibus Global, LLC</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Cibus, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" ALIGN="center"><B>Authorized Equity</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Calyxt Certificate of Incorporation authorizes the issuance of up to 325,000,000 shares of stock, consisting of 275,000,000 shares of common stock, and 50,000,000 shares of preferred stock, par value $0.0001.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">The Cibus Operating Agreement authorizes the issuance of 83,300,852 Cibus Series A Preferred Units, 31,285,438 Cibus Series B Preferred Units, 38,173,979 Cibus Series C Preferred Units, 44,000,000 Cibus Series D Preferred Units,
19,886,364 Cibus Series E Preferred Units, 50,000,000 Cibus Series F Preferred Units, 341,282,000 voting common units</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">The Amended Certificate of Incorporation authorizes the issuance of up to (1) a number of shares of common stock equal to (A) if the Subsequent Reverse Stock Split has not occurred, 1,500,000,000, and (B) if the Subsequent Reverse
Stock Split has occurred, 1,500,000,000 divided by the Subsequent Reverse Stock Split Factor, rounded up to the nearest whole number, par value $0.0001</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">339 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Pre-Merger</FONT>
Calyxt, Inc.</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Common Stock)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Pre-Merger</FONT> Cibus
Global, LLC<BR>(Common and Preferred Units)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Cibus, Inc. (Post-Mergers)</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and 66,414,403 <FONT STYLE="white-space:nowrap">non-voting</FONT> common units.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">As of January&nbsp;13, 2023, there were 67,810,963 Cibus Series A Preferred Units,
30,817,791 Cibus Series B Preferred Units, 33,195,500 Cibus Series C Preferred Units, 44,000,000 Cibus Series D Preferred Units, 19,884,227 Cibus Series E Preferred Units, 26,485,598 Cibus Series F Preferred Units, 0 voting common units and
63,903,905 <FONT STYLE="white-space:nowrap">non-voting</FONT> common units issued and outstanding.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">per share, consisting of (i) a number of shares of Class&nbsp;A Common Stock equal to (A) if the Subsequent Reverse Stock Split has not occurred, 1,050,000,000, and (B) if the Subsequent Reverse Stock Split has occurred,
1,050,000,000 divided by the Subsequent Reverse Stock Split Factor, rounded up to the nearest whole number, and (ii) a number of shares of Class&nbsp;B Common Stock equal to (A) if the Subsequent Reverse Stock Split has not occurred, 450,000,000,
and (B) if the Subsequent Reverse Stock Split has occurred, 450,000,000 divided by the Subsequent Reverse Stock Split Factor, rounded up to the nearest whole number, and (2) a number of shares of preferred stock equal to (A) if the Subsequent
Reverse Stock Split has not occurred, 50,000,000, and (B) if the Subsequent Reverse Stock Split has occurred, 50,000,000 divided by the Subsequent Reverse Stock Split Factor, rounded up to the nearest whole number, par value $0.0001 per
share.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" ALIGN="center"><B>Number and Qualification of Directors</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Calyxt Certificate of Incorporation and Calyxt Bylaws, subject to the rights of the holders of any series of Calyxt preferred stock,
provide that the Calyxt Board shall consist of no less than five and no more than eleven members.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Under the Stockholder&#146;s Agreement, so long as Cellectis and its affiliates beneficially own at least 15% of the then outstanding shares of Calyxt Common
Stock, Cellectis has the right to nominate a number of</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">The Cibus Board shall consist of between one and 14 members. The number of directors may be increased by a vote of the Cibus Board. The members of the Cibus Board shall be appointed as follows: (i)&nbsp;each of (a)&nbsp;the Cibus
Board; (b)&nbsp;Rory Riggs, (c)&nbsp;Jean Pierre Lehmann, and (d)&nbsp;Blocker 1 (collectively, the &#147;Major Members&#148;) is entitled to appoint one member to the Cibus Board (each a &#147;Major Director&#148;); (ii) the remaining members of
the Cibus</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">The Amended Certificate of Incorporation, subject to the rights of the holders of any series of Cibus, Inc. preferred stock, provides that the Cibus, Inc. Board shall initially consist of six members and thereafter will be fixed
from time to time by resolution of the Cibus, Inc. Board.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">340 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Pre-Merger</FONT>
Calyxt, Inc.</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Common Stock)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Pre-Merger</FONT> Cibus
Global, LLC<BR>(Common and Preferred Units)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Cibus, Inc. (Post-Mergers)</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" ALIGN="center"><B>Structure, Term and Election of Board of Directors</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">designees to the Calyxt Board equal to the greater of (i)&nbsp;three designees and (ii)&nbsp;the majority of directors. If at any time the
total number of Cellectis designees on the Calyxt Board is fewer than total number of designees Calyxt is entitled to, then Cellectis may, at any time, nominate additional nominees, and (A)&nbsp;increase the size of the Calyxt Board to enable
Cellectis to nominate such additional designees and (B)&nbsp;appoint additional nominees to such newly created directorships. So long as Cellectis beneficially owns at least 15% of the then outstanding shares of Calyxt Common Stock, the size of the
Calyxt Board may not be changed without Cellectis&#146; prior approval.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The Calyxt
Certificate of Incorporation and the Calyxt Bylaws provide for the division of the Calyxt Board into three staggered classes, each consisting of as close to <FONT STYLE="white-space:nowrap">one-third</FONT> of the entire Calyxt Board as possible.
Each director shall serve for a term ending on the date of the third annual meeting of stockholders following the annual meeting of stockholders at which such director was elected, provided, however, that the term of each director shall continue
until the election and qualification of such director&#146;s successor and be subject to such director&#146;s earlier death, resignation or removal.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Board will be appointed (the &#147;Designated Directors&#148;) by a resolution of the holders of more than 50% of Cibus Global&#146;s
preferred stock and voting common units (a &#147;Resolution of Members&#148;).</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Cibus Operating Agreement, each Major Director shall serve for the term fixed by such director&#146;s nominating Major Member, and each
Designated Director will serve for the term fixed by the applicable Resolution of Members. If no term is fixed upon the appointment of a director, such director shall serve until the earlier of such director&#146;s death, resignation or
removal.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Amended Certificate of Incorporation, subject to the rights of the holders of any series of Cibus, Inc. preferred stock, each
director on the Cibus, Inc. Board shall be elected annually at each annual meeting of the Cibus, Inc. stockholders for <FONT STYLE="white-space:nowrap">one-year</FONT> terms expiring at the next succeeding annual meeting. Each director shall hold
office until such director&#146;s successor shall have been duly elected and qualified or until such director&#146;s death, resignation or removal.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Amended Bylaws, subject to the rights of the holders of any series of Cibus, Inc. preferred stock, each director to be elected by the
stockholders shall be elected by the majority of the votes cast by stockholders, provided, that if the number of nominees for election at any such meeting is determined by the Cibus, Inc. secretary, as of the date that is ten days prior to the
scheduled mailing date of the proxy statement for such meeting, to exceed the number of directors to be elected at such meeting, each director to be so elected shall be elected by a plurality of the votes cast by stockholders at such meeting. If
directors are to be elected by a plurality of votes cast, stockholders shall not be permitted to vote against a nominee.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" ALIGN="center"><B>Removal of Directors</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Under the Calyxt Certificate of Incorporation, any or all members of the Calyxt Board may be removed for cause by a majority vote of the shares then entitled to vote generally in the</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">A Major Director may be removed from office without or without cause, (i)&nbsp;upon the unanimous approval of all Major Members other than the Major Member who appointed such Major Director,</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Under the Amended Bylaws, subject to the rights of the holders of any series of Cibus, Inc. preferred stock, any or all members of the Cibus, Inc. Board may be removed, with or without cause,
by</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">341 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Pre-Merger</FONT>
Calyxt, Inc.</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Common Stock)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Pre-Merger</FONT> Cibus
Global, LLC<BR>(Common and Preferred Units)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Cibus, Inc. (Post-Mergers)</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">election of directors, voting together as a single class.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Subject to Cellectis&#146; rights to nominate directors to the Calyxt Board, any Cellectis nominee to the Calyxt Board may be removed (with or without cause)
by Cellectis at any time upon notice to Calyxt, and may otherwise only be removed for cause.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(ii)&nbsp;by the Major Member who appointed such Major Director, or (iii)&nbsp;automatically upon the Major Member who appointed such Major Director no longer being a Major Member. A Designated Director may be removed with or
without cause upon a Resolution of Members or upon the affirmative vote of the majority of directors present and entitled to vote.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">a majority vote of the shares then entitled to vote generally in the election of directors.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" ALIGN="center"><B>Director Action by Written Consent</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Calyxt Bylaws provide that any action required or permitted to be taken at any meeting of the Calyxt Board or any committee thereof, may be taken without a meeting, if a written consent to such action is signed by all members of
the Calyxt Board or of such committee, as the case may be, and such written consent is filed with the minutes of proceedings of the Calyxt Board or committee, as applicable.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Cibus Operating Agreement provides that any action of the Cibus Board may be taken without a meeting, if a written consent to such action
is signed by the number of directors required to authorize such action at a meeting of the Cibus Board at which the directors entitled to vote thereon were present and voted.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The Cibus Operating Agreement provides that the Cibus Board may not take the following
actions without a Resolution of Members: (i)&nbsp;create or designate additional classes or series of units; (ii)&nbsp;increase in the authorized number of any class or series of unit; (iii)&nbsp;undertake any merger, consolidation, or sale of all
or substantially all assets of Cibus Global; (iv)&nbsp;cause any unit split, dividend, recapitalization, reconstitution or reorganization of Cibus Global; (v)&nbsp;authorize any distributions to members other than as provided for the Cibus Operating
Agreement, (vi)&nbsp;file a bankruptcy petition on behalf of Cibus Global, (vii)&nbsp;dissolve or liquidate the company, (viii)&nbsp;continue to operate the company after dissolution thereof; (ix)&nbsp;cause any voluntary change of tax status or
elections; or (x)&nbsp;change the nature of Cibus Global&#146;s business.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">The Amended Certificate of Incorporation and the Amended Bylaws do not explicitly provide for director action by written consent. Under the DGCL, any action required or permitted to be taken at any meeting of the board of directors
or any committee thereof, may be taken without a meeting, if a written consent to such action is signed by all members of the board of directors or of such committee, as the case may be, and such written consent is filed with the minutes of
proceedings of the board of directors or committee, as applicable.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">342 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Pre-Merger</FONT>
Calyxt, Inc.</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Common Stock)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Pre-Merger</FONT> Cibus
Global, LLC<BR>(Common and Preferred Units)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Cibus, Inc. (Post-Mergers)</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" ALIGN="center"><B>Special Meetings of the Board of Directors</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Calyxt Bylaws provide that special meetings of the Calyxt Board may be called by the Chief Executive Officer of Calyxt, the Chairman of the Calyxt Board or at the request in writing of at least two members of the Calyxt Board.
Notice of the time and place of all special meetings of the Calyxt Board shall be given to each director at least 24 hours before the date and time of the meeting.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">The Cibus Operating Agreement provides that a meeting of the Cibus Board may be called at any time and for any purpose by any member thereof. Notice of the time and place of such meeting shall be given via overnight delivery, or
electronic delivery, to each member of the Cibus Board entitled to vote thereat, not fewer than 48 hours and not more than 30 days prior to the meeting.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">The Amended Bylaws provide that special meetings of the Cibus, Inc. Board may be called by the Chair of the Cibus, Inc. Board on one day&#146;s prior notice.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" ALIGN="center"><B>Cumulative Voting</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Calyxt Certificate of Incorporation provides that there will be no cumulative voting in the election of directors.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">The Cibus Operating Agreement does not provide for cumulative voting in the election of directors.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">The Amended Certificate of Incorporation provides that there will be no cumulative voting in the election of directors.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" ALIGN="center"><B>Vacancies on the Board of Directors</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Calyxt Certificate of Incorporation and the Calyxt Bylaws provide that any vacancy occurring on the Calyxt Board shall be filled only by vote of a majority of the directors then in office, even if less than a quorum, or by a
sole remaining director. A director elected to fill a vacancy shall hold office until the next election of the class for which such director shall have been chosen.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Following the removal of a Major Director (other than in the case of an IPO or if such Major Director&#146;s nominating Major Member is no longer a Major Member), a replacement for such Major Director will be appointed by such
director&#146;s Major Member. Following the removal of a Designated Director, or a Major Director whose removal is due to an initial public offering or because such director&#146;s Major Member is no longer a Major Member, a replacement director
will be appointed by a Resolution of Members.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">The Amended Certificate of Incorporation and Amended Bylaws provide that, subject to the rights of the holders of any series of Cibus, Inc. preferred stock, any vacancy occurring on the Cibus, Inc. Board shall be filled only by vote
of a majority of the directors then in office, even if less than a quorum, or by a sole remaining director. Notwithstanding the foregoing, the Cibus, Inc. Board may determine by resolution that any vacancy or newly created directorship shall be
filled by the stockholders. A director elected to fill a vacancy shall hold office until the next election of directors.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" ALIGN="center"><B>Voting Stock</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Under the Calyxt Bylaws, each stockholder shall, at every meeting of the stockholders, be entitled to one vote for each share of stock held by such stockholder.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Under the Cibus Operating Agreement (i)&nbsp;each preferred unit shall entitle its holder to cast one vote at meetings of the Cibus Unitholders (or in written consents</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Under the Amended Certificate of Incorporation, each holder of Class&nbsp;A Common Stock and Class&nbsp;B Common Stock will be entitled to one vote for each share</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">343 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Pre-Merger</FONT>
Calyxt, Inc.</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Common Stock)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Pre-Merger</FONT> Cibus
Global, LLC<BR>(Common and Preferred Units)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Cibus, Inc. (Post-Mergers)</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">in lieu of meetings) on matters upon which holders of preferred units are entitled to vote and (ii)&nbsp;each voting common unit shall entitle its holder to cast one vote at meetings of the Cibus Unitholders (or in written consents
in lieu of meetings) on matters upon which holders of voting common units are entitled to vote. The <FONT STYLE="white-space:nowrap">non-voting</FONT> common units are <FONT STYLE="white-space:nowrap">non-voting</FONT> in all respects.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">held on all matters which stockholders generally are entitled to vote.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as otherwise noted below, the holders of Cibus, Inc. common stock shall vote
together as a single class on all matters.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of Class&nbsp;A Common Stock are
entitled to vote separately on any amendment to the Amended Certificate of Incorporation that would alter or change the powers, preferences or special rights of Class&nbsp;A Common Stock in a manner that is materially and disproportionately adverse
as compared to Class&nbsp;B Common Stock.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Holders of Class&nbsp;B Common Stock are
entitled to vote separately on: (i)&nbsp;any amendment to the Amended Certificate of Incorporation that would alter or change the powers, preferences or special rights of Class&nbsp;B Common Stock in a manner that is materially and
disproportionately adverse as compared to Class&nbsp;A Common Stock; (ii)&nbsp;merger, consolidation or other transactions intended to result in the Combined Company no longer being structured as an umbrella partnership C corporation; and
(iii)&nbsp;an amendment to the Amended Certificate of Incorporation to effect a transaction described in clause&nbsp;(ii).</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" ALIGN="center"><B>Quorum at Stockholder / Unitholder Meetings</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Calyxt Bylaws provide that the presence, in person or by proxy, of the holders of a majority of the then outstanding capital stock of Calyxt entitled to vote at a meeting of stockholders shall constitute a</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">The Cibus Operating Agreement provides that the presence in person or via electronic communication, including by proxy, of such unitholders holding a majority of the units then entitled to vote at a meeting of unitholders shall</TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">The Amended Bylaws provide that the presence, in person or by proxy, of the holders of a majority of the then outstanding capital stock of Cibus, Inc. entitled to vote at a meeting of stockholders
shall</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">344 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Pre-Merger</FONT>
Calyxt, Inc.</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Common Stock)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Pre-Merger</FONT> Cibus
Global, LLC<BR>(Common and Preferred Units)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Cibus, Inc. (Post-Mergers)</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">quorum for the transaction of business.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">constitute a quorum for the transaction of business.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">constitute a quorum for the transaction of business.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" ALIGN="center"><B>Stockholder / Unitholder Action by Written Consent</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Calyxt Certificate of Incorporation and the Calyxt Bylaws provide that stockholders may not take any action by written consent in lieu of a meeting.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Cibus Operating Agreement, any action of Cibus Unitholders may be taken without a meeting, without prior notice and without a vote,
if a consent in writing, setting forth the action to be taken, is signed by the unitholders holding the majority of units entitled to vote thereon.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Certain actions of Cibus Global, including but not limited to (i)&nbsp;any amendment of the Cibus Operating Agreement that changes the terms of the Cibus
Series F Preferred Units, (ii)&nbsp;any change in tax status or election of Cibus Global, (iii)&nbsp;any sale or merger of Cibus, or (iv)&nbsp;any increase or decrease in the number of authorized Cibus Series F Preferred Units, require the
affirmative vote of the holders of a majority of the issued and outstanding Cibus Series F Preferred Units.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">The Amended Certificate of Incorporation provides that stockholders may not take any action by written consent in lieu of a meeting, except that the holders of Class&nbsp;B Common Stock may take any action by written consent in lieu
of a meeting where such action is required or permitted to be taking by the holders of Class&nbsp;B Common Stock, voting separately as a class, if consented to in writing by holders of a majority of the total voting power of Class&nbsp;B Common
Stock.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" ALIGN="center"><B>Notice of Stockholder / Unitholder Meeting</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Under the Calyxt Bylaws, notice of each stockholder meeting must specify the place, if any, date and time thereof and the means of remote communications, if any, by which stockholders and proxyholders may be deemed to be present in
person and vote at such meeting, the record date for determining stockholders entitled to vote at such meeting, if the record date is different from the record date for determining stockholders entitled to notice of the meeting and, in the case of a
special meeting, the purpose(s) for which the meeting is called. Notice shall be given not less than 10 days nor more than 60 days prior to the date of the</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Under the Cibus Operating Agreement, notice of the date and place of each meeting of Cibus Unitholders shall be sent via overnight or first class mail to each unitholder then entitled to vote, not fewer than 10 days and not more
than 30 days prior to the meeting.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Under the Amended Bylaws, notice of a stockholder meeting must state the place, if any, date and time thereof and the means of remote communications, if any, by which stockholders and proxyholders may be deemed to be present in
person and vote at such meeting, and in the case of a special meeting, the purpose(s) for which the meeting is called. Notice shall be given not less than 10 days nor more than 60 days prior to the date of the meeting to each stockholder entitled to
vote at such meeting.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">345 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Pre-Merger</FONT>
Calyxt, Inc.</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Common Stock)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Pre-Merger</FONT> Cibus
Global, LLC<BR>(Common and Preferred Units)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Cibus, Inc. (Post-Mergers)</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">meeting to each stockholder entitled to vote at such meeting. Without limiting the manner by which notice otherwise may be given to stockholders, any notice shall be effective if given by a form of electronic transmission consented
to (in a manner consistent with the DGCL) by the stockholder to whom the notice is given.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" ALIGN="center"><B>Special Stockholder / Unitholder Meetings</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Calyxt Certificate of Incorporation and the Calyxt Bylaws provide that a special meeting of stockholders may be called only by the affirmative vote of the majority of the members of the Calyxt Board, and may not be called by any
other person or persons.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">The Cibus Operating Agreement provides that a special meeting of the Cibus Unitholders may be called by the Major Members.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">The Amended Certificate of Incorporation and Amended Bylaws provide that, subject to the rights of the holders of any series of Cibus, Inc. preferred stock, a special meeting of the Cibus, Inc. stockholders may be called by only
(i)&nbsp;the Chair of the Cibus, Inc. Board, (ii)&nbsp;the Chief Executive Officer of Cibus, Inc., or (iii)&nbsp;at the direction of the Cibus, Inc. Board pursuant to a written resolution adopted by a majority of the total number of directors that
Cibus, Inc. would have if there were no vacancies. Cibus, Inc. stockholders are not permitted to call special meetings of the stockholders.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" ALIGN="center"><B>Stockholder / Unitholder Nominations and Proposals</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Calyxt Bylaws provide that nominations of any person for election to the Calyxt Board or the proposal of other business to be transacted
at an annual meeting may be made (i)&nbsp;pursuant to Calyxt&#146;s notice of meeting, (ii)&nbsp;by the Calyxt Board, or (iii)&nbsp;by any Calyxt Stockholder who is entitled to vote at the meeting and who timely complies with the notice procedures
set forth below.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The Calyxt Bylaws further provide that a stockholder&#146;s notice
must be received in writing by Calyxt&#146;s secretary at Calyxt&#146;s principal</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">The Cibus Operating Agreement does not contain advance notice requirements for unitholder proposals.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">The Amended Bylaws provide that at an annual meeting of Cibus, Inc. stockholders, no business shall be conducted which has not been properly brought before the meeting. To be properly brought before a meeting, business must
(i)&nbsp;be brought before the meeting by or at direction of the Cibus, Inc. Board, (ii)&nbsp;otherwise be properly brought by a stockholder who (a)&nbsp;has complied with the requirements for bringing proposals in the Amended Bylaws, (b)&nbsp;was a
stockholder of record at the time of giving the notice and at the</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">346 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Pre-Merger</FONT>
Calyxt, Inc.</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Common Stock)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Pre-Merger</FONT> Cibus
Global, LLC<BR>(Common and Preferred Units)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Cibus, Inc. (Post-Mergers)</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">executive offices not less 90 days nor more than 120 days prior to the first anniversary of the preceding year&#146;s annual meeting, and no later than the later of 70 days prior to the date of the meeting or 10 days following the
date of the public announcement of the date of the meeting first made by Calyxt.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">stockholder meeting, and (c)&nbsp;is entitled to vote at the annual meeting of stockholders, or (iii)&nbsp;relate to an item of business that
is a proper subject to stockholder action under applicable law.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">To be in proper
form, a stockholder&#146;s notice must set forth in writing certain information, including information regarding (1)&nbsp;the proposing stockholder and number and types of shares owned by such stockholder, (2)&nbsp;any material interests of such
stockholder in connection with the proposal or nomination and (3)&nbsp;in the case of nomination of a director, certain information regarding the nominee and the number and types of shares owned by the nominee. Further, Cibus, Inc. may require the
stockholder and its nominees, as applicable, to furnish additional information upon request. Pursuant to the Amended Bylaws, for each person whom a stockholder giving notice proposes to nominate for election as a director, such notice must include,
among other things, (A)&nbsp;a completed questionnaire with respect to the identity, background and qualification of the proposed nominee and (B)&nbsp;a written representation and agreement that such nominee is qualified and intends to serve as a
director for a full term if elected, will not enter into certain types of agreements in connection with Cibus, Inc. and if elected, will comply with all corporate governance, ethics, conflict of interest, confidentiality and stock ownership and
trading policies and guidelines of Cibus, Inc.</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">347 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Pre-Merger</FONT>
Calyxt, Inc.</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Common Stock)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Pre-Merger</FONT> Cibus
Global, LLC<BR>(Common and Preferred Units)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Cibus, Inc. (Post-Mergers)</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Amended Bylaws, for a stockholders&#146; notice to be
timely, such notice must be delivered to the Cibus, Inc. secretary not less than 90 nor more than 120 calendar days prior to the first anniversary of the date on which Cibus, Inc. held the preceding year&#146;s annual meeting of the stockholders,
provided, however, that if the date of the annual meeting is scheduled for a date more than 30 calendar days prior to or more than 30 calendar days after the anniversary of the preceding year&#146;s annual meeting, notice by the stockholder to be
timely, must be delivered not later than the close of business of the later of the 90<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> calendar prior to such annual meeting and the 10<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>
calendar day following the day on which public disclosure of the date of such meeting is first made.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The presiding officer of any annual meeting shall, if the facts warrant, determine that a proposal or nomination was not properly brought before the meeting in
accordance with the provisions of the Amended Bylaws, and such proposal or nomination will be disregarded.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" ALIGN="center"><B>Forum Selection</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Calyxt Certificate of Incorporation provides that unless Calyxt consents in writing to the selection of an alternative forum, the Court of Chancery in the State of Delaware shall be the sole and exclusive forum for any
stockholder to bring (i)&nbsp;any derivative action or proceeding brought on behalf of Calyxt, (ii)&nbsp;any action asserting a claim of breach of fiduciary duty owed by any director, officer or other employee of Calyxt to Calyxt or</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">The Cibus Operating Agreement does not provide for a specific forum.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">The Amended Certificate of Incorporation provides that unless Cibus, Inc. consents in writing to the selection of an alternative forum, the Court of Chancery in the State of Delaware shall be the sole and exclusive forum for any
stockholder to bring (i)&nbsp;any derivative action or proceeding brought on behalf of Cibus, Inc., (ii) any action asserting a claim of breach of fiduciary duty owed by any director, officer or
other</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">348 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Pre-Merger</FONT>
Calyxt, Inc.</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Common Stock)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Pre-Merger</FONT> Cibus
Global, LLC<BR>(Common and Preferred Units)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Cibus, Inc. (Post-Mergers)</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Calyxt Stockholders, (iii)&nbsp;any action asserting a claim against Calyxt, its directors, officers or employees arising pursuant to any provision of the DGCL, the Calyxt Certificate of Incorporation or the Calyxt Bylaws, or
(iv)&nbsp;any action asserting a claim against Calyxt, its directors, officers or employees governed by the internal affairs doctrine.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">employee of Cibus, Inc. to Cibus, Inc. or its stockholders, (iii)&nbsp;any action asserting a claim against Cibus, Inc., its directors, officers or employees arising pursuant to any provision of the DGCL, the Amended Certificate of
Incorporation or the Amended Bylaws, or (iv)&nbsp;any action asserting a claim against Cibus, Inc., its directors, officers or employees governed by the internal affairs doctrine.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" ALIGN="center"><B>Registration Rights</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Under the Stockholders Agreement, Cellectis has certain registration rights, including the right to demand that Calyxt file a registration statement, or request that their shares be covered by a registration statement that Calyxt is
otherwise filing.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Under Cibus&#146; Fourth Amended and Restated Registration Rights Agreement, the holders of at least 25% of Cibus Global&#146;s issued and outstanding units, acting together, have certain registration rights, including the right to
demand that Cibus Global file a registration statement, or request that their shares be covered by a registration statement that Cibus Global is otherwise filing.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Under the Registration Rights Agreement, only holders of <FONT STYLE="white-space:nowrap">Up-C</FONT> Units have registration rights, pursuant to the terms and subject to the conditions set forth therein. The Amended Certificate of
Incorporation and the Amended Bylaws do not otherwise provide that Cibus, Inc. stockholders have registration rights.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" ALIGN="center"><B>Dividends, Distributions and Stock Repurchases</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Calyxt Bylaws provide that except as otherwise provided by law or the Calyxt Certificate of Incorporation, the Calyxt Board may from time
to time declare and pay dividends upon the shares of Calyxt&#146;s capital stock, which dividends may be paid in either cash, property or shares of stock of Calyxt.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Stockholders Agreement, so long as Cellectis and its affiliates beneficially owns at least 15% of the then outstanding shares of Calyxt Common
Stock, Calyxt may only declare dividends on Calyxt Common Stock with Cellectis&#146; prior approval.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Cibus Operating Agreement, the Cibus Board may, in its sole discretion, declare certain amounts for distribution to Cibus
Unitholders on a quarterly basis, after taking into account reserves for actual or anticipated liabilities, working capital and capital spending plans. Distributions to Cibus Unitholders shall be made in the order set forth in Section&nbsp;5.4.1 of
the Cibus Operating Agreement.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Upon the termination of the service of any employee
or other agent of Cibus Global who owns voting or <FONT STYLE="white-space:nowrap">non-voting</FONT> common units, Cibus Global shall have the option, at</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Amended Certificate of Incorporation provides that, subject to applicable law and rights, if any of holders of Cibus, Inc. preferred
stock, the Cibus, Inc. Board may from time to time declare and pay dividends upon the shares of Class&nbsp;A Common Stock, which dividends may be paid in either cash, property or shares of stock of Cibus, Inc. Except as provided below, dividends of
cash or property may not be declared or paid on shares of Class&nbsp;B Common Stock.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The Cibus, Inc. Board may not declare or make any stock dividend, stock split, reverse stock</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">349 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Pre-Merger</FONT>
Calyxt, Inc.</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Common Stock)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Pre-Merger</FONT> Cibus
Global, LLC<BR>(Common and Preferred Units)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Cibus, Inc. (Post-Mergers)</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Cibus Board&#146;s discretion, within 90 days of such termination, to purchase any or all of such individual&#146;s <FONT STYLE="white-space:nowrap">non-voting</FONT> common units or voting common units or preferred units issued
upon conversion of such <FONT STYLE="white-space:nowrap">non-voting</FONT> common units. The purchase price for any such units shall be the fair market value of the units on the date of the termination.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">split, combination of stock, reclassification or recapitalization on any class of Common Stock (each, a &#147;Stock Adjustment&#148;) unless (i)&nbsp;a corresponding Stock Adjustment for all other classes of Cibus, Inc. common stock
not so adjusted at the time outstanding is made in the same proportion and the same manner and (ii)&nbsp;the Stock Adjustment has been reflected in the same economically equivalent manner on all Cibus, Inc. common stock. Stock dividends with respect
to each class of Cibus, Inc. common stock may only be paid with shares of stock of the same class of Cibus, Inc. common stock.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" ALIGN="center"><B>Liquidation</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Calyxt Certificate of Incorporation and the Calyxt Bylaws do not provide for required actions upon liquidation of the company.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">The Cibus Board may not cause the dissolution of the company or adopt a plan of liquidation without a Resolution of Members. In the event of a dissolution of Cibus Global, the proceeds of the liquidation shall be distributed in the
following order of priority: (i)&nbsp;to creditors of Cibus Global, whether or not they are unitholders thereof; (ii)&nbsp;to the setting up of any reserves that the Cibus Board may deem reasonably necessary for any contingent or unforeseen
liabilities of the company; and (iii)&nbsp;to the Cibus Unitholders in the same order as set forth for distributions to the Cibus Unitholders.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Under the Amended Certificate of Incorporation, in the event of any voluntary or involuntary liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> of Cibus, Inc.&#146;s affairs, after the payment of debts
and other liabilities including rights of holders of preferred stock, if any, the holders of Class&nbsp;A Common Stock will be entitled to receive an amount per share equal to the par value thereof, and thereafter the holders of Class&nbsp;A Common
Stock shall be entitled to receive the remaining assets of Cibus, Inc. available for distribution ratably in proportion to the number of shares of Class&nbsp;A Common Stock. The holders of Class&nbsp;B Common Stock shall not be entitled to receive,
with respect to such shares, any assets of Cibus, Inc. in excess of the par value thereof, in the event of any voluntary or involuntary dissolution or liquidation of Cibus, Inc.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">350 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Pre-Merger</FONT>
Calyxt, Inc.</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Common Stock)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Pre-Merger</FONT> Cibus
Global, LLC<BR>(Common and Preferred Units)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Cibus, Inc. (Post-Mergers)</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" ALIGN="center"><B>Amendment to Governing Documents</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Calyxt may amend the Calyxt Certificate of Incorporation, provided that, Articles 5 (Board of Directors), 6 (Stockholders), 7 (Limitations on
Liability and Indemnification), 8 (Corporate Opportunities), 9 (Exclusive Jurisdiction), 10 (Miscellaneous) and 11 (Amendment of Certificate of Incorporation) may not be amended or repealed in any respect, and no other provision may be adopted,
amended or repealed which would have the effect of modifying the foregoing articles, without the affirmative vote of the holders of not less than 66 2/23% of the total voting power of all outstanding securities of Calyxt generally entitled to vote
in the election of directors, voting together as a single class.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Calyxt Board
or not less than 66 2/3% of the holders of then-outstanding Calyxt Common Stock entitled to vote thereon at any annual or special meeting of stockholders, may alter, amend, or repeal the Calyxt Bylaws, or create new bylaws.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Stockholders Agreement, so long as Cellectis beneficially owns at least
15% of the then outstanding shares of Calyxt Common Stock, Cellectis&#146; prior approval is required for any amendment to Calyxt&#146;s governing documents that would change Calyxt&#146;s name, jurisdiction of incorporation, principal office
location or corporate purpose.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">The Cibus Operating Agreement may only be amended by (i)&nbsp;a Resolution of Members, and (ii)&nbsp;by a resolution of the holders of more than 50% of Cibus Global&#146;s preferred units, provided, however, that (a)&nbsp;prior to
the effective date of a registration statement for Cibus Global&#146;s securities, no amendment to the Cibus Operating Agreement shall adversely affect the Major Members without by a resolution of more than 50% of the Major Members,
(b)&nbsp;provided, further, that so long as 10% of the applicable series of preferred units are issued and outstanding, no amendment shall be made with respect to such series without a resolution of more than 50% of the holders of such series and
(c)&nbsp;provided, further, that certain definitions cannot be amended without the consent of the parties to whom such definitions relate. The foregoing restrictions do not apply to ministerial or clerical corrections, or changes that the Cibus
Board, in good faith, deems reasonably appropriate or necessary to comply with governmental or tax authorities.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Amended Certificate of Incorporation, holders of Cibus, Inc. common stock shall have no voting power with respect to any amendment
to the Amended Certificate of Incorporation that relates solely to the terms of any preferred stock.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Amended Certificate of Incorporation, the Cibus, Inc. Board shall have the power, without stockholder approval, to adopt, alter, amend, change
or repeal the Amended Bylaws by affirmative vote of the majority of directors then in office. Additionally, Cibus, Inc. shall have the power to amend, alter, change, or repeal any provision of the Amended Certificate of Incorporation at any
time.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" ALIGN="center"><B>Stockholder / Unitholder Agreement</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Pursuant to the Stockholders Agreement, Cellectis has certain rights for so long as it beneficially owns at least 15% of the then outstanding shares of Calyxt</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Cibus Global does not currently have a unitholder agreement in place. Applicable provisions are described elsewhere herein to the</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Cibus, Inc. does not intend to have a stockholders agreement in place.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">351 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Pre-Merger</FONT>
Calyxt, Inc.</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Common Stock)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Pre-Merger</FONT> Cibus
Global, LLC<BR>(Common and Preferred Units)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Cibus, Inc. (Post-Mergers)</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Common Stock, including certain board nomination and designation rights, the right to approve amendments to the Calyxt Certificate of Incorporation and Calyxt Bylaws, the right to approve the payment of any regular or special
dividends, the right to approve any public or private offering, merger, amalgamation or consolidation or any sale, conveyance, transfer or disposition of Calyxt&#146;s assets, and to approve any appointment to or removal from the Calyxt Board.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">extent they are incorporated into the Cibus Operating Agreement.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" ALIGN="center"><B>Indemnification; Limitation of Liability</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Calyxt Certificate of Incorporation provides that Calyxt shall indemnify its directors for monetary damages for breach of fiduciary duties as a director to the fullest extent of Delaware Law. The Calyxt Certificate of
Incorporation further provides that Calyxt shall indemnify its directors and officers, provided, that Calyxt will not indemnify its directors and officers with respect to a proceeding (or part thereof) initiated by such director or officer, unless
the Calyxt Board approved such proceeding.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as otherwise provided by Delaware Law, no Cibus Unitholder shall, pursuant to the Cibus Operating Agreement, (i)&nbsp;be personally
liable for any debt, liability or other obligation of Cibus Global, (ii)&nbsp;have any liability in excess of (a)&nbsp;the amount of capital contributions of such unitholder, (b)&nbsp;its share of assets and undistributed profits of Cibus Global, if
any, and (c)&nbsp;the amount of any wrongful distribution to such unitholder, only if and to the extent that such unitholder had actual knowledge at the time of the distribution that such distribution was made in violation of the DGCL.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The Cibus Operating Agreements provides that no Cibus Unitholder or director shall be
liable to Cibus or any other unitholder for any loss or damage sustained by Cibus Global or a Cibus Unitholder, unless the loss or damage is the result of fraud, intentional or reckless misconduct, or knowing violation of law by such individual.
Further, no Cibus Unitholder or director shall be liable to Cibus Global or any other unitholder for</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Amended Certificate of Incorporation provides that Cibus, Inc. shall indemnify its directors and officers for monetary damages for breach
of fiduciary duties as a director or officer thereof. Notwithstanding the preceding sentence, a director or officer of Cibus, Inc. shall be liable to the extent provided by applicable law, (i)&nbsp;with respect to any officer or director,
(a)&nbsp;for any breach of such director&#146;s or officer&#146;s duty of loyalty to Cibus, Inc. or its stockholders, (b)&nbsp;for acts and omissions not in good faith or which involve intentional misconduct or knowing violations of law, or
(c)&nbsp;any transaction from which such director or officer derived an improper personal benefit, (ii)&nbsp;with respect to any director, pursuant to Section&nbsp;102(b)(7) of the DGCL, and (iii)&nbsp;with respect to any officer in any action by or
in the right of Cibus, Inc.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The Amended Certificate of Incorporation further
provides that Cibus, Inc. shall indemnify any person who was or is a party or is threatened to be made a party to,</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">352 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Pre-Merger</FONT>
Calyxt, Inc.</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Common Stock)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Pre-Merger</FONT> Cibus
Global, LLC<BR>(Common and Preferred Units)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Cibus, Inc. (Post-Mergers)</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">any act performed in good faith in connection with Cibus Global&#146;s affairs.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The Cibus Operating Agreement further provides that to the fullest extent of Delaware
Law, Cibus Global will pay the expenses incurred directors and Cibus Unitholders, for monetary damages arising from or in connection with any action or omitted action undertaken by the aforementioned individuals in connection with Cibus
Global&#146;s affairs, provided, however, such individual shall repay Cibus Global such amounts as are determined to be attributable to actions taken by such individuals in bad faith.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">any threatened, action, suit or proceeding, whether civil, criminal, administrative, or investigative by reason of the fact that he or she is
or was a director or officer of Cibus, Inc., or is or was serving at the request of Cibus, Inc. as a director, officer, employee or agent of another company, partnership, joint venture, trust or other</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">enterprise, including with respect to an employee benefit plan, whether the basis of such proceeding is alleged action in an official capacity as director,
officer, employee or agent, or in any other capacity while serving as a director, officer, employee or agent, to the fullest extent provided by the DGCL against expenses (including attorneys&#146; fees, judgments, fines, Employee Retirement
Income</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Security Act excise taxes or penalties and amounts paid or to be paid in settlement) actually and reasonably incurred by him or her in connection
with such action, suit or proceeding. Cibus, Inc. will not indemnify its directors and officers with respect to a proceeding (or part thereof) initiated by such director or officer (other than proceedings initiated to enforce such person&#146;s
rights to indemnification), unless the Cibus, Inc. Board approved such proceeding or indemnification is otherwise required by the DGCL.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The Amended Certificate of Incorporation provides that expenses (including attorneys&#146; fees) incurred by a Cibus, Inc. officer or director in defending or
settling any civil, criminal, administrative or investigative action, suit or proceeding shall be paid by Cibus, Inc. in advance of the final disposition of such action,</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">353 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Pre-Merger</FONT>
Calyxt, Inc.</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Common Stock)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Pre-Merger</FONT> Cibus
Global, LLC<BR>(Common and Preferred Units)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Cibus, Inc. (Post-Mergers)</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">suit or proceeding upon receipt of an undertaking by or on behalf of such director or officer to repay such amount if it shall ultimately be determined that he is not entitled to be indemnified by Cibus, Inc. as authorized in this
provision.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" ALIGN="center"><B>Preemptive Rights</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Calyxt Certificate of Incorporation and the Calyxt Bylaws do not provide that Calyxt Stockholders have preemptive rights.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">The Cibus Operating Agreement provides that in the event that Cibus Global or its subsidiaries propose to issue new or additional membership units, subject to certain exclusions, the Cibus Board must first give written notice of the
offering to certain holders of preferred units and the opportunity to participate in such offering.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">The Amended Certificate of Incorporation and the Amended Bylaws do not provide that Cibus, Inc. stockholders have preemptive rights.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" ALIGN="center"><B>Conversion of Shares / Units</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Calyxt Certificate of Incorporation and the Calyxt Bylaws do not provide for conversion of Calyxt&#146;s stock.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Pursuant to the Cibus Operating Agreement, upon the resolution of the majority of holders of each of Cibus Series D Preferred Units, Cibus Series E Preferred Units and Cibus Series F Preferred Units, all issued and outstanding Cibus
Preferred Units will automatically be converted into voting common units on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis. Further, prior to the issuance of any distributions to Cibus
Unitholders, any holder of Cibus Preferred Units may convert such units into voting common units on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis. So long as Cibus Preferred Units are
outstanding, Cibus Global may reserve a number of units and keep available out of the authorized but unissued membership units, for the purpose of effecting the conversion of the Cibus Preferred Units in accordance with the foregoing sentences.</TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Pursuant to the Amended Certificate of Incorporation, Cibus, Inc. may at all times reserve and keep available out of its authorized and unissued shares of Class&nbsp;A Common Stock, solely for the purpose of the issuance in
connection with the exchange of the <FONT STYLE="white-space:nowrap">Up-C</FONT> Units, the number of shares of Class&nbsp;A Common Stock that are issuable upon the conversion of the <FONT STYLE="white-space:nowrap">Up-C</FONT>
Units.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">354 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Pre-Merger</FONT>
Calyxt, Inc.</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Common Stock)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Pre-Merger</FONT> Cibus
Global, LLC<BR>(Common and Preferred Units)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Cibus, Inc. (Post-Mergers)</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" ALIGN="center"><B>Rights of First Refusal; <FONT STYLE="white-space:nowrap">Co-Sale</FONT> Rights</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Calyxt Certificate of Incorporation and the Calyxt Bylaws do not provide for any rights of first refusal or <FONT STYLE="white-space:nowrap">co-sale</FONT> rights in connection with Calyxt Common Stock.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a Cibus Unitholder receives a bona fide offer to purchase any or all of such unitholder&#146;s units, such unitholder must first notify
Cibus Global in writing of such unitholder&#146;s intention to sell its units (the &#147;<U>Offer Notice</U>&#148;). The Offer Notice must set forth (i)&nbsp;the number of units being offered to be purchased, (ii)&nbsp;the price at which such units
are being offered, (iii)&nbsp;the identity of the offeror, and (iv)&nbsp;the material terms of such offer. Cibus Global or its assignee may elect to purchase all or part of the units described in the Offer Notice by providing written notice of its
intention to purchase the units (a &#147;<U>Purchase Notice</U>&#148;) within 10 days of receipt of the Offer Notice and under the same terms thereof. Cibus Global is required to complete such purchase within 30 days of sending a Purchase Notice to
the selling Cibus Unitholder. If Cibus Global fails to consummate such purchase, after a period of 120 days following delivery of the Offer Notice, the offering Cibus Unitholder may sell its units to the original offeror.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">If (a)&nbsp;the Cibus Board, (b)&nbsp;the Cibus Unitholders and (c)&nbsp;the holders of
the Cibus Series F Preferred Units, approve any sale of Cibus Global, then Cibus Unitholders must comply with certain requirements in connection with the sale of Cibus Global, including but not limited to, appointing a unitholder representative,
refrain from exercising any dissenters&#146; rights or rights of appraisal, if any, and executing all documentation necessary to support the sale of Cibus Global.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">The Amended Certificate of Incorporation and the Amended Bylaws do not provide for any rights of first refusal or <FONT STYLE="white-space:nowrap">co-sale</FONT> rights in connection with Cibus, Inc. common stock.</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">355 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom401831_58"></A>PRINCIPAL STOCKHOLDERS OF CALYXT, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except where specifically noted, the following information and all of the information in this proxy statement/prospectus does not give effect
to the Reverse Stock Splits. The following table sets forth certain information regarding beneficial ownership of Calyxt Common Stock as of March 31, 2023, for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person whom Calyxt, Inc. knows to own beneficially more than 5% of Calyxt Common Stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each director and named executive officer individually; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all directors and executive officers as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the rules of the SEC, beneficial ownership includes voting or investment power with respect to securities and includes the
shares that may be acquired within 60 days of the date for which information is presented. Shares that may be acquired within 60 days are deemed outstanding for computing the percentage of the person holding such rights but are not outstanding for
purposes of computing the percentage of any other person. The percentage of beneficial ownership for the following table is based on 49,730,657 shares of Calyxt Common Stock outstanding as of March 31, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, the address for each listed director and named executive officer is c/o Calyxt, Inc., 2800 Mount Ridge Road,
Roseville, MN 55113. The address of Cellectis is 8, rue de la Croix Jarry, 75013, Paris, France. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Calyxt Common Stock<BR>Beneficially Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name of Beneficial Owner</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage<BR>of Class</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>5% Beneficial Owners:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cellectis S.A. <SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,963,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Armistice Capital Master Fund Ltd.
<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,760,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Calyxt Common Stock<BR>Beneficially Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name of Beneficial Owner&nbsp;&#134;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<BR>of Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage<BR>of Class</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Directors and Named Executive Officers:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Laurent Arthaud</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Philippe Dumont <SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Jonathan B. Fassberg<SUP STYLE="font-size:75%; vertical-align:top"> (4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60,827</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Anna Ewa Kozicz-Stankiewicz <SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Kimberly K. Nelson <SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Christopher J. Neugent<SUP STYLE="font-size:75%; vertical-align:top"> (7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86,612</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Yves J. Ribeill <SUP STYLE="font-size:75%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">311,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Michael A. Carr <SUP STYLE="font-size:75%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">427,276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">William F. Koschak <SUP STYLE="font-size:75%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">416,938</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Travis J. Frey, Ph.D. <SUP STYLE="font-size:75%; vertical-align:top">(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">312,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Debra Frimerman <SUP STYLE="font-size:75%; vertical-align:top">(12)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">308,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Directors and current executive officers as a group (11&nbsp;persons) <SUP
STYLE="font-size:75%; vertical-align:top">(13)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,135,164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As of March 31, 2023, there were no directors or named executive officers that beneficially owned ordinary
shares of Cellectis S.A. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents beneficial ownerships of less than one percent of Calyxt, Inc.&#146;s outstanding shares of common
stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based upon an Amendment No.&nbsp;6 to Schedule 13D filed by Cellectis with the SEC on January&nbsp;13, 2023, in
which Cellectis reports sole voting power over 23,963,175 shares and sole dispositive power over 23,963,175 shares. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">356 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents 7,760,000 shares underlying Calyxt Common Warrants held by Armistice Capital Master Fund Ltd.
(&#147;Master Fund&#148;) that grant the Master Fund the right to acquire upon exercise of the outstanding Calyxt Common Warrants within 60 days of March&nbsp;31, 2023, which warrants are subject to a beneficial ownership limitation that precludes
the Master Fund from exercising any portion of them to the extent that, following the exercise, the Master Fund&#146;s ownership of Calyxt Common Stock would exceed 9.99% of the total number of Calyxt, Inc. outstanding shares. The reported
securities are directly owned by the Master Fund, a Cayman Islands exempted company, and may be deemed to be indirectly beneficially owned by (i)&nbsp;Armistice Capital, LLC (&#147;Armistice Capital&#148;), as the investment manager of the Master
Fund; and (ii)&nbsp;Steven Boyd, as the Managing Member of Armistice Capital. Each of Armistice Capital and Mr.&nbsp;Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein,
and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section&nbsp;16 of the Exchange Act, or for any other purpose. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 47,898 shares of Calyxt Common Stock that Mr.&nbsp;Dumont has the right to acquire upon the exercise
of stock options within 60 days of March&nbsp;31, 2023. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 38,923 shares of Calyxt Common Stock that Mr.&nbsp;Fassberg has the right to acquire upon the exercise
of stock options within 60 days of March 31, 2023. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 48,743 shares of Calyxt Common Stock that Ms.&nbsp;Kozicz has the right to acquire upon the exercise
of stock options within 60 days of March&nbsp;31, 2023. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 55,981 shares of Calyxt Common Stock that Ms.&nbsp;Nelson has the right to acquire upon the exercise
of stock options within 60 days of March&nbsp;31, 2023. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 44,708 shares of Calyxt Common Stock that Mr.&nbsp;Neugent has the right to acquire upon the exercise
of stock options within 60 days of March&nbsp;31, 2023. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 211,832 shares of Calyxt Common Stock that Dr.&nbsp;Ribeill has the right to acquire upon the exercise
of stock options within 60 days of March&nbsp;31, 2023. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 189,166 shares of Calyxt Common Stock that Mr.&nbsp;Carr has the right to acquire upon the exercise of
stock options within 60 days of March&nbsp;31, 2023. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 270,164 shares of Calyxt Common Stock that Mr.&nbsp;Koschak has the right to acquire upon the exercise
of stock options within 60 days of March 31, 2023. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 191,832 shares of Calyxt Common Stock that Dr.&nbsp;Frey has the right to acquire upon the exercise of
stock options within 60 days of March&nbsp;31, 2023. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 193,832 shares of Calyxt Common Stock that Ms.&nbsp;Frimerman has the right to acquire upon the
exercise of stock options within 60 days of March&nbsp;31, 2023. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Calyxt, Inc. amounts include 1,293,079 shares of Calyxt Common Stock the directors and current executive
officers have the right to acquire upon the exercise of options exercisable within 60 days of March 31, 2023. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">357 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom401831_59"></A>PRINCIPAL UNITHOLDERS OF CIBUS GLOBAL </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information with respect to the beneficial ownership of Cibus Units as of March 31, 2023 for: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person whom Cibus Global knows to own beneficially more than 5% of Cibus Global&#146;s outstanding voting
securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each director and NEO individually; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all directors and executive officers as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table does not include equity incentive awards granted after March 31, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The percentage of beneficial ownership prior to the Transactions in the table below is based on 225,134,079 outstanding voting Cibus Units as
of March 31, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the rules of the SEC, beneficial ownership includes voting or investment power with respect to
securities and includes Cibus Warrants to purchase voting units that are exercisable within 60 days of the date of this prospectus. Cibus Global voting units issuable pursuant to Cibus Warrants are deemed outstanding for computing the percentage of
the person holding such Cibus Warrants but are not outstanding for purposes of computing the percentage of any other person. Unless otherwise indicated, the address for each listed director and NEO is c/o Cibus Global, LLC, 6455 Nancy Ridge Drive,
San Diego, California 92121. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares of Voting Cibus<BR>Global Units<BR>Beneficially Owned<BR></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5% Stockholders:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BV Partners, LLC<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,667,148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.23</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FMR LLC<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,544,493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14.46</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cibus Investments, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,831,763</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.59</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Directors and Named Executive Officers:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rory Riggs<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,161,804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13.71</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Beetham, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58,123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Greg Gocal, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">173,291</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">&nbsp;(7)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wade King, MD</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">142,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Finn</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">257,043</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jean-Pierre Lehmann<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,736,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12.34</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gerhard Prante, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95,329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eugene Linden</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<SUP STYLE="font-size:75%; vertical-align:top">(8)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Lu<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,063,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.36</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Keith Walker, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">243,214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<SUP STYLE="font-size:75%; vertical-align:top">(9)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Directors and executive officers as a group (10 persons)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73,963,959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31.86</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents beneficial ownership of less than one percent of outstanding voting Cibus Global Units.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents (a) 17,069,116 Cibus Preferred Units and (b)&nbsp;Cibus Warrants to purchase 1,598,032 voting Cibus
Global units held by the Blocker owned by private funds managed by BV Partners, LLC, of which entity Mark T. Finn and Jonathan F. Finn serve as managing members. As per agreement, Mark T. Finn and Jonathan F. Finn hold direct voting and dispositive
power over the units held by the funds managed by BV Partners, LLC. Mark T. Finn and Jonathan F. Finn each disclaims beneficial ownership of the units held by such private funds except to the extent of his pecuniary interest therein.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents Cibus Preferred Units held by the Blockers established by entities advised or <FONT
STYLE="white-space:nowrap">sub-advised</FONT> by Fidelity Management&nbsp;&amp; Research Company, comprising: 2,311,010 Cibus Preferred Units held by FSGRWCO CB Holdings LLC, 8,554,302 Cibus Preferred Units held by GRTHCOCP CB Holdings LLC,
8,770,694 Cibus Preferred Units held by GROWTHCO CB Holdings LLC, 7,514,641 Cibus Preferred Units </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">358 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
held by BCGF CB Holdings LLC, 277,529 Cibus Preferred Units held by BCGFCP CB Holdings LLC, 704,270 Cibus Preferred Units held by PYLBCG CB Holdings LLC, 548,277 Cibus Preferred Units held by
BCGFK CB Holdings LLC, 2,356,149 Cibus Preferred Units held by GRWTHCOK CB Holdings LLC and 1,507,621 Cibus Preferred Units held by FSBCGF CB Holdings LLC. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">These accounts are managed by direct or indirect subsidiaries of FMR LLC. Abigail P. Johnson is a Director, the Chair, the Chief Executive
Officer and the President of FMR LLC. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or
through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders&#146; voting agreement under which all Series
B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders&#146; voting agreement, members of the
Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Neither FMR
LLC nor Abigail P. Johnson has the sole power to vote or direct the voting of the shares owned directly by the various investment companies registered under the Investment Company Act (&#147;Fidelity Funds&#148;) advised by Fidelity
Management&nbsp;&amp; Research Company (&#147;FMR Co&#148;), a wholly owned subsidiary of FMR LLC, which power resides with the Fidelity Funds&#146; Boards of Trustees. FMR Co carries out the voting of the shares under written guidelines established
by the Fidelity Funds Boards of Trustees. The address for FMR LLC is 245 Summer Street, Boston, MA 02210. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes (a) (i) 22,218,173 Cibus Preferred Units and (ii)&nbsp;Cibus Warrants to purchase 9,505,992 voting
Cibus Global units, in each case for which Mr.&nbsp;Riggs has sole voting and dispositive control, (b) (i) 75,866 Cibus Preferred Units and (ii)&nbsp;Cibus Warrants to purchase 14,981 voting Cibus Global units held jointly with Robin Riggs, and (c)
346,792 Cibus Preferred Units held by the Rory Riggs Family Trust, for which Mr.&nbsp;Riggs is trustee and has sole voting and dispositive power with respect to the Cibus Preferred Units held by the trust. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes (a) 20,995,907 Cibus Preferred Units and (ii)&nbsp;Cibus Warrants to purchase 7,740,842 voting Cibus
Global units held by JPL Investments SA, which Mr.&nbsp;Lehmann is deemed to beneficially own. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes (a) 8,279,472 Cibus Preferred Units held by Lufam Genetic Biotech Ltd. and (b) 3,783,774 Cibus
Preferred Units held by Rowiss Biotech Investment Ltd., which Mr.&nbsp;Lu is deemed to beneficially own. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes (a) 221,573 Cibus Preferred Units and (b) Cibus Warrants to purchase 35,470 voting Cibus Units.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes (a) 97,307 Cibus Preferred Units and (b) Cibus Warrants to purchase 75,984 voting Cibus Units.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes (a) 1,115 Cibus Preferred Units and (b) Cibus Warrants to purchase 32,000 voting Cibus Units.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes (a) 241,006 Cibus Preferred Units and (b) Cibus Warrants to purchase 2,208 voting Cibus Units.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">359 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom401831_60"></A>PRINCIPAL STOCKHOLDERS OF CIBUS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except where specifically noted, the following information and all of the information in this proxy statement/prospectus does not give effect
to the Reverse Stock Splits. The table below sets forth certain information with respect to the beneficial ownership of the Class&nbsp;A Common Stock and Class&nbsp;B Common Stock of Cibus, Inc. upon consummation of the Transactions based on
beneficial ownership of Calyxt Common Stock and Cibus Units as of March 31, 2023 by: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each director of Cibus, Inc.; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each named executive officer of Cibus, Inc.; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all of Cibus, Inc.&#146;s directors and executive officers as a group; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person or entity expected by Cibus Global and Calyxt, Inc. to become the beneficial owner of more than 5% of
the Class&nbsp;A Common Stock and Class&nbsp;B Common Stock of Cibus, Inc. upon the consummation of the Transactions. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below does not include equity incentive awards granted after March 31, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The below tables each assume that the consummation of the Transactions occurred on March 31, 2023 and that, assuming prior to, or concurrent
with, the consummation of the Transactions (a)&nbsp;Cibus Global completed the sale of $50.0&nbsp;million of additional Cibus Series F Preferred Units to New Ventures Agtech Solutions, LLC, (b)&nbsp;Calyxt issued an aggregate of 3,487,503
fully-vested restricted stock units to certain employees with respect to 3,487,503 shares of Class A Common Stock and (c)&nbsp;prior to the consummation of the Transactions Cibus Global issued an aggregate of 1,244,600 Cibus PIUs reserved for
issuance to certain of its employees. Immediately prior to the consummation of the Transactions, (i)&nbsp;Cibus Global is expected to have (A) 250,134,079 Cibus Units (exclusive of Cibus PIU) outstanding, (B) 64,193,846 Cibus PIUs outstanding and
(C)&nbsp;outstanding Cibus Warrants to purchase 29,751,050 Cibus Units and (ii)&nbsp;Calyxt, Inc. is expected to have 53,739,250 shares of Common Stock outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below assumes that upon the Closing, no Electing Members elected to receive <FONT STYLE="white-space:nowrap">Up-C</FONT> Units and
that all Electing Members chose to receive Class&nbsp;A Common Stock such that there would be a total of 1,097,366,833 shares of Class&nbsp;A Common Stock and a total of 0 Class&nbsp;B Common Stock of Cibus, Inc. outstanding upon the closing of the
Transactions. The table does not reflect the effect of the Reverse Stock Splits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the rules of the SEC, beneficial
ownership includes voting or investment power with respect to securities and includes the shares issuable pursuant to options that are exercisable within 60 days of the date of this prospectus. Shares issuable pursuant to options are deemed
outstanding for computing the percentage of the person holding such options but are not outstanding for purposes of computing the percentage of any other person. Unless otherwise indicated, the address of each person or entity listed in the table is
c/o Cibus Global, LLC, 6455 Nancy Ridge Drive, San Diego, California 92121. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;A Common Stock<BR>Beneficially Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;B Common Stock<BR>Beneficially Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage<BR>of Total<BR>Class&nbsp;A<BR>Common<BR>and<BR>Class&nbsp;B<BR>Common</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage<BR>of Total<BR>Class&nbsp;A<BR>Common<BR>and<BR>Class&nbsp;B<BR>Common</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Directors and Named Executive Officers:</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rory Riggs <SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">196,502,752</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17.91</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Beetham, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,121,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.74</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Greg Gocal, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,041,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.46</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wade King, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,032,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.01</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Finn</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,927,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jean-Pierre Lehmann <SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">84,352,897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.69</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gerhard Prante, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,588,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Keith Walker, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,934,525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">360 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;A Common Stock<BR>Beneficially Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;B Common Stock<BR>Beneficially Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage<BR>of Total<BR>Class&nbsp;A<BR>Common<BR>and<BR>Class&nbsp;B<BR>Common</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage<BR>of Total<BR>Class&nbsp;A<BR>Common<BR>and<BR>Class&nbsp;B<BR>Common</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All current executive officers and directors as a group (8 persons)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">339,501,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30.83</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Greater than 5% stockholders:</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FMR LLC <SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">103,180,923</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.40</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New Ventures Agtech Solutions, LLC
<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79,261,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.22</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BV Partners, LLC <SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57,197,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.21</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents beneficial ownership of less than one percent of Calyxt, Inc.&#146;s outstanding shares of Class A
Common Stock and Class B Common Stock upon consummation of the Transactions. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes (a) 115,781,122 shares for which Mr.&nbsp;Riggs has sole voting and dispositive control, (b) 269,960
shares held jointly with Robin Riggs, (c) 1,190,239 shares held by the Rory Riggs Family Trust, for which Mr.&nbsp;Riggs is trustee and has sole voting and dispositive power with respect to the shares held by the trust and (d) 79,261,431 shares held
by New Ventures Agtech Solutions, LLC for which Mr.&nbsp;Riggs has voting and investment power. Includes approximately 25,000,000 shares of Class A Common Stock issuable in respect of approximately 7,900,000 Cibus Units pledged as collateral to
secure certain personal indebtedness. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 84,352,897 shares held by JPL Investments SA, which Mr.&nbsp;Lehmann is deemed to beneficially own.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of the following shares to be issued with respect to the Blockers established by entities advised or
subadvised by Fidelity Management &amp; Research Company: 7,326,958 shares to be issued to Fidelity Mt. Vernon Street Trust: Fidelity Series Growth Company Fund with respect to Cibus Preferred units held by FSGRWCO CB Holdings LLC, 27,121,049 shares
to be issued to Fidelity Growth Company Commingled Pool with respect to Cibus Preferred Units held by GRTHCOCP CB Holdings LLC, 27,807,110 shares to be issued to Fidelity Mt. Vernon Street Trust: Fidelity Growth Company Fund with respect to Cibus
Preferred Units held by GROWTHCO CB Holdings LLC, 23,824,848 shares to be issued to Fidelity Securities Fund: Fidelity Blue Chip Growth Fund with respect to Cibus Preferred Units held by BCGF CB Holdings LLC, 879,894 shares to be issued to Fidelity
Blue Chip Growth Commingled Pool with respect to Cibus Preferred Units held by BCGFCP CB Holdings LLC, 2,232,858 shares to be issued to FIAM Target Date Blue Chip Growth Commingled Pool with respect to Cibus Preferred Units held by PYLBCG CB
Holdings LLC, 1,738,280 shares to be issued to Fidelity Securities Fund: Fidelity Blue Chip Growth K6 Fund with respect to Cibus Preferred Units held by BCGFK CB Holdings LLC, 7,470,070 shares to be issued to Fidelity Mt. Vernon Street Trust :
Fidelity Growth Company K6 Fund with respect to Cibus Preferred Units held by GRWTHCOK CB Holdings LLC and 4,779,848 shares to be issued to Fidelity Securities Fund: Fidelity Series Blue Chip Growth Fund with respect to Cibus Preferred Units held by
FSBCGF CB Holdings LLC. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">These accounts are managed by direct or indirect subsidiaries of FMR LLC. Abigail P. Johnson is
a Director, the Chair, the Chief Executive Officer and the President of FMR LLC. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Members of the Johnson family, including Abigail P.
Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a
shareholders&#146; voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of
the shareholders&#146; voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Neither FMR LLC nor Abigail P. Johnson has the sole power to vote or direct the voting of the shares owned directly by the various investment
companies registered under the Investment Company Act </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">361 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
(&#147;Fidelity Funds&#148;) advised by Fidelity Management&nbsp;&amp; Research Company (&#147;FMR Co&#148;), a wholly owned subsidiary of FMR LLC, which power resides with the Fidelity
Funds&#146; Boards of Trustees. FMR Co carries out the voting of the shares under written guidelines established by the Fidelity Funds Boards of Trustees. The address for FMR LLC is 245 Summer Street, Boston, MA 02210. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Rory Riggs holds voting and investment power over the shares held by the New Ventures Agtech Solutions, LLC.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents shares issued with respect to the Blocker established by private funds managed by BV Partners, LLC,
of which entity Mark T. Finn and Jonathan F. Finn serve as managing members. As per agreement, Mark T. Finn and Jonathan F. Finn hold direct voting and dispositive power over the shares held by the funds managed by BV Partners, LLC. Mark T. Finn and
Jonathan F. Finn each disclaims beneficial ownership of the shares held by such private funds except to the extent of his pecuniary interest therein. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below does not include equity incentive awards granted after March 31, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below assumes that each (a)&nbsp;director of Cibus, Inc., (b) executive officer of Cibus, Inc. and (c)&nbsp;person or entity
expected by Cibus Global and Calyxt, Inc. to become the beneficial owner of more than 5% of the Class&nbsp;A Common Stock and Class&nbsp;B Common Stock of Cibus, Inc. upon the consummation of the Transactions, in each case that is a Top 99 Holder,
elects to receive <FONT STYLE="white-space:nowrap">Up-C</FONT> Units to the maximum extent permitted under the Merger Agreement and that no other Top 99 Holder makes such election, such that there would be a total of 888,061,125 shares of
Class&nbsp;A Common Stock and 209,305,707 shares of Class&nbsp;B Common Stock outstanding upon the closing of the Transactions. The table does not reflect the effect of any Reverse Stock Splits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the rules of the SEC, beneficial ownership includes voting or investment power with respect to securities and includes the
shares issuable pursuant to options that are exercisable within 60 days of the date of this prospectus. Shares issuable pursuant to options are deemed outstanding for computing the percentage of the person holding such options but are not
outstanding for purposes of computing the percentage of any other person. Unless otherwise indicated, the address of each person or entity listed in the table is c/o Cibus Global, LLC, 6455 Nancy Ridge Drive, San Diego, California 92121. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;A Common Stock<BR>Beneficially Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;B Common Stock<BR>Beneficially Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage<BR>of Total<BR>Class&nbsp;A<BR>Common<BR>and<BR>Class&nbsp;B<BR>Common</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage<BR>of Total<BR>Class&nbsp;A<BR>Common<BR>and<BR>Class&nbsp;B<BR>Common</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Directors and Named Executive Officers:</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rory Riggs<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53,011,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.83</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">143,491,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13.08</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Beetham, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,946,047</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.73</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">175,063</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Greg Gocal, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,748,413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.44</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">293,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wade King, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,604,908</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">427,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Finn</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,260,121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">667,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jean-Pierre Lehmann<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,114,604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.92</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63,238,294</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.76</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gerhard Prante, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,301,708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">287,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Keith Walker, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,208,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">725,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All current executive officers and directors as a group (8 persons)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">130,196,128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17.86</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">209,305,708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19.07</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Greater than 5% stockholders:</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FMR LLC<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">103,180,923</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.40</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New Ventures Agtech Solutions,
LLC<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,963,072</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,298,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.86</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BV Partners, LLC <SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57,197,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.21</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents beneficial ownerships of less than one percent of Calyxt, Inc.&#146;s outstanding shares of Class A
Common Stock and Class B Common Stock upon consummation of the Transactions. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">362 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes (a) 115,781,122 shares for which Mr.&nbsp;Riggs has sole voting and dispositive control, (b) 269,960
shares held jointly with Robin Riggs, (c) 1,190,239 shares held by the Rory Riggs Family Trust, for which Mr.&nbsp;Riggs is trustee and has sole voting and dispositive power with respect to the shares held by the trust and (d) 79,261,431 shares held
by New Ventures Agtech Solutions, LLC for which Mr.&nbsp;Riggs has voting and investment power. Includes approximately 25,000,000 shares of Class&nbsp;A Common Stock issuable in respect of approximately 7,900,000 Cibus Units pledged as collateral to
secure certain personal indebtedness. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 84,352,897 shares held by JPL Investments SA, which Mr.&nbsp;Lehmann is deemed to beneficially own.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents shares issued with respect to the Blockers established by entities advised or <FONT
STYLE="white-space:nowrap">sub-advised</FONT> by Fidelity Management&nbsp;&amp; Research Company, comprising: 7,326,958 shares issued with respect to FSGRWCO CB Holdings LLC, 27,121,049 shares issued with respect to GRTHCOCP CB Holdings LLC,
27,807,110 shares issued with respect to GROWTHCO CB Holdings LLC, 23,824,848 shares issued with respect to BCGF CB Holdings LLC, 879,894 shares issued with respect to BCGFCP CB Holdings LLC, 2,232,858 shares issued with respect to PYLBCG CB
Holdings LLC, 1,738,280 shares issued with respect to BCGFK CB Holdings LLC, 7,470,070 shares held with respect to GRWTHCOK CB Holdings LLC and 4,779,848 shares held with respect to FSBCGF CB Holdings LLC. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">These accounts are managed by direct or indirect subsidiaries of FMR LLC. Abigail P. Johnson is a Director, the Chair, the Chief Executive
Officer and the President of FMR LLC. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or
through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders&#146; voting agreement under which all Series
B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders&#146; voting agreement, members of the
Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Neither FMR
LLC nor Abigail P. Johnson has the sole power to vote or direct the voting of the shares owned directly by the various investment companies registered under the Investment Company Act (&#147;Fidelity Funds&#148;) advised by Fidelity
Management&nbsp;&amp; Research Company (&#147;FMR Co&#148;), a wholly owned subsidiary of FMR LLC, which power resides with the Fidelity Funds&#146; Boards of Trustees. FMR Co carries out the voting of the shares under written guidelines established
by the Fidelity Funds Boards of Trustees. The address for FMR LLC is 245 Summer Street, Boston, MA 02210. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Rory Riggs holds voting and investment power over the shares held by the New Ventures Agtech Solutions, LLC.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents shares issued with respect to the Blocker established by private funds managed by BV Partners, LLC,
of which entity Mark T. Finn and Jonathan F. Finn serve as managing members. As per agreement, Mark T. Finn and Jonathan F. Finn hold direct voting and dispositive power over the shares held by the funds managed by BV Partners, LLC. Mark T. Finn and
Jonathan F. Finn each disclaims beneficial ownership of the shares held by such private funds except to the extent of his pecuniary interest therein. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">363 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom401831_61"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sidley Austin LLP, New York, New York, will pass on the validity of the Shares offered by this proxy statement/prospectus. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom401831_62"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Calyxt, Inc. as of December 31, 2022 and 2021, and for each of the three years in the period ended
December 31, 2022, included in the Proxy Statement of Calyxt, Inc., which is referred to and made part of this Prospectus and Registration Statement, have been audited by Ernst &amp; Young LLP, independent registered public accounting firm, as set
forth in their report (which contains an explanatory paragraph describing conditions that raise substantial doubt about Calyxt, Inc.&#146;s ability to continue as a going concern as described in Note 2, Going Concern, to the consolidated financial
statements), appearing elsewhere herein, and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Cibus Global, LLC as of December 31, 2022 and 2021 and for the years then ended included in this
Proxy Statement/Prospectus and in the Registration Statement have been so included in reliance on the report of BDO USA, LLP, an independent auditor, appearing elsewhere herein, given on the authority of said firm as experts in auditing and
accounting. The report on the consolidated financial statements contains an explanatory paragraph regarding Cibus Global, LLC&#146;s ability to continue as a going concern. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">364 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom401831_63"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt, Inc. is subject to the information and reporting requirements of the Exchange Act and, in accordance with this law, is required to
file periodic reports, proxy statements and other information with the SEC. You can read Calyxt, Inc.&#146;s SEC filings, including the registration statement, over the internet at the SEC&#146;s website at www.sec.gov. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt, Inc. makes available free of charge, on or through the investor relations section of Calyxt, Inc.&#146;s website, Annual Reports on
Form <FONT STYLE="white-space:nowrap">10-K,</FONT> Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> and amendments to those reports filed or furnished
pursuant to Section&nbsp;13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after Calyxt, Inc. electronically files such material with, or furnishes it to, the SEC. Calyxt, Inc. will provide without charge to each person, including
any beneficial owner, to whom this prospectus is delivered, upon his or her written or oral request, a copy of any or all of the information that has been incorporated by reference into this prospectus but not delivered with this prospectus,
excluding exhibits to those documents unless they are specifically incorporated by reference into those documents. You may obtain copies of this prospectus and the documents incorporated by reference without charge by writing to Calyxt, Inc.&#146;s
investor relations team at 2800 Mount Ridge Road, Roseville, Minnesota 55113, by telephone at (651) <FONT STYLE="white-space:nowrap">683-2807</FONT> or on Calyxt, Inc.&#146;s website at www.calyxt.com. Information contained on Calyxt, Inc.&#146;s
website is not incorporated into this prospectus and you should not consider information contained on Calyxt, Inc.&#146;s website to be part of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this proxy statement/prospectus, Calyxt, Inc. has filed with the SEC a registration statement on Form <FONT
STYLE="white-space:nowrap">S-4,</FONT> of which this proxy statement/prospectus is a part, under the Securities Act to register the shares of Class A Common Stock that Calyxt, Inc. will issue to Cibus Unitholders in the Mergers. This proxy
statement/prospectus is a part of that registration statement and constitutes a prospectus of Calyxt, Inc., as well as a proxy statement of Calyxt, Inc. for the Calyxt Special Meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Calyxt, Inc. has supplied all information contained in this proxy statement/prospectus relating to Calyxt, and Cibus Global has supplied all
information contained in this proxy statement/prospectus relating to Cibus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you would like to request documents from Calyxt or Cibus,
please send a request in writing or by telephone to either Calyxt or Cibus at the following addresses: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Calyxt, Inc.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2800 Mount Ridge Road<BR>Roseville, MN 55113<BR>Telephone: (651) <FONT STYLE="white-space:nowrap">683-2807</FONT><BR>Attn: Investor
Relations<BR>Email: Investors@Calyxt.com</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Cibus Global, LLC</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6455 Nancy Ridge Drive<BR>San Diego, CA 92121<BR>Telephone: (858) <FONT STYLE="white-space:nowrap">450-0008</FONT><BR>Attn: Investor
Relations<BR>Email: Investors@Cibus.com</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">365 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom401831_64"></A>OTHER MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Delinquent Section&nbsp;16(a) Reports </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;16(a) of the Exchange Act requires Calyxt, Inc.&#146;s directors and officers and persons who own more than 10% of Calyxt Common
Stock to file reports of ownership and changes in ownership with the SEC, and to furnish Calyxt, Inc. with copies of the reports. Specific due dates for these reports are prescribed by SEC rules and Calyxt, Inc. is required to report in this proxy
statement/prospectus any failure by directors, officers, or 10% holders to file such reports on a timely basis. Based on Calyxt, Inc.&#146;s review of such reports and written representations from Calyxt, Inc.&#146;s directors and officers, Calyxt,
Inc. believes that all such filing requirements were timely met during 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Procedure for Submitting Stockholders Proposals and Director Nominees at
the 2024 Annual Meeting </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rules of the SEC permit Calyxt Stockholders, after timely notice to Calyxt, Inc., to present proposals in
Calyxt, Inc.&#146;s proxy statement for stockholder action where such proposals are consistent with applicable law, constitute a proper matter for stockholder action, and are not properly omitted by Calyxt, Inc. in accordance with the rules of the
SEC. To be timely for Calyxt, Inc.&#146;s 2024 Annual Meeting, a stockholder&#146;s notice of a proposal must be delivered to or mailed and received by the Secretary of Calyxt, Inc. at Calyxt, Inc.&#146;s principal executive offices, 2800 Mount
Ridge Road, Roseville, MN 55113, no later than November 23, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Calyxt Bylaws, in order for a proposal to be properly
brought before the next annual meeting by a stockholder or for a stockholder&#146;s nominee for director to be considered at such annual meeting, the stockholder must give written notice of such stockholder&#146;s intent to bring a matter before the
annual meeting or to nominate the director, which must be received by Calyxt, Inc. not less than 90 days nor more than 120 days prior to the first anniversary of the preceding year&#146;s annual meeting of stockholders. In the case of Calyxt,
Inc.&#146;s 2024 Annual Meeting, to be timely under the Calyxt Bylaws, a stockholder&#146;s notice must be received not later than February 2, 2024, nor earlier than January 3, 2024. Each such notice must set forth certain information with respect
to the stockholder who intends to bring a proposal before the meeting or to make the nomination, and the director nominee or proposal, as set forth in greater detail in the Calyxt Bylaws. If Calyxt, Inc. receives notice of a stockholder proposal
after February 2, 2024, such proposal also will be considered untimely pursuant to <FONT STYLE="white-space:nowrap">Rules&nbsp;14a-4</FONT> and <FONT STYLE="white-space:nowrap">14a-5(e)</FONT> and the persons named in proxies solicited by the Calyxt
Board for the 2024 Annual Meeting may exercise discretionary voting power with respect to such proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that the date of
Calyxt, Inc.&#146;s 2024 Annual Meeting is advanced more than 30 days prior to the anniversary of Calyxt, Inc.&#146;s 2023 Annual Meeting or delayed more than 30 days after such anniversary date, then to be timely such notice must be received by
Calyxt, Inc. no earlier than 120 days prior to such 2024 Annual Meeting and no later than the later of 70 days prior to the date of the meeting or the 10th day following the day on which public announcement of the date of the meeting was first made
by Calyxt, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to satisfying the requirements under the Calyxt Bylaws, to comply with the universal proxy rules,
stockholders who intend to solicit proxies in support of director nominees other than Calyxt, Inc.&#146;s nominees must provide notice that sets forth the information required by Rule <FONT STYLE="white-space:nowrap">14a-19</FONT> under the Exchange
Act, which notice must be postmarked or transmitted electronically to Calyxt, Inc. at its principal executive offices no later than March 1, 2024. If the date of the 2024 Annual Meeting is changed by more than 30 calendar days from the anniversary
of the 2023 Annual Meeting, then notice must be provided by the later of 60 calendar days prior to the date of the 2024 Annual Meeting or the 10th calendar day following the day on which public announcement of the date of the 2024 Annual Meeting is
first made. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">366 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stockholder Communications with the Calyxt Board </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stockholders may contact the Calyxt Board about bona fide issues or questions about Calyxt, Inc. by sending a letter to the following address:
Calyxt, Inc., 2800 Mount Ridge Road, Roseville, MN 55113, Attention: Board of Directors. Each communication should specify the applicable addressee or addressees to be contacted, the general topic of the communication, and the number of shares of
Calyxt Common Stock that are owned of record (if a record holder) or beneficially. If a stockholder wishes to contact the independent members of the Calyxt Board, the stockholder should address such communication to the attention of the
&#147;Independent Directors&#148; at the address above. Calyxt, Inc.&#146;s General Counsel will initially receive and process communications before forwarding them to the addressee, and generally will not forward a communication that is unrelated
to the duties and responsibilities of the Calyxt Board, including a communication the General Counsel determines to be primarily commercial in nature, is related to an improper or irrelevant topic, or is a request for general information about
Calyxt, Inc. or its products or services. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Delivery of Documents to Stockholders Sharing an Address </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A number of brokers with account holders who are Calyxt Stockholders will be &#147;householding&#148; Calyxt, Inc.&#146;s proxy materials. A
single Notice of Special Meeting or, if requested, set of proxy materials may be delivered to multiple stockholders sharing an address unless contrary instructions have been received from the affected stockholders. Once you have received notice from
your broker that they will be &#147;householding&#148; communications to your address, &#147;householding&#148; will continue until you are notified otherwise or until you revoke your consent. If, at any time, you no longer wish to participate in
&#147;householding&#148; and would prefer to receive a separate Notice of Special Meeting and/or separate set of proxy materials, please notify your broker and direct your written request to Calyxt, Inc., Inc., 2800 Mount Ridge Road, Roseville, MN
55113, Attn: Secretary, or call (651) <FONT STYLE="white-space:nowrap">683-2807.</FONT> Calyxt, Inc. undertakes to deliver promptly to a stockholder upon such written or oral request a separate Notice of Special Meeting, and, if requested, set of
proxy materials. Stockholders who currently receive multiple copies of the proxy materials at their address and would like to request &#147;householding&#148; of their communications should contact their broker. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">367 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="index"></A><A NAME="rom401831_65"></A>INDEX TO FINANCIAL STATEMENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CALYXT, INC.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Audited Consolidated Financial Statements</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin401831_1">Report of Independent Registered Public Accounting Firm (PCAOB ID:
42)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin401831_2">Consolidated Balance Sheets at December 31, 2022 and 2021</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin401831_3">Consolidated Statements of Operations for the years ended December&nbsp;
31, 2022, 2021 and 2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin401831_4">Consolidated Statements of Stockholders&#146; Equity for the years ended December&nbsp;31,
2022, 2021 and 2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin401831_5">Consolidated Statements of Cash Flows for the years ended December&nbsp;
31, 2022, 2021 and 2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin401831_6">Notes to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CIBUS GLOBAL, LLC</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Audited Consolidated Financial Statements as of December&nbsp;31, 2022 and 2021 and for the
Years Ended December&nbsp;31, 2022 and 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin401831_12">Report of Independent Auditor </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-32</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin401831_13">Consolidated Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-34</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin401831_14">Consolidated Statements of Operations and Comprehensive
Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-36</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin401831_15">Consolidated Statements of Members&#146; Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-37</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin401831_16">Consolidated Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-38</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin401831_17">Notes to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-39</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin401831_1"></A>Report of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Shareholders and the Board of Directors of Calyxt, Inc. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Opinion on the Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited the
accompanying consolidated balance sheets of Calyxt, Inc. (the Company) as of December&nbsp;31, 2022 and 2021, the related consolidated statements of operations, stockholders&#146; equity, and cash flows for each of the three years in the period
ended December&nbsp;31, 2022, and the related notes (collectively referred to as the &#147;consolidated financial statements&#148;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial
position of the Company at December&nbsp;31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December&nbsp;31, 2022, in conformity with U.S. generally accepted accounting
principles. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Company&#146;s Ability to Continue as a Going Concern</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the
financial statements, the Company has incurred recurring losses from operations, utilized cash from operations, and has stated that substantial doubt exists about the Company&#146;s ability to continue as a going concern. Management&#146;s
evaluation of the events and conditions and management&#146;s plans regarding these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis for Opinion</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These financial statements are
the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight
Board (United States) (&#147;PCAOB&#148;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the
PCAOB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial
reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#146;s internal control over financial
reporting. Accordingly, we express no such opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our audits included performing procedures to assess the risks of material misstatement of the
financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits
also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Adoption of ASU No. 2016-02 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As discussed in Notes 1
and 8 to the consolidated financial statements, the Company changed its method of accounting for leases in 2022 due to the adoption of ASU No. 2016-02,&nbsp;Leases. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Audit Matter</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated
or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective or complex judgments. The
communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the
critical audit matter or on the accounts or disclosures to which it relates. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="27%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="71%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Description&nbsp;of&nbsp;the Matter</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Common Stock Warrants</I></B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As discussed in Note 5 to the consolidated financial statements, the Company entered into a follow-on public offering and issued common warrants to purchase
shares of common stock. These warrants were initially recorded as a liability at their fair value on the date issued. Subsequent changes in the fair value of the warrants are recorded in earnings.&nbsp;As of December 31, 2022, the fair value of the
warrants was $291 thousand. The Company has recognized an unrealized gain on the fair value of the warrants of $5,120 thousand in other income (expense), net in the year ended December 31, 2022.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Auditing the Company&#146;s valuation of the common stock warrants was complex due to
the degree of judgment required in evaluating the significant assumptions, principally the expected volatility used in the Black-Scholes model.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>How We Addressed the Matter in Our Audit</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">To test the Company&#146;s valuation of the warrants determined by the Black-Scholes model, we performed audit procedures that included, among others, assessing the methodology used and testing significant assumptions and the
underlying data used by the Company in its analysis, including assessing the completeness and accuracy of such underlying data. We involved internal valuation specialists in assessing the fair value methodology applied and evaluating the
reasonableness of the assumptions used by management, including evaluating significant assumptions by comparing them to independently developed estimates. We performed sensitivity analyses of significant assumptions to evaluate the changes in the
fair value of the warrants that would result from changes in the assumptions. Furthermore, we assessed the appropriateness of the disclosures in the consolidated financial statements.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Ernst&nbsp;&amp; Young LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the Company&#146;s auditor since 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Minneapolis, Minnesota </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;2, 2023 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CALYXT, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin401831_2"></A>CONSOLIDATED BALANCE SHEETS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In Thousands, Except Par Value and Share Amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>3,427</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>99</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>606</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>4,132</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-current</FONT> restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Land, buildings, and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>4,516</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>13,615</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>158</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>22,421</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37,194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities and stockholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>340</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>173</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">339</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>107</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Due to related parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>175</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of financing lease obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>97</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>291</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>479</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,662</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,854</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing lease obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>13,447</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>79</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>15,188</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,062</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Stockholders&#146; equity:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.0001&nbsp;par value; 275,000,000&nbsp;shares authorized; 48,944,771&nbsp;shares
issued and 48,844,619&nbsp;shares outstanding as of December&nbsp;31, 2022, and 38,874,146&nbsp;shares issued and 38,773,994&nbsp;shares outstanding as of December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>5</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>220,422</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">211,263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock in treasury, at cost; 100,152&nbsp;shares as of December&nbsp;31, 2022, and
December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(1,043</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,043</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(212,151</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(196,092</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total stockholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>7,233</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities and stockholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>22,421</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37,194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:80pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See accompanying notes to the Consolidated Financial Statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CALYXT, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin401831_3"></A>CONSOLIDATED STATEMENTS OF OPERATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In Thousands Except Shares and Per Share Amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>157</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,851</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of goods sold</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>157</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,570</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11,276</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>11,553</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,082</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general, and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>10,974</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,789</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restructuring costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>22,527</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,762</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(22,370</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29,332</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(43,832</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain upon extinguishment of Payroll Protection Program loan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(87</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,414</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(878</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-operating</FONT> income (expenses)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>5,566</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(126</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(16,891</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29,199</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(44,836</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(16,891</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29,199</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(44,836</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Basic and diluted net loss per share</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(0.37</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.78</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1.32</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Weighted average shares outstanding - basic and diluted</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>45,997,525</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37,475,763</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,882,406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Anti-dilutive stock options, restricted stock units, performance stock units, and common stock
warrants</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>15,960,659</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,001,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,552,418</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:250pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See accompanying notes to the Consolidated Financial Statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CALYXT, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin401831_4"></A>CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#146; EQUITY </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In Thousands Except Shares Outstanding) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B><br><B>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common</B><br><B>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional</B><br><B><FONT STYLE="white-space:nowrap">Paid-In</FONT></B><br><B>Capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;in</B><br><B>Treasury</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Other</B><br><B>Comprehensive</B><br><B>Income (Loss)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>Stockholders&#146;</B><br><B>Equity</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Balances at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,951,329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">185,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,043</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(122,057</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62,508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(44,836</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(44,836</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,971</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,971</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement
of restricted stock units</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">381,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Issuance of common stock from the <FONT STYLE="white-space:nowrap">follow-on</FONT> offering, net
of $1.0&nbsp;million of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Shares withheld for net share settlement</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(17,792</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(17</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(17</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Balances at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37,065,044</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">204,807</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,043</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(166,893</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29,199</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29,199</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement
of restricted stock units</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">270,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Issuance of common stock from ATM Facility, net of $0.5&nbsp;million of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,438,647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Shares withheld for net share settlement</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Balances at December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,773,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">211,263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,043</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(196,092</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,891</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,891</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Issuance of common stock and payment of minimum employee taxes withheld upon net share settlement
of restricted stock units</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">304,517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Issuance of common stock from ATM Facility, net of offering expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,006,108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Issuance of common stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants in
registered offering, net of $0.5&nbsp;million of offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,880,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,051</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Issuance of common stock upon exercise of <FONT STYLE="white-space:nowrap">pre-funded</FONT>
warrants</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,880,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cumulative effect of adoption of lease accounting standard</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Balances at December&nbsp;31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>48,844,619</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>5</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>220,422</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(1,043</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(212,151</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>7,233</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See accompanying notes to the Consolidated Financial Statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CALYXT, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin401831_5"></A>CONSOLIDATED STATEMENTS OF CASH FLOWS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In Thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(16,891</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29,199</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(44,836</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used by operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain upon extinguishment of Payroll Protection Program loan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,528</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,534</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,869</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>3,998</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,971</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized (gain) loss on
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> of common stock warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(5,120</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,887</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,765</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Due to/from related parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>3</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(594</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(211</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inventory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>389</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,122</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(229</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(360</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(148</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(166</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,542</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(2,415</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">572</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(231</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(467</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash used by operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(19,364</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(18,811</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(43,672</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and (purchases) of short-term investments, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,698</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11,698</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of land, buildings, and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(1,520</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(497</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,786</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash (used) provided by investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(1,520</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13,484</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from common stock issuance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>11,538</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Costs incurred related to the issuance of stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(1,173</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(501</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(963</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from Payroll Protection Program loan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repayments of financing lease obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(376</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(364</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(360</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from the exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash provided by financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>9,989</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net decrease in cash, cash equivalents, and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(10,895</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,868</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(41,749</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents, and restricted cash - beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>14,421</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60,038</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash, cash equivalents, and restricted cash &#151; end of period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>3,526</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See accompanying notes to the Consolidated Financial Statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CALYXT, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin401831_6"></A>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Overview </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Calyxt, Inc. was founded in 2010 and
incorporated in Delaware. Calyxt is a plant-based synthetic biology company. The Company leverages its proprietary PlantSpring<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> technology platform to engineer plant metabolism to produce
innovative, high-value, and sustainable materials and products for use in helping customers meet their sustainability targets and financial goals. The Company&#146;s primary focus and commercialization strategy is on engineering synthetic biology
solutions through its PlantSpring technology platform for manufacture using its proprietary and differentiated BioFactory<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> production system for a diverse base of target customers across a
range of end markets, including the cosmeceutical, nutraceutical, and pharmaceutical industries. The Company also commercializes its PlantSpring technology platform by licensing elements of the platform and historically developed traditional
agriculture seed-trait product candidates, as well as selectively developing product candidates for customers in traditional agriculture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to its
IPO on July&nbsp;25, 2017, the Company was a wholly owned subsidiary of Cellectis. As of December&nbsp;31, 2022, Cellectis owned 49.1&nbsp;percent of the Company&#146;s issued and outstanding common stock. Cellectis has certain contractual rights as
well as rights pursuant to the Company&#146;s certificate of incorporation and bylaws, in each case, for so long as it maintains threshold beneficial ownership levels in the Company&#146;s shares. See &#147;Risk Factors&#151;Although Cellectis and
its affiliates hold less than a majority of the Company&#146;s outstanding common stock, Cellectis possesses certain rights that prevent other stockholders from influencing significant decisions.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation and Use of Estimates </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company has prepared its consolidated financial statements in accordance with accounting principles generally accepted in the United States (U.S. GAAP or GAAP) and has included the accounts of Calyxt and its subsidiary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of consolidated financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the
reported amounts in the consolidated financial statements and accompanying notes, including those related to revenue recognition, the net realizable value of inventories, stock-based compensation, and valuation allowances on deferred tax assets.
Actual results could materially differ from these estimates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash, Cash Equivalents, Restricted Cash, and Investments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All investments purchased with an original maturity of three months or less are accounted for as cash equivalents. The Company&#146;s restricted cash balances
are cash and cash equivalents deposited in an amount equal to the future rent payments as required under the Company&#146;s equipment lease facility. The Company may request the return of excess restricted cash collateral annually in December. The
amount of the restricted cash balance the Company expects to have returned in 2023 is reflected as a current asset. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company periodically invests its
cash in high grade, highly liquid securities, and investment funds. The Company considers securities purchased with more than ninety days to their original maturity at issuance to be short-term investments. These short-term investments are
classified as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> securities based on the Company&#146;s intent to generally match maturities with Calyxt&#146;s projected monthly cash usage. The Company
held these securities to their planned maturity or liquidated them earlier in response to variations in the Company&#146;s monthly cash usage. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company ensures the credit risk in this portfolio is in accordance with its internal policies and if necessary, makes changes to investments to ensure credit risk is minimized. The Company has not experienced any counterparty credit losses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accounts Receivable </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accounts receivable are unsecured and are recorded at net realizable value. The Company makes judgments as to its ability to collect outstanding receivables
based upon patterns of collectability, historical experience, and its evaluation of specific accounts and will provide an allowance for credit losses when collection becomes doubtful. The Company performs credit evaluations of its customers&#146;
financial condition on an <FONT STYLE="white-space:nowrap">as-needed</FONT> basis. Payment is generally due fifteen or thirty days from the invoice date depending upon the product, and accounts past 30 days are individually analyzed for
collectability. When all collection efforts have been exhausted, the account is written off. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Inventory </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inventories are recorded at the lower of cost or net realizable value and include all costs of seed production and grain the Company purchased as well as costs
to store and transport the grain. As of December&nbsp;31, 2020, inventory included the costs to process the grain into finished products. Consideration received from growers when they purchase seed is recorded as a reduction of inventory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company evaluates inventory balances for obsolescence or estimated net realizable value on a regular basis based on the age of the inventory and its sales
forecasts. At each <FONT STYLE="white-space:nowrap">period-end,</FONT> the Company made assumptions regarding projected selling prices for its products considering futures market prices for the underlying agricultural markets and its associated risk
management strategies, anticipated costs, and other factors that take into consideration its limited operating history and compare those prices to the current weighted average inventory costs. If the Company&#146;s costs were higher than the
projected selling prices, then a valuation adjustment was recorded. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the commercialization of its high oleic soybean products, the Company
expensed all grain costs as R&amp;D. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Forward Purchase Contracts </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Company&#146;s former <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">go-to-market</FONT></FONT> soybean strategy, it would enter
into hedging contracts to convert fixed price grain inventories and fixed price grain production agreements to floating prices, consistent with how the grain was sold. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The seed contracts often required the Company to pay prices for the seed produced at commodity futures market prices plus a premium. The seed growers had the
option to fix their price with the Company throughout the term of the agreement. The Company paid a portion of the seed cost in December each year and the remainder upon delivery in either the first or second quarter of the following year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The grain grower contracts required the Company to pay prices for all grain produced at commodity futures market prices plus a premium. The grain growers had
the option to fix their price with the Company throughout the term of the agreement. The grain grower contracts allowed for delivery of grain to the Company at harvest, if so specified when the agreement was executed, otherwise delivery occurred on
a date that was elected by the Company through August&nbsp;31, 2021. The Company paid for grain within a contractually determined number of days following delivery and final pricing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon delivery, the inventory was carried at historical cost but sold at prevailing market prices. As a result, the Company entered into hedging arrangements
by selling futures contracts which converted its market exposure to these fixed prices to floating prices. By executing these hedging strategies, the Company could closely match the expected economic terms of the grain sale with the market, which
helped stabilize margins until such inventory was sold. The Company did not account for these economic hedges as accounting hedges. All unrealized gains or losses on outstanding hedging contracts were recognized in Cost of Goods sold. The Company
expected that any gains or losses from these hedging arrangements would be offset by gains or losses on the grain inventories when such grain inventories were sold. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to August&nbsp;1, 2020, the Company designated all of its commodity derivative contracts as cash flow
hedges based on the nature of its business activities. As a result, all gains or losses associated with recording those commodity derivative contracts at fair value were recorded as a component of accumulated other comprehensive income (loss)
(AOCI). The Company reclassified amounts from AOCI to cost of goods sold when the underlying products were sold to which those hedges related. For the year ended December&nbsp;31, 2020, the Company reclassified a nominal amount from AOCI to cost of
goods sold, and there were no such reclassifications in 2021 or 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Land, Buildings, and Equipment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Land, buildings, and equipment are stated at cost less accumulated depreciation. Assets under capital lease are stated at the lesser of their net present value
of future lease payments or fair market value. Repair and maintenance costs are expensed as incurred. The cost and accumulated depreciation of property and equipment retired, or otherwise disposed of, are removed from the related accounts, and any
residual values are charged to expense. Depreciation is recorded using the straight-line method over estimated useful lives as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Buildings and improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">10-20&nbsp;years</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Shorter&nbsp;of&nbsp;lease&nbsp;term&nbsp;or&nbsp;15&nbsp;years</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office furniture and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets under capital lease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">4-20</FONT> years</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">3-5</FONT> years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vehicles</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">3-6</FONT> years</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Impairment of Long-Lived Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has a single asset group and reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying
amount of that asset group may not be recoverable. If the impairment tests indicate that the carrying value of the asset group is greater than the expected undiscounted cash flows to be generated by the asset group, further analysis is performed to
determine the fair value of the asset group. To the extent the fair value of the asset group is less than its carrying value, an impairment loss is recognized equal to the amount the carrying value exceeds the fair value of the asset group. If the
Company&#146;s plans or intentions change with regard to a specific asset within the asset group, that asset&#146;s remaining useful life is assessed, and depreciation is accelerated if necessary. Assets to be disposed of are carried at the lower of
their carrying value or fair value less costs to sell. Fair value is measured using a discounted cash flow model or independent appraisals, as appropriate. The Company has not recognized any impairment losses in these consolidated financial
statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue Recognition </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company
accounts for a contract as revenue when it has approval and commitment to perform from both parties, the rights of the parties are identified, payment terms are established, the contract has commercial substance, and collectability of the
consideration is probable. Changes to contracts are assessed for whether they represent a modification or should be accounted for as a new contract. The Company considers the following indicators, among others, when determining if it is acting as a
principal in the transaction and recording revenue on a gross basis: (i)&nbsp;the Company is primarily responsible for fulfilling the promise to provide the specified good or service, (ii)&nbsp;the Company has inventory risk before the specified
good or service has been transferred to a customer or after transfer of control to the customer and (iii)&nbsp;the Company has discretion in establishing the price for the specified good or service. If a transaction does not meet the Company&#146;s
indicators of being a principal in the transaction, then the Company is acting as an agent in the transaction and the associated revenues are recognized on a net basis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes revenue when control of the good or service has passed to the customer. The following
indicators are evaluated in determining when control has passed to the customer: (i)&nbsp;the customer has legal title to the product, (ii)&nbsp;the Company has transferred physical possession of the product or service to the customer,
(iii)&nbsp;the Company has a right to receive payment for the good or service, (iv)&nbsp;the customer absorbs the significant risks and rewards of ownership of the good and (v)&nbsp;the customer has accepted the good. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company generally does not incur costs to obtain new contracts. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Performance Obligations </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A performance obligation is a
promise in a contract to transfer a distinct good or service to the customer. A contract&#146;s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied.
The Company&#146;s contracts may contain multiple performance obligations if a promise to transfer the individual good or service is separately identifiable from other promises in the contracts and, therefore, is considered distinct. Performance
obligations that are not considered distinct are combined with other goods or services in the contract until that combination meets the distinct criteria above. For contracts with multiple performance obligations, the Company determines the
standalone selling price of each performance obligation and allocates the total transaction price using the relative selling price basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following
is a description of the principal goods and services from which the Company generates revenue: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Product Sales </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Historically, the Company sold soybean grain, oil, and meal. The Company recognized sales revenue at the point in time that title transferred to the customer,
which was based on shipping terms. Sales included shipping and handling charges if billed to the customer and were reported net of trade promotion and other costs, including estimated allowances for returns, unsalable products, and prompt pay
discounts. Sales, use, value-added, and other excise taxes were not recognized in revenue. Trade promotions were recorded based on estimated participation and performance levels for offered programs at the time of sale. The Company generally did not
allow a right of return. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During 2021 and 2020, the Company sold soybean grain to a processor and subsequent to the sale they utilized the Company&#146;s
rented third-party storage facility to hold the grain until such time they requested it be delivered. The Company was responsible for all handling charges and delivery activities. In those instances, the Company recognized revenue from the sale of
grain to the processor upon the transfer of the control of the grain, which was determined to be at the time of the issuance of the purchase order and assignment of warehouse receipts to the customer. The Company determined that the reason for the
arrangement was substantive, in that the customer had requested the arrangement, the product was separately identified as belonging to the customer, the product was ready for physical transfer, and the Company did not have the ability to use the
product or direct it to another customer. The Company concluded that any remaining performance obligations (e.g., for custodial services) were immaterial in relation to the contract. The Company concurrently accrued all estimated future storage,
handling, and delivery costs associated with that sale. All arrangements of this nature were completed prior to December&nbsp;31, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In certain
transactions occurring in the third quarter of 2020, the Company sold grain to a processor with a commitment to provide consideration to the processor in exchange for the soybean meal resulting from the grain crushing activity. The Company
determined the consideration payable to the processor was not in exchange for a distinct good or service, as the soybean meal was considered highly interrelated to the grain because they both possess Calyxt specific genetic traits, and the
transactions were entered into in contemplation of one another, and therefore, were not considered to be distinct within the context of the contract. For these transactions, the Company recognized revenue from the sale of grain in the amount of the
final net cash settlement with the processor, as the consideration payable to the processor was treated as a reduction of revenue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Technology Licensing </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes revenue from license agreements, which may consist of nonrefundable <FONT STYLE="white-space:nowrap">up-front</FONT> payments, milestone
payments, annual licensing fee payments, royalty payments, and payments for services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nonrefundable <FONT STYLE="white-space:nowrap">up-front</FONT>
payments are deferred and recognized as revenue over the term of the license agreement. If a license agreement is terminated before the original term of the agreement is fulfilled, all remaining deferred revenue is recognized at termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Annual licensing fee payments are generally associated with services in the contract and are recognized over time as the customer receives the benefits of the
services. If necessary, the Company establishes and increases a contract asset as the revenue is recognized. For these types of payments, the Company recognizes revenue using an input method, such as the completed contract or time elapsed methods,
or an output method, such as the work performed or units produced methods. The Company will apply each method of revenue recognition consistently for like contracts and assess any revenue estimates periodically for cumulative adjustments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In certain instances, the receipt of payments in these arrangements are dependent upon the achievement of certain scientific, regulatory, commercial, or other
milestones. The Company recognizes milestone payments when the triggering event has occurred, there are no further contingencies or services to be provided with respect to that event, and the counterparty has no right to refund of the payment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Royalty revenues are expected to arise following the commercialization of products developed using the licensed technology by the counterparty to the license
agreement. The royalties may be a percentage of sales or another measurement achieved by the licensee. Royalty revenues will be recognized at the later of (i)&nbsp;when the licensee is generating sales subject to royalty payments or (ii)&nbsp;the
performance obligation to which the sales-based or usage-based royalties relates has been satisfied. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Product Development Agreements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes revenue from product development agreements, which may consist of nonrefundable <FONT STYLE="white-space:nowrap">up-front</FONT>
payments, milestone payments, annual payments, and payments for services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nonrefundable <FONT STYLE="white-space:nowrap">up-front</FONT> payments are
recognized as revenue over the term of the development agreement. If a development agreement is terminated before the original term of the agreement is fulfilled, all remaining deferred revenue is recognized at termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In certain instances, the receipt of payments in these arrangements are dependent upon the achievement of certain scientific, regulatory, commercial, or other
milestones. Milestone payments are considered variable consideration which are evaluated against the Company&#146;s performance obligations for determination of when it is appropriate to recognize revenue. For purposes of revenue recognition, the
Company considers whether the performance obligation is achieved, which may be (i)&nbsp;when a triggering event has occurred, (ii)&nbsp;there are no further contingencies or services to be provided with respect to that event, and (iii)&nbsp;the
customer has no right to require refund of their payment. The Company recognizes milestone payments as revenue when it is highly probable that any revenue recognized will not be subsequently reversed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Annual payments are generally associated with services in the contract and are recognized over time as the customer receives the benefits of the services. If
necessary, the Company establishes and increases a contract asset as the revenue is recognized. For these types of payments, the Company recognizes revenue using an input method, such as the completed contract or time elapsed methods, or an output
method, such as the work performed or units produced methods. The Company will apply each method of revenue recognition consistently for like contracts and assess any revenue estimates periodically for cumulative adjustments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Agreements for the performance of R&amp;D services and cost reimbursements are recognized as revenue over time based on work performed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Collaborative Arrangements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For arrangements that do not represent contracts with a customer, the Company analyzes the transaction to assess whether the arrangement involves joint
operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards that are dependent on the commercial success of such activities. The Company had no such arrangements as of
December&nbsp;31, 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Advertising Costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company expenses advertising costs as incurred. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company
recognizes R&amp;D expenses as incurred. These expenses consist of direct costs for R&amp;D and <FONT STYLE="white-space:nowrap">R&amp;D-related</FONT> allocations of overhead costs such as facilities and information technology costs. Costs incurred
in connection with customer-funded activities are expensed as incurred. Costs to acquire technologies that are utilized in R&amp;D that have no alternative future use are expensed as incurred. Prior to the commercialization of the Company&#146;s
soybean product, the Company expensed all grain costs as R&amp;D. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patents </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company expenses patent costs, including related legal costs, as incurred. Costs to write and support the research for filing patents are recorded as
R&amp;D expenses in the statements of operations. Costs to maintain, <FONT STYLE="white-space:nowrap">in-license,</FONT> and defend patents are recorded as SG&amp;A expenses in the statements of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company generally
measures the fair value of employee and nonemployee stock-based awards on their grant date and records compensation expense on a straight-line basis over the related service period of the award, which is generally the vesting period. The Company
uses the Black-Scholes option pricing model to value its stock option awards. The Company generally measures compensation expense for grants of restricted stock units using the Company&#146;s share price on the date of grant. The Company uses a
Monte Carlo simulation pricing model when estimating the fair values of PSUs. The Company estimates fair values and accounts for employee and nonemployee awards in a similar manner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Due to the Company&#146;s limited history, it does not always have sufficient historical stock option activity to make predictive assumptions based solely on
its stock or stock option activity for the Black-Scholes option pricing model. As a result, the Company may need to use data from other comparable public companies or alternative calculation methods to make predictive assumptions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company estimates its future stock price volatility using the weighted-average historical volatility calculated from a group of comparable public
companies over the expected term of the option. The group of comparable public companies is determined by management on an annual basis. When selecting a comparable company, management considers relevant factors including industry and strategy,
size, maturity, and financial leverage. The comparable companies used by management to calculate expected volatility may change from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-year</FONT></FONT> because of changes in
those factors and because a new comparable company may become publicly traded. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The expected term of stock options is estimated using the average of the
vesting tranches and the contractual life of each grant for employee options, or the simplified method, as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment
termination behavior for its stock option grants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Due to the limited historical experience of the Company&#146;s stock awards program, it has elected to
account for forfeitures of awards as they occur. If an award is forfeited prior to vesting, the associated reduction in expense is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reflected net in stock-based compensation expense in that period. Stock-based compensation expense is recorded in R&amp;D and SG&amp;A expenses in the Company&#146;s consolidated statements of
operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Current income
taxes are recorded based on statutory obligations for the current operating period for the jurisdictions in which the Company has operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred
taxes are provided on an asset and liability method, whereby deferred tax assets are recognized for deductible temporary differences and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the
differences between the reported amounts of assets and liabilities and their tax basis. Deferred tax assets are reduced by a valuation allowance when the Company believes it is more likely than not that some portion or all the deferred tax assets
will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Currency Transactions </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Transactions in
foreign currencies are translated at the exchange rates effective on the transaction dates. Assets and liabilities denominated in foreign currencies are translated at the <FONT STYLE="white-space:nowrap">period-end</FONT> exchange rate. Foreign
currency gains and losses are recognized in <FONT STYLE="white-space:nowrap">non-operating</FONT> expenses in the consolidated statements of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Foreign currency fluctuations affect the Company&#146;s foreign currency cash flows related primarily to payments to Cellectis. The Company&#146;s principal
foreign currency exposure is to the euro. The Company does not hedge these exposures, and it does not believe that the current level of foreign currency risk is significant to its operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Loss Per Share </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Due to the Company&#146;s net
loss position for the years ended December&nbsp;31, 2022, 2021, and 2020, all its outstanding stock options, restricted stock units, PSUs, and Common Warrants are considered anti-dilutive and excluded from the calculation of net loss per share.
Accordingly, the treasury method was not used in determining the number of anti-dilutive stock options and restricted stock units. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently Issued
Accounting Pronouncements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standard Update (ASU) <FONT
STYLE="white-space:nowrap">No.&nbsp;2016-02,</FONT> Leases (Topic 842) and in July 2018, ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-10,</FONT> Codification Improvements to Topic 842, Leases, and ASU
<FONT STYLE="white-space:nowrap">2018-11,</FONT> Leases (Topic 842) &#150; Targeted Improvements (collectively, the New Lease Standard). The New Lease Standard requires lessees to record assets and liabilities on the balance sheet for all leases
with terms longer than 12 months. The New Lease Standard establishes ROU model that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Leases will be classified as
either finance or operating, with the classification affecting the pattern of expense recognition in the income statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company adopted the New
Lease Standard as of January&nbsp;1, 2022, using the transition method which does not require revisions to comparative periods. The Company elected to implement the transition package of practical expedients permitted within the New Lease Standard,
which among other things, allows it to carryforward the historical lease classification. In addition, the Company elected the hindsight practical expedient to determine the lease term for existing leases and it also made an accounting policy
election to not record leases with an initial term of 12 months or less on its consolidated balance sheet. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s adoption of the New Lease
Standard required it to remove the previously reported amounts for land, buildings, and equipment associated with its headquarters and laboratory facility lease as well as the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
associated liability. The Company assessed the elements of its lease agreement and upon adoption, recorded an operating lease associated with the sale leaseback of land component of the lease,
and a second operating lease associated with the building component of the lease. The Company recorded operating lease assets and liabilities of $14.1&nbsp;million within its consolidated balance sheet as of January&nbsp;1, 2022. The New Lease
Standard had no impact on the Company&#146;s consolidated statements of operations or cash flows. The $0.8&nbsp;million cumulative effect of the adoption of the New Lease Standard was recorded to stockholders&#146; equity. See Note 8 for further
information regarding the Company&#146;s leases. </P> <P STYLE="margin-top:0pt;margin-bottom:0pt;page-break-before:always"></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2016, the FASB issued
ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-13,</FONT> &#147;Financial Instruments &#150; Credit Losses (Topic 326)&#148; (ASU <FONT STYLE="white-space:nowrap">2016-13).</FONT> ASU <FONT STYLE="white-space:nowrap">2016-13</FONT> creates
accounting requirements on how to account for credit losses on most financial assets and certain other instruments. This will require the estimation of lifetime expected credit losses and corresponding recognition of allowance for losses on trade
and other receivables, loans, and other instruments held at amortized cost. The ASU requires certain recurring disclosures and is effective for annual periods, and interim periods within those annual periods, beginning on or after December&nbsp;15,
2023. The Company is analyzing the impact of this standard on its results of operations and financial position.</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. GOING CONCERN </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has incurred losses since its inception. The Company&#146;s net loss was $16.9&nbsp;million for the year ended December&nbsp;31, 2022, and it used
$19.4&nbsp;million of cash for operating activities for the year ended December&nbsp;31, 2022. The Company&#146;s primary sources of liquidity are its cash and cash equivalents, with additional liquidity accessible, subject to market conditions and
other factors, including limitations that may apply to the Company under applicable SEC and Nasdaq Capital Market (Nasdaq) regulations, from the capital markets, including under the Open Market Sale Agreement<SUP
STYLE="font-size:75%; vertical-align:top">SM</SUP> with Jefferies LLC (as amended, the ATM Facility). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, the Company had
$3.5&nbsp;million of cash, cash equivalents, and restricted cash. The Company&#146;s restricted cash is associated with its equipment financing leases and was $0.1&nbsp;million as of December&nbsp;31, 2022, and will be returned following the payoff
of the lease obligations in 2023. Current liabilities were $1.7&nbsp;million as of December&nbsp;31, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;3, 2022, the Company entered
into an amendment to the Open Market Sale Agreement with Jefferies for the ATM Facility that enables it, subject to the applicable baby shelf rules described below, to offer and sell up to 15,661,000 shares of its common stock. At its discretion,
the Company determines the timing and number of shares to be issued under the ATM Facility. During the fourth quarter of 2022, the Company issued approximately 2.0&nbsp;million shares of common stock under the ATM Facility for proceeds of
$0.1&nbsp;million net of commissions and payments for other share issuance costs. From December&nbsp;31, 2022, through the date of this report, the Company has not issued any additional shares under the ATM Facility. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the February 2022 Offering, the Company issued 3,880,000 shares of its common stock, <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants to
purchase up to 3,880,000 shares of its common stock, and Common Warrants to purchase up to 7,760,000 shares of its common stock in the <FONT STYLE="white-space:nowrap">Follow-On</FONT> Offering. In the aggregate, the Company received net proceeds of
$10.0&nbsp;million, after deducting approximately $0.9&nbsp;million of underwriting discounts and estimated other offering expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has
incurred losses since its inception and anticipates that it will continue to generate losses for the next several years. Over the longer term and until the Company can generate cash flows sufficient to support its operating capital requirements, it
expects to finance a portion of future cash needs through (i)&nbsp;cash on hand, (ii)&nbsp;commercialization activities, which may result in various types of revenue streams from (a)&nbsp;future product development agreements and technology
licenses, including upfront and milestone payments, annual license fees, and royalties; and (b)&nbsp;product sales from its proprietary BioFactory production system; (iii)&nbsp;government or other third-party funding, (iv)&nbsp;public or private
equity or debt financings, or (v)&nbsp;the execution of an alternative strategic </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
transaction pursuant to the board of directors&#146; ongoing evaluation process, or (vi)&nbsp;a combination of the foregoing. However, capital generated by commercialization activities, if any,
is expected to be received over a period of time and near-term additional capital may not be available on reasonable terms, if at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although the
Company has access to the ATM Facility, based on the Company&#146;s public float, as of the date of the filing of this Annual Report, the Company is only permitted to utilize a &#147;shelf&#148; registration statement for primary offerings,
including the registration statement under which the ATM Facility is operated, subject to Instruction I.B.6 to Form <FONT STYLE="white-space:nowrap">S-3,</FONT> which is referred to as the &#147;baby shelf&#148; rules. For so long as the
Company&#146;s public float is less than $75,000,000, it may not sell more than the equivalent of <FONT STYLE="white-space:nowrap">one-third</FONT> of its public float during any 12 consecutive months pursuant to the baby shelf rules. While
alternative public and private transaction structures may be available, these may require additional time and cost, may result in substantial dilution to existing stockholders, particularly in light of the Company&#146;s current stock price, may
impose operational restrictions on the Company, and may not be available on attractive terms or at all. Accordingly, the Company continuously assesses market conditions and available financing alternatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s ability to continue as a going concern will depend on its ability to obtain additional public or private equity or debt financing, obtain
government or private grants and other similar types of funding, to consummate an alternative strategic transaction, attain further operating efficiencies, reduce or contain expenditures, and, ultimately, to generate revenue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company believes that its cash, cash equivalents, and restricted cash as of December&nbsp;31, 2022, considering continuing actions taken to reduce its
operating expenses to enable the Transactions to close, the legal settlement discussed in Note 8 to the consolidated financial statements, and funding to be provided by Cibus are sufficient to fund its operations through the second quarter of 2023.
The Company&#146;s management has concluded there is substantial doubt regarding its ability to continue as a going concern because it will need to raise additional capital to support its business plan for a period of 12 months or more from the date
of this filing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and
satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that
might result from the outcome of the uncertainties described above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management has implemented various cost reduction and other cash-focused measures to
manage liquidity. If the Company is unable to raise additional capital in a sufficient amount or on acceptable terms or to consummate an alternative strategic transaction, the Company may have to implement increasingly stringent cost saving measures
and significantly delay, scale back, or cease operations, in part or in full. If the Company raises additional funds through the issuance of additional debt or equity securities, including as part of a strategic alternative, it could result in
substantial dilution to its existing stockholders and increased fixed payment obligations, and these securities may have rights senior to those of the Company&#146;s shares of common stock. Any of these events could significantly harm the
Company&#146;s business, financial condition, and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE AND CONCENTRATIONS OF CREDIT RISK
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Financial Instruments Measured at Fair Value and Financial Statement Presentation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial instruments including cash and cash equivalents, restricted cash, accounts payable, and all other current liabilities have carrying values that
approximate fair value. The Company measures Common Warrants on a quarterly basis. The accounting guidance establishes a three-tier hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value as of the
measurement date as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Level&nbsp;1: Fair values are based on unadjusted quoted prices in active trading markets for identical assets and
liabilities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Level&nbsp;2: Fair values are based on observable quoted prices other than those in Level&nbsp;1, such as
quoted prices for similar assets or liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Level&nbsp;3:
Fair values are based on at least one significant unobservable input for the asset or liability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value Measurements and Financial Statement
Presentation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2021, the Company had no financial instruments measured at fair value. The fair values of the Company&#146;s
financial instruments measured at fair value and their respective levels in the fair value hierarchy as of December&nbsp;31, 2022, were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Values of Assets</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Values of Liabilities</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>In Thousands</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other items reported at fair value:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>291</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>291</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company estimates the fair value of the Common Warrants as of the date of issuance and at the end of every fiscal period
using a Black-Scholes option pricing model, which requires it to make predictive assumptions regarding future stock price volatility and dividend yield. The Company estimates the risk-free interest rate based on the United States Treasury <FONT
STYLE="white-space:nowrap">zero-coupon</FONT> yield curve for the remaining life of the Common Warrants. The Company estimates its future stock price volatility using its historical volatility over the remaining life of the Common Warrants. The
Company does not pay dividends and does not expect to pay dividends in the foreseeable future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The estimated fair values of the Common Warrants, and the
assumptions used for the Black-Scholes option pricing model were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="23%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B><br><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated fair value of Common Warrants:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>0.04</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumptions:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term to liquidation (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>4.6</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>85.0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>4.0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, the Company had no other financial instruments measured at fair value. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">non-current</FONT> portion of the Company&#146;s financing lease obligations are also considered a financial instrument,
which the Company measures at fair value for disclosure purposes. It is a Level&nbsp;2 liability and as of December&nbsp;31, 2021, it had a fair value of $14.5&nbsp;million. There is no <FONT STYLE="white-space:nowrap">non-current</FONT> portion of
the financing lease obligation at December&nbsp;31, 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Concentrations of Credit Risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company invests its cash, cash equivalents, and restricted cash in highly liquid securities and investment funds. The Company diversifies the risk
associated with investing in securities by allocating its investments to a diverse portfolio of short-dated, high investment-grade securities, which it classifies as short-term investments that are recorded at fair value in its consolidated
financial statements. The Company maintains the credit risk in this portfolio in accordance with its internal policies and if necessary, makes changes to investments to minimize credit risk. The Company has not experienced any counterparty credit
losses. As of December&nbsp;31, 2022, the Company did not hold any short-term investments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. RELATED-PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is party to several agreements that govern its relationship with Cellectis, some of which require the Company to make payments to Cellectis.
Pursuant to the Company&#146;s management services agreement with Cellectis, it incurred no management fee expenses in 2022, and it incurred nominal management fee expenses in 2021 and 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cellectis has also guaranteed the lease agreement for the Company&#146;s headquarters. Cellectis&#146; guarantee of the Company&#146;s obligations under the
lease will terminate at the end of the second consecutive calendar year in which the Company&#146;s tangible net worth exceeds $300&nbsp;million. The Company agreed to indemnify Cellectis for any obligations incurred by Cellectis under its guaranty
of the obligations under the lease, effective upon Cellectis&#146; ownership falling to 50&nbsp;percent or less of the Company&#146;s outstanding common stock. This indemnification obligation was triggered in October 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TALEN<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> is the Company&#146;s primary gene editing technology. TALEN<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> technology was invented by researchers at the University of Minnesota and Iowa State University and exclusively licensed to Cellectis. The Company obtained an exclusive license for the TALEN<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> technology for commercial use in plants from Cellectis. The Company also licenses other technology from Cellectis. Cellectis is entitled to royalties on any revenue the Company generates from
sales of products less certain amounts as defined in the license agreement, royalties on certain cumulative revenue thresholds, and a percentage of any sublicense revenues. The Company has incurred nominal license and royalty fees for the years
ended December&nbsp;31, 2022, 2021, and 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. STOCKHOLDERS&#146; EQUITY </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preferred Stock </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Preferred stock of
50.0&nbsp;million shares, with a $0.0001 par value, is authorized but unissued. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Follow-on</FONT> Public Offerings
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the February 2022 Offering, the Company issued 3,880,000 shares of its common stock, <FONT STYLE="white-space:nowrap">Pre-Funded</FONT>
Warrants to purchase up to 3,880,000 shares of its common stock, and Common Warrants to purchase up to 7,760,000 shares of its common stock. The aggregate offering price for each share of common stock and accompanying Common Warrant was $1.41 per
share. The aggregate offering price for each <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant and accompanying Common Warrant was $1.4099 per share. In the aggregate, the Company received net proceeds of $10.0&nbsp;million, after deducting
approximately $0.9&nbsp;million of underwriting discounts and estimated other offering expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Pre-Funded</FONT>
Warrants </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant entitled the holder to purchase one share of the Company&#146;s common stock
at an exercise price of $0.0001 per share. The <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants were recorded as a component of stockholders&#146; equity within additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital. The <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants were exercised in full on May&nbsp;4, 2022, and subsequently settled with the counterparty. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Common Stock Warrants </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each Common Warrant entitles the
holder to purchase one share of common stock at an exercise price of $1.41 per share. The Common Warrants became exercisable on August&nbsp;23, 2022, and expire on August&nbsp;23, 2027. The Common Warrants are recorded as a liability in the
Company&#146;s consolidated balance sheet. Per the terms of the Common Warrants, a holder of an outstanding warrant is not entitled to exercise any portion of such warrant if, upon exercise of such portion of the warrant, the holder&#146;s ownership
of the Company&#146;s common stock (together with its affiliates) or the combined voting power of the Company&#146;s securities beneficially owned by such holder (together with its affiliates) would exceed the 4.99&nbsp;percent after giving effect
to the exercise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Warrant transactions for the year ended December&nbsp;31, 2022, are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number of<br><FONT STYLE="white-space:nowrap">Pre-Funded</FONT><br>Warrants</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Weighted<br>Average<br>Exercise<br>Price</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number of<br>Common<br>Warrants</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Weighted<br>Average<br>Exercise<br>Price</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2021:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issued</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,880,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,760,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited/canceled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,880,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2022:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,760,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable as of December&nbsp;31, 2022:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,760,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;20, 2020, the Company completed a <FONT STYLE="white-space:nowrap">follow-on</FONT> offering of its common
stock. It sold an aggregate of 3,750,000 shares of common stock at a price of $4.00 per share. In the aggregate, the Company received net proceeds from the <FONT STYLE="white-space:nowrap">follow-on</FONT> offering of $14.0&nbsp;million, after
deducting $1.0&nbsp;million of placement and agent fees and other offering expenses. As part of the <FONT STYLE="white-space:nowrap">follow-on</FONT> offering, Cellectis purchased 1,250,000 shares of common stock for a value of $5.0&nbsp;million,
the proceeds of which are included in the net proceeds of $14.0&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ATM Facility </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;21, 2021, the Company entered into an ATM Facility with Jefferies LLC, as sole selling agent. The Company issued approximately
1.4&nbsp;million shares of common stock under the ATM Facility in 2021. In the aggregate, the Company received net proceeds from the ATM Facility of $4.1&nbsp;million through early January 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;3, 2022, the Company entered into an amendment to the Open Market Sale Agreement that enables it, subject to the applicable baby shelf rules,
to offer and sell up to 15,661,000 shares of its common stock. At its discretion, the Company determines the timing and number of shares to be issued under the ATM Facility. During the fourth quarter of 2022, the Company issued approximately
2.0&nbsp;million shares of common stock under the ATM Facility for proceeds of $0.1&nbsp;million net of commissions and payments for other share issuance costs. From December&nbsp;31, 2022, through the date of this report, the Company has not issued
any additional shares under the ATM Facility. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. STOCK-BASED COMPENSATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company uses broad-based stock plans to attract and retain highly qualified officers and employees and to help ensure that management&#146;s interests are
aligned with those of its shareholders. The Company has also granted equity-based awards to directors, nonemployees, and certain employees of Cellectis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2014, the Company adopted the 2014 Plan, which allowed for the grant of stock options, and in June 2017, it adopted the 2017 Plan, which allowed
for the grant of stock options, restricted stock units, PSUs, and other types of equity awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;19, 2021, James Blome ceased serving as
the Company&#146;s Chief Executive Officer. The Company recorded a benefit to earnings from a $2.5&nbsp;million recapture of <FONT STYLE="white-space:nowrap">non-cash</FONT> stock compensation expense from the forfeiture of Mr.&nbsp;Blome&#146;s
unvested stock options, restricted stock units, and PSUs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;16, 2021, the Company filed a Registration Statement on Form <FONT
STYLE="white-space:nowrap">S-8</FONT> with the SEC which registered an additional 4,299,904 shares of common stock that may be issued or delivered and sold pursuant to the 2017 Plan and 600,000 shares of common stock that may be issued or delivered
and sold pursuant to the Calyxt, Inc. Inducement Plan. Shares of common stock are issuable under the Inducement Plan upon the settlement of PSUs which were granted to Mr.&nbsp;Michael&nbsp;A. Carr in July 2021 as a material inducement to accept
employment as the Company&#146;s President and Chief Executive Officer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, 2,718,149 shares were registered and available for grant under effective
registration statements, while 3,112,568 shares were available for grant in the form of stock options, restricted stock, restricted stock units, and PSUs under the 2017 Plan. Stock-based awards currently outstanding also include awards granted under
the 2014 Plan and the Inducement Plan. No further awards will be granted under either the 2014 Plan or the Inducement Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Options
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The estimated fair values of stock options granted, and the assumptions used for the Black-Scholes option pricing model were as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated fair values of stock options granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>0.86</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumptions:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">1.9%&nbsp;-&nbsp;3.5</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">0.6%&nbsp;-&nbsp;1.2</FONT></TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">0.3%&nbsp;-&nbsp;1.7</FONT></TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B><FONT STYLE="white-space:nowrap">89.7%&nbsp;-&nbsp;92.8</FONT></B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">80.1%&nbsp;-&nbsp;91.0</FONT></TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">77.4%&nbsp;-&nbsp;81.2</FONT></TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>5.5&nbsp;- 6.9</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.5&nbsp;- 6.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.0&nbsp;- 10.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company estimates the fair value of each option on the grant date, or other measurement date if applicable, using a
Black-Scholes option pricing model, which requires it to make predictive assumptions regarding employee exercise behavior, future stock price volatility, and dividend yield. The Company estimates the risk-free interest rate based on the United
States Treasury <FONT STYLE="white-space:nowrap">zero-coupon</FONT> yield curve at the date of grant for the expected term of the option. The Company estimates its future stock price volatility using the weighted-average historical volatility
calculated from a group of comparable public companies over the expected term of the option. The expected term of stock options is estimated using the average of the vesting tranches and the contractual life of each grant for employee options, or
the simplified method, as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The use of the simplified method
is dependent upon the type of equity award granted and the term of the award. The Company does not pay dividends and does not expect to pay dividends in the foreseeable future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Option strike prices are set at 100&nbsp;percent or more of the closing share price on the date of grant and generally vest over three to six years following
the grant date. Options generally expire 10 years after the date of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information on stock option activity is as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Options</B><br><B>Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-</B><br><B>Average</B><br><B>Exercise</B><br><B>Price Per</B><br><B>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Options</B><br><B>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-</B><br><B>Average</B><br><B>Exercise</B><br><B>Price Per</B><br><B>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,789,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,658,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,609,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited or expired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(425,952</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of December&nbsp;31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>3,396,624</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>9.94</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>5,841,453</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>7.35</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense related to stock option awards was as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>In Thousands</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2,031</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, options outstanding and exercisable had no aggregate intrinsic value and the
weighted average remaining contractual term was 5.0 years as of that date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash proceeds from the exercise of stock options less shares used for
minimum withholding taxes and the intrinsic value of options exercised were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>In Thousands</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash proceeds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intrinsic value of options exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, unrecognized compensation expense related to <FONT STYLE="white-space:nowrap">non-vested</FONT>
stock options was $3.1&nbsp;million. This expense will be recognized over 22 months on average. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Stock Units </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company grants restricted stock units which generally vest over three to five years after the date of grant. Information on restricted stock unit activity
is as follows:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of</B><br><B>Restricted&nbsp;Stock</B><br><B>Units&nbsp;Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-</B><br><B>Average</B><br><B>Grant&nbsp;Date&nbsp;Fair</B><br><B>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested balance at December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">571,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,077,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(303,728</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(115,969</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Unvested balance at December&nbsp;31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,229,206</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1.99</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The total grant-date fair value of restricted stock unit awards that vested was as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>In Thousands</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant-date fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,940</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information on the weighted average grant date fair value of restricted stock units issued was as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>In Thousands</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average grant date fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1.26</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense related to restricted stock units was as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>In Thousands</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,318</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, unrecognized compensation expense related to restricted stock units was $1.2&nbsp;million. This
expense will be recognized over 22 months on average. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for stock-based compensation awards granted to employees of Cellectis as
deemed dividends. The Company recorded deemed dividends as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>In Thousands</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deemed dividends from grants to Cellectis employees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>90</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(289</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Performance Stock Units </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">time-to-time,</FONT></FONT> the Company issues PSUs to certain individuals in management
in order to align their objectives with stockholders of the Company. Depending upon the type of PSU award, the Company uses a Monte Carlo simulation pricing model when estimating the fair values of these awards. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2022 Grant </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March 2022, the Company granted 530,000
PSUs under the 2017 Plan to five employees including four executive officers. The PSUs include three annual performance periods (2022, 2023, and 2024) and target performance levels for each of those periods linked to the achievement of Company
objectives as determined annually for the respective period by the Compensation Committee. Once the annual objectives are approved, the associated expense will be recognized on a straight-line basis over the period through the determination date,
which can be no later than March&nbsp;15 of the following year. Earned awards will be settled in shares of Company stock no later than the March&nbsp;15 determination date in the following calendar year. The grant date for the tranche of awards
linked to 2022 performance is May&nbsp;4, 2022. Determination of expense for the 2023 and 2024 tranches of PSUs will be made when the associated business objectives are determined. See Note 14 for more information about the vesting of these PSU
awards. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2021 Grant </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In July 2021, the Company
granted 600,000 PSUs under the Inducement Plan to Mr.&nbsp;Carr. The PSUs will vest if the Company&#146;s stock remains above three specified price levels for 30 calendar days over the three-year performance period. The PSUs will be settled in
unrestricted shares of the Company&#146;s common stock on the vesting date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The estimated fair values of PSUs granted in 2021 and the assumptions used
were as follows:</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Estimated fair values of performance stock units granted: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">At least $12 per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2.16</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">At least $15 per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1.89</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">At least $20 per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1.55</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumptions:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>3.0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>90.0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>0.4</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company estimated the fair value of each tranche of the PSUs on the grant date using the Monte Carlo simulation pricing
model, which required it to make predictive assumptions as to the expected term of the grant, future stock price volatility, and dividend yield. The expected term represents the expected service period of the PSUs granted. Expected volatility was
based on the historical volatility of the Company&#146;s common stock over the expected term. The Company estimates the risk-free interest rate based on the United States Treasury <FONT STYLE="white-space:nowrap">zero-coupon</FONT> yield curve at
the date of grant for the expected term of the option. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2019 Grant forfeitures </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2022, PSU grants made to two executive officers in 2019 were forfeited because the underlying performance criteria were not met. These PSUs contained a
market condition and had a five-year service period. The Company will continue to expense these PSUs over the remaining service period for these two executive officers. During 2021, the Company recognized a benefit from the forfeiture of 166,667
PSUs held by Mr.&nbsp;Blome, its former Chief Executive Officer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PSU activity for the year ended December&nbsp;31, 2022, is as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>PSUs</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2021:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>745,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issued</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>530,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited/canceled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(145,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Awarded</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2022:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,130,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense related to PSUs is as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>In Thousands</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>649</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, unrecognized compensation expense related to PSUs was $0.9&nbsp;million. This expense will be
recognized over 19 months on average. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. INCOME TAXES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table reconciles the United States statutory income tax rate to the Company&#146;s effective income tax rate: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">United States statutory rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>21.0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State tax, net of federal benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1.0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(1.7</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.7</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.5</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Officer compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(1.4</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1.0</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rate change</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">R&amp;D credit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2.2</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PPP Loan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized (gain) loss on
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> of common stock warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>6.4</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.1</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(27.5</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(25.4</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(24.4</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effective income tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred assets and liabilities consist of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>In Thousands</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>40,914</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2,950</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,724</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing lease obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease ROU liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2,921</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax credit carry forwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>3,685</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capitalized R&amp;D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2,183</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>14</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">339</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">703</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>124</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">391</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>52,791</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49,082</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(49,843</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(45,369</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(39,898</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2,948</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fixed assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(89</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,667</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,609</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease ROU assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(2,859</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(46</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(2,948</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,713</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,609</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax asset or liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company provides for a valuation allowance when it is more likely than not that it will not realize a portion of the
deferred tax assets. The Company has established a full valuation allowance for deferred tax assets described above due to the uncertainty that enough taxable income will be generated in the taxing jurisdiction to utilize the assets. Therefore, the
Company has not reflected any benefit of such deferred tax assets in the accompanying consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has
$239.2&nbsp;million of tax loss carryforwards. Of this amount, $55.2&nbsp;million are state operating loss carryforwards and $184.0&nbsp;million are federal operating loss carryforwards. The federal carryforward periods are as follows:
$142.0&nbsp;million do not expire and $41.9&nbsp;million expire between 2032 and 2037. The state net operating losses will expire between 2027 and 2041, with some amounts having indefinite carryover. The Company also has federal and state R&amp;D
credit carryovers of $2.6&nbsp;million and $1.3&nbsp;million, which will expire between 2032 and 2042. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is subject to federal income taxes in
the United States as well as various state and local jurisdictions. The Company has reviewed its tax positions and concluded that no liability for uncertain tax positions is required as of December&nbsp;31, 2022. The Company will classify any future
interest and penalties as a component of income tax expense if incurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company does not expect the amount of uncertain tax positions to change
significantly in the next 12 months. The Company&#146;s major taxing jurisdictions are in the United States, at both the federal and state levels. The number of years open for examination varies depending on the tax jurisdiction but are generally
from three to five years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. LEASES, COMMITMENTS, AND CONTINGENCIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Litigation and Claims </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the fourth quarter of
2022, the Company reached a settlement with one of its technology vendors regarding alleged intellectual property infringement. As a result of the settlement, the Company received $0.75&nbsp;million in the fourth quarter of 2022. See Note 14 for
further information regarding this legal settlement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is not currently a party to any other material pending legal proceedings. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sale-Leaseback of Headquarters and Laboratory Facilities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2017, the Company consummated a sale-leaseback transaction with a third party for its corporate headquarters and laboratory facilities in
Roseville, Minnesota, which encompasses approximately 44,000 square feet including office and lab space, the first pilot BioFactory production system, greenhouses, and outdoor research plots. The Company is deemed the owner for accounting purposes.
The lease has a term of twenty years and includes four options to each extend the lease for five years subject to there being no default under the lease terms beyond any cure period and the Company occupying the property at the time of extension. In
2017, the Company received $7.0&nbsp;million in connection with the sale of the land and uncompleted facility. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The lease commenced in May 2018. Under the
lease, the Company pays an annual base rent of eight percent of the total project cost with scheduled increases in rent of 7.5&nbsp;percent on the sixth, eleventh, and sixteenth anniversaries of the start of the lease commencement as well as on the
first day of each renewal term. Currently, the Company pays an annual base rent of $1.4&nbsp;million. The first increase will occur during 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company is also responsible for all operating costs and expenses associated with the property. If the landlord decides to sell the property, the Company has a right of first refusal to purchase the property on the same terms offered to any third
party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrent with entering the lease, Cellectis guaranteed the lease agreement for the Company&#146;s headquarters. However, the Company previously
agreed to indemnify Cellectis for any obligations under this guaranty, effective upon Cellectis&#146; ownership falling to 50&nbsp;percent or less of the Company&#146;s outstanding common stock. Accordingly, the Company&#146;s indemnification
obligation was triggered in October 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to 2022, this lease was considered a failed sale leaseback based on the nature of the transactions and
was reported as a financing-type lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As discussed in Note 1, Recently Issued Accounting Pronouncements, the Company adopted the New Lease Standard as
of January&nbsp;1, 2022, using the transition method which does not require revisions to comparative periods. The Company elected to implement the transition package of practical expedients permitted within the New Lease Standard, which among other
things, allows it to carryforward the historical lease classification. In addition, the Company elected the hindsight practical expedient to determine the lease term for existing leases and it also made an accounting policy election to not record
leases with an initial term of 12 months or less on its consolidated balance sheet. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s adoption of the New Lease Standard required it to
remove the previously reported amounts for land, buildings, and equipment associated with its headquarters and laboratory facilities lease as well as the associated liability. The Company assessed the elements of its lease agreement and upon
adoption, recorded an operating lease associated with the sale leaseback of land underlying the headquarter facility, and a second operating lease associated with the building. The Company recorded operating lease assets and liabilities of
$14.1&nbsp;million within its consolidated balance sheet as of January&nbsp;1, 2022. The New Lease Standard had no impact on the Company&#146;s consolidated statements of operations or cash flows. The $0.8&nbsp;million cumulative effect of the
adoption of the New Lease Standard was recorded to stockholders&#146; equity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The impact of adoption of the New Lease Standard on the Company&#146;s December&nbsp;31, 2021, consolidated
balance sheet was as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">As Reported<br>December&nbsp;31,<br>2021</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Adoption&nbsp;of<br>Lease&nbsp;Standard</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">As Adjusted<br>December&nbsp;31,<br>2021</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Land, buildings, and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,543</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,453</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities and stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of financing lease obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing lease obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(17,371</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,814</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,814</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(196,092</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(195,260</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(178,025</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,453</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(180,478</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sale-Leaseback of Equipment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company also has an equipment financing arrangement that is considered a financing-type lease which matures in 2023. The Company was required to deposit
cash into a restricted account in an amount equal to the future rent payments required by the lease. As of December&nbsp;31, 2022, restricted cash totaled $0.1&nbsp;million, and will be returned following the payoff of the lease obligations in 2023.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recognition of Lease Liabilities </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company
records its operating lease liabilities at the present value of the future lease payments over the lease term. If the lease term includes options to extend or terminate the lease, those elements are included in the determination of lease term when
it is reasonably certain that the option will be exercised. The rate used to determine the present value of future lease payments is the rate stated in the lease agreement, or if not stated, the Company&#146;s incremental borrowing rate is used, up
to an effective rate that enables the lease liability to amortize to zero over the lease term. Rent expense for operating leases is recorded in SG&amp;A expense in the consolidated statements of operations and in operating cash flows in the
consolidated statements of cash flows. The Company also records operating lease ROU assets at an initial amount equal to the operating lease liability. Those ROU assets are amortized to lease expense within SG&amp;A over the lease term using the
effective interest method to ensure the ROU asset amortizes to zero concurrent with the associated liability, and the ROU asset amortization expense is also reported in operating cash flows in the consolidated statements of cash flows. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company records its financing lease liabilities at the present value of the future lease payments over the lease term. If the lease term includes options
to extend or terminate the lease, those elements are included in the determination of lease term when it is reasonably certain that the option will be exercised. The rate used to determine the present value of future lease payments is the rate
stated in the lease agreement, or if not stated, the Company&#146;s incremental borrowing rate is used, up to an effective rate that enables the lease liability to amortize to zero over the lease term. Expense associated with financing leases is
recorded in interest, net in the consolidated statements of operations and in operating cash flows in the consolidated statements of cash flows. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company is obligated under a <FONT STYLE="white-space:nowrap">non-cancellable</FONT> operating lease for office and laboratory space at its facility in Roseville, Minnesota. The lease has a remaining term of 15.3 years and has a ROU asset of
$13.6&nbsp;million as of December&nbsp;31, 2022. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Roseville, Minnesota lease includes four options to each extend the lease for five years. These options
to extend the lease are not recognized as part of the ROU assets and operating lease liabilities as it is not reasonably certain that the Company will exercise those options. The Company&#146;s agreement does not include options to terminate the
lease. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Lease Expense </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The components of lease
expense were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>In Thousands</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance lease costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>75</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,548</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Variable lease costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>942</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">NA</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">NA</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2,565</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,477</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">NA-</FONT> not applicable prior to the New Lease Standard </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Operating lease cost for short-term leases was not material for the year ended December&nbsp;31, 2022. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Lease Information </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other information related
to leases was as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,&nbsp;2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>In Thousands except for lease term and discount rate</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Operating</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Financing</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for amounts included in the measurement of lease liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating cash flows</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing cash flows</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average remaining lease term (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average discount rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, future minimum payments under operating and finance leases were as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>In Thousands</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Operating</B><br><B>Leases</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Financing</B><br><B>Leases</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>Leases</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 1,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 1,546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2027</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total including interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: imputed interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,540</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,543</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>13,814</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B> 97</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>13,911</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. EMPLOYEE BENEFIT PLAN </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company provides a 401(k) defined contribution plan for all regular full-time employees who have completed two months of service. The Company matches
employee contributions up to certain amounts and those matching contributions vest immediately. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>In Thousands</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employee benefit plan expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>259</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. SUPPLEMENTAL INFORMATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain balance sheet amounts are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>In Thousands</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents, and restricted cash:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>3,427</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>99</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-current</FONT> restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>3,526</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>In Thousands</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common warrants &#150; financing costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>396</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>210</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>606</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>In Thousands</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease obligations &#150; current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>367</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>112</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>479</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>In Thousands</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Land, buildings, and equipment:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Land under capital lease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Buildings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>900</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Buildings under capital lease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>364</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements under capital lease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office furniture and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>7,803</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office furniture and equipment under capital lease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>414</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>912</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Construction in progress</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">849</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vehicles</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total land, buildings, and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>10,393</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less accumulated depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(5,877</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,728</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>4,516</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain statements of operations amounts are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>In Thousands</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Soybean grain</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Soybean meal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Soybean oil</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>157</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>157</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,851</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>In Thousands</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>946</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general, and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>3,052</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>3,998</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,971</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>In Thousands</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest, net:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(75</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,431</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,435</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>60</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock warrants &#150; financing cost amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(72</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(87</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,414</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(878</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Supplemental statement of cash flows information is as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>In Thousands</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>69</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> transactions not reported in the consolidated statement of cash flows are as
follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>In Thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Receivable from Jefferies for shares issued under ATM Facility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(260</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> additions to land, buildings, and
equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(691</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cumulative effect of adoption of lease accounting standard on stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>832</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Establishment of operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and associated operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>14,090</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. SEGMENT INFORMATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company operates in a single reportable segment, the development and commercialization of products derived from plant cells. The chief operating decision
maker is the Company&#146;s Chief Executive Officer, who makes resource allocation decisions and assesses business performance based on financial information presented on a consolidated basis. There are no segment managers who are held accountable
by the chief operating decision </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
maker, or anyone else, for operations, operating results, and planning for levels or components below the consolidated unit level. Accordingly, the Company has determined that it operates in a
single reportable segment, the development and commercialization of products derived from plant cells. The Company&#146;s current commercial focus is North America, and all revenue in 2022 was recognized in the United States. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. LONG-TERM DEBT </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s long-term debt was
comprised of a $1.5&nbsp;million promissory note pursuant to the PPP loan established by the Coronavirus Aid, Relief, and Economic Security Act (the CARES Act) implemented by the SBA. The Company received the funds under the PPP loan on
April&nbsp;19, 2020. Subject to certain conditions, the PPP loan and accrued interest were eligible to be forgiven in whole or in part by applying for forgiveness pursuant to the CARES Act and the Paycheck Protection Program. In order to be eligible
for forgiveness, the proceeds of the PPP loan were required to be applied to certain eligible expenses, including payroll costs, interest on certain mortgage obligations, rent payments on certain leases, and certain qualified utility payments, with
not more than 40&nbsp;percent of the amount applied to <FONT STYLE="white-space:nowrap">non-payroll</FONT> costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company applied the proceeds from
the PPP loan toward qualifying expenses. On October&nbsp;21, 2020, as modified December&nbsp;29, 2020, the Company applied for forgiveness of the full principal amount and all accrued interest. On April&nbsp;8, 2021, the Company was notified by the
SBA that the full principal amount and all accrued interest of the PPP loan had been forgiven. Accordingly, the Company recognized a gain upon the extinguishment of the PPP loan for $1.5&nbsp;million during the second quarter of 2021. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. RESTRUCTURING COSTS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;4, 2020, the
Company approved a move to a streamlined <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">go-to-market</FONT></FONT> strategy for its soybean product line. The impact of the action included staffing adjustments related to soybean
processing and product sales, as well as the gradual exit of all supply chain contractual commitments that were not associated with the soybean <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">go-to-market</FONT></FONT> strategy. In
the fiscal year ended December&nbsp;31, 2020, the Company recorded $0.7&nbsp;million of restructuring costs for severance and other related payments, and also recorded a $0.9&nbsp;million recapture benefit of
<FONT STYLE="white-space:nowrap">non-cash</FONT> stock compensation expense from the forfeiture or modification of unvested stock awards. The Company did not incur any other material costs from the disposal of any assets or contractual terminations
in the years ended December&nbsp;31, 2021, and 2020. As of December&nbsp;31, 2020, all severance and transitional expenses were recorded, with $0.4&nbsp;million to be paid during 2021. As of December&nbsp;31, 2021, all amounts related to the
restructuring had been paid. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. SUBSEQUENT EVENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Merger with Cibus Global LLC </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;13,
2023, the Company and Cibus Global, LLC entered into a definitive merger agreement under which the Company and Cibus will merge in an <FONT STYLE="white-space:nowrap">all-stock</FONT> transaction. As a part of the proposed merger, beginning at the
earlier of March&nbsp;15, 2023 and the date the Company&#146;s unrestricted cash balance first drops below $1,500,000, the Company can request, and Cibus has agreed to provide, an unsecured, interest-free revolving line of credit of up to $3,000,000
in cash, which amount may be increased to $4,000,000 under certain conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Transactions (as defined in Note 14), beginning at
the earlier of March&nbsp;15, 2023 and the date Calyxt&#146;s unrestricted cash balance first drops below $1,500,000, Calyxt can request, and Cibus has agreed to provide, an unsecured, interest-free revolving line of credit of up to $3,000,000 in
cash, which amount may be increased to $4,000,000 if Cibus elects to extend the outside date (as defined in the Merger Agreement) to June&nbsp;30, 2023 (the Interim Funding.&#148; Funds can be drawn by Calyxt in $500,000 increments and may only be
used to fund operating expenses incurred in the ordinary course of business consistent with past practice and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consistent with the negative covenants in the Merger Agreement. The full outstanding balance of the Interim Funding will be reduced to zero in connection with the closing of the Transactions, if
consummated. The full outstanding balance of the Interim Funding will be forgiven by Cibus if the Merger Agreement is terminated for any reason other than certain under certain conditions, as detailed in the Merger Agreement. The Interim Funding is
subject to acceleration in connection with certain bankruptcy events. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Modification of Stock Options </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;1, 2023, the Company&#146;s Board of Directors approved the modification of the award terms of all outstanding stock options that have <FONT
STYLE="white-space:nowrap">90-day</FONT> post-separation exercise periods from the current 90 days to five years from date of grant. These modifications may result in additional stock compensation expense that will be recognized immediately for
vested awards or over the remaining service period for unvested awards as of that date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Grant of Restricted Stock Units </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;1, 2023, the Company&#146;s Board of Directors authorized the grant of an aggregate of 3,487,503 RSUs. These awards will vest upon completion of
the Transactions, and accordingly, the expense associated with these awards will be recognized over the period from the date of grant to the estimated closing date of the Transactions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Performance Stock Units </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;1, 2023,
the Company&#146;s Board of Directors determined the 2022 tranche of PSUs would vest at 100%. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Litigation and Claims </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the fourth quarter of 2022, the Company reached a settlement with one of its technology vendors regarding alleged intellectual property infringement. The
Company received the final installment of $0.75&nbsp;million in the first quarter of 2023. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fin401831_12"></A>Independent Auditor&#146;s Report </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Board of Directors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cibus Global, LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, California </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Opinion </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited the consolidated financial statements of Cibus Global, LLC (the &#147;Company&#148;), which comprise the consolidated balance sheets as of
December&nbsp;31, 2022 and 2021, and the related consolidated statements of operations, comprehensive loss, members&#146; deficit, and cash flows for the years then ended, and the related notes to the consolidated financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the financial position of the Company as of
December&nbsp;31, 2022 and 2021, and the results of its operations and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis for Opinion </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audits in
accordance with auditing standards generally accepted in the United States of America (&#147;GAAS&#148;). Our responsibilities under those standards are further described in the Auditor&#146;s Responsibilities for the Audit of the Financial
Statements section of our report. We are required to be independent of the Company and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we
have obtained is sufficient and appropriate to provide a basis for our audit opinion. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Change in Accounting Principle </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As discussed in Note 2 to the consolidated financial statements, the Company changed its method of accounting for leases in 2022 due to the adoption of
Accounting Standards Codification Topic 842, Leases.<B></B> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Substantial Doubt About the Company&#146;s Ability to Continue as a Going Concern
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As described in
Note 1 to the consolidated financial statements, the Company has suffered recurring losses from operations, has a net capital deficiency, and has stated that substantial doubt exists about the Company&#146;s ability to continue as a going concern.
Management&#146;s evaluation of the events and conditions and management&#146;s plans regarding these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of
this uncertainty. Our opinion is not modified with respect to this matter. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Responsibilities of Management for the Financial Statements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with accounting principles generally
accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement,
whether due to fraud or error. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In preparing the consolidated financial statements, management is required to evaluate whether there are conditions or
events, considered in the aggregate, that raise substantial doubt about the Company&#146;s ability to continue as a going concern within one year after the date that the consolidated financial statements are issued or available to be issued. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Auditor&#146;s Responsibilities for the Audit of the Financial Statements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether
due to fraud or error, and to issue an auditor&#146;s report that includes </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a
material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the
override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the consolidated financial
statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In performing an audit in accordance with GAAS, we: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Exercise professional judgment and maintain professional skepticism throughout the audit. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to
fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are
appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company&#146;s internal control. Accordingly, no such opinion is expressed. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting
estimates made by management, as well as evaluate the overall presentation of the consolidated financial statements. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise
substantial doubt about the Company&#146;s ability to continue as a going concern for a reasonable period of time. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are required to
communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ BDO USA, LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, California </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April 14, 2023 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Cibus Global, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin401831_13"></A>Consolidated Balance Sheets </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except unit amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Due from related parties, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Right-of-use asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43,183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities and Members&#146; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Due to related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notes payable, current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent, current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities, current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,654</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing lease liabilities, current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capital lease obligations, current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notes payable, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing lease liabilities, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Royalty liability - related parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43,252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54,993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies (See Note 15)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Members&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A convertible preferred units, no par value; 83,300,852 units authorized at
December&nbsp;31, 2022 and 2021; 67,810,963 and 67,781,328 units issued and outstanding at December&nbsp;31, 2022 and 2021, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64,097</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B convertible preferred units, no par value; 31,285,438 units authorized at
December&nbsp;31, 2022 and 2021; 30,817,791 units issued and outstanding at December&nbsp;31, 2022 and 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C convertible preferred units, no par value; 38,173,979 units authorized at
December&nbsp;31, 2022 and 2021; 33,195,500 units issued and outstanding at December&nbsp;31, 2022 and 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series D convertible preferred units, no par value; 44,000,000 units authorized at
December&nbsp;31, 2022 and 2021; 44,000,000 units issued and outstanding at December&nbsp;31, 2022 and 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54,195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54,195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series E convertible preferred units, no par value; 19,886,364 units authorized at
December&nbsp;31, 2022 and 2021; 19,884,227 units issued and outstanding at December&nbsp;31, 2022 and 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series F convertible preferred units, no par value; 50,000,000 and no units authorized at
December&nbsp;31, 2022 and 2021, respectively; 26,485,598 and none issued and outstanding at December&nbsp;31, 2022 and 2021, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Voting common units, no par value; 341,282,000 and 291,281,999 units authorized at
December&nbsp;31, 2022 and 2021, respectively; none issued and outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nonvoting common units, no par value; 66,414,403 units authorized at December&nbsp;31, 2022 and
2021; 63,903,905 and 56,805,754 units issued and outstanding at December&nbsp;31, 2022 and 2021, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unit subscription receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,078</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,072</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56,829</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(412,138</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(356,585</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total members&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(30,912</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29,588</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and members&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 43,183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Cibus Global, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin401831_14"></A>Consolidated Statements of Operations and Comprehensive Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Revenue</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration and research</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration and research - related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">908</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,563</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,461</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,779</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(49,130</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(32,112</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other (income) expense, net</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense, royalty liability - related parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on extinguishment of debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,178</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other (income) expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss from continuing operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(55,553</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(33,962</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss from discontinued operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(23</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(55,553</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(33,985</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency translation adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(55,566</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(33,944</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Cibus Global, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin401831_15"></A>Consolidated Statements of Members&#146; Deficit </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except unit amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Convertible<BR>Preferred<BR>Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nonvoting<BR>Common<BR>Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unit<BR>Subscription<BR>Receivable</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR>Paid-In<BR>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Other<BR>Comprehensive<BR>Income</B><br><B>(Loss)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Members&#146;<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><B>Balance at December 31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">161,275,460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">222,078</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36,862,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,066</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53,301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(36</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(322,600</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(50,403</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Issuance of Series D convertible preferred units, net of issuance costs of $250</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,519,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Issuance of Series E convertible preferred units, net of issuance costs of $615</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,884,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Issuance of restricted units</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,645,004</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Issuance of restricted units for services</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">232,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Issuance of common units for services</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">338,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Issuance of common warrants for services</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Repurchase of restricted units</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(272,410</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Equity-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,941</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,941</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Interest on subscription receivable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Foreign currency translation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(33,985</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(33,985</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><B>Balance at December 31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">195,678,846</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">274,358</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56,805,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,072</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(356,585</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29,588</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Issuance of Series F convertible preferred units, net of issuance costs of $161</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,485,598</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Issuance of Series A preferred units upon exercise of Series A preferred warrants</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,635</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Issuance of restricted units</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,073,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Issuance of restricted units for services</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">483,113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Repurchase of restricted units</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(457,962</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(26</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(31</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Equity-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Warrant modification</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Interest on subscription receivable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Foreign currency translation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(55,553</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(55,553</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7pt; font-family:Times New Roman"><B>Balance at December 31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">222,194,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">327,205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63,903,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,078</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56,829</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(412,138</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(30,912</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Cibus Global, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin401831_16"></A>Consolidated Statements of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from operating activities, continuing operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(55,553</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(33,985</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss from discontinued operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,941</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> interest expense, royalty liability - related
parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> issuance of restricted units to board of
directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on extinguishment of debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,178</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Due from related parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(33</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(49</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(563</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(197</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(72</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,572</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,547</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">610</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Due to related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(89</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(85</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(357</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset and lease liabilities, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(101</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(28</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities, continuing operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(44,550</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(32,243</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from investing activities, continuing operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,229</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,864</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from sale of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities, continuing operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,213</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,842</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from financing activities, continuing operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Principal payments on financing leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(201</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(246</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from financing leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Principal payments on notes payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(904</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(486</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of notes payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,038</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from exercise of Series A preferred warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of Series D convertible preferred units, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of Series E convertible preferred units, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of Series F convertible preferred units, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of SAFE Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repurchase of restricted units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(31</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of restricted units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities, continuing operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52,364</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of exchange rate changes on cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase in cash and cash equivalents, continuing operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Discontinued Operations:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,088</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net decrease in cash and cash equivalents from discontinued operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,088</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash and cash equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents - beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents - end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 24,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Cibus Global, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin401831_17"></A>Notes to Consolidated Financial Statements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Nature of Business and Organization </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cibus Global,
LLC, a Delaware limited liability company, (&#147;Cibus&#148; or the &#147;Company&#148;) was formed on May&nbsp;10, 2019. At the time immediately prior to the effective date of the formation, Cibus was organized as a British Virgin Islands company
(&#147;Cibus Global, Ltd.&#148;), which was formed on November&nbsp;5, 2001. In 2019 the Company was converted to be a Delaware limited liability company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cibus is a plant trait company using gene editing technologies to develop and license gene edited plant traits that improve farming productivity or produce
renewable low carbon plant products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidity and Going Concern </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has experienced recurring net losses and negative cash flows from operations since its inception and has relied on its ability to fund its
operations through equity financings. The Company expects to continue to incur net losses for at least the next several years. As of December&nbsp;31, 2022, the Company had an accumulated deficit of $412.1&nbsp;million and cash and cash equivalents
of $24.3&nbsp;million. The Company&#146;s expected operating losses and negative cash flows raise substantial doubt about the Company&#146;s ability to continue as a going concern within one year from the date these financial statements were
available to be issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s ability to continue as a going concern is dependent upon its ability to raise additional funding. Management
intends to raise additional capital through a combination of equity or equity-linked securities offerings, debt issuances, commercial sales transactions, and collaboration and license agreements. However, the Company may not be able to secure
additional financing in a timely manner or on favorable terms, if at all. Furthermore, if the Company issues equity securities to raise additional funds, its existing members may experience dilution, and the new equity securities may have rights,
preferences and privileges senior to those of the Company&#146;s existing members. If the Company raises additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to its
potential products or proprietary technologies or grant licenses on terms that are not favorable to the Company. If the Company is unable to raise capital when needed or on attractive terms, it would be forced to delay, reduce or eliminate its
research and development programs or other operations. If any of these events occur, the Company&#146;s ability to achieve the development and commercialization goals would be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the
realization of assets and settlement of liabilities in the normal course of business. They do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of
liabilities that may result from uncertainty related to its ability to continue as a going concern. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Summary of Significant Accounting Policies
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation and Consolidation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America
(&#147;GAAP&#148;) and include the accounts of Cibus Global, LLC and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of the
Company&#146;s consolidated financial statements and related disclosures in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
liabilities, and disclosures of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period.
Management evaluates its estimates on an ongoing basis. Although estimates are based on the Company&#146;s historical experience, knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ
from these estimates and assumptions. Key estimates made by the Company include revenue recognition, useful lives and impairment of long-lived assets, valuation of equity-based awards and related equity-based compensation expense, and the valuation
of the Royalty Liability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value Measurements of Financial Instruments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company follows Accounting Standards Codification (&#147;ASC&#148;) Topic 820, <I>Fair Value Measurements and Disclosures</I>, for financial assets and
liabilities that are recognized or disclosed at fair value in these consolidated financial statements on a recurring basis. Under ASC 820, fair value refers to the price that would be received to sell an asset or paid to transfer a liability in an
orderly transaction between market participants in the market in which the reporting entity transacts its business. ASC 820 clarifies fair value should be based on assumptions market participants would use when pricing the asset or liability and
establishes a hierarchy that prioritizes inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to observable unadjusted quoted prices in active markets for identical assets or liabilities (Level 1
measurements) and the lowest priority to unobservable inputs (Level 3 measurements). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The carrying amounts reflected in the accompanying consolidated
balance sheets for accounts receivable, accounts payable and accrued expenses approximate their fair value due to their short-term nature.&nbsp;Based on the borrowing rates currently available to the Company for debt with similar terms and
consideration of default and credit risk, the carrying value of the debt approximates fair value, which is considered a Level&nbsp;2 fair value measurement.</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash and Cash Equivalents </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company considers
all liquid investments purchased with original maturities of three months or less to be cash equivalents. Cash and cash equivalents include cash in readily available checking and money market accounts. The Company maintains its cash in bank deposit
accounts which, at times, may exceed federally insured limits. The Company has not experienced any losses with these financial institutions. As of December&nbsp;31, 2022 and 2021, the Company had cash balances deposited at major financial
institutions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accounts Receivable </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accounts
receivable are recorded at the amounts billed relating to contracted research and development services provided. The Company makes judgments as to its ability to collect outstanding receivables and provides an allowance for receivables when
collection becomes doubtful. Accounts receivable are written off when management believes that all efforts to collect the amounts outstanding have been exhausted. The allowance for doubtful accounts is estimated by management based on evaluations of
its historical bad debt, current collection experience and estimate of remaining collectability. Bad debt expense is recorded as necessary to maintain an appropriate level of allowance for doubtful accounts in selling, general and administrative
expense in the accompanying consolidated statements of operations and comprehensive loss. Accounts receivable is presented net of allowance for doubtful accounts which was $0 as of December&nbsp;31, 2022 and 2021. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment are
recorded at cost, less accumulated depreciation and amortization. Depreciation of lab equipment, furniture, and computer equipment and software is recorded using the straight-line method over the estimated useful lives of the respective assets,
ranging from three to ten years. Amortization of leasehold improvements are recorded using a straight-line method over the lesser of the estimated useful lives of the improvements or the remaining life of the lease. Expenditures which substantially
increase the useful life of an asset, are capitalized. Expenditures for repairs and maintenance are expensed as incurred. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Assets in progress include the construction of lab equipment and software to be used in the Company&#146;s
facility. The assets will be placed in service when the construction is completed and will be amortized over the useful life of the asset. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Long-Lived Assets </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company periodically
reviews the carrying value and estimated lives of all of its long-lived assets, including property and equipment, to determine whether indicators of impairment may exist which warrant adjustments to carrying values or estimated useful lives. Should
an impairment exist, the impairment loss would be measured based on the excess of the carrying amount of the asset or asset group over the estimated asset&#146;s fair value. Management determined no impairment existed during the years ended
December&nbsp;31, 2022 and 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Deferred Rent </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company records rent expense on a straight-line basis over the lease term. Prior to the adoption of Topic&nbsp;842, as defined below, on January 1, 2022,
deferred rent was recorded for the accumulated difference between the actual rent and the recognized rent expenses over the term of the lease and results from certain rent escalation clauses and rent abatements. Deferred rent was $0 and
$1.3&nbsp;million as of December&nbsp;31, 2022 and 2021, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Leases </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company determines if an arrangement is or contains a lease at inception. Beginning January 1, 2022, for leases with a term greater than one year, lease
right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The Company excludes short-term leases, if any, having initial terms of 12 months or less at
lease commencement as an accounting policy election. In determining the net present value of lease payments, the Company uses its incremental borrowing rate, which represents an estimated rate of interest that the Company would have to pay to borrow
equivalent funds on a collateralized basis, at the lease commencement date. Leases are classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the consolidated statements of
operations and comprehensive loss. Variable lease payments primarily include common area maintenance, utilities, real estate taxes, insurance, and other operating costs that are passed on from the lessor in proportion to the space leased by the
Company. The Company has elected the practical expedient to not separate between lease and non-lease components. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Asset Retirement Obligation
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company records asset retirement obligations (&#147;AROs&#148;) for the estimated cost of removing constructed leasehold improvement assets
and restoring the leased premises back to their original condition, at the time when the contractual obligations are incurred. AROs represent the present value of the expected costs for the related restoration activities. The ARO assets and
liabilities are recorded in property and equipment, net and other non-current liabilities, respectively, in the Company&#146;s balance sheets. The Company records accretion expense, which represents the increase in the asset retirement obligations,
over the remaining or operational life of the associated leasehold improvements. Accretion expense is recorded as selling, general and administrative in the statements of operations using an accretion rate based on the credit adjusted risk-free
interest rate. Changes resulting from revisions to the timing or amount of the original estimate of cash flows are recognized as an increase or a decrease in the asset retirement cost, or income when the asset retirement cost is depleted. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue Recognition </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s revenues
represent amounts earned from collaboration agreements related to contract research. The Company recognizes revenues under Topic 606 <I>Revenue from Contracts with Customers</I> (&#147;Topic 606&#148;)
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
when control of services is transferred to the Company&#146;s customers in an amount that reflects the consideration the Company expects to receive from the Company&#146;s customers in exchange
for those services. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the
contract and recognizing the revenue when the performance obligations have been satisfied. The Company recognizes revenue for satisfied performance obligations only when the Company determines there are no uncertainties regarding payment terms or
transfer of control. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is
separately identified in the contract. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sales tax and other taxes the Company collects concurrent with revenue-producing activities are excluded from
revenue. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Collaboration Agreements Related to Contract Research </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Performance obligations under collaboration arrangements include providing intellectual property licenses, performing research and development consulting
services and providing other materials. To date, the Company has concluded that the licenses of intellectual property in its collaboration arrangements have not been distinct, as intellectual property has not been licensed without related research
and development support services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Topic 606, milestone fees are variable consideration that is initially constrained and included in the
arrangement consideration only when it is probable that the milestones will be achieved. Arrangement consideration, including upfront fees, milestone fees and fees for research services, is recognized over the period as services are provided using
an input method to determine the amount to recognize each reporting period. The Company reviews the inputs each period, such as the Company&#146;s level of effort expended, including the time the Company estimates it will take to complete the
activities, or costs incurred relative to the total expected inputs to satisfy the performance obligation. Generally, input measures are labor hours expended or a time-based measure of progress towards the satisfaction of the performance obligation.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Contract Assets and Liabilities </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Contract
assets primarily include amounts related to contractual rights to consideration for completed performance not yet invoiced. The Company had recorded no contract assets as of December&nbsp;31, 2022 or 2021. The Company records contract liabilities
when cash payments are received or due in advance of performance, primarily related to advances of upfront and milestone payments from contract research and collaboration agreements. Contract liabilities consist of deferred revenue on the
accompanying consolidated balance sheets. The Company expects to recognize the amounts included in deferred revenues within one year. The deferred revenue balance of $0.1&nbsp;million at December&nbsp;31, 2021 was all recognized in 2022. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table represents the deferred revenue activity (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of January 1, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consideration earned</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,563</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consideration received</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of December 31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consideration earned</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,110</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consideration received</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of December 31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Costs to Obtain Contracts </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that otherwise would
have been recognized is one year or less. These costs are included in selling, general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss. Deferred contract acquisition costs were zero as of
December&nbsp;31, 2022 and 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Selling, General and Administrative Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All selling and marketing expenses, including advertising expenses and allocated facility costs including rent, utilities, maintenance expenses and
depreciation and amortization, are included in selling, general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company expenses patent application costs and related legal costs for maintenance of such patents as incurred and are included in selling, general, and
administrative expenses in the accompanying consolidated statements of operations and comprehensive loss. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development costs are expensed as incurred in performing research and development activities and include salaries, lab supplies,
consultant fees, and allocated facility costs including rent, utilities, maintenance expenses and depreciation and amortization. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Royalty Liability
&#150; Related Parties </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the warrant transfer and exchange agreement dated December 31, 2014 (the &#147;Warrant Exchange
Agreement&#148;), management estimates the total amount of royalty payments over the life of the Warrant Exchange Agreement that the Company will be required to make to holders of certain warrants that were exchanged for the rights to future royalty
payments (the &#147;Royalty Liability&#148;). The Royalty Liability is based on the Company&#146;s current estimates of future royalties expected to be paid over the life of the arrangement. The Company will periodically assess the expected royalty
payments using a combination of internal projections and external sources. In order to determine the amortization of the Royalty Liability, the Company is required to estimate the total amount of future royalty payments to the warrant holders over
the life of the Warrant Exchange Agreement. This estimate contains significant assumptions that impact both the amount recorded at execution and the interest expense that will be recognized over the royalty period. The Company will periodically
assess the estimated royalty payments and to the extent the amount or timing of such payments is materially different than the original estimates, an adjustment will be recorded prospectively to increase or decrease interest expense. There are a
number of factors that could materially affect the amount and timing of royalty payments and correspondingly, the amount of interest expense recorded by the Company, most of which are not within the Company&#146;s control. Such factors include, but
are not limited to, delays or discontinuation of development of the Company&#146;s products, regulatory approval, the introduction of competing products, manufacturing or other delays, intellectual property matters, adverse events that result in
authority imposed restrictions on the use of the products, significant changes in foreign exchange rates as the royalties are made in U.S. dollars, and other events or circumstances that are not currently foreseen. Changes to any of these factors
could result in increases or decreases to interest expense. See Note 11 for further details. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Equity-Based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Equity-based compensation to employees and nonemployee service providers, for awards of restricted units, is measured at the fair value of the award on the
date of grant based on the total number of awards that are ultimately expected to vest, less any consideration to be paid by the employee. The Company recognizes forfeitures as they occur. The compensation expense resulting from equity-based
compensation to employees is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
recognized ratably over the requisite service period, which generally is the vesting period, of the award in operating expenses in the accompanying consolidated statements of operations and
comprehensive loss. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to
May 10, 2019, the Company was a British Virgin Island Limited Company and elected to be treated as a partnership for income tax purposes in the United States. Commencing May&nbsp;10, 2019, the Company operated as a Delaware limited liability company
and elected to continue to be treated as a partnership for income tax purposes in the United States (see Note 1). As such, the Company is not a tax paying entity for United States federal income tax purposes. Each member is individually responsible
for their share of the Company&#146;s net income (loss) for federal income tax purposes. The Company also has operations in jurisdictions outside the United States, some of which are subject to corporate tax. However, the Company&#146;s operations
in these jurisdictions did not give rise to a material amount of corporate income tax during the period. Accordingly, the Company has not recorded a provision for income taxes in the accompanying consolidated statements of operations and
comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for uncertain tax positions in accordance with the provisions of Accounting Standards Codification (ASC) 740,
<I>Income Taxes</I>. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as
to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company does not have any material uncertain tax positions
as of December&nbsp;31, 2022 and 2021 and does not expect a material change in the next twelve months. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Currency </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements are presented in United States dollars (&#147;USD&#148;) as the reporting currency. For those foreign
subsidiaries where the Company has determined that the functional currency is the entity&#146;s local currency, the assets and liabilities of such subsidiaries are translated into USD using exchange rates in effect at the balance sheet date. The
revenue and expenses of such subsidiaries are translated into USD using average exchange rates in effect during the reporting period. Any translation adjustments are presented as accumulated other comprehensive income (loss), within members&#146;
deficit in the accompanying consolidated statements of members&#146; deficit. Foreign currency transaction gains and losses are included in other (income) expense, net within the accompanying consolidated statements of operations and comprehensive
loss and were immaterial for all periods presented. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently Adopted Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (the &#147;FASB&#148;) or other standard setting bodies
and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company&#146;s financial position, results of
operations, or cash flows upon adoption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February&nbsp;2016, the FASB issued Accounting Standards Update (&#147;ASU&#148;) No. 2016-02, Leases
(&#147;Topic 842&#148;) (&#147;ASC 842&#148;), which establishes the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors). The standard requires lessees to
apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether the lease is effectively a financed purchase by the lessee. A lessee is also required to record a right-of-use asset and a lease
liability for all leases with a term greater than 12 months regardless of the lease classification. ASC 842 provides lessees with the option to not account for leases with a term of 12 months or less as leases. ASC 842 supersedes the previous leases
standard, ASC 840 Leases, and requires a modified retrospective transition approach for leases existing at, or entered into after the beginning of the earliest comparative period presented in the financial
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
statements. In July 2018, the FASB issued supplemental adoption guidance and clarification to ASC 842 within ASU No. 2018-10, Codification Improvements to Topic 842, Leases and ASU No. 2018-11,
Leases (Topic 842): Targeted Improvements. ASU No. 2018-11 provides another transition method in addition to the existing modified retrospective transition method by allowing entities to initially apply the new leasing standard at the adoption date
and recognize a cumulative-effect adjustment to the opening balance of accumulated deficit in the period of adoption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January 1, 2022, the Company
adopted ASC 842 using the modified retrospective approach. Accordingly, prior period financial information and disclosures have not been adjusted and continue to be reported in accordance with the Company&#146;s historical accounting under the
previous lease standard. In addition, the Company elected the package of practical expedients available for existing contracts, which allowed it to carry forward historical assessments of lease identification, lease classification, and initial
direct costs. As a result of adopting ASC 842, the Company recognized operating right-of-use assets and lease liabilities of $7.6 million and $8.8 million, respectively, on January 1, 2022, which are related to the Company&#146;s facility operating
leases. The difference between the right-of-use assets and lease liabilities is primarily attributed to the elimination of deferred rent and unamortized lease incentives. There was no adjustment to the opening balance of accumulated deficit as a
result of the adoption of ASC 842. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently Issued Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified
effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company&#146;s financial position, results of operations, or cash flows upon adoption. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2016, FASB issued ASU <FONT STYLE="white-space:nowrap">2016-13,</FONT> <I>Financial Instruments&#151;Credit Losses (Topic 326)</I>. The amendments in
ASU <FONT STYLE="white-space:nowrap">2016-13</FONT> affect entities holding financial assets and net investment in leases that are not accounted for at fair value through net income. The amendments affect loans, debt securities, trade receivables,
net investments in leases, <FONT STYLE="white-space:nowrap">off-balance-sheet</FONT> credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. The
amendments in ASU <FONT STYLE="white-space:nowrap">2016-13</FONT> require a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The allowance for credit losses
is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. On April&nbsp;8, 2020, the FASB has changed the
effective date of this standard applicable to the Company to January&nbsp;1, 2023. The Company is currently evaluating the potential impact of this standard on its financial position, results of operations, and cash flows. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Discontinued Operations </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;27, 2020 (the &#147;Closing Date&#148;), the Company completed the sale of substantially all of its intangible assets related to the canola
breeding program (&#147;Breeding Program&#148;) to Farmer&#146;s Business Network (&#147;FBN&#148; or &#147;Buyer&#148;), including the Company&#146;s ownership interests in the canola germplasm and certain rights to agreements that are material to
the breeding program (Breeding Program Assets). The sale excluded the net tangible assets, including SU Canola inventories and any rights and obligations under the commercialization agreements at the Closing Date, which were subsequently liquidated
by the Company. As the consideration for the Breeding Program sale the Company received a $2.0&nbsp;million upfront payment and additional success fees upon achievement of certain levels of gross sales of canola products by FBN. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company received a deposit of $1.0&nbsp;million to cover amounts payable under a trait license to be applied to the Buyer&#146;s trait fee obligations
under the trait license. The interest on the deposit is to be credited to the Buyer on the deposit until the end of the first calendar month in which the first commercial sale occurs. The deposit amount and related accrued interest are included in
other <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities in the accompanying consolidated balance sheets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Due to the resulting major strategic shift in the Company&#146;s operating activities, the sale of the
Breeding Program met the accounting requirements for reporting as a discontinued operation. Accordingly, the accompanying consolidated financial statements for all periods presented reflect this group of nonfinancial assets as a discontinued
operation. Discontinued operations include the results of the canola breeding and commercialization activities except for certain corporate overhead costs, which are included in continuing operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following tables present amounts included in the discontinued operations on the Company&#146;s consolidated statements of operations and comprehensive
loss and statements of cash flows for the years ended December&nbsp;31, 2022 and 2021. No balances were recorded on the consolidated balance sheets as of December 31, 2022 or 2021. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2022&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Revenue</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Product sales, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of product sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss from discontinued operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(23</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2022&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from operating activities, discontinued operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss from discontinued operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(23</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inventory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,160</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(136</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(174</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities, discontinued operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,088</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from investing activities, discontinued operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities, discontinued operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from financing activities, discontinued operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in financing activities, discontinued operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Property and Equipment, net </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment consists of the following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Useful&nbsp;Life</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lab equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="white-space:nowrap">5-10&nbsp;years</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="white-space:nowrap">5-7</FONT> years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">5 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">3 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets in progress</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">869</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Accumulated depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13,602</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11,922</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 5,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depreciation and amortization for the years ended December&nbsp;31, 2022 and 2021 was $1.7&nbsp;million and $1.5&nbsp;million,
respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Asset Retirement Obligations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain lease agreements require the Company to return designated areas of leased space to its original condition upon termination of the lease agreement. At
the inception of such leases, the Company records an asset retirement obligation and a corresponding capital asset in an amount equal to the estimated fair value of the obligation. To determine the fair value of the obligation, the Company estimates
the cost for a third-party to perform the restoration work. In subsequent periods, for each asset retirement obligation, the Company records operating expense to accrete the asset retirement obligation liability to full value and depreciation
expense against the asset retirement obligation, over the term of the associated lease agreement. The Company used a credit-adjusted risk free rate of 5.64% to discount the future obligation, and an inflation rate of 5% to determine the future value
of the original estimate of restoration costs. The asset retirement obligation is expected to be resolved in July 2025. Asset retirement obligations were $0.3 million and $0 as of December 31, 2022 and 2021, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents the changes in asset retirement obligation during the year ended December 31, 2022 (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of January 1, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Obligations incurred</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of December 31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Accrued Expenses </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accrued expenses consist of the following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued salaries, wages, and payroll taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued field trials</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Notes Payable </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;5, 2020, the Company received a $2.2&nbsp;million loan under the Paycheck Protection Program (&#147;PPP&#148;) established under the Coronavirus
Aid, Relief, and Economic Security Act (the &#147;CARES Act&#148;). The PPP note bore interest at a fixed rate of 1% per annum and had an initial term of two years. The note was unsecured, and guaranteed by the Small Business Administration
(&#147;SBA&#148;). The Company was permitted to prepay the PPP note at any time prior to maturity with no prepayment penalties. The principal amount and accrued interest of the PPP note was eligible for forgiveness if the proceeds were used for
qualifying expenses, which includes payroll, rent, and utilities during the eight-week period commencing on May&nbsp;5, 2020. The Company was obligated to repay any portion of the principal amount of the PPP note that was not forgiven, and any
accrued interest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the second quarter of 2021, the Company received notification from the SBA that the entire $2.2&nbsp;million PPP loan was forgiven.
The forgiven debt was recorded as a gain on extinguishment of debt on the consolidated statement of operations and comprehensive loss for the year ended December 31, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has also financed certain annual license costs. The Company has recorded notes payable related to financed license costs of $0.2&nbsp;million on
the consolidated balance sheet as of December&nbsp;31, 2022 and 2021. The financing arrangements for the licenses have a term of one year and accrue interest at an annual rate between 9% and 10%. The Company makes monthly principal and interest
payments. The notes related to annual licenses mature in July 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, the Company has purchased various fixed assets using notes. The total
notes payable balance related to financed equipment was $1.1&nbsp;million and $1.5 million as of December&nbsp;31, 2022, and 2021, respectively. The financed equipment is subject to annual interest rates between 7.3% and 17.6% and has a weighted
average remaining term of 2.7 years. Notes used to finance equipment mature between January 2023 and December 2027. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes future
payments on notes payable: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Years Ending December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2027</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(178</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(736</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Noncurrent portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Fair Value Measurements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value, and expands disclosure for each major asset and
liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction
between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the
accounting guidance establishes a three-tier fair-value hierarchy, which prioritizes the inputs used in measuring fair value as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Level&nbsp;1:
Observable inputs such as quoted prices in active markets; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Level&nbsp;2: Inputs, other than the quoted prices in active markets, that are observable
either directly or indirectly; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Level&nbsp;3: Unobservable inputs in which there is little or no market data, which require the reporting
entity to develop its own assumptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The carrying amounts of the Company&#146;s interest receivable, included in prepaid expenses and other current
assets, accounts payable, accrued liabilities, and notes payable are generally considered to be representative of&nbsp;their&nbsp;fair value because of the short-term nature of these instruments. The Company&#146;s investments, which includes money
market funds are measured at fair value in&nbsp;accordance with the fair value hierarchy. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Quoted<BR>Market&nbsp;Price<BR>for Identical<BR>Assets<BR>(Level&nbsp;1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant&nbsp;Other<BR>Observable&nbsp;Inputs<BR>(Level 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant<BR>Unobservable<BR>Inputs<BR>(Level&nbsp;3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(in thousands)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>At December&nbsp;31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>At December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Included in cash and cash equivalents on the accompanying consolidated balance sheets </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Convertible Preferred Units and Voting Common Units </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has authorized multiple series of convertible preferred units (collectively, the &#147;Preferred Units&#148;), in addition to voting and <FONT
STYLE="white-space:nowrap">non-voting</FONT> common units (see Note 10). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Preferred Units </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of authorized and outstanding Preferred Units was as follows (in thousands, except unit amounts): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Authorized<BR>Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Outstanding<BR>Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liquidation<BR>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A convertible preferred units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">83,300,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67,810,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64,097</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">111,428</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B convertible preferred units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,285,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,817,791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57,013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C convertible preferred units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,173,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,195,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69,711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series D convertible preferred units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54,195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series E convertible preferred units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,886,364</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,884,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series F convertible preferred units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,485,598</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52,971</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">266,646,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">222,194,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">327,205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">381,119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December 31, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Authorized<BR>Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Outstanding<BR>Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liquidation</B><br><B>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A convertible preferred units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">83,300,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67,781,328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">111,391</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B convertible preferred units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,285,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,817,791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57,013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C convertible preferred units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,173,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,195,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69,711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series D convertible preferred units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54,195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series E convertible preferred units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,886,364</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,884,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">216,646,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">195,678,846</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">274,358</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">328,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Conversion </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Preferred Units are convertible, at the option of the holder at any time and without any additional consideration, into an equivalent number of voting
common units. In addition, upon (i)&nbsp;the closing of a Qualified Public Offering (defined as a firm commitment underwritten public offering of the Company&#146;s equity securities to the public at a price per unit of at least (a) $4.00 per unit
and gross proceeds of $200 million, or (b) $4.00 per share with a minimum market capitalization of $1.0 billion or (c) $4.00 per unit and an equity financing of at least $250), (ii) the closing of certain liquidation or change in control events, or
(iii) a resolution of the Preferred Members, all issued and outstanding Preferred Units shall automatically be converted into voting common units on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of a voluntary or
involuntary liquidation, proceeds or any other assets of the Company will be distributed to the Company&#146;s equity holders as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unreturned Capital on Series F convertible preferred units (&#147;Series F Preferred Units&#148;)
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unreturned Capital on Series E convertible preferred units (&#147;Series E Preferred Units&#148;)
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unreturned Capital on Series D convertible preferred units (&#147;Series D Preferred Units&#148;)
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unreturned Capital on Series C convertible preferred units (&#147;Series C Preferred Units&#148;)
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unreturned Capital on Series B convertible preferred units (&#147;Series B Preferred Units&#148;)
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Series A Preferred Return, if applicable </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unreturned Capital on Series A convertible preferred units (&#147;Series A Preferred Units, and together with
the Series F Preferred Units, the Series E Preferred Units, the Series D Preferred Units, the Series C Preferred Units and the Series B Preferred Units, the &#147;Preferred Units&#148;) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Nonvoting and voting common units </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any distribution remaining, after the Series F, E, D, C, B, and A preferred members and nonvoting and voting common members have received their portion in
proportion to and to the extent of each such holders&#146; Unreturned Capital Amount, will be distributed to the holders of all units on a pro rata basis in proportion to their overall percentage interest. The &#147;Unreturned Capital Amount&#148;
for members holding Series F, E, D, C, B, and A Preferred Units as of December&nbsp;31, 2022 was $53.0&nbsp;million, $35.0&nbsp;million, $55.0&nbsp;million, $69.7&nbsp;million, $57.0&nbsp;million, and $88.9&nbsp;million, respectively. The members
holding Series A Preferred Units accrued a cumulative Series A Preferred Return at 10% per annum, until the initial closing of the Series B Preferred Units purchase agreement at July&nbsp;29, 2015. The cumulative Series A Preferred Return was
$22.5&nbsp;million as of December&nbsp;31, 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Redemption </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Preferred Units are not redeemable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preferred Unit
Issuances </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended December 31, 2022, 26.5 million Series F Preferred Units were issued at $2.00 per unit, with offering costs of
$0.2 million. Of the 26.5 million Series F Preferred Units issued, 17.2 million units were issued in connection with the conversion of Simple Agreements for Future Equity (&#147;SAFEs&#148;). Additionally, during the year ended December 31, 2022,
the Company issued 29,635 Series A Preferred Units as a result of the exercise of warrants to purchase Series A Preferred Units. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended
December&nbsp;31, 2021, 19.9&nbsp;million Series E Preferred Units were issued at $1.76 per unit, with offering expenses of $0.6&nbsp;million. During the year ended December&nbsp;31, 2021, 14.5&nbsp;million Series&nbsp;D Preferred Units were issued
at $1.25 per unit, with offering expenses of $0.2&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting Common Units </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Voting common units are reserved for the conversion of Series A, B, C, D, E and F Preferred Units and nonvoting common units. Each voting common unit entitles
the holder to cast one vote at all member meetings. No voting common units have been issued as of December&nbsp;31, 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Simple Agreements for
Future Equity </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended December 31, 2022, the Company entered into SAFEs with various investors, totaling $34.5 million. These SAFEs
converted into Series F Preferred Units upon the closing of the Series F Preferred Unit financing. SAFEs were carried at fair value during the year ended December 31, 2022, prior to conversion. No SAFEs were outstanding as of December 31, 2022. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Warrants to Purchase Preferred Units </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company had
warrants to purchase Preferred Units outstanding at December&nbsp;31, 2022 and 2021 as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December 31, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred<BR>Units<BR>Underlying<BR>Warrants</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average<BR>Exercise<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Expiry Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A Preferred Units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,489,402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2023-2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B Preferred Units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">467,647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C Preferred Units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,978,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">2024-2027</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="12"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December 31, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred<BR>Units<BR>Underlying<BR>Warrants</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average<BR>Exercise<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Expiry Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A Preferred Units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,519,524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2022-2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B Preferred Units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">467,647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2022-2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C Preferred Units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,978,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2024-2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Warrants to Purchase Series A Preferred Units </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company had outstanding warrants to purchase a total of 15.5&nbsp;million Series&nbsp;A Preferred Units at December&nbsp;31, 2022 and 2021. These warrants
were primarily issued in connection with the sale of Series&nbsp;A Preferred Units. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 15.5&nbsp;million warrants to purchase Series A Preferred Units
have an exercise price of $1.25 and were originally granted with expiration dates between February&nbsp;2022 and January 2027. The warrants are classified as equity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2022, the Company extended the expiration date of 50,000 and 42,959 warrants to purchase Series A Preferred Units from April 30, 2022 and December 22,
2022, respectively, to December 31, 2022. The incremental fair value associated with the modification was immaterial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsequently, in December 2022, the
Company extended the expiration date of 50,000 and 39,433 warrants to purchase Series A Preferred Units from December 31, 2022 to June 30, 2023. The incremental fair value associated with the modification was immaterial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended December 31, 2022, 487 warrants expired. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2020, the Company received $6.2&nbsp;million in cash from a related party for the right to exercise 8.2&nbsp;million warrants to purchase Series A
Preferred Units. This was recorded as a $4.1&nbsp;million unit subscription </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
receivable from the related party. In connection with the exercise, the Company granted 8.2&nbsp;million warrants to purchase voting common units. These warrants have an exercise price of
$1.25&nbsp;per unit with a 6-year term and can be exercised immediately at the issuance date. This was accounted for as equity under the relevant accounting guidance applicable to derivative instruments. The unit subscription receivable bears simple
interest at an annual rate of 0.15% and is collateralized by the Series A Preferred Units purchased with the note (the &#147;Promissory Note&#148;). The Promissory Note was originally payable on the earlier of (i)&nbsp;January&nbsp;31, 2022 and
(ii)&nbsp;the date of any qualified liquidation/change event as defined in the Company&#146;s LLC agreement. Subsequently, the payment due date was extended to the earlier of (i)&nbsp;January&nbsp;31, 2024 and (ii)&nbsp;ninety (90) days after any
underwriter <FONT STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT> period applicable to the related party after the date of the consummation of the Company&#146;s first underwritten public offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Warrants to Purchase Series B Preferred Units </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company has outstanding warrants to purchase a total of 0.5&nbsp;million Series&nbsp;B Preferred Units at December&nbsp;31, 2022 and 2021. These warrants were issued for services provided in connection with the issuance of the Series&nbsp;B
Preferred Units in 2016. Such warrants are fully exercisable and entitle the holder to purchase Series&nbsp;B Preferred Units at an exercise price of $1.85 per unit with a term of seven years from the date of issuance. The warrants are classified as
equity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2022, the Company extended the expiration of 221,161 warrants to purchase Series B Preferred Units from September 30, 2022 to December
31, 2022. The incremental fair value associated with the modification was immaterial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsequently, in December 2022, the Company extended the expiration
date of 221,161 and 201,081 warrants to purchase Series B Preferred Units from December 22, 2022 and March 31, 2023, respectively, to June 30, 2023. The incremental fair value associated with the modification was immaterial. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Warrants to Purchase Series C Preferred Units </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company has outstanding warrants to purchase a total of 5.0&nbsp;million Series C Preferred Units at December&nbsp;31, 2021 and 2020. These warrants were issued to existing members and directors in connection with the issuance of Series C Preferred
Units and for services provided in connection with the offerings. Such warrants are fully exercisable and entitle the holder to purchase the Series C Preferred Units at an exercise price of $2.10 per unit and expire between September 2024 and
September 2027. The warrants are classified as equity. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Non-voting Common Units and Equity-Based Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Non-voting Common Units </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s <FONT
STYLE="white-space:nowrap">non-voting</FONT> common units include units issued under the Company&#146;s Stock Option Plan which was terminated in 2016 and units issued under the Company&#146;s Restricted Units Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the Company&#146;s non-voting common units according to these restrictions: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested <FONT STYLE="white-space:nowrap">non-voting</FONT> units outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,475,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,475,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Units outstanding under the restricted units plan, subject to threshold values</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted units <FONT STYLE="white-space:nowrap">non-vested</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,993,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,019,984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted units vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,434,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,310,711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62,428,846</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,330,695</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total <FONT STYLE="white-space:nowrap">non-voting</FONT> common units outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63,903,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56,805,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non-voting members and holders of vested restricted units issued under the Restricted Units Plan (defined
below) are entitled to share in distributions from the Company (after members holding Series F, Series E, Series D, Series C, Series B and Series A Preferred Units receive their distributions), up to, the amount of the distribution exceeds a
predetermined threshold value. Non-voting common units, except for nonvested restricted units, are to be converted to voting common units, upon certain qualified financing events, as defined in the underlying restricted unit purchase agreements.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Units </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s
restricted units are issued in accordance with the restricted units purchase plan (&#147;Restricted Units Plan&#148;) which allowed for a total of 66,414,403 units to be issued as of December&nbsp;31, 2022, which number will automatically increase
in connection with any future equity financing transactions undertaken by the Company such that the total number of common units which may be issued under the Restricted Units Plan shall represent 15% of the Company&#146;s outstanding equity on a
fully-diluted basis. There are 7.8&nbsp;million units that are excluded from the current Restricted Units Plan and will not count in the total which is allowed to be issued. Under the Restricted Units Plan, the Company issued restricted units to
members of the Board, employees, advisors, consultants or similar other service providers. The restricted units are subject to both a vesting schedule and a defined threshold value, equal to the estimated fair value of a nonvoting common unit on the
issuance date. Restricted units issued under the Restricted Units Plan vest based on a grant date vesting schedule as determined by the Board of Directors, generally over a period of 48 months. Units are sold to participants for $0.01 per unit.
Holders of vested units are entitled to share in distributions from the Company after members holding Series F, Series E, Series D, Series C, Series B and Series A Preferred Units receive their distributions with respect to such Preferred Units and
the amount of the distribution exceeds the predetermined threshold value. The Restricted Units Plan has a term ending on May&nbsp;31, 2026, after which no additional units shall be issued pursuant to the Restricted Units Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Restricted Units Plan, the Company may exercise the right to repurchase certain units after the release of the vesting restriction if the holder
ceases to provide continuous service to the Company. The repurchase price of vested units is the fair value of the units, as determined by the Company, at the date of the termination of continuous service subject to a previously defined threshold
value. The repurchase price for nonvested units is $0.01, which is the price at which the units were initially purchased by the holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of
December&nbsp;31, 2022, 40,434,902 of the units issued under the Restricted Units Plan had vested in accordance with the terms of the underlying purchase agreements, which were subject to a weighted average threshold value of $0.80 per unit, and
21,993,944 of the restricted units were nonvested. In the event of a qualified public offering, as defined in the underlying restricted unit purchase agreements, vested units convert to common units at a conversion rate of the then-fair-market value
of each vested unit less the applicable threshold value of each vested unit, divided by the value of the qualified offering price per unit of common units. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the years ending December&nbsp;31, 2022 and 2021, the grant date fair value of the underlying common units for grants of restricted units was
determined using an option pricing model (&#147;OPM&#148;). Under the OPM, once the fair market value of the enterprise value is established, units are valued creating a series of call options with exercise prices based on the liquidation
preferences and conversion behavior of the different classes of equity. Accordingly, the aggregate equity value is allocated to each of the classes of member units issued and outstanding based on their rights and preferences. In order to determine
the fair market value of the enterprise, the Company utilized a market approach to estimate the Company&#146;s equity value. The threshold units were valued using the Black-Scholes valuation model. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the valuation inputs for restricted units granted: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended December&nbsp;31,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">2.4%&nbsp;&#150;&nbsp;4.0%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">1.0%&nbsp;&#150;&nbsp;1.4%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">67.5%&nbsp;&#150;&nbsp;73.1%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">69.7%&nbsp;&#150;&nbsp;74.4%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">5.50&nbsp;&#150;&nbsp;6.08</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">5.50&nbsp;&#150;&nbsp;6.08</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected distribution yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of common units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">$0.86&nbsp;&#150;&nbsp;$0.90</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">$0.27&nbsp;&#150;&nbsp;$0.86</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes information regarding nonvested restricted units: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted&nbsp;Average<BR>Grant Date<BR>Fair Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Restricted units nonvested at January&nbsp;1, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,019,984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,556,113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,124,191</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repurchased</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(457,962</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Restricted units nonvested at December&nbsp;31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,993,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted units vested at December&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,434,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total restricted units outstanding under the restricted units plan at December&nbsp;31,
2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62,428,846</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The total fair value of vested restricted units during the years ended December&nbsp;31, 2022 and 2021 was $1.2&nbsp;million
and $4.0&nbsp;million, respectively. The weighted-average grant-date fair value of restricted units granted during the year ended December 31, 2021 was $0.23 per unit. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Equity-Based Compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes
equity-based compensation for the difference between the grant date fair value and the amount per unit paid by the employee. The grant date fair value of restricted units is estimated based on the valuation of the Company&#146;s equity securities.
Equity-based compensation is recognized ratably over the requisite service period, which is generally the vesting period. During the years ended December&nbsp;31, 2022 and 2021, the Company recognized $1.2&nbsp;million and $1.9&nbsp;million,
respectively, of equity-based compensation related to restricted units of which $0.8&nbsp;million and $0.9&nbsp;million, respectively, was included in selling, general and administrative expense and $0.4&nbsp;million and $1.0&nbsp;million,
respectively, was included in research and development expense in the accompanying consolidated statements of operations and comprehensive loss. The Company has unrecognized compensation costs related to restricted units of $7.1&nbsp;million as of
December&nbsp;31, 2022, and the weighted average period over which these costs are expected to be recognized is 3.4 years. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Royalty Liability
&#150; Related Parties </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2014 the Company entered into the Warrant Exchange Agreement with certain members holding Series A Preferred Units,
including members of the Board and management, who were also the holders of warrants to purchase Series A Preferred Units. Under the Warrant Exchange Agreement, the holders of certain warrants (the &#147;Royalty Holders&#148;) were provided the
right to exchange their warrants for future royalty payments equal to 10% of the Subject Revenues. &#147;Subject Revenues&#148; include all revenues earned by the Company, including consideration attributable to canola seed products and other crop
traits developed using the Company&#146;s gene </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
editing technology, but excludes specifically, (i)&nbsp;revenues attributable to the Nucelis product line, (ii)&nbsp;amounts received from the sale or disposition of the Company&#146;s assets to
the extent the purchaser agrees to be bound by the Warrant Exchange Agreement, (iii)&nbsp;payments for the Company&#146;s capital stock, and (iv)&nbsp;revenues attributable to collaboration and research projects. Royalty payments will begin in the
first fiscal quarter after which the aggregate Subject Revenues during any consecutive <FONT STYLE="white-space:nowrap">12-month</FONT> period equals or exceeds $50.0&nbsp;million, at which point the Company will be obligated to pay all aggregated
but unpaid payments under the Warrant Exchange Agreement. This condition had not occurred as of December&nbsp;31, 2022. Additionally, the Company granted the Royalty Holders a continuing security interest in certain intellectual property of the
Company to secure the payment and performance of the Company&#146;s obligations under the Warrant Exchange Agreement. The initial term of the Warrant Exchange Agreement is 30 years and may be extended for an additional
<FONT STYLE="white-space:nowrap">30-year</FONT> term if the holders provide written notice and make a payment of $100. The exchange right was limited to 12,397,200 warrants, which were fully exchanged in 2014 and 2015. The aggregate value of
warrants exchanged was $9.9&nbsp;million and the amount was initially recorded as a Royalty Liability in the years ended December&nbsp;31, 2015 and 2014. Changes in the liability are accreted to interest expense using the effective interest method
over the term of the royalty arrangement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of determining the Royalty Liability, the Company estimates the total amount of future royalty
payments required to be paid to Royalty Holders over the life of the agreement. The Company will periodically assess the expected royalty payments using a combination of internal projections and external sources. The Company&#146;s estimate resulted
in an effective annual interest rate of 27% and 9% for the years ended December&nbsp;31, 2022 and 2021, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Royalty Liability activity is
as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Royalty liability at January&nbsp;1, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39,681</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense recognized</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Royalty liability at December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43,252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense recognized</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Royalty liability at December 31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Related Party Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Due to Related Parties </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is party to an
arrangement with a company influenced by a member of the Board under which research and development services are performed for the Company. During the years ended December&nbsp;31, 2022 and 2021, the Company incurred $0.3&nbsp;million each year of
research and development expenses under this arrangement. The amount outstanding at December&nbsp;31, 2022 and 2021 was $0.1&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Due from
Related Parties </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is party to a license and marketing agreement with a company controlled by a member of the Board, pursuant to which
the amounts due from related parties are recorded at the amounts billed to the related parties for services provided or product sold. The Company makes judgments as to its ability to collect amounts outstanding from related parties and provides an
allowance for amounts outstanding when collection becomes doubtful. Amounts due from related parties are written off when management believes that all realistic efforts to collect the amounts outstanding have been exhausted. The allowance for
amounts due from related parties is estimated by management based on the current collection experience and estimate of remaining collectability. The amounts due from related parties presented on the consolidated balance sheets as of
December&nbsp;31, 2022 and 2021 were $0.3 million and $0.2 million, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>License and Marketing Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In July 2012, the Company entered into a license and marketing agreement with RTDC Company, Ltd (&#147;RTDC&#148;), which is controlled by a member of the
Company&#146;s Board. Under the agreement the Company develops and commercializes certain crop varieties that include traits produced using the Company&#146;s proprietary technology and RTDC is obligated to make certain funding payments. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;21, 2020 (the &#147;Agreement Date&#148;), the Company and RTDC amended the license and marketing agreement, under which RTDC agreed to pay the
Company $4.5&nbsp;million. The parties also agreed to continue funding of the research and development activities. Continued funding is recorded in the consolidated statements of operations and comprehensive loss as revenue under Collaboration and
research-related party. During the years ended December 31, 2022 and 2021 the Company recognized $0.9 million and $0.8 million, respectively, under the license and marketing agreement. In connection with the agreement with RTDC, the Company recorded
$0.2 million as due from related parties on the consolidated balance sheet as of December 31, 2022 and 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. Supplemental Cash Flow Information
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> investing and financing transactions are as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2022&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosure of cash flow information</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for amounts included in the measurement of operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for amounts included in the measurement of financing lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosures of noncash investing and financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment acquired through accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series F issuance costs, accrued and unpaid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Asset retirement obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
assets obtained in exchange for operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. Collaboration Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
August&nbsp;2018, the Company entered into a research and development agreement with a China-based producer and marketer of specialty ingredients (the &#147;Producer&#148;) under which the Company employs its suite of technologies, including the
Rapid Trait Development System (&#147;RTDS&#148;) to develop a series of bacterial strains with specific traits for the Producer. Under such agreement, the Company is entitled to an upfront cash payment, conditional payments based on achieving
certain milestones and royalties based on the Producer&#146;s commercial sales of products made using the bacterial strains. In April 2020, the Company and Producer amended such agreement to update the conditional payment terms and extended the
period of service. The Company recognized revenue over time and utilized direct labor hours incurred to measure its progress in transferring control of the promised service. The Company recognized $0 and $0.3&nbsp;million of revenue in the
fulfillment of the performance obligation for the years ended December&nbsp;31, 2022 and 2021.&nbsp;The contract was completed in 2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. Commitments and Contingencies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Leases </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has leases for its
office space, including its corporate headquarters and laboratory space in San Diego, California, with terms that expire in May 2025 and August 2025, respectively. The Company has one option to extend the laboratory space lease for one year. As the
Company is not reasonably certain to exercise this option at lease commencement, the option was not recognized as part of the associated operating lease right-of-use (&#147;ROU&#148;) asset or liability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, the Company has certain leases for greenhouse and warehouse facilities, with terms that expire in September 2023 and August 2026, respectively.
The Company has one option to extend the term of the greenhouse lease, for five years, and one option to extend the warehouse lease, for five years. However, as the Company is not reasonably certain to exercise either of those options at lease
commencement, neither option was recognized as part of the associated operating lease ROU asset or liability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain leases include rent abatement, rent
escalations, tenant improvement allowances and additional charges for common area maintenance and other costs. The Company is required to pay base rent expense as well as its proportionate share of the facilities operating expenses. The non-lease
components, consisting primarily of common area maintenance, are paid separately based on actual costs incurred. Therefore, the variable non-lease components were not included in the right of use asset and lease liability and are reflected as
expense in the period incurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the years ended December 31, 2022 and 2021, the Company incurred rent expenses under these leases of $3.4 million and
$2.5 million, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aggregate future minimum payments under operating leases, weighted average remaining term, and weighted average discount rate
as of December&nbsp;31, 2022 are as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="21%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Years Ending December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total minimum lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: amounts representing interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(972</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Present value of lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,654</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non-current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average remaining lease term (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average incremental borrowing rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.23</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December 31, 2021, prior to adoption of ASC 842, the Company had aggregate future obligations for the </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company&#146;s operating leases as follows: $2.8 million in 2022, $2.8 million in 2023, $2.8 million in 2024, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">$1.2 million in 2025, and none thereafter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Financing Leases </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has financing leases for certain equipment. During the year ended December 31, 2022, the Company recorded expense of $0.2 million related to the
amortization of its financing lease right-of-use assets, and $35,000 related to interest on financing lease liabilities, for total financing lease costs of $0.3 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aggregate future minimum payments under financing leases, weighted average remaining term, and weighted average discount rate as of December 31, 2022 are as
follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="23%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Years Ending December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total minimum lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: amounts representing interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(20</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Present value of lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(150</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non-current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average remaining lease term (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average incremental borrowing rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.52</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December 31, 2021, prior to adoption of ASC 842, the Company had aggregate future obligations for the </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company&#146;s financing leases as follows: $0.2 million in 2022, $0.2 million in 2023, and $0.1 million in 2024. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cibus Non-profit Foundation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During 2022, Cibus
created the Cibus Charitable Foundation, Inc., a nonprofit legal entity referred to as the </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cibus Foundation. As of December 31, 2022, the Cibus Foundation
has not received any donations or commenced operations. Cibus is obligated to make donations to the Cibus Foundation each fiscal year at a rate of 1.0% of all net royalty revenue in the applicable fiscal year that is equal to or greater than $100
million up to, and including, $1.0 billion, and then steps up to 2.0% in respect of any portion of such net royalty revenue in excess of $1.0 billion. For purposes of this calculation, &#147;net royalty revenue&#148; refers to all royalty payments
received by Cibus, net of all taxes (other than income taxes) and all amounts payable pursuant to the Royalty Liability. The donation payable by Cibus may be reduced, including to zero, to the extent necessary to comply with any covenant or
obligation in any instrument evidencing third-party indebtedness, to permit a financing to occur, to preclude undercapitalization, to satisfy working capital requirements or provide for strategic needs of Cibus, to ensure timely payment of the
Cibus&#146; liabilities and debts to third parties as they become due, or to comply with applicable law. Cibus has agreed not to enter any change of control transaction unless the surviving entity assumes the obligation to pay such donations to the
Cibus Foundation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This obligation is contingent upon the Cibus Foundation obtaining and maintaining its status as a charitable organization (IRS 501c3
registration not yet achieved) and must use all donations received consistent with its mission statement: to drive sustainable agriculture and sustainable agricultural communities in the developing world. Accordingly, as of December 31, 2022, the
Company has not recorded a liability related to its obligations to the Cibus Foundation within the accompanying consolidated financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Litigation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is subject to potential
liabilities under various claims and legal actions that are pending or may be asserted. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These matters arise in the ordinary course and conduct of the business. The Company regularly assesses
contingencies to determine the degree of probability and range of possible loss for potential accrual in the consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that
a liability has been incurred and the amount of the loss can be reasonably estimated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;3, 2019, Houston Casualty Company (&#147;HCC&#148;)
filed a Complaint for Declaratory Relief and Recoupment related to an insurance claim involving the Company&#146;s hybrid canola products sold in 2018. On October&nbsp;10, 2019 the Company filed a counterclaim for certain breaches and damages. The
Company is unable to estimate a range of reasonably possible outcomes for this matter since the proceedings are in the <FONT STYLE="white-space:nowrap">pre-trial</FONT> stage with significant uncertainty as to factual issues. The Company does not
believe, based on currently available information, that the outcome of this matter will have a material adverse effect on the Company&#146;s financial condition in the event HCC should prevail, though the outcome could be material to the
Company&#146;s results of operations for a particular period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16. Subsequent Events </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company evaluated subsequent events from December 31, 2022 through April 14, 2023, which represents the date the financial statements were available to be
issued. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Series F Preferred Units </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March
2023, the Company completed, in a private placement, the sale and issuance of 2,940,000 Series F Preferred Units at $2.00 per unit, for total gross proceeds of approximately $5.9 million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Merger Agreement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January 13, 2023, the Company
entered into an agreement and plan of merger (&#147;Merger Agreement&#148;) with Calyxt, Inc. (&#147;Calyxt&#148;), a Delaware corporation and Calypso Merger Sub, LLC., a wholly-owned subsidiary of Calyxt. Pursuant to the Merger Agreement, among
other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into the Company, with the Company continuing as a wholly owned subsidiary of Calyxt and the surviving
corporation of the merger. The Merger Agreement and the transactions contemplated by the Merger Agreement were approved by the members of the board of directors of the Company, but are subject to numerous closing conditions, including Calyxt
shareholder approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the terms and conditions of the Merger Agreement, at the closing of the transactions contemplated by the Merger
Agreement, all of the issued and outstanding membership units of the Company, and all warrants or options to purchase membership units of the Company will be cancelled and converted into the right to receive Calyxt equity securities based on a
specified exchange ratio provided for in the Merger Agreement (subject to adjustment for the Reverse Stock Splits). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="rom401831_66"></A>ANNEX A-1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">AGREEMENT AND
PLAN OF MERGER </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">by and among </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CALYXT, INC., </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CALYPSO MERGER
SUBSIDIARY, LLC, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CIBUS GLOBAL, LLC, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">NEW VENTURES I HOLDINGS, LLC, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">BCGF CB HOLDINGS LLC, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">BCGFCP CB
HOLDINGS LLC, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">BCGFK CB HOLDINGS LLC, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">FSBCGF CB HOLDINGS LLC, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PYLBCG
CB HOLDINGS LLC, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">FSGRWCO CB HOLDINGS LLC, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">GROWTHCO CB HOLDINGS LLC, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">GRTHCOCP CB HOLDINGS LLC </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">and
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">GRWTHCOK CB HOLDINGS LLC </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Dated as of January&nbsp;13, 2023 </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexarom401831_1"><B>ARTICLE I </B>THE MERGERS<B></B> </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_2">Mergers; Effective Time of the Mergers</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_3">Closing; Actions at the Closing</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_4">Effects of the Mergers</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_5">Directors and Officers</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_6">Additional Action</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexarom401831_7"><B>ARTICLE II </B>CONVERSION OF SECURITIES<B></B>
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_8">Conversion of Securities</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_9">Payment Fund</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_10">Allocation Schedule</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_11">Withholding Rights</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_12">Merger Consideration Election Procedures</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexarom401831_13"><B>ARTICLE III </B>REPRESENTATIONS AND WARRANTIES OF MERGER
 PARTNER AND BLOCKERS<B></B> </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_14">Organization, Standing and Power</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_15">Capitalization</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_16">Subsidiaries</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_17">Authority; No Conflict; Required Filings and Consents</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_18">Financial Statements; Information Provided</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_19">Absence of Certain Changes</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_20">Merger Partner Tax Matters</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_21">Assets</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_22">Owned and Leased Real Property</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_23">Intellectual Property</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_24">Contracts</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_25">Litigation</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_26">Environmental Matters</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.14</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_27">Labor and Employment</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.15</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_28">Employee Benefit Plans</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.16</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_29">Compliance with Laws</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.17</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_30">Unlawful Payments</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.18</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_31">Permits</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.19</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_32">Insurance</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(continued) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.20</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_33">Cybersecurity and Privacy</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.21</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_34">Brokers</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.22</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_35">Blocker Organization, Standing and Power</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.23</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_36">Blocker Capitalization</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.24</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_37">No Business</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.25</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_38">Blocker Authority; No Conflict; Required Filings and Consents</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.26</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_39">Blocker Compliance with Laws</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.27</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_40">Blocker Brokers</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.28</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_41">Blocker Tax Matters</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.29</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_42">No Other Representations and Warranties</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.30</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_43">Reliance</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexarom401831_44"><B>ARTICLE IV </B>REPRESENTATIONS AND WARRANTIES OF PUBLIC
 COMPANY AND MERGER SUBSIDIARY<B></B> </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_45">Organization, Standing and Power</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_46">Capitalization</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_47">Subsidiaries</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_48">Authority; No Conflict; Required Filings and Consents</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_49">Operations of Merger Subsidiary</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_50">SEC Filings; Financial Statements</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_51">Absence of Certain Changes</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_52">Tax Matters</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_53">Assets</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_54">Owned and Leased Real Property</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_55">Intellectual Property</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_56">Contracts</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_57">Litigation</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.17</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_58">Compliance with Laws</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.18</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_59">Unlawful Payments</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.19</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_60">Permits</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.20</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_61">Insurance</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.21</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_62">Cybersecurity and Privacy</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.22</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_63">Brokers</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(continued) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.23</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_64">Transactions with Affiliates</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.24</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_65">[Reserved]</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.25</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_66">Nasdaq Market Quotation</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.26</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_67">No Shareholder Rights Plan; No Antitakeover Law</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.27</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_68">Valid Issuance</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.28</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_69">No Other Representations and Warranties</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.29</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_70">Reliance</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexarom401831_71"><B>ARTICLE V </B><FONT STYLE="white-space:nowrap">PRE-CLOSING
</FONT> COVENANTS<B></B> </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_72">Operation of Merger Partner&#146;s Business</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_73">Operation of Public Company&#146;s Business</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_74">Operation of Blockers</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_75">Public Company No Solicitation</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_76">Merger Partner <FONT STYLE="white-space:nowrap">Non-Solicitation</FONT></A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_77">Notification of Certain Matters</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_78">Proxy Statement/Prospectus; Registration Statement</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_79">Nasdaq Listing</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_80">Public Company Stockholders&#146; Meeting</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_81">Merger Partner and Blocker Member Approval</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_82">Access to Information</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_83">Closing Efforts</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_84">Public Disclosure</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.14</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_85">Antitrust</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.15</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_86">Warrant Restructuring</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.16</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_87">Transaction Documentation</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.17</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_88">Merger Partner Funding</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.18</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_89">Section&nbsp;16 Matters</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexarom401831_90"><B>ARTICLE VI </B>CONDITIONS TO CONSUMMATION OF THE MERGERS
<B></B> </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_91">Conditions to Obligations of Public Company and Merger Subsidiary</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_92">Conditions to Obligations of Merger Partner and the Blockers</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexarom401831_93"><B>ARTICLE VII </B>ADDITIONAL AGREEMENTS<B></B>
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_94">Employee Matters</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_95">D&amp;O Indemnification</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-iii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(continued) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_96">Tax Matters</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_97">Transaction Litigation</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_98">Asset Transfers</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexarom401831_99"><B>ARTICLE VIII </B>TERMINATION AND AMENDMENT<B></B>
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_100">Termination</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_101">Effect of Termination</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_102">Fees and Expenses</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_103">Amendment</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_104">Extension; Waiver</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexarom401831_105"><B>ARTICLE IX </B>DEFINITIONS<B></B> </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexarom401831_106"><B>ARTICLE X </B>MISCELLANEOUS<B></B> </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_107">Notices</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_108">Entire Agreement</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_109">Third-Party Beneficiaries</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_110">Assignment</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_111">Severability</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_112">Counterparts and Signature</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_113">Interpretation</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_114">Governing Law</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_115">Remedies</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_116">Confidentiality</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_117">Submission to Jurisdiction</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="#annexarom401831_118"><FONT STYLE="white-space:nowrap">Non-Survival</FONT> of Representations, Warranties and Covenants</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-iv </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(continued) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>EXHIBITS </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="4%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Page</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Exhibit A</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Public Company Support Agreements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Exhibit B</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Merger Partner Support Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Exhibit <FONT STYLE="white-space:nowrap">C-1</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">First Blocker Merger Certificate of Merger</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Exhibit <FONT STYLE="white-space:nowrap">C-2</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Blocker Certificate of Merger</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Exhibit <FONT STYLE="white-space:nowrap">C-3</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Merger Partner Certificate of Merger</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Exhibit <FONT STYLE="white-space:nowrap">D-1</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Public Company Directors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Exhibit <FONT STYLE="white-space:nowrap">D-2</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Public Company Officers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Exhibit E</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Interim Funding Term Sheet</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Exhibit F</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amendment to License Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Exhibit G</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Allocation Schedule</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Exhibit H</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Term Sheet for Tax Receivables Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Exhibit I</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Unitholder Representative Engagement Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-v </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT AND PLAN OF MERGER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS AGREEMENT AND PLAN OF MERGER (this &#147;<U>Agreement</U>&#148;) is entered into as of January&nbsp;13, 2023, by and among: Calyxt, Inc.,
a Delaware corporation (&#147;<U>Public Company</U>&#148;); Calypso Merger Subsidiary, LLC, a Delaware limited liability company and wholly-owned subsidiary of Public Company (&#147;<U>Merger Subsidiary</U>&#148;); Cibus Global, LLC, a Delaware
limited liability company (&#147;<U>Merger Partner</U>&#148;); New Ventures I Holdings, LLC, a Delaware limited liability company (&#147;<U>Blocker 1</U>&#148;); BCGF CB Holdings LLC, a Delaware limited liability company (&#147;<U>Blocker
2</U>&#148;); BCGFCP CB Holdings LLC, a Delaware limited liability company (&#147;<U>Blocker 3</U>&#148;); BCGFK CB Holdings LLC, a Delaware limited liability company (&#147;<U>Blocker 4</U>&#148;); FSBCGF CB Holdings LLC, a Delaware limited
liability company (&#147;<U>Blocker 5</U>&#148;); PYLBCG CB Holdings LLC, a Delaware limited liability company (&#147;<U>Blocker 6</U>&#148;); FSGRWCO CB Holdings LLC, a Delaware limited liability company (&#147;<U>Blocker 7</U>&#148;); GROWTHCO CB
Holdings LLC, a Delaware limited liability company (&#147;<U>Blocker 8</U>&#148;); GRTHCOCP CB Holdings LLC, a Delaware limited liability company (&#147;<U>Blocker 9</U>&#148;); and GRWTHCOK CB Holdings LLC, a Delaware limited liability company
(&#147;<U>Blocker 10</U>&#148;; and, collectively with Blocker 1, Blocker 2, Blocker 3, Blocker 4, Blocker 5, Blocker 6, Blocker 7, Blocker 8 and Blocker 9, the &#147;<U>Blockers</U>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Merger
Subsidiary is a newly-formed, wholly-owned Subsidiary of Public Company, and was formed for the sole purpose of the Merger Partner Merger; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, (a)&nbsp;Public Company and Blocker 1 intend to effect a merger (the &#147;<U>First Blocker Merger</U>&#148;) in which Blocker 1 will
merge with and into Public Company with Public Company being the surviving entity in such merger; (b)&nbsp;Public Company and Blocker 2 intend to effect a merger (the &#147;<U>Second Blocker Merger</U>&#148;) in which Blocker 2 will merge with and
into Public Company with Public Company being the surviving entity in such merger; (c)&nbsp;Public Company and Blocker 3 intend to effect a merger (the &#147;<U>Third Blocker Merger</U>&#148;) in which Blocker 3 will merge with and into Public
Company with Public Company being the surviving entity in such merger; (d)&nbsp;Public Company and Blocker 4 intend to effect a merger (the &#147;<U>Fourth Blocker Merger</U>&#148;) in which Blocker 4 will merge with and into Public Company with
Public Company being the surviving entity in such merger; (e)&nbsp;Public Company and Blocker 5 intend to effect a merger (the &#147;<U>Fifth Blocker Merger</U>&#148;) in which Blocker 5 will merge with and into Public Company with Public Company
being the surviving entity in such merger; (f)&nbsp;Public Company and Blocker 6 intend to effect a merger (the &#147;<U>Sixth Blocker Merger</U>&#148;) in which Blocker 6 will merge with and into Public Company with Public Company being the
surviving entity in such merger; (g)&nbsp;Public Company and Blocker 7 intend to effect a merger (the &#147;<U>Seventh Blocker Merger</U>&#148;) in which Blocker 7 will merge with and into Public Company with Public Company being the surviving
entity in such merger; (h)&nbsp;Public Company and Blocker 8 intend to effect a merger (the &#147;<U>Eighth Blocker Merger</U>&#148;) in which Blocker 8 will merge with and into Public Company with Public Company being the surviving entity in such
merger; (i)&nbsp;Public Company and Blocker 9 intend to effect a merger (the &#147;<U>Ninth Blocker Merger</U>&#148;) in which Blocker 9 will merge with and into Public Company with Public Company being the surviving entity in such merger; and
(j)&nbsp;Public Company and Blocker 10 intend to effect a merger (the &#147;<U>Tenth Blocker Merger</U>&#148; and, collectively with the First Blocker Merger, Second Blocker Merger, Third Blocker Merger, Fourth Blocker Merger, Fifth Blocker Merger,
Sixth Blocker Merger, Seventh Blocker Merger, Eighth Blocker Merger and Ninth Blocker Merger, the &#147;<U>Blocker Mergers</U>&#148;) in which Blocker 10 will merge with and into Public Company with Public Company being the surviving entity in such
merger; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, following the Blocker Mergers, Public Company, Merger Subsidiary and Merger Partner intend to effect a merger (the
&#147;<U>Merger Partner Merger</U>&#148; and, collectively with the Blocker Mergers, the &#147;<U>Mergers</U>&#148;), pursuant to which Merger Subsidiary will merge with and into Merger Partner, Merger Subsidiary will cease to exist, and Merger
Partner will survive, with the former security holders of Merger Partner receiving the Merger Consideration set forth in Section&nbsp;2.1(b); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, in connection with the consummation of the Merger Partner Merger, Public Company,
the Electing Members and Merger Partner will enter into a Tax Receivable Agreement, in a form to be agreed by Merger Partner and Public Company consistent with the terms set forth on <U>Exhibit H</U> promptly following the date of this Agreement,
pursuant to which the Public Company will agree to make payments to the post-Closing holders of Merger Partner Common Units (other than the Public Company) from time to time with respect to the effect of tax attributes resulting from Exchanges and
the Blocker Mergers on the liability for Taxes of the Public Company (the &#147;<U>Tax Receivable Agreement</U>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, in
connection with the consummation of the Merger Partner Merger, Public Company, the Electing Members and Merger Partner will enter into an Exchange Agreement, in a form to be agreed by Merger Partner and Public Company promptly following the date of
this Agreement, pursuant to which the post-Closing holders of Merger Partner Common Units (other than the Public Company) shall have the right (on the terms and subject to the conditions to be agreed therein) to exchange their Merger Partner Common
Units and shares of Public Company Class&nbsp;B Common Stock for shares of Public Company Class&nbsp;A Common Stock (the &#147;<U>Exchange Agreement</U>&#148;, and any such exchanges, &#147;<U>Exchanges</U>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, in connection with the consummation of the Merger Partner Merger, Public Company and the Electing Members will enter into a
Registration Rights Agreement, in a form to be agreed by Merger Partner and Public Company promptly following the date of this Agreement, providing for, among other things, the registration for resale of any shares Public Company Class&nbsp;A Common
Stock received by post-Closing holders of Merger Partner Common Units (other than the Public Company) in connection with any Exchanges (the &#147;<U>Registration Rights Agreement</U>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, each recipient of shares of Public Company Class&nbsp;B Common Stock shall also be a Participating Member in respect of the shares of
Public Company Class&nbsp;A Stock such Person shall receive in the Merger Partner Merger, as contemplated herein; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Parties
intend for the Transactions to be treated in accordance with the Intended Tax Treatment set forth in Section&nbsp;7.3(b); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS,
immediately prior to the Mergers, Public Company intends to repay the outstanding balance owed to Merger Partner in connection with the Interim Funding through the transfer of a portion of its assets to Merger Partner and immediately thereafter,
Public Company intends to contribute the residual of its assets and liabilities to Merger Partner, as a contribution to the capital of Merger Partner in exchange for Merger Partner Common Units, in each case, pursuant to Section&nbsp;7.5 (the
&#147;<U>Asset Transfers</U>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Boards of Directors (or equivalent governing bodies) of Public Company, Merger
Subsidiary and Merger Partner deem it advisable and in the best interests of each company and their respective equity holders to consummate the Mergers and the other Transactions in accordance with and on the terms contemplated by this Agreement;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the managing member of Blocker 1 executed and delivered to Public Company on or prior to the date hereof, a written consent
wherein the managing member (i)&nbsp;determined that the Transactions are fair to, advisable, and in the best interests of Blocker 1 and its sole member and (ii)&nbsp;adopted this Agreement and approved the Transactions, including the First Blocker
Merger, in each case, consistent with the applicable provisions of Blocker 1&#146;s Organizational Documents and Delaware Law; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS,
concurrently with the execution and delivery of this Agreement and as a condition and inducement to Merger Partner&#146;s willingness to enter into this Agreement, the Persons set forth on <U>Schedule A</U> attached hereto (the &#147;<U>Public
Company Support Stockholders</U>&#148;) have entered into Voting Agreements, dated as of the date of this Agreement, in the form attached hereto as <U>Exhibit A</U> (the &#147;<U>Public Company Support Agreements</U>&#148;), pursuant to which the
Public Company Support Stockholders have, subject to the terms and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
conditions set forth therein, agreed to vote all of their respective shares of capital stock of Public Company in favor of Public Company Stockholder Matters and the Other Public Company
Stockholder Matters at the Public Company Stockholders&#146; Meeting to be convened to approve the Mergers and the other Transactions; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, concurrently with the execution and delivery of this Agreement and as a condition and inducement to Public Company&#146;s willingness
to enter into this Agreement, the Persons set forth on <U>Schedule B</U> attached hereto (the &#147;<U>Merger Partner Support Holders</U>&#148;) have each entered into a Voting Agreement, dated as of the date of this Agreement, in the form attached
hereto as <U>Exhibit B</U> (the &#147;<U>Merger Partner Support Agreement</U>&#148;), pursuant to which the Merger Partner Support Holders have, subject to the terms and conditions set forth therein, agreed to vote all of their respective shares of
membership interest in Merger Partner in favor of the Merger Partner Member Approvals by executing and delivering an action by written consent, representing the Merger Partner Member Approvals (together with the actions by written consent
representing the Blocker Approvals, the &#147;<U>Written Consents</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the foregoing and the
respective representations, warranties, covenants and agreements set forth below, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Public Company, Merger Subsidiary, Merger Partner and each
Blocker agree as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="annexarom401831_1"></A>ARTICLE I </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE MERGERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_2">
</A>1.1 <U>Mergers; Effective Time of the Mergers</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Blocker Mergers</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Upon the terms and subject to the conditions set forth in this Agreement, and in accordance with the applicable provisions of Delaware
Law, Public Company and each Blocker shall cause the corresponding Blocker Merger to be consummated (and for the avoidance of doubt, each Blocker shall only be responsible for causing the merger of itself with and into Public Company pursuant to its
corresponding Blocker Merger). Each Blocker Merger shall be consummated at the applicable Blocker Merger Effective Time in accordance with this Agreement upon the filing and effectiveness of a certificate of merger relating to the corresponding
Blocker Merger in substantially the form of <U>Exhibit <FONT STYLE="white-space:nowrap">C-1</FONT></U> (with respect to the First Blocker Merger) or <U>Exhibit <FONT STYLE="white-space:nowrap">C-2</FONT></U> (with respect to all subsequent Blocker
Mergers other than the First Blocker Merger) (the applicable certificate of merger corresponding to each Blocker Merger being such Blocker Merger&#146;s applicable &#147;<U>Blocker Certificate of Merger</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Upon the applicable Blocker Merger Effective Time, the separate company existence of each Blocker being merged shall cease and Public
Company, as the surviving corporation of such Blocker Merger, shall continue its corporate existence under Delaware Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) Subject
to the provisions of this Agreement, Public Company and each Blocker shall cause the corresponding Blocker Certificate of Merger to be executed, acknowledged and filed with the Secretary of State of the State of Delaware (and for the avoidance of
doubt, each Blocker shall only be responsible for causing its applicable Blocker Certificate of Merger to be executed, acknowledged and filed). The applicable Blocker Merger shall become effective at the time when the corresponding Blocker
Certificate of Merger has been duly filed with the Secretary of State of the State of Delaware or at such later time as may be agreed by Public Company, Merger Partner and the applicable Blocker in writing and specified in the corresponding Blocker
Certificate of Merger (the effective time of each Blocker Merger being such Blocker Merger&#146;s applicable &#147;<U>Blocker Merger Effective Time</U>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Merger Partner Merger</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Upon the terms and subject to the conditions set forth in this Agreement, and in accordance with the applicable provisions of Delaware
Law, Public Company, Merger Subsidiary and Merger Partner shall cause the Merger Partner Merger to be consummated. The Merger Partner Merger shall be consummated at the Merger Partner Merger Effective Time immediately following the Blocker Mergers
in accordance with this Agreement upon the filing and effectiveness of a certificate of merger relating to the Merger Partner Merger in substantially the form of <U>Exhibit <FONT STYLE="white-space:nowrap">C-3</FONT></U> (the &#147;<U>Merger Partner
Certificate of Merger</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Upon the Merger Partner Merger Effective Time, the separate company existence of Merger
Subsidiary shall cease and Merger Partner, as the surviving limited liability company in the Merger Partner Merger, shall continue its existence as a limited liability company under Delaware Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) Subject to the provisions of this Agreement, Public Company, Merger Subsidiary and Merger Partner and shall cause the Merger Partner
Certificate of Merger to be executed, acknowledged and filed with the Secretary of State of the State of Delaware. The Merger Partner Merger shall become effective at the time when the Merger Partner Certificate of Merger has been duly filed with
the Secretary of State of the State of Delaware or at such later time as may be agreed by Public Company and Merger Partner in writing and specified in the Merger Partner Certificate of Merger (the &#147;<U>Merger Partner Merger Effective
Time</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_3"></A>1.2 <U>Closing; Actions at the Closing</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Closing shall take place at 10:00 a.m., Eastern time, on the Closing Date remotely by electronic exchange of documents and/or at the
offices of Jones Day, 250 Vesey Street, New York, NY 10281, unless another date, place or time is agreed to in writing by Public Company and Merger Partner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) At the Closing: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)
Merger Partner and each Blocker shall deliver to Public Company and Merger Subsidiary the various certificates, instruments and documents referred to in Section&nbsp;6.1 that are required to be delivered by it; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Public Company and Merger Subsidiary shall deliver to Merger Partner the various certificates, instruments and documents referred to in
Section&nbsp;6.2; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) Public Company and Merger Partner shall file with the Secretary of State of the State of Delaware the Blocker
Certificate of Merger for each of the Blocker Mergers and the Merger Partner Certificate of Merger, respectively; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) Public Company,
Merger Subsidiary, Merger Partner and each Blocker shall take, or cause to be taken, the actions set forth in Sections 1.1(a) and 1.1(b) that are required to be taken by it; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) Public Company shall issue the shares of Public Company Class&nbsp;A Common Stock and Public Company Class&nbsp;B Common Stock
constituting the Merger Consideration and deposit them with the Exchange and Paying Agent pursuant to Section&nbsp;2.2(a); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) Merger
Partner shall issue the Merger Partner Common Units constituting the Merger Consideration and deposit them with the Exchange and Paying Agent pursuant to Section&nbsp;2.2(a); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii) Merger Partner shall issue the Merger Partner Common Units to be issued to Public Company pursuant to Section&nbsp;2.1(b)(ii) and 7.5;
and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(viii) Each Blocker shall deliver a properly executed certification that such entity&#146;s equity interests are not &#147;U.S. real
property interests&#148; in accordance with the Treasury Regulations under Sections 897 and 1445 of the Code, together with a notice to the IRS in accordance with the provisions of Treasury Regulations section
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
1.897-2(h)(2) and Merger Partner shall deliver a properly executed certification satisfying the requirements of Temporary Treasury Regulations section
<FONT STYLE="white-space:nowrap">1.1445-11T</FONT> to the effect that fifty percent (50%) or more of the value of the gross assets of Merger Partner does not consist of &#147;U.S. real property interests&#148;, or that ninety percent (90%) or more
of the value of the gross assets of Merger Partner does not consist of &#147;U.S. real property interests&#148; plus cash or cash equivalents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_4"></A>1.3 <U>Effects of the Mergers</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) At and after the Blocker Merger Effective Time corresponding to the First Blocker Merger, without any action on the part of Blocker 1 or
Public Company or the holders of securities of the foregoing, (i)&nbsp;Blocker 1 shall merge with and into Public Company, the separate existence of Blocker 1 shall cease, and Public Company shall survive the First Blocker Merger and continue its
corporate existence, (ii)&nbsp;the effect of the First Blocker Merger shall be as provided in this Agreement and the applicable provisions of Delaware Law, (iii)&nbsp;the certificate of incorporation of Public Company shall be amended and restated
in its entirety in a manner to be mutually agreed as soon as reasonably practicable following the date hereof by Merger Partner and Public Company (the &#147;<U>Amended Certificate</U>&#148;) and (iv)&nbsp;the
<FONT STYLE="white-space:nowrap">by-laws</FONT> of Public Company shall be amended and restated in their entirety in a manner to be mutually agreed as soon as reasonably practicable following the date hereof by Merger Partner and Public Company (the
&#147;<U>Amended <FONT STYLE="white-space:nowrap">By-Laws</FONT></U>&#148;). Without limiting the foregoing, Public Company, as the surviving corporation in the First Blocker Merger, shall thereupon and thereafter possess all of the rights,
property, privileges, powers and franchises, of a public as well as a private nature, of each of Public Company and Blocker 1, and shall become subject to all the restrictions, disabilities and duties of each of Public Company and Blocker 1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) At and after the applicable Blocker Merger Effective Time of each Blocker Merger (other than the First Blocker Merger), without any action
on the part of applicable Blocker being merged (other than Blocker 1) or Public Company or the holders of securities of the foregoing, (i)&nbsp;such Blocker shall merge with and into Public Company, the separate existence of such Blocker shall
cease, and Public Company shall survive such Blocker Merger and continue its corporate existence and (ii)&nbsp;the effect of such Blocker Merger shall be as provided in this Agreement and the applicable provisions of Delaware Law. Without limiting
the foregoing, Public Company, as the surviving corporation in each Blocker Merger (other than the First Blocker Merger), shall thereupon and thereafter possess all of the rights, property, privileges, powers and franchises, of a public as well as a
private nature, of each of Public Company and the Blocker being merged in such Blocker Merger, and shall become subject to all the restrictions, disabilities and duties of each of Public Company and the Blocker being merged in such Blocker Merger.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) At and after the Merger Partner Merger Effective Time without any action on the part of Merger Partner, Merger Subsidiary or Public
Company or the holders of securities of the foregoing, (i)&nbsp;Merger Subsidiary shall merge with and into Merger Partner, the separate existence of Merger Subsidiary shall cease, and Merger Partner shall survive the Merger and continue its
existence as a limited liability company, (ii)&nbsp;the effect of the Merger Partner Merger shall be as provided in this Agreement and the applicable provisions of Delaware Law and (iii) the limited liability company agreement of Merger Partner
shall be amended and restated in its entirety in a manner to be mutually agreed as soon as reasonably practicable following the date hereof by Merger Partner, Public Company and the Electing Members (the &#147;<U>Amended Operating
Agreement</U>&#148;). Without limiting the foregoing, Merger Partner, as the surviving limited liability company of the Merger Partner Merger, shall thereupon and thereafter possess all of the rights, property, privileges, powers and franchises, of
a public as well as a private nature, of the Merger Partner and Merger Subsidiary, and shall become subject to all the restrictions, disabilities and duties of each of Merger Partner and Merger Subsidiary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_5"></A>1.4 <U>Directors and Officers</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) At and after the Blocker Merger Effective Time corresponding to the First Blocker Merger, without any action on the part of Blocker 1 or
Public Company or the holders of securities of the foregoing, the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
individuals set forth on <U>Exhibit <FONT STYLE="white-space:nowrap">D-1</FONT></U> shall be the directors of Public Company, each to hold office in accordance with the Amended Certificate and
Amended <FONT STYLE="white-space:nowrap">By-Laws</FONT> of Public Company and until their respective successors are duly elected and qualified or until such director&#146;s earlier death, resignation or removal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) At and after the Blocker Merger Effective Time corresponding to the First Blocker Merger, without any action on the part of Blocker 1 or
Public Company or the holders of securities of the foregoing, the individuals set forth on <U>Exhibit <FONT STYLE="white-space:nowrap">D-2</FONT></U> shall be the officers of Public Company, each to hold office in accordance with the Amended
Certificate and Amended <FONT STYLE="white-space:nowrap">By-Laws</FONT> of Public Company and until their respective successors are duly appointed or until such officer&#146;s earlier death, resignation or removal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_6"></A>1.5 <U>Additional Action</U>. Public Company, at any time from and after the effective time of the Blocker
Mergers and Merger Partner Merger, may take any lawful action, including executing and delivering any document, in the name and on behalf of either Merger Subsidiary, any Blocker or Merger Partner necessary or desirable in order to consummate and
give effect to the Transactions. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="annexarom401831_7"></A>ARTICLE II </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONVERSION OF SECURITIES </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_8">
</A>2.1 <U>Conversion of Securities</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Blocker Mergers</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) At the applicable Blocker Merger Effective Time for each Blocker Merger, by virtue of such Blocker Merger and without any action on the
part of Public Company, the Blocker being merged, any holder of limited liability company interests or capital stock, as applicable, in such Blocker or any other Person, (A)&nbsp;each limited liability company interest or share of capital stock, as
applicable, of the Blocker being merged that is owned by such Blocker in treasury or by Public Company or any direct or indirect wholly-owned Subsidiary of Public Company as of immediately prior to the applicable Blocker Merger Effective Time shall
be cancelled and cease to exist and no payment of consideration shall be delivered in exchange therefor and (B)&nbsp;each limited liability company interest or share of capital stock, as applicable, of the Blocker being merged issued and outstanding
immediately prior to the applicable Blocker Merger Effective Time (other than the limited liability company interests or share of capital stock, as applicable, referenced in clause (A)&nbsp;above) shall be automatically cancelled and converted into
the right to receive the applicable portion of the Merger Consideration (in the form of shares of Public Company Class&nbsp;A Common Stock) corresponding to that Blocker Merger as set forth on the Allocation Schedule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) The shares of capital stock of Public Company outstanding immediately prior to each applicable Blocker Merger Effective Time shall
remain outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Merger Partner Merger</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) At the Merger Partner Merger Effective Time, by virtue of the Merger Partner Merger and without any action on the part of Public Company,
Merger Subsidiary, Merger Partner, any holder of limited liability company interests in Merger Partner or any other Person: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(A) each
Merger Partner Unit that is owned by Merger Partner in treasury as of immediately prior to the Merger Partner Merger Effective Time shall be cancelled and cease to exist and no payment of consideration shall be delivered in exchange therefor; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(B) each Merger Partner Unit (other than a Merger Partner PIU) held by an Electing Member (as determined pursuant to Section&nbsp;2.5(b))
issued and outstanding immediately prior to the Merger Partner </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Merger Effective Time shall automatically be cancelled and converted into the right to receive in exchange therefor, at the election by such Electing Member pursuant to Section&nbsp;2.5, either
(I)&nbsp;the number of shares of Public Company Class&nbsp;A Common Stock set forth on the Allocation Schedule, or (II)&nbsp;the number of Merger Partner Common Units set forth on the Allocation Schedule and an equal number of shares of Public
Company Class&nbsp;B Common Stock (a Merger Partner Common Unit and a share of Public Company Class&nbsp;B Common Stock, collectively, an &#147;<U><FONT STYLE="white-space:nowrap">Up-C</FONT> Unit</U>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(C) each Merger Partner Warrant issued and outstanding immediately prior to the Merger Partner Merger Effective Time shall automatically be
exchanged for the right to receive the number of shares of Public Company Class&nbsp;A Common Stock set forth on the Allocation Schedule; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(D) each Merger Partner Unit (other than a Merger Partner PIU) held by a Participating Member (or an Electing Member with respect to any
Merger Partner Units held by such Electing Member that are not Excluded Units) issued and outstanding immediately prior to the Merger Partner Merger Effective Time shall (without duplication of any conversions pursuant to Section&nbsp;2.1(b)(i)(B)
above) automatically be cancelled and converted into the right to receive the number of shares of Public Company Class&nbsp;A Common Stock set forth on the Allocation Schedule; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(E) each Merger Partner PIU issued and outstanding immediately prior to the Merger Partner Merger Effective Time shall, (I)&nbsp;to the
extent not a &#147;restricted unit&#148; under the award agreements and governing documents applicable to such Merger Partner PIU as of such time, be automatically cancelled and converted into the right to receive the number of shares of Public
Company Class&nbsp;A Common Stock set forth on the Allocation Schedule and (II)&nbsp;to the extent a &#147;restricted unit&#148; (or unvested) under the award agreements and other governing documents applicable to such Merger Partner PIU as of such
time, be automatically cancelled and converted into the right to receive the number of restricted shares of Public Company Class&nbsp;A Common Stock pursuant to a Public Company Stock Plan, as set forth on the Allocation Schedule and subject to the
same vesting schedule as was applicable to such Merger Partner PIU. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Immediately following the consummation of the Merger Partner
Merger, and without any action on the part of Public Company, Merger Subsidiary, Merger Partner, any other holder of limited liability company interests in Merger Partner or any other Person, (A)&nbsp;each limited liability company interest of
Merger Subsidiary issued and outstanding immediately prior to the Merger Partner Merger Effective Time shall be automatically be cancelled and cease to exist, (B)&nbsp;each Merger Partner Unit or Merger Partner Warrant held by the Public Company by
operation of the Blocker Mergers issued and outstanding immediately prior to the Merger Partner Merger Effective Time shall automatically be converted or exchanged for the number of Merger Partner Common Units set forth in the Allocation Schedule,
(C)&nbsp;each Merger Partner Warrant held by Public Company as a result of the exchanges set forth in Section&nbsp;2.1(b)(i)(C) shall automatically be converted or exchanged for the number of Merger Partner Common Units set forth in the Allocation
Schedule and (D)&nbsp;Merger Partner shall issue an aggregate number of Merger Partner Common Units to Public Company in an equal amount to the number shares of Public Company Class&nbsp;A Common Stock issued pursuant to Sections 2.1(b)(i)(B)(I),
2.1(b)(i)(D), and 2.1(b)(i)(E) (without duplication of Merger Partner Common Units issued pursuant to the foregoing clauses (B)&nbsp;and (C)) as set forth in the Allocation Schedule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Certain Adjustments to Per Share Amounts</U>. All <FONT STYLE="white-space:nowrap">per-share</FONT> or
<FONT STYLE="white-space:nowrap">per-unit</FONT> amounts of the Merger Consideration shall be equitably adjusted, as applicable and appropriate, to reflect fully the effect of, and to provide the holders of equity securities of Public Company,
Blockers or Merger Partner the same economic effect as contemplated by this Agreement prior to the occurrence of, any reclassification, stock split, reverse split, stock dividend (including any dividend or distribution of securities convertible into
Company Stock), reorganization, recapitalization or other like change with respect to the Public Company Common Stock or the Merger Partner Units or any securities convertible or exchangeable into or exercisable for shares of Public Company Common
Stock or Merger Partner Units occurring (or for which a record date is established) after the date of this Agreement and prior to the consummation of the First Blocker Merger. Nothing in this Section&nbsp;2.1(c)
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
will be construed to permit Public Company, Merger Partner, Merger Sub, or Blockers to take any action prohibited by the terms of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>No Fractional Shares</U>. Notwithstanding any other provision of this Agreement, no fractional shares of Public Company Class&nbsp;A
Common Stock or Public Company Class&nbsp;B Common Stock shall be issued in exchange for any Merger Partner Units or equity securities in a Blocker, and no holder of any of the foregoing shall be entitled to receive a fractional share of Public
Company Class&nbsp;A Common Stock or Public Company Class&nbsp;B Common Stock. Any fractional share of Public Company Class&nbsp;A Common Stock or Public Company Class&nbsp;B Common Stock issuable pursuant to Sections 2.1(a) or 2.1(b), shall be
rounded up to the nearest whole share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_9"></A>2.2 <U>Payment Fund</U>. The procedures for exchanging outstanding
Merger Partner Units, Merger Partner Warrants or equity securities of any Blocker for the shares of Public Company Class&nbsp;A Common Stock, shares of Public Company Class&nbsp;B Common Stock, or Merger Partner Common Units to be issued to such
holders in connection with the Mergers are as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Deposit at Closing</U>. At the Closing, (i)&nbsp;Public Company shall
deliver to the Exchange and Paying Agent shares of Public Company Class&nbsp;A Common Stock and Public Company Class&nbsp;B Common Stock issued in book entry form equal to the amount of the Merger Consideration payable in shares of Public Company
Class&nbsp;A Common Stock and Public Company Class&nbsp;B Common Stock and (ii)&nbsp;Merger Partner shall deliver to the Exchange and Paying Agent Merger Partner Common Units in book entry form equal to the amount of the Merger Consideration payable
in Merger Partner Common Units (the &#147;<U>Payment Fund</U>&#148;). For the avoidance of doubt, any Merger Partner Common Units to be issued to Public Company pursuant to Section&nbsp;2.1(b)(ii), shall be issued by Merger Partner directly to
Public Company immediately following the consummation of the Merger Partner Merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Exchange and Paying Agent</U>. The Exchange
and Paying Agent shall, pursuant to instructions from Public Company and Merger Partner in accordance with the Exchange and Paying Agent Agreement and the Allocation Schedule, deliver (i)&nbsp;the applicable portion of the Merger Consideration to be
paid in shares of Public Company Class&nbsp;A Common Stock, shares of Public Company Class&nbsp;B Common Stock and Merger Partner Common Units to the equity holders of Merger Partner and (ii)&nbsp;the applicable portion of the Merger Consideration
for each Blocker Merger to be paid in shares of Public Company Class&nbsp;A Common Stock to the equity holders of the corresponding Blocker being merged in such Blocker Merger. The Payment Fund shall not be used for any purpose other than as
specified in this Section&nbsp;2.2(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Exchange Procedures</U>. Promptly, but in no event more than three (3)&nbsp;Business Days,
following the date the Registration Statement is declared effective by the SEC, Public Company shall cause the Exchange and Paying Agent to mail to each Person who was a member of Merger Partner or any Blocker as of immediately prior to the
effective time of each respective Mergers, (i)&nbsp;a Letter of Transmittal and (ii)&nbsp;instructions for effecting the issuance of the portion of the Merger Consideration, as applicable, payable with respect thereto pursuant to the terms of this
Agreement and the Allocation Schedule. Upon proper delivery of a duly completed and executed Letter of Transmittal, each such Person shall be entitled to receive the number of shares of Public Company Class&nbsp;A Common Stock, shares of Public
Company Class&nbsp;B Common Stock and Merger Partner Common Units as determined in accordance with Section&nbsp;2.1 and reflected on the Allocation Schedule. If payment is to be made to a Person other than the Person who is reflected in the books
and records of the applicable company as the applicable member, it shall be a condition of payment that the Person requesting such payment shall have established to the satisfaction of Public Company and the Exchange and Paying Agent that any
transfer and other Taxes required by reason of such payment to a Person other than the applicable member have been paid or are not applicable. From and after the Merger Partner Merger Effective Time, or each applicable Blocker Merger Effective Time,
as applicable, other than Electing Members (with respect to Excluded Units) each Person that was a member of Merger Partner or the corresponding Blocker being merged, respectively (or the holder of an economic interest therein) shall have no rights
as a member or holder of any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such economic interests and, until the procedures contemplated by this Section&nbsp;2.2 have been complied with, any such former limited liability company or economic interest shall represent
only the right to receive the applicable portion of the Merger Consideration, respectively, on the terms and subject to the conditions of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>No Further Ownership Rights</U>. All Merger Consideration paid in accordance with the terms hereof shall be deemed to have been paid in
satisfaction of all rights pertaining to the applicable limited liability company or other interests in Merger Partner and each Blocker, respectively, and from and after the Merger Partner Merger Effective Time and the applicable Blocker Merger
Effective Time, as applicable, (except as necessary to reflect the issuance of Merger Partner Common Units as Merger Consideration pursuant to Section&nbsp;2.1) there shall be no further registration of transfers on the register or members or other
books of Merger Partner or the corresponding Blocker which were outstanding as of immediately prior to the Merger Effective Time and the applicable Blocker Merger Effective Time, as applicable. If, after the Merger Partner Merger Effective Time and
the applicable Blocker Merger Effective Time, as applicable, claims of ownership are presented to Public Company, Merger Partner or the Exchange and Paying Agent for any reason, they shall be cancelled and exchanged as provided in this Article II,
subject to Section&nbsp;2.2(f). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Termination of Payment Fund</U>. Any portion of the Payment Fund deposited with the Exchange and
Paying Agent (including shares of Public Company Class&nbsp;A Common Stock or Public Company Class&nbsp;B Common Stock issued to a Public Company reserve account) that remains undistributed as of one year after the Closing shall be delivered to
Public Company (subject to abandoned property, escheat or similar Law), upon demand, and any Person who is entitled to such amount under this Section&nbsp;2.2 shall (subject to Section&nbsp;2.2(f)) be entitled to seek payment of such amount from
Public Company only as a general creditor thereof.<U> </U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>No Liability</U>. To the extent permitted by applicable Law, none of
Public Company, Merger Subsidiary, Merger Partner, any Blocker or the Exchange and Paying Agent shall be liable to any Person for any amount delivered to a public official pursuant to any applicable abandoned property, escheat or similar Law. If the
applicable exchange procedures shall not have been completed prior to the first (1st) anniversary of the Closing Date (or immediately prior to such earlier date on which the related consideration payable pursuant to this Article II would otherwise
escheat to or become the property of any Governmental Entity), any such consideration in respect thereof shall, to the extent permitted by applicable Law, become the property of Public Company, free and clear of all claims or interest of any Person
previously entitled thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_10"></A>2.3 <U>Allocation Schedule</U>. The Allocation Schedule sets forth a true,
correct and complete allocation of the amounts payable to the equity holders of Merger Partner and the Blockers pursuant to this Agreement as of the date of this Agreement and the pro forma equity capitalization of Public Company and Merger Partner
giving effect to the Mergers. Merger Partner shall deliver an updated Allocation Schedule reflecting any transfers of equity interests in Merger Partner or any Blocker or issuances of equity or equity linked securities of Merger Partner after the
date hereof (which issuances for the avoidance of doubt shall only be made in compliance with the terms of this Agreement), as well as the elections contemplated by Section&nbsp;2.5, to Public Company at least three (3)&nbsp;Business Days prior to
the Closing, which updated Allocation Schedule shall not, for the avoidance of doubt, change the aggregate number of shares of Public Company Class&nbsp;A Common Stock and Public Company Class&nbsp;B Common Stock comprising the Merger Consideration
or the aggregate number of Merger Partner Common Units to be issued in connection with the Mergers (subject to the election rights of the Electing Members pursuant to Section&nbsp;2.5); <U>provided</U>, <U>however</U>, that in the event Merger
Partner sells additional Merger Partner Series F Preferred Units after the date of this Agreement at a cash price per Series F Preferred Unit of $2.00 and otherwise on terms substantially the same as issuances of Series F Preferred Units by Merger
Partner prior to the date hereof (each, an &#147;<U>Additional Merger Partner Unit</U>&#148;) the Allocation Schedule shall be updated to reflect such issuances of Additional Series F Preferred Unit(s) of Merger Partner and the number of shares of
Public Company Class&nbsp;A Common Stock, Public Company Class&nbsp;B Common Stock and Member Partner Class&nbsp;B Units comprising the Merger Consideration in exchange therefor and any additional Member Partner Class&nbsp;A Units to be issued as a
result pursuant to Section&nbsp;2.1(b)(ii). Public Company, Merger Partner and the Exchange and Paying Agent shall be entitled to rely conclusively on the Allocation Schedule as in effect from time to time
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and any amounts delivered by Public Company and Merger Partner to any security holder of Merger Partner or a Blocker (or delivered by Public Company to the Exchange and Paying Agent for further
delivery to such Persons) in accordance with the Allocation Schedule, shall be deemed for all purposes to have been delivered to the applicable equity holder in full satisfaction of the obligations of Public Company and Merger Partner under this
<U>Article II</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_11"></A>2.4 <U>Withholding Rights</U>. Public Company, Merger Partner and the Exchange and
Paying Agent will be entitled to deduct and withhold from the amounts otherwise payable by it pursuant to this Agreement to any Person, such amounts as it reasonably determines that it is required to deduct and withhold with respect to the making of
such payment under the Code, or any provision of state, local or foreign Tax Law, and to collect any necessary Tax forms, including Forms <FONT STYLE="white-space:nowrap">W-8</FONT> or <FONT STYLE="white-space:nowrap">W-9,</FONT> as applicable, or
any similar information, from any equity holders of Merger Partner or a Blocker and any other recipients of payments hereunder, <U>provided</U>, that if any payment to the equity holders of Merger Partner or a Blocker is subject to deduction or
withholding (other than any payment to a Merger Partner employee in its capacity as such or a requirement to deduct or withhold that is attributable to a failure to provide a duly completed Form <FONT STYLE="white-space:nowrap">W-8</FONT> or <FONT
STYLE="white-space:nowrap">W-9,</FONT> as applicable, to the Exchange and Paying Agent), then the Public Company or the Exchange and Paying Agent shall (i)&nbsp;provide notice to Merger Partner or the applicable Blocker as soon as reasonably
practicable after such determination and prior to such payment and (ii)&nbsp;reasonably cooperate with Merger Partner or the applicable Blocker to reduce or eliminate any such deduction or withholding to the extent permitted by applicable Law. In
the event that any amount is so deducted and withheld, and properly remitted, such amount will be treated for all purposes of this Agreement as having been paid to the Person to whom the payment from which such amount was withheld was made. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_12"></A>2.5 <U>Merger Consideration Election Procedures</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Promptly, but in no event more than three (3)&nbsp;Business Days, following the date the Registration Statement declared effective by the
SEC (the &#147;<U>Mailing Date</U>&#148;), Merger Partner will mail, or cause the Exchange and Paying Agent to mail, to each holder of Merger Partner Units (other than Merger Partner PIUs) that is a Top 99 Merger Partner Holder as of the Mailing
Date (or another date selected by Merger Partner which is reasonably acceptable to Public Company) a merger consideration election form in a form mutually satisfactory to Merger Partner and Public Company (the &#147;<U>Election Form</U>&#148;). The
Election Form will accompany the Disclosure Statement and copies of the form of Tax Receivable Agreement, Amended Operating Agreement, Exchange Agreement and Registration Rights Agreement and the Election Form will include counterpart signatures to
each of the foregoing agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Each Election Form will permit each holder (other than Blockers) of Merger Partner Units that is a
Top 99 Merger Partner Holder, to elect on a <FONT STYLE="white-space:nowrap">per-Merger</FONT> Partner Unit basis (other than in respect of Merger Partner PIUs), to receive as Merger Consideration in the Merger Partner Merger in the form of either
(A)&nbsp;shares of Public Company Class&nbsp;A Common Stock or <FONT STYLE="white-space:nowrap">(B)&nbsp;Up-C</FONT> Units (subject to the limitations in this Section&nbsp;2.5(b), any such holder validly electing to receive <FONT
STYLE="white-space:nowrap">Up-C</FONT> Units in exchange for any one or more of its Merger Partner Units, an &#147;<U>Electing Member</U>&#148;, and the Merger Partner Units that such Electing Member will exchange for
<FONT STYLE="white-space:nowrap">Up-C</FONT> Units, the &#147;<U>Excluded Units</U>&#148;); <U>provided</U>, <U>however</U>, that no Electing Member will be entitled to receive <FONT STYLE="white-space:nowrap">Up-C</FONT> Units to the extent such
holder&#146;s Excluded Units exchanged therefor would represent more than ninety-five percent (95%), or such lower percentage as may be determined by Merger Partner and set forth on the Election Form, of the total number of Merger Partner Units held
by such Person as of immediately prior to the Merger Partner Merger Effective Time (for the avoidance of doubt, any Merger Partner Units held by such Person in excess of such amount will not constitute Excluded Units and will instead receive shares
of Public Company Class&nbsp;A Common Stock in exchange for the Merger Partner Units representing such excess, notwithstanding such Person&#146;s election). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Any Merger Partner Units with respect to which an election may be made and the Exchange and Paying Agent does not receive a properly
completed Election Form during the period (the &#147;<U>Election Period</U>&#148;) from the Mailing Date to 5:00 p.m., New York Time, on the Business Day that is five (5)&nbsp;Business Days prior to </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Closing Date or such other date as Merger Partner and Public Company will, prior to the Closing, mutually agree (the &#147;<U>Election Deadline</U>&#148;) will be deemed to be held by a
Participating Member and will receive the form of Merger Consideration set forth in Section&nbsp;2.1(b)(i)(D). If the Closing Date is delayed to a subsequent date, the Election Deadline shall be similarly delayed to a subsequent date, and Merger
Partner and Public Company shall promptly announce any such delay and, when determined, the rescheduled Election Deadline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Any
election made pursuant to this Section&nbsp;2.5 will have been properly made only if the Exchange and Paying Agent has actually received a properly completed Election Form (including duly executed counterpart signature pages to the Tax Receivable
Agreement, the Amended Operating Agreement, the Exchange Agreement and the Registration Rights Agreement) during the Election Period. Any Election Form may be revoked or changed by the Person submitting it, by written notice received by the Exchange
and Paying Agent during the Election Period. In the event an Election Form is revoked during the Election Period, the Merger Partner Units represented by such Election Form will be subject to Section&nbsp;2.5(c) except to the extent a subsequent
election is properly made during the Election Period. Any Election Form indicating Electing Member status must be accompanied by duly executed signature pages to the Tax Receivable Agreement, the Amended Operating Agreement, the Exchange Agreement
and the Registration Rights Agreement for such Election Form to be validly received. Subject to the terms of this Agreement and of the Election Form, the Exchange and Paying Agent will have reasonable discretion to determine whether any election,
revocation or change has been properly or timely made and to disregard immaterial defects in the Election Forms, and any good faith decisions of the Exchange and Paying Agent regarding such matters will be binding and conclusive. None of Merger
Partner, Public Company or the Exchange and Paying Agent will be under any obligation to notify any Person of any defect in an Election Form. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="annexarom401831_13"></A>ARTICLE III </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REPRESENTATIONS AND WARRANTIES OF MERGER PARTNER AND BLOCKERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Merger Partner represents and warrants to Public Company that, except as set forth in Merger Partner Disclosure Schedule, the statements
contained in Sections 3.1 through 3.21, and 3.29 and 3.30 (with respect to Merger Partner) are true and correct as of the date of this Agreement and as of the Closing Date, except to the extent such representations and warranties are specifically
made as of a particular date (in which case such representations and warranties will be true and correct as of such date). Each Blocker (solely with respect to itself and not to any other Blocker or Merger Partner) represents and warrants to Public
Company that, except as set forth in Merger Partner Disclosure Schedule, the statements contained in Sections 3.22 through 3.28, and 3.29 and 3.30 (solely with respect to such Blocker) are true and correct as of the date of this Agreement and as of
the Closing Date, except to the extent such representations and warranties are specifically made as of a particular date (in which case such representations and warranties will be true and correct as of such date). Merger Partner Disclosure Schedule
shall be arranged in sections and paragraphs corresponding to the numbered and lettered sections and paragraphs contained in this Article III; <U>provided</U>, <U>however</U>, that the disclosures in any section or paragraph of Merger Partner
Disclosure Schedule shall qualify (a)&nbsp;the corresponding section or paragraph in this Article III and (b)&nbsp;such other sections or paragraphs in this Article III (whether or not there is a specific cross reference) to the extent that it is
reasonably apparent on the face of the disclosure that such disclosure also qualifies or applies to such other section or paragraph. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_14">
</A>3.1 <U>Organization, Standing and Power</U>. Merger Partner is a limited liability company duly organized, validly existing and in good standing under the Laws of the State of Delaware. Except as would not, individually or in the aggregate,
reasonably be expected to result in a Merger Partner Material Adverse Effect, Merger Partner is duly qualified to conduct business and is in good standing under the Laws of each jurisdiction in which the nature of its businesses or the ownership or
leasing of its properties requires such qualification. Merger Partner has all requisite power and authority to (i)&nbsp;carry on the businesses in which it is engaged, (ii)&nbsp;own and use the properties owned and used by it and (iii)&nbsp;perform
its obligations under all Merger Partner Contracts. Merger Partner has made available to Public Company complete and accurate copies of the Organizational Documents of Merger Partner as in effect on the date of this Agreement. Merger Partner is not
in material default under or in material violation of any provision of its Organizational Documents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_15"></A>3.2 <U>Capitalization</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Section 3.2(a) of the Merger Partner Disclosure Schedule sets forth the authorized capital of Merger Partner and the issued and
outstanding equity interests of Merger Partner, in each case as of the date of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Section 3.2(b) of Merger Partner
Disclosure Schedule sets forth a complete and accurate list, as of the date of the Agreement, of (i)&nbsp;the members and holders of limited liability company interests of each of Merger Partner, showing the number and class(es) held by each holder
and (ii)&nbsp;the holders of warrants to purchase limited liability company interest of the Merger Partner. Section&nbsp;3.2(b) of Merger Partner Disclosure Schedule also indicates all limited liability company interests that are subject to a
threshold value, vesting or otherwise subject to a repurchase or redemption right, indicating the name of the applicable member or interest holder, the threshold value, vesting schedule (including any acceleration provisions with respect thereto),
and the repurchase price payable by Merger Partner. All of the limited liability company interests of Merger Partner have been duly authorized, validly issued, and free of all preemptive rights. To the Knowledge of Merger Partner, all of the limited
liability company interests of Merger Partner have been offered, issued and sold by Merger Partner in compliance in all material respects with all applicable federal and state securities Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Except as set forth in Section&nbsp;3.2(b), (A) there are no limited liability company interests of any class of Merger Partner, or any
security exchangeable into or exercisable for such membership interests, issued, reserved for issuance or outstanding, (B)&nbsp;there are no options, warrants, securities, calls, rights, commitments or agreements to which Merger Partner is a party
or by which Merger Partner is bound obligating Merger Partner to issue, exchange, transfer, deliver or sell, or cause to be issued, exchanged, transferred, delivered or sold, additional limited liability company interests of Merger Partner or any
security or rights convertible into or exchangeable or exercisable for any such membership interests, or obligating Merger Partner to grant, extend, accelerate the vesting of, otherwise modify or amend or enter into any such option, warrant, equity
security, call, right, commitment or agreement, and (C)&nbsp;Merger Partner have no obligation (contingent or otherwise) to purchase, redeem or otherwise acquire any of their limited liability company interests or to make any distribution in respect
thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Except for the Organizational Documents of Merger Partner or as set forth on Section&nbsp;3.2(d) of the Merger Partner
Disclosure Schedule, there is no agreement, written or, to the Knowledge of Merger Partner, oral, between Merger Partner and any holder of its limited liability company interests or, to the Knowledge of Merger Partner, among any holders of the
limited liability company interests of Merger Partner, relating to the sale or transfer (including agreements relating to rights of first refusal, <FONT STYLE="white-space:nowrap">co-sale</FONT> rights or &#147;drag along&#148; rights), registration
under the Securities Act or the securities Laws of any other jurisdiction, or voting, of the limited liability company interests of Merger Partner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The Allocation Schedule sets forth as of the date of this Agreement a true, correct and complete summary of the allocation of the amounts
payable to the equity holders of Merger Partner and the Blockers pursuant to this Agreement and the pro forma equity capitalization of each of Public Company and Merger Partner giving effect to the Closing. The allocation of payments set forth on
the Allocation Schedule complies with the terms of Organizational Documents of Merger Partner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_16"></A>3.3
<U>Subsidiaries</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Section 3.3(a) of Merger Partner Disclosure Schedule sets forth each Subsidiary of Merger Partner, all of which
are wholly-owned by Merger Partner. Merger Partner does not own or control directly or indirectly or have any direct or indirect equity participation or similar interest in, or any obligation to provide funding to, any corporation, partnership,
limited liability company, joint venture, trust or other business association or entity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Each Subsidiary of Merger Partner (i)&nbsp;is duly organized, validly existing and in
standing under the Laws of the jurisdiction of its formation, (ii)&nbsp;is duly qualified to conduct business and is in good standing under the Laws of each jurisdiction in which the nature of its businesses or the ownership or leasing of its
properties requires such qualification except as would not, individually or in the aggregate, reasonably be expected to result in a Merger Partner Material Adverse Effect, and (iii)&nbsp;has all requisite power and authority to carry on the
businesses in which it is engaged and to own and use the properties owned and used by it. Merger Partner has delivered to Public Company complete and accurate copies of the Organizational Documents of each Subsidiary of Merger Partner. There are no
outstanding or authorized options, warrants, rights, agreements or commitments to which Merger Partner or any Subsidiary of Merger Partner is a party or which are binding on any of them providing for the issuance, disposition or acquisition of any
equity interests of any such Subsidiary other than to Merger Partner or another Subsidiary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) All of the outstanding capital stock of
or other voting securities of or ownership interests in each Subsidiary of Merger Partner, is owned by Merger Partner, directly or indirectly, free and clear of any Lien and free of any transfer restriction (other than transfer restrictions of
general applicability as may be provided under the Securities Act or other applicable securities Laws), including any restriction on the right to vote, sell or otherwise dispose of such capital stock or other voting securities or ownership
interests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Except for its interests in each Subsidiary of Merger Partner, Merger Partner does not own, directly or indirectly, any
capital stock, membership interest, partnership interest, joint venture interest or other equity interest in any other Person. There are no outstanding contractual obligations of Merger Partner or any of the Subsidiaries of Merger Partner in any
Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_17"></A>3.4 <U>Authority; No Conflict; Required Filings and Consents</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Merger Partner has all requisite power and authority to execute and deliver this Agreement and the other agreements contemplated hereby
and to perform its respective obligations hereunder and thereunder. The execution and delivery by Merger Partner of this Agreement and the other agreements contemplated hereby and, subject to obtaining the Merger Partner Member Approval, which are
the only approval required from the members of Merger Partner, the performance by Merger Partner of this Agreement and the consummation by Merger Partner of the Transactions have been duly and validly authorized by all necessary company or other
corporate action on the part of Merger Partner. This Agreement and all other agreements contemplated hereby have been duly and validly executed and delivered by each of Merger Partner and, assuming the due execution and delivery hereof and thereof
by the other parties hereto and thereto, constitutes or will constitute a valid and binding obligation of Merger Partner, enforceable against it in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency,
moratorium, and other similar Laws affecting creditors&#146; rights generally and by general principles of equity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Merger Partner
Board (by unanimous written consent) has: (i)&nbsp;determined that the Transactions are fair to, advisable, and in the best interests of Merger Partner and its Subsidiaries; (ii)&nbsp;authorized, approved and declared advisable this Agreement and
the Transactions, including the Merger Partner Merger; and (iii)&nbsp;determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the Merger Partner Board has unanimously voted to adopt this Agreement and
thereby approve the Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Subject to the filing of the Merger Partner Certificate of Merger as required by Delaware Law,
neither the execution and delivery by Merger Partner of this Agreement or any other agreement contemplated hereby, nor the performance by Merger Partner of its obligations hereunder or thereunder, nor the consummation by Merger Partner of the
Transactions, will (i)&nbsp;conflict with or violate any provision of the Organizational Documents of Merger Partner, each as amended or restated to date, (ii)&nbsp;require on the part of Merger Partner or any of its Subsidiaries any notice to or
filing with, or any permit, authorization, consent or approval of, any Governmental Entity, (iii)&nbsp;conflict with, result in a breach of, constitute (with or without due notice or lapse of time or both) a default under, result in the acceleration
of obligations under, create in any party the right to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
accelerate, terminate, modify or cancel, or require any notice, consent or waiver under, any contract, lease, sublease, license, sublicense, franchise, permit, indenture, agreement or mortgage
for borrowed money, instrument of Indebtedness, Lien (other than Permitted Liens) or other arrangement to which Merger Partner or any of its Subsidiaries is a party or by which Merger Partner or any of its Subsidiaries is bound or to which any of
the assets of Merger Partner or any of its Subsidiaries are subject, (iv)&nbsp;result in the imposition of any Lien other than Permitted Liens upon any assets of Merger Partner or any of its Subsidiaries or (v)&nbsp;violate any order, writ,
injunction, decree, statute, rule or regulation applicable to Merger Partner or any of its Subsidiaries or any properties or assets of any of the foregoing, except in the case of clauses (ii)&nbsp;through (v) as would not, individually or in the
aggregate, reasonably be expected to result in a Merger Partner Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_18"></A>3.5
<U>Financial Statements; Information Provided</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Merger Partner has made available to Public Company the Merger Partner Financial
Statements. The Merger Partner Financial Statements (i)&nbsp;comply as to form with all applicable accounting requirements and (ii)&nbsp;were prepared in accordance with GAAP applied on a consistent basis throughout the periods covered thereby;
<U>provided</U>, <U>however</U>, that the Merger Partner Financial Statements referred to in clause (b)&nbsp;of the definition of such term are subject to normal recurring <FONT STYLE="white-space:nowrap">year-end</FONT> adjustments (which,
individually and in the aggregate, will not be material) and do not include footnotes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Each of the Merger Partner Financial
Statements fairly presents the consolidated assets, liabilities, business, financial condition, results of operations and cash flows of Merger Partner and its Subsidiaries as of the date thereof and for the period referred to therein, and is
consistent with the books and records of Merger Partner and its Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Merger Partner maintains accurate books and records
reflecting its assets and liabilities and maintains proper and a system of internal accounting control over financial reporting designed to provide reasonable assurance that (i)&nbsp;transactions are executed with management&#146;s authorization,
(ii)&nbsp;transactions are recorded as necessary to permit preparation of the financial statements of Merger Partner and to maintain accountability for Merger Partner&#146;s assets, (iii)&nbsp;access to assets of Merger Partner is permitted only in
accordance with management&#146;s authorization, (iv)&nbsp;the reporting of assets of Merger Partner is compared with existing assets at regular intervals, and (v)&nbsp;accounts, notes and other receivables and inventory were recorded accurately,
and proper and adequate procedures are implemented to effect the collection thereof on a current and timely basis. Merger Partner has disclosed to Merger Partner&#146;s auditors and audit committee (and made available to Public Company a summary of
the significant aspects of such disclosure)&nbsp;(A) all significant deficiencies and material weaknesses, if any, in the design or operation of internal control over financial reporting that are reasonably likely to adversely affect Merger
Partner&#146;s ability to record, process, summarize and report financial information and (B)&nbsp;any Fraud, whether or not material, that involves management or other employees who have a significant role in Merger Partner&#146;s or its
Subsidiaries&#146; internal control over financial reporting. Merger Partner has not identified any material weaknesses in the design or operation of Merger Partner&#146;s internal control over financial reporting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Neither Merger Partner nor any of its Subsidiaries has any Liability, except for: (i)&nbsp;Liabilities disclosed, reflected or reserved
against in Public Company&#146;s most recent interim consolidated unaudited balance sheet for the period ended September&nbsp;30, 2022; (ii) Liabilities that have been incurred by Merger Partner or its Subsidiaries since September&nbsp;30, 2022 in
the Ordinary Course of Business; (iii)&nbsp;Liabilities for performance of obligations of Merger Partner or any of its Subsidiaries under Merger Partner Contracts (other than those arising as a result of a breach or default thereunder or as a result
of failure to comply with applicable Law); (iv) Liabilities for payment of fees and expenses incurred in connection with the Transactions; (v)&nbsp;Liabilities which would not, individually or in the aggregate, reasonably be expected to be material
to Merger Partner and its Subsidiaries, taken as a whole; and (vi)&nbsp;Liabilities described in Section&nbsp;3.5(d) of the Merger Partner Disclosure Schedule. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The information (including information relating to the Blockers) to be supplied by or on
behalf of Merger Partner for inclusion or incorporation by reference in the registration statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> to be filed by Public Company pursuant to which shares of Public Company Class&nbsp;A Common Stock
and Public Company Class&nbsp;B Common Stock issued in connection with the Mergers shall be registered under the Securities Act (the &#147;<U>Registration Statement</U>&#148;), or supplied by or on behalf of Merger Partner for inclusion in any
filing pursuant to Rule 165 and Rule 425 under the Securities Act or Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (each a &#147;<U>Regulation <FONT STYLE="white-space:nowrap">M-A</FONT> Filing</U>&#148;), shall not at
the time the Registration Statement or any such Regulation <FONT STYLE="white-space:nowrap">M-A</FONT> Filing is filed with the SEC, at any time it is amended or supplemented or at the time the Registration Statement is declared effective by the
SEC, as applicable, contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein not misleading, in light of the circumstances under which they
were made. The information (including information relating to the Blockers) to be supplied by or on behalf of Merger Partner for inclusion or incorporation by reference in the proxy statement/prospectus (the &#147;<U>Proxy
Statement/Prospectus</U>&#148;) to be sent to the stockholders of Public Company in connection with the meeting of Public Company&#146;s Stockholders&#146; Meeting shall not, on the date the Proxy Statement/Prospectus is first mailed to stockholders
of Public Company, or at the time of the Public Company Meeting or as of the Effective Time, contain any statement that, at such time and in light of the circumstances under which it shall be made, is false or misleading with respect to any material
fact, or omit to state any material fact necessary in order to make the statements made in the Proxy Statement/Prospectus not false or misleading; or omit to state any material fact necessary to correct any statement in any earlier communication
with respect to the solicitation of proxies for the Public Company Meeting that has become, in light of the circumstances in which they were made, false or misleading. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Between January&nbsp;1, 2020 and the date of this Agreement, there have been no formal investigations regarding financial reporting or
accounting policies and practices discussed with, reviewed by or initiated at the direction of the chief executive officer, chief financial officer, principal accounting officer or general counsel of Merger Partner, the Merger Partner Board or any
committee thereof, other than ordinary course audits or reviews of accounting policies and practices or internal controls. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_19">
</A>3.6 <U>Absence of Certain Changes</U>. Since December&nbsp;31, 2021, except for the execution and performance of this Agreement and the discussions, negotiations and transactions related thereto, (a)&nbsp;there has occurred no event or
development which, individually or in the aggregate, has had, or could reasonably be expected to have in the future, a Merger Partner Material Adverse Effect, (b)&nbsp;Merger Partner and its Subsidiaries have conducted their businesses in the
Ordinary Course of Business and (c)&nbsp;neither Merger Partner nor any Subsidiary has taken any of the actions set forth in clauses (a)&nbsp;through (o) of Section&nbsp;5.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_20"></A>3.7 <U>Merger Partner Tax Matters</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Each of Merger Partner and its Subsidiaries has properly filed on a timely basis all income and other material Tax Returns that it was
required to file, and all such Tax Returns were true, correct and complete in all material respects. Each of Merger Partner and its Subsidiaries has paid on a timely basis all income or other material Taxes, whether or not shown on any Tax Return,
that were due and payable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) All material Taxes that Merger Partner or any of its Subsidiaries was required by Law to withhold or
collect have been duly withheld or collected and, to the extent required, have been properly paid to the appropriate Governmental Entity, in each case in compliance in all material respects with applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) No examination or audit of any Tax Return of Merger Partner or any of its Subsidiaries by any Governmental Entity is currently in progress
or, to the Knowledge of Merger Partner, has been threatened by any Governmental Entity. No deficiencies for Taxes of Merger Partner or any of its Subsidiaries have been claimed, proposed or assessed by any Governmental Entity in writing. Neither
Merger Partner nor any of its Subsidiaries has been informed in writing by any jurisdiction in which Merger Partner or any of its Subsidiaries does not file a Tax Return that the jurisdiction believes that Merger Partner or any of its Subsidiaries
was required to file any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Tax Return that was not filed or is subject to Tax in such jurisdiction. Neither Merger Partner nor any of its Subsidiaries has (i)&nbsp;waived any statute of limitations with respect to Taxes or
agreed to extend the period for assessment or collection of any Taxes, which waiver or extension is still in effect, (ii)&nbsp;requested any extension of time within which to file any Tax Return (other than any automatic extension granted in the
ordinary course of business and consistent with past custom and practice of Merger Partner), or (iii)&nbsp;executed or filed any power of attorney with any taxing authority, which is still in effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Neither Merger Partner nor any of its Subsidiaries has participated in any &#147;reportable transaction&#148; as defined in Treasury <FONT
STYLE="white-space:nowrap">Regulations&nbsp;Section&nbsp;1.6011-4(b)&nbsp;or</FONT> a &#147;listed transaction&#148; within the meaning of Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.6011-4(b)(2)</FONT> or any analogous
provision of state or local Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) There are no Liens with respect to Taxes on any of the assets of Merger Partner or its Subsidiaries,
other than Permitted Liens. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) With the exception of customary commercial leases or contracts that are not primarily related to Taxes
entered into in the Ordinary Course of Business and liabilities thereunder, neither Merger Partner nor any of its Subsidiaries (i)&nbsp;has any liability under Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.1502-6</FONT> (or
any comparable or similar provision of state, local <FONT STYLE="white-space:nowrap">or&nbsp;non-U.S.&nbsp;law),</FONT> as a transferee or successor, or pursuant to any contractual obligation for any Taxes of any Person other than Merger Partner or
any of its Subsidiaries, or (ii)&nbsp;is a party to or bound by any Tax indemnity, Tax sharing, Tax allocation or similar agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)
During the <FONT STYLE="white-space:nowrap">two-year</FONT> period ending on the date hereof, neither Merger Partner (including any predecessor thereof) nor any of its Subsidiaries (including any predecessor thereof) has constituted either a
&#147;distributing corporation&#148; or a &#147;controlled corporation&#148; in a distribution of stock qualifying for <FONT STYLE="white-space:nowrap">tax-free</FONT> treatment under Section&nbsp;355 of the Code (or so much of Section&nbsp;356 of
the Code as relates to Section&nbsp;355 of the Code). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) Other than Section&nbsp;3.15, this Section&nbsp;3.7 provides the sole and
exclusive representations and warranties of Merger Partner in respect of Tax matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_21"></A>3.8 <U>Assets</U>.
Except as would not be, individually or in the aggregate, material to Merger Partner and its Subsidiaries, taken as a whole, Merger Partner or its applicable Subsidiary is the true and lawful owner of, and has good title to, all of the assets
(tangible or intangible) purported to be owned by Merger Partner or such Subsidiary, free and clear of all Liens other than Permitted Liens. Merger Partner and each Subsidiary owns or leases all material tangible assets sufficient for the conduct of
its businesses as presently conducted, which tangible assets are reflected in the Merger Partner Financial Statements (other than to the extent disposed of in the Ordinary Course of Business). Except as would not, individually or in the aggregate,
reasonably be expected to result in a Merger Partner Material Adverse Effect, each such tangible asset is free from defects, has been maintained in accordance with normal industry practice, is in good operating condition and repair (subject to
normal wear and tear) and is suitable for the purposes for which it presently is used. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_22"></A>3.9 <U>Owned and
Leased Real Property</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Neither Merger Partner nor any of its Subsidiaries owns any real property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Merger Partner has delivered to Public Company complete and accurate copies of all material Leases of Merger Partner and its Subsidiaries.
Neither Merger Partner nor any Subsidiary occupies any space other than pursuant to a Lease. With respect to each such Lease, except as would not, individually or in the aggregate, reasonably be expected to result in a Merger Partner Material
Adverse Effect: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) such Lease is legal, valid, binding, enforceable and in full force and effect against Merger Partner or its
Subsidiary that is the party thereto, as applicable, and, to the Knowledge of Merger Partner, against each other party thereto; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) such Lease will continue to be legal, valid, binding, enforceable and in full force
and effect against Merger Partner or the Subsidiary that is the party thereto, as applicable, and, to the Knowledge of Merger Partner, against each other party thereto immediately following the Closing in accordance with the terms thereof as in
effect immediately prior to the Closing; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) none of Merger Partner, any Subsidiary of Merger Partner or, to the Knowledge of Merger
Partner, any other party, is in breach or violation of, or default under, any such Lease, and no event has occurred, is pending or, to the Knowledge of Merger Partner, is threatened, which, after the giving of notice, with lapse of time, or
otherwise, would constitute any such breach or default by Merger Partner or any Subsidiary of Merger Partner or, to the Knowledge of Merger Partner, any other party under such Lease; and no event has occurred that would give rise to a termination
right under such Lease; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) neither Merger Partner nor any Subsidiary of Merger Partner has assigned, transferred, conveyed, mortgaged,
subleased, licensed, deeded in trust or encumbered any interest in the leasehold or subleasehold; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) to the Knowledge of Merger
Partner, there are no Liens (other than Permitted Liens) applicable to the real property subject to such Lease which would reasonably be expected to impair the current uses or the occupancy by Merger Partner or any Subsidiary of Merger Partner of
the property subject thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Each of Merger Partners and its Subsidiaries owns, and has good and valid title to, or, in the case of
leased properties and assets, valid leasehold interests in, all tangible properties or tangible assets and equipment used or held for use in its business or operations or purported to be owned by it, in each case, that are material to Merger Partner
and its Subsidiaries, taken as a whole, including: (A)&nbsp;all such tangible assets reflected on the Merger Partner Financial Statements; and (B)&nbsp;all other such tangible assets reflected in the books and records of Merger Partner or any of its
Subsidiaries as being owned by Merger Partner or such Subsidiary. All of such assets are owned or, in the case of leased assets, leased by Merger Partner or any of its Subsidiaries free of any Liens other than Permitted Liens. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_23"></A>3.10 <U>Intellectual Property</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Section 3.10(a) of the Merger Partner Disclosure Schedule sets forth a true, correct and complete list of all Patents, Copyright
registrations, Trademark registrations, applications for Trademark registration, material unregistered Trademarks, Design registrations and applications for Design registration, and Internet domain names owned (in whole or in part) by or exclusively
licensed to Merger Partner or any of its Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) (i) Merger Partner and its Subsidiaries (A)&nbsp;solely own all Intellectual
Property owned or purported to be owned by Merger Partner or any of its Subsidiaries and (B)&nbsp;possess, hold or have obtained valid and enforceable licenses or other rights under all other Intellectual Property necessary to operate the business
of Merger Partner in the manner now operated and as currently proposed to be operated by it as disclosed in the Registration Statement and Prospectus, except, in each case of (A)&nbsp;and (B), as such failure to own or obtain such licenses would
not, individually or in the aggregate, reasonably be expected to result in a Merger Partner Material Adverse Effect; (ii)&nbsp;none of the Intellectual Property owned by, exclusively licensed to, or to the Knowledge of Merger Partner, otherwise
licensed to or used by, the Merger Partner and its Subsidiaries (collectively, the &#147;<U>Merger Partner Intellectual Property</U>&#148;) has been adjudged invalid or unenforceable, in whole or in part; (iii)&nbsp;to the Knowledge of Merger
Partner, no third party is infringing, misappropriating, or otherwise violating any Merger Partner Intellectual Property, except, where such infringement, misappropriation or other violation would not, individually or in the aggregate, reasonably be
expected to result in a Merger Partner Material Adverse Effect; (iv)&nbsp;since January&nbsp;1, 2020 to the date of this Agreement, to the Knowledge of Merger Partner, there has been no actual or threatened action, suit, proceeding or claim by
others challenging the validity, enforceability or scope of, or challenging Merger Partner&#146;s ownership of or rights in or to, any Merger Partner Intellectual Property, and Merger Partner is not aware of any facts or circumstances that would
render </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any Merger Partner Intellectual Property invalid or unenforceable by Merger Partner or one of its Subsidiaries, or of inadequate scope to protect the interests of Merger Partner in conducting its
business, except in each case, as would not, individually or in the aggregate, reasonably be expected to result in a Merger Partner Material Adverse Effect; (v)&nbsp;since January&nbsp;1, 2020 to the date of this Agreement, to the Knowledge of
Merger Partner, there has been no actual, or threatened action, suit, proceeding or claim by a third party alleging that Merger Partner or any of its Subsidiaries infringes, misappropriates, or otherwise violates, any Intellectual Property of third
parties, and Merger Partner has not received any notice alleging, or is otherwise aware of, any facts or circumstances that would give rise to such an action, proceeding or claim, except, in each case, where such infringement, misappropriation or
other violation would not, individually or in the aggregate, reasonably be expected to result in a Merger Partner Material Adverse Effect; (vi)&nbsp;Merger Partner has taken all reasonable steps to protect, maintain and safeguard the Merger Partner
Intellectual Property, including the execution of appropriate nondisclosure, confidentiality agreements and invention assignment agreements and invention assignments with their directors, officers, employees, contractors and other agents and since
January&nbsp;1, 2020 to the date of this Agreement, to the Knowledge of Merger Partner, no such individual is in or has been in violation of any term of such nondisclosure, confidentiality agreements and invention assignment agreements; and
(vii)&nbsp;since January&nbsp;1, 2020 to the date of this Agreement, to the Knowledge of Merger Partner, no material technology employed by Merger Partner or its Subsidiaries has been obtained or is being used by Merger Partner or its Subsidiaries
in violation of any contractual or legal obligation binding on Merger Partner, its Subsidiaries or any of its officers, directors or employees, which violation relates to the breach of a confidentiality obligation, obligation to assign Intellectual
Property to a previous employer or obligation otherwise not to use the Intellectual Property of a third party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) To the Knowledge of
Merger Partner, the material information technology systems of the Merger Partner and its Subsidiaries are adequate for their respective businesses as currently conducted in all material respects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_24"></A>3.11 <U>Contracts</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Section 3.11(a) of Merger Partner Disclosure Schedule lists the following agreements (each a &#147;<U>Merger Partner Contract</U>&#148;)
to which Merger Partner or any Subsidiary of Merger Partner is a party as of the date of this Agreement which contains any remaining material rights or obligations: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) any agreement (or group of related agreements)&nbsp;(A) which involves expected payments in an amount in excess of $500,000 in the
aggregate, (B)&nbsp;in which Merger Partner or any of its Subsidiaries has granted &#147;most favored nation&#148; pricing provisions or exclusive marketing or distribution rights or has agreed to purchase goods or services exclusively from a
certain party, (C)&nbsp;which limits the freedom of Merger Partner or its Subsidiaries to engage in any line of business or compete with any Person or (D)&nbsp;which contains any <FONT STYLE="white-space:nowrap">non-solicitation</FONT> provision, in
each case, except for restrictions that would not materially affect the ability of Merger Partner and its Subsidiaries to conduct its business, in each case, that is not terminable by Merger Partner or its Subsidiaries, as applicable, on 90
days&#146; notice or less; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) any agreement relating to the disposition or acquisition of material assets or any ownership interests
in any Person, in each case, involving payments in excess of $500,000, other than agreements in which the applicable acquisition or disposition has been consummated and there are no material ongoing liabilities or obligations; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) any agreement providing for any material royalty, milestone or similar payments by Merger Partner or its Subsidiaries; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) any agreement concerning the establishment or operation of a joint venture with a third party; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) any agreement (or group of related agreements) under which Merger Partner or any
Subsidiary has created, incurred, assumed or guaranteed (or may create, incur, assume or guarantee) material Indebtedness (including capitalized lease obligations) or under which it has imposed (or may impose) a Lien (other than Permitted Liens) on
any of its assets, tangible or intangible; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) any agreement for the disposition of any material assets or business of Merger Partner
or any Subsidiary or any agreement for the acquisition of material assets or business of any other Person (other than purchases of inventory or components in the Ordinary Course of Business); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii) any noncompetition agreement restricting Merger Partner or any of its Subsidiaries from competing in any line of business or
jurisdiction; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(viii) any written employment agreement or consulting agreement that is not on Merger Partner&#146;s standard form of
employment agreement or consulting agreement, each of which has been previously made available to Public Company (excluding employment agreements that are terminable &#147;at will&#148; without the payment of severance or other amounts upon
termination, and consulting agreements which are terminable on 30 days or less notice without the payment of additional consideration); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ix) any agreement providing for severance, retention, change in control payments, or transaction-based bonuses or incentives; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(x) any material settlement agreement or agreement that includes the admission of wrongdoing by Merger Partner or any of its Subsidiaries or
any of their respective officers or directors; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xi) any agreement with respect to an interest rate, currency or other swap or derivative
transaction (other than those solely between Merger Partner or any of its Subsidiaries); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xii) any agreement between Merger Partner or
any of its Subsidiaries, on the one hand, and any director, officer or employee of Merger Partner or any of its Subsidiaries or any Person beneficially owning five percent or more of the outstanding equity interests of Merger Partner or any of their
respective Affiliates, on the other hand; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xiii) except as set forth in the Organizational Documents of Merger Partner or in Merger
Partner&#146;s standard form of restricted unit grant agreement, any agreement that contains a put, call or similar right pursuant to which Merger Partner or any of its Subsidiaries or after the Merger Partner Merger Effective Time, Public Company
or any of its Subsidiaries or Affiliates, could be required to purchase or sell, as applicable, in a single transaction or series of transactions, (A)&nbsp;any equity interests of any Person or (B)&nbsp;any asset or group of related assets that have
a fair market value or purchase price of more than $500,000 individually or in the aggregate; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xiv) any agreement relating to royalty,
dividend or similar arrangement to be paid, or received, by Merger Partner or any of its Subsidiaries that is based on the revenue or profits of Merger Partner or any of its Subsidiaries or any material agreement involving fixed price or fixed
volume arrangements; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xv) any agreement under which the consequences of a default or termination would not, individually or in the
aggregate, reasonably be expected to result in a Merger Partner Material Adverse Effect; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xvi) any agreement with expected annual
receipts or payables of more than $500,000 annually, under which Merger Partner or any of its Affiliates or Subsidiaries has (A)&nbsp;granted a license, sublicense, covenant not to sue or assert, immunity from suit, right to coexist or other right
under any Intellectual Property to any other Person; (B)&nbsp;received from any other Person a grant of a license, sublicense, covenant not to sue or assert, immunity from suit, right to coexist or other right under any Intellectual Property (other
than licenses to any shrink wrap, click wrap or other software that is generally commercially available and not customized costing less than $50,000 per year or as a <FONT STYLE="white-space:nowrap">one-time</FONT> fee); (C) assigned any rights
under any Intellectual Property </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to any other Person; or (D)&nbsp;received an assignment of any rights under Intellectual Property from any Person (other than assignments from employees on the form assignment agreement used by
Merger Partner with such employees); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xvii) any agreement the primary purpose of which is to provide for the sharing, indemnification or
allocation of Taxes between or among the Merger Partner and its Subsidiaries, or between or among the Subsidiaries of Merger Partner; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xviii) any other agreement (or group of related agreements) that is material to Merger Partner and its Subsidiaries, taken as a whole,
including any material contacts (as defined in Item 601(b)(10) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> as promulgated under the Securities Act). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Merger Partner has made available to Public Company a complete and accurate copy of each Merger Partner Contract (as amended to date) as
of the date of this Agreement. With respect to each Merger Partner Contract: (i)&nbsp;the Merger Partner Contract is legal, valid, binding and enforceable and in full force and effect against Merger Partner or the Subsidiary that is the party
thereto, as applicable, and, to the Knowledge of Merger Partner, against each other party thereto; (ii)&nbsp;the Merger Partner Contract will continue to be legal, valid, binding and enforceable and in full force and effect against Merger Partner or
the Subsidiary that is the party thereto, as applicable, and, to the Knowledge of Merger Partner, against each other party thereto immediately following the Closing in accordance with the terms thereof as in effect immediately prior to the Closing;
and (iii)&nbsp;neither Merger Partner, any Affiliate or Subsidiary nor, to the Knowledge of Merger Partner, any other party, is in breach or violation of, or default under, any such Merger Partner Contract, and no event has occurred, is pending or,
to the Knowledge of Merger Partner, is threatened, which, after the giving of notice, with lapse of time, or otherwise, would constitute any such breach or default by Merger Partner, any Subsidiary or, to the Knowledge of Merger Partner, any other
party under such Merger Partner Contract, in each case, where any such breach or violation would not, individually or in the aggregate, reasonably be expected to result in a Merger Partner Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_25"></A>3.12 <U>Litigation</U>. As of the date hereof, there is no Legal Proceeding pending or, to the Knowledge of
Merger Partner, threatened with respect to, (A)&nbsp;against or affecting (i)&nbsp;Merger Partner or any Subsidiary of Merger Partner, (ii)&nbsp;any current or former officer, director, employee, consultant, agent or member of any of the foregoing
in its, his or her capacity as such, (iii)&nbsp;any of the material assets owned or used by Merger Partner and its Subsidiaries or (iv)&nbsp;to the Knowledge of Merger Partner, any Blocker and (B)&nbsp;no notice of any Legal Proceeding involving or
relating to Merger Partner, any of its Subsidiaries, or any Blocker, whether pending or threatened, has been received by Merger Partner, any of its Subsidiaries, or to the Knowledge of Merger Partner any Blocker, in each case as would not,
individually or in the aggregate, reasonably be expected to result in a Merger Partner Material Adverse Effect, a Public Company Material Adverse Effect (after giving effect to the Closing) or that would have the effect of preventing, delaying
beyond the Outside Date, or making illegal, the Transactions (including the Mergers). As of the date of this Agreement, there are no material judgments, orders, injunctions, decrees, stipulations or awards (whether rendered by a court,
administrative agency or other Governmental Entity, by arbitration or otherwise) against or involving Merger Partner or any Subsidiary of Merger Partner or, to the Knowledge of Merger Partner, any Blocker. As of the date of this Agreement, there is
no material Legal Proceeding by Merger Partner or any Subsidiary of Merger Partner pending, or which Merger Partner, any Subsidiary of Merger Partner or, to the Knowledge of Merger Partner, any Blocker has commenced preparations to initiate, against
any other Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_26"></A>3.13 <U>Environmental Matters</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Since January&nbsp;1, 2020, Merger Partner and its Subsidiaries have complied with all applicable Environmental Laws except as would not,
individually or in the aggregate, reasonably be expected to result in a Merger Partner Material Adverse Effect. There is no pending or, to the Knowledge of Merger Partner, threatened material Legal Proceeding relating to any Environmental Law
involving Merger Partner or any Subsidiary of Merger Partner. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) To the Knowledge of Merger Partner, neither Merger Partner nor any Subsidiary of Merger
Partner has any material liabilities or material obligations arising from the release or threatened release of any Materials of Environmental Concern into the environment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Neither Merger Partner nor any Subsidiary of Merger Partner is a party to or bound by any court order, administrative order, consent order
or other agreement between Merger Partner or any Subsidiary and any Governmental Entity entered into in connection with any material legal obligation or material liability arising under any Environmental Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Merger Partner has no Knowledge of any material environmental liability relating to any solid or hazardous waste transporter or treatment,
storage or disposal facility that has been used by Merger Partner or any Subsidiary of Merger Partner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_27"></A>3.14 <U>Labor and Employment</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Each such current Merger Partner Employee is retained <FONT STYLE="white-space:nowrap">at-will</FONT> and none of such current Merger
Partner Employees is a party to a written employment agreement or contract with Merger Partner or any Subsidiary contradicting their <FONT STYLE="white-space:nowrap">at-will</FONT> employment. Each current Merger Partner Employee has entered into
Merger Partner&#146;s or such Subsidiary&#146;s standard form of confidentiality, <FONT STYLE="white-space:nowrap">non-competition</FONT> and assignment of inventions agreement, a copy of which has previously been delivered to Public Company. All of
the agreements referenced in the preceding sentence will continue to be in full force and effect immediately following the Closing in accordance with the terms thereof as in effect immediately prior to the Closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Since January&nbsp;1, 2020, neither Merger Partner nor any Subsidiary of Merger Partner has breached or violated any (i)&nbsp;applicable
Law respecting employment and employment practices, terms and conditions of employment and wages and hours, including any such Law respecting employment discrimination, employee classification (for overtime purposes or as employee versus independent
contractor), workers&#146; compensation, family and medical leave, the Immigration Reform and Control Act and occupational safety and health requirements, or (ii)&nbsp;employment or other individual service provider agreement, in each case except as
would not, individually or in the aggregate, reasonably be expected to be material to Merger Partner and its Subsidiaries, taken as a whole. As of the date hereof, no material claims, controversies, investigations, audits or other Legal Proceedings
are pending or, to the Knowledge of Merger Partner, threatened, with respect to such Laws or agreements, either by private Persons or by Governmental Entities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Neither Merger Partner nor any Subsidiary of Merger Partner is a party to or bound by any collective bargaining agreement, nor has either
of them experienced any actual or, to the Knowledge of Merger Partner, threatened strikes, grievances, claims of unfair labor practices or other collective bargaining disputes. Merger Partner has no Knowledge of any material organizational effort
made or threatened (including the filing of a petition for certification) either currently or within the past two (2)&nbsp;years, by or on behalf of any labor union with respect to Merger Partner Employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Each such consultant or independent contractor is or was a party to a written agreement or contract with Merger Partner or its
Subsidiaries. Merger Partner and its Subsidiaries have not incurred, and, to the Knowledge of Merger Partner, no circumstances exist under which, Merger Partner and its Subsidiaries could reasonably be expected to incur, any material liability
arising from the misclassification of employees as consultants or independent contractors, or from the misclassification of consultants or independent contractors as employees. Each such consultant and independent contractor has entered a
confidentiality and assignment of inventions agreement with Merger Partner, a copy of which has previously been made available to Public Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) As of the date hereof, no charges or complaints are open and pending against Merger Partner or any Subsidiary with the Equal Employment
Opportunity Commission, the Office of Federal Contract Compliance </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Programs (the &#147;<U>OFCCP</U>&#148;), or similar Governmental Entity or pursuant to internal complaint procedures, and, to the Knowledge of Merger Partner, as of the date hereof no current or
former employee of Merger Partner or any Subsidiary has made, during the last twelve (12)&nbsp;months, an oral or, during the last three (3)&nbsp;years, a written complaint of discrimination, retaliation or other similar wrongdoing. True, correct
and complete information regarding any closed charges or complaints filed since December&nbsp;31, 2020 through the date of this Agreement with the Equal Employment Opportunity Commission, the OFCCP or similar Governmental Entity (or, with respect to
discrimination, retaliation, or similar wrongdoing, pursuant to internal complaint procedures) has been made available to Public Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) Since January&nbsp;1, 2020, neither Merger Partner nor any Subsidiary has caused (i)&nbsp;a plant closing as defined in the Worker
Adjustment and Retraining Notification Act (the &#147;<U>WARN Act</U>&#148;) affecting any site of employment or one or more operating units within any site of employment of Merger Partner or any Subsidiary or (ii)&nbsp;a mass layoff as defined in
the WARN Act, nor has Merger Partner or any Subsidiary been affected by any transaction or engaged in layoffs or employment terminations sufficient in number to trigger application of any similar foreign, state or local Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_28"></A>3.15 <U>Employee Benefit Plans</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Section 3.15(a) of Merger Partner Disclosure Schedule contains a complete and accurate list of all material Merger Partner Benefit Plans.
Complete and accurate copies of (i)&nbsp;all Merger Partner Benefit Plans which have been reduced to writing, together with all amendments thereto, (ii)&nbsp;written summaries of all material unwritten Merger Partner Benefit Plans, (iii)&nbsp;all
related trust agreements, insurance contracts, and most recent summary plan description together with the summary or summaries of material modifications thereto, (iv)&nbsp;the most recently filed annual report on IRS Form 5500 and all schedules
thereto and (for all funded plans) all plan financial statements for the last plan year for each Merger Partner Benefit Plan, (v)&nbsp;all reports regarding the satisfaction of the nondiscrimination requirements of Sections 410(b), 401(k), and
401(m) of the Code for the past year, (vi)&nbsp;the most recent determination letter or opinion letter issued by the Internal Revenue Service with respect to any Merger Partner Benefit Plan intended to be qualified under Section&nbsp;401(a) of the
Code, and (vii)&nbsp;any material written or electronic communications from or to the Internal Revenue Service, the Department of Labor (&#147;<U>DOL</U>&#148;) or any other Governmental Entity received in the three (3)&nbsp;year period preceding
the date of this Agreement with respect to a Merger Partner Benefit Plan (including any voluntary correction submissions), have been delivered or made available to Public Company. No Merger Partner Benefit Plan is or has been subject to <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Neither Merger Partner, any of its Subsidiaries, nor any of their respective ERISA
Affiliates sponsors, maintains or contributes to or in the last six years has sponsored, maintained, contributed to or been required to contribute to, or has (or is reasonably expected to have) any material current or contingent liability with
respect to any (i) &#147;employee pension benefit plan,&#148; as defined in Section&nbsp;3(2) of ERISA, that is subject to Title IV or Section&nbsp;302 of ERISA or Section&nbsp;412 of the Code, (ii)&nbsp;a &#147;multiemployer plan&#148; within the
meaning of Section&nbsp;4001(a)(3) of ERISA, or (iii)&nbsp;a &#147;multiple employer plan&#148; subject to Sections 4063 or 4064 of ERISA or Section&nbsp;413(c) of the Code. No liability under Section&nbsp;302 or Title IV of ERISA or
Section&nbsp;412 of the Code has been incurred by Merger Partner, any of its Subsidiaries or any of their respective ERISA Affiliates that has not been satisfied in full. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Each Merger Partner Benefit Plan has been administered in all material respects in accordance with its terms and each of Merger Partner,
its Subsidiaries and its ERISA Affiliates has met its obligations in all material respects with respect to each Merger Partner Benefit Plan and has timely made all required contributions, premiums and other payments thereto, in each case in all
material respects. Merger Partner, its Subsidiaries, each of its ERISA Affiliates and each Merger Partner Benefit Plan are in compliance in all material respects with the currently applicable provisions of ERISA and the Code (including
Section&nbsp;409A of the Code) and the regulations thereunder. Each Merger Partner Benefit Plan that is intended to be qualified under Section&nbsp;401(a) of the Code has been determined by the IRS to be qualified under Section&nbsp;401(a) of the
Code and, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
no fact or event has occurred that would adversely affect the qualification or tax exemption of any such Merger Partner Benefit Plan. There is no legally binding commitment to create any
additional Merger Partner Benefit Plans or to modify any existing Merger Partner Benefit Plans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) There are no Legal Proceedings
(except claims for benefits payable in the normal operation of Merger Partner Plans and proceedings with respect to qualified domestic relations orders) against or involving any Merger Partner Benefit Plan or asserting any rights or claims to
benefits under any Merger Partner Benefit Plan that could give rise to any material liability. No Merger Partner Benefit Plan is or within the last three (3)&nbsp;calendar years has been the subject of, or has received or provided notice that it is
the subject of, examination by a Governmental Entity or a participant in a government sponsored amnesty, voluntary compliance or similar program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The execution and delivery of this Agreement and the consummation of the Transactions will not, either alone or in combination with
another event, (A)&nbsp;entitle any current or former employee, director, officer or independent contractor of Merger Partner or any of its Subsidiaries to severance pay, retention bonuses, <FONT STYLE="white-space:nowrap">non-competition</FONT>
payments or any other material compensatory payment, (B)&nbsp;accelerate the time of payment or vesting, or increase the amount of compensation due to any such employee, director, officer or independent contractor, or (C)&nbsp;directly or indirectly
require Merger Partner to transfer or set aside any assets to fund any material benefits under any Merger Partner Benefit Plan. No director, officer, employee or other service provider of Merger Partner or any of its Subsidiaries is entitled to a
gross up, make whole or other similar payment as a result of the imposition of Taxes under Section&nbsp;4999 or Section&nbsp;409A of the Code pursuant to any agreement or arrangement with the Merger Partner or any of its Subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_29"></A>3.16 <U>Compliance with Laws</U>. Each of Merger Partner, its Subsidiaries has since January&nbsp;1, 2020
conducted, and is conducting, its business and operations in compliance in all material respects with all applicable Laws. Since January&nbsp;1, 2020, neither Merger Partner nor any Subsidiary has received any notice or other communication from any
Governmental Entity or other Person alleging any material noncompliance with any applicable Law. To the Knowledge of Merger Partner, neither Merger Partner nor any Subsidiary has any material liability for failure to comply with any Law and, to the
Knowledge of Merger Partner, there is no act, omission, event or circumstance that would reasonably be expected to give rise to any such liability. Neither Merger Partner nor any Subsidiary has conducted any internal investigation with respect to
any actual, potential or alleged violation of any Law by any manager, member or other equity holder, officer or Merger Partner Employee or concerning any actual or alleged Fraud. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_30"></A>3.17 <U>Unlawful Payments</U>. Since January&nbsp;1, 2020, Merger Partner and its Subsidiaries are and have
been in compliance in all material respects with the Foreign Corrupt Practices Act, 15 U.S.C. &#167;&#167; <FONT STYLE="white-space:nowrap">78dd-1,</FONT> et seq., the Organization for Economic Cooperation and Development Convention Against Bribery
of Foreign Public Officials in International Business Transactions and legislation implementing such convention, all other international anti-bribery conventions and all applicable anti-corruption or bribery Laws in any jurisdiction in which Merger
Partner or any Subsidiary has conducted its business (collectively, &#147;<U>Anti-Bribery Laws</U>&#148;). Since January&nbsp;1, 2020, neither Merger Partner nor any Subsidiary has received any written communication from any Governmental Entity that
alleges that Merger Partner or any Subsidiary, or any current or former Representatives thereof, is or may be in violation of, or has, or may have, any liability under, any Anti-Bribery Laws, and no such actual or potential violation of Anti-Bribery
Laws has been discovered by or brought to the attention of Merger Partner or any Subsidiary since January&nbsp;1, 2020. Since January&nbsp;1, 2020, neither Merger Partner nor any Subsidiary has made or anticipates making any disclosures to any
Governmental Entity for potential violations of Anti- Bribery Laws. To the Knowledge of Merger Partner, none of Merger Partner and its Subsidiaries&#146; current or former Representatives is currently an officer, agent or employee of a Governmental
Entity. Neither Merger Partner nor any Subsidiary nor any of their respective current or former Representatives has directly or indirectly offered, given, reimbursed, paid or promised to pay, or authorized the payment of, any money or other thing of
value (including any fee, gift, sample, travel expense or entertainment) or any commission payment payable to (a)&nbsp;any Person who is an official, officer, agent, employee or representative of any Governmental Entity or of any
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
existing or prospective customer (whether or not owned by a Governmental Entity), (b) any political party or official thereof or (c)&nbsp;any candidate for political or political party office, in
each case while knowing or having reason to believe that all or any portion of such money or thing of value would be offered, given, reimbursed, paid or promised, directly or indirectly, for purposes not allowable under the Anti-Bribery Laws, to any
such official, officer, agent, employee, representative, political party, political party official, candidate, individual affiliated with any such customer, political party or official or political office. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_31"></A>3.18 <U>Permits</U>. Each of Merger Partner and its Subsidiaries owns or holds all material Permits that are
required for Merger Partner and its Subsidiaries, respectively, to conduct their business as presently conducted or as proposed to be conducted. Each such Permit is in full force and effect. Merger Partner or the applicable Subsidiary, as the case
may be, is in compliance in all material respects with the terms of each such Permit; and, as of the date of this Agreement, to the Knowledge of Merger Partner, no suspension or cancellation of such Permit is threatened and, to the Knowledge of
Merger Partner, there is no basis for believing that such Permit will not be renewable upon expiration, other than in the Ordinary Course of Business. Each such Permit will continue in full force and effect immediately following the Closing. Merger
Partner has made available to Public Company all such Permits as of the date of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_32"></A>3.19
<U>Insurance</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Merger Partner has made available to Public Company a true and complete list, as of the date of this Agreement, all
material insurance policies (including fire, theft, casualty, comprehensive general liability, workers compensation, business interruption, environmental, director and officer liability, product liability and automobile insurance policies and bond
and surety arrangements) to which Merger Partner or any Subsidiary is a party, a named insured or otherwise the beneficiary of coverage (the &#147;<U>Merger Partner Insurance Policies</U>&#148;), all of which are in full force and effect. The Merger
Partner Insurance Policies are of the type and in the amounts customarily carried by organizations conducting businesses or owning assets similar to those of Merger Partner. There is no material claim pending under the Merger Partner Insurance
Policies as to which coverage has been questioned, denied or disputed by the underwriter of such policy. All premiums due and payable under all of the Merger Partner Insurance Policies have been paid, and, to the Knowledge of Merger Partner, neither
Merger Partner nor any Subsidiary may be liable for retroactive premiums or similar payments, and Merger Partner and its Subsidiaries are otherwise in compliance with the terms of the Merger Partner Insurance Policies in all material respects.
Merger Partner has no Knowledge of any threatened termination of, or premium increase with respect to, any of the Merger Partner Insurances Policies. Each Merger Partner Insurance Policy will continue to be enforceable and in full force and effect
immediately following the Closing in accordance with the terms thereof as in effect immediately prior to the Closing. There is no material claim by Merger Partner or any of its Subsidiaries pending under any Merger Partner Insurance Policy in favor
of Merger Partner and its Subsidiaries that has been denied or disputed by the insurer other than denials and disputes in the Ordinary Course of Business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Section 3.19(b) of Merger Partner Disclosure Schedule identifies all claims asserted by Merger Partner pursuant to any Merger Partner
Insurance Policy since December&nbsp;31, 2019 and describes the nature and status of each such claim. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_33"></A>3.20 <U>Cybersecurity and Privacy</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Each of Merger Partner and its Subsidiaries comply, and have complied, in all respects with all: (i)&nbsp;applicable Privacy Laws;
(ii)&nbsp;policies, statements, and contractual obligations relating to the receipt, collection, compilation, use, storage, processing, sharing, safeguarding, security, disposal, destruction, disclosure, or transfer of Personal Information of the
Merger Partner and its Subsidiaries; and (iii)&nbsp;all applicable industry standards including, without limitation, PCI DSS, and all other applicable requirements of the payment card brands (clauses (i)-(iii) of this Section&nbsp;3.20(a))
collectively, the &#147;<U>Merger Partner Privacy Requirements</U>&#148;). The consummation of any of the Transactions will not violate any applicable Merger Partner Privacy Requirements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Merger Partner and its Subsidiaries have taken all organizational, physical,
administrative, and technical measures required by the Merger Partner Privacy Requirements and consistent with standards prudent in the industry in which Merger Partner and its Subsidiaries operate to protect: (i)&nbsp;the integrity, security, and
operations of all Merger Partner IT Systems; and (ii)&nbsp;all Personal Information and all other data owned, controlled, or stored by Merger Partner and its Subsidiaries from and against data security incidents or other misuse. In connection with
each third party servicing, outsourcing, hosting or otherwise processing Personal Information collected, held, or processed by or on behalf of Merger Partner and its Subsidiaries, Merger Partner and its Subsidiaries has in accordance with the Merger
Partner Privacy Requirements entered into valid, binding and enforceable written data processing agreements with any such third party that ensures appropriate protection for Personal Information. None of Merger Partner and its Subsidiaries sells,
rents or otherwise makes available, or permits any third party to, sell, rent or otherwise make available, to any Person any Personal Information, except as stated in the applicable privacy policies and in compliance with Privacy Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) There have been no actual or suspected data security incidents, data breaches, ransomware incidents, or other adverse events or incidents
related to any Merger Partner IT Systems, Personal Information, or data in the custody or control of Merger Partner or its Subsidiaries or any third party acting on behalf of Merger Partner or its Subsidiaries. Merger Partner and its Subsidiaries
have not been subject to any claims or proceedings related to any data security incidents, ransomware incidents, or any violations of any Merger Partner Privacy Requirements, and there are no facts or circumstances which could reasonably serve as
the basis for any such allegations or claims. Merger Partner and its Subsidiaries have taken commercially reasonable steps to provide for archival, <FONT STYLE="white-space:nowrap">back-up,</FONT> recovery and restoration of its material business
data. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Merger Partner and its Subsidiaries own or have a valid right to access and use all Merger Partner IT Systems. To the Knowledge
of Merger Partner, the Merger Partner IT Systems do not contain any viruses, worms, Trojan horses, bugs, faults or other devices, errors, contaminants or effects that are designed to (A)&nbsp;disrupt or adversely affect the functionality of any
Merger Partner IT Systems or (B)&nbsp;enable or assist any Person to access without authorization any Merger Partner IT Systems. The Merger Partner IT Systems have not materially malfunctioned or failed within the past two years. Merger Partner and
its Subsidiaries have taken reasonable, and to ensure the continued, uninterrupted, and error-free operation of the Merger Partner IT Systems. No Person has gained unauthorized access to any Merger Partner IT Systems. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_34"></A>3.21 <U>Brokers</U>. No broker, finder or investment banker is entitled to any brokerage, finder&#146;s or
other fee or commission based upon arrangements made by or on behalf of Merger Partner nor any Subsidiary in respect of any of the Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_35"></A>3.22 <U>Blocker Organization, Standing and Power</U>. Such Blocker is either a corporation or a limited
liability company, as applicable, duly organized, validly existing and in good standing under the Laws of the State of Delaware. Except as would not, individually or in the aggregate, reasonably be expected to have the effect of preventing, delaying
beyond the Outside Date, or making illegal, the Transactions (including the Mergers), such Blocker is duly qualified to conduct business and is in good standing under the Laws of each jurisdiction in which the nature of its businesses or the
ownership or leasing of its properties requires such qualification. Such Blocker has all requisite power and authority to (i)&nbsp;carry on the businesses in which it is engaged, (ii)&nbsp;own and use the properties owned and used by it and
(iii)&nbsp;perform its obligations under all Contracts to which it is a party. Merger Partner has made available to Public Company complete and accurate copies of the Organizational Documents of such Blocker as in effect on the date of this
Agreement. Such Blocker is not in material default under or in material violation of any provision of its Organizational Documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_36">
</A>3.23 <U>Blocker Capitalization</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Section 3.23(a) of the Merger Partner Disclosure Schedule sets forth the authorized capital
of such Blocker and, as of the date of this Agreement, the issued and outstanding equity interests of such Blocker. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Section 3.23(b) of Merger Partner Disclosure Schedule sets forth a complete and accurate
list, as of the date of the Agreement, of the members and holders of limited liability company interests, or the stockholders, as applicable, of such Blocker, showing the number and class(es) held by each holder. Section&nbsp;3.23(b) of Merger
Partner Disclosure Schedule also indicates all equity securities that are subject to a threshold value, vesting or otherwise subject to a repurchase or redemption right, indicating the name of the applicable member or interest holder, the threshold
value, vesting schedule (including any acceleration provisions with respect thereto), and the repurchase price payable by applicable Blocker. All of the equity securities of such Blocker have been duly authorized, validly issued, and free of all
preemptive rights. To the actual knowledge of such Blocker, all of the equity securities of such Blocker have been offered, issued and sold by such Blocker in compliance in all material respects with all applicable federal and state securities Laws.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Except as set forth in Section&nbsp;3.23(b), (A) there are no equity securities of any class of such Blocker, or any security
exchangeable into or exercisable for such equity securities, issued, reserved for issuance or outstanding, (B)&nbsp;there are no options, warrants, securities, calls, rights, commitments or agreements to which such Blocker is a party or by which
such Blocker is bound obligating such Blocker to issue, exchange, transfer, deliver or sell, or cause to be issued, exchanged, transferred, delivered or sold, additional equity securities of such Blocker or any security or rights convertible into or
exchangeable or exercisable for any such equity securities, or obligating such Blocker to grant, extend, accelerate the vesting of, otherwise modify or amend or enter into any such option, warrant, equity security, call, right, commitment or
agreement, and (C)&nbsp;such Blocker has no obligation (contingent or otherwise) to purchase, redeem or otherwise acquire any of its equity securities or to make any distribution in respect thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Except for the Organizational Documents of such Blocker or as set forth on Section&nbsp;3.23(d) of the Merger Partner Disclosure Schedule,
there is no agreement, written or, to the actual knowledge of such Blocker, oral, between such Blocker and any holder of its equity securities or, to the actual knowledge of such Blocker, among any holders of the equity securities of such Blocker,
relating to the sale or transfer (including agreements relating to rights of first refusal, <FONT STYLE="white-space:nowrap">co-sale</FONT> rights or &#147;drag along&#148; rights), registration under the Securities Act or the securities Laws of any
other jurisdiction, or voting, of the equity securities of such Blocker. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_37"></A>3.24 <U>No Business</U>. Except
for the ownership of limited liability company interests in Merger Partner, such Blocker (i)&nbsp;has not conducted any business and (ii)&nbsp;does not have and has not had any employees, assets, or liabilities (contingent or otherwise) other than
reasonable reserves of cash or other liquid amounts as may be necessary or reasonably appropriate in order to provide for ongoing corporate maintenance of such Blocker. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_38"></A>3.25 <U>Blocker Authority; No Conflict; Required Filings and Consents</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Such Blocker has all requisite power and authority to execute and deliver this Agreement and the other agreements contemplated hereby and
to perform its respective obligations hereunder and thereunder. The execution and delivery by such Blocker of this Agreement and the other agreements contemplated hereby and, subject to obtaining the Blocker Approvals, which are the only approval
required from the securityholders of such Blocker, the performance by such Blocker of this Agreement and the consummation by such Blocker of the Transactions have been duly and validly authorized by all necessary company or other corporate action on
the part of such Blocker. This Agreement and all other agreements contemplated hereby have been duly and validly executed and delivered by such Blocker party thereto and, assuming the due execution and delivery hereof and thereof by the other
parties hereto and thereto, constitutes or will constitute a valid and binding obligation of such Blocker, enforceable against it in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, moratorium, and
other similar Laws affecting creditors&#146; rights generally and by general principles of equity. The manager or managing member, as applicable, of each Blocker has (i)&nbsp;determined that the Transactions are fair to, advisable, and in the best
interests of such Blocker and its respective members and (ii)&nbsp;adopted this Agreement and approved the Transactions, including the applicable Blocker Merger, in its capacity as a manager or managing member, as applicable, of such Blocker. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Subject to the filing of the Blocker Certificate of Merger for such Blocker Merger as required by Delaware Law, neither the execution and
delivery by such Blocker of this Agreement or any other agreement </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
contemplated hereby, nor the performance by such Blocker of its obligations hereunder or thereunder, nor the consummation by such Blocker of the Transactions, will (i)&nbsp;conflict with or
violate any provision of the Organizational Documents of such Blocker, each as amended or restated to date, (ii)&nbsp;require on the part of such Blocker any notice to or filing with, or any permit, authorization, consent or approval of, any
Governmental Entity, (iii)&nbsp;conflict with, result in a breach of, constitute (with or without due notice or lapse of time or both) a default under, result in the acceleration of obligations under, create in any party the right to accelerate,
terminate, modify or cancel, or require any notice, consent or waiver under, any contract, lease, sublease, license, sublicense, franchise, permit, indenture, agreement or mortgage for borrowed money, instrument of Indebtedness, Lien (other than
Permitted Liens) or other arrangement to which such Blocker is a party or by which such Blocker is bound or to which any of the assets of such Blocker are subject, (iv)&nbsp;result in the imposition of any Lien other than Permitted Liens upon any
assets of such Blocker or (v)&nbsp;violate any order, writ, injunction, decree, statute, rule or regulation applicable to such Blocker or any of its properties or assets, except in the case of clauses (ii)&nbsp;through (v) as would not, individually
or in the aggregate, reasonably be expected to have the effect of preventing, delaying beyond the Outside Date, or making illegal, the Transactions (including the Mergers). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_39"></A>3.26 <U>Blocker Compliance with Laws</U>. To the actual knowledge of such Blocker, such Blocker, has since
January&nbsp;1, 2020 conducted, and is conducting, its business and operations in compliance in all material respects with all applicable Laws. To the actual knowledge of such Blocker, since January&nbsp;1, 2020, such Blocker has not received any
notice or other communication from any Governmental Entity or other Person alleging any material noncompliance with any applicable Law. To the actual knowledge of such Blocker, such Blocker does not have any material liability for failure to comply
with any Law and, to the actual knowledge of such Blocker, there is no act, omission, event or circumstance that would reasonably be expected to give rise to any such liability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_40"></A>3.27 <U>Blocker Brokers</U>. No broker, finder or investment banker is entitled to any brokerage,
finder&#146;s or other fee or commission based upon arrangements made by or on behalf of such Blocker with respect to any of the Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_41"></A>3.28 <U>Blocker Tax Matters</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Each Blocker has properly filed on a timely basis all income and other material Tax Returns that it was required to file, and all such Tax
Returns were true, correct and complete in all material respects. Each Blocker has paid on a timely basis all income or other material Taxes, whether or not shown on any Tax Return, that were due and payable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) All material Taxes that each Blocker was required by Law to withhold or collect have been duly withheld or collected and, to the extent
required, have been properly paid to the appropriate Governmental Entity, in each case in compliance in all material respects with applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) No examination or audit of any Tax Return of a Blocker by any Governmental Entity is currently in progress or, to the Knowledge of such
Blocker, has been threatened by any Governmental Entity. No deficiencies for Taxes of any Blocker have been claimed, proposed or assessed by any Governmental Entity in writing. No Blocker has been informed in writing by any jurisdiction in which
such Blocker does not file a Tax Return that the jurisdiction believes that such Blocker was required to file any Tax Return that was not filed or is subject to Tax in such jurisdiction. No Blocker has (i)&nbsp;waived any statute of limitations with
respect to Taxes or agreed to extend the period for assessment or collection of any Taxes, which waiver or extension is still in effect, (ii)&nbsp;requested any extension of time within which to file any Tax Return (other than any automatic
extension granted in the ordinary course of business and consistent with past custom and practice of such Blocker), or (iii)&nbsp;executed or filed any power of attorney with any taxing authority, which is still in effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) To the actual knowledge of such Blocker, such Blocker has not participated in any &#147;reportable transaction&#148; as defined in
Treasury <FONT STYLE="white-space:nowrap">Regulations&nbsp;Section&nbsp;1.6011-4(b)&nbsp;or</FONT> a &#147;listed transaction&#148; within the meaning of Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.6011-4(b)(2)</FONT> or any
analogous provision of state or local Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) There are no Liens with respect to Taxes on any of the assets of any Blocker, other than
Permitted Liens. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) With the exception of customary commercial leases or contracts, if any, that are not primarily related to Taxes
entered into in the Ordinary Course of Business and liabilities thereunder, no Blocker (i)&nbsp;has any liability under Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.1502-6</FONT> (or any comparable or similar provision of
state, local <FONT STYLE="white-space:nowrap">or&nbsp;non-U.S.&nbsp;law),</FONT> as a transferee or successor, or pursuant to any contractual obligation for any Taxes of any Person, or (ii)&nbsp;is a party to or bound by any Tax indemnity, Tax
sharing, Tax allocation or similar agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) During the <FONT STYLE="white-space:nowrap">two-year</FONT> period ending on the date
hereof, no Blocker (including any predecessor thereof) has constituted either a &#147;distributing corporation&#148; or a &#147;controlled corporation&#148; in a distribution of stock qualifying for <FONT STYLE="white-space:nowrap">tax-free</FONT>
treatment under Section&nbsp;355 of the Code (or so much of Section&nbsp;356 of the Code as relates to Section&nbsp;355 of the Code). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h)
Each Blocker is, and has been at all times since its inception, classified for U.S. federal and state income Tax purposes as a corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_42"></A>3.29 <U>No Other Representations and Warranties</U>. Except as previously set forth in this Article III or in
any certificate delivered by Merger Partner to Public Company and/or Merger Subsidiary pursuant to this Agreement or otherwise in the case of Fraud, Merger Partner and Blockers make no representation or warranty, express or implied, at law or in
equity, with respect to it or any of its assets, liabilities or operations, and any such other representations or warranties are hereby expressly disclaimed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_43"></A>3.30 <U>Reliance</U>. Each of Merger Partner and each Blocker acknowledges that, except for the
representations and warranties contained in Article IV, neither Public Company nor any other Person on behalf of Public Company has made, and each of Merger Partner and each Blocker (as to itself) has not relied on, any other express or implied
representation or warranty by or on behalf of Public Company or such Person. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="annexarom401831_44"></A>ARTICLE IV </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REPRESENTATIONS AND WARRANTIES OF PUBLIC COMPANY AND MERGER SUBSIDIARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of Public Company and Merger Subsidiary represents and warrants to Merger Partner and the Blockers, as of the date of this Agreement and
as of the Closing Date, that, except (a)&nbsp;as set forth in Public Company Disclosure Schedule or (b)&nbsp;as disclosed in Public Company SEC Reports filed since January&nbsp;1, 2020 that were publicly available on EDGAR at least one
(1)&nbsp;Business Day prior to the date of this Agreement (but (i)&nbsp;without giving effect to any amendment thereof filed with, or furnished to the SEC on or after the Business Day prior to the date of this Agreement and (ii)&nbsp;excluding any
risk factor or similar disclosure under the headings &#147;Risk Factors&#148;, &#147;Forward-Looking Statements&#148; or other similar cautionary, predictive or forward-looking disclosures contained therein), it being understood and agreed that any
matter disclosed in such Public Company SEC Reports shall be deemed to be disclosed in a section of the Public Company Disclosure Schedule only to the extent to which its relevance is reasonably apparent on the face of the disclosure in such Public
Company SEC Reports the statements contained in this Article IV are true and correct as of the date of this Agreement, except to the extent such representations and warranties are specifically made as of a particular date (in which case such
representations and warranties will be true and correct as of such date). The Public Company Disclosure Schedule shall be arranged in sections and paragraphs corresponding to the numbered and lettered sections and paragraphs contained in this
Article IV; <U>provided</U>, <U>however</U>, that the disclosures in any section or paragraph of Public Company Disclosure Schedule shall qualify (a)&nbsp;the corresponding section or paragraph in this Article IV and (b)&nbsp;such other sections or
paragraphs in this Article IV (whether or not there is a specific cross reference) to the extent that it is reasonably apparent on the face of the disclosure that such disclosure also qualifies or applies to such other section or paragraph. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_45"></A>4.1 <U>Organization, Standing and Power</U>. Each of Public
Company and Merger Subsidiary is a corporation or limited liability company and duly organized, validly existing and in good standing under the Laws of the State of Delaware. Except as would not, individually or in the aggregate, reasonably be
expected to result in a Public Company Material Adverse Effect, each of Public Company and Merger Subsidiary is duly qualified to conduct business and is in good standing under the Laws of each jurisdiction in which the nature of its businesses or
the ownership or leasing of its properties requires such qualification. Each of Public Company and Merger Subsidiary has all requisite power and authority to (i)&nbsp;carry on the businesses in which it is engaged, (ii)&nbsp;own and use the
properties owned and used by it and (iii)&nbsp;perform its obligations under all Public Company Contracts. Public Company has made available to Merger Partner complete and accurate copies of the Organizational Documents of Public Company and Merger
Subsidiary as in effect on the date of this Agreement. Each of Public Company and Merger Subsidiary is not in material default under or in material violation of any provision of its Organizational Documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_46"></A>4.2 <U>Capitalization</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The authorized capital stock of Public Company consists of 275,000,000 shares of Public Company Common Stock and 50,000,000 shares of
Public Company Preferred Stock, $0.0001 par value per share (&#147;<U>Public Company Preferred Stock</U>&#148;). As of December&nbsp;30, 2022 (the &#147;<U>Measurement Date</U>&#148;), there were (a) 48,844,619 shares of Public Company Common Stock
outstanding, (b)&nbsp;no shares of Public Company Preferred Stock outstanding, (c) 100,152 shares of Public Company Common Stock held in treasury and (d)&nbsp;no shares of Public Company Common Stock are owned by any Subsidiary of Public Company.
Since the Measurement Date through the date of this Agreement, Public Company has not issued any shares of Public Company Common Stock or Public Company Preferred Stock except for issuances of shares of Public Company Common Stock upon the exercise
of Public Company Stock Options, Public Company RSUs, Public Company PSUs, or Public Company Warrants that were outstanding at such time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) As of December&nbsp;30, 2022, there were outstanding options to purchase 5,845,733 shares of Public Company Common Stock (each, a
&#147;<U>Public Company Stock Option</U>&#148; and collectively, the &#147;<U>Public Company Stock Options</U>&#148;); 1,258,447 restricted stock units with respect to 1,258,447 shares of Public Company Stock (each, a &#147;<U>Public Company
RSU</U>&#148; and collectively, the &#147;<U>Public Company RSUs</U>&#148;); and 1,130,000 performance stock units with respect to 1,130,000 shares of Public Company Stock, assuming achievement of the applicable performance measures at the maximum
level, (each, a &#147;<U>Public Company PSU</U>&#148; and collectively, the &#147;<U>Public Company PSUs</U>&#148;). Public Company has made available to Merger Partner complete and accurate copies of all stock or equity related plans, agreements,
or arrangements of Public Company (collectively, the &#147;<U>Public Company Stock Plans</U>&#148;) and the forms of all award agreements evidencing awards under the Public Company Stock Plans. Section&nbsp;4.2(b) of the Public Company Disclosure
Schedule contains a correct and complete list, as of December&nbsp;30, 2022, of each award issued under the Public Company Stock Plans, including the date of grant, number of Public Company Common Shares, and, where applicable, outstanding dividend
equivalent rights, exercise price, whether such award is intended to be an incentive stock option, and vesting schedule. As of December&nbsp;30, 2022, Public Company had reserved 11,313,227 shares of Public Company Common Stock for issuance to
employees pursuant to the Public Company Stock Plans, of which 2,718,149 shares remain available for issuance thereunder as of the date thereof. Public Company has not granted, issued or authorized the grant or issuance of any Public Company Stock
Options on the Business Day prior to the date of this Agreement or on the date of this Agreement. With respect to each Public Company Stock Option, Public Company RSU, Public Company PSU, and any other award granted with respect to Public Company
Common Stock (whether outstanding or previously exercised or settled, as applicable)&nbsp;(i) each such award or grant was duly authorized no later than the date on which the grant or award was by its terms to be effective by all necessary company
or other corporate action, including, as applicable, approval by the Public Company Board (or a duly constituted and authorized committee thereof), or a duly authorized delegate thereof, and any required stockholder approval by the necessary number
of votes or written consents, (ii)&nbsp;each such grant or award was made in accordance with the terms of the applicable Public Company Stock Plan, the Securities Act, the Exchange Act, to the extent applicable, and all other applicable Laws and are
not and have not been the subject of any internal investigation, review or inquiry, and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
each Public Company Stock Option has an exercise price per Public Company Common Share equal to or greater than the fair market value of a Public Company Common Share on the date of such grant.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Section 4.2(c)&nbsp;of the Public Company Disclosure Schedule lists the number of shares of Public Company Common Stock reserved for
future issuance pursuant to warrants or other outstanding rights (other than Public Company Stock Options, Public Company RSUs, and Public Company PSUs) to purchase shares of Public Company Common Stock outstanding as of the close of business on the
Business Day prior to the date of this Agreement (such outstanding warrants or other rights, the &#147;<U>Public Company Warrants</U>&#148;) and the agreement or other document under which such Public Company Warrants were granted, and the exercise
price, the date of grant and the expiration date thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Except as set forth in this&nbsp;Section&nbsp;4.2&nbsp;or in&nbsp;ARTICLE
II, (A)&nbsp;there are no equity securities of any class of Public Company, or any security exchangeable into or exercisable for such equity securities, issued, reserved for issuance or outstanding and (B)&nbsp;there are no options, warrants, equity
securities, calls, rights, commitments or agreements of any character to which Public Company or any of its Subsidiaries is a party or by which Public Company or any of its Subsidiaries is bound obligating Public Company or any of its Subsidiaries
to issue, exchange, transfer, deliver or sell, or cause to be issued, exchanged, transferred, delivered or sold, additional shares of capital stock or other equity interests of Public Company or any security or rights convertible into or
exchangeable or exercisable for any such shares or other equity interests, or obligating Public Company or any of its Subsidiaries to grant, extend, accelerate the vesting of, otherwise modify or amend or enter into any such option, warrant, equity
security, call, right, commitment or agreement. Except as set forth in the Support Agreements or pursuant to any Public Company Stock Plan, Public Company is not a party to or is bound by any, and to the Knowledge of Public Company, there are no,
agreements or understandings with respect to the voting (including voting trusts and proxies) or sale or transfer (including agreements imposing transfer restrictions) of any shares of capital stock or other equity interests of Public Company.
Except as contemplated by this Agreement or described in this&nbsp;Section&nbsp;4.2(d), there are no registration rights to which Public Company or any of its Subsidiaries is a party or by which it or they are bound with respect to any equity
security of any class of Public Company. Stockholders of Public Company are not entitled to dissenters&#146; or appraisal rights under applicable Delaware Law in connection with the Mergers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) All outstanding shares of Public Company Common Stock are, and all shares of Public Company Common Stock subject to issuance as specified
in&nbsp;Sections 4.2(b)&nbsp;and&nbsp;4.2(c)&nbsp;or pursuant to&nbsp;ARTICLE II, upon issuance on the terms and conditions specified in the instruments pursuant to which they are issuable, will be, duly authorized, validly issued, fully paid and
nonassessable and not subject to or issued in violation of any purchase option, call option, right of first refusal, preemptive right, subscription right or any similar right under any provision of the DGCL, Public Company&#146;s certificate of
incorporation or bylaws or any agreement to which Public Company is a party or is otherwise bound. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_47"></A>4.3
<U>Subsidiaries</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Section 4.3 of Public Company Disclosure Schedule sets forth each Subsidiary of Public Company, all of which are
wholly-owned by Public Company. Except as listed on Section&nbsp;4.3 of the Public Company Disclosure Schedule, Public Company does not own or control directly or indirectly or have any direct or indirect equity participation or similar interest in,
or any obligation to provide funding to, any corporation, partnership, limited liability company, joint venture, trust or other business association or entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Each Subsidiary of Public Company (i)&nbsp;is duly organized, validly existing and in standing under the Laws of the jurisdiction of its
formation, (ii)&nbsp;is duly qualified to conduct business and is in good standing under the Laws of each jurisdiction in which the nature of its businesses or the ownership or leasing of its properties requires such qualification except as would
not, individually or in the aggregate, reasonably be expected to result in a Public Company Material Adverse Effect, and (iii)&nbsp;has all requisite power and authority to carry on the businesses in which it is engaged and to own and use the
properties owned and used by it. Public Company has </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
delivered to Merger Partner complete and accurate copies of the Organizational Documents of each Subsidiary of Public Company. There are no outstanding or authorized options, warrants, rights,
agreements or commitments to which Public Company or any Subsidiary of Public Company is a party or which are binding on any of them providing for the issuance, disposition or acquisition of any equity interests of any such Subsidiary other than to
Public Company or another Subsidiary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) All of the outstanding capital stock of or other voting securities of or ownership interests
in, each Subsidiary of Public Company, is owned by Public Company, directly or indirectly, free and clear of any Lien and free of any transfer restriction (other than transfer restrictions of general applicability as may be provided under the
Securities Act or other applicable securities Laws), including any restriction on the right to vote, sell or otherwise dispose of such capital stock or other voting securities or ownership interests. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Except for its interests in each Subsidiary of Public Company, Public Company does not own, directly or indirectly, any capital stock,
membership interest, partnership interest, joint venture interest or other equity interest in any other Person. There are no outstanding contractual obligations of Public Company or any of its Subsidiaries in any Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_48"></A>4.4 <U>Authority; No Conflict; Required Filings and Consents</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Each of Public Company and Merger Subsidiary has all requisite power and authority to execute and deliver this Agreement and the other
agreements contemplated hereby and to perform its respective obligations hereunder and thereunder. The execution and delivery by Public Company and Merger Subsidiary of this Agreement and the other agreements contemplated hereby and, subject to
obtaining the Public Company Stockholder Approval, which is the only approval required from the shareholders of Public Company and its Subsidiaries, the performance by Public Company and Merger Subsidiary of this Agreement and the consummation by
Public Company and Merger Subsidiary of the Transactions have been duly and validly authorized by all necessary corporate action on the part of Public Company and Merger Subsidiary, respectively. This Agreement and all other agreements contemplated
hereby have been duly and validly executed and delivered by Public Company and Merger Subsidiary and, assuming the due execution and delivery hereof and thereof by the other parties hereto and thereto, constitutes or will constitute a valid and
binding obligation of each of Public Company and Merger Subsidiary, as applicable, enforceable against it in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, moratorium, and other similar Laws
affecting creditors&#146; rights generally and by general principles of equity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Public Company Board (at a meeting or meetings
duly called and held and at which all members were present) has unanimously: (i)&nbsp;determined that the Transactions are fair to, advisable and in the best interests of Public Company and its stockholders; (ii)&nbsp;authorized, approved and
declared advisable this Agreement and the Transactions, including the issuance of shares of Public Company Common Stock to the stockholders of Blockers and Merger Partner pursuant to the terms of this Agreement; and (iii)&nbsp;determined to
recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholders of Public Company vote to approve the Public Company Stockholder Matters and the Other Public Company Stockholder Matters. The board of
directors of Merger Subsidiary (by unanimous written consent) has: (A)&nbsp;determined that the Transactions are fair to, advisable, and in the best interests of Merger Subsidiary and its sole stockholder; (B)&nbsp;authorized, approved and declared
advisable this Agreement and the Transactions, including the Merger Partner Merger; and (C)&nbsp;determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the sole stockholder of Merger Subsidiary vote
to adopt this Agreement and thereby approve the Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Subject to the filing of the each Blocker Certificate of Merger and the
Merger Partner Certificate of Merger as required by Delaware Law, neither the execution and delivery by Public Company or Merger Subsidiary of this Agreement or any other agreement contemplated hereby, nor the performance by Public Company or Merger
Subsidiary of their respective obligations hereunder or thereunder, nor the consummation by Public Company or Merger Subsidiary of the Transactions, will (i)&nbsp;conflict with or violate any provision of the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Organizational Documents of Public Company or Merger Subsidiary, each as amended or restated to date, (ii)&nbsp;require on the part of Public Company or Merger Subsidiary or any of their
respective Subsidiaries any notice to or filing with, or any permit, authorization, consent or approval of, any Governmental Entity, (iii)&nbsp;conflict with, result in a breach of, constitute (with or without due notice or lapse of time or both) a
default under, result in the acceleration of obligations under, create in any party the right to accelerate, terminate, modify or cancel, or require any notice, consent or waiver under, any contract, lease, sublease, license, sublicense, franchise,
permit, indenture, agreement or mortgage for borrowed money, instrument of Indebtedness, Lien (other than Permitted Liens) or other arrangement to which Public Company or any of its Subsidiaries is a party or by which any of them are bound or to
which any of their assets are subject, (iv)&nbsp;result in the imposition of any Lien other than Permitted Liens upon any assets of Public Company or any of its Subsidiaries or (v)&nbsp;violate any order, writ, injunction, decree, statute, rule or
regulation applicable to Public Company or any of its Subsidiaries or any of their respective properties or assets of any of the foregoing, except in the case of clauses (ii)&nbsp;through (v) as would not, individually or in the aggregate,
reasonably be expected to result in a Public Company Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_49"></A>4.5 <U>Operations of
Merger Subsidiary</U>. Merger Subsidiary a wholly owned subsidiary of Public Company and has not engaged in any business activities or conducted any operations of any kind, entered into any agreement or arrangement with any Person, or incurred,
directly or indirectly, any liabilities, in each case except in connection with its incorporation and the negotiation of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_50">
</A>4.6 <U>SEC Filings; Financial Statements</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Public Company has timely filed or furnished (as applicable) all forms, reports,
certifications and other documents required to be filed by Public Company with the SEC since January&nbsp;1, 2020. All such registration statements, forms, reports and other documents filed by Public Company with the SEC prior to the date hereof are
referred to herein as the &#147;<U>Public Company SEC Reports</U>.&#148; None of the Subsidiaries of Public Company are required to make any filings with the SEC. All of Public Company SEC Reports (a)&nbsp;were filed on a timely basis, and
(b)&nbsp;at the time filed, complied as to form in all material respects with the requirements of the Securities Act and the Exchange Act applicable to such Public Company SEC Reports and (c)&nbsp;do not, as of the date hereof, contain a material
misstatement, untrue fact or omission except as set forth in disclosures of the Public Company SEC Reports. The certifications and statements required by (i)&nbsp;Rule <FONT STYLE="white-space:nowrap">13a-14</FONT> or Rule <FONT
STYLE="white-space:nowrap">15d-14(a)</FONT> under the Exchange Act and (ii) 18 U.S.C. &#167;1350 (Section 906 of the Sarbanes-Oxley Act) relating to the Public Company SEC Reports (collectively, the &#147;<U>Certifications</U>&#148;) are accurate
and complete and comply as to form and content with all applicable Laws. The Public Company SEC Reports at the time filed (a)&nbsp;complied as to form in all material respects with applicable accounting requirements and the published rules and
regulations of the SEC with respect thereto, (b)&nbsp;were prepared in accordance with GAAP applied on a consistent basis throughout the periods involved and at the dates involved (except as may be indicated in the notes to such financial statements
or, in the case of unaudited interim financial statements, as permitted by the SEC on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> under the Exchange Act) and (c)&nbsp;fairly presented in accordance with GAAP the consolidated financial position
of Public Company and its Subsidiaries as of the dates indicated and the consolidated results of its operations, cash flows and stockholders&#146; equity for the periods indicated, except that the unaudited interim financial statements were or are
subject to normal and recurring <FONT STYLE="white-space:nowrap">year-end</FONT> adjustments. Other than as expressly disclosed in the Public Company SEC Reports filed prior to the date hereof or have been permitted or required by any Governmental
Authority, there has been no material change in Public Company&#146;s accounting methods or principles that would be required to be disclosed in Public Company&#146;s financial statements in accordance with GAAP. The interactive data in eXtensible
Business Reporting Language (XBRL) included or incorporated by reference in the Public Company SEC Reports fairly presents the information called for in all material respects and has been prepared in accordance with the SEC&#146;s rules and
guidelines applicable thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) As of the date of this Agreement, there are no outstanding or unresolved comments received from the
SEC with respect to any Public Company SEC Report and, to the Knowledge of Public Company, none of the Public Company SEC Reports is the subject of ongoing SEC review. As of the date of this Agreement, there has
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
been no material correspondence between the SEC and Public Company since January&nbsp;1, 2020 that is not set forth in the Public Company SEC Reports or that has not otherwise been disclosed to
Merger Partner prior to the date of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Public Company maintains accurate books and records reflecting its assets and
liabilities and maintains proper and adequate system of internal control over financial reporting (as defined in Rules <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f)</FONT> of the Exchange Act) that
is sufficient to provide assurance that (i)&nbsp;transactions are executed with management&#146;s authorization, (ii)&nbsp;transactions are recorded as necessary to permit preparation of the financial statements of Public Company and to maintain
accountability for Public Company&#146;s assets, (iii)&nbsp;access to assets of Public Company is permitted only in accordance with management&#146;s authorization, (iv)&nbsp;the reporting of assets of Public Company is compared with existing assets
at regular intervals, and (v)&nbsp;accounts, notes and other receivables and inventory were recorded accurately, and proper and adequate procedures are implemented to effect the collection thereof on a current and timely basis. Public Company has
disclosed to Public Company&#146;s auditors and audit committee (and made available to Merger Partner a summary of the significant aspects of such disclosure)&nbsp;(A) all significant deficiencies and material weaknesses, if any, in the design or
operation of internal control over financial reporting that are reasonably likely to adversely affect Public Company&#146;s ability to record, process, summarize and report financial information and (B)&nbsp;any Fraud, whether or not material, that
involves management or other employees who have a significant role in Public Company&#146;s or its Subsidiaries&#146; internal control over financial reporting. Public Company has not identified any material weaknesses in the design or operation of
Public Company&#146;s internal control over financial reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Neither Public Company nor any of its Subsidiaries has any
Liability, except for: (i)&nbsp;Liabilities disclosed, reflected or reserved against in Public Company&#146;s most recent interim consolidated unaudited balance sheet as of September&nbsp;30, 2022; (ii) Liabilities that have been incurred by Public
Company or its Subsidiaries since September&nbsp;30, 2022 in the Ordinary Course of Business; (iii)&nbsp;Liabilities for performance of obligations of Public Company or any of its Subsidiaries under Public Company Contracts (other than those arising
as a result of a breach or default thereunder or as a result of failure to comply with applicable Law); (iv) Liabilities for payment of fees and expenses incurred in connection with the Transactions; (v)&nbsp;Liabilities which would not,
individually or in the aggregate, reasonably be expected to be material to Public Company and its Subsidiaries, taken as a whole; and (vi)&nbsp;Liabilities described in Section&nbsp;4.6(d) of the Public Company Disclosure Schedule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The information in the Registration Statement to be supplied by or on behalf of Public Company for inclusion or incorporation by reference
in the Registration Statement or supplied by or on behalf of Public Company for inclusion in any Regulation <FONT STYLE="white-space:nowrap">M-A</FONT> Filing, shall not at the time the Registration Statement or any such Regulation <FONT
STYLE="white-space:nowrap">M-A</FONT> Filing is filed with the SEC, at any time it is amended or supplemented or at the time the Registration Statement is declared effective by the SEC, as applicable, contain any untrue statement of a material fact
or omit to state any material fact required to be stated therein or necessary in order to make the statements therein not misleading, in light of the circumstances under which they were made. The information to be supplied by or on behalf of Public
Company for inclusion or incorporation by reference in the Proxy Statement/Prospectus to be sent to the stockholders of Public Company in connection with the Public Company Stockholder Meeting, which information shall be deemed to include all
information about or relating to Public Company, the Public Company Stockholder Matters, the Other Public Company Stockholder Matters (as applicable) or the Public Company Stockholder Meeting, shall not, on the date the Proxy Statement/Prospectus is
first mailed to stockholders of Public Company, or at the time of the Public Company Stockholder Meeting or as of the Effective Time, contain any statement that, at such time and in light of the circumstances under which it shall be made, is false
or misleading with respect to any material fact, or omit to state any material fact necessary in order to make the statements made in the Proxy Statement/Prospectus not false or misleading; or omit to state any material fact necessary to correct any
statement in any earlier communication with respect to the solicitation of proxies for the Public Company Meeting that has become, in light of the circumstances in which they were made, false or misleading. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Public Company&#146;s independent registered accounting firm has at all times since its first date of service to Public Company has been:
(i)&nbsp;a registered public accounting firm (as defined in Section&nbsp;2(a)(12) of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Sarbanes-Oxley Act); (ii) to the Knowledge of Public Company, &#147;independent&#148; with respect to Public Company within the meaning of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT>
under the Exchange Act; and (iii)&nbsp;to the Knowledge of Public Company, in compliance with subsections (g)&nbsp;through (l) of Section&nbsp;10A of the Exchange Act and the rules and regulations promulgated by the SEC and Public Company Board.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) Between January&nbsp;1, 2020 and the date of this Agreement, there have been no formal investigations regarding financial reporting
or accounting policies and practices discussed with, reviewed by or initiated at the direction of the chief executive officer, chief financial officer, principal accounting officer or general counsel of Public Company, the Public Company Board or
any committee thereof, other than ordinary course audits or reviews of accounting policies and practices or internal controls required by the Sarbanes-Oxley Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_51"></A>4.7 <U>Absence of Certain Changes</U>. Since December&nbsp;31, 2021, except for the execution and performance
of this Agreement and the discussions, negotiations and transactions related thereto, (a)&nbsp;there has occurred no event or development which, individually or in the aggregate, has had, or could reasonably be expected to have in the future, a
Public Company Material Adverse Effect, (b)&nbsp;Public Company and the Subsidiaries have conducted their businesses in the Ordinary Course of Business and (c)&nbsp;neither Public Company nor any Subsidiary has taken any of the actions set forth in
clauses (a)&nbsp;through (s) of Section&nbsp;5.2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_52"></A>4.8 <U>Tax Matters</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Each of Public Company and its Subsidiaries has properly filed on a timely basis all income and other material Tax Returns that it was
required to file, and all such Tax Returns were true, correct and complete in all material respects. Each of Public Company and its Subsidiaries has paid on a timely basis all income or other material Taxes, whether or not shown on any Tax Return,
that were due and payable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Neither Public Company nor any of its Subsidiaries is or has ever been a member of an affiliated group
with which it has filed (or been required to file) consolidated, combined, unitary or similar U.S. federal Tax Returns, other than a group of which the common parent is Public Company. With the exception of customary commercial leases or contracts
that are not primarily related to Taxes entered into in the Ordinary Course of Business and liabilities thereunder, neither Public Company nor any of its Subsidiaries (i)&nbsp;has any liability under Treasury Regulations <FONT
STYLE="white-space:nowrap">Section&nbsp;1.1502-6</FONT> (or any comparable or similar provision of state, local <FONT STYLE="white-space:nowrap">or&nbsp;non-U.S.&nbsp;law),</FONT> as a transferee or successor, or pursuant to any contractual
obligation for any Taxes of any Person other than Public Company or any of its Subsidiaries, or (ii)&nbsp;is a party to or bound by any Tax indemnity, Tax sharing, Tax allocation or similar agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) All material Taxes that Public Company or any of its Subsidiaries was required by Law to withhold or collect have been duly withheld or
collected and, to the extent required, have been properly paid to the appropriate Governmental Entity, in each case in compliance in all material respects with applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Public Company has delivered or made available to Merger Partner (i)&nbsp;complete and correct copies of all income and other material Tax
Returns of Public Company and any of its Subsidiaries relating to Taxes for all taxable periods for which the applicable statute of limitations has not yet expired, (ii)&nbsp;complete and correct copies of all private letter rulings, revenue agent
reports, information document requests, notices of proposed deficiencies, deficiency notices, protests, petitions, closing agreements, settlement agreements, pending ruling requests and any similar documents submitted by, received by, or agreed to
by or on behalf of Public Company or any of its Subsidiaries relating to Taxes for all taxable periods for which the statute of limitations has not yet expired, and (iii)&nbsp;complete and correct copies of all material agreements, rulings,
settlements or other Tax documents with or from any Governmental Entity relating to Tax incentives of Public Company or any of its Subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) No examination or audit of any Tax Return of Public Company or any of its Subsidiaries by any Governmental Entity is currently in progress
or, to the Knowledge of Public Company, has been threatened by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any Governmental Entity. No deficiencies for Taxes of Public Company or any of its Subsidiaries have been claimed, proposed or assessed by any Governmental Entity in writing. Neither Public
Company nor any of its Subsidiaries has been informed in writing by any jurisdiction in which Public Company or any of its Subsidiaries does not file a Tax Return that the jurisdiction believes that Public Company or any of its Subsidiaries was
required to file any Tax Return that was not filed or is subject to Tax in such jurisdiction. Neither Public Company nor any of its Subsidiaries has (i)&nbsp;waived any statute of limitations with respect to Taxes or agreed to extend the period for
assessment or collection of any Taxes, which waiver or extension is still in effect, (ii)&nbsp;requested any extension of time within which to file any Tax Return (other than any automatic extension granted in the ordinary course of business and
consistent with past custom and practice of Public Company), or (iii)&nbsp;executed or filed any power of attorney with any taxing authority, which is still in effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Neither Public Company nor any of its Subsidiaries has made any payment or provided any benefit, is obligated to make any payment or
provide any benefit, or is a party to any plan, program, policy, agreement or arrangement that could obligate it to make any payment or provide any benefit that may be treated as an &#147;excess parachute payment&#148; under Section&nbsp;280G of the
Code (without regard to Sections 280G(b)(4) and 280G(b)(5) of the Code). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) Neither Public Company nor any of its Subsidiaries has been
a United States real property holding corporation within the meaning of Section&nbsp;897(c)(2) of the Code during the applicable period specified in Section&nbsp;897(c)(l)(A)(ii) of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) There are no Liens with respect to Taxes upon any of the assets or properties of Public Company or any of its Subsidiaries, other than
Permitted Liens. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) Neither Public Company nor any of its Subsidiaries has participated in any &#147;reportable transaction&#148; as
defined in Treasury <FONT STYLE="white-space:nowrap">Regulations&nbsp;Section&nbsp;1.6011-4(b)&nbsp;or</FONT> a &#147;listed transaction&#148; as set forth in Treasury
<FONT STYLE="white-space:nowrap">Regulations&nbsp;Section&nbsp;301.6111-2(b)(2)&nbsp;or</FONT> any analogous provision of state or local law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) During the <FONT STYLE="white-space:nowrap">two-year</FONT> period ending on the date hereof, Public Company nor any predecessor thereof
has constituted either a &#147;distributing corporation&#148; or a &#147;controlled corporation&#148; in a distribution of stock qualifying for <FONT STYLE="white-space:nowrap">tax-free</FONT> treatment under Section&nbsp;355 of the Code (or so much
of Section&nbsp;356 of the Code as relates to Section&nbsp;355 of the Code). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other than Section&nbsp;4.16, this Section&nbsp;4.8 provides the sole and
exclusive representations and warranties of Public Company and its Subsidiaries in respect of Tax matters </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_53"></A>4.9 <U>Assets</U>. Except as would not be, individually or in the aggregate, material to Public Company and
its Subsidiaries, taken as a whole, Public Company or its applicable Subsidiary is the true and lawful owner of, and has good title to, all of the assets (tangible or intangible) purported to be owned by Public Company or such Subsidiary, free and
clear of all Liens other than Permitted Liens. Public Company and each Subsidiary owns or leases all material tangible assets sufficient for the conduct of its businesses as presently conducted, which tangible assets are reflected in the Public
Company Financial Statements (other than to the extent disposed of in the Ordinary Course of Business). Except as would not, individually or in the aggregate, reasonably be expected to result in a Public Company Material Adverse Effect, each such
tangible asset is free from defects, has been maintained in accordance with normal industry practice, is in good operating condition and repair (subject to normal wear and tear) and is suitable for the purposes for which it presently is used. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_54"></A>4.10 <U>Owned and Leased Real Property</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Neither Public Company nor any of its Subsidiaries owns any real property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Public Company has delivered to Merger Partner complete and accurate copies of all material Leases of Public Company and its Subsidiaries.
Neither Public Company nor any Subsidiary occupies any space </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other than pursuant to a Lease. With respect to each such Lease, except as would not, individually or in the aggregate, reasonably be expected to result in a Public Company Material Adverse
Effect: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) such Lease is legal, valid, binding, enforceable and in full force and effect against Public Company or its Subsidiary that
is the party thereto, as applicable, and, to the Knowledge of Public Company, against each other party thereto; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) such Lease will
continue to be legal, valid, binding, enforceable and in full force and effect against Public Company or the Subsidiary that is the party thereto, as applicable, and, to the Knowledge of Public Company, against each other party thereto immediately
following the Closing in accordance with the terms thereof as in effect immediately prior to the Closing; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) none of Public Company,
any Subsidiary of Public Company or, to the Knowledge of Public Company, any other party, is in breach or violation of, or default under, any such Lease, and no event has occurred, is pending or, to the Knowledge of Public Company, is threatened,
which, after the giving of notice, with lapse of time, or otherwise, would constitute any such breach or default by Public Company or any Subsidiary of Public Company or, to the Knowledge of Public Company, any other party under such Lease; and no
event has occurred that would give rise to a termination right under such Lease; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) neither Public Company nor any Subsidiary of
Public Company has assigned, transferred, conveyed, mortgaged, subleased, licensed, deeded in trust or encumbered any interest in the leasehold or subleasehold; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) to the Knowledge of Public Company, there are no Liens (other than Permitted Liens) applicable to the real property subject to such Lease
which would reasonably be expected to impair the current uses or the occupancy by Public Company or any Subsidiary of Public Company of the property subject thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Each of Public Company and its Subsidiaries owns, and has good and valid title to, or, in the case of leased properties and assets, valid
leasehold interests in, all tangible properties or tangible assets and equipment used or held for use in its business or operations or purported to be owned by it, in each case, that are material to Public Company and its Subsidiaries, taken as a
whole, including: (A)&nbsp;all such tangible assets reflected on the Public Company Financial Statements and (B)&nbsp;all other such tangible assets reflected in the books and records of Public Company or any of its Subsidiaries as being owned by
Public Company or such Subsidiary. All of such assets are owned or, in the case of leased assets, leased by Public Company or any of its Subsidiaries free of any Liens other than Permitted Liens. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_55"></A>4.11 <U>Intellectual Property</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Section 4.11(a) of the Public Company Disclosure Schedule sets forth a true, correct and complete list of all Patents, Copyright
registrations, Trademark registrations, applications for Trademark registration, material unregistered Trademarks, Design registrations and applications for Design registration, and Internet domain names owned (in whole or in part) by or exclusively
licensed to Public Company or any of its Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) (i) Public Company and its Subsidiaries (A)&nbsp;solely own all Intellectual
Property owned or purported to be owned by Public Company or any of its Subsidiaries and (B)&nbsp;possess, hold or have obtained valid and enforceable licenses or other rights under all other Intellectual Property necessary to operate the business
of Public Company in the manner now operated and as currently proposed to be operated by it as disclosed in the Registration Statement and Prospectus, except, in each case of (A)&nbsp;and (B), as such failure to own or obtain such licenses would
not, individually or in the aggregate, reasonably be expected to result in a Public Company Material Adverse Effect; (ii)&nbsp;none of the Intellectual Property owned by, exclusively licensed to, or to the Knowledge of Public Company, otherwise
licensed to or used by, Public Company and its Subsidiaries </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(collectively, the &#147;<U>Public Company Intellectual Property</U>&#148;) has been adjudged invalid or unenforceable, in whole or in part; (iii)&nbsp;to the Knowledge of Public Company, no
third party is infringing, misappropriating, or otherwise violating any Public Company Intellectual Property, except, where such infringement, misappropriation or other violation would not, individually or in the aggregate, reasonably be expected to
result in a Public Company Material Adverse Effect; (iv)&nbsp;since January&nbsp;1, 2020 to the date of this Agreement, to the Knowledge of Public Company, there has been no actual or threatened action, suit, proceeding or claim by others
challenging the validity, enforceability or scope of, or challenging Public Company&#146;s ownership of or rights in or to, any Public Company Intellectual Property, and Public Company is not aware of any facts or circumstances that would render any
Public Company Intellectual Property invalid or unenforceable by Public Company or one of its Subsidiaries, or of inadequate scope to protect the interests of Public Company in conducting its business, except in each case, as would not, individually
or in the aggregate, reasonably be expected to result in a Public Company Material Adverse Effect; (v)&nbsp;since January&nbsp;1, 2020 to the date of this Agreement, to the Knowledge of Public Company, there has been no actual, or threatened action,
suit, proceeding or claim by a third party alleging that Public Company or any of its Subsidiaries infringes, misappropriates, or otherwise violates, any Intellectual Property of third parties, and Public Company has not received any notice
alleging, or is otherwise aware of, any facts or circumstances that would give rise to such an action, proceeding or claim, except, in each case, where such infringement, misappropriation or other violation would not, individually or in the
aggregate, reasonably be expected to result in a Public Company Material Adverse Effect; (vi)&nbsp;Public Company has taken all reasonable steps to protect, maintain and safeguard the Public Company Intellectual Property, including the execution of
appropriate nondisclosure, confidentiality agreements and invention assignment agreements and invention assignments with their directors, officers, employees, contractors and other agents and since January&nbsp;1, 2020 to the date of this Agreement,
to the Knowledge of Public Company, no such individual is in or has been in violation of any term of such nondisclosure, confidentiality agreements and invention assignment agreements; and (vii)&nbsp;since January&nbsp;1, 2020 to the date of this
Agreement, to the Knowledge of Public Company, no material technology employed by Public Company or its Subsidiaries has been obtained or is being used by Public Company or its Subsidiaries in violation of any contractual or legal obligation binding
on Public Company or its Subsidiaries or any of its officers, directors or employees, which violation relates to the breach of a confidentiality obligation, obligation to assign Intellectual Property to a previous employer or obligation otherwise
not to use the Intellectual Property of a third party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) To the Knowledge of Public Company, the material information technology
systems of Public Company and its Subsidiaries are adequate for their respective businesses as currently conducted in all material respects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_56"></A>4.12 <U>Contracts</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Section 4.12(a) of Public Company Disclosure Schedule lists the following agreements in effect as of the date of this Agreement (each a
&#147;<U>Public Company Contract</U>&#148;) to which Public Company or any of its Subsidiaries is a party as of the date of this Agreement and which contains any remaining material rights or obligations: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) any agreement (or group of related agreements)&nbsp;(A) which calls for performance over a period of more than one year, (B)&nbsp;which
involves more than the sum of $500,000, (C) in which Public Company or any of its Subsidiaries has granted &#147;most favored nation&#148; pricing provisions or exclusive marketing or distribution rights or has agreed to purchase goods or services
exclusively from a certain party, (D)&nbsp;which limits the freedom of Public Company or its Subsidiaries to engage in any line of business or compete with any Person or (E)&nbsp;which contains any
<FONT STYLE="white-space:nowrap">non-solicitation</FONT> provision, in each case, except for restrictions that would not materially affect the ability of Public Company and its Subsidiaries to conduct its business, in each case, that is not
terminable by Public Company or its Subsidiaries, as applicable, on 90 days&#146; notice or less; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) any agreement relating to the
disposition or acquisition of material assets or any ownership interests in any Person, in each case, involving payments in excess of $500,000, other than agreements in which </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the applicable acquisition or disposition has been consummated and there are no material ongoing liabilities or obligations; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) any agreement providing for any material royalty, milestone or similar payments by Public Company or its Subsidiaries; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) any agreement concerning the establishment or operation of a partnership, joint venture or limited liability company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) any agreement (or group of related agreements) under which Public Company or any of its Subsidiaries has created, incurred, assumed or
guaranteed (or may create, incur, assume or guarantee) material Indebtedness (including capitalized lease obligations) or under which it has imposed (or may impose) a Lien (other than Permitted Liens) on any of its assets, tangible or intangible;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) any agreement for the disposition of any material assets or business of Public Company or any of its Subsidiaries or any agreement
for the acquisition of material assets or business of any other Person (other than purchases of inventory or components in the Ordinary Course of Business); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii) any noncompetition agreement restricting Public Company or any of its Subsidiaries from competing in any line of business or
jurisdiction; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(viii) any written employment agreement or consulting agreement that is not on Public Company&#146;s standard form of
employment agreement or consulting agreement, each of which has been previously made available to Merger Partner (excluding employment agreements that are terminable &#147;at will&#148; without the payment of severance or other amounts upon
termination, and consulting agreements which are terminable on 30 days or less notice without the payment of additional consideration); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ix) any agreement providing for severance, retention, change in control payments, or transaction-based bonuses or incentives; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(x) any material settlement agreement or agreement that includes the admission of wrongdoing by Public Company or any of its Subsidiaries or
any of their respective officers or directors; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xi) any agreement with respect to an interest rate, currency or other swap or derivative
transaction (other than those solely between Public Company or any of its Subsidiaries); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xii) any agreement between Public Company or
any of its Subsidiaries, on the one hand, and any director, officer or employee of Public Company or any of its Subsidiaries or any Person beneficially owning five percent or more of the outstanding Public Company Common Stock or any of their
respective Affiliates, on the other hand; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xiii) except as set forth in the Organizational Documents of Public Company or in Public
Company&#146;s standard form of Public Company RSU grant agreement, any agreement that contains a put, call or similar right pursuant to which Public Company or any of its Subsidiaries or after the Merger Partner Merger Effective Time, Merger
Partner or any of its Subsidiaries or Affiliates, could be required to purchase or sell, as applicable, in a single transaction or series of transactions, (A)&nbsp;any equity interests of any Person or (B)&nbsp;any asset or group of related assets
that have a fair market value or purchase price of more than $500,000 individually or in the aggregate; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xiv) any agreement relating to
royalty, dividend or similar arrangement to be paid, or received, by Public Company or any of its Subsidiaries that is based on the revenue or profits of Public Company or any of its Subsidiaries or any material agreement involving fixed price or
fixed volume arrangements; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xv) any agreement under which the consequences of a default or termination would not,
individually or in the aggregate, reasonably be expected to result in a Public Company Material Adverse Effect; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xvi) any agreement
under which Public Company or any of its Subsidiaries has (A)&nbsp;granted a license, sublicense, covenant not to sue or assert, immunity from suit, right to coexist or other right under any Intellectual Property to any other Person;
(B)&nbsp;received from any other Person a grant of a license, sublicense, covenant not to sue or assert, immunity from suit, right to coexist or other right under any Intellectual Property (other than licenses to any shrink wrap, click wrap or other
software that is generally commercially available and not customized costing less than $50,000 per year or as a <FONT STYLE="white-space:nowrap">one-time</FONT> fee); (C) assigned any rights under any Intellectual Property to any other Person; or
(D)&nbsp;received an assignment of any rights under Intellectual Property from any Person (other than assignments from employees on the form assignment agreement used by Public Company with such employees); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xvii) any other agreement (or group of related agreements) that is material to Public Company and its Subsidiaries, taken as a whole,
including any material contacts (as defined in Item 601(b)(10) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> as promulgated under the Securities Act). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Public Company has made available to Merger Partner a complete and accurate copy of each Public Company Contract (as amended to date) as
of the date of this Agreement. With respect to each Public Company Contract: (i)&nbsp;Public Company Contract is legal, valid, binding and enforceable and in full force and effect against Public Company or the Subsidiary that is the party thereto,
as applicable, and, to Public Company&#146;s Knowledge, against each other party thereto; (ii)&nbsp;Public Company Contract will continue to be legal, valid, binding and enforceable and in full force and effect against Public Company or the
Subsidiary that is the party thereto, as applicable, and, to Public Company&#146;s Knowledge, against each other party thereto immediately following the Closing in accordance with the terms thereof as in effect immediately prior to the Closing; and
(iii)&nbsp;neither Public Company or Subsidiary nor, to the Knowledge of Public Company, any other party, is in breach or violation of, or default under, any such Public Company Contract, and no event has occurred, is pending or, to the Knowledge of
Public Company, is threatened, which, after the giving of notice, with lapse of time, or otherwise, would constitute any such breach or default by Public Company, any Subsidiary or, to the Knowledge of Public Company, any other party under such
Public Company Contract, in each case, where any such breach or violation would not, individually or in the aggregate, reasonably be expected to result in a Public Company Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_57"></A>4.13 <U>Litigation</U>. As of the date hereof, there is no Legal Proceeding pending or, to the Knowledge of
Public Company, threatened with respect to,(A) against or affecting (i)&nbsp;Public Company or any Subsidiary of Public Company, (ii)&nbsp;or any current or former officer, director, employee, consultant, agent or member of any of the foregoing in
its, his or her capacity as such, or (iii)&nbsp;any of the material assets owned or used by Public Company and its Subsidiaries and (B)&nbsp;no notice of any Legal Proceeding involving or relating to Public Company or any of its Subsidiaries,
whether pending or threatened, has been received by Public Company or any of its Subsidiaries, in each case as would not, individually or in the aggregate, reasonably be expected to result in a Public Company Material Adverse Effect or that would
have the effect of preventing, delaying beyond the Outside Date, or making illegal, the Transactions (including the Mergers). As of the date of this Agreement, there are no material judgments, orders, injunctions, decrees, stipulations or awards
(whether rendered by a court, administrative agency or other Governmental Entity, by arbitration or otherwise) against or involving Public Company or any Subsidiary of Public Company. As of the date of this Agreement, there is no material Legal
Proceeding by Public Company or any Subsidiary of Public Company, or which Public Company or any Subsidiary of Public Company has commenced preparations to initiate, against any other Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.14 <U>Environmental Matters</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Since January&nbsp;1, 2020, Public Company and its Subsidiaries have complied with all applicable Environmental Laws except as would not,
individually or in the aggregate, reasonably be expected to result in a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Public Company Material Adverse Effect. There is no pending or, to the Knowledge of Public Company, threatened material Legal Proceeding relating to any Environmental Law involving Public Company
or any Subsidiary of Public Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) To the Knowledge of Public Company, neither Public Company nor any Subsidiary of Public Company
has any material liabilities or material obligations arising from the release or threatened release of any Materials of Environmental Concern into the environment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Neither Public Company nor any Subsidiary of Public Company is a party to or bound by any court order, administrative order, consent order
or other agreement between Public Company or any Subsidiary of Public Company and any Governmental Entity entered into in connection with any material legal obligation or material liability arising under any Environmental Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Public Company has no Knowledge of any material environmental liability relating to any solid or hazardous waste transporter or treatment,
storage or disposal facility that has been used by Public Company or any Subsidiary of Public Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.15 <U>Labor and Employment</U>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Public Company has made available to Merger Partner a true and correct list of all current Public Company Employees as of the date of
this Agreement. Each such current Public Company Employee is retained <FONT STYLE="white-space:nowrap">at-will</FONT> and none of such current Public Company Employees is a party to a written employment agreement or contract with Public Company or
any of its Subsidiaries contradicting their <FONT STYLE="white-space:nowrap">at-will</FONT> employment. Each current Public Company Employee has entered into Public Company&#146;s or such Subsidiary&#146;s standard form of confidentiality, <FONT
STYLE="white-space:nowrap">non-competition</FONT> and assignment of inventions agreement, a copy of which has previously been delivered to Merger Partner. All of the agreements referenced in the preceding sentence will continue to be in full force
and effect immediately following the Closing in accordance with the terms thereof as in effect immediately prior to the Closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)
Since January&nbsp;1, 2020, neither Public Company nor any Subsidiary of Public Company has breached or violated any (i)&nbsp;applicable Law respecting employment and employment practices, terms and conditions of employment and wages and hours,
including any such Law respecting employment discrimination, employee classification (for overtime purposes or as employee versus independent contractor), workers&#146; compensation, family and medical leave, the Immigration Reform and Control Act
and occupational safety and health requirements, or (ii)&nbsp;employment or other individual service provider agreement, in each case except as would not, individually or in the aggregate, reasonably be expected to be material to Public Company and
its Subsidiaries, taken as a whole. As of the date hereof, no material claims, controversies, investigations, audits or other Legal Proceedings are pending or, to the Knowledge of Public Company, threatened, with respect to such Laws or agreements,
either by private Persons or by Governmental Entities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Neither Public Company nor any Subsidiary of Public Company is a party to or
bound by any collective bargaining agreement, nor has either of them experienced any actual or, to the Knowledge of Public Company, threatened strikes, grievances, claims of unfair labor practices or other collective bargaining disputes. Public
Company has no Knowledge of any material organizational effort made or threatened (including the filing of a petition for certification) either currently or within the past two (2)&nbsp;years, by or on behalf of any labor union with respect to
Public Company Employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Public Company has made available to Merger Partner a true and correct list of all consultants and
independent contractors as of the date of this Agreement engaged by or for the benefit of Public Company or its Subsidiaries. Each such consultant or independent contractor is or was a party to a written agreement or contract with Public Company or
its Subsidiaries. Public Company and its Subsidiaries have not incurred, and, to the Knowledge of Public Company, no circumstances exist under which Public Company and its Subsidiaries could </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reasonably be expected to incur, any material liability arising from the misclassification of employees as consultants or independent contractors, or from the misclassification of consultants or
independent contractors as employees. Each such consultant and independent contractor has entered into Public Company&#146;s standard form of confidentiality and assignment of inventions agreement with Public Company, a copy of which has previously
been made available to Merger Partner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) As of the date hereof, no charges or complaints are open and pending against Public Company or
any of its Subsidiaries with the Equal Employment Opportunity Commission, the OFCCP, or similar Governmental Entity or pursuant to internal complaint procedures, and, to the Knowledge of Public Company, as of the date hereof no current or former
employee of Public Company or any of its Subsidiaries has made, during the last twelve (12)&nbsp;months, an oral or, during the last three years, a written complaint of discrimination, retaliation or other similar wrongdoing. True, correct and
complete information regarding any closed charges or complaints filed since December&nbsp;31, 2020 through the date of this Agreement with the Equal Employment Opportunity Commission, the OFCCP or similar Governmental Entity (or, with respect to
discrimination, retaliation, or similar wrongdoing, pursuant to internal complaint procedures) has been made available to Merger Partner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Since January&nbsp;1, 2020, neither Public Company nor any of its Subsidiaries has caused (i)&nbsp;a plant closing as defined in the WARN
Act affecting any site of employment or one or more operating units within any site of employment of Public Company or any of its Subsidiaries or (ii)&nbsp;a mass layoff as defined in the WARN Act, nor has Public Company or any of its Subsidiaries
been affected by any transaction or engaged in layoffs or employment terminations sufficient in number to trigger application of any similar foreign, state or local Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.16 <U>Employee Benefit Plans</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Section 4.16(a) of Public Company Disclosure Schedule contains a complete and accurate list of all material Public Company Benefit Plans.
Complete and accurate copies of (i)&nbsp;all Public Company Benefit Plans which have been reduced to writing, together with all amendments thereto, (ii)&nbsp;written summaries of all material unwritten Public Company Benefit Plans, (iii)&nbsp;all
related trust agreements, insurance contracts, and most recent summary plan description together with the summary or summaries of material modifications thereto, (iv)&nbsp;the most recently filed annual report on IRS Form 5500 and all schedules
thereto and (for all funded plans) all plan financial statements for the last plan year for each Public Company Benefit Plan, (v)&nbsp;all reports regarding the satisfaction of the nondiscrimination requirements of Sections 410(b), 401(k), and
401(m) of the Code for the past year, (vi)&nbsp;the most recent determination letter or opinion letter issued by the Internal Revenue Service with respect to any Public Company Benefit Plan intended to be qualified under Section&nbsp;401(a) of the
Code, and (vii)&nbsp;any material written or electronic communications from or to the Internal Revenue Service, the DOL or any other Governmental Entity received in the three (3)&nbsp;year period preceding the date of this Agreement with respect to
a Public Company Benefit Plan (including any voluntary correction submissions), have been delivered or made available to Public Company. No Public Company Benefit Plan is or has been subject to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Law.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Neither Public Company, any of its Subsidiaries, nor any of their respective ERISA Affiliates sponsors, maintains or contributes to
or in the last six years has sponsored, maintained, contributed to or been required to contribute to, or has (or is reasonably expected to have) any material current or contingent liability with respect to any (i) &#147;employee pension benefit
plan,&#148; as defined in Section&nbsp;3(2) of ERISA, that is subject to Title IV or Section&nbsp;302 of ERISA or Section&nbsp;412 of the Code, (ii)&nbsp;a &#147;multiemployer plan&#148; within the meaning of Section&nbsp;4001(a)(3) of ERISA, or
(iii)&nbsp;a &#147;multiple employer plan&#148; subject to Sections 4063 or 4064 of ERISA or Section&nbsp;413(c) of the Code. No liability under Section&nbsp;302 or Title IV of ERISA or Section&nbsp;412 of the Code has been incurred by Public
Company, any of its Subsidiaries or any of their respective ERISA Affiliates that has not been satisfied in full. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Each Public Company
Benefit Plan has been administered in all material respects in accordance with its terms and each of Public Company, its Subsidiaries and its ERISA Affiliates has met its obligations in all </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
material respects with respect to each Public Company Benefit Plan and has timely made all required contributions, premiums and other payments thereto, in each case in all material respects.
Public Company, its Subsidiaries, each of its ERISA Affiliates and each Public Company Benefit Plan are in compliance in all material respects with the currently applicable provisions of ERISA and the Code (including Section&nbsp;409A of the Code)
and the regulations thereunder. Each Public Company Benefit Plan that is intended to be qualified under Section&nbsp;401(a) of the Code has been determined by the IRS to be qualified under Section&nbsp;401(a) of the Code and, no fact or event has
occurred that would adversely affect the qualification or tax exemption of any such Public Company Benefit Plan. There is no legally binding commitment to create any additional Public Company Benefit Plans or to modify any existing Public Company
Benefit Plans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) There are no Legal Proceedings (except claims for benefits payable in the normal operation of Public Company Plans and
proceedings with respect to qualified domestic relations orders) against or involving any Public Company Benefit Plan or asserting any rights or claims to benefits under any Public Company Benefit Plan that could give rise to any material liability.
No Public Company Benefit Plan is or within the last three (3)&nbsp;calendar years has been the subject of, or has received or provided notice that it is the subject of, examination by a Governmental Entity or a participant in a government sponsored
amnesty, voluntary compliance or similar program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The execution and delivery of this Agreement and the consummation of the
Transactions will not, either alone or in combination with another event, (A)&nbsp;entitle any current or former employee, director, officer or independent contractor of Public Company or any of its Subsidiaries to severance pay, retention bonuses, <FONT
STYLE="white-space:nowrap">non-competition</FONT> payments or any other material compensatory payment, (B)&nbsp;accelerate the time of payment or vesting, or increase the amount of compensation due to any such employee, director, officer or
independent contractor, or (C)&nbsp;directly or indirectly require Public Company to transfer or set aside any assets to fund any material benefits under any Public Company Benefit Plan. No director, officer, employee or other service provider of
Public Company or any of its Subsidiaries is entitled to a gross up, make whole or other similar payment as a result of the imposition of Taxes under Section&nbsp;4999 or Section&nbsp;409A of the Code pursuant to any agreement or arrangement with
Public Company or any of its Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_58"></A>4.17 <U>Compliance with Laws</U>. Each of Public Company and
its Subsidiaries, to the Knowledge of Public Company, has since January&nbsp;1, 2020 conducted, and is conducting, its business and operations in compliance in all material respects with all applicable Laws. Since January&nbsp;1, 2020, neither
Public Company nor any Subsidiary, to the Knowledge of Public Company, has received any notice or other communication from any Governmental Entity or other Person alleging any material noncompliance with any applicable Law. To the Knowledge of
Public Company, neither Public Company nor any Subsidiary has any material liability for failure to comply with any Law and, to the Knowledge of Public Company, there is no act, omission, event or circumstance that would reasonably be expected to
give rise to any such liability. Neither Public Company nor any Subsidiary has conducted any internal investigation with respect to any actual, potential or alleged violation of any Law by any manager, member or other equity holder, officer or
Public Company Employee or concerning any actual or alleged Fraud. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_59"></A>4.18 <U>Unlawful Payments</U>. Since
January&nbsp;1, 2020, Public Company and its Subsidiaries are and have been in compliance in all material respects with all Anti-Bribery Laws. Since January&nbsp;1, 2020, neither Public Company nor any Subsidiary has received any written
communication from any Governmental Entity that alleges that Public Company or any of its Subsidiaries, or any current or former Representatives thereof, is or may be in violation of, or has, or may have, any liability under, any Anti-Bribery Laws,
and no such actual or potential violation of Anti-Bribery Laws has been discovered by or brought to the attention of Public Company or any of its Subsidiaries since January&nbsp;1, 2020. Since January&nbsp;1, 2020, neither Public Company nor any of
its Subsidiaries has made or anticipates making any disclosures to any Governmental Entity for potential violations of Anti-Bribery Laws. To Public Company&#146;s Knowledge, none of Public Company and its Subsidiaries&#146; current or former
Representatives is currently an officer, agent or employee of a Governmental Entity. Neither Public Company nor any Subsidiary nor any of their respective current or former Representatives has directly or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
indirectly offered, given, reimbursed, paid or promised to pay, or authorized the payment of, any money or other thing of value (including any fee, gift, sample, travel expense or entertainment)
or any commission payment payable to (a)&nbsp;any Person who is an official, officer, agent, employee or representative of any Governmental Entity or of any existing or prospective customer (whether or not owned by a Governmental Entity), (b) any
political party or official thereof or (c)&nbsp;any candidate for political or political party office, in each case while knowing or having reason to believe that all or any portion of such money or thing of value would be offered, given,
reimbursed, paid or promised, directly or indirectly, for purposes not allowable under the Anti-Bribery Laws, to any such official, officer, agent, employee, representative, political party, political party official, candidate, individual affiliated
with any such customer, political party or official or political office. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_60"></A>4.19 <U>Permits</U>. Each of
Public Company and its Subsidiaries owns or holds all material Permits that are required for Public Company and its Subsidiaries, respectively, to conduct their business as presently conducted or as proposed to be conducted. Each such Permit is in
full force and effect. Public Company or the applicable Subsidiary, as the case may be, is in compliance in all material respects with the terms of each such Permit; and, as of the date of this Agreement, to the Knowledge of Public Company, no
suspension or cancellation of such Permit is threatened and, to the Knowledge of Public Company, there is no basis for believing that such Permit will not be renewable upon expiration, other than in the Ordinary Course of Business. Each such Permit
will continue in full force and effect immediately following the Closing. Public Company has made available to Merger Partner all such Permits as of the date of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_61"></A>4.20 <U>Insurance</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Public Company has made available to Merger Partner a true and complete list, as of the date of this Agreement, all material insurance
policies (including fire, theft, casualty, comprehensive general liability, workers compensation, business interruption, environmental, director and officer liability, product liability and automobile insurance policies and bond and surety
arrangements) to which Public Company or any of its Subsidiaries is a party, a named insured or otherwise the beneficiary of coverage (the &#147;<U>Public Company Insurance Policies</U>&#148;), all of which are in full force and effect. The Public
Company Insurance Policies are of the type and in the amounts customarily carried by organizations conducting businesses or owning assets similar to those of Public Company. There is no material claim pending under the Public Company Insurance
Policies as to which coverage has been questioned, denied or disputed by the underwriter of such policy. All premiums due and payable under all of the Public Company Insurance Policies have been paid, and, to the Knowledge of Public Company, neither
Public Company nor any Subsidiary may be liable for retroactive premiums or similar payments, and Public Company and its Subsidiaries are otherwise in compliance with the terms of the Public Company Insurance Policies in all material respects.
Public Company has no Knowledge of any threatened termination of, or premium increase with respect to, any of the Public Company Insurances Policies. Each Public Company Insurance Policy will continue to be enforceable and in full force and effect
immediately following the Closing in accordance with the terms thereof as in effect immediately prior to the Closing. There is no material claim by Public Company or any of its Subsidiaries pending under any Public Company Insurance Policy in favor
of Public Company and its Subsidiaries that has been denied or disputed by the insurer other than denials and disputes in the Ordinary Course of Business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Section 4.20(b) of Public Company Disclosure Schedule identifies all claims asserted by Public Company pursuant to any Public Company
Insurance Policy since December&nbsp;31, 2019 and describes the nature and status of each such claim. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_62"></A>4.21 <U>Cybersecurity and Privacy</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Each of Public Company and its Subsidiaries comply, and have complied, in all material respects with all: (i)&nbsp;applicable Privacy
Laws; (ii)&nbsp;policies, statements, and contractual obligations relating to the receipt, collection, compilation, use, storage, processing, sharing, safeguarding, security, disposal, destruction, disclosure, or transfer of Personal Information of
Public Company and its Subsidiaries; and (iii)&nbsp;all applicable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
industry standards including, without limitation, PCI DSS, and all other applicable requirements of the payment card brands (clauses (i)-(iii) of this Section&nbsp;4.21(a)) collectively, the
&#147;<U>Public Company Privacy Requirements</U>&#148;). The consummation of any of the Transactions will not violate any applicable Public Company Privacy Requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Public Company and its Subsidiaries have taken all organizational, physical, administrative, and technical measures required by the Public
Company Privacy Requirements and consistent with standards prudent in the industry in which Public Company and its Subsidiaries operate to protect: (i)&nbsp;the integrity, security, and operations of all Public Company IT Systems; and (ii)&nbsp;all
Personal Information and all other data owned, controlled, or stored by Public Company and its Subsidiaries from and against data security incidents or other misuse. In connection with each third party servicing, outsourcing, hosting or otherwise
processing Personal Information collected, held, or processed by or on behalf of Public Company and its Subsidiaries, Public Company and its Subsidiaries has in accordance with Public Company Privacy Requirements entered into valid, binding and
enforceable written data processing agreements with any such third party that ensures appropriate protection for Personal Information. None of Public Company and its Subsidiaries sells, rents or otherwise makes available, or permits any third party
to, sell, rent or otherwise make available, to any Person any Personal Information, except as stated in the applicable privacy policies and in compliance with Privacy Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) There have been no actual or suspected data security incidents, data breaches, ransomware incidents, or other adverse events or incidents
related to any Public Company IT Systems, Personal Information, or data in the custody or control of Public Company or its Subsidiaries or any third party acting on behalf of Public Company or its Subsidiaries. Public Company and its Subsidiaries
have not been subject to any claims or proceedings related to any data security incidents, ransomware incidents, or any violations of any Public Company Privacy Requirements, and there are no facts or circumstances which could reasonably serve as
the basis for any such allegations or claims. Public Company and its Subsidiaries have taken commercially reasonable steps to provide for archival, <FONT STYLE="white-space:nowrap">back-up,</FONT> recovery and restoration of its material business
data. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Public Company and its Subsidiaries own or have a valid right to access and use all Public Company IT Systems. To Public
Company&#146;s Knowledge, the Public Company IT Systems do not contain any viruses, worms, Trojan horses, bugs, faults or other devices, errors, contaminants or effects that are designed to (A)&nbsp;disrupt or adversely affect the functionality of
any Public Company IT Systems or (B)&nbsp;enable or assist any Person to access without authorization any Public Company IT Systems. The Public Company IT Systems have not materially malfunctioned or failed within the past two years. Public Company
and its Subsidiaries have taken reasonable, and to ensure the continued, uninterrupted, and error-free operation of the Public Company IT Systems. No Person has gained unauthorized access to any Public Company IT Systems. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_63"></A>4.22 <U>Brokers</U>. No broker, finder or investment banker is entitled to any brokerage, finder&#146;s or
other fee or commission based upon arrangements made by or on behalf of Public Company or Merger Subsidiary respect of any of the Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_64"></A>4.23 <U>Transactions with Affiliates</U>. Except as set forth in the Public Company SEC Reports filed prior
to the date of this Agreement, since December&nbsp;31, 2021, no event has occurred that would be required to be reported by Public Company pursuant to Item 404 of Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_65"></A>4.24 [Reserved]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_66"></A>4.25 <U>Nasdaq Market Quotation</U>. As of the date of this Agreement, the issued and outstanding shares of
Public Company Common Stock are registered pursuant to Section&nbsp;12(b) of the Exchange Act and are listed for trading on the Nasdaq under the symbol &#147;CLXT.&#148; As of the date of this Agreement, Public Company is in compliance in all
material respects with the rules of the Nasdaq and there is no action or proceeding pending or, to the Knowledge of Public Company threatened, against Public Company by the Nasdaq, the Financial Industry
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Regulatory Authority or the SEC with respect to any intention by such entity to deregister the Public Company Common Stock or terminate the listing of Public Company Common Stock on the Nasdaq.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_67"></A>4.26 <U>No Shareholder Rights Plan; No Antitakeover Law</U>. As of the date of this Agreement, no
&#147;fair price,&#148; &#147;moratorium,&#148; &#147;control share acquisition&#148; or other anti-takeover statute or similar domestic or foreign Law applies with respect to Public Company or any of its Subsidiaries in connection with this
Agreement, the Mergers, the issuance of the Merger Consideration or any of the other Transactions. There is no stockholder rights plan, &#147;poison pill&#148; or similar anti-takeover agreement or plan in effect to which Public Company or any of
its Subsidiaries is subject, party or otherwise bound which will be triggered by the execution and delivery of this Agreement or the Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_68"></A>4.27 <U>Valid Issuance</U>. The Public Company Class&nbsp;A Common Stock and Public Company Class&nbsp;B
Common Stock to be issued in the Mergers will, when issued in accordance with the provisions of this Agreement, be validly issued, fully paid and nonassessable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_69"></A>4.28 <U>No Other Representations and Warranties</U>. Except as previously set forth in this Article&nbsp;IV
or in any certificate delivered by Public Company or Merger Subsidiary to Merger Partner pursuant to this Agreement or otherwise in the case of Fraud, neither Public Company nor Merger Subsidiary makes any representation or warranty, express or
implied, at law or in equity, with respect to it or any of its assets, liabilities or operations, and any such other representations or warranties are hereby expressly disclaimed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_70"></A>4.29 <U>Reliance</U>. Public Company acknowledges that, except for the representations and warranties
contained in Article III, none of Merger Partner, any Blocker or any other Person has made, and Public Company has not relied on, any other express or implied representation or warranty by or on behalf of Merger Partner, any Blocker or any other
Person. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="annexarom401831_71"></A>ARTICLE V </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">PRE-CLOSING</FONT> COVENANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_72"></A>5.1 <U>Operation of Merger Partner</U><U>&#146;</U><U>s Business</U>. Except as contemplated by this
Agreement, in connection with implementing the Transactions in a manner consistent with this Agreement, as set forth on Section&nbsp;5.1 of Merger Partner Disclosure Schedule or as required by applicable Law (including any <FONT
STYLE="white-space:nowrap">COVID-19</FONT> Measures), during the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Period, without the written consent of Public Company (which consent shall not be unreasonably withheld, conditioned or delayed),
Merger Partner shall use commercially reasonable efforts to, and shall cause each Subsidiary to use commercially reasonable efforts to, conduct its operations only in the Ordinary Course of Business and in compliance with all applicable Laws in all
material respects. Without limiting the generality of the foregoing, during the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Period and except as set forth on Section&nbsp;5.1 of Merger Partner Disclosure Schedule or in connection with
implementing the Transactions in a manner consistent with this Agreement, Merger Partner shall not, and shall cause each of its Subsidiaries not to, without the written consent of Public Company (such consent shall not be unreasonably withheld,
conditioned or delayed): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) issue or sell any equity interests in Merger Partner or any options, warrants or rights to acquire any such
equity interests, or declare, accrue, set aside or pay any dividend or make any other distribution in respect of its equity interests, or repurchase or redeem any equity interests in Merger Partner or any Subsidiary; <U>provided</U> that Merger
Partner (i)&nbsp;may issue additional equity interests to Merger Partner Employees, to the extent contemplated in the Allocation Schedule, and (ii)&nbsp;may issue additional Series F Preferred Units in Merger Partner to other Persons for a per unit
cash purchase price of $2.00 and otherwise on terms consistent with the terms and conditions for issuances of Series F Preferred Units in Merger Partner prior to the date of this Agreement (which threshold and minimum subscription price is subject
to adjustment adjusted, as applicable and appropriate, to reflect fully the effect of any reclassification, split, reverse split, distribution (including any distribution of securities convertible into membership units of Merger Partner),
reorganization, recapitalization or other like </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
change with respect to the equity securities of Merger Partner or any securities convertible or exchangeable into or exercisable equity securities of Merger Partner); <U>provided further</U> that
any interests issued to Merger Partner Support Holders to pursuant to clause (i)&nbsp;or (ii) shall be &#147;Subject Units&#148; under the Merger Partner Support Agreement pursuant to documentation reasonably satisfactory to Public Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) split, combine or reclassify any equity interests other than the conversion of preferred units of Merger Partner to voting common units of
Merger Partner as contemplated by the Merger Partner Member Approval and in a manner consistent with the Allocation Schedule; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) create,
incur or assume any Indebtedness (other than (x)&nbsp;interest accrued with respect to Indebtedness outstanding as of the date hereof in accordance with its terms, (y)&nbsp;new Indebtedness for borrowed money not exceeding $5,000,000 in the
aggregate, or (z)&nbsp;Indebtedness payable in connection with leases for equipment); (ii) assume, guarantee, endorse or otherwise agree to be liable (whether directly, contingently or otherwise) for the obligations of any other Person, other than
for Subsidiaries of Merger Partner; or (iii)&nbsp;make any loans, advances or capital contributions to, or investments in, any other Person (other than investments of cash in cash equivalents in the Ordinary Course of Business); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) except as required to comply with applicable Law or pursuant to agreements, plans or arrangements existing on the date hereof,
(i)&nbsp;adopt, enter into, terminate or amend any employment or severance plan, agreement or arrangement, any Merger Partner Plan or any collective bargaining agreement, that in each case, would result in materially increased costs to Merger
Partner or Public Company after the Closing, (ii)&nbsp;increase the compensation or fringe benefits of, or pay any bonus to, any director, officer, employee or consultant, except for increases in compensation consistent with the Ordinary Course of
Business and in no event more than 20&nbsp;percent or that would require disclosure in the Registration Statement after it is filed with the SEC, (iii)&nbsp;amend or accelerate the payment, right to payment or vesting of any compensation or
benefits, including any outstanding equity awards, that in each case, would result in materially increased costs to Merger Partner or Public Company after the Closing, (iv)&nbsp;except as contemplated in any other provision of this
Section&nbsp;5.1(d), pay any material benefit not provided for as of the date of this Agreement under any Merger Partner Plan, or the removal of existing restrictions in any benefit plans or agreements or awards made thereunder, or (v)&nbsp;take any
action to fund any Merger Partner Plan other than the payment of premiums due or contributions owed in the Ordinary Course of Business; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) acquire, sell, lease, <FONT STYLE="white-space:nowrap">in-license,</FONT> <FONT STYLE="white-space:nowrap">out-license,</FONT> abandon,
allow to lapse, agree to coexist with respect to or otherwise dispose of any material assets or property (including any Intellectual Property or any shares or other equity interests in or securities of any Subsidiary or any other Person), in each
case, other than in the Ordinary Course of Business; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) mortgage or pledge any of its material property or material assets or enter into
an agreement that subjects any such material property or material assets to any Lien other than Permitted Liens; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) form any Subsidiary
or acquire any equity interest or other interest in any other Person (other than investments of cash and cash equivalents in the Ordinary Course of Business) or enter into a joint venture with any other Person; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) forgive any loans to any Person, including its employees, officers, directors or Affiliates, other than the settlement of accounts
receivable in the Ordinary Course of Business; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) change the nature or scope of its business being carried on as of the date of this
Agreement in any material respect or commence any new business not being ancillary or incidental to such business; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) change its
accounting methods, principles or practices in any material respect, except insofar as may be required by a generally applicable change in GAAP or applicable Law; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) except as required by applicable Law, make or change any material Tax election, amend
any material Tax Return, change an annual accounting period, enter into any closing agreement, waive or extend any statute of limitations with respect to Taxes, settle or compromise any Tax liability, claim or assessment, or surrender any right to
claim a material refund of Taxes; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) settle any Legal Proceedings involving cash payments by Merger Partner in excess of $1,000,000 in
the aggregate; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) amend its Organizational Documents (other than, for the avoidance of doubt, as contemplated by Section&nbsp;5.16 or
otherwise in connection with implementing the Transactions in a manner consistent with this Agreement); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n) make or commit to make
capital expenditures in excess of $4,000,000 in the aggregate; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o) agree in writing or otherwise to take any of the foregoing actions.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nothing contained in this Agreement shall give Public Company, directly or indirectly, the right to control or direct the operations of
Merger Partner and its Subsidiaries prior to the Merger Partner Merger Effective Time. Prior to the Merger Partner Merger Effective Time, the Merger Partner and its Subsidiaries shall exercise, consistent with the terms and conditions of this
Agreement, complete unilateral control and supervision over its business operations </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_73"></A>5.2 <U>Operation of
Public Company</U><U>&#146;</U><U>s Business</U>. Except as contemplated by this Agreement, in connection with implementing the Transactions in a manner consistent with this Agreement, as set forth on Section&nbsp;5.2 of Public Company Disclosure
Schedule or as required by applicable Law (including any <FONT STYLE="white-space:nowrap">COVID-19</FONT> Measures), during the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Period, without the written consent of Merger Partner (which consent
shall not be unreasonably withheld, conditioned or delayed), Public Company shall use commercially reasonable efforts to, and shall cause each Subsidiary to use commercially reasonable efforts to, conduct its operations only in the Ordinary Course
of Business and in compliance with all applicable Laws in all material respects and take all necessary steps (including timely making all filings required by the SEC) to prepare for the filing of the annual meeting proxy statement (including all
required Form <FONT STYLE="white-space:nowrap">10-K,</FONT> Item III information). Without limiting the generality of the foregoing, during the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Period and except as set forth on Section&nbsp;5.2 of
Public Company Disclosure Schedule, or in connection with implementing the Transactions in a manner consistent with this Agreement, Public Company shall not, and shall cause each Subsidiary not to, without the written consent of Merger Partner (such
consent shall not be unreasonably withheld, conditioned or delayed): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Issue, grant, pledge or sell, or authorize the issuance of, any
equity interests in Public Company or any of its Subsidiaries or any options, warrants or rights to acquire any such equity interests, or other securities or any other instrument convertible into or exchangeable for any equity interests of Public
Company or its Subsidiaries, or declare, accrue, set aside or pay any dividend or make any other distribution in respect of its equity interests, or repurchase or redeem any equity interests in Public Company or any of its Subsidiaries; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) split, combine or reclassify any equity interests, effect any merger, consolidation, share exchange, business combination,
recapitalization or similar transaction other than the Mergers; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) (i) create, incur or assume any Indebtedness (other than interest
accrued with respect to Indebtedness outstanding as of the date hereof in accordance with its terms); (ii) assume, guarantee, endorse or otherwise agree to be liable (whether directly, contingently or otherwise) for the obligations of any other
Person; or (iii)&nbsp;make any loans, advances or capital contributions to, or investments in, any other Person (other than investments of cash in cash equivalents in the Ordinary Course of Business); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) hire, engage or offer to hire any new officers, directors, employees or consultants; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) except as required to comply with applicable Law or pursuant to agreements, plans or
arrangements existing on the date hereof and disclosed in Section&nbsp;5.2 of Public Company Disclosure Schedule, (i)&nbsp;adopt, enter into, terminate or amend any employment or severance plan, agreement or arrangement, any Public Company Benefit
Plan or any collective bargaining agreement, (ii)&nbsp;increase the compensation or fringe benefits of, or pay any bonus to, any director, officer, employee or consultant, (iii)&nbsp;amend or accelerate the payment, right to payment or vesting of
any compensation or benefits, including any outstanding Public Company Stock Options, Public Company RSUs, or Public Company PSUs, (iv)&nbsp;except as contemplated in any other provision of this Section&nbsp;5.2, pay any material benefit not
provided for as of the date of this Agreement under any Public Company Benefit Plan, or the removal of existing restrictions in any benefit plans or agreements or awards made thereunder, or (v)&nbsp;take any action to fund any Public Company Benefit
Plan other than the payment of premiums due or contributions owed in the Ordinary Course of Business; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) acquire, sell, lease, <FONT
STYLE="white-space:nowrap">in-license,</FONT> <FONT STYLE="white-space:nowrap">out-license</FONT> or dispose of any material assets or material property (including any Intellectual Property or any shares or other equity interests in or securities of
any Subsidiary or any other Person), other than in the Ordinary Course of Business; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) mortgage or pledge any of its material property
or material assets or enter into an agreement that subjects any such material property or material assets to any Lien other than Permitted Liens; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) discharge or satisfy any Lien other than in the Ordinary Course of Business or as required by Law or a contract existing on the date of
this Agreement or entered into in compliance with this Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) form any Subsidiary or acquire any equity interest or other
interest in any other Person (other than investments of cash and cash equivalents in the Ordinary Course of Business) or enter into a joint venture with any other Person; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) other than as contemplated by the transactions set forth in this Agreement, amend its Organizational Documents; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) (i) materially change pricing or royalties or other payments set or charged by Public Company or any of its Subsidiaries to its customers
or licensees or (ii)&nbsp;agree to materially change pricing or royalties or other payments set or charged by Persons who have licensed rights to Intellectual Property to Public Company or any of its Subsidiaries; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) accelerate collection of accounts receivable or delay payment of accounts payable, other than in accordance with GAAP; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) forgive any loans to any Person, including its employees, officers, directors or Affiliates, other than the settlement of accounts
receivable in the Ordinary Course of Business; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n) change the nature or scope of its business being carried on as of the date of this
Agreement in any material respect or commence any new business not being ancillary or incidental to such business; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o) change its
accounting methods, principles or practices in any material respect, except insofar as may be required by a generally applicable change in GAAP or applicable Law; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(p) except as required by applicable Law, make or change any material Tax election, amend any material Tax Return, change an annual accounting
period, enter into any closing agreement, waive or extend any statute of limitations with respect to Taxes, settle or compromise any Tax liability, claim or assessment, or surrender any right to claim a material refund of Taxes; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(q) make or commit to make any capital expenditure in excess of $25,000 per item or $50,000 in the aggregate; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(r) institute or settle any Legal Proceeding (other than to enforce the terms of this
Agreement and the other agreements relating to the transaction or otherwise in accordance with Section&nbsp;7.4); or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(s) agree in writing
or otherwise to take any of the foregoing actions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_74"></A>5.3 <U>Operation of Blockers</U>. During the <FONT
STYLE="white-space:nowrap">Pre-Closing</FONT> Period and except (a)&nbsp;as set forth on Section&nbsp;5.3 of Merger Partner Disclosure Schedule, (b)&nbsp;in connection with implementing the Transactions in a manner consistent with this Agreement,
(c)&nbsp;the distribution of cash or other liquid amounts held by such Blocker as of the date of this Agreement or received by such Blocker in a Merger Partner distribution permitted under Section&nbsp;5.1, (d) in the Ordinary Course of Business, or
(e)&nbsp;as required by the terms of this Agreement, each Blocker shall not, without the written consent of Public Company (such consent shall not be unreasonably withheld, conditioned or delayed) conduct any business, take any action or enter into,
amend or terminate any agreement or commitment. Further, during the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Period, each Blocker, to the extent it has not already done so, shall file all Tax Returns due on or prior to the Closing Date
and pay all Taxes reasonably owing in connection with such Tax Returns. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_75"></A>5.4 <U>Public Company No
Solicitation</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Public Company agrees that, during the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Period, it shall not,
and shall not authorize any of its Representatives to (and it shall use its reasonable best effort to cause its Representatives not to), directly or indirectly: (i)&nbsp;solicit, initiate or knowingly encourage, induce or facilitate the
communication, making, submission or announcement of any Acquisition Proposal or Acquisition Inquiry or take any action that could reasonably be expected to lead to an Acquisition Proposal or Acquisition Inquiry; (ii)&nbsp;furnish any information
regarding Public Company to any Person for the purpose of encouraging, or in response to, an Acquisition Proposal or Acquisition Inquiry, <U>provided</U> that the foregoing clause (ii)&nbsp;shall not prohibit filings required by applicable
securities Laws, including but not limited to Section&nbsp;15(c) or 15(d) of the Exchange Act, or stock exchange rule, or otherwise directing such Person to Public Company&#146;s SEC filings; (iii)&nbsp;engage in discussions (other than to inform
any Person of the existence of the provisions in this Section&nbsp;5.4) or negotiations with any Person with respect to any Acquisition Proposal or Acquisition Inquiry; (iv)&nbsp;approve, endorse or recommend any Acquisition Proposal (subject to
Section&nbsp;5.9); (v) execute or enter into any letter of intent or any Contract contemplating or otherwise relating to any Acquisition Transaction (other than a confidentiality agreement permitted under this Section&nbsp;5.4(a)); (vi) publicly
propose to do any of the foregoing; or (vii)&nbsp;agree, resolve or commit (or, for the avoidance of doubt, Public Company Board or any committee thereof to resolve, agree or commit) to do any of the foregoing; <U>provided</U>, <U>however</U>, that,
notwithstanding anything contained in this Section&nbsp;5.4 and subject to compliance with this Section&nbsp;5.4, prior to obtaining the Public Company Stockholder Approval, Public Company may furnish
<FONT STYLE="white-space:nowrap">non-public</FONT> information regarding Public Company to, and enter into discussions or negotiations with, any Person in response to an unsolicited bona fide written Acquisition Proposal by such Person, which Public
Company Board determines in good faith, after consultation with Public Company&#146;s outside financial advisors and outside legal counsel, constitutes, or would be reasonably likely to result in, a Superior Offer (and is not withdrawn) if:
(A)&nbsp;neither Public Company nor any of its Representatives shall have materially breached this Section&nbsp;5.4, (B) Public Company Board concludes in good faith based on the advice of outside legal counsel, that the failure to take such action
would be reasonably likely to be inconsistent with the fiduciary duties of Public Company Board under applicable Law; (C)&nbsp;at least two (2)&nbsp;Business Days prior to initially furnishing any such nonpublic information to, or entering into
discussions with, such Person, Public Company gives Merger Partner written notice of the identity of such Person and of Public Company&#146;s intention to furnish nonpublic information to, or enter into discussions with, such Person ; (D) Public
Company receives from such Person an executed confidentiality agreement containing provisions (including <FONT STYLE="white-space:nowrap">non-disclosure,</FONT> use restrictions, <FONT STYLE="white-space:nowrap">non-solicitation</FONT> and <FONT
STYLE="white-space:nowrap">no-hire</FONT> provisions), in the aggregate, at least as favorable to Public Company as those contained in the Confidentiality Agreement; and (E)&nbsp;at least two (2)&nbsp;Business Days prior to furnishing any such <FONT
STYLE="white-space:nowrap">non-public</FONT> information to such Person, Public Company furnishes such <FONT STYLE="white-space:nowrap">non-public</FONT> information to Merger Partner (to the extent such information has not been previously furnished
by Public Company to Merger Partner). Without limiting the generality of the foregoing, Public Company acknowledges </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and agrees that, in the event any Representative of Public Company (whether or not such Representative is purporting to act on behalf of Public Company) takes any action that, if taken by Public
Company, would constitute a breach of this Section&nbsp;5.4, the taking of such action by such Representative shall be deemed to constitute a breach of this Section&nbsp;5.4 by Public Company for purposes of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If Public Company or any Representative of Public Company receives an Acquisition Proposal or Acquisition Inquiry at any time during the <FONT
STYLE="white-space:nowrap">Pre-Closing</FONT> Period, then Public Company shall promptly (and in any event within 24 hours) advise Merger Partner orally and in writing of (i)&nbsp;the receipt of such Acquisition Proposal or Acquisition Inquiry,
(ii)&nbsp;any <FONT STYLE="white-space:nowrap">non-public</FONT> information provided to a Person who has made an Acquisition Proposal or Acquisition Inquiry in response to a request from such Person, (iii)&nbsp;the identity of the Person making or
submitting such Acquisition Proposal or Acquisition Inquiry, and (iv)&nbsp;the material terms thereof as well as complete copies of any written Acquisition Proposals, Acquisition Inquiries or any other written communications from such Person or its
Representatives, including any proposed agreements, and Public Company thereafter shall keep Merger Partner reasonably informed, on a reasonably current basis, with respect to the status and material terms of any such Acquisition Proposal or
Acquisition Inquiry, including informing Merger Partner on a reasonably current basis (and, in any event, within 24 hours) of any material amendment or modification or proposed material amendment or modification to any such Acquisition Proposal or
Acquisition Inquiry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Public Company shall immediately cease and cause to be terminated any existing discussions, negotiations and
communications with any Person that relate to any Acquisition Proposal or Acquisition Inquiry that has not already been terminated as of the date of this Agreement and request the destruction or return of any
<FONT STYLE="white-space:nowrap">non-public</FONT> information of Public Company provided to such Person as soon as practicable after the date of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_76"></A>5.5 <U>Merger Partner <FONT STYLE="white-space:nowrap">Non-Solicitation</FONT></U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Merger Partner agrees that, during the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Period, neither it nor any of its Subsidiaries
shall, nor shall it or any of its Subsidiaries authorize any of their respective Representatives to (and it and each of its Subsidiaries shall use its reasonable best efforts to cause its Representatives not to), directly or indirectly:
(i)&nbsp;solicit, initiate or knowingly encourage, induce or facilitate the communication, making, submission or announcement of any Acquisition Proposal or Acquisition Inquiry or take any action that could reasonably be expected to lead to an
Acquisition Proposal or Acquisition Inquiry; (ii)&nbsp;furnish any information regarding Merger Partner or any of its Subsidiaries to any Person for the purpose of encouraging, or in response to, an Acquisition Proposal or Acquisition Inquiry,
<U>provided</U> that the foregoing shall not prohibit filings required by Law, including but not limited to Section&nbsp;15(c) or 15(d) of the Exchange Act, or stock exchange rule; (iii)&nbsp;engage in discussions (other than to inform any Person of
the existence of the provisions in this Section&nbsp;5.5) or negotiations with any Person with respect to any Acquisition Proposal or Acquisition Inquiry; (iv)&nbsp;approve, endorse or recommend any Acquisition Proposal; (v)&nbsp;execute or enter
into any letter of intent or any Contract contemplating or otherwise relating to any Acquisition Transaction; (vi)&nbsp;publicly propose to do any of the foregoing; or (vii)&nbsp;agree, resolve or commit to do any of the foregoing; <U>provided</U>,
<U>however</U>, that notwithstanding anything contained in this Section&nbsp;5.5 and subject to compliance with this Section&nbsp;5.5, prior to obtaining the Merger Partner Member Approval applicable to it, Merger Partner may furnish <FONT
STYLE="white-space:nowrap">non-public</FONT> information regarding it to, and enter into discussions or negotiations with, any Person in response to an unsolicited bona fide written Acquisition Proposal by such Person, which its board of managers
determines in good faith, after consultation with its outside financial advisors and outside legal counsel, constitutes, or would be reasonably likely to result in, a Superior Offer (and is not withdrawn) if: (A)&nbsp;none of Merger Partner nor any
of its Representatives shall have materially breached this Section&nbsp;5.5; (B) the board of managers of Merger Partner concludes in good faith based on the advice of outside legal counsel, that the failure to take such action would be reasonably
likely to be inconsistent with the fiduciary duties of such board of managers under applicable Law; (C)&nbsp;at least two (2)&nbsp;Business Days prior to initially furnishing any such nonpublic information to, or entering into discussions with, such
Person, Merger Partner gives Public Company written notice of the identity of such Person and of Merger Partner&#146;s intention to furnish nonpublic information to, or enter into discussions with, such Person ; (D) it receives from such Person an
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
executed confidentiality agreement containing provisions (including <FONT STYLE="white-space:nowrap">non-disclosure,</FONT> use restrictions,
<FONT STYLE="white-space:nowrap">non-solicitation</FONT> and <FONT STYLE="white-space:nowrap">no-hire</FONT> provisions), in the aggregate, at least as favorable to it as those contained in the Confidentiality Agreement; and at least two
(2)&nbsp;Business Days prior to furnishing any such <FONT STYLE="white-space:nowrap">non-public</FONT> information to such Person, Merger Partner furnishes such <FONT STYLE="white-space:nowrap">non-public</FONT> information to Public Company (to the
extent such information has not been previously furnished by Merger Partner to Public Company). Without limiting the generality of the foregoing, Merger Partner acknowledges and agrees that, in the event any Representative of it or any of its
Subsidiaries (whether or not such Representative is purporting to act on behalf of it or any of its Subsidiaries) takes any action that, if taken by it, would constitute a breach of this Section&nbsp;5.5, the taking of such action by such
Representative shall be deemed to constitute a breach of this Section&nbsp;5.5 by Merger Partner for purposes of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If
Merger Partner or its Subsidiaries or Representatives receives an Acquisition Proposal or Acquisition Inquiry at any time during the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Period, then it shall promptly (and in any event within 24
hours) advise Public Company orally and in writing of (i)&nbsp;the receipt of such Acquisition Proposal or Acquisition Inquiry, (ii)&nbsp;any <FONT STYLE="white-space:nowrap">non-public</FONT> information provided to a Person who has made an
Acquisition Proposal or Acquisition Inquiry in response to a request from such Person, (iii)&nbsp;the identity of the Person making or submitting such Acquisition Proposal or Acquisition Inquiry, and (iv)&nbsp;the material terms thereof as well as
complete copies of any written Acquisition Proposals, Acquisition Inquiries or any other written communications from such Person or its Representatives, including any proposed agreements, and Merger Partner thereafter shall keep Public Company
reasonably informed, on a reasonably current basis, with respect to the status and material terms of any such Acquisition Proposal or Acquisition Inquiry, including informing Public Company on a reasonably current basis (and, in any event, within 24
hours) of any material amendment or modification or proposed material amendment or modification to any such Acquisition Proposal or Acquisition Inquiry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Merger Partner shall immediately cease and cause to be terminated any existing discussions, negotiations and communications with any
Person that relate to any Acquisition Proposal or Acquisition Inquiry that has not already been terminated as of the date of this Agreement and request the destruction or return of any <FONT STYLE="white-space:nowrap">non-public</FONT> information
of Merger Partner or its Subsidiaries provided to such Person as soon as practicable after the date of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_77">
</A>5.6 <U>Notification of Certain Matters</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) During the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Period, Merger Partner
shall promptly (and in no event later than one (1)&nbsp;Business Day after Merger Partner becomes aware of same) notify Public Company (and, if in writing, furnish copies of any relevant documents) if any of the following occurs: (i)&nbsp;any notice
or other communication is received from any Person alleging that the consent of such Person is or may be required in connection with any of the Transactions; (ii)&nbsp;any Legal Proceeding against or involving or otherwise affecting Merger Partner,
to the Knowledge of Merger Partner, a Blocker or any of their respective Subsidiaries is commenced, or, to the Knowledge of Merger Partner, threatened against Merger Partner, a Blocker or any of their respective Subsidiaries or, to the Knowledge of
Merger Partner, any director or officer of Merger Partner, a Blocker or any of their respective Subsidiaries, (iii)&nbsp;any inaccuracy in any representation or warranty made by it in this Agreement; or (iv)&nbsp;the failure of the Merger Partner
or, to the Knowledge of Merger Partner, any Blocker to comply with any of their respective covenants or obligations in this Agreement; in the case of (iii)&nbsp;and (iv) that will or could reasonably be expected to result in the failure by Merger
Partner or any Blocker to satisfy any of the conditions set forth in Section&nbsp;6.1. Any failure to timely provide a notification under clauses (iii)&nbsp;and (iv) above shall be disregarded for purposes of determining compliance with Section
6.1(c) and for all purposes under Section&nbsp;8.1. No notification given to Public Company pursuant to this Section&nbsp;5.6(a) shall change, limit or otherwise affect any of the representations, warranties, covenants or obligations of Merger
Partner, the Blockers or any of their respective Subsidiaries contained in this Agreement or Merger Partner Disclosure Schedule for purposes of Article VI, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) During the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Period, Public Company shall promptly (and in no event later than one
(1)&nbsp;Business Day after Public Company becomes aware of same) notify Merger Partner (and, if in writing, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
furnish copies of any relevant documents) if any of the following occurs: (i)&nbsp;any notice or other communication is received from any Person alleging that the consent of such Person is or may
be required in connection with any of the Transactions; (ii)&nbsp;any Legal Proceeding against or involving or otherwise affecting Public Company or its Subsidiaries is commenced, or, to the Knowledge of Public Company, threatened against Public
Company or, to the Knowledge of Public Company, any director or officer of Public Company, (iii)&nbsp;any inaccuracy in any representation or warranty made by it in this Agreement; or (iv)&nbsp;the failure of Public Company or Merger Subsidiary to
comply with any of their respective covenants or obligations in this Agreement; in the case of (iii)&nbsp;and (iv) that will or could reasonably be expected to result in the failure by Public Company or Merger Subsidiary to satisfy any of the
conditions set forth in Section&nbsp;6.2. Any failure to timely provide a notification under clauses (iii)&nbsp;and (iv) above shall be disregarded for purposes of determining compliance with Section&nbsp;6.2(c) and for all purposes under
Section&nbsp;8.1. No notification given to Merger Partner pursuant to this Section&nbsp;5.6(b) shall change, limit or otherwise affect any of the representations, warranties, covenants or obligations of Public Company contained in this Agreement or
Public Company Disclosure Schedule for purposes of Article VI, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_78"></A>5.7 <U>Proxy
Statement/Prospectus; Registration Statement</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) As promptly as practical after the execution of this Agreement and contingent upon
receipt from Merger Partner of the information required by the following sentence, Public Company, with the cooperation of Merger Partner, shall prepare and file with the SEC the Registration Statement, in which the Proxy Statement/Prospectus will
be included. Merger Partner shall (i)&nbsp;provide to Public Company as promptly as practical (and in any event by January&nbsp;22, 2023) all information, including financial statements of Merger Partner and its Subsidiaries for the fiscal years
2021 and 2020 and for the interim period ended September&nbsp;30, 2022 and 2021 and descriptions of its business and financial condition, as Public Company may reasonably request for preparation of the Registration Statement and the Proxy
Statement/Prospectus and (ii)&nbsp;cause the timely cooperation of its independent public accountants in connection with the preparation and filing of the Registration Statement and the Proxy Statement/Prospectus, including by causing such
accountants to provide a consent to the inclusion of such accountant&#146;s reports in respect of the audited financial statements of Merger Partner in the Registration Statement and/or in the Proxy Statement/Prospectus (as applicable) and to the
reference to such accountant firm as an &#147;expert&#148; therein. Each Blocker shall provide to Public Company as promptly as practical (and in any event by January&nbsp;22, 2023) all information about itself as Public Company may reasonably
request and which is required to be included in the Registration Statement and the Proxy Statement/Prospectus. Public Company shall respond to any comments of the SEC and shall use reasonable best efforts to have the Registration Statement declared
effective under the Securities Act as promptly as practicable after such filing, and Public Company shall cause the Proxy Statement/Prospectus to be mailed to its stockholders at the earliest practicable time after the Registration Statement is
declared effective under the Securities Act. Public Company shall notify Merger Partner promptly upon the receipt of any comments from the SEC or its staff and of any request by the SEC or its staff for amendments or supplements to the Registration
Statement, the Proxy Statement/Prospectus or any filing pursuant to Section&nbsp;6.2(b) or for additional information and shall promptly supply Merger Partner with copies of all correspondence between Public Company or any of its representatives, on
the one hand, and the SEC, or its staff, on the other hand, with respect to the Registration Statement, the Proxy Statement/Prospectus, the Merger or any filing pursuant to Section&nbsp;5.7(b). Public Company shall use commercially reasonable
efforts to cause all documents that it is responsible for filing with the SEC under this Section&nbsp;5.7 to comply in all material respects with all applicable requirements of Law and the rules and regulations promulgated thereunder. Whenever
either Public Company or Merger Partner shall become aware of the occurrence of any event which is required to be set forth in an amendment or supplement to the Proxy Statement/Prospectus, the Registration Statement or any filing pursuant to
Section&nbsp;6.2(b), Public Company or Merger Partner, as the case may be, shall promptly inform the others of such occurrence and cooperate in filing with the SEC or its staff, and/or mailing to stockholders of Public Company, such amendment or
supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Notwithstanding anything to the contrary stated above, prior to filing and mailing, as applicable, the Registration
Statement or Proxy Statement/Prospectus (or any amendment or supplement thereto) or responding </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to any comments of the SEC with respect thereto, Public Company shall provide Merger Partner and each Blocker a reasonable opportunity to review and comment on such document or response and shall
consider in good faith any such comments proposed by Merger Partner or each Blocker (but only with respect to matters pertaining to such Blocker). Public Company will advise Merger Partner and each Blocker, promptly after Public Company receives
notice thereof, of the time when the Registration Statement has become effective or any supplement or amendment has been filed, of the issuance of any stop order or the suspension of the qualification of Public Company Common Stock for offering or
sale in any jurisdiction, of the initiation or threat of any proceeding for any such purpose, or of any request by the SEC for the amendment or supplement of the Registration Statement or for additional information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Public Company and Merger Partner and, to the extent applicable, the Blockers shall promptly make all necessary filings of such party with
respect to the Mergers and the issuance of the Public Company Class&nbsp;A Common Stock and Public Company Class&nbsp;B Common Stock constituting Merger Consideration under the Securities Act, the Exchange Act, applicable state blue sky laws and the
rules and regulations thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_79"></A>5.8 <U>Nasdaq Listing</U>. Public Company agrees to use its reasonable
best efforts: (a)&nbsp;to maintain its existing listing on Nasdaq and to obtain approval of the listing of the combined corporation on Nasdaq; (b)&nbsp;to the extent required by the rules and regulations of Nasdaq, to prepare and submit to Nasdaq a
notification form for the listing of the shares of Public Company Class&nbsp;A Common Stock to be issued in connection with the Mergers; (c)&nbsp;if not previously implemented, to prepare and timely submit to Nasdaq a notification form of any
reverse stock split effected with the Merger Party&#146;s consent and, to the extent required to effect the foregoing, to submit a copy of the amendment to Public Company&#146;s certificate of incorporation to effect such reverse stock split
certified by the Secretary of State of the State of Delaware to Nasdaq; (d)&nbsp;to the extent required by Nasdaq Listing Rule 5110, to file an initial listing application for the Public Company Class&nbsp;A Common Stock on Nasdaq and to cause such
Nasdaq initial listing application (&#147;<U>Nasdaq Listing Application</U>&#148;) to be approved; and (e)&nbsp;in the event of receipt of a Nasdaq delisting determination, Public Company shall request a hearing to appeal the delisting determination
and shall pay the appropriate fee to Nasdaq to appeal the delisting determination. Public Company shall promptly inform Merger Partner of all material verbal or written communications between Nasdaq and Public Company or its representatives. Public
Company and Merger Partner will use commercially reasonable efforts to coordinate with respect to compliance with Nasdaq rules and regulations. Merger Partner will cooperate with Public Company to cause the Nasdaq Listing Application to be approved
and shall promptly furnish to Public Company all information concerning Merger Partner, the Blockers and their respective equity holders that may be required or reasonably requested in connection with any action contemplated by this
Section&nbsp;5.8. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_80"></A>5.9 <U>Public Company Stockholders</U><U>&#146;</U><U> Meeting</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) As promptly as reasonably practicable after the Registration Statement is declared effective by the SEC, Public Company shall take all
action reasonably necessary under applicable Law to call, give notice of and hold a meeting of the holders of Public Company Common Stock for the purpose of seeking approval of (i)&nbsp;the Blocker Mergers, (ii)&nbsp;the issuance of Public Company
Class&nbsp;A Common Stock and Public Company Class&nbsp;B Common Stock under this Agreement and in accordance with the Nasdaq Listing Rules; (iii)&nbsp;the amendment of Public Company&#146;s Organizational Documents, in the form of the Amended
Certificate and the Amended <FONT STYLE="white-space:nowrap">By-Laws,</FONT> to, among other things, authorize the shares of Public Company Class&nbsp;A Common Stock and Public Company Class&nbsp;B Common Stock to be issued pursuant to this
Agreement in connection with the Mergers and (iv)&nbsp;any other proposals the Parties reasonably deem necessary or desirable to consummate the Transactions (the matters contemplated by the foregoing Sections 5.9(a)(i), (ii) and (iii)&nbsp;are
collectively referred to as the &#147;<U>Public Company Stockholder Matters</U>,&#148; and the matters contemplated by Section&nbsp;5.9(a)(iv) are referred to herein as, the &#147;<U>Other Public Company Stockholder Matters</U>,&#148; and such
meeting, the &#147;<U>Public Company Stockholders</U><U>&#146;</U><U> Meeting</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Public Company will take all necessary
actions to duly call, give notice of, convene and hold the Public Company Stockholders&#146; Meeting as promptly as practicable (but in no event later than sixty (60)&nbsp;days) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
after the Registration Statement is declared effective by the SEC. Absent a Public Company Board Adverse Recommendation Change pursuant to Section&nbsp;5.9(c), Public Company shall use its
reasonable best efforts to solicit the holders of Public Company Common Stock to obtain the Public Company Stockholder Approval. Public Company shall take reasonable measures to ensure that all proxies solicited in connection with Public Company
Stockholders&#146; Meeting are solicited in compliance with all applicable Laws. Notwithstanding anything to the contrary contained herein, if on the date of Public Company Stockholders&#146; Meeting, or a date preceding the date on which Public
Company Stockholders&#146; Meeting is scheduled, Public Company reasonably believes that (i)&nbsp;it will not receive proxies sufficient to obtain approval of the Public Company Stockholder Matters, whether or not a quorum would be present, or
(ii)&nbsp;it will not have sufficient shares of Public Company Common Stock represented (whether in Person or by proxy) to constitute a quorum necessary to conduct the business of Public Company Stockholders&#146; Meeting, Public Company may make
one or more successive postponements or adjournments of Public Company Stockholders&#146; Meeting as long as the date of Public Company Stockholders&#146; Meeting is not postponed or adjourned more than an aggregate of 60 days in connection with any
postponements or adjournments. Public Company and Merger Partner shall coordinate and reasonably cooperate in connection with soliciting and obtaining the Public Company Stockholder Approval, including the preparation and delivery of any information
relating to the parties hereto, the Mergers and the Transactions as may be reasonably requested by each of the Public Company and Merger Partner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Public Company agrees that, subject to Section&nbsp;5.9(d): (i) Public Company Board shall recommend that the holders of Public Company
Common Stock vote to approve Public Company Stockholder Matters and the Other Public Company Stockholder Matters and (ii)&nbsp;the Proxy Statement/Prospectus shall include a statement to the effect that Public Company Board recommends that Public
Company&#146;s stockholders vote to approve Public Company Stockholder Matters and the Other Public Company Stockholder Matters (the recommendation of Public Company Board with respect to Public Company Stockholder Matters and the Other Public
Company Stockholder Matters being referred to as the &#147;<U>Public Company Board Recommendation</U>&#148;). Neither Public Company Board nor any committee thereof shall (x)&nbsp;withhold, amend, qualify, withdraw or modify (and Public Company
Board or any committee thereof shall not resolve to or publicly propose to withhold, amend, qualify, withdraw or modify) the Public Company Board Recommendation in a manner adverse to Merger Partner; or (y)&nbsp;within ten (10)&nbsp;Business
Days&#146; of Merger Partner&#146;s written request to do so, fail to recommend after the commencement of an Acquisition Proposal through a tender or exchange offer pursuant to Rule <FONT STYLE="white-space:nowrap">14d-2</FONT> under the Exchange
Act for outstanding shares of Public Company Common Stock, against acceptance of such tender offer or exchange offer by its stockholders (which request may only be made once with respect to any such Acquisition Proposal and each material
modification thereto) (the actions set forth in the foregoing clauses collectively, a &#147;<U>Public Company Board Adverse Recommendation Change</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Notwithstanding anything to the contrary contained in Section&nbsp;5.4(a) of this Agreement, if at any time prior to the approval of
Public Company Stockholder Matters and the Other Public Company Stockholder Matters at Public Company Stockholders&#146; Meeting by the Required Public Company Stockholder Vote: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) if Public Company has received a written Acquisition Proposal (which Acquisition Proposal did not arise in connection with a breach of
Section&nbsp;5.3) from any Person that has not been withdrawn and after consultation with outside legal counsel, Public Company Board shall have determined, in good faith, that such Acquisition Proposal is a Superior Offer, Public Company Board may
make a Public Company Board Adverse Recommendation Change if and only if all of the following apply: (A)&nbsp;Public Company Board determines in good faith, after consultation with Public Company&#146;s outside legal counsel, that the failure to do
so would be reasonably likely to be inconsistent with the fiduciary duties of Public Company Board to Public Company&#146;s stockholders under applicable Law; (B)&nbsp;Public Company shall have given Merger Partner prior written notice of its
intention to consider making a Public Company Board Adverse Recommendation Change at least three (3)&nbsp;Business Days prior to making any such Public Company Board Adverse Recommendation Change (a &#147;<U>Determination Notice</U>&#148;) (which
notice shall not constitute a Public Company Board Adverse Recommendation Change); and (C)&nbsp;(1) Public Company shall have provided to Merger Partner a copy of such Acquisition Proposal in accordance with Section&nbsp;5.4(b), (2) Public Company
shall have given Merger Partner the three (3)&nbsp;Business </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Days after the Determination Notice to propose revisions to the terms of this Agreement or make another proposal and shall have made its Representatives reasonably available to negotiate in good
faith with Merger Partner (to the extent Merger Partner desires to negotiate) with respect to such proposed revisions or other proposal, if any, and (3)&nbsp;after considering the results of any such negotiations and giving effect to the proposals
made by Merger Partner, if any, after consultation with outside legal counsel, Public Company Board shall have determined, in good faith, that such Acquisition Proposal is a Superior Offer and that the failure to make Public Company Board Adverse
Recommendation Change would be reasonably likely to be inconsistent with the fiduciary duties of Public Company Board to Public Company&#146;s stockholders under applicable Law. For the avoidance of doubt, the provisions of this
Section&nbsp;5.9(d)(i) shall also apply to any material change to the facts and circumstances relating to such Acquisition Proposal and require a new Determination Notice, except that the references to three (3)&nbsp;Business Days shall be deemed to
be two (2)&nbsp;Business Days. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Other than in connection with an Acquisition Proposal, Public Company Board may make a Public
Company Board Adverse Recommendation Change in response to a Public Company Change in Circumstance, if and only if: (A)&nbsp;Public Company Board determines in good faith, after consultation with Public Company&#146;s outside legal counsel, that the
failure to do so would be reasonably likely to be inconsistent with the fiduciary duties of Public Company Board to Public Company&#146;s stockholders under applicable Law; (B)&nbsp;Public Company shall have given Merger Partner a Determination
Notice at least three (3)&nbsp;Business Days prior to making any such Public Company Board Adverse Recommendation Change; and (C)&nbsp;(1) Public Company shall have specified Public Company Change in Circumstance in reasonable detail,
(2)&nbsp;Public Company shall have given Merger Partner the three (3)&nbsp;Business Days after the Determination Notice to propose revisions to the terms of this Agreement or make another proposal, and shall have made its Representatives reasonably
available to negotiate in good faith with Merger Partner (to the extent Merger Partner desires to do so) with respect to such proposed revisions or other proposal, if any, and (3)&nbsp;after considering the results of any such negotiations and
giving effect to the proposals made by Merger Partner, if any, after consultation with outside legal counsel, Public Company Board shall have determined, in good faith, that the failure to make Public Company Board Adverse Recommendation Change in
response to such Public Company Change in Circumstance would be reasonably likely to be inconsistent with the fiduciary duties of Public Company Board to Public Company&#146;s stockholders under applicable Law. For the avoidance of doubt, the
provisions of this Section&nbsp;5.9(d)(ii) shall also apply to any material change to the facts and circumstances relating to such Public Company Change in Circumstance and require a new Determination Notice, except that the references to three
(3)&nbsp;Business Days shall be deemed to be two (2)&nbsp;Business Days. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Nothing contained in Section&nbsp;5.3(a) shall prohibit
Public Company or Public Company Board from (i)&nbsp;complying with Rules <FONT STYLE="white-space:nowrap">14d-9</FONT> and <FONT STYLE="white-space:nowrap">14e-2(a)</FONT> promulgated under the Exchange Act, (ii)&nbsp;issuing a &#147;stop, look and
listen&#148; communication or similar communication of the type contemplated by Section&nbsp;14d-9(f) under the Exchange Act or (iii)&nbsp;otherwise making any disclosure to Public Company&#146;s stockholders; that Public Company Board determines in
good faith, after consultation with its outside legal counsel, is required under applicable securities Laws; <U>provided</U> that in each of cases (i), (ii) and (iii)&nbsp;in no event shall Public Company make a Public Company Board Adverse
Recommendation Change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_81"></A>5.10 <U>Merger Partner and Blocker Member Approval</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Merger Partner shall use reasonable best efforts to secure the Written Consent necessary to secure the Merger Partner Member Approval as
promptly as practical following the date that the SEC declares the Registration Statement effective and each Blocker shall secure the Written Consents necessary to secure the applicable Blocker Approvals as promptly as practical following the date
that the SEC declares the Registration Statement effective. As promptly and practical following the receipt of Merger Partner Member Approval and Blocker Approvals, Merger Partner shall deliver to Public Company copy of the Written Consents
evidencing the Merger Partner Member Approval and Blocker Approvals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) As promptly as practical following the date that the SEC
declares the Registration Statement effective, Merger Partner shall mail or otherwise distribute the Disclosure Statement, in a form reasonably </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
acceptable to Public Company, to the equity holders of Merger Partner and, to the extent required by Law, to the equity holders of any Blockers, and shall promptly inform Public Company of the
date on which such Disclosure Statement (including the notices contained therein) was sent to such equity holders. The Disclosure Statement shall include a written notice to all members of Merger Partner and the Blockers that did not execute the
Written Consents informing them that this Agreement and the Mergers were adopted and approved by the equityholders of Merger Partner and the Blockers. Public Company and its counsel shall be given an adequate opportunity to review and comment on the
Disclosure Statement, and Merger Partner shall reflect all reasonable comments of Public Company or its counsel thereon. Public Company and Merger Partner shall coordinate and reasonably cooperate in connection with soliciting and obtaining the
Merger Partner Member Approval, including the preparation and delivery of any information relating to the parties hereto, the Mergers and the Transactions as may be reasonably requested by each of the Public Company and Merger Partner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Merger Partner shall ensure that the Disclosure Statement does not contain any untrue statement of a material fact or omit to state a
material fact necessary in order to make the statements made therein, in the light of the circumstances under which they were made, not misleading (provided that Merger Partner shall not be responsible for the accuracy or completeness of any
information concerning Public Company or Merger Subsidiary furnished by Public Company in writing for inclusion in the Disclosure Statement). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Public Company shall ensure that any information furnished by Public Company to Merger Partner in writing for inclusion in the Disclosure
Statement does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made therein, in the light of the circumstances under which they were made, not misleading. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_82"></A>5.11 <U>Access to Information</U>. During the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Period and
subject to the terms of the Confidentiality Agreement, Public Company and Merger Partner shall each (and shall cause each of their respective Subsidiaries to) use commercially reasonable efforts to afford the officers, attorneys, accountants, tax
advisors, lenders and other authorized representatives of the other party reasonable access upon reasonable notice and during normal business hours and without unreasonable interference with the operation of the business of such other party to all
Personnel, offices, properties, books and records of such party and its Subsidiaries, so that the other party may have full opportunity to make such investigation as it shall desire to make of the management, business, properties and affairs of said
party and the Subsidiaries. Public Company and Merger Partner shall (and shall cause each Subsidiary to) furnish to the other parties such financial and operating data and other information as to the business of said party and the Subsidiaries as
the other parties shall reasonably request. Each Blocker shall furnish to Public Company and Merger Partner such financial and operating data and other information as to the business of such Blocker as the other parties shall reasonably request in
connection with this Agreement and the transactions contemplated hereby but only to the extent that such information is reasonably available. Notwithstanding the foregoing, nothing herein will require a party or its Subsidiaries to (i)&nbsp;provide
the other party with access or information that said party is expressly prohibited by applicable Law from granting or disclosing or that would breach such party&#146;s confidentiality obligations to a third party in effect as of the date of this
Agreement, or (ii)&nbsp;take any action that would, in the advice of counsel, constitute a waiver of the attorney-client privilege or the attorney work product privilege in the event of a legal proceeding with the other party; <U>provided</U>, that
in the event that a party or any Subsidiary relies on this sentence to withhold access or disclosure, said party shall, to the extent permitted by Law, applicable confidentiality obligations and the protection of such attorney-client privilege,
promptly notify the other party of the nature of the withheld information and provide the other party of a reasonable opportunity to seek an appropriate remedy or waive compliance with the terms of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_83"></A>5.12 <U>Closing Efforts</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Upon the terms and subject to the conditions of this Agreement, each of Public Company and Merger Partner shall each use its reasonable
best efforts to take all actions and to do all things necessary, proper or advisable to consummate the Transactions to be completed at Closing as promptly as practicable, including </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
using its reasonable best efforts to ensure that the conditions to the obligations of the other parties to consummate the Merger are satisfied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Public Company and Merger Partner shall each use its reasonable best efforts to obtain, at its expense, all waivers, permits, consents,
approvals or other authorizations from Governmental Entities or from third parties pursuant to the Public Company Contracts or Merger Partner Contracts (as applicable), and to effect all registrations, filings and notices with or to Governmental
Entities, in each case, as may be required for such party to consummate the Transactions and to otherwise comply with all applicable Laws in connection with the consummation of the Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_84"></A>5.13 <U>Public Disclosure</U>. No party shall issue any press release or public announcement relating to the
subject matter of this Agreement without the prior written approval of the other parties; <U>provided</U>, <U>however</U>, that (a)&nbsp;Merger Partner and Blockers each acknowledge and agree that Public Company (i)&nbsp;may issue, without the
approval of any other party, an initial joint press release with respect to this Agreement and the matters contemplated hereby, in form and substance mutually agreed by Public Company, Merger Partner and each Blocker (provided that such press
release shall not name any Blocker or its Affiliate or investment adviser without the prior consent of such Blocker), (ii) intends to publicly file this Agreement with the SEC, and (iii)&nbsp;may seek confidential treatment under applicable SEC
rules with respect to certain matters and terms contained in this Agreement; (b)&nbsp;Public Company or Merger Partner may make any public disclosure it believes in good faith is required by applicable Law or stock market rule (in which case the
disclosing party shall use reasonable best efforts to advise the other parties and provide them with a copy of the proposed disclosure prior to making the disclosure); and (c)&nbsp;Public Company and its Affiliates shall not be bound by the
provisions of this Section&nbsp;5.13 following the Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_85"></A>5.14 <U>Antitrust</U>. If at any time
after the date hereof but prior to the Closing, Merger Partner determines, in its reasonable discretion after consultation with Public Company and its legal advisors, that the Transactions require filings under the HSR Act to be submitted with the
applicable Governmental Entities, then as promptly as reasonably practicable following such determination, Public Company and Merger Partner shall cooperate in the preparation of such filings and, upon completion thereof (in form and substance
mutually agreeable to Merger Partner and Public Company), each of Merger Partner and Public Company shall make or cause to be made any such required filings under the HSR Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_86"></A>5.15 <U>Warrant Restructuring</U>. From and after the date hereof until the date that is five
(5)&nbsp;Business Days prior to the Closing Date or the earlier termination of this Agreement pursuant to Section&nbsp;8.1, Merger Partner shall use commercially reasonable efforts to obtain any and all consents from each holder of Merger Partner
Warrants necessary to effectuate the treatment of the Merger Partner Warrants set forth in Section&nbsp;
2.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_87"></A>5.16 <U>Transaction Documentation</U>. From the date hereof until the time when the Registration
Statement becomes effective or the earlier termination of this Agreement pursuant to Section&nbsp;8.1, Public Company and Merger Partner shall use reasonable best efforts to negotiate and settle on mutually agreeable final forms of the Tax
Receivable Agreement, the Exchange Agreement, the Amended Certificate, the Amended <FONT STYLE="white-space:nowrap">By-Laws,</FONT> the Amended Operating Agreement, the Registration Rights Agreement and the Asset Transfer Agreements as promptly as
practicable following the date hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_88"></A>5.17 <U>Merger Partner Funding</U>. No later than two
(2)&nbsp;Business Days following Merger Partner&#146;s receipt of a written request from Public Company, Merger Partner shall make available to Public Company and its Subsidiaries, funds up to a maximum aggregate amount of $3,000,000 in cash (the
&#147;<U>Interim Funding</U>&#148;); <U>provided</U>, <U>however</U>, that in the event Merger Partner elects to extend the Outside Date pursuant to Section&nbsp;8.1(b), the maximum aggregate amount of the Interim Funding shall automatically
increase to $4,000,000. The Interim Funding shall be made available on the terms and conditions consistent with those set forth on <U>Exhibit E</U> and on such other terms and conditions as are mutually agreed by Merger Partner and Public Company.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_89"></A>5.18 <U>Section 16 Matters</U>. Prior to the Closing, each
of Public Company and Merger Partner, as applicable, shall use all reasonable efforts to approve in advance in accordance with the applicable requirements of Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act, the
acquisition of <FONT STYLE="white-space:nowrap">Up-C</FONT> Units, the exchange of <FONT STYLE="white-space:nowrap">Up-C</FONT> Units for shares of Public Company Class&nbsp;A Common Stock (and any dispositions of Merger Partner Common Units or
shares of Public Company Class&nbsp;B Common Stock thereby) resulting from the transactions contemplated by this Agreement by each officer or director (including by deputization) of the Public Company or the Merger Partner who is subject to
Section&nbsp;16 of the Exchange Act (or who will become subject to Section&nbsp;16 of the Exchange Act) as a result of the transactions contemplated hereby. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="annexarom401831_90"></A>ARTICLE VI </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDITIONS TO CONSUMMATION OF THE MERGERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_91"></A>6.1 <U>Conditions to Obligations of Public Company and Merger Subsidiary</U>. The obligation of each of
Public Company and Merger Subsidiary to consummate the Mergers is subject to the satisfaction of the following conditions precedent, each of which may be waived in writing in the sole discretion of Public Company: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) the Fundamental Representations contained in Article III shall have been true and correct in all material respects as of the date of this
Agreement and shall be true and correct in all material respects on and as of the Closing Date with the same force and effect as if made on and as of such date (except to the extent such representations and warranties are specifically made as of a
particular date, in which case such representations and warranties shall be true and correct in all material respects as of such particular date); the representations and warranties contained in Article III (other than the Fundamental
Representations contained in Article III) shall have been true and correct as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on the Closing Date except (i)&nbsp;in
each case, or in the aggregate, where the failure to be true and correct would not reasonably be expected to result in a Merger Partner Material Adverse Effect (without giving effect to any references therein to any Merger Partner Material Adverse
Effect or other materiality qualifications), or (ii)&nbsp;for those representations and warranties which address matters only as of a particular date (which representations shall have been true and correct, subject to the qualifications as set forth
in the preceding clause (i), as of such particular date); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Each of Merger Partner and the Blockers shall have performed or complied
with, in all material respects, its agreements and covenants required to be performed or complied with by it under this Agreement as of or prior to the Closing; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Public Company shall have received a certificate of an officer of Merger Partner certifying to the satisfaction of the conditions set
forth in Sections 6.1(a) and (b); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) no judgment, order, decree, stipulation or injunction shall be in effect that would reasonably be
expected to (i)&nbsp;temporarily or permanently prevent or enjoin consummation of the Transactions, or (ii)&nbsp;cause the Transactions to be rescinded following consummation of such transaction; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) there shall have occurred no Effect since the date of this Agreement that, individually or taken together with all other Effects, has had,
or would reasonably be expected to result in, a Merger Partner Material Adverse Effect; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Public Company shall have received copies of
the Written Consents evidencing the Merger Partner Member Approval and the Blocker Approvals; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) Public Company shall have obtained
Stockholder Approval; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) The Registration Statement shall have become effective under the Securities Act and no stop order suspending
the effectiveness of the Registration Statement shall have been issued and no Legal Proceeding for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that purpose, and no similar Legal Proceeding with respect to the Proxy Statement/Prospectus, shall have been initiated or threatened in writing by the SEC or its staff that has not been
withdrawn; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) If filings under the HSR Act are required, as determined pursuant to Section&nbsp;5.14, any applicable waiting period
shall have expired or been terminated; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) The Nasdaq Listing Application shall have been approved, and the shares of the Public Company
Class&nbsp;A Common Stock to be issued as Merger Consideration shall have been approved for listing (subject to official notice of issuance) on Nasdaq; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) Merger Partner shall have delivered to Public Company a copy of (i)&nbsp;the Tax Receivable Agreement, and the Exchange Agreement, each
duly executed by Merger Partner and each Electing Member and (ii)&nbsp;the Registration Rights Agreement, duly executed by each Electing Member; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) Merger Partner shall have delivered to Public Company a copy of the Amended Operating Agreement, duly executed by Merger Partner and each
Electing Member. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_92"></A>6.2 <U>Conditions to Obligations of Merger Partner and the Blockers</U>. The
obligations of Merger Partner and the Blockers to consummate the Mergers is subject to the satisfaction of the following conditions precedent, each of which may be waived in writing in the sole discretion of Merger Partner: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) the Fundamental Representations contained in Article IV shall have been true and correct in all material respects as of the date of this
Agreement and shall be true and correct in all material respects on and as of the Closing Date with the same force and effect as if made on and as of such date (except to the extent such representations and warranties are specifically made as of a
particular date, in which case such representations and warranties shall be true and correct in all material respects as of such particular date). The representations and warranties contained in Article IV (other than the Fundamental Representations
contained in Article IV) shall have been true and correct as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on the Closing Date except (i)&nbsp;in each case, or in
the aggregate, where the failure to be true and correct would not reasonably be expected to result in a Public Company Material Adverse Effect (without giving effect to any references therein to any Public Company Material Adverse Effect or other
materiality qualifications), or (ii)&nbsp;for those representations and warranties which address matters only as of a particular date (which representations shall have been true and correct, subject to the qualifications as set forth in the
preceding clause (i), as of such particular date); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) each of Public Company and Merger Subsidiary shall have performed or complied, in
all material respects, with its agreements and covenants required to be performed or complied with under this Agreement as of or prior to the Closing; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Public Company shall have received a certificate of an officer of Merger Partner certifying to the satisfaction of the conditions set
forth in Sections 6.2(b) and (c); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) no judgment, order, decree, stipulation or injunction shall be in effect, that would reasonably be
expected to (i)&nbsp;temporarily or permanently prevent or enjoin prevent consummation of the Transactions, or (ii)&nbsp;cause the Transactions to be rescinded following consummation of such transaction; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) there shall have occurred no Effect since the date of this Agreement that, individually or taken together with all other Effects, has had,
or would reasonably be expected to result in, a Public Company Material Adverse Effect; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Public Company shall have obtained the Public
Company Stockholder Approval; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) Merger Partner shall have obtained the Written Consents evidencing the Merger Partner
Member Approval and the Blocker Approvals; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) Public Company shall have delivered to Merger Partner an amendment to the license
agreement between Public Company and Cellectis S.A. in substantially the form attached hereto as <U>Exhibit F</U>; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) The Registration
Statement shall have become effective under the Securities Act and no stop order suspending the effectiveness of the Registration Statement shall have been issued and no Legal Proceeding for that purpose, and no similar Legal Proceeding with respect
to the Proxy Statement/Prospectus, shall have been initiated or threatened in writing by the SEC or its staff that has not been withdrawn; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) (i) the existing shares of Public Company Common Stock shall be listed on Nasdaq and not subject to any pending <FONT
STYLE="white-space:nowrap">de-listing</FONT> notice (except as set forth in the Public Company Disclosure Schedule) or <FONT STYLE="white-space:nowrap">de-listing</FONT> appeal process that would not be remedied by the consummation of the
Transactions, (ii)&nbsp;the Nasdaq Listing Application shall have been approved, and (iii)&nbsp;the shares of the Public Company Class&nbsp;A Common Stock to be issued as Merger Consideration shall have been approved for listing (subject to official
notice of issuance) on Nasdaq; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) The Support Agreements will continue to be in full force and effect as of immediately following the
Merger Partner Merger Effective Time; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) If filings under the HSR Act are required, as determined pursuant to Section&nbsp;5.14, any
applicable waiting period shall have expired or been terminated; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) Merger Partner shall have received a written resignation, in a form
reasonably satisfactory to Merger Partner, dated as of the Closing Date and effective as of the Merger Partner Merger Effective Time, executed by each of the officers and directors of Public Company that are not included in the <U>Exhibit <FONT
STYLE="white-space:nowrap">D-1</FONT></U> or <U>Exhibit <FONT STYLE="white-space:nowrap">D-2</FONT></U>, from their positions as such, of Public Company, including any characterization of the resigning officers cessation from employment; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n) Public Company shall have delivered to Merger Partner a copy of the Tax Receivable Agreement, the Exchange Agreement and the Registration
Rights Agreement each duly executed by Public Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o) Public Company shall have delivered to Merger Partner a copy of the Amended
Operating Agreement, duly executed by Public Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(p) Public Company shall have delivered to Merger Partner an agreement evidencing
termination of Public Company as a party to that certain Management Services Agreement by and among Cellectis S.A., Cellectis, Inc. and Public Company, in form and substance reasonably acceptable to Merger Partner, effective as of or prior to the
Closing; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(q) Public Company shall have taken all steps necessary to effectuate Section&nbsp;2.1(b)(i)(E), including amending the
Public Company Stock Plans as needed to issue the awards contemplated by Section&nbsp;2.1(b)(i)(E) and filing applicable registration statements with respect thereto. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="annexarom401831_93"></A>ARTICLE VII </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ADDITIONAL AGREEMENTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_94">
</A>7.1 <U>Employee Matters</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Solely to the extent any of the eligible participants in the Public Company 2021 Executive Severance
Plan (the &#147;<U>Executive Severance Plan</U>&#148;) set forth on Schedule 7.1 are employed by Public Company </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
immediately prior to the Closing and who (a)&nbsp;resign employment with Public Company, Merger Partner, and their affiliates on the Closing Date for any reason or (b)&nbsp;are terminated by
Public Company or Merger Partner other than for Cause, death, or Disability (as such terms are defined in the Executive Severance Plan) on the Closing Date, shall be deemed to undergo a Qualifying Termination during a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Change-In-Control</FONT></FONT> Period and shall, effective as of the Closing, be entitled to receive the corresponding Severance Benefits as set forth in the Executive Severance Plan
and applicable Participation Agreement. Any capitalized terms used in this Section&nbsp;7.1 and not otherwise defined in this Agreement shall have the meanings ascribed thereto in the Executive Severance Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Nothing in this Agreement shall confer upon any employee, officer, director or consultant of Public Company, Merger Partner, Blockers or
any of their respective Subsidiaries any right to continue in the employ or service of Public Company, Merger Partner or any Subsidiary thereof, or shall interfere with or restrict in any way the rights of Public Company, Merger Partner or any
Subsidiary thereof to discharge or terminate the services of any employee, officer, director or consultant at any time for any reason whatsoever, with or without cause. Nothing in this Agreement shall be deemed to (i)&nbsp;establish, amend, or
modify any Public Company Benefit Plan or Merger Partner Benefit Plan or any other benefit or employment plan, program, agreement or arrangement, or (ii)&nbsp;alter or limit the ability of Public Company, Merger Partner or any Subsidiary to amend,
modify or terminate any particular Public Company Benefit Plan, Merger Partner Benefit Plan or any other benefit or employment plan, program, agreement or arrangement after the Closing. Without limiting the generality of Section&nbsp;10.3 and
subject to 7.2, nothing in this Agreement, express or implied, is intended to or shall confer upon any Person, including any current or former employee, officer, director or consultant of Public Company, Merger Partner, any Blocker or any of their
respective Subsidiaries, any third party beneficiary rights or any other right, benefit or remedy of any nature whatsoever under or by reason of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_95"></A>7.2 <U>D&amp;O Indemnification</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) From the Closing through the sixth (6<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) anniversary of the Closing Date occurs,
Public Company shall indemnify and hold harmless each Person who is now, or has been at any time prior to the date hereof, or who becomes prior to the Closing, a director, manager or officer of Merger Partner, Public Company or any of their
respective Subsidiaries (the &#147;<U>Indemnified Persons</U>&#148;), against all claims, losses, liabilities, damages, judgments, fines and reasonable fees, costs and expenses, including attorneys&#146; fees and disbursements, incurred in
connection with any claim, action, suit, proceeding or investigation, whether civil, criminal, administrative or investigative, arising out of or pertaining to the fact that the Indemnified Person is or was an officer, director, manager, employee,
trustee, fiduciary or agent of Merger Partner, Public Company or any of their respective Subsidiaries, or, while a director, manager or officer of Merger Partner, Public Company or any of their respective Subsidiaries, is or was serving at the
request of Merger Partner, Public Company or any of their respective Subsidiaries as a director, manager, officer, employee or agent of another Person, whether asserted or claimed prior to, at or after the Closing, to the extent permitted under the
applicable certificate of incorporation and bylaws or other organizational document. Each Indemnified Person will be entitled to advancement of expenses (including attorneys&#146; fees) incurred in the defense of any such claim, action, suit,
proceeding or investigation from Public Company following receipt by Public Company from the Indemnified Party of a request therefor; <U>provided</U>&nbsp;that any Person to whom expenses are advanced provides an undertaking, to the extent then
required by Delaware Law, to repay such advances if it is ultimately determined that such Person is not entitled to indemnification. From the Closing through the sixth anniversary of the Closing Date, the certificate of incorporation and bylaws of
Public Company will contain provisions at least as favorable as the provisions relating to the indemnification, advance of expenses and elimination of liability for monetary damages set forth in the certificate of incorporation and bylaws of Public
Company immediately prior to the Closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Prior to the Closing, Public Company shall purchase
<FONT STYLE="white-space:nowrap">a&nbsp;six-year&nbsp;prepaid</FONT> &#147;D&amp;O tail policy&#148; (the &#147;<U>Public Company Tail Policy</U>&#148;) for <FONT STYLE="white-space:nowrap">the&nbsp;non-cancellable&nbsp;extension</FONT> of the
directors&#146; and officers&#146; liability coverage of Public Company&#146;s existing directors&#146; and officers&#146; insurance policies for a claims reporting or discovery period of at least six years from and after the Closing with respect to
any claim related to any period of time at or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prior to the Merger Partner Merger Effective Time with terms, conditions, retentions and limits of liability to be mutually agreed by Public Company and Merger Partner prior to the Closing (which
approval will not be unreasonably withheld, conditioned or delayed), but that are no more favorable than the coverage provided under Public Company&#146;s existing policies as of the date of this Agreement with respect to coverage of any actual or
alleged error, misstatement, misleading statement, act, omission, neglect, breach of duty or any matter claimed against a director or officer of Public Company by reason of him or her serving in such capacity that existed or occurred at or prior to
the Closing (including in connection with this Agreement or the Mergers). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Prior to the Closing, Merger Partner shall purchase <FONT
STYLE="white-space:nowrap">a&nbsp;six-year&nbsp;prepaid</FONT> &#147;D&amp;O tail policy&#148; (the &#147;<U>Merger Partner Tail Policy</U>&#148;) for <FONT STYLE="white-space:nowrap">the&nbsp;non-cancellable&nbsp;extension</FONT> of the
directors&#146; and officers&#146; liability coverage of Merger Partner&#146;s existing directors&#146; and officers&#146; insurance policies for a claims reporting or discovery period of at least six years from and after the Effective Time with
respect to any claim related to any period of time at or prior to the Effective Time with terms, conditions, retentions and limits of liability that are no less favorable than the coverage provided under Merger Partner&#146;s existing policies as of
the date of this Agreement with respect to any actual or alleged error, misstatement, misleading statement, act, omission, neglect, breach of duty or any matter claimed against a manager, director or officer of Merger Partner by reason of him or her
serving in such capacity that existed or occurred at or prior to the Closing (including in connection with this Agreement or the Merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Public Company shall pay all expenses, including reasonable attorneys&#146; fees, that may be incurred by a Person in successfully
enforcing such Person&#146;s rights provided in this Section&nbsp;7.2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Public Company and Merger Partner agree that all rights to
exculpation, indemnification and advancement of expenses for acts or omissions occurring at or prior to the Closing, whether asserted or claimed prior to, at or after the Closing, now existing in favor of the current or former directors, managers,
officers or employees, as the case may be, of Public Company, Merger Partner or any of their respective Subsidiaries as provided in their respective certificates of incorporation or bylaws or other organization documents or in any agreement in
existence immediately prior to the Closing shall survive the Mergers and shall continue in full force and effect. The provisions of this&nbsp;Section 7.2 are intended to be in addition to the rights otherwise available to the current officers,
managers and directors of Public Company, Merger Partner or any of their respective Subsidiaries by Law, charter, statute, bylaw or agreement, and shall operate for the benefit of, and shall be enforceable by, each of the Indemnified Persons, their
heirs and their representatives. The obligations set forth in this&nbsp;Section 7.2 shall not be terminated, amended or otherwise modified in any manner that adversely affects any Indemnified Person, or any Person who is a beneficiary under the
policies referred to in this&nbsp;Section 7.2 and their heirs and representatives, without the prior written consent of such affected Indemnified Person or other Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) If Public Company or any of its successors or assigns shall (i)&nbsp;consolidate with or merge into any other Person and shall not be the
continuing or surviving corporation or entity of such consolidation or merger, or (ii)&nbsp;transfer all or substantially all of its properties and assets to any Person, then, and in each such case, proper provisions shall be made so that the
successors and assigns of such Person shall assume all of the obligations of such Person set forth in this&nbsp;Section 7.2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) Nothing
in this Agreement is intended to, shall be construed to or shall release, waive or impair any rights to directors&#146; and officers&#146; insurance claims under any policy that is or has been in existence with respect to Merger Partner, Public
Company or any of their respective Subsidiaries for any of their respective directors, managers, officers or other employees, it being understood and agreed that the indemnification provided for in this Section&nbsp;7.2 is not prior to or in
substitution for any such claims under such policies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_96"></A>7.3 <U>Tax Matters</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Public Company shall pay all transfer, documentary, sales, use, stamp, registration, value added or other similar Taxes incurred in
connection with the Transactions (collectively, the &#147;<U>Transfer Taxes</U>&#148;) and file all </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
necessary Tax Returns with respect to all Transfer Taxes, and, if required by applicable Law, Public Company and Merger Partner shall, and shall cause their respective Affiliates to, join in the
execution of any such Tax Returns and other document. Notwithstanding any other provision of this Agreement, Public Company and Merger Partner shall (and shall cause their respective Affiliates to) cooperate in good faith to minimize, to the extent
permissible under applicable Law, the amount of any such Transfer Taxes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) For U.S. federal income tax purposes (and for purposes of
any applicable state or local income tax that follows U.S. federal income tax treatment), each of the Parties intends that (the &#147;<U>Intended Tax Treatment</U>&#148;) (i) the Public Company&#146;s acquisition of interests in Merger Partner by
operation of the Merger Partner Merger, and Public Company&#146;s issuance of Public Company Class&nbsp;A Common Stock and Public Company Class&nbsp;B Common Stock to Participating Members, Electing Members, holders of Merger Partner Warrants, and
holders of Merger Partner PIUs at the Merger Partner Merger Effective Time, shall be treated as a transaction governed by Section&nbsp;351 of the Code, (ii)&nbsp;the Blocker Mergers will each qualify as a &#147;reorganization&#148; within the
meaning of Section&nbsp;368(a) of the Code, and (iii)&nbsp;and the other changes to the capital structure of Merger Partner at Closing contemplated by Sections 2.1(b)(i)(B) and 2.1(b)(ii) shall be treated as a
<FONT STYLE="white-space:nowrap">non-taxable</FONT> amendment to the partnership agreement under Section&nbsp;761(c) of the Code, or as otherwise nontaxable under Revenue Ruling <FONT STYLE="white-space:nowrap">84-52,</FONT> <FONT
STYLE="white-space:nowrap">1984-1</FONT> C.B. 157 (or otherwise under Section&nbsp;721 of the Code). This Agreement is hereby adopted as and shall constitute a &#147;plan of reorganization&#148; within the meaning of Treasury Regulations <FONT
STYLE="white-space:nowrap">Section&nbsp;1.368-2(g)</FONT> with respect to each of the Blocker Mergers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Each of the Parties intends
for the Transactions to qualify for the Intended Tax Treatment and will not, without the Unitholder Representative&#146;s or Public Company&#146;s consent (not to be unreasonably withheld, conditioned, or delayed), take any inconsistent position on
any Tax Return or during the course of any audit, litigation or other proceeding with respect to Taxes, except as otherwise required by a determination within the meaning of Section&nbsp;1313(a) of the Code. Each of the Parties agrees to promptly
notify all other Parties of any challenge to the Intended Tax Treatment by any Governmental Authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) No Party shall knowingly take
or cause to be taken any action, or fail to take or cause to be taken any action, which action or failure to act would reasonably be expected to prevent the Transactions from so qualifying for the Intended Tax Treatment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Public Company and Merger Partner shall use reasonable best efforts to execute and deliver customary representations reasonably requested
by counsel to Public Company or counsel to Merger Partner, as applicable, for purposes of rendering opinions regarding the Intended Tax Treatment and other tax matters in connection with the Transactions, at such time or times as may be reasonably
requested by such counsel, including in connection with the Closing and any filing of any Form <FONT STYLE="white-space:nowrap">S-4.</FONT> In the event that the SEC (or its staff) requires a tax opinion regarding the Intended Tax Treatment, Merger
Partner shall use its reasonable best efforts to cause Akin Gump Strauss Hauer&nbsp;&amp; Feld LLP to deliver such opinion (subject to customary assumptions and limitations) to Merger Partner. For the avoidance of doubt, the delivery of tax opinions
by counsel to Public Company or counsel to Merger Partner shall not be a condition to Closing under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) The Unitholder
Representative shall prepare, or cause to be prepared, at the expense of Merger Partner, all income Tax Returns with respect to Pass-Through Income Taxes of Merger Partner (and its Subsidiaries) for any
<FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Tax Period (other than the portion of any Straddle Period ending on the Closing Date) that are due after the Closing Date (taking into account applicable extensions) (each, a &#147;<U>Pass-Through
Return</U>&#148;). Each Pass-Through Return, as prepared by the Unitholder Representative, shall be submitted to the Public Company for its review and approval no later than 45 days prior to its due date (taking into account applicable extensions).
Public Company shall propose any comments on such Pass-Through Returns no later than 15 days prior to their due date (taking into account applicable extensions), and the Unitholder Representative and the Unitholder Representative shall consider in
good faith any such comments. Public Company shall cause all Pass-Through Returns as prepared by the Unitholder Representative, to be timely filed and will promptly provide a copy of all filed Pass-Through Returns to the Unitholder Representative.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) In the event of any proposed audit, adjustment, assessment, examination, claim or other
controversy or proceeding relating to Pass-Through Income Taxes or any Pass-Through Return (a &#147;<U>Tax Contest</U>&#148;) with respect to a Straddle Period, Public Company will, within 15 days of it (or any of its Subsidiaries) being notified of
such Tax Contest, notify the Unitholder Representative of such Tax Contest in writing. All Tax Contests for any taxable periods initiated or continuing after the Closing Date shall be controlled in accordance with the terms of the Merger Partner
Operating Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) After the Closing, Public Company (and its Subsidiaries) will not, without the consent of the Unitholder
Representative (which consent will not be unreasonably withheld, conditioned or delayed) or as required by applicable Law, (i)&nbsp;amend or otherwise modify any Pass-Through Return, (ii)&nbsp;extend or waive, or cause to be extended or waived, any
statute of limitations or other period for the assessment of any Pass-Through Income Taxes for <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Tax Periods (other than the portion of any Straddle Period ending on the Closing Date) or audit of any
Pass-Through Return, (iii)&nbsp;initiate with a taxing authority discussions or examinations or voluntary disclosures with respect to Pass-Through Taxes for <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Tax Period or (iv)&nbsp;make or change
any income election or accounting method or practice with respect to Pass-Through Income Taxes for <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Tax Periods (other than the portion of any Straddle Period ending on the Closing Date) or
Pass-Through Returns. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) Public Company, Merger Partner and the Unitholder Representative shall reasonably cooperate (and cause its
Affiliates to reasonably cooperate), as and to the extent reasonably requested by each other Party and the Unitholder Representative, in connection with the preparation and filing of Tax Returns or any Tax Contest. Such cooperation shall include the
provision of available records and information that are reasonably relevant to any such matter and making employees available on a mutually convenient basis to provide additional information and explanation with respect thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) Public Company and the sole member of each Blocker shall reasonably cooperate (and cause their respective affiliates to reasonably
cooperate) with respect to the administration of tax matters relating to such Blocker (including the preparation of Tax Returns and the conduct of any tax audits, adjustments, assessments, examinations, claims or other controversies or proceedings).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) Merger Partner has in effect, or shall make effective starting no later than the taxable year of the Closing, a valid election under
Section&nbsp;754 of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_97"></A>7.4 <U>Transaction Litigation</U>. In the event that any litigation
related to this Agreement or the Transactions is brought, or, to the Knowledge of Public Company, threatened, against Public Company, any members of Public Company&#146;s Board or the Public Company Support Stockholders under the Public Company
Support Agreements (such litigation, &#147;<U>Public Company Transaction Litigation</U>&#148;), Public Company shall promptly notify Merger Partner of such Public Company Transaction Litigation and shall keep Merger Partner reasonably informed with
respect to the status thereof. Public Company shall give Merger Partner a reasonable opportunity to participate in the defense or settlement, at Merger Partner&#146;s sole expense and subject to a customary joint defense agreement, of any Public
Company Transaction Litigation and shall consider in good faith Merger Partner&#146;s advice with respect to such Public Company Transaction Litigation; <U>provided</U> that Public Company shall retain the right to control the defense of such Public
Company Transaction Litigation in its sole discretion and the disclosure of information to Merger Partner in connection therewith shall be subject to the provisions of Section&nbsp;5.11 (without giving effect to the words &#147;upon reasonable
notice and during normal business hours&#148;); <U>provided</U>, that Public Company shall not settle or moot, or agree to settle or moot, any Public Company Transaction Litigation without the prior written consent of Merger Partner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_98"></A>7.5 <U>Asset Transfers</U>. Immediately prior to the consummation of the Mergers, Public Company shall
consummate the Asset Transfers in accordance with the terms of one or more Transfer Agreements in the form(s) to be agreed between Public Company and Merger Partner as promptly following the date hereof as practicable (the &#147;<U>Asset Transfer
Agreements</U>&#148;). In exchange for the Asset Transfers, Merger Partner will agree that the outstanding Interim Funding subject to repayment thereafter shall be reduced to zero ($0) and Merger Partner shall issue to Public Company the number of
Merger Partner Common Units set forth in the Allocation Schedule. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="annexarom401831_99"></A>ARTICLE VIII </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TERMINATION AND AMENDMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_100"></A>8.1 <U>Termination</U>. This Agreement may be terminated at any time prior to the Closing, whether before
or, subject to the terms hereof, after receipt of the approval of the stockholders of Public Company or the members of Merger Partner and/or the Blockers: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) by mutual written consent of Public Company and Merger Partner; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) by either Public Company or Merger Partner if the Merger shall not have been consummated by the Outside Date; <U>provided</U>, that if on
the Outside Date, each of the conditions to closing set forth in Sections 6.1 and 6.2 shall not have been satisfied or waived by the parties entitled to the benefit thereof (other than conditions that, by their nature, are to be satisfied or waived
at the Closing), then at the written election of Merger Partner (which written election shall include acknowledgment and agreement by Merger Partner that the Interim Funding available to Public Company shall be increased pursuant to
Section&nbsp;5.17), the Outside Date may be extended to June&nbsp;30, 2023 (and in the case of such extension, any reference to the Outside Date in any other provision of this Agreement shall be a reference to the Outside Date, as extended);
<U>provided</U>, <U>however</U>, that the right to terminate this Agreement under this Section this Section&nbsp;8.1(b) shall not be available to a party if the failure of the Mergers to have been consummated on or before the Outside Date was
primarily due to such party&#146;s action or failure to act, where such action or failure to act constitutes a breach of this Agreement (with any action or failure to act by a Blocker being considered an action or failure to act by Merger Partner);
or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) by either Public Company or Merger Partner if a Governmental Entity of competent jurisdiction shall have issued a nonappealable
final order, decree or ruling or taken any other nonappealable final action, in each case having the effect of permanently restraining, enjoining or otherwise prohibiting any of the Mergers; <U>provided</U>, <U>however</U>, that the right to
terminate this Agreement under this Section&nbsp;8.1(c) shall not be available to a party if the issuance of such order, decree, ruling or the taking of such action was primarily due to such party&#146;s action or failure to act, where such action
or failure to act constitutes a breach of this Agreement (with any action or failure to act by a Blocker being considered an action or failure to act by Merger Partner); or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) by Public Company, if there has been a breach of or failure to perform any representation, warranty, covenant or agreement on the part of
Merger Partner or a Blocker set forth in this Agreement, which breach or failure to perform (i)&nbsp;would cause the conditions set forth in Section&nbsp;6.1(a) or 6.1(b) not to be satisfied and (ii)&nbsp;shall not have been cured, if capable of
being cured, or waived within 30 days following receipt by Merger Partner of written notice of such breach or failure to perform from Public Company; <U>provided</U>, <U>however</U>, that the right to terminate this Agreement under this
Section&nbsp;8.1(d) shall not be available to Public Company if Public Company or Merger Subsidiary then in material breach of any representation, warranty or covenant set forth in this Agreement; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) by Merger Partner, if there has been a breach of or failure to perform any representation, warranty, covenant or agreement on the part of
Public Company or Merger Subsidiary set forth in this Agreement, which breach or failure to perform (i)&nbsp;would cause the conditions set forth in Section&nbsp;6.2(a) or 6.2(b) not to be satisfied and (ii)&nbsp;shall not have been cured, if
capable of being cured, or waived within 30 days following receipt by Public Company of written notice of such breach or failure to perform from Merger Partner; <U>provided</U>, <U>however</U>, that the right to terminate this Agreement under this
Section&nbsp;8.1(e) shall not be available to Merger Partner if Merger Partner is then in material breach of any representation, warranty or covenant set forth in this Agreement; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) by Merger Partner, at any time prior to receipt of the Public Company Stockholder Approval, if: (i)&nbsp;the Public Company Board shall
have effected a Public Company Board Adverse Recommendation Change; or (ii)&nbsp;Public Company shall have committed a material breach of Public Company&#146;s obligations under Section&nbsp;5.4 of this Agreement; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) by Public Company, at any time prior to receipt of the Public Company Stockholder Approval, if each of the following occur:
(i)&nbsp;Public Company shall have received a Superior Offer; (ii)&nbsp;Public Company shall </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
have complied with its obligations under Section&nbsp;5.4 with respect to such Superior Offer, including with respect to making a Public Company Board Recommendation Change with respect to such
Superior Offer; (iii)&nbsp;the Public Company Board approves such Superior Offer, and Public Company substantially concurrently with the termination of this Agreement enters into, a definitive agreement with respect to such Superior Offer; and
(iv)&nbsp;prior to or substantially concurrently with such termination, Public Company pays to Merger Partner the amounts contemplated by Sections 8.3(b) and 8.3(d); or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) by either Public Company or Merger Partner if (i)&nbsp;Public Company Stockholders&#146; Meeting (including any adjournments and
postponements thereof) shall have been held and completed and Public Company&#146;s stockholders shall have taken a final vote on Public Company Stockholder Matters and the Other Public Company Stockholder Matters and (ii)&nbsp;any of the Public
Company Stockholder Matters or the Other Public Company Stockholder Matters shall not have been approved at the Public Company Stockholders&#146; Meeting (or at any adjournment or postponement thereof) by the Required Public Company Stockholder
Vote; <U>provided</U>, <U>however</U>, that the right to terminate this Agreement pursuant to this Section&nbsp;8.1(h) shall not be available to Public Company if Public Company&#146;s actions or failure to act has been a principal cause of the
failure of Public Company to obtain the Required Public Company Stockholder Vote and such action or failure to act constitutes a breach by Public Company of this Agreement; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) by Public Company, if (x)&nbsp;the Merger Partner Member Approval and the Blocker Approvals shall not have been obtained prior to 5:00
p.m., New York time, on the date that is ten (10)&nbsp;Business Days following the date that the SEC declares the Registration Statement effective or (y)&nbsp;Merger Partner shall have committed a material breach of Merger Partner&#146;s obligations
under Section&nbsp;5.5. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The party desiring to terminate this Agreement pursuant to this Section&nbsp;8.1 (other than pursuant to
Section&nbsp;8.1(a)) shall give notice of such termination to the other party specifying the provisions hereof pursuant to which such termination is made and the basis therefore described in reasonable detail. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_101"></A>8.2 <U>Effect of Termination</U>. In the event of the termination of this Agreement as provided in
Section&nbsp;8.1, this Agreement shall be of no further force or effect; <U>provided</U><I>, </I><U>however</U><I>,</I> that (a)&nbsp;this Section&nbsp;8.2, Section&nbsp;8.3, Article X and the definitions of the defined terms in such Sections
(including the definitions of such defined terms in Article IX) shall survive the termination of this Agreement and shall remain in full force and effect, and (b)&nbsp;the termination of this Agreement and the provisions of Section&nbsp;8.3 shall
not relieve any party of any liability for Fraud committed prior to such termination or for any Willful Breach prior to such termination of any representation, warranty, covenant, obligation or other provision contained in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_102"></A>8.3 <U>Fees and Expenses</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Except as otherwise expressly provided herein (including in this Section&nbsp;8.3), whether or not the Mergers are consummated, each party
will pay all fees and expenses (including legal and accounting fees and expenses) incurred by it in connection with the Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)
If: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) (A) this Agreement is terminated pursuant to Section&nbsp;8.1(b), Section&nbsp;8.1(e) or Section&nbsp;8.1(h) and (B)&nbsp;an
Acquisition Proposal with respect to Public Company shall have been publicly announced or disclosed to Public Company or Public Company Board after the date of this Agreement but prior to the termination of this Agreement (which shall not have been
withdrawn), and (C)&nbsp;within twelve (12)&nbsp;months after the date of such termination, Public Company enters into a definitive agreement with respect to or consummates an Acquisition Proposal; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) this Agreement is terminated by Merger Partner pursuant to Section&nbsp;8.1(f) or by Public Company pursuant to Section&nbsp;8.1(g);
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">then Public Company shall pay to Merger Partner an amount equal to $1,000,000 (a &#147;<U>Public Company Termination Fee</U>&#148;) within three
(3)&nbsp;Business Days of the termination of this Agreement or, in the cause of clause (i)&nbsp;above, the date of the applicable triggering event. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) If this Agreement is terminated by Public Company pursuant to Section&nbsp;8.1(i) or by
Merger Partner pursuant to Section&nbsp;8.1(e) at a time when Public Company had the right to terminate this Agreement pursuant to Section&nbsp;8.1(i), then Merger Partner shall pay to Public Company an amount equal to $1,000,000 (a &#147;<U>Merger
Partner Termination Fee</U>&#148;) and reimburse Public Company for Public Company&#146;s reasonable and documented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs and expenses incurred in
connection with this Agreement (such reimbursement not to exceed $500,000) within three (3)&nbsp;Business Days of the termination of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Any amounts due under this Section&nbsp;8.3 shall be paid by wire transfer of same day funds. If a party fails to pay when due any amount
payable by it under this Section&nbsp;8.3, then such party shall (i)&nbsp;reimburse the other party for reasonable costs and expenses (including reasonable fees and disbursements of counsel) incurred by it in connection with the collection of such
overdue amount and the enforcement by such party of its rights under this Section&nbsp;8.3 and (ii)&nbsp;pay to the other party interest on such overdue amount (for the period commencing as of the date such overdue amount was originally required to
be paid and ending on the date such overdue amount is actually paid in full) at a rate per annum equal to the &#147;prime rate&#148; (as published in The Wall Street Journal or any successor thereto) in effect on the date such overdue amount was
originally required to be paid. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The parties agree that, subject to Section&nbsp;8.2, (i) payment of the Public Company Termination
Fee set forth in this Section&nbsp;8.3 shall, in the circumstances in which it is owed in accordance with the terms of this Agreement, constitute the sole and exclusive remedy of Merger Partner and Blockers following the termination of this
Agreement, it being understood that in no event shall Public Company be required to pay a Public Company Termination Fee on more than one occasion and (ii)&nbsp;following payment of the Public Company Termination Fee (x)&nbsp;Public Company shall
have no further liability to Merger Partner or the Blockers in connection with or arising out of this Agreement or the termination thereof, any breach of this Agreement by Public Company giving rise to such termination, or the failure of the
Transactions to be consummated, (y)&nbsp;neither Merger Partner or a Blocker nor any of their respective Affiliates shall be entitled to bring or maintain any other claim, action or proceeding against Public Company or Merger Subsidiary or seek to
obtain any recovery, judgment or damages of any kind against such parties (or any partner, member, stockholder, director, officer, employee, Subsidiary, Affiliate, agent or other Representative of such parties) in connection with or arising out of
this Agreement or the termination thereof, any breach by any such parties giving rise to such termination or the failure of the Transactions to be consummated and (z)&nbsp;Merger Partner, Blockers and their respective Affiliates shall be precluded
from any other remedy against Public Company, Merger Subsidiary and their respective Affiliates, at law or in equity or otherwise, in connection with or arising out of this Agreement or the termination thereof, any breach by such party giving rise
to such termination or the failure of the Transactions to be consummated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Each of the parties acknowledges that (i)&nbsp;the
agreements contained in this Section&nbsp;8.3 are an integral part of the Transactions, (ii)&nbsp;without these agreements, the parties would not enter into this Agreement and (iii)&nbsp;any amount payable pursuant to this Section&nbsp;8.3 is not a
penalty, but rather is liquidated damages in a reasonable amount that will compensate the applicable party in the circumstances in which such amount is payable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_103"></A>8.4 <U>Amendment</U>. Prior to the Closing, this Agreement may be amended by Public Company and Merger
Partner at any time before or after receipt of the Public Company Stockholder Approval or the Merger Partner Member Approval, but, after receipt of the Public Company Stockholder Approval or the Merger Partner Member Approval, no amendment shall be
made which by Law requires further approval by such stockholders or members, as applicable, without such further approval; <U>provided</U>, <U>however</U>, that any such amendment that adversely effects a Blocker shall also require the approval of
such Blocker. This Agreement may not be amended except by an instrument in writing signed by Public Company, Merger Partner and the applicable Blockers (if any). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_104"></A>8.5 <U>Extension; Waiver</U>. (a)&nbsp;At any time prior to the Closing, Public Company and Merger Partner
may, to the extent legally allowed, (i)&nbsp;extend the time for the performance of any of the obligations or other acts of the other parties hereto, (ii)&nbsp;waive any inaccuracies in the representations and warranties contained herein or in any
document delivered pursuant hereto and (iii)&nbsp;waive compliance with any of the agreements or conditions </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
contained herein; (b)&nbsp;any agreement on the part of a party hereto to any such extension or waiver shall be valid only if set forth in a written instrument signed on behalf of such party;
(c)&nbsp;such extension or waiver shall not be deemed to apply to any time for performance, inaccuracy in any representation or warranty, or noncompliance with any agreement or condition, as the case may be, other than that which is specified in the
extension or waiver; and (d)&nbsp;the failure of any party to this Agreement to assert any of its rights under this Agreement or otherwise shall not constitute a waiver of such rights. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="annexarom401831_105"></A>ARTICLE IX </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEFINITIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes
of this Agreement, each of the following terms has the meaning set forth below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Acquisition Inquiry</U>&#148; means, with
respect to a Party, an inquiry, indication of interest or request for information (other than an inquiry, indication of interest or request for information made or submitted by Merger Partner, on the one hand, or Public Company, on the other hand,
to the other Party) that could reasonably be expected to lead to an Acquisition Proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Acquisition Proposal</U>&#148; means,
with respect to a Party, any offer or proposal, whether written or oral (other than an offer or proposal made or submitted by or on behalf of Merger Partner or any of its Subsidiaries, on the one hand, or by or on behalf of Public Company or any of
its Subsidiaries, on the other hand, to the other Party) contemplating or otherwise relating to or that could reasonably be interpreted to lead to any Acquisition Transaction with such Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Acquisition Transaction</U>&#148; means any transaction or series of related transactions involving: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) any merger, consolidation, amalgamation, share exchange, business combination, issuance of securities, acquisition of securities,
reorganization, recapitalization, tender offer, exchange offer or other similar transaction: (i)&nbsp;in which a Party is a constituent entity; (ii)&nbsp;in which a Person or &#147;group&#148; (as defined in the Exchange Act and the rules
promulgated thereunder) of Persons directly or indirectly acquires beneficial or record ownership of securities representing (A)&nbsp;with respect to Public Company more than 20% of the outstanding securities of any class of voting securities of a
Party or any of its Subsidiaries or (B)&nbsp;with respect to Merger Partner more than 35% of the outstanding securities of any class of voting securities of a Party or any of its Subsidiaries; or (iii)&nbsp;in which (Y)&nbsp;Public Company or any of
its Subsidiaries issues securities representing more than 20% of the outstanding securities of any class of voting securities of Public Company or any of its Subsidiaries or (Z)&nbsp;Merger Partner or any of its Subsidiaries issues securities
representing more than 35% of the outstanding securities of any class of voting securities of Merger Partner or any of its Subsidiaries; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) any sale, lease, exchange, transfer, license, acquisition or disposition of any business or businesses or assets that constitute or
account for 20% or more of the consolidated book value or the fair market value of the assets of a Party and its Subsidiaries, taken as a whole. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Additional Merger Partner Unit</U>&#148; has the meaning set forth in Section&nbsp;2.3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Affiliate</U>&#148; means, with respect to a Person, any other Person who is an &#147;affiliate&#148; of that Person within the
meaning of Rule 405 promulgated under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Agreement</U>&#148; has the meaning set forth in the first paragraph
of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Allocation Schedule</U>&#148; means the schedule attached hereto as <U>Exhibit G</U> (as such schedule may be
updated, corrected, amended or modified in accordance with Section&nbsp;2.3 from time to time), setting forth for each holder of a Merger Partner Unit and of a Merger Partner Warrant and of an equity interest in each Blocker: (i)&nbsp;the name
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and address for such Person; (ii)&nbsp;the number and class of interests of Merger Partner and each Blocker, as applicable, held by such Person; and (iii)&nbsp;the portion of the Merger
Consideration attributable to such Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Amended <FONT STYLE="white-space:nowrap">By-Laws</FONT></U>&#148; has the meaning set
forth in Section&nbsp;1.3(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Amended Certificate</U>&#148; has the meaning set forth in Section&nbsp;1.3(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Amended Operating Agreement</U>&#148; has the meaning set forth in Section&nbsp;1.3(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Anti-Bribery Laws</U>&#148; has the meaning set forth in Section&nbsp;3.17. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Asset Transfer Agreements</U>&#148; has the meaning set forth in Section&nbsp;7.5. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Asset Transfers</U>&#148; has the meaning set forth in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Blocker 1</U>&#148; has the meaning set forth in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Blocker 2</U>&#148; has the meaning set forth in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Blocker 3</U>&#148; has the meaning set forth in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Blocker 4</U>&#148; has the meaning set forth in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Blocker 5</U>&#148; has the meaning set forth in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Blocker 6</U>&#148; has the meaning set forth in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Blocker 7</U>&#148; has the meaning set forth in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Blocker 8</U>&#148; has the meaning set forth in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Blocker 9</U>&#148; has the meaning set forth in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Blocker 10</U>&#148; has the meaning set forth in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Blocker Approvals</U>&#148; means a written consent of the sole member of each of Blocker 2 through Blocker 10 wherein the sole
member of each such Blocker adopted this Agreement and approved the Transactions, including the applicable Blocker Merger, in each case, consistent with the applicable provisions of such Blocker&#146;s Organizational Documents and Delaware Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Blocker Certificate of Merger</U>&#148; has the meaning set forth in Section&nbsp;1.1(a)(i). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Blocker Merger Effective Time</U>&#148; has the meaning set forth in Section&nbsp;1.1(a)(iii). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Business Day</U>&#148; means any day other than (a)&nbsp;a Saturday or Sunday or (b)&nbsp;a day on which banking institutions located
in Wilmington, Delaware or New York, New York are permitted or required by Law, executive order or governmental decree to remain closed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>CERCLA</U>&#148; means the federal Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Certifications</U>&#148; has the meaning set forth in Section&nbsp;4.6(a). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Closing</U>&#148; means the closing of the Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Closing Date</U>&#148; means (a)&nbsp;the second (2<SUP STYLE="font-size:75%; vertical-align:top">nd</SUP>) Business Day after the
satisfaction or waiver of the conditions set forth in Article VI (other than the delivery of items to be delivered at the Closing and other than satisfaction of those conditions that by their nature are to be satisfied at the Closing, it being
understood that the occurrence of the Closing shall remain subject to the delivery of such items and the satisfaction or waiver of such conditions at the Closing) or (b)&nbsp;such other date as may be mutually agreed to in writing by Merger Partner
and Public Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Code</U>&#148; means the Internal Revenue Code of 1986, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Confidentiality Agreement</U>&#148; means the Confidentiality Agreement dated September&nbsp;7, 2022 between Merger Partner and
Public Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Copyright</U>&#148; has the meaning set forth in the definition of &#147;Intellectual Property&#148; herein.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U><FONT STYLE="white-space:nowrap">COVID-19</FONT></U>&#148; means
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> or <FONT STYLE="white-space:nowrap">COVID-19,</FONT> and any evolutions thereof or related or associated epidemics, pandemics or disease outbreaks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U><FONT STYLE="white-space:nowrap">COVID-19</FONT> Measures</U>&#148; means any quarantine, &#147;shelter in place,&#148; &#147;stay at
home,&#148; workforce reduction, social distancing, shutdown, closure, sequester or any other applicable Law, order or recommendations of a Governmental Entity, or any applicable directive or guidance from any applicable industry group widely
followed by the party&#146;s industry peer companies in response to <FONT STYLE="white-space:nowrap">COVID-19.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Delaware
Law</U>&#148; means, as the context requires, the DGCL and/or the DLLCA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Design</U>&#148; has the meaning set forth in the
definition of &#147;Intellectual Property&#148; herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Determination Notice</U>&#148; has the meaning set forth in
Section&nbsp;5.9(d)(i). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>DGCL</U>&#148; means the Delaware General Corporation Law, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Disclosure Statement</U>&#148; means a written information statement, which shall include a copy of the Proxy Statement/Prospectus
and shall contain the information prescribed by Section&nbsp;5.10(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>DLLCA</U>&#148; means the Delaware Limited Liability
Company Act, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>DOL</U>&#148; has the meaning set forth in Section&nbsp;3.15(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Effect</U>&#148; has the meaning set forth in the definition of &#147;Merger Partner Material Adverse Effect&#148; herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Eighth Blocker Merger</U>&#148; has the meaning set forth in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Electing Member</U>&#148; has the meaning set forth in Section&nbsp;2.5(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Election Deadline</U>&#148; has the meaning set forth in Section&nbsp;2.5(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Election Form</U>&#148; has the meaning set forth in Section&nbsp;2.5(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Election Period</U>&#148; has the meaning set forth in Section&nbsp;2.5(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Employee Benefit Plans</U>&#148; means all (a) &#147;employee benefit plans,&#148; as defined in Section&nbsp;3(3) of ERISA, together
with plans or arrangements that would be so defined if they were not (i)&nbsp;otherwise exempt from ERISA </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by Section&nbsp;3(3) of ERISA or another Section of ERISA, (ii)&nbsp;maintained outside the United States or (iii)&nbsp;individually negotiated or applicable only to one individual and
(b)&nbsp;any other written or oral benefit arrangement or obligation to provide benefits as compensation for services rendered, including employment or consulting agreements (except for agreements that provide termination at no cost to Merger
Partner), severance agreements, arrangements, plans or pay policies, stay or retention bonuses or compensation, incentive (including equity or equity-linked) plans, programs or arrangements, patent award programs, relocation benefits, loan, sick
leave, vacation pay, plant closing benefits, salary continuation or insurance for disability, individual consulting, or other compensation arrangements, retirement, supplemental retirement, pension, deferred compensation, profit sharing, bonus,
stock option or purchase plans or programs, hospitalization, medical insurance, life insurance, dental insurance, tuition reimbursement or scholarship programs, any plans subject to Section&nbsp;125 of the Code and any plans providing benefits or
payments in the event of a change of control, change in ownership or effective control, or sale of a substantial portion (including all or substantially all) of the assets of any business or portion thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Employment Agreement</U>&#148; has the meaning set forth in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Environmental Law</U>&#148; means any Law relating to the environment, occupational health and safety, or exposure of Persons or
property to Materials of Environmental Concern, including any statute, regulation, administrative decision or order pertaining to: (a) the presence of or the treatment, storage, disposal, generation, transportation, handling, distribution,
manufacture, processing, use, import, export, labeling, recycling, registration, investigation or remediation of Materials of Environmental Concern or documentation related to the foregoing; (b)&nbsp;air, water and noise pollution;
(c)&nbsp;groundwater and soil contamination; (d)&nbsp;the release, threatened release, or accidental release into the environment, the workplace or other areas of Materials of Environmental Concern, including emissions, discharges, injections,
spills, escapes or dumping of Materials of Environmental Concern; (e)&nbsp;transfer of interests in or control of real property which may be contaminated; (f)&nbsp;community or worker
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-to-know</FONT></FONT> disclosures with respect to Materials of Environmental Concern; (g)&nbsp;the protection of wild life, marine life and wetlands, and endangered and
threatened species; (h)&nbsp;storage tanks, vessels, containers, abandoned or discarded barrels and other closed receptacles; and (i)&nbsp;health and safety of employees and other Persons. As used above, the term &#147;release&#148; shall have the
meaning set forth in CERCLA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>ERISA</U>&#148; means the Employee Retirement Income Security Act of 1974, as amended, and the
rules and regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>ERISA Affiliate</U>&#148; means any entity that is, or at any applicable time was,
a member of (a)&nbsp;a controlled group of corporations (as defined in Section&nbsp;414(b) of the Code), (b) a group of trades or businesses under common control (as defined in Section&nbsp;414(c) of the Code), or (c)&nbsp;an affiliated service
group (as defined under Section&nbsp;414(m) of the Code or the regulations under Section&nbsp;414(o) of the Code). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Exchange and
Paying Agent</U>&#148; means Broadridge Corporate Issuer Solutions, Inc., in its capacity as exchange and paying agent, or another bank or trust company reasonably and mutually acceptable to Public Company and Merger Partner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Exchange and Paying Agent Agreement</U>&#148; means an agreement, in form and substance reasonably acceptable to Merger Partner, to
be entered into at or prior to the Effective Time by the Exchange and Paying Agent and Public Company, governing the disbursement of the Payment Fund. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Exchange Act</U>&#148; means the Securities Exchange Act of 1934, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Exchange Agreement</U>&#148; has the meaning set forth in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Exchanges</U>&#148; has the meaning set forth in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Excluded Units</U>&#148; has the meaning set forth in Section&nbsp;2.5(b). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Executive Severance Plan</U>&#148; has the meaning set forth in
Section&nbsp;7.1(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Fifth Blocker Merger</U>&#148; has the meaning set forth in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>First Blocker Merger</U>&#148; has the meaning set forth in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Fourth Blocker Merger</U>&#148; has the meaning set forth in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Fraud</U>&#148; with respect to a party means intentional common law fraud under Delaware law in the making of the representations
and warranties in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Fundamental Representations</U>&#148; means, with respect to Merger Partner, the
representations in Sections 3.1, 3.2, 3.3(c), 3.4 (other than 3.4(c)(iii) and 3.4(c)(iv)), 3.21, 3.22, 3.23, 3.24 and 3.25 (other than 3.25(b)(iii) and 3.25(b)(iv)) and, with respect to Public Company, the representations in Sections 4.1, 4.2, 4.4
(other than 4.4(c)(iii) and 4.4(c)(iv)), 4.5, 4.22 and 4.25). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>GAAP</U>&#148; means United States generally accepted accounting
principles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Governmental Entity</U>&#148; means any federal, state, local or foreign government or any court, arbitrational
tribunal, administrative agency or commission or government authority acting under the authority of the federal or any state, local or foreign government. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>HSR</U>&#148; means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the rules and regulations promulgated
thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Indebtedness</U>&#148; with respect to any Person means (a)&nbsp;any indebtedness or other obligation for borrowed
money or under bonds, notes, debentures or similar instruments, letters of credit, acceptance credit or similar facilities, as well as any cash advances; (b)&nbsp;any obligation incurred for all or any part of the purchase price of property or other
assets (including earnout, milestone, royalty and similar obligations) or for the cost of property or other assets constructed or of improvements thereto, other than accounts payable included in current liabilities and incurred in respect of
property purchased in the Ordinary Course of Business; (c)&nbsp;letters of credit issued for the account of such Person to the extent drawn; (d)&nbsp;lease obligations required to be capitalized by GAAP; (e)&nbsp;all guarantees and similar
obligations of such Person with respect to obligations of another Person of the nature described in clauses (a), (b), (c) or (d)&nbsp;above; (f) all bankers acceptances and overdrafts; (g)&nbsp;declared but unpaid dividends or distributions; and
(h)&nbsp;all interest, prepayment premiums and penalties, guarantees, and any other fees, expenses, indemnities and other amounts payable as a result of the prepayment or discharge of any indebtedness listed in clause (a)&nbsp;above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Intellectual Property</U>&#148; means, in any and all jurisdictions throughout the world, all (a)&nbsp;patents, patent applications,
inventors&#146; certificates, utility models, statutory invention registrations, and other indicia of ownership of an invention, discovery or improvement issued by a Governmental Authority, including reissues, divisionals, continuations, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part,</FONT></FONT> extensions, reexaminations and other <FONT STYLE="white-space:nowrap">pre-grant</FONT> and post-grant forms of the foregoing (collectively,
&#147;<U>Patents</U>&#148;), (b) trademarks, service marks, trade dress, slogans, logos, symbols, trade names, brand names and other identifiers of source or goodwill recognized by any Governmental Authority, including registrations and applications
for registration thereof and including the goodwill symbolized thereby or associated therewith (collectively, &#147;<U>Trademarks</U>&#148;), and Internet domain names and associated uniform resource locators, (c)&nbsp;copyrights, whether in
published and unpublished works of authorship, registrations, applications, renewals and extensions therefor, mask works, and any and all similar rights recognized in a work of authorship by a Governmental Authority (collectively,
&#147;Copyrights&#148;), (d) any rights in any inventions, discoveries, improvements and all other confidential or proprietary Information (including <FONT STYLE="white-space:nowrap">know-how,</FONT> data, formulas, processes and procedures,
research records, records of inventions, test information, and market surveys), and all rights to limit the use or disclosure thereof (collectively, &#147;Trade Secrets&#148;), (e) registered and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
unregistered design rights (collectively, &#147;Designs&#148;), (f) rights of privacy and publicity, and (g)&nbsp;any and all other intellectual or industrial property rights recognized by any
Governmental Authority under the Laws of any country throughout the world. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Intended Tax Treatment</U>&#148; has the meaning set
forth in Section&nbsp;7.3(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Interim Funding</U>&#148; has the meaning set forth in Section&nbsp;5.17. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Knowledge</U>&#148; and words of similar effect means (a)&nbsp;with respect to Public Company, the actual knowledge of each of the
individuals identified in Section&nbsp;9.01 of the Public Company Disclosure Schedule, in each case after due and reasonable inquiry of their respective direct reports and (b)&nbsp;with respect to Merger Partner and the Blockers, the actual
knowledge of each of the individuals identified in Section&nbsp;9.01 of the Merger Partner Disclosure Schedule, in each case after due and reasonable inquiry of their respective direct reports. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Law</U>&#148; means any United States federal, state or local or foreign law, common law, statute, standard, ordinance, code, rule,
regulation, resolution or promulgation, or any decree, order, injunction, rule, judgment, consent of or by any Governmental Entity, or any Permit or similar right granted under any of the foregoing, or any similar provision having the force or
effect of law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Lease</U>&#148; means any lease, sublease, license, or occupancy agreement pursuant to which Merger Partner (or
its Subsidiaries) or Public Company (or its Subsidiaries), as applicable, leases or subleases from or to another party any real property, or otherwise occupies any real property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Legal Proceeding</U>&#148; means any action, suit, proceeding (including administrative proceeding), claim, complaint, hearing,
information request, notice of violation, arbitration, inquiry or investigation of or before any Governmental Entity or before any arbitrator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Letter of Transmittal</U>&#148; means a letter of transmittal in the form to be mutually agreed between Public Company and Merger
Partner promptly following the execution and delivery of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Lien</U>&#148; means any mortgage, pledge, security
interest, encumbrance, charge or other lien (whether arising by contract or by operation of Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Mailing Date</U>&#148; has the
meaning set forth in Section&nbsp;2.5(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Management Services Agreement</U>&#148; means that certain Management Services
Agreement, dated January&nbsp;1, 2016, by and among Cellectis SA, a French <I>Soci&eacute;t&eacute; Anonyme</I>, Cellectis, Inc., a Delaware corporation, and Public Company, as amended by that certain First Amendment to the Management Services
Agreement, dated July&nbsp;25, 2017, and that certain Second Amendment to Management Services Agreement, dated January&nbsp;29, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Materials of Environmental Concern</U>&#148; means any: pollutants, contaminants or hazardous substances (as such terms are defined
under CERCLA), pesticides (as such term is defined under the Federal Insecticide, Fungicide and Rodenticide Act), solid wastes and hazardous wastes (as such terms are defined under the Resource Conservation and Recovery Act), chemicals, other
hazardous, radioactive or toxic materials, oil, petroleum and petroleum products (and fractions thereof), or any other material (or article containing such material) listed or subject to regulation under any Law due to its potential, directly or
indirectly, to harm the environment or the health of humans or other living beings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Measurement Date</U>&#148; has the meaning
set forth in 4.2(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Mergers</U>&#148; has the meaning set forth in the Recitals. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Merger Consideration</U>&#148; means the shares of Public Company Class&nbsp;A
Common Stock and Public Company Class&nbsp;B Common Stock and Merger Partner Common Units, as applicable, calculated in accordance with Section&nbsp;2.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Merger Partner</U>&#148; has the meaning set forth in the first paragraph of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Merger Partner Benefit Plan</U>&#148; means any Employee Benefit Plan in respect of any employees, independent contractors,
directors, officers or members of Merger Partner or any of its Subsidiaries that are sponsored or maintained by Merger Partner or any of its Subsidiaries or with respect to which Merger Partner or any of its Subsidiaries is required to make
payments, transfers or contributions or has or may have any actual, potential or contingent liability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Merger Partner
Board</U>&#148; means the board of managers of Merger Partner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Merger Partner Certificate of Merger</U>&#148; has the meaning
set forth in Section&nbsp;1.1(b)(i). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Merger Partner Change in Circumstance</U>&#148; means a change in circumstances (other than
an Acquisition Proposal) that affects the business, assets or operations of Merger Partner that occurs or arises after the date of this Agreement that was neither known to Merger Partner or Merger Partner Board nor reasonably foreseeable on, or
prior to, the date of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Merger Partner Common Unit</U>&#148; means the units of Merger Partner designated as
&#147;Common Units&#148; with such rights and restrictions as to be set forth in the Amended Operating Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Merger Partner
Contract</U>&#148; has the meaning set forth in Section&nbsp;3.11(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Merger Partner Disclosure Schedule</U>&#148; means Merger
Partner Disclosure Schedule provided by Merger Partner to Public Company on the date hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Merger Partner Employee</U>&#148;
means any employee (whether current or former) of Merger Partner or any Subsidiary of Merger Partner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Merger Partner Financial
Statements</U>&#148; means: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) the consolidated audited balance sheets, statements of operations and comprehensive loss, statements of
convertible preferred stock and stockholders&#146; deficit and statements of cash flows of Merger Partner as of the end of and for each of the fiscal years ended December&nbsp;31, 2020 and 2021, as certified without qualification by BDO USA, LLC,
Merger Partner&#146;s independent public accountants; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) the consolidated unaudited balance sheets of Merger Partner for any interim
periods after December&nbsp;31, 2021, including at September&nbsp;30, 2022, and the related consolidated unaudited statements of operations and comprehensive loss, statements of convertible preferred stock and stockholders&#146; deficit and
statements of cash flows for each of the interim period then ended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Merger Partner Intellectual Property</U>&#148; has the
meaning set forth in Section&nbsp;3.10(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Merger Partner Insurance Policies</U>&#148; has the meaning set forth in
Section&nbsp;3.19(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Merger Partner IT Systems</U>&#148; means any computer systems, networks, hardware, software and other
information technology equipment used in connection with the business of Merger Partner and its Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Merger Partner
Material Adverse Effect</U>&#148; means any change, event, effect, circumstance or development (collectively, &#147;<U>Effects</U>&#148;) that, considered together with all other Effects, has or would reasonably be expected to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
have a material adverse effect on the business, condition (financial or otherwise), assets, liabilities or results of operations of Merger Partner or its Subsidiaries, taken as a whole;
<U>provided</U>, <U>however</U>, that Effects resulting from the following shall not be taken into account in determining whether there has been a Merger Partner Material Adverse Effect: (a)&nbsp;general business or economic conditions generally
affecting the industry in which Merger Partner and its Subsidiaries operate, (b)&nbsp;acts of war, the outbreak or escalation of armed hostilities, acts of terrorism (including cyberterrorism), earthquakes, wildfires, hurricanes or other natural
disasters, health emergencies, including pandemics (including <FONT STYLE="white-space:nowrap">COVID-19)</FONT> and related or associated epidemics, disease outbreaks and any governmental or industry responses thereto (including quarantine
restrictions), (c) changes in financial, banking, securities markets, or general economic, regulatory, legislative or political conditions (including changes in interest or exchange rates), (d) any change in, or any compliance with or action taken
for the purpose of complying with, any Law or GAAP (or interpretations of any Law or GAAP), (e) resulting from the announcement of this Agreement or the pendency of the Transactions, (g)&nbsp;the failure of Merger Partner to meet internal
expectations or projections or the results of operations of Merger Partner in and of itself (it being understood, however, that any Effect causing or contributing to such failure may be taken into account in determining whether a Merger Partner
Material Adverse Effect has occurred, unless such Effects are otherwise excepted from this definition) or (h)&nbsp;resulting from the taking of any action required to be taken by this Agreement, except in each case with respect to clauses
(a)&nbsp;through (c), to the extent disproportionately affecting Merger Partner and its Subsidiaries, taken as a whole, relative to other similarly situated companies in the industries in which Merger Partner and its Subsidiaries operate (and then
only the amount of such disproportionate impact shall be taken into account). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Merger Partner Member Approval</U>&#148; means
approval of (i)&nbsp;a majority of the issued and outstanding Series D Preferred Units in Merger Partner, (ii)&nbsp;a majority of the issued and outstanding Series E Preferred Units in Merger Partner, (iii)&nbsp;a majority of the issued and
outstanding Series F Preferred Units in Merger Partner and (iv)&nbsp;a majority of the issued and outstanding Preferred Units in Merger Partner in each of cases (i)&nbsp;through (iv) to (a)&nbsp;agree to convert all issued and outstanding Preferred
Units in Merger Partner into Voting Common Units on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis and (b)&nbsp;approve the Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Merger Partner Merger Effective Time</U>&#148; has the meaning set forth in Section&nbsp;1.1(b)(iii). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Merger Partner PIU</U>&#148; means Common Units of the Merger Partner, which are &#147;profits interests&#148; (as described in IRS
Revenue Procedure <FONT STYLE="white-space:nowrap">93-27</FONT> and IRS Revenue Procedure <FONT STYLE="white-space:nowrap">2001-43)</FONT> in Merger Partner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Merger Partner Preferred Unit</U>&#148; means a membership unit representing a preferred membership interest in Merger Partner, which
may be designated as a Series A Preferred Unit, Series B Preferred Unit, Series C Preferred Unit, Series D Preferred Unit, Series E Preferred Unit or Series F Preferred Unit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Merger Partner Privacy Requirements</U>&#148; has the meaning set forth in Section&nbsp;3.20(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Merger Partner Support Agreement</U>&#148; has the meaning set forth in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Merger Partner Support Holders</U>&#148; has the meaning set forth in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Merger Partner Termination Fee</U>&#148; has the meaning set forth in Section&nbsp;8.3(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Merger Partner Unit</U>&#148; means a membership unit representing a membership interest in Merger Partner, which may be designated
as a Series A Preferred Unit, Series B Preferred Unit, Series C Preferred Unit, Series D Preferred Unit, Series E Preferred Unit, Series F Preferred Unit, Voting Common Unit or Common Units. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Merger Partner Warrant</U>&#148; means a warrant to purchase membership units representing a membership interest in Merger Partner.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Merger Subsidiary</U>&#148; has the meaning set forth in the first paragraph of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Ninth Blocker Merger</U>&#148; has the meaning set forth in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>OFCCP</U>&#148; has the meaning set forth in Section&nbsp;3.14(g). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Ordinary Course of Business</U>&#148; means the ordinary course of business consistent with past custom and practice (including with
respect to frequency and amount) of the applicable Person, including, without limitation, with respect to the preparation and making of filings with the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Organizational Documents</U>&#148; means, with respect to any Person (other than an individual), (a) the certificate or articles of
incorporation or organization and any joint venture, limited liability company, operating or partnership agreement and other similar documents adopted or filed in connection with the creation, formation or organization of such Person and
(b)&nbsp;all <FONT STYLE="white-space:nowrap">by-laws,</FONT> stockholder agreements, voting agreements and similar documents, instruments or agreements relating to the organization or governance of such Person, in each case, as amended or
supplemented. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Outside Date</U>&#148; means May&nbsp;15, 2023, as may be extended pursuant to Section&nbsp;8.1(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Participating Member</U>&#148; means any member of Merger Partner prior to the Merger Partner Merger Effective Time, other than the
Blockers, the Electing Members or Public Company or its Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Pass-Through Income Tax</U>&#148; means any income Tax
with respect to which the holders of units of Merger Partner outstanding as of immediately prior to the Closing (or any of their direct or indirect owners) would be primarily liable as a matter of Tax Law (e.g., the income Tax liability for items of
income, gain, loss, deduction and credit passed-through to owners of an entity treated as a partnership for U.S. federal income Tax purposes). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Pass-Through Return</U>&#148; has the meaning set forth in Section&nbsp;7.3(e). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Patent</U>&#148; has the meaning set forth in the definition of &#147;Intellectual Property&#148; herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Payment Fund</U>&#148; has the meaning set forth in Section&nbsp;2.2(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Permits</U>&#148; means all permits, licenses, registrations, certificates, orders, exemptions, approvals, franchises, variances,
clearances and similar rights issued by or obtained from any Governmental Entity (including those issued or required under Environmental Laws and those relating to the occupancy or use of owned or leased real property). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Permitted Lien</U>&#148; means than (a)&nbsp;mechanic&#146;s, material men&#146;s and similar liens to secure claims for labor,
materials or supplies arising in the Ordinary Course of Business of the applicable party and its Subsidiaries, (b)&nbsp;liens arising under worker&#146;s compensation, unemployment insurance, social security, retirement and similar legislation,
(c)&nbsp;liens on goods in transit incurred pursuant to documentary letters of credit, in each case arising in the Ordinary Course of Business of the applicable Party and its Subsidiaries, (d)&nbsp;any liens for current Taxes not yet due and payable
or for Taxes that are being contested in good faith and, in each case, for which adequate reserves have been made in accordance with GAAP on the applicable party&#146;s unaudited interim balance sheet, as applicable, (e)&nbsp;statutory liens to
secure obligations to landlords, lessors or renters under leases or rental agreements, (f)&nbsp;deposits or pledges made in connection with, or to secure payment of, workers&#146; compensation, unemployment insurance or similar programs mandated by
Law in the Ordinary Course of Business of the applicable party and its Subsidiaries, <FONT STYLE="white-space:nowrap">(g)&nbsp;non-exclusive</FONT> licenses of Intellectual Property granted by a party or any of its Subsidiaries, as applicable, in
the Ordinary Course of Business and that do not (in any case or in the aggregate) materially detract from the value of the Intellectual Property subject thereto, and (h)&nbsp;liens that, individually or in the aggregate, are not material to Merger
Partner (and its Subsidiaries) or Public Company (and its Subsidiaries), as applicable, taken as a whole. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Person</U>&#148; means any natural Person, firm, limited liability company, general
or limited partnership, association, corporation, unincorporated organization, company, joint venture, trust, Governmental Entity or other entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Personal Information</U>&#148; has the definition that &#147;Personal information,&#148; &#147;Personal data,&#148; &#147;protected
health information&#148; and similar terms are assigned under applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U><FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Period</U>&#148; means the period commencing on the date of this Agreement and
ending at the Effective Time or such earlier date as this Agreement is terminated in accordance with its terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U><FONT
STYLE="white-space:nowrap">Pre-Closing</FONT> Tax Period</U>&#148; means any taxable period ending on or before the Closing Date and the portion of any Straddle Period through and including the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Privacy Laws</U>&#148; means any Laws that govern the receipt, collection, compilation, use, storage, sharing, safeguarding,
security, disposal, destruction, disclosure, transfer or other processing of Personal Information, and any Laws governing privacy, data security, data or security breach notification, and any order of a Governmental Entity dealing with same,
including, without limitation: (i)&nbsp;Section&nbsp;5 of the Federal Trade Commission Act, the Health Information Portability and Accountability Act, the <FONT STYLE="white-space:nowrap">CAN-SPAM</FONT> Act, the Telephone Consumer Protection Act,
the California Online Privacy Protection Act, the California Consumer Privacy Act, the Illinois Biometric Information Privacy Act and other Laws governing the processing of biometric data, the Massachusetts Data Security Regulations set forth at 201
CMR 17.00, and any other United States federal and state Laws implementing, supplementing or amending the foregoing or otherwise concerning privacy, data protection, data security, or electronic marketing; and (ii)&nbsp;any Laws in any relevant
jurisdiction concerning privacy, data protection, data security, or electronic marketing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Proxy Statement/Prospectus</U>&#148;
means the proxy statement/prospectus, which shall be included in the Registration Statement, to be sent to Public Company&#146;s stockholders in connection with the Public Company Stockholders&#146; Meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Public Company</U>&#148; has the meaning set forth in the first paragraph of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Public Company Benefit Plan</U>&#148; means any Employee Benefit Plan in respect of any employees, independent contractors,
directors, officers or shareholders of Public Company or any of its Subsidiaries that are sponsored or maintained by Public Company or any Subsidiary or with respect to which Public Company or any of its Subsidiaries is required to make payments,
transfers or contributions or has or may have any actual, potential or contingent liability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Public Company Board</U>&#148;
means the board of directors of Public Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Public Company Board Adverse Recommendation Change</U>&#148; has the meaning set
forth in Section&nbsp;5.9(c). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Public Company Board Recommendation</U>&#148; has the meaning set forth in Section&nbsp;5.9(c).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Public Company Change in Circumstance</U>&#148; means a change in circumstances (other than an Acquisition Proposal) that
affects the business, assets or operations of Public Company that occurs or arises after the date of this Agreement that was neither known to Public Company or Public Company Board nor reasonably foreseeable on, or prior to, the date of this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Public Company Class</U><U></U><U>&nbsp;A Common Stock</U>&#148; means the Class&nbsp;B Common Stock, par value
$0.0001 per share, of Public Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Public Company Class</U><U></U><U>&nbsp;B Common Stock</U>&#148; means the Class&nbsp;B
Common Stock, par value $0.0001 per share, of Public Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Public Company Common Stock</U>&#148; means the common stock, $0.0001 par value per
share, of Public Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Public Company Contract</U>&#148; has the meaning set forth in Section&nbsp;4.12(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Public Company Disclosure Schedule</U>&#148; means Public Company Disclosure Schedule provided by Public Company to Merger Partner on
the date hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Public Company Employee</U>&#148; means any employee (whether current or former) of Public Company or any of
its Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Public Company Financial Statements</U>&#148; means: each of the consolidated financial statements (including,
in each case, any related notes and schedules) contained in Public Company SEC Reports. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Public Company Insurance
Policy</U>&#148; has the meaning set forth in Section&nbsp;4.20(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Public Company Intellectual Property</U>&#148; has the
meaning set forth in Section&nbsp;4.11. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Public Company IT Systems</U>&#148; means any computer systems, networks, hardware,
software and other information technology equipment used in connection with the business of Public Company and its Subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Public Company Material Adverse Effect</U>&#148; means any Effect that, considered together with all other Effects, has or would
reasonably be expected to have a material adverse effect on the business, condition (financial or otherwise), assets, liabilities or results of operations of Public Company or its Subsidiaries, taken as a whole; <U>provided</U>, <U>however</U>, that
Effects resulting from the following shall not be taken into account in determining whether there has been a Public Company Material Adverse Effect: (a)&nbsp;general business or economic conditions generally affecting the industry in which Public
Company and its Subsidiaries operate, (b)&nbsp;acts of war, the outbreak or escalation of armed hostilities, acts of terrorism (including cyberterrorism), earthquakes, wildfires, hurricanes or other natural disasters, health emergencies, including
pandemics (including <FONT STYLE="white-space:nowrap">COVID-19)</FONT> and related or associated epidemics, disease outbreaks and any governmental or industry responses thereto (including quarantine restrictions), (c) changes in financial, banking,
securities markets, or general economic, regulatory, legislative or political conditions (including changes in interest or exchange rates), (d) any change in, or any compliance with or action taken for the purpose of complying with, any Law or GAAP
(or interpretations of any Law or GAAP), (e) resulting from the announcement of this Agreement or the pendency of the Transactions, (g)&nbsp;the failure of Public Company to meet internal expectations or projections or the results of operations of
Public Company in and of itself (it being understood, however, that any Effect causing or contributing to such failure may be taken into account in determining whether a Public Company Material Adverse Effect has occurred, unless such Effects are
otherwise excepted from this definition) or (h)&nbsp;resulting from the taking of any action required to be taken by this Agreement, except in each case with respect to clauses (a)&nbsp;through (c), to the extent disproportionately affecting Public
Company and its Subsidiaries, taken as a whole, relative to other similarly situated companies in the industries in which Public Company and its Subsidiaries operate (and then only the amount of such disproportionate impact shall be taken into
account). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Public Company Privacy Requirements</U>&#148; has the meaning set forth in Section&nbsp;4.21(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Public Company PSU</U>&#148; has the meaning set forth in Section&nbsp;4.2(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Public Company RSU</U>&#148; has the meaning set forth in Section&nbsp;4.2(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Public Company SEC Reports</U>&#148; has the meaning set forth in Section&nbsp;4.6. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Public Company Stock Option</U>&#148; has the meaning set forth in Section&nbsp;4.2(b). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Public Company Stock Plan</U>&#148; has the meaning set forth in
Section&nbsp;4.2(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Public Company Stockholder Approval</U>&#148; means the approval of the Public Company Stockholder Matters
and the Other Public Company Stockholder Matters by the stockholders of Public Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Public Company Stockholder
Matters</U>&#148; has the meaning set forth in Section&nbsp;5.9(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Public Company Stockholder Meeting</U>&#148; has the meaning
set forth in Section&nbsp;5.9(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Public Company Support Stockholders</U>&#148; has the meaning set forth in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Public Company Support Agreements</U>&#148; has the meaning set forth in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Public Company Termination Fee</U>&#148; has the meaning set forth in Section&nbsp;8.3(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Public Company Transaction Litigation</U>&#148; has the meaning set forth in Section&nbsp;7.4. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Registration Rights Agreement</U>&#148; has the meaning set forth in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Registration Statement</U>&#148; means the registration statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> (or any other
applicable form under the Securities Act to register Public Company Common Stock) to be filed with the SEC by Public Company registering the public offering and sale of Public Company Common Stock to the equity holders of Blockers and Merger Partner
in the Mergers, as may be amended prior to the time it is declared effective by the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Representatives</U>&#148; means, with
respect to any Person, such Person&#146;s directors, officers, employees, agents, attorneys, accountants, investment bankers, advisors and representatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Required Public Company Stockholder Vote</U>&#148; means the affirmative vote of the holders of a majority of the issued and
outstanding shares Public Company Common Stock entitled to vote thereon at a meeting of the holders of Public Company Common Stock duly called and convened in accordance with the Proxy Statement/Prospectus, Delaware Law, Public Company&#146;s
Organizational Documents and the rules and regulations of Nasdaq. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Sarbanes-Oxley Act</U>&#148; means the Sarbanes-Oxley Act of
2002. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>SEC</U>&#148; means the United States Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Second Blocker Merger</U>&#148; has the meaning set forth in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Securities Act</U>&#148; means the Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Seventh Blocker Merger</U>&#148; has the meaning set forth in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Sixth Blocker Merger</U>&#148; has the meaning set forth in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Straddle Period</U>&#148; means any taxable period that beings on or before the Closing Date and ends after the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Subsidiary</U>&#148; means, with respect to any Person, any corporation, partnership, trust, limited liability company or other <FONT
STYLE="white-space:nowrap">non-corporate</FONT> business enterprise in which such Person (or another Subsidiary of such Person) holds stock or other ownership interests representing (a)&nbsp;more than 50% of the voting power of all outstanding stock
or ownership interests of such entity or (b)&nbsp;the right to receive more than 50% of the net assets of such entity available for distribution to the holders of outstanding stock or ownership interests upon a liquidation or dissolution of such
entity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Superior Offer</U>&#148; means an unsolicited bona fide written Acquisition
Proposal (with all references to 20% in the definition of Acquisition Transaction being treated as references to greater than 50% for these purposes) that: (a)&nbsp;was not obtained or made as a result of a breach of (or in violation of) this
Agreement; (b)&nbsp;is on terms and conditions that Public Company Board (or, in the case of a Superior Offer with respect to Merger Partner, the managers of Merger Partner) determines in good faith, based on such matters that it deems relevant
(including the likelihood of consummation thereof, the financing terms thereof, any <FONT STYLE="white-space:nowrap">break-up</FONT> fees, and conditions to consummation), as well as any written offer by Merger Partner (or, in the case of a Superior
Offer with respect to Merger Partner, by Public Company) to amend the terms of this Agreement, and following consultation with its outside legal counsel and outside financial advisors, if any, are more favorable, from a financial point of view, to
Public Company&#146;s stockholders (or, in the case of a Superior Offer with respect to Merger Partner, the members of Merger Partner and the Blockers) than the terms of the Transactions; (c)&nbsp;is not subject to any financing conditions (and if
financing is required, such financing is then fully committed to the third party); and (d)&nbsp;is reasonably capable of being completed on the terms proposed without unreasonable delay. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Tax</U>&#148; or &#147;<U>Taxes</U>&#148; means any and all taxes, charges, fees, duties, contributions, levies or other similar
assessments or liabilities, including income, gross receipts, corporation, ad valorem, premium, value-added, net worth, capital stock, capital gains, documentary, recapture, alternative or <FONT STYLE="white-space:nowrap">add-on</FONT> minimum,
disability, registration, recording, excise, real property, personal property, sales, use, license, lease, service, service use, transfer, withholding, employment, unemployment, insurance, social security, national insurance, business license,
business organization, environmental, workers compensation, payroll, profits, severance, stamp, occupation, escheat, windfall profits, customs duties, franchise, estimated and other taxes of any kind whatsoever imposed by the United States of
America or any state, local or foreign government, or any agency or political subdivision thereof, and any interest, fines, penalties, assessments or additions to tax imposed with respect to or related to such items. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Tax Contest</U>&#148; has the meaning set forth in Section&nbsp;7.3(g). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Tax Receivable Agreement</U>&#148; has the meaning set forth in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Tax Returns</U>&#148; means any and all reports, returns (including information returns), declarations, or statements relating to
Taxes, including any schedule or attachment thereto and any amendment thereof, filed with or submitted to, or required to be filed with or submitted to, any Governmental Entity in connection with the determination, assessment, collection or payment
of Taxes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Tenth Blocker Merger</U>&#148; has the meaning set forth in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Termination Fee</U>&#148; means the Public Company Termination Fee or the Merger Partner Termination Fee, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Third Blocker Merger</U>&#148; has the meaning set forth in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Top 99 Merger Partner Holder</U>&#148; means, any holder of Merger Partner Units (other than Blockers) that, prior to the Mailing
Date, is among the 99 largest members of Merger Partner (or such lower number of largest members treated as 99 partners for purposes of the private placement safe harbor set forth in Treasury Regulations
<FONT STYLE="white-space:nowrap">Section&nbsp;1.7704-1(h)),</FONT> measured based on each member&#146;s membership interest in Merger Partner (including warrants or options to purchase and instruments convertible into membership interests of Merger
Partner), on a fully-diluted, as converted basis (including any Merger Partner Units subject to an irrevocable commitment as of the date hereof to purchase Merger Partner Units at any point prior to the Blocker Merger Effective Time for the First
Blocker Merger). For purposes of this definition, &#147;holder of Merger Partner Units&#148; shall include any investor who has delivered an irrevocable commitment as of the date hereof to purchase Merger Partner Units at any point prior to the
Blocker Merger Effective Time for the First Blocker Merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Trade Secret</U>&#148; has the meaning set forth in the definition
of &#147;Intellectual Property&#148; herein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Trademark</U>&#148; has the meaning set forth in the definition of
&#147;Intellectual Property&#148; herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Transactions</U>&#148; mean, collectively, the Mergers, the Asset Transfers and the
other transactions contemplated by this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Transfer Taxes</U>&#148; has the meaning set forth in Section&nbsp;7.3(a).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Treasury Regulations</U>&#148; means the United States Treasury regulations promulgated under the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Unitholder Representative</U>&#148; means Rory Riggs, or any successor to such Person pursuant to the Unitholder Representative
Engagement Agreement, dated as of the Closing Date, by and between Unitholder Representative and Merger Partner, in substantially the form attached hereto as <U>Exhibit I</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U><FONT STYLE="white-space:nowrap">Up-C</FONT> Unit</U>&#148; has the meaning set forth in Section&nbsp;2.1(b)(i)(B). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>WARN Act</U>&#148; has the meaning set forth in Section&nbsp;3.15(g). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Willful Breach</U>&#148; means an intentional and material breach of this Agreement that is the consequence of an act or omission by
the breaching party with the actual knowledge that the taking of such act or failure to take such act would cause or constitute such material breach and result in the consequences caused by such material breach. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Written Consents</U>&#148; has the meaning set forth in the Recitals. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="annexarom401831_106"></A>ARTICLE X </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MISCELLANEOUS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_107">
</A>10.1 <U>Notices</U>. All notices and other communications hereunder shall be in writing and shall be deemed to have been duly delivered and received hereunder (a)&nbsp;one (1) Business Day after being sent for next Business Day delivery, fees
prepaid, via a reputable international overnight courier service, (b)&nbsp;upon delivery in the case of delivery by hand or (c)&nbsp;on the date delivered in the place of delivery if sent by email or facsimile (with a written or electronic
confirmation of delivery) prior to 6:00 p.m. New York City time, otherwise on the next succeeding Business Day, in each case to the intended recipient as set forth below: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) if to Public Company or Merger Subsidiary (prior to the Closing), to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Calyxt, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">2800 Mount Ridge
Road </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Roseville, MN 55113 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Debra Frimerman, General Counsel </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> [***] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">with a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Sidley Austin LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">787 Seventh
Ave </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">New York, New York 10019 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: John H. Butler </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: [***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) if to Merger Partner or to Public Company (after the Closing): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Cibus Global, LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">6455 Nancy
Ridge Drive </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">San Diego, CA 92121 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Rory Riggs, Chief Executive Officer, and Wade King, MD, Chief Financial Officer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> [***] and [***] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">with a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Jones Day </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">4655 Executive
Drive, Suite 1500 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">San Diego, CA 92121-3134 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Cameron A. Reese </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">E-mail:</FONT> [***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) if (prior to the Closing) to any Blocker, to the applicable Blocker address (with a
copy which shall not constitute notice) listed on <U>Schedule C</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_108"></A>10.2 <U>Entire Agreement</U>. This
Agreement (including the schedules and exhibits hereto and the documents and instruments referred to in this Agreement that are to be delivered at the Closing) constitutes the entire agreement among the parties to this Agreement and supersedes any
prior understandings, agreements or representations by or among the parties hereto, or any of them, written or oral, with respect to the subject matter hereof; provided that the Confidentiality Agreement shall remain in effect in accordance with its
terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_109"></A>10.3 <U>Third-Party Beneficiaries</U>. This Agreement is not intended to, and shall not, confer
upon any other Person any rights or remedies hereunder, except that Indemnified Persons shall be third-party beneficiaries of Section&nbsp;7.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_110"></A>10.4 <U>Assignment</U>. Neither this Agreement nor any of the rights, interests or obligations under this
Agreement may be assigned or delegated, in whole or in part, by operation of Law or otherwise by any of the parties hereto without the prior written consent of the other parties, and any such assignment without such prior written consent shall be
null and void. Subject to the preceding sentence, this Agreement shall be binding upon, inure to the benefit of, and be enforceable by, the parties hereto and their respective successors and permitted assigns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_111"></A>10.5 <U>Severability</U>. Any term or provision of this Agreement that is invalid or unenforceable in any
situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions hereof or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. If
the final judgment of a court of competent jurisdiction declares that any term or provision hereof is invalid or unenforceable, the parties hereto agree that the court making such determination shall have the power to limit the term or provision, to
delete specific words or phrases, or to replace any invalid or unenforceable term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or
provision, and this Agreement shall be enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence, the parties hereto agree to replace such invalid or unenforceable term or provision with a
valid and enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_112"></A>10.6 <U>Counterparts and Signature</U>. This Agreement may be executed in two (2)&nbsp;or more counterparts,
each of which shall be deemed an original but all of which together shall be considered one (1)&nbsp;and the same agreement and shall become effective when counterparts have been signed by each of the parties hereto and delivered to the other
parties, it being understood that all parties need not sign the same counterpart. This Agreement may be executed and delivered by facsimile or by an electronic scan delivered by electronic transmission. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_113"></A>10.7 <U>Interpretation</U>. Except where expressly stated
otherwise in this Agreement, the following rules of interpretation apply to this Agreement: (a) &#147;either&#148; and &#147;or&#148; are not exclusive and &#147;include,&#148; &#147;includes&#148; and &#147;including&#148; are not limiting; (b)
&#147;hereof,&#148; &#147;hereto,&#148; &#147;hereby,&#148; &#147;herein&#148; and &#147;hereunder&#148; and words of similar import when used in this Agreement refer to this Agreement as a whole and not to any particular provision of this
Agreement; (c) &#147;date of this Agreement&#148; refers to the date set forth in the initial caption of this Agreement; (d) &#147;extent&#148; in the phrase &#147;to the extent&#148; means the degree to which a subject or other thing extends, and
such phrase does not mean simply &#147;if&#148;; (e) the descriptive headings and table of contents included herein are included for convenience only and shall not affect in any way the meaning or interpretation of this Agreement or any provision
hereof; (f)&nbsp;definitions contained in this Agreement are applicable to the singular as well as the plural forms of such terms; (g)&nbsp;references to a contract or agreement mean such contract or agreement as amended or otherwise supplemented or
modified from time to time; (h)&nbsp;references to a Person are also to its permitted successors and assigns; (i)&nbsp;references to an &#147;Article,&#148; &#147;Section,&#148; &#147;Exhibit&#148; or &#147;Schedule&#148; refer to an Article or
Section of, or an Exhibit or Schedule to, this Agreement; (j)&nbsp;references to &#147;$&#148; or otherwise to dollar amounts refer to the lawful currency of the United States; (k)&nbsp;references to a federal, state, local or foreign Law include
any rules, regulations and delegated legislation issued thereunder; (l)&nbsp;references to &#147;Party&#148; or &#147;party&#148; refer to a party to this Agreement; (m)&nbsp;references to accounting terms used and not otherwise defined herein have
the meaning assigned to them under GAAP and (n)&nbsp;references to a &#147;day&#148; mean calendar days. When reference is made in this Agreement to information that has been &#147;made available&#148; to Public Company, that shall consist of only
the information that was (i)&nbsp;contained in Merger Partner&#146;s electronic data room no later than 5:00 p.m., Eastern time, on the second (2nd) Business Day prior to the date of this Agreement or (ii)&nbsp;delivered to Public Company or its
counsel prior to the date of this Agreement. When reference is made in this Agreement to information that has been &#147;made available&#148; to Merger Partner, that shall consist of only the information that was (i)&nbsp;contained in Public
Company&#146;s electronic data room no later than 5:00 p.m., Eastern time, on the second (2nd) Business Day prior to the date of this Agreement or (ii)&nbsp;delivered to Merger Partner or its counsel prior to the date of this Agreement. The language
used in this Agreement shall be deemed to be the language chosen by the parties hereto to express their mutual intent, and no rule of strict construction shall be applied against any party hereto. No summary of this Agreement prepared by any party
shall affect the meaning or interpretation of this Agreement. If any date on which a party is required to make a payment or a delivery pursuant to the terms hereof is not a Business Day, then such party shall make such payment or delivery on the
next succeeding Business Day. Time shall be of the essence in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_114"></A>10.8 <U>Governing
Law</U>. This Agreement (and any claims or disputes arising out of or related hereto or the Transactions or to the inducement of any party to enter herein, whether for breach of contract, tortious conduct or otherwise and whether predicated on
common law, statute or otherwise) shall be governed in all respects, including validity, interpretation, and effect, by and construed in accordance with the internal Laws of the State of Delaware (including in respect of the statute of limitations
or other limitations period applicable to any claim, controversy or dispute) without giving effect to any choice or conflict of Law provision or rule (whether of the State of Delaware or any other jurisdiction) that would cause the application of
Laws of any jurisdictions other than those of the State of Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_115"></A>10.9 <U>Remedies</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Except as otherwise expressly provided in this Agreement, any and all remedies herein expressly conferred upon a party will be deemed
cumulative with and not exclusive of any other remedy conferred hereby, or by Law or equity upon such party, and the exercise by a party of any one (1)&nbsp;remedy will not preclude the exercise of any other remedy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The parties hereto agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed
in accordance with their specific terms or were otherwise breached. It is accordingly agreed that the parties shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and
provisions of this Agreement, in each case without posting a bond or undertaking, this being in addition to any other remedy to which they are entitled at Law or in equity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Each of the parties agrees that it will not oppose the granting of an injunction, specific performance and other equitable relief on the basis that (i)&nbsp;the party seeking such remedy has an
adequate remedy at Law or (ii)&nbsp;
an award of specific performance is not an appropriate remedy for any reason at Law or equity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_116"></A>10.10
<U>Confidentiality</U>. The parties acknowledge that Public Company and Merger Partner have previously executed the Confidentiality Agreement, which Confidentiality Agreement shall continue in full force and effect in accordance with its terms,
except as expressly modified herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_117"></A>10.11 <U>Submission to Jurisdiction</U>. Each of the parties to
this Agreement (a)&nbsp;consents to submit itself to the exclusive Personal jurisdiction of the Court of Chancery of the State of Delaware, New Castle County, or, if that court does not have jurisdiction, a federal court sitting in Wilmington,
Delaware in any action or proceeding arising out of or relating to this Agreement or any of the Transactions, (b)&nbsp;agrees that all claims in respect of such action or proceeding may be heard and determined in any such court, (c)&nbsp;agrees that
it shall not attempt to deny or defeat such Personal jurisdiction by motion or other request for leave from any such court, (d)&nbsp;agrees not to bring any action or proceeding arising out of or relating to this Agreement or any of the Transactions
in any other court, and (e)&nbsp;waives any right it may have to a trial by jury with respect to any action or proceeding arising out of or relating to this Agreement. Each of the parties hereto waives any defense of improper venue or inconvenient
forum to the maintenance of any action or proceeding so brought and waives any bond, surety or other security that might be required of any other party with respect thereto. Any party hereto may make service on another party by sending or delivering
a copy of the process to the party to be served at the address and in the manner provided for the giving of notices in Section&nbsp;10.1. Nothing in this Section&nbsp;10.11, however, shall affect the right of any party to serve legal process in any
other manner permitted by Law. Nothing in this Section&nbsp;10.11 shall limit the right of a party to seek injunctive relief under Section&nbsp;10.9(b) in any applicable jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexarom401831_118"></A>10.12 <U><FONT STYLE="white-space:nowrap">Non-Survival</FONT> of Representations, Warranties and
Covenants</U>. None of the representations, warranties, covenants, obligations, agreements or other provisions in this Agreement or in any certificate, statement or instrument delivered pursuant to this Agreement, including any rights arising out of
any breach of such representations, warranties, covenants, obligations, agreements or other provisions, shall survive the Closing, and each such representation, warranty, covenant, obligation, agreement or other provision shall terminate and expire
upon the occurrence of the Merger Partner Merger Effective Time (and there shall be no liability after the Closing in respect thereof), except for (a)&nbsp;those covenants and agreements contained herein that by their terms expressly apply in whole
or in part at or after the Closing, and then only with respect to any breaches occurring at or after the Closing, and (b)&nbsp;this ARTICLE X. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>[Remainder of the Page Intentionally Left Blank] </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MERGER SUBSIDIARY:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">CALYPSO MERGER SUBSIDIARY, LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By Its Managing Member:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">CALYXT, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Debra Frimerman</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Debra Frimerman</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: General Counsel and Corporate Secretary</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to Merger Agreement</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PUBLIC COMPANY:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">CALYXT, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Debra Frimerman</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Debra Frimerman</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: General Counsel and Corporate Secretary</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to Merger Agreement</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MERGER PARTNER:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">CIBUS GLOBAL, LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Rory Riggs</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Rory Riggs</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to Merger Agreement</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BLOCKER 1:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">NEW VENTURES I HOLDINGS, LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jonathan Finn</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jonathan Finn</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Member and Managing Member of BV</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Partners LLC, acting as Managing Member of New Ventures I LLC, acting as sole member and managing member of New Ventures I Holdings, LLC</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to Merger Agreement</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BLOCKER 2:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">BCGF CB HOLDINGS LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By: Fidelity Securities Fund: Fidelity Blue Chip</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Growth Fund, its manager</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Chris Maher</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Chris Maher</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Authorized Signatory</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Address:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Mag&nbsp;&amp; Co.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">c/o Brown Brothers Harriman&nbsp;&amp; Co.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Attn: Corporate Actions /Vault</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">140 Broadway</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">New York, NY 10005</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Email: BBH.Fidelity.CA.Notifications@BBH.com</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Phone Number: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">617-772-1070</FONT></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Fax Number: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">201-325-3651</FONT></FONT></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to Merger Agreement</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BLOCKER 3:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">BCGFCP CB HOLDINGS LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: Fidelity Blue Chip Growth Commingled Pool,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">its manager</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: Fidelity Management Trust Company, as</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Trustee</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Chris Maher</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Chris Maher</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Authorized Signatory</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Address:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Mag&nbsp;&amp; Co.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">c/o Brown Brothers Harriman&nbsp;&amp; Co.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Attn: Corporate Actions /Vault</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">140 Broadway</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">New York, NY 10005</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Email: BBH.Fidelity.CA.Notifications@BBH.com</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Phone Number: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">617-772-1070</FONT></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Fax Number: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">201-325-3651</FONT></FONT></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to Merger Agreement</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BLOCKER 4:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">BCGFK CB HOLDINGS LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: Fidelity Securities Fund: Fidelity Blue Chip</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Growth K6 Fund, its manager</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Chris Maher</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Chris Maher</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Authorized Signatory</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Address:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">The Northern Trust Company</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Attn: Trade Securities Processing</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">333 South Wabash Ave, 32nd Floor</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Chicago, Illinois 60604</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Fidelity Securities Fund: Fidelity Blue Chip</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Growth K6 Fund</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Reference Account # F71082</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Email: NTINQUIRY@NTRS.COM</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Fax number: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">312-557-5417</FONT></FONT></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to Merger Agreement</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BLOCKER 5:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">FSBCGF CB HOLDINGS LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: Fidelity Securities Fund: Fidelity Series Blue</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Chip Growth Fund, its manager</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Chris Maher</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Chris Maher</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Authorized Signatory</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Address:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">State Street Bank&nbsp;&amp; Trust</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">PO Box 5756</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Boston, Massachusetts 02206</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Attn: WAVECHART + CO fbo Fidelity Securities</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Fund: Fidelity Series Blue Chip Growth Fund</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Email: SSBCORPACTIONS@StateStreet.com</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Fax Number: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">617-988-9110</FONT></FONT></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to Merger Agreement</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BLOCKER 6:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">PYLBCG CB HOLDINGS LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: FIAM Target Date Blue Chip Growth</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Commingled Pool, its manager</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: Fidelity Institutional Asset Management Trust</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Company as Trustee</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Chris Maher</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Chris Maher</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Authorized Signatory</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Address:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">State Street Bank&nbsp;&amp; Trust</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">PO Box 5756</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Boston, Massachusetts 02206</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Attn: WAVECHART + CO fbo Fidelity Securities</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Fund: Fidelity Series Blue Chip Growth Fund</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Email: SSBCORPACTIONS@StateStreet.com</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Fax Number: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">617-988-9110</FONT></FONT></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to Merger Agreement</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BLOCKER 7:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">FSGRWCO CB HOLDINGS LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: Fidelity Mt. Vernon Street Trust: Fidelity Series</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Growth Company Fund, its manager</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Chris Maher</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Chris Maher</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Authorized Signatory</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Address:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Mag&nbsp;&amp; Co.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">c/o Brown Brothers Harriman&nbsp;&amp; Co.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Attn: Corporate Actions /Vault</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">140 Broadway</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">New York, NY 10005</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Email: BBH.Fidelity.CA.Notifications@BBH.com</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to Merger Agreement</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BLOCKER 8:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">GROWTHCO CB HOLDINGS LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: Fidelity Mt. Vernon Street Trust: Fidelity</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Growth Company Fund, its manager</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Chris Maher</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Chris Maher</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Authorized Signatory</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Address:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">BNY Mellon</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">PO Box 392002</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Pittsburgh PA 15230</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Email: fidelitycorporateevents@bnymellon.com</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to Merger Agreement</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BLOCKER 9:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">GRTHCOCP CB HOLDINGS LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: Fidelity Growth Company Commingled Pool,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">its manager</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: Fidelity Management Trust Company, as</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Trustee</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Chris Maher</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Chris Maher</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Authorized Signatory</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Address:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Mag&nbsp;&amp; Co.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">c/o Brown Brothers Harriman&nbsp;&amp; Co.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Attn: Corporate Actions /Vault</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">140 Broadway</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">New York, NY 10005</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Email: BBH.Fidelity.CA.Notifications@BBH.com</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to Merger Agreement</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BLOCKER 10:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">GRWTHCOK CB HOLDINGS LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: Fidelity Mt. Vernon Street Trust: Fidelity</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Growth Company K6 Fund, its manager</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Chris Maher</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Chris Maher</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Authorized Signatory</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Address:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">BNY Mellon</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">PO Box 392002</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Pittsburgh PA 15230</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Email: fidelitycorporateevents@bnymellon.com</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to Merger Agreement</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Schedule A </U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Support Stockholders </U></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Cellectis S.A. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Michael Carr </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Philippe Dumont </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Jonathan Fassberg </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ewa Kozicz </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Kim Nelson </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Chris Neugent </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Yves Ribeill </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Bill Koschak </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Travis Frey </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Debra Frimerman </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Schedule B </U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Support Holders </U></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">New Ventures I Holdings, LLC </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">BCGF CB Holdings LLC </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">BCGFCP CB Holdings LLC </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">BCGFK CB Holdings LLC </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">FSBCGF CB Holdings LLC </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">PYLBCG CB Holdings LLC </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">FSGRWCO CB Holdings LLC </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">GROWTHCO CB Holdings LLC </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">GRTHCOCP CB Holdings LLC </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">GRWTHCOK CB Holdings LLC </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Rory Riggs </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Wade King, MD </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">13.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Peter Beetham, Ph.D. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">14.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Greg Gocal Ph.D. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">15.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Jean-Pierre Lehmann </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">16.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mark Finn </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">17.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Gerhard Prante </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">18.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Keith Walker </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">19.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Cibus Investments LLC </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">20.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Lufam Genetic Biotech Ltd. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">21.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Rowiss Biotech Investment Ltd. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Schedule C </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notice Information for Blocker 1 through Blocker 10 pursuant to Section&nbsp;10.1 of the Agreement: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="26%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Blocker:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Notice to:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>With a copy (which shall not</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>constitute notice) to:</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Blocker&nbsp;1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">New Ventures I Holdings, LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New Ventures I Holdings, LLC</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Jonathan
Finn</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o BV PARTNERS LLC</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3500 Pacific Avenue</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Virginia Beach, VA 23451</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Akin Gump Strauss Hauer&nbsp;&amp; Feld LLP</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One
Bryant Park</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bank of America Tower</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10036-6745</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Tuvia Tendler</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> [***]</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Blocker 2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">BCGF CB HOLDINGS LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mag&nbsp;&amp; Co.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Brown Brothers
Harriman&nbsp;&amp; Co.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Corporate Actions /Vault</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">140
Broadway</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10005</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BBH.Fidelity.CA.Notifications@BBH.com</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Phone Number: <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">617-772-1070</FONT></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Fax Number: <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">201-325-3651</FONT></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fenwick&nbsp;&amp; West LLP</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">555 California
Street</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Francisco, CA 94104</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Jordan Roberts</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> [***]</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Blocker 3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">BCGFCP CB HOLDINGS LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mag&nbsp;&amp; Co.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Brown Brothers
Harriman&nbsp;&amp; Co.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Corporate Actions /Vault</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">140
Broadway</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10005</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BBH.Fidelity.CA.Notifications@BBH.com</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Phone Number: <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">617-772-1070</FONT></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Fax Number: <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">201-325-3651</FONT></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fenwick&nbsp;&amp; West LLP</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">555 California
Street</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Francisco, CA 94104</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Jordan Roberts</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> [***]</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Blocker 4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">BCGFK CB HOLDINGS LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Northern Trust Company</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Trade
Securities Processing</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">333 South Wabash Ave, 32nd Floor</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chicago, Illinois 60604</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fidelity Securities Fund: Fidelity Blue
Chip</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Growth K6 Fund</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reference Account # F71082</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: NTINQUIRY@NTRS.COM</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Fax number: <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">312-557-5417</FONT></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fenwick&nbsp;&amp; West LLP</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">555 California
Street</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Francisco, CA 94104</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Jordan Roberts</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> [***]</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Blocker 5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">FSBCGF CB HOLDINGS LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">State Street Bank&nbsp;&amp; Trust</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PO Box
5756</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts 02206</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: WAVECHART + CO fbo
Fidelity</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities Fund: Fidelity Series Blue Chip Growth Fund</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: SSBCORPACTIONS@StateStreet.com</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Fax number: <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">617-988-9110</FONT></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fenwick&nbsp;&amp; West LLP</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">555 California
Street</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Francisco, CA 94104</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Jordan Roberts</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> [***]</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="26%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Blocker:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Notice to:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>With a copy (which shall not</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>constitute notice) to:</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Blocker&nbsp;6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">PYLBCG CB HOLDINGS LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">State Street Bank&nbsp;&amp; Trust</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PO Box
5756</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts 02206</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: FLAPPER CO fbo FIAM
Target Date Blue Chip Growth Commingled Pool</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: SSBCORPACTIONS@StateStreet.com</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Fax number: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">617-988-9110</FONT></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fenwick&nbsp;&amp; West LLP</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">555 California
Street</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Francisco, CA 94104</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Jordan Roberts</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> [***]</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Blocker 7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">FSGRWCO CB HOLDINGS LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mag&nbsp;&amp; Co.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Brown Brothers
Harriman&nbsp;&amp; Co.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Corporate Actions /Vault</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">140
Broadway</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10005</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">BBH.Fidelity.CA.Notifications@BBH.com</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fenwick&nbsp;&amp; West LLP</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">555 California
Street</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Francisco, CA 94104</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Jordan Roberts</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> [***]</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Blocker 8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">GROWTHCO CB HOLDINGS LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BNY Mellon</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PO Box 392002</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pittsburgh PA 15230</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">fidelitycorporateevents@bnymellon.com</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fenwick&nbsp;&amp; West LLP</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">555 California
Street</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Francisco, CA 94104</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Jordan Roberts</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> [***]</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Blocker 9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">GRTHCOCP CB HOLDINGS LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mag&nbsp;&amp; Co.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Brown Brothers
Harriman&nbsp;&amp; Co.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Corporate Actions /Vault</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">140
Broadway</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10005</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">BBH.Fidelity.CA.Notifications@BBH.com</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fenwick&nbsp;&amp; West LLP</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">555 California
Street</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Francisco, CA 94104</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Jordan Roberts</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> [***]</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Blocker&nbsp;10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">GRWTHCOK CB Holdings LLC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BNY Mellon</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PO Box 392002</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pittsburgh PA 15230</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">fidelitycorporateevents@bnymellon.com</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fenwick&nbsp;&amp; West LLP</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">555 California
Street</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Francisco, CA 94104</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Jordan Roberts</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> [***]</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Public Company Support Agreements </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit B </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Merger Partner Support Agreement </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit <FONT STYLE="white-space:nowrap">C-1</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>First Blocker Merger Certificate of Merger </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit <FONT STYLE="white-space:nowrap">C-2</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form of Blocker Certificate of Merger </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit <FONT STYLE="white-space:nowrap">C-3</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Merger Partner Certificate of Merger </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit <FONT STYLE="white-space:nowrap">D-1</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Public Company Directors </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit <FONT STYLE="white-space:nowrap">D-2</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Public Company Officers </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit E </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Interim Funding Term Sheet </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[See attached.] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit E </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>FINAL FORM </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Project Calypso
</U></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Proposed Calypso Funding Terms </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All terms not
otherwise defined herein shall have the meanings assigned to them in the Merger Agreement </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Amount</B>: line of credit up to $3,000,000; provided, however, that the line of credit may be increased to
$4,000,000 at the Merger Partner&#146;s sole discretion at which point the Outside Date would automatically be extended to June&nbsp;30, 2023. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Availability</B>: becomes available to Public Company upon the earlier to occur of (a)&nbsp;March&nbsp;15,
2023 and (b)&nbsp;Public Company&#146;s unrestricted cash balance dropping below $1,500,000. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Draws</B>: Public Company may draw in $500,000 increments to the extent necessary to maintain its
unrestricted cash balance at $1,500,000 or above. Merger Partner will wire funds within two business days of a written request for a draw from Public Company. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Use of Funds</B>: Public Company may only use the funds for operating expenses incurred in the ordinary
course of business consistent with past practice and consistent with the negative covenants in the Merger Agreement. For the avoidance of doubt, this will exclude capex that has not been disclosed other than equipment repairs in the ordinary course
of business, bonuses to officers and employees, dividends to stockholders, and loans to affiliates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Maturity</B>: Third Business Day after Closing of the Transactions (subject to acceleration described in
Section&nbsp;7 and termination of the Merger Agreement by Merger Partner as described in Section&nbsp;8).<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Interest</B>: No interest </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Acceleration Event</B>. The Loan will automatically accelerate and become immediately due and payable in
connection with a voluntary bankruptcy or involuntary bankruptcy that is not dismissed in 180 days related to . No further draws may be made under the Loan following the occurrence of a bankruptcy related event. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Repayment</B>: 100% forgiven if the Merger Agreement is terminated other than in connection with (a)&nbsp;a
termination of the Agreement by Merger Partner resulting from the Fraud or Willful Breach of Public Company, in which case Public Company will no longer be permitted to make draws under the loan and loan will become due and payable on the date that
is two years from the date funds are first drawn or (b)&nbsp;(i) a termination of the Agreement by Public Company pursuant to Section&nbsp;8.1(g) of the Agreement or (ii)&nbsp;a termination of the Agreement by Merger Partner pursuant to
Section&nbsp;8.1(f) of the Agreement, in which case Public Company will no longer be permitted to make draws under the loan and the loan will become due and payable on the date that is 30 days of termination of the Agreement. The Closing of the
Transactions contemplated by the Merger Agreement will not constitute a termination for purposes of this paragraph. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Security</B>: Loan will be unsecured. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Other Provisions</B>: The Loan will not have any other events of default or events of acceleration that are
not expressly provided for in this term sheet. </P></TD></TR></TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NTD: It is the parties expectation that the Loan will be 100% repaid immediately prior to the closing of the
Merger Agreement pursuant to a Contribution Agreement pursuant to which all the assets of Public Company will be transferred to Merger Partner first in repayment of the Loan and thereafter in exchange for the Merger Partner equity provided in the
Merger Agreement (or such other structure or documentation requested by Merger Partner providing substantially similar economics to Public Company). </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit F </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Amendment to License Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[See attached.] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit F </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">FINAL FORM </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">FIRST AMENDMENT TO THE
LICENSE AGREEMENT </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This FIRST AMENDMENT TO THE LICENSE SERVICES AGREEMENT (the &#147;<B>First Amendment</B>&#148;) is made and entered
into effective as of __________, 2023 (the &#147;<B>First Amendment Effective Date</B>&#148;) by and between Cellectis S.A., a corporation existing and registered under the laws of France (&#147;<B>Cellectis</B>&#148;), and Calyxt, Inc., a
corporation existing and registered under the laws of Delaware (&#147;<B>Calyxt</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Parties entered into that
certain License Agreement dated July&nbsp;25, 2017 (the &#147;<B>Agreement</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Parties wish to amend the Agreement
in accordance with the terms as set forth in this First Amendment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, the Parties agree as follows: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 1 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D<SMALL>EFINITIONS</SMALL> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.01
<I>Generally</I>.<I> </I>All Capitalized terms used in this First Amendment not otherwise defined herein have the meaning assigned to them in the Agreement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 2 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A<SMALL>MENDMENTS</SMALL> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.01
<I>Bare Sublicense Revenue</I>. The definition of &#147;<B>Bare Sublicense Revenue</B>&#148; in Article 1 of the Agreement is hereby in its entirety and replaced with the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Bare Sublicense Revenue</B>&#148; means any and all consideration, payments and revenue (including the fair market
value of any <FONT STYLE="white-space:nowrap">non-cash</FONT> consideration) received by Calyxt pursuant to any Bare Sublicense to the extent attributable to the rights in the Licensed Cellectis Patents and the Licensed Plant Patents that are
granted to a third party in such Bare Sublicense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.02 <I>Calyxt Field</I>. The definition of &#147;<B>Calyxt Field</B>&#148; in Article 1
of the Agreement is hereby deleted in its entirety and replaced with the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Calyxt Field</B>&#148; means
the field of researching, developing and commercializing microorganism, agricultural and food products, including, but not limited to traits, seeds, proteins, oils, carbohydrates, food, and food and animal feed ingredients, excluding (i)&nbsp;any
application in connection with animals and animal cells and (ii)&nbsp;therapeutic applications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.03 <I>Licensed Plant Patents</I>. The
following definition is inserted into Article 1 of the Agreement in alphabetical order: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Licensed Plant
Patent</B><B>s</B>&#148; means (i)&nbsp;each Patent set forth on Exhibit A to the First Amendment, (ii)&nbsp;all foreign equivalents and counterparts to each Patent described in clause (i), and (iii)&nbsp;each Patent claiming priority to or having
common priority with each Patent described in clauses (i)&nbsp;and (ii) anywhere in the world. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.04 <I>Licensed Cellectis Patents</I>. The definition of &#147;<B>Licensed Cellectis
Patents</B>&#148; in Article 1 of the Agreement is hereby deleted in its entirety and replaced with the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Licensed Cellectis Patents</B>&#148; means any and all Patents that are: (i)&nbsp;related to the Calyxt Field;
(ii)&nbsp;necessary for Calyxt to operate in the Calyxt Field; and (iii)&nbsp;Licensable by Cellectis and existing as of the Effective Date, in each case excluding Licensed Plant Patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.05 <I>Patent-Related Expenses</I>. The definition of &#147;<B>Patent-Related Expenses</B>&#148; in Article 1 of the Agreement is hereby deleted
in its entirety and replaced with the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Patent-Related Expenses</B>&#148; means (i)&nbsp;external costs
and expenses (including <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> attorneys&#146; fees, patent agent fees and governmental filing fees) that Cellectis or any of its Affiliates actually incurs in
prosecuting and maintaining the Licensed Cellectis Patents which are exclusively and solely related to the Calyxt Field, and (ii)&nbsp;the Pro Rata Share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.06 <I>Pro Rata Share</I>. The following definition is inserted into Article 1 of the Agreement in alphabetical order: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Pro Rata Share</B>&#148; means (i)&nbsp;external costs and expenses (including <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> attorneys&#146; fees, patent agent fees and governmental filing fees) that Cellectis or any of its Affiliates actually incurs in prosecuting and maintaining a Licensed Plant Patent which are
exclusively and solely related to the Calyxt Field <I>multiplied by</I> (ii)&nbsp;a fraction, (A)&nbsp;the <I>numerator</I> of which is one, and (B)&nbsp;the <I>denominator</I> of which is (x)&nbsp;the number of express third party licensees of such
Licensed Plant Patent, <I>plus</I> (y)&nbsp;one (1). By way of example only, if a Licensed Plant Patent is licensed to four third party licensees, then subclause (ii)&nbsp;of the definition of Pro Rata Share for this Licensed Plant Patent shall be
1/5. For the avoidance of doubt, if a Licensed Plant Patent is licensed to a third party and the grant of license collectively includes such third party&#146;s Affiliates, for the purposes of calculating the Pro Rata Share, such third party and its
Affiliates shall be counted collectively as one third party licensee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.07 <I>Calyxt License</I>. Section&nbsp;2.01 of the Agreement is
hereby deleted in its entirety and replaced with the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.01. <I>Calyxt License</I>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(i) <I>Licensed Cellectis IP</I>. Subject to the terms and conditions of this Agreement, Cellectis hereby grants to Calyxt an exclusive (except
as otherwise provided herein and subject to existing licenses granted by Cellectis to third parties prior to the Effective Date) worldwide, perpetual license, with the right to sublicense (in accordance with Section&nbsp;2.03) under the Licensed
Cellectis IP to use, have used , make, have made, sell, have sold, offer for sale, export, import and otherwise exploit any and all Calyxt Licensed Products within the Calyxt Field (the &#147;<B>Calyxt License</B>&#148;). Notwithstanding the
foregoing, the Calyxt License shall be <FONT STYLE="white-space:nowrap">non-exclusive</FONT> solely in the <FONT STYLE="white-space:nowrap">Non-Exclusive</FONT> Field, such that the rights as set forth above in this Section&nbsp;2.01 are granted to
Calyxt on a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> basis in the <FONT STYLE="white-space:nowrap">Non-Exclusive</FONT> Field under the Calyxt License. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(ii) <I>Licensed Plant Patents</I>. Subject to the terms and conditions of this Agreement, Cellectis hereby grants to Calyxt a <FONT
STYLE="white-space:nowrap">non-exclusive,</FONT> worldwide, perpetual, irrevocable, royalty-free and fully <FONT STYLE="white-space:nowrap">paid-up</FONT> license (with the right to sublicense to any Person through multiple tiers and without any of
the restrictions imposed by Section&nbsp;2.03) under the Licensed Plant Patents to use, make, have made, sell, offer to sell, export, import and otherwise exploit the Licensed Plant Patents within the Calyxt Field. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.08 <I>UMinn License</I>. Section&nbsp;2.04 of the Agreement is hereby deleted in its entirety and replaced with the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.04. <I>UMinn license</I>. The Parties acknowledge and agree that Calyxt has received a copy of the UMinn License
and certain Licensed Cellectis IP is owned by the University of Minnesota (&#147;<B>UMinn IP</B>&#148;) and the Calyxt License with respect to the UMinn IP is granted as a sublicense under, and subject to the terms and conditions of, the UMinn
License. Accordingly, in exercising its rights under the Calyxt License, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Calyxt shall comply with any and all terms and conditions of the UMinn License as they would apply to Calyxt as a sublicensee with respect to any UMinn IP. Without limiting the generality of the
foregoing, promptly following receipt of written notice thereof, Calyxt shall reimburse Cellectis for any and all payments required to be made by Cellectis to the University of Minnesota pursuant to Sections 11.6.4 (Milestone Payments), 11.11
(Annual Fee), and 11.12 (Commercialization Fee) of the UMinn License, but solely to the extent that any such payments are required as a result of the applicable activities of Calyxt hereunder or thereunder. Calyxt shall not be liable to the
University of Minnesota for any other payments and as party to the UMinn License, as between the Parties, Cellectis will be responsible for all such payments owed to UMinn under the UMinn License. Notwithstanding anything to the contrary in this
Agreement, Calyxt can deduct from any payment owed by Calyxt to Cellectis hereunder for any particular activity any amount reimbursed to Cellectis under this Section&nbsp;2.04 that arises from the same activity. Without the prior written consent of
Calyxt, Cellectis shall not (A)&nbsp;terminate the UMinn License, or (B)&nbsp;amend or waive any rights under the UMinn License in any manner that would reasonably be expected to have a material adverse effect on any of Calyxt&#146;s rights under
this Agreement. In addition, Calyxt shall provide, and shall cause its sublicensees to provide, to Cellectis all reports, information, and other assistance in connection with Calyxt&#146;s and its sublicensees&#146; activities pursuant to this
Agreement that are reasonably required to enable Cellectis to comply with its obligations under the UMinn License solely to the extent that such obligations relate to Calyxt&#146;s activities pursuant to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.09 <I>Calyxt Improvements</I>. Section&nbsp;2.05(b) of the Agreement is hereby deleted in its entirety. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.10 <I>No Other Licenses</I>. Section&nbsp;2.07 of the Agreement is hereby deleted in its entirety and replaced with the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.07. <I>No Other Licenses</I>. Except as expressly provided in this Agreement, no other licenses are granted to
either Party under this Agreement. Each Party acknowledges and agrees that (a)&nbsp;any use by Calyxt or any of its sublicensees of the Licensed Cellectis IP or Licensed Plant Patents outside the scope of the Calyxt License or the Licensed TALEN
Mark outside the scope of the Calyxt TM License is expressly prohibited and (b)&nbsp;any use by Cellectis or any of its sublicensees of the Calyxt Improvements is expressly prohibited. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.11 <I>Prosecution and Maintenance</I>. Section&nbsp;9.1(a) of the Agreement is hereby amended by inserting the words &#147;and Licensed Plant
Patents&#148; following the words &#147;Licensed Cellectis IP,&#148; in the first sentence of such section. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.12 <I>Prosecution and
Maintenance</I>. Section&nbsp;9.1(b) is deleted in its entirety and replaced with the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) As between the
Parties, Calyxt shall have the sole and exclusive right to prosecute and maintain all Intellectual Property Rights owned or otherwise controlled by Calyxt or any of its Affiliates, including all Intellectual Property Rights in or to any Calyxt
Improvements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.13 <I>Prosecution and Maintenance</I>. The following section (c)&nbsp;is added in alphabetical order to Section&nbsp;9.01 of
the Agreement: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Within sixty (60)&nbsp;days of the First Amendment Effective Date, and thereafter on an annual basis,
at least thirty (30)&nbsp;days prior to the beginning of each calendar year, Cellectis will provide to Calyxt a budget for the estimated Patent-Related Expenses that are expected to be incurred during such calendar year. Cellectis will consider in
good faith to implement any changes to such budget that are reasonably requested by Calyxt (each an &#147;<B>Annual Prosecution Budget</B>&#148;). Cellectis will use commercially reasonable efforts to adhere to the Annual Prosecution Budget and will
not incur any Patent-Related Expenses in an unreasonable manner (including by filing Patents subject to Patent-Related Expenses in multiple countries without first obtaining Calyxt&#146;s prior written consent). If practicable, Cellectis will notify
Calyxt before incurring any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
additional Patent-Related Expense and the Parties will discuss strategies to mitigate any such additional Patent-Related Expense. Calyxt will be responsible for reimbursing Cellectis for
Patent-Related Expenses in accordance with Section&nbsp;5.03. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.14 <I>Survival</I>. Section&nbsp;10.04 of the Agreement is hereby deleted in
its entirety and replaced with the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;10.04. <I>Survival</I>. Notwithstanding anything in this
Agreement to the contrary, Sections 2.01(ii), 2.05(a), 2.07, 3.02, 5.04 (only to the extent any royalties or Bare Sublicense Revenue are due to Cellectis during the applicable reporting period), 6.02, 6.03, 9.01(b) and 10.04, and Articles 7, 8 and
11 shall survive any expiration or termination of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.15 <I>Change of Control</I>. The Agreement is hereby amended by adding
the following as a new Section&nbsp;11.13: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.13. <I>Change of Control</I>. Unless that certain Lease
Guaranty, dated as of September&nbsp;1, 2017, executed by Cellectis, S.A. in favor of NLD Mount Ridge LLC as landlord under that certain Lease Agreement, dated as of the same date, with Calyxt, Inc. (as the same may be amended or restated from time
to time, the &#147;<B>Lease Guaranty</B>&#148;) has been terminated such that Cellectis S.A. and its Affiliates have no further liabilities or obligations thereunder, and with no amounts having been paid by Cellectis S.A. or its Affiliates
thereunder other than those amounts that have been fully repaid to Cellectis S.A. or its Affiliates prior to the consummation of such Change of Control, Cellectis may terminate this Agreement by giving written notice to Calyxt, such termination to
take effect forthwith or as otherwise stated in the notice, in case of any Change of Control of Calyxt. For the purpose of this Section&nbsp;11.13: (a) &#147;<B>Change of Control</B>&#148; means the occurrence of any of the following events:
(i)&nbsp;any third party acquires direct or indirect Control of Calyxt, by any means (including acquisition of shares, share exchange or share transfer); or (ii)&nbsp;Calyxt, directly or indirectly, conveys, transfers, divests or leases (including
general succession and all types of corporate split) in one or more transactions to any third party either: (x)&nbsp;all or substantially all of the assets of Calyxt or (y)&nbsp;all or substantially all of its assets that are material to the purpose
of performance of its obligations under this Agreement, and (b) &#147;<B>Control</B>&#148; means the ownership of more than 50% (fifty percent) of the issued share capital or other equity interest or the legal power to direct or cause the direction
of the general management and policies of a Person, whether directly or indirectly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 3 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">M<SMALL>ISCELLANEOUS</SMALL> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.01
<I>Other Provisions</I>. All provisions of the Agreement not expressly amended herein shall remain in full force and effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.02 <I>No
Calyxt Improvements</I>. Calyxt represents and warrants to Cellectis that as of the date hereof there are no Calyxt Improvements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.03
<I>Miscellaneous</I>. The provisions of Article 11 of the Agreement apply to the First Amendment <I>mutatis mutandis</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature
Page Follows] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have caused this First Amendment to be duly executed by
their respective authorized officers as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CELLECTIS S.A.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CALYXT, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to First Amendment to License Agreement</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Licensed Plant Patents </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit G </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Allocation Schedule </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="27%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="27%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Agreement<BR>Sect. Ref.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Public Company Shares of Common Stock</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Security Type</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Notes</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><U><FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Shares of Public Company Common Stock</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Fully Diluted Shares (Treasury Stock Method)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,251,747</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Common Stock (converts to Class&nbsp;A)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Reflects issued and outstanding shares, all restricted stock units assumed to fully vest upon closing and 150,000 performance share units assumed to vest upon closing</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Share Grants Available for Issuance Prior to Closing</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,487,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Common Stock (converts to Class&nbsp;A)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Reflects shares grants available for issuance prior to closing by Public Company</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Total Fully Diluted Shares (Treasury Stock Method)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,739,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Common Stock (converts to Class&nbsp;A)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><U>Blocker Merger Consideration</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.1(a)(i)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">New Ventures I Holdings, LLC</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,197,299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Public Company Class&nbsp;A Common Stock</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.1(a)(i)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">GROWTHCO CB Holdings LLC (Fidelity)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,807,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Public Company Class&nbsp;A Common Stock</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.1(a)(i)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">GRTHCOCP CB Holdings LLC (Fidelity)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,121,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Public Company Class&nbsp;A Common Stock</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.1(a)(i)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">BCGF CB Holdings LLC (Fidelity)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,824,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Public Company Class&nbsp;A Common Stock</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.1(a)(i)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">GRWTHCOK CB Holdings LLC (Fidelity)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,470,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Public Company Class&nbsp;A Common Stock</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.1(a)(i)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">FSGRWCO CB Holdings LLC (Fidelity)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,326,959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Public Company Class&nbsp;A Common Stock</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.1(a)(i)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">FSBCGF CB Holdings LLC (Fidelity)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,779,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Public Company Class&nbsp;A Common Stock</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.1(a)(i)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">PYLBCG CB Holdings LLC (Fidelity)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,232,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Public Company Class&nbsp;A Common Stock</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.1(a)(i)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">BCGFK CB Holdings LLC (Fidelity)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,738,289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Public Company Class&nbsp;A Common Stock</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.1(a)(i)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">BCGFCP CB Holdings LLC (Fidelity)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">879,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Public Company Class&nbsp;A Common Stock</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Total Blocker Merger Consideration</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">160,378,225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Public Company Class&nbsp;A Common Stock</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="27%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="27%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Agreement<BR>Sect. Ref.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Public Company Shares of Common Stock</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Security Type</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Notes</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>Merger Partner Merger Consideration</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.1(b)(i)(A)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Merger Partner Units held in treasury</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Public Company Class&nbsp;A Common Stock</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.1(b)(i)(B)(I)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Merger Partner Units (other than PIUs) held by Electing Members (Class A Election)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Public Company Class&nbsp;A Common Stock</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">To be updated to reflect valid Elections received by Election Deadline</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.1(b)(i)(C)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Merger Partner Warrants</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,787,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Public Company Class&nbsp;A Common Stock</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.1(b)(i)(D)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Merger Partner Units (other than PIUs) held by Participating Members</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">548,755,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Public Company Class&nbsp;A Common Stock</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Includes shares issued in exchange for Merger Partner preferred units and Merger Partner <FONT STYLE="white-space:nowrap">non-voting</FONT> common units (Class&nbsp;A); excludes Blockers</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.1(b)(i)(E)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Merger Partner PIUs (restricted and unrestricted)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">186,123,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Public Company Class&nbsp;A Common Stock / Restricted Public Company Class&nbsp;A Common Stock</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">To be updated to reflect vesting of Merger Partner PIUs as of immediately prior to Closing; includes Merger Partner Class&nbsp;G grants to be allocated prior to Closing</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.1(b)(i)(B)(II)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Merger Partner Units (other than PIUs) held by Electing Members (Class B Election)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Public Company Class&nbsp;B Common Stock</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">To be updated to reflect valid Elections received by Election Deadline</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Total Merger Partner Merger Consideration</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">794,666,782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Total Shares of Public Company Class&nbsp;A Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,008,784,257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Total Shares of Public Company Class&nbsp;B Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Total Shares of Public Company Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,008,784,257</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="27%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="27%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Agreement<BR>Sect. Ref.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Merger Partner Common Units</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" STYLE="border-bottom:1.00pt solid #000000"><B>Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Security Type</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Notes</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><U>Merger Partner Common Units Issued to Public Company at Closing</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.1(b)(ii)(A)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Limited liability interests of Merger Subsidiary</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Merger Partner Common Units (voting)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.1(b)(ii)(B)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Merger Partner Units and Merger Partner Warrants exchanged in Blocker Mergers</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">160,378,225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Merger Partner Common Units (voting)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Equal to total Blocker Merger Consideration</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.1(b)(ii)(C)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Merger Partner Warrants held by Public Company after exchange per 2.1(b)(i)(C)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,787,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Merger Partner Common Units (voting)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.1(b)(ii)(D)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Aggregate number of shares of Public Company Class&nbsp;A Common Stock issued per 2.1(b)(i)(B)(I), 2.1(b)(i)(D), and 2.1(b)(i)(E)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">734,879,195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Merger Partner Common Units (voting)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Asset Transfers</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,739,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Merger Partner Common Units (voting)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Equal to total fully diluted shares (treasury stock method) of Public Company</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.1(b)(i)(B)(II)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Merger Partner Units (other than PIUs) held by Electing Members</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Merger Partner Common Units <FONT STYLE="white-space:nowrap">(non-voting)</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Equal to total number of shares of Public Company Class&nbsp;B Common Stock</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Total Merger Partner Units (voting)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,008,784,257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Total Merger Partner Units <FONT STYLE="white-space:nowrap">(non-voting)</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Total Merger Partner Common Units (voting and <FONT STYLE="white-space:nowrap">non-voting)</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,008,784,257</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Check PC Class&nbsp;A vs. MP voting</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Check PC Class&nbsp;B vs. MP <FONT STYLE="white-space:nowrap">non-voting</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1-120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit H &#151; TERM SHEET </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TAX RECEIVABLES AGREEMENT </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit I </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form of Unitholder Representative Engagement Agreement </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="rom401831_66a"></A>ANNEX A-2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION VERSION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FIRST
AMENDMENT TO </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT AND PLAN OF MERGER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This First Amendment to the Agreement and Plan of Merger (this &#147;<U>Amendment</U>&#148;), dated April&nbsp;14, 2023, is by and between
Calyxt, Inc., a Delaware corporation (&#147;<U>Public Company</U>&#148;) and Cibus Global, LLC, a Delaware limited liability company (&#147;<U>Merger Partner</U>&#148;), and amends that certain Agreement and Plan of Merger, dated January&nbsp;13,
2023, by and among Public Company; Merger Partner; Calypso Merger Subsidiary, LLC, a Delaware limited liability company; New Ventures I Holdings, LLC, a Delaware limited liability company; BCGF CB Holdings LLC, a Delaware limited liability company;
BCGFCP CB Holdings LLC, a Delaware limited liability company; BCGFK CB Holdings LLC, a Delaware limited liability company; FSBCGF CB Holdings LLC, a Delaware limited liability company; PYLBCG CB Holdings LLC, a Delaware limited liability company;
FSGRWCO CB Holdings LLC, a Delaware limited liability company; GROWTHCO CB Holdings LLC, a Delaware limited liability company; GRTHCOCP CB Holdings LLC, a Delaware limited liability company; and GRWTHCOK CB Holdings LLC, a Delaware limited liability
company (the &#147;<U>Agreement</U>&#148;), as contemplated by <U>Section</U><U></U><U>&nbsp;8.4</U> of the Agreement. The capitalized terms used but not defined herein shall have the meanings given to them in the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, <U>Section</U><U></U><U>&nbsp;8.4</U> of the Agreement provides that the Agreement may be amended in writing by Public Company and
Merger Partner; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Parties desire to amend the Agreement to address certain scrivener&#146;s errors, as set forth herein.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the foregoing and the respective covenants and agreements set forth below, and for other good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Public Company and Merger Partner hereby agree as follows: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENTS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Public Company Class</U><U></U><U>&nbsp;A Common Stock</U>. <U>Article IX</U> of the
Agreement is hereby amended to delete the definition of &#147;Public Company Class&nbsp;A Common Stock&#148; and replace it with the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Public Company Class</U><U></U><U>&nbsp;A Common Stock</U>&#148; means the Class&nbsp;A Common Stock, par value $0.0001 per share, of
Public Company. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MISCELLANEOUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Effect of Amendment</U>. Except as and to the extent expressly modified by this Amendment, the
Agreement, as so amended by this Amendment, will remain in full force and effect in all respects. Each reference to &#147;hereof,&#148; &#147;herein,&#148; &#147;hereby,&#148; and &#147;this Agreement&#148; in the Agreement will from and after the
effective date hereof refer to the Agreement as amended by this Amendment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Integration</U>.
This Amendment, together with the Agreement and the documents executed pursuant thereto, supersede all negotiations, agreements and understandings among the Parties with respect to the subject matter hereof (except for the Confidentiality Agreement)
and constitute the entire agreement between the Parties with respect thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices; Governing Law; Submission to
Jurisdiction</U>. <U>Sections</U> <U>10.1</U>, <U>10.8</U> and <U>10.11</U>, in each case, of the Agreement are incorporated into this Amendment by reference as if fully set forth herein, <I>mutatis mutandis</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.4&nbsp;&nbsp;&nbsp;&nbsp;<U>Headings</U>. The insertion of headings are for convenience of reference only and shall not affect
or be utilized in construing or interpreting this Amendment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.5&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterparts; Signature</U>. This
Amendment may be executed in two or more counterparts, each of which shall be deemed an original but all of which together shall be considered one and the same amendment and shall become effective when counterparts have been signed by each of the
parties hereto and delivered to the other parties, it being understood that all parties need not sign the same counterpart. This Amendment may be executed and delivered by facsimile or by an electronic scan delivered by electronic transmission. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature page follows</I>.] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have caused this Amendment to be executed as of the day and
year first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PUBLIC COMPANY:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">CALYXT, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael Carr</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Michael Carr</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">President and Chief Executive Officer</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page &#150; First Amendment to Agreement and Plan of
Merger</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have caused this Amendment to be executed as of the day and
year first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MERGER PARTNER:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">CIBUS GLOBAL, LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Rory Riggs</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Rory Riggs</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page &#150; First Amendment to Agreement and Plan of
Merger</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="rom401831_67"></A>ANNEX B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CIBUS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NAME </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;1.1.</B>&nbsp;&nbsp;&nbsp;&nbsp;<U>Name</U>. The name of the corporation is Cibus, Inc. (the
&#147;<B>Corporation</B>&#148;). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REGISTERED OFFICE AND AGENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2.1.</B>&nbsp;&nbsp;&nbsp;&nbsp;<U>Registered Office and Agent</U>. The address of the Corporation&#146;s
registered office in the State of Delaware is 251 Little Falls Drive, City of Wilmington, County of New Castle, Delaware 19808. The name of the Corporation&#146;s registered agent at such address is Corporation Service Company. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PURPOSE
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.1.</B>&nbsp;&nbsp;&nbsp;&nbsp;<U>Purpose</U>. The purpose of the Corporation is to engage in any
lawful act or activity for which corporations may be organized under the General Corporation Law of the State of Delaware, as the same exists or may hereafter be amended (the &#147;<B>DGCL</B>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IV </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CAPITAL
STOCK </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.1.</B>&nbsp;&nbsp;&nbsp;&nbsp;<U>Capitalization</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Authorized Shares</U>. The total number of shares of all classes of capital stock which the Corporation is
authorized to issue is [&#9679;]<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP> shares, consisting of (i) [&#9679;]<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP> shares of common stock, par value $0.0001 per share (the
&#147;<B>Common Stock</B>&#148;) divided into (A) [&#9679;]<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP> shares of Class&nbsp;A Common Stock, par value </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To equal (A) if the Subsequent Reverse Stock Split (as such term is defined in the proxy statement/prospectus
included in the registration statement on Form S-4 filed with the Securities and Exchange Commission on April 14, 2023 (the &#147;Proxy Statement/Prospectus&#148;)) has not occurred, 1,550,000,000, and (B) if the Subsequent Reverse Stock Split has
occurred, 1,550,000,000 divided by the Subsequent Reverse Stock Split Factor (as such term is defined in the Proxy Statement/Prospectus), rounded up to the nearest whole number. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To equal (A) if the Subsequent Reverse Stock Split has not occurred, 1,500,000,000, and (B) if the Subsequent
Reverse Stock Split has occurred, 1,500,000,000 divided by the Subsequent Reverse Stock Split Factor, rounded up to the nearest whole number. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To equal (A) if the Subsequent Reverse Stock Split has not occurred, 1,050,000,000, and (B) if the Subsequent
Reverse Stock Split has occurred, 1,050,000,000 divided by the Subsequent Reverse Stock Split Factor, rounded up to the nearest whole number. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
$0.0001 per share (the &#147;<B>Class</B><B></B><B>&nbsp;A Common Stock</B>&#148;), and (B) [&#9679;]<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP> shares of Class&nbsp;B Common Stock,
par value $0.0001 per share (the &#147;<B>Class</B><B></B><B>&nbsp;B Common Stock</B>&#148;), and (ii) [&#9679;]<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP> shares of preferred stock, par value $0.0001 per share (the &#147;<B>Preferred
Stock</B>&#148;). Upon the effectiveness of this Certificate of Incorporation (as defined below), each outstanding share of Common Stock as of immediately prior to such time shall automatically and without further action on the part of the
Corporation or any holder thereof be converted into an equivalent number of shares of Class&nbsp;A Common Stock of the Corporation (<I>i.e.</I>, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-to-one</FONT></FONT> basis)
for no consideration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Changes in Authorized Shares</U>. Subject to the rights of the holders of any one or
more series of Preferred Stock then outstanding, the number of authorized shares of any class of the Common Stock or the Preferred Stock may be increased or decreased, in each case by the affirmative vote of the holders of a majority of the total
voting power of the outstanding shares of capital stock of the Corporation entitled to vote thereon, voting together as a single class, irrespective of the provisions of Section&nbsp;242(b)(2) of the DGCL, and no vote of the holders of any class of
the Common Stock or the Preferred Stock voting separately as a class shall be required therefor. Notwithstanding the immediately preceding sentence, the number of authorized shares of any particular class may not be decreased below the number of
shares of such class then outstanding, plus, in the case of </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;A Common Stock, the number of shares of Class&nbsp;A Common Stock issuable in
connection with (A)&nbsp;the exchange of all outstanding shares of Class&nbsp;B Common Stock, together with the corresponding Common Units (as defined in the Third Amended and Restated Operating Agreement of Cibus Global LLC, as such agreement may
be amended from time to time in accordance with the terms thereof (the &#147;<B>OpCo Operating Agreement</B>&#148;)) (each share of Class&nbsp;B Common Stock, together with the corresponding Common Unit, collectively, a &#147;<B>Paired
Interest</B>&#148;) pursuant to the Exchange Agreement, dated [&#9679;], 2023, by and among the Corporation, Cibus Global, LLC and the holders from time to time party thereto (the &#147;<B>Exchange Agreement</B>&#148;), and (B)&nbsp;the exercise of
outstanding options, warrants, exchange rights, conversion rights or similar rights for Class&nbsp;A Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.2.</B>&nbsp;&nbsp;&nbsp;&nbsp;<U>Classes of Shares</U>. The designation, relative rights, preferences and
limitations of the shares of each class of stock are as follows: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Common Stock</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;<U>Voting Rights</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(A)&nbsp;&nbsp;&nbsp;&nbsp;Each holder of Class&nbsp;A Common Stock shall be entitled to one vote for each share of Class&nbsp;A Common Stock
held of record by such holder on all matters on which stockholders generally are entitled to vote, and each holder of Class&nbsp;B Common Stock shall be entitled to one vote for each share of Class&nbsp;B Common Stock held of record by such holder
on all matters on which stockholders generally are entitled to vote, except that, in each case, to the fullest extent permitted by law and subject to <U>Section</U><U></U><U>&nbsp;4.2(a)(ii)</U>, holders of shares of each class of Common Stock, as
such, shall have no voting power with respect to, and shall not be entitled to vote on, any amendment to this Second Amended and Restated Certificate of Incorporation (including any certificate of designations relating to any series of Preferred
Stock) (the &#147;<B>Certificate of Incorporation</B>&#148;) that relates solely to the terms of any outstanding Preferred Stock if the holders of such Preferred Stock are entitled to vote as a separate class thereon under this Certificate of
Incorporation (including any certificate of designations relating to any series of Preferred Stock) or under the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(B)&nbsp;&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(1)&nbsp;&nbsp;&nbsp;&nbsp;The holders of the outstanding shares of Class&nbsp;A Common Stock shall be entitled to vote separately upon any
amendment to this Certificate of Incorporation (including by merger, consolidation, </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To equal (A) if the Subsequent Reverse Stock Split has not occurred, 450,000,000, and (B) if the Subsequent
Reverse Stock Split has occurred, 450,000,000 divided by the Subsequent Reverse Stock Split Factor, rounded up to the nearest whole number. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To equal (A) if the Subsequent Reverse Stock Split has not occurred, 50,000,000, and (B) if the Subsequent
Reverse Stock Split has occurred, 50,000,000 divided by the Subsequent Reverse Stock Split Factor, rounded up to the nearest whole number. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>2 </I></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
conversion, reorganization or similar event) that would alter or change the powers, preferences or special rights of such class of Common Stock in a manner that is materially and
disproportionately adverse as compared to the Class&nbsp;B Common Stock and (2)&nbsp;the holders of the outstanding shares of Class&nbsp;B Common Stock shall be entitled to vote separately upon any amendment to this Certificate of Incorporation
(including by merger, consolidation, conversion, reorganization or similar event) that would alter or change the powers, preferences or special rights of such class of Common Stock in a manner that is materially and disproportionately adverse as
compared to the Class&nbsp;A Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(2)&nbsp;&nbsp;&nbsp;&nbsp;The holders of the outstanding shares of Class&nbsp;B Common Stock
shall be entitled to vote separately upon any (A)&nbsp;merger, consolidation, conversion, reorganization or similar event in connection with any transaction or series of transactions intended to result in the Corporation and its subsidiaries no
longer being structured as an umbrella partnership C corporation (an &#147;<B><FONT STYLE="white-space:nowrap">Up-C</FONT> Reorganization Transaction</B>&#148;) or (B)&nbsp;amendment to this Certificate of Incorporation (including by merger,
consolidation, conversion, reorganization or similar event) to effect an <FONT STYLE="white-space:nowrap">Up-C</FONT> Reorganization Transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(C)&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise required in this Certificate of Incorporation or by applicable law, the holders of Common
Stock shall vote together as a single class on all matters (or, if any holders of Preferred Stock are entitled to vote together with the holders of Common Stock, as a single class with the holders of Preferred Stock). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;<U>Dividends; Stock Splits or Combinations</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(A)&nbsp;&nbsp;&nbsp;&nbsp;Subject to applicable law and the rights, if any, of the holders of any outstanding series of Preferred Stock or
any class or series of stock having a preference senior to or the right to participate with the Class&nbsp;A Common Stock with respect to the payment of dividends, such dividends and other distributions of cash, stock or property may be declared and
paid on the Class&nbsp;A Common Stock out of the assets of the Corporation that are by law available therefor, at the times and in the amounts as the board of directors of the Corporation (the &#147;<B>Board</B>&#148;) in its discretion may
determine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(B)&nbsp;&nbsp;&nbsp;&nbsp;Except as provided in <U>Section</U><U></U><U>&nbsp;4.2(a)(ii)(C)</U> with respect to stock
dividends, dividends of cash or property may not be declared or paid on shares of Class&nbsp;B Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(C)&nbsp;&nbsp;&nbsp;&nbsp;In no event will any stock dividend, stock split, reverse stock split, combination of stock, reclassification or
recapitalization be declared or made on any class of Common Stock (each, a &#147;<B>Stock Adjustment</B>&#148;) unless (a)&nbsp;a corresponding Stock Adjustment for all other classes of Common Stock not so adjusted at the time outstanding is made in
the same proportion and the same manner and (b)&nbsp;the Stock Adjustment has been reflected in the same economically equivalent manner on all Common Stock. Stock dividends with respect to each class of Common Stock may only be paid with shares of
stock of the same class of Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;<U>Liquidation</U>. In the event of any voluntary or involuntary
liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the affairs of the Corporation, after payment or provision for payment of the debts and other liabilities of the Corporation and of the preferential and other amounts,
if any, to which the holders of Preferred Stock are entitled, if any, the holders of all outstanding shares of Class&nbsp;A Common Stock shall be entitled to receive, <I>pari passu</I>, an amount per share equal to the par value thereof, and
thereafter the holders of all outstanding shares of Class&nbsp;A Common Stock shall be entitled to receive the remaining assets of the Corporation available for distribution ratably in proportion to the number of shares of Class&nbsp;A Common Stock.
Without limiting the rights of the holders of Class&nbsp;B Common Stock to exchange their shares of Class&nbsp;B Common Stock, together with the corresponding Common Units constituting the remainder of any Paired Interests in which such shares are
included, for shares of Class&nbsp;A Common Stock in accordance with the Exchange Agreement (or for the consideration payable in respect of shares of Class&nbsp;A Common Stock in such voluntary or involuntary liquidation, dissolution or <FONT
STYLE="white-space:nowrap">winding-up),</FONT> the holders of shares of Class&nbsp;B Common Stock, as such, shall not be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>3 </I></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
entitled to receive, with respect to such shares, any assets of the Corporation in excess of the par value thereof, in the event of any voluntary or involuntary liquidation, dissolution or
winding up of the affairs of the Corporation. A consolidation, reorganization or merger of the Corporation with any other Person (defined below) or Persons, or a sale of all or substantially all of the assets of the Corporation, shall not be
considered to be a dissolution, liquidation or winding up of the Corporation within the meaning of this <U>Section</U><U></U><U>&nbsp;4.2(a)(iii).</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Preferred Stock</U>. The Board is authorized, subject to any limitations prescribed by law, to provide for the
issuance of shares of Preferred Stock from time to time in one or more series of any number of shares, provided that the aggregate number of shares issued and not retired of any and all such series shall not exceed the total number of shares of
Preferred Stock hereinabove authorized, and with such powers, including voting powers, if any, and the designations, preferences and relative, participating, optional or other special rights, if any, and any qualifications, limitations or
restrictions thereof, all as shall hereafter be stated and expressed in the resolution or resolutions providing for the designation and issue of such shares of Preferred Stock from time to time adopted by the Board pursuant. The powers, including
voting powers, if any, preferences and relative, participating, optional and other special rights of each series of Preferred Stock, and the qualifications, limitations or restrictions thereof, if any, may differ from those of any and all other
series at any time outstanding. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Specific Provisions With Respect To Class</U><U></U><U>&nbsp;B Common
Stock</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;<U>Retirement of Shares of Class</U><U></U><U>&nbsp;B Common Stock</U>. No holder of Class&nbsp;B
Common Stock may transfer shares of Class&nbsp;B Common Stock to any individual, partnership, firm, corporation, limited liability company, association, trust, unincorporated organization or other entity (a &#147;<B>Person</B>&#148;) unless such
holder transfers a corresponding number of Common Units to the same Person in accordance with the provisions of the OpCo Operating Agreement. If any outstanding share of Class&nbsp;B Common Stock ceases to be held by a holder of the corresponding
Common Unit, such share shall automatically and without further action on the part of the Corporation or any holder of Class&nbsp;B Common Stock be transferred to the Corporation for no consideration and retired. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;<U>Reservation of Shares of Class</U><U></U><U>&nbsp;A Common Stock</U>. The Corporation shall at all times
reserve and keep available out of its authorized and unissued shares of Class&nbsp;A Common Stock, solely for the purpose of the issuance in connection with the exchange of Paired Interests, the number of shares of Class&nbsp;A Common Stock that are
issuable upon conversion of all outstanding Paired Interests, pursuant to the Exchange Agreement. The Corporation covenants that all the shares of Class&nbsp;A Common Stock that are issued upon the exchange of such Paired Interests will, upon
issuance, be validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;<U>Taxes</U>. The issuance of shares of Class&nbsp;A Common Stock upon the exercise by holders of Paired
Interests of their right under the Exchange Agreement to exchange Paired Interests for shares of Class&nbsp;A Common Stock shall be made without charge to such holders for any transfer taxes, stamp taxes or duties or other similar tax in respect of
the issuance; <I>provided</I>, <I>however</I>, that if any such shares of Class&nbsp;A Common Stock are to be issued in a name other than that of the then record holder of the Paired Interests being exchanged (or The Depository Trust Company or its
nominee for the account of a participant of The Depository Trust Company that will hold the shares for the account of such holder), then such holder and/or the Person in whose name such shares are to be delivered, shall pay to the Corporation the
amount of any tax that may be payable in respect of any transfer involved in the issuance or shall establish to the reasonable satisfaction of the Corporation that the tax has been paid or is not payable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;<U>Issuance of Common Units</U>. To the extent Common Units are issued pursuant to the OpCo Operating Agreement
to anyone other than the Corporation or a wholly owned subsidiary of the Corporation, an equivalent number of shares of Class&nbsp;B Common Stock (subject to adjustment as set forth herein) shall be issued at par to the same Person to which such
Common Units are issued. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>4 </I></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v)&nbsp;&nbsp;&nbsp;&nbsp;<U>Certificates</U>. All certificates or book entries
representing shares of Class&nbsp;B Common Stock, shall bear a legend substantially in the following form (or in such other form as the Board may determine): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THE SECURITIES REPRESENTED BY THIS [CERTIFICATE][BOOK ENTRY] ARE SUBJECT TO THE RESTRICTIONS (INCLUDING RESTRICTIONS ON TRANSFER) SET FORTH IN THE SECOND
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF THE CORPORATION (A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE CORPORATION AND SHALL BE PROVIDED FREE OF CHARGE TO ANY STOCKHOLDER MAKING A REQUEST THEREFOR). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.3.</B>&nbsp;&nbsp;&nbsp;&nbsp;<U>Registered Owners</U>. The Corporation shall be entitled to treat the Person
in whose name any share of its stock is registered as the owner thereof for all purposes and shall not be bound to recognize any equitable or other claim to, or interest in, such share on the part of any other Person, whether or not the Corporation
shall have notice thereof, except as expressly provided by applicable law. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE V </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.1.</B>&nbsp;&nbsp;&nbsp;&nbsp;<U>Board of Directors</U>. The business and affairs of the Corporation shall be
managed by, or under the direction of, the Board. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.2.</B>&nbsp;&nbsp;&nbsp;&nbsp;<U>Composition</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise provided for or fixed pursuant to the provisions of Section&nbsp;4.2(b) of this Certificate of
Incorporation relating to the rights of the holders of any series of Preferred Stock to elect additional Directors, the total number of directors of the Corporation (the &#147;<B>Directors</B>&#148;) constituting the entire Board shall, (i)&nbsp;as
of the date of this Certificate of Incorporation, be six and (ii)&nbsp;thereafter, shall be fixed exclusively by one or more resolutions adopted from time to time by the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;During any period when the holders of any series of Preferred Stock have the right to elect additional Directors as
provided for or fixed pursuant to the provisions of <U>Section </U><U>4.2(b)</U> (&#147;<B>Preferred Stock Directors</B>&#148;), upon the commencement, and for the duration, of the period during which such right continues: (i)&nbsp;the election,
term of office, filling of vacancies, removal and other features of such directorships shall be governed by the terms of the resolution or resolutions adopted by the Board pursuant to <U>Section</U><U></U><U>&nbsp;4.2(b)</U> applicable thereto, and
such Preferred Stock Directors so elected shall not be subject to the provisions of this Article V unless otherwise provided therein, (ii)&nbsp;the then total authorized number of Directors shall automatically be increased by such specified number
of Preferred Stock Directors, and the holders of the related Preferred Stock shall be entitled to elect the Preferred Stock Directors pursuant to the provisions of the Board&#146;s designation for the series of Preferred Stock, and (iii)&nbsp;each
such Preferred Stock Director shall serve until such Preferred Stock Director&#146;s successor shall have been duly elected and qualified, or until such Preferred Stock Director&#146;s right to hold such office terminates pursuant to such
provisions, whichever occurs earlier, subject to his or her earlier death, disqualification, resignation or removal. Except as otherwise provided by the Board in the resolution or resolutions establishing such series, whenever the holders of any
series of Preferred Stock having such right to elect Preferred Stock Directors are divested of such right pursuant to the provisions of such stock, the terms of office of all such Preferred Stock Directors elected by the holders of such Preferred
Stock, or elected to fill any vacancies resulting from the death, resignation, disqualification or removal of such Preferred Stock Directors, shall forthwith terminate and the total and authorized number of Directors shall be reduced accordingly.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Directors shall be elected annually at each annual meeting for
<FONT STYLE="white-space:nowrap">one-year</FONT> terms expiring at the next succeeding annual meeting of stockholders. Each director shall hold office until such director&#146;s successor shall have been duly elected and qualified or until such
director&#146;s earlier death, resignation or removal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;There shall be no cumulative voting in the election of
Directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>5 </I></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;Unless and except to the extent that the Bylaws of the
Corporation, as may be amended from time to time in accordance therewith (the &#147;<B>Bylaws</B>&#148;), shall so require, the election of Directors need not be by written ballot. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.3.</B>&nbsp;&nbsp;&nbsp;&nbsp;<U>Vacancies and Newly Created Directorships</U>. Subject to any limitations
imposed by applicable law and the rights of the holders of any one or more series of Preferred Stock then outstanding, newly created directorships resulting from any increase in the authorized number of Directors or any vacancies on the Board
resulting from death, resignation, retirement, disqualification, removal from office or other cause shall, unless the Board determines by resolution that any such vacancies or newly created directorships shall be filled by the stockholders and
except as otherwise provided by applicable law, be filled only by the affirmative vote of a majority of the remaining Directors then in office, even if less than a quorum of the Board, and not by the stockholders. Any Director so chosen shall hold
office until the earlier expiration of the term of office of the director whom he or she has replaced or his or her successor shall be duly elected and qualified or until such Director&#146;s earlier death, disqualification, resignation or removal.
No decrease in the number of Directors shall shorten the term of any Director then in office. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.4.</B>&nbsp;&nbsp;&nbsp;&nbsp;<U>Nomination of Director Candidates</U>. Advance notice of stockholder
nominations for the election of Directors must be given in the manner provided in the Bylaws. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VI </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;6.1.</B>&nbsp;&nbsp;&nbsp;&nbsp;<U>No Action by Written Consent</U>. Subject to the rights of the holders of any
outstanding Preferred Stock, any action required or permitted to be taken by the stockholders of the Corporation at any annual or special meeting of stockholders may be taken only by a vote of the stockholders at an annual or special meeting of
stockholders, duly noticed and called in accordance with the DGCL, this Certificate of Incorporation and the Bylaws of the Corporation, and may not be taken in writing by such stockholders; provided, however, that any action required or permitted to
be taken by the holders of Class&nbsp;B Common Stock, voting separately as a class, may be effected by the consent in writing of the holders of a majority of the total voting power of the Class&nbsp;B Common Stock entitled to vote thereon, voting
together as a single class in lieu of a duly called annual or special meeting of holders of Class&nbsp;B Common Stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;6.2.</B>&nbsp;&nbsp;&nbsp;&nbsp;<U>Meetings</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;An annual meeting of stockholders for the election of Directors to succeed those whose terms expire and for the
transaction of such other business as may properly come before the meeting shall be held at such place, on such date, and at such time as the Board shall determine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Subject to any special rights of the holder of any series of Preferred Stock, and to the requirements of applicable
law, special meetings of stockholders of the Corporation may be called only by the chairperson of the Board, the chief executive officer of the Corporation or at the direction of the Board pursuant to a written resolution adopted by a majority of
the total number of Directors that the Corporation would have if there were no vacancies. Any business transacted at a special meeting of stockholders shall be limited to matters set forth in the notice of the special meeting. The ability of holders
of Common Stock to call a special meeting of the stockholders is hereby specifically denied. At any annual meeting or special meeting of stockholders, only such business will be conducted or considered as has been brought before such meeting in the
manner provided in the Bylaws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Advance notice of stockholder nominations for the election of Directors and of
business to be brought by stockholders before any meeting of the stockholders of the Corporation shall be given in the manner provided in the Bylaws of the Corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>6 </I></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VII </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LIMITATIONS ON LIABILITY AND INDEMNIFICATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7.1.</B>&nbsp;&nbsp;&nbsp;&nbsp;<U>Limitation of Liability</U>. No Director or officer of the Corporation shall
be personally liable to the Corporation or its stockholders for monetary damages for any breach of fiduciary duty by such a Director or officer as a Director or officer. Notwithstanding the foregoing sentence, a Director or officer, as applicable,
shall be liable to the extent provided by applicable law (a)&nbsp;with respect to any Director or officer, (i)&nbsp;for any breach of the Director&#146;s or officer&#146;s duty of loyalty to the Corporation or its stockholders, (ii)&nbsp;for acts or
omissions not in good faith or which involve intentional misconduct or a knowing violation of law, or (iii)&nbsp;for any transaction from which such Director or officer derived an improper personal benefit, (b)&nbsp;with respect to any Director,
pursuant to Section&nbsp;174 of the DGCL, (c)&nbsp;with respect to any officer, in any action by or in the right of the Corporation. Solely for purposes of this <U>Section</U><U></U><U>&nbsp;7.1</U>, &#147;officer&#148; shall have the meaning
provided in Section&nbsp;102(b)(7) of the DGCL as currently in effect and as it may hereafter be amended. No amendment to or repeal of this <U>Section</U><U></U><U>&nbsp;7.1</U> shall apply to or have any effect on the liability or alleged liability
of any Director or officer of the Corporation for or with respect to any acts or omissions of such Director or officer occurring prior to such amendment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7.2.</B>&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Each person who was or is made a party or is threatened to be made a party to or is otherwise subject to or involved
in any claim, demand, action, suit or proceeding, whether civil, criminal, administrative or investigative (a &#147;<B>Proceeding</B>&#148;), by reason of the fact that he or she is or was a Director, officer of the Corporation or is or was serving
at the request of the Corporation as a director, officer, employee or agent of another company or of a partnership, joint venture, trust or other enterprise, including service with respect to an employee benefit plan (an
&#147;<B>Indemnitee</B>&#148;), whether the basis of such Proceeding is alleged action in an official capacity as a Director, officer, employee or agent or in any other capacity while serving as a Director, officer, employee or agent, shall be
indemnified by the Corporation to the fullest extent permitted or required by the DGCL and any other applicable law, as the same exists or may hereafter be amended (but, in the case of any such amendment, only to the extent that such amendment
permits the Corporation to provide broader indemnification rights than such law permitted the Corporation to provide prior to such amendment), against all expense, liability and loss (including, without limitation, court costs, attorneys&#146; fees,
witness fees, amounts paid in settlement or judgment, fines, ERISA excise taxes or penalties and amounts paid in settlement) reasonably incurred or suffered by such Indemnitee in connection therewith (&#147;<B>Indemnifiable Losses</B>&#148;);
provided, however, that, except as provided in <U>Section</U><U></U><U>&nbsp;7.2(d)</U> with respect to Proceedings to enforce rights to indemnification, the Corporation shall indemnify any such Indemnitee pursuant to this
<U>Section</U><U></U><U>&nbsp;7.2(a)</U> in connection with a Proceeding (or part thereof) initiated by such Indemnitee only (i)&nbsp;if such Proceeding (or part thereof) was authorized by the Board or (ii)&nbsp;if indemnification is expressly
required by the DGCL. An Indemnitee&#146;s right to indemnification pursuant to this <U>Section</U><U></U><U>&nbsp;7.2(a)</U> does not include and is separate from an Indemnitee&#146;s right to Advancement of Expenses (as defined below) under
<U>Section</U><U></U><U>&nbsp;7.2(b)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Each Indemnitee shall have the right to advancement by the
Corporation of any and all expenses (including, without limitation, attorneys&#146; fees and expenses) incurred in defending any such Proceeding in advance of its final disposition (an &#147;<B>Advancement of Expenses</B>&#148;); provided, however,
that, if the DGCL so requires, an Advancement of Expenses incurred by an Indemnitee in his or her capacity as a Director or officer (and not in any other capacity in which service was or is rendered by such Indemnitee, including without limitation
service to an employee benefit plan) shall be made pursuant to this <U>Section</U><U></U><U>&nbsp;7.2(b)</U> only upon delivery to the Corporation of an undertaking (an &#147;<B>Undertaking</B>&#148;), by or on behalf of such Indemnitee, to repay,
without interest, all amounts so advanced if it shall ultimately be determined by final judicial decision from which there is no further right to appeal (a &#147;<B>Final Adjudication</B>&#148;) that such Indemnitee is not entitled to be indemnified
for such expenses under <U>Section</U><U></U><U>&nbsp;7.2(a)</U>. An Indemnitee&#146;s right to an Advancement of Expenses pursuant to this <U>Section</U><U></U><U>&nbsp;7.2(b)</U> is not subject to the satisfaction of any standard of conduct and is
not conditioned upon any prior determination that Indemnitee is entitled to indemnification under <U>Section</U><U></U><U>&nbsp;7.2(a)</U> with respect to the related Proceeding or the absence of any prior determination to the contrary. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>7 </I></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;The rights to indemnification and to the Advancement of Expenses
conferred in <U>Sections 7.2(a)</U> and <U>7.2(b)</U> shall be separate contract rights and such rights shall continue as to an Indemnitee who has ceased to be a Director, officer, employee or agent and shall inure to the benefit of the
Indemnitee&#146;s heirs, executors and administrators. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;If a claim under
<U>Section</U><U></U><U>&nbsp;7.2(a)</U> or <U>Section</U><U></U><U>&nbsp;7.2(b)</U> is not paid in full by the Corporation within 60&nbsp;calendar days after a written claim has been received by the Corporation, except in the case of a claim for an
Advancement of Expenses, in which case the applicable period shall be 20 calendar days, the Indemnitee may at any time thereafter bring suit against the Corporation to recover the unpaid amount of the claim. If successful in whole or in part in any
such suit, or in a suit brought by the Corporation to recover an Advancement of Expenses pursuant to the terms of an Undertaking, the Indemnitee shall be entitled to the fullest extent permitted or required by the DGCL, as the same exists or may
hereafter be amended (but, in the case of any such amendment, only to the extent that such amendment permits the Corporation to provide broader reimbursements of prosecution or defense expenses than such law permitted the Corporation to provide
prior to such amendment), to be paid also the expense of prosecuting or defending such suit. In (i)&nbsp;any suit brought by the Indemnitee to enforce a right to indemnification hereunder (but not in a suit brought by the Indemnitee to enforce a
right to an Advancement of Expenses) it shall be a defense that, and (ii)&nbsp;any suit brought by the Corporation to recover an Advancement of Expenses pursuant to the terms of an Undertaking, the Corporation shall be entitled to recover such
expenses, without interest, upon a Final Adjudication that, the Indemnitee has not met any applicable standard for indemnification set forth in the DGCL. Neither the failure of the Corporation (including the Board or a committee thereof, its
stockholders or independent legal counsel) to have made a determination prior to the commencement of such suit that indemnification of the Indemnitee is proper in the circumstances because the Indemnitee has met the applicable standard of conduct
set forth in the DGCL, nor an actual determination by the Corporation (including the Board or a committee thereof, its stockholders or independent legal counsel) that the Indemnitee has not met such applicable standard of conduct, shall create a
presumption that the Indemnitee has not met the applicable standard of conduct or, in the case of such a suit brought by the Indemnitee, be a defense to such suit. In any suit brought by an Indemnitee to enforce a right to indemnification or to an
Advancement of Expenses hereunder, or brought by the Corporation to recover an Advancement of Expenses hereunder pursuant to the terms of an Undertaking, the burden of proving that the Indemnitee is not entitled to be indemnified, or to such
Advancement of Expenses, shall be on the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;The rights to indemnification and to the Advancement of
Expenses conferred in this <U>Section</U><U></U><U>&nbsp;7.2</U> shall not be exclusive of any other right which any person may have or hereafter acquire under any statute, this Certificate of Incorporation, the Bylaws, agreement, vote of
stockholders or disinterested Directors or otherwise. Nothing contained in this <U>Section</U><U></U><U>&nbsp;7.2</U> shall limit or otherwise affect any such other right or the Corporation&#146;s power to confer any such other right. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;The Corporation shall not be liable under this <U>Section</U><U></U><U>&nbsp;7.2</U> to make any payment to an
Indemnitee in respect of any Indemnifiable Losses to the extent that the Indemnitee has otherwise actually received payment (net of any expenses incurred in connection therewith and any repayment by the Indemnitee made with respect thereto) under
any insurance policy or from any other source in respect of such Indemnifiable Losses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;Any repeal or
modification of this <U>Section</U><U></U><U>&nbsp;7.2</U> shall only be prospective and shall not affect the rights or protections or increase the liability of any Director under this <U>Section</U><U></U><U>&nbsp;7.2</U> in effect at the time of
the alleged occurrence of any act or omission to act giving rise to liability or indemnification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7.3.</B>&nbsp;&nbsp;&nbsp;&nbsp;<U>Insurance</U>. The Corporation may maintain insurance, at its expense, to
protect itself and any director, officer, employee or agent of the Corporation or another corporation, partnership, joint venture, trust or other enterprise against any expense, liability or loss, whether or not the Corporation would have the power
to indemnify such person against such expense, liability or loss under the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7.4.</B>&nbsp;&nbsp;&nbsp;&nbsp;<U>Savings Clause</U>. If this Article VII or any portion hereof shall be
invalidated on any ground by any court of competent jurisdiction, then the Corporation shall nevertheless indemnify each Indemnitee to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>8 </I></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
full extent not prohibited by any applicable portion of this Article VII that shall not have been invalidated, or by any other applicable law. If this Article VII or any portion hereof shall be
invalid due to the application of the indemnification provisions of another jurisdiction, then the Corporation shall indemnify each Indemnitee to the full extent under any other applicable law. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VIII </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORUM;
SEVERABILITY </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.1.</B>&nbsp;&nbsp;&nbsp;&nbsp;<U>Forum</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Unless the Corporation consents in writing to the selection of an alternative forum, the sole and exclusive forum
for (i)&nbsp;any derivative action or proceeding brought on behalf of the Corporation, (ii)&nbsp;any action or proceeding asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of the Corporation to the
Corporation or the Corporation&#146;s stockholders, (iii)&nbsp;any action or proceeding asserting a claim arising pursuant to any provision of the DGCL or the Certificate of Incorporation or the Bylaws (as either may be amended from time to time),
or (iv)&nbsp;any action or proceeding asserting a claim governed by the internal affairs doctrine, shall be the Court of Chancery in the State of Delaware (or, if the Court of Chancery does not have jurisdiction, the federal district court for the
District of Delaware), in all cases to the fullest extent permitted by law and subject to the court&#146;s having personal jurisdiction over the indispensable parties named as defendants. If any action the subject matter of which is within the scope
of the preceding sentence is filed in a court other than a court located within the State of Delaware (a &#147;<B>Foreign Action</B>&#148;) in the name of any stockholder, such stockholder shall be deemed to have consented to (i)&nbsp;the personal
jurisdiction of the state and federal courts located within the State of Delaware in connection with any action brought in any such court to enforce the preceding sentence and (ii)&nbsp;having service of process made upon such stockholder in any
such action by service upon such stockholder&#146;s counsel in the Foreign Action as agent for such stockholder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Unless the Corporation consents in writing to the selection of an alternative forum, the federal district courts of
the United States of America shall be, to the fullest extent permitted by law, the sole and exclusive forum for any action asserting a claim arising under the Securities Act of 1933. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.2.</B>&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice and Consent</U>. To the fullest extent permitted by law, any person or
entity purchasing or otherwise acquiring or holding any interest in any security of the Corporation shall be deemed to have notice of and to have consented to the provisions of this Article VIII. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;8.3.</B>&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U>. If any provision or provisions of this Certificate of
Incorporation shall be held to be invalid, illegal or unenforceable as applied to any person or entity or circumstance for any reason whatsoever, then, to the fullest extent permitted by law, (a)&nbsp;the validity, legality and enforceability of
such provisions in any other circumstance and of the remaining provisions of this Certificate of Incorporation (including, without limitation, each paragraph of this Certificate of Incorporation containing any such provision held to be invalid,
illegal or unenforceable that is not itself held to be invalid, illegal or unenforceable) and the application of such provision to other Persons or circumstances shall not in any way be affected or impaired thereby, and (b)&nbsp;to the fullest
extent possible, the provisions of the Certificate of Incorporation (including, without limitation, each such portion of any paragraph of this Certificate of Incorporation containing any such provision held to be invalid, illegal or unenforceable)
shall be construed so as to permit the Corporation to protect its Directors, officers, employees and agents from personal liability in respect of their good faith service to or for the benefit of the Corporation to the fullest extent permitted by
law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>9 </I></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IX </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;9.1.</B>&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendments to the Bylaws</U>. In furtherance and not in limitation of the
rights, powers, privileges, and discretionary authority granted or conferred by the DGCL or other statutes or laws of the State of Delaware, the Board shall have the power, without stockholder approval, to adopt, alter, amend, change or repeal the
Bylaws by the affirmative vote of a majority of the Directors then in office, subject to any limitation set forth in the Bylaws. The Corporation may in its Bylaws confer powers upon the Board in addition to the foregoing and in addition to the
powers and authorities expressly conferred upon the Board by applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;9.2.</B>&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendments to the Certificate of Incorporation</U>. The Corporation reserves
the right at any time and from time to time to amend, alter, change or repeal any provision contained in this Certificate of Incorporation, and other provisions authorized by the DGCL and laws of the State of Delaware at the time in force may be
added or inserted, in the manner now or hereafter prescribed herein or by applicable law; and all rights, preferences and privileges of whatsoever nature conferred upon stockholders, Directors or any other Persons whomsoever by and pursuant to this
Certificate of Incorporation in its present form or as hereafter amended are granted and held subject to this reservation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature
page follows.] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned has executed this Second Amended and Restated
Certificate of Incorporation this &nbsp;&nbsp;&nbsp;&nbsp; day of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Authorized Person</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="rom401831_68"></A>ANNEX C </B></P>
<P STYLE="font-size:160pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CIBUS, INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">AMENDED AND
RESTATED BYLAWS </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">As Adopted and Effective </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">on [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 2023 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Page</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexctoc401831_1">STOCKHOLDERS MEETINGS </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexctoc401831_2">Time and Place of Meetings</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexctoc401831_3">Annual Meetings</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexctoc401831_4">Special Meetings</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexctoc401831_5">Notice of Meetings</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexctoc401831_6">Inspectors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexctoc401831_7">Quorum</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexctoc401831_8">Voting; Proxies</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexctoc401831_9">Order of Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexctoc401831_10">Notice of Stockholder Proposals</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexctoc401831_11">Notice of Director Nominations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexctoc401831_12">Additional Provisions Relating to the Notice of Stockholder Business
 and Director Nominations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexctoc401831_13">Record Dates</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexctoc401831_14">Adjournments</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexctoc401831_15">Voting List</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexctoc401831_16">DIRECTORS </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexctoc401831_17">Function</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexctoc401831_18">Number, Election and Terms</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">17.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexctoc401831_19">Vacancies and Newly Created Directorships</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexctoc401831_20">Removal</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">19.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexctoc401831_21">Resignation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">20.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexctoc401831_22">Regular Meetings</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">21.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexctoc401831_23">Special Meetings</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">22.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexctoc401831_24">Quorum</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">23.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexctoc401831_25">Participation in Meetings by Remote
Communications</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">24.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexctoc401831_26">Committees</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">25.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexctoc401831_27">Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">26.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexctoc401831_28">Rules</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">27.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexctoc401831_29">Chairman of the Board</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexctoc401831_30">NOTICES </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">28.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexctoc401831_31">Generally</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">29.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexctoc401831_32">Waivers</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(i) </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(continued) </B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Page</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexctoc401831_33">OFFICERS </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">30.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexctoc401831_34">Generally</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">31.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexctoc401831_35">Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">32.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexctoc401831_36">Succession</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">33.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexctoc401831_37">Authority and Duties</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexctoc401831_38">STOCK </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">34.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexctoc401831_39">Certificates</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">35.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexctoc401831_40">Transfer</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">36.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexctoc401831_41">Lost, Stolen or Destroyed Certificates</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexctoc401831_42">GENERAL </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">37.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexctoc401831_43">Fiscal Year</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">38.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexctoc401831_44">Reliance Upon Books, Reports and Records</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">39.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexctoc401831_45">Amendments</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">40.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexctoc401831_46">Electronic Signatures</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(ii) </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><A NAME="annexctoc401831_1"></A><U>STOCKHOLDERS MEETINGS</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexctoc401831_2"></A>1.&nbsp;&nbsp;&nbsp;&nbsp;<U>Time and Place of Meetings</U>. All meetings of stockholders will be held at such
time and place, within or without the State of Delaware, as may be designated by the Board of Directors (the &#147;<B><I>Board</I></B>&#148;) of Cibus, Inc., a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), from time to time or, in
the absence of a designation by the Board, by the Chairman, the Chief Executive Officer or the Secretary, and stated in the notice of the meeting. Notwithstanding the foregoing, the Board may, in its sole discretion, determine that a meeting of
stockholders will not be held at any place, but may instead be held by means of remote communications, subject to such guidelines and procedures as the Board may adopt from time to time in accordance with the General Corporation Law of the State of
Delaware, as amended (the &#147;<B><I>DGCL</I></B>&#148;).<B> </B>The Board may cancel or reschedule to an earlier or later date any previously scheduled annual or special meeting of stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexctoc401831_3"></A>2.&nbsp;&nbsp;&nbsp;&nbsp;<U>Annual Meetings</U>. At each annual meeting of stockholders, the stockholders
will elect the directors from the nominees for director, to succeed those directors whose terms expire at such meeting and will transact such other business, in such case as may properly be brought before the meeting in accordance with
<U>Bylaws</U><U></U><U>&nbsp;8</U>, <U>9</U>, <U>10</U> and <U>11</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexctoc401831_4"></A>3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Special Meetings</U>. Subject to the rights, if any, of any series of Preferred
Stock to call a special meeting of stockholders under circumstances specified in a Preferred Stock Designation, a special meeting of stockholders may be called only (i)&nbsp;by the Chairman, (ii)&nbsp;by the Chief Executive Officer, or (iii)&nbsp;by
the Board pursuant to a written resolution adopted by a majority of the total number of directors that the Company would have if there were no vacancies on the Board (the&nbsp;&#147;<B><I>Whole Board</I></B>&#148;), in each case to transact only
such business as is specified in the notice of the meeting or authorized by a majority of the Whole Board to be brought before the meeting. For the avoidance of doubt, stockholders shall not be permitted to propose business to be brought before a
special meeting of stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexctoc401831_5"></A>4.&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice of Meetings</U>. Written notice of
every meeting of stockholders, stating the place, if any, date and time thereof, the means of remote communications, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such meeting, and, in the case of
a special meeting, the purpose or purposes for which the meeting is called, will be given, in a form permitted by <U>Bylaw 28</U> or by the DGCL, not less than ten nor more than 60 calendar days before the date of the meeting to each stockholder of
record entitled to vote at such meeting, except as otherwise provided by law. When a meeting is adjourned to another place, date, or time, notice need not be given of the adjourned meeting if the place, if any, date and time thereof, and the means
of remote communications, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such adjourned meeting, are provided in a manner permitted by Section&nbsp;222 of the DGCL (or any successor provision);
<I><U>provided</U></I><I>, </I><I><U>however</U></I>, that if the adjournment is for more than 30 calendar days, or if after the adjournment a new record date is fixed for the adjourned meeting, written notice of the place, if any, date and time
thereof, and the means of remote communications, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such adjourned meeting, must be given in conformity herewith or as otherwise provided or permitted by
the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexctoc401831_6"></A>5.&nbsp;&nbsp;&nbsp;&nbsp;<U>Inspectors</U>. The Board will, in advance of any meeting of
stockholders, appoint one or more inspectors to act at the meeting and make a written report thereof. The Board may designate one or more persons as alternate inspectors to replace any inspector who fails to act. If no inspector or alternate is able
to act at a meeting of stockholders, the presiding officer of the meeting will appoint one or more inspectors to act at the meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexctoc401831_7">
</A>6.&nbsp;&nbsp;&nbsp;&nbsp;<U>Quorum</U>. Except as otherwise provided by law or in a Preferred Stock Designation, the holders of a majority in voting power of the shares of stock issued and outstanding and entitled to vote at the meeting,
present in person or represented by proxy, will constitute a quorum at a meeting of stockholders for the transaction of business thereat. A quorum, once established, will not be broken by the subsequent withdrawal of enough votes to leave less than
a quorum. If, however, such a quorum shall not be present or represented at any meeting of the stockholders, the presiding officer of the meeting shall have the power to adjourn the meeting from time to time, in the manner provided in <U>Bylaw
13</U>, until a quorum is present or represented. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexctoc401831_8"></A>7.&nbsp;&nbsp;&nbsp;&nbsp;<U>Voting; Proxies</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>General</U>. Except as otherwise provided by law, by the Company&#146;s Second Amended and Restated Certificate
of Incorporation (the &#147;<B><I>Certificate of Incorporation</I></B>&#148;), or in a Preferred Stock Designation, each stockholder will be entitled at every meeting of the stockholders to one vote for each share of stock having voting power
standing in the name of such stockholder on the books of the Company on the record date for the meeting and such votes may be cast either in person or by proxy. Every proxy must be authorized in a manner permitted by Section&nbsp;212 of the DGCL (or
any successor provision). Any stockholder directly or indirectly soliciting proxies from other stockholders must use a proxy card color other than white, which shall be reserved for exclusive use by the Board. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Vote Required for Stockholder Action</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;When a quorum is present at any meeting of stockholders and except as otherwise provided by law, the Certificate of
Incorporation, these Bylaws or in a Preferred Stock Designation, the affirmative vote of a majority of the shares present in person or represented by proxy at the meeting and entitled to vote on the matter will be the act of the stockholders with
respect to all matters other than the election of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;Each director to be elected by stockholders
shall be elected as such by the majority of the votes cast by stockholders upon his or her election at a meeting for the election of directors at which a quorum is present, except that, if the number of nominees for election at any such meeting is
determined by the Secretary as of the date that is ten days prior to the scheduled mailing date of the proxy statement for such meeting to exceed the number of directors to be elected at such meeting, each director to be so elected shall be elected
as such by a plurality of the votes cast by stockholders at such meeting. For purposes of this <U>Bylaw 7(b)(ii)</U>, a majority of votes cast shall mean that the number of shares voted &#147;for&#148; a director&#146;s election exceeds 50% of the
number of votes cast on the issue of that director&#146;s election (including votes &#147;for,&#148; votes &#147;against&#148; and votes to withhold authority with respect to that director&#146;s election, but excluding any abstentions or broker <FONT
STYLE="white-space:nowrap">non-votes).</FONT> If directors are to be elected by a plurality of the votes cast, stockholders shall not be permitted to vote against a nominee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;A director who stands for <FONT STYLE="white-space:nowrap">re-election</FONT> is expected to tender his or her
resignation if he or she fails to receive the required number of votes for <FONT STYLE="white-space:nowrap">re-election.</FONT> The Board shall nominate for election or <FONT STYLE="white-space:nowrap">re-election</FONT> as director only candidates
who agree to tender, promptly following the annual meeting at which they are elected or <FONT STYLE="white-space:nowrap">re-elected</FONT> as director, irrevocable resignations that will be effective upon (A)&nbsp;the failure to receive the required
vote at the next annual meeting at which they stand for <FONT STYLE="white-space:nowrap">re-election</FONT> and (B)&nbsp;the Board&#146;s acceptance of such resignation in the Board&#146;s exclusive discretion. In addition, the Board shall fill
director vacancies and new directorships only with persons who agree to tender, promptly following their appointment to the Board, irrevocable resignations that will be effective upon (X)&nbsp;the failure to receive the required vote at the next
annual meeting at which they stand for <FONT STYLE="white-space:nowrap">re-election</FONT> and (Y)&nbsp;the Board&#146;s acceptance of such resignation in the Board&#146;s exclusive discretion. If an incumbent director fails to receive the required
vote for <FONT STYLE="white-space:nowrap">re-election,</FONT> the Nominating and Corporate Governance Committee will act on an expedited basis to determine whether to recommend that the Board accept the director&#146;s resignation and will submit
such recommendation for prompt consideration by the Board. A director whose resignation is under consideration is expected to abstain from participating in any decision regarding that resignation. The Nominating and Corporate Governance Committee
and the Board may consider any factors they deem relevant in deciding whether to accept or reject a director&#146;s resignation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexctoc401831_9">
</A>8.&nbsp;&nbsp;&nbsp;&nbsp;<U>Order of Business</U>. The<B> </B>Chairman, or an officer of the Company designated from time to time by a majority of the Whole Board, will call meetings of stockholders to order and will act as presiding officer
thereof. The presiding officer of any meeting may adjourn, recess and convene any meeting of stockholders. Unless otherwise determined by the Board prior to the meeting, the presiding officer of any meeting of stockholders will also determine the
order of business and have the authority in his or her sole discretion to determine the rules of procedure and regulate the conduct of the meeting, including without limitation by: (a)&nbsp;imposing restrictions on the persons (other than
stockholders of the Company or their duly appointed proxy holders) that may attend the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
meeting; (b)&nbsp;ascertaining whether any stockholder or his or her proxy holder may be excluded from the meeting based upon any determination by the presiding officer, in his or her sole
discretion, that any such person has disrupted or is likely to disrupt the proceedings thereat; (c)&nbsp;determining the circumstances in which any person may make a statement or ask questions at the meeting; (d)&nbsp;ruling on all procedural
questions that may arise during or in connection with the meeting; (e)&nbsp;determining whether any nomination or business proposed to be brought before the meeting has been properly brought before the meeting; and (f)&nbsp;determining the time or
times at which the polls for voting at the meeting will be opened and closed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexctoc401831_10"></A>9.&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice of Stockholder Proposals</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Business to Be Conducted at Annual Meeting</U>. At an annual meeting of stockholders, only such business may be
conducted as has been properly brought before the meeting. To be properly brought before an annual meeting, business (other than the nomination of a person for election as a director, which is governed by <U>Bylaw</U><U></U><U>&nbsp;10</U>, and, to
the extent applicable, <U>Bylaw 11</U>), must (i)&nbsp;be brought before the meeting by or at the direction of the Board, (ii)&nbsp;otherwise be properly brought before the meeting by a stockholder who (A)&nbsp;has complied with all applicable
requirements of this <U>Bylaw</U><U></U><U>&nbsp;9</U> and <U>Bylaw</U><U></U><U>&nbsp;11</U> in relation to such business, (B)&nbsp;was a stockholder of record of the Company at the time of giving the notice required by
<U>Bylaw</U><U></U><U>&nbsp;11(a)</U> and is a stockholder of record of the Company at the time of the annual meeting, and (C)&nbsp;is entitled to vote at the annual meeting, and (iii)&nbsp;relate to an item of business that is a proper subject to
stockholder action under applicable law. For the avoidance of doubt, the foregoing clause (ii)&nbsp;will be the exclusive means for a stockholder to submit business before an annual meeting of stockholders (other than proposals properly made in
accordance with Rule <FONT STYLE="white-space:nowrap">14a-8</FONT> under the Securities Exchange Act of 1934, as amended (such act, and the rules and regulations promulgated thereunder, the &#147;<B><I>Exchange Act</I></B>&#148;) and included in the
notice of meeting given by or at the direction of the Board). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Required Form for Stockholder Proposals</U>.
To be in proper form, a stockholder&#146;s notice to the Secretary must set forth in writing the following information, which must be updated and supplemented, if necessary, so that the information provided or required to be provided will be true
and correct on the record date of the annual meeting and as of such date that is ten business days prior to the annual meeting or any adjournment or postponement thereof; which update shall be delivered to the Secretary no later than five business
days after the record date for the annual meeting and not later than eight business days prior to the date of the annual meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;<U>Information Regarding the Proposing Person</U>. As to each Proposing Person (as such term is defined in
<U>Bylaw</U><U></U><U>&nbsp;11(d)(ii))</U>: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(A)&nbsp;&nbsp;&nbsp;&nbsp;the name and address of such Proposing Person, as they appear on
the Company&#146;s stock transfer book; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(B)&nbsp;&nbsp;&nbsp;&nbsp;the class, series and number of shares of the Company directly or
indirectly beneficially owned or held of record by such Proposing Person (including any shares of any class or series of the Company as to which such Proposing Person has a right to acquire beneficial ownership, whether such right is exercisable
immediately or only after the passage of time); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(C)&nbsp;&nbsp;&nbsp;&nbsp;a representation (1)&nbsp;that the stockholder giving the
notice is a holder of record of stock of the Company entitled to vote at the annual meeting and intends to appear at the annual meeting to bring such business before the annual meeting, (2)&nbsp;as to whether any Proposing Person intends, or is part
of a group that intends, to deliver a proxy statement and form of proxy to holders of at least the percentage of shares of the Company entitled to vote and required to approve the proposal and, if so, identifying such Proposing Person and
(3)&nbsp;as to whether any Proposing Person intends to engage in or be a participant in a solicitation (within the meaning of Rule <FONT STYLE="white-space:nowrap">14a-1(l)</FONT> under the Exchange Act) with respect to the proposal and, if so, the
name of each participant (as defined in Item 4 of Schedule 14A under the Exchange Act) in such solicitation; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(D)&nbsp;&nbsp;&nbsp;&nbsp;a description of any (1)&nbsp;option, warrant, convertible
security, stock appreciation right or similar right or interest (including any derivative securities, as defined under Rule <FONT STYLE="white-space:nowrap">16a-1</FONT> under the Exchange Act or other synthetic arrangement having characteristics of
a long position), assuming for purposes of these Bylaws presently exercisable, with an exercise or conversion privilege or a settlement or payment mechanism at a price related to any class or series of securities of the Company or with a value
derived in whole or in part from the value of any class or series of securities of the Company, whether or not such instrument or right is subject to settlement in whole or in part in the underlying class or series of securities of the Company or
otherwise, directly or indirectly held of record or owned beneficially by such Proposing Person and whether or not such Proposing Person may have entered into transactions that hedge or mitigate the economic effects of such security or instrument
and (2)&nbsp;each other direct or indirect right or interest that may enable such Proposing Person to profit or share in any profit derived from, or to manage the risk or benefit from, any increase or decrease in the value of the Company&#146;s
securities, in each case regardless of whether (x)&nbsp;such right or interest conveys any voting rights in such security to such Proposing Person, (y)&nbsp;such right or interest is required to be, or is capable of being, settled through delivery
of such security, or (z)&nbsp;such Proposing Person may have entered into other transactions that hedge the economic effect of any such right or interest (any such right or interest referred to in this clause (D)&nbsp;being
a&nbsp;&#147;<B><I>Derivative Interest</I></B>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(E)&nbsp;&nbsp;&nbsp;&nbsp;any proxy, contract, agreement, arrangement,
understanding or relationship pursuant to which the Proposing Person has a right to vote any shares of the Company or which has the effect of increasing or decreasing the voting power of such Proposing Person; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(F)&nbsp;&nbsp;&nbsp;&nbsp;any contract, agreement, arrangement, understanding or relationship including any repurchase or similar so called
&#147;stock borrowing&#148; agreement or arrangement, the purpose or effect of which is to mitigate loss, reduce economic risk or increase or decrease voting power with respect to any capital stock of the Company or which provides any party,
directly or indirectly, the opportunity to profit from any decrease in the price or value of the capital stock of the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(G)&nbsp;&nbsp;&nbsp;&nbsp;any material pending or threatened legal proceeding involving the Company, any affiliate of the Company or any of
their respective directors or officers, to which such Proposing Person or its affiliates is a party or has a material interest (excluding an interest that is substantially the same as all stockholders); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(H)&nbsp;&nbsp;&nbsp;&nbsp;any rights directly or indirectly held of record or beneficially by the Proposing Person to dividends on the
shares of the Company that are separated or separable from the underlying shares of the Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(I)&nbsp;&nbsp;&nbsp;&nbsp;any equity
interests, including any convertible, derivative or short interests, in any principal competitor of the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(J)&nbsp;&nbsp;&nbsp;&nbsp;any performance-related fees (other than an asset-based fee) to which the Proposing Person or any affiliate or
immediate family member of the Proposing Person may be entitled as a result of any increase or decrease in the value of shares of the Company or Derivative Interests; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(K)&nbsp;&nbsp;&nbsp;&nbsp;an accounting of any equity interests, including any convertible, derivative or short interests, in any
competitor, as defined for purposes of Section&nbsp;8 of the Clayton Antitrust Act of 1914, as amended, of the Company; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(L)&nbsp;&nbsp;&nbsp;&nbsp;any other information relating to such Proposing Person that would be required to be disclosed in a proxy
statement or other filing required pursuant to Section&nbsp;14(a) of the Exchange Act to be made in connection with a general solicitation of proxies or consents by such Proposing Person in support of the business proposed to be brought before the
meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;<U>Information Regarding the Proposal</U>: As to each item of
business that the stockholder giving the notice proposes to bring before the annual meeting: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(A)&nbsp;&nbsp;&nbsp;&nbsp;a description in
reasonable detail of the business desired to be brought before the annual meeting and the reasons why such stockholder or any other Proposing Person believes that the taking of the action or actions proposed to be taken would be in the best
interests of the Company and its stockholders; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(B)&nbsp;&nbsp;&nbsp;&nbsp;a description in reasonable detail of any material interest of
any Proposing Person in such business and a description in reasonable detail of all agreements, arrangements and understandings among the Proposing Persons or between any Proposing Person and any other person or entity (including their names) in
connection with the proposal; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(C)&nbsp;&nbsp;&nbsp;&nbsp;the text of the proposal or business (including the text of any resolutions
proposed for consideration and, in the event that such business includes a proposal to amend these Bylaw, the language of the proposed amendment). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company may require any Proposing Person to furnish such other information as may be reasonably required by the Company or one of its representatives in good faith to determine such Proposing Person&#146;s compliance with these Bylaws or the
accuracy and completeness of any notice or solicitation given or made on behalf of such Proposing Person. Such Proposing Person shall provide such other information within ten calendar days after the Company has requested such other information.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>No Right to Have Proposal Included</U>. A stockholder is not entitled to have its proposal included in the
Company&#146;s proxy materials solely as a result of such stockholder&#146;s compliance with the foregoing provisions of this <U>Bylaw</U><U></U><U>&nbsp;9</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Requirement to Attend Annual Meeting</U>. If a stockholder does not appear at the annual meeting to present its
proposal, such proposal will be disregarded (notwithstanding that proxies in respect of such proposal may have been solicited, obtained or delivered). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexctoc401831_11"></A>10.&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice of Director Nominations</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Nomination of Directors</U>. Subject to the rights, if any, of any series of Preferred Stock to nominate or elect
directors under circumstances specified in a Preferred Stock Designation, only persons who are nominated in accordance with the procedures set forth in this <U>Bylaw</U><U></U><U>&nbsp;10</U> will be eligible to serve as directors. Nominations of
persons for election as directors of the Company may be made only at an annual meeting of stockholders and only (i)&nbsp;by or at the direction of the Board or (ii)&nbsp;by a stockholder who (A)&nbsp;has complied with all applicable requirements of
this <U>Bylaw</U><U></U><U>&nbsp;10</U> and <U>Bylaw</U><U></U><U>&nbsp;11</U> in relation to such nomination, (B)&nbsp;was a stockholder of record of the Company at the time of giving the notice required by <U>Bylaw</U><U></U><U>&nbsp;11(a)</U> and
is a stockholder of record of the Company at the time of the annual meeting, (C)&nbsp;is entitled to vote in the election of directors at the annual meeting and (D)&nbsp;subject to <U>Bylaw 11</U>, has nominated a number of nominees that does not
exceed the number of directors that will be elected at such meeting. In addition to the requirements of this <U>Bylaw 10</U> with respect to any nomination proposed to be made at an annual meeting, each Nominating Person shall comply with all
applicable requirements of the Exchange Act (including Rule <FONT STYLE="white-space:nowrap">14a-19</FONT> promulgated thereunder) and DGCL with respect to any such nominations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Required Form for Director Nominations</U>. To be in proper form, a stockholder&#146;s notice to the Secretary
must set forth in writing: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;<U>Information Regarding the Nominating Person</U>. As to each Nominating Person (as
such term is defined in <U>Bylaw</U><U></U><U>&nbsp;11(d)(iii))</U>: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(A)&nbsp;&nbsp;&nbsp;&nbsp;the information set forth in
<U>Bylaw</U><U></U><U>&nbsp;9(b)(i)</U> (except that for purposes of this <U>Bylaw</U><U></U><U>&nbsp;10</U>, the term &#147;<B><I>Nominating Person</I></B>&#148; will be substituted for the term &#147;<B><I>Proposing Person</I></B>&#148; in all
places where it appears in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<U>Bylaw</U><U></U><U>&nbsp;9(b)(i)</U>, the term &#147;<B><I>elect</I></B>&#148; will be substituted for the term &#147;<B><I>approve</I></B>&#148; and any reference to
&#147;<B><I>business</I></B>&#148; or &#147;<B><I>proposal</I></B>&#148; therein will be deemed to be a reference to the &#147;<B><I>nomination</I></B>&#148; or &#147;<B><I>nominee</I></B>&#148; contemplated by this <U>Bylaw 10(b)</U>, as the
context requires). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(B)&nbsp;&nbsp;&nbsp;&nbsp;a written representation as to whether such Nominating Person intends, or is part of a
group that intends, to solicit proxies in support of director nominees other than the nominees of the Board or a duly authorized committee thereof in accordance with Rule <FONT STYLE="white-space:nowrap">14a-19</FONT> under the Exchange Act; and
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(C)&nbsp;&nbsp;&nbsp;&nbsp;for any Nominating Person that the stockholder&#146;s notice indicates intends, or is part of a group that
intends, to solicit proxies in support of director nominees other than the nominees of the Board or a duly authorized committee thereof in accordance with Rule <FONT STYLE="white-space:nowrap">14a-19</FONT> under the Exchange Act, a written
agreement (in substantially the form provided by the Secretary upon written request), on behalf of such Nominating Person and any group of which it is a member, pursuant to which such Nominating Person acknowledges and agrees that (1)&nbsp;the
Company shall disregard any proxies or votes solicited for the Nominating Person&#146;s nominees if such Nominating Person (i)&nbsp;notifies the Company that such Nominating Person no longer intends, or is part of a group that no longer intends, to
solicit proxies in support of director nominees other than the nominees of the Board or a duly authorized committee thereof in accordance with Rule <FONT STYLE="white-space:nowrap">14a-19</FONT> under the Exchange Act or (ii)&nbsp;fails to comply
with Rules <FONT STYLE="white-space:nowrap">14a-19(a)(2)</FONT> and (3)&nbsp;under the Exchange Act, and (2)&nbsp;if any Nominating Person provides notice pursuant to Rule <FONT STYLE="white-space:nowrap">14a-19(a)(1)</FONT> under the Exchange Act,
such Nominating Person shall deliver to the Secretary, no later than five business days prior to the applicable meeting, reasonable documentary evidence (as determined by the Company or one of its representatives in good faith) that the requirements
of Rule <FONT STYLE="white-space:nowrap">14a-19(a)(3)</FONT> under the Exchange Act have been satisfied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company may require any Nominating Person to
furnish such other information as may be reasonably required by the Company or one of its representatives in good faith to determine such Nominating Person&#146;s compliance with these Bylaws or the accuracy and completeness of any notice or
solicitation given or made on behalf of such Nominating Person. Such Nominating Person shall provide such other information within ten calendar days after the Company has requested such other information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;<U>Information Regarding the Nominee</U>: As to each person whom the stockholder giving notice proposes to
nominate for election as a director: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(A)&nbsp;&nbsp;&nbsp;&nbsp;all information with respect to such proposed nominee that would be
required to be set forth in a stockholder&#146;s notice pursuant to <U>Bylaw</U><U></U><U>&nbsp;9(b)(i)</U> if such proposed nominee were a Nominating Person; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(B)&nbsp;&nbsp;&nbsp;&nbsp;all information relating to such proposed nominee that would be required to be disclosed in a proxy statement or
other filing required pursuant to Section&nbsp;14(a) under the Exchange Act to be made in connection with a general solicitation of proxies for an election of directors in a contested election (including such proposed nominee&#146;s written consent
to be named in the proxy materials as a nominee and to serve as a director if elected); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(C)&nbsp;&nbsp;&nbsp;&nbsp;a reasonably detailed
description of all direct and indirect compensation and other material monetary agreements, arrangements or understandings during the past three years, any other material relationships, between or among such Nominating Person and its affiliates and
associates, or others acting in concert therewith, on the one hand, and each proposed nominee and his or her affiliates, associates or others acting in concert therewith, on the other hand, including all information that would be required to be
disclosed pursuant to Items 403 and 404 under Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> if the stockholder giving the notice or any other Nominating Person were the &#147;registrant&#148; for purposes of such rule and the proposed
nominee were a director or executive officer of such registrant; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(D)&nbsp;&nbsp;&nbsp;&nbsp;a completed questionnaire (in the form provided by the Secretary
upon written request) with respect to the identity, background and qualification of the proposed nominee and the background of any other person or entity on whose behalf the nomination is being made; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(A)&nbsp;&nbsp;&nbsp;&nbsp;a written representation and agreement (in the form provided by the Secretary upon written request) that the
proposed nominee (1)&nbsp;is qualified and if elected intends to serve as a director of the Company for the entire term for which such proposed nominee is standing for election, (2)&nbsp;is not and will not become a party to (x)&nbsp;any agreement,
arrangement or understanding with, and has not given any commitment or assurance to, any person or entity as to how the proposed nominee, if elected as a director of the Company, will act or vote on any issue or question (a &#147;<B><I>Voting
Commitment</I></B>&#148;) that has not been disclosed to the Company or (y)&nbsp;any Voting Commitment that could limit or interfere with the proposed nominee&#146;s ability to comply, if elected as a director of the Company, with the proposed
nominee&#146;s fiduciary duties under applicable law, (3)&nbsp;is not and will not become a party to any agreement, arrangement or understanding with any person or entity other than the Company with respect to any direct or indirect compensation,
reimbursement or indemnification in connection with service or action as a director that has not been disclosed therein, and (4)&nbsp;if elected as a director of the Company, the proposed nominee would be in compliance and will comply, with all
applicable publicly disclosed corporate governance, ethics, conflict of interest, confidentiality and stock ownership and trading policies and guidelines of the Company (including, without limitation, the policy set forth in <U>Bylaw 7(c)</U> and
the related agreement of the proposed nominee to tender, promptly following the meeting at which he or she is elected as director, an irrevocable resignation that will be effective as provided in such <U>Bylaw 7(c)</U>). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company may require any Nominating Person or proposed nominee to furnish such other information as may be reasonably required by the Company or one of its
representatives in good faith to determine the qualifications and eligibility of such proposed nominee to serve as a director. Such nominee, or such Nominating Person on behalf of the nominee, shall provide such other information within ten calendar
days after the Company has requested such other information. The Company may request that any nominee submit to interviews (which may be conducted via virtual meeting) with the Board or any committee thereof, and such nominee shall, and the
Nominating Person shall cause the nominee to, make himself or herself available for any such interviews within ten business days following the Company&#146;s request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>No Right to Have Nominees Included</U>. A stockholder is not entitled to have its nominees included in the
Company&#146;s proxy materials solely as a result of such stockholder&#146;s compliance with the foregoing provisions of this <U>Bylaw 10</U>, except to the extent required by Rule 14a-19 under the Exchange Act and other applicable requirements of
state and federal law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Requirement to Attend Annual Meeting</U>. If a stockholder does not appear at the
annual meeting to present its nomination, such nomination will be disregarded (notwithstanding that proxies in respect of such nomination may have been solicited, obtained or delivered). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Rule <FONT STYLE="white-space:nowrap">14a-19</FONT> Compliance</U>. If (i)&nbsp;any Nominating Person provides
notice pursuant to Rule <FONT STYLE="white-space:nowrap">14a-19(a)(1)</FONT> under the Exchange Act and (ii)&nbsp;such Nominating Person subsequently either (A)&nbsp;notifies the Company that such Nominating Person no longer intends to, or is part
of a group that no longer intends to, solicit proxies in support of director nominees other than the nominees of the Board or a duly authorized committee thereof in accordance with Rule <FONT STYLE="white-space:nowrap">14a-19</FONT> under the
Exchange Act or (B)&nbsp;fails to comply with the requirements of Rules <FONT STYLE="white-space:nowrap">14a-19(a)(2)</FONT> and (3)&nbsp;under the Exchange Act, then the Company shall disregard any proxies or votes solicited for the Nominating
Person&#146;s nominees, notwithstanding that proxies or votes in favor thereof may have been received by the Company. If any Nominating Person provides notice pursuant to Rule <FONT STYLE="white-space:nowrap">14a-19(a)(1)</FONT> under the Exchange
Act, such Nominating Person shall deliver to the Secretary, no later than five business days prior to the applicable meeting, reasonable documentary evidence (as determined by the Company or one of its representatives in good faith) that the
requirements of Rule <FONT STYLE="white-space:nowrap">14a-19(a)(3)</FONT> under the Exchange Act have been satisfied. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexctoc401831_12"></A>11.&nbsp;&nbsp;&nbsp;&nbsp;<U>Additional Provisions
Relating to the Notice of Stockholder Business and Director Nominations</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Timely Notice</U>. To be
timely, a stockholder&#146;s notice required by <U>Bylaw</U><U></U><U>&nbsp;9(a)</U> or <U>Bylaw</U><U></U><U>&nbsp;10(a)</U> must be delivered to or mailed and received by the Secretary at the principal executive offices of the Company not less
than 90 nor more than 120 calendar days prior to the first anniversary of the date on which the Company held the preceding year&#146;s annual meeting of stockholders; <I><U>provided</U></I><I>, </I><I><U>however</U></I>, that if the date of the
annual meeting is scheduled for a date more than 30 calendar days prior to or more than 30 calendar days after the anniversary of the preceding year&#146;s annual meeting, notice by the stockholder to be timely must be so delivered not later than
the close of business on the later of the 90th calendar day prior to such annual meeting and the 10th calendar day following the day on which public disclosure of the date of such meeting is first made. In no event will a recess or adjournment of an
annual meeting (or any announcement of any such recess or adjournment) commence a new time period (or extend any time period) for the giving of a stockholder&#146;s notice as described above. Notwithstanding the foregoing, in the event the number of
directors to be elected to the Board at the annual meeting is increased by the Board, and there is no public announcement by the Company naming the nominees for the additional directors at least 100 calendar days prior to the first anniversary of
the date on which the Company held the preceding year&#146;s annual meeting of stockholders, a stockholder&#146;s notice pursuant to <U>Bylaw 10(a)</U> will be considered timely, but only with respect to nominees for the additional directorships, if
it is delivered to or mailed and received by the Secretary at the principal executive offices of the Company not later than the close of business on the tenth calendar day following the day on which such public announcement is first made by the
Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Updating Information in Notice</U>. A stockholder providing notice of business proposed to be
brought before an annual meeting pursuant to <U>Bylaw</U><U></U><U>&nbsp;9</U> or notice of any nomination to be made at an annual meeting pursuant to <U>Bylaw</U><U></U><U>&nbsp;10</U> must further update and supplement such notice, from time to
time, if necessary, so that the information provided or required to be provided in such notice pursuant to <U>Bylaw</U><U></U><U>&nbsp;9</U> or <U>Bylaw</U><U></U><U>&nbsp;10</U>, as applicable, is true and correct as of the record date for notice
of the meeting and as of the date that is ten days prior to the meeting or any recess, adjournment or postponement thereof. Any such update and supplement must be delivered to, or mailed and received by, the Secretary at the principal executive
offices of the Company, as promptly as practicable. Notwithstanding the foregoing, following the conclusion of the relevant time period to provide timely notice to the Company pursuant to <U>Bylaw 11(a)</U>, a stockholder will not be permitted to
update the information provided or required to be provided in such notice to substitute or replace a nominee. For the avoidance of doubt, any information provided pursuant to this <U>Bylaw 11(b)</U> shall not, and shall not be deemed to, cure any
deficiencies in any Proposing Person or Nominating Person&#146;s notice, extend any applicable deadlines under these Bylaws or enable or be deemed to permit such Proposing Person or Nominating Person to amend any proposal or nomination or to submit
any new or amended proposal, including by changing or adding nominees, matters, business or resolutions proposed to be brought before a meeting, except as otherwise set forth in these Bylaws. Business or a nomination proposed to be brought by a
stockholder may not be brought before a meeting if such stockholder or any Proposing Person or Nominating Person, as applicable, takes action contrary to the representations made in the stockholder notice applicable to such business or nomination or
if the stockholder notice applicable to such business or nomination contains an untrue statement of a material fact or omits to state a material fact necessary to make the statements therein not misleading, or if after being submitted to the
Company, the stockholder notice applicable to such business or nomination was not updated in accordance with these Bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Determinations of Form, Effect of Noncompliance, Etc.</U> The presiding officer of any annual meeting will, if
the facts warrant, determine that a proposal was not made in accordance with the procedures prescribed by <U>Bylaw</U><U></U><U>&nbsp;9</U> and this <U>Bylaw</U><U></U><U>&nbsp;11</U> or that a nomination was not made in accordance with the
procedures prescribed by <U>Bylaw</U><U></U><U>&nbsp;10</U> and this <U>Bylaw</U><U></U><U>&nbsp;11</U>, and if he or she should so determine, he or she will so declare to the meeting and the defective proposal or nomination, as applicable, will be
disregarded. Notwithstanding anything in these Bylaws to the contrary, unless otherwise required by applicable law: (i)&nbsp;no nominations shall be made or business shall be conducted at any annual meeting or special meeting except in accordance
with the procedures set forth in <U>Bylaws 9</U>, <U>10</U> and <U>11</U>, and (ii)&nbsp;if a Proposing Person intending to propose business or a Nominating Person </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
intending to make nominations at an annual meeting or special meeting pursuant to <U>Bylaws 9</U>, <U>10</U> and <U>11</U>, as applicable, does not provide the information required under
<U>Bylaws 9</U>, <U>10</U> and <U>11</U> to the Company in accordance with the applicable timing requirements set forth in these Bylaws, or the Proposing Person or Nominating Person (or a qualified representative thereof) does not appear at the
meeting to present the proposed business or nominations, such business or nominations shall not be considered, notwithstanding that proxies in respect of such business or nominations may have been received by the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain Definitions</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;For purposes of <U>Bylaw</U><U></U><U>&nbsp;9</U> and <U>Bylaw</U><U></U><U>&nbsp;10</U> and this
<U>Bylaw</U><U></U><U>&nbsp;11</U>, &#147;<B><I>public disclosure</I></B>&#148; means disclosure in a press release reported by the Dow Jones News Service, Bloomberg, Associated Press or comparable national news service or in a document filed by the
Company with the Securities and Exchange Commission pursuant to Exchange Act or furnished by the Company to stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;For purposes of <U>Bylaw</U><U></U><U>&nbsp;9</U> and this <U>Bylaw</U><U></U><U>&nbsp;11</U>,
&#147;<B><I>Proposing Person</I></B>&#148; means (A)&nbsp;the stockholder providing the notice of business proposed to be brought before an annual meeting, (B)&nbsp;the beneficial owner or beneficial owners, if different, on whose behalf the notice
of the business proposed to be brought before the annual meeting is given, and (C)&nbsp;any Affiliate or Associate (each within the meaning of Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> under the Exchange Act) of such stockholder or
beneficial owner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;For purposes of <U>Bylaw</U><U></U><U>&nbsp;10</U> and this
<U>Bylaw</U><U></U><U>&nbsp;11</U>, &#147;<B><I>Nominating Person</I></B>&#148; means (A)&nbsp;the stockholder providing the notice of the nomination proposed to be made at an annual meeting, (B)&nbsp;the beneficial owner or beneficial owners, if
different, on whose behalf the notice of nomination proposed to be made at the annual meeting is given, and (C)&nbsp;any Affiliate or Associate (each within the meaning of Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> under the Exchange Act) of
such stockholder or beneficial owner. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexctoc401831_13"></A>12.&nbsp;&nbsp;&nbsp;&nbsp;<U>Record Dates</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Voting Record Dates</U>. In order that the Company may determine the stockholders entitled to notice of any
meeting of stockholders, the Board may fix a record date, which will not precede the date upon which the Board resolution fixing the same is adopted and will not be more than 60 nor less than 10 calendar days before the date of such meeting. If the
Board so fixes a date, such date shall also be the record date for determining the stockholders entitled to vote at such meeting unless the Board determines, at the time it fixes such record date, that a later date on or before the date of the
meeting shall be the date for making such determination. If no record date is fixed by the Board, the record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders will be at the close of business on the
calendar day next preceding the day on which notice is given, or, if notice is waived, at the close of business on the calendar day next preceding the day on which the meeting is held. A determination of stockholders of record entitled to notice of
or to vote at a meeting of the stockholders will apply to any recess or adjournment of the meeting; <I><U>provided</U></I><I>, </I><I><U>however</U></I>, that the Board may fix a new record date for the determination of stockholders entitled to vote
at the recessed or adjourned meeting, and in such case shall also fix as the record date for stockholders entitled to such notice of such recessed or adjourned meeting the same or an earlier date as that fixed for determination of stockholders
entitled to vote in accordance with the foregoing provisions of this <U>Bylaw 12(a)</U> at the recessed or adjourned meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Payment Record Dates</U>. In order that the Company may determine the stockholders entitled to receive payment
of any dividend or other distribution or allotment of any rights or the stockholders entitled to exercise any rights in respect of any change, conversion or exchange of stock, or for the purpose of any other lawful action, the Board may fix a record
date, which record date will not be more than 60 calendar days prior to such action. If no record date is fixed, the record date for determining stockholders for any such purpose will be at the close of business on the calendar day on which the
Board adopts the resolution relating thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Identity of Registered Holder</U>. The Company will be
entitled to treat the person in whose name any share of its stock is registered as the owner thereof for all purposes, and will not be bound to recognize any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
equitable or other claim to, or interest in, such share on the part of any other person, whether or not the Company has notice thereof, except as expressly provided by applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexctoc401831_14"></A>13.&nbsp;&nbsp;&nbsp;&nbsp;<U>Adjournments</U>. A meeting of stockholders may be adjourned from time to time
by the presiding officer of the meeting. Upon any adjourned meeting being reconvened, any business may be transacted which properly could have been transacted in the absence of such adjournment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexctoc401831_15"></A>14.&nbsp;&nbsp;&nbsp;&nbsp;<U>Voting List</U>. A complete list of stockholders entitled to vote at any
meeting of stockholders, arranged in alphabetical order and showing the address of each stockholder and the number of shares registered in the name of each stockholder, shall be open to the examination of any stockholder, for any purpose germane to
the meeting, for a period of ten days ending on the day before the meeting date, (i)&nbsp;on a reasonably accessible electronic network, provided that the information required to gain access to such list is provided with the notice of the meeting,
or (ii)&nbsp;during ordinary business hours, at the principal place of business of the Company. In the event that the Company determines to make the list available on an electronic network, the Company may take reasonable steps to ensure that such
information is available only to the stockholders of the Company. Except as otherwise provided by law, such list shall be the only evidence as to who are the stockholders entitled to examine the list of stockholders required by this <U>Bylaw 14</U>
or to vote in person or by proxy at any meeting of the stockholders. The Company shall not be required to include electronic mail addresses or other electronic contact information on such list. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><A NAME="annexctoc401831_16"></A>DIRECTORS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexctoc401831_17"></A>15.&nbsp;&nbsp;&nbsp;&nbsp;<U>Function</U>. The business and affairs of the Company will be managed under the
direction of the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexctoc401831_18"></A>16.&nbsp;&nbsp;&nbsp;&nbsp;<U>Number, Election and Terms</U>. Subject to the
rights, if any, of any series of Preferred Stock to elect additional directors under circumstances specified in a Preferred Stock Designation, and to the minimum and maximum number of authorized directors provided in the Certificate of
Incorporation, the authorized number of directors may be fixed from time to time only by a resolution adopted from time to time by the Board. Directors will be elected at each annual meeting of stockholders to serve as such until the next annual
meeting of stockholders and until their successors are elected and qualified; provided that any directors that are to be elected by the holders of any series of the Preferred Stock will be so elected in the manner provided in the applicable
Preferred Stock Designation and in accordance with the Certificate of Incorporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexctoc401831_19"></A>17.&nbsp;&nbsp;&nbsp;&nbsp;<U>Vacancies and Newly Created Directorships</U>. Subject to any limitations
imposed by applicable law and the rights, if any, of the holders of any one or more series of Preferred Stock to elect additional directors under circumstances specified in a Preferred Stock Designation, newly created directorships resulting from
any increase in the authorized number of directors and any vacancies on the Board resulting from death, resignation, retirement, disqualification, removal from office or other cause, shall, unless the Board determines by resolution that any such
vacancies or newly created directorships shall be filled by the stockholders, be filled only by the affirmative vote of a majority of the remaining directors then in office, even though less than a quorum of the Board, and not by the stockholders.
Any director so chosen will hold office for the remainder of the full term of the class of directors in which the new directorship was created or the vacancy occurred and until such director&#146;s successor is elected and qualified, or until such
director&#146;s earlier death, disqualification, resignation or removal. No decrease in the authorized number of directors will shorten the term of any incumbent director. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexctoc401831_20"></A>18.&nbsp;&nbsp;&nbsp;&nbsp;<U>Removal</U>. Unless otherwise restricted by statute or by the Certificate of
Incorporation, any director or the entire Board may be removed, with or without cause, by the holders of a majority of the shares then entitled to vote at an election of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexctoc401831_21"></A>19.&nbsp;&nbsp;&nbsp;&nbsp;<U>Resignation</U>. Any director may resign at any time upon notice given in
writing or by electronic transmission to the Chairman or the Secretary. Any resignation is effective when the resignation is delivered to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Company unless the resignation specifies a later effective date or an effective date that is contingent upon the occurrence or <FONT STYLE="white-space:nowrap">non-occurrence</FONT> of one or
more specified events. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexctoc401831_22"></A>20.&nbsp;&nbsp;&nbsp;&nbsp;<U>Regular Meetings</U>. Regular meetings of the Board
may be held immediately after the annual meeting of the stockholders and at such other time and place either within or without the State of Delaware as may from time to time be determined by the Board. Notice of regular meetings of the Board need
not be given. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexctoc401831_23"></A>21.&nbsp;&nbsp;&nbsp;&nbsp;<U>Special Meetings</U>. Special meetings of the Board may be
called by the Chairman on one day&#146;s notice to each director by whom such notice is not waived, given in a manner permitted by <U>Bylaw 28</U> or by the DGCL, and will be called by the Chairman, in like manner and on like notice, upon the
request of a majority of the Whole Board. The time and place of any such special meeting shall be as specified in the notice of such meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexctoc401831_24"></A>22.&nbsp;&nbsp;&nbsp;&nbsp;<U>Quorum</U>. At all meetings of the Board, a majority of the Whole Board will
constitute a quorum for the transaction of business. Except for action to be taken by committees of the Board as provided in <U>Bylaw 24</U>, and except for actions required by these Bylaws or the Certificate of Incorporation to be taken by a
majority of the Whole Board, the act of a majority of the directors present at any meeting at which there is a quorum will be the act of the Board. If a quorum is not present at any meeting of the Board, the directors present thereat may adjourn the
meeting from time to time to another place, time, or date, without notice other than announcement at the meeting, until a quorum is present. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexctoc401831_25"></A>23.&nbsp;&nbsp;&nbsp;&nbsp;<U>Participation in Meetings by Remote Communications</U>. Members of the Board or
any committee designated by the Board may participate in a meeting of the Board or any such committee, as the case may be, by means of conference telephone or other communications equipment by means of which all persons participating in the meeting
can hear each other, and such participation in a meeting will constitute presence in person at the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexctoc401831_26"></A>24.&nbsp;&nbsp;&nbsp;&nbsp;<U>Committees</U>. The Board may designate one or more committees, each committee
to consist of one or more of the directors. The Board may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee. In the absence or disqualification of
a member of a committee, the member or members present at any meeting and not disqualified from voting, whether or not such member or members constitute a quorum, may unanimously appoint another member of the Board to act at the meeting in the place
of any such absent or disqualified member. Any such committee, to the extent provided in the resolution of the Board, or in these Bylaws, will have and may exercise all the powers and authority of the Board in the management of the business and
affairs of the Company, and may authorize the seal of the Company to be affixed to all papers which may require it; but no such committee will have the power or authority in reference to the following matters: (a)&nbsp;approving or adopting, or
recommending to the stockholders, any action or matter (other than the election or removal of directors) expressly required by the DGCL to be submitted to stockholders for approval or (b)&nbsp;making, adopting, amending or repealing any provision of
these Bylaws. Unless the Board provides otherwise, each committee designated by the Board may make, alter and repeal rules and procedures for the conduct of its business. In the absence of such rules and procedures, each committee shall conduct its
business in the same manner as the Board conducts its business. Any resolution of the Board establishing or directing any committee of the Board or establishing or amending the charter of any such committee may establish requirements or procedures
relating to the governance and/or operation of such committee that are different from, or in addition to, those set forth in these Bylaws and, to the extent that there is any inconsistency between these Bylaws and any such resolution or charter, the
terms of such resolution or charter shall be controlling. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexctoc401831_27"></A>25.&nbsp;&nbsp;&nbsp;&nbsp;<U>Compensation</U>. The Board may establish the compensation of directors,
including without limitation compensation for membership on the Board and on committees of the Board, attendance at meetings of the Board or committees of the Board, and for other services provided to the Company or at the request of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexctoc401831_28"></A>26.&nbsp;&nbsp;&nbsp;&nbsp;<U>Rules</U>. The Board may adopt rules and regulations for the conduct of
meetings and the oversight of the management of the affairs of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexctoc401831_29"></A>27.&nbsp;&nbsp;&nbsp;&nbsp;<U>Chairman of the Board</U>.
The Board, by a majority vote of the Whole Board, shall elect a Chairman from among the members of the Board. The Chairman shall not be considered an officer of the Company in his or her capacity as such. The Chairman may be removed from that
capacity by a majority vote of the Whole Board. The Chairman shall preside at meetings of the Board and of the stockholders of the Company and exercise and perform such other powers and duties as may from time to time be assigned to him or her by
the Board or as may be prescribed by these Bylaws.&nbsp;In the absence of the Chairman, such other director of the Company designated by the Chairman or by the Board shall act as chairman of any such meeting. The Chairman or the Board may appoint a
Vice Chairman of the Board to exercise and perform such other powers and duties as may from time to time be assigned to him or her by the Chairman or by the Board. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><A NAME="annexctoc401831_30"></A><U>NOTICES</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexctoc401831_31"></A>28.&nbsp;&nbsp;&nbsp;&nbsp;<U>Generally</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Form of Notices</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;Without limiting the manner by which notice otherwise may be given effectively to stockholders, any notice to
stockholders given by the Company pursuant to applicable law or under the Certificate of Incorporation or these Bylaws may be given in writing directed to the stockholder&#146;s mailing address (or by electronic transmission directed to the
stockholder&#146;s electronic mail address, as applicable) as it appears on the records of the Company and shall be given (A)&nbsp;if mailed, when the notice is deposited in the U.S. mail, postage prepaid; (B) if delivered by courier service, the
earlier of when the notice is received or left at such stockholder&#146;s address; or (C)&nbsp;if given by electronic mail, when directed to such stockholder&#146;s electronic mail address unless the stockholder has notified the Company in writing
or by electronic transmission of an objection to receiving notice by electronic mail or such notice is prohibited by <U>Bylaw 28(a)(iii)</U>. A notice by electronic mail must include a prominent legend that the communication is an important notice
regarding the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;Without limiting the manner by which notice otherwise may be given effectively to
stockholders, but subject to <U>Bylaw 28(a)(iii)</U>, any notice to stockholders given by the Company pursuant to applicable law or under the Certificate of Incorporation or these Bylaws shall be effective if given by a form of electronic
transmission consented to by the stockholder to whom the notice is given. Any such consent shall be revocable by the stockholder by written notice or electronic transmission to the Company. The Company may give a notice by electronic mail in
accordance with <U>Bylaw 28(a)(i)</U> without obtaining the consent required by this <U>Bylaw 28(a)(ii)</U>. Notice given pursuant to this <U>Bylaw 28(a)(ii)</U> shall be deemed given (A)&nbsp;if by facsimile telecommunication, when directed to a
number at which the stockholder has consented to receive notice; (B)&nbsp;if by a posting on an electronic network together with separate notice to the stockholder of such specific posting, upon the later of (1)&nbsp;such posting and (2)&nbsp;the
giving of such separate notice; and (C)&nbsp;if by any other form of electronic transmission, when directed to the stockholder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding the foregoing, a notice may not be given by an electronic transmission from and after the time
that (A)&nbsp;the Company is unable to deliver by such electronic transmission two consecutive notices given by the Company and (B)&nbsp;such inability becomes known to the Secretary or an Assistant Secretary or to the transfer agent, or other
person responsible for the giving of notice, provided, however, the inadvertent failure to discover such inability shall not invalidate any meeting or other action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;An affidavit of the Secretary or an Assistant Secretary or of the transfer agent or other agent of the Company
that notice has been given shall, in the absence of fraud, be prima facie evidence of the facts stated therein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices to Directors</U>. Notices to directors may be given by mail or courier service, telephone, electronic
transmission or as otherwise may be permitted by applicable law or these Bylaws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexctoc401831_32"></A>29.&nbsp;&nbsp;&nbsp;&nbsp;<U>Waivers</U>. Whenever any
notice is required to be given by law or under the provisions of Certificate of Incorporation or these Bylaws, a waiver thereof in writing, signed by the person entitled to such notice, or a waiver by electronic transmission by the person entitled
to such notice, whether before or after the time of the event for which notice is to be given, will be deemed equivalent to such notice. Attendance of a person at a meeting will constitute a waiver of notice of such meeting, except when the person
attends a meeting for the express purpose of objecting at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><A NAME="annexctoc401831_33"></A><U>OFFICERS</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexctoc401831_34"></A>30.&nbsp;&nbsp;&nbsp;&nbsp;<U>Generally</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;The officers of the Company will be elected annually by the Board and will consist of a Chief Executive Officer, a
President, a Secretary and a Treasurer, all of whom shall be elected at the annual meeting of the Board. The Board may also choose one or more Vice Presidents (who may be given particular designations with respect to authority, function, or
seniority), one or more Assistant Secretaries, one or more Assistant Treasurers and such other officers as the Board may from time to time determine. Notwithstanding the foregoing, the Board may authorize the Chief Executive Officer to appoint any
person to any office other than the Secretary or Treasurer. Any number of offices may be held by the same person. Any of the offices may be left vacant from time to time as the Board may determine. In the case of the absence or disability of any
officer of the Company or for any other reason deemed sufficient by a majority of the Board, the Board may delegate the absent or disabled officer&#146;s powers or duties to any other officer or to any director. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Chief Executive Officer</U>. The Chief Executive Officer shall have general charge and supervision of the
business of the Company subject to the direction of the Board, and shall perform all duties and have all powers that are commonly incident to the office of chief executive or that are delegated to such officer by the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>President</U>. The President shall have such powers and perform such duties as may be assigned to him or her
from time to time by the Board or the Chief Executive Officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Vice Presidents</U>. Each Vice President
shall have such powers and perform such duties as may be assigned to him or her from time to time by the Board or the Chief Executive Officer. The Board may assign to any Vice President the title of Executive Vice President, Senior Vice President or
any other title selected by the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Secretary; Assistant Secretary</U>. The Secretary, or an Assistant
Secretary, shall attend all sessions of the Board and all meetings of the stockholders and record all votes and the minutes of all proceedings in a book to be kept for that purpose, and shall perform like duties for committees when required. He or
she shall give, or cause to be given, notice of all meetings of the stockholders and meetings of the Board, and shall perform such other duties as may be assigned by the Board. The Secretary, or an Assistant Secretary, shall keep in safe custody the
seal of the Company and have authority to affix the seal to all documents requiring it and attest to the same. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;<U>Treasurer; Assistant Treasurer</U>. The Treasurer, or an Assistant Treasurer, shall have the custody of the
corporate funds and other property of the Company, except as otherwise provided by the Board, and shall keep full and accurate accounts of receipts and disbursements in books belonging to the Company and shall deposit all moneys and other valuable
effects in the name and to the credit of the Company in such depositories as may be designated by the Board. The Treasurer, or an Assistant Treasurer, shall disburse the funds of the Company as may be ordered by the Board, taking proper vouchers for
such disbursements, and whenever requested by the Board, shall render an account of all his or her transactions as treasurer and of the financial condition of the Company, and shall perform such other duties as may be assigned by the Board. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;<U>Delegation of Authority</U>. The Board may from time to time
delegate the powers or duties of any officer to any other officer or agent, notwithstanding the provisions herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;<U> Voting Securities Owned by the Company</U>. Powers of attorney, proxies, waivers of notice of meeting, consents
and other instruments relating to securities owned by the Company may be executed in the name of and on behalf of the Company by the Chief Executive Officer, the President, any Vice President or any other officer authorized to do so by the Board and
any such officer may, in the name of and on behalf of the Company, take all such action as any such officer may deem advisable to vote in person or by proxy at any meeting of security holders of any company in which the Company may own securities
and at any such meeting shall possess and may exercise any and all rights and power incident to the ownership of such securities and which, as the owner thereof, the Company might have exercised and possessed if present. The Board may, by
resolution, from time to time confer like powers upon any other person or persons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;<U>Chairman of the
Board</U>. The Board, in its discretion, may choose a Chairman (who shall be a director but need not be elected as an officer). The Chairman of the Board shall preside at all meetings of the stockholders and all meetings of the Board. The Chairman
of the Board shall perform such other duties and may exercise such other powers as may from time to time be assigned by these Bylaws or by the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexctoc401831_35"></A>31.&nbsp;&nbsp;&nbsp;&nbsp;<U>Compensation</U>. The compensation of all directors who are also officers and
agents of the Company and the executive officers of the Company will be fixed by the Board or by a committee of the Board. The Board may fix or delegate the power to fix, the compensation of other officers and agents of the Company to an officer of
the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexctoc401831_36"></A>32.&nbsp;&nbsp;&nbsp;&nbsp;<U>Succession</U>. The officers of the Company will hold office
until their successors are elected and qualified or until such officer&#146;s earlier death, resignation or removal. Any officer may be removed at any time by the affirmative vote of a majority of the Whole Board. Any vacancy occurring in any office
of the Company may be filled by the Board or by the Chairman as provided in <U>Bylaw</U><U></U><U>&nbsp;30</U>. Any officer of the Company may resign at any time by giving written notice of his or her resignation to the Chief Executive Officer, the
President or the Secretary. Such resignation shall be effective upon receipt unless such notice provides that the resignation is effective at some later time or upon the occurrence of some later event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexctoc401831_37"></A>33.&nbsp;&nbsp;&nbsp;&nbsp;<U>Authority and Duties</U>. Each of the officers of the Company will have such
authority and will perform such duties as are customarily incident to their respective offices or as may be specified from time to time by the Board. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><A NAME="annexctoc401831_38"></A><U>STOCK</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexctoc401831_39"></A>34.&nbsp;&nbsp;&nbsp;&nbsp;<U>Certificates</U>.<B> </B>The Board may provide by resolution or resolutions
that some or all of any or all classes or series of the stock of the Company shall be uncertificated shares. Certificates, if any, representing shares of stock of the Company will be in such form as is determined by the Board, subject to applicable
legal requirements and the Certificate of Incorporation. Each such certificate shall be numbered and shall be signed by, or in the name of the Company by, the Chairman, or Chief Executive Officer or Chief Financial Officer, and by the Treasurer or
an Assistant Treasurer or the Secretary or an Assistant Secretary.&nbsp;Any or all of the signatures on a certificate may be a facsimile signature or electronic signature.&nbsp;In case any officer, transfer agent or registrar who has signed or whose
facsimile signature or electronic signature has been placed upon a certificate shall have ceased to be such officer, transfer agent or registrar before such certificate is issued, it may be issued by the Company with the same effect as if he or she
were such officer, transfer agent or registrar at the date of issue.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexctoc401831_40"></A>35.&nbsp;&nbsp;&nbsp;&nbsp;<U>Transfer</U>. Transfers of shares shall be made upon the books of the Company
(i)&nbsp;only by the holder of record thereof, or by a duly authorized agent, transferee or legal representative and (ii)&nbsp;in the case of certificated shares, upon the surrender to the Company of the certificate or certificates for such
shares.&nbsp;No transfer shall be made that is inconsistent with the provisions of applicable law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexctoc401831_41"></A>36.&nbsp;&nbsp;&nbsp;&nbsp;<U>Lost, Stolen or Destroyed
Certificates</U>. The Secretary may direct a new certificate or certificates or uncertificated shares to be issued in place of any certificate or certificates theretofore issued by the Company alleged to have been lost, stolen or destroyed, upon the
making of an affidavit of that fact, satisfactory to the Secretary, by the person claiming the certificate of stock to be lost, stolen or destroyed. As a condition precedent to the issuance of a new certificate or certificates, the Secretary may
require the owners of such lost, stolen or destroyed certificate or certificates to give the Company a bond in such sum and with such surety or sureties as the Secretary may direct as indemnity against any claims that may be made against the Company
with respect to the certificate alleged to have been lost, stolen or destroyed or the issuance of the new certificate or uncertificated shares. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><A NAME="annexctoc401831_42"></A><U>GENERAL</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexctoc401831_43"></A>37.&nbsp;&nbsp;&nbsp;&nbsp;<U>Fiscal Year</U>. The fiscal year of the Company will end on December&nbsp;31 of
each calendar year or such other date as may be fixed from time to time by the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexctoc401831_44"></A>38.&nbsp;&nbsp;&nbsp;&nbsp;<U>Reliance Upon Books, Reports and Records</U>. Each director, each member of a
committee designated by the Board, and each officer of the Company will, in the performance of his or her duties, be fully protected in relying in good faith upon the records of the Company and upon such information, opinions, reports, or statements
presented to the Company by any of the Company&#146;s officers or employees, or committees of the Board, or by any other person or entity as to matters the director, committee member, or officer believes are within such other person&#146;s
professional or expert competence and who has been selected with reasonable care by or on behalf of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexctoc401831_45">
</A>39.&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendments</U>. Except as otherwise provided by law or by the Certificate of Incorporation or these Bylaws, these Bylaws or any of them may be amended in any respect or repealed at any time, either (a)&nbsp;at any
meeting of stockholders, provided that any amendment or supplement proposed to be acted upon at any such meeting has been properly described or referred to in the notice of such meeting, or (b)&nbsp;by the Board, provided that no amendment adopted
by the Board may vary or conflict with any amendment adopted by the stockholders in accordance with the Certificate of Incorporation and these Bylaws. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexctoc401831_46"></A>40.&nbsp;&nbsp;&nbsp;&nbsp;<U>Electronic Signatures</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise required by the Certificate of Incorporation (including as otherwise required by any Preferred
Stock Designation) or these Bylaws (including, without limitation, as otherwise required by <U>Bylaw 40(b)</U>), any document, including, without limitation, any consent, agreement, certificate or instrument, required by the DGCL, the Certificate of
Incorporation (including any Preferred Stock Designation) or these Bylaws to be executed by any officer, director, stockholder, employee or agent of the Corporation may be executed using a facsimile or other form of electronic signature to the
fullest extent permitted by applicable law. All other contracts, agreements, certificates or instruments to be executed on behalf of the Corporation may be executed using a facsimile or other form of electronic signature to the fullest extent
permitted by applicable law. The terms &#147;<B><I>electronic mail</I></B>,&#148; &#147;<B><I>electronic mail address</I></B>,&#148; &#147;<B><I>electronic signature</I></B>&#148; and &#147;<B><I>electronic transmission</I></B>&#148; as used herein
shall have the meanings ascribed thereto in the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding anything to the contrary in these
Bylaws, whenever <U>Bylaws 9</U>, <U>10</U>, or <U>11</U> require one or more persons (including a stockholder) to deliver a document or information (other than a document authorizing another person to act for a stockholder by proxy at a meeting of
stockholders pursuant to Section 212 of the DGCL) to the Company or any officer, employee or agent thereof (including any notice, request, questionnaire, revocation, representation or other document or agreement), the Company shall not be required
to accept delivery of such document or information unless the document or information is in writing exclusively (and not in an electronic transmission) and delivered exclusively by hand (including, without limitation, overnight courier service) or
by certified or registered mail, return receipt requested. For the avoidance of doubt, the Company expressly opts out of Section 116 of the DGCL with respect to the delivery of information and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
documents (other than a document authorizing another person to act for a stockholder by proxy at a meeting of stockholders pursuant to Section 212 of the DGCL) to the Company required by
<U>Bylaws 9</U>, <U>10</U>, or <U>11</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="rom401831_69"></A>ANNEX D </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B><I>Execution Version</I></B><B> </B></P> <P STYLE="font-size:180pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">TAX RECEIVABLE AGREEMENT </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">among </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>CIBUS, INC. (f/k/a
Calyxt, Inc.) </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">THE
PERSONS NAMED HEREIN </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Dated as of [&#9679;] </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexdtoc401831_1">Article I DEFINITIONS </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexdtoc401831_2">Definitions </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexdtoc401831_3">Article II DETERMINATION OF CERTAIN REALIZED TAX BENEFIT
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexdtoc401831_4">Exchange Basis Adjustment</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexdtoc401831_5">Tax Benefit Schedule</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexdtoc401831_6">Procedures, Amendments</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexdtoc401831_7">Tax Classifications; Elections</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexdtoc401831_8">Article III TAX BENEFIT PAYMENTS </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexdtoc401831_9">Payments</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexdtoc401831_10">No Duplicative Payments</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexdtoc401831_11">Pro Rata Payments; Coordination of Benefits With Other Tax Receivable
Agreements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexdtoc401831_12">Overpayments</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexdtoc401831_13">Article IV TERMINATION </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexdtoc401831_14">Early Termination and Breach of Agreement</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexdtoc401831_15">Early Termination Notice</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexdtoc401831_16">Payment upon Early Termination</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexdtoc401831_17">Article V SUBORDINATION AND LATE PAYMENTS </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexdtoc401831_18">Subordination</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexdtoc401831_19">Late Payments by the Corporate Taxpayer</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexdtoc401831_20">Article VI NO DISPUTES; CONSISTENCY; COOPERATION
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexdtoc401831_21">Participation in the Corporate Taxpayer&#146;s and OpCo&#146;s
 Tax Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexdtoc401831_22">Consistency</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexdtoc401831_23">Cooperation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexdtoc401831_22a">Article VII MISCELLANEOUS </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexdtoc401831_23a">Notices</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexdtoc401831_24">Counterparts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexdtoc401831_25">Entire Agreement; Third Party Beneficiaries</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexdtoc401831_26">Governing Law</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexdtoc401831_27">Severability</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexdtoc401831_28">Successors; Assignment; Amendments; Waivers</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexdtoc401831_29">Titles and Subtitles</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexdtoc401831_30">Waiver of Jury Trial, Jurisdiction</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexdtoc401831_31">Reconciliation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexdtoc401831_32">Withholding</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexdtoc401831_33">Admission of the Corporate Taxpayer into a Consolidated Group;
 Transfers of Corporate Assets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexdtoc401831_34">Confidentiality</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexdtoc401831_35">Change in Law</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.14</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexdtoc401831_36">Independent Nature of TRA Parties&#146; Rights and Obligations
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.15</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexdtoc401831_37">TRA Party Representative</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-i- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TAX RECEIVABLE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This TAX RECEIVABLE AGREEMENT (this &#147;<U>Agreement</U>&#148;), dated as of [&#9679;], is hereby entered into by and among Cibus, Inc<I>.
(f/k/a Calyxt, Inc.)</I>, a Delaware corporation (the &#147;<U>Corporate Taxpayer</U>&#148;), the TRA Party Representative and each of the other persons from time to time party hereto (the &#147;<U>TRA Parties</U>&#148;). Capitalized terms used but
not defined herein have their respective meanings set forth in the Merger Agreement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the TRA Parties directly or indirectly hold Units in Cibus Global, LLC, a Delaware limited liability company
(&#147;<U>OpCo</U>&#148;), which is classified as a partnership for United States federal income tax purposes, or held Blocker Stock immediately prior to the Blocker Mergers; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Corporate Taxpayer, OpCo, Calypso Merger Subsidiary, LLC, a Delaware limited liability company (&#147;<U>Opco Merger
Sub</U>&#148;), the Blockers and the other parties thereto entered into that certain Agreement and Plan of Merger, dated January&nbsp;13, 2023 (as further amended or modified in whole or in part from time to time in accordance with such agreement,
the &#147;<U>Merger Agreement</U>&#148;), pursuant to which, among other things, (a)&nbsp;the Blockers will each be merged with and into the Corporate Taxpayer (such mergers, the &#147;<U>Blocker Mergers</U>&#148;), and (b)&nbsp;following the
Blocker Mergers, at the Closing, Opco Merger Sub will merge with and into OpCo, with OpCo surviving (such merger, the &#147;<U>Company Merger</U>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, immediately prior to the consummation of the Blocker Mergers, each Blocker was taxable as a corporation for United States federal
income tax purposes; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, as of immediately following the Company Merger, the Corporate Taxpayer is the sole managing member of OpCo
and holds Units that were (a)&nbsp;received in connection with the Blocker Mergers and Company Merger, (b)&nbsp;received in exchange for the Corporate Taxpayer&#146;s contribution to OpCo in a transaction described under Section&nbsp;721 of the
Code, or (c)&nbsp;otherwise received pursuant to the transactions contemplated by the Merger Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, as a result of the
Blocker Mergers, the Corporate Taxpayer will be entitled to utilize Blocker NOLs; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, after the Closing Date, any Units held by the
TRA Parties, together with Class&nbsp;B common stock of the Corporate Taxpayer, may be exchanged for Class&nbsp;A common stock of the Corporate Taxpayer (the &#147;<U>Class</U><U></U><U>&nbsp;A Shares</U>&#148;) constituting the Stock Exchange
Payment or, alternatively, at the election of the Corporate Taxpayer, the Cash Exchange Payment (a &#147;<U>Future</U> <U>Exchange</U>&#148;), pursuant to the provisions of the LLC Agreement and the Exchange Agreement, dated as of [&#9679;], among
the Corporate Taxpayer, OpCo, and the holders of Units from time to time party thereto, as amended from time to time (the &#147;<U>Exchange Agreement</U>&#148;), and in either case contributed to OpCo by the Corporate Taxpayer, provided that, at the
election of the Corporate Taxpayer in its sole discretion and in accordance with the Exchange Agreement, the Corporate Taxpayer may effect a direct exchange of such cash or Class&nbsp;A Shares for such Units (a &#147;<U>Direct Exchange</U>,&#148;
which shall also constitute a Future Exchange); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, OpCo and each of its direct and indirect Subsidiaries that is treated as a
partnership for United States federal income tax purposes (but only if such indirect Subsidiaries are held only through Subsidiaries treated as partnerships or disregarded entities) will have in effect (and with respect to any Subsidiary that is not
wholly-owned, OpCo shall use commercially reasonable efforts to cause such Subsidiary to have in effect) an election under Section&nbsp;754 of the Code for the Taxable Year (a &#147;<U>Section</U><U></U><U>&nbsp;754</U><U> Election</U>&#148;) that
includes the Closing Date and each subsequent Taxable Year in which an Future Exchange occurs, in each case, to the extent eligible to do so; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-1- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, as a result of the Blocker Mergers, Future Exchanges, and Section&nbsp;754
Elections, the income, gain, deduction, loss, expense and other tax items of the Corporate Taxpayer may be affected by (i)&nbsp;the Exchange Basis Adjustments, (ii)&nbsp;Blocker NOLs; and (iii)&nbsp;any deduction attributable to any payment
(including amounts attributable to Imputed Interest) made under this Agreement (collectively, the &#147;<U>Tax Attributes</U>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the parties to this Agreement desire to provide for certain payments and make certain arrangements with respect to the effect of the
Tax Attributes on the liability for Taxes of the Corporate Taxpayer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the foregoing and the respective
covenants and agreements set forth in this Agreement, and intending to be legally bound hereby, the parties hereto agree as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="annexdtoc401831_1">
</A>ARTICLE I </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>DEFINITIONS</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexdtoc401831_2"></A>Section&nbsp;1.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Definitions</U>. As used in this Agreement, the terms set forth in
this Article I shall have the following meanings (such meanings to be equally applicable to both the singular and plural forms of the terms defined). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Acquired Units</U>&#148; means the Units acquired by the Corporate Taxpayer in the Blocker Mergers or an Future Exchange. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Actual Tax Liability</U>&#148; means, with respect to any Taxable Year, the actual liability for Taxes, which shall not be less than
zero, of (i)&nbsp;the Corporate Taxpayer and (ii)&nbsp;without duplication, OpCo and its Subsidiaries, but only with respect to Taxes imposed on OpCo and its Subsidiaries and allocable to the Corporate Taxpayer or to the other members of the
consolidated group of which the Corporate Taxpayer is the parent, <I>provided</I>, that, if applicable, such amounts shall be determined in accordance with a Determination (including interest imposed in respect thereof under applicable law);
provided, further, that the actual liability for Taxes described in clauses (i)&nbsp;and (ii) shall be calculated using the Assumed Rate, solely for purposes of calculating the U.S. state and local Actual Tax Liability of the Corporate Taxpayer.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Affiliate</U>&#148; of any particular Person means any other Person controlling, controlled by or under common control with such
Person, where &#147;control&#148; means the possession, directly or indirectly, of the power to direct the management and policies of a Person whether through the ownership of voting securities, its capacity as a sole or managing member or
otherwise, including any private equity fund now or hereafter existing that is controlled by one or more general partners or managing members of, or shares the same management company with, such Person. For purposes of this Agreement, no TRA Party
shall be considered to be an Affiliate of the Corporate Taxpayer or OpCo. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Agreed Rate</U>&#148; means a per annum rate equal to
SOFR plus 100 basis points. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Assumed Rate</U>&#148; means, with respect to any Taxable Year, the tax rate equal to the sum of the
product of (x)&nbsp;OpCo&#146;s tax apportionment percentage(s) for each U.S. state and local jurisdiction in which OpCo or the Corporate Taxpayer files Tax Returns for the relevant Taxable Year and (y)&nbsp;the highest corporate tax rate(s) for
each such U.S. state and local jurisdiction in which OpCo or the Corporate Taxpayer files Tax Returns for each relevant Taxable Year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Attributable</U>&#148; means the portion of any Tax Attribute of the Corporate Taxpayer or its Subsidiaries or, without duplication,
OpCo or its Subsidiaries, that is attributable to a TRA Party and shall be determined by reference to the Tax Attributes, under the following principles: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) any Exchange Basis Adjustments shall be determined separately with respect to each TRA Party and are Attributable to a TRA Party in an
amount equal to the total Exchange Basis Adjustments relating to the Units that are exchanged by such TRA Party as part of a Future Exchange; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-2- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) any Blocker NOLs shall be determined separately with respect to each TRA Party and are
Attributable to each TRA Party in an amount equal to the Blocker NOLs relating to the Blocker Stock acquired (via the Blocker Mergers) from such TRA Party <FONT STYLE="white-space:nowrap">(pro-rata</FONT> based on the number of shares owned by such
TRA Party in such Blocker); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) any deduction to the Corporate Taxpayer or its Subsidiaries, as applicable, with respect to a
Taxable Year in respect of any payment (including amounts attributable to Imputed Interest) made under this Agreement is Attributable to the Person that is required to include the Imputed Interest or other payment in income (without regard to
whether such Person is actually subject to Taxes thereon). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A &#147;<U>Beneficial Owner</U>&#148; of a security is a Person who directly
or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares: (i)&nbsp;voting power, which includes the power to vote, or to direct the voting of, such security and/or (ii)&nbsp;investment power, which
includes the power to dispose of, or to direct the disposition of, such security. The terms &#147;<U>Beneficially Owned</U>&#148; and &#147;<U>Beneficial Ownership</U>&#148; shall have correlative meanings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Blocker</U>&#148; means any New Ventures I Holdings, LLC, a Delaware limited liability company (&#147;<U>Blocker 1</U>&#148;); BCGF
CB Holdings LLC, a Delaware limited liability company (&#147;<U>Blocker 2</U>&#148;); BCGFCP CB Holdings LLC, a Delaware limited liability company (&#147;<U>Blocker 3</U>&#148;); BCGFK CB Holdings LLC, a Delaware limited liability company
(&#147;<U>Blocker 4</U>&#148;); FSBCGF CB Holdings LLC, a Delaware limited liability company (&#147;<U>Blocker 5</U>&#148;); PYLBCG CB Holdings LLC, a Delaware limited liability company (&#147;<U>Blocker 6</U>&#148;); FSGRWCO CB Holdings LLC, a
Delaware limited liability company (&#147;<U>Blocker 7</U>&#148;); GROWTHCO CB Holdings LLC, a Delaware limited liability company (&#147;<U>Blocker 8</U>&#148;); GRTHCOCP CB Holdings LLC, a Delaware limited liability company (&#147;<U>Blocker
9</U>&#148;); and GRWTHCOK CB Holdings LLC, a Delaware limited liability company (&#147;<U>Blocker 10</U>&#148;; and, collectively with Blocker 1, Blocker 2, Blocker 3, Blocker 4, Blocker 5, Blocker 6, Blocker 7, Blocker 8 and Blocker 9, the
&#147;<U>Blockers</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Blocker NOLs</U>&#148; means any U.S. federal, state, or local net operating losses, capital
losses, disallowed interest expense carryforwards under Section&nbsp;163(j) of the Code (and any comparable provision of state or local tax law), and credit carryforwards of the Blockers relating to taxable periods (or portions thereof) ending on or
prior to the Closing Date that the Corporate Taxpayer is entitled to utilize as a result of the Blocker Mergers. Notwithstanding the foregoing, the term &#147;Blocker NOLs&#148; shall not include any tax attribute of a Blocker that is used to offset
Taxes attributable to such Blocker, if such offset Taxes are attributable to taxable periods ending on or prior to the date of the Blocker Mergers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Blocker Shareholder</U>&#148; means, a Person who, prior to a Blocker Merger, holds Blocker Stock, and as a result of such Blocker
Merger, holds stock of the Corporate Taxpayer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Blocker Stock</U>&#148; means, with respect to any Blocker, the membership
interests or stock of such Blocker, as applicable, outstanding immediately prior to the Blocker Mergers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Board</U>&#148; means
the Board of Directors of the Corporate Taxpayer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Business Day</U>&#148; means a day other than a Saturday, Sunday or other day
on which commercial banks in New York, New York, San Francisco, California or Wilmington, Delaware are authorized or required by Law to close. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Cash Exchange Payment</U>&#148; has the meaning set forth in the Exchange Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Class</U><U></U><U>&nbsp;A Shares <FONT STYLE="white-space:nowrap">5-Day</FONT> VWAP</U>&#148; means, on any date, the arithmetic
average of the VWAP for each of the five (5)&nbsp;consecutive Trading Days ending on such date, or if such date is not a Trading Day, the immediately preceding Trading Day. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Change of Control</U>&#148; means the occurrence of any of the following events:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) any Person or any group of Persons acting together which would constitute a &#147;group&#148; for purposes of Section&nbsp;13(d) of
the Exchange Act or any successor provisions thereto (excluding any Excluded) is or becomes the Beneficial Owner, directly or indirectly, of securities of Corporate Taxpayer representing more than 50% of the combined voting power of Corporate
Taxpayer&#146;s then outstanding voting securities (assuming the full exercise for cash and settlement in shares of all outstanding warrants, if any, issued by Corporate Taxpayer or OpCo or any OpCo PIUs issued by OpCo at such time irrespective of
any conditions or limitations thereon), other than in connection with any merger or consolidation that does not constitute a Change of Control under clause (ii)&nbsp;below; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) there is consummated a merger or consolidation of Corporate Taxpayer with any other corporation or other entity, and, immediately after
the consummation of such merger or consolidation, the Beneficial Owners of voting securities of Corporate Taxpayer immediately prior to such merger or consolidation (assuming that all outstanding options, warrants, rights and other convertible or
exchangeable securities issued by Corporate Taxpayer or OpCo (whether or not then currently exercisable) have been exercised and the holders thereof are holders of voting securities of Corporate Taxpayer) do not represent or are not converted into
more than 50% of the combined voting power of the then outstanding voting securities of the Person resulting from such merger or consolidation or the ultimate parent entity thereof (calculated on a fully-diluted basis using the treasury stock
method); or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) the shareholders of Corporate Taxpayer approve a plan of complete liquidation or dissolution of Corporate Taxpayer or
there is consummated an agreement or series of related agreements for the sale, lease or other disposition, directly or indirectly, by Corporate Taxpayer of all or substantially all of the assets of Corporate Taxpayer, taken as a whole, other than
such sale or other disposition by Corporate Taxpayer of all or substantially all of the assets of Corporate Taxpayer, taken as a whole, to an entity of which at least 50% of the combined voting power of the voting securities of such entity
(calculated on a fully diluted basis using the treasury stock method) are Beneficially Owned by the Beneficial Owners of voting securities of Corporate Taxpayer immediately prior to such merger or consolidation (assuming that all outstanding
options, warrants, rights and other convertible or exchangeable securities issued by Corporate Taxpayer or OpCo (whether or not then currently exercisable) have been exercised and the holders thereof are holders of voting securities of Corporate
Taxpayer). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, a &#147;Change of Control&#148; shall not be deemed to have occurred by virtue of the
consummation of any transaction or series of integrated transactions immediately following which the record holders of the shares of the Corporate Taxpayer immediately prior to such transaction or series of transactions continue to have
substantially the same proportionate ownership in, and own substantially all of the shares of, an entity which owns all or substantially all of the assets of the Corporate Taxpayer immediately following such transaction or series of transactions.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Closing Date</U>&#148; means the date of the consummation of the transactions contemplated by the Merger Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Control</U>&#148; means the possession, direct or indirect, of the power to direct or cause the direction of the management and
policies of a Person, whether through ownership of voting securities, by contract or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Corporate Taxpayer
Return</U>&#148; means the United States federal and/or state and/or local and/or foreign Tax Return, as applicable, of the Corporate Taxpayer filed with respect to Taxes of any Taxable Year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Cumulative Net Realized Tax Benefit</U>&#148; for a Taxable Year means the cumulative amount of Realized Tax Benefits for all Taxable
Years of the Corporate Taxpayer, up to and including such Taxable Year, net of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-4- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
cumulative amount of Realized Tax Detriments for the same period. The Realized Tax Benefit and Realized Tax Detriment for each Taxable Year shall be determined based on the most recent Tax
Benefit Schedules or Amended Schedules, if any, in existence at the time of such determination; provided that the computation of the Cumulative Net Realized Tax Benefit shall be adjusted to reflect any applicable Determination with respect to any
Realized Tax Benefits and/or Realized Tax Detriments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Default Rate</U>&#148; means a per annum rate equal to SOFR plus 500 basis
points. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Determination</U>&#148; shall have the meaning ascribed to such term in Section&nbsp;1313(a) of the Code or similar
provision of state, foreign or local tax law, as applicable, or any other event (including the execution of IRS Form 870-AD) that finally and conclusively establishes the amount of any liability for Taxes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Early Termination Date</U>&#148; means the date of an Early Termination Notice for purposes of determining the Early Termination
Payment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Early Termination Rate</U>&#148; means a per annum rate equal to SOFR plus 400 basis points. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Exchange Basis Adjustment</U>&#148; means the adjustment to the tax basis of a Reference Asset under Sections 732, 734(b) and/or 1012
of the Code (in situations where, as a result of one or more Future Exchanges, OpCo becomes an entity that is disregarded as separate from its owner for United States federal income tax purposes) or under Sections 734(b), 743(b), 754 and/or 755 of
the Code (in situations where, following a Future Exchange, OpCo remains in existence as an entity treated as a partnership for United States federal income tax purposes) and, in each case, comparable sections of United States state and local tax
laws, as a result of a Future Exchange and the payments made pursuant to this Agreement in respect of such Future Exchange. The amount of any Exchange Basis Adjustment shall be determined using the Market Value with respect to such Future Exchange,
except, for the avoidance of doubt, as otherwise required by a Determination. For the avoidance of doubt, payments made under this Agreement shall not be treated as resulting in an Exchange Basis Adjustment to the extent such payments are treated as
Imputed Interest, and the amount of any Exchange Basis Adjustment resulting from a Future Exchange of one or more Units shall be determined without regard to any <FONT STYLE="white-space:nowrap">Pre-Exchange</FONT> Transfer of such Units and as if
any such <FONT STYLE="white-space:nowrap">Pre-Exchange</FONT> Transfer had not occurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Exchange Date</U>&#148; means the date
of any Future Exchange. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Excluded Holders</U>&#148; mean the initial TRA Party Representative and his immediate family members,
together with their respective Affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Excluded Party</U>&#148; means a Person or group of Persons relevant to an event
described in clause (i) of the definition of &#147;Change of Control&#148; in which the Excluded Holders (x) directly or indirectly hold Beneficial Ownership of securities representing more than 50% of the total voting power in such Person or held
by such group or (y) participate, through a plan or arrangement between the Excluded Holders and such Person or group of Persons, as &#147;roll-over&#148; equity investors in respect of which such Excluded Holders directly or indirectly receive or
retain Beneficial Ownership of rights or securities representing more than 10% of the economic interests in OpCo (or its successor) following such event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Future</U> <U>Exchange</U>&#148; is defined in the Recitals of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Hypothetical Tax Liability</U>&#148; means, with respect to any Taxable Year, an amount, not less than zero, equal to the liability
for Taxes of (i)&nbsp;the Corporate Taxpayer and (ii)&nbsp;without duplication, OpCo and its Subsidiaries, but only with respect to Taxes imposed on OpCo and its Subsidiaries and allocable to the Corporate Taxpayer or to the other members of the
consolidated group of which the Corporate Taxpayer is the parent, in each case determined using the same methods, elections, conventions and similar practices used in computing the Actual Tax Liability, but, in each case, (a)&nbsp;calculating
depreciation, amortization or similar deductions and income, gain </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-5- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or loss using the <FONT STYLE="white-space:nowrap">Non-Stepped</FONT> Up Tax Basis as reflected on the Basis Schedule including amendments thereto for the Taxable Year, (b)&nbsp;without taking
into account any Blocker NOLs, and (c)&nbsp;excluding any deduction attributable to any payment (including amounts attributable to Imputed Interest) made under this Agreement for the Taxable Year. For the avoidance of doubt, Hypothetical Tax
Liability shall be determined: (i)&nbsp;without taking into account the carryover or carryback of any tax item (or portions thereof) that is attributable to a Tax Attribute, as applicable, and (ii)&nbsp;using the Assumed Rate solely for purposes of
calculating the U.S. state and local Hypothetical Tax Liability of the Corporate Taxpayer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Imputed Interest</U>&#148; in respect
of a TRA Party shall mean any interest imputed under Section&nbsp;1272, 1274 or 483 or other provision of the Code and any similar provision of state or local tax law with respect to the Corporate Taxpayer&#146;s payment obligations in respect of
such TRA Party under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>IRS</U>&#148; means the United States Internal Revenue Service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>LLC Agreement</U>&#148; means, with respect to OpCo, the Third Amended and Restated Limited Liability Company Agreement of OpCo,
dated on or about the date hereof, as amended from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Market Value</U>&#148; shall mean on any date, (a)&nbsp;if the
Class&nbsp;A Shares trade on a national securities exchange or automated or electronic quotation system, the Class&nbsp;A Shares <FONT STYLE="white-space:nowrap">5-Day</FONT> VWAP or (b)&nbsp;if the Class&nbsp;A Shares are not then traded on a
national securities exchange or automated or electronic quotation system, as applicable, the &#147;Appraiser FMV&#148; (as defined in the Exchange Agreement) on such date of one (1)&nbsp;Class&nbsp;A Share that would be obtained in an arms-length
transaction between an informed and willing buyer and an informed and willing seller, neither of whom is under any compulsion to buy or sell, respectively, and without regard to the particular circumstances of the buyer or seller. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U><FONT STYLE="white-space:nowrap">Non-Stepped</FONT> Up Tax Basis</U>&#148; means with respect to any Reference Asset at any time, the
tax basis that such asset would have had at such time if no Exchange Basis Adjustments had been made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>OpCo PIU</U>&#148; means
Units of OpCo, which are &#147;profits interests&#148; (as described in IRS Revenue Procedure 93-27 and IRS Revenue Procedure 2001-43) in OpCo. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Payment Date</U>&#148; means any date on which a payment is required to be made pursuant to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Permitted Transferee</U>&#148; has the meaning set forth in the LLC Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Person</U>&#148; means any individual, corporation, firm, partnership, joint venture, limited liability company, estate, trust,
business association, organization, governmental entity or other entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U><FONT STYLE="white-space:nowrap">Pre-Exchange</FONT>
Transfer</U>&#148; means any transfer (including upon the death of a holder of Units) or distribution in respect of one or more Units (a)&nbsp;that occurs after the Closing Date but prior to a Future Exchange of such Units, and (b)&nbsp;to which
Section&nbsp;743(b) or 734(b) of the Code applies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Realized Tax Benefit</U>&#148; means, for a Taxable Year, the excess, if any,
of the Hypothetical Tax Liability over the Actual Tax Liability. If all or a portion of the actual liability for such Taxes for the Taxable Year arises as a result of an audit by a Taxing Authority of any Taxable Year, such liability shall not be
included in determining the Realized Tax Benefit unless and until there has been a Determination, provided that the Corporate Taxpayer may set aside any payment hereunder and defer payment thereof to any TRA Party (only to the extent of the
reasonably expected reduction in the Realized Tax Benefit or Realized Tax Detriment, as applicable) until such Determination or a Determination with respect to any Realized Tax Detriment if in the reasonable discretion of the Corporate Taxpayer the
full amount of the Realized Tax Benefit or Realized Tax Detriment, as applicable, is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-6- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
not expected to be so realized as a result of such audit. Any such deferred payments shall bear interest at the Agreed Rate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Realized Tax Detriment</U>&#148; means, for a Taxable Year, the excess, if any, of the Actual Tax Liability over the Hypothetical Tax
Liability. If all or a portion of the actual liability for such Taxes for the Taxable Year arises as a result of an audit by a Taxing Authority of any Taxable Year, such liability shall not be included in determining the Realized Tax Detriment
unless and until there has been a Determination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Reference Asset</U>&#148; means an asset that is held by OpCo, or by any of its
direct or indirect Subsidiaries treated as a partnership or disregarded entity (but only if such indirect Subsidiaries are held only through Subsidiaries treated as partnerships or disregarded entities) for purposes of the applicable tax, at the
time of a Future Exchange or the Blocker Mergers, as applicable. A Reference Asset also includes any asset the tax basis of which is determined, in whole or in part, for purposes of the applicable tax, by reference to the tax basis of an asset that
is described in the preceding sentence, including for U.S. federal income tax purposes, any asset that is &#147;substituted basis property&#148; under Section&nbsp;7701(a)(42) of the Code with respect to a Reference Asset. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Schedule</U>&#148; means any of the following: (a)&nbsp;a Basis Schedule, (b)&nbsp;a Tax Benefit Schedule, or (c)&nbsp;the Early
Termination Schedule, and, in each case, any amendments thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>SOFR</U>&#148; means with respect to any day, a rate per annum
equal to the Secured Overnight Financing Rate published for such day by the Federal Reserve Bank of New York, as the administrator of the benchmark (or a successor administrator), on the Federal Reserve Bank of New York&#146;s website. In no event
will SOFR plus an applicable margin be less than 0% (for example, SOFR with respect to the Early Termination Rate shall not be less than <FONT STYLE="white-space:nowrap">(-4%)).</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Stock Exchange Payment</U>&#148; has the meaning set forth in the Exchange Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Subsidiaries</U>&#148; means, with respect to any Person, as of any date of determination, any other Person as to which such Person,
owns, directly or indirectly, or otherwise controls more than 50% of the voting power or other similar interests or the sole general partner interest or managing member or similar interest of such Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Subsidiary Stock</U>&#148; means any stock or other equity interest in any subsidiary entity of OpCo that is treated as a C
corporation for United States federal income tax purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Tax Attributes</U>&#148; has the meaning set forth in the Recitals.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Tax Benefit Payment</U>&#148; has the meaning set forth in Section&nbsp;3.1(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Tax Benefit Schedule</U>&#148; has the meaning set forth in Section&nbsp;2.2(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Tax Return</U>&#148; means any return, declaration, report, or similar statement filed or required to be filed with respect to Taxes
(including any attached schedules), including any information return, claim for refund, amended return and declaration of estimated Taxes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Taxable Year</U>&#148; means a taxable year of the Corporate Taxpayer as defined in Section&nbsp;441(b) of the Code or comparable
section of state, local or foreign tax law, as applicable (and, therefore, for the avoidance of doubt, may include a period of less than 12 months for which a Tax Return is made), ending on or after the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Taxes</U>&#148; means any and all United States federal, state, local and foreign taxes, assessments or similar charges that are
based on or measured with respect to net income or profits, whether as an exclusive or an alternative basis, and including franchise taxes that are based on or measured with respect to net income or profits, and any interest, penalties, or additions
related to such amounts or imposed in respect thereof under applicable law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-7- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Taxing Authority</U>&#148; shall mean any domestic, federal, national, state,
county or municipal or other local government, any subdivision, agency, commission or authority thereof, or any quasi-governmental body exercising any taxing authority or any other authority exercising tax regulatory authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>TRA Party Representative</U>&#148; means, initially, Rory Riggs, and thereafter, if Rory Riggs becomes unable to perform the TRA
Party Representative&#146;s responsibilities hereunder or resigns from such position, either (i)&nbsp;a replacement TRA Party Representative selected by Rory Riggs at or prior to the time of such inability or resignation, or (ii)&nbsp;if Rory Riggs
has not selected a replacement TRA Party Representative at or prior to the time of such inability or resignation, that TRA Party or a committee of TRA Parties determined from time to time by a plurality vote of the TRA Parties ratably in accordance
with their right to receive Early Termination Payments under this Agreement determined as if all TRA Parties directly holding Units had fully exchanged their Units for Class&nbsp;A Shares or other consideration and the Corporate Taxpayer had
exercised its right of early termination on the date of the most recent Future Exchange; provided, however, that if the TRA Parties fail to appoint a TRA Party Representative within ninety (90)&nbsp;days of the Corporate Taxpayer&#146;s request in
writing to do so, the TRA Party having the right to receive the largest Early Termination Payment (in accordance with this sentence) shall be the TRA Party Representative. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Trading Day</U>&#148; means a day on which the Trading Market is open for the transaction of business (unless such trading shall have
been suspended for the entire day). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Trading Market</U>&#148; means the Nasdaq Stock Market or such other principal United States
securities exchange on which Class&nbsp;A Shares are listed, quoted or admitted to trading. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Treasury Regulations</U>&#148; means
the final, temporary and proposed regulations under the Code promulgated from time to time (including corresponding provisions and succeeding provisions) as in effect for the relevant taxable period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Units</U>&#148; has the meaning set forth in the LLC Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Valuation Assumptions</U>&#148; shall mean, as of an Early Termination Date, the assumptions that in each Taxable Year ending on or
after such Early Termination Date, (a)&nbsp;the Corporate Taxpayer will have taxable income sufficient to fully utilize the tax items arising from the Tax Attributes (other than any items addressed in clause (b)) during such Taxable Year or future
Taxable Years (including, for the avoidance of doubt, deductions and other tax items arising from Tax Attributes that would result from future Tax Benefit Payments that would be paid in accordance with the Valuation Assumptions, further assuming
that such applicable future payments would be paid on the due date (including extensions) for filing the Corporate Taxpayer Tax Return for the applicable Taxable Year) in which such deductions would become available, (b)&nbsp;any Blocker NOLs and
loss carryovers generated by deductions arising from any Tax Attributes, which Blocker NOLs and/or loss carryovers are available in the Taxable Year that includes such Early Termination Date, will be used by the Corporate Taxpayer on a pro rata
basis from the Early Termination Date through (A)&nbsp;the scheduled expiration date of such Blocker NOLs and/or loss carryovers (if any) or (B)&nbsp;if there is no such scheduled expiration date, then the 15th year anniversary of the Early
Termination Date, (c)&nbsp;the United States federal income tax rates that will be in effect for each such Taxable Year will be those specified for each such Taxable Year by the Code and other law as in effect on the Early Termination Date, the
Assumed Rate will be calculated based on such rates and the apportionment factors applicable in the most recently ended Taxable Year, in each case, except to the extent any change to such tax rates for such Taxable Year has already been enacted into
law as of the Early Termination Date, and SOFR that will be in effect for each such Taxable Year will be the rate in effect on the Early Termination Date, (d)&nbsp;any <FONT STYLE="white-space:nowrap">non-amortizable,</FONT> <FONT
STYLE="white-space:nowrap">non-depreciable</FONT> Reference Assets (other than any Subsidiary Stock) will be disposed of on the fifteenth anniversary of a Future Exchange which gave rise to the applicable Exchange Basis Adjustment and any short-term
investments will be disposed of 12 months following the Early Termination Date; <U>provided</U> that, in the event of a Change of Control, such <FONT STYLE="white-space:nowrap">non-amortizable,</FONT>
<FONT STYLE="white-space:nowrap">non-depreciable</FONT> assets shall be deemed disposed of at the time of sale of the relevant asset (if earlier than such fifteenth anniversary), (e) any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-8- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Subsidiary Stock will never be disposed of and (f)&nbsp;if, at the Early Termination Date, there are Units that have not been exchanged, then each such Unit is exchanged in a fully taxable
transaction for the Market Value of the Class&nbsp;A Shares that would be transferred if the Future Exchange occurred on the Early Termination Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>VWAP</U>&#148; means the daily per share volume-weighted average price of Class&nbsp;A Shares on the Trading Market, as displayed
under the heading &#147;Bloomberg VWAP&#148; on the Bloomberg page designated for Class&nbsp;A Shares (or its equivalent successor if such page is not available) in respect of the period from the open of trading on such Trading Day until the close
of trading on such Trading Day (or if such volume-weighted average price is unavailable, (a) the per share volume-weighted average price of a Class&nbsp;A Share on such Trading Day (determined without regard to afterhours trading or any other
trading outside the regular trading session or trading hours), or (b)&nbsp;if such determination is not feasible, the market price per Class&nbsp;A Share, in either case as determined by a nationally recognized independent investment banking firm
retained in good faith for this purpose by the Corporate Taxpayer). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Glossary of Defined Terms</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Section</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Acquired Units</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Actual Tax Liability</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Affiliate</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Agreed Rate</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Recital</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Amended Schedule</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;2.3(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Assumed Rate</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attributable</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Basis Schedule</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;2.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Beneficially Owned</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Beneficial Owner</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Beneficial Ownership</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Blocker</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Blocker Mergers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Recital</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Blocker NOLs</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Blocker Shareholder</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Blocker Stock</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Board</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Business Day</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Cash Exchange Payment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Change of Control</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Class&nbsp;A Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Recital</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Closing Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Merger</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Recital</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Control</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Corporate Taxpayer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Recital</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Corporate Taxpayer Return</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Cumulative Net Realized Tax Benefit</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Default Cap</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;3.1(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Default Rate</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Determination</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Direct Exchange</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Recital</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Early Termination Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Early Termination Effective Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;4.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Early Termination Notice</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;4.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Early Termination Payment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 4.3(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Early Termination Rate</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Early Termination Schedule</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;4.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exchange Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Recital</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-9- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Glossary of Defined Terms</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Section</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exchange Basis Adjustment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exchange Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Expert</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;7.9</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Future Exchange</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Recital</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Hypothetical Tax Liability</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Imputed Interest</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Interest Amount</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;3.1(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">IRS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Joinder Requirement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;7.6(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">LIBOR</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Liquidity Exceptions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;4.1(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">LLC Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Mandatory Assignment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;7.6(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Market Value</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Material Objection Notice</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;4.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Material Payment Default</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;4.1(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Merger Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Recital</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Net Tax Benefit</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;3.1(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Non-Stepped</FONT> Up Tax Basis</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Non-TRA</FONT> Portion</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;2.2(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Objection Notice</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;2.3(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">OpCo</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Recital</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Opco Merger Sub</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Recital</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">OpCo PIU</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Other Tax Receivable Obligations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;3.3(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Payment Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Permitted Transferee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Person</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-Exchange</FONT> Transfer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Realized Tax Benefit</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Realized Tax Detriment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Reconciliation Dispute</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;7.9</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Reconciliation Procedures</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;2.3(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Reference Asset</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Schedule</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Senior Obligations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;5.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">SOFR</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Section&nbsp;754 Election</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Recital</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Stock Exchange Payment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Subsidiaries</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Subsidiary Stock</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Taxable Year</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Tax Attributes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Recital</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Tax Benefit Payment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Tax Benefit Schedule</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;2.2(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Taxes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Taxing Authority</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Tax Return</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">TRA Parties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Recital</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">TRA Party Representative</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">TRA Portion</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;2.2(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Treasury Regulations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Units</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Valuation Assumptions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section&nbsp;1.1</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-10- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="annexdtoc401831_3"></A>ARTICLE II </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>DETERMINATION OF CERTAIN REALIZED TAX BENEFIT</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexdtoc401831_4"></A>Section&nbsp;2.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Exchange Basis Adjustment</U>. Within one hundred twenty
(120)&nbsp;calendar days after the filing of the United States federal income tax return of the Corporate Taxpayer for the Taxable Year that includes the Closing Date and each Taxable Year thereafter while this Agreement (or any amended and/or
restated version thereof) remains in effect, the Corporate Taxpayer shall deliver to each TRA Party who received (or is deemed to receive) cash or Class&nbsp;A Shares in such Taxable Year pursuant to a Future Exchange, as applicable, and, with
respect to the Taxable Year that includes the Closing Date, to each Blocker Shareholder, a schedule (the &#147;<U>Basis Schedule</U>&#148;) that shows, in reasonable detail necessary to perform the calculations required by this Agreement,
(a)&nbsp;the actual tax basis and the <FONT STYLE="white-space:nowrap">Non-Stepped</FONT> Up Tax Basis of the Reference Assets as of the Closing Date or the applicable Exchange Date (as applicable) occurring during such Taxable Year, (b)&nbsp;the
Exchange Basis Adjustment with respect to the Reference Assets Attributable to such TRA Party as a result of the Future Exchanges effected in such Taxable Year and prior Taxable Years by such TRA Party, calculated in the aggregate, (c)&nbsp;the
Blocker NOLs Attributable to such TRA Party for the Taxable Year of the Closing, if any, (d)&nbsp;the period (or periods) over which the Reference Assets are amortizable and/or depreciable and (e)&nbsp;the period (or periods) over which each
Exchange Basis Adjustment in respect of such TRA Party is amortizable and/or depreciable, in each case, with respect to schedules provide to the TRA Party Representative calculated in the aggregate for all TRA Parties and with respect to schedules
provided to a TRA Party, calculated with respect to the TRA Party to which such Basis Schedule is delivered. Each TRA Party shall bear no costs and expenses incurred in connection with the provision and preparation of the Basis Schedules and Tax
Benefit Schedules for each TRA Party in compliance with this Agreement, as well as the procedures set forth in Section&nbsp;2.3(b), if applicable. Each Basis Schedule will become final as provided in Section&nbsp;2.3(a) and may be amended as
provided in Section&nbsp;2.3(b) (subject to the procedures set forth in Section&nbsp;2.3(b)). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexdtoc401831_5"></A>Section&nbsp;2.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Tax Benefit Schedule</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Tax Benefit Schedule</U>. Within one hundred and twenty (120)&nbsp;calendar days after the filing of the United
States federal income tax return of the Corporate Taxpayer for any Taxable Year in which there is a Realized Tax Benefit or Realized Tax Detriment Attributable to a TRA Party, the Corporate Taxpayer shall provide to such TRA Party a schedule
showing, in reasonable detail necessary to perform the calculations required by this Agreement, the calculation of the Tax Benefit Payment (and any Realized Tax Benefit or Realized Tax Detriment) or the lack of a Tax Benefit Payment (and any
Realized Tax Detriment), as applicable, Attributable to such TRA Party for such Taxable Year (a &#147;<U>Tax Benefit Schedule</U>&#148;). Each Tax Benefit Schedule will become final as provided in Section&nbsp;2.3(a) and may be amended as provided
in Section&nbsp;2.3(b) (subject to the procedures set forth in Section&nbsp;2.3(b)). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Applicable
Principles</U>. Subject to Section&nbsp;3.3(a), the Realized Tax Benefit or Realized Tax Detriment for each Taxable Year is intended to measure the decrease or increase in the Actual Tax Liability for such Taxable Year attributable to the Tax
Attributes, determined using a &#147;with and without&#148; methodology. For the avoidance of doubt, the Actual Tax Liability will take into account the deduction of the portion of the Tax Benefit Payment that must be accounted for as interest under
the Code based upon the characterization of Tax Benefit Payments as additional consideration payable by the Corporate Taxpayer for the Units acquired in a Future Exchange or Blocker Merger. Carryovers or carrybacks of any Tax item attributable to
the Tax Attributes shall be considered to be subject to the rules of the Code and the Treasury Regulations or the appropriate provisions of United States state and local and foreign income and franchise tax law, as applicable, governing the use,
limitation and expiration of carryovers or carrybacks of the relevant type. If a carryover or carryback of any tax item includes a portion that is attributable to any Tax Attribute (&#147;<U>TRA Portion</U>&#148;) and another portion that is not
(&#147;<U><FONT STYLE="white-space:nowrap">Non-TRA</FONT> Portion</U>&#148;), such portions shall be considered to be used in accordance with the &#147;with and without&#148; methodology so that the amount of any
<FONT STYLE="white-space:nowrap">Non-TRA</FONT> Portion is deemed utilized, to the extent available, prior to the amount of any TRA Portion, to the extent available (with the TRA Portion being applied on a proportionate basis consistent with the
provisions of Section&nbsp;3.3). The parties agree that (i)&nbsp;all Tax Benefit </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-11- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Payments (other than Imputed Interest) made to TRA Parties that exchanged shares of a Blocker for <U>Class</U><U></U><U>&nbsp;A Shares</U> of the Corporate Taxpayer in a Blocker Merger will be
treated as <FONT STYLE="white-space:nowrap">non-qualifying</FONT> property or money received in the Blocker Merger for purposes of Sections 356 of the Code, (ii)&nbsp;all Tax Benefit Payments (other than the portion of Tax Benefit Payments treated
as Imputed Interest) made to transferors in a Future Exchange will be treated as subsequent upward purchase price adjustments that have the effect of creating additional Exchange Basis Adjustments to Reference Assets for the Corporate Taxpayer in
the Taxable Year of payment, (iii)&nbsp;as a result, such additional Exchange Basis Adjustments described in clause (ii)&nbsp;will be incorporated into the calculation for the Taxable Year of the applicable payment and into the calculations for
subsequent Taxable Years, as appropriate, (iv)&nbsp;the Actual Tax Liability shall take into account the deduction of the portion of the Tax Benefit Payment that must be accounted for as Imputed Interest under applicable law and (v)&nbsp;the
liability for U.S. federal income Taxes of the Corporate Taxpayer and the amount of taxable income of the Corporate Taxpayer for U.S. federal income tax purposes as determined for purposes of calculating the Actual Tax Liability and the Hypothetical
Tax Liability shall include, without duplication, such U.S. federal income liability for Taxes and such U.S. federal taxable income that is economically borne by or allocated to the Corporate Taxpayer as a result of the provisions of Sections 5.06
and 5.07 of the LLC Agreement; provided, however, that such liability for Taxes and such taxable income shall be included in the Hypothetical Tax Liability and the Actual Tax Liability subject to the adjustments and assumptions set forth in the
definitions thereof and, to the extent any such amount is taken into account on an Amended Schedule, such amount shall adjust a Tax Benefit Payment, as applicable, in accordance with Section&nbsp;2.3(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Administrative Assumptions</U>. For the avoidance of doubt, the Corporate Taxpayer shall be entitled to make
reasonable simplifying assumptions in making determinations contemplated by this Agreement, including reasonable assumptions regarding basis recovery periods based on available balance sheet information (and the parties hereby agree that that the
Corporate Taxpayer&#146;s determination of the Realized Tax Benefit and Realized Tax Detriment with respect to U.S. state and local Taxes may or may not take into account jurisdiction-specific U.S. state and local adjustments to the U.S. federal
taxable income base or to the U.S. federal rules regarding the utilization of tax attribute carryovers based on the administrative burden of such calculation, as reasonably determined by the Corporate Taxpayer after consultation with its accounting
and tax advisors and the TRA Party Representative). Notwithstanding anything to the contrary, to the extent the Corporate Taxpayer reasonably determines (in consultation with its accounting and tax advisors and the TRA Party Representative) that the
administrative burden and costs associated with calculating the Tax Attributes with respect to any subsidiary of OpCo would materially outweigh the Tax Benefit Payment attributable to such Tax Attributes, the Corporate Taxpayer shall be permitted to
determine that such Tax Attributes shall not be treated as Tax Attributes for all purposes of this Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexdtoc401831_6">
</A>Section&nbsp;2.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Procedures, Amendments</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Procedure</U>. Every time the
Corporate Taxpayer delivers to a TRA Party an applicable Schedule under this Agreement, including any Amended Schedule delivered pursuant to Section&nbsp;2.3(b), and any Early Termination Schedule or amended Early Termination Schedule, the Corporate
Taxpayer shall also (x)&nbsp;deliver to such TRA Party supporting schedules, valuation reports, if any, and work papers, as determined by the Corporate Taxpayer or reasonably requested by such TRA Party, providing reasonable detail regarding data
and calculations that were relevant for the preparation of the Schedule, and (y)&nbsp;allow the TRA Party Representative and its advisors reasonable access to the appropriate representatives at the Corporate Taxpayer or its advisors, as determined
by the Corporate Taxpayer, at the relevant accounting firm that prepared the applicable Schedule, if applicable, in connection with the review of such Schedule. Without limiting the generality of the preceding sentence, the Corporate Taxpayer shall
ensure that each Tax Benefit Schedule or Early Termination Schedule delivered to a TRA Party, together with any supporting schedules and work papers, provides a reasonably detailed presentation of the calculation of the Actual Tax Liability (the
&#147;with&#148; calculation), the Hypothetical Tax Liability (the &#147;without&#148; calculation), and identifies any material assumptions or operating procedures or principles that were used for purposes of such calculations. An applicable
Schedule or amendment thereto shall become final and binding on all parties thirty (30)&nbsp;calendar days from the date on which all relevant TRA Parties </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-12- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
are treated as having received the applicable Schedule or amendment thereto under Section&nbsp;7.1 unless the TRA Party Representative (i)&nbsp;within thirty (30)&nbsp;calendar days from such
date provides the Corporate Taxpayer with notice of an objection to such Schedule or amendment setting forth in reasonable detail the basis of such objection (&#147;<U>Objection Notice</U>&#148;) or (ii)&nbsp;provides a written waiver of such right
of any Objection Notice within the period described in clause (i)&nbsp;above, in which case such Schedule or amendment thereto shall become binding on the date such waiver is received by the Corporate Taxpayer. If the Corporate Taxpayer and the TRA
Party Representative, for any reason, are unable to successfully resolve the issues raised in the Objection Notice within thirty (30)&nbsp;calendar days after receipt by the Corporate Taxpayer of an Objection Notice, the Corporate Taxpayer and the
TRA Party Representative shall employ the reconciliation procedures described in Section&nbsp;7.9 of this Agreement (the &#147;<U>Reconciliation Procedures</U>&#148;). The TRA Party Representative will represent the interests of each of the TRA
Parties and shall raise and pursue, in accordance with this Section&nbsp;2.3(a), any objection to a Schedule or amendment thereto timely given in writing to the TRA Party Representative by a TRA Party unless the TRA Party Representative determines
in its sole discretion that such objection is unlikely to be accepted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Amended Schedule</U>. The applicable
Schedule for any Taxable Year may be amended from time to time by the Corporate Taxpayer (i)&nbsp;in connection with a Determination affecting such Schedule, (ii)&nbsp;to correct inaccuracies in the Schedule, including those identified as a result
of the receipt of additional factual information relating to a Taxable Year after the date the Schedule was provided to a TRA Party, (iii)&nbsp;to comply with the Expert&#146;s determination under the Reconciliation Procedures, (iv)&nbsp;to reflect
a change in the Realized Tax Benefit or Realized Tax Detriment for such Taxable Year attributable to a carryback or carryforward of a loss or other tax item to such Taxable Year, (v)&nbsp;to reflect a change in the Realized Tax Benefit or Realized
Tax Detriment for such Taxable Year attributable to an amended Tax Return filed for such Taxable Year, or (vi)&nbsp;to adjust an applicable Basis Schedule to take into account payments made pursuant to this Agreement (any such Schedule, an
&#147;<U>Amended Schedule</U>&#148;). The Corporate Taxpayer shall provide an Amended Schedule to each TRA Party within thirty (30)&nbsp;calendar days of the occurrence of an event referenced in clauses (i)&nbsp;through (vi) of the preceding
sentence. In the event a Schedule is amended after such Schedule becomes final pursuant to Section&nbsp;2.3(a) or, if applicable, Section&nbsp;7.9, (A) the Amended Schedule shall not be taken into account in calculating any Tax Benefit Payment in
the Taxable Year to which the amendment relates but instead shall be taken into account in calculating the Cumulative Net Realized Tax Benefit for the Taxable Year in which the amendment actually occurs, and (B)&nbsp;as a result of the foregoing,
any increase of the Net Tax Benefit attributable to an Amended Schedule shall accrue the Interest Amount (or any other interest hereunder) after the due date (without extensions) for filing the United States federal income tax return of the
Corporate Taxpayer for the Taxable Year in which the amendment actually occurs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexdtoc401831_7"></A>Section&nbsp;2.4&nbsp;&nbsp;&nbsp;&nbsp;<U>Tax Classifications; Elections</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Exchange Basis Adjustments</U>. The parties to this Agreement acknowledge and agree to treat (A)&nbsp;to the
fullest extent permitted by law each Direct Exchange as giving rise to Exchange Basis Adjustments and (B)&nbsp;to the fullest extent permitted by law each other Future Exchange using cash or Class&nbsp;A Shares contributed to OpCo by the Corporate
Taxpayer as a direct purchase of Units by the Corporate Taxpayer from the applicable TRA Party pursuant to Section&nbsp;707(a)(2)(B) of the Code and as giving rise to Exchange Basis Adjustments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Section 754 Election</U>. For the Taxable Year that includes the date hereof and for each Taxable Year in which
a Future Exchange occurs and with respect to which the Corporate Taxpayer has obligations under this Agreement, the Corporate Taxpayer, in its capacity as the sole managing member of OpCo, shall ensure that OpCo and each of OpCo&#146;s direct and
indirect Subsidiaries that is treated as a partnership for United States federal income tax purposes (but only if such indirect Subsidiaries are held only through Subsidiaries treated as partnerships or disregarded entities) have in effect (and with
respect to any Subsidiary that is not wholly-owned, OpCo shall use commercially reasonable efforts to cause such Subsidiary to have in effect) an election under Section&nbsp;754 of the Code (and under any similar provisions of applicable U.S. state
or local law) for each such Taxable Year to the extent eligible to make such election. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-13- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="annexdtoc401831_8"></A>ARTICLE III </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>TAX BENEFIT PAYMENTS</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexdtoc401831_9"></A>Section 3.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Payments</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Payments</U>. Within five (5)&nbsp;Business Days after a Tax Benefit Schedule delivered to a TRA Party becomes
final in accordance with Section&nbsp;2.3(a), or, if applicable, Section&nbsp;7.9, the Corporate Taxpayer shall pay such TRA Party for such Taxable Year the Tax Benefit Payment determined pursuant to Section&nbsp;3.1(b) that is Attributable to such
TRA Party. Each such Tax Benefit Payment shall be made by wire transfer of immediately available funds to the bank account previously designated by such TRA Party to the Corporate Taxpayer or as otherwise agreed by the Corporate Taxpayer and such
TRA Party. The payments provided for pursuant to the above sentence shall be computed separately for each TRA Party. For the avoidance of doubt, no Tax Benefit Payment shall be made in respect of estimated tax payments, including federal estimated
income tax payments. Notwithstanding anything to the contrary in this Agreement, with respect to each Future Exchange by or with respect to any TRA Party, if such TRA Party notifies the Corporate Taxpayer in writing of a stated maximum selling price
(within the meaning of Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;15A.453-1(c)(2)),</FONT> then the aggregate Tax Benefit Payments to such TRA Party in respect of such Future Exchange (other than amounts accounted for as
interest under the Code) shall not exceed such stated maximum selling price.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;A &#147;<U>Tax Benefit
Payment</U>&#148; in respect of a TRA Party for a Taxable Year means an amount, not less than zero, equal to the sum of the portion of the Net Tax Benefit that is Attributable to such TRA Party and the Interest Amount with respect thereto. For the
avoidance of doubt, for Tax purposes, the Interest Amount shall not be treated as interest (to the extent permitted by applicable law and other than amounts accounted for as Imputed Interest) but instead shall be treated as additional consideration
for the applicable Blocker Merger or Future Exchange, unless otherwise required by law. Subject to Section&nbsp;3.3(a), the &#147;<U>Net Tax Benefit</U>&#148; for a Taxable Year shall be an amount equal to the excess, if any, of eighty-five percent
(85%) of the Cumulative Net Realized Tax Benefit as of the end of such Taxable Year, over the total amount of payments previously made under the first sentence of Section&nbsp;3.1(a) (excluding payments attributable to Interest Amounts);
<U>provided</U> that if there is no such excess (or a deficit exists) no TRA Party shall be required to make a payment (or return a payment) to the Corporate Taxpayer in respect of any portion of any Tax Benefit Payment previously paid by the
Corporate Taxpayer to such TRA Party. The &#147;<U>Interest Amount</U>&#148; shall equal the interest on the Net Tax Benefit calculated at the Agreed Rate from the due date (without extensions) for filing the Corporate Taxpayer Return with respect
to Taxes for such Taxable Year until the Payment Date under Section&nbsp;3.1(a). The Net Tax Benefit and the Interest Amount shall be determined separately with respect to each Blocker Merger and each Future Exchange. The Net Tax Benefit and the
Interest Amount with respect to each Future Exchange shall be determined on a Unit by Unit basis by reference to the resulting Exchange Basis Adjustment to the Corporate Taxpayer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexdtoc401831_10"></A>Section&nbsp;3.2&nbsp;&nbsp;&nbsp;&nbsp;<U>No Duplicative Payments</U>. It is intended that the provisions of
this Agreement will result in the payments specified in Section&nbsp;3.1 being made to the TRA Parties and will not result in duplicative payment of any amount (including interest) required under this Agreement. The provisions of this Agreement
shall be construed in the appropriate manner to ensure such intentions are realized. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexdtoc401831_11"></A>Section&nbsp;3.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Pro Rata Payments; Coordination of Benefits With Other Tax
Receivable Agreements</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding anything in Section&nbsp;3.1 to the contrary, to the extent that the
aggregate Realized Tax Benefit of the Corporate Taxpayer with respect to the Tax Attributes is limited in a particular Taxable Year because the Corporate Taxpayer does not have sufficient taxable income, the Net Tax Benefit for the Corporate
Taxpayer shall be allocated among all TRA Parties eligible for Tax Benefit Payments under this Agreement in proportion to the respective amounts of Net Tax Benefit that would have been allocated to each such TRA Party if the Corporate Taxpayer had
sufficient taxable income so that there were no such limitation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;If for any reason (including as contemplated
by Section&nbsp;3.3(a)) the Corporate Taxpayer does not fully satisfy its payment obligations to make all Tax Benefit Payments due under this Agreement in respect of a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-14- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
particular Taxable Year, then the Corporate Taxpayer and the TRA Parties agree that (i)&nbsp;Tax Benefit Payments for such Taxable Year shall be allocated to all parties eligible for Tax Benefit
Payments under this Agreement in proportion to the relative amounts of Tax Benefit Payments that would have been allocable to each TRA Party if the Corporate Taxpayer had sufficient cash available to make such Tax Benefit Payments and (ii)&nbsp;no
Tax Benefit Payment shall be made in respect of any subsequent Taxable Year until all Tax Benefit Payments in respect of prior Taxable Years have been made in full. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Any Tax Benefit Payment or Early Termination Payment required to be made by the Corporate Taxpayer to the TRA
Parties under this Agreement shall rank senior in right of payment to any principal, interest or other amounts due and payable in respect of any similar agreement (&#147;<U>Other Tax Receivable Obligations</U>&#148;). The effect of any other similar
agreement shall not be taken into account in respect of any calculations made hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexdtoc401831_12"></A>Section&nbsp;3.4&nbsp;&nbsp;&nbsp;&nbsp;<U>Overpayments</U>. To the extent the Corporate Taxpayer makes a
payment to a TRA Party in respect of a particular Taxable Year under Section&nbsp;3.1(a) in an amount in excess of the amount of such payment that should have been made to such TRA Party in respect of such Taxable Year (taking into account
Section&nbsp;3.3) under the terms of this Agreement, then such TRA Party shall not receive further payments under Section&nbsp;3.1(a) until such TRA Party has foregone an amount of payments equal to such excess. For clarity, the operation of this
Section&nbsp;3.4 with respect to any particular TRA Party shall not affect the rights or obligations of any other TRA Party under this Agreement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="annexdtoc401831_13"></A>ARTICLE IV </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>TERMINATION</U> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexdtoc401831_14">
</A>Section&nbsp;4.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Early Termination and Breach of Agreement</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;The Corporate
Taxpayer may, terminate this Agreement with respect to all amounts payable to the TRA Parties and with respect to all of the Units held by the TRA Parties at any time by paying to each TRA Party the Early Termination Payment in respect of such TRA
Party; <U>provided</U>, <U>however</U>, that this Agreement shall only terminate upon the receipt of the entire Early Termination Payment by all TRA Parties and payments described in the next sentence, if any and <U>provided</U> <U>further</U> that
the Corporate Taxpayer may withdraw any notice to execute its termination rights under this Section&nbsp;4.1(a) prior to the time at which any Early Termination Payment has been paid. Upon payment of the entire Early Termination Payment by the
Corporate Taxpayer to all of the TRA Parties, none of the TRA Parties or the Corporate Taxpayer shall have any further payment rights or obligations under this Agreement, other than for any (i)&nbsp;Tax Benefit Payment due and payable that remains
unpaid as of the Early Termination Date and as of the date of payment of the Early Termination Payment and (ii)&nbsp;any Tax Benefit Payment due for the Taxable Year ending immediately prior to, ending with or including the date of the Early
Termination Notice (except to the extent that the amount described in clause (i)&nbsp;or this clause (ii)&nbsp;are included in the Early Termination Payment). If a Future Exchange occurs after the Early Termination Date, the Corporate Taxpayer shall
have no obligations under this Agreement with respect to such Future Exchange other than the obligations under this Section&nbsp;4.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;In the event that the Corporate Taxpayer (1)&nbsp;materially breaches any of its material obligations under this
Agreement, whether as a result of failure to make any payment when due, failure to honor any other material obligation required hereunder or by operation of law as a result of the rejection of this Agreement in a case commenced under the Bankruptcy
Code (or other similar law), all obligations hereunder shall be accelerated and such obligations shall be calculated as if an Early Termination Notice had been delivered on the date of such breach and shall include, but not be limited to,
(i)&nbsp;the Early Termination Payments calculated as if an Early Termination Notice had been delivered on the date of such breach, (ii)&nbsp;any Tax Benefit Payment in respect of a TRA Party agreed to by the Corporate Taxpayer and such TRA Party as
due and payable but unpaid as of the date of such breach, and (iii)&nbsp;any Tax Benefit Payment in respect of any TRA Party due for the Taxable Year </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-15- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ending immediately prior to, with or including the date of such breach (except to the extent included in clause (i)&nbsp;or clause (ii)); <U>provided</U>, that procedures similar to the
procedures of Section&nbsp;4.3(b) shall apply with respect to the determination of the amount payable by the Corporate Taxpayer pursuant to this sentence. Notwithstanding the foregoing, in the event that the Corporate Taxpayer breaches a material
obligation under this Agreement (and, in the case of a breach of a material obligation other than a Material Payment Default, does not cure such breach reasonably promptly upon written notice thereof), each TRA Party shall be entitled to elect to
receive the amounts set forth in clauses (i), (ii) and (iii)&nbsp;above or to seek specific performance of the terms hereof. The parties agree that the failure to make any payment due pursuant to this Agreement on the date such payment is due shall
be deemed to be a breach of a material obligation under this Agreement for all purposes of this Agreement if the TRA Party Representative provides written notice of breach of a material obligation to the Corporate Taxpayer and such breach has not
been remedied within three (3)&nbsp;months of the date of such notice (such breach, a &#147;<U>Material Payment Default</U>&#148;), and that it will not be considered to be a breach of a material obligation under this Agreement to make a payment due
pursuant to this Agreement within three (3)&nbsp;months of the date such payment is due. Notwithstanding anything in this Agreement to the contrary, it shall not be a breach of this Agreement if the Corporate Taxpayer fails to make any Tax Benefit
Payment when due to the extent that the Corporate Taxpayer (x)&nbsp;has insufficient funds, or cannot make such payment as a result of obligations imposed in connection with any Senior Obligations, and cannot take commercially reasonable actions to
obtain sufficient funds, to make such payment or (y)&nbsp;would become insolvent as a result of making such payment (in each case, as determined by the Board in good faith) (clause (x)&nbsp;and this clause (y)&nbsp;together, the &#147;<U>Liquidity
Exceptions</U>&#148;); <U>provided</U> that the interest provisions of Section&nbsp;5.2 shall apply to such late payment and any such payment obligation shall nonetheless accrue for the benefit of the TRA Parties and the Corporate Taxpayer shall
make such payment at the first opportunity that the Liquidity Exceptions do not apply, and <U>provided, further,</U> that if the Liquidity Exceptions apply and the Corporate Taxpayer declares or pays any dividend of cash to its shareholders while
any Tax Benefit Payment is due and payable and remains unpaid, then the Liquidity Exceptions shall no longer apply. In the case of a breach of a material obligation other than a Material Payment Default, the Corporate Taxpayer will not be considered
to have breached such obligation for purposes of this Section&nbsp;4.1(b) until the Corporate Taxpayer shall have been provided by the TRA Party Representative a written notice of, and a reasonable opportunity to cure, such breach and shall have
failed to cure such breach. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;In the event of a Change of Control, all obligations hereunder will be accelerated
and such obligations shall be calculated as if an Early Termination Notice had been delivered on the date of such Change of Control and shall include, without duplication, (1)&nbsp;the Early Termination Payments calculated with respect to the TRA
Parties as if the Early Termination Date is the date of such Change of Control, (2)&nbsp;any Tax Benefit Payment due and payable and that remains unpaid as of the date of such Change of Control, and (3)&nbsp;any Tax Benefit Payment in respect of any
TRA Party due for the Taxable Year ending immediately prior to, with or including the date of such Change of Control (except to the extent included in clause (1)&nbsp;or clause (2)). In the event of a Change of Control, (i)&nbsp;the TRA Parties
shall be entitled to receive the amounts set forth in clauses (1), (2) and (3)&nbsp;of the preceding sentence, (ii)&nbsp;any Early Termination Payment described in the preceding sentence shall be calculated utilizing the Valuation Assumptions by
substituting the phrase &#147;date of a Change of Control&#148; in each place &#147;Early Termination Date&#148; appears and (iii)&nbsp;Section&nbsp;4.2 and Section&nbsp;4.3 shall apply, mutatis mutandis, with respect to payments to the TRA Parties
upon the Change of Control. Upon payment by the Corporate Taxpayer of the full amount prescribed by this Section&nbsp;4.1(c) pursuant to a Change of Control, the Corporate Taxpayer shall have no further payment obligations under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexdtoc401831_15"></A>Section&nbsp;4.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Early Termination Notice</U>. If the Corporate Taxpayer chooses to
exercise its right of early termination in accordance with Section&nbsp;4.1(a) above, the Corporate Taxpayer shall deliver to each TRA Party a notice (the &#147;<U>Early Termination Notice</U>&#148;) and a schedule (the &#147;<U>Early Termination
Schedule</U>&#148;) specifying the Corporate Taxpayer&#146;s intention to exercise such right and showing in reasonable detail the calculation of the Early Termination Payment(s) due for each TRA Party. Each Early Termination Schedule shall become
final and binding on all parties thirty (30)&nbsp;calendar days from the first date on which all TRA Parties are treated as having received such Schedule or amendment thereto under Section&nbsp;7.1 unless, prior to such thirtieth calendar day, the
TRA Party Representative (a)&nbsp;provides the Corporate Taxpayer with written notice of a material objection to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-16- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such Schedule made in good faith and setting forth in reasonable detail the basis for such objection (&#147;<U>Material Objection Notice</U>&#148;) or (b)&nbsp;provides a written waiver of such
right of a Material Objection Notice, in which case such Schedule will become binding on the date the waiver is received by the Corporate Taxpayer (the &#147;<U>Early Termination Effective Date</U>&#148;). If the Corporate Taxpayer and the TRA Party
Representative, for any reason, are unable to successfully resolve the issues raised in such notice within thirty (30)&nbsp;calendar days after receipt by the Corporate Taxpayer of the Material Objection Notice, the Corporate Taxpayer and the TRA
Party Representative shall employ the Reconciliation Procedures in which case such Schedule shall become binding in accordance with Section&nbsp;7.9. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexdtoc401831_16"></A>Section&nbsp;4.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Payment upon Early Termination</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Within three (3)&nbsp;Business Days after the Early Termination Effective Date, the Corporate Taxpayer shall pay to
each TRA Party an amount equal to the Early Termination Payment in respect of such TRA Party. Such payment shall be made by wire transfer of immediately available funds to a bank account or accounts designated by each TRA Party or as otherwise
agreed by the Corporate Taxpayer and such TRA Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Early Termination Payment</U>&#148; in respect
of a TRA Party shall equal the present value, discounted at the Early Termination Rate as of the applicable Early Termination Effective Date, of all Tax Benefit Payments in respect of such TRA Party that would be required to be paid by the Corporate
Taxpayer beginning from the Early Termination Date and assuming that (i)&nbsp;the Valuation Assumptions in respect of such TRA Party are applied, (ii)&nbsp;for each Taxable Year, the Tax Benefit Payment is paid on the last day of such Taxable Year
and (iii)&nbsp;for purposes of calculating the Early Termination Rate, SOFR shall be SOFR as of the date of the Early Termination Notice. For the avoidance of doubt, an Early Termination Payment shall be made to each applicable TRA Party regardless
of whether such TRA Party has exchanged all of its Units as of the Early Termination Effective Date. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="annexdtoc401831_17"></A>ARTICLE V </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SUBORDINATION AND LATE PAYMENTS</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexdtoc401831_18"></A>Section&nbsp;5.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Subordination</U>. Notwithstanding any other provision of this
Agreement to the contrary, any Tax Benefit Payment or Early Termination Payment required to be made by the Corporate Taxpayer to the TRA Parties under this Agreement shall rank subordinate and junior in right of payment to any principal, interest or
other amounts due and payable in respect of any obligations in respect of indebtedness for borrowed money of the Corporate Taxpayer and its Subsidiaries (&#147;<U>Senior Obligations</U>&#148;), shall rank senior in right of payment to any principal,
interest or other amounts due and payable in respect of any Other Tax Receivable Obligation, and shall rank <I>pari passu</I> with all current or future unsecured obligations of the Corporate Taxpayer that are not Senior Obligations or Other Tax
Receivable Obligations. To the extent that any payment under this Agreement is not permitted to be made at the time payment is due as a result of this Section&nbsp;5.1 and the terms of agreements governing Senior Obligations, such payment obligation
nevertheless shall accrue for the benefit of TRA Parties and the Corporate Taxpayer shall make such payments at the first opportunity that such payments are permitted to be made in accordance with the terms of the Senior Obligations and
Section&nbsp;5.2 shall apply to such payment. To the extent the Corporate Taxpayer or its Subsidiaries (including OpCo and its Subsidiaries) incur, create or assume any Senior Obligations after the date hereof, the Corporate Taxpayer shall not, and
shall cause its Subsidiaries to not, agree to any provision that restricts in any material respect the amounts payable hereunder if a principal purpose of the Corporate Taxpayer agreeing to such provision is to circumvent the payment of amounts
payable hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexdtoc401831_19"></A>Section&nbsp;5.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Late Payments by the Corporate
Taxpayer</U>. The amount of all or any portion of any Tax Benefit Payment or Early Termination Payment not made to the TRA Parties when due under the terms of this Agreement, whether as a result of Section&nbsp;5.1 or otherwise, shall be payable
together with any interest thereon, computed at the Default Rate and commencing from the date on which such Tax Benefit Payment or Early Termination Payment was due and payable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-17- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="annexdtoc401831_20"></A>ARTICLE VI </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>NO DISPUTES; CONSISTENCY; COOPERATION</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexdtoc401831_21"></A>Section&nbsp;6.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Participation in the Corporate Taxpayer</U><U>&#146;</U><U>s and
OpCo</U><U>&#146;</U><U>s Tax Matters</U>. Except as otherwise provided in this Agreement, the Merger Agreement or the LLC Agreement, the Corporate Taxpayer shall have full responsibility for, and sole discretion over, all tax matters concerning the
Corporate Taxpayer and OpCo, including the preparation, filing or amending of any Tax Return and defending, contesting or settling any issue pertaining to Taxes. Notwithstanding the foregoing, the Corporate Taxpayer shall notify the TRA Party
Representative in writing of the commencement of, and keep the TRA Party Representative reasonably informed with respect to, the portion of any audit of the Corporate Taxpayer and OpCo or any of OpCo&#146;s Subsidiaries by a Taxing Authority the
outcome of which is reasonably expected to significantly and adversely affect the rights and obligations of a TRA Party under this Agreement, and shall provide to the TRA Party Representative (at its sole cost and expense) reasonable opportunity to
participate in or provide information and other input to the Corporate Taxpayer, OpCo and their respective advisors concerning the conduct of any such portion of such audit; <U>provided</U>, <U>however</U>, that the Corporate Taxpayer and OpCo shall
not be required to take any action requested by the TRA Party Representative that is inconsistent with any provision of the LLC Agreement or the Merger Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexdtoc401831_22"></A>Section&nbsp;6.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Consistency</U>. The Corporate Taxpayer and the TRA Parties agree
to report and cause their respective Affiliates to report for all purposes, including United States federal, state, local and foreign tax purposes and financial reporting purposes, all tax-related items (including the Exchange Basis Adjustments and
each Tax Benefit Payment) in a manner consistent with that set forth in this Agreement or specified by the Corporate Taxpayer in any Schedule (or Amended Schedule, as applicable) required to be provided by or on behalf of the Corporate Taxpayer
under this Agreement that is final and binding on the parties unless otherwise required by law. The Corporate Taxpayer shall (and shall cause OpCo and its other Subsidiaries to) use commercially reasonable efforts (for the avoidance of doubt, taking
into account the interests and entitlements of all TRA Parties under this Agreement) to defend the tax treatment contemplated by this Agreement and any Schedule (or Amended Schedule, as applicable) in any audit, contest or similar proceeding with
any Taxing Authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexdtoc401831_23"></A>Section&nbsp;6.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Cooperation</U>. Each of the TRA
Parties shall (a)&nbsp;furnish to the Corporate Taxpayer in a timely manner such information, documents and other materials as the Corporate Taxpayer may reasonably request for purposes of making any determination or computation necessary or
appropriate under this Agreement, preparing any Tax Return or contesting or defending any audit, examination or controversy with any Taxing Authority, (b)&nbsp;make itself available to the Corporate Taxpayer and its representatives to provide
explanations of documents and materials and such other information as the Corporate Taxpayer or its representatives may reasonably request in connection with any of the matters described in clause (a)&nbsp;above, and (c)&nbsp;reasonably cooperate in
connection with any such matter, and the Corporate Taxpayer shall reimburse each such TRA Party for any reasonable third-party costs and expenses incurred pursuant to this Section (excluding any costs or expenses which OpCo is obligated to bear
pursuant to the LLC Agreement or the Merger Agreement) . </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-18- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="annexdtoc401831_22a"></A>ARTICLE VII </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>MISCELLANEOUS</U> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexdtoc401831_23a">
</A>Section&nbsp;7.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>. All notices, requests, claims, demands and other communications hereunder shall be in writing and shall be deemed duly given and received (a)&nbsp;on the date of delivery if delivered
personally, or by facsimile or email with confirmation of transmission by the transmitting equipment or (b)&nbsp;on the first Business Day following the date of dispatch if delivered by a recognized <FONT STYLE="white-space:nowrap">next-day</FONT>
courier service. All notices hereunder shall be delivered as set forth below, or pursuant to such other instructions as may be designated in writing by the party to receive such notice: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If to the Corporate Taxpayer, to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6455 Nancy Ridge
Drive </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">San Diego, CA 92121 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention:&nbsp;Rory Riggs, Chief Executive Officer, and Wade King, MD, Chief Financial Officer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> [***] and [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">with a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Jones Day </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4655 Executive Drive,
Suite 1500 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">San Diego, CA 92121-3134 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention:&nbsp;Cameron A. Reese </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:&nbsp;[***]</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Akin Gump Strauss
Hauer&nbsp;&amp; Feld LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One Bryant Park </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">New York, NY 10036 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention:
Stuart Leblang and Jonathan Pavlich </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Email: [***] and [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If to the TRA Parties, to the address and other contact information set forth in the records of OpCo from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any party may change its address, fax number or email by giving the other party written notice of its new address, fax number or email in the manner set forth
above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexdtoc401831_24"></A>Section&nbsp;7.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterparts</U>. This Agreement may be executed in
one or more counterparts, all of which shall be considered one and the same agreement and shall become effective when one or more counterparts have been signed by each of the parties and delivered to the other parties, it being understood that all
parties need not sign the same counterpart. Delivery of an executed signature page to this Agreement by electronic transmission shall be as effective as delivery of a manually signed counterpart of this Agreement. No party shall raise the use of <FONT
STYLE="white-space:nowrap">e-mail</FONT> to deliver a signature or the fact that any signature or agreement or instrument was transmitted or communicated through the use of <FONT STYLE="white-space:nowrap">e-mail</FONT> as a defense to the formation
or enforceability of a contract and each party forever waives any such defense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexdtoc401831_25"></A>Section&nbsp;7.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Entire Agreement; Third Party Beneficiaries</U>. This Agreement
(together with all Exhibits and Schedules to this Agreement), the Merger Agreement (together with the transaction documents contemplated thereby), the LLC Agreement, and the Confidentiality Agreement constitutes the entire agreement and supersedes
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-19- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
all prior agreements and understandings, both written and oral, among the parties with respect to the subject matter hereof. This Agreement shall be binding upon and inure solely to the benefit
of each party hereto and their respective successors and permitted assigns, and nothing in this Agreement, express or implied, is intended to or shall confer upon any other Person any right, benefit or remedy of any nature whatsoever under or by
reason of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexdtoc401831_26"></A>Section&nbsp;7.4&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing Law</U>. This Agreement
shall be governed by, and construed in accordance with, the law of the State of Delaware, without regard to the conflicts of laws principles thereof that would mandate the application of the laws of another jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexdtoc401831_27"></A>Section&nbsp;7.5&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U>. If any term or other provision of this Agreement
is invalid, illegal or incapable of being enforced by any law or public policy, all other terms and provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic or legal substance of the transactions
contemplated hereby is not affected in any manner materially adverse to any party. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the parties hereto shall negotiate in good faith to
modify this Agreement so as to effect the original intent of the parties as closely as possible in an acceptable manner in order that the transactions contemplated hereby are consummated as originally contemplated to the greatest extent possible.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexdtoc401831_28"></A>Section&nbsp;7.6&nbsp;&nbsp;&nbsp;&nbsp;<U>Successors; Assignment; Amendments; Waivers</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Each TRA Party may assign any of its rights under this Agreement to any Person as long as such transferee has
executed and delivered, or, in connection with such transfer, executes and delivers, a joinder to this Agreement, in form and substance reasonably satisfactory to the Corporate Taxpayer (the &#147;<U>Joinder Requirement</U>&#148;), agreeing to
become a TRA Party for all purposes of this Agreement. If any TRA Party sells, exchanges, distributes, or otherwise transfers Units to any Person (other than the Corporate Taxpayer or the OpCo) in accordance with the terms of the Exchange Agreement
and/or LLC Agreement, such TRA Party shall have the option to assign to the transferee of such Units its rights under this Agreement with respect to such transferred Units; <U>provided</U>, <U>further</U>, that such transferee has satisfied the
Joinder Requirement. For the avoidance of doubt, if a TRA Party transfers Units in accordance with the terms of the Exchange Agreement and/or LLC Agreement but does not assign to the transferee of such Units its rights under this Agreement with
respect to such transferred Units, such TRA Party shall continue to be entitled to receive the Tax Benefit Payments arising in respect of a subsequent Future Exchange of such Units and such transferee may not enforce the provisions of this
Agreement. Notwithstanding any other provision of this Agreement, an assignee of only rights to receive a Tax Benefit Payment in connection with a Future Exchange has no rights under this Agreement other than to enforce its right to receive a Tax
Benefit Payment pursuant to this Agreement. The Corporate Taxpayer may not assign any of its rights or obligations under this Agreement to any Person (other than in connection with a Mandatory Assignment) without the prior written consent of the TRA
Party Representative (not to be unreasonably withheld, conditioned or delayed). Any purported assignment in violation of the terms of this Section&nbsp;7.6 shall be null and void. The implementation of this Section&nbsp;7.6(a) is intended to be a
&#147;book entry system&#148; as defined in Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;5f.103-1(c),</FONT> and this Section&nbsp;7.6(a) shall be interpreted consistently therewith, so that rights under this Agreement are at
all times maintained in &#147;registered form&#148; for purposes of the Code and Treasury Regulations. The Corporate Taxpayer shall maintain a register of any Person entitled to payments under this Agreement, and no Person shall be entitled to any
payment under this Agreement unless such Person&#146;s name appears on such register. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;No provision of this
Agreement may be amended unless such amendment is approved in writing by the Corporate Taxpayer and by the TRA Party Representative and no provision of this Agreement may be waived unless such waiver is in writing and signed by the party against
whom the waiver is to be effective (or, in the case of a waiver by all TRA Parties, signed by the TRA Party Representative); <U>provided</U> that no such amendment or waiver shall be effective if such amendment or waiver will have a disproportionate
and adverse effect on the payments certain TRA Parties will or may receive under this Agreement unless such amendment or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-20- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
waiver is consented in writing by the TRA Parties disproportionately and adversely affected who would be entitled to receive at least majority of the total amount of the Early Termination
Payments payable to all TRA Parties disproportionately and adversely affected hereunder if the Corporate Taxpayer had exercised its right of early termination on the date of the most recent Future Exchange prior to such amendment or waiver
(excluding, for purposes of this sentence, all payments made to any TRA Party pursuant to this Agreement since the date of such most recent Future Exchange). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;All of the terms and provisions of this Agreement shall be binding upon, shall inure to the benefit of and shall be
enforceable by the parties hereto and their respective successors, assigns, heirs, executors, administrators and legal representatives. The Corporate Taxpayer shall require and cause any direct or indirect successor (whether by purchase, merger,
consolidation or otherwise) to all or substantially all of the business or assets of the Corporate Taxpayer, by written agreement, expressly to assume and agree to perform this Agreement in the same manner and to the same extent that the Corporate
Taxpayer would be required to perform if no such succession had taken place (any such assignment, a &#147;<U>Mandatory Assignment</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexdtoc401831_29"></A>Section&nbsp;7.7&nbsp;&nbsp;&nbsp;&nbsp;<U>Titles and Subtitles</U>. The titles of the sections and
subsections of this Agreement are for convenience of reference only and are not to be considered in construing this Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexdtoc401831_30">
</A>Section&nbsp;7.8&nbsp;&nbsp;&nbsp;&nbsp;<U>Waiver of Jury Trial, Jurisdiction</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;EACH PARTY TO THIS
AGREEMENT HEREBY IRREVOCABLY WAIVES ALL RIGHTS TO TRIAL BY JURY IN ANY PROCEEDING BROUGHT TO RESOLVE ANY DISPUTE BETWEEN OR AMONG ANY OF THE PARTIES (WHETHER ARISING IN CONTRACT, TORT OR OTHERWISE) ARISING OUT OF, CONNECTED WITH, RELATED OR
INCIDENTAL TO THIS AGREEMENT, THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT AND/OR THE RELATIONSHIPS ESTABLISHED AMONG THE PARTIES HEREUNDER. THE PARTIES HERETO FURTHER WARRANT AND REPRESENT THAT EACH HAS REVIEWED THIS WAIVER WITH ITS LEGAL
COUNSEL, AND THAT EACH KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Subject to Section&nbsp;7.9, each of the parties submits to the exclusive jurisdiction of first, the Chancery Court
of the State of Delaware or if such court declines jurisdiction, then to the Federal District Court for the District of Delaware, in any action, suit or proceeding arising out of or relating to this Agreement, agrees that all claims in respect of
such action, suit or proceeding shall be heard and determined in any such court and agrees not to bring any action, suit or proceeding arising out of or relating to this Agreement in any other courts. Nothing in this Section&nbsp;7.8, however, shall
affect the right of any party to serve legal process in any other manner permitted by law or at equity. Each party agrees that a final judgment in any action, suit or proceeding so brought shall be conclusive and may be enforced by suit on the
judgment or in any other manner provided by law or at equity. The parties hereby waive, to the fullest extent permitted by applicable law, any objection which they now or hereafter may have to personal jurisdiction or to the laying of venue of any
such ancillary suit, action or proceeding brought in any court referred to in this Section&nbsp;7.8 and such parties agree not to plead or claim the same. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexdtoc401831_31"></A>Section&nbsp;7.9&nbsp;&nbsp;&nbsp;&nbsp;<U>Reconciliation</U>. In the event that the Corporate Taxpayer and
the TRA Party Representative are unable to resolve a disagreement with respect to the matters (x)&nbsp;governed by Section 2.3 and 4.2 or (y)&nbsp;described in the definition of &#147;SOFR&#148; within the relevant period designated in this
Agreement (&#147;<U>Reconciliation Dispute</U>&#148;), the Reconciliation Dispute shall be submitted for determination to a nationally recognized expert (the &#147;<U>Expert</U>&#148;) in the particular area of disagreement mutually acceptable to
both parties. The Expert shall be a partner or principal in a nationally recognized accounting or law firm, and unless the Corporate Taxpayer and the TRA Party Representative agree in writing otherwise, the Expert shall not, and the firm that
employs the Expert shall not, have any material relationship with the Corporate Taxpayer, the TRA Party Representative, any relevant TRA Party or other actual or potential conflict of interest. If the Corporate Taxpayer and the TRA Party
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-21- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Representative are unable to agree on an Expert within fifteen (15)&nbsp;calendar days of receipt by the respondent(s) of written notice of a Reconciliation Dispute, the Expert shall be appointed
by the International Chamber of Commerce Centre for Expertise. The Expert shall resolve any matter relating to the Basis Schedule or an amendment thereto or the Early Termination Schedule or an amendment thereto within thirty (30)&nbsp;calendar days
and shall resolve any matter relating to a Tax Benefit Schedule or an amendment thereto within fifteen (15)&nbsp;calendar days or as soon thereafter as is reasonably practicable, in each case after the matter has been submitted to the Expert for
resolution. Notwithstanding the preceding sentence, if the matter is not resolved before any payment that is the subject of a disagreement would be due (in the absence of such disagreement) or any Tax Return reflecting the subject of a disagreement
is due, the undisputed amount shall be paid on the date prescribed by this Agreement and such Tax Return may be filed as prepared by the Corporate Taxpayer, subject to adjustment or amendment upon resolution. The costs and expenses relating to the
engagement of such Expert or amending any Tax Return shall be borne by the Corporate Taxpayer except as provided in the next sentence. The Corporate Taxpayer and the TRA Party Representative shall bear their own costs and expenses of such
proceeding, unless (i)&nbsp;the Expert adopts the TRA Party Representative&#146;s position, in which case the Corporate Taxpayer shall reimburse the TRA Party Representative for any reasonable <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs and expenses in such proceeding, or (ii)&nbsp;the Expert adopts the Corporate Taxpayer&#146;s position, in which case the TRA Party Representative shall reimburse the Corporate Taxpayer
for any reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs and expenses in such proceeding. Any dispute as to whether a dispute is a Reconciliation Dispute within the meaning of this
Section&nbsp;7.9 shall be decided by the Expert. The Expert shall finally determine any Reconciliation Dispute and the determinations of the Expert pursuant to this Section&nbsp;7.9 shall be binding on the Corporate Taxpayer and each of the TRA
Parties and may be entered and enforced in any court having jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexdtoc401831_32"></A>Section&nbsp;7.10&nbsp;&nbsp;&nbsp;&nbsp;<U>Withholding</U>. The Corporate Taxpayer and its agents shall be
entitled to deduct and withhold from any payment payable pursuant to this Agreement such amounts as the Corporate Taxpayer is required to deduct and withhold with respect to the making of such payment under the Code or any provision of state, local
or foreign tax law; provided, however, that the Corporate Taxpayer shall use commercially reasonable efforts to notify and shall reasonably cooperate with the applicable TRA Party prior to the making of such deductions and withholding payments to
determine whether any such deductions or withholding payments (other than any deduction or withholding required by reason of such TRA Party&#146;s failure to comply with the last sentence of this Section&nbsp;7.10) are required under applicable law
and in obtaining any available exemption or reduction of, or otherwise minimizing to the extent permitted by applicable law, such deduction and withholding. To the extent that amounts are so withheld and timely paid over to the appropriate Taxing
Authority by the Corporate Taxpayer, such withheld amounts shall be treated for all purposes of this Agreement as having been paid to the Person in respect of whom such withholding was made. Each TRA Party shall promptly provide the Corporate
Taxpayer with any applicable tax forms and certifications (including IRS Form <FONT STYLE="white-space:nowrap">W-9</FONT> or the applicable version of IRS Form <FONT STYLE="white-space:nowrap">W-8)</FONT> reasonably requested by the Corporate
Taxpayer in connection with determining whether any such deductions and withholdings are required under the Code or any provision of state, local or foreign tax law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexdtoc401831_33"></A>Section&nbsp;7.11&nbsp;&nbsp;&nbsp;&nbsp;<U>Admission of the Corporate Taxpayer into a Consolidated Group;
Transfers of Corporate Assets</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;If the Corporate Taxpayer is or becomes a member of an affiliated,
consolidated, combined or unitary group of corporations that files a consolidated, combined or unitary income Tax Return pursuant to Sections 1501 et seq. of the Code or any corresponding provisions of state, local or foreign tax law, then:
(i)&nbsp;the provisions of this Agreement shall be applied with respect to the group as a whole; and (ii)&nbsp;Tax Benefit Payments, Early Termination Payments and other applicable items hereunder shall be computed with reference to the
consolidated, combined or unitary taxable income of the group as a whole. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;If any Person the income of which is
included in the income of the Corporate Taxpayer or the Corporate Taxpayer&#146;s affiliated or consolidated group transfers one or more Reference Assets to a corporation (or a Person classified as a corporation for U.S. federal income tax purposes)
with which such entity does not file a consolidated Tax Return pursuant to Section&nbsp;1501 of the Code or any corresponding provisions of state, local or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-22- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
foreign tax law and which such entity&#146;s income is not included in the income of the Corporate Taxpayer or the Corporate Taxpayer&#146;s affiliated or consolidated group, such Person, for
purposes of calculating the amount of any Tax Benefit Payment or Early Termination Payment due hereunder, shall be treated as having disposed of such asset in a fully taxable transaction on the date of such transfer. The consideration deemed to be
received in a transaction contemplated in the prior sentence shall be equal to the fair market value of the deemed transferred asset (as determined by an independent expert mutually agreed upon by the Corporate Taxpayer and the TRA Party
Representative, unless such condition is waived by the TRA Party Representative) on a gross basis, i.e., disregarding (i)&nbsp;the amount of debt to which such asset is subject, in the case of a transfer of an encumbered asset or (ii)&nbsp;the
amount of debt allocated to such asset, in the case of a transfer of a partnership interest. The transactions described in this Section&nbsp;7.11(b) shall be taken into account in determining the Realized Tax Benefit or Realized Tax Detriment, as
applicable, for such Taxable Year based on the income, gain or loss deemed allocated to the Corporate Taxpayer using the <FONT STYLE="white-space:nowrap">Non-Stepped</FONT> Up Tax Basis of the Reference Assets in calculating its Hypothetical Tax
Liability for such Taxable Year and using the actual tax basis of the Reference Assets in calculating its Actual Tax Liability, determined using the &#147;with and without&#148; methodology. Thus, for example, in determining the Hypothetical Tax
Liability of the Corporate Taxpayer the taxable income of the Corporate Taxpayer shall be determined by treating OpCo as having sold the applicable Reference Asset for its fair market value, recovering any basis applicable to such Reference Asset
(using the <FONT STYLE="white-space:nowrap">Non-Stepped</FONT> Up Tax Basis), while the Actual Tax Liability of the Corporate Taxpayer would be determined by recovering the actual tax basis of the Reference Asset that reflects any Exchange Basis
Adjustments. For purposes of this Section&nbsp;7.11, a transfer of a partnership interest (including, for the avoidance of doubt, a Unit) or an election by any Person the income of which is included in the income of Corporate Taxpayer to be treated
as a corporation for U.S. federal income tax purposes (or other applicable provisions of state and local and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax laws) shall be treated as a transfer of the transferring partner&#146;s share of each
of the assets and liabilities of that partnership. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexdtoc401831_34"></A>Section&nbsp;7.12&nbsp;&nbsp;&nbsp;&nbsp;<U>Confidentiality</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Each TRA Party and each of their respective assignees acknowledges and agrees that the information of the Corporate
Taxpayer is confidential and, except in the course of performing any duties as necessary for the Corporate Taxpayer and its Affiliates, as required by law or legal process or to enforce the terms of this Agreement, such Person shall keep and retain
in confidence in accordance with this Agreement, and not disclose to any Person, any confidential matters acquired pursuant to this Agreement of the Corporate Taxpayer and its Affiliates and successors, concerning OpCo and its Affiliates and
successors or the holders of Units, learned by the TRA Party heretofore or hereafter. This Section&nbsp;7.12 shall not apply to (i)&nbsp;any information that has been made publicly available by the Corporate Taxpayer or any of its Affiliates,
becomes public knowledge (except as a result of an act of the TRA Party in violation of this Agreement) or is generally known, (ii)&nbsp;the disclosure of information to the extent necessary for the TRA Party to assert its rights hereunder or defend
itself in connection with any action or proceeding arising out of, or relating to, this Agreement, (iii)&nbsp;any information that was in the possession of, or becomes available to, the TRA Party from a source other than the Corporate Taxpayer, its
Affiliates or its or their respective representatives (<U>provided</U> that such source is not known by the TRA Party to be bound by a legal, contractual or fiduciary confidentiality obligation not to disclose such information) and (iv)&nbsp;the
disclosure of information to the extent necessary for the TRA Party to prepare and file its Tax Returns, to respond to any inquiries regarding the same from any governmental or taxing authority or to prosecute or defend any action, proceeding or
audit by any governmental or taxing authority with respect to such returns. Notwithstanding anything to the contrary herein, each TRA Party and each of their assignees (and each employee, representative or other agent of the TRA Party or its
assignees, as applicable) may disclose to any and all Persons the tax treatment and tax structure of the Corporate Taxpayer, OpCo and their Affiliates, and any of their transactions, and all materials of any kind (including opinions or other tax
analyses) that are provided to the TRA Party relating to such tax treatment and tax structure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;If a TRA Party
or an assignee commits a breach, or threatens to commit a breach, of any of the provisions of this Section&nbsp;7.12, the Corporate Taxpayer shall have the right and remedy to seek to have the provisions of this Section&nbsp;7.12 specifically
enforced by injunctive relief or otherwise by any court of competent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-23- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
jurisdiction without the need to post any bond or other security, it being acknowledged and agreed that any such breach or threatened breach will cause irreparable injury to the Corporate
Taxpayer or any of its Affiliates and that money damages alone will not provide an adequate remedy. Such rights and remedies shall be in addition to, and not in lieu of, any other rights and remedies available at law or in equity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexdtoc401831_35"></A>Section&nbsp;7.13&nbsp;&nbsp;&nbsp;&nbsp;<U>Change in Law</U>. Notwithstanding anything herein to the
contrary, if, in connection with an actual or proposed change in law, a TRA Party reasonably believes that the existence of this Agreement could cause income (other than income arising from receipt of a payment under this Agreement) recognized by
the TRA Party upon any Future Exchange by such TRA Party to be treated as ordinary income rather than capital gain (or otherwise taxed at ordinary income rates) for United States federal income tax purposes or would have other material adverse tax
consequences to such TRA Party, then at the election of such TRA Party and to the extent specified by such TRA Party, this Agreement (i)&nbsp;shall cease to have further effect with respect to such TRA Party, (ii)&nbsp;shall not apply to a Future
Exchange by such TRA Party occurring after a date specified by such TRA Party, or (iii)&nbsp;shall otherwise be amended in a manner determined by such TRA Party; <U>provided</U> that such amendment shall not result in an increase in payments under
this Agreement at any time as compared to the amounts and times of payments that would have been due in the absence of such amendment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexdtoc401831_36">
</A>Section&nbsp;7.14&nbsp;&nbsp;&nbsp;&nbsp;<U>Independent Nature of TRA Parties</U><U>&#146;</U><U> Rights and Obligations</U>. The obligations of each TRA Party hereunder are several and not joint with the obligations of any other TRA Party, and
no TRA Party shall be responsible in any way for the performance of the obligations of any other TRA Party hereunder. The decision of each TRA Party to enter into this Agreement has been made by such TRA Party independently of any other TRA Party.
Nothing contained herein, and no action taken by any TRA Party pursuant hereto, shall be deemed to constitute the TRA Parties as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the TRA Parties
are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated hereby and the Corporate Taxpayer acknowledges that the TRA Parties are not acting in concert or as a group, and the Corporate Taxpayer
will not assert any such claim, with respect to such obligations or the transactions contemplated hereby. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexdtoc401831_37"></A>Section&nbsp;7.15&nbsp;&nbsp;&nbsp;&nbsp;<U>TRA Party Representative</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Without further action of any of the Corporate Taxpayer, the TRA Party Representative or any TRA Party, and as
partial consideration in respect of the benefits conferred by this Agreement, the TRA Party Representative is hereby irrevocably constituted and appointed as the TRA Party Representative, with full power of substitution, to take any and all actions
and make any decisions required or permitted to be taken by the TRA Party Representative under this Agreement. The TRA Party Representative agrees that with respect to any material notice, information or other communication it receives from the
Corporate Taxpayer in its capacity as a TRA Party Representative, it will promptly share such notice, information or communication with each TRA Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;If at any time the TRA Party Representative shall incur out of pocket expenses in connection with the exercise of
its duties hereunder, upon written notice to the Corporate Taxpayer from the TRA Party Representative of documented costs and expenses (including fees and disbursements of counsel and accountants) incurred by the TRA Party Representative in
connection with the performance of its rights or obligations under this Agreement and the taking of any and all actions in connection therewith, the Corporate Taxpayer shall reduce the future payments (if any) due to the TRA Parties hereunder pro
rata by the amount of such expenses which it shall instead remit directly to the TRA Party Representative (provided that, for applicable tax purposes, such amounts will be deemed to be distributed first to the TRA Parties and then paid over to the
TRA Party Representative by the TRA Parties). In connection with the performance of its rights and obligations under this Agreement and the taking of any and all actions in connection therewith, the TRA Party Representative shall not be required to
expend any of its own funds (though, for the avoidance of doubt but without limiting the provisions of this Section&nbsp;7.15(b), it may do so at any time and from time to time in its sole discretion). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-24- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;The TRA Party Representative shall not be liable to any TRA Party
for any act of the TRA Party Representative arising out of or in connection with the acceptance or administration of its duties under this Agreement, except to the extent any liability, loss, damage, penalty, fine, cost or expense is actually
incurred by such TRA Party as a proximate result of the bad faith or willful misconduct of the TRA Party Representative (it being understood that any act done or omitted pursuant to the advice of legal counsel shall be conclusive evidence of such
good faith judgment). The TRA Party Representative shall not be liable for, and shall be indemnified by the TRA Parties (on a several but not joint basis) for, any liability, loss, damage, penalty or fine incurred by the TRA Party Representative
(and any cost or expense incurred by the TRA Party Representative in connection therewith and herewith and not previously reimbursed pursuant to subsection (b)&nbsp;above) arising out of or in connection with the acceptance or administration of its
duties under this Agreement, and such liability, loss, damage, penalty, fine, cost or expense shall be treated as an expense subject to reimbursement pursuant to the provisions of subsection (b)&nbsp;above, except to the extent that any such
liability, loss, damage, penalty, fine, cost or expense is the proximate result of the bad faith or willful misconduct of the TRA Party Representative (it being understood that any act done or omitted pursuant to the advice of legal counsel shall be
conclusive evidence of such good faith judgment); <U>provided</U>, however, in no event shall any TRA Party be obligated to indemnify the TRA Party Representative hereunder for any liability, loss, damage, penalty, fine, cost or expense to the
extent (and only to the extent) that the aggregate amount of all liabilities, losses, damages, penalties, fines, costs and expenses indemnified by such TRA Party hereunder is or would be in excess of the aggregate payments under this Agreement
actually remitted to such TRA Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;Subject to Section&nbsp;7.6(b), a decision, act, consent or instruction
of the TRA Party Representative shall constitute a decision of all TRA Parties and shall be final, binding and conclusive upon each TRA Party, and the Corporate Taxpayer may rely upon any decision, act, consent or instruction of the TRA Party
Representative as being the decision, act, consent or instruction of each TRA Party. The Corporate Taxpayer is hereby relieved from any liability to any person for any acts done by the Corporate Taxpayer in accordance with any such decision, act,
consent or instruction of the TRA Party Representative. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I></I>[<I>The remainder of this page is intentionally blank</I>]<I> </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-25- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Corporate Taxpayer, the TRA Party Representative and each TRA Party
have duly executed this Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U>CORPORATE TAXPAYER:</U></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[&#9679;]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">[&#9679;]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">[&#9679;]</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page &#150;
Tax Receivable Agreement] </I></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Corporate Taxpayer, the TRA Party Representative and each TRA Party
have duly executed this Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U>TRA PARTY REPRESENTATIVE:</U></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">[&#9679;]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">[&#9679;]</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">[&#9679;]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">[&#9679;]</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">[&#9679;]</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page &#150;
Tax Receivable Agreement] </I></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Corporate Taxpayer, the TRA Party Representative and each TRA Party
have duly executed this Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B><U>TRA PARTIES:</U></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">[&#9679;]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(Signature)</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page &#150;
Tax Receivable Agreement] </I></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="rom401831_70"></A>ANNEX E </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Execution Version </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXCHANGE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">EXCHANGE AGREEMENT (this &#147;<B><I>Agreement</I></B>&#148;), dated as of [&#9679;], 2023, by and among Cibus, Inc. (f/k/a Calyxt, Inc.), a
Delaware corporation, Cibus Global, LLC, a Delaware limited liability company, and the holders from time to time party hereto, other than the Corporation (as defined herein), of Common Units (as defined herein) from time to time party hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the parties hereto desire to provide for the redemption and/or exchange of Paired Interests (as defined herein), on the terms and
subject to the conditions set forth herein and the OpCo LLC Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the mutual covenants and
undertakings contained herein and for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;1.1 <U>Definitions</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following definitions shall be for all purposes, unless otherwise clearly indicated to the contrary, applied to the terms used in this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Appraiser FMV</I></B>&#148; means the fair market value of a Class&nbsp;A Common Share as determined by an
independent appraiser mutually agreed upon by the Corporation and the relevant Exchanging Member (such agreement not to be unreasonably withheld), whose determination shall be final and binding for those purposes for which Appraiser FMV is used in
this Agreement. Appraiser FMV shall be the fair market value determined without regard to any discounts for minority interest, illiquidity or other discounts. The cost of any independent appraisal in connection with the determination of Appraiser
FMV in accordance with this Agreement shall be borne by OpCo. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Board</I></B>&#148; means the Board of Directors of the
Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Business Day</I></B>&#148; means a day other than a Saturday, Sunday or other day on which commercial banks in
New York, New York are authorized or required by Law to close. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Cash Exchange Class&nbsp;A 5-Day VWAP</I></B>&#148; means the
arithmetic average of the VWAP for each of the five (5)&nbsp;consecutive Trading Days ending on the Trading Day immediately prior to the Exchange Notice Date (in the case of an Unrestricted Exchange) or the Exchange Date (in the case of any other
Exchange). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Cash Exchange Notice</I></B>&#148; has the meaning set forth in <U>Section&nbsp;2.1(c)</U> of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Cash Exchange Payment</I></B>&#148; means, with respect to the portion of any Exchange for which a Cash Exchange Notice is
delivered by the Corporation and the Corporation has elected to make a Cash Exchange Payment in accordance with <U>Section&nbsp;2.1(c)</U>: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) if the Class&nbsp;A Common Shares trade on a National Securities Exchange or automated or electronic quotation system, an amount of cash
equal to the product of: (x)&nbsp;the number of Class&nbsp;A Common Shares that would have been received by the Exchanging Member in the Exchange for that portion of the Paired Interests subject to a Cash Exchange Notice, had such Paired Interests
not been subject to a Cash Exchange Notice and OpCo or the Corporation, as applicable, had paid the Stock Exchange Payment with respect to such number of Paired Interests, and (y)&nbsp;the Cash Exchange Class&nbsp;A 5-Day VWAP; or </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) if Class&nbsp;A Common Shares are not then traded on a National Securities Exchange or
automated or electronic quotation system, as applicable, an amount of cash equal to the product of (x)&nbsp;the number of Class&nbsp;A Common Shares that would have been received by the Exchanging Member in the Exchange for that portion of the
Paired Interests subject to a Cash Exchange Notice, had such Paired Interests not been subject to a Cash Exchange Notice and OpCo or the Corporation, as applicable, had paid the Stock Exchange Payment with respect to such number of Paired Interests,
and (y)&nbsp;the Appraiser FMV of one (1)&nbsp;Class&nbsp;A Common Share that would be obtained in an arms-length transaction between an informed and willing buyer and an informed and willing seller, neither of whom is under any compulsion to buy or
sell, respectively, and without regard to the particular circumstances of the buyer or seller. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Certificate
Delivery</I></B>&#148; means, in the case of any Class B Common Shares to be transferred and surrendered by an Exchanging Member in connection with an Exchange which are represented by a certificate or certificates, the process by which the
Exchanging Member shall also present and surrender such certificate or certificates representing such Class B Common Shares during normal business hours at the principal executive offices of the Corporation, or if any agent for the registration or
transfer of Class B Common Shares is then duly appointed and acting, at the office of such transfer agent, along with any instruments of transfer reasonably required by the Corporation or such transfer agent, as applicable, duly executed by the
Exchanging Member or the Exchanging Member&#146;s duly authorized representative. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Change of Control</I></B>&#148; has the
meaning given to such term in the Tax Receivable Agreement; <I>provided</I> that, for the avoidance of doubt, any event that constitutes both a Pubco Offer and a Change of Control of the Corporation shall be considered a Pubco Offer for purposes of
this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Class A Common Shares</I></B>&#148; means the shares of Class&nbsp;A Common Stock of the Corporation, par
value $0.0001 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Class B Common Shares</I></B>&#148; means the shares of Class B Common Stock of the Corporation, par
value $0.0001 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Code</I></B>&#148; means the U.S. Internal Revenue Code of 1986, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Commission</I></B>&#148; means the U.S. Securities and Exchange Commission, including any Governmental Entity succeeding to the
functions thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Common Units</I></B>&#148; means the units of OpCo designated as a &#147;Common Unit<B><I>s</I></B>&#148;
pursuant to the OpCo LLC Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Corporation</I></B>&#148; means Cibus, Inc., a Delaware corporation, and any successor
thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Direct Exchange</I></B>&#148; has the meaning set forth in <U>Section 2.6</U> of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I></I></B>&#147;<B><I>Direct Exchange Election Notice</I></B>&#148; has the meaning set forth in <U>Section 2.6</U> of this
Agreement.<B><I> </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Exchange</I></B>&#148; has the meaning set forth in <U>Section 2.1(a)</U> of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Exchange Act</I></B>&#148; means the U.S. Securities Exchange Act of 1934, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Exchange Blackout Period</I></B>&#148; means (i)&nbsp;any &#147;black out&#148; or similar period under the Corporation&#146;s
policies covering trading in the Corporation&#146;s securities to which the applicable Exchanging Member is subject (or will be subject at such time as it owns Class&nbsp;A Common Shares), which period restricts the ability of such Exchanging Member
to immediately resell Class&nbsp;A Common Shares to be delivered to such Exchanging Member in connection with a Stock Exchange Payment and (ii)&nbsp;the period of time commencing on (x)&nbsp;the date of the declaration of a dividend by the
Corporation and ending on the first day following (y)&nbsp;the record date determined by the Board with respect to such dividend declared pursuant to <U>clause (x)</U>, which period of time shall be no longer than 10 Business Days; <I>provided</I>
that, in no event shall an Exchange Blackout Period which respect to <U>clause (ii)</U>&nbsp;of the definition hereof occur more than four (4)&nbsp;times per calendar year. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Exchange Date</I></B>&#148; means, subject in all cases to the provisions of
<U>Section&nbsp;2.2(a)</U> hereof, in the case of any Unrestricted Exchange, the date that is five (5)&nbsp;Business Days after the date the Exchange Notice is given pursuant to <U>Section 2.1(b)</U>, unless the Exchanging Member submits a written
request to extend such date and the Corporation in its sole discretion agrees in writing to such extension, and in any other case, the Quarterly Exchange Date; <I>provided</I> that, if the Exchange Date for any Exchange with respect to which the
Corporation elects to make a Stock Exchange Payment would otherwise fall within any Exchange Blackout Period, then the Exchange Date shall occur on the next Business Day following the end of such Exchange Blackout Period; <I>provided</I>,
<I>further</I>, that in the event the Corporation is required under the terms of this Agreement, or otherwise elects, to make a Stock Exchange Payment, the Exchange may be conditioned (including as to timing) by the Exchanging Member on the closing
of an underwritten distribution of the Class&nbsp;A Common Shares that may be issued in connection with such proposed Exchange. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Exchange Notice Date</I></B>&#148; means, with respect to an Exchange, the date the applicable Exchange Notice is delivered in
accordance with <U>Section 2.1(b)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Exchange Notice Date Value</I></B>&#148; means, in the case of an Exchange (other than
an Unrestricted Exchange), the arithmetic average of the VWAP for each of the five (5)&nbsp;consecutive Trading Days ending on the Trading Day immediately prior to the Exchange Notice Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Exchange Rate</I></B>&#148; means, at any time, the number of Class&nbsp;A Common Shares for which a Paired Interest is entitled
to be exchanged at such time. On the date of this Agreement, the Exchange Rate shall be 1 for 1, subject to adjustment pursuant to <U>Section 2.4</U> hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Exchanged Units</I></B>&#148; means any Common Unit to be Exchanged (as part of a Paired Interest) for the Cash Exchange Payment
or Stock Exchange Payment, as applicable, on the applicable Exchange Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Exchanging Member</I></B>&#148; means, with
respect to any Exchange, the LLC Unitholder exchanging Units pursuant to <U>Section 2.1(a)</U> of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Exchange
Notice</I></B>&#148; has the meaning set forth in <U>Section 2.1(b)</U> of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Governmental Entity</I></B>&#148;
means any nation or government, any state, province or other political subdivision thereof, any entity exercising executive, legislative, judicial, regulatory or administrative functions of or pertaining to government, including any court,
arbitrator (public or private) or other body or administrative, regulatory or quasi-judicial authority, agency, department, board, commission or instrumentality of any federal, state, local or foreign jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>HSR Act</I></B>&#148; has the meaning set forth in <U>Section 2.1(b)</U> of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Law</I></B>&#148; means any statute, act, code, law (including common law), ordinance, rule, regulation, determination, guidance
or governmental order, in each case, of any Governmental Entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>LLC Unitholder</I></B>&#148; means each holder of one or
more Common Units that may from time to time be a party to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Managing Member</I></B>&#148; has the meaning
given to such term in the OpCo LLC Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>National Securities Exchange</I></B>&#148; means a securities exchange that has
registered with the Commission under Section&nbsp;6 of the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>OpCo</I></B>&#148; means Cibus Global, LLC, a
Delaware limited liability company, and any successor thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>OpCo LLC Agreement</I></B>&#148; means the Third Amended and
Restated Limited Liability Company Agreement of OpCo, dated on or about the date hereof, as such agreement may be amended from time to time. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Paired Interest</I></B>&#148; means one Common Unit and one Class B Common
Share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Permitted Exchange Event</I></B>&#148; means any of the following events, which has or is occurring, or is otherwise
satisfied, as of the Exchange Date: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) The Exchange is part of one or more Exchanges by an LLC Unitholder and any related persons
(within the meaning of Section&nbsp;267(b) or 707(b)(1) of the Code) that is part of a &#147;<B><I>block transfer</I></B>&#148; within the meaning of Treasury Regulations Section&nbsp;1.7704-1(e)(2) (for this purpose, treating the Managing Member as
a &#147;general partner&#148; within the meaning of Treasury Regulations Section&nbsp;1.7704-1(k)(1)), a &#147;<B><I>Block Transfer</I></B>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) The Exchange is in connection with a Pubco Offer or Change of Control; <I>provided</I> that, any such Exchange pursuant to this <U>clause
(ii)</U>&nbsp;shall be effective immediately prior to the consummation of the closing of the Pubco Offer or Change of Control date (and, for the avoidance of doubt, shall not be effective if such Pubco Offer is not consummated or Change of Control
does not occur); or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) The Exchange is permitted by the Managing Member, in its reasonable discretion, in connection with
circumstances not otherwise set forth herein, if the Managing Member determines, after consultation with its outside legal counsel and tax advisor, that OpCo would not (at a &#147;more likely than not&#148; standard) be treated as a
&#147;<B><I>publicly traded partnership</I></B>&#148; under Section&nbsp;7704 of the Code (or any successor or similar provision) as a result of or in connection with such Exchange. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Permitted Transferee</I></B>&#148; has the meaning given to such term in <U>Section 3.1</U> of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Person</I></B>&#148; means any individual, estate, corporation, partnership, limited partnership, limited liability company,
limited company, joint venture, trust, unincorporated or governmental organization or any agency or political subdivision thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Private Placement Safe Harbor</I></B>&#148; means the &#147;<B><I>private placement</I></B>&#148; safe harbor set forth in
Treasury Regulations Section&nbsp;1.7704-1(h)(1). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Pubco Offer</I></B>&#148; has the meaning set forth in <U>Section 2.7</U>
of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Quarterly Exchange Date</I></B>&#148; means, either (x)&nbsp;for each fiscal quarter, the first (1<SUP
STYLE="font-size:75%; vertical-align:top">st</SUP>)&nbsp;Business Day occurring after the sixtieth (60th)&nbsp;day after the expiration of the applicable Quarterly Exchange Notice Period or (y)&nbsp;such other date as the Corporation shall determine
in its sole discretion; <I>provided</I> that, such date is at least sixty (60)&nbsp;days after the expiration of the Quarterly Exchange Notice Period; <I>provided</I>, <I>further</I>, that the Corporation shall use commercially reasonable efforts to
ensure that at least one Quarterly Exchange Date occurs each fiscal quarter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Quarterly Exchange Date Value</I></B>&#148;
means the arithmetic average of the VWAP for each of the five (5)&nbsp;consecutive Trading Days ending on the Trading Day immediately prior to the Exchange Date; <I>provided</I> that, if such an Exchange (other than an Unrestricted Exchange) is in
connection with a Secondary Offering or other negotiated transaction, the Quarterly Exchange Date Value shall be the per share price of Class&nbsp;A Common Shares in such transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Quarterly Exchange Notice Period</I></B>&#148; means, for each fiscal quarter, the period commencing on the third
(3rd)&nbsp;Business Day after the day on which the Corporation releases its earnings for the prior fiscal period, beginning with the first such date that falls from and after the effectiveness of the Corporation&#146;s Registration Statement on Form
S-3 to be filed pursuant to the terms and conditions of the Registration Rights Agreement (or such other date within such quarter as the Corporation shall determine in its sole discretion) and ending ten (10)&nbsp;Business Days thereafter.
Notwithstanding the foregoing, the Corporation may change the definition of Quarterly Exchange Notice Period with respect to any Quarterly Exchange Notice Period scheduled to occur in a calendar quarter subsequent to the then-current calendar
quarter, if (x)&nbsp;the revised definition provides for a Quarterly Exchange Notice Period occurring at least once in each calendar quarter, (y)&nbsp;the first Quarterly </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Exchange Notice Period pursuant to the revised definition will occur no less than 10 Business Days from the date written notice of such change is sent to each LLC Unitholder (other than the
Corporation) and (z)&nbsp;the revised definition, together with the revised Quarterly Exchange Date resulting therefrom, do not materially adversely affect the ability of the LLC Unitholders to exercise their Exchange rights pursuant to this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Redemption</I></B>&#148; has the meaning set forth in <U>Section 2.1(a)</U> of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Registration Rights Agreement</I></B>&#148; means that certain Registration Rights Agreement, dated as of the date hereof, by and
among the Corporation and the other parties thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Retraction Notice</I></B>&#148; has the meaning set forth in <U>Section
2.1(d)</U> of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Secondary Offering</I></B>&#148; has the meaning set forth in <U>Section&nbsp;2.1(f)</U> of
this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I></I></B>&#147;<B><I>Secondary Offering Paired Interests</I></B>&#148; has the meaning set forth in
<U>Section&nbsp;2.1(a)</U> of this Agreement.<B><I> </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Securities Act</I></B>&#148; means the U.S. Securities Act of
1933, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Stock Exchange Payment</I></B>&#148; means, with respect to the portion of any Exchange for which a Cash
Exchange Notice is not delivered by the Corporation, on behalf of OpCo, a number of Class&nbsp;A Common Shares equal to the product of the number of Exchanged Units multiplied by the Exchange Rate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Taxing Authority</I></B>&#148; has the meaning set forth in the Tax Receivable Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Tax Receivable Agreement</I></B>&#148; means that certain Tax Receivable Agreement, dated as of the date hereof, by and among the
Corporation and the other parties thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Trading Day</I></B>&#148; means a day on which the Trading Market is open for the
transaction of business (unless such trading shall have been suspended for the entire day). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Trading Market</I></B>&#148;
means the Nasdaq Stock Market or such other principal United States securities exchange on which Class&nbsp;A Common Shares are listed, quoted or admitted to trading. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Unrestricted Exchanges</I></B>&#148; means any Exchange that is in connection with a Permitted Exchange Event or that occurs
during a period in which OpCo meets the requirements of the Private Placement Safe Harbor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>VWAP</I></B>&#148; means the daily
per share volume-weighted average price of Class&nbsp;A Common Shares on the Trading Market, as displayed under the heading &#147;Bloomberg VWAP&#148; on the Bloomberg page designated for Class&nbsp;A Common Shares (or its equivalent successor if
such page is not available) in respect of the period from the open of trading on such Trading Day until the close of trading on such Trading Day (or if such volume-weighted average price is unavailable, (a)&nbsp;the per share volume-weighted average
price of a Class&nbsp;A Common Share on such Trading Day (determined without regard to afterhours trading or any other trading outside the regular trading session or trading hours), or (b)&nbsp;if such determination is not feasible, the market price
per Class&nbsp;A Common Share, in either case as determined by a nationally recognized independent investment banking firm retained in good faith for this purpose by the Managing Member). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;2.1 <U>Exchange Procedure</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) From and after the effectiveness of the Corporation&#146;s Registration Statement on Form S-3 to be filed pursuant to the terms and
conditions of the Registration Rights Agreement, each LLC Unitholder (other than the Corporation) shall be entitled, upon the terms and subject to the conditions hereof, to surrender Paired </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Interests to OpCo and the Corporation, as applicable, in exchange for the delivery by OpCo of the Stock Exchange Payment or, at the election of the Corporation, the Cash Exchange Payment (such
exchange, a &#147;<B><I>Redemption</I></B>&#148; and, together with a Direct Exchange (as defined below), an &#147;<B><I>Exchange</I></B>&#148;); <I>provided</I>, that (absent a waiver by the Managing Member) any such Exchange is for a minimum of
the lesser of (i)&nbsp;25,000 Common Units (which minimum shall be equitably adjusted in accordance with any adjustments to the Exchange Rate) and (ii)&nbsp;all of the Common Units held by such LLC Unitholder; <I>provided</I>, <I>further</I>, that
in the event that an Exchanging Member is participating in an underwritten offering or other block sale of Class&nbsp;A Common Shares following such Exchange and a portion of its Paired Interests are being surrendered to OpCo or the Corporation, as
applicable, in furtherance thereof (such portion, the &#147;<B><I>Secondary Offering Paired Interests</I></B>&#148;), then OpCo and the Corporation shall settle the Exchange of such Secondary Offering Paired Interests by delivery of a Stock Exchange
Payment hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) An LLC Unitholder shall exercise its right to make an Exchange as set forth in <U>Section 2.1(a)</U> above by
delivering to OpCo, with a copy to the Corporation, a written election of exchange in respect of the Paired Interests to be exchanged substantially in the form of <U>Exhibit A</U> hereto (an &#147;<B><I>Exchange Notice</I></B>&#148;) in accordance
with this <U>Section 2.1(b)</U>. An LLC Unitholder may deliver an Exchange Notice with respect to an Unrestricted Exchange at any time, and, in any other case, during the Quarterly Exchange Notice Period preceding the desired Exchange Date. An
Exchange Notice with respect to an Unrestricted Exchange may specify that the Exchange is to be contingent (including, without limitation, as to timing) upon the consummation of a purchase by another Person (whether in a tender or exchange offer, an
underwritten offering or otherwise) of the Class&nbsp;A Common Shares into which the Paired Interests are exchangeable, or contingent (including, without limitation, as to timing) upon the closing of an announced merger, consolidation or other
transaction or event in which such Class&nbsp;A Common Shares would be exchanged or converted or become exchangeable for or convertible into cash or other securities or property. Notwithstanding anything to the contrary contained in this Agreement,
if, in connection with an Exchange in accordance with this <U>Section&nbsp;2.1</U>, a filing is required under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ( the<B><I> &#147;HSR Act</I></B>&#148;), then the Exchange Date with
respect to all Paired Interests which would be exchanged into Class&nbsp;A Common Shares resulting from such Exchange shall be delayed until the earlier of (i)&nbsp;such time as the required filing under the HSR Act has been made and the waiting
period applicable to such Exchange under the HSR Act shall have expired or been terminated or (ii)&nbsp;such filing is no longer required, at which time such Exchange shall automatically occur without any further action by the holders of any such
Paired Interests. Each of the LLC Unitholders and the Corporation agree to promptly take all actions required to make such filing under the HSR Act and the filing fee for such filing shall be paid by OpCo. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Subject to Sections 2.1(a) and 2.2(a), within three (3)&nbsp;Business Days of the giving of an Exchange Notice, the Corporation, on behalf
of OpCo, may elect to settle all or a portion of the Exchange in cash (in lieu of Class&nbsp;A Common Shares) by giving written notice of such election to OpCo and the Exchanging Member within such three (3)&nbsp;Business Day period (such notice,
the &#147;<B><I>Cash Exchange Notice</I></B>&#148;). The Cash Exchange Notice shall set forth the portion of the Paired Interests which will be exchanged for cash in lieu of Class&nbsp;A Common Shares. Any portion of the Exchange not settled for a
Cash Exchange Payment shall be settled for a Stock Exchange Payment. Subject to Section&nbsp;2.1(a), at any time following the giving of a Cash Exchange Notice and prior to the Exchange Date, the Corporation may elect (exercisable by giving written
notice of such election to the Exchanging Member) to revoke the Cash Exchange Notice with respect to all or any portion of the Paired Interests and make the Stock Exchange Payment with respect to any such Paired Interests on the Exchange Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Exchanging Member may elect to retract its Exchange Notice with respect to an Unrestricted Exchange by giving written notice of such
election to OpCo, with a copy to the Corporation, no later than (1)&nbsp;Business Day prior to the Exchange Date. Subject to the terms of this Section&nbsp;2.1(d), an Exchanging Member may deliver an Exchange Notice with respect to an Exchange
(other than an Unrestricted Exchange) during the Quarterly Exchange Notice Period which conditions such Exchange upon the Quarterly Exchange Date Value being equal to or greater than ninety percent (90%)&nbsp;of the Exchange Notice Date Value and if
such requirement is not met, then the Exchanging Member may elect to retract its Exchange Notice by giving written notice of such election to OpCo, with a copy to the Corporation, no later than 12:00 p.m. (New York time) on the Trading Day preceding
the Exchange Date (a &#147;<B><I>Retraction Notice</I></B>&#148;). The delivery of a Retraction Notice shall terminate all of </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Exchanging Member&#146;s, the Corporation&#146;s and OpCo&#146;s rights and obligations under this <U>Article II</U> arising from such retracted Exchange Notice (but not, for the avoidance of
doubt, from any Exchange Notice not retracted or that may be delivered in the future); <I>provided</I> that, an Exchanging Member may deliver a Retraction Notice only once in every twelve (12)-month period (and any additional Retraction Notice
delivered by such Exchanging Member within such twelve (12)-month period shall be deemed null and void <I>ab initio</I> and ineffective with respect to the revocation of the Exchange specified therein). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Notwithstanding anything to the contrary in this Agreement, if the Corporation closes an underwritten distribution of the Class&nbsp;A
Common Shares and the LLC Unitholders (any of them alone, or together with the Corporation) were entitled to resell Class&nbsp;A Common Shares in connection therewith (by the exercise by such LLC Unitholders of Exchange rights or otherwise) (a
&#147;<B><I>Secondary Offering</I></B>&#148;), then, except as provided in the following proviso, the immediately succeeding Quarterly Exchange Date shall be automatically cancelled and of no force or effect (and no LLC Unitholder shall be entitled
to deliver a Quarterly Exchange Date Notice with respect to an Exchange that is not an Unrestricted Exchange in respect of such Quarterly Exchange Date); <I>provided</I> that, the Corporation and OpCo may effect an Exchange if the Corporation
determines (in its reasonable discretion), after consultation with its legal counsel and tax advisors, that such Exchange, together with any other Exchanges that have occurred or are expected to occur, would not be reasonably likely to result in the
OpCo being treated as a &#147;publicly traded partnership&#148; within the meaning of Section&nbsp;7704 of the Code. Notwithstanding anything to the contrary in this Agreement (a)&nbsp;for such periods that OpCo does not meet the requirements of the
Private Placement Safe Harbor, any Secondary Offering (other than that pursuant to which all Exchanges are Unrestricted Exchanges) shall only be undertaken if, during the applicable taxable year, the total number of Quarterly Exchange Dates and
prior Secondary Offerings (other than any pursuant to which all Exchanges are Unrestricted Exchanges) on which Exchanges occur is three (3)&nbsp;or fewer and (b) OpCo and the Corporation shall not be deemed to have failed to comply with their
respective obligations under the Registration Rights Agreement, if a Secondary Offering cannot be undertaken due to the restriction set forth in the preceding clause (a). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;2.2 <U>Exchange Payment</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Exchange shall be consummated on the Exchange Date; <I>provided</I> that, in the event that an Exchange Notice with respect to an
Unrestricted Exchange is delivered pursuant to <U>Section&nbsp;2.1(b)</U> and specifies that it is predicated upon the settlement of an Exchange of Paired Interests sooner than on the Exchange Date, the Corporation and OpCo shall use their
respective commercially reasonable efforts to consummate the Exchange on the date specified in such Exchange Notice, which shall thereafter be deemed the Exchange Date for purposes of such Exchange; <I>provided further</I>, that, notwithstanding
anything to the contrary contained in this Agreement, in the event that an Exchange Notice is delivered in connection with a Secondary Offering or a block sale pursuant to Rule 144 of the Securities Act or other then available exemption from
registration thereunder that is not an underwritten distribution but is an Unrestricted Exchange, and the Corporation has at least three (3)&nbsp;Business Days&#146; notice prior to the settlement date thereof, the Exchange Date shall be the
settlement date of such Secondary Offering or such block sale and the Exchange shall be consummated no later than the settlement of such Secondary Offering or such block sale on such date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) In connection with any Exchange, the Exchanging Member shall make any applicable Certificate Delivery requested or required by the
Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) On the Exchange Date (to be effective immediately prior to the close of business on the Exchange Date), in the case of a
Redemption, (i)&nbsp;the Corporation shall contribute to OpCo, for delivery to the Exchanging Member (x)&nbsp;the Stock Exchange Payment with respect to any Exchanged Units not subject to a Cash Exchange Notice and (y)&nbsp;the Cash Exchange Payment
with respect to any Exchanged Units subject to a Cash Exchange Notice, (ii)&nbsp;the Exchanging Member shall (A)&nbsp;transfer and surrender the Exchanged Units to OpCo, free and clear of all liens and encumbrances and (B)&nbsp;transfer and
surrender the corresponding number of Class B Common Shares to the Corporation, free and clear of all liens and encumbrances, and the Corporation shall cancel such </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Class B Common Shares, (iii)&nbsp;OpCo shall issue to the Corporation a number of Common Units equal to the number of Exchanged Units surrendered pursuant to the preceding <U>clause (ii)</U>,
(iv)&nbsp;solely to the extent necessary in connection with a Redemption, the Corporation shall undertake all actions, including, without limitation, an issuance, reclassification, distribution, division or recapitalization, with respect to the
Class&nbsp;A Common Shares to maintain a one-to-one ratio (or such other ratio then in effect) between the number of Common Units owned by the Corporation, directly or indirectly, and the number of outstanding Class&nbsp;A Common Shares, taking into
account the issuance in the preceding <U>clause (iii)</U>, any Stock Exchange Payment, and any other action taken in connection with this <U>Section 2.2</U>, and (v)&nbsp;OpCo shall (x)&nbsp;cancel the redeemed Exchanged Units and (y)&nbsp;transfer
to the Exchanging Member the Cash Exchange Payment and/or the Stock Exchange Payment, as applicable. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) On the Exchange Date (to be effective immediately prior to the close of business on the Exchange Date), in the case of a Direct Exchange,
(i)&nbsp;the Corporation shall deliver to the Exchanging Member, (x)&nbsp;the Stock Exchange Payment with respect to any Paired Interests not subject to a Cash Exchange Notice and (y)&nbsp;the Cash Exchange Payment with respect to any Paired
Interests subject to a Cash Exchange Notice, (ii)&nbsp;the Exchanging Member shall transfer to the Corporation the Exchanged Units and the corresponding Class B Common Shares (it being understood that (A)&nbsp;the Corporation shall cancel the
surrendered Class B Common Shares and (B)&nbsp;the Exchanged Units shall remain outstanding and the Corporation shall be treated for all purposes of this Agreement as the owner of such Exchanged Units), free and clear of all liens and encumbrances,
and (iii)&nbsp;solely to the extent necessary in connection with a Direct Exchange, the Corporation shall undertake all actions, including, without limitation, an issuance, reclassification, distribution, division or recapitalization, with respect
to the Class&nbsp;A Common Shares to maintain a one-to-one ratio (or such other ratio then in effect) between the number of Common Units owned by the Corporation, directly or indirectly, and the number of outstanding Class&nbsp;A Common Shares,
taking into account any Stock Exchange Payment and any other action taken in connection with this <U>Section 2.2</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Upon the
Exchange of all of an LLC Unitholder&#146;s Common Units, such LLC Unitholder shall cease, in accordance with the terms of the OpCo LLC Agreement, to be a Member (as such term is defined in the OpCo LLC Agreement) of OpCo. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;2.3 <U>Expenses and Restrictions</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Except as expressly set forth in this Agreement, OpCo and each Exchanging Member shall bear its own expenses in connection with the
consummation of any Exchange, whether or not any such Exchange is ultimately consummated, except that OpCo shall bear any transfer taxes, stamp taxes or duties, or other similar taxes in connection with, or arising by reason of, any Exchange;
<I>provided</I>, <I>however</I>, that if any Class&nbsp;A Common Shares are to be issued in a name other than that of the LLC Unitholder that requested the Exchange, then such LLC Unitholder and/or the person in whose name such shares are to be
issued shall pay to OpCo the amount of any transfer taxes, stamp taxes or duties, or other similar taxes in connection with, or arising by reason of, such Exchange or shall establish to the reasonable satisfaction of OpCo that such tax has been paid
or is not payable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Notwithstanding anything to the contrary herein, to the extent that OpCo is otherwise eligible for the Private
Placement Safe Harbor in any taxable year, the Corporation and OpCo shall use commercially reasonable efforts to restrict issuances of Common Units in an amount sufficient for OpCo to continue to be eligible for the Private Placement Safe Harbor,
and, to the extent that the Corporation or OpCo determines that OpCo does not meet the requirements of the Private Placement Safe Harbor at any point in any taxable year, the Corporation or OpCo may impose such additional restrictions on Exchanges
(other than Exchanges that are Secondary Offerings) during such taxable year as the Corporation or OpCo may determine to be necessary or advisable so that OpCo is not treated as a &#147;<B><I>publicly traded partnership</I></B>&#148; under
Section&nbsp;7704 of the Code; <I>provided</I> that, the restrictions imposed pursuant to this sentence shall not apply to any Unrestricted Exchange. Notwithstanding anything to the contrary herein, no Exchange shall be permitted (and, if attempted,
shall be void <I>ab initio</I>) if, in the good faith determination of the Corporation or of OpCo, such an Exchange would pose a material risk that OpCo would be a &#147;publicly traded partnership&#148; under Section&nbsp;7704 of the Code;
<I>provided</I>, <I>however</I>, that this sentence shall not apply to prohibit a Block Transfer unless a change in applicable Law after </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the date of the signing of the Merger Agreement (as defined in the OpCo LLC Agreement) modifies the application or availability of Treasury Regulations Section&nbsp;1.7704-1(e)(2). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) For the avoidance of doubt, and notwithstanding anything to the contrary herein, an LLC Unitholder shall not be entitled to effect an
Exchange (other than an Exchange in connection with settlement of a Secondary Offering or other Block Transfer) to the extent the Corporation reasonably determines in good faith that such Exchange (i)&nbsp;would be prohibited by law or regulation
(including, without limitation, the unavailability of any requisite registration statement filed under the Securities Act, or any exemption from the registration requirements thereunder), or (ii)&nbsp;would not be permitted under any other
agreements with the Corporation or its subsidiaries to which such LLC Unitholder is party (including, without limitation, the OpCo LLC Agreement) or any written policies of the Corporation related to unlawful or inappropriate trading applicable to
its directors, officers or other personnel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Corporation may adopt reasonable procedures for the implementation of the exchange
provisions set forth in this <U>Article II</U>, including, without limitation, procedures for the giving of notice of an election of exchange. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;2.4 <U>Adjustment</U>. The Exchange Rate shall be adjusted accordingly if there is: (a)&nbsp;any subdivision (by any unit split,
unit distribution, reclassification, reorganization, recapitalization or otherwise) or combination (by reverse unit split, reclassification, reorganization, recapitalization or otherwise) of the Common Units that is not accompanied by an identical
subdivision or combination of the Class&nbsp;A Common Shares or (b)&nbsp;any subdivision (by any share or stock split, stock dividend or distribution, reclassification, reorganization, recapitalization or otherwise) or combination (by reverse share
or stock split, reclassification, reorganization, recapitalization or otherwise) of the Class&nbsp;A Common Shares that is not accompanied by an identical subdivision or combination of the Common Units. If there is any reclassification,
reorganization, recapitalization or other similar transaction in which the Class&nbsp;A Common Shares are converted or changed into another security, securities or other property, then upon any subsequent Exchange, an Exchanging Member shall be
entitled to receive the amount of such security, securities or other property that such Exchanging Member would have received if such Exchange had occurred immediately prior to the effective time of such reclassification, reorganization,
recapitalization or other similar transaction, taking into account any adjustment as a result of any subdivision (by any share or stock split, distribution or dividend, reclassification, reorganization, recapitalization or otherwise) or combination
(by reverse share or stock split, reclassification, recapitalization or otherwise) of such security, securities or other property that occurs after the effective time of such reclassification, reorganization, recapitalization or other similar
transaction. Except as may be required in the immediately preceding sentence, no adjustments in respect of distributions shall be made upon the exchange of any Common Unit. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;2.5 <U>Class&nbsp;A Common Shares to be Issued</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Corporation shall at all times reserve and keep available out of its authorized but unissued Class&nbsp;A Common Shares, solely for the
purpose of issuance upon an Exchange, such number of Class&nbsp;A Common Shares as may be issued upon any such Exchange; <I>provided</I> that, nothing contained herein shall be construed to preclude the Corporation and OpCo from satisfying its
obligations in respect of the Exchange of the Paired Interests by the sale of Class&nbsp;A Common Shares which are held in the treasury of the Corporation or are held by OpCo or any of their subsidiaries or by delivery of purchased Class&nbsp;A
Common Shares (which may or may not be held in the treasury of the Corporation or held by any subsidiary thereof), or by the sale/issuance of the Cash Exchange Payment in accordance with the terms hereof. The Corporation and OpCo covenant that all
Class&nbsp;A Common Shares issued upon an Exchange will, upon issuance, be validly issued, fully paid and non-assessable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The
Corporation and OpCo shall at all times ensure that the execution and delivery of this Agreement by each of the Corporation and OpCo and the consummation by each of the Corporation and OpCo of the transactions contemplated hereby (including, without
limitation, the issuance of the Class&nbsp;A Common Shares) have been duly authorized by all necessary corporate or limited liability company action, as the case may be, on </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the part of the Corporation and OpCo, including, but not limited to, all actions necessary to ensure that the acquisition of Class&nbsp;A Common Shares pursuant to the transactions contemplated
hereby, to the fullest extent of the Board&#146;s power and authority and to the extent permitted by law, shall not be subject to any &#147;moratorium,&#148; &#147;control share acquisition,&#148; &#147;business combination,&#148; &#147;fair
price&#148; or other form of anti-takeover laws and regulations of any jurisdiction that may purport to be applicable to this Agreement or the transactions contemplated hereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The Corporation and OpCo covenant and agree that, to the extent that a registration statement under the Securities Act is effective and
available for Class&nbsp;A Common Shares to be issued with respect to any Exchange, shares that have been registered under the Securities Act shall be issued in respect of such Exchange. In the event that any Exchange in accordance with this
Agreement is to be effected at a time when any required registration has not become effective or otherwise is unavailable, upon the request and with the reasonable cooperation of the LLC Unitholder requesting such Exchange, the Corporation and OpCo
shall use commercially reasonable efforts to promptly facilitate such Exchange pursuant to any reasonably available exemption from such registration requirements. The Class&nbsp;A Common Shares to be issued following completion of an Exchange may,
in the reasonable discretion of the Corporation, be restricted and/or legended securities to the extent required under the Securities Act, the regulations promulgated thereunder or any other applicable or federal or state securities laws. The
Corporation and OpCo shall use commercially reasonable efforts to list the Class&nbsp;A Common Shares required to be issued upon the Exchange prior to such issue upon each National Securities Exchange or inter-dealer quotation system upon which the
outstanding Class&nbsp;A Common Shares may be listed or traded at the time of such issue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;2.6 <U>Direct Exchange</U>.
Notwithstanding anything to the contrary in this <U>Article II</U>, the Corporation may, in its sole and absolute discretion, elect to effect on the Exchange Date the Exchange of Paired Interests for the Cash Exchange Payment and/or the Stock
Exchange Payment, as the case may be (and subject to the terms of <U>Section 2.2(a), (c)</U>&nbsp;and <U>(d)</U>), through a direct exchange of such Paired Interests between the Exchanging Member and the Corporation (a &#147;<B><I>Direct
Exchange</I></B>&#148;). Upon such Direct Exchange pursuant to this <U>Section 2.6</U>, the Corporation shall acquire the Exchanged Units (which shall remain outstanding) and the Corporation shall be treated for all purposes of this Agreement as the
owner of such Exchanged Units; <I>provided</I> that, any such election by the Corporation shall not relieve OpCo of its obligation arising with respect to such applicable Exchange Notice. The Corporation may, at any time prior to an Exchange Date,
deliver written notice (an &#147;<B><I>Direct Exchange Election Notice</I></B>&#148;) to OpCo and the Exchanging Member setting forth its election to exercise its right to consummate a Direct Exchange; <I>provided</I> that, such election does not
prejudice the ability of the parties to consummate an Exchange or Direct Exchange on the Exchange Date. A Direct Exchange Election Notice may be revoked by the Corporation at any time; <I>provided</I> that, any such revocation does not prejudice the
ability of the parties to consummate an Exchange or Direct Exchange on the Exchange Date. The right to consummate a Direct Exchange in all events shall be exercisable for all of the Paired Interests that would otherwise have been subject to an
Exchange. Except as otherwise provided in this <U>Section 2.6</U>, a Direct Exchange shall be consummated pursuant to the same timeframe and in the same manner as the relevant Exchange would have been consummated had the Corporation not delivered a
Direct Exchange Election Notice. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 2.7. <U>Pubco Offer or Change of Control</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) In the event that a tender offer, share exchange offer, issuer bid, take-over bid, recapitalization or similar transaction with respect to
any Class&nbsp;A Common Shares (a &#147;<B><I>Pubco Offer</I></B>&#148;) is proposed by the Corporation or is proposed to the Corporation or its stockholders and approved by the Board or is otherwise effected or to be effected with the consent or
approval of the Board or the Corporation will undergo a Change of Control, the LLC Unitholders shall be permitted to deliver an Exchange Notice (which Exchange Notice shall be effective immediately prior to the consummation of such Pubco Offer or
Change of Control (and, for the avoidance of doubt, shall be contingent upon such Pubco Offer or Change of Control and not be effective if such Pubco Offer or Change of Control is not consummated)). In the case of a Pubco Offer proposed by the
Corporation, the Corporation will use its reasonable best efforts expeditiously and in good faith to take all such actions and do all such things as are necessary or desirable to enable and permit the LLC Unitholders to participate in such Pubco
Offer to the same extent or on an economically equivalent basis as the holders of </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Class&nbsp;A Common Shares without discrimination (but excluding, for the avoidance of doubt, the LLC Unitholders&#146; rights under the Tax Receivable Agreement in determining whether such
participation is on an economically equivalent basis). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Corporation shall send written notice to OpCo and the LLC Unitholders at
least thirty (30)&nbsp;Business Days prior to the closing date of the transactions contemplated by the Pubco Offer or the Change of Control notifying them of their rights pursuant to this <U>Section 2.7</U>, and setting forth, in the case of a Pubco
Offer, (i)&nbsp;a copy of the written proposal or agreement pursuant to which the Pubco Offer will be effected, (ii)&nbsp;the consideration payable in connection therewith, (iii)&nbsp;the terms and conditions of transfer and payment and
(iv)&nbsp;the date and location of and procedures for selling Common Units, or in the case of a Change of Control, (x)&nbsp;a description of the event constituting the Change of Control, (y)&nbsp;the date of the Change of Control, and (z)&nbsp;a
copy of any written proposals or agreement relating thereto. In the event that the information set forth in such notice changes from that set forth in the initial notice, a subsequent notice shall be delivered by the Corporation as promptly as
reasonably practicable, but in any event no less than five (5)&nbsp;days prior to the closing of the Pubco Offer or date of the Change of Control. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;3.1 <U>Additional LLC Unitholders</U>. To the extent an LLC Unitholder validly transfers any or all of such holder&#146;s Common
Units to another person in a transaction in accordance with, and not in contravention of, the OpCo LLC Agreement or any other agreement or agreements with the Corporation or any of its subsidiaries to which a transferring LLC Unitholder may be
party, then such transferee (each, a &#147;<B><I>Permitted Transferee</I></B>&#148;) shall execute and deliver a joinder to this Agreement, substantially in the form of <U>Exhibit B</U> hereto, whereupon such Permitted Transferee shall become an LLC
Unitholder hereunder. To the extent OpCo issues Common Units in the future, OpCo shall be entitled, in its sole discretion, to make any holder of such Common Units an LLC Unitholder hereunder through such holder&#146;s execution and delivery of a
joinder to this Agreement, substantially in the form of <U>Exhibit B</U> hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;3.2 <U>Addresses and Notices</U>. All
notices, requests, claims, demands and other communications hereunder shall be in writing and shall be given (and shall be deemed to have been duly given upon receipt) by delivery in person, by courier service, by fax, by electronic mail (delivery
receipt requested) or by registered or certified mail (postage prepaid, return receipt requested) to the respective parties at the following addresses (or at such other address for a party as shall be as specified in a notice given in accordance
with this <U>Section 3.2</U>): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If to the Corporation, to: </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">6455 Nancy Ridge Drive </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">San Diego, CA 92121 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: Rory Riggs, Chief Executive Officer, and Wade King, MD, Chief Financial Officer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">E-mail: [***] and [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">with a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Jones Day </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">4655 Executive Drive, Suite 1500 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">San Diego, CA 92121-3134 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: Cameron A. Reese </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">E-mail: [***] </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If to OpCo, to: </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cibus Global, LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">6455 Nancy Ridge Drive </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">San Diego, CA 92121 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: Rory Riggs, Chief Executive Officer, and Wade King, MD, Chief
Financial Officer </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">E-mail: [***] and [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">with a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Jones Day </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">4655 Executive Drive, Suite 1500 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">San Diego, CA 92121-3134 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: Cameron A. Reese </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">E-mail: [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Akin Gump Strauss Hauer&nbsp;&amp; Feld LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">One Bryant Park </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">New York, NY 10036 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: Stuart Leblang and Jonathan Pavlich </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Email: [***] and [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) If to any LLC Unitholder, to the address or other contact information set forth in the records of OpCo from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;3.3 <U>Further Action</U>. The parties shall execute and deliver all documents, provide all information and take or refrain from
taking action as may be necessary or appropriate to achieve the purposes of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;3.4 <U>Binding Effect</U>. This
Agreement shall be binding upon and inure to the benefit of all of the parties and, to the extent permitted by this Agreement, their successors, executors, administrators, heirs, legal representatives and assigns. No LLC Unitholder may assign its
rights under this Agreement without the consent of the Corporation and OpCo. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;3.5 <U>Severability</U>. If any term or other
provision of this Agreement is held to be invalid, illegal or incapable of being enforced by any rule of law, or public policy, all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect so long as the
economic or legal substance of the transactions is not affected in any manner materially adverse to any party. Upon a determination that any term or other provision is invalid, illegal or incapable of being enforced, the parties hereto shall
negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in a mutually acceptable manner in order that the transactions contemplated hereby be consummated as originally contemplated
to the fullest extent possible. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;3.6 <U>Amendment</U>. The provisions of this Agreement may be amended only by the
affirmative vote or written consent of each of (i)&nbsp;the Corporation, (ii)&nbsp;OpCo and (iii)&nbsp;LLC Unitholders holding at least a majority of the then outstanding Common Units (excluding Common Units held by the Corporation); <I>provided</I>
that, for purposes of this clause (iii), in addition to the consent required by clauses (i)&nbsp;and (ii), no amendment may materially, disproportionately and adversely affect the rights of an LLC Unitholder (other than the Corporation and its
subsidiaries) without the consent of such LLC Unitholder (or, if there is more than one such LLC Unitholder that is so affected, without the consent of a majority in interest of such affected LLC Unitholders (other than the Corporation and its
subsidiaries) in accordance with their holdings of Common Units). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;3.7 <U>Waiver</U>. No failure by any party to insist upon
the strict performance of any covenant, duty, agreement or condition of this Agreement or to exercise any right or remedy consequent upon a breach thereof shall constitute waiver of any such breach of any other covenant, duty, agreement or
condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;3.8 <U>Submission to Jurisdiction; Waiver of Jury Trial</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Any and all disputes which cannot be settled amicably with respect to this Agreement, including, without limitation, any action (at law or
in equity), claim, litigation, suit, arbitration, hearing, audit, review, </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
inquiry, proceeding, investigation or ancillary claims of any party, arising out of, relating to or in connection with the validity, negotiation, execution, interpretation, performance or
non-performance of this Agreement or any matter arising out of or in connection with this Agreement and the rights and obligations arising hereunder or thereunder, or for recognition and enforcement of any judgment in respect of this Agreement and
the rights and obligations arising hereunder or thereunder brought by a party hereto or its successors or assigns, shall be brought and determined exclusively in the Delaware Chancery Court, or if such court shall not have jurisdiction, any federal
court located in the State of Delaware, or, if neither of such courts shall have jurisdiction, any other Delaware state court. Each of the parties hereby irrevocably submits with regard to any such dispute for itself and in respect of its property,
generally and unconditionally, to the sole and exclusive personal jurisdiction of the aforesaid courts and agrees that it will not bring any dispute relating to this Agreement or any of the transactions contemplated by this Agreement in any court
other than the aforesaid courts. Each party irrevocably consents to service of process in any dispute in any of the aforesaid courts by the mailing of copies thereof by registered or certified mail, postage prepaid, or by recognized overnight
delivery service, to such party at such party&#146;s address referred to in <U>Section 3.2</U>. Each party hereby irrevocably and unconditionally waives, and agrees not to assert as a defense, counterclaim or otherwise, in any action brought by any
party with respect to this Agreement (i)&nbsp;any claim that it is not personally subject to the jurisdiction of the aforesaid courts for any reason other than the failure to serve process in accordance with this <U>Section 3.8</U>; (ii)&nbsp;any
claim that it or its property is exempt or immune from the jurisdiction of any such court or from any legal process commenced in such courts (whether through service of notice, attachment prior to judgment, attachment in aid of execution of
judgment, execution of judgment or otherwise); or (iii)&nbsp;any objection which such party may now or hereafter have (A)&nbsp;to the laying of venue of any of the aforesaid actions arising out of or in connection with this Agreement brought in the
courts referred to above; (B)&nbsp;that such action brought in any such court has been brought in an inconvenient forum and (C)&nbsp;that this Agreement, or the subject matter hereof or thereof, may not be enforced in or by such courts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) To the extent that any party has or hereafter may acquire any immunity from jurisdiction of any court or from any legal process (whether
through service or notice, attachment prior to judgment, attachment in aid of execution, execution or otherwise) with respect to itself, or to such party&#146;s property, each such party hereby irrevocably waives such immunity in respect of such
party&#146;s obligations with respect to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) EACH PARTY ACKNOWLEDGES THAT IT IS KNOWINGLY AND VOLUNTARILY AGREEING TO THE
CHOICE OF DELAWARE LAW TO GOVERN THIS AGREEMENT AND TO THE JURISDICTION OF DELAWARE COURTS IN CONNECTION WITH PROCEEDINGS BROUGHT HEREUNDER. THE PARTIES INTEND THIS TO BE AN EFFECTIVE CHOICE OF DELAWARE LAW AND AN EFFECTIVE CONSENT TO JURISDICTION
AND SERVICE OF PROCESS UNDER 6 DEL. C. &#167; 2708. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) EACH PARTY, FOR ITSELF AND ITS AFFILIATES, HEREBY IRREVOCABLY AND UNCONDITIONALLY
WAIVES TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW ALL RIGHT TO TRIAL BY JURY IN ANY ACTION OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THE ACTIONS OF THE PARTIES OR THEIR RESPECTIVE AFFILIATES
PURSUANT TO THIS AGREEMENT OR THE OTHER TRANSACTION DOCUMENTS IN THE NEGOTIATION, ADMINISTRATION, PERFORMANCE OR ENFORCEMENT HEREOF OR THEREOF. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The parties hereby waive, to the fullest extent permitted by applicable law, any objection which they now or hereafter may have to
personal jurisdiction or to the laying of venue of any such ancillary suit, action or proceeding brought in any court referred to in <U>Section&nbsp;3.8(a)</U> and such parties agree not to plead or claim the same. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;3.9 <U>Counterparts</U>. This Agreement may be executed and delivered (including, without limitation, by facsimile transmission
or by e-mail delivery of a &#147;<B><I>.pdf</I></B>&#148; format data file) in one or more counterparts, and by the different parties hereto in separate counterparts, each of which when executed and delivered shall be deemed to be an original but
all of which taken together shall constitute one and the same agreement. Copies of executed counterparts transmitted by telecopy, by e-mail delivery of a &#147;<B><I>.pdf</I></B>&#148; format data file or other electronic transmission service shall
be considered original executed counterparts for purposes of this <U>Section 3.9</U>. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;3.10 <U>Tax Treatment</U>. This Agreement shall be treated as part of the
partnership agreement of OpCo as described in Section&nbsp;761(c) of the Code and Sections 1.704-1(b)(2)(ii)(h) and 1.761-1(c) of the Treasury Regulations promulgated thereunder. As required by the Code and the Treasury Regulations, the parties
shall report any Exchange consummated hereunder as a taxable sale of the Exchanged Units (together with an equal number of Class B Common Shares) by an LLC Unitholder to the Corporation in exchange for (i)&nbsp;the payment by the Corporation of the
Stock Exchange Payment, the Cash Exchange Payment, or other applicable consideration to the Exchanging Member, and, if applicable, (ii)&nbsp;corresponding payments under the Tax Receivable Agreement, and no party shall take a contrary position on
any income tax return, amendment thereof or communication with any Taxing Authority unless an alternate position is permitted under the Code and Treasury Regulations and the Corporation consents in writing to such alternate position, such consent
not to be unreasonably withheld, conditioned, or delayed. Further, in connection with any Exchange consummated hereunder, OpCo and/or the Corporation shall provide the Exchanging Member with all reasonably necessary information to enable the
Exchanging Member to file its income Tax returns for the taxable year that includes the Exchange, including, without limitation, information with respect to assets under Section&nbsp;751 of the Code (including, without limitation, relevant
information regarding &#147;<B><I>unrealized receivables</I></B>&#148; or &#147;<B><I>inventory items</I></B>&#148;) and basis adjustments under Section&nbsp;743(b) of the Code as soon as practicable and in all events within 60 days following the
close of such taxable year (and use commercially reasonable efforts to provide estimates of such information within 90 days of the applicable Exchanges). Within thirty (30)&nbsp;days following the Exchange Date, the Corporation shall deliver a Code
Section&nbsp;743 notification to OpCo in accordance with Treasury Regulations Section&nbsp;1.743-1(k)(2). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;3.11
<U>Withholding</U>. The Corporation and OpCo shall be entitled to deduct and withhold from any payments made to an LLC Unitholder pursuant to any Exchange consummated under this Agreement all taxes that each of the Corporation and OpCo is required
to deduct and withhold with respect to such payments under the Code and any other provision of applicable law (including, without limitation, under Section&nbsp;1445 and Section&nbsp;1446(f) of the Code). In connection with any Exchange, the
Exchanging Member shall, to the extent it is legally entitled to deliver such form, deliver to the Corporation or OpCo, as applicable, a certificate, dated as of the Exchange Date, in a form reasonably acceptable to the Corporation certifying as to
such Exchanging Member&#146;s taxpayer identification number and that such Exchanging Member is a not a foreign person for purposes of Section&nbsp;1445 and Section&nbsp;1446(f) of the Code (which certificate may be an Internal Revenue Service Form
W-9 if then sufficient for such purposes under applicable law) (such certificate, a &#147;<B><I>Non-Foreign Person Certificate</I></B>&#148;). If an Exchanging Member is unable to provide a Non-Foreign Person Certificate in connection with an
Exchange, then (i)&nbsp;OpCo shall provide a certificate substantially in the form described in Treasury Regulations Section&nbsp;1.1446(f)-2(c)(2)(ii)(C) setting forth the liabilities of OpCo allocated to the Exchanged Units subject to the Exchange
under Section&nbsp;752 of the Code or (ii)&nbsp;each of the Exchanging Member and OpCo shall, to the extent it is legally entitled to do so, deliver a certificate reasonably acceptable to the Corporation to permit OpCo and the Corporation to comply
with Sections 1445 and 1446(f), and the Corporation or OpCo, as and to the extent applicable, shall be permitted to deduct and withhold on the amount realized by such Exchanging Member in respect of such Exchange if and as provided in
Section&nbsp;1446(f) of the Code and Treasury Regulations thereunder. The Corporation or OpCo, as applicable, may at their sole discretion reduce the Class&nbsp;A Common Shares issued to an LLC Unitholder in an Exchange in an amount that corresponds
to the amount of the required withholding described in the immediately preceding sentence. All such amounts so deducted and withheld shall be treated for all purposes of this Agreement as having been paid to such LLC Unitholder in respect of which
such deduction or withholding was made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;3.12 <U>Specific Performance</U>. The parties hereto agree that irreparable damage
would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that such parties shall be entitled to specific performance of the
terms and provisions hereof, in addition to any other remedy to which they are entitled at law or in equity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;3.13
<U>Independent Nature of LLC Unitholders&#146; Rights and Obligations</U>. The obligations of each LLC Unitholder hereunder are several and not joint with the obligations of any other LLC Unitholder, and no LLC Unitholder shall be responsible in any
way for the performance of the obligations of any other LLC Unitholder hereunder. The decision of each LLC Unitholder to enter into this Agreement has been made by such </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
LLC Unitholder independently of any other LLC Unitholder. Nothing contained herein, and no action taken by any LLC Unitholder pursuant hereto, shall be deemed to constitute the LLC Unitholders as
a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the LLC Unitholders are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated hereby. The
Corporation acknowledges that the LLC Unitholders are not acting in concert or as a group, and the Corporation will not assert any such claim, with respect to such obligations or the transactions contemplated hereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION&nbsp;3.14 <U>Applicable Law</U>. This Agreement shall be governed by, and construed in accordance with, the law of the State of
Delaware, without regards to its principles of conflicts of laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I></I>[<I>Remainder of Page Intentionally Left Blank</I>]<I> </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed and
delivered, all as of the date first set forth above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Cibus, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Signature Page to Exchange Agreement </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed and
delivered, all as of the date first set forth above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Cibus Global, LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Signature Page to Exchange Agreement </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EXCHANGE NOTICE </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cibus, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6455 Nancy Ridge Drive </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, CA 92121 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Rory Riggs, Chief Executive Officer, and Wade King, MD, Chief Financial Officer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">E-mail: [***] and [***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cibus Global, LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6455 Nancy Ridge Drive </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, CA 92121 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Rory Riggs, Chief Executive Officer, and Wade King, MD, Chief Financial Officer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">E-mail: [***] and [***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reference is hereby
made to the Exchange Agreement, dated as of [&#149;], 2023 (as amended from time to time, the &#147;<B><I>Exchange Agreement</I></B>&#148;), among Cibus Global, LLC, a Delaware limited liability company (together with any successor thereto,
&#147;<B><I>OpCo</I></B>&#148;), Cibus, Inc. (f/k/a Calyxt, Inc.), a Delaware corporation (the &#147;<B><I>Corporation</I></B>&#148;) and managing member of OpCo, and the LLC Unitholders from time to time party thereto (each, a
&#147;<B><I>Holder</I></B>&#148;). Capitalized terms used but not defined herein shall have the meanings given to them in the Exchange Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned Holder hereby transfers the number of Paired Interests set forth below in Exchange for the Stock Exchange Payment to be issued
in its name as set forth below, or the Cash Exchange Payment, as applicable, as set forth in the Exchange Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned
Holder agrees and acknowledges that as set forth in the Exchange Agreement, the Class&nbsp;A Common Shares to be issued following completion of an Exchange may, in the reasonable discretion of the Corporation, be restricted and/or legended
securities under the Securities Act, the regulations promulgated thereunder or any other applicable federal or state securities laws, which may not be sold or transferred without a registration statement filed under the Securities Act or an
applicable exemption from the registration requirements thereunder. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Legal Name of Holder:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Address:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Number of Paired Interests to be
Exchanged:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Brokerage
Account Details:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned hereby represents and warrants that (i)&nbsp;the undersigned has full legal capacity to execute and deliver this Exchange
Notice and to perform the undersigned&#146;s obligations hereunder; (ii)&nbsp;this Exchange Notice has been duly executed and delivered by the undersigned and is the legal, valid and binding obligation of the undersigned enforceable against it in
accordance with the terms thereof or hereof, as the case may be, subject to applicable bankruptcy, insolvency and similar laws affecting creditors&#146; rights generally and the availability of equitable remedies; (iii)&nbsp;the Paired Interests
subject to this Exchange Notice are being transferred to the Corporation or OpCo, as applicable, free and clear of any pledge, lien, security interest, encumbrance, equities or claim; and (iv)&nbsp;no consent, approval, authorization, order,
registration or qualification of any third party or with any court or governmental agency or body having jurisdiction over the undersigned or the Paired Interests subject to this Exchange Notice is required to be obtained by the undersigned for the
transfer of such Paired Interests to the Corporation or OpCo, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned hereby irrevocably constitutes and appoints
any officer of the Corporation or of OpCo as the attorney of the undersigned, with full power of substitution and resubstitution in the premises, to do any and all things and to take any and all actions that may be necessary to transfer to the
Corporation or OpCo, as applicable, the Paired Interests subject to this Exchange Notice and to deliver to the undersigned the Stock Exchange Payment or Cash Exchange Payment, as applicable, to be delivered in exchange therefor. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF the undersigned, by authority duly given, has caused this Exchange Notice
to be executed and delivered by the undersigned or by its duly authorized attorney. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>JOINDER </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Joinder
Agreement (&#147;<B><I>Joinder Agreement</I></B>&#148;) is a joinder to the Exchange Agreement, dated as of [&#9679;], 2023 (as amended from time to time, the &#147;<B><I>Exchange Agreement</I></B>&#148;), among Cibus, Inc. (f/k/a Calyxt, Inc.), a
Delaware corporation (together with any successor thereto, the &#147;<B><I>Corporation</I></B>&#148;), Cibus Global, LLC, a Delaware limited liability company, and each of the LLC Unitholders from time to time party thereto. Capitalized terms used
but not defined in this Joinder Agreement shall have their meanings given to them in the Exchange Agreement. This Joinder Agreement shall be governed by, and construed in accordance with, the law of the State of Delaware. In the event of any
conflict between this Joinder Agreement and the Exchange Agreement, the terms of this Joinder Agreement shall control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned
hereby joins and enters into the Exchange Agreement having acquired Common Units in Cibus Global, LLC. By signing and returning this Joinder Agreement to the Corporation, the undersigned accepts and agrees to be bound by and subject to all of the
terms and conditions of and agreements of an LLC Unitholder contained in the Exchange Agreement, with all attendant rights, duties and obligations of an LLC Unitholder thereunder. The parties to the Exchange Agreement shall treat the execution and
delivery hereof by the undersigned as the execution and delivery of the Exchange Agreement by the undersigned and, upon receipt of this Joinder Agreement by the Corporation and by Cibus Global, LLC, the signature of the undersigned set forth below
shall constitute a counterpart signature to the signature page of the Exchange Agreement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="79%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Address for Notices:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attention:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">With copies to:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="rom401831_71"></A>ANNEX F </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION RIGHTS AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This REGISTRATION RIGHTS AGREEMENT (this &#147;<U>Agreement</U>&#148;) is made as of [&#9679;], 2023 by and among Cibus, Inc. (f/k/a Calyxt,
Inc.), a Delaware corporation (the &#147;<U>Company</U>&#148;), and the persons identified on the Schedule of Investors attached hereto (collectively, the &#147;<U>Investors</U>&#148; and, each individually, an &#147;<U>Investor</U>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS,
pursuant to the Merger Agreement, dated as of January&nbsp;13, 2023, by and between the Company; Calypso Merger Subsidiary, LLC; Cibus Global LLC; New Ventures I Holdings, LLC; BCGF CB Holdings LLC; BCGFCP CB HOLDINGS LLC; BCGFK CB Holdings LLC;
FSBCGF CB Holdings LLC; PYLBCG CB Holdings LLC; FSGRWCO CB Holdings LLC; GROWTHCO CB Holdings LLC; GRTHCOCP CB Holdings LLC; and GRWTHCOK CB Holdings LLC (the &#147;<U>Merger Agreement</U>&#148;), the Company will enter into that certain Second
Amended and Restated Certificate of Incorporation of the Company (such agreement, as it may be amended, restated, amended and restated, supplemented or otherwise modified form time to time, the &#147;<U>Amended Certificate of
Incorporation</U>&#148;), which will create two classes of the Company&#146;s common stock: (i)&nbsp;Class&nbsp;A Common Stock (as defined below), which shares will have full voting and economic rights and (ii)&nbsp;Class&nbsp;B Common Stock (as
defined below), which shares will have full voting, but no economic rights; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, pursuant to the Merger Agreement, the Investors may
elect to receive a certain number of shares of Class&nbsp;B Common Stock, with an equal number of membership units (&#147;<U>Cibus Common Units</U>&#148;) of Cibus Global LLC, a Delaware limited liability company (&#147;<U>Cibus Global</U>&#148;) (a
Cibus Common Unit and a share of Class&nbsp;B Common Stock, collectively, an &#147;<U><FONT STYLE="white-space:nowrap">Up-C</FONT> Unit</U>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the <FONT STYLE="white-space:nowrap">Up-C</FONT> Units will generally be exchangeable for shares of Class&nbsp;A Common Stock on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis pursuant to the terms of an exchange agreement to be entered into between the Company, Cibus Global and the Investors, subject to certain procedures set
forth therein; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, in connection with the consummation of the transactions contemplated by the Merger Agreement and pursuant to
the terms of the Merger Agreement, the parties hereto desire to enter into this Agreement in order to grant certain registration rights to the Investors as set forth below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the mutual covenants contained herein and other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the parties to this Agreement hereby agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.&nbsp;&nbsp;&nbsp;&nbsp;<U>Definitions</U>. For purposes of this Agreement, the following terms shall have the meanings
specified in this <U>Section</U><U></U><U>&nbsp;1</U>: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Additional Investor</U>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;9</U>, and shall be deemed to include each such Person&#146;s Affiliates, immediate family members, heirs, successors and assigns who may succeed to such Person as a Holder hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Affiliate</U>&#148; of any Person means any other Person controlled by, controlling or under common control with such Person;
<I>provided</I> that the Company and its Subsidiaries shall not be deemed to be Affiliates of any Holder. As used in this definition, &#147;control&#148; (including, with its correlative meanings, &#147;controlling,&#148; &#147;controlled by&#148;
and &#147;under common control with&#148;) shall mean possession, directly or indirectly, of power to direct or cause the direction of management or policies (whether through ownership of securities, by contract or otherwise). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Agreement</U>&#148; has the meaning set forth in the preamble. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Amended Certificate of Incorporation</U>&#148; has the meaning set forth in the recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Automatic Shelf Registration Statement</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2(c)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Business Day</U>&#148; means any day of the year on which national banking institutions in New York are open to the public for
conducting business and are not required or authorized to close. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Capital Stock</U>&#148; means (i)&nbsp;with respect to any
Person that is a corporation, any and all shares, interests or equivalents in capital stock of such corporation (whether voting or nonvoting and whether common or preferred), (ii) with respect to any Person that is not a corporation, individual or
governmental entity, any and all partnership, membership, limited liability company or other equity interests of such Person that confer on the holder thereof the right to receive a share of the profits and losses of, or the distribution of assets
of the issuing Person, and (iii)&nbsp;any and all warrants, rights (including conversion and exchange rights) and options to purchase any security described in the clause <U>(i)</U>&nbsp;or <U>(ii)</U> above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Cibus Common Units</U>&#148; has the meaning set forth in the recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Cibus Global</U>&#148; has the meaning set forth in the recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Cibus Global <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Majority-In-Interest</FONT></FONT></U>&#148; means, as
of any time, those Investors party hereto who hold a majority of the then-outstanding Cibus Common Units (excluding Cibus Common Units held by the Company). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Class</U><U></U><U>&nbsp;A Common Stock</U>&#148; means the Company&#146;s Class&nbsp;A common stock, par value $0.0001 per share.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Class</U><U></U><U>&nbsp;B Common Stock</U>&#148; means the Company&#146;s Class&nbsp;B common stock, par value $0.0001 per
share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company</U>&#148; has the meaning set forth in the preamble. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Demand Registrations</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>End of Suspension Notice</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2(e)(ii)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Exchange Act</U>&#148; means the U.S. Securities Exchange Act of 1934, as amended from time to time, or any successor federal law
then in force, together with all rules and regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Exchange Agreement</U>&#148; means Exchange
Agreement, dated of even date herewith, by and among the Company, Cibus Global and the Investors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>FINRA</U>&#148; means the
Financial Industry Regulatory Authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Form <FONT STYLE="white-space:nowrap">S-1</FONT></U>&#148; means the SEC&#146;s
long-form registration form, Form <FONT STYLE="white-space:nowrap">S-1,</FONT> or any successor or replacement long-form registration form. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Form <FONT STYLE="white-space:nowrap">S-3</FONT></U>&#148; means the SEC&#146;s short-form registration form, Form <FONT
STYLE="white-space:nowrap">S-3,</FONT> or any successor or replacement short-form registration form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Free Writing
Prospectus</U>&#148; means a free-writing prospectus, as defined in Rule 405. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Holdback Period</U>&#148; has the meaning set
forth in <U>Section</U><U></U><U>&nbsp;4(a)(i)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Holder</U>&#148; means any Person who is the registered holder of
Registrable Securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Holder Indemnified Parties</U>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;7(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Joinder</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;9</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>MNPI</U>&#148; means material <FONT STYLE="white-space:nowrap">non-public</FONT> information within the meaning of Regulation FD
promulgated under the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Person</U>&#148; means an individual, a partnership, a corporation, a limited liability
company, an association, a joint stock company, a trust, a joint venture, an unincorporated organization and a governmental entity or any department, agency or political subdivision thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Piggyback Registrations</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Public Offering</U>&#148; means any sale or distribution to the public of Capital Stock of the Corporation pursuant to an offering
registered under the Securities Act, whether by the Company, by Holders and/or by any other holders of the Company&#146;s Capital Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Registrable Securities</U>&#148; means (i)&nbsp;any shares of Class&nbsp;A Common Stock issued by the Company in connection with the
exchange by any <FONT STYLE="white-space:nowrap">Up-C</FONT> Unit Holder (as defined below) of <FONT STYLE="white-space:nowrap">Up-C</FONT> Units for shares of Class&nbsp;A Common Stock, in accordance with the terms of the Exchange Agreement, and
(ii)&nbsp;any shares of Class&nbsp;A Common Stock issued or issuable with respect to the securities referred to in clause <U>(i)</U>&nbsp;above by way of dividend, distribution, split or combination of securities, or any recapitalization, merger,
consolidation or other reorganization. As to any particular Registrable Securities owned by any Person, such securities shall cease to be Registrable Securities on the date (i)&nbsp;such securities have been sold or distributed pursuant to a Public
Offering, or (ii)&nbsp;such securities are sold in a transaction in compliance with Rule 144 under the Securities Act. For purposes of this Agreement, a Person shall be deemed to be a Holder, and the Registrable Securities shall be deemed to be in
existence, whenever such Person has the right to acquire, directly or indirectly, such Registrable Securities (upon conversion or exercise in connection with a transfer of securities or otherwise, but disregarding any restrictions or limitations
upon the exercise of such right), whether or not such acquisition has actually been effected, and such Person shall be entitled to exercise the rights of a holder of Registrable Securities hereunder, <I>provided</I> that a holder of Registrable
Securities may only request that the resale of Registrable Securities in the form of Class&nbsp;A Common Stock of the Company be registered under this Agreement. Notwithstanding the foregoing, if a Holder holds Registrable Securities that are
eligible to be sold without restriction under Rule 144 under the Securities Act (other than the restriction set forth under Rule 144(i)), then, at such Holder&#146;s request the Company shall cause, at the Company&#146;s sole cost and expense, the
Company&#146;s transfer agent to remove any restrictive legend set forth on the Registrable Securities held by such Holder in connection with any sale of such Registrable Securities pursuant to Rule 144. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Registration Expenses</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;6(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Rule 144</U>,&#148; &#147;<U>Rule 158</U>,&#148; &#147;<U>Rule 405</U>&#148; and &#147;<U>Rule 415</U>&#148; mean, in each case, such
rule promulgated under the Securities Act (or any successor provision) by the Securities and Exchange Commission, as the same shall be amended from time to time, or any successor rule then in force. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Schedule of Investors</U>&#148; means the schedule attached to this Agreement entitled &#147;Schedule of Investors&#148;, which shall
reflect each Holder from time to time party to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Securities Act</U>&#148; means the U.S. Securities Act of 1933,
as amended from time to time, or any successor federal law then in force, together with all rules and regulations promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Share Settlement</U>&#148; means &#147;Share Settlement&#148; as defined in the Exchange Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Shelf Offering</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2(c)(ii)</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Shelf Offering Notice</U>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;2(c)(ii)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Shelf Offering Request</U>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;2(c)(ii)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Shelf Registrable Securities</U>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;2(c)(ii)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Shelf Registration</U>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;2(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Shelf Registration Statement</U>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;2(c)(i)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Subsidiary</U>&#148; means, with respect to the Company, any Company, limited
liability company, partnership, association or other business entity of which (i)&nbsp;if a Company, a majority of the total voting power of Capital Stock of such Person entitled (without regard to the occurrence of any contingency) to vote in the
election of directors is at the time owned or controlled, directly or indirectly, by the Company, or (ii)&nbsp;if a limited liability company, partnership, association or other business entity, either (x)&nbsp;a majority of the Capital Stock of such
Person entitled (without regard to the occurrence of any contingency) to vote in the election of managers, general partners or other oversight board vested with the authority to direct management of such Person is at the time owned or controlled,
directly or indirectly, by the Company or (y)&nbsp;the Company or one of its Subsidiaries is the sole manager or general partner of such Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Suspension Event</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2(e)(ii)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Suspension Notice</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2(e)(ii)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Suspension Period</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2(e)(i)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Underwritten Takedown</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2(c)(ii)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U><FONT STYLE="white-space:nowrap">Up-C</FONT> Units</U>&#148; has the meaning set forth in the recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U><FONT STYLE="white-space:nowrap">Up-C</FONT> Unit Holders</U>&#148; means the holders of <FONT STYLE="white-space:nowrap">Up-C</FONT>
Units, and shall be deemed to include their respective Affiliates, heirs, successors and assigns who may succeed to such Person as a Holder hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Violation</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;7(a)</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp;<U>Demand Registrations</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Requests for Registration</U>. Subject to the terms and conditions of this Agreement, each Holder may request
registration under the Securities Act of all or any portion of their Registrable Securities on Form <FONT STYLE="white-space:nowrap">S-1</FONT> or any other appropriate long-form registration form under the Securities Act in connection with an
underwritten offering, <I>provided</I> that such request must relate to Registrable Securities with a market value of at least $20&nbsp;million. All registrations requested pursuant to this <U>Section</U><U></U><U>&nbsp;2(a)</U> are referred to
herein as &#147;<U>Demand Registrations</U>.&#148; Within seven days after the filing of the registration statement relating to the Demand Registration, the Company shall give written notice of the Demand Registration to all other Holders and,
subject to the terms of <U>Section</U><U></U><U>&nbsp;2(d)</U>, shall include in such Demand Registration (and in all related registrations and qualifications under state blue sky laws and in any related underwriting) all Registrable Securities with
respect to which the Company has received written requests for inclusion therein within 15 days after the receipt of the Company&#146;s notice; <I>provided</I> that the Company shall provide notice of the Demand Registration to all other Holders
prior to the <FONT STYLE="white-space:nowrap">non-confidential</FONT> filing of the registration statement with respect to the Demand Registration. Each Holder agrees that (1)&nbsp;such notice constitutes MNPI and that it will not engage in any
transaction in any securities of the Company until such notice and the information contained therein ceases to constitute MNPI and (2)&nbsp;such Holder shall treat as confidential the receipt of the notice of Demand Registration and shall not
disclose </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or use the information contained in such notice of Demand Registration without the prior written consent of the Company until such time as the information contained therein is or becomes
available to the public generally, other than as a result of disclosure by the Holder in breach of the terms of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;At any time in which the Shelf Registration Statement in Section&nbsp;2(c)(i) is effective, Section&nbsp;2(a) shall
be inapplicable, and Section&nbsp;2(c) shall control. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Shelf Registrations</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;Subject to the availability of required financial information, as promptly as practicable after the Company
receives written notice of a request that a registration be made pursuant to Rule 415 under the Securities Act (a &#147;<U>Shelf Registration</U>&#148;), the Company shall file with the Securities and Exchange Commission a registration statement
under the Securities Act for the Shelf Registration (a &#147;<U>Shelf Registration Statement</U>&#148;). The Company shall use its reasonable best efforts to cause any Shelf Registration to be registered on Form
<FONT STYLE="white-space:nowrap">S-3</FONT> (or any successor form), and the Company shall use its reasonable best efforts to remain eligible to use Form <FONT STYLE="white-space:nowrap">S-3</FONT> (including, if applicable, an automatic shelf
registration statement (as defined in Rule 405 under the Securities Act) (an &#147;<U>Automatic Shelf Registration Statement</U>&#148;)). The Company shall use its reasonable best efforts to cause any Shelf Registration Statement to be declared
effective under the Securities Act as soon as practicable after the initial filing of such Shelf Registration Statement, and once effective, the Company shall cause such Shelf Registration Statement to remain continuously effective, and to be
supplemented and amended to the extent necessary to ensure that such Shelf Registration Statement is available or, if not available, that another Shelf Registration Statement is available, for the resale of all the Registrable Securities held by the
Holders, for no time period longer than the period ending on the earliest of (A)&nbsp;the tenth anniversary of the initial effective date of such Shelf Registration Statement, (B)&nbsp;the date on which all Registrable Securities covered by such
Shelf Registration Statement have been sold pursuant to the Shelf Registration Statement, and (C)&nbsp;the date as of which there are no longer any Registrable Securities covered by such Shelf Registration Statement in existence. Without limiting
the generality of the foregoing, the Company shall use its reasonable best efforts to prepare a Shelf Registration Statement with respect to all of the Registrable Securities owned by or issuable to the <FONT STYLE="white-space:nowrap">Up-C</FONT>
Unit Holders in accordance with the terms of the Exchange Agreement to enable and cause such Shelf Registration Statement to be filed and maintained with the Securities and Exchange Commission within 30 days following the consummation of the
transactions contemplated by the Merger Agreement; provided that any of the <FONT STYLE="white-space:nowrap">Up-C</FONT> Unit Holders may, with respect to itself, instruct the Company in writing not to include in such Shelf Registration Statement
the Registrable Securities owned by or issuable to such <FONT STYLE="white-space:nowrap">Up-C</FONT> Unit Holder. In order for any of the <FONT STYLE="white-space:nowrap">Up-C</FONT> Unit Holders to be named as a selling securityholder in such Shelf
Registration Statement, the Company may require such Holder to deliver all information about such Holder that is required to be included in such Shelf Registration Statement in accordance with applicable law, including Item 507 of Regulation <FONT
STYLE="white-space:nowrap">S-K</FONT> promulgated under the Securities Act, as amended from time to time, or any similar successor rule thereto. Notwithstanding anything to the contrary in <U>Section</U><U></U><U>&nbsp;2(c)(ii)</U>, any Holder that
is named as a selling securityholder in such Shelf Registration Statement may make a secondary resale under such Shelf Registration Statement without the consent of the Holders representing a majority of the Registrable Securities or any other
Holder if such resale does not require a supplement to the Shelf Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;In the event that a
Shelf Registration Statement is effective, Holders of Registrable Securities shall have the right at any time or from time to time to elect to sell pursuant to an offering (including an underwritten offering (an &#147;<U>Underwritten
Takedown</U>&#148;)) Registrable Securities available for sale pursuant to such registration statement (&#147;<U>Shelf Registrable Securities</U>&#148;), so long as the Shelf Registration Statement remains in effect, <I>provided</I> that the amount
of Registrable Securities requested to be included in such Shelf Offering Request (including any Registrable Securities included pursuant to the third succeeding sentence) is reasonably expected to result in aggregate gross proceeds in excess of
$20&nbsp;million. The Company shall pay all Registration Expenses in connection with any Underwritten Takedown. The applicable Holders shall make such election by delivering to the Company a written request (a &#147;<U>Shelf Offering
Request</U>&#148;) for such offering specifying the number of Shelf Registrable Securities that such Holders desire to sell pursuant to such offering </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(the&nbsp;&#147;<U>Shelf</U>&nbsp;<U>Offering</U>&#148;). As promptly as practicable, but no later than two Business Days after receipt of a Shelf Offering Request, the Company shall give written
notice (the &#147;<U>Shelf Offering Notice</U>&#148;) of such Shelf Offering Request to all other holders of Shelf Registrable Securities. The Company, subject to <U>Sections 2(d)</U> and <U>8</U> hereof, shall include in such Shelf Offering the
Shelf Registrable Securities of any other Holder that shall have made a written request to the Company for inclusion in such Shelf Offering (which request shall specify the maximum number of Shelf Registrable Securities intended to be sold by such
Holder) within seven days after the receipt of the Shelf Offering Notice. The Company shall, as expeditiously as possible (and in any event within 10 days after the receipt of a Shelf Offering Request, unless a longer period is agreed to by the
Holders representing a majority of the Registrable Securities that made the Shelf Offering Request), use its reasonable best efforts to facilitate such Shelf Offering. Each Holder agrees that (1)&nbsp;such notice constitutes MNPI and that it will
not engage in any transaction in any securities of the Company until such notice and the information contained therein ceases to constitute MNPI and (2)&nbsp;such Holder shall treat as confidential the receipt of the Shelf Offering Notice and shall
not disclose or use the information contained in such Shelf Offering Notice without the prior written consent of the Company until such time as the information contained therein is or becomes available to the public generally, other than as a result
of disclosure by the Holder in breach of the terms of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding the foregoing, if a
Holder wishes to engage in an underwritten block trade off of a Shelf Registration Statement (either through filing an Automatic Shelf Registration Statement or through a take-down from an existing Shelf Registration Statement), then notwithstanding
the foregoing time periods, such Holders only need to notify the Company of the block trade Shelf Offering two Business Days prior to the day such offering is to commence (unless a longer period is agreed to by Holders representing a majority of the
Registrable Securities wishing to engage in the underwritten block trade) and the Company shall promptly notify other Holders and such other Holders must elect whether or not to participate by the next Business Day (<I>i.e.</I>, one Business Day
prior to the day such offering is to commence) (unless a longer period is agreed to by Holders representing a majority of the Registrable Securities wishing to engage in the underwritten block trade) and the Company shall as expeditiously as
possible use its reasonable best efforts to facilitate such offering (which may close as early as three Business Days after the date it commences); <I>provided</I> that Holders representing a majority of the Registrable Securities wishing to engage
in the underwritten block trade shall use commercially reasonable best efforts to work with the Company and the underwriters prior to making such request in order to facilitate preparation of the registration statement, prospectus and other offering
documentation related to the underwritten block trade. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;The Company shall, at the request of Holders
representing a majority of the Registrable Securities covered by a Shelf Registration Statement, file any prospectus supplement or, if the applicable Shelf Registration Statement is an Automatic Shelf Registration Statement, any post-effective
amendments and otherwise take any action necessary to include therein all disclosure and language deemed necessary or advisable by such Holders to effect such Shelf Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Priority on Demand Registrations and Shelf Offerings</U>. The Company shall not include in any Demand
Registration or Shelf Offering any securities that are not Registrable Securities without the prior written consent of Holders representing a majority of the Registrable Securities included in such registration or offering. If a Demand Registration
or a Shelf Offering is an underwritten offering and the managing underwriters advise the Company in writing that in their opinion the number of Registrable Securities and, if permitted hereunder, other securities requested to be included in such
offering exceeds the number of Registrable Securities and other securities, if any, that can be sold therein without adversely affecting the marketability, proposed offering price, timing or method of distribution of the offering, the Company shall
include in such registration or offering, as applicable, prior to the inclusion of any securities which are not Registrable Securities the number of Registrable Securities requested by Holders to be included that, in the opinion of such
underwriters, can be sold, without any such adverse effect, pro rata among the respective Holders thereof on the basis of the amount of Registrable Securities owned by each such Holder that such Holder of Registrable Securities shall have requested
to be included therein. Alternatively, if the number of Registrable Securities which can be included on a Shelf Registration Statement is otherwise limited by Instruction I.B.6 to Form <FONT STYLE="white-space:nowrap">S-3</FONT> (or any successor
provision thereto), </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to the extent applicable, the Company shall include in such registration or offering prior to the inclusion of any securities which are not Registrable Securities the number of Registrable
Securities requested to be included which can be included on such Shelf Registration Statement in accordance with the requirements of Form <FONT STYLE="white-space:nowrap">S-3,</FONT> pro rata among the respective Holders thereof on the basis of the
amount of Registrable Securities owned by each such Holder that such Holder of Registrable Securities shall have requested to be included therein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Restrictions on Demand Registration and Shelf Offerings</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;The Company shall not be obligated to effect any Demand Registration within 90 days after the effective date of a
previous Demand Registration or a previous registration in which Registrable Securities were included pursuant to <U>Section</U><U></U><U>&nbsp;3</U> and in which there was no reduction in the number of Registrable Securities requested to be
included. The Company may postpone, for up to 60 days from the date of the request, the filing or the effectiveness of a registration statement for a Demand Registration or suspend the use of a prospectus that is part of a Shelf Registration
Statement for up to 60 days from the date of the Suspension Notice (as defined below) and therefore suspend sales of the Shelf Registrable Securities (such period, the &#147;<U>Suspension Period</U>&#148;) by providing written notice to the Holders
if (A)&nbsp;the Company&#146;s board of directors determines in its reasonable good faith judgment that the offer or sale of Registrable Securities would reasonably be expected to have a material adverse effect on any proposal or plan by the Company
or any Subsidiary to engage in any material acquisition of assets or stock (other than in the ordinary course of business) or any material merger, consolidation, tender offer, recapitalization, reorganization or other transaction involving the
Company or any Subsidiary, (B)&nbsp;upon advice of counsel, the sale of Registrable Securities pursuant to the registration statement would require disclosure of MNPI not otherwise required to be disclosed under applicable law, and (C)&nbsp;either
(x) the Company has a bona fide business purpose for preserving the confidentiality of such transaction or (y)&nbsp;disclosure of such MNPI would have a material adverse effect on the Company or the Company&#146;s ability to consummate such
transaction; <I>provided</I> that in such event, the Holders shall be entitled to withdraw such request for a Demand Registration or underwritten Shelf Offering and the Company shall pay all Registration Expenses in connection with such Demand
Registration or Shelf Offering. The Company may delay a Demand Registration or underwritten Shelf Offering hereunder only once in any twelve-month period, except with the consent of the applicable Holder(s). The Company also may extend the
Suspension Period with the consent of the applicable Holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;In the case of an event that causes the Company
to suspend the use of a Shelf Registration Statement as set forth in paragraph (f)(i) above or pursuant to applicable subsections of <U>Section</U><U></U><U>&nbsp;5(a)(vi)</U> (a &#147;<U>Suspension Event</U>&#148;), the Company shall give a notice
to the Holders of Registrable Securities registered pursuant to such Shelf Registration Statement (a &#147;<U>Suspension Notice</U>&#148;) to suspend sales of the Registrable Securities and such notice shall state generally the basis for the notice
and that such suspension shall continue only for so long as the Suspension Event or its effect is continuing. If the basis of such suspension is nondisclosure of MNPI, the Company shall not be required to disclose the subject matter of such MNPI to
Holders. A Holder shall not affect any sales of the Registrable Securities pursuant to such Shelf Registration Statement (or such filings) at any time after it has received a Suspension Notice from the Company and prior to receipt of an End of
Suspension Notice (as defined below). Each Holder agrees that (1)&nbsp;such notice constitutes MNPI and that it will not engage in any transaction in any securities of the Company until such notice and the information contained therein ceases to
constitute MNPI and (2)&nbsp;such Holder shall treat as confidential the receipt of the Suspension Notice and shall not disclose or use the information contained in such Suspension Notice without the prior written consent of the Company until such
time as the information contained therein is or becomes available to the public generally, other than as a result of disclosure by the Holder in breach of the terms of this Agreement. Holders may recommence effecting sales of the Registrable
Securities pursuant to the Shelf Registration Statement (or such filings) following further written notice to such effect (an &#147;<U>End of Suspension Notice</U>&#148;) from the Company, which End of Suspension Notice shall be given by the Company
to the Holders and their counsel, if any, promptly following the conclusion of any Suspension Event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding any provision herein to the contrary, if the Company gives a Suspension Notice with respect to
any Shelf Registration Statement pursuant to this <U>Section</U><U></U><U>&nbsp;2(e)</U>, the Company agrees that it </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shall (A)&nbsp;extend the period of time during which such Shelf Registration Statement shall be maintained effective pursuant to this Agreement by the number of days during the period from the
date of receipt by the Holders of the Suspension Notice to and including the date of receipt by the Holders of the End of Suspension Notice, and (B)&nbsp;provide copies of any supplemented or amended prospectus necessary to resume sales, with
respect to each Suspension Event; <I>provided</I> that such period of time shall not be extended beyond the date that there are no longer Registrable Securities covered by such Shelf Registration Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;<U>Selection of Underwriters</U>. Holders representing a majority of the Registrable Securities included in any
Demand Registration shall have the right to select the investment banker(s) and manager(s) to administer the offering (including assignment of titles), subject to the Company&#146;s approval not be unreasonably withheld, conditioned or delayed. If
any Shelf Offering is an Underwritten Takedown, the Holders representing a majority of the Registrable Securities participating in such Underwritten Takedown shall have the right to select the investment banker(s) and manager(s) to administer the
offering relating to such Shelf Offering (including assignment of titles), subject to the Company&#146;s approval not be unreasonably withheld, conditioned or delayed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;<U>Other Registration Rights</U>. The Company represents and warrants that it is not a party to, or otherwise
subject to, any other agreement granting registration rights to any other Person with respect to any securities of the Company. Except as provided in this Agreement, the Company shall not grant to any Persons the right to request the Company or any
Subsidiary to register any Capital Stock of the Company or of any Subsidiary, or any securities convertible or exchangeable into or exercisable for such securities, without the prior written consent of the Cibus Global
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Majority-in-Interest.</FONT></FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Piggyback Registrations</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Right to Piggyback</U>. Following the consummation of the Merger Agreement, whenever the Company proposes to
register any of its securities under the Securities Act (other than (i)&nbsp;pursuant to a Demand Registration, (ii)&nbsp;in connection with registrations on Form <FONT STYLE="white-space:nowrap">S-4</FONT> or
<FONT STYLE="white-space:nowrap">S-8</FONT> promulgated by the Securities and Exchange Commission or any successor or similar forms or (iii)&nbsp;a registration on any form that does not include substantially the same information as would be
required to be included in a registration statement covering the sale of Registrable Securities) and the registration form to be used may be used for the registration of Registrable Securities (a &#147;<U>Piggyback Registration</U>&#148;), the
Company shall give prompt written notice (in any event within three Business Days after its receipt of notice of any request for registration on behalf of holders of the Company&#146;s securities (other than by the Holders) to all Holders of its
intention to effect such Piggyback Registration and, subject to the terms of <U>Section</U><U></U><U>&nbsp;3(c)</U> and <U>Section</U><U></U><U>&nbsp;3(d)</U>, shall include in such Piggyback Registration (and in all related registrations or
qualifications under blue sky laws and in any related underwriting) all Registrable Securities with respect to which the Company has received written requests for inclusion therein within 20 days after delivery of the Company&#146;s notice. A
Piggyback Registration shall not be considered a Demand Registration or a Shelf Offering Request for purposes of <U>Section</U><U></U><U>&nbsp;2</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Piggyback Expenses</U>. The Registration Expenses of the Holders shall be paid by the Company in all Piggyback
Registrations, whether or not any such registration became effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Priority on Primary
Registrations</U>. If a Piggyback Registration is an underwritten primary registration on behalf of the Company, and the managing underwriters advise the Company in writing that in their reasonable and good faith opinion the number of securities
requested to be included in such registration (including all Registrable Securities and all other securities proposed to be included in such underwritten offering) exceeds the number which can be sold in such offering without adversely affecting the
marketability, proposed offering price, timing or method of distribution of the offering, the Company shall include in such registration (i)&nbsp;first, the securities the Company proposes to sell, (ii)&nbsp;second, the Registrable Securities
requested to be included in such registration which, in the opinion of the underwriters, can be sold without any such adverse effect, pro rata among the Holders on the basis of the number of Registrable Securities owned by each such Holder that such
Holder of Registrable Securities shall have requested to be included therein, and (iii)&nbsp;third, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other securities requested to be included in such registration which, in the opinion of the underwriters, can be sold without any such adverse effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Priority on Secondary Registrations</U>. If a Piggyback Registration is an underwritten secondary registration
on behalf of holders of the Company&#146;s securities (other than the Holders), and the managing underwriters advise the Company in writing that in their reasonable and good faith opinion the number of securities requested to be included in such
registration (including all Registrable Securities and all other securities proposed to be included in such underwritten offering) exceeds the number which can be sold in such offering without adversely affecting the marketability, proposed offering
price, timing or method of distribution of the offering, the Company shall include in such registration (i)&nbsp;first, the securities requested to be included therein by the initial holders requesting such registration which, in the opinion of the
underwriters, can be sold without any such adverse effect, (ii)&nbsp;second, the Registrable Securities of Holders requested to be included in such registration which, in the opinion of the underwriters, can be sold without any such adverse effect,
pro rata among the such Holders on the basis of the number of Registrable Securities owned by each such Holder that such Holder of Registrable Securities shall have requested to be included therein and (iii)&nbsp;third, other securities requested to
be included in such registration which, in the opinion of the underwriters, can be sold without any such adverse effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Selection of Underwriters</U>. If any Piggyback Registration is an underwritten offering, the selection of
investment banker(s) and manager(s) for the offering shall be at the election of the Company (in the case of a primary registration) or at the election of the majority of the holders of other Company securities requesting such registration (in the
case of a secondary registration); <I>provided</I> that Holders representing a majority of the Registrable Securities included in such Piggyback Registration may request that one or more investment banker(s) or manager(s) be included in such
offering (such request not to be binding on the Company or such other initiating holders of Company securities). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;<U>Right to Terminate Registration</U>. The Company shall have the right to terminate or withdraw any registration
initiated by it under this <U>Section</U><U></U><U>&nbsp;3</U> whether or not any Holder has elected to include securities in such registration. The Registration Expenses of such withdrawn registration shall be borne by the Company in accordance
with <U>Section</U><U></U><U>&nbsp;6</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.&nbsp;&nbsp;&nbsp;&nbsp;<U>Holdback Agreements</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;If requested by the Company or the managing underwriter(s), each Holder participating in an underwritten Public
Offering shall enter into customary <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the managing underwriter(s) of such Public Offering. In the absence of any such <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement, each
Holder participating in an underwritten Public Offering agrees as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;in the event of an underwritten
Public Offering by the Company (whether for the account of the Company or otherwise), not to offer, sell, contract to sell or otherwise dispose of any Registrable Securities, or any securities convertible into or exchangeable or exercisable for such
securities, including any sale pursuant to Rule 144 under the Securities Act (except as part of such underwritten Public Offering), during the seven days prior to, and during the <FONT STYLE="white-space:nowrap">90-day</FONT> period (the
&#147;<U>Holdback Period</U>&#148;) beginning on the effective date of the registration statement for such underwritten Public Offering (or, in the case of an underwritten Public Offering pursuant to an effective shelf registration statement
pursuant to Rule 415, the pricing date for such underwritten Public Offering); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;in the event that
(A)&nbsp;the Company issues an earnings release or discloses other material information or a material event relating to the Company and its Subsidiaries occurs during the last 17 days of any Holdback Period or (B)&nbsp;prior to the expiration of any
Holdback Period, the Company announces that it will release earnings results during the <FONT STYLE="white-space:nowrap">16-day</FONT> period beginning upon the expiration of such Holdback Period, then to the extent necessary for a managing or <FONT
STYLE="white-space:nowrap">co-managing</FONT> underwriter of a registered offering hereunder to comply </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with FINRA Rule 2711(f)(4), if agreed to by the Holders representing a majority of the Registrable Securities included in such Underwritten Takedown, the Holdback Period shall be extended until
18 days after the earnings release or disclosure of other material information or the occurrence of the material event, as the case may be. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.&nbsp;&nbsp;&nbsp;&nbsp;<U>Registration Procedures</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Whenever the Holders have requested that any Registrable Securities be registered pursuant to this Agreement or have
initiated a Shelf Offering, the Company shall use its reasonable best efforts to effect the registration and the sale of such Registrable Securities in accordance with the intended method of disposition thereof, and pursuant thereto the Company
shall as expeditiously as possible: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;in accordance with the Securities Act and all applicable rules and
regulations promulgated thereunder, prepare and file with the Securities and Exchange Commission a registration statement, and all amendments and supplements thereto and related prospectuses, with respect to such Registrable Securities and use its
reasonable best efforts to cause such registration statement to become effective (provided that before filing a registration statement or prospectus or any amendments or supplements thereto, the Company shall furnish to the counsel selected by the
Holders representing a majority of the Registrable Securities covered by such registration statement copies of all such documents proposed to be filed, which documents shall be subject to the review and comment of such counsel); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;notify each holder of Registrable Securities of (A)&nbsp;the issuance by the Securities and Exchange Commission
of any stop order suspending the effectiveness of any registration statement or the initiation of any proceedings for that purpose, (B)&nbsp;the receipt by the Company or its counsel of any notification with respect to the suspension of the
qualification of the Registrable Securities for sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose and (C)&nbsp;the effectiveness of each registration statement filed hereunder; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;prepare and file with the Securities and Exchange Commission such amendments and supplements to such
registration statement and the prospectus used in connection therewith as may be necessary to keep such registration statement effective for a period ending when all of the securities covered by such registration statement have been disposed of in
accordance with the intended methods of distribution by the sellers thereof set forth in such registration statement (but in any event not before the expiration of any longer period required under the Securities Act) and comply with the provisions
of the Securities Act with respect to the disposition of all securities covered by such registration statement during such period in accordance with the intended methods of disposition by the sellers thereof set forth in such registration statement;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;furnish to each seller of Registrable Securities thereunder such number of copies of such registration
statement, each amendment and supplement thereto, the prospectus included in such registration statement (including each preliminary prospectus), each Free Writing Prospectus and such other documents as such seller may reasonably request in order to
facilitate the disposition of the Registrable Securities owned by such seller; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v)&nbsp;&nbsp;&nbsp;&nbsp;use its reasonable best
efforts to register or qualify such Registrable Securities under such other securities or blue sky laws of such jurisdictions as any seller reasonably requests and do any and all other acts and things which may be reasonably necessary or advisable
to enable such seller to consummate the disposition in such jurisdictions of the Registrable Securities owned by such seller (provided that the Company shall not be required to (A)&nbsp;qualify generally to do business in any jurisdiction where it
would not otherwise be required to qualify but for this subparagraph, (B)&nbsp;consent to general service of process in any such jurisdiction or (C)&nbsp;subject itself to taxation in any such jurisdiction); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi)&nbsp;&nbsp;&nbsp;&nbsp;notify each seller of such Registrable Securities (A)&nbsp;promptly after it receives notice thereof, of the date
and time when such registration statement and each post-effective amendment thereto has become </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
effective or a prospectus or supplement to any prospectus relating to a registration statement has been filed and when any registration or qualification has become effective under a state
securities or blue sky law or any exemption thereunder has been obtained, (B)&nbsp;promptly after receipt thereof, of any request by the Securities and Exchange Commission for the amendment or supplementing of such registration statement or
prospectus or for additional information and (C)&nbsp;at any time when a prospectus relating thereto is required to be delivered under the Securities Act, of the happening of any event as a result of which the prospectus included in such
registration statement contains an untrue statement of a material fact or omits any fact necessary to make the statements therein not misleading, and, subject to <U>Section</U><U></U><U>&nbsp;2(e)</U>, at the request of any such seller, the Company
shall prepare a supplement or amendment to such prospectus so that, as thereafter delivered to the purchasers of such Registrable Securities, such prospectus shall not contain an untrue statement of a material fact or omit to state any fact
necessary to make the statements therein not misleading; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii)&nbsp;&nbsp;&nbsp;&nbsp;use reasonable best efforts to cause all such
Registrable Securities to be listed on each securities exchange on which similar securities issued by the Company are then listed and, if not so listed, to be listed on a securities exchange and, without limiting the generality of the foregoing, to
arrange for at least two market markers to register as such with respect to such Registrable Securities with FINRA; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(viii)&nbsp;&nbsp;&nbsp;&nbsp;use reasonable best efforts to provide a transfer agent and registrar for all such Registrable Securities not
later than the effective date of such registration statement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ix)&nbsp;&nbsp;&nbsp;&nbsp;enter into and perform such customary
agreements (including underwriting agreements in customary form) and take all such other actions as the Holders representing a majority of the Registrable Securities being sold or the underwriters, if any, reasonably request in order to expedite or
facilitate the disposition of such Registrable Securities (including, without limitation, effecting a stock split, combination of shares, recapitalization or reorganization); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(x)&nbsp;&nbsp;&nbsp;&nbsp;make available for inspection by any seller of Registrable Securities, any underwriter participating in any
disposition pursuant to such registration statement and any attorney, accountant or other agent retained by any such seller or underwriter, all financial and other records, pertinent corporate and business documents and properties of the Company as
shall be necessary to enable them to exercise their due diligence responsibility, and cause the Company&#146;s officers, directors, employees, agents, representatives and independent accountants to supply all information reasonably requested by any
such seller, underwriter, attorney, accountant or agent in connection with such registration statement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xi)&nbsp;&nbsp;&nbsp;&nbsp;take
all reasonable actions to ensure that any Free-Writing Prospectus utilized in connection with any Demand Registration or Piggyback Registration hereunder complies in all material respects with the Securities Act, is filed in accordance with the
Securities Act to the extent required thereby, is retained in accordance with the Securities Act to the extent required thereby and, when taken together with the related prospectus, shall not contain any untrue statement of a material fact or omit
to state a material fact necessary to make the statements therein, in light of the circumstances under which they were made, not misleading; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xii)&nbsp;&nbsp;&nbsp;&nbsp;otherwise use its reasonable best efforts to comply with all applicable rules and regulations of the Securities
and Exchange Commission, and make available to its security holders, as soon as reasonably practicable, an earnings statement covering the period of at least twelve months beginning with the first day of the Company&#146;s first full calendar
quarter after the effective date of the registration statement, which earnings statement shall satisfy the provisions of Section&nbsp;11(a) of the Securities Act and Rule 158; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xiii)&nbsp;&nbsp;&nbsp;&nbsp;to the extent that a Holder, in its sole and exclusive judgment, might be deemed to be an underwriter of any
Registrable Securities or a controlling person of the Company, permit such Holder to participate in the preparation of such registration or comparable statement and allow such Holder to provide language for insertion therein, in form and substance
satisfactory to the Company, which in the reasonable judgment of such Holder and its counsel should be included; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xiv)&nbsp;&nbsp;&nbsp;&nbsp;in the event of the issuance of any stop order suspending the
effectiveness of a registration statement, or the issuance of any order suspending or preventing the use of any related prospectus or suspending the qualification of any shares of Class&nbsp;A Common Stock included in such registration statement for
sale in any jurisdiction use reasonable best efforts promptly to obtain the withdrawal of such order; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xv)&nbsp;&nbsp;&nbsp;&nbsp;use
its reasonable best efforts to cause such Registrable Securities covered by such registration statement to be registered with or approved by such other governmental agencies or authorities as may be necessary to enable the sellers thereof to
consummate the disposition of such Registrable Securities; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xvi)&nbsp;&nbsp;&nbsp;&nbsp;cooperate with the Holders of Registrable
Securities covered by the registration statement and the managing underwriter or agent, if any, to facilitate the timely preparation and delivery of certificates (not bearing any restrictive legends) representing securities to be sold under the
registration statement and enable such securities to be in such denominations and registered in such names as the managing underwriter, or agent, if any, or such Holders may request; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xvii)&nbsp;&nbsp;&nbsp;&nbsp;cooperate with each Holder of Registrable Securities covered by the registration statement and each underwriter
or agent participating in the disposition of such Registrable Securities and their respective counsel in connection with any filings required to be made with FINRA; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xviii)&nbsp;&nbsp;&nbsp;&nbsp;use its reasonable best efforts to make available the executive officers of the Company to participate with
the Holders of Registrable Securities covered by the registration statement and any underwriters in any &#147;road shows&#148; or other selling efforts that may be reasonably requested by the Holders in connection with the methods of distribution
for the Registrable Securities; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xix)&nbsp;&nbsp;&nbsp;&nbsp;in the case of any underwritten Public Offering, use its reasonable best
efforts to obtain one or more cold comfort letters from the Company&#146;s independent public accountants in customary form and covering such matters of the type customarily covered by cold comfort letters as the Holders representing a majority of
the Registrable Securities being sold reasonably request; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xx)&nbsp;&nbsp;&nbsp;&nbsp;in the case of any underwritten Public Offering,
use its reasonable best efforts to provide a legal opinion of the Company&#146;s outside counsel, dated the effective date of such registration statement and the date of the closing under the underwriting agreement, the registration statement, each
amendment and supplement thereto, the prospectus included therein (including the preliminary prospectus) and such other documents relating thereto in customary form and covering such matters of the type customarily covered by legal opinions of such
nature, which opinion shall be addressed to the underwriters and the Holders of such Registrable Securities being sold; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xxi)&nbsp;&nbsp;&nbsp;&nbsp;if the Company has not previously paid the filing fee covering the Registrable Securities, pay such fee at such
time or times as the Registrable Securities are to be sold; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xxii)&nbsp;&nbsp;&nbsp;&nbsp;otherwise, in good faith, cooperate
reasonably with, and take such customary actions as may reasonably be requested by the Holders, in connection with such Registration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Any officer of the Company who is a Holder agrees that if and for so long as he or she is employed by the Company
or any Subsidiary thereof, he or she shall participate fully in the sale process in a manner customary and reasonable for persons in like positions and consistent with his or her other duties with the Company and in accordance with applicable law,
including the preparation of the registration statement and the preparation and presentation of any road shows. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;The Company may require each Holder requesting, or electing to participate in, any registration to furnish the
Company such information regarding such Holder and the distribution of such Registrable Securities as the Company may from time to time reasonably request in writing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;If the <FONT STYLE="white-space:nowrap">Up-C</FONT> Unit Holders
or any of their respective Affiliates seek to effectuate an <FONT STYLE="white-space:nowrap">in-kind</FONT> distribution of all or part of their respective Registrable Securities to their respective direct or indirect equityholders, the Company
shall work with the foregoing persons to facilitate such <FONT STYLE="white-space:nowrap">in-kind</FONT> distribution in the manner reasonably requested. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.&nbsp;&nbsp;&nbsp;&nbsp;<U>Registration Expenses</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>The Company&#146;s Obligation</U>. All expenses incident to the Company&#146;s performance of or compliance with
this Agreement (including, without limitation, all registration, qualification and filing fees, fees and expenses of compliance with securities or blue sky laws, printing expenses, messenger and delivery expenses, fees and disbursements of
custodians, and fees and disbursements of counsel for the Company and all independent certified public accountants, underwriters (excluding underwriting discounts and commissions) and other Persons retained by the Company) (all such expenses being
herein called &#147;<U>Registration Expenses</U>&#148;), shall be borne as provided in this Agreement, except that the Company shall, in any event, pay its internal expenses (including, without limitation, all salaries and expenses of its officers
and employees performing legal or accounting duties), the expense of any annual audit or quarterly review, the expense of any liability insurance and the expenses and fees for listing the securities to be registered on each securities exchange on
which similar securities issued by the Company are then listed. Each Person that sells securities pursuant to a Demand Registration or Piggyback Registration hereunder shall bear and pay all underwriting discounts and commissions applicable to the
securities sold for such Person&#146;s account. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Counsel Fees and Disbursements</U>. In connection with each
Demand Registration, each Piggyback Registration and each Shelf Offering that is an underwritten Public Offering, the Company shall reimburse the Holders of Registrable Securities included in such registration for the reasonable fees and
disbursements of one counsel chosen by the Holders representing a majority of the Registrable Securities included in such registration or participating in such Shelf Offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification and Contribution</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>By the Company</U>. The Company shall indemnify and hold harmless, to the extent permitted by law, each Holder,
such Holder&#146;s officers, directors, managers, employees, agents and representatives, and each Person who controls such Holder (within the meaning of the Securities Act) (the &#147;<U>Holder Indemnified Parties</U>&#148;) against all losses,
claims, actions, damages, liabilities and expenses (including with respect to actions or proceedings, whether commenced or threatened, and including reasonable attorney fees and expenses) caused by, resulting from, arising out of, based upon or
related to any of the following statements, omissions or violations (each a &#147;<U>Violation</U>&#148;) by the Company: (i)&nbsp;any untrue or alleged untrue statement of material fact contained in (A)&nbsp;any registration statement, prospectus,
preliminary prospectus or Free-Writing Prospectus, or any amendment thereof or supplement thereto or (B)&nbsp;any application or other document or communication (in this <U>Section</U><U></U><U>&nbsp;7</U>, collectively called an
&#147;<U>application</U>&#148;) executed by or on behalf of the Company or based upon written information furnished by or on behalf of the Company filed in any jurisdiction in order to qualify any securities covered by such registration under the
securities laws thereof, (ii)&nbsp;any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein not misleading or (iii)&nbsp;any violation or alleged violation by the Company of the
Securities Act or any other similar federal or state securities laws or any rule or regulation promulgated thereunder applicable to the Company and relating to action or inaction required of the Company in connection with any such registration,
qualification or compliance. In addition, the Company will reimburse such Holder Indemnified Party for any legal or any other documented expenses reasonably incurred by them in connection with investigating or defending any such losses.
Notwithstanding the foregoing, the Company shall not be liable in any such case to the extent that any such losses result from, arise out of, are based upon, or relate to an untrue statement or alleged untrue statement, or omission or alleged
omission, made in such registration statement, any such prospectus, preliminary prospectus or Free-Writing Prospectus or any amendment or supplement thereto, or in any application, in reliance upon, and in conformity with, written information
prepared and furnished in writing to the Company by such Holder Indemnified Party </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expressly for use therein or by such Holder Indemnified Party&#146;s failure to deliver a copy of the registration statement or prospectus or any amendments or supplements thereto after the
Company has furnished such Holder Indemnified Party with a sufficient number of copies of the same. In connection with an underwritten offering, the Company shall indemnify such underwriters, their officers and directors, and each Person who
controls such underwriters (within the meaning of the Securities Act) to the same extent as provided above with respect to the indemnification of the Holder Indemnified Parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>By Each Holder</U>. In connection with any registration statement in which a Holder is participating, each such
Holder shall furnish to the Company in writing such information and affidavits as the Company reasonably requests for use in connection with any such registration statement or prospectus and, to the extent permitted by law, shall indemnify the
Company, its officers, directors, managers, employees, agents and representatives, and each Person who controls the Company (within the meaning of the Securities Act) against any losses, claims, damages, liabilities and expenses resulting from any
untrue or alleged untrue statement of material fact contained in the registration statement, prospectus or preliminary prospectus or any amendment thereof or supplement thereto or any omission or alleged omission of a material fact required to be
stated therein or necessary to make the statements therein not misleading, but only to the extent that such untrue statement or omission was furnished in writing to the Company by such Holder expressly for use therein; <I>provided</I> that the
obligation to indemnify shall be individual, not joint and several, for each Holder and shall be limited to the net amount of proceeds received by such Holder from the sale of Registrable Securities pursuant to such registration statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Claim Procedure</U>. Any Person entitled to indemnification hereunder shall (i)&nbsp;give prompt written notice
to the indemnifying party of any claim with respect to which it seeks indemnification (provided that the failure to give prompt notice shall impair any Person&#146;s right to indemnification hereunder only to the extent such failure has materially
prejudiced the indemnifying party) and (ii)&nbsp;unless in such indemnified party&#146;s reasonable judgment a conflict of interest between such indemnified and indemnifying parties may exist with respect to such claim, permit such indemnifying
party to assume the defense of such claim with counsel reasonably satisfactory to the indemnified party. If such defense is assumed, the indemnifying party shall not be subject to any liability for any settlement made by the indemnified party
without its consent (but such consent shall not be unreasonably withheld, conditioned or delayed). An indemnifying party who is not entitled to, or elects not to, assume the defense of a claim shall not be obligated to pay the fees and expenses of
more than one counsel for all parties indemnified by such indemnifying party with respect to such claim, unless in the reasonable judgment of any indemnified party a conflict of interest may exist between such indemnified party and any other of such
indemnified parties with respect to such claim. In such instance, the conflicted indemnified parties shall have a right to retain one separate counsel, chosen by the Holders representing a majority of the Registrable Securities included in the
registration if such Holders are indemnified parties, at the expense of the indemnifying party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Contribution</U>. If the indemnification provided for in this <U>Section</U><U></U><U>&nbsp;7</U> is held by a
court of competent jurisdiction to be unavailable to, or is insufficient to hold harmless, an indemnified party or is otherwise unenforceable with respect to any loss, claim, damage, liability or action referred to herein, then the indemnifying
party shall contribute to the amounts paid or payable by such indemnified party as a result of such loss, claim, damage, liability or action in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the one hand
and of the indemnified party on the other hand in connection with the statements or omissions which resulted in such loss, claim, damage, liability or action as well as any other relevant equitable considerations; provided that the maximum amount of
liability in respect of such contribution shall be limited, in the case of each seller of Registrable Securities, to an amount equal to the net proceeds actually received by such seller from the sale of Registrable Securities effected pursuant to
such registration. The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a
material fact relates to information supplied by the indemnifying party or by the indemnified party and the parties&#146; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. The parties
hereto agree that it would not be just or equitable if the contribution pursuant to this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<U>Section</U><U></U><U>&nbsp;7(d)</U> were to be determined by pro rata allocation or by any other method of allocation that does not take into account such equitable considerations. The amount
paid or payable by an indemnified party as a result of the losses, claims, damages, liabilities or expenses referred to herein shall be deemed to include any legal or other expenses reasonably incurred by such indemnified party in connection with
investigating or defending against any action or claim which is the subject hereof. No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(t) of the Securities Act) shall be entitled to contribution from any Person
who is not guilty of such fraudulent misrepresentation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Release</U>. No indemnifying party shall, except
with the consent of the indemnified party, consent to the entry of any judgment or enter into any settlement which cannot be settled in all respects by the payment of money (and such money is so paid by the indemnifying party pursuant to the terms
of such settlement) or which settlement does not include as an unconditional term thereof giving by the claimant or plaintiff to such indemnified party of a release from all liability in respect to such claim or litigation. Notwithstanding anything
to the contrary in this <U>Section</U><U></U><U>&nbsp;7</U>, an indemnifying party shall not be liable for any amounts paid in settlement of any loss, claim, damage, liability, or action if such settlement is effected without the consent of the
indemnifying party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;<U><FONT STYLE="white-space:nowrap">Non-exclusive</FONT> Remedy; Survival</U>. The
indemnification and contribution provided for under this Agreement shall be in addition to any other rights to indemnification or contribution that any indemnified party may have pursuant to law or contract and shall remain in full force and effect
regardless of any investigation made by or on behalf of the indemnified party or any officer, director or controlling Person of such indemnified party and shall survive the transfer of Registrable Securities and the termination or expiration of this
Agreement. Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the
foregoing provisions, the provisions in the underwriting agreement shall control. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.&nbsp;&nbsp;&nbsp;&nbsp;<U>Underwritten
Registrations</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Participation</U>. No Person may participate in any Public Offering hereunder which is
underwritten unless such Person (i)&nbsp;agrees to sell such Person&#146;s securities on the basis provided in any underwriting arrangements approved by the Person or Persons entitled hereunder to approve such arrangements (including, without
limitation, pursuant to any over-allotment or &#147;green shoe&#148; option requested by the underwriters; provided that no Holder shall be required to sell more than the number of Registrable Securities such Holder has requested to include) and
(ii)&nbsp;completes and executes all questionnaires, powers of attorney, indemnities, underwriting agreements and other documents required under the terms of such underwriting arrangements. Each Holder shall execute and deliver such other agreements
as may be reasonably requested by the Company and the lead managing underwriter(s) that are consistent with such Holder&#146;s obligations under <U>Section</U><U></U><U>&nbsp;4</U>, <U>Section</U><U></U><U>&nbsp;5</U> and this
<U>Section</U><U></U><U>&nbsp;8(a)</U> or that are necessary to give further effect thereto. To the extent that any such agreement is entered into pursuant to, and consistent with, <U>Section</U><U></U><U>&nbsp;4</U> and this
<U>Section</U><U></U><U>&nbsp;8(a)</U>, the respective rights and obligations created under such agreement shall supersede the respective rights and obligations of the Holders, the Company and the underwriters created pursuant to this
<U>Section</U><U></U><U>&nbsp;8(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Price and Underwriting Discounts</U>. In the case of an
underwritten Demand Registration or Underwritten Takedown requested by Holders pursuant to this Agreement, the price, underwriting discount and other financial terms of the related underwriting agreement for the Registrable Securities shall be
determined by the Holders representing a majority of the Registrable Securities included in such underwritten offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Suspended Distributions</U>. Each Person that is participating in any registration under this Agreement, upon
receipt of any notice from the Company of the happening of any event of the kind described in <U>Section</U><U></U><U>&nbsp;5(a)(vi)(B)</U> or <U>(C)</U>, shall immediately discontinue the disposition of its Registrable Securities pursuant to the
registration statement until such Person&#146;s receipt of the copies of a supplemented or amended prospectus as contemplated by <U>Section</U><U></U><U>&nbsp;5(a)(vi)</U>. In the event the Company has given any such notice, the applicable time
period </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
set forth in <U>Section</U><U></U><U>&nbsp;5(a)(iii)</U> during which a Registration Statement is to remain effective shall be extended by the number of days during the period from and including
the date of the giving of such notice pursuant to this <U>Section</U><U></U><U>&nbsp;8(c)</U> to and including the date when each seller of Registrable Securities covered by such registration statement shall have received the copies of the
supplemented or amended prospectus contemplated by <U>Section</U><U></U><U>&nbsp;5(a)(vi)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.&nbsp;&nbsp;&nbsp;&nbsp;<U>Additional Parties; Joinder</U>. Subject to the prior written consent of each Investor, any Person
who acquires shares of Class&nbsp;A Common Stock or rights to acquire Class&nbsp;A Common Stock from the Company after the date hereof (including without limitation any Person who acquires <FONT STYLE="white-space:nowrap">Up-C</FONT> Units) shall
have the right to be made a party to this Agreement by the Company (each such Person, an &#147;<U>Additional Investor</U>&#148;) and to succeed to all of the rights and obligations of a Holder under this Agreement by executing a joinder to this
Agreement in the form of Exhibit A attached hereto (a &#147;<U>Joinder</U>&#148;). Upon the execution and delivery of a Joinder by such Additional Investor, the shares of Class&nbsp;A Common Stock acquired by such Additional Investor or issuable
upon exchange of <FONT STYLE="white-space:nowrap">Up-C</FONT> Units acquired by such Additional Investor shall be Registrable Securities to the extent provided herein, such Additional Investor shall be a Holder under this Agreement with respect to
such shares of Class&nbsp;A Common Stock, and the Company shall add such Additional Investor&#146;s name and address to the Schedule of Investors and circulate such information to the parties to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;10.&nbsp;&nbsp;&nbsp;&nbsp;<U>Rule 144 Compliance; Current Public Information</U>. At all times after the Company has filed a
registration statement with the Securities and Exchange Commission pursuant to the requirements of either the Securities Act or the Exchange Act, the Company shall file all reports required to be filed by it under the Securities Act and the Exchange
Act and shall take such further action as any Holder may reasonably request, all to the extent required to enable such Holders to sell Registrable Securities pursuant to Rule 144. Upon request, the Company shall deliver to any Holder a written
statement as to whether it has complied with such requirements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.&nbsp;&nbsp;&nbsp;&nbsp;<U>Transfer of Registrable
Securities</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Restrictions on Transfers</U>. Notwithstanding anything to the contrary contained herein,
except in the case of (i)&nbsp;a transfer to the Company, (ii)&nbsp;a transfer by any Holder or any of its Affiliates to its respective equityholders, (iii)&nbsp;a Public Offering, or (iv)&nbsp;a sale pursuant to Rule 144 after completion of the
transactions contemplated by the Merger Agreement, the transferring Holder shall cause the prospective transferee to execute and deliver to the Company a Joinder agreeing to be bound by the terms of this Agreement; provided that, for the avoidance
of doubt, any pledge by a Holder of Registrable Securities shall not be deemed a transfer under this Agreement. Any transfer or attempted transfer of any Registrable Securities in violation of any provision of this Agreement shall be void, and the
Company shall not record such transfer on its books or treat any purported transferee of such Registrable Securities as the owner thereof for any purpose. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Legend</U>. Each certificate evidencing any Registrable Securities and each certificate issued in exchange for
or upon the transfer of any Registrable Securities (unless such Registrable Securities would no longer be Registrable Securities after such transfer) shall be stamped or otherwise imprinted with a legend in substantially the following form: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO RESTRICTIONS ON TRANSFER AND OTHER PROVISIONS SET FORTH IN A REGISTRATION
RIGHTS AGREEMENT DATED AS OF [&middot;], 2023, BY AND AMONG THE ISSUER OF SUCH SECURITIES (THE &#147;COMPANY&#148;) AND CERTAIN OF THE COMPANY&#146;S STOCKHOLDERS, AS AMENDED FROM TIME TO TIME. A COPY OF SUCH REGISTRATION RIGHTS AGREEMENT WILL BE
FURNISHED WITHOUT CHARGE BY THE COMPANY TO THE HOLDER HEREOF UPON WRITTEN REQUEST.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company shall imprint such legend on
certificates evidencing Registrable Securities outstanding <B></B>prior to the date hereof<B></B>, and shall cause the Company to imprint such legend on certificates, if any, evidencing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap">Up-C</FONT> Units exchangeable for Registrable Securities outstanding <B></B>prior to the date hereof<B></B>. The legend set forth above shall be removed from the
certificates evidencing any securities that have ceased to be Registrable Securities at the Company&#146;s sole cost and expense. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;12.&nbsp;&nbsp;&nbsp;&nbsp;<U>MNPI Provisions</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Each Holder acknowledges that (i)&nbsp;the provisions of this Agreement that require communications by the Company
or other Holders to such Holder may result in such Holder and its Representatives (as defined below) acquiring MNPI (which may include, solely by way of illustration, the fact that an offering of the Company&#146;s securities is pending or the
number of Company securities or the identity of the selling Holders), and (ii)&nbsp;there is no limitation on the duration of time that such Holder and its Representatives may be in possession of MNPI and no requirement that the Company or other
Holders make any public disclosure to cause such information to cease to be MNPI; <I>provided</I> that the Company will use commercially reasonable best efforts to promptly notify each Holder if any proposed registration or offering for which a
notice has been delivered pursuant to this Agreement has been terminated or aborted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Each Holder agrees that
it will maintain the confidentiality of such MNPI and, to the extent such Holder is not a natural person, such confidential treatment shall be in accordance with procedures adopted by it in good faith to protect confidential information of third
parties delivered to such Holder (&#147;<U>Policies</U>&#148;); <I>provided</I> that a holder may deliver or disclose MNPI to (i)&nbsp;its directors, officers, employees, agents, attorneys, affiliates and financial and other advisors (collectively,
the &#147;<U>Representatives</U>&#148;), but solely to the extent such disclosure reasonably relates to its evaluation of exercise of its rights under this Agreement and the sale of any Registrable Securities in connection with the subject of the
notice, (ii)&nbsp;any federal or state regulatory authority having jurisdiction over such Holder, (iii)&nbsp;any Person if necessary to effect compliance with any law, rule, regulation or order applicable to such Holder, (iv)&nbsp;in response to any
subpoena or other legal process, or (v)&nbsp;in connection with any litigation to which such Holder is a party; <I>provided further</I>, that in the case of clause <U>(i)</U>, the recipients of such MNPI are subject to the Policies or agree to hold
confidential the MNPI in a manner substantially consistent with the terms of this <U>Section</U><U></U><U>&nbsp;12</U> and that in the case of clauses <U>(ii)</U>&nbsp;through <U>(v)</U>, such disclosure is required by law and you promptly notify
the Company of such disclosure to the extent such Holder is legally permitted to give such notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Each
Holder, by its execution of a counterpart to this agreement or of a Joinder, hereby (i)&nbsp;acknowledges that it is aware that the U.S. securities laws prohibit any person who has MNPI about a company from purchasing or selling, directly or
indirectly, securities of such company (including entering into hedge transactions involving such securities), or from communicating such information to any other person under circumstances in which it is reasonably foreseeable that such person is
likely to purchase or sell such securities, and (ii)&nbsp;agrees that it will not use or permit any third party to use, and that it will use its reasonable best efforts to assure that none of its representatives will use or permit any third party to
use, any MNPI the Company provides in contravention of the U.S. securities laws and you will cease trading in the Company&#146;s and the Company&#146;s securities while in possession of material <FONT STYLE="white-space:nowrap">non-public</FONT>
information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;Each Holder shall have the right, at any time and from time to time (including after receiving
information regarding any potential Public Offering), to elect to not receive any notice that the Company or any other Holders otherwise are required to deliver pursuant to this Agreement by delivering to the Company a written statement signed by
such Holder that it does not want to receive any notices hereunder (an &#147;<U><FONT STYLE="white-space:nowrap">Opt-Out</FONT> Request</U>&#148;); in which case and notwithstanding anything to the contrary in this Agreement the Company and other
Holders shall not be required to, and shall not, deliver any notice or other information required to be provided to Holders hereunder to the extent that the Company or such other Holders reasonably expect would result in a Holder acquiring MNPI. An <FONT
STYLE="white-space:nowrap">Opt-Out</FONT> Request may state a date on which it expires or, if no such date is specified, shall remain in effect indefinitely. A Holder who previously has given the Company an
<FONT STYLE="white-space:nowrap">Opt-Out</FONT> Request may revoke such request at any time, and there shall be no limit on the ability of a Holder to issue and revoke subsequent <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Requests. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.&nbsp;&nbsp;&nbsp;&nbsp;<U>General Provisions</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendments and Waivers</U>. Except as otherwise provided herein, the provisions of this Agreement may be amended,
modified or waived only with the prior written consent of the Company and the Cibus Global <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Majority-In-Interest;</FONT></FONT> <I>provided</I> that no such amendment, modification or
waiver that would materially and adversely affect a Holder in a manner materially different than any other Holder (<I>provided</I> that the accession by Additional Investors to this Agreement pursuant to <U>Section</U><U></U><U>&nbsp;9</U> shall not
be deemed to adversely affect any Holder), shall be effective against such Holder without the consent of such Holder that is materially and adversely affected thereby. The failure or delay of any Person to enforce any of the provisions of this
Agreement shall in no way be construed as a waiver of such provisions and shall not affect the right of such Person thereafter to enforce each and every provision of this Agreement in accordance with its terms. A waiver or consent to or of any
breach or default by any Person in the performance by that Person of his, her or its obligations under this Agreement shall not be deemed to be a consent or waiver to or of any other breach or default in the performance by that Person of the same or
any other obligations of that Person under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Remedies</U>. The parties to this Agreement
shall be entitled to enforce their rights under this Agreement specifically (without posting a bond or other security), to recover damages caused by reason of any breach of any provision of this Agreement and to exercise all other rights existing in
their favor. The parties hereto agree and acknowledge that a breach of this Agreement would cause irreparable harm and money damages would not be an adequate remedy for any such breach and that, in addition to any other rights and remedies existing
hereunder, any party shall be entitled to specific performance and/or other injunctive relief from any court of law or equity of competent jurisdiction (without posting any bond or other security) in order to enforce or prevent violation of the
provisions of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U>. Whenever possible, each provision of this Agreement shall
be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be prohibited, invalid, illegal or unenforceable in any respect under any applicable law or regulation in any
jurisdiction, such prohibition, invalidity, illegality or unenforceability shall not affect the validity, legality or enforceability of any other provision of this Agreement in such jurisdiction or in any other jurisdiction, but this Agreement shall
be reformed, construed and enforced in such jurisdiction as if such prohibited, invalid, illegal or unenforceable provision had never been contained herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Entire Agreement</U>. Except as otherwise provided herein, this Agreement contains the complete agreement and
understanding among the parties hereto with respect to the subject matter hereof and supersedes and preempts any prior understandings, agreements or representations by or among the parties hereto, written or oral, which may have related to the
subject matter hereof in any way. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Successors and Assigns</U>. This Agreement shall bind and inure to the
benefit and be enforceable by the Company and its successors and assigns and the Holders and their respective successors and assigns (whether so expressed or not). In addition, whether or not any express assignment has been made, the provisions of
this Agreement which are for the benefit Holders are also for the benefit of, and enforceable by, any subsequent or successor Holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination</U>. This Agreement shall terminate and be of no further force or effect when there shall no longer
be any Registrable Securities outstanding; provided, that the provisions of Section&nbsp;6 and Section&nbsp;7 shall survive any such termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>. Any notice, demand or other communication to be given under or by reason of the provisions of this
Agreement shall be in writing and shall be deemed to have been given (a)&nbsp;one (1) Business Day after being sent for next Business Day delivery, fees prepaid, via a reputable international overnight courier service, (b)&nbsp;upon delivery in the
case of delivery by hand or (c)&nbsp;on the date delivered in the place of delivery if sent by email or facsimile (with a written or electronic confirmation of delivery) prior to 6:00 p.m. New York </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
City time, otherwise on the next succeeding Business Day. Such notices, demands and other communications shall be sent to the Company at the address specified below and to any Investor or to any
other party subject to this Agreement at such address as indicated on the Schedule of Investors, or at such address or to the attention of such other Person as the recipient party has specified by prior written notice to the sending party. Any party
may change such party&#146;s address for receipt of notice by providing prior written notice of the change to the sending party as provided herein. The Company&#146;s address is: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Cibus, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">6455 Nancy Ridge
Drive </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">San Diego, CA 92121 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: Wade King, Chief Financial Officer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> [***] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">with a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Jones Day </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">4655 Executive Dr.,
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">San Diego, CA 92121 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: Cameron Reese </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Peter
Devlin </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: [***] ; [***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or to such
other address or to the attention of such other Person as the recipient party has specified by prior written notice to the sending party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;<U>Business Days</U>. If any time period for giving notice or taking action hereunder expires on a day that is not
a Business Day, the time period shall automatically be extended to the immediately following Business Day. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;<U>No Third-Party Beneficiaries</U>. This Agreement is for the sole benefit of the parties hereto and their
respective successors and permitted assigns and nothing herein, express or implied, is intended to or shall confer upon any other Person any legal or equitable right, benefit or remedy of any nature whatsoever, under or by reason of this Agreement
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j)&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing Law</U>. The corporate law of the State of Delaware shall govern all issues and questions
concerning the relative rights of the Company and its stockholders. All other issues and questions concerning the construction, validity, interpretation and enforcement of this Agreement and the exhibits and schedules hereto shall be governed by,
and construed in accordance with, the laws of the State of Delaware, without giving effect to any choice of law or conflict of law rules or provisions (whether of the State of Delaware or any other jurisdiction) that would cause the application of
the laws of any jurisdiction other than the State of Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k)&nbsp;&nbsp;&nbsp;&nbsp;<U>MUTUAL WAIVER OF JURY TRIAL</U>. AS A
SPECIFICALLY BARGAINED FOR INDUCEMENT FOR EACH OF THE PARTIES HERETO TO ENTER INTO THIS AGREEMENT (AFTER HAVING THE OPPORTUNITY TO CONSULT WITH COUNSEL), EACH PARTY HERETO EXPRESSLY WAIVES THE RIGHT TO TRIAL BY JURY IN ANY LAWSUIT OR PROCEEDING
RELATING TO OR ARISING IN ANY WAY FROM THIS AGREEMENT OR THE MATTERS CONTEMPLATED HEREBY. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l)&nbsp;&nbsp;&nbsp;&nbsp;<U>CONSENT TO
JURISDICTION AND SERVICE OF PROCESS</U>. EACH OF THE PARTIES IRREVOCABLY SUBMITS TO THE <FONT STYLE="white-space:nowrap">NON-EXCLUSIVE</FONT> JURISDICTION OF COURT OF CHANCERY OF THE STATE OF DELAWARE, NEW CASTLE COUNTY, OR, IF THAT COURT DOES NOT
HAVE JURISDICTION, A FEDERAL COURT SITTING IN WILMINGTON, DELAWARE, FOR THE PURPOSES OF ANY SUIT, ACTION OR OTHER PROCEEDING ARISING OUT OF THIS AGREEMENT, ANY RELATED AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY OR THEREBY. EACH
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
OF THE PARTIES HERETO FURTHER AGREES THAT SERVICE OF ANY PROCESS, SUMMONS, NOTICE OR DOCUMENT BY U.S. REGISTERED MAIL TO SUCH PARTY&#146;S RESPECTIVE ADDRESS SET FORTH ABOVE SHALL BE EFFECTIVE
SERVICE OF PROCESS FOR ANY ACTION, SUIT OR PROCEEDING WITH RESPECT TO ANY MATTERS TO WHICH IT HAS SUBMITTED TO JURISDICTION IN THIS PARAGRAPH. EACH OF THE PARTIES HERETO IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY OBJECTION TO THE LAYING OF VENUE OF
ANY ACTION, SUIT OR PROCEEDING ARISING OUT OF THIS AGREEMENT, ANY RELATED DOCUMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY AND THEREBY IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE, AND HEREBY AND THEREBY FURTHER IRREVOCABLY AND
UNCONDITIONALLY WAIVES AND AGREES NOT TO PLEAD OR CLAIM IN ANY SUCH COURT THAT ANY SUCH ACTION, SUIT OR PROCEEDING BROUGHT IN ANY SUCH COURT HAS BEEN BROUGHT IN AN INCONVENIENT FORUM. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m)&nbsp;&nbsp;&nbsp;&nbsp;<U>No Recourse</U>. Notwithstanding anything to the contrary in this Agreement, the Company and each Holder agrees
and acknowledges that no recourse under this Agreement or any documents or instruments delivered in connection with this Agreement, shall be had against any current or future director, officer, employee, general or limited partner or member of any
Holder or of any Affiliate or assignee thereof, whether by the enforcement of any assessment or by any legal or equitable proceeding, or by virtue of any statute, regulation or other applicable law, it being expressly agreed and acknowledged that no
personal liability whatsoever shall attach to, be imposed on or otherwise be incurred by any current or future officer, agent or employee of any Holder or any current or future member of any Holder or any current or future director, officer,
employee, partner or member of any Holder or of any Affiliate or assignee thereof, as such for any obligation of any Holder under this Agreement or any documents or instruments delivered in connection with this Agreement for any claim based on, in
respect of or by reason of such obligations or their creation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n)&nbsp;&nbsp;&nbsp;&nbsp;<U>Headings; Interpretation</U>. The headings
in this Agreement are inserted for convenience only and shall not affect the interpretation of this Agreement. The use of the word &#147;including&#148; in this Agreement shall be by way of example rather than by limitation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o)&nbsp;&nbsp;&nbsp;&nbsp;<U>No Strict Construction</U>. The language used in this Agreement shall be deemed to be the language chosen by the
parties hereto to express their mutual intent, and no rule of strict construction shall be applied against any party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(p)&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterparts</U>. This Agreement may be executed in multiple counterparts, any one of which need not contain the
signature of more than one party, but all such counterparts taken together shall constitute one and the same agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(q)&nbsp;&nbsp;&nbsp;&nbsp;<U>Electronic Delivery</U>. This Agreement, the agreements referred to herein, and each other agreement or
instrument entered into in connection herewith or therewith or contemplated hereby or thereby, and any amendments hereto or thereto, to the extent executed and delivered by means of a photographic, photostatic, facsimile or similar reproduction of
such signed writing using a facsimile machine or electronic mail shall be treated in all manner and respects as an original agreement or instrument and shall be considered to have the same binding legal effect as if it were the original signed
version thereof delivered in person. At the request of any party hereto or to any such agreement or instrument, each other party hereto or thereto shall <FONT STYLE="white-space:nowrap">re-execute</FONT> original forms thereof and deliver them to
all other parties. No party hereto or to any such agreement or instrument shall raise the use of a facsimile machine or electronic mail to deliver a signature or the fact that any signature or agreement or instrument was transmitted or communicated
through the use of a facsimile machine or electronic mail as a defense to the formation or enforceability of a contract and each such party forever waives any such defense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(r)&nbsp;&nbsp;&nbsp;&nbsp;<U>Further Assurances</U>. In connection with this Agreement and the transactions contemplated hereby, each Holder
shall execute and deliver any additional documents and instruments and perform any additional acts </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that may be necessary or appropriate to effectuate and perform the provisions of this Agreement and the transactions contemplated hereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(s)&nbsp;&nbsp;&nbsp;&nbsp;<U>No Inconsistent Agreements</U>. The Company shall not hereafter enter into any agreement with respect to its
securities which is inconsistent with or violates the rights granted to the Holders in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * * * </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Registration Rights Agreement as of the
date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CIBUS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">[&#9679;]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">[&#9679;]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CIBUS GLOBAL, LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">[&#9679;]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">[&#9679;]</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE OF INVESTORS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Investor Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number of <FONT STYLE="white-space:nowrap">Up-C</FONT>
Units</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION RIGHTS AGREEMENT JOINDER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned is executing and delivering this Joinder pursuant to the Registration Rights Agreement dated as of [&#9679;], 2023 (as the
same may hereafter be amended, the &#147;<U>Registration Rights Agreement</U>&#148;), among Cibus, Inc. (f/k/a Calyxt, Inc.), a Delaware company (the &#147;<U>Company</U>&#148;), and the other person named as parties therein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By executing and delivering this Joinder to the Company, and upon acceptance hereof by the Company upon the execution of a counterpart hereof,
the undersigned hereby agrees to become a party to, to be bound by, and to comply with the provisions of the Registration Rights Agreement as a Holder of Registrable Securities in the same manner as if the undersigned were an original signatory to
the Registration Rights Agreement, and the undersigned&#146;s shares of Class&nbsp;A Common Stock shall be included as Registrable Securities under the Registration Rights Agreement to the extent provided therein. The Company is directed to add the
address below the undersigned&#146;s signature on this Joinder to the Schedule of Investors attached to the Registration Rights Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, the undersigned has executed and delivered this Joinder as of the day of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 20&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Signature of
Stockholder</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Print Name of
Stockholder</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Its:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD></TR></TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Agreed and Accepted as of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 20&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Cibus, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="rom401831_72"></A>ANNEX G </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">FINAL FORM </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">VOTING AGREEMENT </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">VOTING AGREEMENT, dated as of January&nbsp;13, 2023 (this &#147;<U>Agreement</U>&#148;), by and between Cibus Global, LLC, a Delaware limited
liability company (&#147;<U>Merger Partner</U>&#148;), and the undersigned stockholders (each, a &#147;<U>Holder</U>&#148; and collectively, &#147;<U>Holders</U>&#148;) of Calyxt, Inc., a Delaware corporation (the &#147;<U>Public
Company</U>&#148;)[, and, solely for purposes of Section&nbsp;1.6 and Annex A, the Public Company.]<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> Capitalized terms used herein and not otherwise defined shall have the meanings assigned to
them in the Merger Agreement (as herein defined). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">RECITALS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, concurrently with the execution and delivery of this Agreement, Public Company, Calypso Merger Subsidiary, LLC, a Delaware limited
liability company and wholly-owned subsidiary of Public Company (&#147;<U>Merger Subsidiary</U>&#148;), Merger Partner and the Blockers (as defined in the Merger Agreement) are entering into an Agreement and Plan of Merger, dated as of the date
hereof (as the same may be amended or modified in accordance with its terms, the &#147;<U>Merger Agreement</U>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, as a
condition to Merger Partner&#146;s willingness to enter into the Merger Agreement, Holders have agreed to enter into this Agreement with respect to the Subject Shares (as defined herein); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, as of the date hereof, each Holder is the beneficial owner of the number of shares of Public Company Common Stock (&#147;<U>Public
Company Common Stock</U>&#148;), set forth opposite such Holder&#146;s name on <U>Exhibit A</U> hereto (all such shares set forth opposite each such Holder&#146;s name, together with any shares of Public Company Common Stock that are hereafter
issued to (including upon the exercise of options or warrants) or otherwise acquired, or beneficially owned by such Holder prior to the termination of this Agreement (including the resulting shares of Public Company Common Stock resulting from any
stock split, stock dividend, merger, reorganization, recapitalization, reclassification, combination, exchange of shares affecting the shares of Public Company Common Stock) being referred to as the &#147;<U>Subject Shares</U>&#148; of such Holder);
and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Merger Agreement provides for, among other things, the Mergers and the other Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the premises, and of the representations, warranties, covenants and agreements contained herein, and for
other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, agree as follows: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE I </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Voting and Transfer
of Public Company Common Stock</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.1 <U>Voting</U>. Each Holder shall cause to be present and counted and shall vote (or cause to be
voted or acted upon by written consent with respect to) all of its Subject Shares at any meeting of the stockholders of Public Company or any adjournment or postponement thereof, and in any action proposed to be taken by written consent of the
stockholders of Public Company: (a)&nbsp;to approve the Public Company Stockholder Matters, the Other Public Company Stockholder Matters and any proposal to adjourn or postpone such meeting of stockholders of Public Company to a later date if there
are not sufficient votes to approve the Public Company Stockholder Matters and the Other Public Company Stockholder Matters, provided that, for the avoidance of </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NTD: To be included only in Cellectis version of this Agreement
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-1- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
doubt, Holder shall not be required to approve anything other than the Public Company Stockholder Matters and the Other Public Company Stockholder Matters and (b)&nbsp;against any Acquisition
Proposal (other than the Transactions) or any other action that would reasonably be expected to materially impede, interfere with, discourage, adversely affect, inhibit or delay the timely consummation of the Transactions or the fulfillment of
Public Company or Merger Subsidiary&#146;s conditions to Closing under the Merger Agreement. Each Holder agrees that it will not revoke any consent previously executed in support of the Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.2 <U>No Transfer</U>. During the period beginning on the date of this Agreement and ending immediately prior to the earlier of the Merger
Partner Merger Effective Time and the termination of this Agreement, other than as contemplated by the Merger Agreement or with the written consent of Merger Partner, each Holder shall not, directly or indirectly, except as contemplated by the
Merger Agreement: (a)&nbsp;sell, distribute, assign, convey, transfer, grant, pledge, hypothecate, convey any legal or beneficial ownership in (including by merger (including by conversion into securities or other consideration), by tendering into
any tender or exchange offer), or otherwise encumber or dispose of any Subject Shares; (b)&nbsp;deposit any Subject Shares into a voting trust or enter into a voting agreement or any other arrangement with respect to any such Subject Shares or
purport to grant any proxy with respect thereto; (c)&nbsp;enter into any contract, option or other arrangement or undertaking with respect to the direct or indirect acquisition or sale, assignment, transfer or other disposition of any Subject
Shares; (d)&nbsp;otherwise permit any Liens to be created on any Subject Shares (other than Permitted Liens (as defined herein)) or (e)&nbsp;commit or agree to take any of the foregoing actions (any action described in clauses (a), (b), (c), (d) and
(e), a &#147;<U>Transfer</U>&#148;); <U>provided</U>, that the foregoing shall not prohibit (i)&nbsp;Transfers between such Holder and any Affiliates of such Holder; (ii)&nbsp;Transfers in connection with any estate planning or charitable giving;
(iii)&nbsp;Transfers pursuant to any existing <FONT STYLE="white-space:nowrap">10b5-1</FONT> Plan that has been entered into by such Holder prior to the Merger Partner Merger Effective Time; (iv)&nbsp;exercising any stock option to purchase shares
of Public Company Common Stock, or any securities convertible into or exercisable or exchangeable for Public Company Common Stock, or other similar awards granted pursuant to the Public Company Stock Plans; (v)&nbsp;Transfer Public Company Common
Stock or any securities convertible into or exercisable or exchangeable for shares of Public Company Common Stock upon a vesting event of Public Company&#146;s securities or upon the exercise of options to purchase Public Company Common Stock, in
each case on a &#147;cashless&#148; or &#147;net exercise&#148; basis or in a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">sale-to-cover</FONT></FONT> transaction with respect to tax withholding obligations of such Holder in
connection with such vesting or exercise, whether by means of a &#147;net settlement&#148; or otherwise with respect to awards granted pursuant to the Public Company Stock Plans; or (vi)&nbsp;any Transfer required by Law or required by a Legal
Proceeding to which such Holder is a party; <U>provided</U>, <U>further</U>, that any Transfer pursuant to clauses (i), (ii) or (vi)&nbsp;of this Section&nbsp;1.2 shall be permitted only if, prior to any such Transfer, and as a precondition to the
effectiveness of any such Transfer, the transferee executes and delivers to Merger Partner a joinder to this Agreement in the form attached hereto as <U>Exhibit B</U>. Any Transfer or action in violation of this Section&nbsp;1.2 shall be void <I>ab
initio</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.3 <U>Solicitation</U>. Each Holder shall, and shall instruct and use its reasonable best efforts to cause the
Representatives retained by it and acting on its behalf to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) immediately cease and cause to be terminated any existing
discussions, negotiations and communications with any Person that relate to any Acquisition Proposal or Acquisition Inquiry that has not already been terminated as of the date of this Agreement; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) not to take any action that Public Company would then be prohibited from taking under Section&nbsp;5.4(a) of the Merger
Agreement as if such Holder were Public Company, provided that the foregoing shall not preclude any Holder from having discussions with Merger Partner or Public Company regarding the Merger Agreement or the transactions contemplated thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, from and after the date of the Merger Agreement until the earlier to occur of (x)&nbsp;the Merger Partner Merger Effective Time
and (y)&nbsp;such date and time as the Merger Agreement shall be validly terminated pursuant thereto, if (and only if) Public Company is permitted, pursuant to the Merger Agreement, to have discussions or negotiations in response to an Acquisition
Proposal, each Holder and its Representatives shall be permitted to participate in such discussions or negotiations with such Person making </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-2- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such Acquisition Proposal to the same extent as Public Company is permitted to do so under the Merger Agreement (including with respect to providing a voting agreement with respect to such
Holder&#146;s Subject Shares). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, and notwithstanding anything in this Agreement to the contrary, (a)&nbsp;no Holder&#146;s
obligations under this Section&nbsp;1.3 shall be construed to apply to any actions taken by any other stockholder of Public Company, Public Company or any of its Subsidiaries, the Board of Directors of Public Company or any committee thereof, any of
the directors, officers or employees of any other stockholder of Public Company, Public Company or any of its Subsidiaries (in their capacities as such), or the Representatives of Public Company or any of their respective Subsidiaries, (b)&nbsp;no
Holder shall be responsible for the actions of any of the foregoing and (c)&nbsp;nothing in this Section&nbsp;1.3 shall prevent any Holder or its Representatives, in their capacity as a member of Public Company&#146;s Board of Directors or as an
executive officer of Public Company, as applicable, from engaging in any activity permitted or required by the Merger Agreement in the performance of their fiduciary obligations to Public Company&#146;s stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.4 <U>Further Assurances</U>. Each Holder shall execute and deliver, or cause to be executed and delivered, such further certificates,
instruments and other documents as Merger Partner or Public Company may reasonably request for the purpose of effectively carrying out its obligations under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.5 <U>Additional Public Company Stock</U>. Each Holder acknowledges and agrees that any additional shares of Public Company Common Stock with
respect to which beneficial ownership is acquired by such Holder (other than pursuant to a vesting event pursuant to Public Company Stock Plans, if any, after the date hereof), by transfer or any other mechanism shall automatically become subject to
the terms of this Agreement as though owned by such Holder as of the date hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.6 <U>Holder Guaranty</U>. [Each of Holder, Merger
Partner and Public Company acknowledges and agrees to the matters set forth in <U>Annex A</U> attached hereto, which are hereby incorporated by reference into this Section&nbsp;1.6.]<SUP STYLE="font-size:75%; vertical-align:top">2</SUP> </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE II </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Representations and
Warranties of Each Holder</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Holder, severally and not jointly, hereby represents and warrants to Merger Partner as to itself (and
not as to any other Holder) as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1 <U>Authorization</U>. Such Holder has all requisite capacity, power and authority to execute
and deliver this Agreement and to perform its obligations under this Agreement. This Agreement has been duly executed and delivered by or on behalf of such Holder and, assuming the due authorization, execution and delivery of this Agreement by the
Merger Partner, this Agreement constitutes a legal, valid and binding obligation of such Holder, enforceable against such Holder in accordance with its terms, except to the extent that enforcement may be limited by applicable bankruptcy, insolvency,
fraudulent conveyance, reorganization, moratorium and other Laws affecting creditors&#146; rights generally and by general equitable principles (whether considered in a proceeding in equity or at law). Each Holder that is an entity (a)&nbsp;is duly
organized, validly existing and in good standing (with respect to jurisdictions that recognize such concept or equivalent) under the Laws of the jurisdiction of its organization, (b)&nbsp;the execution and delivery of this Agreement and such
Holder&#146;s performance of its obligations under this Agreement have been duly authorized by all necessary corporate or other organizational action on the part of such Holder and no other corporate or other organizational action on the part of
such Holder is necessary to authorize the execution and delivery of this Agreement or for such Holder to perform its obligations under this Agreement and (c)&nbsp;no approval by any holder of such Holder&#146;s equity, membership or other interests
is necessary to approve this Agreement. </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NTD: To be included only in Cellectis version of this Agreement
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2 <U>Governmental Filings; No Violations; Certain Contracts</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) No consent, approval, order or authorization of, or registration, declaration or filing with or notice to, any Government Authority is
required to be obtained or made by such Holder in connection with the execution and delivery of this Agreement, except for (i)&nbsp;such filings and reports as may be required pursuant to the applicable requirements of the Securities Act, the
Exchange Act and any other applicable state or federal securities, takeover and &#147;blue sky&#148; Laws (collectively, &#147;<U>Required Filings</U>&#148;) and (ii)&nbsp;such consents, authorizations, filings, approvals and registrations which, if
not obtained or made, are not reasonably likely to prevent, materially delay or materially impair the performance of such Holder&#146;s obligations under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The execution and delivery by such Holder of this Agreement does not, and the compliance with the provisions hereof will not, conflict
with, or result in any violation or breach of, or default (with or without notice or lapse of time, or both) under, or give rise to a right of, or result in, termination, cancellation, modification or acceleration of any obligation or to the loss of
a material benefit under, or result in the creation of any Lien in or upon any of the properties, assets or rights of such Holder under, or give rise to any increased, additional, accelerated or guaranteed rights or entitlements under, or require
any consent, waiver or approval of any Person pursuant to, any provision of (i)&nbsp;any written agreement to which such Holder is a party or by which such Holder or any of his properties or assets may be bound, (ii)&nbsp;any Law applicable to such
Holder or by which such Holder or any of its properties or assets may be bound or (iii)&nbsp;following a valid Transfer pursuant to Section&nbsp;1.2, with respect to such Holder that is an entity, the organizational documents of such Holder, except
as would not, individually or in the aggregate, be reasonably expected to prevent or materially delay the ability of such Holder to perform such Holder&#146;s obligations under this Agreement or to consummate the transactions contemplated hereby.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.3 <U>Ownership of Subject Shares; Voting Power</U>. <U>Exhibit A</U> hereto correctly sets forth the number of Subject Shares held
beneficially by such Holder, as of the date of this Agreement. Such Holder is the sole beneficial holder of all of its Subject Shares and has full voting power and power of disposition with respect to all such Subject Shares free and clear of any
liens, claims, proxies, voting trusts or agreements, options or any other encumbrances or restrictions on title, transfer or exercise of any rights of a stockholder in respect of such Subject Shares (collectively, &#147;<U>Encumbrances</U>&#148;),
except for any such Encumbrance that may be imposed pursuant to (a)&nbsp;(i) this Agreement, (ii)&nbsp;the organizational documents of Public Company, or (iii)&nbsp;any applicable restrictions on transfer under the Securities Act, including the
rules and regulations promulgated thereunder, or any &#147;blue sky&#148; Laws of the various states of the United States or (b)&nbsp;expressly contemplated by the Merger Agreement (collectively, &#147;<U>Permitted Liens</U>&#148;). Except pursuant
to this Agreement or the Merger Agreement or as set forth in the organizational documents of Public Company, no Person has any contractual or other right or obligation to purchase or otherwise acquire any of the Holder&#146;s Subject Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.4 <U>Disclosure of All Shares Owned</U>. Such Holder does not beneficially own any shares of Public Company Common Stock other than the
Subject Shares any options, warrants, or other rights to acquire any additional shares of Public Company Common Stock or any security exercisable for or convertible into shares of Public Company Common Stock, in each case, as set forth on <U>Exhibit
A</U> attached hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.5 <U>Reliance</U>. Such Holder understands and acknowledges that the Merger Partner is entering into the Merger
Agreement in reliance upon such Holder&#146;s execution, delivery and performance of this Agreement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE III<U> </U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Representations and Warranties of Merger Partner </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Merger Partner hereby represents and warrants to each Holder as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Merger Partner is an entity duly organized, validly existing and in good standing (with respect to jurisdictions that recognize such
concept or equivalent) under the Laws of the jurisdiction of its organization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Merger Partner has all requisite capacity, power and
authority to execute and deliver this Agreement and to perform its obligations under this Agreement. This Agreement has been duly executed and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-4- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
delivered by or on behalf of Merger Partner and, assuming the due authorization, execution and delivery of this Agreement by the Holder, this Agreement constitutes a legal, valid and binding
obligation of Merger Partner, enforceable against Merger Partner in accordance with its terms, except to the extent that enforcement may be limited by applicable bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and other
Laws affecting creditors&#146; rights generally and by general equitable principles (whether considered in a proceeding in equity or at law). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE IV </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>General
Provisions</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.1 <U>Termination</U>. This Agreement and all obligations, covenants and agreements contained herein, including the
voting agreements contemplated hereby and the proxies granted hereunder, shall automatically terminate and cease to be effective at the earliest to occur of: (a)&nbsp;the Merger Partner Merger Effective Time; (b)&nbsp;the termination of the Merger
Agreement pursuant thereto; (c)&nbsp;the effective date of a written agreement of the parties hereto terminating this Agreement; (d)&nbsp;with respect to the Holder, the date of any modification or amendment to the Merger Agreement, as in effect on
the date hereof, in a manner that reduces the amount and/or changes the form of consideration payable thereunder to the Holder or its equityholders, or otherwise adversely effects the Holder or its equityholders in any respect without the prior
written approval of the Holder; and (e)&nbsp;a Public Company Board Adverse Recommendation Change in accordance with and to the extent permitted by the Merger Agreement; <U>provided</U>, <U>however</U>, that in the case of any termination pursuant
to clause (a)&nbsp;of this sentence (or any other termination that is followed by the occurrence of the Merger Partner Merger Effective Time), Section&nbsp;1.4 (Further Assurances)[, Section&nbsp;1.6 (Holder Guaranty) (including Annex A)]<SUP
STYLE="font-size:75%; vertical-align:top">3</SUP> and this ARTICLE IV shall survive such termination hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.2 <U>Notices</U>. All
notices and other communications to any party hereunder shall be in writing and shall be deemed given if personally delivered, emailed (which is confirmed) or sent by overnight courier (providing proof of delivery) to the parties at the following
addresses: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><U>If to Merger Partner, to</U>: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Cibus Global, LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">6455 Nancy
Ridge Drive </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">San Diego, CA 92121 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rory Riggs, Chief Executive Officer, and Wade King, MD, Chief Financial Officer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***] and [***] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><U>With a copy (which shall not constitute notice) to:</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Jones Day </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">4655 Executive Drive
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Suite 1500 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">San Diego, CA
92121-3134 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cameron A. Reese </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">E-mail: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><U>If to any Holder, to it at</U>: the address listed below such Holder&#146;s name on the signature page of such Holder, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><U>With a copy (which shall not constitute notice) to:</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">[Public Company] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">2800 Mount
Ridge Road </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Roseville, MN 55113 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Debra Frimerman, General Counsel </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">E-mail: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***] </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">3</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NTD: To be included only in Cellectis version of this Agreement </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-5- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">and to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Sidley Austin LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">787 Seventh
Ave </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">New York, New York 10019 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;John H. Butler </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or such other address or email address as such party may hereafter specify by like notice to the other parties hereto. All such notices, requests and other
communications shall be deemed received on the date of actual receipt by the recipient thereof if received prior to 5:00 p.m. local time in the place of receipt and such day is a business day in the place of receipt. Otherwise, any such notice,
request or communication shall be deemed not to have been received until the next succeeding business day in the place of receipt. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.3
<U>Severability</U>. If any term, condition or other provision of this Agreement is determined by a court of competent jurisdiction to be invalid, illegal or incapable of being enforced by any rule of Law or public policy, all other terms,
provisions and conditions of this Agreement shall nevertheless remain in full force and effect. Upon such determination that any term, condition or other provision is invalid, illegal or incapable of being enforced, the parties hereto shall
negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible to the fullest extent permitted by applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.4 <U>Third Party Beneficiaries</U>. This Agreement (including the documents and instruments referred to herein) is not intended to, and does
not, confer upon any Person other than the parties hereto any rights or remedies hereunder, including the right to rely upon the representations and warranties set forth herein. The representations and warranties in this Agreement are the product of
negotiations among the parties hereto and are for the sole benefit of such parties. Any inaccuracies in such representations and warranties are subject to waiver by the parties hereto in accordance herewith without notice or liability to any other
Person. In some instances, the representations and warranties in this Agreement may represent an allocation among the parties hereto of risks associated with particular matters regardless of the knowledge of any of the parties hereto. Consequently,
Persons other than the parties hereto may not rely upon the representations and warranties in this Agreement as characterizations of actual facts or circumstances as of the date hereof or as of any other date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.5 <U>Governing Law; Jurisdiction; Specific Performance; Waiver to Jury Trial</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) This Agreement shall be governed by, and construed in accordance with, the Laws of the State of Delaware applicable to contracts executed
in and to be performed entirely within that State, regardless of the Laws that might otherwise govern under any applicable conflict of Laws principles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) All Actions arising out of or relating to this Agreement or the Transactions shall be heard and determined in the Court of Chancery of the
State of Delaware (or, if the Court of Chancery of the State of Delaware declines to accept jurisdiction over any Legal Proceeding, any state or federal court within the State of Delaware). The parties hereto hereby irrevocably (i)&nbsp;submit to
the exclusive jurisdiction and venue of such courts in any such Legal Proceeding, (ii)&nbsp;waive the defense of an inconvenient forum or lack of jurisdiction to the maintenance of any such Legal Proceeding, (iii)&nbsp;agree to not attempt to deny
or defeat such jurisdiction by motion or otherwise request for leave from any such court and (iv)&nbsp;agree to not bring any Legal Proceeding arising out of or relating to this Agreement or the Transactions in any court other than the Court of
Chancery of the State of Delaware (or, if the Court of Chancery of the State of Delaware declines to accept jurisdiction over any Legal Proceeding, any state or federal court within the State of Delaware), except for Legal Proceedings brought to
enforce the judgment of any such court. The consents to jurisdiction and venue set forth in this Section&nbsp;4.5(b) shall not constitute general consents to service of process in the State of Delaware and shall have no effect for any purpose except
as provided in this paragraph and shall not be deemed to confer rights on any Person other than the parties hereto. Each party hereto agrees that service of process upon such party in any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-6- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Legal Proceeding arising out of or relating to this Agreement shall be effective if notice is given by overnight courier at the address set forth in Section&nbsp;4.2 of this Agreement. The
parties hereto agree that a final judgment in any such Legal Proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by applicable Law; <U>provided</U>, <U>however</U>, that
nothing in the foregoing shall restrict any party&#146;s rights to seek any post-judgment relief regarding, or any appeal from, a final trial court judgment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The parties hereto agree that irreparable damage for which monetary relief, even if available, might not be an adequate remedy, would
occur in the event that any provision of this Agreement is not performed in accordance with its specific terms or is otherwise breached, including if the parties hereto fail to take any action required of them hereunder to consummate the Mergers or
the other Transactions. Subject to the following sentence, the parties acknowledge and agree that (a)&nbsp;the parties shall be entitled to seek an injunction or injunctions, specific performance or other equitable relief to prevent breaches of this
Agreement and to enforce specifically the terms and provisions hereof in the courts described in Section&nbsp;4.5(b), this being in addition to any other remedy to which they are entitled under this Agreement and (b)&nbsp;the right of specific
enforcement is an integral part of the Transactions and without that right none of Holders or Merger Partner would have entered into this Agreement or the Merger Agreement. The parties hereto acknowledge and agree that any party seeking an
injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement in accordance with this Section&nbsp;4.5(c) shall not be required to provide any bond or other security in
connection with any such order or injunction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS
AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE IT HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION
DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT AND ANY OF THE AGREEMENTS DELIVERED IN CONNECTION HEREWITH OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (A)&nbsp;NO REPRESENTATIVE,
AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, (B)&nbsp;IT UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF SUCH
WAIVER, (C)&nbsp;IT MAKES SUCH WAIVER VOLUNTARILY AND (D)&nbsp;IT HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVER AND CERTIFICATIONS IN THIS SECTION&nbsp;4.5(d). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.6 <U>Entire Agreement</U>. This Agreement, the Merger Agreement and the other agreements related to the Transactions (and all exhibits and
schedules hereto and thereto) collectively constitute the entire agreement, and supersedes all other prior agreements and understandings, both written and oral, among the parties with respect to the subject matter hereof and thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.7 <U>Amendment or Supplement</U>. Subject to compliance with applicable Law, at any time prior to the Merger Partner Merger Effective Time,
this Agreement may be amended or supplemented in any and all respects only by written agreement of the parties hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.8
<U>Headings</U>. The headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.9 <U>Counterparts</U>. This Agreement may be executed in one or more counterparts (including by facsimile or electronic mail), each of which
shall be deemed to be an original but all of which taken together shall constitute one and the same agreement, and shall become effective when one or more counterparts have been signed by each of the parties hereto and delivered to the other parties
hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * * * </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-7- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their
duly authorized respective officers as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">CIBUS GLOBAL, LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to Voting Agreement</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
<DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><I>Solely for purposes of Section</I></B><B><I></I></B><B><I>&nbsp;1.6 and Annex A</I></B>:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">CALYXT, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to Voting Agreement</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their
duly authorized respective officers as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[STOCKHOLDER]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Signature of</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">[STOCKHOLDER]</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Printed Name of</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">[STOCKHOLDER]</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Address of [STOCKHOLDER] for purposes of Section&nbsp;4.2 (Notices) of this Agreement: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:26%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:26%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:26%">&nbsp;</P></center>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Subject Shares </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT B</U> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF JOINDER </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>ANNEX A</U> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COVENANTS REGARDING CELLECTIS GUARANTEE </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="rom401831_73"></A>ANNEX H </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">FINAL FORM </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">VOTING AGREEMENT </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">VOTING AGREEMENT, dated as of January&nbsp;13, 2023 (this &#147;<U>Agreement</U>&#148;), by and between Calyxt, Inc., a Delaware corporation
(&#147;<U>Public Company</U>&#148;), and the undersigned equityholders (each, a &#147;<U>Holder</U>&#148; and collectively, &#147;<U>Holders</U>&#148;)<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> of Cibus Global, LLC, a Delaware limited
liability company (&#147;<U>Merger Partner</U>&#148;). Capitalized terms used herein and not otherwise defined shall have the meanings assigned to them in the Merger Agreement (as herein defined). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">RECITALS </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, concurrently
with the execution and delivery of this Agreement, Public Company, Calypso Merger Subsidiary, LLC, a Delaware limited liability company and wholly-owned subsidiary of Public Company (&#147;<U>Merger Subsidiary</U>&#148;), Merger Partner and the
Blockers (as defined in the Merger Agreement) are entering into an Agreement and Plan of Merger, dated as of the date hereof (as the same may be amended or modified in accordance with its terms, the &#147;<U>Merger Agreement</U>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, as a condition to Public Company&#146;s willingness to enter into the Merger Agreement, Holders have agreed to enter into this
Agreement with respect to the Subject Units (as defined herein); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, as of the date hereof, each Holder is the beneficial owner of
the number of limited liability membership units of Merger Partner (&#147;<U>Merger Partner Units</U>&#148;) set forth opposite such Holder&#146;s name on <U>Exhibit A</U> hereto (all such Merger Partner Units set forth opposite each such
Holder&#146;s name, together with any Merger Partner Units that are hereafter issued to (including upon the exercise of options or warrants) or otherwise acquired, or beneficially owned by such Holder prior to the termination of this Agreement
(including the Merger Partner Units resulting from any unit split, unit dividend, merger, reorganization, recapitalization, reclassification, combination, exchange of units affecting Merger Partner Units) being referred to as the &#147;<U>Subject
Units</U>&#148; of such Holder); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Merger Agreement provides for, among other things, the Mergers and the other
Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the premises, and of the representations, warranties, covenants and agreements
contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, agree as follows: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE I </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Voting and
Conversion of Merger Partner Preferred Units </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.1 <U>Voting</U>. Each Holder shall cause to be present and counted and shall vote (or
cause to be voted or acted upon by written consent with respect to) all of its Subject Units at any meeting of the equityholders of Merger Partner or any adjournment or postponement thereof, and in any action proposed to be taken by written consent
of the equityholders of Merger Partner: (a)&nbsp;to approve the Transactions, provided that, for the avoidance of doubt, Holder shall not be required to approve anything other than the Merger Agreement and the consummation of the Transactions;
(b)&nbsp;against any Acquisition Proposal (other than the Transactions); (c) to agree to convert all issued </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Merger Partner D&amp;O group to sign a separate agreement from the 9 Fidelity Blockers. New Ventures to sign
its own agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-1- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and outstanding preferred units of Merger Partner into voting common units of Merger Partner on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT>
basis; and (d)&nbsp;against any other action that would reasonably be expected to materially impede, interfere with, discourage, adversely affect, inhibit or delay the timely consummation of the Transactions or the fulfillment of Merger
Partner&#146;s conditions to Closing under the Merger Agreement. Each Holder agrees that it will not revoke any consent previously executed in support of the Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.2 <U>No Transfer</U>. During the period beginning on the date of this Agreement and ending immediately prior to the earlier of the
applicable Blocker Merger Effective Time and the termination of this Agreement, other than as contemplated by the Merger Agreement or with the written consent of Public Company, each Holder shall not, directly or indirectly, except as contemplated
by the Merger Agreement: (a)&nbsp;sell, distribute, assign, convey, transfer, grant, pledge, hypothecate, convey any legal or beneficial ownership in (including by merger (including by conversion into securities or other consideration), by tendering
into any tender or exchange offer), or otherwise encumber or dispose of any Subject Units; (b)&nbsp;deposit any Subject Units into a voting trust or enter into a voting agreement or any other arrangement with respect to any such Subject Units or
purport to grant any proxy with respect thereto; (c)&nbsp;enter into any contract, option or other arrangement or undertaking with respect to the direct or indirect acquisition or sale, assignment, transfer or other disposition of any Subject Units;
(d)&nbsp;otherwise permit any Liens to be created on any Subject Units (other than Permitted Liens (as defined herein)) or (e)&nbsp;commit or agree to take any of the foregoing actions (any action described in clauses (a), (b), (c), (d) and (e), a
&#147;<U>Transfer</U>&#148;); <U>provided</U>, that the foregoing shall not prohibit (i)&nbsp;Transfers between such Holder and any Affiliates of such Holder; (ii)&nbsp;Transfers in connection with any estate planning or charitable giving;
(iii)&nbsp;exercising any option to purchase Merger Partner Units, or any securities convertible into or exercisable or exchangeable for Merger Partner Units; (iv)&nbsp;Transfer Merger Partner Units or any securities convertible into or exercisable
or exchangeable for Merger Partner Units upon a vesting event of Merger Partner&#146;s securities or upon the exercise of options or warrants to purchase Merger Partner Units, in each case on a &#147;cashless&#148; or &#147;net exercise&#148; basis
or in a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">sale-to-cover</FONT></FONT> transaction with respect to tax withholding obligations of such Holder in connection with such vesting or exercise, whether by means of a &#147;net
settlement&#148; or otherwise; or (v)&nbsp;any Transfer required by Law or required by a Legal Proceeding to which such Holder is a party; <U>provided</U>, <U>further</U>, that any Transfer pursuant to clauses (i), (ii) or (v)&nbsp;of this
Section&nbsp;1.2 shall be permitted only if, prior to any such Transfer, and as a precondition to the effectiveness of any such Transfer, the transferee executes and delivers to Merger Partner a joinder to this Agreement in the form attached hereto
as <U>Exhibit B</U>. Any Transfer or action in violation of this Section&nbsp;1.2 shall be void <I>ab initio</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.3
<U>Solicitation</U>. Each Holder shall, and shall instruct and use its reasonable best efforts to cause the Representatives retained by it and acting on its behalf to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) immediately cease and cause to be terminated any existing discussions, negotiations and communications with any Person that
relate to any Acquisition Proposal or Acquisition Inquiry that has not already been terminated as of the date of this Agreement; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) not to take any action that Merger Partner would then be prohibited from taking under Section&nbsp;5.5(a) of the Merger
Agreement as if such Holder were Merger Partner, provided that the foregoing shall not preclude any Holder from having discussions with Merger Partner or Public Company regarding the Merger Agreement or the transactions contemplated thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, from and after the date of the Merger Agreement until the earlier to occur of (x)&nbsp;the Merger Partner Merger Effective Time
and (y)&nbsp;such date and time as the Merger Agreement shall be validly terminated pursuant thereto, if (and only if) Merger Partner is permitted, pursuant to the Merger Agreement, to have discussions or negotiations in response to an Acquisition
Proposal, each Holder and its Representatives shall be permitted to participate in such discussions or negotiations with such Person making such Acquisition Proposal to the same extent as Merger Partner is permitted to do so under the Merger
Agreement (including with respect to providing a voting agreement with respect to such Holder&#146;s Subject Units). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, and
notwithstanding anything in this Agreement to the contrary, (a)&nbsp;no Holder&#146;s obligations under this Section&nbsp;1.3 shall be construed to apply to any actions taken by any other equityholder of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-2- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Merger Partner, Merger Partner or any of its Subsidiaries, the Board of Managers of Merger Partner or any committee thereof, any of the directors, managers, officers or employees of any other
equityholder of Merger Partner, Merger Partner or any of their respective Subsidiaries (in their capacities as such), or the Representatives of any other equityholder of Merger Partner, Merger Partner or any of their respective Subsidiaries,
(b)&nbsp;no Holder shall be responsible for the actions of any of the foregoing and (c)&nbsp;nothing in this Section&nbsp;1.3 shall prevent any Holder or its Representatives, in their capacity as a member of Merger Partner&#146;s Board of Managers
or as an executive officer of Merger Partner, as applicable, from engaging in any activity permitted or required by the Merger Agreement in the performance of their fiduciary obligations to Merger Partner&#146;s equityholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.4 <U>Further Assurances</U>. Each Holder shall execute and deliver, or cause to be executed and delivered, such further certificates,
instruments and other documents as Merger Partner or Public Company may reasonably request for the purpose of effectively carrying out its obligations under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.5 <U>Additional Merger Partner Units</U>. Each Holder acknowledges and agrees that any additional Merger Partner Units with respect to which
beneficial ownership is acquired by such Holder (other than pursuant to a vesting event pursuant to Merger Partner&#146;s profit interest units, if any, after the date hereof), by transfer or any other mechanism shall automatically become subject to
the terms of this Agreement as though owned by such Holder as of the date hereof. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE II </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Representations and Warranties of Each Holder </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Holder, severally and not jointly, hereby represents and warrants to Public Company as to itself (and not as to any other Holder) as
follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1 <U>Authorization</U>. Such Holder has all requisite capacity, power and authority to execute and deliver this Agreement and
to perform its obligations under this Agreement. This Agreement has been duly executed and delivered by or on behalf of such Holder and, assuming the due authorization, execution and delivery of this Agreement by Public Company, this Agreement
constitutes a legal, valid and binding obligation of such Holder, enforceable against such Holder in accordance with its terms, except to the extent that enforcement may be limited by applicable bankruptcy, insolvency, fraudulent conveyance,
reorganization, moratorium and other Laws affecting creditors&#146; rights generally and by general equitable principles (whether considered in a proceeding in equity or at law). Each Holder that is an entity (a)&nbsp;is duly organized, validly
existing and in good standing (with respect to jurisdictions that recognize such concept or equivalent) under the Laws of the jurisdiction of its organization, (b)&nbsp;the execution and delivery of this Agreement and such Holder&#146;s performance
of its obligations under this Agreement have been duly authorized by all necessary corporate or other organizational action on the part of such Holder and no other corporate or other organizational action on the part of such Holder is necessary to
authorize the execution and delivery of this Agreement or for such Holder to perform its obligations under this Agreement and (c)&nbsp;no approval by any holder of such Holder&#146;s equity, membership or other interests is necessary to approve this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2 <U>Governmental Filings; No Violations; Certain Contracts</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) No consent, approval, order or authorization of, or registration, declaration or filing with or notice to, any Government Authority is
required to be obtained or made by such Holder in connection with the execution and delivery of this Agreement, except for (i)&nbsp;such filings and reports as may be required pursuant to the applicable requirements of the Securities Act, the
Exchange Act and any other applicable state or federal securities, takeover and &#147;blue sky&#148; Laws (collectively, &#147;<U>Required Filings</U>&#148;) and (ii)&nbsp;such consents, authorizations, filings, approvals and registrations which, if
not obtained or made, are not reasonably likely to prevent, materially delay or materially impair the performance of such Holder&#146;s obligations under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The execution and delivery by such Holder of this Agreement does not, and the compliance with the provisions hereof will not, conflict
with, or result in any violation or breach of, or default (with or without </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
notice or lapse of time, or both) under, or give rise to a right of, or result in, termination, cancellation, modification or acceleration of any obligation or to the loss of a material benefit
under, or result in the creation of any Lien in or upon any of the properties, assets or rights of such Holder under, or give rise to any increased, additional, accelerated or guaranteed rights or entitlements under, or require any consent, waiver
or approval of any Person pursuant to, any provision of (i)&nbsp;any written agreement to which such Holder is a party or by which such Holder or any of his properties or assets may be bound, (ii)&nbsp;any Law applicable to such Holder or by which
such Holder or any of its properties or assets may be bound or (iii)&nbsp;following a valid Transfer pursuant to Section&nbsp;1.2, with respect to such Holder that is an entity, the organizational documents of such Holder, except as would not,
individually or in the aggregate, be reasonably expected to prevent or materially delay the ability of such Holder to perform such Holder&#146;s obligations under this Agreement or to consummate the transactions contemplated hereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.3 <U>Ownership of Subject Units; Voting Power</U>. <U>Exhibit A</U> hereto correctly sets forth the number of Subject Units held
beneficially by such Holder, as of the date of this Agreement. Such Holder is the sole beneficial holder of all of its Subject Units and has full voting power and power of disposition with respect to all such Subject Units free and clear of any
liens, claims, proxies, voting trusts or agreements, options or any other encumbrances or restrictions on title, transfer or exercise of any rights of an equityholder in respect of such Subject Units (collectively, &#147;<U>Encumbrances</U>&#148;),
except for any such Encumbrance that may be imposed pursuant to (a)&nbsp;(i) this Agreement, (ii)&nbsp;the organizational documents of Merger Partner, or (iii)&nbsp;any applicable restrictions on transfer under the Securities Act, including the
rules and regulations promulgated thereunder, or any &#147;blue sky&#148; Laws of the various states of the United States or (b)&nbsp;expressly contemplated by the Merger Agreement (collectively, &#147;<U>Permitted Liens</U>&#148;). Except pursuant
to this Agreement or the Merger Agreement or as set forth in the organizational documents of Merger Partner, no Person has any contractual or other right or obligation to purchase or otherwise acquire any of the Holder&#146;s Subject Units. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.4 <U>Disclosure of All Units Owned</U>. Such Holder does not beneficially own any equity securities of Merger Partner other than the Subject
Units any options, warrants, or other rights to acquire any additional equity securities of Merger Partner or any security exercisable for or convertible into equity securities of Merger Partner, in each case, as set forth on <U>Exhibit A</U>
attached hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.5 <U>Reliance</U>. Such Holder understands and acknowledges that Public Company is entering into the Merger Agreement
in reliance upon such Holder&#146;s execution, delivery and performance of this Agreement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE III </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Representations and Warranties of Public Company </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Public Company hereby represents and warrants to each Holder as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Public Company is an entity duly organized, validly existing and in good standing (with respect to jurisdictions that recognize such
concept or equivalent) under the Laws of the jurisdiction of its organization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Public Company has all requisite capacity, power and
authority to execute and deliver this Agreement and to perform its obligations under this Agreement. This Agreement has been duly executed and delivered by or on behalf of Public Company and, assuming the due authorization, execution and delivery of
this Agreement by the Holder, this Agreement constitutes a legal, valid and binding obligation of Public Company, enforceable against Public Company in accordance with its terms, except to the extent that enforcement may be limited by applicable
bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and other Laws affecting creditors&#146; rights generally and by general equitable principles (whether considered in a proceeding in equity or at law). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-4- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE IV </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>General Provisions </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.1
<U>Termination</U>. This Agreement and all obligations, covenants and agreements contained herein, including the voting agreements contemplated hereby and the proxies granted hereunder, shall automatically terminate and cease to be effective at the
earliest to occur of: (a)&nbsp;the Merger Partner Merger Effective Time; (b)&nbsp;the termination of the Merger Agreement pursuant thereto; (c)&nbsp;the effective date of a written agreement of the parties hereto terminating this Agreement; and
(d)&nbsp;with respect to the Holder, the date of any modification or amendment to the Merger Agreement, as in effect on the date hereof, in a manner that reduces the amount and/or changes the form of consideration payable thereunder to the Holder or
its equityholders, or otherwise adversely effects the Holder or its equityholders in any respect without the prior written approval of the Holder; <U>provided</U>, <U>however</U>, that in the case of any termination pursuant to clause (a)&nbsp;of
this sentence, Section&nbsp;1.4 (Further Assurances) and this ARTICLE IV shall survive such termination hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.2 <U>Notices</U>. All
notices and other communications to any party hereunder shall be in writing and shall be deemed given if personally delivered, emailed (which is confirmed) or sent by overnight courier (providing proof of delivery) to the parties at the following
addresses: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><U>If to Public Company, to</U>: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Calyxt, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">2800 Mount Ridge
Road </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Roseville, MN 55113 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Debra Frimerman, General Counsel </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***]</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">and to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Sidley Austin LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">787 Seventh Ave </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">New York, New
York 10019 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;John H. Butler </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><U>If to any Holder, to it at</U>: the address listed below such Holder&#146;s name on the signature page of such Holder, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><U>With a copy (which shall not constitute notice) to:</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Cibus Global, LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">6455 Nancy
Ridge Drive </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">San Diego, CA 92121 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rory Riggs, Chief Executive Officer, and Wade King, MD, Chief Financial Officer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***]</FONT> and [***] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">and to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Jones Day </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">4655 Executive Drive </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Suite 1500
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">San Diego, CA 92121-3134 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cameron A. Reese </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***]</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or such other address or email address as such party may hereafter specify by like notice to the other parties hereto. All such notices, requests and other
communications shall be deemed received on the date of actual </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-5- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
receipt by the recipient thereof if received prior to 5:00 p.m. local time in the place of receipt and such day is a business day in the place of receipt. Otherwise, any such notice, request or
communication shall be deemed not to have been received until the next succeeding business day in the place of receipt. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.3
<U>Severability</U>. If any term, condition or other provision of this Agreement is determined by a court of competent jurisdiction to be invalid, illegal or incapable of being enforced by any rule of Law or public policy, all other terms,
provisions and conditions of this Agreement shall nevertheless remain in full force and effect. Upon such determination that any term, condition or other provision is invalid, illegal or incapable of being enforced, the parties hereto shall
negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible to the fullest extent permitted by applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.4 <U>Third Party Beneficiaries</U>. This Agreement (including the documents and instruments referred to herein) is not intended to, and does
not, confer upon any Person other than the parties hereto any rights or remedies hereunder, including the right to rely upon the representations and warranties set forth herein. The representations and warranties in this Agreement are the product of
negotiations among the parties hereto and are for the sole benefit of such parties. Any inaccuracies in such representations and warranties are subject to waiver by the parties hereto in accordance herewith without notice or liability to any other
Person. In some instances, the representations and warranties in this Agreement may represent an allocation among the parties hereto of risks associated with particular matters regardless of the knowledge of any of the parties hereto. Consequently,
Persons other than the parties hereto may not rely upon the representations and warranties in this Agreement as characterizations of actual facts or circumstances as of the date hereof or as of any other date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.5 <U>Governing Law; Jurisdiction; Specific Performance; Waiver to Jury Trial</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) This Agreement shall be governed by, and construed in accordance with, the Laws of the State of Delaware applicable to contracts executed
in and to be performed entirely within that State, regardless of the Laws that might otherwise govern under any applicable conflict of Laws principles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) All Actions arising out of or relating to this Agreement or the Transactions shall be heard and determined in the Court of Chancery of the
State of Delaware (or, if the Court of Chancery of the State of Delaware declines to accept jurisdiction over any Legal Proceeding, any state or federal court within the State of Delaware). The parties hereto hereby irrevocably (i)&nbsp;submit to
the exclusive jurisdiction and venue of such courts in any such Legal Proceeding, (ii)&nbsp;waive the defense of an inconvenient forum or lack of jurisdiction to the maintenance of any such Legal Proceeding, (iii)&nbsp;agree to not attempt to deny
or defeat such jurisdiction by motion or otherwise request for leave from any such court and (iv)&nbsp;agree to not bring any Legal Proceeding arising out of or relating to this Agreement or the Transactions in any court other than the Court of
Chancery of the State of Delaware (or, if the Court of Chancery of the State of Delaware declines to accept jurisdiction over any Legal Proceeding, any state or federal court within the State of Delaware), except for Legal Proceedings brought to
enforce the judgment of any such court. The consents to jurisdiction and venue set forth in this Section&nbsp;4.5(b) shall not constitute general consents to service of process in the State of Delaware and shall have no effect for any purpose except
as provided in this paragraph and shall not be deemed to confer rights on any Person other than the parties hereto. Each party hereto agrees that service of process upon such party in any Legal Proceeding arising out of or relating to this Agreement
shall be effective if notice is given by overnight courier at the address set forth in Section&nbsp;4.2 of this Agreement. The parties hereto agree that a final judgment in any such Legal Proceeding shall be conclusive and may be enforced in other
jurisdictions by suit on the judgment or in any other manner provided by applicable Law; <U>provided</U>, <U>however</U>, that nothing in the foregoing shall restrict any party&#146;s rights to seek any post-judgment relief regarding, or any appeal
from, a final trial court judgment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The parties hereto agree that irreparable damage for which monetary relief, even if available,
might not be an adequate remedy, would occur in the event that any provision of this Agreement is not performed in accordance with its specific terms or is otherwise breached, including if the parties hereto fail to take any action
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-6- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
required of them hereunder to consummate the Mergers or the other Transactions. Subject to the following sentence, the parties acknowledge and agree that (a)&nbsp;the parties shall be entitled to
seek an injunction or injunctions, specific performance or other equitable relief to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof in the courts described in Section&nbsp;4.5(b), this being in
addition to any other remedy to which they are entitled under this Agreement and (b)&nbsp;the right of specific enforcement is an integral part of the Transactions and without that right none of Holders or Public Company would have entered into this
Agreement or the Merger Agreement. The parties hereto acknowledge and agree that any party seeking an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement in
accordance with this Section&nbsp;4.5(c) shall not be required to provide any bond or other security in connection with any such order or injunction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND
DIFFICULT ISSUES, AND THEREFORE IT HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF OR
RELATING TO THIS AGREEMENT AND ANY OF THE AGREEMENTS DELIVERED IN CONNECTION HEREWITH OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (A)&nbsp;NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS
REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, (B)&nbsp;IT UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF SUCH WAIVER, (C)&nbsp;IT MAKES SUCH WAIVER
VOLUNTARILY AND (D)&nbsp;IT HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVER AND CERTIFICATIONS IN THIS SECTION&nbsp;4.5(d). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.6 <U>Entire Agreement</U>. This Agreement, the Merger Agreement and the other agreements related to the Transactions (and all exhibits and
schedules hereto and thereto) collectively constitute the entire agreement, and supersedes all other prior agreements and understandings, both written and oral, among the parties with respect to the subject matter hereof and thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.7 <U>Amendment or Supplement</U>. Subject to compliance with applicable Law, at any time prior to the Merger Partner Merger Effective Time,
this Agreement may be amended or supplemented in any and all respects only by written agreement of the parties hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.8
<U>Headings</U>. The headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.9 <U>Counterparts</U>. This Agreement may be executed in one or more counterparts (including by facsimile or electronic mail), each of which
shall be deemed to be an original but all of which taken together shall constitute one and the same agreement, and shall become effective when one or more counterparts have been signed by each of the parties hereto and delivered to the other parties
hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * * * </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-7- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their
duly authorized respective officers as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">CALYXT, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to Voting Agreement</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their
duly authorized respective officers as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[EQUITYHOLDER]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Signature of</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">[EQUITYHOLDER]</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Printed Name of</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">[EQUITYHOLDER]</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Address of [EQUITYHOLDER] for purposes of Section&nbsp;4.2 (Notices) of this Agreement: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Subject Units </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT B </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF JOINDER </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="rom401831_74"></A>ANNEX I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Execution Version </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THIRD AMENDED AND RESTATED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LIMITED LIABILITY COMPANY AGREEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CIBUS GLOBAL, LLC
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>a Delaware limited liability company </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated as of [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 2023 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">THE LIMITED LIABILITY COMPANY UNITS OF CIBUS GLOBAL, LLC HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE
&#147;<B><I>SECURITIES ACT</I></B>&#148;), THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION OR ANY OTHER APPLICABLE SECURITIES LAWS AND ARE BEING SOLD IN RELIANCE UPON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND
SUCH LAWS. SUCH UNITS MUST BE ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE OFFERED FOR SALE, PLEDGED, HYPOTHECATED, SOLD, ASSIGNED OR TRANSFERRED AT ANY TIME EXCEPT IN COMPLIANCE WITH (I)&nbsp;THE SECURITIES ACT, ANY APPLICABLE SECURITIES LAWS OF ANY
STATE OR OTHER JURISDICTION, AND ANY OTHER APPLICABLE SECURITIES LAWS; (II)&nbsp;THE TERMS AND CONDITIONS OF THIS THIRD AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT; AND (III)&nbsp;ANY OTHER TERMS AND CONDITIONS AGREED TO IN WRITING
BETWEEN THE COMPANY AND THE APPLICABLE MEMBER. THE UNITS MAY NOT BE TRANSFERRED OF RECORD EXCEPT IN COMPLIANCE WITH SUCH LAWS, THIS THIRD AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT, AND ANY OTHER TERMS AND CONDITIONS AGREED TO IN
WRITING BY THE COMPANY AND THE APPLICABLE MEMBER. THEREFORE, MEMBERS AND OTHER TRANSFEREES OF SUCH UNITS WILL BE REQUIRED TO BEAR THE RISK OF THEIR INVESTMENT OR ACQUISITION FOR AN INDEFINITE PERIOD OF TIME. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-size:8pt"><B>Page</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_1">ARTICLE I DEFINITIONS </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.01</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_2">Definitions </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_3">ARTICLE II FORMATION, TERM, PURPOSE AND POWERS
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.01</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_4">Formation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.02</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_5">Name</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.03</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_6">Term</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.04</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_7">Offices</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.05</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_8">Agent for Service of Process; Existence and Good Standing; Foreign
 Qualification</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.06</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_9">Business Purpose</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.07</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_10">Powers of the Company</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.08</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_11">Members; Reclassification; Admission of New
Members</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.09</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_12">Resignation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_13">Representations of Members</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_14">Amendment and Restatement of Existing
Agreement</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_15">ARTICLE III MANAGEMENT </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.01</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_16">Managing Member</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.02</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_17">Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.03</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_18">Expenses</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.04</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_19">Officers</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.05</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_20">Authority of Members</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.06</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_21">Action by Written Consent or Ratification</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.07</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_22">Investment Company Act Restrictions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.08</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transactions between the Company and the Managing Member</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_24">ARTICLE IV DISTRIBUTIONS </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.01</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_25">Distributions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.02</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_26">Liquidation Distribution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.03</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_27">Limitations on Distribution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.04</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Use of Distribution Funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_29">ARTICLE V CAPITAL CONTRIBUTIONS; CAPITAL ACCOUNTS; TAX ALLOCATIONS;
 TAX MATTERS </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.01</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_30">Initial Capital Contributions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.02</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_31">No Additional Capital Contributions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.03</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_32">Capital Accounts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.04</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_33">Allocations of Profits and Losses</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.05</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_34">Special Allocations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.06</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_35">Tax Allocations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.07</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_36">Tax Advances</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.08</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_37">Partnership Representative</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.09</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_38">Other Allocation Provisions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_39">Survival</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_40">Unitholder Representative Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_41">ARTICLE VI BOOKS AND RECORDS; REPORTS </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.01</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_42">Books and Records</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.02</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_43">Confidentiality</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-i- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_44">ARTICLE VII COMPANY UNITS </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.01</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_45">Units</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.02</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_46">Register</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.03</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_47">Registered Members</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.04</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_48">Issuances, Repurchases and Redemptions,
Recapitalizations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_49">ARTICLE VIII TRANSFER RESTRICTIONS </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.01</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_50">Member Transfers</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.02</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_51">Purported Transfers Void</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.03</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_52">Mandatory Exchanges</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.04</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_53">Encumbrances</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.05</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_54">Approved Qualified Transaction</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.06</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_55">Further Restrictions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.07</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_56">Rights of Assignees</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.08</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_57">Admissions, Resignations and Removals</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.09</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_58">Admission of Assignees as Substitute Members</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_59">Resignation and Removal of Members</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_60">Withholding</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_61">Allocations in Respect of Transferred Units</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_62">ARTICLE IX DISSOLUTION, LIQUIDATION AND TERMINATION
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.01</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_63">No Dissolution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.02</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_64">Events Causing Dissolution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.03</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_65">Distribution upon Dissolution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.04</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_66">Time for Liquidation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.05</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_67">Termination</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.06</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_68">Claims of the Members</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.07</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_69">Survival of Certain Provisions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_70">ARTICLE X LIABILITY AND INDEMNIFICATION </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.01</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_71">Liability of Members</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.02</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_72">Indemnification</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.03</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_73">Survival</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_74">ARTICLE XI VALUATION </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.01</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_75">Fair Market Value</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.02</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_76">Determination</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_77">ARTICLE XII MISCELLANEOUS </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.01</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_78">Severability</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.02</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_79">Notices</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.03</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_80">Cumulative Remedies</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.04</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_81">Binding Effect</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.05</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_82">Interpretation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.06</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_83">Counterparts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.07</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_84">Further Assurances</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.08</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_85">Entire Agreement</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.09</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_86">Governing Law</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_87">Submission to Jurisdiction; Waiver of Jury
Trial</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_88">Expenses</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_89">Amendments and Waivers</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_90">No Third Party Beneficiaries</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.14</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_91">Headings</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-ii- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.15</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_92">Power of Attorney</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.16</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_93">Separate Agreements; Schedules</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.17</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_94">Partnership Status</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.18</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#annexitoc401831_95">Delivery by Facsimile or Email</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-iii- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THIRD AMENDED AND RESTATED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LIMITED LIABILITY COMPANY AGREEMENT OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CIBUS GLOBAL, LLC </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>T<SMALL>HIS</SMALL> T<SMALL>HIRD</SMALL> A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> L<SMALL>IMITED</SMALL>
L<SMALL>IABILITY</SMALL> C<SMALL>OMPANY</SMALL> A<SMALL>GREEMENT</SMALL></B><SMALL></SMALL> (this &#147;<B><I>Agreement</I></B>&#148;) of Cibus Global, LLC, a Delaware limited liability company<B> </B>(the &#147;<B><I>Company</I></B>&#148;), is made
as of <B>[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]</B><B>, 2023 </B>(the &#147;<B><I>Effective Date</I></B>&#148;) by and among Cibus, Inc. (f/k/a Calyxt, Inc.), a Delaware corporation, in its capacity as the
Managing Member of the Company, the Company and the Members set forth on <B>Exhibit A</B> hereto and each other person who is or at any time becomes a Member in accordance with the terms of this Agreement and the Act (as defined below). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL></B><SMALL></SMALL>, the Company was originally formed as Cibus Global, Ltd., a British Virgin Islands company (in
such capacity, &#147;<B><I>Cibus BVI</I></B>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL></B><SMALL></SMALL>, pursuant to the provisions of
Section&nbsp;18-212 of the Delaware Act, and Section&nbsp;388 of the BVI Business Companies Act, and through the filing of a Certificate of Limited Liability Company Domestication and a Certificate of Formation with the Delaware Secretary of State,
Division of Corporations (such Certificate of Formation, collectively with each amendment thereto, the &#147;<B><I>Certificate</I></B>&#148;), on May&nbsp;10, 2019 Cibus BVI was continued and/or converted as the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL></B><SMALL></SMALL>, the Company entered into that certain Limited Liability Company<B> </B>Agreement of the Company,
dated May&nbsp;10, 2019<B>, </B>by and between the Company and certain of the Members, as amended by that certain First Amendment to the Limited Liability Company Agreement of the Company, dated August&nbsp;7, 2019 (together, the
&#147;<B><I>Original Agreement</I></B>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL></B><SMALL></SMALL>, on June&nbsp;23, 2021, the Original
Agreement was amended and restated in its entirety by that certain Amended and Restated Limited Liability Company<B> </B>Agreement of the Company (the &#147;<B><I>Amended Agreement</I></B>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL></B><SMALL></SMALL>, on December&nbsp;2, 2022, in connection with the issuance of certain preferred units, the
Amended Agreement was amended and restated in its entirety by that certain Second Amended and Restated Limited Liability Company Agreement of the Company (the &#147;<B><I>Existing Agreement</I></B>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL></B><SMALL></SMALL>, concurrently with the effectiveness of this Agreement, in accordance with the Agreement and Plan
of Merger, dated as of January&nbsp;13, 2023 (the &#147;<B><I>Merger Agreement</I></B>&#148;), by and among the Managing Member; Calypso Merger Subsidiary, LLC, a Delaware limited liability company and wholly-owned subsidiary of the Managing Member
(&#147;<B><I>Merger Subsidiary</I></B>&#148;); the Company; New Venture I Holdings, LLC, a Delaware limited liability company (&#147;<B><I>Blocker 1</I></B>&#148;); BCGF CB Holdings LLC, a Delaware limited liability company (&#147;<B><I>Blocker
2</I></B>&#148;); BCGFCP CB Holdings LLC, a Delaware limited liability company (&#147;<B><I>Blocker 3</I></B>&#148;); BCGFK CB Holdings LLC, a Delaware limited liability company (&#147;<B><I>Blocker 4</I></B>&#148;); FSBCGF CB Holdings LLC, a
Delaware limited liability company (&#147;<B><I>Blocker 5</I></B>&#148;); PYLBCG CB Holdings LLC, a Delaware limited liability company (&#147;<B><I>Blocker 6</I></B>&#148;); FSGRWCO CB Holdings LLC, a Delaware limited liability company
(&#147;<B><I>Blocker 7</I></B>&#148;); GROWTHCO CB Holdings LLC, a Delaware limited liability company (&#147;<B><I>Blocker 8</I></B>&#148;); GRTHCOCP CB Holdings LLC, a Delaware limited liability company (&#147;<B><I>Blocker 9</I></B>&#148;); and
GRWTHCOK CB Holdings LLC, a Delaware limited liability company (&#147;<B><I>Blocker 10</I></B>&#148; and, collectively with Blocker 1, Blocker 2, Blocker 3, Blocker 4, Blocker 5, Blocker 6, Blocker 7, Blocker 8 and Blocker 9, the
&#147;<B><I>Blockers</I></B>&#148;): (i) Blocker 1 merged with and into the Managing Member, whereupon the separate corporate existence of Blocker 1 ceased and the Managing Member became the surviving entity (the &#147;<B><I>First Blocker
Merger</I></B>&#148;), (ii) Blocker 2 merged with and into the Managing Member, whereupon the separate corporate existence of Blocker 2 ceased and the Managing Member became the surviving entity (the &#147;<B><I>Second</I></B>
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-1- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<B><I>Blocker Merger</I></B>&#148;), (iii) Blocker 3 merged with and into the Managing Member, whereupon the separate corporate existence of Blocker 3 ceased and the Managing Member became the
surviving entity (the &#147;<B><I>Third Blocker Merger</I></B>&#148;), (iv) Blocker 4 merged with and into the Managing Member, whereupon the separate corporate existence of Blocker 4 ceased and the Managing Member became the surviving entity (the
&#147;<B><I>Fourth Blocker Merger</I></B>&#148;), (v) Blocker 5 merged with and into the Managing Member, whereupon the separate corporate existence of Blocker 5 ceased and the Managing Member became the surviving entity (the &#147;<B><I>Fifth
Blocker Merger</I></B>&#148;), (vi) Blocker 6 merged with and into the Managing Member, whereupon the separate corporate existence of Blocker 6 ceased and the Managing Member became the surviving entity (the &#147;<B><I>Sixth</I></B><B><I> Blocker
Merger</I></B>&#148;), (vii) Blocker 7 merged with and into the Managing Member, whereupon the separate corporate existence of Blocker 7 ceased and the Managing Member became the surviving entity (the &#147;<B><I>Seventh Blocker
Merger</I></B>&#148;), (viii) Blocker 8 merged with and into the Managing Member, whereupon the separate corporate existence of Blocker 8 ceased and the Managing Member became the surviving entity (the &#147;<B><I>Eighth Blocker
Merger</I></B>&#148;), (ix) Blocker 9 merged with and into the Managing Member, whereupon the separate corporate existence of Blocker 9 ceased and the Managing Member became the surviving entity (the &#147;<B><I>Ninth Blocker Merger</I></B>&#148;),
(x) Blocker 10 merged with and into the Managing Member, whereupon the separate corporate existence of Blocker 10 ceased and the Managing Member became the surviving entity (the &#147;<B><I>Tenth Blocker Merger</I></B>&#148; and, collectively with
the First Blocker Merger, Second Blocker Merger, Third Blocker Merger, Fourth Blocker Merger, Fifth Blocker Merger, Sixth Blocker Merger, Seventh Blocker Merger, Eighth Blocker Merger, and Ninth Blocker Merger, the &#147;<B><I>Blocker
Mergers</I></B>&#148;), and (xi)&nbsp;immediately following the Blocker Mergers, the Merger Subsidiary merged with and into the Company, whereupon the separate corporate existence of the Merger Subsidiary ceased and the Company became the surviving
entity (the &#147;<B><I>Company </I></B><B><I>Merger</I></B>&#148; and together with the Blocker Mergers, the &#147;<B><I>Mergers</I></B>&#148;) and continued its existence under the Act and in accordance with this Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL></B><SMALL></SMALL>, pursuant to the Company Merger, each of the Series A Preferred Units, Series B Preferred Units,
Series C Preferred Units, Series D Preferred Units, Series E Preferred Units, Series F Preferred Units, Voting Common Units and Common Units (as each is defined in the Existing Agreement) outstanding prior to the effectiveness of this Agreement were
cancelled and certain of the holders thereof received the number of Common Units set forth opposite such Member&#146;s name on <B><U>Exhibit A</U></B> hereto, in each case, in accordance with Section&nbsp;2.1 of the Merger Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL></B><SMALL></SMALL>, immediately prior to the consummation of the Mergers, the Managing Member repaid the outstanding
balance owed to the Company in connection with the Interim Funding through the transfer of a portion of the assets of the Managing Member to the Company and, immediately thereafter, the Managing Member contributed the residual of its assets and
liabilities to the Company as a Capital Contribution in exchange for Common Units (the &#147;<B><I>Managing</I></B> <B><I>Member Initial Contribution</I></B>&#148;) and the Company reduced the outstanding Interim Funding subject to repayment
thereafter to zero ($0); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL></B><SMALL></SMALL>, pursuant to the Merger Agreement, (i)&nbsp;the Members have
agreed to amend and restate the Existing Agreement in its entirety as set forth herein and (ii)&nbsp;Cibus, Inc., by its execution and delivery of this Agreement, is hereby admitted to the Company as the Managing Member, and shall have the rights
and obligations as provided in this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-2- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>N<SMALL>OW</SMALL>, T<SMALL>HEREFORE</SMALL></B><SMALL></SMALL>, in consideration of the
premises and agreements of the parties set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Members and the Managing Member hereby agree to amend and restate the Existing
Agreement to read in its entirety as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="annexitoc401831_1"></A>ARTICLE I </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEFINITIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_2">
</A>1.01&nbsp;&nbsp;&nbsp;&nbsp;<B>Definitions</B>. Capitalized terms used herein without definition have the following meanings (such meanings being equally applicable to both the singular and plural form of the terms defined): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Act</I></B>&#148; means, the Delaware Limited Liability Company Act, 6 Del. C. Section&nbsp;18-101, et seq., as it may be amended
from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Adjusted Capital Account Balance</I></B>&#148; means, with respect to each Member, the balance in such
Member&#146;s Capital Account adjusted (i)&nbsp;by taking into account the adjustments, allocations and distributions described in Treasury Regulations Sections 1.704-1(b)(2)(ii)(d)(4), (5) and (6); and (ii)&nbsp;by adding to such balance such
Member&#146;s share of Company Minimum Gain and Member Nonrecourse Debt Minimum Gain, determined pursuant to Treasury Regulations Sections 1.704-2(g) and 1.704-2(i)(5), and any amounts such Member is obligated to restore pursuant to any provision of
this Agreement or by applicable Law. The foregoing definition of Adjusted Capital Account Balance is intended to comply with the provisions of Treasury Regulations Section&nbsp;1.704-1(b)(2)(ii)(d) and shall be interpreted consistently therewith.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Affiliate</I></B>&#148; means, with respect to a specified Person, any other Person that directly, or indirectly through one
or more intermediaries, Controls, is Controlled by, or is under common Control with, such specified Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Agreement</I></B>&#148; has the meaning set forth in the preamble of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Allocation Schedule</I></B>&#148; has the meaning given to such term in the Merger Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Amended Agreement</I></B>&#148; has the meaning set forth in the recitals of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Approved Qualified Transaction</I></B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;8.05(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Assignee</I></B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;8.07</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Assumed Tax Rate</I></B>&#148; means the highest effective marginal combined U.S. federal, state and local income tax rate
(including the tax imposed under Section&nbsp;1411 of the Code on net investment income) for a Fiscal Year prescribed for an individual or corporate resident in California or New York, New York (whichever results in the application of the highest
state and local tax rate for a given type of income), and taking into account (a)&nbsp;the limitations imposed on the deductibility of expenses and other items, (b)&nbsp;the character (e.g., long-term or short-term capital gain or ordinary or exempt
income) of the applicable income, and (c)&nbsp;the deductibility of state and local income taxes, to the extent applicable, but not taking into account any deduction under Section&nbsp;199A of the Code or any similar state or local law), as
determined in good faith by the Managing Member. For the avoidance of doubt, the Assumed Tax Rate shall be the same for all Members. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Available Cash</I></B>&#148; means, as of a particular date, the amount of cash on hand which the Managing Member, in its
reasonable discretion, deems available for distribution to the Members, taking into account all debts, liabilities and obligations of the Company then due and amounts that the Managing Member, in its reasonable discretion, deems necessary to expend
or retain for working capital or to place into reserves for customary and usual claims with respect to the Company&#146;s operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Blocker 1</I></B>&#148; has the meaning set forth in the recitals of this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Blocker 10</I></B>&#148; has the meaning set forth in the recitals of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Blocker 2</I></B>&#148; has the meaning set forth in the recitals of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Blocker 3</I></B>&#148; has the meaning set forth in the recitals of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Blocker 4</I></B>&#148; has the meaning set forth in the recitals of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Blocker 5</I></B>&#148; has the meaning set forth in the recitals of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Blocker 6</I></B>&#148; has the meaning set forth in the recitals of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Blocker 7</I></B>&#148; has the meaning set forth in the recitals of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Blocker 8</I></B>&#148; has the meaning set forth in the recitals of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Blocker 9</I></B>&#148; has the meaning set forth in the recitals of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Blocker Mergers</I></B>&#148; has the meaning set forth in the recitals of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Blockers</I></B>&#148; has the meaning set forth in the recitals of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Board</I></B>&#148; means the Board of Directors of the Managing Member. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Capital Account</I></B>&#148; means the separate capital account maintained for each Member in accordance with
<U>Section</U><U></U><U>&nbsp;5.03</U> hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Capital Contribution</I></B>&#148; means, with respect to any Member, the
aggregate amount of money contributed to the Company and the initial Carrying Value of any property (other than money), net of any liabilities assumed by the Company upon contribution or to which such property is subject, contributed to the Company
pursuant to <U>Article V</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Carrying Value</I></B>&#148; means, with respect to any Company asset, the asset&#146;s
adjusted basis for U.S. federal income tax purposes, except that the initial carrying value of assets contributed to the Company shall be their respective gross Fair Market Values on the date of contribution as determined by the Managing Member in
its reasonable discretion, and the Carrying Values of all Company assets shall be adjusted to equal their respective Fair Market Values, in accordance with the rules set forth in Treasury Regulation Section&nbsp;1.704-1(b)(2)(iv)(f), except as
otherwise provided herein, as of: (a)&nbsp;the date of the acquisition of any additional limited liability company interest in the Company by any new or existing Member in exchange for more than a de minimis Capital Contribution; (b)&nbsp;the date
of the Distribution of more than a de minimis amount of Company assets to a Member as consideration for an interest in the Company; (c)&nbsp;the liquidation of the Company within the meaning of Treasury Regulations Section&nbsp;1.704-1(b)(2)(ii)(g);
(d) in connection with the grant of an interest in the Company (other than a de minimis interest) as consideration for the provision of services to or for the benefit of the Company by an existing member acting in a partner capacity, or by a new
Member acting in a partner capacity in anticipation of being a Member, (e)&nbsp;the acquisition of an interest in the Company upon the exercise of a noncompensatory option in accordance with Treasury Regulations Section&nbsp;1.704-1(b)(2)(iv)(s);
(f) on the Effective Date in connection with the closing of the transactions contemplated by the Merger Agreement, or (g)&nbsp;any other date specified in the Treasury Regulations; <I>provided</I>, <I>however</I>, that adjustments pursuant to
clauses (a), (b), and (d)&nbsp;above shall be made only if such adjustments are deemed necessary or appropriate by the Managing Member in its reasonable discretion to reflect the relative economic interests of the Members; and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-4- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
provided further, if any noncompensatory option is outstanding, Carrying Values shall be adjusted in accordance with Treasury Regulations Sections 1.704-1(b)(2)(iv)(f)(1) and
1.704-1(b)(2)(iv)(h)(2). The Carrying Value of any Company asset distributed to any Member shall be adjusted immediately before such Distribution to equal its Fair Market Value. In the case of any asset that has a Carrying Value that differs from
its adjusted tax basis, Carrying Value shall be adjusted by the amount of depreciation calculated for purposes of the definition of &#147;<B><I>Profits</I></B>&#148; and &#147;<B><I>Losses</I></B>&#148; rather than the amount of depreciation
determined for U.S. federal income tax purposes, and depreciation shall be calculated by reference to Carrying Value rather than tax basis once Carrying Value differs from tax basis. The Carrying Value of Company assets shall be increased (or
decreased) to reflect any adjustments to the adjusted basis of such assets pursuant to Code Section&nbsp;734(b), but only to the extent that such adjustments are taken into account in determining Capital Accounts pursuant to Treasury Regulations
Section&nbsp;1.704-1(b)(2)(iv)(m); <I>provided</I>, however, that Carrying Values shall not be adjusted pursuant to this sentence to the extent that the Managing Member reasonably determines that an adjustment pursuant to clauses (a)&nbsp;through
(g) the first sentence of this definition is necessary or appropriate in connection with the transaction that would otherwise result in an adjustment pursuant to this sentence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Certificate</I></B>&#148; has the meaning set forth in the recitals of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Change of Control</I></B>&#148; has the meaning given to such term in the Tax Receivable Agreement; provided that, for the
avoidance of doubt, any event that constitutes both a Managing Member Offer and a Change of Control of the Managing Member shall be considered a Managing Member Offer for purposes of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Cibus BVI</I></B>&#148; has the meaning set forth in the recitals of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Class</I></B>&#148; means the classes of Units into which the limited liability company interests in the Company may be classified
or divided from time to time by the Managing Member pursuant to the provisions of this Agreement. As of the date of this Agreement, the only Classes are Common Units. Subclasses within a Class&nbsp;shall not be separate Classes for purposes of this
Agreement. For all purposes hereunder and under the Act, only such Classes expressly established under this Agreement, including by the Managing Member in accordance with this Agreement, shall be deemed to be a class of limited liability company
interests in the Company. For the avoidance of doubt, to the extent that the Managing Member holds limited liability company interests of any Class, the Managing Member shall not be deemed to hold a separate Class&nbsp;of such interests from any
other Member because it is the Managing Member. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Class</I></B><B><I></I></B><B><I>&nbsp;A Common Shares</I></B>&#148; means
the shares of the Class&nbsp;A Common Stock of the Managing Member, par value $0.0001 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Class</I></B><B><I></I></B><B><I>&nbsp;A Common Stock</I></B>&#148; means the Class&nbsp;A common stock of the Managing Member,
par value $0.0001 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Class</I></B><B><I></I></B><B><I>&nbsp;A Restricted Common Stock Consideration</I></B>&#148;
means the restricted Class&nbsp;A Common Shares issued pursuant to the Company Plan to holders of Merger Partner PIUs in the Company Merger in accordance with Section&nbsp;2.1(b)(i)(E)(II) of the Merger Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Class</I></B><B><I></I></B><B><I>&nbsp;B Common Shares</I></B>&#148; means the shares of the Class&nbsp;B Common Stock of the
Managing Member, par value $0.0001 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Class</I></B><B><I></I></B><B><I>&nbsp;B Common Stock</I></B>&#148; means the
Class&nbsp;B common stock of the Managing Member, par value $0.0001 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Closing</I></B>&#148; has the meaning given to
such term in the Merger Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><I>&#147;</I><B><I>Closing Date</I></B>&#148; has the meaning given to such term in the Merger
Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-5- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Code</I></B>&#148; means the Internal Revenue Code of 1986, as amended from time
to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Commission</I></B>&#148; means the U.S. Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Common Percentage Interest</I></B>&#148; means, with respect to any Member, the quotient obtained by dividing the aggregate number
of Common Units then owned by such Member by the aggregate number of Common Units then owned by all Members. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Common
Units</I></B>&#148; means the Units of limited liability company interest in the Company designated as the &#147;<B><I>Common Units</I></B>&#148; herein and having the rights pertaining thereto as are set forth in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company</I></B>&#148; has the meaning set forth in the preamble of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company Merger</I></B>&#148; has the meaning set forth in the recitals of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company Minimum Gain</I></B>&#148; has the meaning ascribed to the term &#147;partnership minimum gain&#148; set forth in Treasury
Regulations Sections 1.704-2(b)(2) and 1.704-2(d). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company Plan</I></B>&#148; means the Cibus, Inc. (f/k/a Calyxt, Inc.) 2017
Omnibus Incentive Plan, as amended, supplemented or modified from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Confidential Information</I></B>&#148; has
the meaning set forth in <U>Section</U><U></U><U>&nbsp;6.02(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Contingencies</I></B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;9.03(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Control</I></B>&#148; (including the terms &#147;Controlled by&#148; and
&#147;under common Control with&#148;) means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, as trustee or
executor, by contract or otherwise, including the ownership, directly or indirectly, of securities having the power to elect a majority of the board of directors or similar body governing the affairs of such Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Conversion</I></B>&#148; has the meaning set forth in the recitals of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Covered Transaction</I></B>&#148; means any liquidation, dissolution or winding up of the Company (whether occurring through one
transaction or a series of related transactions, and whether voluntary or involuntary) and any other sale, redemption or Transfer of Units. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Designated Individual</I></B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.08(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Distribution</I></B>&#148; means the transfer of any money or other property to a Member or its Assignee in respect of its Units
or other Equity Interests in the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Drag Price</I></B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;8.05(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Drag-Along Notice</I></B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;8.05(b)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Drag-Along Right</I></B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;8.05(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Effective Date</I></B>&#148; has the meaning set forth in the preamble of this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Eighth Blocker Merger</I></B>&#148; has the meaning set forth in the recitals of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-6- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Encumbrance</I></B>&#148; means any mortgage, hypothecation, claim, lien,
encumbrance, conditional sales or other title retention agreement, right of first refusal, preemptive right, pledge, option, charge, security interest or other similar interest, easement, judgment or imperfection of title of any nature whatsoever,
other than encumbrances arising under applicable securities Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Equity Interests</I></B>&#148; means (a)&nbsp;capital
stock, membership interests, partnership interests, other equity interests, rights to profits or revenue and any other similar interest in any corporation, partnership, limited liability company or other business entity, (b)&nbsp;any security or
other interest convertible into or exchangeable or exercisable for any of the foregoing, whether at the time of issuance or upon the passage of time or the occurrence of some future event and (c)&nbsp;any warrant, option or other right (contingent
or otherwise) to acquire any of the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>ERISA</I></B>&#148; means The Employee Retirement Income Security Act of 1974,
as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Exchange Act</I></B>&#148; means the U.S. Securities Exchange Act of 1934, as amended, and the rules and
regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Exchange Agreement</I></B>&#148; means the exchange agreement dated as of or about the
date hereof among the Company, Managing Member, the other Members of the Company from time to time party thereto, and the other parties thereto, as amended from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Exchange Transaction</I></B>&#148; means an exchange of Common Units and Class&nbsp;B Common Shares for Class&nbsp;A Common Shares
of the Managing Member pursuant to, and in accordance with, the Exchange Agreement (including pursuant to a Direct Exchange (as defined in the Exchange Agreement)). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Exempt Transfer</I></B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;8.01(c)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Existing Agreement</I></B>&#148; has the meaning set forth in the recitals of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Fair Market Value</I></B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;11.01</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Family Group</I></B>&#148; means, with respect to a Person who is an individual, (a)&nbsp;such Person&#146;s spouse and direct
descendants (whether natural or adopted) (collectively, for purposes of this definition, &#147;<B><I>relatives</I></B>&#148;), and (b)&nbsp;any trust, the trustee of which is such Person and which at all times is and remains solely for the benefit
of such Person and/or such Person&#146;s relatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Fifth Blocker Merger</I></B>&#148; has the meaning set forth in the
recitals of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>First Blocker Merger</I></B>&#148; has the meaning set forth in the recitals of this Agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Fiscal Year</I></B>&#148; means, unless otherwise determined by the Managing Member in its sole discretion in accordance with
<U>Section</U><U></U><U>&nbsp;12.12(b)</U>, any twelve-month period commencing on January&nbsp;1 and ending on December 31. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Fourth Blocker Merger</I></B>&#148; has the meaning set forth in the recitals of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>GAAP</I></B>&#148; means accounting principles generally accepted in the United States of America as in effect from time to time.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Income Amount</I></B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.01(c)(i)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Indemnitee</I></B>&#148; means (a)&nbsp;the Managing Member, (b)&nbsp;any additional or substitute Managing Member, (c)&nbsp;any
Person who is or was a Partnership Representative, officer or director of the Managing Member or any additional or substitute Managing Member, (d)&nbsp;any Person that is required to be indemnified by the Managing
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-7- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Member as an &#147;indemnitee&#148; in accordance with the certificate of incorporation and/or bylaws of the Managing Member as in effect from time to time, (e)&nbsp;any officer or director of
the Managing Member or any additional or substitute Managing Member who is or was serving at the request of the Managing Member or any additional or substitute Managing Member as an officer, director, employee, member, Member, Partnership
Representative, agent, fiduciary or trustee of another Person; provided, that a Person shall not be an Indemnitee by reason of providing, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fee-for-services</FONT></FONT> basis,
trustee, fiduciary or custodial services, (f)&nbsp;any Officer, (g)&nbsp;any other Person the Managing Member in its sole discretion designates as an &#147;Indemnitee&#148; for purposes of this Agreement, (h)&nbsp;any former officer or Manager of
the Company pursuant to Section&nbsp;7.2 of the Merger Agreement and (i)&nbsp;any heir, executor or administrator with respect to Persons named in clauses (a)&nbsp;through (h). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Interim Funding</I></B>&#148; has the meaning given to such term in the Merger Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Issuance Items</I></B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.05(h)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Law</I></B>&#148; means any statute, law, ordinance, regulation, rule, code, executive order, injunction, judgment, decree or
other order issued or promulgated by any national, supranational, state, federal, provincial, local or municipal government or any administrative or regulatory body with authority therefrom with jurisdiction over the Company or any Member, as the
case may be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Liquidation Agent</I></B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;9.03</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Liquidity Limitations</I></B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.01(c)(i)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Managing Member</I></B>&#148; means Cibus, Inc. (f/k/a Calyxt, Inc.), a corporation incorporated under the laws of the State of
Delaware, or any successor Managing Member admitted to the Company in accordance with the terms of this Agreement, in its capacity as the managing member of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Managing Member Initial Contribution&#148;</I></B><I> </I>has the meaning set forth in the recitals of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Managing Member Offer</I></B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;8.03</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Mandatory Exchange</I></B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;8.03</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Member</I></B>&#148; means, at any time, each person listed as a Member (including the Managing Member) on the books and records
of the Company, in each case for so long as he, she or it remains a Member of the Company as provided hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Member
Nonrecourse Debt Minimum Gain</I></B>&#148; means an amount with respect to each partner nonrecourse debt (as defined in Treasury Regulations Section&nbsp;1.704-2(b)(4)) equal to the Company Minimum Gain that would result if such partner nonrecourse
debt were treated as a nonrecourse liability (as defined in Treasury Regulations Section&nbsp;1.704-2(b)(3)) determined in accordance with Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.704-2(i)(3).</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Member Nonrecourse Deductions</I></B>&#148; has the meaning ascribed to the term &#147;partner nonrecourse deductions&#148; set
forth in Treasury Regulations Section&nbsp;1.704-2(i)(2). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Member&#146;s Required Tax Distribution</I></B>&#148; has the
meaning set forth in <U>Section</U><U></U><U>&nbsp;4.01(c)(i)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Merger Agreement</I></B>&#148; has the meaning set forth
in the recitals of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Mergers</I></B>&#148; has the meaning set forth in the recitals of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Merger Partner PIU</I></B>&#148; has the meaning given to such term in the Merger Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-8- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Merger Subsidiary</I></B>&#148; has the meaning set forth in the recitals of
this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Ninth Blocker Merger</I></B>&#148; has the meaning set forth in the recitals of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Nonrecourse Deductions</I></B>&#148; has the meaning set forth in Treasury Regulations Section&nbsp;1.704-2(b)(1). The amount of
Nonrecourse Deductions of the Company for a Fiscal Year equals the net increase, if any, in the amount of Company Minimum Gain of the Company during that fiscal year, determined according to the provisions of Treasury Regulations
Section&nbsp;1.704-2(c). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Officer</I></B>&#148; means each Person designated as an officer of the Company by the Managing
Member pursuant to and in accordance with the provisions of <U>Section</U><U></U><U>&nbsp;3.04</U>, subject to any resolutions of the Managing Member appointing such Person as an officer of the Company or relating to such appointment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Original Agreement</I></B>&#148; has the meaning set forth in the recitals of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Original Member Representative</I></B>&#148; means Rory Riggs or, if Rory Riggs no longer holds any Units of the Company, such
other Person as may be appointed from time to time by holders of a majority of Units held by Original Members who hold Units at the time of determination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Original Members</I></B>&#148; means the Members of the Company as of immediately prior to the Closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Partnership Representative</I></B>&#148; has means any Person acting as &#147;tax matters partner&#148; or the &#147;partnership
representative&#148; pursuant to <U>Section</U><U></U><U>&nbsp;5.08</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Permitted Transferee</I></B>&#148; means any
transferee in an Exempt Transfer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Person</I></B>&#148; means any individual, estate, corporation, partnership, limited
partnership, limited liability company, limited company, joint venture, trust, unincorporated or governmental organization or any agency or political subdivision thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Proceeding</I></B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;10.02(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Profits</I></B>&#148; and &#147;<B><I>Losses</I></B>&#148; means, for each Fiscal Year or other period, the taxable income or loss
of the Company, or particular items thereof, determined in accordance with the accounting method used by the Company for U.S. federal income tax purposes with the following adjustments: (a)&nbsp;all items of income, gain, loss or deduction allocated
pursuant to <U>Section</U><U></U><U>&nbsp;5.05</U> shall not be taken into account in computing such taxable income or loss (but the amounts of items to be specially allocated pursuant to <U>Section</U><U></U><U>&nbsp;5.05</U> shall be determined by
applying rules analogous to those set forth in the remainder of this definition of &#147;Profits&#148; and &#147;Losses&#148;); (b) any income of the Company that is exempt from U.S. federal income taxation and not otherwise taken into account in
computing Profits and Losses shall be added to such taxable income or loss; (c)&nbsp;if the Carrying Value of any asset differs from its adjusted tax basis for U.S. federal income tax purposes, any gain or loss resulting from a disposition of such
asset shall be calculated with reference to such Carrying Value; (d)&nbsp;upon an adjustment to the Carrying Value (other than an adjustment in respect of depreciation) of any asset, pursuant to the definition of Carrying Value, the amount of the
adjustment shall be included as gain or loss in computing such taxable income or loss; (e)&nbsp;if the Carrying Value of any asset differs from its adjusted tax basis for U.S. federal income tax purposes, the amount of depreciation, amortization or
cost recovery deductions with respect to such asset for purposes of determining Profits and Losses, if any, shall be an amount which bears the same ratio to such Carrying Value as the U.S. federal income tax depreciation, amortization or other cost
recovery deductions bears to such adjusted tax basis (provided that, if the U.S. federal income tax depreciation, amortization or other cost recovery deduction is zero, the Managing Member may use any reasonable method for purposes of determining
depreciation, amortization or other cost recovery deductions in calculating Profits and Losses); (f) to the extent that an adjustment to the adjusted tax basis of any Company asset pursuant to Code Section&nbsp;734(b) is required pursuant to
Treasury Regulation Section&nbsp;1.704-1(b)(2)(iv)(m)(4) to be taken into account in determining Capital </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-9- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Accounts as a result of a Distribution other than in liquidation of a Member&#146;s interest in the Company, the amount of such adjustment shall be treated as an item of gain (if the adjustment
increases the basis of the asset) or loss (if the adjustment decreases the basis of the asset) from the disposition of the asset and shall be taken into account for purposes of computing such taxable income or loss and (g)&nbsp;except for items in
(a)&nbsp;above, any expenditures of the Company not deductible in computing taxable income or loss, not properly capitalizable and not otherwise taken into account in computing Profits and Losses pursuant to this definition shall be treated as
deductible items. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Qualified Transaction</I></B>&#148; means a Change of Control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Required Member</I></B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;8.05(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Restricted Securities</I></B>&#148; means any Units in the Company or any equity interests of the Managing Member (including any
Class&nbsp;A Common Shares or Class&nbsp;B Common Shares) received or retained as consideration under the Merger Agreement, including any securities held in escrow or otherwise issued or delivered after the Closing pursuant to the Merger Agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Revised Partnership Audit Provisions</I></B>&#148; means Code Sections 6221 through 6241, as in effect for taxable years of
the Company beginning after December&nbsp;31, 2017, together with any subsequent amendments thereto, Treasury Regulations promulgated thereunder, and published administrative interpretations thereof, and any comparable provisions of state or local
tax Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Second Blocker Merger</I></B>&#148; has the meaning set forth in the recitals of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Securities Act</I></B>&#148; means the U.S. Securities Act of 1933, as amended, and the rules and regulations promulgated
thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Seventh Blocker Merger</I></B>&#148; has the meaning set forth in the recitals of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Similar Law</I></B>&#148; means any law or regulation that could cause the underlying assets of the Company to be treated as
assets of the Member by virtue of its limited liability company interest in the Company and thereby subject the Company and the Managing Member (or other persons responsible for the investment and operation of the Company&#146;s assets) to laws or
regulations that are similar to the fiduciary responsibility or prohibited transaction provisions contained in Title I of ERISA or Section&nbsp;4975 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Sixth Blocker Merger</I></B>&#148; has the meaning set forth in the recitals of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Subsidiary</I></B>&#148; means, with respect to any Person, any corporation, limited liability company, partnership, association
or business entity of which (i)&nbsp;if a corporation, a majority of the total voting power of shares of stock entitled (without regard to the occurrence of any contingency) to vote in the election of directors, managers or trustees thereof is at
the time owned or controlled, directly or indirectly, by that Person or one or more of the other Subsidiaries of that Person or a combination thereof, or (ii)&nbsp;if a limited liability company, partnership, association or other business entity
(other than a corporation), a majority of partnership or other similar ownership interest thereof is at the time owned or controlled, directly or indirectly, by any Person or one or more Subsidiaries of that Person or a combination thereof. For
purposes hereof, a Person or Persons shall be deemed to have a majority ownership interest in a limited liability company, partnership, association or other business entity (other than a corporation) if such Person or Persons shall be allocated a
majority of limited liability company, partnership, association or other business entity gains or losses or shall be or control any managing director or general partner of such limited liability company, partnership, association or other business
entity. For purposes hereof, references to a &#147;Subsidiary&#148; of the Company shall be given effect only at such times that the Company has one or more Subsidiaries, and, unless otherwise indicated, the term &#147;Subsidiary&#148; refers to a
Subsidiary of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Tax Advances</I></B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.07</U>.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-10- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Tax Distributions</I></B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;4.01(c)(ii)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Tax Estimation Period</I></B>&#148; shall mean each period from January&nbsp;1
through March&nbsp;31, from April&nbsp;1 through May&nbsp;31, from June&nbsp;1 through August&nbsp;31, and from September&nbsp;1 through December&nbsp;31 of each taxable year. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Tax Receivable Agreement</I></B>&#148; means the Tax Receivable Agreement dated as of or about the date hereof among the Company,
Managing Member and the other parties from time to time party thereto, as amended from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Tenth Blocker
Merger</I></B>&#148; has the meaning set forth in the recitals of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Third Blocker Merger</I></B>&#148; has the
meaning set forth in the recitals of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>TRA Party</I></B>&#148; has the meaning given to such term in the Tax
Receivable Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Transfer</I></B>&#148; means, in respect of any Unit, property or other asset, any direct or indirect
sale, assignment, transfer, distribution, exchange, mortgage, pledge, hypothecation or other disposition thereof, whether voluntarily or by operation of Law, directly or indirectly, in whole or in part, including the exchange of any Unit for any
other security or the entry into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any Unit, whether any such transaction is to be settled by delivery of such securities,
in cash or otherwise. The term &#147;Transferred&#148; shall have a meaning correlative to the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Transferee</I></B>&#148; means any Person that is a permitted transferee of a Member&#146;s interest in the Company, or part
thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Treasury Regulations</I></B>&#148; means the income tax regulations, including temporary and proposed regulations,
promulgated under the Code, as such regulations may be amended from time to time (including corresponding provisions of succeeding regulations). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Unitholder Representative</I></B>&#148; means Rory Riggs, or any successor to such Person pursuant to the Unitholder
Representative Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Unitholder Representative Agreement</I></B>&#148; that certain Unitholder Representative Engagement
Agreement, dated as of the date hereof, by and among Unitholder Representative and the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Units</I></B>&#148; means the
Common Units and any other Class&nbsp;of Units that is established in accordance with this Agreement, which shall constitute limited liability company interests in the Company as provided in this Agreement and under the Act, entitling the holders
thereof to the relative rights, title and interests in the profits, losses, deductions and credits of the Company at any particular time as set forth in this Agreement, and any and all other benefits to which a holder thereof may be entitled as a
Member as provided in this Agreement, together with the obligations of such Member to comply with all terms and provisions of this Agreement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="annexitoc401831_3"></A>ARTICLE II </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORMATION, TERM, PURPOSE AND POWERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_4"></A>2.01&nbsp;&nbsp;&nbsp;&nbsp;<B>Formation</B>. The Company was formed as a limited liability company under the
provisions of the Act by the filing of the Certificate on May&nbsp;10, 2019. If requested by the Managing Member, the Members shall promptly execute all certificates and other documents consistent with the terms of this Agreement necessary for the
Managing Member to accomplish all filing, recording, publishing and other acts as may be appropriate to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-11- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
comply with all requirements for (a)&nbsp;the formation and operation of a limited liability company under the laws of the State of Delaware, (b)&nbsp;if the Managing Member in its sole
discretion deems it advisable, the operation of the Company as a limited liability company, or entity in which the Members have limited liability, in all jurisdictions where the Company proposes to operate and (c)&nbsp;all other filings required to
be made by the Company. The rights, powers, duties, obligations and liabilities of the Members shall be determined pursuant to the Act and this Agreement. To the extent that the rights, powers, duties, obligations and liabilities of any Member are
different by reason of any provision of this Agreement than they would be in the absence of such provision, this Agreement shall, to the extent permitted by the Act, control. The execution, delivery and filing of the Certificate and each amendment
thereto is hereby ratified, approved and confirmed by the Members. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_5"></A>2.02&nbsp;&nbsp;&nbsp;&nbsp;<B>Name</B>. The name of the Company shall be, and the business of the Company
shall be conducted under the name of &#147;Cibus Global, LLC&#148; and all Company business shall be conducted in that name or in such other names that comply with applicable Law as the Managing Member in its sole discretion may select from time to
time. Subject to the Act, the Managing Member in its sole discretion may change the name of the Company (and amend this Agreement to reflect such change) at any time and from time to time without the consent of any other Person. Prompt notification
of any such change shall be given to all Members. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_6"></A>2.03&nbsp;&nbsp;&nbsp;&nbsp;<B>Term</B>. The term of
the Company commenced on the date of the filing of the Certificate, and the term shall continue until the dissolution of the Company in accordance with <U>Article IX</U>. The existence of the Company shall continue until cancellation of the
Certificate in the manner required by the Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_7"></A>2.04&nbsp;&nbsp;&nbsp;&nbsp;<B>Offices</B>. The Company
may have offices at such places either within or outside the State of Delaware as the Managing Member from time to time may select in its sole discretion. As of the date hereof, the principal place of business and office of the Company is located at
6455 Nancy Ridge Drive, San Diego, California, 92121. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_8"></A>2.05&nbsp;&nbsp;&nbsp;&nbsp;<B>Agent for Service of
Process; Existence and Good Standing; Foreign Qualification</B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;The registered office of the Company in
the State of Delaware shall be located at 251 Little Falls Drive, Wilmington, Delaware, 19808. The name of the registered agent of the Company for service of process on the Company in the State of Delaware at such address shall be Corporation
Service Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;The Managing Member in its sole discretion may take all action which may be necessary
or appropriate (i)&nbsp;for the continuation of the Company&#146;s valid existence as a limited liability company under the Laws of the State of Delaware (and of each other jurisdiction in which such existence is necessary to enable the Company to
conduct the business in which it is engaged) and (ii)&nbsp;for the maintenance, preservation and operation of the business of the Company in accordance with the provisions of this Agreement and applicable laws and regulations. The Managing Member in
its sole discretion may file or cause to be filed for recordation in the proper office or offices in each other jurisdiction in which the Company is formed or qualified, such certificates (including certificates of formation and fictitious name
certificates) and other documents as are required by the applicable statutes, rules or regulations of any such jurisdiction or as are required to reflect the identity of the Members. The Managing Member in its sole discretion may cause the Company
to comply, to the extent procedures are available and those matters are reasonably within the control of the Officers, with all requirements necessary to qualify the Company to do business in any jurisdiction other than the State of Delaware. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_9"></A>2.06&nbsp;&nbsp;&nbsp;&nbsp;<B>Business Purpose</B>. The Company was formed for the object and purpose of, and
the nature and character of the business to be conducted by the Company is, engaging in any lawful act or activity for which limited liability companies may be formed under the Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_10"></A>2.07&nbsp;&nbsp;&nbsp;&nbsp;<B>Powers of the Company</B>. Subject to the limitations set forth in this
Agreement, the Company will possess and may exercise all of the powers and privileges granted to it by the Act including the ownership and operation of the assets and other property contributed to the Company by the Members, by any other Law or this
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-12- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Agreement, together with all powers incidental thereto, so far as such powers are necessary or convenient to the conduct, promotion or attainment of the purpose of the Company set forth in
<U>Section</U><U></U><U>&nbsp;2.06</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_11"></A>2.08&nbsp;&nbsp;&nbsp;&nbsp;<B>Members; Reclassification;
Admission of New Members</B>. Each of the Persons listed on <B>Exhibit A</B> hereto, as the same may be amended from time to time in accordance with this Agreement, by virtue of its execution of this Agreement, are admitted as Members of the
Company. The rights, duties and liabilities of the Members shall be as provided in the Act, except as is otherwise expressly provided herein, and the Members consent to the variation of such rights, duties and liabilities as provided herein. Subject
to <U>Section</U><U></U><U>&nbsp;8.08</U> with respect to substitute Members, a Person may be admitted from time to time as a new Member with the written consent of the Managing Member in its sole discretion. Each new Member shall execute and
deliver to the Managing Member an appropriate supplement to this Agreement pursuant to which the new Member agrees to be bound by the terms and conditions of this Agreement, as it may be amended from time to time. A new Managing Member or substitute
Managing Member may be admitted to the Company solely in accordance with <U>Section</U><U></U><U>&nbsp;
8.09</U> hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_12"></A>2.09&nbsp;&nbsp;&nbsp;&nbsp;<B>Resignation</B>. No Member shall have the right to resign
as a member of the Company other than following the Transfer of all Units owned by such Member in accordance with <U>Article VIII</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_13">
</A>2.10&nbsp;&nbsp;&nbsp;&nbsp;<B>Representations of Members</B>. Each Member severally (and not jointly), on behalf of itself and its successors and assigns, hereby represents and warrants to the Company and each other Member that as of the date
of such Member&#146;s admittance to the Company (or as of the date hereof for any Member as of the date hereof) and as of each subsequent date that such Member acquires any additional Units that: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Organization; Authority</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B>&nbsp;&nbsp;&nbsp;&nbsp;To the extent it is not a natural person, (x)&nbsp;it is duly formed, validly existing and in good standing
(if applicable) under the Laws of the jurisdiction of its formation, and if required by Law is duly qualified to conduct business and is in good standing in the jurisdiction of its principal place of business (if not formed in such jurisdiction),
and (y)&nbsp;has full corporate, limited liability company, partnership, trust or other applicable power and authority to execute and deliver this Agreement and to perform its obligations under this Agreement and all necessary actions by the board
of directors, shareholders, managers, members, partners, trustees, beneficiaries or other Persons necessary for the due authorization, execution, delivery and performance of this Agreement by that Member have been duly taken. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B>&nbsp;&nbsp;&nbsp;&nbsp;It has duly executed and delivered this Agreement, and this Agreement is enforceable against such Member
in accordance with its terms, subject to bankruptcy, moratorium, insolvency and other Laws generally affecting creditors&#146; rights and general principles of equity (whether applied in a proceeding in a court of law or equity). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><FONT STYLE="white-space:nowrap">Non-Contravention</FONT></B>. Its authorization, execution, delivery,
and performance of this Agreement does not breach or conflict with or constitute a default under (x)&nbsp;such Member&#146;s charter or other governing documents to the extent it is not a natural person, (y)&nbsp;any material obligation under any
other material agreement to which that Member is a party or by which it is bound or (z)&nbsp;applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Due Inquiry</B>. It has had, prior to the execution and delivery of this Agreement, the opportunity to
ask questions of and receive answers from representatives of the Company concerning an investment in the Company, as well as the finances, operations, business and prospects of the Company, and the opportunity to obtain additional information to
verify the accuracy of all information so obtained, and received all such information about the Company and the Units as it has requested. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Purpose of Investment</B>. It is acquiring and holding its Units solely for investment purposes, for its
own account and not for the account or benefit of any other Person and not with a view towards the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-13- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
distribution or dissemination thereof, did not decide to enter into this Agreement as a result of any general solicitation or general advertising within the meaning of Rule 502 of Regulation D
under the Securities Act, and acknowledges and understands that no United States federal or state agency has passed upon or made any recommendation or endorsement of the offering of any Units. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Transfer Restrictions</B>. It understands that the Units and the Class&nbsp;B Common Shares are each
being Transferred in a transaction not involving a public offering within the meaning of the Securities Act, and the Units and Class&nbsp;B Common Shares will comprise &#147;<B><I>restricted securities</I></B>&#148; within the meaning of Rule
144(a)(3) under the Securities Act which shall not be sold, pledged, hypothecated or otherwise Transferred except in accordance with the terms of this Agreement and applicable Law. It agrees that, if in the future it decides to offer, resell, pledge
or otherwise Transfer any portion of its Units or Class&nbsp;B Common Shares, such Units and/or Class&nbsp;B Common Shares may be offered, resold, pledged or otherwise Transferred only pursuant to an effective registration statement under the
Securities Act or an applicable exemption from registration and/or qualification under the Securities Act and applicable state securities Laws, and as a condition precedent to any such Transfer, it may be required to deliver to the Company an
opinion of counsel satisfactory to the Company, and agrees, absent registration or an exemption with respect to its Units, not to resell any such Units and/or Class&nbsp;B Common Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Investor Status</B>. It (i)&nbsp;has adequate means of providing for its current needs and possible
contingencies, is able to bear the economic risks of its investment for an indefinite period of time and has a sufficient net worth to sustain a loss of its entire investment in the Company in the event such loss should occur, (ii)&nbsp;is
sophisticated in financial matters and has such knowledge and experience in financial and business matters as to be capable of evaluating the merits and risks of an investment in the Company, (iii)&nbsp;is, or is controlled by, an
&#147;<B><I>accredited investor</I></B>,&#148; as that term is defined in Rule 501(a) of Regulation D, promulgated under the Securities Act, and acknowledges the issuance of Units under this Agreement is being made in reliance on a private placement
exemption to &#147;<B><I>accredited investors</I></B>&#148; within the meaning of Section&nbsp;501(a) of Regulation D under the Securities Act or similar exemptions under federal and state Law, and (iv)&nbsp;is treated as a single partner within the
meaning of Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.7704-1(h)</FONT> (determined taking into account the rules of Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.7704-1(h)(3)).</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_14"></A><B>2.11</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Amendment and Restatement of Existing Agreement</B>. Each of the
Members agrees and acknowledges that this Agreement amends and restates the Existing Agreement, which is no longer in effect. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="annexitoc401831_15">
</A>ARTICLE III </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><A NAME="annexitoc401831_16"></A>3.01&nbsp;&nbsp;&nbsp;&nbsp;Managing Member. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;The business, property and affairs of the Company shall be managed under the sole, absolute and exclusive
direction of the Managing Member, which may from time to time delegate authority to Officers or to others to act on behalf of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;Without limiting the foregoing provisions of this <U>Section</U><U></U><U>&nbsp;3.01</U>, the Managing
Member shall have the general power to manage or cause the management of the Company (which may be delegated to Officers of the Company), including the following powers: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B>&nbsp;&nbsp;&nbsp;&nbsp;to develop and prepare a business plan each year which will set forth the operating goals and plans for the
Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B>&nbsp;&nbsp;&nbsp;&nbsp;to execute and deliver or to authorize the execution and delivery of contracts, deeds,
leases, licenses, instruments of transfer and other documents on behalf of the Company; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-14- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B>&nbsp;&nbsp;&nbsp;&nbsp;to make any expenditures, to lend or borrow money, to
assume or guarantee, or otherwise contract for, indebtedness and other liabilities, to issue evidences of indebtedness and to incur any other obligations; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B>&nbsp;&nbsp;&nbsp;&nbsp;to establish and enforce limits of authority and internal controls with respect to all personnel and
functions; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(v)</B>&nbsp;&nbsp;&nbsp;&nbsp;to engage attorneys, consultants and accountants for the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(vi)</B>&nbsp;&nbsp;&nbsp;&nbsp;to develop or cause to be developed accounting procedures for the maintenance of the Company&#146;s books
of account; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(vii)</B>&nbsp;&nbsp;&nbsp;&nbsp;to do all such other acts as shall be authorized in this Agreement or by the Members
in writing from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_17"></A>3.02&nbsp;&nbsp;&nbsp;&nbsp;<B>Compensation</B>. The Managing Member shall
not be entitled to any compensation for services rendered to the Company in its capacity as Managing Member. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_18">
</A>3.03&nbsp;&nbsp;&nbsp;&nbsp;<B>Expenses</B>. The Company shall pay, or cause to be paid, all costs, fees, operating expenses and other expenses of the Company (including the costs, fees and expenses of attorneys, accountants or other
professionals) incurred in pursuing and conducting, or otherwise related to, the activities of the Company. The Company shall also bear and/or reimburse the Managing Member for (i)&nbsp;any costs, fees or expenses incurred by the Managing Member in
connection with serving as the Managing Member and (ii)&nbsp;all other expenses allocable to the Company or otherwise incurred by the Managing Member in connection with operating the Company&#146;s business (including expenses allocated to the
Managing Member by its Affiliates). To the extent that the Managing Member determines in its sole discretion that such expenses are related to the business and affairs of the Managing Member that are conducted through the Company and/or its
subsidiaries (including expenses that relate to the business and affairs of the Company and/or its subsidiaries and that also relate to other activities of the Managing Member), the Managing Member may cause the Company to pay or bear all expenses
of the Managing Member, including compensation and meeting costs of any board of directors or similar body of the Managing Member, any salary, bonus, incentive compensation and other amounts paid to any Person including Affiliates of the Managing
Member to perform services for the Company, litigation costs and damages arising from litigation, accounting and legal costs and franchise taxes, <I>provided</I> that the Company shall not pay or bear any income tax obligations of the Managing
Member or any obligations of the Managing Member under the Tax Receivable Agreement. Reimbursements pursuant to this <U>Section</U><U></U><U>&nbsp;3.03</U> shall be in addition to any reimbursement to the Managing Member as a result of
indemnification pursuant to <U>Section</U><U></U><U>&nbsp;10.02</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_19"></A>3.04&nbsp;&nbsp;&nbsp;&nbsp;<B>Officers</B>. Subject to the direction and oversight of the Managing Member,
the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> administration of the business of the Company may be carried out by persons who may be designated as officers by the Managing Member, with titles
including &#147;assistant secretary,&#148; &#147;assistant treasurer,&#148; &#147;chairman,&#148; &#147;chief executive officer,&#148; &#147;chief financial officer,&#148; &#147;chief operating officer,&#148; &#147;director,&#148; &#147;general
counsel,&#148; &#147;general manager,&#148; &#147;managing director,&#148; &#147;president,&#148; &#147;principal accounting officer,&#148; &#147;secretary,&#148; &#147;senior chairman,&#148; &#147;senior managing director,&#148;
&#147;treasurer,&#148; &#147;vice chairman,&#148; &#147;executive vice president&#148; or &#147;vice president,&#148; and as and to the extent authorized by the Managing Member in its sole discretion. The officers of the Company shall have such
titles and powers and perform such duties as shall be determined from time to time by the Managing Member and otherwise as shall customarily pertain to such offices. Any number of offices may be held by the same person. In its sole discretion, the
Managing Member may choose not to fill any office for any period as it may deem advisable. All officers and other persons providing services to or for the benefit of the Company shall be subject to the supervision and direction of the Managing
Member and may be removed, with or without cause, from such office by the Managing Member and the authority, duties or responsibilities of any employee, agent or officer of the Company may be suspended by the Managing Member from time to time, in
each case in the sole discretion of the Managing Member. The Managing Member shall not cease to be a Managing Member of the Company as a result of the delegation of any duties hereunder. No officer of the Company, in its capacity as
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-15- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such, shall be considered a Managing Member of the Company by agreement, as a result of the performance of its duties hereunder or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_20"></A>3.05&nbsp;&nbsp;&nbsp;&nbsp;<B>Authority of Members</B>. No Member (other than the Managing Member), in its
capacity as such, shall participate in or have any control over the business of the Company. Except as expressly provided herein, the Units do not confer any rights upon the Members to participate in the affairs of the Company described in this
Agreement. Except as expressly provided herein, no Member (other than the Managing Member) shall have any right to vote on any matter involving the Company, including with respect to any merger, consolidation, combination or conversion of the
Company, or any other matter that a Member might otherwise have the ability to vote on or consent with respect to under the Act, at law, in equity or otherwise. The conduct, control and management of the Company shall be vested exclusively in the
Managing Member. In all matters relating to or arising out of the conduct of the operation of the Company, the decision of the Managing Member shall be the decision of the Company. Except as required or permitted by Law, or expressly provided in the
ultimate sentence of this <U>Section</U><U></U><U>&nbsp;3.05</U> or by separate agreement with the Company, no Member who is not also the Managing Member (and acting in such capacity) shall take any part in the management or control of the operation
or business of the Company in its capacity as a Member, nor shall any Member who is not also the Managing Member (and acting in such capacity) have any right, authority or power to act for or on behalf of or bind the Company in his or its capacity
as a Member in any respect or assume any obligation or responsibility of the Company or of any other Member. Notwithstanding the foregoing, the Company may from time to time appoint one or more Members as officers or employ one or more Members as
employees, and such Members, in their capacity as officers or employees of the Company (and not, for clarity, in their capacity as Members of the Company), may take part in the control and management of the business of the Company to the extent such
authority and power to act for or on behalf of the Company has been delegated to them by the Managing Member. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_21">
</A>3.06&nbsp;&nbsp;&nbsp;&nbsp;<B>Action by Written Consent or Ratification</B>. Any action required or permitted to be taken by the Members pursuant to this Agreement shall be taken if all Members whose consent or ratification is required consent
thereto or provide a consent or ratification in writing. Any action required, required to be approved or permitted to be taken by the Managing Member pursuant to this Agreement may be taken or approved, as applicable, by the Managing Member acting
pursuant to a writing which evidences its approval of or consent to such action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_22"></A>3.07&nbsp;&nbsp;&nbsp;&nbsp;<B>Investment Company Act Restrictions</B>. The Managing Member shall use its
best efforts to ensure that the Company shall not be subject to registration as an investment company pursuant to the Investment Company Act. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="annexitoc401831_24"></A>ARTICLE IV </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DISTRIBUTIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_25">
</A>4.01&nbsp;&nbsp;&nbsp;&nbsp;<B>Distributions</B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Distributions Generally</B>. The Managing
Member, in its sole discretion, may, subject to (i)&nbsp;any restrictions contained in the financing agreements to which the Company or any of its Subsidiaries is a party, (ii)&nbsp;having Available Cash, and (iii)&nbsp;any other restrictions set
forth in this Agreement, make Distributions at any time and from time to time. If any assets of the Company are to be Distributed in kind, they shall be Distributed on the basis of their Fair Market Value. The Members&#146; Capital Accounts shall be
appropriately adjusted before any such Distribution to reflect the increases or decreases to the Capital Accounts which would have occurred if the property Distributed in kind had been sold for its Fair Market Value by the Company prior to the
Distributions. Notwithstanding any other provision of this Agreement to the contrary, no Distribution, Tax Distribution or other payment in respect of Units shall be required to be made to any Member if, and to the extent that, such Distribution,
Tax Distribution or other payment in respect of Units would not be permitted under the Act or other applicable Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-16- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Operating Distributions</B>. The Managing Member, in
its sole discretion, may authorize Distributions (to the extent of Available Cash) by the Company to the Members at any time and from time to time. Subject to <U>Section</U><U></U><U>&nbsp;4.01(c)</U> with respect to Tax Distributions, all
Distributions by the Company other than those made in connection with dissolution of the Company pursuant to <U>Section</U><U></U><U>&nbsp;4.02</U>, shall be made or allocated to holders of Common Units <I>pro rata</I> based on the number of Common
Units held by each such holder. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)&nbsp;&nbsp;&nbsp;&nbsp;Tax Distributions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B>&nbsp;&nbsp;&nbsp;&nbsp;With respect to each Member, the Company shall calculate the excess of (x)(A) the Income Amount allocated or
allocable to such Member for the Tax Estimation Period in question and for all preceding Tax Estimation Periods, if any, within the taxable year containing such Tax Estimation Period multiplied by (B)&nbsp;the Assumed Tax Rate over (y)&nbsp;the
aggregate amount of all prior Tax Distributions in respect of such taxable year and any Distributions made to such Member pursuant to <U>Section</U><U></U><U>&nbsp;4.01(b)</U> and <U>Section</U><U></U><U>&nbsp;4.02</U>, with respect to the Tax
Estimation Period in question and any previous Tax Estimation Period falling in the taxable year containing the applicable Tax Estimation Period referred to in (x)(A) (the amount so calculated pursuant to this sentence is herein referred to as a
&#147;<B><I>Member</I></B><B><I>&#146;</I></B><B><I>s Required Tax Distribution</I></B>&#148;); provided, however, that the Managing Member may make adjustments in its reasonable discretion to reflect transactions occurring during the taxable year;
<I>provided, further</I>, that if the amount of a Tax Distribution actually made with respect to a Tax Estimation Period is greater than or less than such Member&#146;s Tax Distribution that would have been made under this
<U>Section</U><U></U><U>&nbsp;4.01(c)(i)</U> for such period based on subsequent tax information and assuming no limitations based on prohibitions under applicable Law, Available Cash, or insolvency (such limitations, the &#147;<B><I>Liquidity
Limitations</I></B>&#148;) (e.g., because the estimated Tax Distribution for a Tax Estimation Period was greater than or less than the amount calculated based on actual taxable income for such Tax Estimation Period or because such Tax Distribution
would have rendered the Company insolvent), then, for subsequent Tax Estimation Periods, the Managing Member shall cause the Company to adjust each Member&#146;s Required Tax Distribution for the next Tax Estimation Period downward (but not below
zero) or upward (but the resulting Tax Distribution shall in all cases remain <I>pro rata</I> in accordance with each Member&#146;s Common Percentage Interest) to reflect such excess or shortfall; <I>provided</I>, <I>further</I>, that with respect
to the Managing Member and its wholly owned Subsidiaries, the Member&#146;s Required Tax Distribution for any Tax Estimation Period shall be an amount sufficient for the Managing Member and its wholly owned Subsidiaries to receive a Distribution
pursuant to <U>Section</U><U></U><U>&nbsp;4.01(b)</U> and this <U>Section</U><U></U><U>&nbsp;4.01(c)</U> sufficient to enable the Managing Member and its wholly owned Subsidiaries to meet their U.S. federal, state, local and <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> tax obligations and obligations under the Tax Receivable Agreement for such Tax Estimation Period (but the resulting Tax Distribution shall in all cases remain <I>pro rata</I> in accordance with each
Member&#146;s Common Percentage Interest). For purposes of this Agreement, the &#147;<B><I>Income Amount</I></B>&#148; for a Tax Estimation Period shall equal, with respect to any Member, the net taxable income (or, if applicable, gross taxable
income, except to the extent offset by items of loss thereof) of the Company allocated or allocable to such Member for such Tax Estimation Period (excluding any compensation paid to a Member outside of this Agreement). For purposes of computing the
Income Amount, the taxable income shall be determined (i)&nbsp;without regard to any special adjustments of tax items required as a result of any election under Section&nbsp;754 of the Code, including adjustments required by Sections 734 and 743 of
the Code, and (ii)&nbsp;by including adjustments to taxable income in respect of Section&nbsp;704(c) of the Code (including &#147;reverse Section&nbsp;704(c) allocations&#148;). For the avoidance of doubt, taxable income will include any amounts
required to be included in taxable income by a Member as a result of ownership by the Company of an entity classified as a: (i)&nbsp;PFIC (including by reason of a QEF election or a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election) or (ii) &#147;controlled foreign corporation&#148; within the meaning of Section&nbsp;957 of the Code in which a Member (or any of its direct or
indirect owners) could be a &#147;United States shareholder&#148; for U.S. federal income tax purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B>&nbsp;&nbsp;&nbsp;&nbsp;At least five (5)&nbsp;days before the quarterly due date for payment of estimated tax payments by
corporations or individuals (whichever is earlier) on a calendar year under the Code, the Company shall </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">distribute (to the extent of Available Cash and
unless prohibited by applicable Law or by any restrictions applicable to tax distributions contained in the Company&#146;s or its Subsidiaries&#146; then applicable bank financing agreements by which the Company or its Subsidiaries are bound) to the
Members <I>pro rata</I> in accordance with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-17- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
their Common Percentage Interest, an aggregate amount of cash sufficient to provide each such Member with a Distribution at least equal to such Member&#146;s Required Tax Distribution (amounts
distributed pursuant to this <U>Section</U><U></U><U>&nbsp;4.01(c)</U>, &#147;<B><I>Tax Distributions</I></B>&#148;). Notwithstanding anything to the contrary contained in this Agreement, the Managing Member shall make, in its reasonable discretion,
equitable adjustments (downward (but not below zero) or upward) to the Members&#146; Required Tax Distributions for a Tax Estimation Period (but the resulting Tax Distribution shall in all cases remain <I>pro rata</I> in accordance with each
Member&#146;s Common Percentage Interest) to take into account increases or decreases in the number of Common Units held by each Member solely with respect to any relevant period (or portion thereof) following the Closing Date. Any Tax Distributions
shall be treated in all respects as advances against future Distributions pursuant to <U>Section</U><U></U><U>&nbsp;4.01(b)</U> and <U>Section</U><U></U><U>&nbsp;4.02</U><U> </U>and shall be treated for all purposes of this Agreement as having been
paid pursuant to <U>Section</U><U></U><U>&nbsp;4.01(b)</U> and <U>Section</U><U></U><U>&nbsp;4.02</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B>&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding anything to the contrary herein, no Tax Distributions will be required to be made with
respect to items arising with respect to any Covered Transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_26"></A>4.02&nbsp;&nbsp;&nbsp;&nbsp;<B>Liquidation Distribution</B>. Subject to
<U>Section</U><U></U><U>&nbsp;4.01(c)</U> with respect to Tax Distributions, all Distributions by the Company, and all proceeds (whether received by the Company or directly by the Members) in connection with dissolution of the Company shall be made
or allocated among the holders of Common Units pro rata based on the number of Common Units held by each such holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_27">
</A>4.03&nbsp;&nbsp;&nbsp;&nbsp;<B>Limitations on Distribution</B>. Notwithstanding any provision to the contrary contained in this Agreement, the Managing Member shall not make a Distribution to any Member if such Distribution would violate
Section&nbsp;18-607 of the Act or other applicable Law. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="annexitoc401831_29"></A>ARTICLE V </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CAPITAL CONTRIBUTIONS; CAPITAL ACCOUNTS; </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TAX ALLOCATIONS; TAX MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_30"></A>5.01&nbsp;&nbsp;&nbsp;&nbsp;<B>Initial Capital Contributions</B>. The Members have made, on or prior to the
date hereof, Capital Contributions and, in exchange, the Company has issued to the Members the number of Common Units as specified in the books and records of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_31"></A>5.02&nbsp;&nbsp;&nbsp;&nbsp;<B>No Additional Capital Contributions</B>. No Member shall be required to make
additional Capital Contributions to the Company without the consent of such Member or permitted to make additional capital contributions to the Company without the consent of the Managing Member, which may be granted or withheld in its sole
discretion. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><A NAME="annexitoc401831_32"></A>5.03&nbsp;&nbsp;&nbsp;&nbsp;Capital Accounts. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;A separate capital account (a &#147;<B><I>Capital Account</I></B>&#148;) shall be established and maintained
for each Member in accordance with the provisions of Treasury Regulations Section&nbsp;1.704-1(b)(2)(iv) and this <U>Section</U><U></U><U>&nbsp;5.03</U>. The Company may adjust the Capital Accounts of its Members to reflect revaluations of the
property of any Subsidiary of the Company that is treated as a partnership (or entity disregarded from a partnership) for U.S. federal income tax purposes. The Capital Account of each Member shall be credited with such Member&#146;s Capital
Contributions, if any, all Profits allocated to such Member pursuant to <U>Section</U><U></U><U>&nbsp;5.04</U> and any items of income or gain which are specially allocated pursuant to <U>Section</U><U></U><U>&nbsp;5.05</U>; and shall be debited
with all Losses allocated to such Member pursuant to <U>Section</U><U></U><U>&nbsp;5.04</U>, any items of loss or deduction of the Company specially allocated to such Member pursuant to <U>Section</U><U></U><U>&nbsp;5.05</U>, and all cash and the
Carrying Value of any property (net of liabilities assumed by such Member and the liabilities to which such property is subject) distributed by the Company to such Member. Any references in any section of this Agreement to the Capital Account of a
Member shall be deemed to refer to such Capital Account as the same may be credited or debited from time to time as set forth above. In the event of any Transfer of any interest in the Company in accordance with the terms of this
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-18- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Agreement, the Transferee shall succeed to the Capital Account of the transferor to the extent it relates to the transferred interest. The Managing Member shall also (i)&nbsp;make any adjustments
that are necessary or appropriate in accordance with Treasury Regulations Section&nbsp;1.704-1(b)(2)(iv)(q) and (ii)&nbsp;make any appropriate modifications for unanticipated events that might otherwise cause this Agreement not to comply with
Treasury Regulations Section&nbsp;1.704-1(b), provided that, to the extent that any such adjustment is inconsistent with any other provisions of this Agreement and would have a disproportionate (compared to the Managing Member) and material adverse
effect on any Member, such adjustment shall require the consent of such Member (not to be unreasonably withheld, conditioned or delayed). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_33"></A>5.04&nbsp;&nbsp;&nbsp;&nbsp;<B>Allocations of Profits and Losses</B>. Except as otherwise provided in this
Agreement, Profits and Losses (and, to the extent necessary, individual items of income, gain or loss or deduction of the Company) shall be allocated in a manner such that the Capital Account of each Member after giving effect to the special
allocations set forth in <U>Section</U><U></U><U>&nbsp;5.05</U> is, as nearly as possible, equal (proportionately) to (i)&nbsp;the Distributions that would be made pursuant to <U>Section</U><U></U><U>&nbsp;4.02</U> if the Company were dissolved, its
affairs wound up and its assets sold for cash equal to their Carrying Value, all Company liabilities were satisfied in cash in accordance with their terms (limited with respect to each nonrecourse liability to the Carrying Value of the assets
securing such liability) and all remaining or resulting cash was distributed to the Members, minus (ii)&nbsp;such Member&#146;s share of Company Minimum Gain and Member Nonrecourse Debt Minimum Gain, computed immediately prior to the hypothetical
sale of assets. Notwithstanding the foregoing, the Managing Member shall make such adjustments to Capital Accounts as it determines in its reasonable discretion to be appropriate to ensure allocations are made in accordance with a Member&#146;s
interest in the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_34"></A>5.05&nbsp;&nbsp;&nbsp;&nbsp;<B>Special Allocations</B>. Notwithstanding any
other provision in this <U>Article V</U>: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Minimum Gain Chargeback</B>. If there is a net decrease in
Company Minimum Gain or Member Nonrecourse Debt Minimum Gain (determined in accordance with the principles of Treasury Regulations Sections 1.704-2(d) and 1.704-2(i)) during any Company Fiscal Year, the Members shall be specially allocated items of
Company income and gain for such year (and, if necessary, subsequent years) in an amount equal to their respective shares of such net decrease during such year, determined pursuant to Treasury Regulations Section&nbsp;1.704-2(i)(4). The items to be
so allocated shall be determined in accordance with Treasury Regulations Sections 1.704-2(i)(4) and 1.704-2(j)(2). This <U>Section</U><U></U><U>&nbsp;5.05(a)</U> is intended to comply with the minimum gain chargeback requirements in such Treasury
Regulations Sections and shall be interpreted consistently therewith; including that no chargeback shall be required to the extent of the exceptions provided in Treasury Regulations Sections 1.704-2(f) and 1.704-2(i)(4). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Qualified Income Offset</B>. If any Member unexpectedly receives any adjustments, allocations, or
distributions described in Treasury Regulations Section&nbsp;1.704-1(b)(2)(ii)(d)(4), (5) or (6), items of Company income and gain shall be specially allocated to such Member in an amount and manner sufficient to eliminate the deficit balance in
such Member&#146;s Adjusted Capital Account Balance created by such adjustments, allocations or distributions as promptly as possible; provided that, an allocation pursuant to this <U>Section</U><U></U><U>&nbsp;5.05(b)</U> shall be made only to the
extent that a Member would have a deficit Adjusted Capital Account Balance in excess of such sum after all other allocations provided for in this <U>Article V</U> have been tentatively made as if this <U>Section</U><U></U><U>&nbsp;5.05(b)</U> were
not in this Agreement. This <U>Section</U><U></U><U>&nbsp;5.05(b)</U> is intended to comply with the &#147;qualified income offset&#148; requirement of the Code and shall be interpreted consistently therewith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Gross Income Allocation</B>. If any Member has a deficit Capital Account at the end of any Fiscal Year
which is in excess of the sum of (i)&nbsp;the amount such Member is obligated to restore, if any, pursuant to any provision of this Agreement, and (ii)&nbsp;the amount such Member is deemed to be obligated to restore pursuant to the penultimate
sentences of Treasury Regulations Section&nbsp;1.704-2(g)(1) and 1.704-2(i)(5), each such Member shall be specially allocated items of Company income and gain in the amount of such excess as quickly as possible; provided that an allocation pursuant
to this <U>Section</U><U></U><U>&nbsp;5.05(c)</U> shall be made only if and to the extent that a Member would have a deficit Capital Account in excess of such sum after all other allocations provided for in
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-19- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
this <U>Article V</U> have been tentatively made as if <U>Section</U><U></U><U>&nbsp;5.05(b)</U> and this <U>Section</U><U></U><U>&nbsp;5.05(c)</U> were not in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Nonrecourse Deductions</B>. Nonrecourse Deductions shall be allocated to the Members holding Common Units
in accordance with their respective Common Percentage Interest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Member Nonrecourse Deductions</B>.
Member Nonrecourse Deductions for any taxable period shall be allocated to the Member who bears the economic risk of loss with respect to the liability to which such Member Nonrecourse Deductions are attributable in accordance with Treasury
Regulations Section&nbsp;1.704-2(i)(1). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Section 754 Adjustments</B>. To the extent an adjustment to
the adjusted tax basis of any Company asset, pursuant to Code Section&nbsp;734(b) or Section&nbsp;743(b) is required, pursuant to Treasury Regulations Section&nbsp;1.704-1(b)(2)(iv)(m)(2) or Section&nbsp;1.704-1(b)(2)(iv)(m)(4), to be taken into
account in determining Capital Accounts as the result of a Distribution to a Member in complete liquidation of such Member&#146;s interest in the Company, the amount of such adjustment to Capital Accounts shall be treated as an item of gain (if the
adjustment increases the basis of the asset) or loss (if the adjustment decreases such basis) and such gain or loss shall be specially allocated to the Members in accordance with their interests in the Company in the event Treasury Regulations
Section&nbsp;1.704-1(b)(2)(iv)(m)(2) applies, or to the Member to whom such Distribution was made in the event Treasury Regulations Section&nbsp;1.704-1(b)(2)(iv)(m)(4) applies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(g)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Ameliorative Allocations</B>. Any special allocations of income or gain pursuant to <U>Sections
</U><U>5.05(a)</U>, <U>5.05(b)</U> or <U>5.05(c)</U> hereof shall be taken into account in computing subsequent allocations pursuant to <U>Section</U><U></U><U>&nbsp;5.04</U> and this <U>Section</U><U></U><U>&nbsp;5.05(g)</U>, so that the net amount
of any items so allocated and all other items allocated to each Member shall, to the extent possible, be equal to the net amount that would have been allocated to each Member if such allocations pursuant to <U>Sections 5.05(a)</U>, <U>5.05(b)</U> or
<U>5.05(c)</U> had not occurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(h)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Allocations Relating to Taxable Issuance of Company Units</B>. Any
income, gain, loss, or deduction realized as a direct or indirect result of the issuance of Units by the Company to a Member (the &#147;<B><I>Issuance Items</I></B>&#148;) shall be allocated among the Members so that, to the extent possible, the net
amount of such Issuance Items, together with all other allocations under this Agreement to each Member shall be equal to the net amount that would have been allocated to each such Member if the Issuance Items had not been realized. The forfeiture
allocations described in Proposed Regulations Section&nbsp;1.704-1(b)(4)(xii)(c) (2005), and the allocations to which they relate, shall be treated as Issuance Items. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Forfeiture Allocation</B>. In the event that the Units of any Member are forfeited, then for the Fiscal
Year of such forfeiture or other period (as determined by the Managing Member): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B>&nbsp;&nbsp;&nbsp;&nbsp;items of income, gain,
loss, and deduction shall be excluded from the calculation of Profits and Losses and shall be specially allocated to the Member whose Units have been forfeited so as to cause such Member&#146;s Capital Account to equal such Member&#146;s
Distribution entitlements under <U>Section</U><U></U><U>&nbsp;4.01</U> after giving effect to the adjustment in the Member&#146;s Common Percentage Interest resulting from the applicable forfeiture; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B>&nbsp;&nbsp;&nbsp;&nbsp;the Managing Member may elect to apply another allocation or Capital Account adjustment method to a Unit
forfeiture as it reasonably deems appropriate in lieu of the method set forth in this <U>Section</U><U></U><U>&nbsp;5.05(i)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(j)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Noncompensatory Options</B>. If, as a result of an exercise of a noncompensatory option to acquire an
interest in the Company, a Capital Account reallocation is required under Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.704-1(b)(2)(iv)(s)(3),</FONT> the Company shall make corrective allocations pursuant to Treasury
Regulations Section&nbsp;1.704-1(b)(4)(x). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_35"></A>5.06&nbsp;&nbsp;&nbsp;&nbsp;<B>Tax Allocations</B>. For
income tax purposes, each item of income, gain, loss and deduction of the Company shall be allocated among the Members in the same manner as the corresponding items of Profits </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-20- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and Losses and specially allocated items are allocated for Capital Account purposes; <I>provided</I> that, in the case of any asset the Carrying Value of which differs from its adjusted tax basis
for U.S. federal income tax purposes, income, gain, loss and deduction with respect to such asset shall be allocated solely for income tax purposes in accordance with the principles of Sections 704(b) and (c) of the Code (including under
&#147;reverse&#148; Section 704(c) principles) in any manner determined by the Managing Member with the consent of the Original Member Representative (not to be unreasonably withheld, conditioned, or delayed) and permitted by the Code and Treasury
Regulations, <I>provided</I> that the consent of the Original Member Representative shall only be required for so long as the Original Member Representative owns at least 50% of the Units owned by the Original Member Representative immediately
following the Closing Date. The Managing Member shall make such other allocations for tax purposes as it determines in its reasonable discretion, subject to, for so long as the Original Member Representative owns at least 50% of the Units owned by
the Original Member Representative immediately following the Closing Date, the prior written consent, not to be unreasonably withheld, conditioned or delayed, of the Original Member Representative (and its successors or assigns), to be appropriate
to ensure allocations are made in accordance with a Member&#146;s interest in the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_36"></A>5.07&nbsp;&nbsp;&nbsp;&nbsp;<B>Tax Advances</B>. If the Company or any other Person in which the Company
holds an interest is required by Law to withhold or to make tax payments on behalf of or with respect to any Member, or the Company is subjected to tax itself (including any amounts withheld from amounts directly or indirectly payable to the Company
or to any other Person in which the Company holds an interest) by reason of the status of any Member as such or that is specifically attributable to a Member (including U.S. federal, state, or local or
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> withholding, personal property, unincorporated business or other taxes, the amount of any taxes arising under the Revised Partnership Audit Provisions, the amount of any taxes imposed under Code
Section&nbsp;1446(f), and any interest, penalties, additions to tax, and expenses related to any such amounts) (&#147;<B><I>Tax Advances</I></B>&#148;), the Managing Member may cause the Company to withhold such amounts and cause the Company to make
such tax payments as so required. All Tax Advances made on behalf of a Member shall be repaid by reducing the amount of the current or next succeeding Distribution or Distributions which would otherwise have been made to such Member or, if such
Distributions are not sufficient for that purpose, by so reducing the proceeds of liquidation otherwise payable to such Member. For all purposes of this Agreement such Member shall be treated as having received the amount of the Distribution that is
equal to the Tax Advance. Each Member hereby agrees to indemnify and hold harmless the Company and the other Members from and against any liability (including any liability for taxes, penalties, additions to tax or interest) with respect to income
attributable to or Distributions or other payments to such Member. For the avoidance of doubt, any income taxes, penalties, additions to tax and interest payable by the Company or any fiscally transparent entity in which the Company owns an interest
shall be treated as specifically attributable to the Members and shall be allocated among the Members such that the burden of (or any diminution in distributable proceeds resulting from) any such amounts is borne by those Members to whom such
amounts are specifically attributable (whether as a result of their status, actions, inactions or otherwise, including pursuant to an allocation made under <U>Section</U><U></U><U>&nbsp;5.08</U>), in each case as reasonably determined by the
Managing Member. For the avoidance of doubt, any taxes, penalties, and interest payable under the Revised Partnership Audit Provisions by the Company or any fiscally transparent entity in which the Company owns an interest shall be treated as
specifically attributable to the Members of the Company, and the Managing Member shall use commercially reasonable efforts to allocate the burden of (or any diminution in distributable proceeds resulting from) any such taxes, penalties or interest
to those Members to whom such amounts are specifically attributable (whether as a result of their status, actions, inactions or otherwise), as reasonably determined by the Managing Member. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><A NAME="annexitoc401831_37"></A>5.08&nbsp;&nbsp;&nbsp;&nbsp;Partnership Representative. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;The Managing Member is hereby designated as the &#147;partnership representative&#148; as that term is
defined in Revised Partnership Audit Provisions for taxable years of the Company beginning with the taxable year including the Effective Date. In addition, the Managing Member is hereby authorized to designate or remove any other Person selected by
the Managing Member as the Partnership Representative. For each Fiscal Year in which the Partnership Representative is an entity, the Company shall appoint an individual identified by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-21- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Partnership Representative for such Fiscal Year to act on its behalf (the &#147;<B><I>Designated Individual</I></B>&#148;) in accordance with the applicable regulations or analogous
provisions of state or local Law. Each Member hereby expressly consents to such designations and agrees to take, and the Managing Member is authorized to take (or cause the Company to take), such other actions as may be necessary or advisable
pursuant to Treasury Regulations or other Internal Revenue Service or Treasury guidance or state or local Law to cause such designations or evidence such Member&#146;s consent to such designations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;Subject to this <U>Section</U><U></U><U>&nbsp;5.08</U>, the Partnership Representative shall have the sole
authority to act on behalf of the Company in connection with, make all relevant decisions regarding application of, and to exercise the rights and powers provided for in the Revised Partnership Audit Provisions, including making any elections under
the Revised Partnership Audit Provisions or any decisions to settle, compromise, challenge, litigate or otherwise alter the defense of any action, audit or examination before the IRS or any other tax authority (each, an
&#147;<B><I>Audit</I></B>&#148;), and to expend Company funds for professional services and other expenses reasonably incurred in connection therewith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;Without limiting the foregoing, the Partnership Representative shall give prompt written notice to the
Original Member Representative of the commencement of any Audit of the Company or any of its Subsidiaries the resolution of which would reasonably be expected to have a disproportionate (compared to the Managing Member) and material adverse effect
on the Original Members (a &#147;<B><I>Specified Audit</I></B>&#148;). The Partnership Representative shall (i)&nbsp;keep the Original Member Representative reasonably informed of the material developments and status of any such Specified Audit,
(ii)&nbsp;permit the Original Member Representative (or its designee) to participate (including using separate counsel), in each case at the Original Members&#146; sole cost and expense, in any such Specified Audit, and (iii)&nbsp;promptly notify
the Original Member Representative of receipt of a notice of a final partnership adjustment (or equivalent under applicable Laws) or a final decision of a court or IRS Independent Office of Appeals panel (or equivalent body under applicable Laws)
with respect to such Specified Audit. The Partnership Representative or the Company shall promptly provide the Original Member Representative with copies of all material correspondence between the Partnership Representative or the Company (as
applicable) and any governmental entity in connection with such Specified Audit and shall give the Original Member Representative a reasonable opportunity to review and comment on any material correspondence, submission (including settlement or
compromise offers) or filing in connection with any such Specified Audit. Additionally, for so long as the Original Member Representative owns at least 50% of the Units owned by the Original Member Representative immediately following the Closing
Date, the Partnership Representative shall not (and the Company shall not (and shall not authorize the Partnership Representative to)) settle, compromise or abandon any Specified Audit in a manner that would reasonably be expected to have a
disproportionate (compared to the Managing Member) and material adverse effect on the Original Members without the Original Member Representative&#146;s prior written consent (which consent shall not be unreasonably withheld, delayed or
conditioned). The Partnership Representative shall, for so long as the Original Member Representative owns at least 50% of the Units owned by the Original Member Representative immediately following the Closing Date, obtain the prior written consent
of the Original Member Representative (which consent shall not be unreasonably withheld, delayed or conditioned) before (i)&nbsp;making an election under Section&nbsp;6226(a) of the Code (or any analogous provision of state or local Law) or
(ii)&nbsp;taking any material action under the Revised Partnership Audit Provisions that would reasonably be expected to have a disproportionate (compared to the Managing Member) and material adverse effect on the Original Members, in the case of
clauses (i)&nbsp;and (ii); <I>provided</I> that, no consent from the Original Member Representative is required in order to make an election under Section&nbsp;6226(a) of the Code with respect to taxable periods that began on or before the Closing.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;All expenses incurred by the Partnership Representative or Designated Individual or Original Member
Representative in connection with its duties as partnership representative or designated individual or Original Member Representative, as applicable, shall be expenses of the Company (including, for the avoidance of doubt, any costs and expenses
incurred in connection with any claims asserted against the Partnership Representative or Designated Individual or Original Member Representative, as applicable, except to the extent the Partnership Representative or Designated Individual is
determined to have performed its duties in the manner </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-22- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
described in the final sentence of this <U>Section</U><U></U><U>&nbsp;5.08(d)</U>), and the Company shall reimburse and indemnify the Partnership Representative or Designated Individual or
Original Member Representative, as applicable, for all such expenses and costs. Nothing herein shall be construed to restrict the Partnership Representative or Designated Individual or Original Member Representative from engaging lawyers,
accountants, tax advisers, or other professional advisers or experts to assist the Partnership Representative or Designated Individual or Original Member Representative in discharging its duties hereunder. Neither the Partnership Representative nor
Designated Individual nor Original Member Representative shall be liable to the Company, any Member or any Affiliate thereof for any costs or losses to any Persons, any diminution in value or any liability whatsoever arising as a result of the
performance of its duties pursuant to this <U>Section</U><U></U><U>&nbsp;5.08</U> absent (i)&nbsp;willful breach of any provision of this <U>Section</U><U></U><U>&nbsp;5.08</U> or (ii)&nbsp;bad faith, fraud, gross negligence or willful misconduct on
the part of the Partnership Representative or Designated Individual or Original Member Representative, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B>&nbsp;&nbsp;&nbsp;&nbsp;The Company, the Partnership Representative, and the Members expressly agree to be bound by the terms of
Section&nbsp;7.3 of the Merger Agreement. Notwithstanding anything to the contrary contained in this Agreement, in the event of any conflict between Section&nbsp;7.3 of the Merger Agreement and this Agreement, Section&nbsp;7.3 of the Merger
Agreement shall control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_38"></A>5.09&nbsp;&nbsp;&nbsp;&nbsp;<B>Other Allocation Provisions</B>. Certain of the
foregoing provisions and the other provisions of this Agreement relating to the maintenance of Capital Accounts are intended to comply with Treasury Regulations Section&nbsp;1.704-1(b) and shall be interpreted and applied in a manner consistent with
such regulations. In addition to amendments effected in accordance with <U>Section</U><U></U><U>&nbsp;12.12</U> or otherwise in accordance with this Agreement, <U>Sections </U><U>5.03</U>, <U>5.04</U> and <U>5.05</U> may also, so long as any such
amendment does not materially change the relative economic interests of the Members, be amended at any time by the Managing Member if necessary, in the Managing Member&#146;s reasonable discretion after consultation with its tax advisers, to comply
with such regulations or any applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_39"></A>5.10&nbsp;&nbsp;&nbsp;&nbsp;<B>Survival</B>. <U>Sections
5.07</U> and <U>5.08</U> shall be interpreted to apply to Members and former Members and shall survive the Transfer of a Member&#146;s Units and the termination, dissolution, liquidation and winding up of the Company and, for this purpose to the
extent not prohibited by applicable Law, the Company shall be treated as continuing in existence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_40"></A><B>5.11</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Unitholder Representative Matters</B>. Each of the provisions of the
Unitholder Representative Agreement is hereby incorporated by reference into this Agreement, and, without limiting the generality of the foregoing, each Member hereby acknowledges and agrees that amounts otherwise payable to such Member hereunder
may instead be remitted to the Unitholder Representative (as defined in the Unitholder Representative Agreement) in the circumstances, and at the times and in the amounts, set forth in the Unitholder Representative Agreement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="annexitoc401831_41"></A>ARTICLE VI </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BOOKS AND RECORDS; REPORTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><A NAME="annexitoc401831_42"></A>6.01&nbsp;&nbsp;&nbsp;&nbsp;Books and Records. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;At all times during the continuance of the Company, the Company shall prepare and maintain separate books of
account for the Company in accordance with GAAP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;Except as limited by
<U>Section</U><U></U><U>&nbsp;6.01(c)</U>, each Member shall have the right to receive, for a purpose reasonably related to such Member&#146;s interest as a Member in the Company, upon reasonable written demand stating the purpose of such demand and
at such Member&#146;s own expense, a copy of the Certificate and this Agreement and all amendments thereto, together with a copy of the executed copies of all powers of attorney pursuant to which the Certificate and this Agreement and all amendments
thereto have been executed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-23- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)&nbsp;&nbsp;&nbsp;&nbsp;Intentionally Omitted. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;The Managing Member shall cause to be prepared and filed all necessary federal and state income tax returns
for the Company, including making any tax elections. At the Company&#146;s expense, the Managing Member, within 120 days of the close of the Fiscal Year, shall use commercially reasonable efforts to furnish to each Member that was a Member during
such Fiscal Year a Schedule K-1 and such other tax information reasonably required for U.S. federal, state and local income tax reporting purposes. The Company shall use commercially reasonable efforts to provide to each Person that was a Member
during the Fiscal Year (a)&nbsp;by May 15th, August 15th and November 15th of such Fiscal Year, with an estimate of the taxable income, gains, deductions, losses and other items for, respectively, the first, second and third fiscal quarters that
such Person will be required to include in its taxable income and (b)&nbsp;by March 1st of such Fiscal Year, with an estimate of the taxable income, gains, deductions, losses and other items of such Person to be reflected on the Schedule K-1 of such
Person for the prior Fiscal Year (it being understood such estimated information is subject to change based on the final Form <FONT STYLE="white-space:nowrap">K-1</FONT> made available by the Company). The Company also shall provide the Members with
such other information as may be reasonably requested for purposes of allowing the Members to prepare and file their own tax returns; <I>provided</I> that, any costs or expenses with respect to the foregoing shall be borne by the requesting Member.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B>&nbsp;&nbsp;&nbsp;&nbsp;The Managing Member shall make the following elections on the appropriate tax returns and shall not
rescind them without the prior written consent of the Original Member Representative (<I>provided</I> that, the election described in clause (ii)&nbsp;below cannot be rescinded without the prior written consent of the all the Members): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B>&nbsp;&nbsp;&nbsp;&nbsp;to adopt an appropriate federal income tax method of accounting and to keep the Company&#146;s books and
records on such <FONT STYLE="white-space:nowrap">income-tax</FONT> method; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B>&nbsp;&nbsp;&nbsp;&nbsp;to have in effect (and to
cause each direct or indirect Subsidiary that is treated as a partnership for U.S. federal income tax purposes and over 50% owned and controlled by the Company to have in effect, to the extent eligible to do so) an election, pursuant to
Section&nbsp;754 of the Code (and any similar election for state or local tax purposes), to adjust the tax basis of Company properties, for the taxable year of the Company that includes the Effective Date and each subsequent taxable year in which an
Exchange Transaction occurs; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B>&nbsp;&nbsp;&nbsp;&nbsp;any other available election that the Managing Member deems
appropriate; provided that, for so long as the Original Member Representative owns at least 50% of the Units owned by the Original Member Representative immediately following the Closing Date, the Managing Member shall consult in good faith with the
Original Member Representative with respect to any material tax election with respect to the Company that could reasonably be expected to have a disproportionate (as compared to the Managing Member) and adverse effect on the Original Members, and
not make such election without the Original Member Representative&#146;s prior written consent (which consent shall not be unreasonably withheld, delayed or conditioned). No Member may make an election for the Company to be excluded from the
application of the provisions of subchapter K of chapter 1 of subtitle A of the Code or any similar provisions of applicable state Law, and no provision of this Agreement shall be construed to sanction or approve such an election. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><A NAME="annexitoc401831_43"></A>6.02&nbsp;&nbsp;&nbsp;&nbsp;Confidentiality. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;Each of the Members (other than the Managing Member) agrees to hold the Company&#146;s Confidential
Information in confidence and may not disclose or use such information except as otherwise authorized separately in writing by the Managing Member. &#147;<B><I>Confidential Information</I></B>&#148; as used herein includes all <FONT
STYLE="white-space:nowrap">non-public</FONT> information concerning the Company or its Subsidiaries including, but not limited to, ideas, financial product structuring, business strategies, innovations and materials, all aspects of the
Company&#146;s business plan, proposed operation and products, corporate structure, financial and organizational information, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-24- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
analyses, proposed partners, software code and system and product designs, employees and their identities, equity ownership, the methods and means by which the Company plans to conduct its
business, all trade secrets, trademarks, tradenames and all intellectual property associated with the Company&#146;s business. With respect to each Member, Confidential Information does not include information or material that: (i)&nbsp;before or
after it has been disclosed to such Member by the Company, becomes part of public knowledge, not as a result of any action or inaction of such Member in violation of this Agreement; (ii)&nbsp;is approved for release by written authorization of the
Chief Executive Officer, Chief Financial Officer or General Counsel of the Company or of the Managing Member, or any other officer designated by the Managing Member; (iii)&nbsp;is disclosed to such Member or their representatives by a third party
not, to the knowledge of such Member, in violation of any obligation of confidentiality owed to the Company, the Managing Member or any of their respective Subsidiaries with respect to such information; or (iv)&nbsp;is or becomes independently
developed by such Member or their respective representatives without use of or reference to the Confidential Information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;Solely to the extent it is reasonably necessary or appropriate to fulfill its obligations or to exercise its
rights under this Agreement, each of the Members may disclose Confidential Information to its Subsidiaries, Affiliates, partners, directors, officers, employees, counsel, advisers, consultants, outside contractors and other agents, on the condition
that such Persons keep the Confidential Information confidential to the same extent as such Member is required to keep the Confidential Information confidential; <I>provided</I> that, such Member shall remain liable with respect to any breach of
this <U>Section</U><U></U><U>&nbsp;6.02</U> by any such Subsidiaries, Affiliates, partners, directors, officers, employees, counsel, advisers, consultants, outside contractors and other agents (as if such Persons were party to this Agreement for
purposes of this <U>Section</U><U></U><U>&nbsp;6.02</U>). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding anything herein to the
contrary, each of the Members may disclose Confidential Information: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B>&nbsp;&nbsp;&nbsp;&nbsp;to the extent that such Member is
required by Law (by oral questions, interrogatories, request for information or documents, subpoena, civil investigative demand or similar process) to disclose any of the Confidential Information, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B>&nbsp;&nbsp;&nbsp;&nbsp;for purposes of reporting to its stockholders and direct and indirect equity holders (each of whom are
bound by customary confidentiality obligations) the performance of the Company and its Subsidiaries and for purposes of including applicable information in its financial statements to the extent required by applicable Law or applicable accounting
standards; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B>&nbsp;&nbsp;&nbsp;&nbsp;to any bona fide prospective purchaser of the equity or assets of a Member, or the
Units held by such Member (provided, in each case, that such Member determines in good faith that such prospective purchaser would be a Permitted Transferee), or a prospective merger partner of such Member (<I>provided</I> that, (i)&nbsp;such
Persons will be informed by such Member of the confidential nature of such information and shall agree in writing to keep such information confidential in accordance with the contents of this Agreement and (ii)&nbsp;each Member will be liable for
any breaches of this <U>Section</U><U></U><U>&nbsp;6.02</U> by any such Persons (as if such Persons were party to this Agreement for purposes of this <U>Section</U><U></U><U>&nbsp;6.02</U>)). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding any of the foregoing, nothing in this <U>Section</U><U></U><U>&nbsp;6.02</U> will restrict
in any manner the ability of the Managing Member to comply with its disclosure obligations under Law, and the extent to which any Confidential Information is necessary or desirable to disclose. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-25- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="annexitoc401831_44"></A>ARTICLE VII </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMPANY UNITS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_45">
</A>7.01&nbsp;&nbsp;&nbsp;&nbsp;<B>Units</B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;Limited liability company interests in the Company shall
be represented by Units. At the execution of this Agreement, the Units are comprised of only Common Units. Immediately after giving effect to the transactions contemplated by the Merger Agreement, each Member holds the number of Units set forth
opposite such Member&#146;s name on <B>Exhibit A</B> attached hereto. For the avoidance of doubt, in connection with the Class&nbsp;A Restricted Common Stock Consideration issued by the Managing Member to certain holders of Merger Partner PIUs, the
Company has issued to the Managing Member a corresponding number of Common Units. Such Common Units shall be subject to the same vesting or forfeiture terms as the corresponding restricted Class&nbsp;A Common Shares; if any restricted Class&nbsp;A
Common Shares vest or are forfeited, then a corresponding number of the Common Units issued by the Company to the Managing Member shall automatically vest or be forfeited. Common Units which correspond to the Class&nbsp;A Restricted Common Stock
Consideration shall participate in Distributions pursuant to <U>Article IV</U> the extent that the holders of the corresponding restricted Class&nbsp;A Common Shares are entitled to receive dividends thereon pursuant to the terms of the Company
Plan. Any cash or property held by either the Managing Member or the Company or on either&#146;s behalf in respect of dividends paid on restricted Class&nbsp;A Common Shares that fail to vest shall be returned to the Company upon the forfeiture of
such restricted Class&nbsp;A Common Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;Subject to <U>Section</U><U></U><U>&nbsp;7.04</U>, the
Managing Member in its sole discretion may establish and issue, from time to time in accordance with such procedures as the Managing Member shall determine from time to time, additional Units, in one or more classes or series of Units, or other
Company securities, at such price, and with such designations, preferences and relative, participating, optional or other special rights, powers and duties (which may be senior to existing Units, classes and series of Units or other Company
securities), as shall be determined by the Managing Member without the approval of any Member or any other Person who may acquire an interest in any of the Units, including (i)&nbsp;the right of such Units to share in Profits and Losses or items
thereof; (ii)&nbsp;the right of such Units to share in Distributions; (iii)&nbsp;the rights of such Units upon dissolution and winding up of the Company; (iv)&nbsp;whether, and the terms and conditions upon which, the Company may or shall be
required to redeem such Units (including sinking fund provisions); (v) whether such Units are issued with the privilege of conversion or exchange and, if so, the terms and conditions of such conversion or exchange; (vi)&nbsp;the terms and conditions
upon which such Units will be issued, evidenced by certificates and assigned or transferred; (vii)&nbsp;the method for determining the Common Percentage Interest as to such Units; (viii)&nbsp;the terms and conditions of the issuance of such Units
(including the amount and form of consideration, if any, to be received by the Company in respect thereof, the Managing Member being expressly authorized, in its sole discretion, to cause the Company to issue such Units for less than Fair Market
Value); and (ix)&nbsp;the right, if any, of the holder of such Units to vote on Company matters, including matters relating to the relative designations, preferences, rights, powers and duties of such Units. Notwithstanding any other provision of
this Agreement, the Managing Member in its sole discretion, without the approval of any Member or any other Person, is authorized (i)&nbsp;to issue Units or other Company securities of any newly established class or any existing class to Members or
other Persons who may acquire an interest in the Company, including Equity Interests which constitute a &#147;profits interest&#148; to Persons within the meaning of IRS Revenue Procedures 93-27 and 2001-43 and IRS Notice 2005-43 and which will be
issued with the intention that under current interpretations of the Code the recipient will not realize income upon the issuance of such Equity Interests, and that neither the Company nor any Member is entitled to any deduction either immediately or
through depreciation or amortization as a result of the issuance of such Equity Interest; (ii)&nbsp;to amend this Agreement to reflect the creation of any such new class, the issuance of Units or other Company securities of such class, and the
admission of any Person as a Member which has received Units or other Company securities; and (iii)&nbsp;to effect the combination, subdivision and/or reclassification of outstanding Units as may be necessary or appropriate to give economic effect
to equity investments in the Company by the Managing Member that are not accompanied by the issuance by the Company to the Managing Member of additional Units and to update the books and records of the Company accordingly. Except as expressly
provided </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-26- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in this Agreement to the contrary, any reference to &#147;Units&#148; shall include the Common Units and Units of any other class or series that may be established in accordance with this
Agreement. All Units of a particular class shall have identical rights in all respects as all other Units of such class, except in each case as otherwise specified in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding anything to the contrary in this Agreement, the Managing Member shall not cause or permit
the Company to issue, or authorize the issuance of, any Units unless the Managing Member has a sufficient number of Class&nbsp;A Common Stock authorized, available and reserved for issuance upon an exchange of such newly issued Units for
Class&nbsp;A Common Stock pursuant to an Exchange Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding anything to the contrary
in this Agreement, the Company shall not, and the Managing Member shall not cause the Company to, issue any Units if such issuance would result, in the Managing Member&#146;s reasonable discretion, in the Company having more than <FONT
STYLE="white-space:nowrap">one-hundred</FONT> (100) &#147;partners&#148;, within the meaning of Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.7704-1(h)</FONT> (determined taking into account the rules of Treasury Regulations <FONT
STYLE="white-space:nowrap">Section&nbsp;1.7704-1(h)(3))</FONT> or if the Company already has more than <FONT STYLE="white-space:nowrap">one-hundred</FONT> (100) &#147;partners&#148; but such issuance would further increase the number of
&#147;partners&#148; in the Company; provided that, for such purposes, the Company and the Managing Member shall be entitled to assume that each person who is a Member immediately before the Closing is treated as a single partner within the meaning
of Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.7704-1(h)</FONT> (determined taking into account the rules of Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.7704-1(h)(3)),</FONT> unless otherwise
required by applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_46"></A>7.02&nbsp;&nbsp;&nbsp;&nbsp;<B>Register</B>. The books and records of the
Company shall be the definitive record of ownership of each Unit and all relevant information with respect to each Member. Unless the Managing Member in its sole discretion shall determine otherwise, Units shall be uncertificated and recorded in the
books and records of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_47"></A>7.03&nbsp;&nbsp;&nbsp;&nbsp;<B>Registered Members</B>. The Company
shall be entitled to recognize the exclusive right of a Person registered on its records as the owner of Units for all purposes and shall not be bound to recognize any equitable or other claim to or interest in Units on the part of any other Person,
whether or not it shall have express or other notice thereof, except as otherwise provided by the Act or other applicable Law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_48">
</A>7.04&nbsp;&nbsp;&nbsp;&nbsp;<B>Issuances, Repurchases and Redemptions, Recapitalizations</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;<U>Issuances by the Managing Member</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B>&nbsp;&nbsp;&nbsp;&nbsp;Subject to <U>Section</U><U></U><U>&nbsp;7.04(a)(ii)</U> and the Exchange Agreement, if, at any time after
the Closing Date, the Managing Member sells or issues Class&nbsp;A Common Shares or any other Equity Interests of the Managing Member (other than Class&nbsp;B Common Stock), (x) the Company shall concurrently issue to the Managing Member an equal
number of Common Units (if the Managing Member issues Class&nbsp;A Common Stock), or an equal number of such other Equity Interests of the Company corresponding to the Equity Interests issued by the Managing Member (if the Managing Member issues
Equity Interests other than Class&nbsp;A Common Stock), and with substantially the same rights to dividends and Distributions (including Distributions upon liquidation) and other economic rights as those of such Equity Interests of the Managing
Member so issued and (y)&nbsp;the Managing Member shall concurrently contribute to the Company, the net proceeds or other property received by the Managing Member, if any, for such Class&nbsp;A Common Stock or other Equity Interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B>&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding anything to the contrary contained in <U>Section</U><U></U><U>&nbsp;7.04(a)(i)</U> or
<U>Section</U><U></U><U>&nbsp;7.04(a)(iii)</U>, this <U>Section</U><U></U><U>&nbsp;7.04(a)</U> shall not apply to (x)&nbsp;the issuance and distribution to holders of Class&nbsp;A Common Stock or other Equity Interests of the Managing Member of
rights to purchase Equity Interests of the Managing Member under a &#147;poison pill&#148; or similar shareholder rights plan (and upon exchange of Common Units for Class&nbsp;A Common Stock, such Class&nbsp;A Common Stock will be issued together
with a corresponding right under such plan) or (y)&nbsp;the issuance under the Managing Member&#146;s employee benefit plans of any warrants, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-27- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
options, stock appreciation right, restricted stock units, performance based award or other rights to acquire Equity Interests of the Managing Member, but shall in each of the foregoing cases
apply to the issuance of Equity Interests of the Managing Member in connection with the exercise or settlement of such warrants, options, stock appreciation right, restricted stock units, performance based awards (including as set forth in clause
(iii)&nbsp;below, as applicable). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B>&nbsp;&nbsp;&nbsp;&nbsp;In the event any outstanding Equity Interest of the Managing
Member is exercised or otherwise converted and, as a result, any Class&nbsp;A Common Shares or other Equity Interests of the Managing Member are issued (including as a result of the exercise of warrants of the Managing Member), (x) the corresponding
Equity Interest outstanding at the Company, if any, shall be similarly exercised or otherwise converted, if applicable, (y)&nbsp;an equivalent number of Common Units or equivalent Equity Interests of the Company shall be issued to the Managing
Member as required by the first sentence of <U>Section</U><U></U><U>&nbsp;7.04(a)(i)</U>, and (z)&nbsp;the Managing Member shall concurrently contribute to the Company the net proceeds received by the Managing Member from any such exercise or
conversion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;<U>New Company Equity Interests</U>. Except pursuant to the Exchange Agreement,
(x)&nbsp;the Company may not issue any additional Common Units or Equity Interests of the Company to the Managing Member or any of its Subsidiaries (other than the Company and its Subsidiaries) unless substantially simultaneously therewith the
Managing Member or such Subsidiary issues or Transfers an equal number of newly-issued Class&nbsp;A Common Shares of the Managing Member (or relevant Equity Interest of such Subsidiary) to another Person or Persons and contributes the net proceeds
therefrom to the Company, and (y)&nbsp;the Company may not issue any other Equity Interests of the Company to the Managing Member or any of its Subsidiaries (other than the Company and its Subsidiaries) unless substantially simultaneously therewith
the Managing Member or such Subsidiary issues or Transfers, to another Person, an equal number of newly-issued shares of Equity Interests of the Managing Member or such Subsidiary with substantially the same rights to dividends and Distributions
(including Distributions upon liquidation) and other economic rights as those of such Equity Interests of the Company and contributes the net proceeds therefrom to the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;<U>Repurchases and Redemptions</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B>&nbsp;&nbsp;&nbsp;&nbsp;Neither the Managing Member nor any of its Subsidiaries (other than the Company and its Subsidiaries) may
redeem, repurchase or otherwise acquire (A)&nbsp;Class&nbsp;A Common Stock pursuant to a Board approved repurchase plan or program (or otherwise in connection with a transaction approved by the Board) unless substantially simultaneously therewith
the Company redeems, repurchases or otherwise acquires from the Managing Member or such Subsidiary an equal number of Common Units for the same price per security, if any, or (B)&nbsp;any other Equity Interests of the Managing Member or any of its
Subsidiaries (other than the Company and its Subsidiaries) pursuant to a Board approved repurchase plan or program (or otherwise in connection with a transaction approved by the Board) unless substantially simultaneously therewith the Company
redeems, repurchases or otherwise acquires from the Managing Member or such Subsidiary an equal number of the corresponding class or series of Equity Interests of the Company with the same rights to dividends and Distributions (including
Distributions upon liquidation) and other economic rights as those of such Equity Interests of the Managing Member or such Subsidiary for the same price per security, if any. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B>&nbsp;&nbsp;&nbsp;&nbsp;The Company may not redeem, repurchase or otherwise acquire (x)&nbsp;any Common Units from the Managing
Member or any of its Subsidiaries (other than the Company and its Subsidiaries) unless substantially simultaneously the Managing Member or such Subsidiary redeems, repurchases or otherwise acquires pursuant to a Board approved repurchase plan or
program (or otherwise in connection with a transaction approved by the Board) an equal number of Class&nbsp;A Common Shares for the same price per security from holders thereof or (y)&nbsp;any other Equity Interests of the Company from the Managing
Member or any of its Subsidiaries (other than the Company and its Subsidiaries) unless substantially simultaneously the Managing Member or such Subsidiary redeems, repurchases or otherwise acquires pursuant to a Board approved repurchase plan or
program (or otherwise in connection with a transaction approved by the Board) for the same price per security an equal </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-28- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
number of Equity Interests of the Managing Member (or such Subsidiary) of a corresponding class or series with substantially the same rights to dividends and Distributions (including
Distributions upon liquidation) and other economic rights as those of such Equity Interests of the Managing Member or such Subsidiary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B>&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding the foregoing clauses (a)&nbsp;and (c) of this <U>Section</U><U></U><U>&nbsp;7.04</U>, to
the extent that any consideration payable by the Managing Member in connection with the redemption, repurchase or acquisition of Class&nbsp;A Common Shares or other equity securities of the Managing Member or any of its Subsidiaries (other than the
Company and its Subsidiaries) consists (in whole or in part) of Class&nbsp;A Common Shares or such other Equity Interests (including in connection with the cashless exercise of an option or warrant (or other convertible right or security)) other
than under the Managing Member&#146;s employee benefit plans for which there are no corresponding Common Units or other Equity Interests of the Company, the redemption, repurchase or acquisition of the corresponding Common Units or other Equity
Interests of the Company shall be effectuated in a substantially similar manner. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;<U>Equity Subdivisions
and Combinations</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B>&nbsp;&nbsp;&nbsp;&nbsp;The Company shall not in any manner effect any subdivision (by any equity split,
equity distribution, reclassification, recapitalization or otherwise) or combination (by reverse equity split, reclassification, recapitalization or otherwise) of the outstanding Equity Interests of the Company unless accompanied by an identical
subdivision or combination, as applicable, of the outstanding related class or series of Equity Interest of the Managing Member, with corresponding changes made with respect to any other exchangeable or convertible Equity Interests of the Company
and the Managing Member. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B>&nbsp;&nbsp;&nbsp;&nbsp;the Managing Member shall not in any manner effect any subdivision (by any
equity split, equity distribution, reclassification, recapitalization or otherwise) or combination (by reverse equity split, reclassification, recapitalization or otherwise) of any class or series of Equity Interests of the Managing Member, unless
accompanied by an identical subdivision or combination, as applicable, of the outstanding related class or series of Equity Interest of the Company, with corresponding changes made with respect to any applicable exchangeable or convertible Equity
Interests of the Company and the Managing Member. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B>&nbsp;&nbsp;&nbsp;&nbsp;<U>General Authority</U>. For the avoidance of doubt,
but subject to <U>Section</U><U></U><U>&nbsp;7.01</U>, <U>Section</U><U></U><U>&nbsp;7.02</U>, and <U>Section</U><U></U><U>&nbsp;7.04</U>, the Company and the Managing Member shall be permitted to undertake all actions, including an issuance,
cancellation, redemption, reclassification, distribution, division or recapitalization, with respect to the Common Units as the Managing Member determines is necessary to maintain at all times a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">one-to-one</FONT></FONT> ratio between (i)&nbsp;the number of Class&nbsp;A Units owned by the Managing Member, directly or indirectly, and the number of outstanding Class&nbsp;A Common Shares, and (ii)&nbsp;the number of
outstanding Class&nbsp;B Common Shares held by any Member other than the Managing Member and the number of Class&nbsp;A Units held, directly or indirectly, by such Member disregarding, for purposes of maintaining the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-to-one</FONT></FONT> ratios in clause (i)&nbsp;and clause (ii), (A) options, rights or securities of the Managing Member issued under any plan involving the issuance of any Equity
Interests that are convertible into or exercisable or exchangeable for Class&nbsp;A Common Shares, (B)&nbsp;treasury stock, or (C)&nbsp;preferred stock or other debt or equity securities (including warrants, options or rights) issued by the Managing
Member that are convertible or into or exercisable or exchangeable for Class&nbsp;A Common Stock (but in each case prior to such conversion, exercise or exchange). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="annexitoc401831_49"></A>ARTICLE VIII </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TRANSFER RESTRICTIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_50">
</A>8.01&nbsp;&nbsp;&nbsp;&nbsp;<B>Member Transfers</B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise agreed to in writing
between the Managing Member and the applicable Member and reflected in the books and records of the Company or as otherwise provided in this <U>Article VIII</U>, no </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-29- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Member or Assignee thereof may Transfer all or any portion of its Units or other interest in the Company (or beneficial interest therein) without the prior consent of the Managing Member, which
consent may be given or withheld, or made subject to such conditions (including the receipt of such legal opinions and other documents that the Managing Member may require) as are determined by the Managing Member, in each case in the Managing
Member&#146;s sole discretion, and which consent may be in the form of a plan or program entered into or approved by the Managing Member, in its sole discretion. Any such determination in the Managing Member&#146;s sole discretion in respect of
Units shall be final and binding. Such determinations need not be uniform and may be made selectively among Members, whether or not such Members are similarly situated, and shall not constitute the breach of any duty hereunder or otherwise existing
at law, in equity or otherwise. Any purported Transfer of Units that is not in accordance with, or subsequently violates, this Agreement shall be, to the fullest extent permitted by law, null and void. If a Member Transfers all or a portion of its
Common Units to a Transferee in compliance with this Agreement, the Member shall surrender a number of Class&nbsp;B Common Shares to the Managing Member equal to the number of Transferred Common Units, such Class&nbsp;B Common Shares will be
immediately cancelled, and the Managing Member shall issue the same number of Class&nbsp;B Common Shares to such Transferee upon its admittance to the Company as a Member. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding anything otherwise to the contrary in this Agreement, each Member may Transfer Units in
Exchange Transactions pursuant to, and in accordance with, the Exchange Agreement; provided that in the case of any Member other than a Member holding at least 3% of the Common Percentage Interest, that (excluding, for purposes of this calculation,
Common Units then owned by the Managing Member (if any) or any Subsidiary of the Managing Member (if any)) such Exchange Transactions shall be effected in compliance with reasonable policies that the Managing Member may adopt or promulgate from time
to time and advise the Members of in writing (including policies requiring the use of designated administrators or brokers) in its reasonable discretion; provided, further, that if such policies conflict with the terms of the Exchange Agreement, the
provisions of the Exchange Agreement shall apply in lieu thereof to any Exchange Transaction to the extent of such conflict. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding anything otherwise to the contrary in this <U>Section</U><U></U><U>&nbsp;8.01</U>, an
individual Member may Transfer all or any portion of his, her or its Restricted Securities without consideration to (i)&nbsp;any member of his or her Family Group or (ii)&nbsp;any Affiliate of such Member (including any direct or indirect partner,
shareholder, equityholder of such Member or any Affiliated investment fund or vehicle of such Member or such Member&#146;s direct or indirect partners, shareholders or equityholders), but excluding any Affiliate under this <U>clause
(ii)</U>&nbsp;who operates or engages in a business which competes with the business of Managing Member or the Company, and (iii)&nbsp;to a trust solely for the benefit of such Member and such Member&#146;s Family Group (or a <FONT
STYLE="white-space:nowrap">re-Transfer</FONT> of such Restricted Securities by such trust back to such Member upon the revocation of any such trust) or pursuant to the applicable Laws of descent or distribution among such Member&#146;s Family Group,
in each case, in a Transfer that complies with <U>Section</U><U></U><U>&nbsp;8.06</U> (each of clauses (i)-(iii), an &#147;<B><I>Exempt Transfer</I></B>&#148;); <I>provided</I> that the restrictions contained in this Agreement will continue to apply
to the Restricted Securities after any Exempt Transfer and each Transferee of Restricted Securities shall agree in writing, by entering into an appropriate supplemental agreement in such form and terms as the Managing Member may reasonably specify,
prior to and as a condition precedent to the effectiveness of such Exempt Transfer, to be bound by the provisions of this Agreement, without modification or condition, subject only to the consummation of such Exempt Transfer. Upon the Exempt
Transfer of Restricted Securities, the transferor will deliver written notice to the Company, which notice will disclose in reasonable detail the identity of such Transferee(s) and shall include an executed original counterpart of this Agreement in
a form acceptable to the Managing Member. Notwithstanding the foregoing, no party hereto shall avoid the provisions of this Agreement by making one or more Exempt Transfers to one or more Transferees and then disposing of all or any portion of any
such party&#146;s interest in such Transferee if such disposition would result in such Transferee ceasing to be a Permitted Transferee. The Managing Member may implement other policies and procedures to permit the Transfer of Restricted Securities
by the other Members for personal planning purposes and any such Transfer effected in compliance with such policies and procedures shall not require the prior consent of the Managing Member. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-30- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_51"></A>8.02&nbsp;&nbsp;&nbsp;&nbsp;<B>Purported Transfers
Void</B>. Any Transfer or attempted Transfer of any Units in violation of any provision of this Agreement shall, to the fullest extent permitted by Law, be null and void ab <I>inito</I>, and the Company will not record such Transfer on its books or
treat any purported Transferee of such Units as the owner of such securities for any purpose. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_52"></A>8.03&nbsp;&nbsp;&nbsp;&nbsp;<B>Mandatory Exchanges</B>. The Managing Member may in its sole discretion at any
time and from time to time, without the consent of any Member or other Person, cause to be Transferred to the Managing Member in an Exchange Transaction any and all Units, except for Units held by any Member holding at least 3% of the Common
Percentage Interest (excluding, for purposes of this calculation, Common Units then owned by the Managing Member or any Subsidiary of the Managing Member) (a &#147;<B><I>Mandatory Exchange</I></B>&#148;); <I>provided</I> that, if at any time: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;the Company has more than <FONT STYLE="white-space:nowrap">one-hundred</FONT> (100) &#147;partners&#148;,
within the meaning of Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.7704-1(h)</FONT> (determined taking into account the rules of Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.7704-1(h)(3)),</FONT> and
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;there are not binding agreements by and among Members and the Company and/or its assignees to sell
Units in a manner that will not cause the Company to be classified as a &#147;publicly traded partnership&#148; within the meaning of Section&nbsp;7704 of the Code that would cause the Company to have
<FONT STYLE="white-space:nowrap">one-hundred</FONT> (100)&nbsp;or fewer &#147;partners&#148;, within the meaning of Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.7704-1(h)</FONT> (determined taking into account the rules of
Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.7704-1(h)(3)),</FONT> upon the consummation of the transactions contemplated by such agreements (including, agreements to tender Units to the Company or one or more purchasers
approved by the Company), then the Company shall promptly cause a Mandatory Exchange to be effected with respect to a number of Member holding less than 3% of the Common Percentage Interest (excluding, for purposes of this calculation, Common Units
then owned by the Managing Member) sufficient to cause the Company to have no more than <FONT STYLE="white-space:nowrap">one-hundred</FONT> (100) &#147;partners&#148;, within the meaning of Treasury Regulations
<FONT STYLE="white-space:nowrap">Section&nbsp;1.7704-1(h)</FONT> (determined taking into account the rules of Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.7704-1(h)(3)),</FONT> upon the consummation of such Mandatory
Exchange. Any Mandatory Exchange need not be uniform and may be made by the Company and Managing Member selectively among the Members, whether or not such Members are similarly situated; provided that, in the event that a tender offer, share
exchange offer, take-over bid, recapitalization or similar transaction with respect to any Class&nbsp;A Common Shares (a &#147;<B><I>Managing Member Offer</I></B><I>&#148;</I><I>) </I>is proposed by the Managing Member or is proposed to the Managing
Member or its stockholders and approved by the Board or is otherwise effected or to be effected with the consent or approval of the Board that would result in Managing Member undergoing a Change of Control, then the Managing Member shall require,
and each Member shall be deemed to effect, an Exchange Transaction with respect to any and all Units held by all Members conditioned upon, and subject to, the consummation of such Managing Member Offer or Change of Control, in each case, to the
extent that such Member has not effected an Exchange Transaction with respect to all of its Units prior to the consummation of such transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_53"></A>8.04&nbsp;&nbsp;&nbsp;&nbsp;<B>Encumbrances</B>. No Member or Assignee may create an Encumbrance with respect
to all or any portion of its Units (or any beneficial interest therein) other than Encumbrances that run in favor of the Member unless the Managing Member consents in writing thereto, which consent may be given or withheld, or made subject to such
conditions as are determined by the Managing Member, in the Managing Member&#146;s sole discretion. Consent of the Managing Member shall be withheld until the holder of the Encumbrance acknowledges the terms and conditions of this Agreement. Any
purported Encumbrance that is not in accordance with this Agreement shall be, to the fullest extent permitted by law, null and void. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_54">
</A>8.05&nbsp;&nbsp;&nbsp;&nbsp;<B>Approved Qualified Transaction</B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;In the event that the Managing
Member and the holders of a majority of the voting power of all outstanding capital stock of the Managing Member entitled to vote thereon approve a Qualified Transaction (the &#147;<B><I>Approved Qualified Transaction</I></B>&#148;), each other
Member (each, a &#147;<B><I>Required Member</I></B>&#148;) agrees to Transfer all of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-31- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such Required Member&#146;s Units in connection with such Approved Qualified Transaction (the &#147;<B><I>Drag-Along Right</I></B>&#148;) for an amount of consideration per Unit and corresponding
shares of Class&nbsp;B Common Stock equal (before taking into account any rights such Required Member may have under the Tax Receivable Agreement) to the amount of consideration to be received per share of Class&nbsp;A Common Stock by the holders
thereof (the &#147;<B><I>Drag Price</I></B>&#148;), and otherwise with respect to such Units on the same terms and conditions as apply to the Class&nbsp;A Common Shares in such Approved Qualified Transaction, with such modifications as are
appropriate, as determined in good faith by the Managing Member, solely to reflect the fact that Units and corresponding Class&nbsp;B Common Shares rather than Class&nbsp;A Common Shares will be Transferred in the first instance by such Member. Any
Transfer effected in connection with the Drag-Along Right shall be structured in the sole discretion of the Managing Member and, without limitation to any other structure, the Managing Member will use its reasonable best efforts expeditiously and in
good faith to take all such actions and do all such things as are necessary or desirable to enable and permit the Members to participate in such Approved Qualified Transaction to the same extent or on an economically equivalent basis as the holders
of Class&nbsp;A Common Shares without discrimination; provided that, without limiting the generality of this sentence, the Managing Member will use its reasonable best efforts expeditiously and in good faith to ensure that such Members may
participate in each such Approved Qualified Transaction without being required to have their Common Units and Class&nbsp;B Common Shares redeemed (or, if so required, to ensure that any such redemption shall be effective only upon, and shall be
conditional upon, the closing of such Approved Qualified Transaction, or, as applicable, to the extent necessary to exchange the number of Common Units being repurchased). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;The Managing Member shall send written notice (the &#147;<B><I>Drag-Along Notice</I></B>&#148;) to the
Company and the Required Members at least thirty (30)&nbsp;days prior to the closing of the Approved Qualified Transaction notifying them that such Required Members will be required to sell all (but not less than all) of their Units in such sale,
and setting forth (i)&nbsp;a copy of the written proposal or agreement pursuant to which the Approved Qualified Transaction will be effected, (ii)&nbsp;the Drag Price, (iii)&nbsp;the terms and conditions of Transfer and payment and (iv)&nbsp;the
date and location of and procedures for selling the Units. In the event that the information set forth in the Drag-Along Notice changes from that set forth in the initial Drag-Along Notice, a subsequent Drag-Along Notice shall be delivered by the
Managing Member no less than seven (7)&nbsp;days prior to the closing of the Approved Qualified Transaction. Notwithstanding the foregoing, to the extent that any of the foregoing information to be included in the Drag-Along Notice is publicly
available, the Managing Member shall not be required to include such information in the Drag-Along Notice or deliver a subsequent Drag-Along Notice. Each Required Member shall thereafter be obligated to sell their Units and corresponding
Class&nbsp;B Common Shares on the terms set forth in the Drag-Along Notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;Upon receipt of a
Drag-Along Notice, each Required Member receiving such notice shall be obligated to sell all of its Units and corresponding Class&nbsp;B Common Shares in the Approved Qualified Transaction as contemplated by the Drag-Along Notice for the Drag Price,
on the terms and conditions described in this <U>Section</U><U></U><U>&nbsp;8.05</U>, including by executing any document containing customary representations, warranties and agreements with respect to itself and its ownership of the Units or
Class&nbsp;B Common Shares, as applicable, as requested by the Managing Member in connection with the Approved Qualified Transaction, which representations, warranties, indemnities and agreements shall be substantially the same as those contained in
any letter of transmittal to be executed by the holders of Class&nbsp;A Common Shares with such modifications as are appropriate, as determined in good faith by the Managing Member, solely to reflect the fact that Units or Class&nbsp;B Common
Shares, as applicable, rather than Class&nbsp;A Common Shares will be transferred by such Required Member. The Managing Member and each Required Member shall cooperate in good faith in connection with the consummation of the Approved Qualified
Transaction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_55"></A>8.06&nbsp;&nbsp;&nbsp;&nbsp;<B>Further Restrictions</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;Units issued from time to time after the date of this Agreement, including Units issued under equity
incentive plans of the Company or the Managing Member (or upon settlement of awards granted under such plans), may be subject to such additional or other terms and conditions, including with regard to vesting,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-32- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
forfeiture, minimum retained ownership and Transfer, as may be agreed between the Managing Member and the applicable Member and reflected in the books and records of the Company. Such
requirements, provisions and restrictions need not be uniform and may be waived or released by the Managing Member in its sole discretion with respect to all or a portion of the Units owned by any one or more Members at any time and from time to
time, and shall not constitute the breach of any duty hereunder or otherwise existing at law, in equity or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding any contrary provision in this Agreement, in no event may any Transfer of a Unit (other
than, in each case, in accordance with the Exchange Agreement) be made by any Member or Assignee if the Managing Member determines that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B>&nbsp;&nbsp;&nbsp;&nbsp;such Transfer is made to any Person who lacks the legal right, power or capacity to own such Unit; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B>&nbsp;&nbsp;&nbsp;&nbsp;except pursuant to an Exchange Transaction, such Transfer would require the registration of such
transferred Unit or of any Class&nbsp;of Unit pursuant to any applicable U.S. federal or state securities Laws (including the Securities Act or the Exchange Act) or other <FONT STYLE="white-space:nowrap">non-U.S.</FONT> securities Laws or would
constitute a <FONT STYLE="white-space:nowrap">non-exempt</FONT> distribution pursuant to applicable provincial or state securities Laws; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B>&nbsp;&nbsp;&nbsp;&nbsp;such Transfer would cause (i)&nbsp;all or any portion of the assets of the Company to (A)&nbsp;constitute
&#147;plan assets&#148; (under ERISA, the Code or any applicable Similar Law) of any existing or contemplated Member, or (B)&nbsp;be subject to the provisions of ERISA, Section&nbsp;4975 of the Code or any applicable Similar Law, or (ii)&nbsp;the
Managing Member to become a fiduciary with respect to any existing or contemplated Member, pursuant to ERISA, any applicable Similar Law, or otherwise; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B>&nbsp;&nbsp;&nbsp;&nbsp;to the extent requested by the Managing Member, the Company does not receive such legal and/or tax
opinions and written instruments (including copies of any instruments of Transfer and such Assignee&#146;s consent to be bound by this Agreement as an Assignee) that are in a form satisfactory to the Managing Member, as determined in the Managing
Member&#146;s sole discretion; provided that no such legal and/or tax opinions shall be required for a Transfer by a Member holding at least 3% of the Common Percentage Interest (excluding, for purposes of this calculation, Common Units then owned
by the Managing Member (if any) or any Subsidiary of the Managing Member (if any)); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(v)</B>&nbsp;&nbsp;&nbsp;&nbsp;such Transfer
would cause the Company to be treated as having more than <FONT STYLE="white-space:nowrap">one-hundred</FONT> (100) &#147;partners&#148; within the meaning of Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.7704-1(h)</FONT>
(determined taking into account the rules of Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.7704-1(h)(3))</FONT> or if the Company already has more than <FONT STYLE="white-space:nowrap">one-hundred</FONT> (100)
&#147;partners&#148; but such issuance would further increase the number of &#147;partners&#148; in the Company; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(vi)</B>&nbsp;&nbsp;&nbsp;&nbsp;the Managing Member shall reasonably determine that such Transfer would pose a material risk that the
Company would be treated as a &#147;<B><I>publicly traded partnership</I></B>&#148; within the meaning of Section&nbsp;7704 of the Code and the Treasury Regulations promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All determinations with respect to this <U>Section</U><U></U><U>&nbsp;8.06</U> shall be made by the Managing Member in its sole discretion; provided, however,
that all such determinations with respect to a Member holding at least 3% of the Common Percentage Interest (excluding, for purposes of this calculation, Common Units then owned by the Managing Member (if any) or any Subsidiary of the Managing
Member (if any)) shall be made by the Managing Member exercising its reasonable discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;In
addition, notwithstanding any contrary provision in this Agreement, to the extent the Managing Member shall reasonably determine that interests in the Company do not meet the requirements of Treasury Regulations
<FONT STYLE="white-space:nowrap">Section&nbsp;1.7704-1(h)</FONT> (determined taking into account the rules of Treasury Regulations </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-33- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap">Section&nbsp;1.7704-1(h)(3)</FONT> in a taxable year, <I>provided</I> that, for such purpose, the Company and the Managing Member shall assume that each Original
Member is treated as a single partner within the meaning of Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.7704-1(h)</FONT> (determined taking into account the rules of Treasury Regulations
<FONT STYLE="white-space:nowrap">Section&nbsp;1.7704-1(h)(3))</FONT> unless otherwise required by applicable Law), in no event may any Transfer or assignment of Units by any Member be made if such Transfer would, in the Managing Member&#146;s
reasonable discretion, (i)&nbsp;be considered to be effected on or through an &#147;established securities market&#148; or a &#147;secondary market or the substantial equivalent thereof&#148; as such terms are used in Treasury Regulations <FONT
STYLE="white-space:nowrap">Section&nbsp;1.7704-1,</FONT> (ii) materially increase the possibility of the Company becoming a &#147;publicly traded partnership&#148; within the meaning of Section&nbsp;7704 of the Code, or (iii)&nbsp;cause the Company
to be treated as a &#147;publicly traded partnership&#148; within the meaning of Section&nbsp;7704 of the Code or successor provision of the Code or to be treated as an association taxable as a corporation pursuant to the Code. For the avoidance of
doubt, any Transfer that constitutes a &#147;block transfer&#148; within the meaning of Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.7704-1(e)(2)</FONT> shall not be considered to be (i)&nbsp;effected on or through an
&#147;established securities market&#148; or a &#147;secondary market or the substantial equivalent thereof&#148; as such terms are used in Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.7704-1,</FONT> (ii) materially increase
the possibility of the Company becoming a &#147;publicly traded partnership&#148; within the meaning of Section&nbsp;7704 of the Code, or (iii)&nbsp;cause the Company to be treated as a &#147;publicly traded partnership.&#148; Notwithstanding
anything contrary in this Agreement, in no event may any Transfer, assignment of Units, or other Transfer of beneficial entitlement to Units by any Member be made if such Transfer would cause the Company to be treated as having more than <FONT
STYLE="white-space:nowrap">one-hundred</FONT> (100) &#147;partners&#148; within the meaning of Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.7704-1(h)</FONT> (determined taking into account the rules of Treasury Regulations <FONT
STYLE="white-space:nowrap">Section&nbsp;1.7704-1(h)(3))</FONT> or if the Company already has more than <FONT STYLE="white-space:nowrap">one-hundred</FONT> (100) &#147;partners&#148; but such issuance would further increase the number of
&#147;partners&#148; in the Company. For purposes of determining whether a Transfer is a &#147;block transfer&#148; if at any time the Company is managed by a Managing Member such Managing Member shall be treated as a &#147;general partner.&#148;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;Transfers of Units (other than pursuant to an Exchange Transaction) that are otherwise permitted by
this <U>Article VIII</U> may only be made on the first day of a fiscal quarter of the Company, unless the Managing Member otherwise agrees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B>&nbsp;&nbsp;&nbsp;&nbsp;To the fullest extent permitted by law, any Transfer in violation of this <U>Article VIII</U> shall be
deemed null and void <I>ab initio </I>and of no effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_56"></A>8.07&nbsp;&nbsp;&nbsp;&nbsp;<B>Rights of
Assignees</B>. Subject to <U>Section</U><U></U><U>&nbsp;8.06(b)</U>, the Transferee of any permitted Transfer pursuant to this <U>Article VIII</U> will be an assignee only (&#147;<B><I>Assignee</I></B>&#148;), and only will receive, to the extent
transferred, the Distributions and allocations of income, gain, loss, deduction, credit or similar item to which the Member which transferred its Units would be entitled, and such Assignee will not be entitled or enabled to exercise any other rights
or powers of a Member, such other rights, and all obligations relating to, or in connection with, such interest remaining with the transferring Member. The transferring Member will remain a Member even if it has transferred all of its Units to one
or more Assignees until such time as the Assignee(s) is admitted to the Company as a Member pursuant to <U>Section</U><U></U><U>&nbsp;8.08</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_57"></A>8.08&nbsp;&nbsp;&nbsp;&nbsp;<B>Admissions, Resignations and Removals</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;No Person may be admitted to the Company as an additional Managing Member or substitute Managing Member
without the prior written consent of each incumbent Managing Member, which consent may be given or withheld, or made subject to such conditions as are determined by each incumbent Managing Member, in each case in the sole discretion of each
incumbent Managing Member. A Managing Member will not be entitled to resign as a Managing Member of the Company unless another Managing Member shall have been admitted hereunder (and not have previously been removed or resigned). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;No Member will be removed or entitled to resign from being a Member of the Company except in accordance with
<U>Section</U><U></U><U>&nbsp;8.09</U> hereof. Any additional Managing Member or substitute Managing Member </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-34- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
admitted as a Managing Member of the Company pursuant to this <U>Section</U><U></U><U>&nbsp;8.08</U> is hereby authorized to, and shall, continue the Company without dissolution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise provided in <U>Article IX</U> or the Act, no admission, substitution, resignation or
removal of a Member will cause the dissolution of the Company. To the fullest extent permitted by law, any purported admission, resignation or removal that is not in accordance with this Agreement shall be null and void. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_58"></A>8.09&nbsp;&nbsp;&nbsp;&nbsp;<B>Admission of Assignees as Substitute Members</B>. An Assignee will become a
substitute Member only if and when each of the following conditions is satisfied: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;the Managing Member
consents in writing to such admission, which consent may be given or withheld, or made subject to such conditions as are determined by the Managing Member, in each case in the Managing Member&#146;s sole discretion; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;if required by the Managing Member, the Managing Member receives written instruments (including copies of
any instruments of Transfer and such Assignee&#146;s consent to be bound by this Agreement as a substitute Member) that are in a form satisfactory to the Managing Member (as determined in its sole discretion); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;if required by the Managing Member, the Managing Member receives an opinion of counsel satisfactory to the
Managing Member to the effect that such Transfer is in compliance with this Agreement and all applicable Law; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;if required by the Managing Member, the parties to the Transfer, or any one of them, pays all of the
Company&#146;s reasonable expenses connected with such Transfer (including, but not limited to, the reasonable legal and accounting fees of the Company). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding anything herein to the contrary, to the fullest extent permitted by Law, any Person who acquires in any manner whatsoever any Units,
irrespective of whether such Person has accepted and adopted in writing the terms and conditions of this Agreement shall be deemed by acceptance of the benefits of the acquisition thereof to have agreed to be subject to and bound by all of the terms
and conditions of this Agreement to which any predecessor in such Units was subject or by which such predecessor was bound. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_59">
</A>8.10&nbsp;&nbsp;&nbsp;&nbsp;<B>Resignation and Removal of Members</B>. Subject to <U>Section</U><U></U><U>&nbsp;8.06</U>, if a Member (other than the Managing Member) ceases to hold any Units then such Member shall cease to be a Member and to
have the power to exercise any rights or powers of a member of the Company, and shall be deemed to have resigned from the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_60">
</A>8.11&nbsp;&nbsp;&nbsp;&nbsp;<B>Withholding</B>. In the event any transfer is permitted pursuant to this <U>Article VIII</U>, the transferring parties shall demonstrate to the satisfaction of the Managing Member either that no withholding is
required in connection with such transfer under applicable U.S. federal, state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> law (including under Section&nbsp;1445 or 1446 of the Code) or that any amounts required to be withheld in
connection with such transfer under applicable U.S. federal, state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> law (including under Section&nbsp;1446 of the Code, other than by reason of Section&nbsp;1446(f)(4)) have been so withheld.
The transferring parties shall furnish any forms, certifications or other documentation reasonably requested by the Managing Member for purposes of determining whether withholding is required in connection with such transfer or the amount of tax, if
any, required to be withheld has been remitted to the applicable governmental authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_61"></A>8.12&nbsp;&nbsp;&nbsp;&nbsp;<B>Allocations in Respect of Transferred Units</B>. With regard to the Managing
Member&#146;s acquisition of Common Units in connection with the Company Merger, Profits or Losses shall be allocated to the Members of the Company so as to take into account the varying interests of the Members in the Company using an &#147;interim
closing of the books&#148; method in a manner that complies with the provisions of Section&nbsp;706 of the Code and the Treasury Regulations thereunder. If during any taxable year there is any other change in any Member&#146;s Units in
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-35- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Company, the Managing Member shall consult in good faith with the Original Member Representative and the tax advisors to the Company and allocate the Profits or Losses to the Members of the
Company so as to take into account the varying interests of the Members in the Company using an &#147;interim closing of the books&#148; method in a manner that complies with the provisions of Section&nbsp;706 of the Code and the Treasury
Regulations thereunder; provided, however, that such allocations may instead be made in another manner that complies with the provisions of Section&nbsp;706 of the Code and the Treasury Regulations thereunder and that is selected by the Managing
Member in its reasonable discretion (after consulting in good faith with the Original Member Representative); provided that, the Original Member Representative shall not have the consultation right described in this
<U>Section</U><U></U><U>&nbsp;8.11</U> in the event that the Original Member Representative owns less than 50% of the Units owned by the Original Member Representative immediately following the Closing Date. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="annexitoc401831_62"></A>ARTICLE IX </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DISSOLUTION, LIQUIDATION AND TERMINATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_63"></A>9.01&nbsp;&nbsp;&nbsp;&nbsp;<B>No Dissolution</B>. Except as required by the Act, the Company shall not be
dissolved by the admission of additional Members or resignation of Members in accordance with the terms of this Agreement. The Company may be dissolved, liquidated, wound up and terminated only pursuant to the provisions of this <U>Article IX</U>,
and the Members hereby irrevocably waive any and all other rights they may have to cause a dissolution of the Company or a sale or partition of any or all of the Company assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_64"></A>9.02&nbsp;&nbsp;&nbsp;&nbsp;<B>Events Causing Dissolution</B>. The Company shall be dissolved and its affairs
shall be wound up upon the occurrence of any of the following events: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;the entry of a decree of judicial
dissolution of the Company under Section&nbsp;18-802 of the Act upon the finding by a court of competent jurisdiction that it is not reasonably practicable to carry on the business of the Company in conformity with this Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;any event which makes it unlawful for the business of the Company to be carried on by the Members; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;the written consent of all Members; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;at any time, there are no Members, unless the Company is continued in accordance with the Act; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B>&nbsp;&nbsp;&nbsp;&nbsp;the determination of the Managing Member in its reasonable discretion; <I>provided</I> that, in the event of
a dissolution pursuant to this clause (e), the relative economic rights of each Class&nbsp;of Units immediately prior to such dissolution shall be preserved to the greatest extent practicable with respect to Distributions made to Members pursuant to
<U>Section</U><U></U><U>&nbsp;9.03</U> below in connection with the winding up of the Company, taking into consideration tax and other legal constraints that may adversely affect one or more parties hereto and subject to compliance with applicable
Laws and regulations, unless, and to the extent that, with respect to any Class&nbsp;of Units, holders of not less than 90% of the Units of such Class&nbsp;consent in writing to a treatment other than as described above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_65"></A>9.03&nbsp;&nbsp;&nbsp;&nbsp;<B>Distribution upon Dissolution</B>. Upon dissolution, the Company shall not be
terminated and shall continue until the winding up of the affairs of the Company is completed. Upon the winding up of the Company, the Managing Member, or any other Person designated by the Managing Member (the &#147;<B><I>Liquidation
Agent</I></B>&#148;), shall take full account of the assets and liabilities of the Company and shall, unless the Managing Member determines otherwise, liquidate the assets of the Company as promptly as is consistent with obtaining the fair value
thereof. The proceeds of any liquidation shall be applied and distributed in the following order: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;First, to the satisfaction of debts and liabilities of the Company (including satisfaction of all
indebtedness to Members and/or their Affiliates to the extent otherwise permitted by law) including the expenses </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-36- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of liquidation, and including the establishment of any reserve which the Liquidation Agent shall deem reasonably necessary for any contingent, conditional or unmatured contractual liabilities or
obligations of the Company (&#147;<B><I>Contingencies</I></B>&#148;). Any such reserve may be paid over by the Liquidation Agent to any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-at-law,</FONT></FONT> or acceptable
party, as escrow agent, to be held for disbursement in payment of any Contingencies and, at the expiration of such period as shall be deemed advisable by the Liquidation Agent for Distribution of the balance in the manner hereinafter provided in
this <U>Section</U><U></U><U>&nbsp;9.03</U>; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;Second, to the payment to the Members of any debts (and
any accrued interest thereon), owed by the Company to such Members; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;The balance, if any, to the
Members in accordance with <U>Section</U><U></U><U>&nbsp;4.02</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_66"></A>9.04&nbsp;&nbsp;&nbsp;&nbsp;<B>Time
for Liquidation</B>. A reasonable amount of time shall be allowed for the orderly liquidation of the assets of the Company and the discharge of liabilities to creditors so as to enable the Liquidation Agent to minimize the losses attendant upon such
liquidation. Notwithstanding the provisions of <U>Section</U><U></U><U>&nbsp;9.03</U>, but subject to the order of priorities set forth therein, if upon dissolution of the Company the Liquidation Agent determines that an immediate sale of part or
all of the Company&#146;s assets would be impractical or would cause undue loss (or would otherwise not be beneficial) to the Members, the Liquidation Agent may, in its sole discretion, defer for a reasonable time the winding up of any assets except
those necessary to satisfy Company liabilities (other than loans to the Company by Members) and reserves. Subject to the order of priorities set forth in <U>Section</U><U></U><U>&nbsp;9.03</U>, the Liquidation Agent may, in its sole discretion,
distribute to the Members, in lieu of cash, either (i)&nbsp;all or any portion of such remaining Company assets <FONT STYLE="white-space:nowrap">in-kind</FONT> in accordance with the provisions of <U>Section</U><U></U><U>&nbsp;9.03</U>, (ii) as
tenants in common and in accordance with the provisions of <U>Section</U><U></U><U>&nbsp;9.03</U>, undivided interests in all or any portion of such Company assets or (iii)&nbsp;a combination of the foregoing. Any such Distributions in kind shall be
subject to (x)&nbsp;such conditions relating to the disposition and management of such assets as the Liquidation Agent deems reasonable and equitable and (y)&nbsp;the terms and conditions of any agreements governing such assets (or the operation
thereof or the holders thereof) at such time. Any Company assets distributed in kind will first be written up or down to their Fair Market Value, thus creating Profit or Loss (if any), which shall be allocated in accordance with <U>Article V</U>.
The Liquidation Agent shall determine the Fair Market Value of any property distributed in accordance with the valuation procedures set forth in <U>Article XI</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_67"></A>9.05&nbsp;&nbsp;&nbsp;&nbsp;<B>Termination</B>. The Company shall terminate when all of the assets of the
Company, after payment of or due provision for all debts, liabilities and obligations of the Company, shall have been distributed to the holders of Units in the manner provided for in this <U>Article IX</U>, and the Certificate shall have been
cancelled in the manner required by the Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_68"></A>9.06&nbsp;&nbsp;&nbsp;&nbsp;<B>Claims of the Members</B>.
The Members shall look solely to the Company&#146;s assets for the return of their Capital Contributions, and if the assets of the Company remaining after payment of or due provision for all debts, liabilities and obligations of the Company are
insufficient to return such Capital Contributions, the Members shall have no recourse against the Company or any other Member or any other Person. No Member with a negative balance in such Member&#146;s Capital Account shall have any obligation to
the Company or to the other Members or to any creditor or other Person to restore such negative balance during the existence of the Company, upon dissolution or termination of the Company or otherwise, except to the extent required by the Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_69"></A>9.07&nbsp;&nbsp;&nbsp;&nbsp;<B>Survival of Certain Provisions</B>. Notwithstanding anything to the contrary
in this Agreement, the provisions of <U>Sections </U><U>5.07</U>, <U>10.01</U>, <U>10.02</U>, <U>12.09</U> and <U>12.10</U> shall survive the termination of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-37- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="annexitoc401831_70"></A>ARTICLE X </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LIABILITY AND INDEMNIFICATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><A NAME="annexitoc401831_71"></A>10.01&nbsp;&nbsp;&nbsp;&nbsp;Liability of Members. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;No Member and no Affiliate, manager, member, employee or agent of a Member shall be liable for any debt,
obligation or liability of the Company or of any other Member or have any obligation to restore any deficit balance in its Capital Account solely by reason of being a Member of the Company, except to the extent required by the Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;This Agreement is not intended to, and does not, create or impose any duty (including any fiduciary duty) on
any of the Members (including the Managing Member) hereto or on their respective Affiliates. Further, notwithstanding any other provision of this Agreement or any duty otherwise existing at law or in equity, the parties hereto agree that no Member
or Managing Member shall, to the fullest extent permitted by law, have duties (including fiduciary duties) to any other Member or to the Company, and in doing so, recognize, acknowledge and agree that their duties and obligations to one another and
to the Company are only as expressly set forth in this Agreement; provided, however, that each Member shall have the duty to act in accordance with the implied contractual covenant of good faith and fair dealing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;To the extent that, at law or in equity, any Member (including the Managing Member) has duties (including
fiduciary duties) and liabilities relating thereto to the Company, to another Member or to another Person who is a party to or is otherwise bound by this Agreement, the Members (including the Managing Member) acting under this Agreement will not be
liable to the Company, to any such other Member or to any such other Person who is a party to or is otherwise bound by this Agreement, for their good faith reliance on the provisions of this Agreement. The provisions of this Agreement, to the extent
that they restrict or eliminate the duties and liabilities relating thereto of any Member (including the Managing Member) otherwise existing at law or in equity, are agreed by the Members to replace to that extent such other duties and liabilities
of the Members relating thereto (including the Managing Member). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;The Managing Member may consult with
legal counsel, accountants and financial or other advisors selected by it, and any act or omission taken by the Managing Member on behalf of the Company or in furtherance of the interests of the Company in good faith in reliance upon and in
accordance with the advice of such Person as to matters the Managing Member reasonably believes to be within such Person&#146;s professional or expert competence shall be conclusively presumed to have been done or omitted in good faith and in
accordance with such opinion or advice, and the Managing Member will be fully protected in so acting or omitting to act so long as such counsel or accountants or financial or other advisors were selected with reasonable care. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;To the fullest extent permitted by applicable Law, the doctrine of corporate opportunity, or any analogous
doctrine, shall not apply to (a)&nbsp;any Member that is not a director, manager, officer or employee of the Managing Member or any of their respective Subsidiaries, in which case solely acting in their capacity as such, (b)&nbsp;any of their
respective Affiliates (other than the Company, the Managing Member or any of their respective Subsidiaries), (c) any Person that was a Member immediately before the Closing or any of its respective Affiliates (including its respective investors and
equityholders and any associated Persons or investment funds or any of their respective portfolio companies or investments) or (d)&nbsp;any of the respective officers, managers, directors, agents, shareholders, members, and equityholders of any of
the foregoing (but in each case excluding any director, manager, officer or employee of the Managing Member or any of their respective Subsidiaries solely acting in their capacity as such) (each a &#147;<B><I>Business</I></B> <B><I>Opportunities
Exempt Party</I></B>&#148;). The Company and each of the Members, on its own behalf and on behalf of their respective Affiliates and equityholders, hereby renounces any interest or expectancy of the Company in, or in being offered an opportunity to
participate in, business opportunities that are from time to time presented to any Business Opportunities Exempt Party and irrevocably waives any right to require any Business Opportunity Exempt Party to act in a manner inconsistent with the
provisions of this <U>Section</U><U></U><U>&nbsp;10.01(e)</U>. No Business Opportunities Exempt Party who acquires knowledge </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-38- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of a potential transaction, agreement, arrangement or other matter that may be an opportunity for the Managing Member, the Company or any of their respective Subsidiaries, Affiliates or
equityholders shall have any duty to communicate or offer such opportunity to the Company and none of the Managing Member, the Company or any of their respective Subsidiaries, Affiliates or equityholders will acquire or be entitled to any interest
or participation in any such transaction, agreement, arrangement or other matter or opportunity as a result of participation therein by a Business Opportunity Exempt Party. This <U>Section</U><U></U><U>&nbsp;10.01(e)</U> shall not apply to, and no
interest or expectancy of the Company is renounced with respect to, any opportunity offered to any director or officer of the Managing Member or its Subsidiaries if such opportunity is expressly offered or presented to, or acquired or developed by,
such Person solely in his or her capacity as a director or officer of the Managing Member or its Subsidiaries. No amendment or repeal of this <U>Section</U><U></U><U>&nbsp;10.01(e)</U> shall apply to or have any effect on the liability or alleged
liability of any Business Opportunities Exempt Party for or with respect to any opportunities of which any such Business Opportunities Exempt Party becomes aware prior to such amendment or repeal. Any Person purchasing or otherwise acquiring any
interest in any Units shall be deemed to have notice of and consented to the provisions of this <U>Section</U><U></U><U>&nbsp;10.01(e)</U>. Neither the amendment or repeal of this <U>Section</U><U></U><U>&nbsp;10.01(e)</U>, nor the adoption of any
provision of this Agreement inconsistent with this <U>Section</U><U></U><U>&nbsp;10.01(e)</U>, shall eliminate or reduce the effect of this <U>Section</U><U></U><U>&nbsp;10.01(e)</U> in respect of any business opportunity first identified or any
other matter occurring, or any cause of action that, but for this <U>Section</U><U></U><U>&nbsp;10.01(e)</U>, would accrue or arise, prior to such amendment, repeal or adoption. No action or inaction taken by any Business Opportunities Exempt Party
in a manner consistent with this <U>Section</U><U></U><U>&nbsp;10.01(e)</U> shall be deemed to be a violation of any fiduciary or other duty owed to any Person. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_72"></A>10.02&nbsp;&nbsp;&nbsp;&nbsp;<B>Indemnification</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Exculpation and Indemnification</B>. Notwithstanding any other provision of this Agreement, whether
express or implied, to the fullest extent permitted by law, no Indemnitee shall be liable to the Company or any Member for any act or omission in relation to the Company or this Agreement or any transaction contemplated hereby taken or omitted by an
Indemnitee unless such Indemnitee&#146;s conduct constituted fraud, bad faith or willful misconduct. To the fullest extent permitted by law, as the same exists or hereafter be amended (but in the case of any such amendment, only to the extent that
such amendment permits the Company to provide broader indemnification rights than such law permitted the Company to provide prior to such amendment), the Company shall indemnify any Indemnitee who was or is made or is threatened to be made a party
to or is otherwise involved in any threatened, pending or completed action, suit or proceeding (brought in the right of the Company or otherwise), whether civil, criminal, administrative, arbitrative or investigative, and whether formal or informal
(hereinafter a &#147;<B><I>Proceeding</I></B>&#148;), including appeals, by reason of his or her or its status as an Indemnitee or by reason of any action alleged to have been taken or omitted to be taken by Indemnitee in such capacity, for and
against all loss and liability suffered and expenses (including attorneys&#146; fees), judgments, fines and amounts paid in settlement reasonably incurred by such Indemnitee in connection with such action, suit or proceeding, including appeals;
<I>provided</I> that such Indemnitee shall not be entitled to indemnification hereunder if, but only to the extent that, such Indemnitee&#146;s conduct constituted fraud, bad faith or willful misconduct. Notwithstanding the preceding sentence,
except as otherwise provided in <U>Section</U><U></U><U>&nbsp;10.02(c)</U>, the Company shall be required to indemnify an Indemnitee in connection with any action, suit or proceeding (or part thereof)&nbsp;(i) commenced by such Indemnitee only if
the commencement of such action, suit or proceeding (or part thereof) by such Indemnitee was authorized by the Managing Member, and (ii)&nbsp;by or in the right of the Company only if the Managing Member has provided its prior written consent. The
indemnification of any Indemnitee shall, to the extent not in conflict with such policy, be secondary to any and all payment to which such Indemnitee is entitled from any relevant insurance policy issued to or for the benefit of the Company or any
Indemnitee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Advancement of Expenses</B>. To the fullest extent permitted by law, the Company shall
promptly pay reasonable expenses (including attorneys&#146; fees) incurred by any Indemnitee in appearing at, participating in or defending any Proceeding in advance of the final disposition of such Proceeding, including appeals, upon presentation
of an undertaking on behalf of such Indemnitee to repay such amount if it shall ultimately be determined that such Indemnitee is not entitled to be indemnified under this <U>Section</U><U></U><U>&nbsp;10.02</U> or otherwise.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-39- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Notwithstanding the preceding sentence, except as otherwise provided in <U>Section</U><U></U><U>&nbsp;10.02(c)</U>, the Company shall be required to pay expenses of an Indemnitee in connection
with any Proceeding (or part thereof)&nbsp;(i) commenced by such Indemnitee only if the commencement of such action, suit or proceeding (or part thereof) by such Indemnitee was authorized by the Managing Member and (ii)&nbsp;by or in the right of
the Company only if the Managing Member has provided its prior written consent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Unpaid Claims</B>.
If a claim for indemnification (following the final disposition of such Proceeding) or advancement of expenses under this <U>Section</U><U></U><U>&nbsp;10.02</U> is not paid in full within 30 days after a written claim therefor by any Indemnitee has
been received by the Company, such Indemnitee may file proceedings to recover the unpaid amount of such claim and, if successful in whole or in part, shall be entitled to be paid the expense of prosecuting such claim. In any such action the Company
shall have the burden of proving that such Indemnitee is not entitled to the requested indemnification or advancement of expenses under applicable Law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Insurance</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B>&nbsp;&nbsp;&nbsp;&nbsp;To the fullest extent permitted by law, the Company may purchase and maintain insurance on behalf of any
Person described in <U>Section</U><U></U><U>&nbsp;10.02(a)</U> against any liability asserted against such person, whether or not the Company would have the power to indemnify such person against such liability under the provisions of this
<U>Section</U><U></U><U>&nbsp;10.02</U> or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B>&nbsp;&nbsp;&nbsp;&nbsp;In the event of any payment by the Company
under this <U>Section</U><U></U><U>&nbsp;10.02</U>, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of the Indemnitee from any relevant other Person or under any insurance policy issued to or for the
benefit of the Company, such relevant other Person, or any Indemnitee. Each Indemnitee agrees to execute all papers required and take all action necessary to secure such rights, including the execution of such documents as are necessary to enable
the Company to bring suit to enforce any such rights in accordance with the terms of such insurance policy or other relevant document. The Company shall pay or reimburse all expenses actually and reasonably incurred by the Indemnitee in connection
with such subrogation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B>&nbsp;&nbsp;&nbsp;&nbsp;The Company shall not be liable under this
<U>Section</U><U></U><U>&nbsp;10.02</U> to make any payment of amounts otherwise indemnifiable hereunder (including, but not limited to, judgments, fines and amounts paid in settlement, and excise taxes with respect to an employee benefit plan or
penalties) if and to the extent that the applicable Indemnitee has otherwise actually received such payment under this <U>Section</U><U></U><U>&nbsp;10.02</U> or any insurance policy, contract, agreement or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><FONT STYLE="white-space:nowrap">Non-Exclusivity</FONT> of Rights</B>. The provisions of this
<U>Section</U><U></U><U>&nbsp;10.02</U> shall be applicable to all actions, claims, suits or proceedings made or commenced after the date of this Agreement, whether arising from acts or omissions to act occurring before or after its adoption. The
provisions of this <U>Section</U><U></U><U>&nbsp;10.02</U> shall be deemed to be a contract between the Company and each person entitled to indemnification under this <U>Section</U><U></U><U>&nbsp;10.02</U> (or legal representative thereof) who
serves in such capacity at any time while this <U>Section</U><U></U><U>&nbsp;10.02</U> and the relevant provisions of applicable Law, if any, are in effect, and any amendment, modification or repeal hereof shall not affect any rights or obligations
then existing with respect to any state of facts or any action, suit or proceeding then or theretofore existing, or any action, suit or proceeding thereafter brought or threatened based in whole or in part on any such state of facts. If any
provision of this <U>Section</U><U></U><U>&nbsp;10.02</U> shall be found to be invalid or limited in application by reason of any law or regulation, it shall not affect the validity of the remaining provisions hereof. The rights of indemnification
provided in this <U>Section</U><U></U><U>&nbsp;10.02</U> shall neither be exclusive of, nor be deemed in limitation of, any rights to which any person may otherwise be or become entitled or permitted by contract, this Agreement or as a matter of
law, both as to actions in such person&#146;s official capacity and actions in any other capacity, it being the policy of the Company that indemnification of any person whom the Company is obligated to indemnify pursuant to
<U>Section</U><U></U><U>&nbsp;10.02(a)</U> shall be made to the fullest extent permitted by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">For purposes of this
<U>Section</U><U></U><U>&nbsp;10.02</U>, references to &#147;other enterprises&#148; shall include employee benefit plans; references to &#147;fines&#148; shall include any excise taxes assessed on a person with respect to an employee
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-40- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
benefit plan; and references to &#147;serving at the request of the Company&#148; shall include any service as a director, officer, employee or agent of the Company which imposes duties on, or
involves services by, such director, officer, employee, or agent with respect to an employee benefit plan, its participants, or beneficiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This <U>Section</U><U></U><U>&nbsp;10.02</U> shall not limit the right of the Company, to the extent and in the manner permitted by law, to
indemnify and to advance expenses to, and purchase and maintain insurance on behalf of, persons other than persons described in <U>Section</U><U></U><U>&nbsp;10.02(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_73"></A><B>10.03</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Survival</B>. The provisions of this <U>Article X</U> shall survive
the dissolution, liquidation, winding up and termination of the Company. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="annexitoc401831_74"></A>ARTICLE XI </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VALUATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_75">
</A><B>11.01</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Fair Market Value</B>. For all purposes of this Agreement, &#147;<B><I>Fair Market Value</I></B>&#148; of any asset, property or equity interest means the amount which a seller of such asset, property or
equity interest would receive in a sale of such asset, property or equity interest in an arms-length transaction with an unaffiliated third party consummated on a date determined by the Managing Member (which may be the date on which the event
occurred which necessitated the determination of the Fair Market Value) (and after giving effect to any transfer taxes payable in connection with such sale). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_76"></A><B>11.02</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Determination</B>. Fair Market Value shall be determined by the
Managing Member (or, if pursuant to <U>Section</U><U></U><U>&nbsp;9.03</U>, the Liquidation Agent) in its good faith judgment in such manner as it deems reasonable and using all factors, information and data deemed to be pertinent; provided that, no
determination of Fair Market Value shall give effect or take into account any &#147;minority discount&#148; or &#147;liquidity discount&#148; (or any similar discount arising out of the fact that the Units are restricted or is not registered with
the Commission, publicly traded or listed on a securities exchange), but shall value the Company and its Subsidiaries and their respective businesses in their entirety on an enterprise basis using any variety of industry recognized valuation
techniques commonly used to value businesses. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="annexitoc401831_77"></A>ARTICLE XII </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MISCELLANEOUS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_78">
</A>12.01&nbsp;&nbsp;&nbsp;&nbsp;<B>Severability</B>. If any term or other provision of this Agreement is held to be invalid, illegal or incapable of being enforced by any rule of Law, or public policy, all other conditions and provisions of this
Agreement shall nevertheless remain in full force and effect so long as the economic or legal substance of the transactions is not affected in any manner materially adverse to any party. Upon a determination that any term or other provision is
invalid, illegal or incapable of being enforced, the parties hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in a mutually acceptable manner in order that the
transactions contemplated hereby be consummated as originally contemplated to the fullest extent possible. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-41- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_79"></A>12.02&nbsp;&nbsp;&nbsp;&nbsp;<B>Notices</B>. All notices,
requests, claims, demands and other communications hereunder shall be in writing and shall be given (and shall be deemed to have been duly given upon receipt) by delivery in person, by courier service (delivery receipt requested), by electronic mail
or by registered or certified mail (postage prepaid, return receipt requested) to the respective parties at the following addresses (or at such other address for a party as shall be specified in a notice given in accordance with this
<U>Section</U><U></U><U>&nbsp;12.02</U>): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> If to the Company, to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Cibus Global, LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">6455 Nancy
Ridge Drive </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">San Diego, CA 92121 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Rory Riggs, Chief Executive Officer, and Wade King, MD, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Chief Financial Officer </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">E-mail:&nbsp;&nbsp;&nbsp;&nbsp;</FONT> [***] and [***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">with a copy (which shall not constitute notice) to:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Jones Day </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">4655 Executive
Drive, Suite 1500 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">San Diego, CA 92121-3134 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Cameron A. Reese </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">E-mail:</FONT> [***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Akin Gump Strauss Hauer&nbsp;&amp; Feld LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">One Bryant Park </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">New York, NY
10036 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Stuart Leblang and Jonathan Pavlich </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: [***] and [***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> If to any Member other than the Managing Member, to such Member at the address of such Member as set forth on <B>Exhibit A</B>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> If to the Managing Member, to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Cibus, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">6455 Nancy Ridge
Drive </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">San Diego, CA 92121 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Rory Riggs, Chief Executive Officer, and Wade King, MD, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Chief Financial Officer </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">E-mail:&nbsp;&nbsp;&nbsp;&nbsp;</FONT> [***] and [***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">with a copy (which shall not constitute notice) to:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Jones Day </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">4655 Executive
Drive, Suite 1500 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">San Diego, CA 92121-3134 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Cameron A. Reese </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">E-mail:</FONT> [***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_80"></A>12.03<B>&nbsp;&nbsp;&nbsp;&nbsp;Cumulative Remedies</B>.
The rights and remedies provided by this Agreement are cumulative and the use of any one right or remedy by any party shall not preclude or waive its right to use any or all other remedies. Said rights and remedies are given in addition to any other
rights the parties may have by Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-42- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_81"></A>12.04&nbsp;&nbsp;&nbsp;&nbsp;<B>Binding Effect</B>. This
Agreement shall be binding upon and inure to the benefit of all of the parties and, to the extent permitted by this Agreement, their successors, executors, administrators, heirs, legal representatives and assigns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_82"></A>12.05&nbsp;&nbsp;&nbsp;&nbsp;<B>Interpretation</B>. Throughout this Agreement, nouns, pronouns and verbs
shall be construed as masculine, feminine, neuter, singular or plural, whichever shall be applicable. Unless otherwise specified, all references herein to &#147;Articles,&#148; &#147;Sections&#148; and paragraphs shall refer to corresponding
provisions of this Agreement. The word &#147;including&#148; or any variation thereof means &#147;including, without limitation&#148; and shall not be construed to limit any general statement that it follows to the specific or similar items or
matters immediately following it. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Each party hereto acknowledges and agrees that the parties hereto have participated collectively in the
negotiation and drafting of this Agreement and that he or she or it has had the opportunity to draft, review and edit the language of this Agreement; accordingly, it is the intention of the parties that no presumption for or against any party
arising out of drafting all or any part of this Agreement will be applied in any dispute relating to, in connection with or involving this Agreement. Accordingly, the parties hereby waive to the fullest extent permitted by law the benefit of any
rule of law or any legal decision that would require that in cases of uncertainty, the language of a contract should be interpreted most strongly against the party who drafted such language. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_83"></A>12.06&nbsp;&nbsp;&nbsp;&nbsp;<B>Counterparts</B>. This Agreement may be executed and delivered (including by
email or facsimile transmission) in one or more counterparts, and by the different parties hereto in separate counterparts, each of which when executed and delivered shall be deemed to be an original but all of which taken together shall constitute
one and the same agreement. Copies of executed counterparts transmitted by telecopy or other electronic transmission service shall be considered original executed counterparts for purposes of this <U>Section</U><U></U><U>&nbsp;12.06</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_84"></A>12.07&nbsp;&nbsp;&nbsp;&nbsp;<B>Further Assurances</B>. Each Member shall perform all other acts and execute
and deliver all other documents as may be necessary or appropriate to carry out the purposes and intent of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_85">
</A>12.08&nbsp;&nbsp;&nbsp;&nbsp;<B>Entire Agreement</B>. This Agreement and the agreements referred to herein constitutes the entire agreement among the parties hereto pertaining to the subject matter hereof and supersedes all prior agreements and
understandings, whether oral or written, pertaining thereto (including the Existing Agreement). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_86"></A>12.09&nbsp;&nbsp;&nbsp;&nbsp;<B>Governing Law</B>. This Agreement shall be governed by, and construed in
accordance with, the Law of the State of Delaware. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_87"></A>12.10&nbsp;&nbsp;&nbsp;&nbsp;<B>Submission to
Jurisdiction; Waiver of Jury Trial</B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;Any and all disputes which cannot be settled amicably with
respect to this Agreement, including any action (at law or in equity), claim, litigation, suit, arbitration, hearing, audit, review, inquiry, proceeding or investigation or ancillary claims of any party, arising out of, relating to or in connection
with the validity, negotiation, execution, interpretation, performance or <FONT STYLE="white-space:nowrap">non-performance</FONT> of this Agreement or any matter arising out of or in connection with this Agreement and the rights and obligations
arising hereunder or thereunder, or for recognition and enforcement of any judgment in respect of this Agreement and the rights and obligations arising hereunder or thereunder brought by a party hereto or its successors or assigns, shall be brought
and determined exclusively in the Delaware Chancery Court, if such court shall not have jurisdiction, any federal court located in the State of Delaware, or, if neither of such courts shall have jurisdiction, any other Delaware state court. Each of
the parties hereby irrevocably submits with regard to any such dispute for itself and in respect of its property, generally and unconditionally, to the sole and exclusive personal jurisdiction of the aforesaid courts and agrees that it will not
bring any dispute relating to this Agreement or any of the transactions contemplated by this Agreement in any court other than the aforesaid courts. Each party irrevocably consents to service of process in
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-43- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any dispute in any of the aforesaid courts by the mailing of copies thereof by registered or certified mail, postage prepaid, or by recognized overnight delivery service, to such party at such
party&#146;s address referred to in <U>Section</U><U></U><U>&nbsp;12.02</U>. Each party hereby irrevocably and unconditionally waives, and agrees not to assert as a defense, counterclaim or otherwise, in any action brought by any party with respect
to this Agreement (i)&nbsp;any claim that it is not personally subject to the jurisdiction of the aforesaid courts for any reason other than the failure to serve process in accordance with this <U>Section</U><U></U><U>&nbsp;12.10</U>; (ii) any claim
that it or its property is exempt or immune from the jurisdiction of any such court or from any legal process commenced in such courts (whether through service of notice, attachment prior to judgment, attachment in aid of execution of judgment,
execution of judgment or otherwise); or (iii)&nbsp;any objection which such party may now or hereafter have (A)&nbsp;to the laying of venue of any of the aforesaid actions arising out of or in connection with this Agreement brought in the courts
referred to above; (B)&nbsp;that such action brought in any such court has been brought in an inconvenient forum and (C)&nbsp;that this Agreement, or the subject matter hereof or thereof, may not be enforced in or by such courts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;To the extent that any party has or hereafter may acquire any immunity from jurisdiction of any court or
from any legal process (whether through service or notice, attachment prior to judgment, attachment in aid of execution, execution or otherwise) with respect to itself, or to such party&#146;s property, each such party hereby irrevocably waives such
immunity in respect of such party&#146;s obligations with respect to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;EACH PARTY
ACKNOWLEDGES THAT IT IS KNOWINGLY AND VOLUNTARILY AGREEING TO THE CHOICE OF DELAWARE LAW TO GOVERN THIS AGREEMENT AND TO THE JURISDICTION OF DELAWARE COURTS IN CONNECTION WITH PROCEEDINGS BROUGHT HEREUNDER. THE PARTIES INTEND THIS TO BE AN EFFECTIVE
CHOICE OF DELAWARE LAW AND AN EFFECTIVE CONSENT TO JURISDICTION AND SERVICE OF PROCESS UNDER 6 DEL. C. &#167; 2708. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;EACH PARTY, FOR ITSELF AND ITS AFFILIATES, HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES TO THE FULLEST
EXTENT PERMITTED BY APPLICABLE LAW ALL RIGHT TO TRIAL BY JURY IN ANY ACTION OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THE ACTIONS OF THE PARTIES OR THEIR RESPECTIVE AFFILIATES PURSUANT TO THIS
AGREEMENT OR THE OTHER TRANSACTION DOCUMENTS IN THE NEGOTIATION, ADMINISTRATION, PERFORMANCE OR ENFORCEMENT HEREOF OR THEREOF. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_88">
</A>12.11&nbsp;&nbsp;&nbsp;&nbsp;<B>[Intentionally Omitted].</B> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><A NAME="annexitoc401831_89"></A>12.12&nbsp;&nbsp;&nbsp;&nbsp;Amendments and Waivers. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;This Agreement (including the Annexes hereto) may be amended, supplemented, waived or modified by the
Managing Member in its sole discretion without the approval of any other Member or other Person so long as such amendment is executed and delivered to the Company by (i)&nbsp;so long as Rory Riggs owns at least 50% of the Common Units owned by him
immediately following the Closing, Rory Riggs or (ii)&nbsp;if Rory Riggs no longer owns at least 50% of the Common Units owned by him immediately following the Closing, Members holding greater than 50% of the Common Percentage Interest (excluding,
for purposes of this calculation, Common Units then owned by the Managing Member); <I>provided</I> that, no amendment, including any amendment effected by way of merger, consolidation or Transfer of all or substantially all the assets of the
Company, may (i)&nbsp;materially and adversely affect the rights of a holder of Units, as such, other than on a <I>pro rata</I> basis with other holders of Units of the same Class&nbsp;without the consent of such holder (or, if there is more than
one such holder that is so affected, without the consent of a majority in interest of such affected holders in accordance with their holdings of such Class&nbsp;of Units), <I>provided</I> that, the creation or issuance of any new Unit or Equity
Interest of the Company permitted pursuant to <U>Section</U><U></U><U>&nbsp;7.04</U> and any amendments or modifications to Agreement to the extent necessary to reflect such creation or issuance shall not be deemed to disproportionately and
adversely affect a Member or remove a right or privilege specifically granted to a Member in any event; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-44- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(ii)&nbsp;modify the limited liability of any Member, or increase the liabilities of any Member, in each case, without the prior written consent of each such affected Member; or (iii)&nbsp;alter
or change any rights, preferences or privileges of any Units in a manner that is different or prejudicial relative to any other Units in the same class of Units, without the prior written consent of the holders of a majority of such Units. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding anything to the contrary herein, the Managing Member may, without the written consent of any
Member or any other Person, amend, supplement, waive or modify any provision of this Agreement, including <B>Exhibit A</B>, and execute, swear to, acknowledge, deliver, file and record whatever documents may be required in connection therewith, to
reflect: (1)&nbsp;any amendment, supplement, waiver or modification that the Managing Member determines in its reasonable discretion to be necessary or appropriate in connection with the creation, authorization or issuance of Units or any
Class&nbsp;or series of equity interest in the Company pursuant to <U>Section</U><U></U><U>&nbsp;7.01</U> hereof; (2)&nbsp;the admission, substitution, or withdrawal of Members in accordance with this Agreement, pursuant to
<U>Section</U><U></U><U>&nbsp;8.08</U> hereof; (3)&nbsp;a change in the name of the Company, the location of the principal place of business of the Company, the registered agent of the Company or the registered office of the Company; (4)&nbsp;any
amendment, supplement, waiver or modification that the Managing Member determines in its reasonable discretion to be necessary or appropriate to address changes in U.S. federal income tax regulations, legislation or interpretation; and/or (5)&nbsp;a
change in the Fiscal Year or taxable year of the Company and any other changes that the Managing Member determines to be necessary or appropriate as a result of a change in the Fiscal Year or taxable year of the Company including a change in the
dates on which Distributions are to be made by the Company. If an amendment has been approved in accordance with this agreement, such amendment shall be adopted and effective with respect to all Members. Upon obtaining such approvals as may be
required by this Agreement, and without further action or execution on the part of any Member or other Person, any amendment to this Agreement may be implemented and reflected in a writing executed solely by the Managing Member and the Members shall
be deemed a party to and bound by such amendment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;No failure or delay by any party in exercising any
right, power or privilege hereunder (other than a failure or delay beyond a period of time specified herein) shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the
exercise of any other right, power or privilege. The rights and remedies herein provided shall be cumulative and not exclusive of any rights or remedies provided by Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;Except as may be otherwise required by law in connection with the
<FONT STYLE="white-space:nowrap">winding-up,</FONT> liquidation, or dissolution of the Company, each Member hereby irrevocably waives any and all rights that it may have to maintain an action for judicial accounting or for partition of any of the
Company&#146;s property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_90"></A>12.13&nbsp;&nbsp;&nbsp;&nbsp;<B>No Third Party Beneficiaries</B>. This
Agreement shall be binding upon and inure solely to the benefit of the parties hereto and their permitted assigns and successors and nothing herein, express or implied, is intended to or shall confer upon any other Person or entity, any legal or
equitable right, benefit or remedy of any nature whatsoever under or by reason of this Agreement (other than pursuant to <U>Section</U><U></U><U>&nbsp;10.02</U> hereof); <I>provided</I>,<I> however</I>, that each employee, officer, director, agent
or indemnitee of any Person who is bound by this Agreement or its Affiliates is an intended third party beneficiary of <U>Section</U><U></U><U>&nbsp;12.10</U> and shall be entitled to enforce its rights thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_91"></A>12.14&nbsp;&nbsp;&nbsp;&nbsp;<B>Headings</B>. The headings and subheadings in this Agreement are included for
convenience and identification only and are in no way intended to describe, interpret, define or limit the scope, extent or intent of this Agreement or any provision hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_92"></A>12.15&nbsp;&nbsp;&nbsp;&nbsp;<B>Power of Attorney</B>. Each Member, by its execution hereof, hereby makes,
constitutes and appoints the Managing Member as its true and lawful agent and attorney in fact, with full power of substitution and full power and authority in its name, place and stead, to make, execute, sign, acknowledge, swear to, record and file
(a)&nbsp;this Agreement and any amendment to this Agreement that has been consented to and adopted as herein </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-45- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
provided; (b)&nbsp;all amendments to the Certificate required or permitted by law or the provisions of this Agreement; (c)&nbsp;all certificates and other instruments (including consents and
ratifications which the Members have agreed to provide upon a matter receiving the agreed support of Members) deemed advisable by the Managing Member to carry out the provisions of this Agreement and Law or to permit the Company to become or to
continue as a limited liability company or entity wherein the Members have limited liability in each jurisdiction where the Company may be doing business; (d)&nbsp;all instruments that the Managing Member deems appropriate to reflect a change or
modification of this Agreement or the Company in accordance with this Agreement, including the admission of additional Members or substituted Members pursuant to the provisions of this Agreement; (e)&nbsp;all conveyances and other instruments or
papers deemed advisable by the Managing Member to effect the liquidation and termination of the Company; and (f)&nbsp;all fictitious or assumed name certificates required or permitted (in light of the Company&#146;s activities) to be filed on behalf
of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_93"></A>12.16&nbsp;&nbsp;&nbsp;&nbsp;<B>Separate Agreements; </B><B>Schedules</B>.
Notwithstanding any other provision of this Agreement, including <U>Section</U><U></U><U>&nbsp;12.12</U>, the Managing Member in its sole discretion may, or may cause the Company to, without the approval of any Member or other Person, enter into
separate subscription, letter or other agreements with individual Members that have become or will become Members after the date hereof with respect to any matter, which have the effect of establishing rights under, or altering, supplementing or
amending the terms of, this Agreement. The parties hereto agree that any terms contained in any such separate agreement shall govern with respect to such future Member(s) party thereto notwithstanding the provisions of this Agreement. The Managing
Member in its sole discretion may from time to time execute and deliver to the Members schedules which set forth information contained in the books and records of the Company and any other matters deemed appropriate by the Managing Member. Such
schedules shall be for information purposes only and shall not be deemed to be part of this Agreement for any purpose whatsoever. Notwithstanding anything to the contrary, solely for U.S. federal income tax purposes, this Agreement, the Tax
Receivable Agreement, the Exchange Agreement and any other separate agreement described in this <U>Section</U><U></U><U>&nbsp;12.16</U> shall constitute a &#147;partnership agreement&#148; within the meaning of Section&nbsp;761 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_94"></A>12.17&nbsp;&nbsp;&nbsp;&nbsp;<B>Partnership Status</B>. The Members intend to treat the Company as a
partnership for U.S. federal income tax purposes and notwithstanding anything to the contrary herein, no election to the contrary shall be made. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A NAME="annexitoc401831_95"></A>12.18&nbsp;&nbsp;&nbsp;&nbsp;<B>Delivery by Facsimile or Email</B>. This Agreement, the agreements referred
to herein, and each other agreement or instrument entered into in connection herewith or therewith or contemplated hereby or thereby, and any amendments hereto or thereto, to the extent signed and delivered by means of a facsimile machine or email
with scan or facsimile attachment, shall be treated in all manner and respects as an original agreement or instrument and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in
person. No party hereto or to any such agreement or instrument shall raise the use of a facsimile machine or email to deliver a signature or the fact that any signature or agreement or instrument was transmitted or communicated through the use of a
facsimile machine or email as a defense to the formation or enforceability of a contract, and each such party forever waives any such defense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[R<SMALL>EMAINDER</SMALL> <SMALL>OF</SMALL> P<SMALL>AGE</SMALL> I<SMALL>NTENTIONALLY</SMALL> L<SMALL>EFT</SMALL> B<SMALL>LANK</SMALL>]
</B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-46- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>, the
parties hereto have entered into this Agreement or have caused this Agreement to be duly executed by their respective authorized officers, in each case as of the date first above stated. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>COMPANY:</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CIBUS&nbsp;GLOBAL,&nbsp;LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page -
Third Amended and Restated Limited Liability Company Agreement Cibus</I> <I>Global, LLC]</I> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>, the
parties hereto have entered into this Agreement or have caused this Agreement to be duly executed by their respective authorized officers, in each case as of the date first above stated. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MANAGING&nbsp;MEMBER:</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CIBUS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page -
Third Amended and Restated Limited Liability Company Agreement Cibus</I> <I>Global, LLC]</I> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>, the
parties hereto have entered into this Agreement or have caused this Agreement to be duly executed by their respective authorized officers, in each case as of the date first above stated. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>MEMBERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page -
Third Amended and Restated Limited Liability Company Agreement Cibus</I> <I>Global, LLC]</I> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[See attached] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="rom401831_75"></A>ANNEX J </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CERTIFICATE OF AMENDMENT </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">TO THE
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">AMENDED AND RESTATED </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CERTIFICATE OF INCORPORATION </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">OF
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CALYXT, INC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Calyxt, Inc., a corporation
organized and existing under the laws of the State of Delaware, does hereby certify as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The name of the Corporation is Calyxt, Inc (the &#147;Corporation&#148;). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Amended and Restated Certificate of Incorporation of the Corporation was filed with the Secretary of State
of the State of Delaware on July&nbsp;25, 2017. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pursuant to and in accordance with Section&nbsp;242 of the General Corporation Law of the State of Delaware,
this Certificate of Amendment hereby further amends the provisions of the Amended and Restated Certificate of Incorporation of the Corporation to amend and restate in its entirety Section&nbsp;1 of Article 4 as follows: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;Section&nbsp;1. The total number of shares of stock which the Corporation shall have authority to issue is 325,000,000, consisting of
275,000,000 shares of common stock, par value $0.0001 per share (the &#147;Common Stock&#148;), and 50,000,000 shares of preferred stock, par value $0.0001 per share (the &#147;Preferred Stock&#148;). Upon filing and effectiveness of this
Certificate of Amendment with the Secretary of State of Delaware (the &#147;Effective Time&#148;), every [&#9679;]<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> issued and outstanding shares of Common Stock shall without further action by
this Corporation or the holder thereof be combined into and automatically become one share of Common Stock (the &#147;Reverse Stock Split&#148;). The number of authorized shares of Common Stock of the Corporation and the par value of the Common
Stock shall remain as set forth in this Amended and Restated Certificate of Incorporation, as amended. No fractional shares of Common Stock shall be issued in connection with the Reverse Stock Split. In lieu of any fractional shares of Common Stock
to which a stockholder would otherwise be entitled (after taking into account all fractional shares of Common Stock otherwise issuable to such holder), all fractional shares of Common Stock resulting from the Reverse Stock Split shall be rounded up
to the nearest whole share of Common Stock. The capital of the Corporation will not be reduced under or by reason of any amendment herein certified.&#148; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Certificate of Amendment shall become effective as of
[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ] at [a.m./p.m.]. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Certificate of Amendment was duly proposed and adopted in accordance with the provisions of
Section&nbsp;242 of the General Corporation Law of the State of Delaware and the affirmative vote of the holders of a majority of the Corporation&#146;s outstanding stock entitled to vote thereon. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * * * </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be a whole number of shares of Calyxt&#146;s Common Stock between and including 2 and 10. If the reverse
stock split proposal is approved by stockholders, the Certificate of Amendment filed with the Secretary of State of the State of Delaware will include only that reverse stock split ratio determined by Calyxt&#146;s Board of Directors to be in the
best interests of Calyxt and its stockholders. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, this Certificate of Amendment to the Amended and Restated Certificate of
Incorporation has been executed by a duly authorized officer of this Corporation on this day of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; . </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">CALYXT, INC.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="rom401831_76"></A>ANNEX K </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CIBUS, INC. 2017 OMNIBUS INCENTIVE PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(F/K/A CALYXT, INC. 2017 OMNIBUS INCENTIVE PLAN) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AS AMENDED, EFFECTIVE
[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 2023) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. <B><U>Purposes
of the Plan</U></B>. The purposes of this Omnibus Incentive Plan are to attract and retain the best available personnel for positions of substantial responsibility, to provide additional incentive to Employees and Consultants, and to promote the
success of the Company&#146;s business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. <B><U>Definitions</U></B>. As used herein, the following definitions shall apply: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Administrator</U></B>&#148; means the Board or a Committee. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Affiliate</U></B>&#148; means an entity other than a Subsidiary which, together with the Company,
is under common control of a third person or entity. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Applicable Laws</U></B>&#148; means all applicable laws, rules, regulations and requirements,
including, but not limited to, all applicable U.S. federal or state laws, any Stock Exchange rules or regulations, and the applicable laws, rules or regulations of any other country or jurisdiction where Awards are granted under the Plan or
Participants reside or provide services, as such laws, rules and regulations shall be in effect from time to time. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Award</U></B>&#148; means any award of a Nonstatutory Stock Option, Incentive Stock Option, SAR,
Restricted Stock, RSU, Performance Award, Deferred Award, Other Cash-Based Award or Other Share-Based Award under the Plan. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Award Agreement</U></B>&#148; means a written document, the form(s) of which shall be approved from
time to time by the Administrator, reflecting the terms of an Award granted under the Plan and includes any documents attached to or incorporated into such Award Agreement, including, but not limited to, a notice of award grant and a form of
exercise notice. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Board</U></B>&#148; means the Board of Directors of the Company. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Cashless Exercise</U></B>&#148; means a program approved by the Administrator in which payment of
the Option exercise price or tax withholding obligations may be satisfied, in whole or in part, with Shares subject to the Option, including by delivery of an irrevocable direction to a securities broker (on a form prescribed by the Administrator)
to sell Shares and to deliver all or part of the sale proceeds to the Company in payment of the aggregate exercise price and, if applicable, the amount necessary to satisfy the Company&#146;s withholding obligations. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Cause</U></B>&#148; for termination of a Participant&#146;s Continuous Service Status will exist
(unless another definition is provided in an applicable Award Agreement, employment agreement or other applicable written agreement) if the Participant&#146;s Continuous Service Status is terminated for any of the following reasons: (i)&nbsp;the
Participant&#146;s willful failure to perform his or her duties and responsibilities to the Company or the Participant&#146;s violation of any written Company policy; (ii)&nbsp;the Participant&#146;s commission of any act of fraud, embezzlement,
dishonesty or any other willful misconduct that has caused or is reasonably expected to result in injury to the Company; (iii)&nbsp;the Participant&#146;s unauthorized use or disclosure of any proprietary information or trade secrets of the Company
or any other party to whom the Participant owes an obligation of nondisclosure as a result of his or her relationship with the Company; or (iv)&nbsp;the Participant&#146;s material breach of any of his or her obligations under any written agreement
or covenant with the Company. The determination as to whether a Participant&#146;s Continuous Service Status has been terminated for Cause shall be made in good faith by the Company and shall be final and binding on the Participant. The foregoing
definition does not in any way limit the Company&#146;s ability to terminate a Participant&#146;s employment or consulting relationship at any time, and the term &#147;Company&#148; shall be interpreted to include any Subsidiary, Parent, Affiliate,
or any successor thereto, if appropriate. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Code</U></B>&#148; means the Internal Revenue Code of 1986, as amended. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Committee</U></B>&#148; means one or more committees or subcommittees of the Board consisting of
two (2)&nbsp;or more Directors (or such lesser or greater number of Directors as shall constitute the minimum number permitted by Applicable Laws to establish a committee or subcommittee of the Board) appointed by the Board to administer the Plan in
accordance with Section&nbsp;4 below. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(k)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Common Stock</U></B>&#148; means the Company&#146;s common stock, par value $0.0001 per share, as
adjusted in accordance with Section&nbsp;17 below. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(l)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Company</U></B>&#148; means Cibus, Inc., a Delaware corporation (formerly Calyxt, Inc.).
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(m)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Consultant</U></B>&#148; means any person, including an advisor but not an Employee, who is engaged
by the Company, or any Parent, Subsidiary or Affiliate, to provide services (other than capital-raising services), and is compensated for such services, including any Director and any member of the supervisory board or director of any Affiliate or
Parent, whether compensated for such services or not. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(n)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Continuous Service Status</U></B>&#148; means the absence of any interruption or termination of
service as an Employee, Director or Consultant, or as a director of a Parent. Continuous Service Status as an Employee, Director or Consultant, or a director of a Parent shall not be considered interrupted or terminated in the case of:
(i)&nbsp;Company-approved sick leave; (ii)&nbsp;military leave; or (iii)&nbsp;any other bona fide leave of absence approved by the Administrator; <I>provided</I> that such leave is for a period of not more than ninety (90)&nbsp;days, unless
reemployment upon the expiration of such leave is guaranteed by contract or statute, or unless provided otherwise pursuant to a written Company policy. Continuous Service Status as an Employee, Director or Consultant, or as a director of a Parent,
shall not be considered interrupted or terminated in the case of a transfer of employment or location between the Company, and any of its Parents, Subsidiaries or Affiliates, or their respective successors, or a change in status from an Employee to
a Consultant or from a Consultant to an Employee. Notwithstanding the foregoing, the &#147;Continuous Service Status&#148; of an individual who is nominated to become a Director and is not an Employee or Consultant or a director of a Parent shall be
considered to begin on the date such individual begins providing services as a Director; <I>provided</I> that if such individual does not begin providing services within twelve (12)&nbsp;months of the date of grant of an Award, such individual shall
not be considered to have begun Continuous Service Status. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(o)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Current Parent</U></B>&#148; means a person that is a Parent as of June&nbsp;14, 2017, or any other
Person in which a Current Parent owns, directly or indirectly, equity securities possessing than fifty percent (50%) or more of the total combined voting power of all classes of stock. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(p)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Deferred Award</U></B>&#148; shall mean an Award granted pursuant to Section&nbsp;12.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(q)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Director</U></B>&#148; means a member of the Board. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(r)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Disability</U></B>&#148; means &#147;disability&#148; within the meaning of Section&nbsp;22(e)(3)
of the Code. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(s)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Employee</U></B>&#148; means any person employed by the Company, or any Parent, Subsidiary or
Affiliate, under the terms and conditions of an employment contract or with the status of employment determined pursuant to such factors as are deemed appropriate by the Administrator in its sole discretion, subject to any requirements of the
Applicable Laws, including the Code. The payment by the Company of a director&#146;s fee shall not be sufficient to constitute &#147;employment&#148; of such director by the Company or any Parent, Subsidiary or Affiliate. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(t)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Exchange Act</U></B>&#148; means the Securities Exchange Act of 1934, as amended.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(u)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Fair Market Value</U></B>&#148; means (i)&nbsp;with respect to Shares, the per share closing price
for the Shares on the applicable date (or, if there is no reported sale on such date, on the last preceding date on which any reported sale occurred) as reported in the <U>Wall Street Journal</U> on the principal stock market or exchange on which
the Shares are quoted or trade, or if Shares are not so quoted or traded, fair market value of a Share, as determined by the Administrator in good faith on such basis as it deems appropriate and applied consistently with respect to Participants, and
(ii)&nbsp;with respect to property other than Shares, the fair market </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;2&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
value of such properly determined by such methods or procedures as shall be established from time to time by the Administrator. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Family Member</U></B>&#148; means any child, stepchild, grandchild, parent, stepparent,
grandparent, spouse, former spouse, sibling, niece, nephew, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mother-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">father-in-law,</FONT></FONT>
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">son-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">daughter-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">brother-in-law</FONT></FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">sister-in-law</FONT></FONT> (including adoptive relationships) of the Participant, any person sharing the Participant&#146;s
household (other than a tenant or employee), a trust in which these persons (or the Participant) have more than fifty percent (50%) of the beneficial interest, a foundation in which these persons (or the Participant) control the management of
assets, and any other entity in which these persons (or the Participant) own more than fifty percent (50%) of the voting interests. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(w)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Incentive Stock Option</U></B>&#148; means an Option intended to qualify as an incentive stock
option within the meaning of Section&nbsp;422 of the Code, as designated in the applicable Award Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(x)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Listed Security</U></B>&#148; means any security of the Company that is listed or approved for
listing on a national securities exchange. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(y)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Nonstatutory Stock Option</U></B>&#148; means an Option not intended to qualify as an Incentive
Stock Option, as designated in the applicable Award Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(z)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Option</U></B>&#148; means an option representing the right to purchase Shares from the Company,
granted pursuant to Section&nbsp;8 of the Plan. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(aa)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Parent</U></B>&#148; means, subject to Section&nbsp;20(a) of the Plan, any corporation (other than
the Company) in an unbroken chain of corporations above the Company and ending with the Company if, at the time of grant of the Award, each of the corporations other than the Company owns stock possessing fifty percent (50%) or more of the total
combined voting power of all classes of stock in one of the other corporations in such chain. A corporation that attains the status of a Parent on a date after the adoption of the Plan shall be considered a Parent commencing as of such date.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(bb)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Participant</U></B>&#148; means any holder of one or more Awards or Shares issued pursuant to an
Award. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(cc)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Performance Award</U></B>&#148; means an Award granted pursuant to Section&nbsp;11.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(dd)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Performance Period</U></B>&#148; means the period established by the Administrator at the time any
Performance Award is granted or at any time thereafter during which any performance goals specified by the Administrator with respect to such Award are measured. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ee)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Plan</U></B>&#148; means this Cibus, Inc. 2017 Omnibus Incentive Plan (f/k/a Calyxt, Inc. 2017
Omnibus Incentive Plan), as amended. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ff)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Restricted Stock</U></B>&#148; means any Share granted pursuant to Section&nbsp;10.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(gg)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Restricted Stock Unit</U></B>&#148; or &#147;<B><U>RSU</U></B>&#148; means a contractual right
granted pursuant to Section&nbsp;10 that is denominated in Shares. Each RSU represents a right to receive the value of one Share (or a percentage of such value) in cash, Shares or a combination thereof. Awards of RSUs may include the right to
receive dividend equivalents. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(hh)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Share Appreciation Right</U></B>&#148; or &#147;<B><U>SAR</U></B>&#148; means any right granted
pursuant to Section&nbsp;9 to receive upon exercise by the Participant or settlement, in cash, Shares or a combination thereof, the excess of (i)&nbsp;the Fair Market Value of one Share on the date of exercise or settlement over (ii)&nbsp;the
exercise or hurdle price of the right on the date of grant, or if granted in connection with an Option, on the date of grant of the Option. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Share</U></B>&#148; means a share of Common Stock, as adjusted in accordance with Section&nbsp;17
below. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(jj)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Successor Corporation</U></B>&#148; means a successor corporation or a parent or subsidiary of such
successor corporation. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(kk)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Stock Exchange</U></B>&#148; means any stock exchange or consolidated stock price reporting system
on which prices for the Common Stock are quoted at any given time. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;3&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ll)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Subsidiary</U></B>&#148; means, subject to Section&nbsp;20(a) of the Plan, any corporation (other
than the Company) in an unbroken chain of corporations beginning with the Company if, at the time of grant of the Award, each of the corporations other than the last corporation in the unbroken chain owns stock possessing fifty percent (50%) or more
of the total combined voting power of all classes of stock in one of the other corporations in such chain. A corporation that attains the status of a Subsidiary on a date after the adoption of the Plan shall be considered a Subsidiary commencing as
of such date. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(mm)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Substitute Award</U></B>&#148; means an Award granted in assumption of, or in substitution for, an
outstanding award previously granted by a company or other business acquired by the Company or with which the Company combines. Any such assumption or substitution will be effective as of the close of the applicable transaction, and, to the extent
applicable, will be conducted in a manner that complies with Section&nbsp;409A of the Code. A Substitute Award may reflect the original terms of the award being assumed or substituted for and need not comply with other specific terms of this Plan,
and may account for Shares substituted for the securities covered by the original awards and the number of shares subject to the original awards, as well as any exercise or purchase prices applicable to the original awards, adjusted to account for
differences in stock prices in connection with the transaction. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(nn)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Ten Percent Holder</U></B>&#148; means a person who owns stock representing more than ten percent
(10%) of the voting power of the outstanding shares of all classes of stock of the Company or any Parent or Subsidiary, measured as of an Award&#146;s date of grant. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(oo)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B><U>Triggering Event</U></B>&#148; means </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">(i) a sale, transfer or disposition of all or substantially all of the Company&#146;s assets other than to (A)&nbsp;a corporation or other
entity of which at least a majority of its combined voting power is owned directly or indirectly by the Company, (B)&nbsp;a corporation or other entity owned directly or indirectly by the holders of capital stock of the Company in substantially the
same proportions as their ownership of Common Stock, or (C)&nbsp;an Excluded Entity (as defined in subsection (ii)&nbsp;below); or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">(ii)
any merger, consolidation or other business combination transaction of the Company with or into another corporation, entity or person, other than a transaction with or into another corporation, entity or person in which the holders of at least a
majority of the shares of voting capital stock of the Company outstanding immediately prior to such transaction continue to hold (either by such shares remaining outstanding in the continuing entity or by their being converted into shares of voting
capital stock of the surviving entity) a majority of the total voting power represented by the shares of voting capital stock of the Company (or the surviving entity) outstanding immediately after such transaction (an &#147;<B><U>Excluded
Entity</U></B>&#148;); or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">(iii) any direct or indirect purchase or other acquisition by any Person or &#147;group&#148; (as defined in or
under Section&nbsp;13(d) of the Exchange Act), other than a Current Parent or another Person that is controlled by a Current Parent, of more than fifty percent (50%) of the total outstanding equity interests in or voting securities of the Company,
excluding any transaction that is determined by the Board in its reasonable discretion to be a bona fide capital raising transaction. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything stated herein, a transaction shall not constitute a Triggering Event if its sole purpose is to change the state of the
Company&#146;s incorporation, or to create a holding company that will be owned in substantially the same proportions by the persons who hold the Company&#146;s securities immediately before such transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. <B><U>Eligibility</U></B>. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Recipients of Grants</U></B>. Any Employee, Consultant,
<FONT STYLE="white-space:nowrap">non-employee</FONT> Director, individuals nominated to be Directors, a director of a Parent, or any other individual who provides services to the Company or any Affiliate shall be eligible to be selected to receive
an Award under the Plan, to the extent an offer of an Award or a receipt of such Award is permitted by Applicable Laws or accounting or tax rules and regulations. Incentive Stock Options may be granted only to Employees; <I>provided </I>that
Employees of Affiliates shall not be eligible to receive Incentive Stock Options. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;4&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Type of Award</U></B>. Each Award shall be designated in the Award Agreement as a Nonstatutory Stock
Option, Incentive Stock Option, SAR, Restricted Stock, RSU, Performance Award, Deferred Award, Other Cash Based Award or Other Share Based Award under the Plan. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Substitute Awards</U></B><B>. </B>Holders of Options and other types of Awards granted by a company
acquired by the Company or with which the Company combines are eligible for grants of Substitute Awards under the Plan to the extent permitted under applicable regulations of any stock exchange on which the Company is listed. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>No Employment Rights</U></B><B>. </B>Neither the Plan nor any Award shall confer upon any Participant any
right with respect to Continuous Service Status with the Company (any Parent or Subsidiary), nor shall it interfere in any way with such Employee&#146;s or Consultant&#146;s right or the Company&#146;s (Parent&#146;s or Subsidiary&#146;s) right to
terminate his or her employment or consulting relationship at any time, with or without cause, as applicable. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. <B><U>Administration
of the Plan</U></B>. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>General</U></B><B>. </B>The Plan shall be administered by the Board or a Committee, or a combination
thereof, as determined by the Board. The Plan may be administered by different administrative bodies with respect to different classes of Participants and, if permitted by Applicable Laws, the Board may authorize one or more officers of the Company
to make Awards under the Plan to Employees and Consultants (who are not subject to Section&nbsp;16 of the Exchange Act) within parameters specified by the Board. The Administrator may issue rules and regulations for administration of the Plan.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Powers of the Administrator</U></B><B>. </B>Subject to the provisions of the Plan and, in the case of a
Committee or officer, the specific duties delegated by the Board to such Committee or by the Board or such Committee to an officer, the Administrator shall have the authority, in its sole discretion: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">(i) to determine the Fair Market Value of the Common Stock in accordance with Section&nbsp;2(u) above; <I>provided</I> that such determination
shall be applied consistently with respect to Participants under the Plan; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">(ii) to select the Employees and Consultants to whom Awards may
from time to time be granted; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">(iii) to determine the type or types of Awards (including Substitute Awards) to be granted to each
Participant under the Plan; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">(iv) to determine the number of Shares to be covered by each Award; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">(v) to approve the form(s) of agreement(s) and other related documents used under the Plan; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">(vi) to determine the terms and conditions, not inconsistent with the terms of the Plan, of any Award granted hereunder, which terms and
conditions include but are not limited to the exercise or purchase price, the time or times when Awards may be exercised (which may be based on performance criteria), the circumstances (if any) when vesting shall be accelerated or forfeiture
restrictions shall be waived, and any restriction or limitation regarding any Award; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">(vii) to amend any outstanding Award or agreement
related to any Award, including any amendment adjusting vesting (e.g., in connection with a change in the terms or conditions under which such person is providing services to the Company); <I>provided</I> that no amendment shall be made that would
materially and adversely affect the rights of any Participant without his or her consent, as determined in the sole discretion of the Board; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">(viii) to determine whether and under what circumstances an Award may be settled and exercised in cash, Shares, other Awards, other property,
net settlement or any combination thereof, or cancelled, forfeited or suspended, and the method or methods by which Awards may be settled, exercised, cancelled, forfeited or suspended; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">(ix) to determine whether, to what extent and under what circumstances cash, Shares, other Awards, other property and other amounts payable
with respect to an Award under the Plan shall be deferred either automatically or at the election of the holder thereof or of the Administrator; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;5&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">(x) to grant Awards to, or to modify the terms of any outstanding Award Agreement or any
agreement related to any Award held by, Participants who are foreign nationals or employed outside of the United States with such terms and conditions as the Administrator deems necessary or appropriate to accommodate differences in local law, tax
policy or custom which deviate from the terms and conditions set forth in this Plan to the extent necessary or appropriate to accommodate such differences; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">(xi) to correct any defect, supply any omission and reconcile any inconsistency in the Plan or any Award, in the manner and to the extent it
shall deem desirable to carry the Plan into effect; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">(xii) to establish, amend, suspend or waive such rules and regulations and appoint
such agents, trustees, brokers, depositories and advisors and determine such terms of their engagement as it shall deem appropriate for the proper administration of the Plan and due compliance with Applicable Laws or accounting or tax rules and
regulations; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">(xiii) to make any other determination and take any other action that the Administrator deems necessary or desirable for the
administration of the Plan and due compliance with Applicable Laws or accounting or tax rules and regulations; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">(xiv) to construe and
interpret the terms of the Plan, any Award Agreement, and any agreement related to any Award, which constructions, interpretations and decisions shall be final and binding on all Participants. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Indemnification</U></B>. To the maximum extent permitted by Applicable Laws, each member of the Committee
(including officers of the Company, if applicable), or of the Board, as applicable, shall be indemnified and held harmless by the Company against and from (i)&nbsp;any loss, cost, liability or expense that may be imposed upon or reasonably incurred
by him or her in connection with or resulting from any claim, action, suit or proceeding to which he or she may be a party or in which he or she may be involved by reason of any action taken or failure to act under the Plan or pursuant to the terms
and conditions of any Award except for actions taken in bad faith or failures to act in bad faith, and (ii)&nbsp;any and all amounts paid by him or her in settlement thereof, with the Company&#146;s approval, or paid by him or her in satisfaction of
any judgment in any such claim, action, suit or proceeding against him or her; <I>provided</I> that such member shall give the Company an opportunity, at its own expense, to handle and defend any such claim, action, suit or proceeding before he or
she undertakes to handle and defend it on his or her own behalf. The foregoing right of indemnification shall not be exclusive of any other rights of indemnification to which such persons may be entitled under the Company&#146;s Articles of
Incorporation, Certificate of Incorporation or Bylaws, by contract, as a matter of law or otherwise, or under any other power that the Company may have to indemnify or hold harmless each such person. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. <B><U>Stock Subject to the Plan</U></B>. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the provisions of Section&nbsp;17 below and except for Substitute Awards, the maximum aggregate
number of Shares that may be issued under the Plan is a number of Shares equal to 10% of the total Shares outstanding as of the 2023 Amendment Date. The total number of Shares available for issuance under the Plan (the &#147;<B><U>Overall Share
Limit</U></B>&#148;) will be increased on the first day of each Company fiscal year during the term of the Plan beginning in 2024 in an amount equal to the lesser of (i) 7.5% of outstanding Shares on the last day of the immediately preceding fiscal
year or (ii)&nbsp;such number of Shares as determined by the Board in its discretion. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding anything to the contrary contained in this Plan, and subject to the provisions of
Section&nbsp;17 below, the maximum aggregate number of Shares actually issued or transferred by the Company under the Plan upon the exercise of Incentive Stock Options is a number of Shares equal to 10% of the total Shares outstanding as of the 2023
Amendment Date. The total number of Shares that may be issued pursuant to Incentive Stock Options will be increased on the first day of each Company fiscal year during the term of the Plan beginning in 2024 by a number of Shares equal to 7.5% of the
total Shares outstanding as of the 2023 Amendment Date; <U>provided</U>, <U>however</U>, such limit will not, in any event, exceed the Overall Share Limit. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;6&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6. <B><U>Limitation on Grants to Participants</U></B>. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No Participant who is a <FONT STYLE="white-space:nowrap">non-employee</FONT> Director may be granted
compensation for such service in any one calendar year having an aggregate maximum value (calculating the value of any awards based on the grant date fair value for financial reporting purposes) in excess of $1,000,000; <U>provided</U>,
<U>however</U>, that such compensation limit with respect to a <FONT STYLE="white-space:nowrap">non-employee</FONT> Director serving as executive chair of the Board shall be $2,000,000. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Shares issued under the Plan may be authorized, but unissued or reacquired Shares. If an Award should be
forfeited, expire, terminate, lapse or become unexercisable for any reason without having been exercised in full or be settled in cash, in whole or in part, the unpurchased or unissued Shares that were subject thereto shall, unless the Plan shall
have been terminated, become available for future grants under the Plan. In addition, any Shares which are retained by the Company upon exercise, settlement or vesting of an Award in order to satisfy (i)&nbsp;the exercise or purchase price for such
Award or (ii)&nbsp;any withholding obligation for taxes due with respect to such Award shall be available for future grants under the Plan. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7. <B><U>Term of Plan</U></B>. The Plan was originally adopted by the Board of Directors and approved by the shareholders of the Company on June&nbsp;14,
2017, and subsequently amended effective as of May&nbsp;18, 2021 and, subject to and conditioned upon approval by the shareholders of the Company and consummation of the mergers with and involving Cibus Global, LLC, amended effective as of the date
of such consummation, which occurred on [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>], 2023 (the &#147;<B><U>2023 Amendment Date</U></B>&#148;). It shall continue in effect for a term of
ten (10)&nbsp;years from the 2023 Amendment Date unless sooner terminated under Section&nbsp;20 below. No Award shall be granted under the Plan after the earliest to occur of (i)&nbsp;the <FONT STYLE="white-space:nowrap">10-year</FONT> anniversary
of the 2023 Amendment Date; <I>provided</I><I> </I>that to the extent permitted by the listing rules of any stock exchange on which the Company is listed, such <FONT STYLE="white-space:nowrap">10-year</FONT> term may be extended indefinitely so long
as the maximum number of Shares available for issuance under the Plan have not been issued; (ii)&nbsp;the maximum number of Shares available for issuance under the Plan have been issued; or (iii)&nbsp;the Board terminates the Plan in accordance with
Section&nbsp;20. However, unless otherwise expressly provided in the Plan or in an applicable Award Agreement, any Award theretofore granted may extend beyond such date, and the authority of the Administrator to amend, alter, adjust, suspend,
discontinue or terminate any such Award, or to waive any conditions or rights under any such Award, and the authority of the Board to amend the Plan, shall extend beyond such date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8. <B><U>Options</U></B>. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Term of Option</U></B><B>. </B>The term of each Option shall be the term stated in the Award Agreement;
<I>provided</I> that the term shall be no more than ten (10)&nbsp;years from the date of grant thereof or such shorter term as may be provided in the Award Agreement; <I>provided further</I> that, in the case of an Incentive Stock Option granted to
a person who at the time of such grant is a Ten Percent Holder, the term of the Option shall be five (5)&nbsp;years from the date of grant thereof or such shorter term as may be provided in the Award Agreement; and, <I>provided further</I>, that the
Administrator may (but shall not be required to) provide in an Award Agreement for an extension of such term in the event the exercise of the Option would be prohibited by law on the expiration date. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Option Exercise Price</U></B><B>. </B>The per Share exercise price for the Shares to be issued pursuant
to the exercise of an Option shall be such price as is determined by the Administrator and set forth in the Award Agreement, but shall be subject to the following: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">(i) In the case of an Incentive Stock Option </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">(A) granted to an Employee who at the time of grant is a Ten Percent Holder, the per Share exercise price shall be no less than one hundred and
ten percent (110%) of the Fair Market Value on the date of grant; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">(B) granted to any other Employee, the per Share exercise price
shall be no less than one hundred percent (100%) of the Fair Market Value on the date of grant, except in the case of Substitute Awards. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">(ii) In the case of a Nonstatutory Stock Option, the per Share exercise price shall be such price as is determined by the Administrator;
<I>provided</I> that, if the per Share exercise price is less than one hundred </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;7&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">
percent (100%) of the Fair Market Value on the date of grant, it shall otherwise comply with all Applicable Laws, including Section&nbsp;409A of the Code. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">(iii) Notwithstanding the foregoing, Options may be granted with a per Share exercise price other than as required above pursuant to a merger
or other corporate transaction. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Vesting and Exercisability</U></B>. The Administrator shall determine the time or times at which an
Option becomes vested and exercisable in whole or in part. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Incentive Stock Option $100,000 Limitation</U></B><B>. </B>Notwithstanding any designation under
Section&nbsp;8(b) above, to the extent that the aggregate Fair Market Value of Shares with respect to which Options designated as Incentive Stock Options are exercisable for the first time by any Participant during any calendar year (under all plans
of the Company or any Parent or Subsidiary) exceeds $100,000, such excess Options shall be treated as Nonstatutory Stock Options. For purposes of this Section&nbsp;8(d), Incentive Stock Options shall be taken into account in the order in which they
were granted, and the Fair Market Value of the Shares subject to an Incentive Stock Option shall be determined as of the date of the grant of such Option. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Disqualifying Dispositions</U></B><B>. </B>Any Participant who shall make a &#147;disposition&#148; (as
defined in Section&nbsp;424 of the Code) of all or any portion of an Incentive Stock Option within two years from the date of grant of such Incentive Stock Option or within one year after the issuance of the Shares acquired upon exercise of such
Incentive Stock Option shall be required to immediately advise the Company in writing as to the occurrence of the sale and the price realized upon the sale of such Shares. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Permissible Consideration</U></B><B>. </B>The consideration to be paid for the Shares to be issued upon
exercise of an Option, including the method of payment, shall be determined by the Administrator (and, in the case of an Incentive Stock Option and to the extent required by Applicable Laws, shall be determined at the time of grant) and may consist
entirely of (1)&nbsp;cash; (2) check; (3)&nbsp;wireless transfer; (4)&nbsp;other previously owned Shares that have a Fair Market Value on the date of surrender equal to the aggregate exercise price of the Shares as to which the Option is exercised;
(5)&nbsp;a Cashless Exercise; (6)&nbsp;other property; (7)&nbsp;net settlement; (8)&nbsp;such other consideration and method of payment permitted under Applicable Laws; or (9)&nbsp;any combination of the foregoing methods of payment. In making its
determination as to the type of consideration to accept, the Administrator shall consider if acceptance of such consideration may be reasonably expected to benefit the Company and the Administrator may, in its sole discretion, refuse to accept a
particular form of consideration at the time of any Option exercise. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9. <B><U>SARs</U></B>. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Term of SARs</U></B>. The term of each SAR shall be the term stated in the Award Agreement;
<I>provided</I> that the term shall be no more than ten (10)&nbsp;years from the date of grant thereof or such shorter term as may be provided in the Award Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Grant of SARs</U></B>. SARs may be granted under the Plan to Participants either alone
(&#147;freestanding&#148;) or in addition to other Awards granted under the Plan (&#147;tandem&#148;) and may, but need not, relate to a specific Option granted under Section&nbsp;8. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>SAR Exercise Price</U></B>. The exercise or hurdle price per Share to be issued pursuant to the exercise
of a SAR shall be such price as is determined by the Administrator and set forth in the Award Agreement; <I>provided</I>, <I>however</I>, that, except in the case of Substitute Awards, such exercise or hurdle price shall not be less than the Fair
Market Value of a Share on the date of grant of such SAR. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Vesting and Exercisability</U></B>. The Administrator shall determine the time or times at which a SAR
may be exercised or settled in whole or in part. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Settlement</U></B>. Upon the exercise of an SAR, the Company shall pay to the Participant an amount equal
to the number of Shares subject to the SAR multiplied by the excess, if any, of the Fair Market Value of one Share on the exercise date over the exercise or hurdle price of such SAR. The Company shall pay such excess in cash, in Shares valued at
Fair Market Value, or any combination thereof, as determined by the Administrator. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;8&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10. <B><U>Restricted Stock and RSUs</U></B>. The Administrator is authorized to grant Awards of Restricted
Stock and RSUs to Participants with the following terms and conditions and with such additional terms and conditions, in either case not inconsistent with the provisions of the Plan, as the Administrator shall determine: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Award Agreement shall specify the vesting schedule and, with respect to RSUs, the delivery schedule (which
may include deferred delivery later than the vesting date) and whether the Award of Restricted Stock or RSUs is entitled to dividends or dividend equivalents, voting rights or any other rights; <I>provided</I> that if the Award relates to Shares on
which dividends are declared during the period that the Award is outstanding, the Award shall not provide for the payment of such dividend (or a dividend equivalent) to the Participant prior to the time at which such Award, or applicable portion
thereof, becomes nonforfeitable. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Shares of Restricted Stock and RSUs shall be subject to such restrictions as the Administrator may impose
(including any limitation on the right to vote a Share of Restricted Stock or the right to receive any dividend, dividend equivalent or other right), which restrictions may lapse separately or in combination at such time or times, in such
installments or otherwise, as the Administrator may deem appropriate. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any Share of Restricted Stock granted under the Plan may be evidenced in such manner as the Administrator may
deem appropriate, including book-entry registration or issuance of a stock certificate or certificates. In the event any stock certificate is issued in respect of shares of Restricted Stock granted under the Plan, such certificate shall be
registered in the name of the Participant and shall bear an appropriate legend referring to the terms, conditions and restrictions applicable to such Restricted Stock. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Administrator may provide in an Award Agreement that an Award of Restricted Stock is conditioned upon the
Participant making or refraining from making an election with respect to the Award under Section&nbsp;83(b) of the Code. If a Participant makes an election pursuant to Section&nbsp;83(b) of the Code with respect to an Award of Restricted Stock, the
Participant shall be required to file promptly a copy of such election with the Company and the applicable Internal Revenue Service office. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Administrator may determine the form or forms (including cash, Shares, other Awards, other property or any
combination thereof) in which payment of the amount owing upon settlement of any RSU Award may be made. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11. <B><U>Performance
Awards</U></B>. The Administrator is authorized to grant Performance Awards to Participants with the following terms and conditions and with such additional terms and conditions, in either case not inconsistent with the provisions of the Plan, as
the Administrator shall determine: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Performance Awards may be denominated as a cash amount, number of Shares or a combination thereof and are
Awards which may be earned upon achievement or satisfaction of performance conditions specified by the Administrator. In addition, the Administrator may specify that any other Award shall constitute a Performance Award by conditioning the right of a
Participant to exercise the Award or have it settled, and the timing thereof, upon achievement or satisfaction of such performance conditions as may be specified by the Administrator. The Administrator may use such business criteria and other
measures of performance as it may deem appropriate in establishing any performance conditions. Subject to the terms of the Plan, the performance goals to be achieved during any Performance Period, the length of any Performance Period, the amount of
any Performance Award granted and the amount of any payment or transfer to be made pursuant to any Performance Award shall be determined by the Administrator. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A Performance Award may include a <FONT STYLE="white-space:nowrap">pre-established</FONT> formula, such that
payment, retention or vesting of the Award is subject to the achievement during a Performance Period or Performance Periods, as determined by the Administrator, of a level or levels of, or increases in, in each case as determined by the
Administrator, one or more of the following performance measures or any other performance measure reasonably determined by the Administrator, with respect to the Company: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">(i) return measures (including, but not limited to, total shareholder return; return on equity; return on assets or net assets; return on
risk-weighted assets; and return on capital (including return on total capital or return on invested capital)); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;9&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">(ii) revenues (including, but not limited to, total revenue; gross revenue; net revenue; and
net sales); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">(iii) income/earnings measures (including, but not limited to, earnings per share; earnings or loss (including earnings before
or after interest, taxes, depreciation and amortization); gross income; net income; operating income (before or after taxes); <FONT STYLE="white-space:nowrap">pre-or</FONT> <FONT STYLE="white-space:nowrap">after-tax</FONT> income or loss (before or
after allocation of corporate overhead and bonus); <FONT STYLE="white-space:nowrap">pre-</FONT> or <FONT STYLE="white-space:nowrap">after-tax</FONT> operating income; net earnings; net income or loss (before or after taxes); operating margin; gross
margin; and adjusted net income); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">(iv) expense measures (including, but not limited to, expenses; operating efficiencies; and improvement
in or attainment of expense levels or working capital levels (including cash and accounts receivable)); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">(v) cash flow measures (including,
but not limited to, cash flow or cash flow per share (before or after dividends); and cash flow return on investment); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">(vi) share price
measures (including, but not limited to, share price; appreciation in and/or maintenance of share price; and market capitalization); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">(vii)
strategic objectives (including, but not limited to, market share; debt reduction; customer growth; employee satisfaction; research and development achievements; mergers and acquisitions; management retention; dynamic market response; expense
reduction initiatives; reductions in costs; risk management; regulatory compliance and achievements; recruiting and maintaining personnel; and business quality); and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">(viii) other measures (including, but not limited to, economic value-added models or equivalent metrics; economic profit added; gross profits;
economic profit; comparisons with various stock market indices; financial ratios (including those measuring liquidity, activity, profitability or leverage); cost of capital or assets under management; and financing and other capital raising
transactions (including sales of the Company&#146;s equity or debt securities; factoring transactions; sales or licenses of the Company&#146;s assets, including its intellectual property, whether in a particular jurisdiction or territory or
globally; or through partnering transactions)). </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Performance criteria may be measured on an absolute (e.g., plan or budget) or relative basis, may be
established on a corporate-wide basis or with respect to one or more business units, divisions, subsidiaries or business segments, may be based on a ratio or separate calculation of any performance criteria and may be made relative to an index or
one or more of the performance goals themselves. Relative performance may be measured against a group of peer companies, a financial market index or other acceptable objective and quantifiable indices. If the Administrator determines that a change
in the business, operations, corporate structure or capital structure of the Company, or the manner in which the Company conducts its business, or other events or circumstances render the performance objectives unsuitable, the Administrator may
modify the performance objectives or the related minimum acceptable level of achievement, in whole or in part, as the Administrator deems appropriate and equitable. Performance measures may vary from Performance Award to Performance Award and from
Participant to Participant, and may be established on a stand-alone basis, in tandem or in the alternative. The Administrator shall have the power to impose such other restrictions on Awards subject to this Section&nbsp;11(c) as it may deem
necessary or appropriate to ensure that such Awards satisfy all requirements of any Applicable Laws or accounting or tax rules and regulations </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Settlement of Performance Awards shall be in cash, Shares, other Awards, other property, net settlement or any
combination thereof, as determined in the discretion of the Administrator. The Administrator shall specify the circumstances in which, and the extent to which, Performance Awards shall be paid or forfeited in the event of a Participant&#146;s
termination of Continuous Service Status. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Performance Awards shall be settled only after the end of the relevant Performance Period. The Administrator
may, in its discretion, increase or reduce the amount of a settlement otherwise to be made in connection with a Performance Award. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12.
<B><U>Deferred Awards</U></B>. The Administrator is authorized, subject to limitations under Applicable Laws, to grant to Participants Deferred Awards, which may be a right to receive Shares or cash under the Plan (either
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;10&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
independently or as an element of or supplement to any other Award under the Plan), including, as may be required by any Applicable Laws or determined by the Administrator, in lieu of any annual
bonus that may be payable to a Participant under any applicable bonus plan or arrangement. The Administrator shall determine the terms and conditions of such Deferred Awards, including, without limitation, the method of converting the amount of
annual bonus into a Deferred Award, if applicable, and the form, vesting, settlement, forfeiture and cancellation provisions or any other criteria, if any, applicable to such Deferred Awards. Shares underlying a Share-denominated Deferred Award,
which is subject to a vesting schedule or other conditions or criteria, including forfeiture or cancellation provisions, set by the Administrator shall not be issued until on or following the date that those conditions and criteria have been
satisfied. Deferred Awards shall be subject to such restrictions as the Administrator may impose (including any limitation on the right to vote a Share underlying a Deferred Award or the right to receive any dividend, dividend equivalent or other
right), which restrictions may lapse separately or in combination at such time or times, in such installments or otherwise, as the Administrator may deem appropriate. The Administrator may determine the form or forms (including cash, Shares, other
Awards, other property or any combination thereof) in which payment of the amount owing upon settlement of any Deferred Award may be made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">13.
<B><U>Other Cash-Based Awards and Other Share-Based Awards</U></B>. The Administrator is authorized, subject to limitations under Applicable Laws, to grant to Participants Other Cash-Based Awards (either independently or as an element of or
supplement to any other Award under the Plan) and Other Share-Based Awards. The Administrator shall determine the terms and conditions of such Awards. Shares delivered pursuant to an Award in the nature of a purchase right granted under this
Section&nbsp;13 shall be purchased for such consideration, paid for at such times, by such methods and in such forms, including cash, Shares, other Awards, other property, net settlement, broker-assisted Cashless Exercise or any combination thereof,
as the Administrator shall determine; <I>provided </I>that the purchase price therefore shall not be less than the Fair Market Value of such Shares on the date of grant of such right. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">14. <B><U>Exercise of Awards</U></B>. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Exercisability</U></B>. Any Award granted hereunder shall be exercisable at such times and under such
conditions as determined by the Administrator, consistent with the terms of the Plan and reflected in the Award Agreement, including vesting requirements and/or performance criteria with respect to the Company, and Parent or Subsidiary, and/or the
Participant. The Administrator shall determine the time or times at which a SAR may be exercised or settled in whole or in part. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Leave of Absence</U></B>.<B> </B>The Administrator shall have the discretion to determine whether and to
what extent the vesting of Awards shall be tolled during any unpaid leave of absence; <I>provided, however</I>, that in the absence of such determination, vesting of Awards shall be tolled during any such unpaid leave (unless otherwise required by
the Applicable Laws). Notwithstanding the foregoing, in the event of military leave, vesting shall toll during any unpaid portion of such leave; <I>provided</I> that, upon a Participant&#146;s returning from military leave (under conditions that
would entitle him or her to protection upon such return under the Uniform Services Employment and Reemployment Rights Act), he or she shall be given vesting credit with respect to Awards to the same extent as would have applied had the Participant
continued to provide services to the Company (or any Parent or Subsidiary, if applicable) throughout the leave on the same terms as he or she was providing services immediately prior to such leave. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Minimum Exercise Requirements</U></B>.<B> </B>An Award may not be exercised for a fraction of a Share.
The Administrator may require that an Award be exercised as to a minimum number of Shares; <I>provided</I> that such requirement shall not prevent a Participant from exercising the full number of Shares as to which the Award is then exercisable.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Procedures for and Results of Exercise</U></B>.<B> </B>An Award shall be deemed exercised when written
notice of such exercise has been received by the Company in accordance with the terms of the Award Agreement by the person entitled to exercise the Award and the Company has received full payment for the Shares with respect to which the Award is
exercised and has paid, or made arrangements to satisfy, any applicable </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;11&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
withholding requirements in accordance with Section&nbsp;17 below. The exercise of an Award shall result in a decrease in the number of Shares that thereafter may be available, both for purposes
of the Plan and for sale under the Award, by the number of Shares as to which the Option is exercised. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Rights as Holder of Capital Stock</U></B>.<B> </B>Until the issuance of the Shares (as evidenced by the
appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company), no right to vote or receive dividends or any other rights as a holder of capital stock shall exist with respect to the Shares, notwithstanding the
exercise of the Award. No adjustment shall be made for a dividend or other right for which the record date is prior to the date the stock certificate is issued, except as provided in Section&nbsp;17 below. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Termination of Service</U></B>.<B> </B>The Administrator shall establish and set forth in the applicable
Award Agreement the terms and conditions upon which an Award shall remain exercisable, if at all, following termination of a Participant&#146;s Continuous Service Status, which provisions may be waived or modified by the Administrator at any time.
To the extent that an Award Agreement does not specify the terms and conditions upon which an Award shall terminate upon termination of a Participant&#146;s Continuous Service Status, the following provisions shall apply: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">(i) <B><U>General Provisions</U></B>. If the Participant (or other person entitled to exercise the Award) does not exercise the Award to the
extent so entitled within the time specified below, the Award shall terminate and the Shares underlying the unexercised portion of the Award shall revert to the Plan. In no event may any Award be exercised after the expiration of the Award term as
set forth in the Award Agreement (and subject to Sections 8(a) and 9(a) above). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">(ii) <B><U>Termination other than Upon Disability, Death
or for Cause</U></B>.<B> </B>In the event of termination of a Participant&#146;s Continuous Service Status other than under the circumstances set forth in subsections (iii)&nbsp;through (v) below, such Participant may exercise any outstanding Award
at any time within three (3)&nbsp;months following such termination to the extent the Participant was vested in the Shares underlying the Award as of the date of such termination. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">(iii) <B><U>Disability of Participant</U></B>.<B> </B>In the event of termination of a Participant&#146;s Continuous Service Status as a result
of his or her Disability, such Participant may exercise any outstanding Award at any time within six (6)&nbsp;months following such termination to the extent the Participant was vested in the Shares underlying the Award as of the date of such
termination. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">(iv) <B><U>Death of Participant</U></B>.<B> </B>In the event of the death of a Participant during the period of Continuous
Service Status since the date of grant of any outstanding Award, or within three (3)&nbsp;months following termination of the Participant&#146;s Continuous Service Status, the Award may be exercised by the Participant&#146;s estate, or by a person
who acquired the right to exercise the Award by bequest or inheritance, at any time within nine (9)&nbsp;months following the date of death or, if earlier, the date the Award&#146;s Continuous Service Status terminated, but only to the extent the
Participant was vested in the Shares underlying the Award as of the date of death. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">(v) <B><U>Termination for Cause</U></B>.<B> </B>In the
event of termination of a Participant&#146;s Continuous Service Status for Cause, any outstanding Award (including any vested portion thereof) held by such Participant shall immediately terminate in its entirety upon first notification to the
Participant of termination of the Participant&#146;s Continuous Service Status for Cause. If a Participant&#146;s Continuous Service Status is suspended pending an investigation of whether the Participant&#146;s Continuous Service Status will be
terminated for Cause, all the Participant&#146;s rights under any Award, including the right to exercise the Award, shall be suspended during the investigation period. Nothing in this Section&nbsp;14(f)(v) shall in any way limit the Company&#146;s
right to purchase unvested Shares issued upon exercise of an Award as set forth in the applicable Award Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">15. <B><U>Taxes</U></B>. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As a condition of the grant, vesting and exercise of an Award, the Participant (or in the case of the
Participant&#146;s death or a permitted transferee, the person holding or exercising the Award) shall make such </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;12&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
arrangements as the Administrator may require for the satisfaction of any applicable U.S. federal, state or local tax withholding obligations or foreign tax withholding obligations that may arise
in connection with such Award. The Company shall not be required to issue any Shares under the Plan until such obligations are satisfied. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Administrator may permit a Participant (or in the case of the Participant&#146;s death or a permitted
transferee, the person holding or exercising the Award) to satisfy all or part of his or her tax withholding obligations by Cashless Exercise or by surrendering Shares (either directly or by stock attestation) that he or she previously acquired;
<I>provided</I> that, unless the Cashless Exercise is an approved broker-assisted Cashless Exercise, the Shares tendered for payment have been previously held for a minimum duration <I>(</I>e.g., to avoid financial accounting charges to the
Company&#146;s earnings), or as otherwise permitted to avoid financial accounting charges under applicable accounting guidance. Any Shares withheld pursuant to this Section&nbsp;15(b) shall not exceed the statutory minimum amount necessary to
satisfy the Company&#146;s tax withholding obligations (including, but not limited to, U.S. federal and state income taxes, payroll taxes, and foreign taxes, if applicable), unless (i)&nbsp;an additional amount can be withheld and not result in
adverse accounting consequences and (ii)&nbsp;such additional withholding amount is specifically authorized by the Administrator. Any payment of taxes by surrendering Shares to the Company may be subject to restrictions, including, but not limited
to, any restrictions required by rules of the Securities and Exchange Commission. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">16.
<B><U><FONT STYLE="white-space:nowrap">Non-Transferability</FONT> of Awards</U></B>. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>General</U></B>.<B> </B>Except as set forth in this Section&nbsp;16, Awards may not be sold, pledged,
assigned, hypothecated, transferred or disposed of in any manner other than by will or by the laws of descent or distribution. The designation of a beneficiary by a Participant shall not constitute a transfer. An Award may be exercised, during the
lifetime of the holder of the Award, only by such holder or a transferee permitted by this Section&nbsp;16. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Limited Transferability Rights</U></B>.<B> </B>Notwithstanding anything else in this Section&nbsp;16, the
Administrator may in its sole discretion grant Awards that may be transferred by instrument to an inter vivos or testamentary trust in which the Awards are to be passed to beneficiaries upon the death of the trustor (settlor) or by gift to Family
Members. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">17. <B><U>Adjustments Upon Changes in Capitalization, Merger or Certain Other Transactions</U></B>. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Changes in Capitalization</U></B>.<B> </B>Subject to any action required under Applicable Laws by the
holders of capital stock of the Company, the Administrator shall, subject to compliance with Section&nbsp;409A or Section&nbsp;424, as applicable, of the Code, equitably adjust (i)&nbsp;the number, type and class of Shares or other stock or
securities: (x)&nbsp;available for future Awards under Section&nbsp;5 above, (y)&nbsp;set forth in Section&nbsp;5 above and (z)&nbsp;covered by each outstanding Award, (ii)&nbsp;the grant, purchase, exercise or hurdle price covered by each such
outstanding Award, and (iii)&nbsp;any repurchase price per Share applicable to Shares issued pursuant to any Award, or, if deemed appropriate, shall make a provision for a cash payment to the holder of an outstanding Award in the event of a stock
split, reverse stock split, stock dividend, combination, consolidation, recapitalization (including a recapitalization through a large nonrecurring cash dividend) or reclassification of the Shares, repurchase, exchange or subdivision of the Shares
or other securities of the Company, a rights offering, a reorganization, merger, <FONT STYLE="white-space:nowrap">spin-off,</FONT> <FONT STYLE="white-space:nowrap">split-up,</FONT> change in corporate structure or other similar occurrence, in each
case excluding a Triggering Event; <I>provided</I>, <I>however</I>, that the number of Shares subject to any Award denominated in Shares shall always be a whole number. Any adjustment by the Administrator pursuant to this Section&nbsp;17(a) shall be
made in the Administrator&#146;s sole and absolute discretion and shall be final, binding and conclusive. Except as expressly provided herein, no issuance by the Company of shares of stock of any class, or securities convertible into shares of stock
of any class, shall affect, and no adjustment by reason thereof shall be made with respect to, the number or price of Shares subject to an Award. If, by reason of a transaction described in this Section&nbsp;17(a) or an adjustment pursuant to this
Section&nbsp;17(a), a Participant&#146;s Award Agreement or agreement related to any Shares </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;13&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
underlying an Award covers additional or different shares of stock or securities, then such additional or different shares, and the Award Agreement or agreement related to the Shares underlying
an Award in respect thereof, shall be subject to all of the terms, conditions and restrictions which were applicable to the Award and the Shares underlying the Award prior to such adjustment. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Dissolution or Liquidation</U></B>.<B> </B>In the event of the dissolution or liquidation of the Company,
each Award shall terminate immediately prior to the consummation of such action, unless otherwise determined by the Administrator. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Corporate Transactions</U></B>.<B> </B>Unless a Participant&#146;s applicable Award Agreement, employment
agreement or other applicable written agreement provides otherwise, in the event of: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">(i) a dissolution or liquidation of
the Company or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">(ii) a Triggering Event, then: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">each outstanding Award shall either be (A)&nbsp;assumed or an equivalent award shall be substituted by such Successor Corporation, or
(B)&nbsp;terminated in exchange for a payment of cash, securities and/or other property equal to the excess of the Fair Market Value of the portion of the Award Stock that is vested and exercisable immediately prior to the consummation of the
corporate transaction over the per Share exercise price thereof, or (C)&nbsp;any combination of (A)&nbsp;and (B) that is approved by the Administrator; <I>provided</I> that, in the case of an Option or SAR Award, such Award may be cancelled without
consideration if the Fair Market Value on the date of the event is greater than the exercise or hurdle price of such Award. Notwithstanding the foregoing, in the event such Successor Corporation does not agree to such assumption, substitution or
exchange, each such Award shall terminate upon the consummation of the corporate transaction. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Unless a Participant&#146;s applicable Award
Agreement, employment agreement or other applicable written agreement provides otherwise, if a Triggering Event, dissolution or liquidation occurs and any outstanding Award held by the Participant is to be terminated (in whole or in part) pursuant
to the preceding paragraph, the Administrator may accelerate the vesting and exercisability of each such Award in his sole discretion such that the Award shall become vested and exercisable in full prior to the consummation of the corporate
transaction at such time and on such conditions as the Administrator shall determine. The Administrator shall notify the Participant that the Award shall terminate at least five (5)&nbsp;days prior to the date upon which the Award terminates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">18. <B><U>Time of Granting Options</U></B>. The date of grant of an Award shall, for all purposes, be the date on which the Administrator makes the
determination granting such Award, or such later date as is determined by the Administrator; <I>provided</I> that in the case of any Incentive Stock Option, the grant date shall be the later of the date on which the Administrator makes the
determination granting such Incentive Stock Option or the date of commencement of the Participant&#146;s employment relationship with the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">19.
<B><U>General Provisions Applicable to Awards</U></B>. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Awards shall be granted for such cash or other consideration, if any, as the Administrator determines;
<I>provided </I>that in no event shall Awards be issued for less than such minimal consideration as may be required by Applicable Laws. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Awards may, in the discretion of the Administrator, be granted either alone or in addition to or in tandem with
any other Award or any award granted under any other plan of the Company. Awards granted in addition to or in tandem with other Awards, or in addition to or in tandem with awards granted under any other plan of the Company, may be granted either at
the same time as or at a different time from the grant of such other Awards or awards. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the terms of the Plan, payments or transfers to be made by the Company upon the grant, exercise or
settlement of an Award may be made in the form of cash, Shares, other Awards, other property, net </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;14&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
settlement or any combination thereof, as determined by the Administrator in its discretion at the time of grant, and may be made in a single payment or transfer, in installments or on a deferred
basis, in each case in accordance with rules and procedures established by the Administrator. Such rules and procedures may include provisions for the payment or crediting of reasonable interest on installment or deferred payments or the grant or
crediting of dividend equivalents in respect of installment or deferred payments. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except as may be permitted by the Administrator (except with respect to Incentive Stock Options) or as
specifically provided in an Award Agreement, (i)&nbsp;no Award and no right under any Award shall be assignable, alienable, saleable or transferable by a Participant otherwise than by will or pursuant to the laws of descent and distribution and
(ii)&nbsp;during a Participant&#146;s lifetime, each Award, and each right under any Award, shall be exercisable only by such Participant or, if permissible under Applicable Laws, by such Participant&#146;s guardian or legal representative. The
provisions of this Section&nbsp;19(d) shall not apply to any Award that has been fully exercised or settled, as the case may be, and shall not preclude forfeiture of an Award in accordance with the terms thereof. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All certificates for Shares and/or other securities delivered under the Plan pursuant to any Award or the
exercise thereof shall be subject to such stop transfer orders and other restrictions as the Administrator may deem advisable under the Plan or the rules, regulations and other requirements of the Securities Exchange Commission, any stock market or
exchange upon which such Shares or other securities are then quoted, traded or listed, and any applicable securities laws, and the Administrator may cause a legend or legends to be put on any such certificates to make appropriate reference to such
restrictions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Administrator may impose restrictions on any Award with respect to
<FONT STYLE="white-space:nowrap">non-competition,</FONT> confidentiality and other restrictive covenants as it deems necessary or appropriate in its sole discretion. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any Award granted to an individual who is nominated to become a Director and is not an Employee or Consultant
or a director of a Parent at the time of grant shall be forfeited in its entirety if such individual does not commence providing services to the Company within 12 months after the date of grant of such Award. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">20. <B><U>Amendment and Terminations</U></B>. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board may at any time amend, alter, suspend, discontinue or terminate the Plan or any portion thereof at
any time, but no amendment or termination (other than an adjustment pursuant to Section&nbsp;17 above or as necessary to comply with Applicable Laws or accounting or tax rules and regulations) shall be made that would materially and adversely affect
the rights of any Participant under any outstanding Award, without his or her consent, as determined in the sole discretion of the Board except (x)&nbsp;to the extent any such amendment, alteration, suspension, discontinuance or termination is made
to cause the Plan to comply with Applicable Laws or accounting or tax rules and regulations or (y)&nbsp;to impose any &#147;clawback&#148; or recoupment provisions on any Awards in accordance with Section&nbsp;24. In addition, to the extent
necessary and desirable to comply with the Applicable Laws, the Company shall obtain the approval of holders of capital stock with respect to any Plan amendment in such a manner and to such a degree as required by Applicable Laws. Notwithstanding
anything to the contrary in the Plan, the Administrator may amend the Plan, or create <FONT STYLE="white-space:nowrap">sub-plans,</FONT> in such manner as may be necessary to enable the Plan to achieve its stated purposes in any jurisdiction in a <FONT
STYLE="white-space:nowrap">tax-efficient</FONT> manner and in compliance with local rules and regulations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Dissolution or Liquidation</U></B>. In the event of the dissolution or liquidation of the Company, each
Award shall terminate immediately prior to the consummation of such action, unless otherwise determined by the Administrator. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Terms of Awards</U></B>. The Administrator may waive any conditions or rights under, amend any terms of,
or amend, alter, suspend, discontinue or terminate any Award theretofore granted, prospectively or retroactively, without the consent of any relevant Participant or holder of an Award; <I>provided, however</I>, that, subject to Section&nbsp;17, no
such action shall materially adversely affect the rights of any affected Participant or holder under any Award theretofore granted under the Plan, except (x)&nbsp;to the extent any such
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;15&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
action is made to cause the Plan to comply with Applicable Laws or accounting or tax rules and regulations or (y)&nbsp;to impose any &#147;clawback&#148; or recoupment provisions on any Awards in
accordance with Section&nbsp;24. The Administrator shall be authorized to make adjustments in the terms and conditions of, and the criteria included in, Awards in recognition of events (including the events described in Section&nbsp;17) affecting
the Company, or the financial statements of the Company, or of changes in Applicable Laws or accounting principles, whenever the Administrator determines that such adjustments are appropriate in order to prevent dilution or enlargement of the
benefits or potential benefits intended to be made available under the Plan. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>No Repricing</U></B>. Notwithstanding the foregoing, except as provided in Section&nbsp;17, no action
shall directly or indirectly, through cancellation and regrant or any other method, reduce, or have the effect of reducing, the exercise or hurdle price of any Award established at the time of grant thereof without approval of the Company&#146;s
shareholders. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">21. <B><U>Conditions Upon Issuance of Shares</U></B>. Notwithstanding any other provision of the Plan or any agreement
entered into by the Company pursuant to the Plan, the Company shall not be obligated, and shall have no liability for failure, to issue or deliver any Shares under the Plan unless such issuance or delivery would comply with the Applicable Laws, with
such compliance determined by the Company in consultation with its legal counsel. As a condition to the exercise of any Award, the Company may require the person exercising the Award to represent and warrant at the time of any such exercise or
purchase that the Shares are being purchased only for investment and without any present intention to sell or distribute such Shares if, in the opinion of counsel for the Company, such a representation is required by Applicable Laws. Shares issued
upon exercise of Awards prior to the date, if ever, on which the Common Stock becomes a Listed Security shall be subject to a right of first refusal in favor of the Company pursuant to which the Participant shall be required to offer Shares to the
Company before selling or transferring them to any third party on such terms and subject to such conditions as is reflected in the applicable Award Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">22. <B><U>Beneficiaries</U></B>. Unless stated otherwise in an Award Agreement, a Participant may designate one or more beneficiaries with respect to an Award
by timely filing the prescribed form with the Company. A beneficiary designation may be changed by filing the prescribed form with the Company at any time before the Participant&#146;s death. If no beneficiary was designated or if no designated
beneficiary survives the Participant, then after a Participant&#146;s death any vested Award(s) shall be transferred or distributed to the Participant&#146;s estate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">23. <B><U>Addenda</U></B>. The Administrator may approve such addenda to the Plan as it may consider necessary or appropriate for the purpose of granting
Awards to Employees or Consultants, which Awards may contain such terms and conditions as the Administrator deems necessary or appropriate to accommodate differences in local law, tax policy or custom, which, if so required under Applicable Laws,
may deviate from the terms and conditions set forth in this Plan. The terms of any such addenda shall supersede the terms of the Plan to the extent necessary to accommodate such differences but shall not otherwise affect the terms of the Plan as in
effect for any other purpose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">24. <B><U>Cancellation or &#147;Clawback&#148; of Awards</U></B>. The Administrator shall have full authority to implement
any policies and procedures necessary to comply with Section&nbsp;10D of the Exchange Act and any rules promulgated thereunder and any other regulatory regimes. Notwithstanding anything to the contrary contained herein, the Administrator may, to the
extent permitted by Applicable Laws or by any applicable Company policy or arrangement, and shall, to the extent required, cancel or require reimbursement of any Awards granted to the Participant or any Shares issued or cash received upon vesting,
exercise or settlement of any such Awards or sale of Shares underlying such Awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">25. <B><U>Restrictive Covenants</U></B>. The Administrator may impose
restrictions on any Award with respect to <FONT STYLE="white-space:nowrap">non-competition,</FONT> confidentiality and other restrictive covenants as it deems necessary or appropriate in its sole discretion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;16&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">26. <B><U>Compliance with Section</U></B><B><U></U></B><B><U>&nbsp;409A and
Section</U></B><B><U></U></B><B><U>&nbsp;457A of the Code</U></B>. To the extent applicable, it is intended that this Plan and any grants made hereunder comply with the provisions of Section&nbsp;409A and Section&nbsp;457A of the Code. This Plan and
any grants made hereunder shall be administered in a manner consistent with this intent, and any provision that would cause this Plan or any grant made hereunder to fail to satisfy Section&nbsp;409A and Section&nbsp;457A of the Code shall have no
force and effect until amended to comply with Section&nbsp;409A and Section&nbsp;457A of the Code (which amendment may be retroactive to the extent permitted by Section&nbsp;409A and Section&nbsp;457A of the Code and may be made by the Company
without the consent of Participants). If, at the time of a Participant&#146;s separation from service (within the meaning of Section&nbsp;409A of the Code), (a) the Participant will be a specified employee (within the meaning of Section&nbsp;409A of
the Code and using the identification methodology selected by the Company from time to time) and (b)&nbsp;the Company makes a good faith determination that an amount payable hereunder constitutes deferred compensation (within the meaning of
Section&nbsp;409A of the Code) the payment of which is required to be delayed pursuant to the <FONT STYLE="white-space:nowrap">six-month</FONT> delay rule set forth in Section&nbsp;409A of the Code in order to avoid taxes or penalties under
Section&nbsp;409A of the Code, then the Company will not pay such amount on the otherwise scheduled payment date but will instead pay it, without interest, on the tenth business day of the seventh month after such separation from service. Any
reference in this Plan to Section&nbsp;409A and Section&nbsp;457A of the Code shall also include any proposed, temporary or final regulations, or any other guidance, promulgated with respect to such section by the U.S. Department of the Treasury or
the Internal Revenue Service. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">27. <B><U>Successors and Assigns</U></B>. The terms of the Plan shall be binding upon and inure to the benefit of the
Company and any successor entity, including any successor entity contemplated by Section&nbsp;17. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">28. <B><U>Data Privacy</U></B><I>. </I>By participating
in the Plan, the Participant consents to the holding and processing of personal information provided by the Participant to the Company or any subsidiary, trustee or third-party service provider, for all purposes relating to the operation of the
Plan. These include, but are not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">administering and maintaining Participant records, a dissolution or liquidation of the Company;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">providing information to the Company, Subsidiaries, trustees of any employee benefit trust, registrars, brokers
or third-party administrators of the Plan; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">providing information to future purchasers or merger partners of the Company or any subsidiary, or the business
in which the Participant works; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">transferring information about the Participant to any country or territory that may not provide the same
protection for the information as the Participant&#146;s home country. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">29. <B><U>Governing Law</U></B>. The Plan and each Award
Agreement shall be governed by the laws of the State of Delaware, without application of the conflicts of law principles thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">30. <B><U>Waiver of
Jury Trial</U></B><I>. </I>EACH PARTICIPANT WAIVES ANY RIGHT IT MAY HAVE TO TRIAL BY JURY IN RESPECT OF ANY LITIGATION BASED ON, ARISING OUT OF, UNDER OR IN CONNECTION WITH THE PLAN. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">31. <B><U>Dispute Resolution</U></B>. Any dispute or claim arising out of, under or in connection with the Plan or any Award Agreement shall be submitted to
arbitration in Delaware and shall be conducted in accordance with the rules of, but not necessarily under the auspices of, the American Arbitration Association rules in force when the notice of arbitration is submitted. The arbitration shall be
conducted before an arbitration tribunal comprised of three individuals, one selected by the Company, one selected by the Participant, and the third selected by the first two. The Participant and the Company agree that such arbitration will be
confidential and no details, descriptions, settlements or other facts concerning such arbitration shall be disclosed or released to any third party without the specific written consent of the other party, unless required by law or court order or in
connection with enforcement of any decision in such arbitration. Any damages awarded in such arbitration shall be limited to the contract measure of damages, and shall not include punitive damages. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;17&nbsp;- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">32. <B><U>Other Acknowledgments</U></B>. Notwithstanding anything in this Plan or an Award Agreement to the
contrary, nothing in this Plan or in an Award Agreement prevents a Participant from providing, without prior notice to the Company, information to governmental authorities regarding possible legal violations or otherwise testifying or participating
in any investigation or proceeding by any governmental authorities regarding possible legal violations, and for purpose of clarity a Participant is not prohibited from providing information voluntarily to the Securities and Exchange Commission
pursuant to Section&nbsp;21F of the Exchange Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-&nbsp;18&nbsp;- </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g401831g01a06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g401831g01a06.jpg
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B86>UJOI6*ED.V*15?/$,BOK]6W&L:!VOP!X \ > / /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g401831g01a43.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g401831g01a43.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2:H4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )HR^F&@X0DE-! 0      !D< 5H  QLE1QP"   "   < E  !41E;'1A
M #A"24T$)0      $)_]]5M,FVC]2'%8$L(%V8@X0DE-!#H      .4    0
M     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT
M965N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M    "W!R:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/
M8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+
M #A"24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M    %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L
M  !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V
M8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P
M  $       !21T)#     P    !29" @9&]U8D!OX            $=R;B!D
M;W5B0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2
M;'0               !";&0@56YT1B-2;'0               !2<VQT56YT
M1B-0>&Q 8VNEX         IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M    4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O
M<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M$&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M        #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L
M;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ ._
M_C4  @ ! [_^-0 "  $X0DE-!"8       X             /X   #A"24T$
M#0      !    %HX0DE-!!D       0    >.$))30/S       )
M   ! #A"24TG$       "@ !          $X0DE- _4      $@ +V9F  $
M;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M  $ -0    $ +0    8       $X0DE- _@      '   /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H     /______________________
M______\#Z   .$))300(       0     0   D    )      #A"24T$'@
M    !      X0DE-!!H      T$    &              %L   ".     8
M9P P #$ 80 T #,    !                          $
M C@   %L                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   %L     %)G:'1L;VYG   ".     9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   !;     !29VAT
M;&]N9P   C@    #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M    !     ,X0DE-! P     '$D    !    H    &<   '@  #!(   '"T
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MZUE5D,WRQ^54"]QVTV>@W"WY+6>G_2:?YM=/_P"-IT(_]@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                        _^$^AFAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI2'IR
M95-Z3E1C>FMC.60B/SX*/'@Z>&UP;65T82!X;6QN<SIX/2)A9&]B93IN<SIM
M971A+R(@>#IX;7!T:STB061O8F4@6$U0($-O<F4@-BXP+6,P,#(@-SDN,38T
M-#@X+" R,#(P+S W+S$P+3(R.C V.C4S(" @(" @(" B/@H@(" \<F1F.E)$
M1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F
M+7-Y;G1A>"UN<R,B/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U
M=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"\B"B @(" @(" @(" @('AM;&YS.G!D9CTB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]P9&8O,2XS+R(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT
M=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(@H@(" @(" @(" @("!X
M;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*
M(" @(" @(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT(R(*(" @(" @(" @(" @>&UL
M;G,Z<W12968](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]2
M97-O=7)C95)E9B,B"B @(" @(" @(" @('AM;&YS.G!H;W1O<VAO<#TB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W O,2XP+R(^"B @(" @(" @(#QX
M;7 Z0W)E871E1&%T93XR,#(S+3 T+3$R5#$Q.C$T.C4U*S U.C,P/"]X;7 Z
M0W)E871E1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y-:6-R;W-O
M9G3"KB!/9F9I8V4@5V]R9" R,# W/"]X;7 Z0W)E871O<E1O;VP^"B @(" @
M(" @(#QX;7 Z36]D:69Y1&%T93XR,#(S+3 T+3$R5#$Q.C(U.C,R*S U.C,P
M/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T841A=&4^
M,C R,RTP-"TQ,E0Q,3HR-3HS,BLP-3HS,#PO>&UP.DUE=&%D871A1&%T93X*
M(" @(" @(" @/'!D9CI0<F]D=6-E<CY-:6-R;W-O9G3"KB!/9F9I8V4@5V]R
M9" R,# W/"]P9&8Z4')O9'5C97(^"B @(" @(" @(#QD8SIC<F5A=&]R/@H@
M(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:3Y$
M96QT83PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @
M(#PO9&,Z8W)E871O<CX*(" @(" @(" @/&1C.F9O<FUA=#YI;6%G92]E<'-F
M/"]D8SIF;W)M870^"B @(" @(" @(#QX;7!-33I);G-T86YC94E$/GAM<"YI
M:60Z8F,W-V8S96(M-C5E-"TQ830T+6(U8C8M,6(X,F)C9#4P,F4U/"]X;7!-
M33I);G-T86YC94E$/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YA9&]B
M93ID;V-I9#IP:&]T;W-H;W Z,C0U,&5C-#4M,30U-RTV9C0U+3@U-&8M-#4P
M-#,R,F4P8F%D/"]X;7!-33I$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ
M3W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z.31E83@Y-#$M-#$P9BTY.30V
M+3EC8V(M,S0X-&4R8F%A930V/"]X;7!-33I/<FEG:6YA;$1O8W5M96YT240^
M"B @(" @(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @(" @(" @(" \<F1F.E-E
M<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\
M+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A
M;F-E240^>&UP+FEI9#HY-&5A.#DT,2TT,3!F+3DY-#8M.6-C8BTS-#@T93)B
M86%E-#8\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IW:&5N/C(P,C,M,#0M,3)4,3$Z,C4Z,C$K,#4Z,S \+W-T179T.G=H
M96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D
M;V)E(%!H;W1O<VAO<" R,BXP("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!
M9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%
M=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I
M;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI
M:60Z93,Y,V0W.#$M8S Q-2UA831B+6)D,SDM-V1D-V0U93(R-3DT/"]S=$5V
M=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR
M,#(S+3 T+3$R5#$Q.C(U.C,R*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H
M;W @,C(N," H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^
M"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F
M.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.F%C=&EO;CYC;VYV97)T960\+W-T179T.F%C=&EO;CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.G!A<F%M971E<G,^9G)O;2!A<'!L:6-A
M=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T179T
M.G!A<F%M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @
M(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYD97)I=F5D/"]S=$5V=#IA
M8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F-O
M;G9E<G1E9"!F<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @
M=&\@:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T
M:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#II;G-T86YC94E$/GAM<"YI:60Z8F,W-V8S96(M-C5E-"TQ830T+6(U
M8C8M,6(X,F)C9#4P,F4U/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z=VAE;CXR,#(S+3 T+3$R5#$Q.C(U.C,R*S U.C,P
M/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A
M<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @,C(N," H5VEN9&]W<RD\+W-T179T
M.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N
M9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP34TZ2&ES
M=&]R>3X*(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F.FEN<W1A;F-E240^
M>&UP+FEI9#IE,SDS9#<X,2UC,#$U+6%A-&(M8F0S.2TW9&0W9#5E,C(U.30\
M+W-T4F5F.FEN<W1A;F-E240^"B @(" @(" @(" @(#QS=%)E9CID;V-U;65N
M=$E$/GAM<"YD:60Z.31E83@Y-#$M-#$P9BTY.30V+3EC8V(M,S0X-&4R8F%A
M930V/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z;W)I
M9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z.31E83@Y-#$M-#$P9BTY.30V+3EC
M8V(M,S0X-&4R8F%A930V/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT240^"B @
M(" @(" @(#PO>&UP34TZ1&5R:79E9$9R;VT^"B @(" @(" @(#QP:&]T;W-H
M;W Z0V]L;W)-;V1E/C0\+W!H;W1O<VAO<#I#;VQO<DUO9&4^"B @(" @(#PO
M<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO>#IX;7!M971A/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD
M/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$!_\  $0@ X0%? P$1  (1 0,1 ?_$ !\  0 !! ,! 0$
M       !!@<("00%"@,""__$ &@0   & 0($ @0&"0L/!PD)  $" P0%!@<(
M$0 )(3%!41(3%&$5%AIQ@9$*%Q@95Z&QP? B)"8G,C8W1I;1X2,H.$1'5%58
M=G>4MM37\30Y4F1FAIDE*3I%2&=UEZ9"259I=(>DJ-;_Q  < 0$  @(# 0
M             0(#! 4&" ?_Q !>$0 ! P($ P4$!@0'"@D*!P ! @,1!"$
M!1(Q05%A!A,B<8$'%)'P%2.AL<'1%A<RX20U0E64TO$E)C,T-D-$4E-T"%1B
M9&5R=82T-T56<X*#HJ2RU&.%E;7"P]7_V@ , P$  A$#$0 _ -S_ #0^:UJG
M@M8U&Y9G+AJM>F-2=E3@UKU?K*P;2[6G+3T1\:6<-%LGBYH>-)%U#U%KMMDL
M+1ZWCX=XW;1T<J[.9P2#R!OZ?#CS!V/VXRH0G25KF-@!ON!/Q,8K72[ \^W3
M5J1PK ZLK[B76-IRRQ/J5;)-HQ_&M"6#"95HF6?1]F='94'%#UNR0D6;)K(/
M3PMJ@5&KD61U6$@X9NTPGC'I]OSY;<2NZ(.D%)%Q/'F-U1;:^^,;J_;=7.%=
M$_.!R;-\SZC:L;+48!_(8M?X8RO)W&UZ>IM&5GP=HR7M,5&?:SEW;19HP8UB
MN.'D.S5AGBC%=NJW 3-P;CI!OYD^?(6ZXDA)4V @IN)U")N/CQWWF,78Y5O-
MXTXXVY=VFR2UYZS6'V]+[+Y=4<O<ES]KON09"*8YDO$+ O;*O&1]DEHB';Q;
M%I'Q<E9#1T:#)F1)LY%%L/H0DV%[W]8W\_G;!;:BM6E-A&T ;"8''R&-[]OU
M5Z:*!B:N9YN^><353"MP5BT*KE2?O5=C*'8G$VV>/(AO#6=T_3B9!>0:QT@N
MU0;.5%54F+PY2;-EO0MC%I43 !D;B#(],=]DC4%@W#V.6.7\JY<QYCS%DF,(
M$=D.WVR&@:<_&RH@YKX,[!(.T(US\--Q!>,]2X/[:B/K4/3)^JX8 $F "3R
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MH@I7^5Z&3&]["=^!\P)\LZKLICI/+D>?'Y&Q]HW%L:^/Y[NAKKH>^R)]Q_\
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M^R=BQI:LMZ>]053'#UN<6:ZQQZ<9M N)1$R4)#66.KDT*<@F1R4;'#S ^F4
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MB9JUR5G:[)LKI8,A7&4KL_<;;(2[B6?MACG<M&27L+4_M$@#=PU,Y="H"I0
M1Q^_\S]LGK%L0MP*2$A,0;7FP! &PO\ /&,8343D%\P/3SE3-%!TH:^:YAG1
M9G^:<!D"*8MITV84J:X>N!1A(R%/2W]=;66.A'CB 3NM=R%39*29%*F\039*
MGCR(C;ISV]9X0.'GM%N]20"I,K&QX>MYCI!QFCHLY#M5TY:=]=.ES)^4T<BX
MKU>NXIE"&@H96+LU#@*V>97JSUZ_E#NV$M:X21<PDPW?(1K:/&4AP6]D!)4J
M2;2/3]\CT$G%5.R4J NF9!V,[]8WW_/&%V)>2OSDL-TYSI2Q[S-:-0-&"LG(
MKI%IK.SL<LLX^3?C(R+:!:FQ\G+5(LHZ.LL]85_.+>)%RZ>.3LW(/':"Z_GS
MX>7Y=?OL7&R=102KK$=)BQY7&WEC*+F*\H;63E?7G4N8)R_-16,,(9@0JD36
MK,.3DYA(C!U$0SVL#-0/L..\H0D^C+UEPVC)& LE;;-B+-3ODY!4ZR:;81>9
MX'X\[VY_O&*H6D)TK!(FT1^8(O.W/%WWO*1S1<>8'HIUWY+U&5JS6+3=A>@4
M;)\6%1DAF<FWVKUNZ1D]:8V5(]8Q\:PGI6V _!-S%@NBF@N'LY3*)ID<OGSO
M\/AB L!*T@$:C:]@)VY[=3BV_-\Y%$AS)<ZT+/6.LTUO#%HB,?)X\O2,W4I2
M?3M+&-E)-[!RJ"\3+1QTG[=A-R$*]3=$42=1S>-1 Y2(JD.(F+Q'2_IR^3N!
MB6W- ((D;^6,E-3W*=3R]RKZ#RW,7Y$A:$6@QF*6C6]S===R4;)2%%ED9VRR
MKJ%C7K5TFXMDTI*RAQ!VJ=!T_,9PHY-ZQ4\Q:/3$)<A961,S,?AY8L[KLY,M
MFU4\M33%HXJ>5:M$9=TK,**-3O5DBY=E2;>[KM&?TFPQ4NE&(SLY7HN;*^;R
M[20:,)UXR<PS1LJP<).UU$((M'2/PZ_CZX)<TK4J+*GS$F>D\N'/AB_^F/2]
MJJK6A_4;A_FOZBJ!J!)>ZU<8B5L-506)6Z+AA/'#>N/&B\TXH^+WTG(,TH]_
M:74LYK[:12DE5':TU(/3'?<3YW^?7$%0U H$1MU,D[2?+?X;8T$?8J&EJ/<Y
M>U4:L!36D*Y1F:.!\6S;UL+<\LI994+/:Y5%!-PY;(.VE?@:>W<"19R*1;&X
M:MG:B?M8GJGG\!Z#A>.,0=CC*\JP3L3<CYZS\,>W+BV-?&E;)W*FMF1.;OB[
MF5ES!7HNI8YJL%"'Q:-8DG5BE7L+5;+7/7%L 2:,8U:N#V KKJQ663(V%/T3
MBH!BQ%YMUYXR:QW>B#,R#/SPG'9:J.5M:]0G,MTH:]8C+5=KD%IW:0;2:QY(
MUJ2>R]D+"RT[)%4BYQM(I,V9G!9L4A*[8J D+<# 8X*[)HO,G;;AYX@+A"DQ
M.J(Y#G;TQ;+FY<J/.6L[*^GG51I S=7,):G]/@GCH24O+N=8U=[%H3'QA@Y-
MG*5ZL7)_%3D%*K2::[5Q69B(L<9*F92*3=-D)7Z/C_;Y\SB4+"04J$I.X$3^
M!^VVXQCAA7D@:O#:TM,^OK5IK9@\VYSQM8$9_*T>C4W00#EC#,G;.KT_&3QI
M&TYI&0L;\(R3AVX<5&":.'#TRS2NL%_:UGR+SZ?-_CZ;<;%Q.E24I@';GUG>
M]AQX8S5T,\JRQZ2];>OC5=9,LP%X@-8]OR#88:DQ-:DHF2I["_97L>2'#*8E
MWDDZ;23B/;S+>'(JQ:()N%$EW8E1**: H^WYGSYXJM84E @C2(WL; ;>F,%M
M#_)QYBV@O5G,2&%M8&)XK0Y;LS,LC9!QX2/F%LEWNL0SZ1-$UF0AI+&DC%0D
MB,,^"'DY2N90C4'Y44EW31RFW:M48@\^(G>_,_A&P'I%E.(4FZ3JB > /Q_#
M&Z/F2Z1)77?HJS5I3@[I'X]ELJ)4 6-OEHES.1T2M1LIT?) %=QC-VR<N$I$
MM/-%>DBY(=L9\5UZ"P("@I;&-"M*@J)B?M!&*@T :8931CH\P9IBF[7'WB6Q
M'69*#?VN*C7,1'3*\C:)ZQF7:1SMPZ<MD40F@:@59=0YQ0%4?1],"%8+5J45
M<_[!C"WFW\K6T<RMWI76K>6X#%J6GR^6JU3!9RLR-C/8V%G5HIS-HWV"2CBL
MWC,M/4 HNA407%\3<R0(F]9!&W0SM\QYXLVO1JM,C[1CS_\ ,3P9DK47]D?0
M&+\.9>D<#Y6>8HJ%DQ]E6+;KN7%7ME+P;8;9#F<)-UDECQ<FZAR1$T0A7(*0
M[]\F=B^3.HT6@BYO$]>47CG,#RQD089)(D3<'J0/QQLXT0\F#5G$:[&?,"YE
M>I6BZA<OTEH8N.8['9IM:+++H1;B"@Y>8/(43&D1!1M9C'TDZB:E5ZHG'#/N
MR3"[\5$'"4A,7)YQM;;[?3;SQ53B=.E"8!%R?[3,]3BE,M<EK7E@/5%F'41R
ME]8-"T]0^>I5>?O>,LH-GWP%'2LC(O9B2;QI"XPR[7YN)0EGKM[72RM49R\"
MC(O8Y"55;?U19!X'XS'W_O\ 01@'$E(2M))&T?C<7ZWQE-COEX<Q/(VBS6AI
M\UTZTJIF3)VIBN158H,_"14A(T/%+-D#IU(K)1I:CC=5<9N1<HE=M(J"CD$6
MD<S$IUC%21;(-Y-N7S?[>O05UI"DE*8"=^9^T[?;TQCYF3D&W_)_+)TI:"&.
MHJGQ=ET\Y9N.2)K(;NCS+B#L;6W/,ANSQ<7"(S1'[-=C\<VA"N';M1-Q[$Y,
M*:/K4@"--@)V_'UD=#/0S)Q8.@+4J#!  $[1'V6QE=E[E+VC)G,NTF:[FF9(
M"+J^FVCTNK2% <520<3]I=TYA9V:;IE+IRI(^.;/S3C=0Y%V[E5L""Y2^N$R
M8\""8OM$VWCYZ],0' $*3!N3QVG[<5%K'Y6MIU0<QW1AKHB<MU^IP6EU.EI3
MN/Y&L2,E+6LM.R+/WQ,T3-MI)NSCC2!9TT:<'C)8&PM@<E%?UOJDYB\SR^R?
MS_#8G$)6$H4F"=4WF-Q'SSV.,-]3W)GUE4O6/DO6CRK-5]-TW7+-Y%G>4Z/D
M9N_-6'<[)N2/K$\8'0Q_E"(E(J<EVZ-B^"+!3G*L///)1Q%2;=FJU9-D7G\_
MMN)_#$AQ)2$K25 ;$'A\1M^[KC/_ );.G#F4X8F<JVOF&ZO:MJ/D[A%U=A2:
MM0T7"-2I3F,>SCF>DD2*8\QHU*ZE$7<4V3]@KC<#)-UB.=P0:#P^?GE]WVXJ
MLH,:$P!SW/VG&U_B<4PX88<,,.&&'###AAAPPPX88<,,.&&'###AAAPPPX88
M<,,.&&'###AAAPPPX88<,,.&&'##%$9+QQ2\P8]NV*LCP:=FH&1JM.4NZ5Y9
MY(QR4W6+)'.(J:BE'\.\CY5F1]'NEVQG,<^9O42J"=NY15*4Y6)!(((W!D>8
MQ;+3/I4T_P"CO&J6(--N-X[&&/$YF3L(P#"5L<Z=Q-3"A5)&2?35LF9^P2+E
M;U:*)#OY5R#9HW;,FH(,VR"";!2BHR3)]!]V,A.&(PX88<,,.&&'###AAAPP
MPX88<,,.&&,4WNB'2W(ZIXW6N]Q.P<:GHB!"LQN4SV.Z [:PH0+RK@V)6"60
MM),L$!(/(L'ZE:/(@W7-L[]84ARQ F>(XXMJ5ITSX29CYOC*SB<5PX88<,,.
M&&'###AAAPPPX88<,,>6WFQ<W35SHWU>S.%,-K8T)2F-#I%A0+:*4I.RWPC8
M&+IP_$[\LTQ R J(D]2E[. I%W#TCB.X2!/STMS)V-@,2!/ST)_#&M;Y0YS#
M.NSK"7;QQDOT[;]/C*'A^4/,!XOH$;D&)VY;V@'$8_(?9#O,.'LYPEX=L9K=
M._7K9?FWZAU';IOL$!(//>]XB38;;@;CG;$QY]?R\_F+3B?E#G,-[^U82Z]@
M'&:P#_K*(^ ]  ?#W[-(G?<6N+S'KO/\G"/W?/WWMYVQ'RAWF'!W<X2_^62_
MS[_OE_H$ '8>@#PT@#C;>XVZ6_=8WXX6MOUN-NG7[L3\H=YAO]\82Z^>,UN@
M>/3XR@.X;=]A#KUZ!Q.A/ [[7%_L/J>&! YR9B!?U!^%M\1\H=YAO@YPGY[#
MC)8.@>8_&;Q\-O/B-(OO;XBTP1''GSX'$Q8F^\?82?W[1O?;#Y0[S#>WM&$_
MG^UDO^3XR]N@CMW]_3@4B^^QW]>FUN%R#/#$#C\GI]N^ _9#G,. 1_7.$]@\
M\8K?E"S?S;^/D,E(',>?WV!] 8G"WSZ\@>G'RF;3\H<YANW5UA(!Z_W,EQ[>
M/[Y>G3Z]P'W<-(F+['[(WM^<VYB5N$]!QX1M^70&<1\H=YAVP;.<)#OO_<R6
MWZ>[XR^7O'\F[0+3-YY<I^>'4;%;C/I^!O/'IUQ/RASF&_WUA'QWVQFMO]&]
MEV[@/S!U$=NO#0!,S;YM;[XCG%PC>Q^>?+\"(\H^4.\PW8=G6$A$._[62W4-
M^X?LF\/'P]_FTIX$V\C.QM'0\N(P ^'3S \^/(^6'RAWF&CMLYPE_P#+-;RZ
MAULOB/7??;;PWZ<1I'6V^TS$[7'7?C%SB2(GI\\)Z3?B!YS\H<YAVPC[3A+8
M!\,9+#T_E+\WCY^7 I%[F1MU]/F 1B(_L_#G/#:)^R ^R'>8=U_7.$A$/_=D
ML [=/.S?.';IUZ]MP2#,DV@S;B)Z]9OA&\VC[X,?/]H?*'N89U_7.$MP[?M9
M+;#_ /4H_FW\-O 4I F3QY;3O'+K(G"//F+>?#TF1(&)^4.<P[^^<);]_P"#
M);MMW'>S!L&^_<?(-M]]I*!P)Z_,6&]^FQP@29-@?7X6CSQ _9#O,-#^V<)=
MQ_N9+ (=M@V&S;CY]O$.H=>(TBVYO?AN8F")CY\D>FWY3P$>9]</E#O,-Z?K
MK"6P[=L9+"/7_O+^;Q\=NK3QF1;8C>=N7Y3:>(">0CB=L3\H<YAH=W&$Q'OL
M&,EO=_VE]_7RX:1:9OO\)Y';EQZ8D 6DQUL1Q]9/ >>^('[(=YAW?VG"0;CM
MM]K-81_UE_G\AZ[\" !:9F!M]WV<P>ML1;K\/WGY\KS\H=YAO0 <X2$=^NV,
MEOQ -F\O'J'0//B2E/"3M,08GTXB?+E?#\]^'3\<0/V0[S#0_MK"0]1#;[62
MP;;>8_&4?R>/$:1(W(/Y[S!$<1T/Q'I,=?L^. ?9#O,.VW]IPEX;?M9+^0]!
M_9*'?O[@ZB/FT[DS\0/C8[F;S$;XCY^>7'G@'V0[S#=P_7.$A\1_:S6V_%91
M\>_?IUW .S3P%]^.V^XCGUOPZ3'*]R/GSX#? ?LAWF&@/5UA(-__ '9+=.__
M &FW'80\NOGPT@?M2/P^PSQX[;[QA;]WKSOZ?N$S\H<YANV_M.$A'8.GVLEN
MF_8?WS?-T'W]^G$Z 1(GY%C $WM;>,+<+]9@;=1\[=<0/V0YS#@V_7.$^O;]
MK);?W (?&7S^OPX:1%IV)$_=$?/";P D'F+_ #\VMPF'RASF&_WUA(.^V^,E
M>P>?[)@V$1Z>[8>(T<;[BTCUO;C;\#B0)D\B!YGD"./YX#]D.<PX-_USA+IY
M8R6';MM_&4-]^O;MTWX:1UMO:?R^P&V\3:/W_,\</E#G,-Z_KG"6W7K]K);Z
M/XS=NH=0W#80[> I YP#!-O3>.G0B\C$1]EOGX8!]D.\PW?_ )3A+;;<?VLE
MNG0>XA9>^_;Z.@[[!(1Y^6Q OYWVQ,6GYXSYQ;X^N'RAWF&_WUA+?IWQDOXC
M_E+VVZ[CX#VW[1I'$D;7ZSPM<<9G;AA]T^?G!V,?CB0^R'>8;V]IPD(].H8R
M6Z;^[XS=0_'Y@ \-(!N3T-N<?9OZ@6, H-K&^V('[(=YAO\ ?6$M_/[62WE_
ME-Y@/8!WZ!N'$Z!U\["_D8X[;CKA'&"1^\>?/YC$_*'.8: B'M.$_#;]K)8-
M]_\ O*/OZ!N(^'8>(TCB3P'#<\-S$3ZC86G"/MV^,?,XN/ASGZZ^;SEW%=+G
M'&&AA+?DBCU>8!ICA5N[&+L%GBXE^#9P-D4!NX%H[6!%;T%/5* 13T#[;"TB
M"03:=_L&PN?L]1A;Y^?6\<<>W7BF(PX88<,,.&&'###AACP7?9!O_.,V7J(?
MM38L[?\ PM]U$=^WS]M]_/BZ38B">@Z\SPVO?CM8XGY^3P],:<:!$LIV]4N%
MDDS+1TS;*Y%2")5%$3J,I&89M':15DCE52,=NLH4%2"50@F Y! P (6,P3:U
MP"!(_?$'AL-[X'UV$']U_*QM&-XVO300O$ZIVVE?35H03Q72+IE;&6/\3:G9
MB9U+2$1;)6S8[9VR>A%[3?\ (=GQ6_;,'!;@[DP@:ZI/-(ND2!&@BX82::]0
M2!,\[;\]]B))^/2, >?PW'WB/3F<8I/.63)S47 6/$.H3&V8*L.I:H:6LB3,
M#7[M *XUOUTEFT-#RKV.LL9'KV&HK/G)6Z4U"&.1RL9!-!(Y5%%$))X7V*A)
MOL=HVM>_4=<3:!,\3YWOP-[;GEM><4C.<N2^PL?J>DULAU)=MIAU XVT]SWJ
MV$P56T3N2+4M56T_$)F2 K.*BG -W;A!XH+MRBJHFD4BB "LU2!S()GB )Z"
MX(Y1UXXB;1P-^9'7A>!TMBB-;>B\FB_(<3BISG+&V9<@G>S;"X5?'2,V,GCY
MVS)7GE>9V8DFU13]OM4=8$GC!DP4=*,U&+YF[,5=,I3P#.\0.<2;V$GAS_?&
M'[N7S\W/.^<_RLK9 ADVF*9VQB_U#86PVQSOE+ +")NJEAKN/5(.)M4\>.M1
MX1.L6BR5>KS3"5DZ]!N'"RJKA*.9+N'2R/IR%=+3N3ZF>I^$QRG $CT/7SCR
M,3UCIBN>9=A'3]I_P9HCK.'D<?O)V]X/J&4;5:F-.NL;D&^*V>*7=&NS^R3;
M@D8A5Y555-)E27+%&:A5DD51301%;TX$DD\N)O$#H1/XX7-^',_GQ/V^F,@*
M+H&TI56=Y2-O0N1,A/\ 5+94%,ET&TP=H<5[(\<VG8AG,+P";B$9-:W&UA22
M3AY6*L#Q)S8173DH@QDVJJ:L$DZN'/;:8C:>,??A/I;[#]M_NMMC'74)RT)&
M9N]^M6F/(>-\D0<CK9LNF%/&=996FMO,6W"R6"9>TVKN75IBF+*2@X:(1/$R
M,VP4-',E8IR+5Q)MT57*=M0B#/ R3R@_;PYVO))">!X3'K\_,SBR&J#EV6_3
M=C:>R>WR?4<FP="RX?!F3TH*O7FL.*ED<D<Y>D;QBEQ@HAM=:NX6CIA@VMM<
M66CG#J/W2(=%?TTP5/0\#)('7?>-]N,F\8;\S ,?#UV^WC&,L=-.D7#61]#D
M)E_%FGVLZS<YQDYD<VHB@K9LR%CS)>):O&)*EH3K&=!J$I$-[,H^9&3G).7F
M8NY-W*[8L+$0<BN[>F@X),[\-X%_C C[..]\)^$1^?V[>F*-@M L_GO%&AJN
M0CW 6+KGFK%FH:P8^>M82Y1UXRY;<9V%%;XE9'EGTH^A%;8\:%<M::[B(Z.:
M(LVZS!\W<NS(",2),B0#]D1(WML-QL.F'/TVZ<1-]X-NNV,#=3&F^8TCY&J.
M-[[,P5IO@T>D7G(U(9)R+9/'\S9VI)@V+K/(MW;==S8XV+%K\8%H19!%F,BB
MBR?B[(L+>P48FX!L.-QM%YORVD;W.$\=OB?O)YG\KXV=3N*-*]LT;Z0\ITS1
MQB2H95U<YUO> CRBF4]54I7\>K-;$6I5JXP,5)9VD?;)&/<O&\H]:3Y9R*='
M;BD:,,@<R!HO)D_LWV'V3M,^MC>V'3\N'7X[;GGOC'3)7+8J&)\PS>&+?K.P
MVYM-4;*DMC"E4;+F0)J GS3;&,;5QY 5*J2BQ7J<?(M):;<JNV[*& SB.]:^
M>M'I&\:CO$&VU@;FYY_VX?/E?YN;XN;(\OVRX*Q]KVH64G&!'".#7FG-S+9I
MEJ[D&Q6^N5+)MWKR,59\5)0J[08\KV.F$B7&&G:Y)R2S$'\;&"#DK=V>2JX(
MU>4FYGR,_P!FT87WO?E._P"<P?RQ7VHGE,T176M>=..FG*QT8:@X8',MWB+3
M6K[<+C4H**AZFJX1B6M:JZCK(TS:7ED*\@X"J-EW[1(IV+HH."HD5D$Q)$R8
MF0.?P@^6PVBX$CJ#PGA/V=/LQJ*LF+("%S9]J=AE&M2U?-98. #*:\%<X6NM
MD)A..4>2<K7'\ %XCC5Y9\NRG(D:^XE$7\6];LF[P 056F9&HBWG]UMY WVL
M1>X</7^W\.8$]<9SRO*XM:@Z;9FBYGJ%VQ_J/SXRTXQEQ6I.0:0[J>0GRYQ0
M4EJE=(6(G7]?<1R#J3:2\<4R;I%OZLJ9!62,:L[V$B\[G< 7Z6YS!G? F3\_
M:>-N/3%2RO*@?Q-JRY&FU0X=FZ3@*'A$LR7VG05]N):AD6R6J9K,-BAM4J]"
MO;+8;:H$$^EWZD0U5BXQBDJ5=V9=%1/@%=+F.&\$<9Z; 1]V YW\ARWF;[$3
M\VQ6R9I.LFG/5_6--V6E(BQ)KW7%B:\K77,DE!6^D9#<5Z2CY.)=*I1DNU2D
M8.8%NN51%G(1LBF\:B8JS4JQI&Q(MO%N'+K,;Q-K\,(X@]>1%NL3?E//IC</
MJ@Y7>GVQZMM-U>TX5%_C? ]BS!E'">H.,"U6NRC29;!,W(6>WV#XQ7.?L,LV
M&W8>1).QC<'(,(QRV+LIZYPLFWJ%&#\=M^'[P>G'";1UF>/SSXG%IM<'+OP5
M.9;4#1]&LL/8VK_+KM6N60C+!.WFZ*V>(IJYGRT8Q>66=GY*/G)^'D8HJ "]
M)"M%VZIA03%0PGD*)W/$";0./3EOPW!'%.YN>$_/21C@:%>7O68Z>Q]=\WLJ
M/E6FZA]"NI3-E'JSJ.D#+4J<H UAC%O) Z_J4E)EFK,E=1SQ@H8B(G<%,'I%
M(<\$S)Z@3\=A,C[;S<;8'X]>>.;7- .!("0Y7,]C2\4K(F0M42,D\L-#S+5<
MARF+L@+M%EF[R5]BB6->D(.OU995*,D(-_,L9.==BVE8M0S9NX06$DSOO-K0
M;#YZQA>\SU_?C5Z\TWWFVZI%\2IUPE;C;1J76PLA9*]7K 3&T%)S665,=D+
MOI C@X0,7+.!:1C5[(+ORMVR+)RLH^!037U6$7(&T[VD\.$?ODQA_;\)QE%K
M$@-).)LTY+T<XKTR$)/TJ;@\51>HJQY?R<MD%UD%I*Q;>P7&5J"<NYQ8XK#X
M57D:A56-*C7[=NH$DE9$G IM$8DP5$\[1Z;V.YW&W/#A>P@Q;<\IWQ664>41
M,8JOMVILSJEPG(,,,4BTY$U"V&(C;K(CA2N1@U9.F-[#",8EU(RUER8K9P"K
M5Z']<Y*G#3"K]5'V8I%HU"+[];S8CI'SQOA/*=HO\/A'PVQ35:Y3F0;IDFG5
M2HYIQ?+XZR9IVM^I#&>:E6MFC:98JM1EXMC9H:9CGL:2P52:A'TD1*82?L77
MP>@3UYDU5Q49H"J2#&Q%CZ^@VY3/E@29DS._S]D8QFU.:0WNG2G8,RQ"Y,IF
M9\19_A[-)42[U1A8X$JTE2)1C&VVO2T#9&4=-1KF-/*11@<'(0')7IRD*@HW
M-Z<ZN@',&9OQX0>IVM<8#C>-A'/\+;R=L9V,:UI)D^7(WU5):(\2-<F/M5"V
MG!)J.6M5QZVA##C:#LZ-N]A/GPS@UD)+2RAC)&<&@S-T4TO@C83@:!(,3$ 2
M8$Q;GRF_*.,# 3((.WQC[A G>W6V+6YLY8%<T_Y"@\99$UF840N<A&'GIBJ5
MZH95MUNKT&Y@VDU!.'=;JM7FG:TC/D<&39Q0K-54VB:4BLN#=XV!0"3>+<MA
MO\-K$Q^SO:3AU(G[!._R/APQ<2-Y>=KPM :K(Z7/@;*D*WT.5;5%2\@VVKY%
M0GHW'=NG)J.C9_'T,JO7G],R.F\@)5L[9W**DT6Z31 BC8AG"A.()VW$;P9.
MX/(#UXFYP)!C?J?F/MO>)MBK\V\J?%S_ "_I4PWIOS6DYM.7]*56SO;VEMK5
M\DW+R*3A[_-6')]81BZQZY5A8@J;:&K>*VK9>ZHR8F561]E<%.D*I^._+ERO
M /GZ#$?/SSW^1C4)F_&<7B+(<O1(F[-[\A$H1YE9M.JVRD.T'KMHBY=PTO5;
MO%P]DA)B(74,SD&;UH %5)Z:*RJ9RF"\FVYV_P!6]QQV@$F(OS(Q8'GYF+=
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M<XG&$C9W5PKC,]0I,!1I"*6D5HB"(JWL\7%297;QK!QS^.2GG!&2PNVZ<@H
M$6O(B0-[GG:WH;"^V(CUD2(]=_*^V_/%=VOF5Q,+7B5C37IUBL%14OJ>JVJV
M_!.9*ELL.;;?:7)EF*U6F2CJKTU*NX_CI,H/B0::$E)&<$1]"<20!=%Q73U)
MBUA?RXG:1>. VPN>=APX==NN*QROS3JC>J9FVK4S2I&XZD,_YMQ9GW(EE^W+
M/V]X^N^.[0PLKUNS92=.8-&%>FE&(H1L8T!%:NK/Y-TN^GTUV;5@T]9@<MIV
MWXF2>FTBQPCY@[WMYF,8):M-1CO5)J7RAJ/)5PH#O(UBC["E5V\X:Q_%]>.A
M8F(222G#1,$:0-Z441X"PQ++T!6]3ZLWJ@4/(%C,["WQ,0#?>=[SP(PN.>U^
M%CY<.7.TXSAOG-/C[B3+.16.FJ$KNJ?.>GXNG/)F=V^3IYU"/:D[K<?4+#/5
MG%):VQ;UNW3M:B(A@>2&Y2C9BI'I.FC AE')%FD3T%XB_P"/H"+W'7 CX';;
M\./[K#&(NJ[5>YU/QNG.,7HJ%+3T_:?J)@E!1*QJ6 ]J+2V?L@VA4#PD*6&-
M)B4% AB!)@R_<#*O/W8 "#%]P3$CG !'.>,#AU$BQM)VVGCPMY])B 1C).B<
MRJ-K=,T01EIP*6U7W0O;'DICN[1^4'58B['49:T,[#+56Q4[XC3B9)-=O&L(
MUE:&\Z8&7J5'JD$^,L9 L1PG]KH()O%]Q/"!Y3@1)MQVX3\?QX\2;XZ>N<S"
MV4ACDQ6FXWCXNS7O75#ZW8F<?6@TJRK<C$OIYX7&[R&^+C(9^.>ISBK-Y8R2
MD(X%LFH*$0@LNFJV%-QT$6$WX<H)WXP2),'$'[OG]^*;U@Z]$-54+.LDJ/EB
MI2%LOI,@S[>V:JLI9;Q[%21DY0[N)QUBZ;80=7IT&O(2J[MDWD@MDA7VR2,/
M79**BA6:JR/-.W(<9L3S^,B\&^ \QL=_AQ_"?(W&/WI9UL8ATHN*)DBDZ52O
MM2>/H*Y1D5EIQG>[-:9-R=J8RT.VL%MQ$:"?-)%U!0LLK&-XN'N5=K[\4ROG
MT4H^]4X2&3:>9VMSL3O>P-M^1 *YYG[;G\SBZ]'YJ3FHPNFY9]@2$LN0M+=&
MS]&8RNLA=A2C&N3<X3H2[7*3JGC2G+4RU#(J_3AJV$N";J1<MI=.:C%XYN@,
M:1!O%QP/47X;R)N!&]\-O.8/3\Y^SU&,3M9VJE+6)D:KY?E<=-*/D<,<5&I9
M5FXZP%F&64KA5V7P:MD88H*["!6)":9)M4'T0D[FD"%9-3)OS'!4ZU@(GB-P
M(N1/"\&#^X"1,['<Q-N<"8L8'R?6MXG7*]BL%Z/<(IXV;*H:3<]3N<R6,]K5
M*K?7,M;&%H2K:D66O"2KMV@-5F"LF#ZP*.Q72=$9-/9SMW BY,P2#T'*3O8[
M_B#B"./Q$;3$1O;K^8G(:C<U<]4S7K)RH^P=(*Q>L&<A)V4CJ3FVQ8TR)CY2
MOS2DTUC:[ERNU):46B) 5W#&>;M:]"NI%JH4$7K Q-S5*3;F.<[;VL9 OSW
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MQA??TW'(B/@#\QCJXS5NXC=%;/1Z%#161::EPU&ER"-E.10RPTN'J U$]7^
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M2"3)J5ND@S1*$I3:3UBQD'TY1\;".,@"+S^/.8Y;WQB-M^YZ_2'O';8 W#8
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MB</DSNF/PU"9X_T7'V_AX_%G?P\-@X%1-X'I(]+'$@] ?/AY<L ^QG-,0?\
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M_6Y_X>VM[_<)PPQ/WQO!W7]J[6YT[_\ F]M;W^X3AAB/OC>#NO[5VMSIW_\
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MFRA8N2F9)46\=$L'DF_7!-14463!NHZ=*@DB0ZJ@IH)*'!-(AU#^CZ)"&,(
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ME%-EZ*Q!JN]>*CE[;83J%0AR'3*"H%D$8[3F7NM&_.8J[/,]G%]C&!64SK=
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M4,K4J"=*4.)4HP 28 )@ GIC$^E2V'D)$J6TXE(YJ4A0 OS)QIVG-/VJ3*U
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MZT"5^G7:@0FF:BQ=1R(6M!;8AFZLZ)7YZ9+R,W4'#-X6?^$()Y5W\L]^ 'L
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MQP_]O#[HK _X7\=_RKA_]JX?HCVH_F#-OZ"__4Q/Z6=F3MGV5&9VK6#L8/\
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M[[_P?K=NO\8I3;</'K\W7QX]%^QK^(\UGCFP'_R;'W[??;'GSVO_ ,=Y7/\
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M2'21 24.+2)6@%PH3JE0!LA)+;9"$*U526W"I1"DL^[U#BRB#.H*;020E9"
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MRR)_BOA._O;XX>?X;G&M,?#]-_=X=?YO+?CZ_P P!87GCPY&#T\SCY(0-A,
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M%$ZSE]26Q3U*U-!#JG-:FX0%ET!025)U-@0)X@FW"21U54T4P 3JG*FF7<
M3',!2AN.P!N(AU'MN/7;CES*0HDP G4HB_AXD#<FUXB8XDB>*"5$A(N5:0((
M$S MMN8DVVOOBY]KPKDRGV61J,K6'CF<B*^C:I5O"!\,IQU>6:B\+*O'# JZ
M+=JFW 5%U53D*CT Y@'CA:'M#D]?1LU[-:VBF?JU4+*ZB6"[5)7W980AW0I2
MBLE*4IDJX W..6K>S^;4-4Y1/4;BJABE36O(8BI[FD4CO.^<4SJ2E"4&5$J
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MMU]WOZB'#A:9 F#!M8VM M!C>?(2'07X;$G[($2)VWWD09'Z=]OHW_*.V_\
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M&_T_-M\_X_#YPXB(BUYX[=),CS@@=<(B/,03M?:3;H=AQW$8CKX[=>P?/MN
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MW3HU&R%OA&EMLDJ*DJ42$J3C"C6IE-1IAMU)<;;%W=#;*''U0(UI9U2M:0
MI*0"J<=)5.:CBRJ#9(K/BLHSGTM0F?*#&#C:AVBT1%.P_BG*S7&49E?*[^.&
M4;TRHEE):$C)JVR2S:,-)OC*-F:31J].TPLGODTH AU]*M4@AM"UYA5T5,@K
M-DJ?-. VDDE2PNX ,97&RA52;=VR4:-RM:104U8^I*0)4&@\5+4  E!0+J-Z
MTF>:[IOB8C+M@;4;4U9H'">1)[&=UGJ=IYO]GK_P[41N2MS?PMABF:\'+5VF
M1U(DI>TS24B1M$,I"!26 9.60CP@*26TNDZ&U%[Q+!2$I866WG%$BS:' 4%0
MF5A24@E*M,EE?>=T-*EPT0E*@2I3P2IM"18E:DJ"M,63<D2G54C?F@Z57.8H
M'#*4AD89&PS&/J^TOYL:6<,1-)K*^*F69<:Q<QD?V88"&DKI1W:[R$CI%5N_
M4=1<H@Y;-DD$G#BPC4\@D(+*ZMM16=*5+H4=Y4H;5^RXIMH*=(03#:2HQ*0J
MI;4$(6(4'$4S@"3J4$5;G=,*6G= 6]I:&H E:TI ,**>GC>:QI:F*'8,@14=
MG5_',+%3:]3(1#!60BVO-(9""P+4J?P? K123G)58L3"IV:7:34*;U#>&@WT
MK(E9,O9UEX)A*%$*!63X"(<0D,>]%QQLPI#8I_KBI0$)L860DV[HZU(U(.D$
MZPH%M2@][OH2L2%.=^0T$BY401*?%C\ZJN81!XITFXQU,84J5XR[%YGM>+(6
MBJ53'5AM@LXZ[6J&:2ZUGK[-Q$S$-*MH,\Y&1L2],V=J7E!C772:2ZBI2PX2
MV]3M$2EU2'%+1XTFF2A-2ZM"@8*E4FMULF1I2I9$(5B&T=XBH(@*92Z@(5*2
M*@%3+:5@B0D5.AMSB"H 74,8QT;F":P9X-%N3K'BC&M6PSJ=MF)*$QJ%C:V2
M%SI?I3*ZMUDIZW42MC-.BUZHX;J,-5[3++S\7)IW6N2TC8&#^%9(LRGR)014
M,L.QJ=8*BELR6ELY:FL?><)L&O>@ND[NRVSH6I2BXE&(<">Y?=:489>(EP$!
M2%U_NK+28B7"P4U!6/"J%I"0$*5C>-Q7%,.&&'##'41<_!3BDFC"S43+JPDB
MM#S*47(LWZD1+-BD,XBY,C594S"10*H0RS)T"3E(IRB=(H&#? Q54U5WONU0
MQ4=P\Y3O]P\V[W-0T0'6'>[4KNWFR0'&EPM!("DC&Q44=72!@U5+44PJ6$5-
M,:AAUD5%,Y/=U#!<2D.L+@Z'6]3:H.E1@XY+"4C)4CE2+D6,DFS?.XQV=@[;
MO"-9*/6,W?Q[DS=10J#UDX*9!VU5$J[98IDUDR' 2\6:>9?2I3#K;R4..-*4
MTM+B4NLK+;K:E() <:<2IMQ!.I"TJ0H!0(%'F'Z<H2^RZRIQIM]M+S:VRMEY
M <9>0%A)4TZ@A;;B90M!"DD@@XYW&7&+#AAAPPQP8V4C9EFE(Q$@QE8]<RQ4
M'T<[0?,UC-UE&RY4G+915%0R+A%5!4"'$4UDE$C^B<ABAC:>:?;0\PZV\TX)
M0ZTM+C:Q)$H6@J2H2")!(D$8RO,/TSJF:AEVG>1IUM/-K:=3K2%IU-N!*TZD
M*2M,@2E04)!!QSN,F,6'###AAAPPPX88<,,.&&-*7,Y_A5QW_F^6]_\ &.3\
M./1?L:_B+-O^UA/D*1@_A%[<\>?/:_\ QWEG_91ZP/>WSM^=N=L:T@\.NXB/
MGN'OZ[;>'EWWVV\/L! ,^=K6-K ;F_G$7Y#'R2Q&UYB8L;':VYM;APCA.P;^
M7U=0Z"/OVZ^&W7B+VGKP'0<1%[7OS\W0\[[<H!G:+]8-]SAO]>V_AV\-^NWX
M_/W\2-R 1>(Y7XQ&\6-AQVL"F"=@=HM'Y3$\A<[;8>?EY[^&V^_YO=P-XF/Q
M)!C:QOP'/EOB3U]9W/6(!@W$3 Z1@(=!Z /B._CY[[^[] VX#A)/ ".42-A)
M,BW7:8(PBU_0[ B)BXD[")]-CB-@$.NW0 [#L !^8-OK^@.'^MO?C(Z^F\W&
MVPWO @R(OT(B;Q;:.HZ ;WG8-Q$0 =_<'Z#X_7Q%P=M@=[1,@GETXS\  $&X
MX&=I'X'H3(.V]A'3?L'OZ?3W[>7?;??OTXF.)$]"9W$1PN8/E&VV)$SL3:8,
MG<7Y7-YGJ()$%Z)=]P -P[= '8>H?/\ /V[?/Q&P\Q?[^._0CF-B;UM^?'^V
M+W'0V.'?R';H/S"(>_IMM[^WAP%AQ$@Q<_9;C;X<C&)FW.9D'GSY<CSMN.,@
M'F'COXCU\^O;MV\/IX;QY&9]2?NX\;V)G".$"8)N;\[S>8M?S'/#O]7B&V_S
M[AT_3ITXD6@DFU[>0BW78GG8\\!PZ7^P6CK83YV(OB?G_3?L'YO?Q%]_M@B\
MF;@\B2?*(MAPX7XP1<DS<=#?<6B^-^&(\?N,L: @Q:TDT85UDC#61Z&VF7#9
M1ZWB7%N2M< C)+LTEFZCM)BH_*Y4;)N$#KD2,D19,3 </(/M':[[M7VA:!">
M\?;3)$@32T^XM./6GLZ<#/9;L^Z4Z@VRXO3M,5=08G\?B.&,5,U<IUIERMP\
M"WOM-K*D'I#Q5@!HM]K=.5BY#(N),OT/+T)>[' EFHQO/U.7D:,E"3U4<NTI
M!U%R;KU4XDL1,_'5:A7?5%54)0D%VJHZEIM<E"#3+S K0O3$AUNN+>I,%!3K
M$F!CMS"RU3,4RI/=MU3;CB2 M:7VJ5"2DJ"M):<I@Y"M2524$053PJARK++7
MX"U-'.1<1QDS==&F>]-4VCC3"X8VI;2XYMR6ROGQTB*M'6:1%.&@&+%O!.FK
MZ1>6&QJMRS$A-)N5E4BZ]0SWS=2TE1 ?I:.G"E&2DTSU8^M12 $@.+J[)3 0
M4J5XBK%VW@VZPZ4ZNYJJFH(F)2\Q3,(1J5J42A%.)4I1)!"1 3BDH?E&9'L<
ME5K%GK4C 9*LL1>,6-99_6,6JX]9O,(8AT_9CP=7*@R8)6V?]1>I13,<S:9R
MW*KGC3+MTH]A M6Y4S%S.A+QJ"H$&L5F"ZA23$KK:$T*"V-DI:3#A2=6M14F
M0 #C&A9;]WT  4J:1#"3<!-/7(KEZS8J+A3W:2-.D $R2<5,TY8.=KG1<08X
MU!:KH?)U0P]<HQI78:MXF3H+)GB*%TXY6T^DC6A"6BP.QR/94,DM[+9[&Z?+
M5XJT VCX:N,B+*N5*O@U2EN/F7GF\P2\M-@%5U*FG'=)V"&EI4\0LK4M2RD*
M2E*<6:6FGTI824H;<HUMI4=1(I:HU)[U4>):TD,@I"$A*0HH43 LY(<F[.%O
MKBXY4U-XFR9=ZA$::8C$3F;T\N6^/FL?IG;90K,!%9,HZ61U5K@SMM+R;+)S
MSJ-GH-TQLJPR,6F1JP8MANXM;JEO+T%]VM]]=)3+16NA=H74H03*)2X7$&5:
M7 )$0!5);0$MI2L-(I54J/']8$^^-UB%*5$*(4V&UIT@+03<*OC:!'Z5%XO0
MO-:/V4_4(Z3F<$7;$ZMJJN/V%'I;:?N]>G(^3L<5CF"?&9PD1\-3KJ5""929
MSF()RG?'<K*.!I5I%0VXV@E 4REE)4=12E#:6DDQ'!((2(2D0E,) PIUEEU#
MJAJ*7E/$)\,ZG5.0#<R-4%2I4HC4HDDDXNYYY;F0,IDKL72L^P^/ZU<],%&T
MAZG8J0QJ-L>9"Q-3'ZLD60QK*GM40;'MS>)RUL@/A"1:6>.3BK(1^+ \K!LE
M%\KB@[55#JQ-/45C%<MG9??4SJW&AWEP&UA00Z B? "@I*E8JA2FZ=AM.GOV
M&'Z=#QDI[NI;0VX2WQ4A22MLZ@)44KD018J[<F5Y9LCQ>1F>3L3/G+C)6:G]
MLA,H8';97A5L5Y:S&PRTUC*M'S5MC6<+D:M"UD*V2S2#:8A9!E/.W2T&FXCV
M <48^J4P5!*PA #L#2M2F\PKJYHMK$]V#[\MIRRCX4NH*5) -G%A:'4@%.I4
MM^(Z4A5!242PXG_.$&D;=092!XD+"TK5-9YFY4^0\DX4:8?KF?*E7(];4)JE
MRQ9(VRXM?76BSU7U(2MS>QS)U3"W6O,G=ZQ2E9T'=)G9A:5K[6?:GE%:XH0C
M=L3 6B6FFRJ>[I*ZF,R9-95NU*7D$F4.-I<[D+@J"5.+0I)(&,S=1W;KK@3)
M74T50FX$"DI6Z933@TG6VX4=Z4 I!4EM*K21V\'RKK WBX6)GLMP#]LUS;H\
MRG,@PJDDS.^A],VF>+T_V&OM%5)M8[5[<W#%>PQ4D?UJ<&U7)'N6T@LF+HV9
MP)<(D$)-7G%2L WTYKESM#W8,;M*=+A41XP(TI)G&!*RG8"139=3IF2)R_,&
MZW41:SB6PWI!\),R0 ,4#*\IK.MCP'6<*7/551+['8&L>*%=+=>MNG]J\QC6
MJAB:&NE4;,,NU1.\%EL@V>X5"YC#6";B['6H]@YK<'+Q$*1V9Z54K4X6W72E
MRI22E;I3""T:5-,H-- ^!9(]Y)6IP=Z$H 2WJG(E;:"ZE"%I9<!4$!<+[PU/
MO(*UQXTINRD)#9+:U*)UZ=-_<^<LR*SEI&P#I??6VO07VE5U)I>:IE=GL7U>
M7M26.+S!Q\C"4G'%L@T*W%MLCV6$O!(8LG()H-(-:-1<"Z?J/P/I2ZZEQ)4D
M-T[S+842HI*Z<4Z%&X3"(UZ(B!W0^K*@J&'.Y"P0%=X^VZL :04IJA4+23=>
MI204:]6HJ/>JE8!%MZ?RUL]8BU-:>\C8=SOB^.T_:?\ &U.Q35<39'QK;\G7
M*MUHSA-[F62Q]?K'D);XI6O*JW_DU:?-&R3F%K49!UMAZN&9KLG64+_A%4\H
M2E_2VA*?"MNG:0H,L:[D@.J[UU1&IZ$!PJ[M!&(QW##0G6V5..*).AQ]:_&Z
M4 P#W7@;3.EHE90!K(QN@XQX8<,,4U<[$E4*A:+4LW<NTJW7YB<,T9H*.7;K
MX+CW#T&K5LB115=RX,B"*"*9#G45.4A2B(@'''YK7#+<LS#,"A;ON5'4U0:;
M25N.J9:6XEM"4@E2W%)"$@ R5"V-_*Z)699GE^7)6AHUU;34G>NK2VVW[P\A
MHN.+40E"&PHK6HD )!).-)6/'.HK"L5?6DICVZXUD<VU?'N3[#:J\[:WJ85F
MT\JQHYVN,<TBH^1&OS[G'5Y!PS@WS)Q*1S>JJN6R3E=F!$O/^5*[3]FZ;,J&
MIR[,LE.<,]G\XK:ZD>1F50%'-6:7M7F-.:=#XIWWZ6I:J%-%EQZF;;J*@ZU!
M!'I[.4=C>U%3E-13YQEF>,=FJO/LBH:"L:7E5,FG5D#[G8_*ZA52ZQ[Y2-9M
ME:VUU33J*=]RN::4IM+JM5PL;N\W1#JNP>/YC)BU4S=G7+L ZL$O#NHN5@6U
M?RZUR(:_2K=Y$1RT8[O>,&=M@%'RS%B1X]<1)DD47 D+QR60J[14SF54= ]F
M_P!']H<\SP.OO,K9?I$Y9VDJLZ=K7D.LMFG>SO*E.TKJ>X:"UE*6^[4A*3Q&
M>M]EJANOJ\VI\C3F'9;LKV<J&Z.GJ45#%8O,.S/T(WE5.XU4O)J&LFSUS+ZU
M*$NNEMI%1K4M!*L=9$9?U$6ZX66&CY_,M8K\_<L0HIA*M7;VQ5H97,=BK=Y9
M(O7F.*W"PRC>KC$(R4)"HV2"@VY&+T9MT\6=J!K4.=]JLPKET@K,_HJ:KS;L
MV)>"UUM&BLJ\[8S5GOW<IHZ=DH0S1)J*=AFHHZ-T)2W4.*+F-BM[.=C<MRVE
MJW*/LS7U='E?:8GW=QMJBKE4V0Y9692Z6FL[KZJI2NL55KIZJI715E62XV:5
MMI+2<5]CK)N:W,_CZ.R)=LU1I6K 8NAA!4<\LCDFSQ.<<C5:=99$53K*K;U:
M6/HBE+/7[UQ$)L8>0?6UD*[P15+RF29UVB>>R89OF&?LU/N%.C+&*?+BZQG-
M4G-LXIJXYJH4A0E2*2GRY3[BEL>[,+36-@J?)QQ&>9'V7;I,Z=R7+.S#H54N
M/9LJKS5-.YD=#4=F,BS"B7DJ#7)62O-JG-6V&FFZDO5+3>7NAMM(2:&H^5=4
MC^!>R&0[=>J_7!O&/(_+YH&%M$I>L=J.IFVEMRL"1?$L*S@X)T9*H0ZL-6W-
MZ^ XXAYA.5.A-'=#QN49UVR=H6G<[S',:6B5F64-YZND9JGLUREYVFS%=>A&
MO(Z9-+3NY@G*Z<T=+](BC05Q5.-5$GE<XR#L&S6H9R7+LIJZT93G3W9Q-944
M%/E.=-MHRT99[UH[153E75MLJS2I35UR,J]\>*&%4R5TH0,_]%3208Z9L:MI
M1"7;/REMJKA.>C58>9,+B\V9P1>3BUFS-1@\<IJD<K-1:MP2,J)2)$(!2A]6
M[ H=;['Y A]#K;R:+ZQ#[2F7DJ+SI(=:4E*FUWE2"D:28 C'R#VGN,N]NL_<
MIUTZV2[1!M5(^FIIH3EE$@I8?2MQ+S:"DH2X'%Z@F2HF3C*?CM^.A8<,,.&&
M'###AAAPPPX88TI<SG^%7'?^;Y;_ %CD^/1?L;GZ"S:/YV'VT; _=^['GSVO
M_P =Y7&_T7]]6_Q_+A/#&M+??<?+R#W>&_?IV'H'7QX^OW&GA.W#>U[=!/,1
MQ,GY))MPY0.-K7YB.=HL23B?HZ=/=W'Z-OR_3Q8[V!O:+ 6D1.V_"X/68%CT
M! -HF.8@\ 9V WXX>._SA\P^7GU^G8.O81'@+'RBQD$<38S;@;\ 3M.(%ICA
MSD&-X@DVO'+B2+3 @/Y/+?ON/T;=!VV'IWWV$&P$S WM(B('$C<6F-YB,1L!
M,G[H/J1$BVT\#L1/3O\ F_-WXK>?+;:-I\A(D_'<XF3,QL/B(D"+@2+GA:UP
M9=>_U;^ >/;;ZO,._ D[ 6X1/&#821]XXC?$$G8<=K$;\!]DBXN(YXG]/T_H
MV_+NOM?E:>O*T;\]B<+D?9N=A/ 6/I,P;3)Q^0 /#H&^X_4/4-O/IV';;IYA
MQ/'G;@!<FQN!L;Q/P/&=IBXXP!>;$".!.VPML2,3W !#?S#M^?\ X?1Q!Y 1
MTO:]C]L6F\\<0;_L@Q&USL3?^R;X;>6WN^?K^+YO?Q.^YL9L#, 2;VF=KQ.\
M\L3TD&08$R !)OQGEQ^$8#ON';YQ[A\WXO'@!%IW VM8^<2;\CQVW$1! XD
M CA,WVO;G&\;[._3N ]!#Z_'?Z-OJ\>(@=#8R)Y W%A:QF"?NQ, <C:2+S,'
M8B! B]^8N8P^;W]?HVZ@ ;#V\1Z>?AP&U]A!BQ)!@'J.$>G0XB\'D!S!@2 8
M'':W ><''H\T=*)I:8L4*JG(DDG 2*BBBABD(F0E@F3&.<YA I"E* F,8P@
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M^(_3CLB-L_H#?BZ8Z6T7MY1B!V,[5#;(\PG_ -4F!_\ $9^R,3]RAJ._!!<
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M5&K6Y7)HULMA13$"R4PW2>N .L0I@HD!$:0$PPW3"+13M$*:9_\ 5MJ *4[
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MU%1?C7/951.O9N\YG%8M6;TM12/+53TZGPV_FU/FVMU\_65+J'*=-.E;Q(#
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-88<,,.&&'###AAC_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g401831g01a44.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g401831g01a44.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1K@4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &L2^:%(X0DE-! 0      !$< @   @  ' )0  5$96QT80 X0DE-!"4
M     !#C?*;(JC_4;-3S<Z3Z+->M.$))300Z      #E    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P
M4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M     BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O
M;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M         $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M        0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0&[9
M6"         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M    4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2
M;'0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE
M;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC
M<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M   +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU  (  0._
M_C4  @ !.$))300F       .             #^    X0DE-! T       0
M  !:.$))3009       $    'CA"24T#\P      "0           0 X0DE-
M)Q        H  0         !.$))30/U      !( "]F9@ ! &QF9@ &
M   ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    !
M "T    &       !.$))30/X      !P  #_________________________
M____ ^@     _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M #A"24T$"       $     $   )    "0      X0DE-!!X       0
M.$))300:      -!    !@             ")@  !?8    & &< ,  Q &$
M-  T     0                         !              7V   ")@
M                   !                         !     !
M;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   ")@
M  !29VAT;&]N9P  !?8    &<VQI8V5S5FQ,<P    %/8FIC     0
M!7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M        !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE
M<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
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M='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M   ,     C_P        .$))3001       ! 0 X0DE-!!0       0    #
M.$))300,     !")     0   *     Z   !X   ;,   !!M !@  ?_8_^T
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M3^T>L1X[O]B(SZL_7!A?%N$1;MWM,D'8-C!M=1^Y[/Y:7_-CZW1&_ @<#;(
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M^M&0ST[1A;9#I9
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0'_P  1" #6 E(# 1$  A$! Q$!_\0 'P   00" P$!
M      8'" D!!0($"@,+_\0 B!   00! @,$! 4)# T1$@<1 P$"! 4&!Q$
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M9BX2[19SUM?U:C_RS&/K[_(YNJ;:T^S^MY!\U^?*.OM]W7A]@KCK;QY#O?\
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MV%R@]?ZP@M;L?U/H.EO;W[N5!YD.88-#C5-DG)]IQ$U U@TTT>9RW'@<C]I
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M]\XL?NU;V.P_?M)O/I ]&1XZJLOJGS1\N-!!/#H2D6J$@GJ.<6U&HATZ;Z;
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MT!O?8'?%W3>F_CJMCK):7).'YHZ"F-95.M)F96*F61(C(Q^&-OE)(T"GQ,6
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MLB[%/54L*QF:I@B28 02"J2,R2'Q+$G/)C9F0.P%BQ"DV.QQAHX9'U!8IY-
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MVF=B?><>0K\T#_TW&EGGO\7>A\O/IJ-J4ONZ>7T[ITXJIW]UA]\]>WO_ -&
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M[*J?<Z[;<-O*_NV-MCL>^^_4?7U"W7KVL=NF^WET-_?W-P;?O0;_ -/OC?\
M:QU+1?;M^IM?[?<FVWW.OO\ #?-7?O[^FVQ\OKZ[&UL#?2/+[U[F_M)L-OQ=
M#[5N/&/.#AAA#:G_ -#;4#_85E/^\D[BWJ_UI5?W/-_Z;8L,T_8S,/[BJO\
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M2@L5T#]VJ[ =1N:=?6^DNAJYZ+XQYE5SP3UU.8*+/7EJ5?+4$E9(T1G$J11
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MS3I*+;/%'(CN!JV(MUVDG$Y]- KU^-WFN&H+-4&8%Z2;)M1\4JY]-9WLZ@T
ME8GD];C=_C\*34C"#&Z/(YU1D L=CJ.S23!:0%868@^UJ;< 9_ \\&24#92N
M8>CVEI:B2&41(V<PO0<ZFFD#$I4S+#+JD(TD,QUD%K[&O&632"&7-ZM<S:BX
MREJ81(G,899,E6W.C1P T"/(BB.^Q"BP &F&WI(^8G#M8*S33%,3SC3G5,.+
MY1J/D,+-,6G:RWN60J+*9\"5 H<IO]88<:>@SE[^9#Q>D-8U&+)#2% EMAR
MB3=/1EP[4Y159E755%F>5-54N6034=53990T<U33Q2+-50098S1S.I 3UN8)
M/*LAYBEBQ.K<=YU3Y@,NI8*S+\PCIYZZ:*LIZFOK*I(9F7DT\\M<H:-54W6G
MC+Q*PNK'NW^$:S::UG(/BFDT[*X4;4.!SW4NJLO&G1K)\L&GT;3F+32<D4[(
M3H*Q!6('Q5 R6^=V^K8JM7?C+5F4YF_'\^:)32>HOP+697ZU8<LULE?431T]
M]5^8497 M:QZW;?&4F94"<'0T#SQ+6)Q1'6F DZ_5S10Q-,05(*:D*'>]]K
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M\S^?F// =_O6ZVMOMY]?9;KVQ1'LB*NWDJ?/LG3V==_I1.B^WV>@+&XVVO\
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M><'##"'U._H;Z@;)NJX5E";?/23D^3BWJ_UK5?W//Y#^IMYV&+#-#;+,P/\
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M7)/:6>44I\&#G:VFEF7.*=5IJ2""6"* "CB6G-*ZQ"*5*IF,O.D0B1R2WCU
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M<ONH <BF]M)B^H<DRN;E21O7/$T.<%XQ+"9FERV58X]!6GTA9%8:E(9BU[,
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M8KX ^YND_P -6?Y3@^M=\B/[@-1T_P"RS4%/_P#;.'Q:R+[64_U/_CX?8KX
M^YJD_P -6?Y3^9WQGZUYR)?N!5'[[-0>N_O_ )+.OT\/BUD7VLI_J?\ Q\/L
M5\ ?<W1_X6L_RG?VWZXQ]:[Y$?W :C]]FH/W/VV>7R>7W.'Q:R+[64_U/_CX
M?8J]'_W-4?\ AJS[_P"B=\'UKOD1_<!J/WV:@_QL\OD\N'Q:R+[64_U/_CX?
M8KX W_H;I-_*:L'X*G;Z,"^B[Y$5\] :C]]FH/\ &SA\6LB^UE-Y]'_Q\/L5
M\ ?<W2?X:L_RG OHN^1%?ZP-/^^S4#^-G#XM9%]K*?ZG_P ?$#T5>C\=.&J0
M?^-6?Y3C'UKKD1_<!J/=^VS4'V?^-GR</BUD7VLI_J?_ !\3]BO@#[FZ3_#5
MG^4XS]:[Y$E_K U'EM^VW4'R_?9^77W\/BUD7VLI_J?_ !\/L5^C_P"YND_P
MU9_E.#ZUWR)?N!5/[[=0O;Y_Y+>'Q:R(?V,IOJ<_A?#[%?H_^YND_P -6?Y3
MC'UKKD1_<!J/WV:@_P ;.'Q:R+[6T_\ ]?\ CX?8J]'_ -S=)_AJS_*<9^M=
M\B/[@-1^^S4'YNG\EG3Z.'Q:R+[6T_\ ]?\ CX?8KX ^YND_PU9_E.%3A'H\
MN3W3?+:#.L&T=@8[EF+V [2AN8V2YE*-7S1L()IF1K/(9T$VXRD8K9$4S%1W
M1$5$5*L.0Y-3R)+#EU,DD;:D<!]2L#?4#KZXO,O]'?!N55M/F&7Y%34U92R&
M6GF1ZAFC<JRZAKF87LQZW^K;$TFIV6HU/)$1.NV_1-NNR(GW$1/<G&7_ #_.
M^-U^_P#G[,9X88^9/V/M\T\O=OUW3VIM[/?MP^]?;Z>W7$'I^'W=^GLZ8\C7
M/IR@\T.H7.#KKF6%:&ZDY1C-WE5;,I[ZIQXTZKL8X\4QZ*X\&4UI$*-LJ/)$
MY>RQ&%$]C47;IR3B'),UJ<WK)XJ*6:*5E,<D2 JRZ5!ONHOL0>M][^WX]](?
M!?%.9\99[6Y?P_F=525%6&BG@@FF25>5&"X*LJZ=M*@:MU(-BI.([2N5/TAL
MW'AXC-TJYBYF)B& 0L7E,R63CHA1G,=&$.D-()6#''<(3@#9%1H5&Q1HQ6MV
MQK93Q(\(IGILR: :2(6D<Q> 66Z<W2--K+;H +7VQKDG"OI,EI%R^3*^*'HE
MTE:-A7&F71;1I@]8Y8TV&FR[6%L=@O*[Z1<Y*4I],N9,Q<;<YV.D*_*2DH'O
MC/A/=2$?)<ZJ5\(A(;U@*!7Q7OCN50N5BR<JXE=D=Z?,2\7ZFS2.2@(*V0F7
MPBQL=-K@]-B3[;ACTGMZOJRWBMO5-7JU_7R:<LAB)A)J?DR8V:,E;'02MPIL
M=-"Y.N?:L# CUFBFO5='JKI,DJ@0:^[A@K,B08A)?5XH[Q,A72"" 26D9!3N
M[")B'5@F(WQ'D_$,6D1T=<@CE$\81F4),!995TR660#8.+L!<7Q;1<&^D6!8
MDAR3B.)()S50K'%6(L-45"&HB"S ).4 4RK9]( U6PY6EFAOI#](YUE/Q_E_
MU=LB3,)SK!:Z/?4N22H&-0-1X3H626N- B3H7JC("/0%@"?'>UC[*,"5-CS7
M#:UMY24/$])(9(Z.L:\53"JLS60U5N:Z 3"S.0"]CXSUOU.6R?)O23D<KS0\
M/YY,/4<RHDBGI:N2.G.:IIEJ($$PY<_-#3&1 #K)9CN26_G<I?I!;27:S[+2
M'F%L)U\"#&O)D^/D,V9=1ZPD<U;'N)4@Q368:XL.(2"*:0[(A8D8@$8\ W-M
MGRKB5WE=Z?,&DFT+*YD<M((B-"NQENZI:Z:O"I'A[$8Z7A+TD3R3S391Q--+
M5)''4RO'6M)41PE6A29FG+.L;(C(K$JA52H!%\;LG+?Z2<LR)8EP'F@)80%.
MZ#/).S!\R$Z2 462Z))=-4\9TF, $>0H2,<:.$02*X8V-3T<NXG)!,.9DJ25
MO+(2"XLUCSB!<6!(W/0C8XN/B[Z5#+',:'B[G1%FBEUYB7C9E",4;UG4I9 %
M-NJBQVQI$Y2/2!M,V0W2#F$;(9D*9:PZ1L@0S<J1C _"=I4*A&Y%W0V#]==I
M++NV-8LGLM:WCP<JXD+:VILP+<[UF^M[BH 4"<'F_JVD <R^L 6U ;BT/"'I
M(U:O@;B8L*KU[4(ZW5Z[I">M7Y]_6-"JO.OS-(4:K 6U4WDLYY[*)#K['0C7
M"P@5\BREP(,ZFM9<.#+N2A/<2HD60A 1I-J>/'/9'"-A9Y@A+*>4@V.;YDR;
MB"9526CK9$1G=$<LRJTK%Y&4&4@,[DLY&[,23<WQ1FX(](%1&D,_#_$$T,<L
MLZ1RT]4\<<TY!FE1&E*K)*0ID=0&<J-3$@8]=O)EC60X=RK\OV*Y53SZ'),?
MTMPZINZ:R Z//JK&)3 9,@30N^R#(CD:@S#5=FE:J==DXZWDL3P95E\4B&.2
M.E19$8%65U-F4C;>]SN+_A/V3P;2U-#PKPY1U<;0U,&3T$4T+J5DB=:<!HI%
M(NCH5TLI ((L?+$H>,IC9\'##!PPP<,,'##!PPP<,,'##!PPQUIAB1XLDX0K
M),(!B!C(1@G22C&YPP,(3[!CC/1!M>_[%JN17=$7B0-1L/.Q[V]]O+'ECI4D
M"Y ) N 6(!( )VN>F*K[CTKFE%!<6M!<87?0[:DLI]/:1%L'D=%LJR6:#.C*
M0%.0!%!* 4*D$0@B.9VA/>-S'+D!ES'^J+OT-A:W7]UWL;;XP3YU*C6;+Y=(
M/B*RJ2O4;@+Y[;^?GC7)Z7+1?^Q.]ZI_H\_]X]_D_P"7CW\%26_5%[]OQAM_
M]1ZX\_#X)L**>_\ TU_)L??;!]=QT7Z_R)WOR?I\_FGG_P! _GW\^'P5+UY@
M\]P>_P#WK8D9]?I0S];?/3\G^GV8%]+EHMU7X)WWDO3QQ_9UZ)ZCW=]'GY)[
M.'P7(-S(O3\^K;'W_3B/AX?P*<6[EUMTZVM<@>[W8LDTFU!9JGI]C&H :>11
M1,KK W5; ERP3#K4S=S5<UQ8[6-:VP@O!-8$@QG TZ!D#&9CF\8^6,Q.5OJM
MW VOO[_+L<9JGFY\:R:2FH7TD[]M^@/NPXW%/%?!PPP<,,'##!PPP<,,'##!
MPPQTYUC7U@FGLIT.O \B"::=*!$$XKD<YHVD.\;%(YK7*C$57*C7*B;(O%&>
MH@IDYE3/#3QZ@O,GD2)-3?-75(RKJ-C87N;;#  GH+^[&I7+\33HN48ZB^Y;
MJM_XSQ;-FN5J"6S*@4#J6K*< >\F3$@$] 3[M\?3X58NJ;IDE"J>>_KBOVV7
MJB[^(V\N/!SG*!US7+1[ZZE'_P#5Q(1ST5C[E)_ ,<OA1C6V_P (J+;KU];0
M-NGGU\1MT]O$KF^4L-2YIES#S6MIB/K$ML3RY/WM_P"\;\F./PJQ?HOPDH=E
M79%]<5_5?<GZ8ZK\B=>!S?*1US3+A[ZVF'_]7$!'.P1B>E@I._ETQS7)L;1%
M5<@HT1/-5MH&R?.OB.G 9QE)-AFF7$^0K:8GRZ"6_4@?3B3%(!<QN!YE& _!
MCY_"O%U\LDH%Z;_SXKO+=$W_ ,4^6ZHF_O5/?QZ.:Y8OSLQH%]]93C\,F/.E
MB+A21YV-L'PKQ?[+^22@^Q17._5BN^Q:B[*YWZ9Z(BHJ*J[(BIMQ!S?*@;',
M\O!L#8UM,#8]#8RWL>QZ'$A'8@*C,2; !223Y  =<?-V88DS;MY3CC=]]NU=
MUC=]D5R[;RDWV:BN7;R1%5>G%=JVC0$O5TR!1<EIXE  ZDW<6'M.*AIYQU@F
M'B*[QN/$.J_-^<.XZCOC@N:X:GGEN,)\]]5)Y=G?_GOV=IO^V;[TW]^LT]B>
M?#8$ GFI8%M.D$ZNK:TL.^I;?.%X,$PM>&47Z7C<7]VV_4?7CDW,L0>JHS*L
M;>J(JJC;RL<J(B]E55$E+T1WV*K[%Z>?$>M4H+ U,%U8*PYT=U9B0JMXMF8@
M@ [D@@"X./)CD7YT;KM?=6&U]-]QTU>&_GMUQ]$RW%7*B-R;'U5?)$N:Y57Y
MD23OQ2.8Y>MRU=1@*;,350"QTZK&[['3XK']KOTWP,4@ZQN-RNZ,/$HU$=.H
M7Q$=0-SMCE\*L8[2M^$=#VDV56^N*_M(COV*JGB-TWW3;IUWZ<'S'+XK<RNH
MX[HD@UU,"7CD!*2#4XNC@$HWS6 )!-CB-#@@%&!/0:3<^X6WP?"G&/[(Z'KY
M?JO7]?\ TCBF,VRHBXS/+R!U(K:8@=^O,MTWQ&EKVTF_E8WQS3)<<7;;(*1=
M]]MK6 N^V^^WZ/UVV7?;W+QX^&LFW_3;+-NOZ/I=O?\ *[8]\J4](Y#?IX&W
M^]CDN18^B;K>TR)[UM(2)]WO^'PUDP(!S;+ 3T'K]+<^X<W#DR_O4G]XWY,8
M7),=3HM]2HOGLMI!\E\E_F_MX]#.,I-[9IEQM:]JVF-K]+VEVOV\\#%*.L<@
M]Z-^3'!<IQEJ]EV1T2+[EMZ]%Z>?19&_3CT,URL[#,J GR%93G\$F(Y<G[A_
M[UOR8Q\*L7ZK\)*'9/-?7%?T^?\ 3'3Z>!S3+%^=F- -K[U=.-O/>3IB-#_N
M&_O3^3')N3XTY6M;D-&Y7.1K4;;0%5SG*B(UJ)(55<JJB(B;JJJB(FZ\%S7*
MV8*N94#,Q "K64Y8DD   2$DDD  "Y) '7#0_70UAU.D[?>QO.+_ !YP<,,'
M##&O);502O 6SKQ&&J(0))L9A6*J(J(\;B(]JJBHJ(Y$Z*B^7%N:RD5WC:JI
MUD0@/&9X@Z$BX#J6U*2-P"!<;],38^1^HXX+=4R*B+;5B*J;HBSXJ*J>6Z;E
M\M^G$BJICTJ(#[IHS_\ [86/D?J./@S),=*[L#OZ4CT1%5C+6"]R(KD:B]EI
MU797*C4Z=7*B)UX]&> 1F8S1"%3I:4R((U:]M)DU:0;[6)O? *S-I4%FM?2
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MZ2O)./7-BV^4CWZ>-=_=OOB-2GHR_6/RXY)EN*KY9-CZ_9=GI=5J_9=/L?\
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M*BF@J&8TU;33JB\F2(LY:*6GJ") \J,:M0RR*2Q,FO/+49:]%F5!8UD%YJB
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M25I:=%4BB?1<+*TB)S#=T1(M,6II(^1E$A]9ECD,=,D,0*M&8 K%KWUV*@V
M) &Q-][!3J<A[B]VD./)(4'::K9 V*Y$6.Y$1$VW&)A&/(IC,8T9'HZ2Q6,
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M[L:NHD+.Q8N1L6<F_2[%0-_"?F@V )UD<1>4L27>J)>^PF8@[@G8; &V_LV
M(O9&U=6]XQ0(PE:4O:%((QQ%1CV$41VD:CGC%&"]7!.A&=B1(0L%J,'!LF@R
M$L\J'F/)_P!$:MQ=5921<$,UP5(^:+L;LR#%%I+W8R5"VN0.8=]@01:Q-R=C
MU4:2"21==RY,FE&&DJ)THEK.<=)TE6L,2(V1W+R%<Q6JYUC..K7J0BM<@V-:
M-S58\BV88S7GF/@2Q4$L-16]A?5LJBXV_;=>HQ;*[-("S5! 8%/T0PU$@@ "
MX 51T&][[WVO^G5HJU6Z-Z2M<[M.;IE@;5<CD<CE3%:I%<CD54=NJ;]I%5%\
MT547?CNU$=5'2-:VJE@-M]KQ(;>+Q;>W?SWQUJ/]3CZ_,7KN?FCJ>Y\\.;Q=
M8]X.&&#AAB-'-9JX_1O1[*<D@SQP,AGB!CV)D[8^_9?W3TBCEA&81@O6IAK)
MMT0P2A(Z$T+QO[Q&KSOTF\6'A#A/-<SBE2.NDC2ARL$DNU?4'9@MMU@A+5#'
MRC(N-SCW$\"U-(M0&99JNGAT+L2LD@$K [_J46N0BVX4[K:^*3TYR^9Q>\1^
MKER/=!.0:UV,(1$<-A6(Y?4SV]HK7HC!L1B.:J;.^R0G'Q@_IB])86/3Q)6!
M[H7414CW#G20OZ'N%6Q.HEB>XMMB^?A;,Z#B:CX<K*YI9\\&=OEQ2G11'#1,
MSY9*5$CZQ7Q6<@E!!J%C+>^.[%YN^9HHN^EZMW;F>(&BB9 QL>S7*T+A*GJ=
M2.*%[VO*UKF.8]CE551O8?57TO\ I)D93\9*R-5ON8J4EK,!?:!5!*L;+=K6
MZWW%KE_#6=5G$&=\*>LN^<4O#ZU\<21QHL&91QK634:RW=9%6".2$2L%/,*G
M1?PX5UGS<<Q^,Z>Y!G4K4"]MH])"]<R11JFF*3U8QD4\DHP1:ITA[(D)Y9<A
M!*XBB$4B(U=T;N64<?\ I*KY:>*//ZB3F6+JT5*M@QM<.83<]M[$&X) VQI'
M$]=F&2U^:4U+5-/#1NBI))$@<LD,2U"!-1LL4ZS)<DEM.H6OI&FTPY_]=,DY
M>\KU2DY%=W5YIT]L/*W1*JHD4\N1'=$GW+Z=U;$)(FBH:6<$EL1@!("2"4QG
M?,CO>N_2\3\=QV6+-ZB:Y'+YB4J%T+ $L.2""5N;%A<6*LI.,#1<4U]7E,V8
M1R,S0$QNC1 $L#9G V)7RL+ ;CV[_2[T@&LN7\M^5:I>LKF\R33A? Y<^%65
MIJ>PG0_"3[U]&VM&63/#14LX3[%X1 0,N/)&%I^X<CKJIXKXR2+ETV8F2=S'
MR^;"BL06%R1S!8,OB!.FX()L",5Z/BFKK,FFS"(.T\&I9%9+*"I^<HL"P*W)
MZ:>H)VO-CT;'-W=<T&FUXF7R36>9XA/!77EXV/!CTMG8&8^7+@TA83T9*2CA
M2:@=H1P H*QFFBC<;P[W-ZKP1GU9F,4])F,IFJX(XY5=E5'D1BX8Z%)V!"V-
MR2"#8 @G.<)Y^<\H6DE#B:)K.632&U7MIV%P  3L-(8$[$8LM1=TWVV^3Z>-
M^!N ?,7QM>,\3A@X88^8R(3M[*U>R]6?8KOU1$7KT39>OE\R^WAV'8VW'D?*
M_?W[8@&]^EO8;^^_D0>V.:JC455\D157YDZKP)L"3T&YQ.-86VAL.Z*PX22A
MJ+O8S2(XXFF54$\@F(Y[&OV^Q5R(B]-EZHJTN?$9#$)$,JA6:,,-:J]]+%;W
M /8V_%<MG8HI4LH!9=0! -MSY;&_NPE,*U-PO4&1DT7$;^OO#XA<+09 D$A"
M,K[=H6F)"(5XF,(037H,K@*48SL-'>YI@E8VPR[.<LS9ZQ,NK(JMJ"<4U6(B
M3R:@H',37 !902K:20'5U)NI&+&BS*AS!JI:*ICJ#15#TM2(S?E3( 2C&VDF
MQ%])8*P92=2D86#[&,PY8SC ;(&-"H!QF]^X:(BN(T*;E<Q%5&HYK517*C>B
MKMQ?F9 _++*'T&0)J!D*CJ1&+N0#M<*=]NNV+[N "+D%M.Q;2"02 "3U!Z@=
M/(@X1E+J=AV0Y=D6#4U[6V648DRJ+DM1#,4LBG9<L,2 DMR@:!#O$%Q"QF&>
M>.UPUD#%WHT=CJ;.\MK,PK,KI:N&>OH%A>LIHV)DITG%XC)=0+M^V4$L@(+
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MCU)LNXWCV,!7]I514\AC7M-1"N:06_0BHWLIQ\F2(43FF  ;6<-=& ('D"S
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M2PSO'*K3/3()ZJX(DF4.6326(ABB82+2JGRTH+%Y'665I;?1)4&(,"$60EE
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M>>:>JEK8TBBC351F@0RRG,A;3!H"$L(PJ[$$;V$IPA#'F(R>BITCR^*.E?G
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MPY$RQP3VIW!>H ='A1&YGHNY?+/+K?1_3B=F]"#&LC-B4%+&F (D8<#N>R"
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MX:I!/>/F1K=G:\NK0 "=,I91J(OX1M<VP@[7-[3+)$Z+56 3(Q=I-F^Q[<<
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MC$&*0:J>1I/L$& D&1+K6L*HB24[*1V!?V6J8CI+^^14[2#V3.J;U;A^EDN
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MJ.F=::-XX:"5D0ND],143JH55DD=;^'&']'M745T685-755-5.944\TEA&I
M! +$D#8=#8[C?LF><#4S4&SC:GU+]!\L;&TIRG C8'J14Y/IQ"F EV]//M4O
MHBR<M]?PQ+;PH%>( *^%8FC37C.,;.]>WQ39'E68M0S51I&JT1Y:.:HHS6R4
M=8)8HX)(8]!)=RP@8KUCEE^BOQM.305;FF;7EU53>IUGA'+EEC?3.C$ZA\KI
M3P^(:@;;'$7\_P QR3//1RZ^Y!E=#EM5<LR_!JV1.S#)JO*9]F6-F^/+)6+.
MKY4DS(D1_=PPNFCAEEPQ0Y*11(]S!Y&LHTI,RI-=-EM+F4[,V:Q97 8*9*N,
MB!H8BRJ9:>..)5IW "O%9@HOO;<+3SU?#^9U%35557-),X:2KMJB8*NJ",ZC
M>-#^VLNIBQL+$8K6Y(2]SJWJ.N^W:TO WIY?M@B^Q?=YHG%S"223<FUR+F_3
M5]XV^K88K5%Q&JG8ZO<>@)V-[;D=[^S$[-,]>LSU3S:QTXR#(%R.HT:N:K$*
M2BC1 0)%:VXPC%[L5?*G,AL)/FGKK:&D285TMT:&<(/LBH9B^4A$9FD0@&4@
MM?M8W]YO;W7]VWHU$\JT\4MV1!IC50 7U; +[C;K;;H,2Q/7%')DL=A%V)!9
MX"D4#\@1Z@(1#[8<1ZP5[=L?;M,N4ZM0:HL9R/W= YAL>;&?D]?2UU%B7VOM
MO^*XQ[&@$ZH)A\L([%MPY!\!Z>+8;^6_?$?-1BWT;(LBF5%EIAC$;#HH+2YB
MYU$)9Y!BH"9(^G@2CVX<BHBAACMY4*JB3&Q!O=;M*09.T9K1U%8:4U,I+=#;
M9MBP/<'87^K<C8>2CEI6C211&?E-]T.PN6N#>YM?V7VO;#<6F?4<RJI%CY_R
M].RE379\PMK2$*9#MBRYHS4Y*UKLX6:,X8RR&VQIQ"/ERWM.-ZHC]X^4!!9U
MTBUQ8_-OOOO;;;Z>AN,4BT7+6R/KU%F:]^]P=R";=?+VWMB/G.'8ML-!-.2^
ML\8MFOU6JE;.PT#8^-F5M'G(U6O"DZR5JL1O8DJLPJNEC.JJS?L-]LP*WN+$
M^WKN1^/H!O?;IB83J<VN25)%[7L"H._MZ;ZA;J=C:;WH;X<RPP;F>KJVT+1V
M<\F!0J^Y )ICU<V34YL*//$)Z.8]T4KQGV<FRJ-J*N^W&M<11O+3-'!,:6>6
M&:&"J1=;12LMHVTD$$1L0X!\))/6V-CRN.26FK8XI>1+(A2&9+&6.5D(#*F_
MS"0RW&Y%ML/!BF \RN&\P.+6$F_EYOJ$RUQ"NU+GU.2Q/45QIA"E7T:NL<K[
M0XUE%E,CQ5[ZM0!C2CQ(IGB<\QCS/G:DX=XZRS/\KS1VFS+-'S"FILTK4J[4
M-5DL41IP]8C /#.B+S"EG!N'Y;RL+:+393Q9E^=9=5RRS5U;+5TM)FD\-5$E
M'/E5,9VCFJ@Z),DH60<R%4.MXHP22SM);-GV)8WGV)76(Y160;BENH:Q)D&?
M'<8#V.<QS")V'A((P"(PX#A,$T<PV&$1CV(Y.VYIE]'FU%/EM=3Q55/5(5DA
MEBYJ$ JP?2+$,CE'1E*NK .INN.IUM%2YA2S4=;'%+35$92191J0J=P;74W4
MJ&5E(96 (((&*<TY+;Z5;FT(I,WQJRKZF5IED.=S*I75-S&Q^SR+5Q\N'#C3
M"7!9H:]IHDY(MG+$K[!T5T<0P@",O$)_1=7'+Z+AJ.KA>**KRVHS&JBIYJ=I
M:5Y<U:<A]UE>.,TPA60@+(&:U[,>42\ U!I8<ABK8!!%4Y=4ULL > M3339N
MS(HG>J,BQEX61'<@."1H 1<67ZDZ4(3EYO-(M/[29C;HF%?!_'9K0DL)#8]7
M%$P5?):QBG,RT%'\%,[H:F>.45PQ.(O=KU'.\@U\'U?#^65$U$J96*.EGC1I
MIUCID#Q1D :WYVCE.19V61RH)-L=#S+*G?AZ?),MG-*5R[U6D:W-"I!&L:Q,
M "S!T30X'BLQ(!-ABN;1?3#4'5/.<);?XUBE3>Z:66E-AJ);3R&IK^KI:&MN
M'TM!C^.T)XJ#=;0W +D0K"/"BAL4C,)%5T65&A<VRCAS/<\'#4F94%/2U66U
MF65F:3UD1AGCI:*-S'24L,8,;&H0*)PVG3-)<[!@=&RS)LYKY,D:KHZ*"2AE
MHYJ^HF9Z>=(:2%Q3T]%! 45A*FEJA)N6BRA!RC8HETH6C8UB#5NR,5$[.R=I
M$5J*O1$Z(J>[;KQW<   #L+#W#\6.K#MOV\[[?3UMMOC[<3B<5$^FAA/G<JN
M,B:U'L9K-BQC->9H J(6,YBY5D.(40W":[LN497.&KD:KFNVVXY/Z79EAX;A
M9F*ZLUIU6R,S:O5ZCY@5"US<C4N^YL1<8M:R.22$B-2S:E-A;87ZDFUK>\>6
M/+L";75\F(./7LM[-CG#K8@XSCOD$^P:C:ZN5C0$0;D<UTHR1Z\+F-4K$C/(
M1?FQ*2MS%O5X>8BS %E1@KD %CS9KZDU*+Z03*020P90!9T-'+/,J4\3U-22
M0IB74$8CYQ&WA479NFRW%[X=(6,VMH,4_,Y7=PU'WSZ-K63)Q HWM"#=V5:-
MT?N1,51^J*AW@T7M#\7;QR."S;LFX-HZ&TE2-<NH,E/2EC31$FY9F+DR2.=V
M9[L-(-@20.M9-PG3T\*5F=/'65*Z&32+K"23X2MB-_"-@0-)W[G=SLKJJRN>
MPI4A0@#08(L,1$>G8[/8$R-(C"2,)$(Q&=EXU:-XB#2. \::#-9C)#ED-W$;
MRR F"G#*"]C8FVXTJ1N2 ;= 3C:<UXFH\EHRTI4*%'J\ ;2TATDV55ZW.P!Z
M$V\\1XM+BPS4LJ3!M)E'C%>AQ3[$,.S@J3INM5CS*^W\/963V(\9K8\(D(3B
M',1DXRGC3M=F9V K<SC2,R.5HX(A"4:15U(&_0:JBZE#.\DBL""Q<-;1RJ1Z
MW/Y9,]SJH>FR%-1IZ)+K/,ZDD11K8:G<Z451X;FP.U\= TVZOK6'CN/H2$T(
M&N<KC,- Q^L"FQL@O)UI3++LI[V#<5HY,\UA<RV*XYD "::-2AI!6ZIY$1:>
M-;NSR% 01^IJ8ZC2K7-U;E_-UD G2#8025_%%1(SR)19/E:W-]2T=!%&Z1Z(
MF*@R<^)G$I(++,RJ/"2<* 4B%-E5N(XD"R66.4:.$]FP8?6=@87;L\IN9H)3
MI!5!$>6Q8+U?",X(P4[$BFG <RW6EJ*^H,9>FAH5CL2KLT<5+&[R LAB53(7
M)6Y=AX@RZ@C*;V8GB?-,MR#)4;+\KR]S+2E_FP!%#5-54/J/AJ0I$9:S$ "P
M.-M,*>():>-"L;.KH A"PD<#9)[2PDG78KF%JYD,YK>Q/]FC5_12RVH@6!>C
M"8^LF6NJ85IY8T60BDHHBSH>6 %+>"9)!(0"X(&P78EMQ9YQ.N:U]%DN74K_
M  ;0/R:&%0"6(8AYM-M-VE:0ZB=10B^U\=F\$F.QJW'!!+/NX<5+K(CP'/C@
M2ZNC),*Q&1)D8#HX!/<6)&*(W<"ELAC, :(-M[F916IJ9)HQ2T<(IXU>TC&0
M6,Q)>-RS%E5&8$&X+$-:PN>,3 &H.&J-2HRNGO6R)<+/6SKRI(P 0.;$LC.]
M_P!SL;$W55M5VU'\%(=16GR)B5H)MR8)KMH6V]BO>RX"OK!.:5PC=\1'*1"(
MTXT4BM<\K;'/S1QQT]#45\-$T-+&Z FE# 2C69 M0P4*0%L0I%@2VH@+B]XJ
M26A^ \MIJ*2M6BR6.<:$D.F2=45F.@-=P(KDMN=[$7-_O"B1Y%%7RI%)2Q)S
M\@R(<NIOKR/41XTLE@-Y @?>U-E-*]RN\0X F,,UK6.<4J*B\8[.:D1Y7DD4
M&89A5*E%-:II*::J(7F(UK4E1%"H*E;.!H(O<;[7N<0)+E?#LKTU-3D4TBLD
MC-&4=AL-,B+N3MT)-K]L;,R6=3555[#)'"!+&56268[9U5D!J1%?*B!!8QQ,
MC' Z*UW:(P+3A5!C %A%W6G504^8Y32U,I>687I';,()Z=D8>*,O"Q$JG2;A
M7<C3?6Q%SBAFU(7R7A_,HE+!?6*2=HBI*6=HP-7S20+: ;[@$;83-K6RI;UF
MBFS*@3)N_B)&SW*&4@WMD))"\OZ$&P>50D8H$:223M*( >RE]#-"V10,L4%3
M49?(]/*D#.9'AE9I(V97 L%/R=CJM<*+G3BVKJ67.^'Z3-$:HAK,HE$$[S*N
MF"(A],LA5B2!HC ([/N+''7[J-"C+('*CY*^(,D2RKJC()4%KXKT=L8_@%E=
MS*#W@CN#*B=G9O>*K5AB0OA@,VHHM*2Y;54UP@GR\SB6&-E?G"21E ()>)@'
M 9=U9=1 5)-;E;9A3/S\TR:)&K^42TGJ[#4M7X?%RR3H! +@INNP.-66#'4T
MBW95N20((.]B2K9A3RHSD7ME::L\/)27'8QG;:*'(20(:>&'WKH@P583)6JM
M.E414H  8X J2-&""8UD'A( )"DW%[%SXBUBFG/(EJZ<24^<4H4QBY66H507
MYD>DW( )W.]U-AN;=*HN*E+<LYK)#V&\.9]97RC1S@DC>T+Y4(LCO9!^[;VG
M'"8!GD$C3+&%WCE;$D%8:=!2U4D5=$&M/+&LG,%M011'(AW!!&EE!8&SN+J8
MI*D5LPK:'73YO K2RTT53ZH*U0I$M4LG[6M,6MIXBI'*YH7Q:1AP09-2ST(Z
M$5MC";(>&.H9HGF1PVJPG=(00^VX)6/'($B=RJM([NPL<Q#Y;*LVJ],-'F4$
MK59 668H4,H:X0-&URM^H^<+./%>^.AY)Q?'7(*>K+Q5")IY-5F"51GN"#H!
M5 C* "VJQ.I;#;'0)+?&<I0&:QK"*X07O((2JU'(-HGD"=D$O;^R>UZ/B_9J
M\8A$[(FT:W(J:KDD6G1J>;]L)05@E#&Y&GP-J[$W6_8V!!Q.<\/45<6EIE]5
MJ22Z-<$,QWLI0M>Q[6VON.N-=&M[*1+*QB"1P6M\5%D=OQPF,[U_BD>V2UL=
MA6L5KGC0KD3O!LDHUBQP:U54"4?R<\<D3DD(P $3DG3I!,9YH4[C<+?2Q2[:
MWYY44=?22Z*D$:7*@L#XBIL"+&P#6VZC?J#L-OBIY,3/<4[$$@C.RK&.V#Q(
MW#[U+F(C7B1HF#5^Q E4)>XL5<KW.G%&[=M]E"1RUE!:97!JX+,$(;094N#=
MB0+AE#*6A&UHE(OBS9Y%D&L:%UKWL"VH&P V)MXNQ'2YL+>O?GRR+(<1Y0]=
M\EQ6\N,:R.EP.5.I[ZALYM/<5<QDR"UDJNLJ^5%F0I+&/<B'CF$5K7*B%;Y<
M?:V>2RP9)F,D+M%(D!T.A*NMV075E\0V)W!OOWQ@O2!4U5'P;Q#5T5144E3!
MESO%44LLL$\3"2,:XY8B&1A<;C??8X\9&=:_ZW:GU<6FU&UFU-U IZ^S%;0*
MG-,_RK)JZ'<102HT:UB0L@O;.*"PC F2@AFA"V0(4@XV$:TK^UQ>;,,QJ%5*
MFMK)T&EE22>215*; JIL RW-C:XO>^Y&/B*MXCXES2-:?-,ZSJNIU9)UCK\R
MKJR)9$^9*(W8JK@,0K=0&87L3?UC^BQYE<LYB^6^M7.85H;*--+1=/[#+IPB
MOCYM'KZX,JJNV37M[)[@=;(!!R-JD*]]F!;!Q&K9MCAZ[PQF4V:96'J%)F@)
MB>0CPR:0+."=V8A@&MW!/>P^PO15Q/5\3\+Q25T<OK>62G+IZEU.BK*(&AE1
M]PSI#ICG-]Y1<V+@8B#S&U??Z^:G3[)JLJ!95+<,:H,KK,[1 <,+AN[+O#(X
M9$[ER=R9!&(4B!!-5OP%Z6H$^R3QE65"!J9<SC8 VO*4HX$\-_G:'4@WWV%Q
MN#CL]% 74.X*J%722#XC87 Z]-KG:UQ[<1VL3H0QI4MB'03S*H&D[T81(52#
M1>KQN((#WK'[QSGF.8A"(-\@SUX[.)JIWD=BD8)$(!L-"DE(R1:^G8,-][?.
ML <OS@HL "!;?;?IT'>VX%Q;KWQKHL&$:*^VN^\9"$I2QH+U&,]B@MVM8A>Y
M5&"<[L%*5ZD<Y'J]HQQT9%FW,#K& ;$L #IL;L0+A!UL>VPMUZVOBYCACD4R
MU!"H@+G5T*@$FU_,7[WZ"XO8,#EUB0,^5?6<P;1Q6*D1F[FL $2=EJ1@O>Q
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MX>HZOB;B6NI<KH<LI$S"NS"M5S3Y;2SEHJ9I8FC,DF8UKLD>6T*HU4\G+F0
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M,>K!O>:"AW(Z,)[V.(BF[/Z-92G/:2>="-[LJB$PC&)&"M629*"-8(R7GD(
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M?4%TDY@F@T(%>P!":XRP(TCS-[V(Z8HR5Q>HDF#TP62!:?DSPS/>-)7<,=+
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MA[GML H(,B:D)C65V5@,VGU2H];J=(*15%0W*$1) Y4A@@IHCN1XE7F'JUY
MI-FCP<61JLLOJ&<PC]#NH"IF3;:(8M /)D2P5I)25.K8=0>]A6HM1CLPM;F/
MKET>*8D6QJI&/@!;4%A'?8"*1BPY!RE$$8VCFH0CWL80(W16"=V92&JS;+Y7
M6.GIY82X5W]<U>$Z Y2Z@B6Y>R'6K%+\PEL762<0OD50V7YU-,R!S$U.X9JJ
M-E)1@LBCEF,,+*_*L0-6XWQ*[#,"PW*[W KW&+KQ$63DV/R D"AFC+'2TAE:
M)12(C6P";JC3PYB,1CVHP+X!$9&7<\LJVGDIY%#KJFIQ())8WL5GCE%E10=V
MC&_B!74-C8CI<IH\QHI*BGG6:.2GD/R1&M !LDC$-XSI%]@#:]@3O[0A?L/I
M5/N+LGX$_AX^EQU/M"M]+*"?HQQ&Y-[];F_T$C'Q-#&9R/<YZ.:JN8J=VO8>
MK59VV=MCMG(USDW]J.<CD5%5.)MN#Y&_;?8BQ]EC;:QMWQ%N_?2R@[74M8:E
MO<!A^U)N!<['':X-T/N.)QY^.8EZRN8C5ILLJQJZLRZ0:8940WZ6;% ]D>.C
M1KO*E/,Y0Q50CF=MTCL%*X(2?G!Z6*0R>D_B^61@L:YI$S>9_0, 73L>GNO]
M1OF:.0ZH=>GDHHUG<$ @6[VZC<VZ=ML1RRK)23!)%BJ"#$BA[DK&N<P,6*C6
MM>)2HCAN<K.WXN2-RB*=$CIXT:((O-IIVJ91$@U1K<1HHN7.VG5=K,2;; *2
MI)NFS+ZKJ]I+! BI$QN0"&*=F-R??>W47ML<5J<S^O[H-9;8SB26]C+!+@TA
MXV--=)NKG(+GO&U^GM&(37&)DUPQ$-:V+&D%BV/D/.EN9+DQG%ZMP-PA%')!
MF>8FFIRT<M8&K7"4U+2TP$DF<5#NH5**"^BGA+<RLJT"@F,;:Q4ULF8R"*.*
M29 W*,*]'745*^$:BKBZV6S FP-S?#B:$:!#TRHJLF3P:.QYC,@QYH\ZS.BD
M%]3:.8'=S OK=,-.C*1\1]8>O@2 7>1C-*L[N7)O+$DRSJ)(12N?<9<<S<49
MC4RT\]5!P'E]:1D615<8$_%>=4,;+4<09]&%$ZS4]5(CT&7-RH*;11J4@JXR
M(.IY#P]3Y-3Q1JNG.&0O5UR/K]6%2RO$E$YNJ,L:Z9^89[:CH(0VQ+"HPJH!
MC]C09'" ;"(PY?Z0<(;INPX9Q$DP>RAY<BU0<Z6>?+<Z:,P#&BV1[ C[*3*Y
MU+F.85M?!69*^KB$Q<PS-(H@$#2(SQ3\YX(O53R8HZ>G01S:U2:EBA IXH]C
M2$1I*CG331L"L2Z5;FA0'E!)^>XN\G7QM9=@06SP;,[!V4%Q_*YTN1F%="-:
M0[&?&KS%NJ*-(MH$(-K88\6;C47+AUD"9(;4!FI+GT3G2&0@6JY UVPY[D,,
M63I7993QKDE5.M))! \T?J-?+R)I^12URPYD^5FK= :IH3%358023M2F@T4:
M&1Y9Y>:Q !\$D@\4MEV9Q9;D+<> ( @\-R6)</4;%L8RJNE6QZ\,^JR>&"IR
M['6';#':*]%'#N2SE"7P=[5@&$E3:C"UQ6"+'.V4-71B:SPSF>:9/4KEXF:*
M?+I9ZK*,P9&E-.-/RU(L"NAFI)Y'=:FE>4JC,DB<LZ9!=YC24N9PL9+$J )(
MY0+ 7\)1@ VUE92=0!6UB+C%8NGD34OD>RG+7BDDU0Y>\E;>6>*8W;.> L._
MC;D*-)S2G)06$.26OAY=C36S!V+)#+FI>5IH4FS^BLZ3(?3!E^7&HU9'QKE7
MJ,.85-+(',E UPNE)8]-73U$:S2977@(T#*U+.J/'+#!HF6UV9\'5D]+&H;+
M:UGDA$H9]$U@0 R,JC62NH6-U%Q8$%D1KGJ22CQ,%S9W$BWS/()A(6I#+2/$
M"&RLEE1I=;3TT="/D0:#'Y"2((:63X?O#0ZMTA#CBA''Z+P_D467/\%4]-/0
M<B,V0*4:*$7L9FMIDJI@%GGF (9I'("$8USB#.9*V*6 2*[R2:\P6[CF2K<J
MCE6#+'!>T*(5V)YG,!)Q!;4R\/E#Z^?3C?'G*I 2H)">+B1R/,.,YJ.&4Q)*
M12]R3M(%264V7"@(TDWN?6N[Y33+1K)%-9T.Z2*"KL"&8;%1I) 8$%K1HCR^
M&,-R=(F(F  !0J 7O8%]/S@#L!?>UN@^\T(P$L)0J>2K"1ZMDJ3*,0S0-E2F
MH]3>..CQC&V,T;C6LMBD9V6,BQ#2(T,,B7L;\N*-9([\R;E@  N55E0J(TT!
MKEF(C0]SJ.EF8"PD.^D=+CH-Q[!YD@[; >=K8U4-DS)[:/5"20ZG#(&?LL1[
MP6,]%6,MOV'*UGA8K4,&FC&5HH45YI1VA[RP>WTS+2Q/+=1,ZE-6P:.(C48+
MC?4WA,["YD8*BEK1WI/X1<6)WZ[6[Z;"^_<FYN;@7( P_P#62:ZU8E%0*2#B
M6/CC&R"T&U'FLIK7O00A=IJ>,*6<<K:ECF(6;)*Z008V;-%@)%>$F>HM)5U#
M,M+%VC2URQW\*A%4RD&T:*%!/>V()L;$,=08O?2NXM:VD@ $@W)Z];B^-5D@
MR9]D%7C,1B5U9!:2,6$)[NT($-DAWJB*958(IY*L?)M)YG!4\D$D[S K()7"
MK4Q&74\U5(>;+(582$;%G*@2D#<*M]$48U6!50&DD&KP0S:53>^][;L;7U/V
M)%@ --MP;$VNW6214@S'X]5">&Q Y(Y5<-T0U=W0B!<YZ%09 G=WA@0 24[Z
M.TI[22P-C..)V6I7UQB>5E:,W86LRR7(\K@@$!G*BS66)2T: XMFNI(D^:";
M[:M;7N=@+6%KD[:K6Z 83==&''[,9H'N<J$"XPD1BSI;6",L!"F<B#'#1BR9
M)".8P06OM#HO8"-]S(Q;4UQ;8V.^A;D"0@#<OJ"( #=K1J;DD4V^>AO<7O9C
MT!)!<V W87  %[D(-KV_52T33LZ,Z1MZ?8Z8X$G155.F*U*=%<UJJGN56M54
MZJU%Z<=EI/UI2V((]7@L0;@_)KN"  0?.POY8Z?#O%$?.-.UOVH[=O=ASO+S
MXN,5,06Y^-53:?Z+VM/66#H5QEC'0 % C#2!1T*-%0<9SVK)4LAX>^CM1ZDK
MP6*L$9PE&O*/2YGWP5PW+0QNPJ,U)IR4:S) Q"N;W!56!TDD6MJ&_0X'B&J-
M-02*KZ&ELM^Y74 0/?>Q'=;CI?%3?+5B19-L:[<X;(E%&4#^YEV0W/GR K%0
M!Q'CLA64![FVDEAAG>:%)'$CMW&Q5=\P<)47.EFJG "PAH@&.VI2QYA%BI$F
MIMQ;IT&ZXTK(Z=3(]1<$(#8 @W9O/<C>^UA?S.]L)3"E)G&N\J:YMAO:9L&0
MT)WRJN=%@TH"288YC88)487@(<%R#&^2.->B$%'O?(*C^(H@V8<31 WTF5K7
MMLJ7TC8;D!-@3>YL-R#BC$6JLV$EF"<QAIZ$+&" ;'?HH8V%R18=<*3FB'%D
MZQ4H%4CUA:=P.]9 \&.7VI-_=1D"A9#QQE1Z'&]@YK),01$8;N@F["&O.+W4
M9K2)J.D1*LNBQTV=P"6(LK;Z?G*2&(((-A5SG2*^G L62D8,#86O)>QZ6NI)
MM;VGL,.5S>"6OJM$HHPM%'219&66[NAS!2HU95.BPG(TH>PV:G?/*YAB!$Z.
M-Y D8-I&9WC]13Y;DL*)':R2"06#A3#I"G8V4EM18D;J!<,?%>\0#3!0J+64
ME0O2UD&UK@6WN>M^IL<)/72KK(FD^E%C)%;B@4=%41,3H)["CL+C+Y\88):6
M@%CN.(-/'A!L)!B,$QPSB1W:1[E92S^F499D906CBHHC#%<[2ZY"[JBV)<+H
MUD+<*%N!:^.L<#<L4;V4*Q"JTC6!"<J+2I;LI?44!ZEO,WQ(N@B@M^5(E@&J
M[-Y%OQEF4'>"-!L\S69$KJR$,BBB,2KDVDRFG*CFL=N J.,KR>)XV'+8X)_1
M[)-"QD<9I*)%/C E,A4N/<Q!#;&_EMC)U GAXFAC<*"*?:1B PCT#PW/?3<6
MOTN#[$#R/0H;[76G"()HKLF+B]@*9 DA>RAOLI9X,<:XKG/=,86)#?)1LPA#
M.*TDU"@&B,.R/' 5,*C->*<K2WK55DKK31RVY$U5RB5F-QI/*<K)JW*G2]Q<
M,;W.7'J66U2[^KU3@$;E =@!O<!NWF;@'L6!O*&%ICK+$QVN=<8_#H[>QB87
ME4*PFMD9%J37NLUDV]PX;3C]3MM16U (YY48 VE.\@G,B*G&LUT!RG.9(XRT
M4E"E-#EU3&&5CR,SE>.<R@"TYEJ:MKWYA1B?FFXRJ.:FF)/BBEC9C%?6@95%
MVT#HQ!%VM<VZW%\3QY^=.&70*B2C(DR?=8K+LLC\4C$B5>)8-72PI&C$0HG(
M2SR+,P28RM0J.GQ(BJ!P@*1G4O2OES.:7,6</-+DR25!<C08J1:U4B9_FD35
M>:QU 0[M+3AU#%3C!Y%*X2:!%0::JR$BS!6-V )L=-AL#YF_LDER-ZEUV8Z1
M8_1C99 M,3A0X<R/:. 1Z4=^6?>84:-( 1R&BAI7^J44H8ADE07#\(,2#<N[
M>BC,XZCAFGR=C(U=DJ+%/K!T>KRR/+3F)MP\:HP1+ !0I -A<XW/(#'723 !
M4G-](Z:A92?*Y(/3S[&^)R<=1QA\'##$>>9KEMP/FCTQG:<YL-\(PY3;C$LO
MKV$'DV"90*/(A R;%K*-)@V%79I7S;"KDD@SX;YM396-9((Z+,,QU2"8TS\P
M=;GN1U[;7Q1GB$T9C)(!Z_A'W_RX\Y&2\D& 8?S]Q>3?+.9;4;%\7E<J;^8D
M6J.1:G9+2F)>)JDFGP\(#4V6<QJP@"06FNFSDM73E($H&PE QYFY85DAAYZ1
MW;5I*B[*;FQ)VM<6Z=1] OC&RR/F#Y9P -M][6WMO>_M[]+;WQ*!/1=\MB?]
M,'R'V_UVO?M[$U5VWZ)[/G]G'@9E5J;B"Q&U]!Z'WB_OQZ^"XC_5WW.^X^DC
M?ZNEP?(XRGHO.6U/^F$9#MONOZ[2>?S_ %5/9[/=TV\N)&9UG: C?LA'4[]!
M])P^#(Q_5WMW\7X!W]GGB(G,7RE:,:*:N\H6G./<WN39M4\R&L=SIIEN2"UD
MM([=-ZBLP2]RT.3$' U$FQ9*29U2&J4=G)K8OZ;1S9+S-&)]6&JGD%0YC:\<
M98(;D$VWV(&^U_9?KY^6RY X J' N PU6O["+CKU(Z$]-^DNOK7?+7LJ+Z0?
M(%Z[_P!%K;S557RU5\UW]_O]_%$9E5@6Y!M<;:#V[]+?3UQ)RJ(FYE8GVVZ=
M1]?Y>N^#ZUWRV;;?7!\AV_MM;>W?9%355%3KNOGMOY(G#X2J_P"#^WYG4_EP
M^"H1TF8>?0?3L=S_ */9A!Y+R<:8\MSK'-\'YGYNO%EE55(Q:=23<I'DI*.$
M!A+1ELU[LTRF2+O"QF0U[8(PE4O\V5R-&Z\I*IZAF61#&0MR>GG>WU>VVV,1
MG%%R(D97U7\(Z@[G;?WGK]&)TZ(\H.G-KHG@<[5^XG)89QAF/N!3P)S(<.%
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MC!"JREDW W(\[B]^H/GL,)?">1O,L4Q&[QYN5T,:QO0V09%O43[X+8QC).!
MM(,69$E.ASPQ9("G''.T#YL=I&N1/LUP^6^A^LHJ5J;X8B7FJPDD6%BU_$%8
M"_4:CT/8=[XM:;AUJ:G: 3J6<,"Z*4L3J"D"_P Y01WMX1WPWVFWH[M1M.\\
M@9$F?8O=TD.7+(.(1U]73A@/22J]5.@8YJ^P,>9*<8S21HP@,&PD9O:[H,:R
MR[T*5V79O%F"9Y%+&I<L&@<.=5]SXC<BY%P;6 )!.HFA2\+R4E4M0*QI0NKP
M/<6)4C8^6]P#???;?&YU<]'ID^?94[,*'*L:I9TX+!WL&86WF1[(P(H:^#+B
ME\"H*TL*$-W:%ZNF GF:)3L$K7&6ZS_T,39M5BM@SB*FD)7FH(&M(%(]M@;#
M?H"??;'JNX8%;,9Q/R9" &MJ.H"W?J#86L-B-MKFRYULY),IU6JL+'!R?'J>
MVPD-@*,:3ZSD M06$.#'/!D.BQH98#"$KXQ$EB\:^.B/4<<A%81F1XB]%$^>
MT-! <UABGH2MG%.3S$5-)C)O<!B%8[;D6O;%?,.'_7HZ:,RA#3M?5OXU*A65
MK=B0">GN)PIY')J:PJ<0K[&522/@72F@TD>3/LK*+$L)8JL<B:]\^L))EM&"
M%(KHR2".,D*0BN,TB*G&0J?1D:FERZ,U\*2Y=3<F.T!(+MK61M1)(!1E%SN2
MMN@&-KRJ4Y93-3(BLLPC$IN>D1!0"][V([[BPWMMAXL)T$'A>%56%1(-(>#5
M  J'++,U\FTCN8=+LHDJ'C\<LUC)@G*Y5$08VHY$8G&=R;@2@RK*URO3%)"(
M=$H" +--:QJ2.SZ_E+$7O87[XJ5%5/55KU\KD2LY*J/$%CZ!"Q(/06L!8#:_
M7"?TZY8*[3G(ZK(JED%3U>/R*91^->Q]A(FCIAV-G8R$IW%D2)?J:,YK-VL$
M]QMW$:HFCM\D]'U)DV8TV91S&22&"2%HR+*PEIZ.!UO?H>0_8@ CN3BXJ<RF
MJ:<TS(JQLR-<'<:&U  $>?7I<?6-=GO*/CN<VUI;'BU<(TV&R!!&AR2H],.0
M_)9-O-A +5M1UI86&2R+ <Q7B?&D@$K5<U7HZGG'HYR_-:JHJRPB,TU-*L('
M@B:!I"Q!%KZ]8VL"-(W/3%:GS:>G5 A-U5U)O:X8*.@]@([;6[]'VRG3F!F-
M1(IKZAJIH)E1'HI4A]F7Q9*D<Z'//![]:97MCRSP0+(:Q&J]&[HK7*BMVS,>
M'Z#,Z(T-9 E1#ZK24_RB@ZA3SB4@W.P%@0UB2=B!L<8^*>2*0RK(RMJ+>$GJ
M=AML.YW]IL!C4X/I)5:?2+Z1C5) A/OFPP.$RU(.'70JJ59S*>!7104K&1XM
M:6UE,C,V>K1=T/=!!&-M#).&<MR&:>2AAD05'R37DNJP0'53*J:CW9Q;?0/W
M0-L5*FKDJ50.22A._<D]6)OUV%QMW().'I'V^PSO4:A.RWO$8JN8C]D[2-<J
M-56H[=$56M54ZJU-]DV7%J/S^GKCGPPP<,,4C9M@&":C>G:KZ34+"L2SJFC>
MB]D6,:HS''*?)ZP%B+F:0 IX8%U#G1131QY4@#)3 M,P)RC:1&D>U<@K,F7#
M2S*34MNI(['N//[_ +L4R 7%P#L>H!['%G_Q5N6#[7#0;[T&GV_W?@]U^GBS
MYTW[[)_?M^7'K0E[Z1]7YV^C!\5;EA^UQT'^]#I_^#^1[I]'#G3?OLG]^WY<
M-*_N1]0^_P"?T]]\5->D+Y?M!J+FQ]$U64>B>D=-6Y1S=9=59+756F^&UT#(
M:P6B6:RQ5UY#B4P8UM!%+$&6.)/%( R2$9V,:8;7I?4DLACK"TTEQ 2IU,3?
M?:]R1[QWL>U\4WC4LAL.OD#>UO/%LOQ5N6#[7'0;K_VH=/O;_P"+W%ESIOWV
M7_"-^7%32O2P_/S\_IP?%6Y8/M<-!OO0:?>[;^Q[\EZ^?#GS?OTO^$?\N&E?
M(?G^/S/4]\50^G!TQTTT8]%YS/9EH_IU@NE>71V:2A#D^G&(8_A%^R.;6K3X
M)XR7&,5]58^%D"(0,B/XI G$1XR,<Q[VK=Y>SRUD4;R26:X)+%NBD@;FPZ;8
MMZF&)X6#QJP&X!4,;WV/<_5N/HMAGN2OTP7(3S$<MNDUAS"ZJXEI+JSI+14<
M7)L9S>::*1+W'JSU,N08_)D1)/K $\2&D"+'+ZPBLG&$XSE<?L7TL%3!)+RX
MRR2-L1;HU^F_4;#RV'E<X]HH91&)5D!A(*?)NVPMTMM[^OG[O.QZ33TF4;G3
M](=HO9:#9/EE'HWISE6G&GN/V=7=WM!\.VEU"@3;B]GUL29%$6ODEDK$KA2@
M/?X-I6D[;2]X3*4=,]/3$MLTAU$ ];$[;=;7W)L+GL.B4JPD9HBQ*@"ZVTJJ
MD"Y(VO>_T"^/8]E6I>B6)9#8T642<!CY#%?%GS85E2S)MJYMY/@5<!QV5HW.
M,LNPN:@4<3&>+\=;UGB7.%906'O(\FS2JA6I@BE-/)J*."@7Y+F<QKLRV"B&
M4LQV"Q2,/F,1J$V;913SO33-&LR$!D*NS#F!-">%6N6,L>E>I+HN^JP253F6
MDN<YSB+,+S7!BK'BWC#X;1X]$D2,C\+!JYD>\/+D!-9U@:P$^#8 L@NC4]HM
MI";%(])45I*<^29I1AIJA)$CB<![E-F):R[.22+-J W7?5[<M0<2\.5&4UV4
M)E.65695_P &O0YU,U9'6Y8E!.9:E:".*,4[QY@C".5JLAQ<E25%A GT-.-X
M_K'S$^EWH]7:2IU4H\6YRCBQBGU(KH><56.B;?:J@8*AKLG#:PZ@3 ,:)@ZX
M,=C1HC$1$Z<8/-W=&A*NRD@WTDJ=@-MCV/;8>0QL67PPK"&$(#E;&72/$M^E
MQYD7\]NUAB^OXJW+!]KCH-]Z'3[V[?\ 8]\G&%YTW[[)_A&_+B_T+^Y7;IL,
M"\JW+#]KAH,JIU3]:'3[S_>]_P G$\^;]^E_PC_EPTK^Y'U??]_MZXJ>R[E_
MT&%Z;'1?#A:):1"Q*9Z.?5S()>+#TVPUF.RKV+K[A,*-=2:5M*E8:UBPREA@
ML"QG2Q1B$ ,S1$<QUW')*,ND(D< 51N S#<J-[W[^7TX\,$+J"-[':VQVO\
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M'Y^SIC3B+$CR-L<^/6(QA51$55W^CSZ].(;H?<<,>07THFN];I;K-KG!J;.
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M;I$M+%.LA=6:QCA<1OS9II&6&!$T7C50L/1BI 4.2T8(&IKAGG!%B!U-V&P
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MF9&9,D%EL5[8P_ E .WEQF*-#11$00HXW/199'"/%&^(,IHN32DJ:2>1,PJ
MD;RM#$L+!3(>>LIHHI&!*RNNII&53R5#QS,)G1)1F26-?5XEDFM=]1 (VTAV
M'<+VW%R 0+ G#)ZNP)&2P].8CY\@5]&S.--KLA=)>&TB@A7E+(]8/E#CR!Q:
MB70AS657#6$\!F0;V"L<]6VYAFW;A"2'+)^(Y12Q-ETV3<B?+UC!@:JGIJA4
MA1"5YE;#4?!T=3^B$D(EHI"XE:GD7#9@6E%/&-3R02#ES-L4^46_BW.DH'Z
M@ L +*V'*QFVEI(#'LHYHV0PA#L)<=XE$MG':5I#30*Q[Q-&Q[&Q[2((YRTX
MR"DL[VML8$Z7K>:4L)A?D/')EM2&@AD5PPI92&C6)@RAS(03)32-&JU;#E,4
MJ8988\O YU"20E*K46+ ;S1LH U-T2WS2ES8;V*FY^68X=C&:XMD@KZG#?X1
M>G/+NZ/NPRRQ&$5KUR&I>J*C#1Y<\KE%W;HTB((<7=@E8<4Y/G&99%FN6+1U
MC46<T<,5/0US&2**>UU^#:M"5NLL%,H5]?-BF=IAXM4;VM;EU/FM)5))" $8
MM(=.H@]7*V!!)+&UKK8 7 %QY\N870#)-!<M?7@FNN=*<R=)E8AE#&J2!W<^
M0<8(I"*17"+#<)L2*QSXLRO,%M?.:LIL@%O]Q\%\99?QGE;5!C%#Q!EIBAS/
M*FMSXI(XD>1B;6<2*>:'',BJ(V$T3%2IBX#GN1R955,8P7I9-3(U[*FHMH3H
M=U!L5M<, IL;880E9:54Z+7]M6!MPM9)R56)X)(B/(5CGC&PP1QR":KT[#E"
M5"%&XA0/0\+;EDBEC:0VO$Q*TW[?61I-B2#=38$D:A86LVSZ[S+,?"25ZK](
MOYB]^@M>UK"^Q<"-?3*6(Z@K8T@^16!P1RO&]12Y<=XV=RR&<S4>TIQM:<LH
M;G/L#%:DM76\5CK.P:!:AS/.RBFA5F 871&#&Y90=(4,2JK8"(*>6!$Y,1G"
M^*,DL]@0%-K7WN=B"";6\CL--]+N8)&;5O/93Q%-+C>(60%R=TZ0V(I*]1PQ
M=K='-D,2# -L#P%<XULG>R+FM]4XC- TA$">$ZM!!_J3&S7D((OX/'(N_,E
MA(Y<,@FKQCU8@R#2"=MP3<^(]B;WZWOO8=C?39E22[@P+D0D4Y*][Q01$_2O
M<(J>':-K%5@JJN@QVD,A'-3OFOEE5KI#U%<Y=*E.A@+'2LFDNWSRYMJ))^=+
M)*]A86L0@N%%\962K.Y?J0>I&X'8"^]S>VUNOUHZKQ/Q($N)#3K'%(4 $1KH
MQW61QE*39Z[/823%<-!F(/:NIW3),@3+"QEAC9*2K"L8%(U%=1WU#E*5MO?H
MC7+"]GDT*#H12V/?5I(LHL "3N;7MTO<B]S;NU@/"JG#:7,67EEF"!4B%+;+
ME$3Q(?T,$QL-7?IU=G-&*DK'JH8@7)O.D-;)?VRB$Z-E:<K3J#(&U6 "?.<-
M(0%C6UV,TG4MU1?"+ V/A  >6I8.3$0#VN"2I))N[CYQOL-0Z?._4=T7:K-'
M=)V*]A%9II@C5(-6*,BMQ:J3ML4?Z&K';=IJC^P5JHK?L=N.W49+4E*3IN::
M G3\VYB4^'^U\O9CJ\>T<8_M%_\ M&'+XN<>\'##!PPP<,,'##!PPP<,,'##
M!PPP<,,'##!PPP<,,'##&'*B(NZ[=/?LNWR?P<,02!W'TFV("?%MS%WI'A<X
M?9CIC;.60O+>D/UC$V6K+FP]35R%8BM\>EDE^/U$D5$\*M<[QBE[W]#XN^;$
M:,0W82"3F :=C?8B_:PWN>O2PQ;:I^>+1Q\G<&7FV;9=@$T[W.U]6P\^T^]T
M]Z?=3BTQ<W'F/K&#=/>GW4X87'F/K&($<V/+AF6M^N7)AJ5CZ1VUO+%K!9ZJ
MR6OL8<;UK(M\8GX0>MDADIWZ1H]1>6-F,D+M&),BQXSMAE<]MW3R11Q5 9G#
MR1E%70;$VVN>UR=]NV+:1Y^;&(XT:*XUR-+ITB^]ETG4>FVH?1U,]]T]Z?=3
MBTQ<W'<@?3@W3WI]U.&%QYCZQBO?TB/+7FW.#HU;<N\:!!L=*\]C0EU!$R\%
MCM]XO&\IQ[*L;2HM7]ZZ,Q)]*GC5;&*A@(H>T)ST>V_H9X(',DH8.+Z& )ML
M1L.A[V/X+8Q]:*]M'J31BWSPQ OOYGIMVL?IWM01^=H--U\\2RA5W147ZM$;
M=-MO+]1U7IM[^ONVZ<9@9Q#ILS,QV\1C.V_O/Y??C%B#/!^\G;<:U!'E8WM[
M=P>GUJ3#OS-_I[BN78KE$?%,E;)QK)J'(HSB:QQI F2*2TBV0'$CK4)WS$+%
M&KA(YO>-11JY$7H^&(2-+L[#HO@M8=[VO>XL#TZ=-\#3YVUU8P:2#==2^*XW
M[FUC;<@DWQ?#/Y1:6RR^TSR5A\ F5W5A165G<)D,T,B9(QB;C%CCS3L%/:)T
M2GGX;03($'LI"CR03#)'4MK9OF7J\42)2QT:5,RP)'-$$6&G(,<ZUJ2+>6FD
M>[)F%4"2QW=2+: ,8IN%TEJ'K)(8.?))%*Q,U0;20M2/&WR51$ALU#3D ("0
MK*6))(T^'<E6,8%;T-[C>)D!:XQ&-%HY=AG61WCH03443%MD'<W<X!G QJ!#
MHH;C#>D2NC@%'1C@C>WU4\5RUD,T-1-K$T@D)6DI8R &ULFJ.G5_&UV+!P=3
M$[ D&G3\'Q4DL<U-&%:*(H%-34D%B" WBJ&5;#PA&1EMU]C8\G')7FG*=K]K
M[G.*U,.%AW,SJI>ZG:IR++)@7M@:W>N53J8E#$8T#J:*ZPOW)*AM22G=.:U7
MM02J[7J^J@J@K1EM:FUBK&XTD$W/<FQM;;?L!C9*.+,X71)C%ZL!\U6%U(M;
M>_3L2!O<=3UM@[3?>GW4XQ6,S<>8^O!NGO3[J<,+CS'UC$"L@Y;\RLO2(8#S
M< 2*N.XERZY1R^OAK8Q$:2LRS+Z_/IE\Z,YBV"V4.XHX-3'C#7P98,P\HA&F
M$C5O%DA%%)"6;FF42*-(TG< @M?8!;GVD=!?%L6GYZVB3D;ZI3)9AX=OD]-R
M2;#J+ @BXZSU[2>]/N\6>+FX\Q]8P;I[T^ZG#"X\Q]8Q ;G.Y:LNY@=0N3S*
M\;4"1.6OF"J]>9#7V$.+ZTL*2HL,>BTDEDE.\6ODP,@M9ACPU=*9*@0PM8K#
MD5+RFDBB2H$A8.\+QH MP2RD;DD6Z]?]&+2I:;5$(8TD4.K2,9-)0!MR%TM<
M@&_:_2^)[H[RW5$5=]^OE\GY;>2^[;BS]V_XAY]_S.+L,".H]U_S^G'/AB<5
M7>EZY8\NYK^5^CTSPW'<FR:RB:KX[D\JOQ.='KK5M= Q[+8,DR2))@#\.C[4
M(",[UKE><;MG-:YJZQQ32UE3ENFA@6IF6HCE$36L0+WV*MN-K&W7K;&5R>+*
M9JQ4SJ_J91B2"00XMIW'0>W[V/-'BGH4.8:GNHMM9Z*ZR7<.#.CSJ_'KW*,:
MF4B28;^U$D606V['&9'D=DX8[-V=EO9*CQN43N>5&49_H=8<F"2NI4S1P!7L
M2-6]OVP%B+[@[W.^-MRVDX&IYTJ#-8HVM(Y-5E=;E27%[E38CP@$@"_?#QZC
M^BEYG]2W4BVFD^KE22@63(KC8_D-# VLI>Q'6<H3[8O?RQ.'V /&X?<L?W"J
M5FY$QE+P_P 24^LME'K!ETB3GTX<%1<A4!8:;W\1WO8"PMC-9Q/P7GI1LQJP
MQB!6/E2M$H!"@@J8W! "BQN -]R2,-91^A-YCPSXLO)<#UTRL$24V1ZMM\FQ
M9*^8WMH7NIHQ6 I)(^SR,-%24X)U<KGL<YRAXO?@;/0&Y7#T4#LH 9(+A"#L
M0MP+][@@@; ]<8>ERS@.DG@J(ZYVDI7+P%I6(5B;W(Y?B%Q<]+]=NN'(U6]$
MYS@:CMI7U.'ZK80VE6T<K*<F(F-+?/$!4*CY%J-T8T9P7=P2,@W$4KFL4#GH
M4=I!PYG8D=ZKA\59D%CK0Q* +W!(UJ5/4JP((VW'7(YVW".=^KM5YNY6F1PD
M4<A-V:[7 ('0W\)&_0D&^&DA^A2YRS38D6;!UB=1H,[)@),;3X;_  Y51)<=
MIF6,E"/GPQDC=ON&=Q,\!+12J%ROR;\,U:4[2+PXIJ7=2&2H<LH57*G3RP"
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M)#?531D9ZN=4F)#C1Q1Y2HUDJ(<TJ&V<R*0JS1)ZO3[,+BOVF"K2IHC*D<B
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M@Y@QW,$1[?-]OY[CMOCR<O4_U:6W7YY )]H&W7?_ %G!\!X?LL+!/^_'T_\
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MK:\QW-IX;PC)$N!,= K L@!@BD1)+[ G&5A^B^'B ?WRH]]C^DVXL-@;J!<
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M,3M[UPYD'#E5P_FN?\0UF>4D%%FM%E4?P134U6S2U=.]2&=*IXU10(RI*MW
MMY:7GN<Y[!G>7Y+D<&5SS55!55[G,IIX$5:>80E0T 9F-W#!2IN 22H&-!Z\
M],/_ &)\@F^_^G>N2>6__P %\F^WW>*_JOHK^W''?3K\$Y+VZF_K!&_3ROL-
M\4#+Z2/X+P?[/T7FMM__  A8^^W??SSZ\],0N^V)\@GDGE=ZY+Y_,%-ONJO
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MEAQ75Q['7ZOAFMI'RB-JRE:3-:IHXP38"G]>JLO$A8$A M12R*P8@JH# ,K
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M\.9S?Z*J/Z1U\_\ 39=.ACL(<B$9Q&AE"> JA*8!>[(U6/09XY R /5JKV#
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MQ+)D>#P)<ZWDLIH4BOR3TO&2TM.NF++*7).'D0>JUB:*FBIW]3+U*K5U*O6
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MX*PUT4(LE_#6%INNH7MJT;8O!E&7>M&L]6C%2:V7,&<2OO634HHI9K:[>.F
MCM8+<!@NNQPT8^1;E:9%' %I84,5DB=([*9GGOV4RQJ<+IYEB]ZY8I"SS0-/
ML/;X\KGRVRZ1L\9DGRYLF5DI.,>)))1)\)RB5;!9#!& -#U,BC:)? &KZLA>
M@YCJ+  #&KPCPZL4D8RY1'*I6134SM<,M&AW:J:S$4%)J( ),1)!U-=_L&TL
MP/3>TRV[Q2G2MM<]LXUSF%D:SN+2=?6\2.&OB2YA[>=8&5T> $<..(+Q CQ1
M"C@"P0VM;A*FOJZU*.&HF>2&B1X:*-UT\F)W,LJ"P%P9 74;V%RMA?&8I:"D
MHFJ98(D26L=):N169C-(B\N-B"S '2=)(W8VU$FUH*\G3FNYQ_28.:J*WZK.
MBB=%]J:3L5$^1=E143S]O&[<6LK\+^CP*0ULCS4-;>Q;.LP*W\R=0M[#?8G?
M5>&K_&'C;VYGE@\K6RVFO>X\_;]X'%G OYFWYE_&OY?+QH*]![A^#&[C\9_"
M<<^)Q.#AA@X88.&&#AA@X88.&&#AA@X88.&&#AA@X88.&&#AACB]4:U7+LB)
MLJJOLV5.OFG$-T]Y4>\D@ ?2=L.G7%87(EV'\QGI*%5=T=S-5B(J>Y<18FZ*
MGDJ*U>OW..B<8LK<*^C8?.'P!F;6%R;'/:PK?V,.E]CN-QC1>%1^G_'9\\\I
M+$C;;*Z<'OV((['KYW,NH_++HS'QB1AP\:G?!V7JNFMAH3\KS$A%U+9E\?/V
MY*V<6^=.9OF$9E\2H9);1FF*125KQD(-^HMQ!G#5*5)J%YL>7'*-0CC%\M,'
MJRTX C L(+Q,=.LKMJ)M;8!D&5"!J4TY:%LP&:V,DGZ_683F<DL23SAS%!.D
M,+@"^$MDG)ERW95:WEY=Z:0I5KD5E96=E.CWF55<A9ENS,TN)%>6HO8+Z1;U
M^H69.O4I? ,NWY%9OM6RR2$>VK#Q/Q#!%'3QYBXIX>6(X2BNH6%:=(;J\;HY
MC2DI57F(X416 MJ!\3<,Y)/-+/)0H9IA+S)1)+&Y$TE1-*%:.1637)5U!8QL
MI8N#?4J%=8_DDY;7S)E@[3A/&3XD.*<Z99GK2,]6R-.IE?-C?R3(D.WAS=(]
M.)T:\A)'MX]ABM?8#FMEOF&E>SQ?Q&%57KY75)&G"K3TQ+-(*Z-U8BEB8HXS
M*M:2,L4(D(*$:;4CPGD#E@U!<21K&X:KK7!Y;4LL;@2U,BATEH:1E8 ,#&"&
MNSZMO=<H&@&12K&5>:?CMC6]CEEG9MG9-F4B-+L,ZQNBQ'+K \,F0^#+.MZ+
M'*4!):A\1&EUX[>"2';$/.-2@XFSBFY:P5E2G)6)$=8T4E:.5WIE8A+LJ-4S
MLBM=2K.I\-ABK+PUD\SEY:&)Q))+)(&DDVDJHXTK'5=5@9A3TX)4#>-;>W55
M_)'RT5>25F6U^F9(M_6&DR0RQYEG3P&E3H>50+&1/K394^LMG6<7.,O':+;0
MYJVJY#9'L$E23]\E:;B[B&>G>BDS"1H) JW:&$LJ1<@1Z7-([H1ZM 5/,!!B
M321I&+>+A+((JJ.M3+E%0AD9BL]0$9Y3*TG@%4L;!FFE##0 5=Q:S&[G2^7G
M2*;(U *?&%6-JF6R-J%2MN+\6,9=(N<?9B]Q,M\5%:#QP\^UH0QX%E/2L;,G
M)%BR))BRXD8XL>,VS "C J&!H.7ZE+IU34ZPR\U%61@7"JQ;0NK2A9BH&IKY
M$Y/0%ZI^3M7<SUM S".8RQ\MV:,$)K8!0SVU,% 8FPPU<WD6Y7Y4N#9DTX,^
MPKC+(!*'FFH4>026_(+/)UFS'Q\L$ZPFK>W$^:Z5/=(.J/'%[:0HD2,')+Q=
MQ"BZ5KR4,ID"/24<JH7B2 E1/32Z L<:J FD #L=Q8-PED#-J-!=Q&L99*FK
MB+!9'D\1AJ(BY+N3=BQZ78V&.B7D0Y79\902],9+PCJZ^@:%V=ZE"_4:EQK%
M,*K8;>YS!GZ''Q; L1J6%W0QH]+'+)(61(FED(^,>)+27K5"S3>LNIH,MOS9
M:RIS-BWZ Z"MKJAF6Y%F92-"A1!X3X?9$7U!@8D6!+UE?<114T&7@ ^N;!J2
MD@13W"*3N6+.+2\L>B]#:8Q;U>%FB2\,N\\O\78F293(K*2SU/6P7/20J23D
M!J9(>0OMK4QJA]<^JAEGR"U\&&5RN2R?/,V>&:&2M=EGCHHJBT4:F44"1QT'
MB6)2OJJQH/#:^GQ7WO>ID>5QU$50M(>9#+5RP,9ZAA&U<[/6:E:J97$[,Q =
M&"[!5%K%*2.2KEMEUM54R].Y,RLI,/I]/ZJL-FF?/A5^%T&10<II,;!%)E/A
MVU-7=U==*A1>[5L>/"CUHOU,&R(ET.+.(8VF=<P<RS5=762.T$!U5=;2M25<
MX+4TMFE@8HAMX68O&RN2QM1POD>F$>H>&*F@HT43SJ?5J>H-1#$UID)593=]
M3$LG@<,HMC42>0_E;E(K3Z82C#<./'*$F?ZEN":- J=-Z6/#DQAYFD>5!2HT
MATXK31) RQYL;%XH90SLF6/BZQXTXG)-LP76YE+2&AR]](DFKY6*&2@U1N)L
MVKYXVC"LID)5ELFFB>$.'V"!LO<I&$"IZY7*#RXJ6)0PCK '4Q4%+$P<$-RQ
M>X-\*@G)]H!)N[3)YF$2IF17Q<7D6]Q-R[.9UE-D87<8!?XK(--EY*>0DJDN
M-,L)G1Y32-.\]*1TAYO6EREA:1\2Y\E,M*F821TP:=UIUIJ=$0U5-54LX"1P
MH@#Q5U0C*J!2K[CP@K<-PQD;5!JWH%>I*0QF9IJAW*T]33U,/CDF9SIFI*>0
M,6)NC FSL#HYW(CRK3*JQJ9.EHY4*T@Y/ L DRO.7&FBS/X?LR,QY;\G\22Q
MG@U4U#B"M7']:5T'*[6OJI<*"0,45=.*\^@(DBKYE:)HY4"1H+/3FG>+2!'I
M\+4=+9;:"8(BP)4''EN%,ADN'R^-M8D1B9);E9UF24ZN:I!9:F>[:@P$C@;&
MQ>##],\(TCP?(L8P2EE4%)/DYGDYH4NXN[QYK_+)MGD&0S_&WUI;SFEL[B?+
MGF DIL419#TB!$%48W%UF95695D517SM-.L=/1I(Z)&!!2((*:)=*(I"0JJI
MWTH+],7]+04F74<U-0TYIXG-14&,R2R$S5!,DS?*32D%I"20MAJ).]]HF^B7
M_P ;QY:O]CN7?_65FB_P\;GZ4"#QWGQ4W&K+A<;BZY1EZM8][,"/?<=L:]Z/
M?Z3\G]U=Y_;*L\]_KQ8MQH.-SQ7#S0\MW,_EW,CI1S%<M66Z(45[I[ISF6 3
M(&LT3.+&!,#E]M GR#Q86'1Q%>X((*#&4UJ#NR.7>,=%1S-^X>S[AN#AS,N'
MN(J;.)8JW,Z3,(YLI]3$D9IHS&4+54J6+*SVTJ0#I-Q8@Z1GN29_49_E^>9)
M4Y7%)1T%31/'F0J65Q421N6"T\;7"B.V[*>W3&I^#OI=_P"SKD!]G^177GR3
M_P (=?IXG_<I_@_'O3^%Y3U_PO3V??QY,7I'/]=\'WV_K7,]O/K<G[V#X/>E
MW_LZY /WJ:\>7N_GA^7NX?[E/\&X]M_=>4_@YGWK_3ARO21:WK?!WN]5S2PZ
M;=?O]O(X/@[Z7;^SGD!_>KKQ^+Q_#_<J[4_'MO[JRGI_A3@(O21_"^#^A_K;
M-.IN;_7;[_TGP=]+M[,ZY ?/^Q77C^^"_CV]NWLX?[E-_P!;\>V_NK*;]/\
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MR32;TI?MYKN7!4_M%VR+_OS_  <1\*>C+[D>([[_ .^B/_-?O^]B1EW'^_\
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0I(V,A'4WZXD1QA<9G'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g401831g01a45.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g401831g01a45.jpg
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M@DN$)?HZ*Y;Y=C@,W,VNZ:M=?L$0?7B=?=K(:>Y[FOMW]JS>I./! P!@# &
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@%:7I>OH#].^L_
MQ/\ RO.$8+T^_75+WK++<%!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P"M+TO7T!^G?6?XG_E><(P7I]^N
MJ7O666X*# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@%:7I>OH#].^L_P 3_P KSA&"]/OUU2]ZRRW!08 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , K2]+U] ?IWUG^)_Y7G",%Z??KJE[UEEN"@P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M9KA$169$*7\>N8NOL'/BXTP@08?6?,_(R..I?9Q\OI[AMO[8-+_OB'?Y1?\
M1XL^9^1CC:7V<?*/M@TO^^(=_E%_T>+/F?D8XVE]G'RGN#[C6"LQJ .-P9<U
M_3FV8S3F]NNZ:;4Z[["5)3[7L-(6M6M;]>DIWO\ <UBSYGY"54A)VC)-\R9D
MN07& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MMRIVVV$R=N::;W-F;0WI*?BI'J]ZN_6:+M=VW7TZCW\ 8!%5U_R.B$Y0FO\
M1.$FGYUKZ-)C1;7\Y<-#A+B[]-HM3B1*VV*U*>!1F.<MV"9)CK(,#D7[:MF)
MD4&4DT[O6SBW=V3YN1:6W*WE?0S5^I63<:BTCNM9ON-IZWW_ %1I;K[&Y71E
M52F>0 H^!=ZZ=X9!IZPA&(676-VN*<*7:23]H!%"JL3L4=$#M!$RE$4/K(E"
M!!J/J%'@QF93DB5M76TXVW:7U>NZ^[3I=^@B2IM/851NZMM;+2C;6]M;[5DM
MRMTZ&[]&!&V79&B@[;#$",4??U.C;99&3-/JB$77/>^PW E)BR51IBU:COZC
MO[:<5IESV;77/T^+G-.SYNCQ\QR0W_E=4?\ OI;^3Q7-OB?X+_$OA.1RS^,/
M^PS=^<><^, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P".WE.&#V'C9D&
M<+V<#!+GZ4*25IL/XVQQ2!.W!AXKY<WHH'4WMXG)B1Y,E,U.HT1U]YQIUI#B
M-B5Y=^_J^ BHT9YG+6.##/+VW31(8?69$6.T"GOB@BN2%0UDEEY3HU YM@98
M18(Q!MQ)YE0W=8TDB",50\RY8["&O-S\CY?_ "K=:-E4/R/X]R^NFQMI[-:.
MAV-BS69@PH\/*IL$(A50?P<R'$"SITIJ##/S:]J: &BGT,3"UR%LQ!T*.02F
M,(L29I/:>9=$(_*:=:8Y@AN'+(LQTP2L-,N! ; NS)PZ3/@18A6''9M-<>7+
M&/RXRF#8V0VZMB6RXL39KT]WF?1O-HX(& , 8 P!@# & , 8 P!@# & , 8
MP!@# & 5I>EZ^@/T[ZS_ !/_ "O.$8+T^_75+WK++<%!@# *\G31$;(:>->"
MH4K,$B:Q$KDBOTP&YI3H^U6+U:BR]UL@]7QT*. J5O!AY33"P6W7FYI!!UL!
M!(B?'OOZ>.[7P[S]"GV O1H4P?X0K!3ZBIPM2[A3QC=9A)8*TB)+M,)W8<!#
MCRST4HS(JT%)MB'"-,%A?RYZ+O[-6*\'CT]+>[JE?E=M"?HN6\0&#I\B%(&O
MS8$26^.EZUJ5 >DQVWG(4G6O5K4B*M:F'M:UK7O&U>K[V"#WL 8 P!@# & :
MRZ%_9M1_PB4_V/*S7PW\*NJ7N''YE_%W_:C[J(9=R3?7NA<]33.Q5_F\<?'?
M/'0MC276-L(H3*4N1N<F*W&&MCTR'H#4Q<DT+D24)^6M/H1.VK>^DG=6ELI;
M_3KMZ,X6GL[,MJ#G?1-6NF^5;];7MHU?7D,$(6;L\)5GGJ[[Q-I8@>4W+:<F
M;4R&#2[1$DUBP.1&P#S*G0M<F.URQ$/@)8ZVV:&X6A/T:%+W3ZS%Y:VE'2]^
MJ]T]SU2>MM&^:UB4H=RN+J:M<VKV=8WTWNTHJZ:B[/:LI.3$/IM%%MA09SH=
M:DGEQ!\21+=)CFFR1'Y09(29>GHS<08WI]FL6":[[EN)%C[A.L[9BJ7&CKO=
M65VK]:UZO;-+9D[M1=M>1Z*Z73RM+QF>"C @[#;(A"@XP/=TG;4X5.C$(;NE
MM-O(VW)B.O,+TMEUIU.TKW[33K;FO6A:=[DJTUO377H<C@$ ^VV/CL>X=+H=
M^1U<'%(.0NFGB-+BZ,0C3H/GX0;/U%6."ER;$F=5Z] &-T2%)?L-IGUS;0NJ
MJF6:N;NU':\DTU>S;Y[+6V_<DKK?INU6UN*:G:$X[#MW"VFDU>;:NKJ^KOM-
M65]_<O9X6M],XE4[57#DK5^E$8QNQ0X,V%K9X!HO7PEEDBH<0?$=/260TZH]
M3/1ZF5&F"L<K$! J*BQ6*;6:H(U&TKIZ\NN_=K;GT4G:W5J[(G9J.,HK92M&
MZW/NG%/F[I2@MI6NKRE9)R9MFN>:',3RYC*Q%QARH,B*S)CM!MSW&$/5A!^1
M)>;:=:D:9BSHYVOZTU'>=D3 BI;;>H!(<\_*FGI9WZ$^;V^7=?<5E0G&VL=>
MFW]*WPIWW)/5Z,E[ES0& 5EWZS^.,Y$BL7R1T 3(K]T[FP#&B2#FGVI4BPW=
MXZ723BA(Q*+\84!V>13B<1XN3KSYD6B,7C'#(%C>BW#<]I6<K+?RN[7+U<FY
M<INHQK*SBHV<:=VTFK6C96;=]'%2324K---)G-;O'#ZPR$$S'NYI3#/W\<NS
M.+DDRNBC3E+9+UIO8V/)9E";"W"!S(CX6+&G#MQOEVW1BC1D>NUX[NZNF]ZO
M=Z)KEO>_)S.[7+&S4E=KB]T'962MW33ULTU9IW>N_6R9J<+'\7BDY^%[7=H1
M9=1'2Y;,0OLI,D5N "/60A7MLR(*9.QXA DV-0,@14.3&X\'8J.F'<!2K'7N
M/ZU[7=M>1W\FNFG5KKJ-UDK_ %)K:M>R5I723OHKNZ=WHM;V<=+;@K[<FSTN
M2RKVFI$@D^TK_I-NULHXA7_/^ZE6MY7$_P %_B7PFIEG\8?]AF],X\Y\8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@'&%QP<G >C'H TB,1[$I^.7BQ9
M<%.XBM2&Y#S4U#D?6XRV]/H=<3KW*T:=TI.TZ5H"NCGGD!Q6P<Y19H/"*^,@
MV&[F*N_"JD@>YN9*FB*U?C(6 5,5ZCD2]Z)&[G.##>; XDIRTV #9VJN0+B8
M*YJQ9I\^FEK\M].?3=R\BUY$;@M_8^2C#'<@TKE <J4Y55S5RLSL\=4E,STC
MH8B4[*L\:(R:M%=@&VK0Y*KA0O6I<^Y" MX)U00>0&:8,"+;NEV]+V]WE1N'
MA!^EWWG==Z)4*K5J[#L"3B8RJNS$>%RF89Z6&D$@Q9L)7Y9 $?6#C%Q4N<&#
M3YPMP6^3#C9R%P8H-6?IZ7Y^DW3@@8 P!@# (L%2O?I91<.DV;G)K43HQ!5M
M2J>,(2P7/!=LERQ@JL (4"%+W:95=W%J]U9MYW272\$DY6"%;<EQ2<,-/1>7
ME].@]75K[V9KMZ>D6?BE8E0N764H/G@2R"#M*N<H6(B I=FEFI98,Y7:K;@/
M5()<U)'QH)>$%@JT,A3AQP>P)TTWO7RZZ^.UO2QC0Y'FI)L,=Z!<.(6.F!3$
M($]*CL28I&SIJI*Q!+(2.?!12<:OF#3WN-V.O!G7-5T\$AP14F&PU81Q,';F
M_=>UNOR:KKTE_7UG' @MRRM#V#[D)A9=@5[[Y<S/6C2GV8FY#S[JF6E[VWI2
MWG?:VG:DK4G>MX(.7P!@# & , 8 P!@# & , K2]+U] ?IWUG^)_Y7G",%Z?
M?KJE[UEEN"@P#4O;;B5IW/RKE6=<5?K"E^L\W&QX7QTXW=YPZ?,%BX#3D,A
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M0M.E(6G>E)4E6M;2I*M;WI25:WK>MZWO6];UO6_5@@_6 , 8 P!@# & , 8
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M$P63KQT5##7=?JLNB^E[-=+\>I9;0.;TKEH1RN4(&W7@;DIF9L:Q-)3(Z)#
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MD](*VWH4^-$8,!@@$&^1;E[;Y_3D)@X(& , 8 P!@# *TO2]?0'Z=]9_B?\
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M%2S%R%G[IXTU,?(*V+D)8K*=(63NGC-6X:')$T7,EO23O7O'T*QO5B>60O\
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M)0;3G*H]IQ:VG*<I3DY7<YRE*3<FV_4W=KFH<X(W;K/L2["B#71>SY78YP=
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M6YT-(6RL6I5D"AH9V<V]69$B0U#2/G38#"FY>Y&TN.[D:4UI.MI0K>_5KN/
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MQC&IB,-B.,4H59MM/#*.RU9J;=]+.Z//(#TX8 P!@# & , 8 P!@# & , 8
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M02, 8 P!@%:7I>OH#].^L_Q/_*\X1@O3[]=4O>LLMP4& , 8 P!@# & , 8
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MOU?AR8^=1.RC & , 8!6EZ7KZ _3OK/\3_RO.$8+T^_75+WK++<%!@# & ,
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MAWFLPM,K!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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MQ=.[AA8-QBY595*C^=?"CA/+&N>79=*2P:;CB,1&Z>*:WP@]ZPZ>]_\ K?\
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MDE%RA*,I=TS,23+@8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!6EZ7KZ _3OK/\
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M,96O%-;:S:'*C & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# *TO2]?0'Z=]9_B?^5Y
MPC!>GWZZI>]99;@H, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
3, 8 P!@# & , 8 P!@# & ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g401831g01a46.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g401831g01a46.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2N"4&AO=&]S:&]P(#,N,  X0DE-! 0
M    *V:^$1$#A"24T$!       &1P!6@ #&R5'' (   (  !P"4  %1&5L=&
M$ .$))300E       0G_WU6TR;:/U(<5@2P@79B#A"24T$.@      Y0   !
M     !       +<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G
M1E96YU;0    !);G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;
M     +<')I;G1E<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$
M]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7
M     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64
ML .$))300[      (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G
M,    7     $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP
M   $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='
M9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC
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M]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M 08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P
M         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&
MQO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 0
M\>#  !  $!#QX,  $  3A"24T$)@      #@             _@   .$))30
M0-       $    6CA"24T$&0      !    !XX0DE- _,       D
M    $ .$))32<0       *  $          3A"24T#]0      2  O9F8  0
M!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:    !@
M   0 U     0 M    !@       3A"24T#^       <   ______________
M_______________P/H     /____________________________\#Z
M#_____________________________ ^@     ______________________
M_______P/H   X0DE-! @      !     !   "0    D      .$))300>
M     $     #A"24T$&@     #00    8              S8   /+    !@
M!G #  ,0!A #0 -@    $                          0
M #RP   S8                      0                         0
M   0       &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0
M    0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&
M]N9P   S8     4F=H=&QO;F<   /+    !G-L:6-E<U9L3',    !3V)J8P
M    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W
M5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@
MUA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26
MUG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;V
MYG          !,969T;&]N9P          0G1O;6QO;F<   ,V     %)G:'
M1L;VYG   #RP    -U<FQ415A4     0       &YU;&Q415A4     0
M   $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .8V5L;%
M1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R>D
M%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97
M)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V
M)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE
M  "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
MQB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #
MA"24T$*       #     (_\        #A"24T$$0       0$ .$))3004
M     $     SA"24T$#      A(P    $   "?    AP   >   /T@   A!P
M 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_; (0 # @("
MD(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,#
MP,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0
MP,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@ AP"? P
M$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,  0($!08'"
MD*"P$  04! 0$! 0$          0 " P0%!@<("0H+$  !! $# @0"!0<&"
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M/TU&KZN8E0L8RRST[JG4V@;6N+70!^EI979^CV^Q)*']D] ]-I=8/L^0QIH
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M.G!Q:+:\>D;:PXAQYW1O?8YSOI(U7UBPK
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MZJP8></$TA:=M$#/6I56IL<>>VG$;K$<H(.$P.";A%-8@*$,FH!%2%.4#IF
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MZ:Z<L&.KGG-[DMJX^"E<E:KDU291:UZVR;6AVUBSR/3(&M.K&D@DR9O\[6^
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M*/[=(W'%-HQMARSM+O$M8J/KJ4)$WNW7J)JR)'\RI)? U*W 9H,DWC8>=0;
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MI4"J>MXEH6:;99+LQKSYFG??A0-X)5E(.Z)S=8CJU (N8.&CYN6E)9PTV
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MT[>/]*F=<GY6HV%:52#2>1<E5=6[42$<3,!$(V2IDK\M:49YC+3$HPBDV+^
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M=R<>BY$C&^+9MS6..OMW\;=-]3O;I^CYWT_D)Y.++]DR) 8OA<DX!=6B1QM
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MJGU5\H]%3U6EZG,8R49GQ'B^+N\%8KC)S\<&3*S7[ 2YEK3J2@2J&KU@D'0
M:Q.XUA;G]B"HRLL[=U5*;K,%/S\]-+I-]]S:UMB?#H?>1;87R4G"XU\IPAC[
M)S:6R12YG(US*T>UIR^MK: @Z3,15V@I=(D _@,?21V%>DJ8>=JSJ)/6'RSM
M:,B';U\F\EYF9!_?\[?/GH2BXL#YCY-[^_7ZFJSY69^NO&L[]A!K 3-:<*.'
MZ$0Q;VFOV&0G*Z=:'8O$$461F,97$K"TBK DV6D"O'@F<MEW)8R7C7S\_/C[
M=/4\%?5]>>OE;].E.2%\HS-5C,-,NPTM%67@:&\Q9=*%<&T3)1,Q!7V/7R5
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M.++ZT]Z1RJ3Y*SV4SG9%*J D]VU1)D6J%M<=+BU^BJ0IQ)?:6A"2N.TRT0A
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MQ$',0VVAQ20^ZOE=2TT"H@\RU)0TAQQ&MO"E)JU6BJC-I+OI+Z1&:Y4E;A8
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M%X)6V^D\Q"VUFPQ<TEBI+D3BAH(=B62@+;NI=UI4I,BX5RA@K;<CJ!3S-O(
M4;J(#KZ8;Q$5?%\T:!=#-97N\N^K149I\O(S*CL2"Y9.DA/WJ[>JP<:L,D].
MW3*@@FW> !',FH3SJI0ZHU$IZG<.2E*4V&U*)<<<"5*3;FO9M*?6-K!(2; G
M!OE<AJH1&7)0Y&H80V\&TA*''#RA!!%N9Q](L5?Y/KJ(#:#:FK4AG;4:URC)
MMYK)%MK3E!DS3;QU,M%DK4,=B!UQ9O/1C&401\\=I#WKAP9,JC@HI'/L7LAQ
MO/\ <]1*?5^SIF;/ID%^0JLU-'>2(49YSD06 D!;C2E% ))3FW@!>VOG=]T=
M5)D?M*?1 F28<?Z&I12Q&F24-H4KO[@I2ZE)<L!SFPN+7-A<LQ$YFU$S\K'0
ML)E?-,S-2[UM&Q41%7J\R,G)R#U4C=FQCV+.46<O7KMP<B#9JW25675.1)(A
ME! HYM=HW#L=IQY^E49EEE"G7GGH,%MIIM YEK<<6T$H0A(*E+40E*05$C)U
M@INK5Q]U#;53JSKKJDMMM-S)CBUK40E"4)0X2M:E>JE(N5$@ 7QK?W>_:L,9
MV!S4LD7;4+0;4T206>5NYV7(]8GFR+DG>-5W$1-/6,@DDX2_7$%5$"$5)]DF
M(AN(>>% X4J<=,NFPN'ZA%62$2(4:FRF%E)LH)=9;6V2DX4$JN#:]B=>B7.X
ME@/*BSY=<A24@%<>4_/COI"A=!6TZI#@"DV(Y@/(#.DB.?,Z\_VZLM@&W,!R
M-<=OQ3/AMX<Q\!VX]OT!0O\ 0M)_^'0_'_8_'/NSKRFM5C_2U3&+V]/EVL+#
MH[TM?&]P ;6TIYW)>INLQE1F9W*>8(V,OD O9ZB[5R5:#DFH%M8)NK.)%N1"
MP*J))IV"N3<:*3I-!?O6"BH(F;J(+*^5BF<,R79C#%+I#CD!],66@4R*"P^N
M.Q*2VHE@7)CR&72I)4FS@',%)4E/H=J'$##<9UZHU1MN:PJ1%69\BSK"7G6%
MK #ZB/P[#S?*H A2"2DI*24Q]?S.H<OKTY:]?/(]P'F&^V_[->//;I^7;T_0
M-#/_ $+21M_T;$ON<?O/Q/MVP=>?Z9K /+]*U/KO/E;BX%P7AOG&/8,V SYG
M40^W3ED-P#E]<:X_*']V=O6&^P_/S#A] T+/[BTD_P#Y=#]X_>O+R^W3Z9K!
M'Y6J0) QZ=+Z@*'_ #MO$7L1YG8GU_<[<OVZ<M#X?;'N.P>H.<R'4/'Y.6PA
MP^@*$ ?W%I7CFG0\ >89/3;J?;G0UNLFQ^EJD<6Q/E6%^F71D^.VP L1JQ/R
M4&7\M677]I[A+'E'(L_"OI2YE>Q$U=K+*Q;L$L<6]=(KN/?R;AJN5-=))9,%
M4C@19)-0H=LA3!COM6I%)C< \0/QJ73H[R&H?(ZS!C-.HO48:24N(;2I!*20
M;$$I)2<7!OGLWJE3D<:T)E^HSGF5O2N\:=EON-K(@R2 I"W%)(! (!N I(.]
MB.F'RC'[@XL_A>T?F4-Q\*ONZ_R5V<?G#B7^S4;7UB^YC_*/%W\RI/\ 7SM<
M[C+"+G,6?LFA;)Z9H=-K3"+<FL!(TLTW51G96MU>$=$B@?L%%(OX0V)TI,O2
MKBM&Q\<X<-64H_/'QDA0^R-5,/9Q0"Y4X4)MED"?*,5^:[%DR*D]%8:=:CE"
MVT$KAEU\J*667%%*77>[9<U@[<J1(J/;3QRITOLL-RX11A*FUMFFTQ"7$H4I
M',@N..]Y97,E*%$)6>5*I1:G,NXUT\X+;::\'P\1#RF1Z':)"2M+V2E)1LRE
MI:$>XJN"DFV5<-5D+Y*M8F?J*#BOR#NL5^PKS1'S!PD];N*[FNFR$\/IDQ5(
M<7-+<B3&F]^X\SS.-2&DK=$F,VTU4GFHSL!3<):X3"Y4Z,AQUEV,U"]?!LSA
M: MZ&'D1JD*1.F4EE<="VG:I%B/ K,I4@EB2P^P%-H:;YG74! <3S.-.T//]
M;F>L<WAB;47BYUDMU LHQVZN-CCH_P ^*B@HG$1UPA)J/(\B)!V#=#O%WT&]
M2.@;NVY2@NHX[&0H3 EL";'FEU3ZN=Q"E=ZA%D)0&2HCGLTE*4)*Q=1NHE0-
M]9P34IT5"(U3B,+=93S*<CM%H"ZR;L*0>X62+EPLV!6HFR.=*=6D/&D/J'QW
M%V6A2SB,MBL8VF(D4YYTXC5W;5B9)J1L=3NW;9,&A0: /FQSIM]@*10A#%+Y
M:S18==C(9J$>*9#7>(8FK90XKN72TIZ,\D@%R,^IMI9%N9IUMMQ/,$J;<L_C
MCA5CB^F)-/E.0:E$49-/5S+2V7E(4GNW2@J*0Z%64MO\502LI58A3Q:?_A"7
M$M5;VI*00GF(2\:_3E"I ^ T;.R3% 5A1W2.4[=NB=!9,QBKMS)+ <X*=H?E
MMVW4Y%*[3^*(+;+<<,O0%*::OW:%O4N$^OD))N%+<*[@E)YKH)38ZVM^Y_9G
MQNR7A2/4VWFIT<5EB0V^ '4J:KU4;2#R^JI/(E);6DE*VRE8)"KEY>,4ZS)I
M[ZDNXB<(94E(U4Z#^5M./JH_<(&,FN6O/&]LF7C052& Y6LA)0L65R3D1<&Q
M$E.V41+QEKAMYZF]DG:)4(#BV)M1XCX)X<F/LJ4V^*'*C\35:5$[Q"@M,:;/
MI-.])1A+XC(;<YDW3JPJRVW,X^X0B2T)<C1*/Q)6(S;@"FE5-AVC067N10*5
M/1HD^66E94T75+1RG.ES@BK!D=]W-JI<?:V$M.1%6D;W:KTXA7T*V68I,F$;
M4FKF8CPF;#'MDB.VS(J4X<635I')Q[1 Y#KWAV.<.#CN8MGB+A2#Q'"J=6I?
M#LWC'B+BYZDS*0P["1$A0.&H[]4@IJM<AQVD28\-+5768L:+"1!8:6A3UO\
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M2MDH4I" +W4'.:X">6*F"RPLMJDT_+*1;+O?KP4HZ:[= C90JJ<Y&OVIQ5;
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M?ANH1J9684V67D1FS(:==83>1'3*BOQ!*8!*>9Z*I],EG(/>-) (596I?V#
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M"KJ!*F$\[5EV)_%5<#(*B5$@DD:W+D*8E)6):G774*<42;J)>42X%!1"DDN
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M>T2Q[':W>P X7A%2C;%DPR#Y6MG.1ODZUDX6(':7#*K #B"<23T'>RL^7O\
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MC+I\0RYC2:>Z6&V'+NMK#TII]#3*Y"'%I4XZV7$K;*E#4?SF YSG A2 <QC
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M#P[&,BTX^-9H,%W(MSN7BYPPP_+46&FE"R6E$J5=QQ:W'"EL$W*B $I0@)2
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M$#J+7O<]->&*T64&)N%<N;=RP1DZY/1D^W%A7?1O?.8QT@[(39I,E;)]Z9N
M&$&AR$$PB")@,8AJA3NS1FG5&)4&JN[S1)34@M(B]PASNG4K*%<DLH2' D)5
M9M0L20#D:IM4[6':G39M,=H,<)EQ),4/.3>^4P7FEMAT!4(%2FBKG2.<$E(
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MN>MK: \0V -^7KY[<P$ V]0CS'Q#Y.&??X>1VOOL.HW((S;0=1ZN3:^#[0;
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M6HDVH0!5Y-$GUEN!3:;4(T-,U3<A<]I?(MM2DI2V^4H94X+A*5J-Q:XKNRU
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MA[CPOOC-]S;?8;^SH>FUKC2XR ,C8XO<>T^S /3:QMHZ\OYOFY;>^WCP)L<
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M*,?N#BS^%[1^90W'P8^[K_)79O\ G#B7^S477UP^YC_*/%W\RI/]?.U58(@
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M=RS4,9I(-RF*JS>(K-U2]HFXW32:FU6(34YF/.B(<*P(]2B.P9:.113S+CO
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M34(LOTB^S.8,1VO'U<DF3R"DHAM9\B-+E&QD26@GGRO+C1[/371C/K,VE(Y
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M,B8K4&R&W=A[4 A)NFRBI1)2HJ"SS94+BX!-CR@@ ' &VJ-*6EQP%MSG0EM
M1^#""VE(-F5$ =XIH%*2YGGMSW.G'\1_K]77V^KV>OPXYD7VN;7M>UK YZBP
MZCR(VMKS$7.,@>.!;KG \+6Z6VMH#WY[]?4(]>OZ.&+WN;_ ^=[7L<&_QOOH
M+;DY]_UFQ^S].@/;X]0Z["'J^</;SX7'O.=@203MC:^-[]1:Q +'7<YV!OG;
MROYWZX&Q/I\?9\WAM[[CQ-\C VZ$CQ)S>QMN3?)Z]=2#D8W!R+CJ21>X!MN3
M\3UUGW]_?]'$>!O;).#DW-KY-_:3BWOTWMT&YL?.U\YO>^^ +=;W.&QWZDY
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M? !Y]>?/;QY#MSW$!XBV]_;>P]EC[KWQUQ;7(G &]NF>@5G?H;=<$CJ;Z.0
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M+5&'V$MTUN.AU$J&T @L+:[LK0&A=)1Q?X^J\AUI;E/I7=M![]K]S.6R\R_
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M16;LVB""#EV[?KI$('85>/G!W;IP8H[@*B[E0ZQ_#MF$2@78 XDK42%*420
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M!LBHJ<"$,<2D'LE,/9#B2; W)2 +J)O@)O<XZ#)]@WZ:Z$(6XM#;8)6M24)
MW4I2@D $="387-L9.VB)DV<W%QDS'BX,PEH]G)LC.V3Z,=BTD&R;IL+J-DV[
M.2CW H+$%=C(-&KYHKVD';9%=-1,DI5=(4"?72%#!&"+BX-N4G)-\IS@'&I6
MA3:U(5;G0I2%<JDK2"FX-EI4I"@3S$+2I22/62;&^MAX<_Y_T?\ #@-S:XZ
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MBRAR-D.\,=044 (F*AS'$H&,81JJ&66RX6VVT*<5SNE"$I*UV">992 5*Y0
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M?27;EYF"W$<[XEOF+?,UWK:AS*)><"D)L"I.3^FZXR4XJ_93M=:L7\A>WDL
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MI4'PH**K$O!U-^4IM@+0"H$% 24@%)(/:W6HZ4("FW>9M4/D4$(24IC*C*4
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M 5.MU=,J5>B6D4D2+AH4A&@' I8JO-E&<*Q #G. (QS595%  #M F<0,8P@
M\<@A*$A*18<H38;!*+@#&?5ON?#<@"W0ZZZ[EQ962MQPWM^.Z>9Q6.JB 58
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M)'*D)*?Q+="$K0+$F^ M0N?%0&;:XNS)3H6EQY:@YS!2< *NMM:AL,%;+2L
M7* !C3B>/M$/Q /Z-_GXYVZ9WO<V\+];7N,F]K8!&O-;-LWR;X]O6U\$WO;I
MC5X_DTOM'VC_ "ERW^CM7]OR^KC6SMA/_*2%;;Z'8\O\[F^W[3[M;%=D?\79
MEKV^EW_[+#VR?M]PZU??5&7[S=*X^ 6;*N_/;^Y5'^0/I'B^ON=?X;Q5YQ:3
MCQ_"S_GWZM/MV_@_#?\ MZG\.[A];CZ\>\#7*_X<N?L'GOOS#Q$.>WAOX_\
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MV)G(Q\]!Q,PSEF"\7)MY%@V=IOHYRT?,%V3GODS"JV592<BU,D81+W#]XD
M1RL!VFOV-<KQMA- PQA*8YRB,6Q$0,HHDLH8!% 1 RBS=!4YNIU$4CF$3)D$
MK37EF:?4["R=QL[6H*78/V2D:]:2,4Q=H.H]50ZJC%=-9 X*-#JJ**&;FW2,
MHH<XE[1C"+2Y\=>LU>@#%4(:#AS$5[WO2&C&0E4[]+N%^\**&Q^^1_65>T ]
MXE^MGW)RX::^Q8:'("0$BHT@(*G71 K%J4$5U%T7*BR0 D'=JG<MV[@ZA-CF
M7015,85$B&*TU^0@X4O>"6'BP%8H$6$(]H'>D!T9\!%-D?LR@].=V!3;AYT8
MSC;O3"<6FM9$TFG0,6PA(6JUZ+B(N-90\=&L8>/;LV45&@!6$<W03;E329,P
M !;-R@"2)MS$*!A$1::V00,&&^T-%!N5,@[1S,-R)"J*1!_6>94Q77%,H\B"
MLKV0#O#]IIKZ$AXE(J14XN.3*@GW2!2,6Q"HI=X*W=) 5( 33[TQE>P0 +WA
MA/MVA$>&FL%AH<B_G)(F-(X^S_L@K%J5?]<3,B?]=!(%/LTC&2/]E]DF8Q!W
M*(APTU^1@X44B(C#Q8HI*F621&/:"DFL<Z:AUB)BCV"*G422.90H <QTDS"(
MF(40::^?P>@/UL?0</ND9<R0^C&7ZV9T=-1R9/\ 6/L#.%$43KB7853I)F4$
MQB%$&FOLRAHB-_<Z*C6'7_\ !,6K7J*AA_ZA)/J954P^L55!'F<V[36RX::.
M&FCAIHX::.&FCAIHX::.&FCAIHX::.&FCAIHX::.&FCAIHX::.&FCAIHX::.
;&FCAIHX::.&FCAIHX::.&FCAIHX::.&FO__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g401831g01a48.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g401831g01a48.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[2&\4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (:"^A@@X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$""P
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 )3,S  !  $ E,S,
M  $  3A"24T$)@      #@             _@   .$))300-       $
M6CA"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))301$       0     @
M D    )      #A"24T$'@      !      X0DE-!!H      T$    &
M          DV   .V     8 9P P #$ 80 T #@    !
M          $             #M@   DV                      $
M                    $     $       !N=6QL     @    9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   DV     %)G:'1L;VYG   .V     9S
M;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E
M241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0
M  Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0
M  I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !2
M8W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T
M;VUL;VYG   )-@    !29VAT;&]N9P  #M@    #=7)L5$585     $
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M!!$       $! #A"24T$%       !     @X0DE-! P     %UP    !
MH    &,   '@  "YH   %T  &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B
M90!D@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.
M#@X4% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,
M# P,# P,#/_  !$( &, H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$!
M 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $  @,$!08'
M" D*"Q   00! P($ @4'!@@% PPS 0 "$0,$(1(Q!4%181,B<8$R!A21H;%"
M(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#
MTW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W
M$0 " @$"! 0#! 4&!P<&!34!  (1 R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P
M,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S
M1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$
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M6Y\?YC/YK9^C_,J6RRX.=L<US'Q.UT:C]YI:7-<I/>VMA0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M\28Y149356)D:'."E*2FJ.%$8V=X@X:2H[6VQ/_$ !X! 0 " @,! 0$
M       !!08' @0( PD*_\0 :A$  0,# @($!@H-" 8%"00+ 0(#!  %$08A
M$C$'$T%1%")A<77P"!46-52!D:&QM2,R-E63E)6RM+;!TM,T0G-TT=3A\20E
M,U)RLQ<F1&)D"4-38V6$A9*6&#=%9H*C.$=6=J+$@X:F_]H # ,!  (1 Q$
M/P#^_CBE.*4XI3BE.*4XI3BE:]=F>P,-URUH3=3HYR?G9 \>O4VKCN*;?L%E
M/;><%&4MMMYUD$5D=\P\AMEQ>&64C,)6:6(TYD>E].OZENB8+;HCQVVU29LM
M0RF-%;*0M8!("G%*4E#:20"HE2B$(61@G2)KF)H'3SEX>85-FOOMP+3;D**5
MSK@^E:FVR4A2D,-H0MU]:4J5PI#: 7G6DJUHA]2]]-DQK-ON'9.'TU*2+*)
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M"R0E920A1!((2HC!(((."<$'- \TIQ;*76U.M@%QH+27$!0!25H!XDA0(()
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M"6V^O>*@ZE!4TE*\A6#I#I7=?I%NR2K=)ZMV'%XCJT<"@YF2A-:QHXF9O)Y
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M!<M6=#G1G>^N+-WG:LM#2I2>%L^V<.)J&WJFI"1PH+DN,90".%*"L)2!@ ;
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M);[>TVT%Y;D/F,D--,*#P8*EN)"D*65A*U+(1BMEO:-@V_HH-OTU=H6A6;O
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M3W9E^7=>1'LQ30*5&N2+A"1$"8R2I[#.,KXI7$VF_46C18DW=KI4Z="GE-!
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M:T;?0H1YA#(3=;@(LUEXGX0==PJ:Z]M1=V]\63>&B0I6SPUZU?V L6S*\._
M];]FZYUA"-5W6=_V/4I;4.\-BS41*[F&?8I(P4A,8U^%7[ #)F3<(Y%,-QK+
MZE?C6'<'M15]>]7]X[GL6L]B5'L=H#9VR2M<TG6\I3)JFR^M=#R6ZXA^*MCM
MRLOQC?MP%>.C9^.*KL:+&2DLQF"3[(!ZHI2LWUN1V!G^S_2"_;MV)J^[#[%T
M5V"O%?B-?T61I>:.59Z]I.8DJT*>=<[8J\5@(0N*'BK&2-"2_M+!9$BT2S,
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M+[(S=-%E)52LJWKN_M1JB<AM4L[QJEFV0%K>3VE9<:IZ?;(VI:7,RE@EH^M
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M1J?P^G[(U/\ ZXX]HKW]Y[K^3Y?\&GMU9OOM;/Q^+_%I]GK1G[=&I_XQ:?\
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MIVTNDD-$MQ2:QKZ;:0L!@MY!665.M(&PZ\W!('/R_,,^>E:$/^F3TAC3=;W
M)JO;#S<Q7=B6J=IAR:E!V>A0]+WQ&];X#%US,6$2)AI'8VU95N%JL:Y(Y?;&
MB;5(2V01JQ**;CB'E[<YVQV?3MW<\G8TK=W1W99W;E!OFQIS6QU KU&49ZQP
M/96G=R9FD14,N<FD1Y&C+WL, >0C E!95#2)8DP5F1#6*"ZR\VXN<]^WGQ_;
M2M?-4^D3=W+IVW[HI/5_<9]8AM?P6UZB7BUZ0(KM[H4L:2W+I;OT=LXZBT[8
ME#BPBIN_:GNL_"WFOAX'81&'G/J&9@*SO@]XY;CSYP,=H)I6)2OI4*?4-*Z8
MW7L?06W*-&]@92I&:LJQ$IK>PVB7U78X:#GI/=TR)6+C*L5+7M0"LU;8L/QE
M?C;"/)6&#CT0N79%G/'%R.#OYLX[\ ^;NYTK(>Q/I-*/UWONYJK):@O]WK77
MB-UI([CO%9MFGXEFMKVB#\+0$1!5*\[#JEPO<^B'<#D'H6GQ,L:YB1CQ66U%
M&BM/258SL<#F=NW'ESV]U*IM0[B7&X]GKQUH!ZM[2$)UPBL35RV,7=M,*J4)
M1+W)W "@W0F/$V"3:,IMP])F),.I-0KEUC <C.3\!%>NQX,[XP=L=W;\>:5@
MMR])GIND7N)UO*U.\O6Z:[G@]- XP)J&?4U*OL:ES(;=D',R:$1^L(>3W;KF
M -+(RF:7.62-"&BWO:D.8%0'RX^C^T4K%1/2CU"RQ6W)_7.BMHW^O:BU9([Q
ME)P*>UE6HV7T\)L+9U' V!'E7&Y0++,588S4=NV%70C%M3,O15P,L)'..S+(
MS3(]<>7R^2E9;2?2/T,^P:IKNX]=SW6\G;VI[GO*N$[9OFIF QM7U@76[D-/
M2C\!=I= <E=3M@OQL#4W5(M0S].LKTQ#QX[03A;(VSMD9WV]3Y/EI6W/7G<L
M;V(T=JS>D)7IRJP6V:7"WR!@K+@/$X) V,9,A".R&(\@L)+I\4\)(H2.2\A+
M);6/6*5A7 .1GOI5DY-*PC8U#B=ETZ9I\NZ4$B1;8(C)J.4AJ9K%AC"69.MV
MR )<0M(=@J\Z(!.PA>4+2Q) #K<0XUA;:^[;ISMMF,RV@A9;*DNLN EF3'=2
M6Y,1]((XX\IA;C#R,@J;<4 0<$=.X06KC$=B.E2 L)4T\V0'8TAI0<CRF%'/
M"_&?0V\RK! <0G((R#P>F+I*WO7D1*V1D4:XQ1D[3;V*"A;8#-[HLY(U"WKC
M&G%K>1"G3L*;)U]3RE./P!T85E2L/X4K[7B&U!N#S4<K5#=0Q,@J<W<5!G,-
MRX@=( !>0P\AN1PC"7T.I'VM?"T3'9L!IV0$IEM*>B34H&&Q-A/.1)9;!)(9
M6^RMQC)RIA;:C]M53Y659TXI3BE:YZP&3L;8MZW1)XP2! S-FT]J4=S&%-1%
M>I\UF$V58QT*\?52]XV1!2<826VI;)=.HM(>#RSDR3P7D-R5[7V^#9VO%<?:
MC7>ZJ'VSTB6SUUMCJ. 2S"MS[;J4'=$N=-"\\#?!C]M3[87";=W1Q(8>DVFU
MI/)J/$>ZFXR$@\G9MP8<;4L'A7$@PE)QQ.<6QG,>K(*AN\M\5[13>I,3D-,S
MQNY-XZ[T15P(3(."&K%L B07B8-R<4*GX&KD'"SECFO9LD'?!D23[&(0]Y4<
M@^;._J:5IKKKTI6J+M0-A;EF=5[;I>CZ94K);XC:S[-)N,%9\UNW1](Q03(Z
M@7"S35!W)8YZ8B&ZCJB_@U^T3HY_F0T.4&>(-'$-S@C'?]'G\AWI7UV+TE4'
MKJ(V>G<_7;=.H+]0=<43;5?UK9B]9S4]LBD[(V-%ZEK6:Y*4B]6>OQUH&V#-
M1%<LM4L$E&R$(3*QS[:Y$,A9#+BYY&,;\QRS@=O^ [32MC.W_;&C=-].F[;N
MT'9K@]F28A*S0*.,(=<[G,Y!D)R2"@!3R@0U-UZI0=END^864./'5FM3!RE+
M<99'>DG'T?+2I+>.\5AK^W-0ZGI/6':&TG=ZT,_9&L;37+WI&'A9ZI0$)3IJ
MWRI(EIV-#S4&+5\7JO1S[LY&QV)J1*RS6DS"4X6J.+EL=QD<O[?+2OAZR>D"
MB.U-T$A=?ZBF!:4;(7\=B_R.W>OY12(RB3,Y753Y6J8;9TEN(*)GYN'8#B2"
MZ,RGV>9BI8I3,02@Y4@YY<N_UW^:E4DKNKK%KN-$],!(JRR=Y.J!UAD[B&P#
MFBU^QBP;EO8UK(GN&H/<O1-%;1>'(P0%]D&MGQ!IA#2I1AO#.^/G[,[[>?8T
MK%]T=ZH'4O8$+KK$:<VCMBY#T6H[-MC>OWJ*N7AZ/<[?-4T&7JE&L%OA+[M=
M^#-KTK+W./UM7+"]5Z^T.<8MTLIJ.X)P<<_-V?%V_%RI6$9])WHX;=U#TA*0
M%QBY/8O9+=O6:OV9]$,[7<6S2#=(B9BP2"QI-TT*M6/9%\B-4ULAT7VHBYH=
M&+&%&4V\IGEG;)('Q>O+GG:E?'6_230^S(6O$Z*ZY[JW;99+7QFWK)4ZB9K2
M'>HVKW[C<*C19R=G+I>:W!&63;"*5,6#6]#@3)6R3$$TH^28AA\,O$1Q=PR>
M?9RSCGG'KV4K974_:"L[AVI9=65^F7^"DJ?I?3&XK03=8+-6,K2MX+N#M8UY
M8ZU(NHL$'?HJ+IILE9(@\)MJ+24,+[0\3AY*)!S\@/RYV-*AO77T@,1V:V+F
MJ:^U',IIN;3LRNM[$D-N:!R^L'6D_9*N59EZG!V:7N=B#GINO(&AGGZ$VO(D
MQ%RY:6(=Y1Z0.?BSW=^//OSY4KL,Y-*AF^JM*G5<;8-,#61LW43Q5XI+8WE0
M58&@ALJM>N'W,^&'(K95<:+K+S)/K! )MZNVI+"I:KQ#XUW8I33<E4"8L)MM
MV2F%-*MT,%:O]%N('8[;9!1)2I.%K9$B*5!J4\E5)?(SJXR)\1!5<;2I<V&$
MCQWPA!\*MY/:U<8X7'*592AXQY(278S2DUFMV")MM=@;5 %H/@K-"Q=@A3F_
MO9L3,@L2,<6WX^_R$ADLO)\?]RO'*J1'=B2'XKZ"V_&>=CO-GFAUE:FW$'RI
M6E0/FJUCOM2H[$IA8<8DLM/LN#DMIY"7&UCR*0I*AY#7-<^-?:G%*X:QV")J
M=>GK5/EH @JS"RE@FCG/'U843# OR,B6YX>_R#!C//*\/?Y49Y]HT=V7(8BL
M(+C\EYJ.R@<UNO+2VV@>52U) \]?&0^U%COR7UA#,9EU]Y9Y(:90IQQ9\B4)
M)/FJ2Z%JTJ#5R=@W,-8^S=NO"WB[-D^595?:,&PJJ:Y9=]^&XK6U<>$K+3(^
M6Q#IMJQ6I3"9:SR[Y-K?9+2Y28$-85;;2%PH13D(D%"L2KB1S+MRD)5))5E;
M;)CQ0KJHK*4U=CC.HC*GS$%-QNI1-F)5]O'"T#P:W@]C=OCE,<!.$K>$B24A
MV2ZI5SY25=5K9V![)1>C9'6=,BJ'<MN[=W/-SL+J_55$<K8,S/HJ</\ #]QL
M<K/W*=K54K%0J$4X&]/3DO,(6@F4B(Z- DI"18&S!..PDGD!^WN%*B07I$=4
MQUNH=&VQ4[KU]LUKU'M?;=AB=XN5:B%T8#4U[BM>&PIRC;"X'9C+E,G'2>O9
M&G&3D/;JK$D6..-4$\WC#([=N?S<_49^BE303THU9L=":V!KOK?O;9456=$T
M?L;NYBM.:S"?TIK?8=7>OE6!FU6F^UYNW;#DM?,+O3-$I'PV>BMN!D%%C%R<
M4&='%SV.PR>6WST]>ZLHO_I+->UL:]VF@:BV[NK4NF*?3+[OG;U"8I055U?6
MKS4HO8,:EN/N5OK5GO5@AM=S45?+?7Z7"RI-9K4B"H][,R2F&Q/%VX)'?MW9
M[2.RE99&=^:K9>R,YU\I6I-G7D6H6BBTV[;'J[U&D8^HRFQJ1$7ZLV67U[BW
M(VTWJ=4//PX$KMOXD)ID9/%.Q[IJQ@3I <#DGR8^??U_PI7$=5?2!Q/;:RQH
M= U#,Q](EFK><+>I+;N@) U$-5)60@FIPW5D!LV5V]&QD[+B!BQA,C2!6T,3
M$5(&+8 ,8(< Y["//C^VE>%^D/JH^V96D%Z9VHC645V=B>GKV_Q2M>ET)K?,
MX-7D1E<,K>+FSLH>#(L5DCJ<JVL4XV"&LSJ0BBF&DD/C,^0^?;&_QY^:E81K
MGTHE+V1&7V[Q.GK8G4FNZ[O"Y3EZ%V?H&;L;M0T8FW(FYP'2\+M$S<JVK&;4
ME!5EHFEBX*^&H61*>%AS$R/("@=]\;[[=F_?GYJ5D-,])!7;-1Z?<YC1.UJF
MSLG;&@]6:R<=E-<6ZI[%=["3!$=7YVI;'H-SM%'DT4@*.FY7:-?1,)L=+8BL
MM%1Q*CX]PB<_%W=N?DS_ );TJ;U+TNVJY[-7EY_4&QZ?0-A5#?EXUS?C+5IV
M<$LU<Z\5:VW2XS$C4:]L60V%3X:1KU,EB:_-6>J 1AI!$0.Z2.W*BD*CB'TG
ML[/CVSV$X%*YJ!]*%'3>J#-MXZ\7/,04YIJ*I=>@]Q];+K<+I<=\WNKT77=)
M36Z7MJ>DZ=/2+]C>E2DWUBM#@B0,V*2ZB1#<$2XMLX\G,<SC;G\N<>:E;A]=
MNQ\9OU.S88JA7/4^R-+WEK7NT=97QZJ'3M:FSJQ W2#-%F:/8[959ZOV*KV6
M*E8:6BIM[UR5DCE#"$"K;S(.<]XYCUVI6R')I6N>SQL:ZV+1=T1>/9@)Z9K.
MG]M#MX\K4O7K?-8A-:V,AM/EP[+4?9$]&1@YCBD-"4Z\W9XS+WL49@3(;8HW
M&WS;,[XSC#,F[VE1W+4B(SUURC))!(:G6YAQU2!NN9!A!..-SBQ^Y)]KY\*\
M-^*V\]&M-U2.3K$MX,VZ2H#F["N#[;86<)1#FS5+)X&^'8SF/5D%.*4XI4LW
M1=)6B:\EY6MLBE7&5,@J91!3D*< >O5[G8ZGU%R3:;6AU<*!.S04G8%,J2XQ
M  R9.%)PQE:;.SPVIUP::DE:8;2'YDY3>S@@P6')<L-$@@/.,,K:C\0PI];2
M3]MBJR[S'84!UV.$JENK9B0DK&4&;->;BQ2X 02RAYY#K^#E+"'5;<.:YO7%
M"B=:4V&I\.Z4:W'-OD2<U(J0[,V>PR9+TG9+9/DH2C!E@M$Z6?.S9>$H2_)'
MD+;0VUE#:/C<9SMRF/2W0A!<*4M,M@AF-':2&XT1A))X(\5A#;#*,DI;;2"2
M<D_>WPFK=$:B-%2PV"IQYP@O27W%%R1*?4,<;\EY2WGE;9<6K  P!UW5OTJ&
MM9F[5B'E=47^OZXONT-T:JH6W7+5J&7BK%*Z/QL5VSV)[7L1L(K;L)22A=86
M1\2UR=%:B@\/0N9=Z/'EA2<]'B'Q=^V-OC\A/Q5W*^/6GI4Z->M6G;MF],W.
MHZS;H=7N,*4'LO0.Q;W9I?8,Y6:YK/74=J?7.T['L2+OFP9NU1T5!QUK@:['
MA2.'0[#)PSV,8R!VS@C;R;^;U%*SN\^D&*U'K78=XW5U<WCJB;I4KJ"*@ZM9
M)'5ID3L4G=-W&HE:!J>TH"^2NKF)ZO2KKQ6P*_8+5#2%0B669DK!$,<+(N1Q
M8Y@CY-\_'CS]U*XG_JF-$KYVA@=G:RL-!SV%W.]IFF'QVQ]*;6@P#6A:\QBU
M6.Q:AV%=8"'KV;9<*C2WDE2:)8.8L,>^9'L1[XQ),Y[]N_)'D[B>\?M[,JQ&
M1]*_KQV:J4!3-2V>U25Q@MKW"-Q,[0T/JD!%(UANZR:+&LRIC;FRJ5#DHO-C
MJLO,U2'CSBYIZNCO'EA,8%-2,XO(>WN'(X.<D4K[;SZ4NJZ[MMS@K'H392J]
MJZY:6UQM*X1-WT<<S5-@[HKVOIP*JPU7>V8%;MCF5-[8\+&69[7,-9F$N"R)
ML6J0!80\Y!4!GGMC)\_QY^:E7(GO-1BNT5ZZFTRC7:];#I6I[G?&I>(<K<;3
M;/?Z0)1)>7T/!62P3<5'8V8-7MG4"P269-\"M0,?: ,3DV ^@MH><C./7;L\
M_DI6N*O2KCA:W"VC8.K6TJS5[#O0WKA2#IS:'78*/N.V86RW.L6B(!FG=K(A
M(J"K9NOK:\9<IX^,J9@D4LF*F#AW$/9CB\AYX[.?R_/RI78/H;;$CNK7@E_/
MH[U";D9.3#CHMR^:SV0T<#&O)$5+"6G4MMNU.('=/;.!4*Q.NGADQY#1PXSG
ME1SE2M6*[Z1&EV7;&VZ%'ZBVF_2-+6[:%!OVX 7*++UVIVS4=:D[/957:H1-
MP-V/0J;+C0TG&TB^VRJ1E<MLRT&( 0VQ*1Q9/'BY[<L]W9S_ &;\N_%*DD;Z
M8#09<=>5R-(V-!V*E=1Z/VW14Y!JOXE;%!WR#JT_&:UA76YC(3FQQ0-A:U6=
M%/OM#-8O$6[@G++!3B)XMLX/9W=I\^*5=T=Y%2UUFHFB];=\[*UK2MIB:4V+
MN.C 4J8@*QL=,O'UVU@Q%+^-[.T+W7-8V*21#[,MM0IDE%5PB/GWPOAH2OR[
MXK._(X[_ "_3Y^[Y<*RP?NCKUS0?9CL837[*%0.L]H[ 5B8<>^"E%WI?7@F5
MB;1)4O*#\B$A3MC@Y:NUOV\D1PR1$\'TL-.H7ED8)Y 9^:E?5U:[4&]FQYN2
M:U.;0(2*BX*1'E"=NZ(V3DUZ?0^0-&%QNG]CWJ4K,@R(PHAX>U"0KB_NV!TO
M$#%MCS\7T?VT]?7U[?/691(R=7;R(KX>,#4;>H<];(T)/W 4)N*M)%*MPX",
MY\C.=FU4E5O<CA&VQTSU#O5E*RY*VLUY[('5>V=D2^OQIMC6Q%<7S6]:)/$B
M(IP\S[6RDB('%95U$Z%&3AJ*VD4+21;;RIA'BPKTE^4VCDAF[1PA4I+8Y#VQ
MBJ,LMI 2'X4V0K+LI95R6D6\.R6]9A?O*F][V=PO/TYKE5I%& ]_X?+#U.-3
M^#PPGRX]V,9S\[T<-V1D?:LV.,$?^\2ILUS_ /72G//7TL_C.7ET_;.WJ1Q?
M^[Q8<-O_ /51FQ5WY1U=4XI6FO<GIG4>YT5I.O7:S2D!7-3[LAMK3D3&!()Q
ML6NB5.X4ZR:OER<G!.QE;O$+;S(NR%#X,=)A,FQ6!/"1R4+!&<>O81CYZ5J7
M8_1+P!U>W6)7=QYCK3NSN(!VFFYVV:PBK[7A*S7-B6S;5-T"[1I&U1L5+Z]@
MMDW*=MYWMI:![#)RDM\(P>&9##8T<//RG._Q9'E&WKBE;HZUZZ6JB:#NNGL[
M0A*]:;7\9UQ^S]&Z;I&C7JF?.10D=&SL/1XIVS5@BQ0;H;)?PK*),^%4M#!F
MC8&&:3CE]/>/IWSZBISRP ,#SY.2<G.WDP !@#8G).M5)]'%(5F@]RX>2W@$
MK8W<W7;6N;?=-?Z9K6J*?6AF*S;JSFY :MJ]C= EMDS#%VF#+3=#K&R=.$C0
MJ668MF-R@F,<]^8^3G_A\GF BN(W;Z*37&^&[ZNV[<VG$ED:%K_731S5)LUN
MH]>TQKNO5X9I($K5JG<X:(W W-WP..O=DC[NVB(E<P%6KZ8\4:OC'NQP^4C
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M3>MYVQ;#(HEI60OUM8'>D"HG+3)+# WSOG<^?&-NZGG]?IKC3?0\ZP@]=2E
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M@7\(*D0A'"I!$:D@D$XY=V-QD\R>>>W-/BS]'F[_ )Q58SZ,6A"7X+=L):8
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M>^&IO34;XO\ J[8?\ZOO*.KRG%*<4J"=5/V+W6[ZA-/?H\KO+S4_W2ZA[?\
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M-RJM8;F4OA2#DX&^V<_L]345)JSZ2:4-MU9E;GHABI]:]A=C=Q]9]<[^C]M
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M<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*@6GOG&[6?7Q6OYL/7/\ )_TX_?\
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M=MD9[K.&' EMV>&VGA4I;2W&EPD2&"A*N!NZ.S5J40@.N+ZL"Q;C!M)6EM"
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MA().4_?6'C3('$&0V(6E],!9FF7%9D5(6]*+0S+MRJO9H]\DN-C6G94 0$?
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MN@[Y\@'+/K@=N15(OISN<71]VMUSA^"])%OGHT^B(&!PO27NN0;JF, IL.1
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M0B3%2IQQI!6I;'"'5E>+J>D!KP1;CH9;=4X(ZU*X&WL<"U!M6R'"!PK( )P
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M)M[U\M9PH'"+??KG&8!P3@^#H9(&=@16/6QXR(,=]7V\A'A"QG.%229!3GM
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ME0.^_=G;;=OGHBIJ!]9/F9@/SBV5^D^Y<OM3>_,C^KVWZLAU1::]YHW]+/\
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M:?\ 6&B/8?M:(Z6M&:IMG24FZ:2L-YM.IDR8=N*)SJXTE%P9A,OIFR83]F?
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MSM6G6G(.B(SD=Y2%MR-33@VJ]24J'"L04HRU:8SF5 )C%4HH*"[*X@I!U!X
M75AZ[.MW!X$*1!;XA:(RAN"X% .71]!_G.A$0*SPL.IPJMA&8P8$=H00=H<9
MAM#;3+*$H:;0E.$H0E*<83C&$XQC&,_)C&,>/T:Y\-6^XMUUQ;CCBRM:UJ*E
MJ4HE14I1))43DDG<G)(SS[+Z5O'B6HK5P@;XPD)&$I2D )0A(V0E 2E(V2D
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M7.!LJTW:GG+YK*!.5&+PFWEN4['92"4MAU#CO6)('&VVA)5(60&UI2XHE.5
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M67":/]82DX*,\0B,$A0CI.2"M1"5R% \)6$H25):"U[H\WC604XI4#ZR?,S
M?G%LK])]RY?:F]^9']7MOU9#JATS[RQ<[_99VX](2JR#9&?[LC,>[QR,_P"_
M/X/!U/AG\GRY]_,?/?OL.SMSV>7E5]7.ZZ9\L.4_G]<^>O&/HRAIAC"?^>IS
MQY( '(8'KW^N*5@79OYFI_\ .+6OZ3Z;R_TU[\Q_ZO<?JV9]%46I?>:5_2P?
MK"+5\Y0U>TXI3BE.*5ZE,,+=:?6RTM]C#B6'E-H4ZRE["<.I:<SC*V\.X0C#
MF$*QA>$IPKQ\N/#B4I*DJ*4E2<A*B 5)"L<02<9'%@9P1G SRKF'%I0MM*UA
M#A25H"B$+*,\!6D'"BCB5PD@\.3C&37MYRKA7^==VQTQ4]M>DA])//[!L-BK
M^O-&6;:VXKLW2XJ-F+M8(UG:U(UK$UVK"S$A'10ADC;-DUU<G.RCA %>KHTS
M,. 2;X@T8;\B,J.=L9_P^4GO[^5*I>O/1+TNXS5J8,L6WP@%W+0$+2(DN2Z[
M5RT(K.YM>[)O%@LQY-AVRS3=AMZ^7K*>88CM7623L-X@@R[/$UR."$E!XL$9
M/;V=F^_QC?Z1@CG7()).#D' (&"202G& !VA0(S@'89R1G76M=&-,3)6L-;?
M9EO$UMKL+1-V;/TE9J[1HIO37Q0U;;-RU.J)NQ,M/,6YDK9!&C[))2!D2)EO
M6L7.U\B4 LBD2C0<8&P).^2#CLSMMSWQ\6?/7&ON[0>C="T!IVV;M@]C&7BE
MQD!UTS$FL18HZ8_8NU*RW8MCZSN&$.K5&V*DQ\G4+3!Y83EF;IUYKTCYE/\
MMJ&! &>9\^V/..9[-]AN,\Z5_<QZ,3_UO#I?_P#NXZK_ /\ 5H_^WY?EY]$_
M:CS4K>A:$.)\KB$K3XI5Y5IPI/F0K"T*\%8SCQ0M*5ISX>*5)PK'AG&,\D@$
M8(!&0<$9&000=^T$ CN(!J0I23E)*3@C()!PH%*AD=BDDI(Y$$@[&OUR:BG%
M*<4J!]K/V+O9+Z@]P_H\L7+W2_W3:=[/]>VC?_XA'JCU-]S>H/0=V_0)%7SE
M%5Y4%N_^V61QX^[RA^/NSX>\(;&/D_#[O'_)^'..<3SS^W<X!)P#MCD,=^_<
M:56JHSZBO12/D\PV'OD\/\)<61CW?N._O\Y4J1;B^<7JE]?-D\/_ "7^QW^+
MW?\ 1^'E[:?>_4_H./\ '_UET]_G\_95'=O?#3/IJ3^KE^]>RK[RBJ\IQ2G%
M*<4K77?.R0(&$*JT>^R3,R"AFI9AI[/M$7&.J9(4IU"4*3AV08_466W5HQZA
MU;RDJ3EO"_#GLS^G>V:&T>YH"TR(\W4FJ'HT6^1X\LIF6+3H=B3);CK2$*1X
M1>8RA!C,R'&TJBR)$A:7$!M+F8Z4LSTB2BXNH*8T?B6PI:,H??!4@<))'BLK
M\92AG#B4I&^<<5%=?(0@1N9'LY<DHX%!48OV-@4%QHQ#;[*WTH=+?6AP=6,8
M4R\WY5KP[Y7$)]0JDT][##2T^SL:EM_2%<KT]=[0Q<+!(]K(D"SNQKDB-,BN
MRF6W[C*>:>@J" Y'E-%#KB9/ ZVWX(Y82-<3$.*C*M[4<-N%I\!U;CR2V2E8
M02EM"2'!DA25 @%&03QCI!]+)(2%;M% T>B$&(4Q4C=NIGTI4ZHITUJ[TUF%
M!<=':4ER(R$N6DL(4OUR2H=U:&4QJGW\JTGT.N=%5P>?F2V9;]Q@-1UF N2X
MRAI4Q#A+Q?;94^Z%1$I;+3*5,M.%&'.MRC6&O]1*NXB6X-%*&E&<'70D%2RA
M]@--E)(0 "7%A2L+/ H\/  JL]'AI."ZR:UR4P4+)BNV<@1+J_5DL-8OMEE8
MU8KWE;RVSZTQ<L&IEQU"7#%E,.^M>5A/@_V3>J)J>EV3-@7Y<M=BA6=BQ+M4
MEUM[3[\=M,M^$F0CJS&N#5U>DW-2XKJUL^&L<;B7T+89V=T:0D^Y6 T^P8_A
M#DQ<@R$9#S;DA[@<#825+:4R4(2E20%84K[504K<./=L5ZDHEBN0Z9$Y.'"G
MH]J08&)FBENMNR\A+2,L:T8:=)OH608>46\0PUG+8JV(\4=IK'1J3I$]DWTC
M:.M[T:)>;U!A0H0LJ)L:TQ'8,1<=5\F3I+DE$Z1(G.I>N=V>9<D2XK3T@066
MX<5AIO,_ [;I.'<&U!:(RG'' ^IM3RRZM*BSU1W1]J4M-A7"VX4H2Z>/-5G>
M&S.V-9J0+&GNOS$;ADX %4A\/0EXDP8W"5,,C@TR#4UY$Y<P/@B3<//%CQ4.
MX<"SA[$@#^R>H).K-.:>@6[1&DHT6-;D1+=$B1UL2DPK=&8ZB-&B6Z-PI;:;
M2VRSUG$ZAAD'+6#US6B'WI#BE.J"EN..*6ZXHA:U*4HJ4H@'*E*)))[SY<C$
M9:9VI8DPT5LH!,'<W*Z&:0*2J/PAQC+KREJ%8AG'PPO6E((5AHAY9K;:$-$K
M2MKRX_+OI[U'TJZHZ1UZ*Z18$73=Z<TY&NEG88GL28[VG1-F>#*B)MR7F8DM
M^='E+N D2U2EJ:4VB2W&9C,HV]IR';V+0S<8[CDAKKU,RCU?5N-S.K05@A1!
M<:ZM2 UPA("5>,GC*E'>37J)9%*KF)R27+RBHYMPJ1<2YA9.7EN.LY7EWP<=
M4VPMIG+Z_NB/5^OS]\Y^H_0JG4 Z*M"JU5?'M27YZPQY,^]R4.H?G&4MV3&4
MZI\!Y];$-V/&5,<RN:6?#"3U^3KN^JBKN\\PHXB1>O*6HX*<-\"4H7@( 2D*
M<2M80D8;"N ?:UF7-H54TXI3BE0S>7WO4GUYZX^C_C9WT_Z/?R[LG.Z^A+C^
M8CU^G:J6]<K7Z:M_YR^_U[MZ:-^];;^O/8_\L!XO?.U>A+=_RU_1RI9>5U]-
M7#\Y%7/E)5U3BE.*5CULBFYRL6"'='06B2B#Q,BN*6A#^7AG$I:]8VZRXVI:
MLXPAQ#K:FU^5>%8\O,0Z0+0Y?]#ZNLK,5F<]<].7B&Q#?*TMR7WH+R6&2M#K
M"VU..\"6W4NMEIPI=XO$KN6Y\Q9\.0%EOJ9++G6  E 2XDE6%!04 ,DI*3Q#
M(QO77Y%:QDMH3$_7Z9+XJ8<-7<IQ:,CDR>6Y4U*61 48Q*!%8PZ.I]SVEEY3
M@N6<OK2ZIQAMW\F>@SH2@]*NO[E<-*W29I6#I*$W/9U/9Y4I;OMO(4AN)&CJ
M:N460EF6E4\.KC.!M#,.2TZ/])92=H:@N28-G_TMIJ5+N+CC*8SJ0E"6 E1<
M?*$H*>)"^ -\0X0M0(2KJU"OGU56.SO7FKV:KW7;&MKX,>02?'-RMUMLE>*J
MA2,-,XK[MCB'6)(20:;8<Q"R3T8S&/.$2(1YKGK0B_8?2!JS6G1-T::QLD;I
M-T;)Z01%9?LD6ZW]#E^@,O2(K<AZ%&N;>')<BV^%2;?%EM-1FI7 \TIY/$VO
M7NE[.[*N,94Z))?M:GG.M6RA]Q X4+*$%T)'V/K0A+W">()*MP36BMWK[,+E
MB[:JU;"2]QK]P(ELQE<%KE6.ED2K1$/;'2#<C-/$):C9?!I& QY U\YF,1ZI
M27//C\[](N:JZ19=VL>MM>:@3IZ^P^"XW6]2KUJ"%;[BU+:N]J>9MWAJ6_"'
M9\,,$JD0VF8<B8I3J%!M!V'>K="LC3-QLFFX+MSB/]:Q%A(@VZ1+8=;5%F!R
M0IOCZM#+Y>' V^M4AMD<*@I1&SNMW"+QKV<E[6(JAVT<Z'.AJ[(L$EF/"F"3
M"R 2'$-LN#N8<;#=4<H9#0SG@*\RM2FLM9'JWH=Z,]/]&-\?=U\A.L8>O'SI
MJXKM4IQ&K(5NMKA=M<>#$<FN6:"'IL:6[<G7Y3(==9CR2^7H74?6SW^YNW!G
MK[2MB(];F?"HRW@78BWU)7QN.+2T'UC@6V&DMMD\*E  ASBJFHMAF:VFG&#%
MR4E'F"/Y=AV35)&20O+:6C%-/J4.T\E;"6O:&V\O*:5EOS+PM*,XK[&WIZNO
M0=JF5(N/M]=]-7.WW%B5I&%<>JMJKJXY$,6Z^#R2N)&F)$5+*IK3"I3D52V!
MUC9"*L]26-N_PU/,B/'=8=;#<E;0ZUQ "BMI*D86I(2HKX">!*@#L I2?N[$
M=UHW6LAH+$2Z@-5TV-,0=L@C7!U%+A'JJ=7(HC#F4J;S'"7RXTB7*+_4<>QQ
M1S"_+]TE7Z>P?9+VG6G1-JK7>D+9-9O6FK;J-4O3<]++TAJXP-.S;C;@'&N)
MF9 E/>#.(=0E+K@:?85&#J0A>E[O;W;->;% ENM]1<Y[+)>02 IAQ26%D@X4
MVIMU]E2OYH&#QXR19.MD]7L,$5Q]GRVQU<E.,/+$1C"XA:8D=]IHM.,92M):
MLNY%7X>"%K6TK*/.VWH'_P GYJ31KUDO6F'X:!T@MW6^7]J<Y;HZ2K3LUC3S
M+T:)<&FD+; N*'Y"[>LG@2ZXXPH,J4RUFVMX]P<4U/*RJ &XL1P!PY,E(D%M
M;C9)!):2$EP<R % *(*ML^?I56O*<4IQ2G%*@6GOG&[6?7Q6OYL'7/W_ +_Y
M/H^G/+R[?R#3'H.1^LNH:H[5GVPU-Z:C8\WN=L/[<U0MB?[!-?\ ?$?_ ,P5
MG_1_CY1U>5QVMF/*-*D>'WQ\9G&?#P^\MN.9Q^[^KXSG&/=\G(!SOY_F)[>[
MNI5,Y-*@G53]B]UN^H33WZ/*[R\U/MJ74(_]N7;]/D52:9^YS3_H2U<MQ_((
M_(]M7OE'5W3BE=<GI ^H+6_:D-?Z=&J(V=1F&7L1X;CPY%UKL:5F3Q!^<5QE
MYV6C"L.'0;>7,H.P\?"OM/XD!5"ZAZ5=!NZD@&\V9M(U!;HK[00&VW%7& M#
M@<BA+B5),ID+6Y#7CCXE.-)\=QI3>$:QTW[;,)G1&^*X1$[MIV,N.DE99VW+
MK9XE,C/CA3C)!ZQ/#T?P,TXPYZM?K1W6EK;>:<PIIUEUM7D=:=;7C"D.(6G*
M%MK3C.,IRE6/'[GGY]WJS)<ZV/*82KA4H%#K>^4D@C!'$E:22#DA22#@@BM>
M62]3;3*1)@R7XCZ#PAQIPH6D;<3;@WXFR0 MM84E6.%:=J_4[J_75T>^$I*
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M5;Y+R$F398R'9LF ]!D2%+882AZ*4J4IZ-'5(4%*P"\//7V[%^!%X"5*2&V
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M"\^LPC#;F,^&4.(]_CVK&B?8'9KT2%#D*G0GH+B9L5;Z&VG2DEQH)<;PZ@I
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M#J8X!D*+:=\7&06UJ4K/N31G1_I;0<$0M.VUN,I2$HD3G</7"7PX.9$HI"N
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M_*SN7=DYW7T)<?\ EI^CG5+>N5K]-6_\Y?=W\OCIHW[UMOZ\]C_@_P#C8/\
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M!X;RRH,.6E7CY  5UKP;(&!('9)0AI)"'<--81NB):K; 45Q(;#"R,<:$>.
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MXI3BE/E^7BE>$I2A*4(3A*4XPE*4XPE*4IQX82G&/#&,8QC&,8QC&,8QX8Y
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M0;-$K91L?8YZ3<(A<5V4CB&!"X6?C9D<"7A9Y!100[<%)QXLP0^?'-#!.KD
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MQ;U6B"1)RT;WIFA+I!'5A^6F[#I.[4CK\]'R%0]@88:39MQ3!AE=G2GBPSI
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MHD=8<E9;M3@;U,U2.::1A1:Z/!V&I"SDTRXN/<LDO+UEK#4M4YQAD#GU^/\
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M&7-9J(<9ANN7_L#<MT;3BQ1/AL_RC7BMS]:U5E#I+J8R#HT1+/IEWB%QHX
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M*E3VT]@]_01][#B[+/ZFFK?L&  TRMC3@EB'VW9MJ]I[MUDI;NQIN;J<D#$
MTW4-(TW<U/+E*I/.D[%BY2PFRT /$5F7$X.V.6P.<$YQN=SML.>=^=3G?.!C
M.>'?&.>.?%C'ESCMSO6=2>SNTUH9KXLN[+3]5WS%2S,G2)C5<,U :\HNV>W^
MMJ#JI#SB*XQ.'S<)U<FMMS>SQ[9,F1Y3];@CFH>"5F0,E9W!S@X/80=N0[//
MD@GY!FI (.2G(&<A7$!L-\\)2H<.<G!&.W:H7IN3VWK(N%N$O*7JI1V[R:=>
MMM[ZE]20<SM*@D=A!.QN\YZ"9'9UP5'^VPL9K;K)IR(C;-3['%UB7OB:L+#M
M&Q=,K@3/+G^P?-V[#EGER/.,G'"2< DXR<9Y9QRSC .W9BJE,]J^S]8OD!GU
MMVL\13XTX.[U63TT[2Y&Q1M6ZEVW>$M=IJD 4:YS$-,7"[1<94*DJ-WA4@7[
M6B4I$5JJQ.P4S-Y9.<8^/Y?)YLG//Y*BLI:.[03&Y-&ZJV;M>_%1,=M[24A?
M[+"T:H5* E[E4^OFR=O['I$8;&4M0I&NI6]*T8'$QDA(RL]A;NQ&,7 EV+!$
MKS?M^7'D/E/SCS<Z=G+X]\]NW/&_;MG88(WSENZ=_P#8>OW#L"[KT^R+M>JG
MK2/KO1J-*R5LI5THD=H>$LX.UKA<HN&3;V7W-MVE8D)BDV8P2Q1=(E-:Q6OY
MB[O6&RU9GGGRX[.P')V.PY?XU(QOD$[;8(&#D;G8Y&,[#!S@YVP=8M@V7LYN
M2H1-%L,I8+5'REEVF)1-CU(*;200/?:CJ;J7''REBA]-Z0@I&)@[3VNVAL"J
M6"(I3,6BOZN*GERT^Y0R;,;&2>_'FWR<#/<1N>S&WFJ/7;?]E=@.Y=C;&B=Z
M5C6%;MMFUC7&:KJV5I;M<U*WLP;;EPMFS)^M6VFSBBXQ]$+2=74FL1$[=RX*
MQ4B>B8K8H-K=M(L76G@)*=_7]OS=QYTK3J4W]N_>E0U76'H_8#,?.0FBKEMS
MX)UI+PAD?8['N"3W;9=<#%%5\?+TGK#3O7Z_:CM\:![6(Y:;Y$0=G<.LY(PR
M'/S<SL<]^WS<M^[!Q4C8\@<'<;X._(D$'!Y;$>0U[-%;VWG2M>ZWU_)V2^W"
MW34-U EC9B8U\]/G.NWR:LN]>WMW(GH^HQ\;FK(H9LKJFED2J4O1UMJ8X0JS
MK06:I]D]W;_GW;#.V,BFYSMOS.!CF1V#8#)& !VU^W-R=\8Z;T[!F6#PLE\U
M7HS9RXJ;IS,1$R>R]IVF3BKMIMD.K: OQQ5"TM6Z_%26P9!ZYT2[Q3][)NDK
M>(2GAQD%&QD[9SDCN[3V<N8'>?/WU%=S_.5*<4J!]9/F9@/SBV5^D^Y<OM3>
M_,C^KVWZLAU1::]YHO\ 2SOK"55\Y0U>TXI4#[-_,S/_ )Q:U_2?3>7VFO?F
M/_5[C]6S,U1:E]YI7]+ ^L(M7SE#5[3BE3.TO:SU_.IVI:, 0M@L2J!J!NS.
MLGE&&XL=Y^"*-56VA&RO4L&76ZY2HE(K+ ^9!4A-&,14:HH)Z_+2I/$Z,ZN[
ML1%;WCJ3"W(7:<)B^1%B(>L[,7.QNR=5OZ_*M M7D# XZ+D;GJ:P9K,Y(I@8
MZ:F8)P$::6\]&1^0W/F!\E2>[NV[.\]HY[GGO\E<_P#:I]?LR"91[6\>6=BN
MMUE;\A+622P0(S1?L8(F#&3YDE@VZ_8X\:(O8IC3]_<J.55]RRKBU*%RP-SC
MGS\M"<DGOYXV'R#  \@VKXMHT;KEKZ';VQL2L Q@5*L%&F 9>+C;7*R[=B B
M)+3U!B86O4YN0G[(9(Q.Q)37D-28B(EL6=-P*@<04J_,*8>@X[?7US\]17IA
M.J76]-3%B(C6 P$,6?6+1'N.&7*)M,0_7(<^*J(D;,G2@EWJ,;6*Y/3=:AJ<
M$=#Q%<KL_8JH/!@1$U-194U.2,^48/FR#](%9^C16I&JSJRFC4>)$JVDRXHW
M5D("LX$"G/0U3FJ("W'-AEL9?#^)MCGJT;'R"C(^4AY<\*3&,:)<2H-N7E^?
M;]OQ'<;T"B"2,9(4-TI(\8$' ((! )X2 "DX4DA0!&$!]1NNL?6GJG'ZT !B
M7)."EF'PYNTBV&*)JT7(P57'K]N8G46RM1%8K\S-URMP%?FXR"@:W.SM>B8X
M.%FY4$N,#E]._K_9MRJ*R'[6W1*8#%68UA5PZXB3>F&82.%=C8T:1?U"[H/)
M 8D>^,T%AG3;RM>!,B)9' KJ61P6AW1QWFIQR\G*E>RS]==+W!+^)RB@K)>D
M*[*HDXN1G*]. 'U2MR=-@"8:?KTI%S<"H"I34Y6/)"R #1<#.3L2:@D&9DV"
ME,_V>??._?OZ[5P<AU0ZZR4,BOYU57(V*9D(Z3&&K:Y2IN!N1E A=5BA %U>
M0B#8^"=UQ7(:E'UL(ABO2U=!1&RL6:PZ0EUZ_3S[^9YU)))R=SOOMDY)))[S
MD\SOV<@*@4GTTKD9O0#9M<N:*K8ALV*:TS'0FGP50&O+6UJ1G3C$K8"*]F-I
M\U&U36Y1=:ID=/Q]9GSH]\&$E;7< *?48VMQCM[=_EY>N_[,16VFEM1TW0VK
M*1J&@B9$JU&A&(B/RZV(V9)$9<=,EYZ4]@&""=FK%,%'STV0*&(.1+2)C[(P
M[;B6D2!C84JH<4J!]K?V+G9+\']X/<7O^C^]Y8N7NE_NFT[Z=M'UA'JDU-]S
M>H/0EV_0)%7SE%5W3BE.*5 MP_.+U3^OFR?S7^QW+RT_R#4_H./^LNGJH[K[
MX:9]-2/U<O\ Z_'5]Y1U>5U>]Q+[NNJ[RKTSJT0N*C:7K:L4^=OLFQ)M5"GQ
MW8?8Y\C:+8Z8W2-BP_P_68KK/$5./EY:D6R(HANX8:>L\,_79$M@R#G/Q?%W
M[]V,<]^?RJP.,[$]I1K#UV MDG:DJEV8N2N5:J&II&1M=KK<_L^TO5V=G(&X
MZ<HA-F%^PM!Q0.SWM<R.D['IK8DGFVR>M;;5IV"H\>R<CR_$?BSSQVC8]O<*
M?/MYM\?'MGY1W52]![VW?.:7[.7J]S=NN$MKZC&V"J%0&O(\>/-GV*7:;44)
MJUM=!JEB--83BMQ!NH-A4"TW;65S"-K4]L':OPPRY&M]_F[/[>7E'Q4K7O5!
M'8/3ZH"]!7;;&SXZ!SIK1A\8FE1%R/V]1=1]0+KV.NEZ)*=@XZ7D)*;V!<+'
MKFB2==F:B3.7]B+$NT_=#)=@0=N.WYM\8/<._P"CO.*5EFH-Y]N-@VF-I!=Y
MDVX&Q7+6[,MM0'7D5)M5VO+TWO#8FWBZ4_(:@HU53 LSL+IFD4]N7CML$56Y
M3M@ F+[LOV(N("#)P!V]NQ^3R\NPCNSME@]QWY>7LV^/;SUE/8NT7NW^CQU,
M1M&9M=6V/M:"U:_,3)%$D"*V)<)R+:L\-4M_P52>KQ-4K%L/;"H]M.CQ JY&
MWR3C 28,J),:J,KR3]L,XP#DA0)! W((&_9RYGD-S7V8'V9O(1A"N-8<3Q(X
M6LN+"T\U#A204#=7VHW-9)3*?:9>5]'^17H3;FM*]7J5L?;,]H@VV60VB0#,
M+0)6#BZI8Y*TPT=<C2T73=%,>H==V%(!L5&NT(,*'UU5#X6:9C^//!.<\S_9
MY]_/L?+7S45*)4K)).ZCS)/:3VDX)).ZCDDD[UCG2-\[$F5ME\/9>2 NML%)
M]GY^V0NPHAZ^]HK%+.W*YP<76KFR,\Y)Z;%C)^M,@U\#,/6H6ZUO7\28^BN.
M1<*'(9[AM7&L7A]K]U(<&MVFY7FWFK&B>D]BN-,C=.4_ .;1LVV6"Q]F:""2
M-3E3F*AKW0\:(\R:W(YM3NRWVC$V:"B<9HY@9Q\F=NSY=N?;\E3@GD#\F>W'
MT[>?:M<(MGL)9I6"/G:?8@K1. 52'E F*=)M4<*XW#7VA-.SIA\%D%N)?APM
MF=\^V5GE6B1G@'HO44E8)9I]^)R^PW\7GL?-OMGR9Q]! [Q.5\_&\4X',8(
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M! 15FTK6TD1,J]KMFT58J;TI1K63<:7=[5L'70FYFZO;=>1U;=D;#.M1C<G
MWQSWS_9\_?YU=RH  $4 %%Q80D;&1H@P$=' #,A@  !LH'$""$'0V.*(*.VV
MP,,PVVRPRVAII"4)2G'*E0S3WSC=K?KXK7\V#KER\NW\@TQZ#D?K+J&J2U>^
M&I?3,?\ 5VPU?N4=7=.*4XI4$ZJ?L7NMWU":>_1Y7>7FI_NEU#Z<NWZ?(JDT
MS]S>G_0EJ_0(]7OE'5W3BE3&6TQJJ=O\9M*8H=<D=@1#<:@"T% I<D&EPF)7
M$$4XG.?92I" 3.S:8"2+'?D()$Q*(B20TGE8=C SGM';2J=R:5KKM;LA4-0;
M/UIKJT-*2G8E7OMD:D1?A64EVGZA/ZTJ\37*_3J_!S<_<;);YK98:8N'B&D&
MHC("QRR6"Q(D]0KU]?7OI7 M]TNN;KLPTBY3BO@A5A98>QK3:'LUK-JNSHS3
M,[%ZY(Q3?4[.EA=H3D#2AHS7B[,;+3<[$#P[,A@UI?(SZ^O=R/=\E*]CG=#K
M>/'YD)&_E0V6Y2!@B8R<I-_AK #/6/9,IJ./@CZY(U<:=#EV;W"RL=+@/QZ'
MX&("<M\TD"FJ:GW&?G\A]?BI7);.[-4RC:0.WC7!RKW!)NM;U_!!@"3X3MEL
MEEW%$:2#;A6V:[+34O'NVZ5]9%2-?@)P>TQ33$K5<S,9)QAQ4G;YOG]?4U)&
M.[D#L0>8SV9WWW','8X((KBD]T>O"A@2\6NR>J?>EFYE/V+]IY>H;<'L:=U'
M*';2833%.ZKBA]CU>SU=$OL)%;C"WZS99((LB#KD[*1T9&,^OR>3M\QJ*Y6/
M[=]>):9!KL;L-LV=DHZDR@42Q6[>LYX78>Q2=4U-/J,5_P S9AUW#)CSHYWR
M2$#%LJM-@%BZIX3>61^SY\?32MDN32G%*<4IQ2G%*@?63YF8#\XME?I/N7+[
M4OOS(_J]N^K8?K]-46FO>:+_ $L[ZPE5?.4-7M.*5 ^S?S-3_P"<6M?TGTWE
M]IKWYC_U>Y?5DRJ+4OO-*_I8/UA%J^<H:O:X2S(L#M<L#=3=BF+4Y"2J*R_.
MI+7",V!8!"89V80 I!ZXIN1R,N02$M):A,/8&4E[*,X4KI-A^@G9B-B;@J%5
M0ZU(3L14SH^.)M%<>8)OE#TAV?A(*U68B@:<UR--3QN]]P:XMQ]KL8URO1M8
MUY'DSUUF9M T='\<';.,]_/?!WQMC![1N1C-*H=BZ ;&E8>ZTR'BM>5\AB%[
M(0L#O!FS29&Q[Y0MBZ7V!IW1.C9<-%5&)JNNM5P]NJ1TP!BQS$&FRZ?IUGK]
M?*F;#+2%>G'/X^6WF'DQY//WB@R,$$Y'(\CD=NW;YJ\A]%][%1N_"]ARU9OY
M^RID"YP\&%=I.";:N&W:KIR+[+R0)TW3[3!B8KSFLB:YHF"LU:LE5)I,S/T>
M^1^:G;IH9+'/MSGGV9^(YW[QL/G?LY5=F.H]DL773KMI"\UO43@U-W,SL?8L
M2% @'4^.C($[8]ZJ7Q:J[\$+6W)A=U*UZ%;82OPM-I#@1MY&J<+ 5)V.J_&.
M0\OD\N/V<NWR4J+T;HIL<LC7D;>ZIK&LU-EG2D'V"!KUME;1*]BIC54K/;/G
M]N;%DBJA7%6R7M>U82A1XX-I1)3DI4;/LC-ID66'@H D 1C?&V_E[_\ /M[1
M3ERVYCNV(P1MWC8CNVK:#=O6:Q["V;J4>H/UNK:+SKFRZIWO6@\O11\OK>-L
MNO+=1Z'3XB-!Q%,P,ZNLV;7US8=>CFQ-<6Z>!AL(D7PGA&_?ZY'[,_+0$@Y!
MP1N".8/?6GFKO1\;A 2@79L]'S"YR;U.'M^8^-%1>^S$Q4=PPFZ+_=)L:H:/
MUS:)7XQ2E$@*K3XS9=[V+9*[5=@;#KJIL2+%9(L\!///;Y>>^>0\N_QD<J5L
M-U(U*J/NFR-B8A7ZSHZA739,+U2HRZA-TG,17;V?'VO;=W^(LM$0AL0P9=,2
M6O\ 6(7P $J,HE<FI:MNDUS9Z$K $9SR[!W#UY>3NY4K6'5O3K;FTJ?2KS:Z
M!3=4&;.BL6#=PJ;#.-[ VM$;X[1ZJ[.[&B-CLJJT')0,AKVAUBUZIKM6.D)<
MB!F-DW*)KY];@(=DVS@#G)'9S//<YQC.P'=V'M/.E<L[Z/C<P-HW++U"?AJ>
M_(-[[1KR5K5BIM-$E:GL0HN'UCIM+E-T+%[3H] HNL3FZRXR]MBTPU3N]7JE
MYHM1>=92W"SC&<=O;M\@V[N_EMSWI67V?I9L">$L^874>I-;527K1L5':DUO
M?BHJ.B_CILW6T_<R@,3VO;#K'$XNO]?M/S,Q4S-;NZBO<O*WNI6Z#F@K!:KA
M;X([AMW# ^;EW9R<$;$&F>7D_P _4UP%'Z%[M%V5INQ7.4J(<115:6F1L:^E
M:A%0.LL:[MDQL"ZTR@U^PZ-L-OA0]AVH@:/GL:LV+IVHS]*G9>GG5J)IU-J5
M/E9QR\@QG_#L/FVQS[!2NY#DTJ!]K/V+O9+Z@]P_H\L7+W2_W3:=].VCZPCU
M2:F^YO4'H2[?H$BKYRBJ[IQ2G%*@6X?G%ZI_7S9/YK_8[EY:?Y!J?T''_673
MU4=V]\-,^FI/ZN7^K[RCJ\J*;3[#:FTP8,!L&P24:2[ R=M.Q$5&Y6YJMTR%
M(%$E[M="*C 3@])I<:06V@RU6QV'@FD,R#^3LCQ,JZ%!..\^;L\I[A2H]LOO
M9HC7E?VC)#EW"VS>LJ]MN3<K\'KK8V6+38-+R@E=NM*K-K=J.:I*V&,M4G$P
M1[($J8W&^W+ES,HA8Z2.$$_'L=O-_C4D$8SC< C"DG8YYX)P=MP<$;9&XS]3
M?=O2<<1.L6V=)AUQ2[ 6EJ&INWK&3&P%.16H6X25X8SJV)Q2CH78TQ)T%F+*
M<D$RLG' A@2#EK-EJ=7)SS[OGQWD=G(_2*$=H.1V;C.,G&4@DCEN.S;?!!.7
M6;M1K6#T=N'>D>-<9F'TK&6-ZWU)ZBW6M7X2?@*W'6AFJETNS5V,M$7)S,3.
MUR0CB)"&:CU0M@C+$LGX">R?B,\_)\O+-17%,]Q],*'-RXK9!4C#2?Q=GH^O
M:0WC9E1EL$KOQGL-90[%:V<6;)U.+2XNTLM#H>KA.&HN>8BYHD>+6R/GQ\?K
M\E*X&-[EZ[M.WM<ZMI KM_ V26UF.M=8CKR<!7XT?3D'NPB>M*W=?LUN*!7!
M;$T<F#4BVDNEXV>T7)X@":ZN/E9[<?M^7]GRTQ_;S'9Z\N9[.8KW;0[JZCUO
M<X2D*+*D3G;W,U&XV,V)ML'KJC@TO6EDV[LF3/V8_5#*')3%$H=9*E):H V#
MX92^][&5F/<CY=4?&1G'K\7?Y>[STK-X3M=HN:64RY;)2LE@,V,J3C]@46_:
MWDX<&J5"-O\ ,R4W'7VL5TV%C6J7*BV(4^48$%D F95H%T@V!G1(UD?)Z_M%
M*P.R=Z-"0].NULBY>Q2^*CKZ_P!Z%:/H.QJI#6(S7%"*V)9J+&VVQTX*O9V!
M#P0A&)^D)+?M]=-CK%&2D S+U*TQL0R!W]O8>P9^CZ#VTKE4=TM$QT=-$V^Q
MR59+JE=M\S:7OB5L>3JGPCK0Z-@]I5RCW=FE#U_:$W0K3)MUB5B:(],3CTPP
M< /#Y/BID*-9QS[LFGKV=V>S_,&OFG^\_6JK1Y9]AMULB%18FQY*P1)NH-Q-
M62IQ&HQZ+(;&G+I5_B'FPTV"J\/LRA3Y4S:(V)CC("U0\Q%D' E(>XR/IY^3
MUSYB*5]1O=OKI&BS!!]HMPCU:*LS-KB7]0[?;L-/CZ=!5&T6:SW&MJHN)ZIT
MR'KE]ITR7<K#'1M:2)80$(DUEY?&99'R9^;G2N-V+WFZ_P"O(W9I3\U9YX_5
MT!M*6EPX/7FPRXN3E-/P#-BNU5A+>W5%U"4L40 2,\: !-%N CK(-+2T( :Z
MP)^@GR;>49^3GY*DC&#MN,C!![2-P"2#D'8X.,'&""=I*M,O6.L5RPDQAL(1
M.P,1,OPTD-(!2,0])QXYKL8>'+1\3*B&@+?4(4-)Q49(,/M.-&1X1*7!FYJ"
M,$CNVV((^4;'SC:I7O+Q]7J3P_;SUS_B]K.\>7=DYW7T)<?S$8^?%4UYY6O'
MWY@?G.9^:O1I9S(MAW_77?!)$%NZ2*2G./*MX&XT.@7D4M*<^&5CY>L9D<@A
M.,M+)BS&,*RZ*^A$W@<4>Q2!NE^RMI/:$KB3I\%2,X&%<,9#A3S"74*Y*3F+
M1XC][8.RF;PXL=ZD2H4&8E8'^[F0ML*Y%3:QGB2H"\\HZNJUR[*[V/T77:&Y
M 5 N[W#:&R0-8T^&8&LQ@C,H]4KG?Y>8EAJ96KA:B0(6FZ_M,BV%"5PXF3E&
M(V+?)A #B[!%03C';DX]?BI779=._P#L5X8J^PD6N$AX[30%JS4PY>/)ALVV
MLT7M7NZTS;\P;1)"SRU'GJCHG4L-$L-Q%9GRX/>T*ZZ+6K4E(B!.#Y,9S\N?
M/C;NY^4"N1P,@#(["00>7<%$;'EN?+W5>M*]O=JR^RJ#I&]Z]'E9$.QN:3O^
MR1GK-'XFMI4?3KM[V'<8)E>N837Q=<'L\:35EUZ+M ]DSDMVVAP(=8$'%+9.
MVV>\X.WS=_E[1SKC@[[<MSY!G&3\9 \YKC>QG=O8^NIO=]0H](I67:O0[TO4
M]NF[5.$,7^]UNE@OK&A'(:DSE$=F:YM28!UE8]5S]SA-C!DM)N:H0BG/OD!S
MG'/'+89(R<@ <O+GF-@>ZN0 W)VPGB .1Q>,$@)P#GF5'D.%*@"#C/ V+T@=
MRUW(SE>E-=P^P/BG2=W#-S\!*WF*=NNQ>N5-:8OJ(T^PZHK%%/BY3=R%:7PS
M39ZP$0-EE(4N2:%?)E*S7V1OS[<#&/I/+R[[X\]#PDJ(R!DE Q_WM@<J)&$Y
MWRHY &^2H<'>>XV_=>6W<1M\KM45":YLBJ]'4C6=OR:0N4U=U?MW:&[8(G;3
MK!@Z>C[F3<=%Z9)P&U$.CV.8;*@513S<JS+1G<]NVP\W/Z17'XL_+\NQ']GD
MJG2'=;9\39M@ZZEM7:PB;WKE>R;)8I*3VW.!ZSCM?:CU'H/:=Y??MKNM<2CU
MI )[$46J-BL5M,)ZA%BMCDIA%;)K1CMQZGEYL<_+_9(QODD;;8&<G(Y[C QD
MYWW &,'(I5H[37*'H>BY 6@5&(V'M?2%EWU:X>_7XZL4;6M1UU3Z/8MBA2%P
M"J,T?*2L;-;#K-;C$IKL>TY'N3UO-RP+6WH:2 \L[9'+MSW>OR=S;?F.[M[>
MWEV9WQN=L#.1KQ5O263DKB'G+-I%ZI4X:$'Q?"C9JU*D("TB=94=E+J-#2I.
MO@:'.15#CW,522#7;P;A)-B3UV'K8==AP6["R-^8QY"?+N<?Y_'3;?F-O%'/
M)R-B=L#&3D [@#&#D<_(]\-LU^1!HUFT3"![.FU4);$97++L&]P%038-66#:
M5UC;DNL:G*M#T_08F)KJ2PJ_7# #OL@PC[DI'1$'-3:XXOCY<NP'M.VW[:BI
M:=Z0+8[;DYM.;JRXO4PL+JUQBDU&QPQUNAK)5NJ=Z[I;>21,3-%4!.U^SU>0
MU/K%@Q1D(*VS/5V;!/J,K.330W+/>/\ /?ERY<^S/RU(P.8[P>>WEQD;CL!/
M/GD;5<]C]RMOZN&("L6LM,R4_ V23"NY51W7.VZL46(9K%%FH5-\:KVKY'8%
M!^%IZY/520NMGH3%!J(<;#7FW2L-!W*.!CE,; G..6<;9[AN =M^?D\M=D&,
MYSC&<X\,YQC.<>[/AG\./''NSX?)[O=Q45YXI4!TGG!EL[*SS&<.1L[OU:(P
ME/O;)^*&E]-:YG<-JQ[E9!MU,L<4]X?K"8]]I7W;:N7MY'!%TXPK9UFQ NI/
M-/A=XO%P8R.SCB3(SH[TN)/;5%9O'E:B?&[;]\(:5V*$2T6BWO ')SP2X<EM
M7(A:%)(!%7[E%5[3BE.*5 NJZO5]<M+P[F<8.I^OJ]KR;:^3(MEUJ&B@6D):
M<_=-N@6.MR@3S2\8<:=86VXE+B%)Q>ZG'_6&\.C=N7/D7!@_[\:XK,^*X#R(
M<C26E@C8A0(V(JCTR1[G[0UR7$@1X#PYE$FW($&4@Y .6Y$=U!! 4"DA0!R!
M?>457E.*4XI3BE:T;,ZKZZVIM2M[GL!<Z-L&CBZ_&H$['9@TE47%)V$1?II5
M9)-A#30L;38=9HFSV5E.L3]"$:A06X@EXN1(C&^>[EZ_)\_?2L$5T@U\U!T&
M.C;OL6+F]6T;6%/H5P9(J!LW!R6L[@1>'+NZ)*5 ZO2UFV#..#*V&B3A28.5
M8CQ%0T1 2#29##'E/R^7/S_1RQ2L0MOHY=.74454Y=-KNV!BK;7BB+@Q.5D:
MQ'WC;]I(MD_N)Y3%1;B!=C09<O;(REYBHF/IU5K]QFX2-J* 6(-N(8^<8^GX
MNT]F/BIZ^N*LK_3SKTW-:]L<!K2I5"P:\-U\H6Q5BL5D"T62O:KB1X[7U(MU
ML<AR+/-4^KEQ%2G8N)<EVLL3-(JCZ7_9XW(ST^OR9Q])^4U.3C&3C;;)QMG!
MQG&V58VVXE8YFI\QT4U\*^4R)L': U>M T*/MBK(,I2XW<6(/;.Q-TM*N<B_
M27K( F9O&U+L[;&:7-U5BT0\LJ(E&UCY?41&/7Z/D\F*BOMUWT4TUK7:D'MV
M'-N,C9("V;OO 8<Q*1;\*Y9]VR<>IR1?$$A0G\XUO3P7=<:W$9+9#C*C)R#L
MZQ8;.L>Q#@ /G/R^O]N^]*W0Y-*<4IQ2G%*_#CC;+;CKKB&FFD*<==<4E#;;
M:$Y4MQQ:LX2A"$XRI2E9PE*<9SG.,8SGD@$D  DD@  9))V  &Y).P YU!(2
M"I1  !))V  &22>P ;FH/U>2MS06LI5:%M8M4$]>V&G$J;=:$V!*2%W":>;7
MC"VGF@[ PV\RO&%LN)6VK[I&>7FIB!?KDT"#X*^(*B.2EP&FX2U ]H4N.H@_
MS@01SJCTR#[0VQP[>$Q_#4@[$(G.+F-@CF%!M](4" 0000#M5[Y15>TXI4$[
M0I6WH+9LJA"W4U6!:O3[32%..NB:_E(^[FM,M)QE;SSH< ^VRRC'G><4EM'W
M2L<O=,D&_6UHD RGS!2H[!*[@TY"0HD[ !<A)*CLD D["J+4PQ8;FY@D1HXF
MJ W)1!<1,<"0 25%#"@D $DX &2*O#;C;S;;S+B'6G4(<:=;6E;;C:TX4AQM
M:<Y2M"TYPI"TYRE2<XSC.<9QGE&002""""001@@C8@@[@@[$'E5X"% *2000
M""-P01D$'M!&XK]\BIIQ2G%*<4IQ2M?>R6\"-$4>#G(FJ&W:U7.^5?7%.K@K
M4\ZR3/65PLATZ2^+%>M=AS&PD!%3DX^-#5V5DI1R-9A@F&B9)HIAG%*T3NW>
M?<EVU%<&M4T2J4W8#%5K%?>LD]<C&UQEZWMOC9'6/1\KK*NS%!?=M!I%IHA.
MQR:_?XZJ9'#*@*,:,9+F6 NN1G??Y]L\\#S''/NW&:Y# (R,@8."#OMD X4D
M\).Q(4#PGB&^!7S5SN=O Z=V%9ZS6HZ\T," K3NO:<;/M&W6V3&S=Y;=;B96
M$BZOKL:QVI%,ZPZJSNQ>M:4#9KO(5Z8Q%@9MTDV58XUDX^UY8[]^?GWV&V.W
ML[64X.V%93C&<8 5Q$Y4=R>'D,;''#R/99IF_N;5U1KS93C$&/\ 'JHPEI;1
M6I@^?@%#S031PK\/+2L%5Y8N/*&>:)&S+5R"EF6W<#R<2 <R0,W(Y#S#E_C7
M'U]?-_E5+XI3BE.*4XI3BE0'M0KUO7+=$.WX9.N&O;%KR$:S[\E67902Z!5P
MD)QXJ<=/L5DBPV6D84XZZ^AMM*W%I3F]TP,:AL[QV;B3X]P?5_N1K<L3Y3A/
M8&XT9U:E' 2$DD@ FJ/4QSI^\-#=<N!(@,ISCCDW!!@Q6QL<ER1(:0  HDJ
M2E1(!OW**KRG%*<4J [LS@.V=:IXC/JXV"WZA$F2KW-C?&_2^YM<P6'%?(GV
MZW7.N1+/C^O)D&&4^*W$XS?68<<74;"=W'K$2TGM5X)>+/<'\?\ !$AR'5=R
M6U$\JHKSE$K3SYV;8O@#JCR EVB[6]D$]G'+EQFT]ZUI2-S@W[E#5[6H6\>E
M>HM_;-KNT+PA]Z5AX& JLI&.UG6UD L-9K-K/N,5$X.O%%M5BIRER<O-A2TK
MKF;I\U,PDP3'GR+KH,$9#NW/K\_J>W-/7O\ IKB++T<UU9(")A5738D<3"B;
M&2'-"%50@UZ5VUV&H?9;84Y)B2=3.AY,RT7[7L1'2@I<:N+>J<A/0J06W)19
MK;_'Y_-_G4_$!N>_Y-R=AV=O>37XD>B&H9BL[9K$O+W"6'V^.#F>*E%U247&
MR\?V"VGV::G(R,DJH77BWB-I[6D2I6%L<-/5:;K];JE:F($Z*!/8DH(!]?+G
MZ:CXL?+\FY/+Y>\UD,9TZUY!=?[)U^KTS,UJ'MME;N,]:*Q7M:UB6+L3=H@[
M-ZY%9KU$B];"Q;C=<B*N_"C4AH(JI"8CB\$'O$2KTG<8]?7]G+&U/7U[_CK#
M=I=!M8;6JL94IFX7@*/"G>PEA*<Q'ZQLWPA)=D;L7?;E)_!M^UW;X&*LE:EB
MW8[7%S@XB-M])KA,K"Q<WAJ:E'28QY3V_*>WSC)QYS4Y.,9V)!([R 0#YQD_
M*>^LWUAU!H6I=BP6R*K9;EF2A8?8<$N(D'*R_"2,9L",TC!*8?:8K8QXF:Q
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K4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g401831g01a54.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g401831g01a54.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1Y^4&AO=&]S:&]P(#,N,  X0DE-! 0
M    'F*^=W@X0DE-! 0      !D< 5H  QLE1QP"   "   < E  !41E;'1A
M #A"24T$)0      $)_]]5M,FVC]2'%8$L(%V8@X0DE-!#H      .4    0
M     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT
M965N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M    "W!R:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/
M8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+
M #A"24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M    %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L
M  !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V
M8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P
M  $       !21T)#     P    !29" @9&]U8D!OX            $=R;B!D
M;W5B0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2
M;'0               !";&0@56YT1B-2;'0               !2<VQT56YT
M1B-0>&Q ;>7SH         IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M    4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O
M<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M$&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M        #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L
M;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ ._
M_C4  @ ! [_^-0 "  $X0DE-!"8       X             /X   #A"24T$
M#0      !    %HX0DE-!!D       0    >.$))30/S       )
M   ! #A"24TG$       "@ !          $X0DE- _4      $@ +V9F  $
M;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M  $ -0    $ +0    8       $X0DE- _@      '   /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H     /______________________
M______\#Z   .$))300(       0     0   D    )      #A"24T$'@
M    !      X0DE-!!H      T$    &              +#   $\0    8
M9P P #$ 80 U #0    !                          $
M!/$   +#                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   +#     %)G:'1L;VYG   $\0    9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   "PP    !29VAT
M;&]N9P  !/$    #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M    !     ,X0DE-! P     %!\    !    GP   %D   '@  "FX   % ,
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M!#FQZ>]U?T]C?I?^BU-SB[R X T UW>T
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MR-[>>GE5@)!.I!#NA" G8=AG<HA^6A^<D8+.XUI42%1HCM<QTJA0SM;;4QT
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M9A5BLGC:HB:?Y6%W=)P\DAU!25*O&P)D( )?1>X%O/R]<4^6YWTIG6:5E;+
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M^U$7Y1-50 &#@#4."0"1O?:][;B^V)P2+@&U[7M[&_///^W&-P-/55D/MZX
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MQ1/;,OJ*L;H'1D1N?!)'(_H62=191U!EBYOEE<L] ZLQ>31&T&@%G,H))72
M3YB;K9@UC?'H.*>*:(S(RA%OK)(&@CD/OL0+>UK&Y!N8^[E=4M51P%P8>,-8
MS01R.CO+))&U;I6(YB-"#8^(LY5<O"2/D"A>Q>^"0ABJJ<@ZQ^.>3Y4LD'3\
M$>;5,9<I6S,%R\-"2DPB93KDF!;0H_ABS.22 1BE/4&-6*V4 ;2.#9KBZA$V
M=K[&YT*=K%K'';;?]3.,Y'B5/<7];:U-M.QPMV(-53D5XQXZHP@D.?F1Y-<2
M_P#IQ&P^X)BBD]$EC2(94UF<H^-/2%=E66UE<:JCGK8_X]&*-YTIIE:TC.Z
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MXDR/*JDTII6.6TH,+;2IHC$90B]B;@D>8D@[VX'1*)Q+1TQ4,NJ&(686(95
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M3$VBQ&G47R<E(*W,*/YVLGA50U0/#\$QBZ-!X3EFC939O$T.VD$@EB<6YVP
MHIL+S^G+JFP"/RK,ZD]H$366Y((=I805HIA3TDFD&A ? T5KE]1HR1*DCE1J
MZL<RGD^9HF:8N'IZ2;^&20)6B5V%FX\XW&G\6U@2;8FG*-358E)>]V!C%I5%
MR8XF)O\ PT(M8 $V)N;"W&VWW5N,<QVG3); ZGDL6%25JV:^RA,H8#IPZL\E
MS$8"%(<)'#-%!++ 6Y)(W+ USVQI4GRS,JRHJIZ.&6OIH$$E:],Q9(Y9!_&B
MOM(=$A96D1"+7.IA8F%'5UU(MX6F<N!(RJ#95WU$IW4 7O[&YMC(9L!U:_X,
M#:^#(+A2]O+2P@@M*XF9LTE'-:3,BBNZ%B>H0^-I,C9;"M&[FG0R3D"C.LE1
M">L_"7XEYGDF8TG3F:SSYCE5;4)24\%05UY9+*66F^5-V>6+QR@GU!6$.N5$
M:0!6V3+>H8XY(D+ 0RR!)8E(,J/(;>)&C% $+6,B V U,H+;-*G=[?O<S >J
MO;K!ZPJOAVOR?$),LR<RZ6&(0*LQUUR[(4IR%C;)/;$BS44\8GN$8/##(<^-
M8I)FO]&9SG>89?UOE%.V;T]%D4F2U685E/4KI6=J7Q=:4\GAL6F*!6".T8V%
MV%QC8:BNDI\R6 R0K3O 9B9"X)$8U,L9$3>>QN1< >IN0+:[K]8-AD<#/P;8
MSXY0%L]0.029\.1EM>CF,(.F'?\ \6K#_P"52O%>LC96M0DR1O>,G NM_CGF
M692FFZ8\;***.4NM6Q45LI1F1BZ1O)&J'2&5%D[W<_Y1:U6=Q&-7251%(IT(
MAM*=5P&=A=ETMN(U%R0-;6NN+"9=U(W>0N;"03;7$*,=#(^T-F[7QO8L<G8*
MU[1HG2-7A_I#Q(YJJCO*N37,,Y^(74>=2*:W-JZJ0*5*R.T*WT^;R12! #?<
M!02!8FW&/J.H82/#B@>5;:2TQU:E-PWDN%#&_(47XN>,6&CR!JG.DC$&JQ))
MHYF05<?LFC2Q/8^$@=!EC0>9CV->D@[8GM>UKVN21$>FGP5DM/4K5PR213++
M',KQ,8M$B.K*ZM'8@AEU'2H#  $@$G&"^=#RM_#C@C=M06%0NANSK8@*WJ5
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M6_FML,>/OC1U51=6YW$V35.9U%#3TT2TDKH]/E\LAL9):9&LTGG!#-(NH,
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M>EK;\@C[8T<YK$5SEX:GER_/"?KPGE=2D@ WXON3OWV)%NYV]/0[#$2;7)V
MN?IM[;[?KDX[G80T?+^J;96BH8BK4O&<W'R"_>&+,2)25XU-<-:19&1L]J Z
M8A\, \!,S)R'2<P12(UW';_@?T_G,W6F79W!033971)5K45J%? 05$ BLUSJ
MU*/-L"-P"#R,AT^)*C-(IH%U1PJ5=CL 38C8;\$['G8CUQZ6$3A$3]/'\D^/
M]&O<2BP O>P O[#C'4,:ZCAAIAAIAAIAAIAAIABU6]&;;?;=;8YQGFZ<\,&
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M?3@@J;S5Y-CF,9E(XTFE% 9TGH6!>C.F<OZ:<#,8*(U#.S,T2N7!%,P"Z?-
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M*I&#P2 )+&5N7!4I==F:UF!  WL1BUKO@=EZSU=5DN82T<CTDT:1R#RJSAD
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MW2DM-7R4\6=T\+9HT$:HU2WR<<IB9TL!')([ED!"L0+KL ,#)]@79DREEO\
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MO/IC3%=A]I<.'H(:7 L6CEQ4DPS&CR:&K+LJ JP?#(:13'SBR%5<Q<@X[R9
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M]-53GTD=^59.WE&=WY57A5:Y.461M:AM&G6 2NN^B]MM1&]KVN!O:]B"+XM
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M0D:L7)N0H.Y%L<^SC(EH'+T]0? )71&#J(6^X!8LVRD[&Y^XN+=V!)#IZJN
M5K3KJS$K0UD5&L1Y4[8E<Y5\KZ;5=*C&\.E6/TF*CGIKBW2>32]39[E>1QR/
M2/FTWEJ(XUD^7@74265@PL2I )N23S;&'BA>IJ8*6)K-(^AB>VQN; CVX(WM
M]I/4'3/93AM)LSH()I&HY6$00F3R]R_^E]S%*R/O5R=K1HQD;'V]W?*J3:]L
MY/\ !3HG**9J>;+J7-*IHQ%55E?&T\DAL"0@F9EA47N/!5+$FP&-[@Z;R^!
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M-21OYHW,>Q\C'MD=[;R6:>?*\NDJ(_#G;+Z%IA8 &1Z2&1R%%E +L]@  .
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M4+P9YT+!+&;U6GDR[JBACF5*SY990XCJ8)**4OI(N4=$:VESV/8@#;'JQ_\
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M8$B]MCC6/D,X,IC%3"M(U>\S*= 8)K#6#,-8C)%R 0"?K8S.Q/IOWBQ.S9D
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MN.Q$;GU/YX^GC]N/GGX_T_7S_H_TK <"US;UVN=@.P('T'\Q#&O]_P#7_?\
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MY)))-]SB1VK'%3#3##3##3##3##3##3##3##3##^ZZ8AOM]=_I8_WMCR$_\
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M\WSE8A.^744U3'"QLLLB+9(V_P"UF(#<[7V/&+.OG6FHJJH92PBA=BHY:PL
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M .',DCJ6AB=D#:"UB+GL!:^UQ<F_;TN1=7:#IQWBW\3W;;K\ P9 .Z?'ZHD
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MX\+SJ'!'K>Y'._'H#<BY]-MA@;@D<\D$<D,!:_.Y]!V-B;WP_P WE/HGA/\
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M)29_=(J.B_.KG)RCG>>5=P]'JB\=W+N=5(0/$5;#225"BPO<; 6V"[?3;C8
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MIH@\S)!#HB8E&R$-H:2QO1&6@RANYG8^'6%S;+:+-\NJ\LS%=5)6Q&"4:M!
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M=^ ;;[F_FMR>WH-K#&CY(V(JND8B?*=ZHUOZKRO<G")Q_6\\>?.@!(L ;<$
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M\XC=@F&;H8G97YFY&"W%YCUO'-8F6[I&>MA0R3Q3@5HKZDHRJK"6BQP2V5E
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M_;UO<#OM[X^<LK!V.ED<UC(T5SE>O#4X3GRJ_']UU)<'92 VQW(O92&).VP
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M/.FM@+"VQL;6V/.P _*Y%UT<;CX1TQ;:YSAEUDX^;[E2XM77M(44^2.F_%(
MS3K6^"O002I#:"SE.-,#'B0B5L<8D7K"APO;[#SKX3Y'FF79!5TF4S97F:FA
MI\PA9RJ)2;#,/&A(M*TD&N- Q #,'!.U]SEZ?@J::F\%9(&?POFE:9B'1&N5
MTD6N&N=Q;;8D'>L<?Z;,SQ&K=MZ%:/;3*'/*[,#7(:<T@R4>8PRP'EA_RTGN
M4J60F4A5Y>CD;Q&V-=PK/AWEU;3UF3!H*7IVM@2 4\5.C5<<<0,<>N<@&20Z
M58L1==6DWMB_ER2"1:N!0(H)HXEC=#9]:<L1;8VL00;[;WQ1^8[,[I;:9 ;2
M1V5)N#6>Q')#O*$L;A2R^YL-65$'[@='N]-)6F1NBCBCD5"6-2)TR\)ZD_9W
MSF"KB/2F8TSY>X DCKY3')'N=EM$_B *!<77<V %KXUZIZ4J8YP*&5)("HU-
M/(5=6X) L;\[B_ O>^*XVLZ$.H+>F*OM<XR&OP7![<ITQ8&/32%WKJ\=R0."
M;D$SXHH99Y6E1FJ#5^K YK8A#FR,]TNU=,_L]Y?2?*S]09@U7)%('FIHEO%*
M ITJ'-K#65)!6UM5[WQ7HND(UD$M=.TI5M9B4DH2!=1Z[&Q]?<]\L>T^T1^S
M&9X=MU@(<=-L]BV 6:E#"HR/[TR\^U$6(@K\JR$/C$C/GDG(<Z24J=9WOE(F
M(D7L4.3YK!U;3S4M4*7I.AZ97+Z7)X56-$S,5L#M4L0+R%J5&0-<:=4FH$L-
M.]QB&*DC@1%5D8@6&P0*0+':VYXMV'IB7>MQ!O?ZV.*>&HX8:88:88:88XAI
MPE<-.8<1"((,QTA!)$C(8(8VHKG/EED<UC&-1/S.<Y$3QSXU3EFB@C:6:1(H
MD_'([!40>K,2 HW&YVWYMB!-@2=@JEB3L+#G<[7QT@V98J;,HX60TYDZ#R%.
MB%L@IY&#0]GK3O9'.YS(H4>UTTCT:V)JHZ16M5%6SI,VRVOD,-%74M7,%UF*
MGF260+< ,41BP!) &W) P#*>&7==?XA^$6N>?<?GCD0Y1CI'N%ANJMZ"5K+@
MI6V ;D%J9'E1LLR>V=?0KW2 G1H;+V#+($8Q)5<-,C,@ Y /AR@,0 61E&IE
M5@MS8%@K*2HN1<;8@&4\,I[[$'"LRG&[J=PU/>T]J0R!"705MF$=*T99I!T(
M=&+/*YL+B(I8$D<B,66*6-%[HWHV+*Z@DHPL;;@C?[VX_7:\;CU'YXYMC;UM
M1%%/9FB@0SF!5T,I9$(T<IUB3&'7AQOFD8QY)Q<T0HD#7+*23+$/"Q\TD;'4
MFE5;7U7WV"DD *SL2 "0%5&8G@ 7O:^)@+^@YW)L-OUQCL$5%^-5,0P1>55/
MT_OX_P!2_OXU"^Y'I;^>&-=1PPTPPTPPTPPTPPTPPTPQ"O[03IWR3JGZ6=PM
MD\3NFX]>Y21B1@-N\-QZ"28QF%%E2(HS#:]S_<)3**CVEQ.@?,PAJ2.A2-V.
MS2@&94C4C,$5V5BQ4./+>X*$J&!!(-V[[@C;&O=4Y&G4F1UV2R3&G6N01M,(
MS-X8!O?P@\6O>UAXJ<<GMBRZ(_LJ-\-GLRW!R[<W=EMI;W-=M@N,%%X\68*%
M<[5[IX_NE1?>XSLK=/94IMACT-78 B%59<8Y<YX-B)8PC3ML>E.GZ/I9Y_E5
M003Q2QM#30QT>\P DD#(9!J-K&Z-<!1P+8U/HGX=Q]&BO6/,WS!LP-&TCU%(
M49/DV# *SUE0Q5R!MJ\A)()O;&1R;I%W8E*AL%WZB)/)]N0<3D.)9#F,PLM%
MDN]]_B%57DY%N$02;1T4&\8=,3#D\EZ3;U&!58L\T*6LCZS=US*ELP:@N"NE
M=,XCL2(0S$+!L3X3,"FC0TA(OI%]]%',K!EJB"#<7C)M8N0!_$[!@IO>X4;C
M%N _LZKB&G.@.W1QZPOK0088^X3;("K1:VOWTL=Z!\.&&I[D$87";!MY;8Q;
MT00PP4Z1UER,% V$NH,N),]4J$AH8HU5-(5Y/&&KY,4@E-XU_BJ5$B$ZM.Z;
MBS8D&7M=FDJ#([$W81E=BVJUA(=K_P"YVOBM6= =;!:"70>;P"V]9]V.J+6;
M'K&UMZ^:A;TZ1X[.EW;92==&%T(NQ^0#5]B?8$64?^$J[D0U)UM)+Z23/&E7
M2]+%^,LQ4HFI3^]?*52(*+_O&'45"JPHHQH D_AU$HM/F$K:K;&U[;*!^(W(
MV8VN"-1&^.FJ^A?<4"3+K,O>S&+*[RDK)IGQR[+XTS%QA<M782#(A8L.6RGQ
MQSK<39BPEF*+KC2&6.8-/-6V-HGDW-1LYI&B$0RS2@D9[_..7()K="M(80S:
M!5@$DC7X9N!XGE@*.;6\AJCJ<W%H@ @TA; :_;D6._%[G$U=D\ R+;';#"-N
MLDRD7-2<%Q##<0"R9*8FI/MH,8P^AH3;.WA(N;ALMG;7=?;V_J#3#P# 6 %:
MZ$DD BTL<)62BIJJBHC001SRR2)!?Q!$'8L$#V0N%! N56]KV%["[A0QQ(CN
M9&50"]M!:UM]-S:YOM<\VQ%'JBVYSVMRU^Z.(U<>1U1-6'7Y)2QM2(QS*]T[
MH#0Y(V.>PF&*>9'->DT4\;&-5('(LFO#_P"U7^RJ_P ;C2=4Y%F*P]793EQR
MZGH*B(-!FM,LT]0D$4C3H8ZE"X2)-)#C7(9 %,,FW=/]1G)]431EHI#N0]@"
M3=01H;B[>;4!<@$$VQ&_%MQZ1]A7V59<PTF2TI2FCBV;T"-KRAT5DS9A9GQR
MD#2,688M(7+"4))-&V98W=VOD_E.3_%;]G?XA9=G;93FF2YWTSF=R)H:A*.I
MA),4U-/(B.E335<+O%)"3>17_"?P'H\M9E.>4A@E>,-+$2JO8.C6-F7<7MW(
MV(/I:VSK-^T/Q':# ,9O+R4L"MM[5E7"_&#9[5#L@E&50H#RJZ%I@="A,<\;
MB_;3P*6X>&=8YEB@E]P]3?&_XD_M32TGP\^'= WP[CH&R_..I\V.=5\-=4Q!
MJ=130S0TN6A:>*666I:F>?Q:B-+V$:O(.?5S9#T13QYIG-7'4K53FCI(@L>G
MYB345#JTK74+8LX72@%[$+8SWZ5J*^I=JJ\K+[8"\O\ ,;@[+K$D Q;&N1]P
M^!H M=.\@A) *RK& K1IHW(PE@J%+%!),^)OT,^$_0[_  [Z'R;I:3-:C.ZB
MC,\]7FM49VGK)ZN0RR.SR&1M(+-8%V5P;AE!L-<K*Y<SG:LB!,+BT8$=@H!.
MQ[ *3M8"R@&P/%YL[PW&\DJ7?>U<CY E>2.2(C1RV*R&1KXEG8Q5>/-$KHY(
M)4?"]>Q5:CV,>SI,HO&P!8&Q(*@DAK$@V'._8[$['G%EJ"%9#J_ADOY1<DA6
M N.XW&QN+@7VQY/.G[[67JRRG>+9;8^JN73%9;O72X1D UGC%#*"+CUIE:UY
MRCFRU<]H&L8*+Z?<C(JY/5D8XEZ,:[EV79SU6^?K#4UU'+E4E1'%% *'PZLA
MY$5A))K*_P -2Q#+NP N%W;'G;I_K?X@5G5D645E/+%EAS&MCDJ'RQ'5X#*Q
MA*'2DB$ J QG(L";$MY,T.,]>>YU+#CDNZN!XGCP=U53CP95:WS,8P,FUEW5
MR+" \GL+\0O-;3$\1;7TD0+8+_'8;,[)K.JAA44*P>X/N<N54WG:"H+!9(TT
MA0S^:GCE(%RBLQ9B!N!8$7.Q/?GJE2/6!J/B,@4B56LI \1@\*!59M2A068%
M&L&31(]9@?: W9XHIQ>S0V.5EW!C,%29D>>E5OW-8WP73.78DY]W8,H^*8[C
MB=2 WWG<0DV\T4>$6\Q%>(VPB]C!\FB5685\+%$E=@%'F\-ZU0B'Q#J=C1\&
MP!F47-MZ KW)&FG.Y 4%R"22@%[(=(.OFQL 2>+8Z#$OM!KINWV.+=8/09%N
M99*&UE,!FJ58MS76.WE3FHN7A(F,&FQ8<^_M",%BO(JP@><VF,-8WW:3TPL\
MN1Q+4N!5@4R+ 1.(PQ)EDGC9/#\8 ,HAU@%_,'&R@7Q,,P%U5HB'8@6U7 !
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M+7>$<FO%G[0T'A=;Y>R@GYS(J#6]K /#45\7(V\P0&UP1?DB^.:]3H4SA&
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M027F17@565>9$M+($F06<%/1UI%NTQU525M>HX[,;5RQ3U#RPH$C8+L % 8
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M)-%[0N4=3@VMED[!286.D>]KG+E<FJ:JKRVFGK833UC):IB.Q65#I8D6&G4
M& ML&'/.+R(N8HC)^-D!>PL-6X-AZ&UQ];>^+H:RF*F&F&&F&&F&.H-MZ^O?
MV6!@8B/Y6-##!QO41O'*L;*YCG(UWA>.Y$Y3E>53FUGJ8J<WFE2,-?29IH84
M/8A6=E8[V[$B_IB!8+8LR(-]RUKV_I:X_7/V#L@C(6D"D0$PNY:V861A$3G-
M5$>B21*YJN8O'>G/Y>?S(GSJ>&1)HQ(C12JUK-!()D^OB#8@<>W& 96 96!4
M[ [;_K]>W.8]DK$>QR.:[GAS514Y15:J<HJHO"HJ+\^47]-5B/6XM?V]O^?R
MQ'&_CC__ *J_Z]-([[_7?U_WPQHJ<_54_@O&EOM^NWI_R<,:ZCAAJ  %[=S?
M[X8:CAAIAAIAAIAAIAAIAAIAAIAB*.Z/1ML5NYEQ><9KB85G?FL&B+-E'%>^
M>,2-D4+9GR1.DD2.-B,8CW*C&HB(G":P]7D.2UT[U%9E=-4SR!5>66-'9E6V
ME27#>52 P7B_87Q9RT%),_B30QR/QJ=$8A?] )4G3OQZ^^*ZBZ<]H8&O8W&G
M,B(Q"BP4^O'OLCKZ&TQ7&8SX\>K+7%ZZX%QNRBI&VA_W5,;4S$@>Y?[4B-$8
MC<U!/)2Q0P4[*B0BT0"H3&M@"8]K@$  A3:VUMSBK\M%OY39AI;<V86X;UV]
M;XY^8[$;7;A6;K;-,?=D1S7@DAO.NLB2"F-K2JTP&ZQP."XA#QG)!BJBKEBR
MC'8*O($4$9OWBL<:,U-!65-.#'%,$+$OM"BDKN&0FUV!UFZDD&]RI.^(M31/
MNZZN-V)-B!L1?@@>G]#OT8_2]L$+74U4-MKC$=70RK+4@*/-,,,KL#$VR5GI
MSDR)/"[ Z\#'7#$K,.X6O!G6'WP0I4-5LRK9&,K598R$W)5;M9RY M:YUW8
M#8WVMMB7Y6#;^&-N+CBXM_3\[XZX3I,Z>@6A1Q[=4[V!F1&]AYUY9+9&CV$5
ML-/?_>=N6N32A6$3C*]<A^\UKI2;!X7H)96/NJG[WS%=)%:T=AX<=@$*74J5
MC-P4+*2#HTLP.Y(&'RD!N/#!N"2+7N-[DC@CUN+;?6]=8;LIMEM]9C7.*8R/
M6W X5C616\A-G9VKJZU@Q,0L":TM33S9PV@8+AU8%!.1)#55&-4]15M#K081
M6VTM5-/M)+<:@2JQJJDW8W(4 "[,S$BUV))OB9((HVU*OF.VHF[6L!R=[64"
MWL,78U3Q6PTPQIPG*KPG*_*\>5_C^NF&(Y=0/3=A^_U0 '?R%@6-/,XBIM:Z
M:44ZOD>YBRO$*'?"3 ^1&,25L<S6$-;Z4[9(E<Q<-G&0Y9G<<*U]/%))2RB:
MFG,:/+!(A5E:)V&N-E90RM&RLK $&X%K6HI$JF1I2=4?X&'*-V96O<6/H1P/
M3$+^N7/-^.D;I2SW?'%LS.N\LPPG':<2O+-+LL?%H+ZXK<8*R8FOL8T8=;U;
MK;[VA!FDC$8T9D,I,[V.EDAG<\N6Y9-)EY(:):>&-I1KTZ@$N19K69AO8J+@
MFXMC7NLLUS#(NE<VS/+HTEK**E=H6D\PC8@JLY2Q,N@D>1@00;G&"3[-[JBQ
M/"L^WJN]T[$U)MV<AK,CDRRPF=96YF23*=+D)5S&V5T[8S[ M;/UQX5'8283
M"QL4$,#&\XR#JNDR"9XLXDJ7DKW5I:N..]/$0\Q#3/90I82@%F-],:L]B23Y
MF^#OQ3RG)*O-*?K.MDAK<]K8ZF7/HD\8/*/&5(7B;8 F33?:P!-AP/0+CE[A
M^<5$=_C-A4Y#4'R.8VP 6$D:>6!5CDC>]K.U\T*HK9&NY?$Y%8_CCM3JM%54
MU?3K4T%3'6TT@9TFA961O.0P!0LOD8,C $;@@F^/7-+7T-=%!/15--/#4H9*
M=X*B*831ZB/$4QNP+$@^(J_].35&P#*0+I[<[KEX;8'AVA$DF" E- (@E60D
MND*]K#/(>!RY\L=2U70PK5,8]%6:8P1(NQT4]V05_&"OX?Q @7;\(WL?-_EO
MN?N+W#2(A96=%9;:@S %0;6U D$7!VOS<6OB5E;N-@]O915-;D]0983PMFA@
M@+8_U$?W*V%LJ?T*E]C72>R]3WB1(LJP)%^?0$$V!!/H#<_EB(=#PZG8G9@=
MAR=CP+BYX%\5JBHOE%Y3]4U'$V.GO:N.ZJ;&JE5S8SPR WN:B\M:1$Z-SD^%
M_JN<BJUR*B+X<UW"I;5$,=3'+#*KO%)$\,BQR-#):1;%HIE*M&ZJQ"R(P9&-
MP01B9258$$@@W!!((/8@BYN#B%."=%E7AV;TF53YKD]V-0V+;&OIC[&S(!&G
MC9)$(]L9!DD+E&BD<R/O8]K$XX;SVN3C_3'P#^%'1N?9=U+TYT;EV59YEQF,
M59$9'D8S%AXOB*BGQ;-YU!*DDA@5.+V;,:VI@,,U9(\9C*&-P64@#3;S.P+"
MVS6U=QOBX+.B_IT$K0JY,.LXA:\"NIX")-Q=S7V'X>J0@ *[%R+B;-%M"L1#
M&JP?2Q(HV?&6D#1FK4*:BDZ[K^]:U!?Q1&-1:Y52H9BQ)TV U$L?,=Q>P/;&
M&%' "+(0=@+$@G@ ;>M@+=_RQR[?I6Z;\EB%@L<2KBVQXC9X"+(/E63"F.PZ
M[#S4"WQQIU?D@QD]9:C;A9:VQ@=-(ITAX9!#I"*&@EK+&#J=*A833YQ0U"5<
M@F@\*6FF2I>-5L\ 1V64HL(L8PVD(>!J!JMERKNU/(N@$$E74J"22"2!:^][
M_P!L?'+NCCIOSFF(Q_*,%;8U!)&3DD!LRS,P/5GS2^RK)LF<^>MR4,I4MKO-
M,G.?$LWI#.LG0A1CCA@1"7RYM7)*)A5#7_# _AK?R +'S<[!%5=M]-MQ<8I_
M)P 6TL#OPQ!W)OQWN2"=^PVMBX]_L=M=DU;E=7<T*%!9OB>+81DS&W5X&^QQ
M?"RK<O&JQDX5J-. M:1?6KT-KI!#R5+[#"2&0#,AH?.RH5D$@N)&G4D@ .Y#
M-(HV4$D!B0!P"3L,3^!'8FQ-U"$WO=1Y=)/WM;WMQMB*6?\ V?6QI0]';[?8
MJ54Y-B-:-5T3PLYS>&RK:>&WAO'MQ*Y(RIQF,7<IT#WOL@2QDMH)C:RWDF"+
ME35ZN>YB"P$R2$W)#,"0'U*;V'!*M:][E2+^4VH-EM,?_;*D6N1L=O7;:_':
MW;%N*_:%C<-FVSEP&R)J*H4&HJ*"&@-&!954U6%4U84<<R/C'0$6J@B(D*)2
M)'L292',EC<ZP:1IW#2A6+SP-41R@-#+3K*ID0H04?\ B>$2"K>0.=.D,1?1
MA$3PD+JNN/4;D&RWM8^USN"><6KVAP'/[*QJ,0J]O+;%UQ6C>(187,T3@)+
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ML\C.8_!IWN0L2ML-('G",YQ_0'QURS)\AS.FSRIS:OS!JP3033U4=IX1)K1
MTB23Z74:; /X:D7(NM[I0?:D#.WUVD/$P^$/ I-U<;9GLWWO:7*LP80R6JM,
MT)IZVH&E]7'QY(KP %Y9L<\H:N<"<3'7*/EX/B/)4U,<LU%4Y=2HT!FDK:R&
M0?Q2 T"HD:ZI4B<N2C,%9"HU7N,Y!^T5E69Y[E]*U'49=E;5<<%775E6CQ+
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MG>!8S.:J59(L<=GF#9,8IHZ%"I5$,+%) SR?-U#/K+DV IWB(O8%A:Y(.*\
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M:)2+]I=M7>^GN!?OYKV!R"HJ.:B^.'-1?U3A4Y^O'*?R3G]M88<#M[>F+W$
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M!N,.=AWQ@.Q"3J@-W&V\PTK$;X*MH=X,.N;?(YBPV2%8_1Y@%96,)1[2I"#
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MDPGF.A=1<,654/"*IX"J-MN+8BM+"LB2 ,&C)*[[;C2;CO<<W[W.)-?K^_\
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MD ,H.]QB;YR22Q1&"E;$Z6!#!;D"]CLQL"!N5[@[958^$8Q$^.QO'\.$U@"
M"0.!L+<6[8R2\#Z#^F-VF(X:88:88:88CGOK0=CZ7+8(W+V/CQ^U5O'F J5\
MU00__P!D<]\P?RBJMJGSV-X@0.3V_6_MW^N^'Z_7\L1JMVR2+6#1<<3VH;WJ
MY>&I"$YUE*U41/S*^,-T36_E3N>BN<B(O,HON;$JM@S6.F.X.[L=HU)&[-W%
MCN1ABTN^&('75*%D=)82U^0XQ.TRK6)[F./1[D2>J<C.7N98QL<,Z-K7.?W\
MM:[MX3CWQUZ"Z1^(?P[S3+>M'I*++J.AJ\RH<XJA%"<CKE0I%F555RV6*AC7
M>2DN)JF3P6@21T&,MD]354E=&:>\C2E5\-+W!]=0-M^"+[B]\64VZ.RK/-Y,
M<L,CQDG%!\'PJ],F&+):2V6ZR8L(!DT$C(F,X#! .:YW>ODWLY>QKWKXP_8&
MZ R;I_J'XD]0Y1U1E_4<5)'2Y#%4P030K44M7--)\S'%4*)PLQIBT>M(V( U
M1K< ;!U;F$]3^[XIZ<1VUW&H;-8W(![WV %]@#<BPQFRVX:QN X=V"M"1^-T
M\KQVL]-&S3 033O5GSW33/?,]S_Z21\CI)/SN<NOIF.!V]O3&D#]?JP_6V(T
M;MGSD[A7?NU;'#3U]77!(B\M:&X)EP02]R^&22DV$T4J+X2(&!6^>[F4G<>V
M_<WVMZ>_ZOM'$B=JZAU+@>/CR-5A!@K[@I')PYI%U/):/C<G*K_0(4T9O<JK
MV0M3PB(B388N%IAAIAAIAAIAAIAAIAAIAAIAA_?^_P :88PJ?:,_:;6O3-N!
M%L3MN+3C9J_#Z[+,ARW(0Y+86D!O2S1*>NH:8<T6(F^EBK#3B";A_P!W 0OK
MG-K[?WD\0G.NM.J<UR@I19-1QRU,@ >>8D) "-2L% .K8BX(MO:_IPOXL_%J
M;H2>ERC+*9)LSJZ5JAJF:,RQ4R%@B:(=<:R3-YF&MPD8 ;3)< >8O>+?:_W<
MM[.URDLW++:Q)>61E63$RV&02&2.59)("7IV@AN;Q$RL :+7#CMC%&#B&AAC
MCY%3T69359S/-<TJJJMDU"2-I6:G$;-J$8B)*61MT)4LIWU DX\8Y]U-F_4D
MTDV9U$D[O.)@TS>+)<:N)&-X@=1 AA6.% 0 ATJ<6 YX3Z_S^O/UY\+Y_BO/
M'G69]_3];]O]L:]IOM86^HVL1M;BYX)4CN;;8U54^//PO_.\>/GY7Q]?CX_7
M4?U^OUSA8CV/OQR=]K&]N3M[^W/DMK"0.(!Q<Z!P(](AVO<V).]ZO>KFMX1S
MWOY[E7GGE4^$XU0%- LK3")/%>VJ0@%O* % /8 #:UK?4XE" $D6(OL#N!?8
M@7V!^Q-^/3%P]O\ =O/]MSF7&W&2$X-F8T3HJO-*\XZO*K(UDAGD9.ZOEBE.
M#E</$DU:0PD0I6L2469S8T214EI*R*NIZFLB\)U=J>E?09ROX8VW5?#+6+:B
M 0IU$*3?.].Y_F72^919GEM9/&8GB9X8)'1ID$D;-$2KJK(P0!ED#1D&]M04
MCW5]'O4CCW57L%@N]%#!]W.R40H:ZI))HIRJ3(Z,\JDO:^98G*[TOO&OG*KI
M)XQR":DD N0:!Q"1IW_*,P7,J&"H%ED*!9HPX<QRJ!J5BI(!-PPN=PP/)Q]*
MNF<^I.ILCR[.J30%K:9))(A*DK0S 6EB?03H9&VTL ;6-A?$GT5%3E/U5/*<
M?"JB_/[IK) W%\9[&NHX8VN:UZ*U[6N:ORUR(Y%_BBHJ+IACXM8,,JI'%'$K
MT57+%$C>43C^LK&I]53CGZZD9U4@&^X8W )%EM>]@;<BWKVQ #T&_P#,_P!^
MWT&/HV5CV]S5Y;RJ*O'''"JBKY^G*?*<HOTYU 2*PU"Y&IE_"PW1BIY VU @
M'@[$&QOB8@@V(-]MOKQCZ:J8AAS_ 'X73]?K_BXPPU"XYXYYVX-L,-1PPU D
M#_;N?H,,-1PPTPPTPPTPPTPPTPQM?_57^'Z\?Z?[_IJ#$@&W/:YM_,X8A-U&
M[YVFUV9X]6ON_N*G-H3"O54-I'N+&,Y!T1'N#,5O:,O>C&(U41R.1Z=SD=XA
M_:OZ[^-?1V9]'+\)Z7,ZN&JI,U.:0T.3+F/A24\D<<4\C24U7'9UD!6T*-&"
M1XA#D8VCIRERJH\89FP%B#'N1N"-O*00+%M_6Q^EGXMW>I+<+#<"DVCL#%R#
M),KW;KX;QM%CGX58W'*Q\^ DY]->TILX>#26$L*9*W$80LXO 8IA\8*AL%21
MGH/]G#-NI<^^%>1YQ\11..IIUF?,8JFC7+IE;YDII^7AIZ1 RQW*DQ%2;%V(
M!.,#GZK'7LF7_P#0\^BUV\H8Z+DDD[6O??GZCLPNI[J6N(\CDK=G:\>6I;NN
M6+5' 7YN01$[?U.4%U6#V=916Q\460Y&958W%5W1)58ZV#R=Q]9B"@AU!^4]
MW:@RW4":N1@SPJ2DBH@6726D74#Y8T)U+;\2WUB]EPOC5 N"ER-6]CR 6"VW
M-^!?[V[8F!LKN<=NG6YC<S5$U955&;DX]C!DU?=US<BHA\:QBT2_&9=B!R%!
MSVMO:@A6($<E38BU\)8!),4ON),94PI3R)&LJR:X]?E(.GS,-)L3=M*AO2QY
MO?%[&Q9%8VNRW*^>Z&[#2VJ-!JV#>36NEE\^K4JWHU;XGPTPPTPPTPPTPQ@?
M_P"$(Y])B_1;C6*#]_J[A[Q8U6S(U51) L9HLFS-S)%1S?R(?05TB<H]%>QJ
M*U/#VZOU5+IH88@;>-4*"!O=54\^VIE/U &.1?&NL%/T6](6TC,\RH*-O_\
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M]K\#G;^V-4V;=QXA7Q]?HG/CZ)\?W\_6'^+8O_N"X[7/Y;GVMO;WP&03=UE
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MQV^+93CX,-B\!KFCO/<#D!(ZF2-D)]NB#I,D*(Q.K?"?,8:B>OIH&;0U,\S
MR,RK()8@& 9B!8.X\H46W()MCT_^SE#4T4O4% S2F 4U/4!9&8HE09/#U(A-
ME'A@+87U$&[>GI\9SVIRO<JIRJ_'E?\ 8GPFNXCVQZGQNTPPTPQ8?J/R.ZQ3
M:VYN:*:P',%*IG2354<\MBP!+<-]E[6,9%F<]063H_TW(](U?V\+PJ<>^/,/
M651\+.JX>@!F/^+)*%4RI\KG:FJXI&GB+R1SHZ21Z8U-RC V/W&2RIJ9*R-Z
ML*8%96<,JLI (N"I(O<$@#OZ]C K']X-VMR@MWZ[;BRW ?8P].V[+<:644\<
MR'<^2MKVX'/2R6S9(W733O=?=?Y71,E5?68O<WC@?[)>7?'O+NK>H)OC<.H8
M\IDR?)Y,LCZDS.?,:62<YB@FDC:>:KT%X#)?:^C8(5%L9;JB7*IH$_=*Q+*%
M8_PHU0W(VN5W.FPO?<'<^_?XYE77E0Y9)B%E32'TU;GE?BDNY.2U%C9UN3TU
M!B.VGW'D-=3XE271->!N&-8YJ=F=@8-C--B^Y%"?4.R&HIGUZWGO^>/(FC$R
M2.K$%C3I8%2S2$@2,^G2GE5-B61@64D$#1G-<K($LRL%NS"S(P #JR N/QZM
M#:OXD>AV6(N8TNKM-N5U67-_?@;R[=F4V(TF!Y-;%V&-8]8!760WU!!386ZB
MQET%Z80IV19-0[A;A8Q*"V$F3"\CVZ%1T5DILTMI6096($:CJ':=YE1ED_#'
M&?$<R'UTKX41XN^M@+!09H9:O6XFB&D1,5*D LX9%L !M?SD7-A[\XME@.8=
M6...Q11Z',[_ !JRQK)=Q,EKLNH-QKG+1\G/+RL\C9*@FS.LK96RX%CPN#U6
M*Y/EV6X9CF?9&;?EBV14<ZU-)4E3*Y4D<GPW66"&-%T:3&D2B2I;2PL9I-;%
M5C;0++O;492:NZZ!961G:Y)T,"0$N0+V&DW)4\['M3!&['7'7XGGV9#;;9M:
M9K-BS*/;VF9CQ\^/&VF.9WU'VE!:7]"335ME63YEB=7M/09%9"893&3F7V/>
M_CP*KF,R#%*WRV3F8(*E5A/@EF)L5UPP>*%-S<)(TI52UK(;:C96H^-F 6_A
M=V47YV9@";C;586-B;<VQ7]]N!UJ>WOAI<</$K+S(,V$&N,?V^FL;["Z&MRS
MJ IL)2HIQ[WW&0SY8%C6PRV5D0\3[GK,WR')U(I*WTBL5E6')5E($P?PUIBH
M8D).[IE[RH[:?X?@FIJE+$Z6-);8L *MZ[3J-A<$FPNR_BL!8V-[ ^HN3N-E
MG7M%'DD6U.VD68K8.RZ+ L1BRAUM))-:.R*.@ 9=.LIIGR2RG+8M)4N6221\
MDZR/<]ZN[EPU1H\>7PK>'XC^';8:-1TV]K6Q?1:O#77?5;S7O>]_?%P]4<5,
M-,,-,,-,,-,,:*B*G"^470B^QPQ1N58%B68J/)DM&!<.%[D@4V"*7TFN:O<U
MBO:JHCE1%7A>?GCA.4T4NC%EDD!)W ;3Y;6*74!M#[%UU69E4G=1:#%K65F3
M>]U)&_N1P#WM;@<XZ^N/P3#H%QP&QQO'81>WFM^\ZX1P\DB-<C'"R3,E8YT:
ML5.8T14XXY1475H\U+'KC-1#%_E*R2@.FK<JJ,YTW+$[$"YV4G$AF5659)8P
MVW,R,P;L"&(.H@7&V^WKBL6V B1P>J3%$XB5(A_5DCC]Q+VND9' CG(DCWPL
M=.QC.YSHF/DXX:Y6W %U!4M8F][&Q]]Q>QMM?U'MB;4.]@>+,1??@<D;C<>Q
MQ](K&OGG<-"8/*3$KVR#LFC=/&K/2]3U(D<LC>SUH>]5:B-]:-'<*]O,P2P5
MK,18 ,=^?4V]_P M[8!@38'?]<>OVOP<<[4<38:88:88:88:88\W/_".SN_9
M_IOHE=&C#-R\MM9&KQZRMK<)-K^]C>>70QI>.;,]$5K))(&JJ+(UK]-ZP($5
M%ON9)!;??_I6WXV/;WOVN."?'ZI$/3^3)J4.^;!T4[:C%$&'OR1Q?MMWQY3<
M->U^+4KF+W,:%$SNX3RK%>U7>$5..6HK?X(GS\\[J!_&>_<VY/%EVM<;;[B_
MOQL/(G4((SO,M2A3\RQ*B^P8!N_U%R>3OW.))],>1X]MYO\ 87FF611&49H]
MEAJM7L<^NLLED!&K;&5CFN1\#28FAS=JMD;$:^3E612-=JO6-!6YMT_4T.7!
MC612P5T4:7'S I6,C0H?]3$:@O#%0H\S#&Y_#7-Z:BSJ.DGI9)Q4S1(%CLQ9
MI%>%=*J+M9Y4?3<&Z7(# #'I^^S%Z,-J:[=?>/J;3!Y!+F\O8JC$C;4584$&
M@&A7(R:&OGAC6O"MKR%\I1G8PBWF&225OM8A9">C_"#+LUI>FJ>;/J9TKHY)
M(J0U .M*93=;:O,=)8HA.XC15V&Q]B=%Y%34?[US'Y$0S5TZI#-/&!5+"@N-
M+$!D#78;W.DKL#J.,\S6HU$1.>$_776 +7]R3^>-_P ;)961,5\CVL:GRKW(
MU$_FOA/U_AJ5F" LS*HVW<A%&Q_S'8_VP_EZ_3OZ8Q&=27V1O39U.[PY3O+F
MK[MV19I)5_?S ,ER0 4K[KJ@J8=5$K+: 6'MK@QH'.C@B1R,25ZK(]7:PE3D
M^65LC3R(7J)F 9_F&&GBQB6+6/PVTZ[ $ FPQJ&;="=,9Y7OF68Y7%55KHB_
M,M,P95C_  E5*V\H'X02#MMVQ-2FZ1-FJG#LAQ.OJ#0/Q6'A-?>7X):1Y"0#
MM]183C=!4)9F0%S$8ZE9M]CP]KC=HEE07\;+*&[KK :WL8"-F@JYZ=*2)&!B
MHX#30QL-4?AVF4%E.Q<">32VQ4D%2+;[**.!5E4*0LI4D V"!(UB"QC_ "KH
M07&X)N>#;%,&=".P!6VHVTS*W*!<'&-J3G4X^3F+$8ZCVTH=IZN QI49,,L8
M>)XS2H&0V&.QKK</[WK#@C)R'RY%<]KUJQ6DPM* PLT0* /,T[ +<6\[MM>Q
M!L;C%,T%/X'@*'5!<W5K.38"Y8@W.WMN2>>+<X5]G[BM>#F]/G68761566V=
M\4Q,<=98M9Q"Y4+F-9EXUC<F7N2VA8V64V5CUYE37%5-!2R8^&=C%52EV-Q*
M;4EZ@J"U.\*!7A6)+,JM&!"RO$0@5;%62Y+:BX-G) 6TD- B$Z[LH_#N;^F_
M)XVY]"-[G%;7'0MM,7E-5EE?+<16B[SX;O#E!EN<3<GW9."D;@6E%C\!WN09
M80%N,_.AL)KE,AD/Q:'\,DM=!%4EU%$9U4B/PV6,K\K+2II2P42I%&SD&ZZ@
M(E(*A0K@N!<F]9:.))!(HN=1-G\P%U=;@$;,NLLI-R'"M>ZC$V41$3A/CZ)\
M(G[(B?":P]N/;_QB[QKJ.&&F&&F&/B0QLD+V.<YJ.3CEBHUW\$547CGX^/C5
M*9/$BD35(FI2-43F.0'MH<?A;T/V.QQ,ILP.WWW&^V_&,5&ZS =OMSMPJVUM
MA*^JL3!LO#=93-&A1EO$D)[FRS*R!.TX1\\B^HKUE,D=(UKW\N^)7[=G0=;E
M?Q@_>&1T51/3=7Y?29G4T]/1S&"7-0BPU+Q+ K!JHJH:1@I8EV-M3N,=2Z-S
M& 9?+'4R)&T,K%6L%!4M^'>^KL6&VH[[WOBR5[NK2O&978'*/F^8VQ,-7C]+
M1R*;$^Q,5S(ISRATDA$KQVHI!I4CD;$/&]6-EE6.&3@/PO\ V=OB)\1NJ\HR
M2FZ>S#+Z:NG7YG,ZNAJ*:BHJ2+SU,S254<:R2+&?X:\%]-R5)(S>:=2T%)32
M-!.)IM)TQJ1>_J=]O8;7)VOP,CG2SL"W:#%BKG("/O;<7-9(KC+[N1O])*2]
MJ/@ &:]%>+75T:H-7AM<J##M1'ND)D)(G^^GPQ^&O3'PMZ/ROI/IFEA2FI(*
M<U->(]-3F56L*K+73NPUZIGURJC&\8<K>XQQJMJY:ZI>IE8DN7*J;^4.Q-K7
MV(!M[6Q)3(ZQ;FBMJI)'1+8 D!I(Q>',4B-T2.3Z<M5W/E%3QY1?C6]5U-'6
MT=31S"4Q54$M/*(9#')X<R-&^EU>,@Z6/#"XVWO;%"-@KHW^E@P[;@W'\_I<
M;7'(@7A/2)G5'F.,VEWN//9X]C-U67 -3$'60.]2EF;-71R3PU,4KXV=C6RH
MDK%F3P]_UUY>Z!_9'^&/P]ZTRSKO(I<]BSK+JNLJX$ED\2$/5P3P3+,[S2:T
MECJ)%/DN";@J;$9RJZBKZNF:ED?^$R"/2   JJ56QY&QL2-[6YQ6U1T94+*[
M#@,DSK(\EDPNZL;T:SEK\> L<@M[G=_:K?"^N<LE'K/1M+B_SG:NOGLB@X*T
M=@5W<" !A,95+6^P'S@,\SQ4L5,9E\)ECEEF4*(9H/X9D ,0*5#?PEUHI"L&
M-R,:H:0%=#,"NHO<( UR0=['<W4$DVYV'&*0MOL]-N[(,6O%S3-Z@2/!)MM2
MXQ&8C.AN*V&(91@MVQ$-QDCV5G:8[E]O&EJ @TXMBT(J.-XK# 3YTSN=3*7@
MCF$LJS'464F1)#*I.ED-M9\RG8K=2=@1)\@GE.HW5 @( ! L1>^]S8G>POR<
M+_H!Q[);_,,HN-W=U+&[S!;X$HBS*Q:Z8#CF0XYN-AYE#6176/GLJH1L;W-O
M ZZ6K0.,*<"H(B%6)MJ#;/WW-X7@K2PH@TD>&=!+J\;AB5(W#1*3?43=MR;6
ME&7('U^+(7%P&)U$ @BUVN1LQ'?@6],;[?[.W:>ZL\OL2<IW!@9EA&<%N"%M
M*>."G*RYALU8^JG2E2P2#"+3*-SK3%PC#20VD;JYC#:PV(4E4+5S#/ZP)$@C
MC'A:;,+!FTV#:B+$ZPD087&\2-N18#ET9))DDN;_ .:XW[@'N#>W;?C$R-L\
M$K]M<,J\.K'-D&KIK0N0AH\8JFV%W:FWEO82PQ/EX(L+:Q-.)EEF(*(((E(,
M**+EF(DQ4TS5$KRN"&>UP6+6LH  )WL+6 [ >FV+Y$T*%N2!L"0 ;>]N3[]\
M5YJEB?#3##3##3##3#&(O[5#!*C(P-D+J=(4M LIR&M@GE[$>M8?02$&P-<[
MM5W>77U<J0M55=[=7]J]BKKS_P#M"O)'TMETL2L'7,_#:= "4C=!=;7N0W8
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M7QC=,=F4%[7VMI@&T;[(/&,:SK/,D)W3W/Q^VVUS*HQ@P4L46M@J<A-QO/\
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M%$QB^F- R)J.<U%<Y>&)RKG.55\JJZZP    +   #T X';@8]O*JJ JJ%4
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MU:_47IV_D;N3_P#D=,,/4ZM?H+T[?_&;D_\ Y+3##U.K7_HO3M\?],W)^?\
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MCH&-=,,-,,-,,-,,-,,-,,-,,-,,-,,-,,-,,-,,-,,-,,-,,<.Q_P"3SO\
ML97_ ,A^F&(:XAB=1G/0EA.)7UNE!3WNR>+UY]TLL<"UD$],$U2V2S0D1-DB
M=VK'ZD$K'/[6.8Y'=JZ]U9/DE/TYG$W4E5#19"M%(,WJYYA!'!0-9:F0RE)
MK+&6T>4W?2!8FXD>E^=4TH5W\>Z:$)5FO>X!'%][^HO?8XQYR]"5!*V1LW4W
M:.&EC=ZG>)3-5XZHK7>H]V+M_K-16O5[N&\^5:G&O)*=3?LCL8S#\1<KEC+
M013U\D4\BJP4>++\@!4$L A^89U10@N%Q9GX:2K<ME]5Y#K+%F)MNUKB]MCZ
MV-S:^^,O&UV.85B^RVW6/QVE=:X5BV-X8W'KZR*'0(L&A@JY\7N5,D6 =95D
M%KS!YT2)'D)&]L;'.1B>Q\JDHY<MH9<OF-10R4L#4DS%6:2G\-5A8LJ1@WC5
M;$J&M;5O?%ZD0@40!"@A C"LVHBP'<[VWX[8JJVP';?*;&+,;?'L=N;!*B>O
MCOIXX"&OIR131Y&.(1ZC30H%9V4,),G>\<:Q/C'FBB,)27(8C_0^GZ[^OZ/7
M ;/;5B1UCJW#<>BCJYVE5TT$*N?'/&286LZDI,Z0J9QYQAD\A,DSIS9G$D+(
M0UDC6(_K^G^W]<;G8#M37W./J^BQ0&]K#;.SQV'D4,YAEK:D75B4&(DL3RG3
M7!!5IPZ$B."Q>\N%L4[4>UB&W&QV_/\ KS]\5.7B>)W-':495/5GT60SEF68
M3HF3!V)1Q7OBC']KE12)#4]XA$3VRQE-:1$]DK&O1@-A;]?WQ2TFR^UDH/W:
M_!L>4-!E$;$@?8YD*SUQ2^G,Q[2(YGDU%<5*2R9I,Q C)I9GRNDD>Q']6[?K
M]#OC[#;7X8)%FPAPL-B-N,^ 2^$/C!@A(J0Z2&DK<;%CKAJ]5JJZJ%F8''(Z
M<]C9B9'F2(C/38?K]?KU]<;1]F]KQ(JF*#"Z1B4=I+=ULCH7O(BM)U!68R<M
M\JE'22K65:R-/F)CD6LK.]B_=P7H,0M^N-O3[<CC'V)VOVR<57EE8ICK"ZJS
MN<E F]M$/)!86EFRYO+-W8^-)O<6\L%F8Z=)(&6""F*UA$8[V,+?7BW/ZW]\
M4]:["[1V@\O.)T]?&0M$\PBNCC$<37XZ55GAA.F;S[<*9])4N-E"<*20E:#,
M\KUP1)H6%OZW_7]/IBK!=M=O1PV"A8I00 .%4:. 0.&(9P<H%16K$QD7$:Q2
M5U%3"JK?ZT%<(U%XC158<>V_]?UV[XXH.TFV];$7#7X?1C0V#SGF1QB\QS-L
MHF0F0M8Z16PB2PM2- X48+%&KFPPQH]_<P_V]?U^>.12;8;?X[<Q9#28K45]
MT.,4&/8#PN]888V>2<N,9'R.C'6>21\;Y(6,D]JV()'H'!"/&Q']?KTQ7VF&
M&F&(Y=)/_P!GG;G_ +-D/_XNO],,2-TPPTPPTPPTPPTPPTPPTPPTPPTPPTPP
MTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPQ\"!AC(7CE
MCP%02(K9("(HYX7M7PK7QRM<QR*GA4<U473#'Q!K:ZLB]"M "KX.5=Z((L D
M7<OE5].".-G*JJJJ\<^=,+?K]?TQS=,,-,,-,,-,,-,,-,,-,,-,,-,,-,,-
M,,-,,-,,-,,-,,-,,<.Q_P"3SO\ L97_ ,A^F'&(1TCI4Z"<'6&(@A[=G<+D
M6 6&2<F6**OK996Q01-?),_TXW*V-C'.>Y$:C55437,/C3DV9]1?"CK_ "+)
M:&HS+-LWZ9S/+\MH:2-I*BHK*J$Q0)&J\'Q&#%F*HB@L[*H)%]E4B1U])*XO
M&DNMOHH8D_:U['FUN3B#Y6\N.S#EAI%E3UFBG&:UV,7B(BRL[6HY?9<M[G^'
M)XX_@FOB)3?LM?M%!1KZ&ZH>GCD821FF\BAIHVT.?%(4$J&+,=/8&X(QU:HZ
MGR?1(MR&D5HU<QR'?0P+&R[<@"]K<\;XR(83M]<9OTJ;282^=M-90T&T)%C)
M95X!\E>W%[#&;>T@=67E9;5A1L$%60/")95Q0CBT9'.UK6N<S[Y]/Q20Y%D\
M,J21RQ9;21R)+&\4JND2JRR1R*KHP(L595(],<@J-YYFY#R,RV(-U:V_/J#S
MO_3'37W3_N$*-)BN&Y"GX3GQC(JYTUCE!="+&;DD.8%7X1&W>,XU!AAP][?Y
M!6G#6L:U\^*"5C0Z:O=%"K#\O^OUSBC^O7]??'8D83O/BE9F%I'8$W5M'7U,
MV%+59=DY8K[8.TQ\BOQFPP6.H%I!:8^T$M9,GS!EDI[J*^-%,@97UL,HS#?;
M;^_KQ][$7%OOMCM<SV;RB[L@8(JC$,IC)V^P[#I\_P MM9VY?BUKCMI=G&Y9
M2@-QBT=8VQ3K,>Q%='D5"K+81BS2K UKM,!?W[_G?^G-O;%)_P""#J!&L[U\
M&7P%T)^/8X&VI_PD9A22D%5EACLMI64I%10LBP:"R!!OHB,B &N<B()M4D0P
M>!8AJYAOO]>WI^N?Y>_9YEMKU#7@5K64^3"5H;0G/J"!MR\IKK(LTN3;LAP%
MH<+BBG#5]4_'\J':;7'Q6%T-<N5SJ5UB:R)A;UWM]@+7M8??^0QU_P#@CZC)
M;C*2I<^K(X;((:>H(DRO)K#[OR)F(V52I%-5EU*5N-U(UP<PB*$<:QM)_2AL
M+"RL"X71SL/UM^O[V.]QCG0;/[V2CD%KF]O2E15Q -!2#;J9;>P4L-A%FD!T
M1N175$^7);!KK3'#:W(;_'[ VGF"; &/)%4#..86^FXM_MMQ;FXQV VVF\X^
M#8P$=+BN2Y>/B&Y> 73[C,,G?"+2Y[84I5;<,R2RH[^YR&QH!<?!$,".% ^]
MO<S20V8*"PLG86^NW8'T[?K[XZ2]V+W=^Y;.IJ<V/M0[0DYI50=N-EN/BJ"X
MO< 6EAKCZ^KM)Z$"JJKG""#:"J%AK+Z7&I*JQ5PLLQ9K#OQ^MNWM;_:]]MN,
M[(;X0W5B)DVXQ7X-((H8H1L?S3*JTQM/7.B5H((@PXD>-NK0H6U+W4%B*W(F
M.?86[7%+'Z#$<=1DNSW5'88R8&!N<*Z^EL R@BX,SR7'?8]M;<-DD0JNHS4)
M'$MV8T1'3F D 'BQ7$1'I>[5DK#$BMI:[+H&Y>=E1MM/#-E%E7XJ-;(3"1'B
MU:67(&5.(5Q(THBPL+(2(]S62VM#6T!CT[71M:Q"W!/-NWZW]O3?%X-,1PTP
MQ''I)_\ L\[<_P#9LA__ !=D'/\ I_NFA%ML,2.TPPTPPTPPTPPTPPTPPTPP
MTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPP
MTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPQLEC;+'
M)$]%5DK'QO1%X56O:K7(BIY1>%7RGQIASB-]=TNX544H>.5>;;TUU!7AQ5X%
M,'N]F@]8$ .U(QP10XK%L$(D$;4CA@8Q(XXT1C6HUK42)8GBRFX-PH)N#?\
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MV(6_7'Z_7H,$Z?*5/_67OS_WTYWY\\^?^-/]W[::O9>+?A']N^(X?XOE*O\
MZS-^O^^G._\ ZIY_@OZ_PTU;6LOUTB_],0M;#_%\I>.$W,WZ1>>>?\-.=*O/
M*?1UHYOTXX5JI^VFKV7ZV'_C^7\\+#]?K];^IQ<W L'H=M\1I,(QB,N*BQ\>
M4:O8>:18F]DY1!LSR3BG/()FE)*FD?+*Y7*K^/A$34"23<XCBK]0PPTPPTPP
7TPPTPPTPPTPPTPPTPPTPPTPPTPQ__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g401831g01b06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g401831g01b06.jpg
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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=8FQZ4?N2$83*B#T223L.')?"7AD8JNNB>4TG_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g401831g01w46.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g401831g01w46.jpg
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M 0$! 0$! 0$! 0$! 0$! ?_  !$( 5X"8 ,!$0 "$0$#$0'_Q  ?  $  @,
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M0 "2M_GG@JP36;,T5>M7BDGL6)Y&10P0Q-+Y99I9"UD<4;&N>^1[FM8T%SB
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M7:YM>L["I@ZUF/LX2]3@H2;0I"_J$L*ER3P>R$G!L=MM:9K\<E!B%8P_W3)
MUIEMU2,CA]&9/4%2U:PUK&WI:<';V,?'//'D6CEYN1E>>K$)G$@QM=#))"Z7
M:-LKG%H. U5Q:T_HC*X[&ZJQFH<-7RUSS.CG9Z5*? R.[0,,LM^GDK+ZT;6D
M3/CLP0VHZ^\TE9K&O+=HVG6GVFWV'&WF7FT.LO-+2XTZTXG"VW&W$9RA;:T9
MPI"TYRE2<X4G.<9QGFI$%I+7 M<TD.:0000=B"#U!!Z$'J"NH-<U[6O8YKV/
M:',>TAS7-< 6N:X$AS7 @@@D$$$'940,WW%*;2(:@1K':$2WB0(RTE<S(E&0
M$@UDQ/>&#S:C3-\?ARX[\V+-83#'*FELK@3TI'*7#?2C89=.OBQ$>;.6Q+Z4
MUF:G#R/R!L26X(VRRP"N['-D8YL;XW&241P[2QDR@2-WT2MKV*UJB?2 TQJB
M'+U*%7*VC-%@A1@QER=]:O=-UF>DAEC?/%/&(:QFM\T$[17)AD#;[YKJWU:Y
M;_[,U#K:*B6/8E4O[M4FD(PEFTUH97S I)67'D2F1\EA5GAF8;JVHDCV2)8E
MB"ZXWEEB6ZZI"%;/IO2EW5,SZN,N8X7&1OF=4M36()C"QS6.D8[S5\$@!>W=
MK)G2 'F<P-!(YSK_ (EXCAO4AR.H<3GWXJ:Q%49E,;6Q]RJ+<L<DK*\K'92&
M["]S(I-I):C('.;R,F<XAIN:EW #L"HUJ\5:9@A7;8$&V -+PGV*='E(K4N/
M\S7E2F)+:'<-2HR\_+&DH=CNX2XVM.,'>I6,;=M8^W&8K5*Q+6G9W\LL+W1O
MV/<YI+=V/'HO:0YI((*W/"Y>AJ#$8W.8N86,=EJ5;(4YMMB^O:B;-'SMW)CD
M:UW++&[THI&OC> YI Q6S]DU74%!M&R;M+=A5FI#5$B;L=I+\MW"G6HL2#!8
M6XRB00)3I$8? 86\RAZ9)8;6ZVE65I]L3B[F;R53%4&"2W=E$40<2UC>A>^2
M1P#BV**-KY)'!KBUC'$ D;&TU/J3%:0P&4U)FIG0XS$UC9LNC:'ROW>V*&""
M,N8)+%F>2*O7C<]C7S2L:Y[&DN$*T7OFO]@JK&O5*JUV'4P@HBV*L=HA5\9$
M+2!1#(R<Q!@P[*3-*^&:U+8^J?%L#UN09C2)F7FTM.7^H=.V=-7'XZ_;H27X
MNR,U6I)9E?"V:(31NDD?5BK^E&YCN1LSI )&$L#22,+H;7F/X@8J+.X7%9NM
MAK!L-J9'*0X^M%;DJV#5GC@@AR5JZ>29LK.UDJQURZ"9@F+VAKKQYKZWA.$6
MO_8_L$'ZW:\G[$.T^X6P9 S':?36(<-46 ].FQ!@]9LF0F1(XN'+)3HD)#S3
M<^3\KZ?C@O8YLFE]-SZIR<6+K7:5.:0.<TVY'ATC8XWRRB"*)CWRR,BC?(6D
MQLY6G>0+0.(W$"GPXT_/J&_A\QEJL!C9(,7# 8J[YYX:U<W;-B>&.M#-9GBA
M:]C9Y>9_HP/7O[ W),I>CL[E$:]M%\DKKU8/QJ+5$9GGY*+(L5C+;:F8K[BV
M1+)-4LA*8@/J1#AR)&(WL2K*/+&8-E_/C!SY.GCF><VJ[\A=/9UF&J)CN[=S
M0'3&+DB:Z1H+WM:7[D;W&H-8S871!UC4T_E,](<?C+\6"Q33/?E;DG506M+(
MI'.9499,UB6."0MAADD$7*#M;->*NG0 ,X^+(@WC(<85>"&&4QRP=TC"8EN"
MRC"5+2P1'K>S$FLI6I+<EEU&%*PGSG#V86U[-B!LT5AL$\L+;$#N:&=L4CF"
M:%Q YHI0WGC=L-V.!V6UX^TZ]0HWGU;-%]RG6M/I7&".W3=8A9,ZK:C!(CLU
MR\Q3L!(9*QS=SMNLQSP5XO$[(88RUA]YIG+[J8[&'7$-Y>?6E2TLM86K'R.J
M2A:DMH]RU)0K.$YPG.<5!KG;\K7.Y6ESM@3RM&V[CMW-&XW)Z#<*A\C&<@>]
MC#(\1LYW!O.\@D,9N1S/(:XAHW) ) V!7EY2JTX1.$6L.O.SX38N^;YH:'1[
ME6S.OJI&LY8I;(\$7B8B=)"I@-#A+$J=+S$F0#D2>U,G.P9"<85'=&MN>Y2-
MLR6D[&,TYCM1OR%&U7R5Q].&&FZ24L,;+!D=+*YD; ]DE=\99&)&GHX2D=#S
M+3W$ZEJ+7F=T)#@\SCKNG\5%E+=K+1P51,V>6DV!M:K'+/,8IH+T4[9IW02#
MK&^LUP)&S$EU;$=]YJ,],<99==;B1E1TR)2VT*6B,PJ6_%B)>?5C#32I,F-'
MPM2<O/LMX4XG56@.<UI<U@<X O<'%K 3L7.#&O>6M'4AC'.V!Y6N.P/2I'.9
M'(]L;YG,8YS8HS&))7-:2(XS+)%$'O(#6F66.,.(+Y&-W<-2&^X]0D;5LNDH
M>K]SD-G5$:DR>J\"OU"6]#$.-AWFB:)[5Z4+E0WFCX=QMR)->RI,]K&4X4AY
M+>Y.T1=9AZN?DRV#CQ-V8UZ]N2S=8U\X,X=$8CC^V8]IK3@A\;=NS/78M)Y*
MWC%B)-59+1,.E]9V-38BL+E_&5\?AY7Q4W-IO99;.W.^:RPO9?IN:Z*9Y(G:
M" 6O#9,3[,0*]+KC-IT[O.KP++:JW3XQ\O4 +@$<6M9F& #K-SQ-N**%0'B<
M^+'5,D,8;^1YMEO#LAUEERTATM):9:=3S> MR5:=J\^O#=L-L2PTX)+,X@CG
MI0B:1L4;W!C7;[-+CLT.<,E9XEP8^7',RFCM<XNODLKC</'?MXC'NH5K>5N0
MT*;KT]3,6C5KOLSQ1F:1G+S/:QO-(]C';+\U9=+6L&WNSX346S=2:N(T:YE"
M.W;F(IX6RM1X,&H1'I\T1$FNJ)R)3DV=+&(-PGUPH@O+$CR^Q@DR_&?2WMF%
MTG8S6*S66BR%&&+"T)KUBJYTDEU[8V3/C:(FL$;&2F![1(^;F;Z+NR<US2>9
M:NXG4=):FTGI>QA,S9LZMS%3$4LBV."#$1/GFJ13O-F25T\\M5MR![H8:IC?
MNZ/SECXWALTVKMTIK6S:FKT#6-WOL?9MQ152!RJ0LRAE#CK5"1]]LSF&G<,0
M<8F.2\Y=7%9P/%F)2I:7(;4:58X?"Q96IF;,F6Q^.=B:)N1U[DG)-D7#G_D]
M0;CFD] ,Z![NUE@8&$/+F9C56KK6F\GI/'U],YO/1ZFS Q5B[BH#+6P49,(\
M^R;@QP9 !,Z4\SHF"O5N2F4.A;'+<STAB,A+DAYIAM3L>.E;SB&D*?E/MQ8K
M*5+4E.79,EYF/';QGWO/NMLMI4XM*<X)K7..S6EQ <XAH)(:QI>]VPWZ-:TN
M<>YK02=@"5N3Y&1@.D>R-I?'&'/<&@OED;%$P%Q +Y)7LCC;WOD<UC07. -/
M[WVN2TQ0'[L)UQ<=IRV2X<7BK4>(Y-,Y;*2OIW"*VF8\QY,2)C&$J4U$?RN4
M]$87\#3SDIC-Z>P\6=R3:$V4HXACH9YO/,@\1P PLYQ$'.<QO._P!>W9K7N'
M,6ACM1UUJNSHW /S=33F8U3*RY3J_1>$A=-<Y;4O9NL.:V.5XAA[B6Q/+I7Q
M1N[-CW2QV_&>S(C1Y"F7HV7V&GLQY*4HD,9=;2O++Z$+<0EYK*O8ZE#BTI6E
M6$K5C&%9PKV\KG-YFNY7%O,TDM=L2.9I(!+3MN"0"01N MNB>9(XY"Q\9>QC
MS'( )(RYH<62!I< ]F_*X!S@' @$CJO-RE5IPB<(G"+6;?W:>E=;619#9%2V
M%]@-E6P8>R5X77#(H@7<@9(8'(93:HYF)(^%N4E&"0F$B2N%+S#7)9:PZO:]
M.:0OZI=-%B[F-\YKPFQ/5LRV8)HH!((NU+C4= ]O,6;]E-(6B1G.&D[#FFON
M*6&X;LJV-1XC4)H7K3:-/)8ZMC;E2Q<? ; K!GTK'<ADY&RAOG-2!LKH93"Z
M1C><X$MW-U?3B &%M6L[6TS$LLI$ -8=G4*:'J\F>XG*T0G[ *E&QPV1AM*G
M7DE'H28L=*Y4Q<>,VX\BXAT-EKT5F3#VL/G'U&&2>MB<C'/<9&T[&1M:9D$L
MK=^C3"V3G<0U@<XAIL+7&33&'L4(=58S56C8<G*V"ED-38&:GBY)W#F;#)D*
MDUZO6DY07/%I\ B8'22F.-KGC;)A]F2RS)C/-2(\AIM]A]AQ#K+[+J,.-/,N
MMY4AQIQ"DK;<0I2%H5A2<YQG&>::YKFN<US2US26N:X$.:X'8M<#L000001N
M#T*ZPQ[)6,DC>V2.1K7QR,<'L>QX#F/8YI+7-<TAS7-)#@002"O+R%4G")PB
M<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"
M)PB<(G")PBY*:2-Y[&>HENRWV=62 #K4-)T;6H21GY((4TV=<K!*QQV%>YE<
MZ=(&6B7]7EOZCQ/%XP[X#P/B[-GZ_P#!?AE@*50=G9U7+%D,M8;TDGK^;BW#
M5<[HX11LFJ-+-^7>.8[?IY-_DW15W^,7RA]:Y?)GSBAPVK6<'IJE)Z4%.XVZ
M[&6LC&P[L=//+6R<W:EO: 6*NSOY)!R=5#IT76Q<HR9?<BC8:4KE2&XDR;EE
M"E81\BV($>5)^)&<X4ZYAG+;*,*<=4AM*E8X_7KRVIF00-#Y9"0QI>R/F(&^
MP=(YC=SX#FW<>@!) 7U/>O5<;5EN7)'15H0#+(V&:<L:2!S&.O'+)RC?=S@P
MM8W=SRUH)&O^D]@]>[-:=BOZ7O02U$;O8HUSMT&M?-,'0CV:Z- /$GW8T)$0
M<^:@UN,_(S,?0LD18ER6\NR7G_=LF>QNI:E3%MSN/L4XJ%5]&E);VCEDK>=2
MV6Q-#Y"^5L$EM[6]FTB*)T;#RM:U:!HK4'#[)Y743]&9REE+&;R,>9R\&-$D
MU>"_]'5L>^S(^. 15GW8,;$^3MI&NL6632MYI9'[Z.Z6O5(H?J&=S"-XN-5I
M@^2&K;,>=:[ )KL.0\W&K3SK3$DO+ALNNMM)4ZMMM:EI;QE:L83C.>= SV/O
MY'AGH2+'T;EZ1L]QSHZ=::T]K3)::"YD#'N +N@) !/0=5Q#16<PF"\H/C+8
MS>8Q>&KR5,<R.?*Y"ICX9'MCQSWM9);EA8]S6 O<UI)#07$;=5BC463VB]07
M4VU=)#R$S66G0XR)=-PQH$N#5+#+#D++.F!01EUEABR?4LEV*RE<!<E3S<@C
M(\*!PV9KOM ]FD>&N:P^?EC9ELY/*^A@WR,DN5631U&,L6(&N<ZIR&$VR)0S
M8MB;_/R%@M+L,O%#R@-)ZJT57L3:9T?3K19G5\<$L&)R$M.SDIYJ>/N/8QF2
M[5MMF,#J[I"]K[,@!HPLG?-/52OA^+3=.:1!$'Q3.\KV\./RXRU(<D@Z[*KD
M?(IW.,^,Q)1>TB)\AO\ &7OM3;"\JCN2&W+#A!CJS[V<U!8B;,[3V.$U9CP"
M&V+++3A,.GUV0TYXVG^CVQ</2#2,UY4V>OQ8;1VB:-B2JS7&=?6ORQ.+724<
M?+CHS5=MWPRV\I4GD;_3\T:P[L<]KNH%;KH>HUX'5:]!9& :X)'@PP^.G"&8
M0P7%:A0HS:<8QCVLQV6T>?'E6<94K.59SGG);5F>[9L7+,CI;%J:6Q/*\DND
MEF>9)'DG<[N<XGX+Z=QV/IXG'TL7CX&5J..J5Z5.O&-F0UJL3888V@>#(V-;
MOWG;<]25RB]28Q)TCLWK%V9JJE0+-7;,5JEB=C?Y-RQU3'T1;  AE/C+\%R"
MY:8*FUYSG"#3BV\H=99<;['PL@9G\3JW2EP"6K:J0W:K7]15N#M(?.8@>C9!
M(*D@(\8 #NUS@?E3RD;DNB=3<,>)>*W@R6-R=O%9!\9Y79'%?H+?F%C;8O@=
M [*0%IZ@77%I#F,<W9GNOK2M[F@=?=9VKZK]/W/>+HR8] >S'FQ5?T+;AEP"
M$-WQE'U(\A'B3V$/H=C/.1TLRV'XSCK*]3T%E;6"DU+EJ?(+-'3XF8V1O,QX
M^GL&R2*1O0\DL;GQN+2'M#B6.:\!PZ7QITUC=90</],Y7M?H_,ZX?6F?7?V<
MT1_@7K":"Q"[8M[2O8CBGC#VOC>Z,,E8^-SF.H7J5N"Z=?MDN](.Q,_*B S"
M?Z![_+RMH;<*NZMU(FO-RI"U?Z;;+C5::=?=<B2X\ZEN/8E#P\61L>L\)0U+
MBAK_ $Q'M%+_ 'Q8QFQEHW&@&>R6- Z N#K3@UH>QS+X')+.]NA\)M7YK0&I
M'\$N(=C>Q6Y?X"9^4N;7S&+>7"ICFRR$]2QCF8YCWN=#-'/A7/[:O3BDV\#_
M .N5L+_Y:=0__<_=7-*G_O&QG^56;_V3@%UNG_AEU#_^&NDO_P"SZR6SG-37
M3EJ!W,JH6]4O5=+LD7$X!:^P&KJZ9B9SA.7QIB43@3$(7XSEIWX'UY9>3CWL
MNX0ZC.%H3G&[:%N3X^_E[]5_9V:>F\Q:@?\ XLL$<4D9(\1S-&X[B-P>A7(N
M,F*I9S"Z7PV1B$]#*Z^TOC[D1V!?6N36*\S6D@\KNSD=R/ W8[9PZ@+7CT[K
M8;UV7W!TROTQ3EITA9212FNO^6U&*"9G(D+DP65*4M,)$TB/L,?WY]^(ESBL
MX3A,56$;-Q-IU\G#A-=8Z/EJ:@J117PWJ(,E7C+.21PV':&.*6L[;H7T7N[W
M[GGGD]96]IZWJ_@WGI2[)Z(R5FUAGR;M-S 7)P\RPL))$#9[%>_'OU[+,Q,
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MW;=K5;:T+3G*5)6E25(RG.<*QG&<9SC..7FAFN;Q4K-<"'-RFH YI!!!%+*
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MMM[3DEJQQ5N02Q.@D$<<#(XHP^)[V$,8T;.)VW.ZRES XG)8IV$R53Z3Q;S
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M;D5@=ES+-4H*F4M39".TZ"U)YQ5EKF,-D/5TM>3G!Y27$,[1KN:(!LG92->
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M9>]L39"L7Q.T!#Q IX32MNW)5J\\=FU- &ME?%0 )9&YX>(S(_D!<62$,Y@
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M^ZE1UB=;.66!5E.R)=:K\XDM]JNB2LE\T@-&ARC/TQ.7*@Q8GE,TCI".7?8
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MJ3KELJ/2KX^L2QPQ>-+HXMH08H1-(R&"(L@K5JT$-:LWM=];+6*W<P)2K6\
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M'N:X$#[ES[4G"GAUJZQ)<U!I'$WKLIWFO,BDH7YSW SW<=+4M3$#H#+,\@=
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MMGP(]H^&_P U'B#[#\=ODI%R%*<(G")PB<(G")PB<(G")PB<(G"*.S1$F39
M1E#C"8PN$9C/MK4YA]:R.(6&<LIPVIM2$?3+^7*W$9Q[D>Q*_.?;/@1[1\-_
MFH\0?81]^WR4BY"E.$3A$X1.$7H%!8XV-GAR\-@@+*1)$ A!E-X=CRX<II3,
MB.\WG\*;=:6I"L?C/C/G&<9QC.+')XS'YK'7L1EJ<&0QF3J6*.0HVHQ+7MT[
M43H;%>:-W1T<L3W,<.AV.X(.Q7M7L3U)X;-:5\%BO*R:&:-Q;)%+&X/8]CAU
M#FN (/K"U9T;U2K6G;I:;AF8DY(?F2(M'Q(;RIZNU^4TE4C$A;B<)=-NJ==&
M.36<8QD;'^1M3:BLR*Q\P\$_):T[PAUEJ?5QMMS=B:W/5T3V\;G3:>P%J)KK
M L/>T-ES4KI)<:^Y"-CC:_:,=&[*W*D'0=6\1+^I\5CL9V1J,9$R3+<A ;>N
MQN(86 =6U6AK;#8G'^?DV<'"O%([;7GU8N<)PB<(G")PB<(G")PB<(G")PB<
M(G")PB<(G"*I[E_$W3G]\O?\I/<J'U7?9_%4GZS?M?@K8Y2JDX1.$7!CU*_3
MN[X>H74"6FI^[^NU1TR.W*]LNHQR%4N,FZ,0PXLV#IH]TD'BQH+#,8/9S*;!
M'G,&Y<TOAB3"+Q(#*8CNOX:+4<=S-NSEK'V*4M\NP4=.-[)J^/\ TFT=PNC8
M'2\IA!V=,1*V=W:F-T36;KJJSH2?&:29I#'9NEEJ^%;'K*;*SQ35;V;_ $/-
M/BVQSS.CK<XLD LK-,#ZC#7;/'8DD^<OU2>Z?=G1%)LWI [D)]?;AKG6>NNO
M-1<N>O*-<PMAG@:77==7ND_&4/W*6Q]R:;#@X=AD+KK;,YU!',*/#0^PMG8%
MI2I[K_ZVN[=8Z*UQU;O]"HUJT9JD&B!4F:N/(U_8:R4.9,?'2C5F(G3 :;$;
M9+F&Y4:-6H+KSCD%;;[*8SJ9'#?*!X1W>-&AJVD:.:JX*:#4-#-F[;J2W8G1
MTZ>2JNKB*&:!X>]U]KP\O+0(W M)<"-OT5J:+2F8?E):DEUKZ4]00QRMA<'2
MR02!_.YCP0T0D%NVY+@=^FQG=N]>';X6C7?7>AM9T^KUW;-4/U'9B]DL3;D3
MD#2@><#@N5*4"+U5@+*BP3I_,EPC%,MOR'1KC;32(C[<K4_)NX 9'@5%K&/(
M:DI:A_A/)@7Q&GCYZ/FGT.W,->).WL3]KV_TFSDY>3D[%V_-SCER6O-:PZQ=
MBW0T):/T>VX'"6=D_:^=&J06\D<?+R>;G????F&VVQW]WT1^\_=*DWZI>G]U
M<FZ!KT+>VS;]L?\ 5>Y:/<;7D598&HXTPHAQRJW( [@5( :E@1845L<_(:*3
M'Y#TI<9S#4?Z>7/EW'Z,^B[W/Z@C-HZO;[/Z1_H6[!DZPYNU56IEXSL^2#JT
M:QLQA%&-$I<((':+?J.7$.8)P"&)HY2HN%MLKD,R<#J;#S9_"V\1#?EQWGIK
MQ6+, !D-/SB)UV!NX.QL51-"""T<SP).:(R1OW/A_JFIHK5>-U/;PU;/?1#;
MMBG0MO>R 93S&PS$W'EIZBCDG5;;FEKB60N[+L['8S1=ZNM>O-CZHU\[KZ_%
M*45'54U)#:V=I8I\1AO7$"'!C <6:,N-#C9M<EYJ?.-K@M/QER967,3YKBUN
M)MM)XO*X7%G%Y.;'SQ4IW08IV/A= !BHHXF5O.V%D;//7N;+)8,8<PO?OVLA
M)(R'$O4>F]6:A;J'3]3-U+.5I1W=2LS5N.YS:DL33RY XN5LLTOT3&Q\$%%M
MAT<HBB#?-X&M#3L'S9USQ.$45+3YD>T5* R^I$0@BP9F,X2C*7\PX4=V-E2E
M)RM/Q.+4K'L4GSG/A7NQXQR? ^\?G\E2?K-_;^"E7(52<(G")PB<(G")PB<(
MG")PB<(G"**E9\R/::G 9?4B(0:L*IC.$HRE_,.'$<C94I2<K3\2W%JQ[%)\
MY5G"O=CQC$^!]X_/Y*DD[M'KWW_8%*N0JDX1.$3A$X1.$3A$X1.$3A$X1.$4
M4)SYC%MJX]I]2(<^%879;&$HREYR&V.5&4I64Y6G+67G<X]BDXS[\^["O&/$
M^!]X_/Y*/$>X_E\U*^0I3A$X1.$3A$X1.$3A$X1.$3A$X110B0F,VZM#FGU(
MA31Q]Z4QA*,I>=B8'9C+4K*<K3EKYG?&$*3C/OS[L*\8\3X'WC\_DH\1[C^7
MS4KY"E.$3A%\J'>;LYO?;'KV=*NI&DMEV:N5#25GUG8;W5PA%] 0F<("#NR]
MK$#HQA:(9=:^OL]%:C-E&Y.!+!$YB'F,LM.PX1;_ /JW^J7<N@EHZNZNU%KT
M%LK9F^[RRZ4&%Y,O+PVA ;54!4P2(&Q'8?RV78SYV?7:T7ESOH0;PLE,>&DG
MOIDL$7:6=/@BX,PF3F11PT=$D3R!"?(9B08$&(RN1+F39<A;<>+%BL-N/R)#
M[B&6&6UNN+2A*E8(JNTCOK3O9*@P]HZ*V'7-FT">2+AXUEK$M4F%]T!3G1Y0
M?(;>;8F0Y<:0UAS#$R,PX_"?A$HR7A\^%*?(M;-$^H/I#M=G95>ZR3%[)V3K
M'7C5NL=++/JJ$4+:IYRY5<-K2T6)V(7: V258:,78(RHHTV/&!I(BR,**#"P
M[,HBTY],[U<A7>3L#VBT'=*:5U#?=>61)[6>O[<W"A6MNBA!8&H;"JAUJ(Z\
MS)M]$V5!+$2BOFQ(DA[=!:9A,-5LE\)%U>I&Z]>;"/7VM5PPM9;6]R<H-F9(
M1'QK2;0TU(>6-%R9:6V"[B6XDE2L0%O+0EE2EH2G*5*PN.U!B\I9R52I.3-B
MKYQEMLK'0M\\:'.,,+W@-G(#'D]D7$<IW &V^VYS1&HM/8_ 9/)4VMJ:EPK=
M08Q]>:.R\XISXV"S:BA+I*;2Z6, V&L:XO :XG<"U^9I:DG")PB<(G")PB<(
MG")PB<(G")PB<(JGN7\3=.?WR]_RD]RH?5=]G\52?K-^U^"MCE*J3A$X1.$7
MP0^KKMBD:J]6?O=^K(LF$>V'UAHFM]8;#@Q%S)NIMAG-9:6)Q;DRB-Y*Q(Y6
ML [3KDJ7 -R+ &#WL@3&0R*XS@Z81:V:Y[G]5:%1KYK^7:=NW=RT%IB0MXV"
M#B6J8*EF>D3FC)9NTUR.Q7A6Q*-7]GS)(P#4S:(!J331]:V 5^HMP5VL$B*$
M2N[NE!Q:X6>BL3ZP^8=Z4S='595<4H7UEL77:M"(VT;$*QB-.&2OU:4$F@85
ML% GN;$"WXU9-G1P1QB2*(D6S'IF;IU]OGUE>B=\H-'7K-^94-JYV11!SB$T
M,+MN?K+L4;O,_5HY*E* 4&V/E8-O'5=>,-U,F<+5<<IX*&%ON$7^@APB<(G"
M)PBQ,LK%B%1 MUIU<DNDBJ(ZA#>6FL#V&GW\/+4XEQ'R(<3AOXT.>Y6,X7[,
M>,Y>&_N^._R4$C<#U[[?L66X4IPB<(G")PB<(G")PB<(G")PB<(L3+*Q8A40
M*=:=7)+((JBNH0WEIK YEEZ1AY:G$N(RXAU.&_C;<]RL9POV8QC.7AO[OCO\
ME&_4#U[_  66X4IPB<(G")PB<(G")PB<(G")PB<(L3**Q8Q<4)<:=5+*,$7X
MSJ4-Y::0.3&5(2ZM3B7$*<Q);^/#;;F%92KWY1X3[GAO[OCO\D\=O?\ #;YK
M+<(G")PB<(G")PB<(G")PB<(G")PBQ,DK%C&!@AQIU4LG&(2(SR4-Y9;;'XC
M9?2ZM3B74J<^I;^/#;:TJ]JO?E'A/EX;^[X[_)/';W_#;YK+<(G"*BM_Z.:W
MU50=8<O]YUTH%;A%N8,T(F@82DOB69K+4"6IQMUMZ)E4WZQG"D^8Y*)!F82Y
M]/EES7=2Z>9J2I5J/R.1Q@JWZ]\38V?L)9# )&B&1VQW8>TYVD=62LCD&_+L
M=YT#KB30>3R.2BP."U [(86[AC5S],W*U=MQT+C:AC#V;3-[$1/!.TM:6> E
MO:<[>!5?]'CN]U7[@FN]G7OL7IGMAM\S!L,8R,[;52WTDS/:L0^&'(R!]IUH
M8+#GK9]AA8"C"TH77@D>',E1Y(G+*DK1L2T9:.]IJ[W=MWJC]9.ZO>SI!MRC
M:'T!BC-DF- LM=GJZ,:UI.LUZ"63$NC?&N$*-;.)P"):-8H8\D+ 8^D=28E0
M(\:61?3IVEMHO<7IS=D+S0HQLF&VATLW'9Z;%E@# FPDAMQT?9"=?9>K)*'%
M.P2LV,0B)^SS(#)-F2[B([&1(QEO!%P+_P"S8=E^N.E>E6WZSN3L!I+4MD(]
MH[6='U_9FU:)0SD\)(U/IL>P9AB;2>%3Y0IZ>-(PF2+$=<1R7 FQD/*>BOH;
M(H3_ -FAF0R/9WU*2 ^5&GP)Y:D3(,Z&^U*AS(<K8.WGXTJ+)86MF1&D,K0\
MP^RM;3S2TN-K4A6,Y(HAVHT1M#<7K,,;W](X27G[5UE9/I>T%WLU4-4[KO0-
MS@'9%4N(FR7 HT*39<7&I..#-DU"I0"!LG)29+@9!HH;(NAB+N5U8]+QC6A4
M[MCLYNJT]C.P-QVV*W@7/P65:^UU3[E!D2BS@BATT/(SE -TW/=D3Y!*0W@J
MR-#8C!*_A)5@II]C0NFK-Z#(R8Z..Y6RQS,5BM)8KRR773><O?<<V9PMEUDN
MD'.UHCCY*\89$UP?U"AQBU_CL/<P,&=GGQ60TT-*V*60AIWJ]?$LK&A'!BHY
M*K3C&LQX9 \0O>9Y^UNSNDLR,=%UGYN"Y>G")PB<(G")PB<(G")PB<(G")PB
M<(JGN7\3=.?WR]_RD]RH?5=]G\52?K-^U^"MCE*J3A$X1.$566?1FDKJ9DV.
MY:=U9;;#-1';F';/KZI'C,M$2.W$BHDE"HB7.?1&BLLQHZ77UX9CM-LMX2VA
M*<$6 _P8>M7^SSHW_P"DM!_Z?X1/\&'K5_L\Z-_^DM!_Z?X19NN:&T;3S4*R
M5'3.J*M8AN7U#CU<UW4 AH>J3&>A250B@P/%G1<R(<F1$?RP^WEV,^\PY[FG
M5H416OPB<(G")PBQ$P0U,+!RRW7$.ADD4LM)PG+;V"3#3#GR9SCW8^-+6%(]
MN<><YS[O./''AM[OAO\ -1MU!]6_Q67X4IPB<(G")PB<(G")PB<(G")PB<(L
M1,$,S"P<NMUQ#H9!)#+2<)^-[!)EEAS+N<XRK&6TLX4CVYQYSG/N\X\<>&WN
M^&_S4;=0?5O\5E^%*<(G")PB<(G")PB<(G")PB<(G"+$2@[,HP),K=<2\)8)
M,-,IPGXW4DTQDN*<SG&58RWB*G*/;G&,Y4KW>?QQX;>[X;_-/'?W_';Y++\(
MG")PB<(G")PB<(G")PB<(G")PBQ$D.S),BS*G7$O"XQ&,TRG"?B=21Q&PXIS
M.<95A3?TR?9A.<8S[E>[S^./#;W?#?YJ-NH/O^/_ /P++\*4X1.$3A$X1>D2
M&CS Z>(+0HI,45A2AI,=.8:E02 ^<PY%FPID5]*V9,67&=<8D,/(6T\RXMMQ
M*D*SC)%IE_BU?3Q_V'.IO_\ ;_J[_ICA%?.H.O6A^OH\R)T3IK6&G!=BF1R)
M\=K&C5NCPC4^(PJ-%FE(U<'#F9\J-'6MAA^2AQUII2FT*2G.<<(K:8C1HJ7$
MQH[$=+S[TEU+#3;*79,AS+LB0YAM*<+??=4IQYU7EQUQ65K4I6<YX1>?A$X1
M.$3A$X1.$3A$X1.$3A$X1.$3A$X15/<OXFZ<_OE[_E)[E0^J[[/XJD_6;]K\
M%;'*54G")PB<(G")PB<(G")PB<(G")PBBA:),>M51ELLNKB0T6'$QY&,_$SF
M3!C(C8=SY\8^5Q*DM^<9\JQGD^!]X_/YJDCTF^S??[E*^0JDX1.$3A$X1.$3
MA$X1.$3A$X1.$43+1)CUJJ,MEEU<2&U8L3'DXS\3&9,.(B-AW/GQC+JT+2WY
MQGSE.?')\#Z]Q^>_Y*#ONWU==_NZ;J6<A2G")PB<(G")PB<(G")PB<(G")PB
MB9.),=MU6F-,NKA1(-B;EO)QGXF7)+8W$9+N?/C"G<MNX;\XSYRE7CQR? ^O
M<?GO^2CQ'N/Q(^14LY"E.$3A$X1.$3A$X1.$3A$X1.$3A%$R,28Y;ZS,:9=5
M"BCK U+>3C/Q-.R,#OIDNY\^/<YEMWX_.,_Z*O'CD^!]>X_/?\E&W4'U _';
M_BI9R%*<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(JG
MN7\3=.?WR]_RD]RH?5=]G\52?K-^U^"MCE*J3A$X1.$3A$X1.$3A$X1.$3A$
MX18 @7>AGJ\)0TVMDRDPIYU65?(SD;%9?;^+&,X3GY%.Y2OWXS^,8]OC/GD[
M=-_:!]^_R4$]0/7O\ L_R%*<(G")PB<(G")PB<(G")PB<(G"+ $"[T,]7A"&
MFULF$&%O.JRKY&LC8T=]O#6,9PG/R*>SA?OQGQC&/;XSYSR=NF_M ^_?Y*"=
MB!Z]_@L_R%*<(G")PB<(G")PB<(G")PB<(G"*/SC#T6P@0R&FE,EHIE]UU65
M?*TH8B$IM+>,9PC*7,RE87[L9SCVI]N<?GD[=-_:!]^_R4;]=O83]VWS4@Y"
ME.$3A$X1.$3A$X1.$3A$X1.$3A%'YIAZ-8@@9+32F2D,O)=>5E7RM*'8AY;2
MWC&<(RESZE7O]V,YQ[4^W./SR=NF_M ^_?Y*-^NWL)^[;YJ0<A2G")PB<(G"
M)PB<(G")PB<(G")PB<(G")PBUP[@W&RZ]ZL=@KS32T@#;*GJ6[GZZ:BH8<DB
MS P%,E0)S")33\=;L:0VAU"7V76LJ3C"VU)\XSZPM#IHVN&[2]H(]8)ZA:1Q
M+R=_"\/M99;%V7T\CCM.96Y2M1ACGU[,%222&9C9&O87,>T. >QS=QU!"^.K
M_&?=]?\ :2N7_IE0_P"F^9OS2O\ JF_'YK\S?X_.+_\ 7G)_Z/C/]Q3/J?=]
M<?O[)7+'[L_D94/W9QYQG_\ +?\ 7C\X_P!W'FE?]4WX_-/X_.+_ /7C)_Z/
MC/\ <5]"'HU=BMU=BM7;D.;JOY;8!6NWX**"S2T<5'<'CY-=3+?BM)%#Q[:D
M.2<_+G+J'%X5^,*PG\<QMZ..)[!&T-!:20-^IW]J^S?)BUKJG6VG]36]4YFQ
MF;-+,U:U66PRNQT,#Z397QM%>&%I#I"7$N#COX[=%V4Y8KZ<3A$X1.$53W+^
M)NG/[Y>_Y2>Y4/JN^S^*I/UF_:_!6QRE5)PB<(G"+6ON/<[/KOJMV O5++R
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M'B? ^\?G\E'B/<?R^:E?(4IPB<(G"+3_ +]ZZNNVNG^\M=:[ R+/=;361T$
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M"T#*M3H5CC+DL.J?L,N4E["1F&8;9% K?Z?02_3;A(MVV[>2CW<I DEV(HR
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MQS8FP$UN=652S5)!Q]>'H)XBZ7:\*&3E HYJQC3 6PF*?62AX/88H^"?$F2
M6%+*#3D(2])%0S$"<\_%)Q1DA\?'FM/M0GG8R&UJ(IAPB<(H[.$29-E F6UL
M8BBX1F-(;6IS#ZUD<0<,Y93AM3:DI^F7\N5NMY3Y3[<+\Y\3X$>T?#?YJ/$'
MV'X[?)2!7^BKQG*<^W/Y3CW*Q^,_G"?&?=G'[\8\9\Y_'C/[N0I6@O6RY[[<
ML.MJO<*&3 T.1K)Q9)N!KR3KR!4[C SEZ3#/@"='#C6HI?+R<@I]/NCDAN:B
M:),:RAPD1KS/(J!*["[%1MQ3-D2:'MX)(=KU@UAL*:$T;:;2G6E9&;QND>LF
M=<1!E)*YW!]0&7K\K,E!&[^\[6C=IMHP-"0/G! Y%D[%V$[0M$K]719HS.M-
M0I92$!S7.MVP%UJ_[(:U'I*RCAP*2_6+: 8L8^W/;\?NFNF=IERX,:.K 2'*
MFD05KDQB*:6/<W:2G[((5:'7=J7>ACI, *?NRM'D5&!HL7?NNP(S=JK$J],=
M 6P@4HEWVU;8L,+*M*YTNMOK'T$/)IABD&"*I]<7OM?KG7KM2IU(V U,H]+V
ME;:76#VA;-,@;:;>)[KF-1I]E^EJHS6]X&6ENBE@5*+3PKELK#L4/6:V31<$
MV&BD4^>J5U,:;V=)$0=K-S9?>[4^R0-A*:G-"-@-4E.R-&%C]Z$T A1Q$J1D
M0"9M#LS*:0[&=^W&,F TY."T-\BN/3EN[02+_2*CM*2W*&66FJO,PU& 5P#*
M$P*&8M%3*![("PT\3KU@VI#LFC]@PA3K3RQ$G^F*N,2JXFL!H,TBUZV^]V5%
M[.V=>*M'VR;M&M?\*0OJ?*=6NV,!+@XTWHFSZRU\#DP*7]M*5R\W(.<K,G,:
M;-/2)3!^#"-"KFF26C$6X^@+MMVYV_:*]BLV &."G#((?3#FJ3E2A EBKS<8
MM>.5/9)%,(3LZOW77N*B84L U8/L1%B3]\*UHL372A1%M1PB<(M5Q7<G21@P
MR&B2KLVX^<JH!)";KJZ#Q+<NZ[-LNF*R\_/F!F6X\8GM6K$*,CYL(DL%GQ\B
M3&9$2ON39%$H_=2@F=CT*IUK$B<*LZ[_ %PK G""HV^Q]B5ROZ0NU;J(JMS,
M1W),\E1-S0;381\A""E2A09[-HC@"%:MT$,176 [ :TLQ&^C 9$L4>UP-,%;
M"Z+KIHTP]'KARQUBPQ F0<,FZ:.!K'4SH>368#+MED/,0)HT3.$G0!$H11Z9
MV:H.-:Q]H X5ALP5S;E0TM*'B(D')8?<[;MRO:9;:D)DD6!S\(9:;)!=E3!Y
M&;'DC\XD#W97O3CA%C6^W6G7K##J4=R[2K20O<37L*O0]?VV876<GU2VWB&[
M+AQ1;SH:"]5J);S"LG<"YT6,!F?60(RUQD2"+#-=W>OD@')L$:Q'),)D'7K7
M"9CU*P.SS]0M-'3LL)9JM!3!^HL\271%LGOLX-$ZULO3!M:>KR+@6%UV:1>P
M'[D:>GQ\O%Y!JL.-W^YT.3&*P&9#X_%1V_;](MVXDT(ED78--.WBE'(T(V\W
M\0N!!(F;(@*##F"D$B]BB=FP=HE;C+&8;P"C:_)ZMC54K,&%(IFU0=ITZK6"
MLK2(?2N2X1L!6U#!( 7'CLDURY\0*2@0;"U/'1B+V3W:O4X?!<38!UWA%X,2
M#@A4S%&+#S#^#D7;N1L-,,NU$A2F#+^C]D#QT_ZI0(J@8-+0B<FL6:N'"I%=
MVOK7%OE$IMVA#)H:%;JN"LL,223'3/'1#8R,2C0Y28CK\7#S#,E#:_IWG&LY
MQY0KVYQC!%+^$53W+^)NG/[Y>_Y2>Y4/JN^S^*I/UF_:_!6QRE5+0*R=F=TU
M1C>THI4=:R&]$636%?/LC)MPE2"6-AUJC65^2(0B&I^<L.JX_96(?TL9\JJ*
MDNWB*I> 2R*\:WVIT[:SU<K <L8<L%B-%ZXL.]72K)*NG@MIV-2)@ZTP51\R
MPJ,6[4FPJ\DLZRX!;) 6&I)6.BQ59PX1>A([<:<C6XQ2%2+ID\(GV<.GW:]N
M,8.6-TNPU2LVL2(L4X/% R':_.NU:GER4@C% P*S+(W"47:JE:M1D(18 =W)
MU(3*5_ PH?L0Z_ -8E* *K>M[\3LA1_8]3V]>QJG\1QCT1V--JVHK,\RAEJ.
MH00 E1Y>3F7+@QVB+%4KM5H&(6<B9<0)LEVF";':;&&U;;:T!G/V$CM*ETXO
M;C) .AS[O-CZ#LM4^8U+?(,R:Y 'K1"A/#8[1%:E;[+:DL]-OE]AFB<*M:V4
M$1;9I:NG(&8B[-1JCLJM,CD.058/RSU*OU+,0!X%9(BF19!X";$B67$H-&(H
MNYW"THQ:&*7*GVJ+:,6D12C8IRE61[%3LY_8M;U2&%6<E#@20\!9&[W*H0(<
MF.1F0I0FT K9&DNU(C'.*(O5TQVDK^QA5>'6"#(%;$*#ZV1DUX6/G.CY4*W6
MR_U<,1KLJ8OY3,&&O7%GFV?,/,F15X(QXB:9B#GX4F21;6\(G")PBBI:?,CV
MBI0&7U(B$$6#,QG"492_F'"CNQLJ4I.5I^)Q:E8]BD^<Y\*]V/&.3X'WC\_D
MJ23NT>O??]@4JSGQC.?SGQCSXQ^_/_A_OY"J6BE1[RTTU;G&[.#-4C7A2E:L
ML-=L9L3+=DCRNQ-D;VUZVQ>98A\J K8J5,U,%2%ENSO+A"RO1I3F8L%Z8P17
M1'[/:FD40UL9N=8UUD#=*70I;L:G64E-EV'8LVE0:4@- $C9\@[".O[#J;6)
MP=,U@3.G3@9]0JQ5^Q!Q)%5PWNE1B!RU$$1"ZM<UZ@"3[L[],6*%<15RB[2W
M'JS8%4M8,G'B-5S]%G]2%!TZ657 AX*,RXK4^7]6%Q.(O;L/>C1XB#:9(G]:
MVF36A3Q%N*,IAP;'.NMUG55R2/#&+)%"B)$M=4W/0K)[5RT94&G3Y$=,E\7*
MBX(I_M;:M_U5H[LAM\Q4J^I[4-/V-L*AATF9;J+A5J/KIJY16K*ZW&2Y6C!,
MU#/5R4U#P69'QXD,RU]=B0H?@BIC97:C:>L[$>HF-3"=A7@52M8;3K8JG6%^
M$YLBDVW:@G5EUKPB,>CQV*IL>JD#@LA51Y<P6K-\3,B07[#4G%%) 0BS1ON&
M%;T=LW>=%B"-C"A1""'U'6X1'-4+WXY.H-9MZJX4>LBVLU^RBYQHT*L0&</A
ME:WFHFVC$.,5C31PXBVPI-RK>Q:;4M@4XFP;J-YK(*X5<S%SG,8K7;*+BF0I
M)C.?&?AFCIL:2WYQC.$N8QG&,^<<(I/PB<(G"**E2$R/::G 9?4B(0:L*IC.
M$HRE_,.'$=C94I2<K3\2W%JQ[%)]WNSA?NQXQB? ^\?G\E23U:/7O\ I3G.$
MXRK/GQC&<Y\8RK/C&//X2G&5*S_9A.,YSG\8QG/(52U1&=U-"$QXPQ]\L0P2
M42&F-3CU-L@',>OV-<F*!N,P<6'Q#+-,)%1Y</\ JA(UP2-G 3SQJ2,%AYY%
M@B\EN[ Z"DQQQ+88$CA%'EHV7$>N^M":ET<6'B55AC<\!TR)<1  BX6U D1=
MTKSLB:"^Y7 81R-E479L.JD7L/\ </2;1>4"C3K<5*LE@@:'&"4.UF&B\VQW
MO8>L0J1Q >+?&(3/OFJ=@5YK[E,'.(<KV2CS;8(L!*%"+%Q.XNJ9%;/;!CD3
M9NA0ZWJRUC906B6ULO@3MJL!K%2FG(A-B*\>.7'%D #ZK5ZY!DV8D>)M52((
M(61N3 CD5A".Q>M; C8ZJ_),&UZPKY:QGDCA+KK$^&#(VD*5B B3CC0><8A'
MJ8?#R [Y&'/:6R-+N,)K=AKILJ14?2^\-&G$K-_2-"G:]!)DUQVF$YX@K)8E
M0S'7JH;\DA; 5A(GAV+@V'+6A0X0/DNY(CZWGXD_7S8,><1;8T"_5_95<;M%
M:S/^W**'@CK9. ^/EL%*T;GU\NQ['L99FQ$$ALK[<9%OSP1X=F(;KY0H%(0"
M$DBFG")PB<(G"**$B$QBVU<<T^I$.?"L+LMC"492\Y";'*C*RI2<K3EK+[N<
M80I.%>_/OPKPGQ/@?>/S^2CQ'N/XA2E?O]B_CPG+GM5[,+SE*,K\9]N%J2E2
MDIRKQA6<)5G&/.<)SG\<A2M&=:]]=0V/5E7M]^E$Z7=9NMM<W^R4C%1NZY6(
MM^I5HN+$^BHG (LR_5KX-?[%B"R];9)*,3:=.%#F99F<%'E"+-O=@.I4'8LN
MRCA0TQM @5BTM%OJ>HS-CMMA+-S['3_TXU; %6FD7GQ1.G&ZW-@$R<5(W,2$
MTZAL<5#/SR*S"_:#306M:KN$JP&'ZUN6K-WBBF1]-N)&#(I7V8+9)EL/OPP3
MR*>!$5P^//FIULR&0*$)GS9F&FA9',4BAA#NYU[%/YCSS]M94PZ2R3D-:RV+
M-& AP>?KZ"5L!TT/K$H*+K0O^E2AS"QZ202-#03BGS#\!0DVV-(HT+WWUCHY
MLA-I JMTF>6OAX?LYR!J&R@[.:E0M-[*WJ_-E-5ZJ-3Y9Z> I1BRMKM#?UD]
M@>?$HC*MTH>/>(IK'[E:!>;B.R+,<%IF,S%H:,4>YC)[$F.'39( R<(E@FS$
M K9JT]!/T^#,'LNVP>7 I XGS3X6'/(I[HS:1#;=8LY\D!S7) #:NU]>(&K^
MKQ(S&UU?3M.BS9B)C+*T3"# A$R2F/AX?\KRE#9DZ J-,?(KGX1.$3A$X110
MB0F,VZM#FGU(A3AY]Z4QA*,I>=AX'?3+RK*<N)RU\SOC"%IPKWY]^%>$^)\#
M[Q^?R4>(]Q_$*4K6AI"W'%I;;;2I;CBU80A"$8RI:UJ5G"4I2G&5*4K.,)QC
M.<YQC'(4K6Z1VTTE#@""4PX>AP["U$(UUV52K<QFR5J;$I,YJXUIMT,ERQU1
MB+L6FN$BH-)#[.Z77#+L09PDW&&D5<4;LIL[8)4K7:WKRH2[#!$7XE#@R[63
M&0I[NO.SUOT<7CN$E YF83<BJU-VSPG\PI*EFY&!CS#$)&)2B*>"]C]:Q@[=
M78 (&K45.N8]T7MO9E>H"9-AE-ZX^[0;G$EEP :38[,0K:Z=.@D0:%33,3(R
M"VX.0U)%*D$7O?X5VF4RQ\&04LT&60O:=:88*42Y"G85VDDZR(# "*"02(J)
M/L<NZ5-P#&7C,B<-.QS&6F1$,M.'$46K7=K1IZEU"Z3IEKK3%PHU$V!%$%J9
M8Y1>$#V)KB^;3K>9+(,>69D/2:GK&]/^!KTU"I@-,%M2Y1<(V1(L%LSNUKNK
MZPN]MJL4[+MPO3&U-LT2M7JFWBB1+BC6M+.W5<+$@Y7X4UB(3$!<E(\]J*N.
M^'DQY4=];TAAA9%MR/J]:$FK!9!==!#;%;%"UVD\/$#X9JRK"0OMH55@*1H[
M<XRH0._S 6HB_)R/A?YK$RTQ_D^$6=X1.$3A$X1:KB>KW7@W!?D!H)(L.^^#
MF)3T'8=PEQE'M7;YLNX8T5Y]BPJ_SVL;QFV4F0C?(E6)J)%8)MNA(+(>.15&
M]UGZ*U4]"HQ"Q"A5S RJ=+&U\WV'MR;N#+2P^K*;K\L,BEM@JL88Y)@:&UH-
MIQ: F(3>E4QO(62N6^5S*(K?"ZUZU0ZMMP0-M42;2-KV:YT*_"WMSV(G5H%Q
MV45(,7NF5B*]<7ANM[3;[3:B$LP!I6*X:DVDRAYN,W/P.0P12(5H72V:A9]5
MCTE2(?\ I)KFR;/!5LFYE+*,V2&L-1V?7C,@\Y9W[/7YR3]=JUNCC8Y ?!E>
M<2OH7(1:4F618>K]1=*4<\"M=2$60?8ZJ2BF:Q+)[!V)8QXHL-JNR*4(?R%-
MVN6.EQ!M7VQ> K8]YO$9V(5:>=QDB,%3X)%56I>C-;I=:$!+Q<K'99E;+B#M
M:)TJU[8UY+#FH=?)U2R$F32=I6.Y.QM@@)T8?:ZQ+M<JKK8# U,#5%1,8SPB
MM]KJ9H^/8%V2)7[%#F2B-[(%Q\/8>PHM<LC>Q[>2V!:@UIJ[-G17K)6)%X-G
M;2,JY@;,  "M@L:@0\=%L9V,1(OP+U+TD"HMTUS'#6J;6+\*J86P(-;)V,;,
MI@T(9"$4=P)9"EIE6"M%JE"&"L@[%7R0VQ1IXD67<*O%Q\6>T1"?4S2IPZ&L
MAP5;S)D*+K8K$PGL[9,I1AFIR-B2@,BS)7:O999\1[;&PL.336)C\R-9),"8
MI\?%'Q8A%=U.J@:B52N4JN-S6@%4"#:\%9)%2AR<R+$1&H,!F27-3)Y4@XS&
M9;;S)GS)$A>$X][N?&/!%).$53W+^)NG/[Y>_P"4GN5#ZKOL_BJ3]9OVOP5L
M<I52I4UU^UA8,[3R4%EWOZ9RM1-[!PU:;+&P4)T:&#'UF3 3&*M8K_T,&MA8
MSS(' U@BB%A1)N6Z_)<>(L35>L>HZ3=\["JX^U"+)(DV686^FV'?D@[++M.P
M;SM.:_:ZOFQYK=G6-OVS;]8JTDV*G-U:1:)T:OH'0(PN+ (H*,ZAT<E-OI#8
M[\ZU2[+MD_LVKO"CULJ[E)44MNO;O!:#O"#T>1%,Q;'K&H2YI:"[$;G,#GQZ
M84<>=M$4X12>K=2M'TLO3#E= 6&&1U_FI_I-Z3?KV5P,;HX7:5=K,=:"]BG8
MGQ1X3=.RQJHQ'ZMF7&L>$S$/Y# %"B**V'JYHFHUL[:(LZ50GP8069CWP]?+
M8\%J;FNC&U]@U:SF$D+<-A/B:A9=O;&M!!J43'QB$,HN&4G)&B N!)%_&E^K
M%7J6D;#IZU&X^P-=WD-"@.!!TJXQ0<81D.P-1,KYD_>+C>(,V=#CC)<,E#N;
M2@;PP1+KOT!2+),D2*92NJ6EIQ95@F@C<D^^3KITB:5<+4T0,GZIL>H[8 G3
M#L<NR@@3@7>ATZ<V\^WEO[17AM3RU^DV?LBB+]I?72M4R^5"R06@JZ[JVGVV
MJZI%K''IEJKBMCF11R_S3ES.6PUFP(GR@D)BNQXX,*Z @3CL)Z859GL8A$6Q
MO")PB<(L3+*Q8A40+=:=7*+)(JB.H0VIIG ]AM^1\RU.)<1\B'$I;^)MSW*Q
MG"_9C&,Y>&_N^._R4;]0/7O\%EN%*UB:Z>Z":0['_2I=^"_FFI?%SKM=20MZ
M)K[8%OV?3A;@\B?E1E!PMQO=IFMB?C^@EP"6 1%B8#B0A\<B]:R]7P6-(Q=*
M:^/V4$)@W?4MK@D[A<KYL,O ':KV11;U"KH\_:;.1LT&&H;1HM:"9CF4LU[,
MK)MJ+-GHF((D7N$^H.B2\I$^97#S<[Y/J'Y8R^WH)(F3G;;L"\D24Q82PCOG
M(FK1M789,U,SA+I%=IFM/9^"*+;@$6+1THZ\H%2 N:Q9'!\J%-@O(>V-L)V2
MIJ=KO7NJG'<$'+,H@B9'I&JJ ,@3$2DR8$NNM&HCK1J<5(3B*^;YKZK;+U[;
MM6W&),*4J]U$W1;2.07+P9I2KV,3(!FQZCD";&.QG2 J7)B/$HA%@HCYUR&9
MK4KVOI(H9&T!K.*2('<#CLJQE7J HE9BEQMQFQ286K[ JU48$@P6-39D&KA+
M(Y(-_I8:Y"KQ$G-)32PV=(*E')A%[X#1VL:K:25PK-:; %S5ZLFS3+0F<1A!
M2NP;=50E+L-PG5YF6D(\?)5X!#C/$OH$R,2I9XFE:2=FL4LH19S6>M*CJ*G#
MJ%18<X;51$DO)%C9QDN=R.P:+SC<R'#EFYI";'%LSR,K L0U(2,"0,L" T6"
M)A0H4<BGO")PB<(L3+*Q8A40+=:=7*+)(JB.H0VIIK ]EIZ1AU:G$N(RXAU"
M6_B;<PK.,X7E&,8SEX;^[X[_ "4;]0/7O\%E<X\XSCSG'G&<><?C.//]>,_U
M9Q_5PI6N$+J;I$?^E$Q -A9C5&G2->L#D; OJ1-DH[I(B8BU;8 E%D2-V*&#
M$S!>6 BW:*=P#R7,,#%1HI@HQ,(L-6NKW7LK4Z<\&8.W"KXH\NO S!3:-]O#
M5LU9<6JD2S5#!P[:3#]QH9&)4:BY &E99"#D?"=9CKS$L5F0<(H?K7IS#JYX
MZ<NUSEVK[EL1S:,> #D7NO07+TU<C%V&6D@P;V+<LM2AI.P&D-U\$X'J$C[G
M->F!)+/VF"$(IF&Z;Z& ,U6*%"VJ S1445JKLQ]D[ RV(5K2@S-;41[XW+(X
MB7-K5,)28 R<13+G,S%LV#ZA1^/&*-$4HU-JC2HFMVN1K&=,L5'V,0MCLV.C
M95LO5,;?-'#:KQ$IL4I9306J1"UJF6"58(=12+CR#;C^'T8S A,PR*(2>E/7
MB>$S7"55L),*IQA]<0AL78<MU4J+IJ3H&-.P1=M&2C1"+JN4[7X<YB:U+@S4
MQ[-">CVF'#,L$5V46/3*JE_5]?M$HV=J D.9.#['=REXOT89:YAYH">M9.R%
MC%J?8L$RN6*($GF)*H\ANOSQHG*(87Z6(16#PB<(G")PBQ,HK$C%Q0EUIU4L
MHP1?BO)0UEII Y,94A+JU.)=0IS$EOX\-MN85E*O?E&,)RIX;^[X[_)/';W_
M  V^:RW"+5IOISI"-!JL4? N(:;145.!2K'7]B7:O6RKUJC"[H!JU+%V@(;@
M&E5$6 V->0_VB=,F_6Q[),F$'Y9>,,)02+-#NK6J0Y!<\2FYP6T[,>VZ,#YO
MUM(5NO7F<3,GC1*M5HN5( P,:Q6.PFK(?&#H+$ F;(R)CT?Q[&T$64C=;M3Q
MZQJZEJ"3)M5U!KXOJRG@B)>?/A9H9NGPJ%/KY[$IYQZQ,.U4?$%YDEG9,U?Q
MJEO279CSTAPBJW/3VK8N-'<=/6L[K:K:NV#KHQ6KI>KI=C]N8NMKU!8(L$]8
M[45+D)U7$P=0BPTD0],^<W%GR&B,M<:38F+.190=TFT*)CQXL ;<4-1'$N1L
M2]AW(MEC+6MMC:AC?']Y,$,)^FUSM:Z5M&?&5OXG0S,U4JPBAQ:,19@GU"TJ
M8;/QIT&Y9'6FI5VIV(/"V/>Q00LY400^LU>YOAQ)^".:V0  B PX;?XD>-9F
M&P5>?R07,KH&0-(K>UQK2LZL"$0574:=CF+/8[D7EGCQ6P$2%EMI-XS823DL
MK)D9C8($Y#\O, >B&+C.O.YB0H^'%X413_A$X1.$3A%B9)6)',#!#C3JI9*,
M0D1GDH;RRVW Q&S(2ZM3B74*<^H;^/#;;B5>U7ORCPGR\-_=\=_DGCM[_AM\
MUDW&VWFUM.H0ZTZA3;C;B4K;<;6G*5H6A6,I6A:<Y2I*L92I.<XSC.,\(M8P
M74+3E9BZ\B@U;('XU6R2#T:0UM[9JIP>CE60$:9J]4YRTKE3M8*8J=32BDSW
M9(A+U9#3LM9(QW)CQ%/*'HG7^N+ NSUB.7:*N#K:,<<G&9I!A;%XV,<VO97%
M1Y"U-_43KO8S!-MW&,?11I>!<),<9'C162+&N=<=6/A=Q@Y(HA)8WU7Y54VA
M-66F-%['79(HX"2.?*Q51YGSPPUC+"()U;KMEC"EC1:3.1U>K<40112=U TL
M4MLB\$8=PDV.7; -VFRF[[;1T698ZS8-:V<'-D#!)6 -6W!+ZEI+^(:8J8DE
M(UQ$QB1\ZE)(L-GH_P!?L0ZP.:$7&..I].K%$ 06-D7I,:-7*37MC5.H19"%
MGEY(NUZL;6NM?@/D52G%B)\2!-^KCBAJ(Q%[=EZ6Z(MJ9Z#PNW2T%*9(H1!E
MO8=UB1)5=FZL)Z8(L+@Q#3,%,HCKPJ^'D3&HR'VIC;9V$J(><EDI1%M4RWEI
MIIK+CCV6VT-Y>>RG+KN4)PG+CN4(;1EQ><>Y>4(0G*LY]J$X\8P1>3A$X1.$
M3A%S3$ZB[5,7/!V6>V*J(/V972H".]N8A)"M43_#3W%<;*..UY=Q=&'<N=3[
M;3*=&A%AQ?XY@8:*BK9G5@.3C$4@WWHO:.R+%W%  :6+GA>R?6C5VB:O:[$:
M",UBMF0Z]_LV6U6,8Q.DVQR+6HNV09:OPPX)Z<=.!I [ZZM1LQ[(T1(76/8E
M8N4:^T2>J _8=JUIW?%<LLV%(9V_4*)<P=FI.V!2QLU^&*W"$9 Q*Z_.)+'8
MM5$G2Z[:&WI%/UN^"(I5J?4VW:+O_P#I;(#A[PK?.O22-\C8S@Z+-IVP:M8<
MG=2.JEJM)9FY) U6W7?4T\\$@09,ZM575F)4?Z($AF$15]?]8=N)]EO:0QZ[
MDM;6#8[,G$&N[6CT#:\.D$QV[Q4N#1K(\6.TF&)K9ZRZLMPC.*UK6V9KPR96
MCLJ]%:<%FV4BKLV)[6Q-NU.FRS%VD6F*QMG8;KXC;KV*[M.@T#N/U+NM*#00
MB9M8JU8M&>N<_8.HY<4Q7J4.NIMZZK)NRJW+F'^$7X7TQW>,56_")=EV7 L+
M^M]R)U.;JW8&((' K6=@;M"4VN7Z*_#=.6*7$?M>N+35+D-.QY05T-'8(SPB
MJ-!%70BMX3K7LU V-)AO2+O-U3(O5G)4R1+W62Q8*%A%GU]< A:XY?.F">QZ
M&61 NM=71B!4J\)@YCU2(+&U>TOFZD17=U7J6V:K0Y:=S2[F]>"<H0Z=C6S9
M(O98]!X56 H"P%:(1'@0KP2C60H*>/A@1%+9!IZ=-(30=:G$98M)%LYPB<(J
MGN7\3=.?WR]_RD]RH?5=]G\52?K-^U^"MCE*J7,=.K>Y<=56FES5HL@QEBNU
MW==5!;AEUHOL<FT,WJ%.[-T_8LEV,ZP&O&K;J*Z?I!F?3L+&U:8!C"6'JW B
M7(BF+^O^T#;I:;+Q<2-AJVW:J;@EP.\)+%<V5J'.Y*Q9EU<;2ITFOAA%FJFH
MT'J!9))N-5!]SG#VRZY!Z9:WY=9(JM!:*[?XU^9?,7#9L3:T6H:L 5Z0K=EA
MLM/FSQE$1#V&LW76-FTO!&*?N0(*HA:!QRE[%@QR4\[6;#E<JT5VT$6P&YZ3
MV-M.Q-9/TYPD*J8\?3,7637MHE0HM]V5-M(?8HN:)Q+"OD6(P8T"+@C& Q4N
M3<&294*51S=:%0[R157<.NNX#/6WK#18PHG(N&MM26^BWD(YLJ3AO)\]UGNF
MM(I*<1?.(&6R"W=9XY+6)S\YR".*KQ%CM#ON:&R+U:]IGM*(N882LQLUC4$>
MZCB :('WE#B66I(A43K5/:?L,FQINK]JUH]L*G[Y'$Z+'FO+@BK6-&A $BM'
MEYI9%TWX1.$3A$X1.$6(F"&IA8,66\XAT,DDEEI.$Y;>^Y,-,.9<SG'NQ\:6
ML*1[<X\YSGW><<>&WN^&_P U!&Y!]6_Q67X4KF6#U1W#06IT"SV>^$:8U;SD
MJ64K^VX55V)"5AG216E&MA?<9%]JEKJXB55-HU6V!Z(S61UIB'81UK40Y^U6
M".%(H+2!7;"1L>/7#TV[R+AK[7W64SM>O0MRSWZ[>;$>$=T=;[0N=.<DGHH,
M&"L-D=U)LARF-LU^8 KE>K,Z)5(%HB@@TDBR=;TQW0E@PT>^6;:2K4'1UX:F
M%:WO^*/JEAJXRQ]=R.X!$T!#:&'V=@1(5%VR/DV5FRLC[6(M4AS[H2D7<J$J
MI%GQ.K>Y\8+;P2REE68B5*]9TM;R6\B#<.O2DJW*!J]1VB/]]IEW0M/#6371
M@5L$E$N!$83A?=SLO):@"QEX(MW=& ;-7=>0(=M5>4&)96P&5CMCW83L.V@V
M3AF85;!3K6$AQQTZ(*5+<BAXK$HP@4'1 %-F);,-I+)%;_")PB<(G")PB<(L
M1,$-3"P<NMYQ#H9!)#+2<)RV]@DPRPYES.<>[&6\,X4CVYQYSG/N\X\<>&WN
M^&_S4;=0?5O\5EE8\I5CPK/E.<>$Y]JL_C/X2K&4Y2K/]6?<GQG\^<?OX4KF
M'1=)]I 9RCF#1_:\Y R'U_S8H9#?1XU"DE!EHWI WT_(%3[_ "!9&*<UX;U"
MP-C.L.Q\&PN3@:()L\.::ED6-K^G.Z#8370X_:[L0S"I_5>%L!Q_;!&'8&[1
M0;=U@?W>[6;&!O\ "B'PE_I]2W:Q8$6NO-VR38ITJ2.O!(#LF;7:N1>JK2W<
M,:%.AQ!C9,QJQ!(@;ZTMV"/RC%>?&W7L4T!-"B$R[3"#,^/2;-HR/8I$ O!<
M+( 3[&<:OUEK3=8N)%GZ3I[M*!N4DC88MI)UJ\6A1ZYM!-Z30!F!;I^J.L8^
MN714IF>ZRY5*5:M<;GK-PI@YF3#.0;L#FBJM:!(V,S (I5IO3O8#6]?WI!89
M,LN6S5UMD:^!$MGO*!C]NDML]D+1&>$.,D+(SKO!JKWC5+1,S6PF(B9@EZ9,
M@3B@C"YI% !NGNX:RH8E.-[)98 7!LZ,B9W=.PS) 2.R^I]@9$6 4B^D89KZ
M'3;.U*2\%L)*WCT1)4:L-'CD!(@JT179U8UGNNJ;!NETW2.FJLMBT1U^U[9[
M4_=V[4.N>S=67+L22OMMJPI16:_4*1:VMF5P_5:XD;760S<LB$57!2Q2%SR+
M>/A$X1.$3A%B)0=J49$F5/.)=$L$F&F4X3EMU)-,9+BG,YQ[L9;Q%3E'MSC&
M?<KW>?QQX;>[X;_-/'?W_';Y++\(G")PB<(G")PB<(G")PB<(G")PBQ$D.U)
M,BS2GG$O"HQ&,TRG"?C=21Q&PXIS.<>["F_ID^S"<XQGW*]WG\<>&WN^&_S3
MQW]_QV^2R3^6L,/9?<^)G#3F7G?F5'^)KV*^1SZA"VUL>Q'E7S)<0IKQ[TK3
ME.%8(N1?7?5G8>^U#J]?2-]W4JAVFE=?+'M,4?WK=EV*1:QO7+?8G95I<D1+
M^@_'K=MV;;.NLZ3KR*8$K8.:WMI@I4PY B6S:"*<B]4=S8[-1S8S5NL(&=0=
M>TO;%4#[PFUJTO;?@TO9M?V%O?7=^;EOR!.OC)\MK0G H6,UYV*R%+VJ-K9B
MP06JQ:2+VS^J.XDR#?IXRSWR/>U[".N!$/[<ARM/V^HLS-O$:7B+6@TBC7W7
M :4"MM1K-N< VV)8P%K"5P]""[.K]&5'N)%^V#5'<*:>.1?U/?9VO3UMM>([
ME8VY"U_M:M?J644FU@^V7FR+U2"E+UG+Q]#%A" %-G6:KV,8FP:E.'-;)5L
MBVGT#6=OUN;LW&SRDXP+*6M1.C2CAEXC8HHJ9(*2YP8@Q%LA^L*'!WI$6'6S
ME='4!9@&F)$.ZY"F L@[:"+8WA$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3
MA$X15/<OXFZ<_OE[_E)[E0^J[[/XJD_6;]K\%;'*54M&L]S9LF<D8*TS8Y4X
M^?:I^O43ST</&M-ZS'WT3FT(I.E!EQ*W< P+0!PJ;&-.GF![=VUOG,YV%97B
M TBQ">]PZ,:D"SNKR@&/(D%@]?D2+>!(/S+,.V5UNU>R+.(#L3Q(D?-/]HM?
MY2;#G;4PAH/<EMQI,:  EV8BL"^]E[)0ZUINSFM<#Z^W=RFS(FP@EFO]=@S*
M0SK'5&T=B%40;"PI^ER_J9.MWXR"ECL%6@#!\EMRR-@):B38 B@F.[TE:+$Y
M&TT?G)H]-WO=KJS%.OLE(4#1)Q  I KP$O511\Z7L4XE7EBH!$96WH\>87S,
MPF0)A1SA%+!G:XZ9L+=1&:=(2;(V:<1-ANW02+AKHLG;!S3X/9X$B=%BD6.I
MD#E?FVB5B"R@FFB2P!*O0[19K-7J@3(L/'[@%H6G.N.T#NMF)4C=.F7=T6F#
M7[0M<2DUL%0ZYL:W*&XF@4S[-/AUDO/=#AFX\%XB8@1@CD]EF:HW&(O>?[;6
M)B1712=''Y9NUD,XKK8RWA#8.Q5UVP:*#1K&", H1.4M"8.](ME("SH:OSXU
M:U[L&R0L%*O! G[ 186N=R!WSFPCM:LIZ?5=GB:;<GR)0&@D'QM7N5N;J1KA
M=?B@JR*A6.MB;_JTDV5>E,B3H+720Q:;*OEQ^\-RR*U>M?8U'84%@PY2I5)>
MDT#3VS1T%\[&L'U%4W1246^O?528P\<B&9'NQRPPH/;;F1D(B0I\<D]D@["'
MD6S7")PBB9:),>M50E,LNKB0T6'$QY&,Y:9S(@QD1OFSC\8^5Q*DM^?WJQGQ
MR? ^\?FJ3ONW]N_P4LY"J3A$X1.$3A$X1.$3A$X1.$3A$X11,M$F.VJHRF67
M5Q(C5BQ,>1C/Q,YD0XB(V'LX_&,NK0M+?G]ZDY\<GP/KW'Y[_DH.^X]77?[N
MBE><YQC.<8RK.,9SA.,XQG.<8_&,9SG&,9S^[SG.,?VYQCD*5HM5^ZC]J@BI
M<'3-D5*(5NI7U\.S:*\Z2B:ZO)<U5@-M^=Y,0$OZ2V5>R1+&&D&H9(>$A#20
MA%A-G1U6611L7Z@(F3'&J,ZCLP&:0':UMZ("[-7"\AS7&TL:X0 M$..%5-(2
M)PV5L:- M$&0/A5FM3Q.(AB[Q7;;KS%O(K5TQV+([(OA;7<.GV*9@ 0V5,LU
MOL!NIQ\!8=?WYV T[#$PA0$="R7CQ#^F71@=U,=N<JLD!)$^1)'(Q:40(J/K
M7<J]YV Y/M]1AL4!^?7Z1*"UTW&*+K9H]W(V'U5!VUF9-K0<V>=+%QU1D& *
M<LPAX=HP8'/*)-1P)4BNP7VRC$](V#>K>M++^EXHK7MIID=!<!]1?J9LR+79
M->.BG)<F#]M=C.G9 XK')LM#5$ \Q0$X?%NL%%$55C^X=FD["+QYE1F#&!(
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M((JB.H0TIIK ]EEZ1AY:G$N-Y<0ZC#>&FW,+5C.'/9C&,Y>&_N^._P E!(W
M]>^W[%EN%*T8:Z$Z\C12@N+LC:; 4[J<AIXR,4WJB8N76UXO;-=(0S!'5DPZ
M"/5*!L(P.@S*^3&1+%$'@&[W M>(,S!(BPFY>D#-HK&P9M$O5N>V':9A0P.;
MM1:H#ZJDR:U7J+2TAV:Z)UC/)1X@VG:>KI@<U'8DJ<M;Q-V?]6%FL"1Y%81'
MIK32!EVS1]@[- 6$E-.$[#+!R:*F)8YMGVE2-IV!)@85H9:#+&DI%!!4J2&4
MS@/+HN9T C!G'9CMAR10D'Z?>NJP*I8VO[.VQ 71HU$@"ILIG4!U<D92-1@]
M(N#R0ZP:E* I35FHM6JF#+V!+<J"?K0PY6'P#[YAHJ1;YMMH:;;:;Q[6VD);
M0GSE7A"$X2G'N5G*L^$XQCRK.<Y_?G.<_GA%_?")PB<(G")PB<(L3**Q(Q<4
M)=:=5+*,$7HKJ4-99:0.3&5(2ZXIQ+J%.8DMX;PVVYA>4J^3*/"?<\-_=\=_
MDH\?V'\O^"RW"E.$3A$X1.$3A$X1.$3A$X1.$3A%B9)6)',#!+C3JIA*.0D1
MG4H:RRVW Q&S(2ZXIQ+J%.8D-_'AMIQ*O:KWJ1X3[GAO[OCO\E'C^P_E_P %
MEN%*<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(JGN7\
M3=.?WR]_RD]RH?5=]G\52?K-^U^"MCE*J3A$X1.$3A$X1.$3A$X1.$3A$X18
MB8(:F%@Q9;SB'0R226FDX3EM[[DPTPYES.?VL?&EK"D>W]^<Y]WXX\-O=\-_
MFHVZ@^K?XK+\*4X1.$3A$X1.$3A$X1.$3A$X1.$6(F"&IA8.76\XAT,@DAII
M.$Y;>P2898<RYG./=CXTLX4CVYQYSG/N_'CCPV]WPW^:@C<@^K?XK+\*4X1.
M$3A$X1.$3A$X1.$3A$X1.$6(E!VI1D294\XET2P28:93A.6W4DTQDN*<SG'N
MQEO$5.4>W.,9]RO=Y_''AM[OAO\ -1MUW]A'W[?)9?A2G")PB<(G")PB<(G"
M)PB<(G")PBQ$D.U),BS2GG$O"HQ&,TRG"?C=21Q&PXIS.<>["F_ID^S"<XQG
MW*]WG\<>&WN^&_S4;==_81]^WR67X4IPB<(G")PB<(G")PB<(G")PB<(O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g401831g02b46.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g401831g02b46.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1G<4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &<"^99(X0DE-! 0      !D< 5H  QLE1QP"   "   < E  !41E;'1A
M #A"24T$)0      $)_]]5M,FVC]2'%8$L(%V8@X0DE-!#H      .4    0
M     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT
M965N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M    "W!R:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/
M8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+
M #A"24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M    %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L
M  !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V
M8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P
M  $       !21T)#     P    !29" @9&]U8D!OX            $=R;B!D
M;W5B0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2
M;'0               !";&0@56YT1B-2;'0               !2<VQT56YT
M1B-0>&Q :/H$8         IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M    4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O
M<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M$&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M        #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L
M;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ ._
M_C4  @ ! [_^-0 "  $X0DE-!"8       X             /X   #A"24T$
M#0      !    %HX0DE-!!D       0    >.$))30/S       )
M   ! #A"24TG$       "@ !          $X0DE- _4      $@ +V9F  $
M;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M  $ -0    $ +0    8       $X0DE- _@      '   /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H     /______________________
M______\#Z   .$))300(       0     0   D    )      #A"24T$'@
M    !      X0DE-!!H      T$    &              '2   $H     8
M9P P #( 8@ T #8    !                          $
M!*    '2                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   '2     %)G:'1L;VYG   $H     9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   !T@    !29VAT
M;&]N9P  !*     #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M    !     ,X0DE-! P     #WT    !    H    #\   '@  !V(   #V$
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MC]%[;';K'/\ ;_UM3IOVY
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M/0=O,/MW^3!]$7H]!TP5F=?TKCKT[8[=1O\ ?(])_',:X[=]-"T8T//)L2-
M3(\#*:?=<_2-;AOQ2VGJ/(*9C'<?<([TGERVWV'ET]XZG\T/H^@Q@K,ZS/K.
MGQ[:)'A\*#TG\<R"<=NXUV4U)B-Y;(U[ICK,FGW7/TC0[!\::S\_/V-QEO\
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MBCJ<2X_P.W=<P^PQ"WNL19PL8BDF\LK:V?;+K: A-S>9[;M%A68:#*T"X5!
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MD*[!VQ[!KE9>V7?<IRA./S@4P;[& -A^2;D'4.8[#[[9@+9L0H9LUL H&"%
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M(,K]\9(K]&V#>(Y:.2B6X&"(B(^5>.&*F4:$TA:<BE!JS4FVM2;F_D8T%ZM
MRSQXK$V@D%*/F:\LFFQ6\++(H6W.)^%&'4YTH5<J6.S7[$N&UN*S!+:D.AM:
ME!2T) <1F2/<7,%)-Y.!XR\TZL$]DE*BXGVA;H0 E)4N2726U("ER%(4?KC_
M '>HNN,,]5=Y6J'</6ZB]KLWLI#UX+U7+5&.+9!&@XQ.$?IPUME8B&F8=";K
MR!6<^M&+L8V1C'(%3C%B*ES+#'>&;QJZO[$)";)HNWBQ;O%:&5I4I2D-J;2X
MXA2@LD-@$K"\R5*20,5_"\6MWF+6XS3<J[)E*L4MWD+6I62%("LARYD !2M
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MJY&$0,(  WFX;[@&X@(C-AL)0'<VP!L @/,!$0I_)K I . </ R4F+5HF=3
M^@U,"1,Z SM4>V\:C,,7Q)6\!6,7L:$3)+TCF%0"0<I$@FJ#FS,F^Q<K9'Y=
M &\VX!'8.NP30B._T>>@X:P* ?R?X>@P9%LT=%09'T$:]Q/QYCC6-:A.,8D8
MT@XS>"8&T>L:Z[".>NY-4#-F8N8?"MD3<1$ *-YM^^_4=OPWMRW#8 'EN B
M .YGY-8)( X>X?G?2U:U&D'_ ">3I$F#IXB)&.8R<T8QB,SM[9O)GWA'\_IJ
M#$G<&8@T+FW,0 .^5LB;A[KU;@VY\P'\-\@ -O<!A\@ 1$)_)G S$</\/P09
MFT;.O./H=CK'3K5/MS&O>!Q?$29V]M7>HGJ'] !KOJ3I .@,VYB 0#X5\B;
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M8^.VKLDY(W%@N$5&2*<:WF45Y!S6O@K"%!MA-Q=*;:4ZUV95E!3</IQ5:"H
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MWH!(D[ZQS)@@Z3'O#2<_AW_K(XUZ!^AU#;S_ +8<?P<M>=XI_G*^_P#:'?\
MYU5V5C_DS,#3LSOOJE)&W,1J=]3S)J&3(HB.0+L'RA#VQM(>0[",V_#;GSV
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M12B8]T',(B"=[DG*5<JPNW;V2I66NN'C47S-&<@96)6<L0.1/QC=.0:MSKM
M44(07"8&2 YR%[?:,&^.QB.'W2 NVO[.X0' UG8NF'D]L8EJ6UJ^DZHU5T$5
MD.6%[;K*7[*Y:<+9=RNVSS:^SDPL!;8]V9&?1.^LZU;( .XEV'M; )NR&X@
MB)0$0#?;F E 1'83 )0Y@.LO28D$@ E),*$R!H?> 4H* ]W=)UD*C%@P595
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M"AM)*()652JM/QY\P$! VP\@-L <QY".W7S$1$=PWZ:[U0)4K3KJ$P) CG)
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M:-X3?,-6:6&%VK2[;"4>I.,N!I*.U>N<R4H"W5K<]PJ[3*@:THX 58VZW;W
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M#KN(<N>^W3H_*5XZEF>[/'/6?<!V@<C D5(P!Q)!#[0@B#E(VV_2@ZD]QV\
M\ \)S <DRP[]=Z^S$!* #N @,E[OHY[B <]#Q,XF)8 C<YB-9G0Y3M'?I,[T
M& ND1V[4$Q&4G<P!&:-<VD'<R-35!X"(,-A')$MR'EO7F@#VM@WY>LM]^91^
M<=N6J!Q2HI"T-I*5I0H*#D@I482=$P0HF!XGKI4YPZ\V3VKC:2APM>\@B'1
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ML_>?/RJOVJ_$941\?/CUYU3^AWN&$ _KS9U'?;^V*#_U0^D/KZ>Z.S/4?O\
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M8-HCX?*I.(N_J)TV$GPG]OC.^U5'\SN\,(]<TYUWY_ZO0NAB]D0W"G@.P@
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MERW^ [Q4?F>MYDXV^9B0+-@'YEP_QDU^2WHOX%$NZN8)%(IN7:/4F9>T(!T
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M@$!Y8WB'% =TP1W^ ^)KD,C1<*RSJ01L.8Y ? $Z:=]?E["4G_6=5!Y>5=B
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MQSG23YUT%FW(_F)U'(<CSTU(ZSI&W*JC1:2/2FU0>G+V=B/=Y[,]N8C[N7F
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MS(4Q[;]PX!%".1(JH*1TFZATY\^>G/K2LE<?WHU?AMQ)0ZVI*D)E6NHRSVI
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M-N&II6<M*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E?BN&Z*G_Y!O\
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MBVL@ _0ON6RPH J /:-+@3L)[A8P[$;3%;-B_L7.VMK@.%M>4I_FWG&%!04
M02MI1 W*8)@R!?:_-%4 ZBF?;_\ =$?XM];E'UT_[R?O%9;GU%?[I^?+[:@0
MXHW0^R310$GCDB,RL=XA&' DHM'$(891&-,*A +(JQX.4V1A43$')DS=LH@!
MM=8GWF$=>6^AY3S^,:#XBO/WE-MWEL\I));>4H@ 0I"@D.@@D#5(!$^Z2-2)
MK0!SF6)RE;;:UIV,JU1JK"3%U&L.:_7$:Y*EQJO'-&]6KUT%@NJPE;&QDFOK
M#QJX/'Y%'TBBC( W77$^"&KEM96M:<G0%1,C?D(_#I$#H;QSA=[AMM*&+U'%
MC>)//,W:D6R<,3AY4R6&BM+YN2\ ' M!MRT)24+)4HGU#8D,4^*,8F*8#!\'
M=(  $P )3!7(_<.9@$!W,&_S; 'F :IQ*NT<5$DJ41()U*E'7>-]ND[:"MFV
MYVR&G925%ML^Z1&=*4ZP8!23)'/GI6+\V\+N-\\2-:E[8F\82E?7*1=[".RL
MUIJ&,J"KFNRI]A,M&N5"E,(E$%D#"H*!B]X?M\#Q5Z.\#XN?L[O$$/,75JL!
MQVT46S=6Q6%N6CY()4TLB9G,DDE)DFM#C?#&%<0KMG\0[9+]NX<SC"FTE^W6
M07+5XA22IEP@$C123.50S*!V"A8J)KL6RA8EJSC8V.:H,V+%HDFBV;-&R*:"
M"*29-B@1)-,I2@&_R2_*$3#OKM;.S9L+5FSM&4L6UNVAIEEL9$-MMI"4I2D:
M 0-^9(YS.]5V+26F&4H9MV4):MV4E,-MIF$PG0295&H$P($ :+>D65*.'*8*
M9RB<,NU8P!N41^1!6XV^VX_J1 N_:W#Y0!L( (!MK%)+I!T&7?7X:1W]QWG4
M@UJL57%L"A2>T"P0E4P=.X$@[\QIOH:@WNN7LD98GZ4KD2V2-J/6LT6R%@32
M(->U&Q)(M'NV2(MFZ &3+V";F4*HH/9#<X".VMFRT!)&4"9T$228!(C[XC3Q
MK0/W+CN7M@<X 3"9B #!$D'4&>74Z5-MPEK@,UCQ,!'8*ZJ&PB&_ZTN-N7N
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M>(=P9M'M"/&QE6A572HJNQ1.*B!3N5ESJIE*!#&(4@ )DE1B5&20 ))[A ^
MT'*I<<4ZXMU9!6XM3BRE*4)*EJ*E$(0$H0))A*$I2D:)   J7;#OHRL;UZ.C
MYY6FLD7R85]5-20B2+K 5DFW39-U._242[I)JP(U;$ 2%6:D*DU4432,75.V
MG<8B.7GPZ\JHK0^!C,H\*^<IUGPI\%F?9N(G[4>V1:E43DI>+I-O:R< Z%T
M5LMVE@KMF>5Z2>,BS3PC=XSDT%5VS:*2;K*S2I7X'.UPOLU3ASMP*26";+DC
M,]=3D[]D+(L8T7ISE9M5(> N]ZQMW"+%Y!V&3<R$+6/5T^I*Q\U%IGD6\0W,
MB]<09Y&//DTK//I$#XTSG3LB</-DD8:0:WY>Q5^*E7#6.D$X"U1-;BF-<M+
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MFT[]23OKXGG%UCVS3U-F*Q:JO+O8&PP,C'R<1+QRQD7C%ZU4242615+S#F
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MM-ZS:INEK4D!F"$N*;2K-*G$,J[8@#WD QK(&PY# <I3@("!BE, E'M%$#
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M]T5F5JM,ITY5@YL==6BRL6UP&#<3A5"=^I#$>IMC@N9,BM"RA:98DJ"A(6!
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M:OR>_9';=JH4-]AZCSV#WCY>X=?F2GT8>D#,F>"^)TB1*E8/>I2!(DE2F0D
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M:A1NB"%/)4""DI(;(((C6$@] ==!.M77X[\SV !1%_P[&$"AVA ^1Q#<0#<
M =C; /,NX[_)#< V 0H+3JP0M23(C43N#L<W(=QUT ZP@/-Z(4A(U&@C2-=?
M,\B*ZR<?^@&]32QJ[(\-1I_U:_&$"54R:$8:6*U5&-"2%N4S@&?BNZ*Z,@'B
M/#F4!+Y79T2R\B EQ('/*0-Q&L&8.L\N<'45!2[.;,WF$$'*DE)G=.BA/PZZ
MZBORK[_T! P4(-FD.&<MC&)8#/\ J<^3?583 M$O6(1WB2^(!B5YWP- 7'ON
MX!,5?E[ZKRW,3VH\)CGWJZ:Z@<OA5GNSN^(U_1;GQ@HY]VN^^M=R:0_,]PE$
M D>'@1#<2@*F10#?8=@W$O3?8=^?/IOL #2IMY284XE2202DP9@C<9M8(F)D
M$#;6)[2]@I-R2C]3W,I U$942#F@Z'K(C>TJ5(>@A&O(C?Y#A8)9Q>2?BBUA
M3*HQ LBR3DL0)/'E[\7 QGAA=&$!3\0*H$$"F* NS?  2XA Y!)@2-M">?3N
MF) JV$NI45I6C./TB!,&00"01!_#E5V@^_,]H<O6/#OT#_5,C_6&^WT[<]P]
MVW2<EQ^DZ"!J3(B.[WOGIS\*N9[R24O@&(T2@$G3^Q)_; YS5J5Q_P"@A4>6
MI.W/N%?U:%A5"F>I5,IF='K)63$436 KPO=EEPD/'=X5G^=3(E1$O/<PTJ:=
M5$K! @CQ,@1K&Q&YT^RG:79"@IX. R,J@B!(F1E2DS,@'GM!K'>>'?H3O910
M,3NN'@9L4P%D6)=60'W>CV13 $W9^UWISB'R3D$PCN0Y.UTA27$H(44D<H&T
M"-]1M(T[X)K&<2I+:@2G+!VY&>7*(GQTK<BY+E];XP.38$RVX1*/:,)3%]E9
M\ $! =Q+L(;#VN>X"8!'<=4I ^$$B0"-_'7OD#3H(K0DD.+ T!(!WD:*ZC3?
MI$Z\]+IL<E;HZ.<S%#E'419&L>\; 5!4Q$+!"/@1";JC[M *9X^P-&Z:(@00
M,#E!HLF("4Q@$))DI3HJ0# CPUD1S'4G0Q5:%.LYPRXOZ0#M#,DQ, & 8.8[
MZ$ :U2N3<39(9A.,44S-WZ *=@Z*8*-ER&%)TS7*)>T1=HY36;+%$ ,"B1A
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MF)PM89"="*CEZE%2,W2XE29ATX^/.F]D$D[2NNF@\$J!S-$RCR.80W5I=O7
M=G=M!63U "E=WZI \:U3F$H!&5U8$C=:I U^R)[]#O4I7W$C#77X8<B\NH>J
MZORW_P#U(.GEN'7[-8GM9V=4#8Q"E Z3W:\OO%5^R$?TSF_4[=VNAW!/XT#T
M).&N8_##D7;S_!=7_P#^+8/^P.OD]JO"/=3/+4CK,;SH?A)I[(1_3+_O*_&J
M_<2<-;\LPY$_Y+JX^?S,@^8/I]VGM5V#[@'B3XR9&OQ^?2#@Z.3RQTU.GAKT
M\]'W$C#.X;Y@R+N'EZLJX<_G_.7/Y@_AT.*NB24"-=,QC7<Z)GR:J&$-_P!,
MY&FQ(/PU.GR\#%1:9KX1Z9BWTI/"9P!1]BL$K4.(G$UTR+-WUZ2*1L=>>5>-
MR>^;QT9'(L?5SAN[4H;--55UN<A'KD2]DQ$AUF-7+Z[&ZO"H 6ZFTE$#4+6V
M@1IL.TZ&-=*H5A*2L)2ZL)(),J)B)//I&F\QRJ4H/0DX;'KF#(F_N]5U?H <
MO[1W ?/SV]VL/VJZ-DB-_K1^R-HU^WG57L=OFZN9G<_M.AT GIX57[B3AG\<
M.1/^2ZO\_N9!S^C;IH<5=_5$GGFU,?#ER/(QX4]D(_IE]VIT^9(^S:>NE ]"
M3AK?^O!D00__ #75QV]W]I!Y!S^OZ=/:KHGW0/ GH .1G?D('SI[';_IECIJ
M>_GF[^FLD:5:%H]!5B*;9JMRYQR(T3$IS?>H.MF,!2@)BE,<"%VYAS$"[&#<
M!* #L#VF\H@#0D@&0""-8&H F2-1$;>-MS" &UE#ZI"3 5JF .8.G+]PK4:7
M@9"PWW%%3B"^(D)+(I(=D*@G[)EEH.<:)J+"F4YB$()@464!,P)HE4.8-BCM
MN>T*6T.*)RP0K3EW1X'R!')IME..J:;4 \%:DZ]PTB)229CKWZ3:43@[Q%6Z
MZU;7".+8IYVU+ZQD7L@Y2;%>.FB"+MK%$;F9%*BDY3579.#IB^(*YA%7D!2Z
MUR^?4X>Q$H!.A&8@0=23.BMB.Z*Z1C"+=MI/;DEU0U(44@D=PTB2-3,]*T"X
MI>&..X?+,G>*,=8,8Y!F@9R<&NNNY6JMW? [<-E6 E:&*G7YMJS%LJ9X]6<)
MS@M4BB<) IR9=G=AY80\G*1MRF!OIR&@$_*M;BN')8;"V)CWI)43J=A!VYDS
M/74UT&"7!R.\A*(J'141QY.*D43.<JB:B9VYR'(<ABG*8IR@8#%$I@$ $-NN
MLW4%?ZLC+]741.I@SI!ZR>^M2PD*"C*LR&5+T*A"P8U&^DDZU^W!K'*\2V1\
MWTFPS>6ZTVPPWHZ9Y87#EA$6]U?(R2DFSFKR[IT[+*,Z\G&G;3789(F3?KMF
M_;$HB(XUU<FW"<J"2HZ[P!$$3I)V@]\UM,/L!?!*W7(AHF"0#F"U:]PB1S'+
M0R:CKXE.->1X<<PW#$KG'W%+D=2JS4I%%M&-ZK(66O/"L7[IDF8'Z5@;@FY,
M5N"JB(HAL4XAL&VLME0=;2X01,2"J#RCH!.NW+F-ZQCARLSB?6$>ZM0$P=.F
MNJMXUWY&:VYX'<]26>F,M<%H7*519.*W<F1*QE5@]AK"DK&^"1,\4B'+YZ5-
MLX!0QVB_>=HY"GV O:V&I0][GR/.!K(WG78$<A,FK"VRRI;.=*PE(4"F)]\3
M'[A/RBOBO</,+Q92R>#9^Q2M4B[5VGB\]"MVCF0;&KBI;$@1%N^#PYR+K1A&
MRIC )BI*G$FQ]ML:ZN$6[$A![0;GK)TD&8,3W<IB:OX9;BZN<F;(HD^],C28
M]W0; ".NH[]EHST'V(F: (J9JR"X3*78HEA*VB;M ([G-VDE@-N ; 78H!U#
MW:TOM5WF/>/0QIMI TY'0;[UU(P='-Y4P!(D;=P/2NS^XDX:_'#D0.F_X,J_
M3;K_ %%L&^_S_3Y:>U7>:!KU4=2">[IW3ISWI['1I],OG.IYQ//3[?B:#Z$G
M#/3X8,B?\EU??Z/ZBZ_X@Y==/:KL?43_ 'M]-Y $'PZFGLA')YSXJ)Z>?CMM
M726+T+N((2 G)A++60W"D5$2<DFB:-K $6,P9K.BI&,5CN4%!2!,1#M;=K<-
M_*48HYG2%)$2)2#$@D"9Y:Z_ 52<'')YR9TU^W?;[:CD]$WP:4OTA_"RXX@+
MO:+#CZ91RC>:$$#5DHB2BQ9U7U0+5Z+B4:&= Y<!(G[\NXI?>R]C;61=X@XT
M[E;! B8/?WF=.?RFC>$H.JW%P#L%&?L(YB?WBI-?N).&O+,.1>7/];*O^79E
MOMO_  _;C>U7M)2---S.P,S'<><'8U4<(0=GE\]R?G$P".73X4^XD8:WY9AR
M+_R75Q\_^!?/_%[M!BKT:($Z\SW;Z23UVI[(1_2KW_65\.>_?]E/N).&O+,.
M1/,?UKJ_\3'Z1$?R:'%7=3E TUUG[8Y=/NYO8Z/Z9?Q).O7<:S_#>=9>,GT7
MV,^&7A6S]Q!P60KK9IC#V+K5?XV E6D TC)A[7XY9ZC'/G+1CXI%LX.F":BJ
M&RA $!+OOMJ[;8DMUUILB<ZT()3H9) &FNTCPZU;5A! .5Y<@3JH[ZSY@3\=
M.FX#O1JXUXMN$3 G$G9KW<JI,Y=I#>V2=8A6T$\C(I922?LC,V3Q]'%=JI@1
MD4P*+D$W>'-R,0  5QB#S+SC28]PD)) ,'0S&H5KH0=*K9PE,)+KBU:B4A9@
M@;Z@\^?3:O2'4JQ&TNKUVI0X*!%5B#BJ_&]\8#K>!B&*#!L*QP*4#K'2;D,L
M<"E[:@F-MN.M0I2EJ4M1E2B2>6IWT&GX<JW"$)0D)2(2D0!W#;7GXG6KBU35
M5-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*5Y5_21VF"QQQ)98LSM<J-CL3^
M$@(!RZ5\0S;*J,&Y4$Q8F[1R@R724DG8ID.FLBY*L!>VV.!E0/VG[SY[JA4?
MYF<W!69K-=D#/+9>IQK5$$MC))LTB+J+.WA%UW6R37U<UERF%==,S8X*+G,)
MSG$'G\:FKHK3J,ETWT!=&,98%XVL*(2K=J7M+3+UBDHJ,@JHU;E14=%@YAXQ
M[+T5-VK8C@IE-VY-*5;O#C2\I96R2SQ7FE^5[2L=W9X]IM=F8\(PE3,U<2K6
M/9-K1&L5WC3UZJY64!@8SUNV!DM)+I)+,W15VOG73[*5NA/8+Q;EQ2J4:[(V
M"B36,LC/[ RM;-0;HJVG%R0IF0NA \4X90CQC#QY_&M3R#18"J>+:->VHDY>
M?/GK'0JD!L'#A77V,FC-Y9X].<8QML3K%M:M4^[.JR.+Q5FX^^M5FKUTUE)M
M@F83*)JJR1"*$(F+=8D?NY^?W_"E: .<?3/P8Q*<(JX=IQ^1[I,.I@[82(1]
M?]1.EV2:R21UER.7C..(V;CWITG#AP IG3(J< FE6WC*YR53S=6%IHZ,;5V>
M28F<1D%D5%6TP%0FV7BTF2A3& %UW;A 054['?K'.)%55#:4K*&3IN,@6>1I
M=9PV"4DLP6*J,S)J'6DTVOY^06515$Z1 2<MVZ %*!N^.J\(540*4!%2K9J\
M_/-EHV2F2I2=1>@]@Z[9&QE4)2LW"LS,(HV,\!@"(J.U8^3@VLB9[W@$:NW+
M](0.S<I$4KCVG+\KDQ@CDAS%*H$C;JPAI^23 30REU<UMV1R*Q2G3!-V[ SN
M0* %,( 0R(CVA32TI66^'N^FL\7FZ.MZAW5<F%V;QW"R!SD;M9B/C1!G9&1S
M&*<JC%1F+!/PXG!TW3614$J"QA%2K'X@Z%"Q6$(^!K+%9%U:*M29"X R>*JK
M2<K.W9!K8)-PW[#M93PU<GP4>,&!$1/&QB94"D,*PFC77QT\-/WTJ%#C=X?K
M58,J0.:((L98J7D!]4JY6J3:57AGT4X8-' 6E!-D15(A&C&)K4 ]LZKIL"2;
MNTQR)6AUU5#BUGY$Z^.WR'CKSI6#C1]=QK;4:C7E9]%I8(UZG-TIBT54JL6Q
MD&[1%G%+OEYAU(^M6CZ5E+!&&\(52K.T&#$J@)>(=JS2I6*G0H="J8R=)KGE
M7DWCZS6/'Z2QSJNFE@H-]4([8>'5*1$"R<5&O)*-;N#@FF)C%*HY,0 .I63:
M#DE/(\9DF@,6ZQT8ZV-+"Q?NB%792,T[12E7K-%51,K9L_4;'?$03!5)9T2/
M1(4AA14614J]62D?BZS331=11^OD#"+J[KOU12<.%;'*23)"839($2;I$:D;
M-%SM&RA5%&2@@*0*&[9M*5IE:V]TN#)F5PV%PM(3EDFV@,CBX8/7=<AV\ J)
MW!!<%,_%Y$QBJC0Q45"@"RJ?:$Y#BI63L941PI:DZQ+3"B3(M\L+N2EV*JB:
MC^!?P]=L*T.5X]377(LR?**).E03<BB<ZBY&YTP+VE*[^>:(QM(76=L&,>G*
M5M_).%U$OPFL[2?@,"\;'6(51)V<Q7K64,V3!NJ1=MN"1A(05*P]CO.SZQ4J
MPU9M&NPGG\'!5YDFDS3 $H]BX=R\"U.U;@LF#Q\YCBL/#  KND2 8IS'47*"
ME>[?@:3.EP><-B2@@*B6'J2FJ(%$@"JG#-R*B!/[ !4 P@4/DE#Y)?D@&E//
MRK:K2E-*4TI32E-*4TI7F*_-$<1.3^6O1$P58M+NCV2:XSVL37[FQC(^:>U*
M:D9[%3.+LK2(ER*Q$HY@WJR,FA'R:2C)XJV(W=E.U5734VN%+*%O@1E+*@H:
M>\ E8@&"1(*AH0?C%8[XG*)UG0=_4B=1X@[5(9\1OTA/+_NPN8/G_P!"GPP_
M]6_/ZM8W;VW^I)_XSE59'?Z8_P!Q/[08^VGQ'/2$_P"S"9@_YJ7#%[O_ #<_
MGN/NVT[>V_U)/_&<_"HR/<WODA/GK]GP?$;](3Y^F%S!_P U/AA'_P#UL/X=
M.WMO]23_ ,9S\*DH=Y/'XH1^P>9[HJ@\#OI"2_*^["9@';R^*GPP_-T_0Y[_
M 'C_ -D^LVB?>58I4!,CMG=9T&VNDSI%.S<W+I/=E !^6W[.^H,^)7ALXK8?
MTY' -C&=X_,@6K+MJP)D>5IO$*ZP=A:,L..(5I"9S4?UN,H<=$)TBP-I1*,E
MFZ[^?:*/VQ;"JJU5[3!EW.R8?85AEXM+ 2@*:ED.+A1+K0!*MQ$R8W@;ZU8*
M'.W0 L[$YH&@RJY$D'H (WCE-3F!P-^D)V#_ +L-F$>0<QX4N&'?R_WN>7E]
M@B/76L]8MO\ 4D_\9RK^1[^F_P#(G3IRU^SXU7XC?I"?]F%S!O\ ^BGPP[?;
M[-_Q:GUBU_U)'CVSO\/LIV;L_P \>H]Q)^!$>.Q'*GQ'/2$\_P#NPN8/^:EP
MP_9^QSIR^?\ @U';VW^I)_XSGX4"'=)>V_L)^>HF=_&=Z?$;](-N4%/3 Y?6
M3$P=M,W"IPQ%*<G,#$$Q:X!R@<![(F((&+ON41$  :A<VJ0H^H))_1/;NC*9
MT( @'I"I'/?6J5M.+24EY0!$&$I!UWU$:1I47M,SQ&8J]-G%\#DZR:+0N/&T
M7:8/);^?2A9"?L5QQ"PF$8IU!BQ%@@B5:X/FJ"3>35</C-VJ)" HJ*9ML2I_
M#^U&@(6"C0Q!$1I)VGQY[UH1AZ;2[;<!S)"CF,J'(G74^$&9&E3S9^B<E2+^
MIGHCV,:MR3\$>9]:Q[R00=5Q)XY]H8^.(R,46LX^2%KX!XML1$A5=Q[P";6;
M)QM#*@(SS[QY["()WC43L=23$4Q/MU+0M@*+:9T"9&IU&H/UNG=ISK7_ -)1
MDEIAG@ S!?[-W#B1JU6BIAA%NIE*%-+ST',1\W&1WBCI.5US&&/(=VV;H.'*
MS9%T=-,PE,8EID%R]24[%1( V!TF2!'U@8,_>)R76^VL0E4-K*4YI)))T !!
M)@@;P!KSTT\^GH?/2$S_ !L9NRQBJ9QC%4!LRPC-3X3,7:'D^Y.JI9ZO ^'\
M&ZA8I(" E-*.0."XB*J"91#L&'??E! 5F!F0$[2!E.T0#S$'K6D=PTL,*6ET
M)4L92=P4'ZP(45>,Z$&/"IX*APNV"H*-IBG9/LU=6G04BRN8GPL>L[(<JG;;
M.03?D,9+=,ZJ8KEV34#O$#D4 !UB*>9DH>;#D'.9G01IM!&Q//F-.=IFTN&T
MH4V^4DI[-)$:ZDD$;ZDR28,@1($"VI/@X1:M9V<D[E*F0BUU32KM1M'N''B.
MR*SA0WY\.NX.<%>WWI04$YC*;FW[9A@7C 7[ZEM)2WF"$-YDGH0I2223^J2!
M\ZO6^"W5TOL6E)+UQ>V5M;+6X4A3UP\6W&U@+"0A0R@JA.7=)$:6+CV I$)0
MKSF:B6=_:HZ+I=Y11;2$2>%3<K148=TNB?OA%RB)U694CJ%05+V3=LAC;=@9
MM[E%T"XTI2V\ZD)SI"3*#$P$C;K&V\D370\8\ X]P+CB\"XA396U^JWM;T-V
M-QZTSZE?-)>M275//GM%(@K3G!2HD91SCF]$!E?*WI-ZEQ"62AWEYP=Y$PS-
M8^B:W?:3$US++LS:Z)65U,&5@[_"-H,3*1]<5BB@NS>@1*76=-S(.FB!QQ\4
MN&V0AI306D@S)*9@I,2 3S G2!UFL.QPCL7$O(<*08.FLZ0=S/73;7305+_\
M1STA(\_NPN8/^:GPPCR\AW]FPY^73;;6F-Q:'5-DD \NW=/CJ1._+EMRK>=F
MX! =($?JI_">_??I3XC?I"?]F%S#_P U+AA_ZN:>L6W^I)_XSE,CVL/;SKE3
MITY'N[J?$;](3_LPN8/^:EPP_P#5SZNO3GOOIZQ;?ZDG_C.4[-V?YX]?JI/P
MU&W/E'3K;UNX(_2!M:I9G#KTO67GS5O7YE9PR-PK\,J)':*4<X45;G53K8*I
M%6(44C*ICWA"G$2[F NU2+BU#J#ZDF 1*>V<UC2=MY(.WSUID<_I"?@!/?TW
MY:;:5#IZ!3AEXM,J<#+NT8;](+D#ANJ 9RR;&*8[K."L*7Z--,,BU\)&P^O;
MW#OYP',N"B'B&15O M3-P%J3Y9Q'88A<VR;A.>S0OW$Z*<6B1KE&FO6/$^)L
M,-N&2I1C-I/V\Y^)^^IK/B-^D)V_[\)F#?\ ]%/AA_ZN?Q:UO;VO^I)_XSGX
M5?R._P!-O_828^$?;(G>*#P.>D)\O3"9@^OA3X8@V_\ Z<'\ON^G3M[;_4T_
M\9RF1[^FC?9"3^SEX=VG.GQ&_2%?[,+F#_FI\,/_ %;T[>V_U)/_ !G*9'>3
MQVC5")\=!\_LC>M+_2,<(7'!3N!7BOM-Y]*+E#*M.@<&WV2LF.9;ANX>JW'7
M.(;0S@SJOO)ZO03>=B&[],!34?1:Z;Q#?MH&*<H#J_:/V_K-N$VJ4$O-@*[5
M:RDE8 ,*T,$B9Y<C5"FW$H4>U)A*C$  P)/A^T]YK?;T*X /HK^"41ZAAMI]
MOM!.[_EUC7X!O'R1KGGI&@.PTWJ\W]1,[QKX\]ZE$UBU732E-*4TI32E-*4T
MI32E-*4TI32E-*4TI32E-*5YCO25>CRXS.)7BC4OF+\=UV?QK H.I.)&8N=<
MAU9FPG9.$44SM';T'31FL=RFDLZ.0J@E8D^\[#N*HD#29/S/V5''0_0A^D%J
M"8V,:)6E+.2?>M4XPV0JJHV"LR!+.)I1"1"1(*,T@$FR;*$636.HBLX!LJU$
M@J&5,^8-;7XX]$OQ=5O'%?;3%"8(9*5L:D[:)J.N%)>]R=?O(HZ;%=[+D1D&
M[:+%-9!NZ1;@*22+(P@N4SG2HD=_R/X;:[[5E.A^C:XM*M%+.G>*HE2Z-X]Y
M'HS[6]54%I9-S*GED#2)G$RL<BK,SYXT.H14OBV[1B0Y !18Q%,PB9\^?PWJ
MZ*%P$<9]3OLC<E\>M5QD*\^B%BFO=/5675=LG;;O7!BRR0+%+XLYB@($*54P
MF$INP"JBIGEY\_OZ&LVQW!SQ6)U=]#2%,456<NFZS<HV&G.46@$3,T='(*T_
ML8[ML5N*H]@IC=P7[X!^[$%)\P?/GN-?C4^!_B#@H=W#+XU$Z3E@^;JG-9*B
MLBZ=@Y?#&.E&YI\HD,DU>E P[F,4S4J8#V#ALJ)\?D?#IYWVK4&[>B\XQ[#-
M8=)'8[CFT-C:S1;QXL>YTT#R4.R4BQ<B9N24V5=JEB6YD^V4B@J&44.;O#G$
MSSY_=2?'Y&EL]%AQ;7:X6!O8*(K[!2=AE;<FO&7FF-YQ285?1ZD>FBDK*BW8
M*%09K*G?]AP?OW:O>)G'GI4SY@TP]Z,WC6JU<R;3;EC2/<1EDDF%GJ,DWO=,
M6&(L\"^55:*+,O6VZ+*<B7,S"2*2"AN[+/F<;G]5M@.\FH) Z_(_A76+^BIX
MQ4\<6^L,:$P&7EK!&6",%2Z5 &8OXY[%K*/#B67'N73XC9V9=8XJ&$ITT>Z*
M8.V*D^/R/X5S:#Z.3T@4"W<>T&.X%XX>^MD11"^U!9G'QY5%&L)&MP]:I&.W
M+';J*D "%1=NW9R%W5.;2D^/Q!'[)COUKO+UZ-+C#OL?"QMEQ7%2\4@NY;2L
M8;(%4;*JQ$7%QQX,&CSUL8J;A],-5$UC]V!V+4#G(IWRB;A)21^SXZB/LJVK
MIZ+/C%96J+F*+C=G-Q]7JD96:NSG[Y34DV)Y!%A(727*=Q)NWA9"1G7$@@T<
M Z*L6!B(EF*B9E5>RI//7Y'[HFM:E/0G<:,SD)-[.X<H:E55DBF=R9[;2_7@
MJ&,R!W9FCAI(DE(N5=I&<H.&[-VJ219,T6,B<X.W+@7G>-J3XZ]Q^WI\:YC;
MT1'I+:[9:,]KM4A74-1_:%I'HRV4*TLIZC>O'3MC%]RXDGJ9#BU?/X_O6ZR"
M:)W"3Q(K;95(D:Z=-9G[-?.F^M)\?D:O;'WHF^/+'[AC-1&)X1M-.@;O;*#;
M)]211?3<9*2IV$@0/'G; 92'<L6*J2;=%/L!)@;<9 P$FIGS!K*EO]&CQQ6^
MYPDH\Q%#)P,50$:DFBCD2E$>I+NGB3Q_NL+]0YFK5;MBV*DH3MHBHEL0#%#2
MHGQ^1JTL6^BAXVL>2:R_P;P[J/;R+N7CVJU[IJP@Y<]T MBE/([(IG\,B)E0
M%3O0,<%B&/ONI/[?L\_=U%<DGHIN-IG:7DFSQ[&J1SN:E)8QG-WIHN2ED(MI
M%BB4A);NR*]VR()EBE H)J=V5,O9TI/CIW'R?A5N7;T3O'=:'M,*ABZ":1T/
M27%:G41R+4ETGJAY%U)E422=RBAB+J.2LC X24322.F0XMS=T BI/CSY'EY^
M/*L;S/H7^.FLY%"8Q/CR)C*E-4VMDL82.3ZSXY&Z5]DVDFJS-,DKV56S2SI.
M0:/-TE&[-ZY$I.R;NC*3Y@^9[MZ]<O#/3+!CS &(J/:V*<;9:O18*'G6"3A!
MVDSDVC4I':";EL=1NN1-;M%(JB<R9R["78.0*FLY:4II2FE*:4II2FE*\U_I
M\!#XQ/H7PWY_'SK0A\_Z,,0]?Y]=;+#?YQZ(_F%[_P"ZKO'\8JR[NGQ'W^/[
M/GR]*&M;5ZFE*:4II2O-KQ>__*1_1A;]/BP9;_\ A_B1#;^?\&MK;_YJO^N=
MC[76?PZGX<[*M74#703I\=?W[\@.9])6M55X;"FE*:4IMT^;II2OYN7IS<LV
M[!GIO\M99H;\\;;*/\ T[$N4Q[.RS/#U#4,D<P@8 *L4HE$PIJ=@W95 @F3*
M&NLP[*</2E0D**TP=M29V(,1RZZ\JU=RA*G3*@D)$QH9.^Y!@]8Y3I,FI_N&
M#\TL<)%LQ;%*9Z)8:5D6(ADD)A!%!H\;SKZ.C693O4E%E8I%%],2(/A*@R\8
MS13*FN95 JX-&^$O#7<\MB$DDC38*(TYZ <C&P\1:%P4 H+1(,:_K1.NY/V\
MS,P*@>],UZ:PW'>R0PCA5G*5_",1*B_D73[L).K>Y9KNO5SY= 6B+AHJ#9QW
M2[=-5=HF4IT45W8.%7)]I96(M2I;@E:BDI4200(@@"1W0=AK)J%N"X !3"43
M"=IF))UF2/A/.-*YOYF<  XQ\S>8#PYS'+D(;?"-CW[>?(=PYARV#KK*=,CJ
M3)[]!\.O4=W=@WR1ZN>8!&428&HT$>)$_9&_M>4C&"RSI55JBHH[2!!T<Q=Q
M71+V1!-3<WRRE[)1 H^92CY:P#H#SWU(V!WB=])T[M>E:V!"8$: :$_"8VD[
MF/AK5/5$8 I&\"W'N&YFB6Z)?D-U ,51 H?^(<IS=HH_J@,.XB(:G,1(!$'0
MRE)DP--LTQ!TTZ:U+:UMDEM:D$J;7*%JT4RHJ:6-PDH5/O  S$R(C&62H&%K
MF%,J1D#%LHF.+CR]K$91[<C9L55:LR1E% 33*4H&4$ $P@7<QOE"&_/1I"4'
M*E 2"2HY1"9.YTY]=!,<@:RKF\O,1N47%]=W%[<**4%Z[N''G<B/=2C.XI1"
M$#1" 0A"=$@"8@T_,BG["..3_P [\'^7OB,E_P _/?GS\@U>->\MH'4>_'Q"
M>GAXBNEMC$H'U0E! Y D JUW)),G73[O8\ ;<M:2LJFE*:4JT[[^P:Y\M_T*
MV'_W2[U4CZR?]X?>*5 3^9C!'[FR_#?_ .<IF4/I#L5<0^OIOMK88R3ZX@#3
MZ%L0-N9.WB3/QJPP24$G?.H?* /LCSK7HBUK:OTTI32E1Z>EF_[VCQP\M_\
M0WY,Y!U_6!QK)L];NV__ !VO_G35MT#LW/\ <5]@,?;5C^A6_P"]7\$W_P"A
MQI_\03VIOO\ *W_]X?\ RCP^X5+?U$^%2AZQ:KII2FE*:4II2FE*:4II2FE*
M:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II
M2FE*:4II2FE*:4I_/[>NE*:4II2FE*:4II2FE*\\_IJL>V3*>??1IOZBBS<M
M^'3B8@<VY.\:\(P.PH3>T41PH\C"+$$9A_W=6E@)&M!\0*J;=/\ 5N4BFV^&
MH.2X7H<S2DIYD0E>;PW'/OC8UJ[^];ME-A<B5)GO$B/GKH3'=,UZ"HV1;2L>
MQDV9C':2#5L\;&.42&,@[2371$Q!^40PIJ%W(8 $IMRCL(:U"@08YR/Q^[[.
M5;%"TN(2XD^ZI(4#W'6N=I5=-*4Z:4KSO\5%.G)GTZ?!-Q$L4FY\9X)Q);,7
M9!?G=)IRK*VWB(RTV@6T=#B47<FT55R#6B.7K;=)J#M8RW)LKMN;1M:L.NV]
MR\4*0#RR.(63/(%*(GH(CIJW[]EF[0TO><IT.A(,?$3/+QTKT/%'<H#OU]^V
MX_9O_".M* 1())U._P!U;.=N\3Y_?%?6IJ::4JQLF7(V/:%:KJ5AZT&M0[J6
M%AWXMO% V+VA1[\$U12$X<@/W9]O,-5(25J2@;J,#Q-6;AWL&5NQ(0DDBO$5
MZ1/T?3/CYXL\C<4;C*+C&:U_8TMD:G)59*SI1H5"F0=1!0DRI-PYW'C@A0>"
M48]N"(KBD':[';'L;)L6]NEI2<T'-)'ZVITTZ]:Y->.)=65=D" 2.9B.\[^
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MI6_]K:=OLYZ_A7 DK15IEBYBY>)-*1KQ,4G;"08-7C-TD(@84W#9P91%4@F
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#K__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g401831g24o88.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g401831g24o88.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1EX4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &5R^9)(X0DE-!"4      !                      .$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'/V=M         *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  @.__C4  @ ".$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         ".$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@              ^P
M T(          0                         !              -"
M^P                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M^P    !29VAT;&]N9P   T(    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   /L     4F=H=&QO;F<
M  -"     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
M A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46
MHK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F
M=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$  @(! @0$ P0%!@<'!@4U 0 "$0,A
M,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8U
MPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:V
MQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$ /P#U0D 2= .2N8Z]]9>I-L^P
M=!Q_6R7:"XM+QY^C5[=^W_3W/]#_ (Q9'^,KKN99;C?53I1)RNH[?M(:8)98
M[TJ<7?\ F,R'![\G_NM7_HKE4ZOUS*^J^-B?5+H+G9O6]C*\G,<!8]I<-U./
M16^??M=^@9;^BQ,/T_YW^<4L(;$BR=A_W4F.?$=(GA'Z1_2\HK7?57Z\9MC+
M.K_6'[!]I<&LI-[P2XG:VMN/BNQ<7?\ R*GO3.^I?USQ+7LZ3]9/M%]$.?CF
M^VMPD;FAU+WY=7OGV^M[%6H^K?2^A]0Q.L?7/K9'5&V5Y+,5A-]NZMWJ5^O;
MMR+[:]S-C_3IJJ_T5RT[,?ZI_6?K=F?TCJVSJUVUPHM:ZHDUL;6W[/O9CY'T
M*MS_ $GWIUGOZ>XCZ5&P- 9'MQ>I%T[_ !A==Z+G-Z9]<L1S)_[5M8&O#9UM
M=71NQ\REOYUF%_-_Z*VQ>AT7T9-+,C'L;;3:T/KL80YKFG5KFN;])</G=2Z7
MF9E?U*^LS7W7WAOIY< .IN=_0_3R(]]UGYF0S_PKD^KZM]:H_4?J&=]6_K)?
M]3NJ6;J+'..(XP&BPCUF.JD^RG.I]_I?X/+_ $?\Y;:FR@#9 HC73Y91[Q3"
M5@'77][YA_>?2DDQ( DZ <E<OF_XR_JEB7&EN2_*+3M<['K=8P$>%WMJL_ZR
M^Q1B).PM>2 ]2DLSHOUCZ+UVMS^F93;S7_.5$%EC9_?HM#+6M_E[?35S.SL/
MI^*_+SKF8^/4)?8
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                      #_X4!U:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O
M,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E
M4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE
M=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ-#4V
M-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z4D1&
M('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M
M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T
M/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+R(^"B @(" @(" @(#QX;7 Z0W)E871O<E1O;VP^061O8F4@
M4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+WAM<#I#<F5A=&]R5&]O;#X*(" @
M(" @(" @/'AM<#I#<F5A=&5$871E/C(P,C,M,#(M,3-4,3(Z-#4Z,30K,#4Z
M,S \+WAM<#I#<F5A=&5$871E/@H@(" @(" @(" \>&UP.DUO9&EF>41A=&4^
M,C R,RTP,BTQ,U0Q,SHQ."LP-3HS,#PO>&UP.DUO9&EF>41A=&4^"B @(" @
M(" @(#QX;7 Z365T861A=&%$871E/C(P,C,M,#(M,3-4,3,Z,3@K,#4Z,S \
M+WAM<#I-971A9&%T841A=&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@
M(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @
M("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B
M/@H@(" @(" @(" \9&,Z9F]R;6%T/FEM86=E+V5P<V8\+V1C.F9O<FUA=#X*
M(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I
M;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!H;W1O<VAO<#TB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W O,2XP+R(^"B @(" @(" @
M(#QP:&]T;W-H;W Z0V]L;W)-;V1E/C0\+W!H;W1O<VAO<#I#;VQO<DUO9&4^
M"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T
M:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7!-33TB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*(" @(" @(" @(" @>&UL
M;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]2
M97-O=7)C945V96YT(R(*(" @(" @(" @(" @>&UL;G,Z<W12968](FAT=' Z
M+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B/@H@
M(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED.C1",C@P,S(X-S!!
M0D5$,3$Y14,U13$Y,$$T.#(S,S@W/"]X;7!-33I);G-T86YC94E$/@H@(" @
M(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED.C0W,C@P,S(X-S!!0D5$
M,3$Y14,U13$Y,$$T.#(S,S@W/"]X;7!-33I$;V-U;65N=$E$/@H@(" @(" @
M(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z-#<R.# S,C@W
M,$%"140Q,3E%0S5%,3DP030X,C,S.#<\+WAM<$U-.D]R:6=I;F%L1&]C=6UE
M;G1)1#X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @(" @(" @(" @(#QR
M9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYC
M<F5A=&5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#II;G-T86YC94E$/GAM<"YI:60Z-#<R.# S,C@W,$%"140Q,3E%0S5%,3DP
M030X,C,S.#<\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IW:&5N/C(P,C,M,#(M,3-4,3(Z-#4Z,30K,#4Z,S \+W-T179T
M.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT
M/D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R
M94%G96YT/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I
M;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F9R;VT@
M:6UA9V4O9VEF('1O(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W \
M+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%
M=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)
M1#YX;7 N:6ED.C0X,C@P,S(X-S!!0D5$,3$Y14,U13$Y,$$T.#(S,S@W/"]S
M=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE
M;CXR,#(S+3 R+3$S5#$S.C$W.C0S*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T
M;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @
M(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E
M9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z-$$R.# S
M,C@W,$%"140Q,3E%0S5%,3DP030X,C,S.#<\+W-T179T.FEN<W1A;F-E240^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C,M,#(M,3-4,3,Z
M,3@K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I
M/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^
M8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IP87)A;65T97)S/F9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H
M;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A;65T97)S/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IA8W1I;VX^9&5R:79E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYC;VYV97)T960@9G)O;2!A<'!L
M:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T
M179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z
M86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX
M;7 N:6ED.C1",C@P,S(X-S!!0D5$,3$Y14,U13$Y,$$T.#(S,S@W/"]S=$5V
M=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR
M,#(S+3 R+3$S5#$S.C$X*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @
M0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @
M(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @
M(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*
M(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @(" @(" \>&UP34TZ1&5R
M:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" \<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED.C1!,C@P,S(X-S!!0D5$,3$Y
M14,U13$Y,$$T.#(S,S@W/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @
M(" \<W12968Z9&]C=6UE;G1)1#YX;7 N9&ED.C0W,C@P,S(X-S!!0D5$,3$Y
M14,U13$Y,$$T.#(S,S@W/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @
M(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z-#<R.# S,C@W
M,$%"140Q,3E%0S5%,3DP030X,C,S.#<\+W-T4F5F.F]R:6=I;F%L1&]C=6UE
M;G1)1#X*(" @(" @(" @/"]X;7!-33I$97)I=F5D1G)O;3X*(" @(" @/"]R
M9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @"CP_>'!A8VME="!E;F0]
M(G<B/S[_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0'_P  1" !+ /L# 1$  A$! Q$!_\0 '@   @(# 0$! 0
M      H("08'"P4$ P+_Q  ^$  !! (" 00"  ,#!@\    $ @,%!@$'" D
M"A$2$Q05%B$Q%R.W&"(D.4%V&B4R,SA$45AA<W=XE[+7_\0 ' $!  ,! 0$!
M 0            4&!P0" P@!_\0 3!$  @$# P,"! (%!P@&"P   0(#! 41
M !(A!A,Q(D$'%%%A(S(50E)B<18D,S6!@K0E-D-R<W2#D3135&.Q\%5UA)*3
ME*&RL]/4_]H # ,!  (1 Q$ /P!_CQIH\::JZYO=K_'KAF+*0*&)+<NV@D.M
M8UU1RQF!(@U*%*;:NMQ(;)BJWCYI^M\$,6?L8RLH4]7T,.)>\M-DZ2N5XV2D
M+14;8/S-0K9D7ZP0C#2\<AF,<1&<29&-4CJ'KVQV!Y*8R&ON"<-1TK*W9;G"
MU4W*0'CE ))EX)B (.E)N2/?_P!JV\;0_3]!-0&EA)1]T:%JNEM;MW_8)PV5
M?Y@Y$_<8^XR1DDGWQA1U3@:LK.,)^ C/NKYZ;2]!=.4,'>JVDJR@R\M9/V(5
M;'.$C:% OT65I,>['&-4"'XCWJYU?82*.E20XBCHH6GE*^VZ202.S?O1)$#X
MV@ZC@W7_ %)NW,*GD.=GJF7E?DMK<GMQZV$6E_W5A0,4](U,;#&??/LT$%AE
MK^6,(1[8QYX9^B*4[/\ (!QQZ4I*@\?M,%E.?J6.?N=614ZEJ1OQ=^>?4U5"
M.?H&,8Q]@,#Z#7P'\I/40<.L?Q)>;/STJ<+%J2M^6W+1+=LJD(;&QG*DDR>S
M*O<*LH=2<*^Q7Y>$NI2I>%YRW\TEH.C;GZ(H[/*S<!*66*"7U?1:>2*3(QQQ
MQP/!P?XU7U%19:22Y1 >6G262,8^AG1XS]SSGDG.K%.(/JP=MUV0BJUS8TG7
M-C5E3C(QFS=*,_P?? 6,JQAV1E*--295-M1/OE6<L0LGKQAMI*?@P0]C.'86
MY?#VF=6DM=5)!)@D051[L)/LJRJHEC'W<3G/N!J4H^KJA"%KH$F3@&2$=N4#
MW)0DQ.?LO9'W^KAG%3F/QOYKZU&VKQKVA [&K&5,CS H:W0+/491YK+OZ2YU
M21;&GJQ+)2EQ30\J"PT>PC\Z*?/CG&3'<UN%LKK5.:>NIW@?DH3S'*H.-\4B
MY21?NI)4\,%8$"Z4==2U\0EI9EE7C<!PZ']F1#AD/TR,$<J2,'4G/.#77H\:
M:/&FCQIH\::/&FCQIH\::/&FCQIH\::/&FCQIH\::/&FCQIH\::/&FCQIH\:
M:/&FCQIH\::/&FCQII<_G#WF<>*-RB/X&5&XE0LIADFK;)WW&R S53I.QWR&
MAF=6IDV\X=!+;0M\&VW,<A =2G5CU\A8Y#%AD8#0>G>DY9:9+M6Q!T)#TU&P
M]4D>,BH=3^92<&*(@]Q?60045\I^(O4%XCMU30]-2A)UW+75,>?F5B 82PT9
MQA91C$LJDRJ-RP;95W#Z]/\ 4/";>D<;!Y!'G0&O%+7(BU6/>2!9+2+A2GW#
M)F6)2M5;@G\8RM2VT+FI =3I [\.WD21?[[KUG\F&I+6J35 ]!J&&Z*%N !$
M@P)9%\'_ $2L!PYW**/T-\,JRXPQ7?J1IJ*ED EBH%;95U2'U=RI=@33P2#D
M)CYB126)@&UGP7='=3U$=93$MJ?B]0X7;%ZB<N1LS#\<H.!9KG[,/.6\LWG>
M4NO ]F,2M'U$R$,7L>0%>;R+()'?94RB,@Z:ZFZA9:JYU$D$3896KG<R;6YS
M#1J (U]PK"G4@Y7(.=:XMQZ=Z?C^5M-'#E!M*T:(J$CC\:J;<\K<<OF=L\,<
MC4HNG;MWG^U0_D@1(Z-B=*0NEG=8H@1 [T9>Y.:;ON+YDI4M(/UBJ"LK _A
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M^T6[9[G;#E]GKV[03KS^E:#Y3Y[OGY3?V^]V9]N[=LY7M;P-_HW%=F_T[MQ
MUYO%GM,X#\U;[)ZOXS<B(/9-_B:\3:RJLJH;)I<D[ !%B!&R$:G85,J;$S@(
M@\3\T:'>.,$9>240.V+A;R?5PZ?O%KA6HKJ)H(6<1B02P2J'() ;L2R%,@'!
M8 $C .>-*2[VZNE,-+4K+*%+[.W+&2H(!([D:!L9&0"3C)Q@$BP#R&U(ZJCV
MAW@]66FMC7/4^Q.64##WW7UBDJE;X6.UONJUCQ%CAR%!RT1^^J&MIZNGE1IK
M;H)V(R6-;%.8(">6@H=]ENPT_2G4%5!%40VYVAF19(F:>EC+(XRK;)9T<!@0
MR[E&5((X(.HB6_6F"22*6L59(F9) (IV"LIPPW)$RG!!!PQ ((UOCDEV2<+N
M(-6U#<N26XGM4P.]XB3F]7.SFL]NG2=@CX6/K$G+9.KT#09:PU0V.#N-<49%
M7"+@)5A^04&X%@P&0'$Y*&QW2Y25,5#3"H>D94J-E13!49VD5<.\RI(&,3X:
M)G4A<YP03T5-TH:-(9*F<PK4*6AW13DL%"$Y58RR$!URKJIYQC(('. ZTN0F
MG]"]IVEN1&V;BW4=.53;.R+)/W-R%L<PU'PL[5;Y'11V82O0\M9"<%F3$:SA
M@.&(*9R3A9##333ZV]MOE'4UEAJZ*GB[E3)3PQI%O1=SK)$6&]V6,8"L<E@#
MC@GC696VHA@NL%3*^R%*AG9]K-A2'P=JJ7/D<!2?MI\K_A!W3_\ ]\2._P#A
M;D;_ /D'F1_R-ZD_]&G_ .;H?_Z=:#_*.S?]M'_P*G_].K=:=;(2^U*LW>LO
M'$5RX0$19H$B3A9NMR)$-. ,2<8^;7[+'1%AA27@R67'HR;BXZ4"6K(YP0Q+
M;C2*Y+&\,DD,@ DB=HW"LC@.A*L Z,R, 01N1F4^02.=3$;K*B2(24D574E6
M4E6 925<*RD@CA@&'@@'7/\ /5-;YF-J\^M=\=H=]\R&T'JBO"-PC*\NJ5LG
M<)*+7,/MLIS\?N/J*=:!LMJ3EW"Q7%87E!"4IV'H"D6GL\M8PP]94R,6/'X-
M,.T@S]%D[Y)\<^..<ZZLJ#+<DIP<K30HNWR>Y-^(Q_O(8AC]W/OJ\?L<MS74
M+T6T;CWK QNO;)M=,I_&N*F8I>13LW38$++6??%\%6SELH8Z3$%V&8%)#K0]
M#SMAA7F'D+8&QFJ62,]1]635M0.Y!%))7%6Y7M0.L='"<@@JI,(*D8=(W!')
MU.W-_P!#=/Q4L1VRRHE-D<'?*K/4R#D,,_B $$E&=>>!JL_TMG &JV:0V)V&
M[;B 2P-:S!VN=$(G&VL1L5:18@:3V)LW."\)9P17H:6C:U7)12EB@E2-O)]F
MY.*CR@IWKZ[R1K!9J9F#5"K/5[,[FB+%88..<2.K2.HY(6,<JY!B^E*"-VFN
M4^-M.QCA+$!5D"AY96SX[:,H4D@ LY/*@B*/:3S&YB]MG)EGCAQ[ MV>/";Q
MBHZ:U)7%/QN=JR@92QVMF;$4IP1D[)V1GIV(&L#S%?U]6$)+);"D6K#.&3U@
MZ?MO35M-PN$L25H@[U94N-WRRLN?EX< D8)[;[ 7GD.!N!C04NZ=:S7^YBVV
MVEFJ(6J.Q101NH-2P8A9Y%)& VWN R$)!$"S%<2/J>.@_20 %TP"3Y-<K)>)
MO<@(V^94M-5",,@:T2XCY9"<N-N(619G6<YPDAT6K0 R'4N-#/&,X;,<K=;\
M10)F6WV\/ IPLM7(5>0?7M1#$8/L#*YQR0I](N])T?(T2M6U:QS,H+14Z=Q(
MR1^7O.5[A'N1$@SX+#G4 >P?TZW([@M!KY \?-J%[QUC3"QYN8EXB%,HVW-6
M?ADH?#LQ$=%RTL/*PT0^AA\JV5R4 D(9W_C ROQT6(1*LSM@ZPM][E%!6Q"A
MJI@4C5V$U+4DC!C#LJE'<9 BD5E?\JR,Q"Z@>HK/7V&G:X4Z_/TD.'F>+,-1
M2J"#W7C+.&B7]:6-]R?F:-4!87U=+_-N:[#^/&S^#7/&(%V5?8&@E1I<W:!\
M.+W?IB2PS7Y!RRJPEI3E\IAIL8-(6 =8TI+#R,'9&W%6*-FYAZJ]7V$=/UE-
M>+0_:@DG!VQ\?*5:Y=0@]H9@K%4(*J5=#A&1-2G1_54'4T-7:*Y,U$4!8"1@
MQJJ0D1N21_I8'9 S9#$.CKEE=@KW6'+KT;=SK,*Y,R;M(U3M8& G) C/UXOO
M&+:;4>2HJ3::2@,Z0;H,Z%,+;2E8<=L"MM.M82]$MY;N;]KJOIDL% EJ:<NB
MCGLU].6 "Y.0.^A49.YH9#G(?G@4R6&]8R2M/,%8GCNTLH!)/ !)B8-QZ1*H
M_9U<]ZM+C)$$07&+F=706$GJD9/0%^DQD)5B6CI "2V!JXEUQKVQG$<J.V.,
MLMS#N2&Y6+&PZV@5AMRL?#NN;=7VQR< +60J>-I#+#4#!^N8#@8P5<XY)$YU
MA2C^:5R@>K--(?KP983_ & 2@D_N#C'-T/I^.0I_(7JWT$1.'KDK/IQ=DT'/
M$N._:OZ=<2*6Z4PY[Y4XEP764M1AG?N4IQUQI9/\FWT)Q6.LJ):._P!7L7;'
M5".L08QS.OXQ'L0:A)B/IG'D:F^FZDU%I@#'+T[/3,?M&<Q#'MMA>-?OC/@C
M5:OJ3.T+8VDHN%X,\<;%(UB[[$JF+/O>^5XI\2?K=!FG" H#7D%)!J23$RET
M9&/D[28PZ*>+5/U (KBQK4:H>Q=!],I7[[Q61"2""7M4<3@%))DPTD[*?SK"
M2%C'(,NXD9C -=ZQZH@MSK:DJ%BGDB$M25;#K$^0D0(_*9 "S^#VR@'ID.J[
M.K#TUIG*35%6Y&\QM@W35VO[^ Q/:[U9KYB)"V+8ZL;C#T7;[/9;+&SL95HN
M?&^)T'##5R6E92&+$ER)&$P\P*_*]1=;"VU4M!;88JF>!BD]1,6,$<HR&BC2
M-E:1D/#N9%56!0*_)'PLG3GZ1I8:ZJED@IYT$D$<84321-RDK,ZLL:./4@V,
MS(0V4R,V2\A_2?\ %"PT.4SQDW)N'6^T1 7W8#.SY>OW[7TR>TTI8X$^+$U*
MMV6(:.>2D9V;BI.0Q%MNJ+36Y93. WH&B^(5P29?GZ6FGIR0'^75X9D!/+(6
MDDC; YV,J[L8[BYR)>IZ0I6C;Y2HGCF ](G*21,0/#;(T==Q\L"P7R$/C2[O
M #F'RKZ6.:5@UCLZ.LXFN8R_(H_)W1Q#[IT26"P0R([?J>QE:HY5KAHIT>QT
M^QQ:V1KA!*%BR#G8*99)8OMWL='U5:8ZFF:-Y7A[UOJU # D$]F0\,(W;*2Q
ML"8WRX7>A&J/1]2+T[<I*:JD:+M3=FMI6/& >75?REU7UQ.O#H1ABCYT\YVB
M]B<!P9X1RW(NCKA[E=MB,0M8X\@N*R7"V.UW6((F82SF--+0\95J[6ACKB>E
M&642;8(,'^6$_-C$(R/IVP37J[B@D5XXZ??)7'!#1QPN$>,'! D>0K$/V<L^
M"$(UI%^O]+9K6M>98S\R4CHCD%)7E0R(_!YC6-6D)'!PJY!<'2*? KK<Y;]T
MW(G8NR]C;+FH^L"SC$SO7D3>ABK))/3$Q[O@U*GPZB(X>:LKX#?^@08Q</6*
M97!Q5/+!%S7H.6UJ^7:W])T4$"0J960K1T,.(QL0X:21L-LC#'U.5=Y7)V[C
MO=<_LL$W4]3-+',6B1P:NLDRX#OR(T'IWRE?" JD: $E5,:LT()Z4SKJ:JR8
M@S8O*4NQ_B_!VW-WW7XKV3?J^.2&83&K'HIH7[?[Q(;K9+N$_P!VHY6?[SS/
M3\0;T9-RP6\1YXC,,YXSX+_,!B<>XP/W=74=(6[9M,]87_;#PCG'LO9(Q[X)
M)_>TN-V0]2O*3J GC-F:?VE-WWCSN"MWG2ANR(./7 S8<#LZJ3%=M&JMN5ID
MB0C'1+16"Y-J)FQ72(:6,CL23 M9L8$2*W>NG[]0]4**:>!(JZF>*K%.Y#JS
M4\BO'4TLAVMF.0+N0@.@;!,D;.=5&^T,W38%2TQ:CGWTWS" ICNHP,$Z\@=Q
M-VTY*L5)]#A1J2OI0(HT#L)W8Z2RXVVKAK?&\*6A2<97G=W'U6,8RK'MG^2%
M9_EG/]/./XCQ-'8Z7/@W6#!_]CKOOG_F!KZ=#W"FJ[Q/'!('9;;.Y YPOS5$
M.?[6 ^_/TU"#O2ACRNXWE*0TPZII=WT_E*L(5G&<)T]JU.<XSC'_ &ISCWQC
M/]/]ODMTC"S=+VYAX,-3[<<5-1[_ -FHWJ6Z4<%_KX))E619(0P)P06IX2/;
MW!&--U^HNX9JY2=>,OL6M17Y^S.*9G]L< XPQET\F@_@,QNW89M6,9RV$BL-
MBW@W"<?-YV@ M)S[J^*LSZ(N/R5\2F=]L%R_FK9_*)RV:9C]S)F$?3O$G6@=
M54JS6EZK WV]34DXY$ 7^<#/LJH!,WU$.!JLKTGW*0X8+D#PGMICB,#N,<@-
M5L%+5C'U/*BJ=M&(%R][8PEM_%$FPH\?.5+439I'+.$H)=\L7Q'M#1BBNRKP
M2:*H('OAI:=CCZ@3*6/_ ':YSQJ Z'OM+5R55LCF5W"?.1+GV4I%.!GW!:)@
MH_?8^#ASGS*M:-KF4]O&U[]V5]L%KI^JVG[+%@7VL\3]# M+<<CSVH&QN5DB
M6&):2MK,5:-CRUIL[4FEOXMP$B"M]2F@\*QOO3EN6Q=-Q3U6(LP27.L8CU+O
MC$N",YW1P+''M)Y=3CSK&;O?*:[7V2GIY1+(:A;=2HK;MY20Q J0"-KS%W!]
ME;)\$ZZ%.J>'>FM;\.:=PD/K,7;=-P.G!=.V2$E TI$N483"JC[;+2;#:_DS
M)VR5*E;&>2,ZV0/,R3IH;S)#;+B,3J+G53W26[+(T54]4:F-E/,3!LQ*OU6-
M0L8!&"J@'.3G68:""*@2WL@D@6#LNI&!("/Q&/.078L^0<ACD'(!USH.67&3
MD;TC]B\).:NEI9(](M#6TN.NQ2!W7 +YK4LL@9==LV!<C,'$-Q[LEK[9D(G(
MF#D+,*&9'B9R()=W"U5%)U=9'$JJ>ZAIZZG!&Z&< $,F<D D+/3OSM(&3O1L
M9/=9STO=45Y#&RD3T<S#TS0Y(P< !B.8IT&/?C8ZDM0<\N^;7L5UF43<O&>6
M2)R.Y30$I3*C4D%-&6/0\_&#LQ^U['9&$)0MDV@D%XCZ,44..W99B8K-G""-
MK[,BVF@6?HBL>_STE=$316UTEEE*E4K$<DTR1G.")PI:8*Q[:))&6#[2;1<^
MM[8EFIZJFJHQ4W!7CCC5P7IFCPM0SCRIB)"Q%@N\NDBAD!U17Z>7JT/Y<\A7
M^6&]X(B3T)H&T#2<<)/L.DB[:W<RIF:B8@O\S"\2T%3,O!VZXX(6ZU(R)-9A
M#&CP):::8M/6]Z_1%&+;3.%K:R,@[, TU(<HSC:?2\N#%%X*J)'&TJF8GI*D
MCO$YKB.Y14LF"S9*SU( 81@G\PCRLDN<@Y1""'.&U^TOJ4UIVFCZ/'V+MB\Z
MN3HY[8[\0JE1,!**FU;'11FSTR7[UMS#&([%%#R)^+[9<R<3]WO];7MFU@ZB
MGL!JS!3Q5'S?8W=UG79V.]C;L\[N\<Y\8&/?5[NUGBNP@$LTD78[NWMA3N[O
M;SG=XQVQC'U.N>1PEX61'*3GGK/B3:+-8:G4KSL&Z4X^XPP()$Z '6("URXQ
MHPL@A4<X06]7AV7D.IRTELES+?\ G81YMMWJYK99JBZ+&DCPP12B-BP0F1XE
MP2IW #N''OD<\:R6V5%#<+M!;%G(::>2$%<%\1AV) /&<)S[#3DO'STM?$;2
MFZM<;:L^YMH[DB=>68*UYUI<:_3@ZG:I"(^94,)8\QPN2C(8:80#(GQ.<9%F
M6 U14@E<>84VO+*SKZY55+/3QTU/2M,AC[\3RF2,-PQCW' <KD*WE"=R^H Z
MT>#I.BAFBE>>:98W#F)UC"2;<D*^!DKNP6'ZP!4\$Z9[\H>K7JD+?_0GQ Y(
M\QI3FQL78/(+.SIB\Z_O9M8B;5K]C7JS=<Q]7BX2&Q$GZRD9[$$4#4XYB3&S
M95%OI?-_&.$^UKZ+51]7W*BMBVN&&B["0S0B1HYC-B=I&9BRSJA<&1BI[>.!
MD'',!4]/4-36O6RRU'=>2.1D$D8CS&J*% ,18*0@R-V>3@ZJ:]73(RSU9X%5
M$9:\P\Q9.1<^>RG*_@Y)UR-TM'1"U)QGZ\J;%M4VE&58RO&'7,-_R4YC-I^&
M4"RRWB0_F1*!!_JR-5LWMXS$GV^QX&JQ\0J]:&&V[S@2?.L![EHQ2A<>Q.)#
MQY^A')U/'@E)U#CCZ=6OW&1;E J]'Z$W5:[L5  HD)UQFV[*OK=E,%'4_'_E
M&BQLFX**ITIKZ!0AD?>IH9&<QEW4U/7[1, VVOHD12<+B&G@*#WP"R[F\Y+'
MW.OY3-4U/PXJ'H2JU=9;+B(W=MH$E1/40EBR [=J,0I .W:H/C6E>A._\1-^
M[JW3<=) V=ZVZJH4 )ERZ5J/@G@!+_+2 S\A!)'EY9;Q'TUA^-.)3@;(HDGD
M;Y.(DEIQ)]>S5D=#14\A"Q3U#N^PY#&%%*JWI7C,FX#G)0']4:J/PJZ=KJ"Z
M7&MN;0R21T:0TG;F>789I<SOAT4*VR-$5AEMKR+P&.6F_,LUNNO@E(N.FXR1
MA9@(:2B9<$N,E(XUE! 9\<>.X*:$6PYA3;PQ0SKK#[2\90XTXI"L9PK.//2.
MT;JZ,5=&5T93AE92"K CP00"#[$:\2(DJ/'(JO'(C(Z,,JZ."K*P/!5E)!!\
M@D:KIX_]7?'SC9MV#W)K6;V -8X%,VP-'G2< ]$$@3T6=$EQQS0]=&,(%0P;
M]S.,&(<24**1EQ2FOYV:Y=67&Z44E#50TG;D[9+I'(L@:-U<,I,I4$E<'TD%
M688YU0[)\/+18;K%=:*X7=IH>^JT\]53R4[)-&\;1R(M*DC*@;<GXH8.B,S'
M!!4.]6168>,YY:0L@+;3,I:.+-=1-I:PE*B7(+9^SPP#B,8S\E/K"(0!AU>,
M?(>-':3G.&?;%[^'DC-:*J,\K'<)-GV#T].2H^P8%OXL=?'J]%6XP./+TB;A
MQY668!C[G(('/LO&K@.Z!Q5^]/3I:[65Q#E@Q2>$UXPLQ"EE.6*?KM5C9-3*
M\M+RV8H2SRZWG%*8SD?\IO+N<N?2[6^F/P>LZN*/.PRW6+@\;$DD9<\\C,:X
M_-S@X]Q+WO\ %Z;I9'_.(Z"7U>=[1JI\C(.';/Y3C(SR0?'])5*F$<*.1<.Z
MIQ0,9RA+.#^2UY;0]*ZJURT8AM&<?!&?:+&<<RC/R5EQ/SQC&$9SZ^(J@7.A
M;C+4&T\<X6HF()/]X@?3'WTZ/)^2JE]A59')\M%&#QX'Y1X_M^];G/'9?#'9
MW:IMC76WI'8G]HTYR'J>IY=6::,[7Q4,F5BB0C:)AVPM/(AV85J.4LU(*?@Q
MEPE ZO;&%W&QO5T?2]*],$V1V^6H4!N6=A+.WIVGU%R1C/VSK'NH[+>KGUE6
MRR?*BBFND,)8U#K*M'&T-.#L$> P@3(7=@GWYSI\:/CP8D &+C!!P(V-#&CX
M\$1I# H0(;*!Q!!F&\);9'&8;;99:0G"&VT)0G&$XQCS#F9G9F8EF8EF8G)9
MB<DD^Y)))/UU^C554544!550JJ!@*JC   X    'L-?7Y_->M:YL&G=1VR5(
MG;5JS7-FFRTLI+F;!2*S,RI21F6QATD2,C&$EO)8'::89PX\K#3+;;2,)0A*
M<=$=75Q($BJJB-%SA(YI$09))PJL ,DDG Y))\G7+)14<SF2:DI99&QN>2GB
MD<X  RS(6.  !D\  #C2ROJ+-I<<=?SO%#6V[LVR(K(M5V'.4F%I%2$DX9I3
M)E2@2T.#_MH<4'$2 %&BQ8H[*VQQ2B$(PRVI*%:1\/A/LNE1$0TKRTZ2.[>K
M&V5\DD,3N9R6/DD>YUDGQ2H+I6R66FMJTRTU/#5.R22M  [M!'&$5$9=J1QD
M+R H8@#&K<NG.IZ>KO7QHZ=TB,ZBG[+9M&QGY R/8C)68F)JSRD:05,"#D%H
M;D(\"%C:\I&2GU-#0HS&5XPUA":KU?4U%1?ZWY@G=!VJ=%)R%C2)6 7@<,SO
M)XY+D^^KMT);FMO3%NAE$?S,O?J*IHCN1IY)Y!^8A2W;B6.') .(P-6?>5G5
MOU"SL9J6M[AP7Y4";:&P10J_I:\;!FU)%;,)#SK.&)V#'R( [CC6'#P9&M"D
M"-X>:RZ\A+'SPEU6,S/3T\]/?+6].2)6K8(1@XRM0X@D!/T*2,#P?X:K_5=&
M*[IR]4VU6=K?420!SA14P1F>F+, 2H$\<9) ) S@$\:6R]/#?N*%OYE;4$T(
M]=EV@3C+;")5-FJ@L"'B 5M33K;RF"F)N34\5^QS'8PPIE&,M9=<^W'UX0O1
M>OVJ39Z43;2OZ2A(PV?5\K6<8VCC!/VS_P ]93\+[5=:"_5DM>M,(FM%1&G9
MF>1]YK;>PR&C4!=JMDY)SMXY.(J]L^Q^%U?[--^5_:;VP$;)3:M9XE4PU+#E
M8?#\AK37Y$/EF1=L(3CJ<QI$?DC.1&OI>^UOV=PCY+D^E9*H=-T(BV",15./
M7@G%3/G/I/WX''VU#=:V6]575URJ:44GRSS494R3.D@5:2F5LHL94D,K8]62
MN"2#X>S/B(R>@38":!&DX::B"8B6C3&DO!R$9(AK"/!*87C*'1BQ7G1WVE8R
MEQIQ2%8SC.?,1#M'()$8JZ.'1@<%65MRL#[$$ @_4:_1C(DD;1R*&21"CJP!
M5D9=K*0>"""00>"#I%21V3Q(Z@NS-,!.D[1K-GU!>A6WWV*4T? S.J-CP[:T
M$MR[<\AV5")HEGQD@EL!]0<\"0UD91\8IM&W,\_5/31_HW^:IB0-P!CK*<\<
M8&W$\>!DY,;9/#\_G*DLU^Z6ZP2>(4S4%'<",M42"66USDJV4,15I?E)<[<[
M>\H 8;>&U>Q+E_KSAWPVV;ORU68B-C28>.JE*E:VRQ,RQ]HV(XW"5LVLB8+%
M'E2(Q@XBV^R3&VE1$&<8E:T,_!>46&VR7*[TM)L)59#+4*V5"Q0>N17XRN\J
M(O&0[@'&MSZCK9Z*QU\]$8S624[Q4)=]J&IG4I$^X!LB,$SG .5C./.EZ.@_
M0?&+D!NVT<IM7Q%QDHCCT[B'C)2[58>$$)V7=HB089<BG$2TNB3,K58=DCY/
M#F&78PV?JYS*UNN)4UH77-VJ::WQVPNJO7'=(J,"5IH65BIPJE1)*$5<>EE2
M13P,:R3X;]+7)+S+=;JM/V:"%A3"*5Y2]9/Z YW(HVQ0B4GRW<>)AC!)<$\R
M/6\:JI[BM+<8MC\,K]L3DS(QE4B=#QYE_J=\?%01+1$VXEB.Q4XMI/Q*DE;%
M)7'5AF!9<QB0G7J^9AM946(INT=(W"OHKQ!%0JTHK&6"> '"M'DL9CGTJ:<;
MI-Y'""1,A7;--ZYLU->+#5=QHX:NC1ZBWU#Y&VIQA8"5]7;JSMA<#.&*2A6:
M)=(S5G:_6E/62O04C9ME5B.F)R*B3K),ZW85$5X*1/'$*G)1(%D,-S'Q3#JS
MC<!B$E9%'<P.P\[\&E;9)-<DCD=$$KHCNL:R*&D95)"*64*"Y 4$D*"<GZZ_
M/$'3-^>:*.9Z&"%Y$66;OS2F*-G >41K$&<HI+[%92^-N03G71_XVZ;U1H'1
M^N-5:1"C!M9UJM@_PV7%/#%L6%F31^U*MCTB'E0TJ;:C#7YXR384I@QX]3HO
MP%RPVC\\W*MJKA75-76LQJ996,@8$=O:=HB53RJQ*!&JGD!<')R3^J;5;Z2U
MV^DH*%0*:GA58VR"921N>9V'#R3.3*[#AF8D # &\/.'4AI#KK2V;PKL':?I
MB!UN_L-6S"-L;*3$IEZ6%&P^9 .J7XJ6^^2:L)CC+7X(\CEAS CF77/J;RAM
M+F5(W'J-ZS^3%8)-O;%)3;L/GCNTX'&T$\X]_//WU^<.E++>:;K&WU-2M)\L
ME;5%BD[O)M:&I"80Q*"=Q7.2,<\\:?%\P[7Z/T>--<X7OR3=N,7<[8=KQQDP
M*#8<\?>0]1#;.,'%+;KD/7ZZ=EIM+R&%-OW+65@;7E*<)^>%I<]UX6I6V](&
M*OZ8BIV"DI\Y12' )&]WD&>"<B*=#X)QCCQK,.H5>EO<LP\L:>IC\C.U$7[<
M=R)AD8\'W!TQ5Z@K3L;RBX5<<>25#^%@@:)=(&V"R0R?M97K/>=6!98FVW4)
M5G\<F;$H#./;V2M$BE?O\FT8S6/A_5FW7JOM\WH>H@DBP?(J**0DK_$(9SSQ
MZ>=>/BA2_.=/T5SA!=*2ICD8K_V:MC"!\^P,HIU\9P_'T.?]1<95>1W61M#@
M]>W\CL1E?VEJR3';0VLUG7F[A;#)"3@B'<IRZ3'SMCM;(^,YRD-R,CDJ<0EU
MEM'RZQ2:W=1TUYB7B9J:I0\X,]&8T9&(\;HXXF/[0=OH3K^?#:Y07?IJJLKR
M#O4#U%.Z#!(I:[N312K]0)9)XP,G:8QS@KI1K@[R0V]T6]DUP@=V5"7(AX R
M7TQR!IT:GV*L- .DH^5A[[1LGJ$$DGAUA0=YI9;ZQ6+# %$1&38MJ??-%N]V
MH:;JRR1M2RJ#(%JJ*5O"3*K*T,VW)7R\,P .QQNVL4 /B@JI[#<W[T9/;+4]
M3&."T9*G?&3@'\J2Q$X#K@;E5RPZ*>@.;'$_E%2H^_:*W[K*^P!PC1;S -IC
M ;%"9=0E>0[14Y5\&S5:29^6$O1\_$QY;>?97U9;4A:L7K+5<;?*T-71SPN"
M0"8V:-\'&8Y4#1R*?9D9AK2J:X457&)*>IB=2 2-X5US[/&V'0_9E&JQ^U/O
M"XT<)-37*JZCV33=P<K)R&D(6A4:D3,=;8RAS9H[@K-QV;*1#YD5!@UM3B9)
MBJ%%ILEE,;#CV(X2)(D9Z*GNG^E*ZZ5,4E3!+2V]&#RRRJ8VF4'/:@5P&<R?
ME,@';0;B6+!4:)N]_I:*&2.GECGK&!1$C8.L3'@O*RY4;/(CSO9L @*2PH$]
M,#Q.VGN;E-<><FP2K,7KC3$;:8"K3DV;($,7;=6PHUZ+E_Q%E.K9DFZI39J=
M/GR,84H28LE7RVI3BR/HM_7EQ@I;?%:H>V)ZIHWD1  8:6%@RY 'I[DJHL8]
MUCD^@S7>E:%YZUJYPW:I@P5SXDGE4J0"?)2-F9_)!9,_FU"SN^VP9V"]P1FI
M=..HLZ:M+ZWX=ZZ?"5^0++6H.SG,65;66,K0X,)M&[VF*R:VI;1$?$LFX=_'
MRCX2G2M.+/TVM14CM]Q9[E.#P5C9 4SGP33Q1MCC#-C&<YXK].;A>'C@P^UH
MJ*$CD,P8@^/8S2. 1Y4 Z8!]318X'3'6SQXXN5Y[V=LNQZ+!1 :LMX=<H&BJ
M(6R<3\/;Y>XLS)4%I>6TI2G\OV4K&,X;75?A_3R5]\N%>PR(J>5W//$]9.I4
M#^*+.><^/<ZDNM[C!:K9;*-G :HJ4C13Y,-- P=OX*[P GZL.1K=OI<]32.O
MNM,NYR8KK"MU;_V7>HEUQ*DI)@:\#5]6LNMX5G.%(3.T&Q(^S&$X5E/Q^.?K
MPM7!\0)Q)?1 "":2C@B?QD/(TE1SC]R:/S_X8U*]'K_DDSC)6IJ99$/L458X
M<C^_&X)^WCC2^?J9N)%PX_<] ^5U:!/$U]R6CJ]9(ZS1Z'&QJ_N'7D/$5ZR0
MBR6<>P,F9&PU<NT>Z\II<F_*S2PL/*AI%3%PZ%N,=9:/D'*F:@9XVC;&7IIF
M:2-\'\RAFDA;&=H10V-ZYK_5%$]/<35*"(JM5=7 X6:-51TSSAL*L@/&=YP"
M58Z;FZH^TO3'8OH6GGC6VOPW)&M5R/CMTZB+/$ LH=FC16A9:WUJ&>=03,T.
MQD-YF8N5BT&#Q"#DP4PZ-+!/LYSGJ+I^JLM7*.V[4,CLU+4@%DV,25BD8<),
M@.TJV"^-Z94ZN%GO$%R@0%U6K10)X20&+ 8,D8/YHW_,-N=A)1N1S8OMS<>J
M]"4&?VEN>_U;6FOJN&Z;-VJW2PL1%BMMMK6@=IPA:7#I$O*,LQT3'M%2DF4I
ML..#*+=:97"TU+4UDR4]+#)/,Y 6.-2S')QDXX51GU.Q"J.6( SJ4GJ(::)I
MJB1(HD&6=S@?P \LQ\*J@LQP%!) TE9:_4I\[]]\P2-*\#M2:8GZ)L'9<?0-
M"1&P]?W.6V!8 BG18D6PVHR*V-!1T6S*D-FVDYM46,-4*\]EB6+(Q#FRC^H1
M]#VBCMPJ;M4U*RP0--6/#-&L*$ LR1!H&9MHQ&OJ)E<94>I5%%;JBXU-7V:"
M&'MRRB.G22-FE()"J7(D !8Y<\ (IP2=I8V"^IIX8;%W=PCT_P B !1;;LKB
M6263M9=7BB0PY"@WZ'@ -B6N&B'"9&0'B:[<:U6YO]>Z4:N%JAL])'G+9B"2
M%P_0MT@I;I541)C@N./E@Y#$30LYAC=@ "SQ22+NP TBJH + :DNJ:*6:AIZ
MKAY:/(G*# ,<H022!>2%61$.,G:C,Q.%)U#;TWG;QJ77&MF. G)BZQ&N_P!1
M9)B8X[W^UR#$543@[=)/3,]J^<G#7&@("6:M!LG/U,Z4(8CIO]](5_!0<D!!
MAS<EUOTY45$_Z7H(FF+1JE;#&NZ0&)=J5"(HRZ]L*DH4%EV*^"K.4XNF;S#!
M'^CZMQ$N]FII7.$'<.YXG8G"DN6=&.%.YE)!"AG7&WF7F4$-/-.CNM)>;?;<
M0MEQE:,.(>0ZG.4+:6C.%I<2K*%(SA6,YQGW\R[!!P0<YQCWS],?75ZR",@C
M&,Y]L?7/TTI#ZB3N"T]!:)NO!+CI>X38>U-J8:KN[+)4)(>9KVLJ"*:P7-U!
MZ= <>C#;O<'1$5^4A0WS%U^MN3R)S$=*&Q#2]&Z+Z:J6JXKO70O!!!EZ2.52
MLD\Q!59=APRQ19+*S ;Y-A3<JMJF]27J#L/;Z6199)2HJ)(R&2*,$,8PPR&D
M<@*R@D*A8-AB-5F>DP_Z?V]__9[;_P#&G1?DY\0_ZFI/_6<7^%K-1?2']9S?
M[A+_ (BE_P#/_D:A3WO_ .NCY)_[X:)_P9U/Y)])?YL4/^SJ_P#%5&N'J#^N
MJS_7@_P\.NG.Q_S#/_E-_P#T3YA3>3_$_P#CK5%\#^ _\-)M^K$X<?M:GH[G
M+5(KYFU0M.B-ND#,_)Q5=F7Y*Q:QGC<H3C#8L3/JM-;+,>4I3I5KK0*<X2VW
MCS2_AY<]LE7:9&XD'SE,"?UU"QSH/NR=MP![1R'5)ZOH<BGN"+R/YO.0/8Y>
M%CCP >XA)]VC7Z97YYM]G]OY>\'^ ?$LQ<LL[CC5I@?:1CV'5L7&UP!1FOM.
MOM*7G+QQE>U*(VJ0,SAS\N:MTDGYJ>&7C%RM=BBMMTO%P7;BND0P <&*-@)J
MD$#@"2I.5'&%C7ZYU7*VZ25=#;Z1B<4B,)"?#L"4A/GS'  I)\EV.G^>G_AP
MC@]P#T;J"3C4Q^Q)R$3M+<'R:2V6K9NPV!9F9C#LIQC#K]/C/TM#;>QCV=%J
MP[O]5YSG'^I;G^E;Q5U*MF!&^7IN21V(255AGP)6WS8]C(1K1+)1?(6Z")EQ
M*X[\_C/=EP2IQP3&FR+(R#LSD^=6;>0.I;7/.]1%V;27,OD''<+M 29M@TGI
M*Y?IY;-9R[()W)OO[G( A<<T#]JYN%I+Y151J3(K;C<M8"[%+C9D@R:X0QLW
M1EB6V437.L4)5U<6Y>Y@?*T?#@$G 1I<"24G!5%C4E2) <VZCNIKZD4=.Q:F
MIWV^CGOU'*LPP/4L>3''C\Q+L,AE(\CFCZ>C9G%[K?UERDB2YBR[XI<>9<.6
MVNQULG@52FV3 A48]46@VLN.N:@92V#L9Y+\BQ)ID)NT!%"0-:^#_JU]94]?
M>ZBWL%2DD(BMTV"#+*F0PD)/ J.6@X&W:D9!>3.O%;T[/26R&L]33KEZR+@B
M*-\%"N.?P?$_+#+%P52,DVI^F9[3/[2*<SUY[PL?V7S7<.5)<;9V6*]R+7KF
M+9<*F-7Y?(7\R)C7HR')2JCI6ZX11,&QS#(H5):R57^NK!V9#>J1/PIF"UR*
M.(YFX2HP/"S'TRG_ *[:Q):4XF.EKMO46R=O4BDTC$\LB@EH.?>-1NC'_5AE
MX"*"WKYF^KIKF'],G^N]X\_^M&[O\.=L>;SU-_FM7_[I3?XBFUE-G_KVD_WJ
M7_[)M=/#S!M:MH\::4Q]57PNDMEZ%U5S-ID2Z=,\?3R:'M+ ;&72%:LODD(J
M GBE)PI?X5.O>4 J0A/LVW?S#G\I&!=<;T3X?718*NHM<K +6*)J?)P/F(5/
M<0?O2P^K_@!1RPU3NKJ$R00UZ DTY[,V!G\*1@8V/T"2$K_Q<G@<9[Z?OEOK
M[GEU_6G@)N<Y@_8&BJ:_KYV)+(:Q*670TJM8U M,&E_WRHS6IBQZ<XX(RZFO
M9AZ)($N)(FQDY\=74-19;W#>Z,%8ZF9:@-C*QUB8,T;_ +M0,R8.-^Z91D(3
MKYV9Z:]V:JL5=ZA\O)3LH.':EE!5)(SCTR4[$*K 'ME87\D:Q^PW>.Z99RR[
M2VM,I%#K_P"37XN!!RE!>[HF17^1%P=8!<=_TDF60$S(?D*6IBJ&Q[Y<R\RQ
M$G-KL3BGZOH%2/CN8?>3EJ*H08)<#]G<5VC'=C;T_F#+@MLINI^ANN%I*>#N
M]O*S%PR4EQM$K_TW<&[MH>VKJXW/!5Q"%DD96A>1FW>/763ZBO1T%M77%_9K
M&[ZM , BW:O-0X^[M4*)RZ0BB[EUV2:A=FJ8TJZ6Y'-DEMQQ#^)(S7MW%&DI
M4DZH4U;?>BZIZ>>'N4DCY,3ES25&..[2SA?PY"H&["[L!1-"2J;?T3-3VKJ:
M 2PR]NJ1,!AM$\.?"5$61W(PV=ISMSN[4HRV5ZMF^E4[":K/DBZVOW'K:=9R
M^M,=-_Q?9*-,K%^6<(=F*[.U4D2.(4G&%.#1MDGVD?+"4%O9QGVN4'Q LTB
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M((X(/D:1\W=Z;CFOI_F?(;QZ\+]JJK:[K6P(O:&DB+A?)VNW+7,DT8W-8J1
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M;@4._P ODEN0EBJ00XWC^?LXJ,:5GVQ[MX]\^U=D^'-<#^%<:1U]C)'-$?\
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2CQIH\::/&FCQIH\::/&FO__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g401831g93a75.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g401831g93a75.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[14B4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %0:^4X(X0DE-!"4      !                      .$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'W%F:         *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  @.__C4  @ ".$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         ".$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@             !)P
M!,(          0                         !              3"   !
M)P                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   !
M)P    !29VAT;&]N9P  !,(    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   2<     4F=H=&QO;F<
M  3"     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
M   %.$))300,      L+     0   *     G   !X   22    KO !@  ?_8
M_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,"0D,
M$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,# P,
M# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1"  G * # 2(  A$!
M Q$!_]T !  *_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !
M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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MQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$ /P#U5)<]];/K75T&IM4
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 1$  A$! Q$!_\0 'P   @(" P$! 0            H("08'! 4+ @,!_\0
M1!   04  @$# 0(("0H'    ! $" P4&  <("1$2$Q0A"A46(CE!=G<7(S$V
M-SAXM;="0U%Y@9&RMKCP)#(U1G&A\?_$ !T!  (" @,!               (
M!@<$!0$#"0+_Q !+$0 " @$# P("!@4(!@<)   ! @,$!0 &$0<2(1,Q%$$(
M(C91=;45,F%B=#,W0E)V@9&S%S0U<Z'$0W%WL;3#\!8C)$1C<H*V\?_:  P#
M 0 "$0,1 #\ ?XX:-'#1HX:-'#1HX:-'#1HX:-56^JCN>X\9UO@8^O+'04.+
MNKB\%["O\Y.6"7#/%!4_DM4'V@*QE@5=JLUZZ9C9HX+"<(<4EWQ2. FB^NF3
MW%CL-BEQ$MNKCK-FTF7M4VDCD5E2#X&O+/%VO%!/W6BP#!9GB1'/ "O4'5_(
M9RABL<,9+9K49Y["9.S59XW4A8?A(99H^'BAF+6"P#!9&C5'/LKPW\0==Y =
M,=:/\FC]3=W/0X/8-9CMUA+V>V.0G,6A%?7V'8>7^VRS#PST-Y;A!+)7L@6R
M*@-#-(? ,0R&N>GN0W9MO"MO66]9L[6BR\..RF+M-/+WTIWABFR]'U69%>K:
ML1Q\PA?6D66*5RJ.%@^R;VY<'B3NR6Y/8VZF3BHY#'V6FD[JDS1129.IZA95
M:M8GBCYB"^LRR1R-VHP5A>*2.:..:%[)8I6,DBDC<CF21R-1S'L<U51S'M5'
M-<BJBHJ*B^R\;E6#*&4AE8!E8'D$$<@@CP01Y!'N-,L"" 0000""#R"#Y!!'
M@@CR"/?7WSG7.CAHT<-&CAHT<-&CAHT<-&CAHT<-&CAHT<-&CAHT<-&CAHT<
M-&CAHT<-&CAHT<-&CAHT<-&CAHUC>MV.1P.?L-7NM3G<9EZF+Z]IH]5=5V?H
MJZ'W]DE.MK8D0 5BK[-:Z>=B.<J-3W543F33I7,A8CJ4*EF[:F/;%6J02V;$
MA^Z.&%7D<@>3VJ>!YUT6;5:E"]FY8@JUXAS)/9EC@AC'WO)(RHH^7DCD^-5M
M[CUG?3DPI\U9/Y!#Z<X>58IFX?$[[5 (J.5KI(;ZMS3LZ9$BI[I(#;$M>U4=
M'\T7WY9M#HGU*OQK*NWFJ1LH8&_>Q]23R.0&KR6?B4/[)(5X((/!U!;G5+9%
M-BAS'Q+@\$4ZENPG[2)EA$# ?NRGP?'.L[ZC]5KP [JL1*3)>1^0JKTU[(1Z
MCL$._P"M)YB97(V(0<W=U-!3'%S/5(X1Z^S+EFD<V.)KWN1JX&9Z2]0L'&\]
MS;5R:O&"6FQSU\FH4>[M'0FL3H@'EFDB0*/+$#67C.HNS<JZQ5\Y6BF<@"*Z
MLU!BQ\!0]N.*%V)\!4E8D^!R2-6%1R1S1QS0R,EBE8R2*6-[7QR1O:CF21O:
MJM>Q[51S'M56N:J*BJBHO*Y(*DJP(8$@@@@@@\$$'R"#X(/D'4U!! ((((!!
M!Y!!\@@CP01['7WSC7.CAHU CL_S79TOV6W"]\=)Z/%]>:&XLJC*=HP7=5KJ
M#1U@9,0ZW-A1!@#D50BPDC%GU7VNTN@19V.=6D+]RU5F^I0VWFAB]T[:NXW$
M6[,]>AG%LU\A5N01.J&S+5CB1X(^UTDF@$D]F*-U)A<D UUEM^C Y48_<6!M
M4,9:GE@IY=;$-VO:B1U0SRUXXU:&/M=))(N^:Q&C ^BWSRGS?O:.#P[[,(K%
M"L:[2Y_-TV7CJW0S"V<NGT-$'2OJ?LRK"1$K"X[ 5PRN8\>#ZL2JU$7F=U-M
M5DZ>9IX#%-%=J4JU$0%&CG-ZW5CK&OV?4=2L@F3T^0R+W+R.-9>_[%==D99H
MO3EBM5JL%00]K)*;EFO' 8.SPPXD$J%.057N'(U*[)U9%'ELU2ERK.53Y^FJ
MR9U7W68BOKAA)I57]:R20N>J_K]_?D\H0/5HTJTC=TE>I6@=OZSPPI&S?WLI
M.IC3A:O4JP.W<\%:"%V]^YHXE1FY_:5)_OUD',O63HX:-0BN_4E\$<W=6^=O
M?*/JBKO*&SL*6YK"[R2,JNM:HJ8&Q!)9]E5&$"%P3#S,]U^,D;FHJ^W)W!TQ
MW_9@ALU]J9:6"Q%'/!*D"E9(ID62.13W^5=&5@>/8\ZB4N^]GP2RP3;@Q\<L
M,CQ2QM(X9)(V*.C?4_65E*D?>-9OU]YP^'G:EH+1=?\ DUTEI;X^1D(% )V)
MFA[X^:1R-9"!2GGB6ALKG.1J1BB2O]U1/C[KS R.Q-YXF)I\CM?.5:Z F2P^
M-M-7C '),D\<;Q(./FS@:RZ6[=L9&18J6>Q4\S$!(1=@29R? "12.DCG]BJ3
M_CJ4W(GJ1:.&C1PT:.&C41.QO/?PVZCVE[UUV7Y%=:XO<9F84>_S%Y</&M:J
M<T 6T%B+@0=Z1NGKSA"XT1SO>$B)W\KO;DQQG3[>N9HU\EB]MY.]0M*[5[4$
M*M%,L<CPN4;O'(66-T/('E3]VHS>WEM?&6YJ-_-T:MNN56:O*["2,NBR*& 0
MCDHZL."?##YGC4LQ"ACA1C@YF$"&#PE"D1K\HYQB(VS031K]WNR6)[7M7V^]
MKD7D0=&C=XW4JZ,R.I]U92593^T$$']NI(CJZJZ$,CJKJP]F5@"I'["""-<C
MGSKZU%WMOS7\4.AM<[!=Q=\=?=>;%E:%<.SNDM7AV3:RR65 35A2"1/H%?0F
M^D_Y?G?3?]R>R\E>'V-N[<%,9#"X#(Y*D99(19K1!XC+%QZD?)8?63N'(X^8
M^_4>R6Z]N8>S\'D\Q3I6A&DI@G=E<1R<]C\!3X;@\>?D3J0N7TU!M<UGMCE+
M4.^R^LI*K29R[KY%E N**\!@LZBT"E5&K((> 2.4/(K6J^&5CO9/?VY'+=6Q
M1M6:5N%Z]NI/-6LP2#B2&Q!(T4T3CSP\<B,C#GPP(UNZ]B&W7@M5I%FKV8HY
MX)4/*2PRH)(Y$/CE71E93\P0==[S'UW:.&C757E[29FGLM#I+BKS]!3!SV%O
M=W=@)55%4 ,Q9"3K&R.E@#"$'C17S$DS10Q,17/>U$5>=L$$]J:*O6AEL6)G
M6.&""-YII9&/"QQ11JSR.Q\*J*6)\ '77--#7BDGGEC@AB4O+-,ZQ11HOEGD
MD<JB*!Y+,0!\SJL?;>M%Z<N'NY:$COQFE+'G<.67B</O-52#N8[XK)%H*S.2
M4MG OWN;/2'6<;VI[L<[W;\K3H=$>I5^ 6%V_P#"(RAD2_?H5)V!'/!KR6?7
MB8>Q6>.(@^X]^(!<ZI[(IRF$Y<V6#%7:G4MV(EX/'(F6$12+\^87D!']W,O?
M'SR]\:O*BO,L.@^W\GV(^LAC(M:8"8RKU-0-*YL<95MD- )4ZBM#DE<D$1IE
M1"'-,CHH9Y'M5J0W<6S=S[3D2/<.&MXT2L5AGD5):DS*"2D-RN\U61P!W&-)
MBX7ABH!!U)L+N7!;A1GP^3K73& TD2%H[$:D@!I*TRQV$4D\!VB"D^ 2=20Y
M&=;W49N__*;"] D4])9UEKKMG>UY%X+EJ2UQF=AI\N+9 TA&RVVR[%U.+P6%
MR3;VTK*$.STFF"*O;T^"ES%=>VC9PX93MW:=_<*S3Q2Q4Z,$BP/;GANV3-::
M*2=:5&EC:E[(7[GP\4MAXJM5U@KQM/:D@B*NT?S6XJ>%:*&2.2U;F1IEK0R5
M(!%75UB:U;M7K%6G3J^M)'"LL\Z&69UB@263E1]]#^46)[U.M<V+47.)W=+4
M":4C'Z*PR%Y^.<?8'$U0.ZQ&OZ^TVRPF[QA%P$;32W&9TITU/<"OJ=(!264@
MXDW&X-JWL D5EYH+V/GF>JMVM%<@]&Y'&LTE"]3R-6E?Q]Y872<06JL8F@<3
M5I)X@SCG#[AJ9AY(%BEJ7(HEG-6>2K-ZM9W,:VZEFE8M5+E4RJT32P3N8I5]
M.=(G*J>O\Q?+?K+PLZ1O^Y^S)I2HA9&4^1R8$T,5WNMB= 1+4YFH69',A69@
MQ!MI8R1RPT],%86<D)+AHQ".S9>S\IO?.U\)BP$+@S7+DBDP4*4;*)K4P7@M
MV]RI#$"K33O'$&0,77YW/N2AM7$S92\2W:1%5K(P$MRTX)C@CYY Y[2\DA!$
M42O(0Q4*R1/8/:WF]ZN7D&-G@1+W=VQ)!1V3ZOS9$E9UCU;G&RMAELIFFDQ4
MU,&)$1 -;;32%.M[<B44*4\F>:KK&O1CL1L7H]MUK,CUZ$**D=S*VE$N4RMG
MM)$8**9II'*NT-*J@AA4.ZQJJRRE4+F1W9U(S*PHLUV5F9Z^/@8QT,?#R 7(
M=A%"B@JLEJ=O4D8JK.S%$U:KUM^#9;$^E&,[<\H<_F+Z:%CB:# =<G;&O#F>
MU'+&FFOM3C)2EB558]&9J*-[D58YU8B.=4N4^DU2CG9,-M6Q:KAB%L9')1TI
M' ^?PM>K="\^X)M$@>Z@^!8E#H7:>)7R>?@KS$<M#2I/:12?E\1-/5+<>QXK
M@<^S$>3I3R)_!YO([K:D.TG178^5[_&KH929\K/3R=;;LF*-JO<RDK["[T69
MN)HV->KH9M54&$JC(@ 2R96#\WFV_I&[:R<\=7/XRWMYI65%MK,,GCT)/',\
MD<%>U"I)'UEJ3(HY:21%'=K59OHMG*$+SXF]7S*QJ6:N8C1N, .3Z4;RSP2D
M 'ZIL1NQX"(['@7B>B57;2B\#LME]^%I:G3Y/LCM'-'4&M@LP[O.?BO32QMH
MB*VW;&;4M <Y[&5KX8&#?)R-A9\E]Z)ZY2TK&_[=K'/5FJV\9B;,=BFT3P61
M+44^NLD)*2^H."9 3W<#DGC5L]*8[4.SZ]>XD\5BO>R$#PV5D26#TYR/2:.4
M!X^SR.P@=OW#5MW*?U9&CAHU5!ZNT$3NB^N271M6>+MD2".543YLB(Q^L?,Q
MKE^]&R/&@<]$7V<L3%5%5J<H;Z0*J=KXAR 67/1JK<>0&Q]XL ?N8JI(^94?
M<-4YUJ53MW%N0"RYJ-0>!R U&Z6 /N 2JD\>_ ]^!J+OBEV+:^0&?\6?&HZ>
M<\7K7MO2=B:]T[G2JW!=;UU?H,,":Y?DL]98:'26&<B&=_%P155;$B-CCB^$
M'V'EY]UU-C;+E9I4PV?NY?(%N6XQ6'ABN8R*0GGOAEN79J:H?"+#"..T*5B6
MSLI-N2KL_:TC-(F*S-O)WBQ)(QV*BBM8Z.3W[H9;-N2JJ_JJ(8EXX4!6 >-C
MID-'#1HX:->;?N^OBNV_.;9=5 V0],;V;Y8:'KX.W+@D)%JBMIV^9G![(D:%
M\<Q X,UDPJ:"*1DDL<3HV/:YR.3TSH9%,1L2EEI(FF3%[2K9%X48*\J4L.EE
MHE9@0K2"(JK$$ D$@@:1BY3;([LM8]'6)[^XIZ:R,"RQM:R30*[*""50N&(!
M!(! /.K$/*3T)/)SQVZPTO;>;VN$[FSF)J3+_6U&9'O*+8UU#6PO+M;L"EM!
MIP;@&H"BG.LHA;IEK&)"^4.L-^$J1UOM3K[M;<F4JX>U1R&%LWI4KU)K306*
M4MB5@D4$D\3+)#),Y6.(O 8B[!7E0E>9ON#I%G\)0GR4%JGE*]6-IK,< FAL
MQPHO=)*L4BE)$B4,T@67U H++&P!XL%] _SXW6]L[_P[[>TMAJ7T67(U_2VA
MO3)CK@2GHYA!=%U[/8$OE*L 0 S!KS*QSN?)4UH%_6M(6M@I@0*Z^D%T^H8^
M*OO/#58Z@GMK3S=:NBQPO-85WK9%8U 6-Y'C:O:*@":62O)V^JTSR3+H]O&Y
M;DEVQDIWL>E7:SBIYF+RI'"5$](NQ+.B(PFK@DF)$ECY],1(C/?%9U?VCAHT
M<-&O/M]8?]))Y0_M%B?\*\)ST0Z,?S9;5_A[_P";Y#29=3/MSN#_ ']7\OJ:
M?FP7\Q<7^R><_N</GGWD?]H7OXRU_GOIPZ/^I4_X6O\ Y*:RSF'K*TCGZ_OZ
M0 S]S?6W_%H./=]'K^;R/\:R?_+Z4SK)]LW_  RA_P"=INKP?_J7^)']F?HK
M_##+\3O?7VVWA_:C/_FMO3)[3^RVV_P'$?E]?4HN174@T<-&DI?7.\WM]VQY
M&:GQ=SE^?5=+]+&5E3<45>3(.+N.Q6@"V=U<Z%L3FK8#YDHUN?I*PKZH@)E6
M?<0L^U6+'0/#T&V+C\1MJINJS7CFS><26:&Q(H9Z&-]1XH(*Q8'TVM+'\3/*
MG#NDL<)/;$0RK=6]UW,EG+& @F>/%8IHXI(48JMN\$62:6< CO$#/Z$2-RJ-
M&\@'=)XV_P"/7X.SV-V)UG1;;NOO47I[4Z:I%MQ.OJ?KYVWL<[!8#L*#'U=H
M5L,J-!=0Q2,2RI*T4R(*97#K=231R,9I=Q_20QN-RD]'!X!LS5JS/#)D9\C\
M#%9:-BCM4B2G;8P,P/ISRNI=>&]#M()V>$Z)WKU"*WE<NN+GL1K*E**E\7)
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M<D@[(W.5Z_QCT2R"48[]Q,9-/8QR6IUHSVHEALRU!(PKR3Q(SK'*T7:9%5B
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MQL#?/BP\MFRH/R\UJA/W\_LU'NB5!3/GLFRCNCBJ48F^?$S23V!_C7K$_/\
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M<4LDF=ZURM?G139XV0E6YD?S*NK\V*)5BC/T5X58WMA'"OT6&V$[8D2-&HB
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G6QM*K0K@]WHU((J\9;C@NRQ*H9S\W;EC\R=;!YKM9NCAHT<-&O_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
